PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Ohri, SS; Bankston, AN; Mullins, SA; Liu, Y; Andres, KR; Beare, JE; Howard, RM; Burke, DA; Riegler, AS; Smith, AE; Hetman, M; Whittemore, SR				Ohri, Sujata Saraswat; Bankston, Andrew N.; Mullins, S. Ashley; Liu, Yu; Andres, Kariena R.; Beare, Jason E.; Howard, Russell M.; Burke, Darlene A.; Riegler, Amberly S.; Smith, Allison E.; Hetman, Michal; Whittemore, Scott R.			Blocking Autophagy in Oligodendrocytes Limits Functional Recovery after Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article						autophagy; oligodendrocytes; spinal cord injury	ENDOPLASMIC-RETICULUM STRESS; CELL TRANSPLANTATION THERAPY; TRAUMATIC BRAIN-INJURY; CNS MYELINATION; MAMMALIAN TARGET; ER STRESS; TRANSGENIC MICE; STEM-CELLS; NEUROPROTECTION; RAPAMYCIN	Autophagy mechanisms are well documented in neurons after spinal cord injury (SCI), but the direct functional role of autophagy in oligodendrocyte (OL) survival in SCI pathogenesis remains unknown. Autophagy is an evolutionary conserved lysosomal-mediated catabolic pathway that ensures degradation of dysfunctional cellular components to maintain homeostasis in response to various forms of stress, including nutrient deprivation, hypoxia, reactive oxygen species, DNA damage, and endoplasmic reticulum (ER) stress. Using pharmacological gain and loss of function and genetic approaches, we investigated the contribution of autophagy in OL survival and its role in the pathogenesis of thoracic contusive SCI in female mice. Although upregulation of Atg5 (an essential autophagy gene) occurs after SCI, autophagy flux is impaired. Purified myelin fractions of contused 8 d post-SCI samples show enriched protein levels of LC3B, ATG5, and BECLIN 1. Data show that, while the nonspecific drugs rapamycin (activates autophagy) and spautin 1 (blocks autophagy) were pharmacologically active on autophagy in vivo, their administration did not alter locomotor recovery after SCI. To directly analyze the role of autophagy, transgenic mice with conditional deletion of Atg5 in OLs were generated. Analysis of hindlimb locomotion demonstrated a significant reduction in locomotor recovery after SCI that correlated with a greater loss in spared white matter. Immunohistochemical analysis demonstrated that deletion of Atg5 from OLs resulted in decreased autophagic flux and was detrimental to OL function after SCI. Thus, our study provides evidence that autophagy is an essential cytoprotective pathway operating in OLs and is required for hindlimb locomotor recovery after thoracic SCI.	[Ohri, Sujata Saraswat; Bankston, Andrew N.; Mullins, S. Ashley; Liu, Yu; Andres, Kariena R.; Beare, Jason E.; Howard, Russell M.; Burke, Darlene A.; Riegler, Amberly S.; Smith, Allison E.; Hetman, Michal; Whittemore, Scott R.] Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; [Ohri, Sujata Saraswat; Bankston, Andrew N.; Mullins, S. Ashley; Liu, Yu; Andres, Kariena R.; Howard, Russell M.; Burke, Darlene A.; Riegler, Amberly S.; Smith, Allison E.; Hetman, Michal; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; [Hetman, Michal; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; [Hetman, Michal; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; [Beare, Jason E.] Univ Louisville, Sch Med, Cardiovasc Innovat Inst, Louisville, KY 40292 USA	Ohri, SS (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, MDR 616,511 South Floyd St, Louisville, KY 40202 USA.	sujata.saraswat@louisville.edu; swhittemore@louisville.edu	Beare, Jason E/D-2870-2016	Beare, Jason E/0000-0003-3988-1223; Smith, Allison/0000-0001-5659-8062	NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045734]; NIH-NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM10350]; Norton Healthcare; Kentucky Spinal Cord and Head Injury Research Trust; Commonwealth of Kentucky Research Challenge for Excellence Trust Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045734] Funding Source: NIH RePORTER	This work was supported by NIH-NINDS NS045734, NIH-NIGMS GM10350, Norton Healthcare, the Kentucky Spinal Cord and Head Injury Research Trust, and Commonwealth of Kentucky Research Challenge for Excellence Trust Fund to S. R. W. We thank Christine Nunn for surgical assistance and animal care; and Johnny Morehouse for BMS analyses.	Alluin O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111072; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Bareyre FM, 2008, J NEUROL SCI, V265, P63, DOI 10.1016/j.jns.2007.05.004; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bercury KK, 2014, J NEUROSCI, V34, P4466, DOI 10.1523/JNEUROSCI.4314-13.2014; Cai ZB, 2015, NEUROSCI BULL, V31, P452, DOI 10.1007/s12264-015-1540-x; Cao L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.317; Chen HC, 2013, J SURG RES, V179, pE203, DOI 10.1016/j.jss.2012.02.023; Coutts M, 2008, EXP NEUROL, V209, P368, DOI 10.1016/j.expneurol.2007.09.002; D'Antonio M, 2009, J NEUROSCI RES, V87, P3241, DOI 10.1002/jnr.22066; Dietz V, 2014, BRAIN, V137, P654, DOI 10.1093/brain/awt262; Dincman TA, 2012, J NEUROSCI METH, V209, P219, DOI 10.1016/j.jneumeth.2012.06.017; Doerflinger NH, 2003, GENESIS, V35, P63, DOI 10.1002/gene.10154; Emery B, 2010, CURR OPIN NEUROBIOL, V20, P601, DOI 10.1016/j.conb.2010.05.005; Enzmann GU, 2006, J NEUROTRAUM, V23, P479, DOI 10.1089/neu.2006.23.479; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014; Fawcett JW, 2006, ADV EXP MED BIOL, V557, P11; Fuss B, 2001, MOL CELL NEUROSCI, V18, P221, DOI 10.1006/mcne.2001.1011; Gomez-Sanchez JA, 2015, J CELL BIOL, V210, P153, DOI 10.1083/jcb.201503019; Grummisch JA, 2016, MOL CELL NEUROSCI, V74, P25, DOI 10.1016/j.mcn.2016.03.005; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; He Z, 2008, CELL DEATH DIFFER, V20, P1415; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Jang SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116624; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kulbatski I, 2008, PROG HISTOCHEM CYTO, V43, P123, DOI 10.1016/j.proghi.2008.04.001; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larocca JN, 2006, CURR PROTOC CELL BIO, V33; Lebrun-Julien F, 2014, J NEUROSCI, V34, P8432, DOI 10.1523/JNEUROSCI.1105-14.2014; Lin WS, 2009, NAT NEUROSCI, V12, P379, DOI 10.1038/nn.2273; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Liu S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.527; Lv XH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06010; Magnuson DSK, 2005, J NEUROTRAUM, V22, P529, DOI 10.1089/neu.2005.22.529; Mallon BS, 2002, J NEUROSCI, V22, P876, DOI 10.1523/JNEUROSCI.22-03-00876.2002; Marino G, 2011, CURR OPIN CELL BIOL, V23, P198, DOI 10.1016/j.ceb.2010.10.001; Messer JS, 2017, CELL MOL LIFE SCI, V74, P1281, DOI 10.1007/s00018-016-2403-y; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Narayanan SP, 2009, J NEUROSCI, V29, P6860, DOI 10.1523/JNEUROSCI.0232-09.2009; Ohri SS, 2013, NEUROBIOL DIS, V58, P29, DOI 10.1016/j.nbd.2013.04.021; Ohri SS, 2011, GLIA, V59, P1489, DOI 10.1002/glia.21191; Penas C, 2007, J NEUROCHEM, V102, P1242, DOI 10.1111/j.1471-4159.2007.04671.x; Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524; Pla A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153097; Radad K, 2015, EXPERT REV NEUROTHER, V15, P195, DOI 10.1586/14737175.2015.1002087; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Shen CZ, 2016, EXP THER MED, V12, P2803, DOI 10.3892/etm.2016.3736; Shi XD, 2017, J CEREBR BLOOD F MET, V37, P1447, DOI 10.1177/0271678X16656201; Simons M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a020479; Su P, 2016, NEUROSCIENCE, V319, P155, DOI 10.1016/j.neuroscience.2016.01.035; Tanabe F, 2011, AUTOPHAGY, V7, P1462, DOI 10.4161/auto.7.12.17892; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Tyler WA, 2009, J NEUROSCI, V29, P6367, DOI 10.1523/JNEUROSCI.0234-09.2009; Valenzuela V, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.8; Vazquez P, 2012, AUTOPHAGY, V8, P187, DOI 10.4161/auto.8.2.18535; Wahl SE, 2014, J NEUROSCI, V34, P4453, DOI 10.1523/JNEUROSCI.4311-13.2014; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Wang SK, 2014, EMBO REP, V15, P1053, DOI 10.15252/embr.201338343; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; WIGHT PA, 1993, J CELL BIOL, V123, P443, DOI 10.1083/jcb.123.2.443; Williams A, 2006, CURR TOP DEV BIOL, V76, P89, DOI 10.1016/S0070-2153(06)76003-3; Yin Y, 2017, AGEING RES REV, V34, P3, DOI 10.1016/j.arr.2016.08.008; Yoon C, 2012, ADV EXP MED BIOL, V760, P1; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051	79	21	21	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 27	2018	38	26					5900	5912		10.1523/JNEUROSCI.0679-17.2018			13	Neurosciences	Neurosciences & Neurology	GM7MO	WOS:000438372400008	29793971	Green Published, Bronze			2021-06-18	
J	Jha, RM; Molyneaux, BJ; Jackson, TC; Wallisch, JS; Park, SY; Poloyac, S; Vagni, VA; Janesko-Feldman, KL; Hoshitsuki, K; Minnigh, MB; Kochanek, PM				Jha, Ruchira M.; Molyneaux, Bradley J.; Jackson, Travis C.; Wallisch, Jessica S.; Park, Seo-Young; Poloyac, Samuel; Vagni, Vincent A.; Janesko-Feldman, Keri L.; Hoshitsuki, Keito; Minnigh, M. Beth; Kochanek, Patrick M.			Glibenclamide Produces Region-Dependent Effects on Cerebral Edema in a Combined Injury Model of Traumatic Brain Injury and Hemorrhagic Shock in Mice	JOURNAL OF NEUROTRAUMA			English	Article						cerebral edema; glibenclamide/glyburide; HS; Sur1; TBI	CONTROLLED CORTICAL IMPACT; NONSELECTIVE CATION CHANNEL; SULFONYLUREA RECEPTOR 1; SEVERE HEAD-INJURY; REACTIVE ASTROCYTES; RESUSCITATION; CONTUSION; ISCHEMIA; DAMAGE; ATP	Cerebral edema is critical to morbidity/mortality in traumatic brain injury (TBI) and is worsened by hypotension. Glibenclamide may reduce cerebral edema by inhibiting sulfonylurea receptor-1 (Sur1); its effect on diffuse cerebral edema exacerbated by hypotension/resuscitation is unknown. We aimed to determine if glibenclamide improves pericontusional and/or diffuse edema in controlled cortical impact (CCI) (5m/sec, 1mm depth) plus hemorrhagic shock (HS) (35min), and compare its effects in CCI alone. C57BL/6 mice were divided into five groups (n=10/group): naive, CCI+vehicle, CCI+glibenclamide, CCI+HS+vehicle, and CCI+HS+glibenclamide. Intravenous glibenclamide (10min post-injury) was followed by a subcutaneous infusion for 24h. Brain edema in injured and contralateral hemispheres was subsequently quantified (wet-dry weight). This protocol brain water (BW)=80.4% vehicle vs. 78.3% naive, p<0.01) but was not reduced by glibenclamide (I%BW=80.4%). Ipsilateral edema also developed in CCI alone (I%BW=80.2% vehicle vs. 78.3% naive, p<0.01); again unaffected by glibenclamide (I%BW=80.5%). Contralateral (C) %BW in CCI+HS was increased in vehicle (78.6%) versus naive (78.3%, p=0.02) but unchanged in CCI (78.3%). At 24h, glibenclamide treatment in CCI+HS eliminated contralateral cerebral edema (C%BW=78.3%) with no difference versus naive. By 72h, contralateral cerebral edema had resolved (C%BW=78.5 +/- 0.09% vehicle vs. 78.3 +/- 0.05% naive). Glibenclamide decreased 24h contralateral cerebral edema in CCI+HS. This beneficial effect merits additional exploration in the important setting of TBI with polytrauma, shock, and resuscitation. Contralateral edema did not develop in CCI alone. Surprisingly, 24h of glibenclamide treatment failed to decrease ipsilateral edema in either model. Interspecies dosing differences versus prior studies may play an important role in these findings. Mechanisms underlying brain edema may differ regionally, with pericontusional/osmolar swelling refractory to glibenclamide but diffuse edema (via Sur1) from combined injury and/or resuscitation responsive to this therapy. TBI phenotype may mandate precision medicine approaches to treat brain edema.	[Jha, Ruchira M.; Molyneaux, Bradley J.; Jackson, Travis C.; Wallisch, Jessica S.; Vagni, Vincent A.; Janesko-Feldman, Keri L.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Jha, Ruchira M.; Molyneaux, Bradley J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Molyneaux, Bradley J.] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Park, Seo-Young] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Poloyac, Samuel; Hoshitsuki, Keito; Minnigh, M. Beth] Univ Pittsburgh, Sch Med, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesia, Pittsburgh, PA USA; [Jha, Ruchira M.; Jackson, Travis C.; Wallisch, Jessica S.; Vagni, Vincent A.; Janesko-Feldman, Keri L.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Jha, Ruchira M.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA; [Park, Seo-Young] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA	Jha, RM (corresponding author), Univ Pittsburgh, Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	jharm3@upmc.edu	Hoshitsuki, Keito/F-9429-2019	Hoshitsuki, Keito/0000-0002-6723-0711; Wallisch, Jessica/0000-0002-7908-9479	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T-32HL007820, KL2 TR000146, KL2-TR001856, K23NS101036, T32 HD040686, R01 NS087978]; United States Department of DefenseUnited States Department of Defense [W81XWH-10-1-0623, W81XWH-14-2-0018]; UPP Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001856] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS101036, R01NS087978] Funding Source: NIH RePORTER	We are grateful for National Institutes of Health (NIH) grants: T-32HL007820 (R.M.J.), KL2 TR000146 (R.M.J.), KL2-TR001856 (R.M.J.), K23NS101036 (R.M.J.), T32 HD040686 (J.S.W.), and R01 NS087978 (P.M.K.) for providing generous support. We are also grateful for United States Department of Defense grants W81XWH-10-1-0623 (P.M.K.) and W81XWH-14-2-0018 (P.M.K.) for providing generous support. We are also grateful to the UPP Foundation Grant for its generous support (RMJ).	Brockman EC, 2013, J CEREBR BLOOD F MET, V33, P1457, DOI 10.1038/jcbfm.2013.104; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Chen JQ, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.898190; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Feldmann H, 1979, Acta Neurochir Suppl (Wien), V28, P74; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Huang KB, 2015, CRIT CARE MED, V43, pE341, DOI 10.1097/CCM.0000000000001093; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Jha R., 2016, CRIT CARE MED, V45, pe255; Jha R, 2015, J NEUROTRAUM, V32, pA119; Katayama Y, 1998, ACT NEUR S, V71, P289; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Krieg SM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00455; Krieg SM, 2017, J NEUROTRAUM, V34, P1329, DOI 10.1089/neu.2016.4514; Krieg SM, 2015, J NEUROTRAUM, V32, P221, DOI 10.1089/neu.2013.3274; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Langfitt T W, 1966, W V Med J, V62, P49; LANGFITT THOMAS W., 1964, TRANS AMER NEUROL ASS, V89, P214; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liang FY, 2015, NEUROSCI LETT, V598, P29, DOI 10.1016/j.neulet.2015.05.006; Lopez-Rodriguez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128782; Makar TK, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0432-3; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; McBride DW, 2014, J NEUROTRAUM, V31, P1948, DOI 10.1089/neu.2014.3439; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Munoz A, 2003, STROKE, V34, P164, DOI 10.1161/01.STR.0000048215.36747.D1; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nagata K, 2016, J TRAUMA ACUTE CARE, V81, P1088, DOI 10.1097/TA.0000000000001215; Naraharisetti SB, 2007, J CHROMATOGR B, V860, P34, DOI 10.1016/j.jchromb.2007.10.010; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Ortega FJ, 2012, EXP NEUROL, V235, P282, DOI 10.1016/j.expneurol.2012.02.010; Ortega FJ, 2013, J CEREBR BLOOD F MET, V33, P356, DOI 10.1038/jcbfm.2012.166; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Portella G, 2000, ACT NEUR S, V76, P273; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schattling B, 2012, NAT MED, V18, P1805, DOI 10.1038/nm.3015; SCHUTTA HS, 1968, BRAIN, V91, P281, DOI 10.1093/brain/91.2.281; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2014, NEUROCRIT CARE, V20, P319, DOI 10.1007/s12028-013-9923-1; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Teng ZP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06932-3; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; Tress EE, 2014, NEUROSCI LETT, V578, P17, DOI 10.1016/j.neulet.2014.06.020; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Xu ZM, 2017, J NEUROTRAUM, V34, P925, DOI 10.1089/neu.2016.4491; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675; Zafardoost P, 2016, TRAUMA MON, V21, DOI 10.5812/traumamon.25113; Zhang MA, 2016, ENERGY STORAGE MATER, V4, P1, DOI 10.1016/j.ensm.2016.02.001; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	84	21	22	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2018	35	17					2125	2135		10.1089/neu.2016.4696		JUN 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GQ7LU	WOS:000434471100001	29648981	Green Published			2021-06-18	
J	Chenoweth, JA; Gaona, SD; Faul, M; Holmes, JF; Nishijima, DK				Chenoweth, James A.; Gaona, Samuel D.; Faul, Mark; Holmes, James F.; Nishijima, Daniel K.		Sacramento County Prehosp Res Co	Incidence of Delayed Intracranial Hemorrhage in Older Patients After Blunt Head Trauma	JAMA SURGERY			English	Article							PRESCRIPTION ANTIPLATELET AGENTS; BRAIN-INJURY; PREINJURY ANTICOAGULANTS; CLOPIDOGREL USE; WARFARIN; MANAGEMENT; GUIDELINE; RISK	IMPORTANCE Current guidelines conflict on the management of older adults who have blunt head trauma taking anticoagulant and antiplatelet medications. This is partially due to the limited data comparing patients who are taking these medications with those who are not. OBJECTIVE To investigate the incidence of delayed traumatic intracranial hemorrhage in older adults with head trauma, including those taking anticoagulant and antiplatelet medications. DESIGN, SETTING, AND PARTICIPANTS This prospective observational cohort study included patients 55 years and older who had blunt head trauma and were transported via emergency medical services between August 1, 2015, and September 30, 2016. The setting was a multicenter study conducted at 11 hospitals in northern California. Patients were excluded if they had traumatic intracranial hemorrhage on the initial cranial computed tomographic scan, did not have a cranial computed tomographic scan performed at the initial emergency department visit, refused consent for a follow-up telephone call, or did not have reliable means of follow-up. MAIN OUTCOME AND MEASURE The primary outcome of this study Was the incidence of delayed traumatic intracranial hemorrhage within 14 days of injury. RESULTS Among 859 patients enrolled in the study, the median age was 75 years (interquartile range, 64-85 years), and 389 (45.3%) were male. A total of 343 patients (39.9%) were taking an anticoagulant or antiplatelet medication. Three patients (0.3%; 95% CI, 0.1%-1.0%) had a delayed traumatic intracranial hemorrhage. Of the 3 patients, 1of 75 patients (1.3%; 95% CI, 0.0%-7.2%) who were taking warfarin sodium alone and 2 of 516 patients (0.4%; 95% CI, 0.1%14%) who were not taking any anticoagulant or antiplatelet medication had a delayed traumatic intracranial hemorrhage. Thirty-nine patients (4.5%; 95% CI, 3.2%-6.2%) were lost to follow-up. CONCLUSIONS AND RELEVANCE Overall, the incidence of delayed intracranial hemorrhage in older adults who have blunt head trauma is low, including patients taking an anticoagulant or antiplatelet medication. These findings suggest that routine observation and serial cranial computed tomography may not be necessary in these patients.	[Chenoweth, James A.; Gaona, Samuel D.; Holmes, James F.; Nishijima, Daniel K.] Univ Calif Davis, Sch Med, Dept Emergency Med, 4150 V St,Patient Support Serv Bldg Ste 2100, Sacramento, CA 95817 USA; [Faul, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA	Chenoweth, JA (corresponding author), Univ Calif Davis, Sch Med, Dept Emergency Med, 4150 V St,Patient Support Serv Bldg Ste 2100, Sacramento, CA 95817 USA.	jachenoweth@ucdavis.edu	Chenoweth, James/AAP-4537-2021; Chenoweth, James/AAN-9965-2021	Chenoweth, James/0000-0001-9537-0116; Faul, Mark/0000-0002-7683-0348	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01CE002177]; Mentored Clinical Research Training Program Award from the National Center for Advancing Translational Sciences, National Institutes of Health [UL1TR000002, KL2TR000134]	This work was funded by grant U01CE002177 from the Centers for Disease Control and Prevention. Dr Nishijima was supported through a Mentored Clinical Research Training Program Award (grant UL1TR000002 and linked award KL2TR000134) from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health	Quintero-Gonzalez JA, 2010, INVEST CLIN, V51, P269; American College of Surgeons Trauma Quality Improvement Program, ACS TQIP BEST PRACT; Barnes GD, 2015, AM J MED, V128, P1300, DOI 10.1016/j.amjmed.2015.05.044; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Chung Pearl, 2015, J Med Case Rep, V9, P173, DOI 10.1186/s13256-015-0652-2; Desai NR, 2014, AM J MED, V127, P1075, DOI 10.1016/j.amjmed.2014.05.013; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; Menditto VG, 2012, ANN EMERG MED, V59, P451, DOI 10.1016/j.annemergmed.2011.12.003; Miller J, 2015, J TRAUMA ACUTE CARE, V79, P310, DOI 10.1097/TA.0000000000000725; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Ostini R, 2008, PHARMACOEPIDEM DR S, V17, P1077, DOI 10.1002/pds.1638; Peck KA, 2014, J TRAUMA ACUTE CARE, V76, P431, DOI 10.1097/TA.0000000000000107; Peck KA, 2011, J TRAUMA, V71, P1600, DOI 10.1097/TA.0b013e31823b9ce1; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	19	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	JUN	2018	153	6					570	575		10.1001/jamasurg.2017.6159			6	Surgery	Surgery	GJ8PU	WOS:000435653000019	29450470	Green Published, Bronze			2021-06-18	
J	Ezaz, G; Murphy, SL; Mellinger, J; Tapper, EB				Ezaz, Ghideon; Murphy, Susan L.; Mellinger, Jessica; Tapper, Elliot B.			Increased Morbidity and Mortality Associated with Falls Among Patients with Cirrhosis	AMERICAN JOURNAL OF MEDICINE			English	Article						Emergency medicine; Hepatic encephalopathy; Intracranial hemorrhage; Liver disease	HOSPITALIZED-PATIENTS; VITAMIN-D; RISK; INJURIES; PREDICTORS	BACKGROUND: Injuries are more morbid and complicated to manage in patients with cirrhosis. However, data are limited regarding the relative risk of injury and severity of injury from falls in patients with cirrhosis compared with those without cirrhosis. METHODS: We examined the nationally representative National Emergency Department Sample, an all-payer database including all patients presenting with falls, 2009-2012. We determined the relative risks for and clinical associations with severe injuries. Outcomes included hospitalization, length of stay, costs, and in-hospital death. Outcomes were compared with those of patients with congestive heart failure. RESULTS: We identified 102,977 visits involving patients with cirrhosis and 26,996,120 involving patients without cirrhosis who presented with a fall. Overall and compared with patients with congestive heart failure, the adjusted risk of severe injury was higher for patients with cirrhosis. These included intracranial hemorrhage (2.33; 95% confidence interval [CI], 2.02-2.68), skull fracture (1.75; 95% CI, 1.53-2.00), and pelvic fracture (1.71; 95% CI, 1.56-1.88). Risk was lower for less-severe injuries, such as concussion (0.95; 95% CI, 0.86-1.06) and lower-leg fracture (0.86; 95% CI, 0.80-0.91). Risk factors significantly positively associated with severe injury on multivariate analysis were hepatic encephalopathy, alcohol abuse, and infection. Cirrhosis was associated with increased risk of in-hospital death, longer length of stay, and higher costs after a fall. All outcomes were worse compared with those for patients with congestive heart failure CONCLUSION: Falls are common in patients with cirrhosis, and they are more likely to incur severe injuries, with increased hospital costs and risk of death. Poor outcomes are most associated with ascites, hepatic encephalopathy, alcohol abuse, and infection, highlighting the subgroups at highest risk and most likely to benefit from preventative interventions. (C) 2018 Elsevier Inc. All rights reserved.	[Ezaz, Ghideon] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Gastroenterol & Hepatol, Boston, MA USA; [Murphy, Susan L.; Tapper, Elliot B.] Vet Affairs Hosp, Ann Arbor, MI USA; [Murphy, Susan L.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Mellinger, Jessica; Tapper, Elliot B.] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA; [Mellinger, Jessica; Tapper, Elliot B.] Inst Healthcare Policy & Innovat, Ann Arbor, MI USA	Tapper, EB (corresponding author), Univ Michigan, Sch Med, Dept Med, Div Gastroenterol & Hepatol, 3912 Taubman,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	etapper@umich.edu					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BATES DW, 1995, AM J MED, V99, P137, DOI 10.1016/S0002-9343(99)80133-8; Beste LA, 2015, GASTROENTEROLOGY, V149, P1471, DOI 10.1053/j.gastro.2015.07.056; Bischoff-Ferrari HA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3692; Cohen SM, 2005, J ARTHROPLASTY, V20, P460, DOI 10.1016/j.arth.2004.05.004; Cook WL, 2006, CLIN J AM SOC NEPHRO, V1, P1197, DOI 10.2215/CJN.01650506; Horan JM, 2003, EPIDEMIOL REV, V25, P24, DOI 10.1093/epirev/mxg010; Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x; Janssen HCJP, 2002, AM J CLIN NUTR, V75, P611; Mathur AK, 2017, WORLD J GASTROENTERO, V23, P1857, DOI 10.3748/wjg.v23.i10.1857; Nehra MS, 2013, J CLIN GASTROENTEROL, V47, pE50, DOI 10.1097/MCG.0b013e3182688d2f; Palmer CS, 2016, INJURY, V47, P109, DOI 10.1016/j.injury.2015.07.003; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Roman E, 2011, AM J GASTROENTEROL, V106, P476, DOI 10.1038/ajg.2010.413; Schwartz AV, 2002, DIABETES CARE, V25, P1749, DOI 10.2337/diacare.25.10.1749; Soriano G, 2012, HEPATOLOGY, V55, P1922, DOI 10.1002/hep.25554; Stepanova M, 2017, CLIN GASTROENTEROL H, V15, P759, DOI 10.1016/j.cgh.2016.07.020; Tapper EB, 2015, CLIN GASTROENTEROL H, V13, P1670, DOI 10.1016/j.cgh.2015.03.019; Tapper EB, 2015, HEPATOLOGY, V62, P584, DOI 10.1002/hep.27830; Tapper EB, 2015, MAYO CLIN PROC, V90, P646, DOI 10.1016/j.mayocp.2015.03.003; Teh SH, 2007, GASTROENTEROLOGY, V132, P1261, DOI 10.1053/j.gastro.2007.01.040; Tromp AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895-4356(01)00349-3	22	21	22	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	JUN	2018	131	6					645	+		10.1016/j.amjmed.2018.01.026			8	Medicine, General & Internal	General & Internal Medicine	GG7JS	WOS:000432874900040	29453941				2021-06-18	
J	Lepage, C; de Pierrefeu, A; Koerte, IK; Coleman, MJ; Pasternak, O; Grant, G; Marx, CE; Morey, RA; Flashman, LA; George, MS; McAllister, TW; Andaluz, N; Shutter, L; Coimbra, R; Zafonte, RD; Stein, MB; Shenton, ME; Bouix, S				Lepage, Christian; de Pierrefeu, Amicie; Koerte, Inga K.; Coleman, Michael J.; Pasternak, Ofer; Grant, Gerald; Marx, Christine E.; Morey, Rajendra A.; Flashman, Laura A.; George, Mark S.; McAllister, Thomas W.; Andaluz, Norberto; Shutter, Lori; Coimbra, Raul; Zafonte, Ross D.; Stein, Murray B.; Shenton, Martha E.; Bouix, Sylvain			White matter abnormalities in mild traumatic brain injury with and without post-traumatic stress disorder: a subject-specific diffusion tensor imaging study	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury; Post-traumatic stress disorder; Diffusion tensor imaging; Fractional anisotropy; Magnetic resonance imaging	CONCUSSION SYMPTOMS QUESTIONNAIRE; POSTCONCUSSION SYMPTOMS; AXONAL INJURY; HEAD-INJURY; VETERANS; VALIDITY; METAANALYSIS; DEPRESSION; ANISOTROPY; RELIABILITY	Mild traumatic brain injuries (mTBIs) are often associated with posttraumatic stress disorder (PTSD). In cases of chronic mTBI, accurate diagnosis can be challenging due to the overlapping symptoms this condition shares with PTSD. Furthermore, mTBIs are heterogeneous and not easily observed using conventional neuroimaging tools, despite the fact that diffuse axonal injuries are the most common injury. Diffusion tensor imaging (DTI) is sensitive to diffuse axonal injuries and is thus more likely to detect mTBIs, especially when analyses account for the inter-individual variability of these injuries. Using a subject-specific approach, we compared fractional anisotropy (FA) abnormalities between groups with a history of mTBI (n = 35), comorbid mTBI and PTSD (mTBI + PTSD; n = 22), and healthy controls (n = 37). We compared all three groups on the number of abnormal FA clusters derived from subject-specific injury profiles (i.e., individual z-score maps) along a common white matter skeleton. The mTBI + PTSD group evinced a greater number of abnormally low FA clusters relative to both the healthy controls and the mTBI group without PTSD (p < .05). Across the groups with a history of mTBI, increased numbers of abnormally low FA clusters were significantly associated with PTSD symptom severity, depression, post-concussion symptoms, and reduced information processing speed (p < .05). These findings highlight the utility of subject-specific microstructural analyses when searching for mTBI-related brain abnormalities, particularly in patients with PTSD. This study also suggests that patients with a history of mTBI and comorbid PTSD, relative to those without PTSD, are at increased risk of FA abnormalities.	[Lepage, Christian; de Pierrefeu, Amicie; Koerte, Inga K.; Coleman, Michael J.; Pasternak, Ofer; Shenton, Martha E.; Bouix, Sylvain] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA; [Lepage, Christian] Univ Ottawa, Dept Psychol, Ottawa, ON, Canada; [de Pierrefeu, Amicie] Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland; [Koerte, Inga K.] Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Grant, Gerald] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA; [Grant, Gerald] Duke Univ, Durham, NC USA; [Marx, Christine E.; Morey, Rajendra A.] Duke Univ, Med Ctr, Durham, NC USA; [Marx, Christine E.; Morey, Rajendra A.] VA Mid Atlantic MIRECC, Durham, NC USA; [Flashman, Laura A.; McAllister, Thomas W.] Geisel Sch Med Dartmouth, Hanover, NH USA; [George, Mark S.] Med Univ South Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Andaluz, Norberto] Univ Cincinnati, Coll Med, Dept Neurosurg, Mayfield Clin,Neurotrauma Ctr,UC Neurosci Inst, Cincinnati, OH 45267 USA; [Shutter, Lori] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Shutter, Lori] Univ Cincinnati, Pittsburgh, PA USA; [Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Zafonte, Ross D.] Brigham & Womens Hosp, Massachusetts Gen Hosp, Spaulding Rehabil Hosp, 75 Francis St, Boston, MA 02115 USA; [Zafonte, Ross D.; Shenton, Martha E.] Harvard Med Sch, Boston, MA USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Shenton, Martha E.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA	Bouix, S (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	sylvain@bwh.harvard.edu	Shenton, Martha/V-8780-2019; Shutter, Lori A/G-2957-2013; Morey, Rajendra A/P-3079-2018; Coimbra, Raul/AAP-3019-2020	Morey, Rajendra A/0000-0002-6517-6969; Coimbra, Raul/0000-0002-3759-6851; Shutter, Lori/0000-0002-1390-0628; George, Mark/0000-0003-1767-1815; Lepage, Chris/0000-0001-5719-0982	Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Award;  [W81XWH-08-2-0159]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD090641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER	CL was supported by the Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Award, which was awarded in support of his PhD in clinical psychology from the University of Ottawa. The authors would like to acknowledge the following grants that, in part, supported this work: W81XWH-08-2-0159 (Imaging core PI: Shenton, Consortium PI: Stein, Site PIs: George, Grant, Marx, McAllister, and Zafonte).	Aoki Y, 2016, NEUROSCI BIOBEHAV R, V66, P119, DOI 10.1016/j.neubiorev.2016.04.021; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Army US, 1944, ARMY INDIVIDUAL TEST; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delic J, 2016, RADIOLOGY, V279, P859, DOI 10.1148/radiol.2015151388; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ginzburg K, 2010, J AFFECT DISORDERS, V123, P249, DOI 10.1016/j.jad.2009.08.006; Helmer K. G., 2016, SPIE MED IMAGING; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLM S, 1979, SCAND J STAT, V6, P65; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Mirzaalian H, 2016, NEUROIMAGE, V135, P311, DOI 10.1016/j.neuroimage.2016.04.041; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mounce LTA, 2013, J HEAD TRAUMA REHAB, V28, P397, DOI 10.1097/HTR.0b013e318252dd75; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Sartory G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058150; SHEEHAN DV, 1998, J CLIN PSYCHIAT S20, V59, P1; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tsourtos G, 2002, PSYCHOL MED, V32, P259, DOI 10.1017/S0033291701005001; Watts R, 2014, RADIOLOGY, V272, P217, DOI 10.1148/radiol.14131856; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wrocklage KM, 2016, J INT NEUROPSYCH SOC, V22, P399, DOI 10.1017/S1355617716000059	55	21	21	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2018	12	3					870	881		10.1007/s11682-017-9744-5			12	Neuroimaging	Neurosciences & Neurology	GI6PB	WOS:000434491400023	28676987	Green Accepted			2021-06-18	
J	Ringer, FB; Soberay, KA; Rogers, ML; Hagan, CR; Chu, C; Schneider, M; Podlogar, MC; Witte, T; Holm-Denoma, J; Plant, EA; Gutierrez, PM; Joiner, TE				Ringer, Fallon B.; Soberay, Kelly A.; Rogers, Megan L.; Hagan, Christopher R.; Chu, Carol; Schneider, Matt; Podlogar, Matthew C.; Witte, Tracy; Holm-Denoma, Jill; Plant, E. Ashby; Gutierrez, Peter M.; Joiner, Thomas E.			Initial Validation of Brief Measures of Suicide Risk Factors: Common Data Elements Used by the Military Suicide Research Consortium	PSYCHOLOGICAL ASSESSMENT			English	Article						military; risk assessment; suicidal ideation; suicidal behavior; suicide	TRAUMATIC BRAIN-INJURY; INTERPERSONAL-PSYCHOLOGICAL THEORY; PSYCHOMETRIC PROPERTIES; THWARTED BELONGINGNESS; ANXIETY SENSITIVITY; COMPLETED SUICIDE; PTSD CHECKLIST; SCREENING TOOL; INTENT-SCALE; YOUNG-ADULTS	The Military Suicide Research Consortium (MSRC) developed a 57-item questionnaire assessing suicide risk factors, referred to as the Common Data Elements (CDEs), in order to facilitate data sharing and improve collaboration across independent studies. All studies funded by MSRC are required to include the CDEs in their assessment protocol. The CDEs include shortened measures of the following: current and past suicide risk, lethality and intent of past suicide attempts, hopelessness, thwarted belongingness, anxiety sensitivity, posttraumatic stress disorder symptoms, traumatic brain injury, insomnia, and alcohol abuse. This study aimed to evaluate the psychometric properties of the CDE items drawn from empirically validated measures. Exploratory factor analysis was used to examine the overall structure of the CDE items, and confirmatory factor analyses were used to evaluate the distinct properties of each scale. Internal consistencies of the CDE scales and correlations with full measures were also examined. Merged data from 3,140 participants (81.0% military service members, 75.6% male) across 19 MSRCfunded studies were used in analyses. Results indicated that all measures exhibited adequate internal consistency, and all CDE shortened measures were significantly correlated with the corresponding full measures with moderate to strong effect sizes. Factor analyses indicated that the shortened CDE measures performed well in comparison with the full measures. Overall, our findings suggest that the CDEs are not only brief but also provide psychometrically valid scores when assessing suicide risk and related factors that may be used in future research.	[Ringer, Fallon B.; Rogers, Megan L.; Hagan, Christopher R.; Chu, Carol; Schneider, Matt; Podlogar, Matthew C.; Plant, E. Ashby; Joiner, Thomas E.] Florida State Univ, Dept Psychol, 1107 West Call St, Tallahassee, FL 32306 USA; [Soberay, Kelly A.; Gutierrez, Peter M.] Denver Vet Affairs Med Ctr, Educ & Clin Ctr, Rocky Mt Mental Illness Res, Denver, CO USA; [Witte, Tracy] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA; [Holm-Denoma, Jill] Univ Denver, Dept Psychol, Denver, CO 80208 USA; [Gutierrez, Peter M.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA	Ringer, FB (corresponding author), Florida State Univ, Dept Psychol, 1107 West Call St, Tallahassee, FL 32306 USA.	ringer@psy.fsu.edu	Rogers, Megan/AAC-1894-2021	Rogers, Megan/0000-0002-4969-7035; Ringer, Fallon/0000-0003-1426-6718	Military Suicide Research Consortium; Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-10-2-0181, W81XWH-10-2-0178]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH093311-04]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH093311] Funding Source: NIH RePORTER	This research was supported in part by a grant from the Military Suicide Research Consortium, an effort supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award W81XWH-10-2-0181 and W81XWH-10-2-0178. This research was also supported, in part, by a grant from the National Institute of Mental Health (T32 MH093311-04). Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Military Suicide Research Consortium, the Department of Defense, or the National Institute of Mental Health. We thank the following principal investigators (PIs) who provided the data presented in this article: Michael D. Anestis, PI of the study "Identifying Factors Associated with Future Suicidal Self-Directed Violence within a Sample of Mississippi National Guard Personnel"; Courtney Bagge and Ken Conner, PIs of the study "Warning Signs for Suicide Attempts"; Sean M. Barnes, PI of the study "Behaviorally Assessing Suicide Risk"; Rebecca A. Bernert, PI of the study "A Behavioral Sleep Intervention for the Prevention of Suicidal Behaviors in Military Veterans"; Nigel E. Bush, PI of the studies "Usability and Utility of a Virtual Hope Box (VHB) for Reducing Suicidal Ideation" and "Effectiveness of VHB Smartphone App in Enhancing Veteran's Coping with Suicidal Ideation"; Julie Cerel, PI of the study "Suicide Bereavement in Military and their Families"; Katherine A. Comtois, PI of the study "Military Continuity Project (MCP): A Suicide Prevention Study"; Jesse Cougle, PI of the study "Controlled Evaluation of a Computerized Anger-Reduction Treatment for Suicide Prevention"; Collin Davidson, PI of the study "Longitudinal Assessment of Physical Activity and Suicide Risk"; Peter M. Gutierrez and Thomas E. Joiner, PIs of the study "Toward a Gold Standard for Suicide Risk Assessment for Military Personnel"; Lori Johnson, PI of the study, "Suicide Risk Assessments within Suicide-Specific Group Therapy Treatment for Veterans"; Matthew K. Nock, PI of the study "New Approaches to the Measurement and Modification of Suicide-Related Cognition"; Brad Schmidt, PI of the study "Development and Evaluation of a Brief, Suicide Prevention Intervention Reducing Anxiety Sensitivity"; Gina M. Signoracci, PI of the study "Assessment of Cognitive Functioning as It Relates to Risk for Suicide in Veterans with HIV/AIDS"; and Deborah A. Yurgelun-Todd and Perry Renshaw, PIs of the study "Neuroimaging Correlates of Suicide."	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anestis MD, 2015, J CLIN PSYCHOL, V71, P1023, DOI 10.1002/jclp.22198; Anestis MD, 2015, COMPR PSYCHIAT, V60, P78, DOI 10.1016/j.comppsych.2015.03.006; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beck A., 1988, MANUAL BECK HOPELESS; Beck A.T., 1991, MANUAL BECK SCALE SU; Beck A.T., 1974, DEV SUICIDAL INTENT; BECK AT, 1988, J CLIN PSYCHOL, V44, P499, DOI 10.1002/1097-4679(198807)44:4<499::AID-JCLP2270440404>3.0.CO;2-6; BECK AT, 1990, AM J PSYCHIAT, V147, P190; BECK AT, 1985, AM J PSYCHIAT, V142, P559; BECK RW, 1974, PSYCHOL REP, V34, P445, DOI 10.2466/pr0.1974.34.2.445; Brenner LA, 2013, J HEAD TRAUMA REHAB, V28, P21, DOI 10.1097/HTR.0b013e31827df0b5; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943; Centers for Disease Control and Prevention, 2013, WEB BAS INJ STAT QUE; Chu C, 2016, J CLIN SLEEP MED, V12, P647, DOI 10.5664/jcsm.5784; Coll JE, 2011, SOC WORK HEALTH CARE, V50, P487, DOI 10.1080/00981389.2010.528727; Denneson LM, 2015, SUICIDE LIFE-THREAT, V45, P399, DOI 10.1111/sltb.12136; Gradus JL, 2010, AM J EPIDEMIOL, V171, P721, DOI 10.1093/aje/kwp456; Holma KM, 2010, AM J PSYCHIAT, V167, P801, DOI 10.1176/appi.ajp.2010.09050627; Hooper D., 2008, ELECT J BUSINESS RES, V6, P53, DOI DOI 10.1037/1082-989X.12.1.58; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Joiner TE, 2005, J ABNORM PSYCHOL, V114, P291, DOI 10.1037/0021-843X.114.2.291; Joiner TE, 2002, BEHAV RES THER, V40, P471, DOI 10.1016/S0005-7967(01)00017-1; Joiner TE, 2016, PSYCHOL REV, V123, P235, DOI 10.1037/rev0000020; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; LEVY P, 1967, J CLIN PSYCHOL, V23, P84, DOI 10.1002/1097-4679(196701)23:1<84::AID-JCLP2270230123>3.0.CO;2-2; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Meneses-Gaya Carolina de, 2009, Psychol. Neurosci., V2, P83, DOI 10.3922/j.psns.2009.1.12; Metalsky GI, 1997, COGNITIVE THER RES, V21, P359, DOI 10.1023/A:1021882717784; MIECZKOWSKI TA, 1993, SUICIDE LIFE-THREAT, V23, P37; Military Suicide Research Consortium, 2016, MISS AND GOALS; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; Oglesby ME, 2015, PSYCHIAT RES, V226, P252, DOI 10.1016/j.psychres.2014.12.057; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Pease JL, 2016, SOC WORK, V61, P83, DOI 10.1093/sw/swv050; Pigeon Wilfred R, 2012, J Clin Psychiatry, V73, pe1160, DOI 10.4088/JCP.11r07586; Ramchand R, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0575-z; Ribeiro JD, 2016, PSYCHOL MED, V46, P225, DOI 10.1017/S0033291715001804; Ribeiro JD, 2012, SUICIDE LIFE-THREAT, V42, P405, DOI 10.1111/j.1943-278X.2012.00099.x; Ribeiro JD, 2012, J AFFECT DISORDERS, V136, P743, DOI 10.1016/j.jad.2011.09.049; Schneider B, 2009, ARCH SUICIDE RES, V13, P303, DOI 10.1080/13811110903263191; Smolenski D. J., 2015, DEP DEFENSE SUICIDE; STROSAHL K, 1992, COMPR PSYCHIAT, V33, P366, DOI 10.1016/0010-440X(92)90057-W; Taylor S, 2007, PSYCHOL ASSESSMENT, V19, P176, DOI 10.1037/1040-3590.19.2.176; Van Orden KA, 2008, J CONSULT CLIN PSYCH, V76, P72, DOI 10.1037/0022-006X.76.1.72; Van Orden KA, 2012, PSYCHOL ASSESSMENT, V24, P197, DOI 10.1037/a0025358; Van Orden KA, 2010, PSYCHOL REV, V117, P575, DOI 10.1037/a0018697; Villatte Jennifer L, 2015, Mil Behav Health, V3, P316; Weathers F. W., 1993, ANN M INT SOC TRAUMA; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; World Health Organization, 2015, SUICIDE	57	21	21	1	6	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	JUN	2018	30	6					767	778		10.1037/pas0000519			12	Psychology, Clinical	Psychology	GH5YS	WOS:000433515100006	29130694	Green Accepted, Bronze			2021-06-18	
J	Ong, LK; Chow, WZ; Tebay, C; Kluge, M; Pietrogrande, G; Zalewska, K; Crock, P; Aberg, D; Bivard, A; Johnson, SJ; Walker, FR; Nilsson, M; Isgaard, J				Ong, Lin Kooi; Chow, Wei Zhen; Tebay, Clifford; Kluge, Murielle; Pietrogrande, Giovanni; Zalewska, Katarzyna; Crock, Patricia; Aberg, David; Bivard, Andrew; Johnson, Sarah J.; Walker, Frederick R.; Nilsson, Michael; Isgaard, Jorgen			Growth Hormone Improves Cognitive Function After Experimental Stroke	STROKE			English	Article						cognition; growth hormone; insulin-like growth factor-1; neuronal plasticity; stroke; vascular endothelial growth factor A; vascular remodeling	TRAUMATIC BRAIN-INJURY; STRESS-INDUCED DISRUPTION; FOCAL CEREBRAL-ISCHEMIA; PHOTOTHROMBOTIC STROKE; SECONDARY NEURODEGENERATION; REPLACEMENT THERAPY; GH REPLACEMENT; MICE; PERFORMANCE; POSTSTROKE	Background and Purpose-Cognitive impairment is a common outcome for stroke survivors. Growth hormone (GH) could represent a potential therapeutic option as this peptide hormone has been shown to improve cognition in various clinical conditions. In this study, we evaluated the effects of peripheral administration of GH at 48 hours poststroke for 28 days on cognitive function and the underlying mechanisms. Methods-Experimental stroke was induced by photothrombotic occlusion in young adult mice. We assessed the associative memory cognitive domain using mouse touchscreen platform for paired-associate learning task. We also evaluated neural tissue loss, neurotrophic factors, and markers of neuroplasticity and cerebrovascular remodeling using biochemical and histology analyses. Results-Our results show that GH-treated stroked mice made a significant improvement on the paired-associate learning task relative to non-GH-treated mice at the end of the study. Furthermore, we observed reduction of neural tissue loss in GH-treated stroked mice. We identified that GH treatment resulted in significantly higher levels of neurotrophic factors (IGF-1 [insulin-like growth factor-1] and VEGF [vascular endothelial growth factor]) in both the circulatory and peri-infarct regions. GH treatment in stroked mice not only promoted protein levels and density of presynaptic marker (SYN-1 [synapsin-1]) and marker of myelination (MBP [myelin basic protein]) but also increased the density and area coverage of 2 major vasculature markers (CD31 and collagen-IV), within the peri-infarct region. Conclusions-These findings provide compelling preclinical evidence for the usage of GH as a potential therapeutic tool in the recovery phase of patients after stroke. Visual Overview-An online visual overview is available for this article.	[Ong, Lin Kooi; Walker, Frederick R.; Nilsson, Michael; Isgaard, Jorgen] Univ Newcastle, Prior Res Ctr Stroke & Brain Injury, Callaghan, NSW, Australia; [Chow, Wei Zhen; Tebay, Clifford; Kluge, Murielle; Pietrogrande, Giovanni; Zalewska, Katarzyna] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia; [Crock, Patricia] Univ Newcastle, John Hunter Childrens Hosp, Prior Res Ctr Grow Well, Dept Paediat Endocrinol & Diabet, Callaghan, NSW, Australia; [Johnson, Sarah J.] Univ Newcastle, Sch Elect Engn & Comp, Callaghan, NSW, Australia; [Bivard, Andrew] Univ Newcastle, John Hunter Hosp, Dept Neurol, Callaghan, NSW, Australia; [Ong, Lin Kooi; Chow, Wei Zhen; Tebay, Clifford; Kluge, Murielle; Pietrogrande, Giovanni; Zalewska, Katarzyna; Bivard, Andrew; Johnson, Sarah J.; Walker, Frederick R.; Nilsson, Michael] Hunter Med Res Inst, New Lambton Hts, NSW 2305, Australia; [Ong, Lin Kooi; Walker, Frederick R.; Nilsson, Michael] Natl Hlth & Med Res Council Ctr Res Excellence St, New Lambton Hts, NSW, Australia; [Isgaard, Jorgen] Univ Gothenburg, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil, Gothenburg, Sweden; [Isgaard, Jorgen] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Internal Med, Gothenburg, Sweden	Ong, LK (corresponding author), Hunter Med Res Inst, New Lambton Hts, NSW 2305, Australia.; Isgaard, J (corresponding author), Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Internal Med, Gothenburg, Sweden.	jorgen.isgaard@medic.gu.se	Ong, Lin Kooi/H-2797-2012; NILSSON, MICHAEL/ABE-7821-2020; Aberg, N. David/O-4068-2019	Ong, Lin Kooi/0000-0001-8664-0540; NILSSON, MICHAEL/0000-0002-8826-1621; 	Swedish Government [ALFGBG 74 390]; University of Gothenburg; James S. McDonnell Foundation; Hunter Medical Research Institute; Brawn Bequest; Priority Research Centre for Stroke and Brain Injury Research Support Grant; Mary Costello Alzheimer's Pilot Grant; University of Newcastle, Australia	This study was supported by the Swedish Government (ALFGBG 74 390), University of Gothenburg, James S. McDonnell Foundation, Hunter Medical Research Institute, The Brawn Bequest, Priority Research Centre for Stroke and Brain Injury Research Support Grant, Mary Costello Alzheimer's Pilot Grant, and The University of Newcastle, Australia.	Aberg D, 2011, J CLIN ENDOCR METAB, V96, pE1055, DOI 10.1210/jc.2010-2802; Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Balkaya MG, 2018, BEHAV BRAIN RES, V352, P161, DOI 10.1016/j.bbr.2017.07.039; Barnett JH, 2016, CURR TOP BEHAV NEURO, V28, P449, DOI 10.1007/7854_2015_5001; Devesa J, 2016, CLIN MED INSIGHTS-EN, V9, P47, DOI 10.4137/CMEDED.S38201; Devesa J, 2013, HORM BEHAV, V63, P331, DOI 10.1016/j.yhbeh.2012.02.022; Diederich K, 2014, STROKE, V45, P614, DOI 10.1161/STROKEAHA.113.001907; Enhamre-Brolin E, 2013, BEHAV BRAIN RES, V238, P273, DOI 10.1016/j.bbr.2012.10.036; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Horner AE, 2013, NAT PROTOC, V8, P1961, DOI 10.1038/nprot.2013.122; Johnson SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10607; Kluge MG, 2017, GLIA, V65, P1885, DOI 10.1002/glia.23201; Kongsui R, 2015, NEUROSCIENCE, V310, P629, DOI 10.1016/j.neuroscience.2015.09.061; Kuhn HG, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a025981; Labat-gest V, 2013, JOVE-J VIS EXP, DOI 10.3791/50370; Lee DR, 2003, BRAIN RES, V989, P221, DOI 10.1016/S0006-8993(03)03373-0; Lee SC, 2010, EUR J NEUROL, V17, P45, DOI 10.1111/j.1468-1331.2009.02731.x; Levine DA, 2015, JAMA-J AM MED ASSOC, V314, P41, DOI 10.1001/jama.2015.6968; Moreau OK, 2013, J NEUROTRAUM, V30, P998, DOI 10.1089/neu.2012.2705; Nithianantharajah J, 2015, SCI REP-UK, V5, DOI 10.1038/srep14613; Nyberg F, 2013, NAT REV ENDOCRINOL, V9, P357, DOI 10.1038/nrendo.2013.78; Ong LK, 2017, J CEREBR BLOOD F MET, V37, P1338, DOI 10.1177/0271678X16654920; Ong LK, 2017, BRAIN BEHAV IMMUN, V60, P117, DOI 10.1016/j.bbi.2016.10.001; Pathipati P, 2009, BEHAV BRAIN RES, V204, P93, DOI 10.1016/j.bbr.2009.05.023; Reimunde P, 2011, BRAIN INJURY, V25, P65, DOI 10.3109/02699052.2010.536196; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Schmidt A, 2015, STROKE, V46, P1127, DOI 10.1161/STROKEAHA.115.008905; Shepherd A, 2016, J MOL NEUROSCI, V60, P371, DOI 10.1007/s12031-016-0837-1; Song J, 2012, ANN REHABIL MED-ARM, V36, P447, DOI 10.5535/arm.2012.36.4.447; Stochholm K, 2018, CLIN ENDOCRINOL, V88, P515, DOI 10.1111/cen.13502; Sun JH, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.05; Thoren AE, 2005, J CEREBR BLOOD F MET, V25, P440, DOI 10.1038/sj.jcbfm.9600035; Tynan RJ, 2013, ACTA NEUROPATHOL, V126, P75, DOI 10.1007/s00401-013-1102-0; Walker FR, 2014, J CEREBR BLOOD F MET, V34, P208, DOI 10.1038/jcbfm.2013.211; Walser M, 2011, GROWTH HORM IGF RES, V21, P16, DOI 10.1016/j.ghir.2010.11.002; Waters M J, 2011, Pediatr Endocrinol Rev, V9, P549; Weinstein G, 2014, INT J STROKE, V9, P48, DOI 10.1111/ijs.12275; Yanev P, 2017, J CEREBR BLOOD F MET, V37, P2768, DOI 10.1177/0271678X16674737; Zalewska K, 2017, BRAIN BEHAV IMMUN; Zalewska K, 2018, BRAIN BEHAV IMMUN, V69, P210, DOI 10.1016/j.bbi.2017.11.014; Zalewska K, 2017, NEUROSCIENCE, V352, P30, DOI 10.1016/j.neuroscience.2017.03.005; Zhang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108518; Zhao Z, 2017, CEREB BLOOD FLOW MET; Zhao ZD, 2017, J CEREBR BLOOD F MET, V37, P3709, DOI 10.1177/0271678X17696100	46	21	22	2	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	MAY	2018	49	5					1257	+		10.1161/STROKEAHA.117.020557			23	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	GD7AX	WOS:000430662100043	29636425	Bronze			2021-06-18	
J	Yoshihara-Hirata, C; Yamashiro, K; Yamamoto, T; Aoyagi, H; Ideguchi, H; Kawamura, M; Suzuki, R; Ono, M; Wake, H; Nishibori, M; Takashiba, S				Yoshihara-Hirata, Chiaki; Yamashiro, Keisuke; Yamamoto, Tadashi; Aoyagi, Hiroaki; Ideguchi, Hidetaka; Kawamura, Mari; Suzuki, Risa; Ono, Mitsuaki; Wake, Hidenori; Nishibori, Masahiro; Takashiba, Shogo			Anti-HMGB1 Neutralizing Antibody Attenuates Periodontal Inflammation and Bone Resorption in a Murine Periodontitis Model	INFECTION AND IMMUNITY			English	Article						periodontal disease; cytokine; infectious disease; molecular imaging; bone resorption	MOBILITY-GROUP BOX-1; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; EPITHELIAL-CELLS; HMGB1; PROTEIN; MICE; LOCALIZATION; PATHOGENESIS	High mobility group box 1 (HMGB1) is a non-histone DNA-binding protein that is secreted into the extracellular milieu in response to inflammatory stimuli. The secreted HMGB1 mediates various inflammatory diseases, including periodontitis; however, the underlying mechanisms of HMGB1-induced periodontal inflammation are not completely understood. Here, we examined whether anti-HMGB1 neutralizing antibody inhibits periodontal progression and investigated the molecular pathology of HMGB1 in vitro and in vivo. In vitro analysis indicated that HMGB1, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-1 beta (IL-1 beta) were secreted in response to tumor necrosis wfactor-alpha (TNF-alpha) stimuli in human gingival epithelial cells (HGECs) and human monocytic leukemia cells (THP-1) treated with phorbol myristate acetate. Increased levels of GM-CSF and IL-1 beta were observed in the conditioned media from TNF-alpha-stimulated HGECs and THP-1 in vitro. Simultaneous stimulation with TNF-alpha and anti-HMGB1 antibody significantly decreased TNF-alpha induced inflammatory cytokine secretion. Experimental periodontitis was induced in mice using Porphyromonas gingivalis-soaked ligatures. The extracellular translocation was confirmed in gingival epithelia in the periodontitis model mice by immunofluorescence analysis. Systemic administration of anti-HMGB1 neutralizing antibody significantly inhibited translocation of HMGB1. The anti-HMGB1 antibody inhibited periodontal inflammation, expression of IL-1 beta and C-X-C motif chemokine ligand 1 (CXCL1), migration of neutrophils, and bone resorption, shown by bioluminescence imaging of myeloperoxidase activity, quantitative reverse transcription-PCR (RT-PCR), and micro-computed tomography analysis. These findings indicate that HMGB1 is secreted in response to inflammatory stimuli caused by periodontal infection, which is crucial for the initiation of periodontitis, and the anti-HMGB1 antibody attenuates the secretion of a series of inflammatory cytokines, consequently suppressing the progression of periodontitis.	[Yoshihara-Hirata, Chiaki; Yamashiro, Keisuke; Yamamoto, Tadashi; Aoyagi, Hiroaki; Ideguchi, Hidetaka; Kawamura, Mari; Suzuki, Risa; Takashiba, Shogo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathophysiol Periodontal Sci, Okayama, Japan; [Ono, Mitsuaki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama, Japan; [Wake, Hidenori; Nishibori, Masahiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Okayama, Japan	Takashiba, S (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathophysiol Periodontal Sci, Okayama, Japan.	stakashi@okayama-u.ac.jp	YAMAMOTO, Tadashi/B-2213-2011; Yamashiro, Keisuke/B-2455-2011; Takashiba, Shogo/C-9830-2010	YAMAMOTO, Tadashi/0000-0001-7180-1567; Yamashiro, Keisuke/0000-0003-1208-892X; Takashiba, Shogo/0000-0002-4712-6829	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP 24792327]; Kobayashi Magobei Memorial Medical Foundation; Ryobi-Teien Foundation; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Japan AMED [H27 seeds B-8-1]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16H06994, 16K20670] Funding Source: KAKEN	This work was supported by research funds from a JSPS KAKENHI Grant-in-Aid for Young Scientists (B) (JP 24792327), the Kobayashi Magobei Memorial Medical Foundation, and the Ryobi-Teien Foundation, by a Grant-in-Aid for the COE projects by MEXT, Japan, entitled "Center of excellence for molecular and gene targeting therapies with micro-dose molecular imaging modalities," and by a Translational Research Network Program (no. H27 seeds B-8-1) from Japan AMED. We declare no potential conflicts of interest with respect to the authorship and/or publication of this article.	Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Andersson U, 2014, J INTERN MED, V276, P420, DOI 10.1111/joim.12309; Andersson U, 2004, J INTERN MED, V255, P344, DOI 10.1111/j.1365-2796.2003.01303.x; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; [Anonymous], 1999, J PERIODONTOL, V70, P457; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Nogueira AVB, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/816320; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002; Ebe N, 2011, J DENT RES, V90, P235, DOI 10.1177/0022034510385688; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; Jonsson D, 2009, INFLAMM RES, V58, P791, DOI 10.1007/s00011-009-0049-z; Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P2320, DOI 10.1161/01.ATV.0000145573.36113.8a; Kanellakis P, 2011, ARTERIOSCL THROM VAS, V31, P313, DOI 10.1161/ATVBAHA.110.218669; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Knorr M, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00295; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Morimoto Y, 2008, J PERIODONTAL RES, V43, P76, DOI 10.1111/j.1600-0765.2007.00996.x; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x; Suda K, 2010, SURG TODAY, V40, P592, DOI 10.1007/s00595-009-4232-1; Tseng JC, 2015, OPTICAL IMAGING IVIS; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Willenbrock S, 2012, CYTOKINE, V57, P210, DOI 10.1016/j.cyto.2011.11.011; Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zupan J, 2013, BIOCHEM MEDICA, V23, P43, DOI 10.11613/BM.2013.007	34	21	22	0	8	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0019-9567	1098-5522		INFECT IMMUN	Infect. Immun.	MAY	2018	86	5							e00111-18	10.1128/IAI.00111-18			11	Immunology; Infectious Diseases	Immunology; Infectious Diseases	GD6RY	WOS:000430637300029	29531138	Green Published, Bronze			2021-06-18	
J	Xie, BS; Wang, YQ; Lin, Y; Zhao, CC; Mao, Q; Feng, JF; Cao, JY; Gao, GY; Jiang, JY				Xie, Bao-shu; Wang, Yi-qin; Lin, Yong; Zhao, Cheng-cheng; Mao, Qing; Feng, Jun-feng; Cao, Jia-yu; Gao, Guo-yi; Jiang, Ji-yao			Circular RNA Expression Profiles Alter Significantly after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						circRNA; hippocampus; microarray; TBI	LONG NONCODING RNA; NEURONAL CELL-DEATH; MICRORNA EXPRESSION; MESSENGER-RNA; IN-VITRO; MIR-21; CORTEX; MILD; APOPTOSIS; IMPROVES	Circular RNAs (circRNAs) are involved in a variety of diseases. However, the roles of circRNAs in traumatic brain injury (TBI) remain unknown. In this study, circRNA microarray was used to profile the altered circRNAs in the rat hippocampus following TBI. A total of 192 circRNAs were observed to be differentially expressed (fold change [FC] >= 1.5 and p < 0.05) after TBI, including 98 upregulated and 94 downregulated. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis indicated that many messenger RNAs (mRNAs) transcribed from the host genes of altered circRNAs were implicated in brain damage and neural regeneration. CircRNA/microRNA (miRNA) interaction was predicted using Arraystar's homemade miRNA target prediction software based on TargetScan and miRanda. Thus, our studies have demonstrated altered circRNA expression pattern in the rat hippocampus after TBI, which may play important roles in post-TBI physiological and pathological processes. These findings may provide not only a new direction for studying the molecular mechanisms underlying TBI but also a new possibility for the treatment of TBI by modulating circRNAs.	[Xie, Bao-shu; Lin, Yong; Zhao, Cheng-cheng; Mao, Qing; Feng, Jun-feng; Cao, Jia-yu; Gao, Guo-yi; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China; [Xie, Bao-shu; Lin, Yong; Zhao, Cheng-cheng; Feng, Jun-feng; Gao, Guo-yi; Jiang, Ji-yao] Shanghai Inst Head Trauma, Shanghai, Peoples R China; [Wang, Yi-qin] Shanghai Jiao Tong Univ, Rui Jin Hosp, Sino French Res Ctr Life Sci & Gen, Sch Med,State Key Lab Med Gen, Shanghai, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China.; Jiang, JY (corresponding author), Shanghai Inst Head Trauma, Shanghai, Peoples R China.	jiyaojiang@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772058, 81471856]	This research was supported by the National Natural Science Foundation of China (No. 81772058 and 81471856).	Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Ban JJ, 2017, BIOCHEM BIOPH RES CO, V488, P316, DOI 10.1016/j.bbrc.2017.05.040; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Boone DK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06341-6; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Cai Q, 2016, NEURAL REGEN RES, V11, P1285, DOI 10.4103/1673-5374.189194; Cancelliere C, 2017, J HEAD TRAUMA REHAB, V32, pE37, DOI 10.1097/HTR.0000000000000260; Chandran R, 2017, NEUROCHEM INT, V111, P12, DOI 10.1016/j.neuint.2017.01.015; Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Chen Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120217; Di Pietro V, 2017, J NEUROTRAUM, V34, P1948, DOI 10.1089/neu.2016.4857; Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007; El-Menyar A, 2017, WORLD NEUROSURG, V107, P6, DOI [10.1016/J.WNEU.2017.07.070, 10.1016/j.wneu.2017.07.070]; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Kumar L, 2017, MOL NEUROBIOL, V54, P7224, DOI 10.1007/s12035-016-0213-8; Lasda E, 2014, RNA, V20, P1829, DOI 10.1261/rna.047126.114; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liu NK, 2011, PHYSIOL GENOMICS, V43, P571, DOI 10.1152/physiolgenomics.00168.2010; Liu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep22572; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Ma J, 2016, AM J TRANSL RES, V8, P1895; Mehta SL, 2017, STROKE, V48, P2541, DOI 10.1161/STROKEAHA.117.017469; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Pan RY, 2017, ONCOTARGET, V8, P60280, DOI 10.18632/oncotarget.19941; Popovich P. G, 2017, NEUROSCIENTIST; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Shin JH, 2014, BBA-GENE REGUL MECH, V1839, P826, DOI 10.1016/j.bbagrm.2014.06.019; Sun LQ, 2018, BEHAV BRAIN RES, V340, P126, DOI 10.1016/j.bbr.2016.09.020; Sun LQ, 2017, ONCOTARGET, V8, P59181, DOI 10.18632/oncotarget.19469; Sun LQ, 2017, BIOCHEM BIOPH RES CO, V482, P1141, DOI 10.1016/j.bbrc.2016.12.001; Wang CF, 2017, J NEUROTRAUM, V34, P2100, DOI 10.1089/neu.2016.4642; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zhao CC, 2017, J NEUROTRAUM, V34, P1636, DOI 10.1089/neu.2016.4759; Zhong JJ, 2017, BRAIN BEHAV IMMUN, V65, P183, DOI 10.1016/j.bbi.2017.05.001; Zhong JJ, 2016, BRAIN RES, V1646, P589, DOI 10.1016/j.brainres.2016.07.002	47	21	23	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1659	1666		10.1089/neu.2017.5468		APR 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000430056000001	29357736				2021-06-18	
J	Li, MQ; Xu, T; Zhou, F; Wang, MM; Song, HX; Xiao, X; Lu, BY				Li, Maiquan; Xu, Tao; Zhou, Fei; Wang, Mengmeng; Song, Huaxin; Xiao, Xing; Lu, Baiyi			Neuroprotective Effects of Four Phenylethanoid Glycosides on H2O2-Induced Apoptosis on PC12 Cells via the Nrf2/ARE Pathway	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						Keap1; Nrf2; Neuroprotective; PC12 cells; PhGs	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; MOUSE MODEL; ANTIOXIDANT; PROTECTS; DISEASE; SYSTEM; VITRO	Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcription factor against oxidative stress and neurodegenerative disorders. Phenylethanoid glycosides (PhGs; salidroside, acteoside, isoacteoside, and echinacoside) exhibit antioxidant and neuroprotective bioactivities. This study was performed to investigate the neuroprotective effect and molecular mechanism of PhGs. PhGs pretreatment significantly suppressed H2O2-induced cytotoxicity in PC12 cells by triggering the nuclear translocation of Nrf2 and reversing the downregulated protein expression of heme oxygenase 1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), glutamate cysteine ligase-catalytic subunit (GCLC), and glutamate-cysteine ligase modifier subunit (GCLM). Nrf2 siRNA or HO-1 inhibitor zinc protoporphyrin (ZnPP) reduced the neuroprotective effect. PhGs showed potential interaction with the Nrf2 binding site in Kelch-like ECH-association protein 1 (Keap1). This result may support the hypothesis that PhGs are activators of Nrf2. We demonstrated the potential binding between PhGs and the Keap1-activated Nrf2/ARE pathway, and that PhGs with more glycosides had enhanced effects.	[Li, Maiquan; Xu, Tao; Zhou, Fei; Wang, Mengmeng; Song, Huaxin; Lu, Baiyi] Zhejiang Univ, Zhejiang Key Lab Agrofood Proc,Minist Agr & Rural, Natl Engn Lab Intelligent Food Technol & Equipmen, Key Lab Agroprod Nutr Evaluat,Key Lab Agroprod Po, Hangzhou 310058, Zhejiang, Peoples R China; [Xiao, Xing] Guangzhou Univ Chinese Med, Coll Clin Med 1, Guangzhou 510006, Guangdong, Peoples R China	Lu, BY (corresponding author), Zhejiang Univ, Zhejiang Key Lab Agrofood Proc,Minist Agr & Rural, Natl Engn Lab Intelligent Food Technol & Equipmen, Key Lab Agroprod Nutr Evaluat,Key Lab Agroprod Po, Hangzhou 310058, Zhejiang, Peoples R China.	11413040@zju.edu.cn; txu@zju.edu.cn; feizhou@zju.edu.cn; 11613027@zju.edu.cn; 21713034@zju.edu.cn; fushengmengxx@gmail.com; bylu@zju.edu.cn		Xu, Tao/0000-0002-7683-7785	National Major R & D Program of China [2017YFD0400200]; Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [R15C200002]; Special Project of Agricultural Product Quality Safety Risk Assessment, Ministry of Agriculture and Rural affairs of China [GJFP2018015]	This study was supported by the National Major R & D Program of China (No. 2017YFD0400200), the Zhejiang Provincial Natural Science Foundation of China (No. R15C200002) and the Special Project of Agricultural Product Quality Safety Risk Assessment (No. GJFP2018015), Ministry of Agriculture and Rural affairs of China.	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Buendia I, 2016, PHARMACOL THERAPEUT, V157, P84, DOI 10.1016/j.pharmthera.2015.11.003; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dong Q, 2007, CARBOHYD RES, V342, P1343, DOI 10.1016/j.carres.2007.03.017; Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545; Fu G, 2008, CURR MED CHEM, V15, P2592, DOI 10.2174/092986708785908996; Georgiev M, 2011, FOOD CHEM, V128, P100, DOI 10.1016/j.foodchem.2011.02.083; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Jiang YR, 2016, J AGR FOOD CHEM, V64, P2459, DOI 10.1021/acs.jafc.5b03474; JIMENEZ C, 1994, NAT PROD REP, V11, P591, DOI 10.1039/np9941100591; Kerr F, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006593; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; Koo KA, 2005, PLANTA MED, V71, P778, DOI 10.1055/s-2005-871213; Kuang R, 2009, PLANTA MED, V75, P1499, DOI 10.1055/s-0029-1185806; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Li N, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/103985; Li XF, 2011, BRAIN RES, V1382, P9, DOI 10.1016/j.brainres.2011.01.015; Liang QN, 2011, ARCH TOXICOL, V85, P1267, DOI 10.1007/s00204-011-0664-7; Liu YL, 2013, J ETHNOPHARMACOL, V149, P431, DOI 10.1016/j.jep.2013.06.042; Liu YG, 2015, EUR J MED CHEM, V95, P313, DOI 10.1016/j.ejmech.2015.03.038; Maheshwari A, 2009, FEBS J, V276, P870, DOI 10.1111/j.1742-4658.2008.06831.x; Min D., 2005, CHINESE PHARMACOL B, V505, P11; Muegge I, 1999, J MED CHEM, V42, P2498, DOI 10.1021/jm990073x; Press C., 2005, VIRTUAL SCREENING DR; RICHARDSON JS, 1992, ANN NY ACAD SCI, V648, P326, DOI 10.1111/j.1749-6632.1992.tb24570.x; Scapagnini G, 2011, MOL NEUROBIOL, V44, P192, DOI 10.1007/s12035-011-8181-5; Sheng GQ, 2002, EUR J PHARMACOL, V451, P119, DOI 10.1016/S0014-2999(02)02240-9; Skibinski G, 2017, P NATL ACAD SCI USA, V114, P1165, DOI 10.1073/pnas.1522872114; Sun AY, 1998, J BIOMED SCI, V5, P401; Wang HQ, 2009, BRAIN RES, V1283, P139, DOI 10.1016/j.brainres.2009.05.101; Xiong LN, 2016, J MED FOOD, V19, P54, DOI 10.1089/jmf.2015.3462; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974; Zhang LL, 2012, FOOD CHEM TOXICOL, V50, P2591, DOI 10.1016/j.fct.2012.05.045; Zhao Q, 2010, BRAIN RES, V1346, P224, DOI 10.1016/j.brainres.2010.05.018	39	21	23	0	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	APR	2018	19	4							1135	10.3390/ijms19041135			17	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	GJ0XU	WOS:000434978700214	29642608	DOAJ Gold, Green Published			2021-06-18	
J	Attwood, MJ; Roberts, SP; Trewartha, G; England, ME; Stokes, KA				Attwood, Matthew J.; Roberts, Simon P.; Trewartha, Grant; England, Mike E.; Stokes, Keith A.			Efficacy of a movement control injury prevention programme in adult men's community rugby union: a cluster randomised controlled trial	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CONTROL EXERCISE PROGRAM; FIFA 11+; KNEE OSTEOARTHRITIS; FOOTBALL INJURIES; SOCCER PLAYERS; FEMALE SOCCER; WARM-UP; RATES; EPIDEMIOLOGY; PREVALENCE	Background Exercise programmes aimed at reducing injury have been shown to be efficacious for some non-collision sports, but evidence in adult men's collision sports such as rugby union is lacking. Objective To evaluate the efficacy of a movement control injury prevention exercise programme for reducing match injuries in adult men's community rugby union players. Methods 856 clubs were invited to participate in this prospective cluster randomised (single-blind) controlled trial where clubs were the unit of randomisation. 81 volunteered and were randomly assigned (intervention/control). A 42-week exercise programme was followed throughout the season. The control programme reflected 'normal practice' exercises, whereas the intervention focused on proprioception, balance, cutting, landing and resistance exercises. Outcome measures were match injury incidence and burden for: (1) all >= 8 days time-loss injuries and (2) targeted (lower limb, shoulder, head and neck, excluding fractures and lacerations) >= 8 days time-loss injuries. Results Poisson regression identified no clear effects on overall injury outcomes. A likely beneficial difference in targeted injury incidence (rate ratio (RR), 90% CI=0.6, 0.4 to 1.0) was identified, with a 40% reduction in lower-limb incidence (RR, 90% CI=0.6, 0.4 to 1.0) and a 60% reduction in concussion incidence (RR, 90% CI=0.4, 0.2 to 0.7) in the intervention group. Comparison between arms for clubs with highest compliance (>= median compliance) demonstrated very likely beneficial 60% reductions in targeted injury incidence (RR, 90% CI=0.4, 0.2 to 0.8) and targeted injury burden (RR, 90% CI=0.4, 0.2 to 0.7). Conclusions The movement control injury prevention programme resulted in likely beneficial reductions in lower-limb injuries and concussion. Higher intervention compliance was associated with reduced targeted injury incidence and burden.	[Attwood, Matthew J.; Roberts, Simon P.; Trewartha, Grant; Stokes, Keith A.] Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England; [Attwood, Matthew J.] Cardiff Metropolitan Univ, Sch Sport & Hlth Sci, Cardiff, S Glam, Wales; [England, Mike E.] Rugby Football Union, London, England	Stokes, KA (corresponding author), Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England.	k.stokes@bath.ac.uk	Attwood, Matthew J/N-2057-2019; Stokes, Keith/C-2605-2009	Attwood, Matthew J/0000-0002-3911-1897; Stokes, Keith/0000-0002-5049-2838	Rugby Football Union; Private Physiotherapy Education Fund	This research is funded by the Rugby Football Union and the Private Physiotherapy Education Fund.	Bizzini M, 2015, BRIT J SPORT MED, V49, P577, DOI 10.1136/bjsports-2015-094765; Burger N, 2017, AM J SPORT MED, V45, P278, DOI 10.1177/0363546516677548; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Crichton J, 2012, BRIT J SPORT MED, V46, P538, DOI 10.1136/bjsports-2011-090688; Dempsey AR, 2015, 33 INT C BIOM SPORTS; Falese L, 2016, RES SPORTS MED, V24, P426, DOI 10.1080/15438627.2016.1239105; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Finch CF, 2016, INJURY PREV, V22, P123, DOI 10.1136/injuryprev-2015-041667; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Geary K, 2014, CLIN J SPORT MED, V24, P502, DOI 10.1097/JSM.0000000000000071; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Grimmer KA, 2000, J ADOLESCENT HEALTH, V27, P266, DOI 10.1016/S1054-139X(00)00120-8; Grooms DR, 2013, J ATHL TRAINING, V48, P782, DOI 10.4085/1062-6050-48.4.08; Hagglund M, 2013, BRIT J SPORT MED, V47, P974, DOI 10.1136/bjsports-2013-092644; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Headey J, 2007, AM J SPORT MED, V35, P1537, DOI 10.1177/0363546507300691; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hislop M.D., 2016, BMJ OPEN SPORT EXERC, V2, P000043, DOI [10.1136/bmjsem-2015-000043, DOI 10.1136/BMJSEM-2015-000043]; Hislop MD, 2017, BRIT J SPORT MED, V51, P1140, DOI 10.1136/bjsports-2016-097434; Hopkins WG, 2016, SPORTS MED, V46, P1563, DOI 10.1007/s40279-016-0517-x; Hume PA, 2017, SPORTS MED, V47, P1209, DOI 10.1007/s40279-016-0608-8; Jeffreys I., 2006, UKSCA J, V6, P15; LaBella CR, 2011, ARCH PEDIAT ADOL MED, V165, P1033, DOI 10.1001/archpediatrics.2011.168; Lohmander LS, 2004, ARTHRITIS RHEUM-US, V50, P3145, DOI 10.1002/art.20589; Longo UG, 2012, AM J SPORT MED, V40, P996, DOI 10.1177/0363546512438761; Maffulli N, 2010, BRIT J SPORT MED, V44, P21, DOI 10.1136/bjsm.2009.069526; McCullagh P., 1989, GEN LINEAR MODELS; McKay CD, 2016, BRIT J SPORT MED, V50, P382, DOI 10.1136/bjsports-2015-095192; McNoe BM, 2010, AM J SPORT MED, V38, P2542, DOI 10.1177/0363546510377415; O'Brien J, 2014, SPORTS MED, V44, P1305, DOI 10.1007/s40279-014-0208-4; Petersen J, 2011, AM J SPORT MED, V39, P2296, DOI 10.1177/0363546511419277; Rae K, 2005, BRIT J SPORT MED, V39, P907, DOI 10.1136/bjsm.2004.017517; RFU, 2011, RECR RET PLAY 2011; Roberts SP, 2017, AM J SPORT MED, V45, P480, DOI 10.1177/0363546516668296; Roberts SP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003998; Salaffi F, 2005, AGING CLIN EXP RES, V17, P255; Soligard T, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2469; Steffen K, 2013, BRIT J SPORT MED, V47, P794, DOI 10.1136/bjsports-2012-091886; Tucker R, 2017, BRIT J SPORT MED, V51; Williams S, 2016, BRIT J SPORT MED, V50, P651, DOI 10.1136/bjsports-2015-094798	40	21	21	1	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAR	2018	52	6					368	+		10.1136/bjsports-2017-098005			8	Sport Sciences	Sport Sciences	FZ2IO	WOS:000427401500007	29055883	Green Published, Other Gold			2021-06-18	
J	Carotenuto, A; Arcara, G; Orefice, G; Cerillo, I; Giannino, V; Rasulo, M; Iodice, R; Bambini, V				Carotenuto, Antonio; Arcara, Giorgio; Orefice, Giuseppe; Cerillo, Ilaria; Giannino, Valentina; Rasulo, Mario; Iodice, Rosa; Bambini, Valentina			Communication in Multiple Sclerosis: Pragmatic Deficit and its Relation with Cognition and Social Cognition	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Language and language disorder; Multiple sclerosis	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; AMYOTROPHIC-LATERAL-SCLEROSIS; LANGUAGE DISORDERS; IMPAIRMENT; DYSFUNCTION; BEHAVIOR; MIND; SCHIZOPHRENIA; MULTICENTER	Objective: Cognitive functions have been largely investigated in multiple sclerosis. Less attention has been paid to social communication abilities, despite their presumptive affect on quality of life. We run the first comprehensive assessment of pragmatic skills in multiple sclerosis, evaluating also the relationship between pragmatics and other cognitive domains. Methods: Forty-two multiple sclerosis patients and 42 controls were tested for pragmatic abilities, neuro-cognition, social cognition, depression, and fatigue. Results: Patients performed poorly in most pragmatic tasks compared to controls. Globally, 55% of patients performed below the 5th percentile in the total pragmatic score. Notably, pragmatic skills did not differ between cognitively impaired and unimpaired patients. However, an association was found between pragmatics and verbal fluency, as measured in the Word List Generation. Finally, we observed an association of pragmatic abilities with social cognition, and a trend with psychosocial functioning. Conclusion: Overall, the study shows a diffuse pragmatic impairment in multiple sclerosis, not associated with the patient's global neuropsychological profile. By contrast, our findings suggest a close relation between pragmatics and specific cognitive aspects such as executive functions, and between pragmatics and social cognition. This study underlines the need of looking beyond classical cognitive performance, to consider underestimated communicative disturbances of high clinical relevance.	[Carotenuto, Antonio; Orefice, Giuseppe; Cerillo, Ilaria; Giannino, Valentina; Rasulo, Mario; Iodice, Rosa] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Via Pansini 5, I-80131 Naples, Italy; [Arcara, Giorgio] San Camillo Hosp IRCCS, Venice, Italy; [Bambini, Valentina] Sch Adv Studies IUSS, Ctr Neurocognit Epistemol & Theoret Syntax NEtS, Pavia, Italy	Carotenuto, A (corresponding author), Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Via Pansini 5, I-80131 Naples, Italy.	carotenuto.antonio87@gmail.com	Bambini, Valentina/K-6643-2016; Arcara, Giorgio/K-6351-2016; Carotenuto, Antonio/AAE-1249-2020; IODICE, Rosa/J-4016-2018	Bambini, Valentina/0000-0001-5770-228X; Arcara, Giorgio/0000-0001-6270-6883; Carotenuto, Antonio/0000-0002-1574-9693; IODICE, Rosa/0000-0002-6939-4760			Agrell B., 1995, SCANDINAVIAN J LOGOP, V20, P27, DOI [10.3109/14015439509098727, DOI 10.3109/14015439509098727]; Amato MP, 2006, MULT SCLER, V12, P787, DOI 10.1177/1352458506070933; Arcara G, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00070; Arrondo G., 2009, EUROPEAN NEUROLOGICA, V2, P11; Bambini V, 2016, COMPR PSYCHIAT, V71, P106, DOI 10.1016/j.comppsych.2016.08.012; Bambini V, 2016, BRAIN LANG, V153, P1, DOI 10.1016/j.bandl.2015.12.002; Bambini V, 2010, ITAL J LINGUIST, V22, P1; Bambini Valentina, 2012, HDB PRAGMATICS, P134, DOI DOI 10.1075/HOP.16.NEU2; Benedict RHB, 2003, MULT SCLER J, V9, P393, DOI 10.1191/1352458503ms902oa; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Blake ML, 2015, NEUROPSYCHOL REHABIL, V25, P15, DOI 10.1080/09602011.2014.932290; Bosco FM, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00166; Brownell H, 2013, J HEAD TRAUMA REHAB, V28, P446, DOI 10.1097/HTR.0b013e31825b5e85; Calabrese M, 2010, MULT SCLER J, V16, P1220, DOI 10.1177/1352458510376405; Catani M, 2014, CURR OPIN NEUROBIOL, V28, P165, DOI 10.1016/j.conb.2014.07.018; Catani M, 2013, NEUROSCI BIOBEHAV R, V37, P1724, DOI 10.1016/j.neubiorev.2013.07.001; Chalah MA, 2017, J INT NEUROPSYCH SOC, V23, P266, DOI 10.1017/S1355617716001156; Champagne-Lavau M, 2009, J NEUROLINGUIST, V22, P413, DOI 10.1016/j.jneuroling.2009.02.002; Chiaravalloti ND, 2008, LANCET NEUROL, V7, P1139, DOI 10.1016/S1474-4422(08)70259-X; Cummings L, 2014, PRAGMATIC DISORDERS, V3; Cummings L., 2017, RES CLIN PRAGMATICS; Dodich A, 2015, NEUROL SCI, V36, P1907, DOI 10.1007/s10072-015-2281-3; Ferre P, 2011, REHABIL RES PRACT, V2011, DOI 10.1155/2011/131820; Friend KB, 1999, CLIN NEUROPSYCHOL, V13, P78, DOI 10.1076/clin.13.1.78.1979; Gabbatore I, 2015, J HEAD TRAUMA REHAB, V30, pE14, DOI 10.1097/HTR.0000000000000087; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Goverover Y, 2018, MULT SCLER J, V24, P1096, DOI 10.1177/1352458517709955; Henry A, 2011, J INT NEUROPSYCH SOC, V17, P1122, DOI 10.1017/S1355617711001147; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1166, DOI 10.1016/j.neuropsychologia.2005.10.006; Hyter YD, 2017, PERSP PRAGMAT PHILO, V11, P493, DOI 10.1007/978-3-319-47489-2_19; Klein OA, 2019, NEUROPSYCHOL REHABIL, V29, P491, DOI 10.1080/09602011.2017.1309323; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lethlean JB, 1997, APHASIOLOGY, V11, P39, DOI 10.1080/02687039708248454; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Luzzatti C., 1991, AACHENER APHASIA TES; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Mattioli F, 2016, MULT SCLER J, V22, P222, DOI 10.1177/1352458515587597; Messer Rachel H., 2015, HLTH AGING CLIN CARE, DOI [10.4137/hacce.s22981, DOI 10.4137/HACCE.S22981, 10.4137/HACCE.S22981]; Mondini S., 2011, ESAME NEUROPSICOLOGI; Montel SR, 2007, MULT SCLER J, V13, P393, DOI 10.1177/1352458506071170; Morere DA, 2012, ASSESSING LITERACY D, P141, DOI [10.1007/978-1-4614-5269-0_8, DOI 10.1007/978-1-4614-5269-0_8]; Parola A, 2016, J NEUROLINGUIST, V39, P10, DOI 10.1016/j.jneuroling.2015.12.003; Pottgen J, 2013, J NEUROL NEUROSUR PS, V84, P523, DOI 10.1136/jnnp-2012-304157; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Preziosa P, 2016, HUM BRAIN MAPP, V37, P1627, DOI 10.1002/hbm.23125; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; Renauld S, 2016, MULT SCLER RELAT DIS, V10, P103, DOI 10.1016/j.msard.2016.09.005; Rocca MA, 2015, LANCET NEUROL, V14, P302, DOI 10.1016/S1474-4422(14)70250-9; Roxburgh RHSR, 2005, NEUROLOGY, V64, P1144, DOI 10.1212/01.WNL.0000156155.19270.F8; Sacco K, 2008, J COGN SCI, V9, P111; Shao Z, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00772; Sperber D, 2002, MIND LANG, V17, P3, DOI 10.1111/1468-0017.00186; Spinnler H., 1987, MLA GRUPPO ITALIANO; Stemmer B., 2008, HDB NEUROSCIENCE LAN, P367; Strong MJ, 2017, AMYOTROPH LAT SCL FR, V18, P153, DOI 10.1080/21678421.2016.1267768; Tillema JM, 2016, MULT SCLER J, V22, P901, DOI 10.1177/1352458515607650; Vrenken Hugo, 2007, Expert Rev Neurother, V7, P271, DOI 10.1586/14737175.7.3.271	60	21	21	1	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2018	33	2					194	205		10.1093/arclin/acx061			12	Psychology, Clinical; Psychology	Psychology	FY4QD	WOS:000426808700006	28655166	Bronze			2021-06-18	
J	Choi, GS; Kwak, SG; Do Lee, H; Chang, MC				Choi, Gyu-sik; Kwak, Sang Gyu; Do Lee, Han; Chang, Min Cheol			EFFECT OF HIGH-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON CHRONIC CENTRAL PAIN AFTER MILD TRAUMATIC BRAIN INJURY: A PILOT STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						central pain; traumatic brain injury; repetitive transcranial magnetic stimulation; high-frequency; spinothalamocortical tract; diffusion tensor tractography	MOTOR CORTEX STIMULATION; DIFFUSE AXONAL INJURY; SPINOTHALAMIC TRACT; CONTROLLED TRIAL; POSTSTROKE PAIN; MECHANISMS; RELIEF; EXCITABILITY; MODULATION; SYMPTOMS	Objective: Central pain can occur following traumatic brain injury, leading to poor functional recovery, limitation of activities of daily living, and decreased quality of life. The aim of this study was to determine whether high-frequency (10 Hz) repetitive transcranial magnetic stimulation, applied over the primary motor cortex of the affected hemisphere, can be used to manage chronic central pain after mitd traumatic brain injury. Design: Prospective randomized feasibility study. Methods; Twelve patients with mild traumatic brain injury anil chronic central pain were randomly assigned to transcranial magnetic stimulation (high-frequency stimulation, 10 sessions) or sham groups. Diffuse tensor tractography revealed partially injured spinothalamocortical tracts in all recruited patients. A numerical rating scale (NRS) was used to evaluate pain intensity during pre-treatment and immediately after the 5(th) transcranial magnetic stimulation session (post1), 10(th) transcranial magnetic stimulation session (post2), and 1 (post3), 2 (post4), and 4 weeks (post 5) after finishing treatment. Physical and mental health status were evaluated using the Short Form 36 Health Survey (SF-36), including physical and mental component scores (PCS, MCS). Results: The NRS score of the repetitive transcranial magnetic stimulation group was significantly lower than the sham group score at all clinical evaluation time-points during and after transcranial magnetic stimulation sessions. The transcranial magnetic stimulation group's SF-36 PCS score was significantly higher at post2, post3, post4, and post5 compared with the sham group. Conclusion; High-frequency transcranial magnetic stimulation may be used to manage chronic central pain and improve quality of life in patients with mild traumatic brain injury. However, this is a pilot study and further research is needed.	[Choi, Gyu-sik] Cheokbareun Rehabil Clin, Pohang Si, Gyeongsangbuk D, South Korea; [Kwak, Sang Gyu] Catholic Univ Daegu, Coll Med, Dept Med Stat, Daegu, South Korea; [Do Lee, Han; Chang, Min Cheol] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Daegu 705717, South Korea	Chang, MC (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Daegu 705717, South Korea.	wheel633@gmail.com	Kwak, Sanggyu/AAG-4341-2021				Almeida TF, 2004, BRAIN RES, V1000, P40, DOI 10.1016/j.brainres.2003.10.073; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; de Oliveira RAA, 2014, J PAIN, V15, P1271, DOI 10.1016/j.jpain.2014.09.009; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; Brissebrat B., 2016, ANN PHYS REHABIL MED, V59, pe145; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; de Andrade DC, 2011, PAIN, V152, P320, DOI 10.1016/j.pain.2010.10.032; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Devulder J, 2002, ACTA NEUROL BELG, V102, P97; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Goto T, 2008, PAIN, V140, P509, DOI 10.1016/j.pain.2008.10.009; Gu SY, 2017, BRAIN STIMUL, V10, P270, DOI 10.1016/j.brs.2016.10.010; Hasan M, 2014, NEUROMODULATION, V17, P731, DOI 10.1111/ner.12198; Hirayama A, 2006, PAIN, V122, P22, DOI 10.1016/j.pain.2005.12.001; Hong JH, 2010, EUR NEUROL, V64, P163, DOI 10.1159/000319040; Hosomi K, 2013, PAIN, V154, P1352, DOI 10.1016/j.pain.2013.04.017; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Jang SH, 2016, BRAIN INJURY, V30, P1026, DOI 10.3109/02699052.2016.1146961; Jang SH, 2016, BRAIN INJURY, V30, P933, DOI 10.3109/02699052.2016.1146966; Jang SH, 2013, NEUROSCI LETT, V543, P47, DOI 10.1016/j.neulet.2013.02.058; Jensen TS, 2003, PAIN, V102, P1, DOI 10.1016/S0304-3959(03)00006-X; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Kim JH, 2015, J HEAD TRAUMA REHAB, V30, pE40, DOI 10.1097/HTR.0000000000000121; Kobayashi M, 2015, NEUROMODULATION, V18, P249, DOI 10.1111/ner.12301; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lee SJ, 2012, AM J PHYS MED REHAB, V91, P1077, DOI 10.1097/PHM.0b013e3182745a04; Lefaucheur JP, 2004, J NEUROL NEUROSUR PS, V75, P612, DOI 10.1136/jnnp.2003.022236; Leung A, 2016, PAIN PHYSICIAN, V19, pE347; Leung A, 2009, J PAIN, V10, P1205, DOI 10.1016/j.jpain.2009.03.010; Mansur CG, 2005, NEUROLOGY, V64, P1802, DOI 10.1212/01.WNL.0000161839.38079.92; Matsumura Y, 2013, NEUROMODULATION, V16, P349, DOI 10.1111/ner.12019; Mylius V, 2012, PAIN, V153, P1350, DOI 10.1016/j.pain.2012.04.009; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Ohn SH, 2012, NEUROREHAB NEURAL RE, V26, P344, DOI 10.1177/1545968311423110; Pagano RL, 2012, PAIN, V153, P2359, DOI 10.1016/j.pain.2012.08.002; Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005; Saitoh Y, 2004, J NEUROSURG, V100, P935, DOI 10.3171/jns.2004.100.5.0935; Saitoh Y, 2013, IEEE ENG MED BIO, P6163, DOI 10.1109/EMBC.2013.6610960; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; TEASDALE G, 1974, LANCET, V2, P81; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; VESTERGAARD K, 1995, PAIN, V61, P177, DOI 10.1016/0304-3959(94)00140-A; Ware J, 2001, SCORE VERSION 2 SF 3; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Ziemann U, 1998, J NEUROSCI, V18, P1115	49	21	22	0	4	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAR	2018	50	3					246	252		10.2340/16501977-2321			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	GF3NY	WOS:000431864100003	29392332	DOAJ Gold			2021-06-18	
J	Jenkins, PO; De Simoni, S; Bourke, NJ; Fleminger, J; Scott, G; Towey, DJ; Svensson, W; Khan, S; Patel, M; Greenwood, R; Cole, JH; Sharp, DJ				Jenkins, Peter O.; De Simoni, Sara; Bourke, Niall J.; Fleminger, Jessica; Scott, Gregory; Towey, David J.; Svensson, William; Khan, Sameer; Patel, Maneesh; Greenwood, Richard; Cole, James H.; Sharp, David J.			Dopaminergic abnormalities following traumatic brain injury	BRAIN			English	Article						traumatic brain injury; dopamine; cognitive impairment; SPECT imaging; ioflupane	CONTROLLED CORTICAL IMPACT; NAIVE PARKINSONS-DISEASE; DIFFUSE AXONAL INJURY; COGNITIVE IMPAIRMENT; HEAD-INJURY; TRANSPORTER EXPRESSION; PREFRONTAL CORTEX; RAT STRIATUM; SCALE; PET	Traumatic brain injury can reduce striatal dopamine levels. The cause of this is uncertain, but is likely to be related to damage to the nigrostriatal system. We investigated the pattern of striatal dopamine abnormalities using 123 I-Ioflupane single-photon emission computed tomography (SPECT) scans and their relationship to nigrostriatal damage and clinical features. We studied 42 moderate- severe traumatic brain injury patients with cognitive impairments but no motor parkinsonism signs and 20 healthy controls. 123 I-Ioflupane scanning was used to assess dopamine transporter levels. Clinical scan reports were compared to quantitative dopamine transporter results. Advanced MRI methods were used to assess the nigrostriatal system, including the area through which the nigrostriatal projections pass as defined from high-resolution Human Connectome data. Detailed clinical and neuropsychological assessments were performed. Around 20% of our moderate-severe patients had clear evidence of reduced specific binding ratios for the dopamine transporter in the striatum measured using 123 I-Ioflupane SPECT. The caudate was affected more consistently than other striatal regions. Dopamine transporter abnormalities were associated with reduced substantia nigra volume. In addition, diffusion MRI provided evidence of damage to the regions through which the nigrostriatal tract passes, particularly the area traversed by dopaminergic projections to the caudate. Only a small percentage of patients had evidence of macroscopic lesions in the striatum and there was no relationship between presence of lesions and dopamine transporter specific binding ratio abnormalities. There was also no relationship between reduced volume in the striatal subregions and reduced dopamine transporter specific binding ratios. Patients with low caudate dopamine transporter specific binding ratios show impaired processing speed and executive dysfunction compared to patients with normal levels. Taken together, our results suggest that the dopaminergic system is affected by a moderate-severe traumatic brain injury in a significant proportion of patients, even in the absence of clinical motor parkinsonism. Reduced dopamine transporter levels are most commonly seen in the caudate and this is likely to reflect the pattern of nigrostriatal tract damage produced by axonal injury and associated midbrain damage.	[Jenkins, Peter O.; De Simoni, Sara; Bourke, Niall J.; Fleminger, Jessica; Scott, Gregory; Cole, James H.; Sharp, David J.] Imperial Coll London, Hammersmith Hosp, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London, England; [Towey, David J.; Svensson, William; Khan, Sameer] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Dept Nucl Med, London, England; [Patel, Maneesh] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Imaging Dept, London, England; [Greenwood, Richard] UCL, Inst Neurol, Div Clin Neurol, London, England	Sharp, DJ (corresponding author), Imperial Coll London, Dept Med, Div Brain Sci, C3NL, Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013; Cole, James H/I-5197-2019; Towey, David/I-6571-2016	Cole, James H/0000-0003-1908-5588; Fleminger, Jessica/0000-0002-5744-5137; Towey, David/0000-0002-6209-3826; Scott, Gregory/0000-0001-8063-5871	National Institute of Health Research Professorship [NIHR-RP-011-048]; Guarantors of Brain Clinical Fellowship; National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	D.J.S. is funded by a National Institute of Health Research Professorship (NIHR-RP-011-048). P.O.J. is funded by Guarantors of Brain Clinical Fellowship. The research was also supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Backman L, 1997, BRAIN, V120, P2207, DOI 10.1093/brain/120.12.2207; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Benamer HTS, 2003, MOVEMENT DISORD, V18, P977, DOI 10.1002/mds.10482; Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006; Cheng HC, 2010, ANN NEUROL, V67, P715, DOI 10.1002/ana.21995; Cools R, 2002, BRAIN, V125, P584, DOI 10.1093/brain/awf052; DIVAC I, 1967, J COMP PHYSIOL PSYCH, V63, P184, DOI 10.1037/h0024348; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Ekman U, 2012, LANCET NEUROL, V11, P679, DOI 10.1016/S1474-4422(12)70138-2; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goetz CG, 2007, MOVEMENT DISORD, V22, P41, DOI 10.1002/mds.21198; Gulley JM, 2003, EUR J PHARMACOL, V479, P139, DOI 10.1016/j.ejphar.2003.08.064; Guttman M, 1997, NEUROLOGY, V48, P1578, DOI 10.1212/WNL.48.6.1578; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kehagia AA, 2010, LANCET NEUROL, V9, P1200, DOI 10.1016/S1474-4422(10)70212-X; Keuken MC, 2014, NEUROIMAGE, V94, P40, DOI 10.1016/j.neuroimage.2014.03.032; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Krauss JK, 2002, NEUROSURGERY, V50, P927, DOI 10.1097/00006123-200205000-00003; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; Ma Y, 2002, SYNAPSE, V45, P125, DOI 10.1002/syn.10090; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Marek KL, 1996, NEUROLOGY, V46, P231, DOI 10.1212/WNL.46.1.231; Marie RM, 1999, NEUROSCI LETT, V260, P77, DOI 10.1016/S0304-3940(98)00928-8; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; Mattay VS, 2002, ANN NEUROL, V51, P156, DOI 10.1002/ana.10078; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Mozley LH, 2001, AM J PSYCHIAT, V158, P1492, DOI 10.1176/appi.ajp.158.9.1492; Muller U, 2000, J NEURAL TRANSM, V107, P303, DOI 10.1007/s007020050025; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Racette BA, 2006, NEUROTOXICOLOGY, V27, P357, DOI 10.1016/j.neuro.2005.11.005; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sockeel P, 2006, J NEUROL NEUROSUR PS, V77, P579, DOI 10.1136/jnnp.2005.075929; Staal JA, 2011, J NEUROTRAUM, V28, P841, DOI 10.1089/neu.2010.1658; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wenning GK, 1998, MOVEMENT DISORD, V13, P438, DOI 10.1002/mds.870130311; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	53	21	21	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2018	141		3				797	810		10.1093/brain/awx357			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FY4RP	WOS:000426813600024	29360949	Bronze			2021-06-18	
J	Wallace, C; Smirl, JD; Zetterberg, H; Blennow, K; Bryk, K; Burma, J; Dierijck, J; Wright, AD; van Donkelaar, P				Wallace, Colin; Smirl, Jonathan D.; Zetterberg, Henrik; Blennow, Kaj; Bryk, Kelsey; Burma, Joel; Dierijck, Jill; Wright, Alexander David; van Donkelaar, Paul			Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics	BMJ OPEN SPORT & EXERCISE MEDICINE			English	Article								Objectives To determine the effect of heading a soccer ball on serum neurofilament light (NF-L) protein, plasma tau protein and symptom metrics including total number of symptoms reported and symptom severity scores on the Standardized Concussion Assessment Tool- 3rd edition (SCAT3). Methods Eleven male collegiate soccer players were recruited to take part in three experimental conditions including heading, sham and control conditions. Participants were required to perform 40 headers in 20 min in the heading condition, and control 40 soccer balls directed at them with their hands, chest or thigh in the sham condition. No ball contact was made during the control condition. Blood sampling and SCAT3 symptom assessments were completed prior to and 1 hour following conditions. A subset of participants returned 3 weeks following the heading condition for blood sampling. Results NF-L was elevated at 1 hour (p=0.004) and 1 month (p=0.04) following the heading condition, and at 1 hour (p=0.02) following the control condition. Tau levels remained unchanged following all conditions. The total number of symptoms (TS) and symptom severity (SS) scores from the SCAT3 were both elevated following the heading condition (p=0.01 and p=0.03, respectively). Both TS and SS decreased following sham (p=0.04 and p=0.04) and control conditions (p=0.04 and p=0.04). Conclusion An acute bout of soccer heading is associated with increased NF-L concentrations at 1 hour and 1 month following the session and can lead to symptoms commonly reported following sport-related concussion.	[Wallace, Colin] Univ British Columbia, Dept Pathol & Lab Med, Fac Med, Vancouver, BC, Canada; [Wallace, Colin; Smirl, Jonathan D.; Burma, Joel; van Donkelaar, Paul] Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Inst Neurosci & Physiol,Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Bryk, Kelsey] Univ Delaware, Coll Hlth Sci, Newark, DE USA; [Dierijck, Jill] Dalhousie Univ, Fac Hlth, Halifax, NS, Canada; [Wright, Alexander David] Univ British Columbia, Fac Med, Vancouver, BC, Canada	Wallace, C (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Fac Med, Vancouver, BC, Canada.; Wallace, C (corresponding author), Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada.	colin.wallace@alumni.ubc.ca	Burma, Joel/AAL-1073-2021	Burma, Joel/0000-0001-9756-5793; Smirl, Jonathan/0000-0003-1054-0038; Wright, Alexander D./0000-0001-6442-5583; Wallace, Colin/0000-0002-3720-6526	Canadian Institutes for Health Research (CIHR), Canada Foundation for Innovation (CFI); Mitacs; Mitacs Accelerate Programme	This research was funded by grants to PvD from the Canadian Institutes for Health Research (CIHR), Canada Foundation for Innovation (CFI) and Mitacs. CW was supported by the Mitacs Accelerate Programme.	Armstrong S, 2009, J AM COLL HEALTH, V57, P521, DOI 10.3200/JACH.57.5.521-526; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Count FB, 2006, 270 MILLION PEOPLE A; Dorminy M, 2015, BRAIN INJURY, V29, P1158, DOI 10.3109/02699052.2015.1035324; Gill J, 2017, NEUROLOGY, V88, P595, DOI 10.1212/WNL.0000000000003587; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Grinberg LT, 2016, J ALZHEIMERS DIS, V54, P169, DOI 10.3233/JAD-160312; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mehnert Michael J, 2005, Pain Physician, V8, P391; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Rissin DM, 2006, NANO LETT, V6, P520, DOI 10.1021/nl060227d; Shahim P, 2018, NEUROLOGY, V90, pE1780, DOI 10.1212/WNL.0000000000005518; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2015, MOL CELL NEUROSCI, V66, P99, DOI 10.1016/j.mcn.2015.02.003	29	21	21	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2398-9459	2055-7647		BMJ OPEN SPORT EXERC	BMJ Open Sport Exerc. Med.	MAR	2018	4	1							e000433	10.1136/bmjsem-2018-000433			5	Sport Sciences	Sport Sciences	VJ4QA	WOS:000596798200126	30233810	DOAJ Gold, Green Published			2021-06-18	
J	Lagerstedt, L; Egea-Guerrero, JJ; Rodriguez-Rodriguez, A; Bustamante, A; Montaner, J; El Rahal, A; Andereggen, E; Rinaldi, L; Sarrafzadeh, A; Schaller, K; Sanchez, JC				Lagerstedt, Linnea; Jose Egea-Guerrero, Juan; Rodriguez-Rodriguez, Ana; Bustamante, Alejandro; Montaner, Joan; El Rahal, Amir; Andereggen, Elisabeth; Rinaldi, Lara; Sarrafzadeh, Asita; Schaller, Karl; Sanchez, Jean-Charles			Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; SERUM; EXPRESSION; BIOMARKERS; S100-BETA; MARKER; S100B	Traumatic brain injury is a common event where 70%-90% will be classified as mild TBI (mTBI). Among these, only 10% will have a brain lesion visible via CT scan. A triage biomarker would help clinicians to identify patients with mTBI who are at risk of developing a brain lesion and require a CT scan. The brain cells damaged by the shearing, tearing and stretching of a TBI event set off inflammation cascades. These cause altered concentrations of a high number of both pro-inflammatory and anti-inflammatory proteins. This study aimed to discover a novel diagnostic biomarker of mTBI by investigating a broad panel of inflammation biomarkers and their capacity to correctly identify CT-positive and CT-negative patients. Patients enrolled in this study had been diagnosed with mTBI, had a GCS score of 15 and suffered from at least one clinical symptom. There were nine patients in the discovery group, 45 for verification, and 133 mTBI patients from two different European sites in the validation cohort. All patients gave blood samples, underwent a CT scan and were dichotomised into CT-positive and CT-negative groups for statistical analyses. The ability of each protein to classify patients was evaluated with sensitivity set at 100%. Three of the 92 inflammation proteins screened-MCP-1, MIP-1alpha and IL-10-were further investigated in the verification group, and at 100% sensitivity their specificities reached 7%, 0% and 31%, respectively. IL-10 was validated on a larger cohort in comparison to the most studied mTBI diagnostic triage protein to date, S100B. Levels of both proteins were significantly higher in CT-positive than in CT-negative patients (p < 0.001). S100B's specificity at 100% sensitivity was 18% (95% CI 10.8-25.2), whereas IL-10 reached a specificity of 27% (95% CI 18.9-35.1). These results showed that IL-10 might be an interesting and clinically useful diagnostic tool, capable of differentiating between CT-positive and CT-negative mTBI patients.	[Lagerstedt, Linnea; Sanchez, Jean-Charles] Univ Geneva, Fac Med, Dept Human Prot Sci, Geneva, Switzerland; [Jose Egea-Guerrero, Juan; Rodriguez-Rodriguez, Ana] Virgen del Rocio Univ Hosp, NeuroCrit Care Unit, Seville, Spain; [Bustamante, Alejandro; Montaner, Joan] Univ Autonoma Barcelona, VHIR, Neurovasc Res Lab, Barcelona, Spain; [Montaner, Joan] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Stroke Res Programme,IBiS, Seville, Spain; [Montaner, Joan] Hosp Univ Virgen Macarena, Dept Neurol, Seville, Spain; [El Rahal, Amir; Sarrafzadeh, Asita; Schaller, Karl] Geneva Univ Hosp, Dept Clin Neurosci, Geneva Neurosci Ctr, Div Neurosurg, Geneva, Switzerland; [Andereggen, Elisabeth; Rinaldi, Lara] Geneva Univ Hosp, Emergency Ctr, Geneva, Switzerland; [Andereggen, Elisabeth] Geneva Univ Hosp, Dept Surg, Geneva, Switzerland	Sanchez, JC (corresponding author), Univ Geneva, Fac Med, Dept Human Prot Sci, Geneva, Switzerland.	Jean-Charles.Sanchez@unige.ch	IBiS, Neurovascular/P-5842-2016; Montaner, Joan/D-3063-2015; Egea-Guerrero, Juan Jose/P-5080-2014	Montaner, Joan/0000-0003-4845-2279; Lagerstedt, Linnea/0000-0002-3405-9938; Egea-Guerrero, Juan Jose/0000-0002-4166-313X			Adrian H, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0294-16.2016; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bogoslovsky T, 2016, DIAGNOSTICS, P6; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Graber DJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0298-4; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Heidari K, 2015, BRAIN INJURY, V29, P33, DOI 10.3109/02699052.2014.948068; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Lagerstedt L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175572; Lescuyer Pierre, 2005, Mol Diagn, V9, P1, DOI 10.2165/00066982-200509010-00001; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; Mayer CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062101; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Neher MD, 2014, SOUTH MED J, V107, P248, DOI 10.1097/SMJ.0000000000000086; North SH, 2012, ANNU REV ANAL CHEM, V5, P35, DOI 10.1146/annurev-anchem-062011-143105; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L., 2015, BRAIN NEUROTRAUMA MO; Papa L, 2016, JAMA NEUROL; Papa L, 2017, J NEUROTRAUMA; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pelsers MMAL, 2005, CLIN CHEM LAB MED, V43, P802, DOI 10.1515/CCLM.2005.135; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Posti J.P., 2017, J NEUROTRAUMA; Raj R, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-67; Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Wang YP, 2016, COLD REG SCI TECHNOL, V126, P10, DOI 10.1016/j.coldregions.2016.02.013; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Werhane ML, 2017, CONCUSSION CNC30; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	44	21	21	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2018	13	2							e0193278	10.1371/journal.pone.0193278			12	Multidisciplinary Sciences	Science & Technology - Other Topics	FW8RO	WOS:000425604300107	29466474	DOAJ Gold, Green Published			2021-06-18	
J	Delco, ML; Bonnevie, ED; Bonassar, LJ; Fortier, LA				Delco, Michelle L.; Bonnevie, Edward D.; Bonassar, Lawrence J.; Fortier, Lisa A.			Mitochondrial dysfunction is an acute response of articular chondrocytes to mechanical injury	JOURNAL OF ORTHOPAEDIC RESEARCH			English	Article						cartilage; mechanobiology; osteoarthritis; posttraumatic; mitochondria	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC OSTEOARTHRITIS; OXYGEN-TENSION; GLUCOSE-CONCENTRATION; OXIDANT RELEASE; CARTILAGE; DEATH; CULTURE; IMPACT; MECHANOTRANSDUCTION	Mitochondrial (MT) dysfunction is known to occur in chondrocytes isolated from end-stage osteoarthritis (OA) patients, but the role of MT dysfunction in the initiation and early pathogenesis of post-traumatic OA (PTOA) remains unclear. The objective of this study was to investigate chondrocyte MT function immediately following mechanical injury in cartilage, and to determine if the response to injury differed between a weight bearing region (medial femoral condyle; MFC) and a non-weight bearing region (distal patellofemoral groove; PFG) of the same joint. Cartilage was harvested from the MFC and PFG of 10 neonatal bovids, and subjected to injurious compression at varying magnitudes (5-17MPa, 5-34GPa/s) using a rapid single-impact model. Chondrocyte MT respiratory function, MT membrane polarity, chondrocyte viability, and cell membrane damage were assessed in situ. Cartilage impact resulted in MT depolarization and impaired MT respiratory function within 2h of injury. Cartilage from a non-weight bearing region of the joint (PFG) was more sensitive to impact-induced MT dysfunction and chondrocyte death than cartilage from a weight-bearing surface (MFC). Our findings suggest that MT dysfunction is an acute response of chondrocytes to cartilage injury, and that MT may play a key mechanobiological role in the initiation and early pathogenesis of PTOA. Clinical significance: Direct therapeutic targeting of MT function in the early post-injury time frame may provide a strategy to block perpetuation of tissue damage and prevent the development of PTOA. (c) 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:739-750, 2018.	[Delco, Michelle L.; Fortier, Lisa A.] Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA; [Bonnevie, Edward D.; Bonassar, Lawrence J.] Cornell Univ, Sibley Sch Mech & Aerosp Engn, Ithaca, NY 14853 USA; [Bonassar, Lawrence J.] Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY USA	Fortier, LA (corresponding author), Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA.	laf4@cornell.edu			Weill Cornell Medical College [5 UL1 TR000457-09]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32OD011000-20]; Harry M. Zweig Memorial Fund for Equine Research; National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [1K08AR068470]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002384, UL1TR000457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K08AR068470] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32OD011000] Funding Source: NIH RePORTER	Grant sponsor: Weill Cornell Medical College; Grant number: 5 UL1 TR000457-09; Grant sponsor: National Institutes of Health; Grant number: 5T32OD011000-20; Grant sponsor: Harry M. Zweig Memorial Fund for Equine Research; Grant sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Grant number: 1K08AR068470.	Alexander PG, 2013, CARTILAGE, V4, P52, DOI 10.1177/1947603512455195; Ali MH, 2004, AM J PHYSIOL-LUNG C, V287, pL486, DOI 10.1152/ajplung.00389.2003; Anderson DD, 2011, J ORTHOP RES, V29, P802, DOI 10.1002/jor.21359; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; Blanco FJ, 2011, NAT REV RHEUMATOL, V7, P161, DOI 10.1038/nrrheum.2010.213; Bonnevie ED, 2016, OSTEOARTHR CARTILAGE, V24, pS46, DOI 10.1016/j.joca.2016.01.107; Bonnevie ED, 2015, CARTILAGE, V6, P226, DOI 10.1177/1947603515595071; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Brouillette MJ, 2014, BIOMECH MODEL MECHAN, V13, P565, DOI 10.1007/s10237-013-0518-8; Buckwalter Joseph A, 2012, HSS J, V8, P37, DOI 10.1007/s11420-011-9251-y; CHAMPAGNE AM, 1987, EXP CELL RES, V171, P404, DOI 10.1016/0014-4827(87)90172-8; Cheng DS, 2012, PM&R, V4, pS82, DOI 10.1016/j.pmrj.2012.02.009; Chubinskaya S, 2013, CARTILAGE, V4, p13S, DOI 10.1177/1947603513487457; Cillero-Pastor B, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-235; Cole B. J, 2009, BIOL JOINT RECONSTRU; Coleman MC, 2016, ARTHRITIS RHEUMATOL, V68, P662, DOI 10.1002/art.39460; Curl WW, 1997, ARTHROSCOPY, V13, P456, DOI 10.1016/S0749-8063(97)90124-9; Dai Dao-Fu, 2014, Longev Healthspan, V3, P6, DOI 10.1186/2046-2395-3-6; Delco ML, 2017, J ORTHOP RES, V35, P440, DOI 10.1002/jor.23462; Diaz-Romero J, 2005, J CELL PHYSIOL, V202, P731, DOI 10.1002/jcp.20164; Farnsworth NL, 2012, J BIOMECH, V45, P2556, DOI 10.1016/j.jbiomech.2012.07.035; Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095; Garrido CP, 2009, OSTEOARTHR CARTILAGE, V17, P1244, DOI 10.1016/j.joca.2009.03.007; Gavriilidis C, 2013, ARTHRITIS RHEUM-US, V65, P378, DOI 10.1002/art.37782; Goetz JE, 2017, J ORTHOP RES, V35, P590, DOI 10.1002/jor.23327; Goodwin W, 2010, J ORTHOP RES, V28, P1057, DOI 10.1002/jor.21091; Grimshaw MJ, 2000, OSTEOARTHR CARTILAGE, V8, P386, DOI 10.1053/joca.1999.0314; Heywood HK, 2006, J CELL PHYSIOL, V206, P402, DOI 10.1002/jcp.20491; Huser CAA, 2007, ARTHRITIS RHEUM-US, V56, P2322, DOI 10.1002/art.22717; Huser CAM, 2006, OSTEOARTHR CARTILAGE, V14, P1002, DOI 10.1016/j.joca.2006.03.012; Jadin KD, 2005, J HISTOCHEM CYTOCHEM, V53, P1109, DOI 10.1369/jhc.4A6511.2005; Johnson K, 2000, ARTHRITIS RHEUM-US, V43, P1560, DOI 10.1002/1529-0131(200007)43:7<1560::AID-ANR21>3.3.CO;2-J; Kramer WC, 2011, INT J CLIN EXP MED, V4, P285; Kurz B, 2004, ARTHRITIS RHEUM, V50, P123, DOI 10.1002/art.11438; Leary S, 2013, AVMA GUIDELINES EUTH; Lee HC, 2005, INT J BIOCHEM CELL B, V37, P822, DOI 10.1016/j.biocel.2004.09.010; Madeti BK, 2015, FRONT MECH ENG, V10, P176, DOI 10.1007/s11465-014-0306-x; Maneiro E, 2003, ARTHRITIS RHEUM, V48, P700, DOI 10.1002/art.10837; MAROUDAS A, 1970, BIOPHYS J, V10, P365, DOI 10.1016/S0006-3495(70)86307-X; Martin JA, 2009, J BONE JOINT SURG AM, V91A, P1890, DOI 10.2106/JBJS.H.00545; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Novakofski KD, 2015, OSTEOARTHR CARTILAGE, V23, P1130, DOI 10.1016/j.joca.2015.02.023; Ohashi T, 2006, BIORHEOLOGY, V43, P201; Olsen RKJ, 2015, J INHERIT METAB DIS, V38, P703, DOI 10.1007/s10545-015-9861-5; Pagano G, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/541230; Rajpurohit R, 1996, J CELL PHYSIOL, V168, P424, DOI 10.1002/(SICI)1097-4652(199608)168:2<424::AID-JCP21>3.0.CO;2-1; Ruiz-Romero C, 2009, MOL CELL PROTEOMICS, V8, P172, DOI 10.1074/mcp.M800292-MCP200; Sauter E, 2012, J ORTHOP RES, V30, P593, DOI 10.1002/jor.21552; Schnabel M, 2002, OSTEOARTHR CARTILAGE, V10, P62, DOI 10.1053/joca.2001.0482; Schneider N, 2007, CELL BIOL INT, V31, P878, DOI 10.1016/j.cellbi.2007.02.002; Schuh RA, 2011, J NEUROSCI RES, V89, P1979, DOI 10.1002/jnr.22650; Silverberg JL, 2013, J ORTHOP RES, V31, P686, DOI 10.1002/jor.22303; Soubannier V, 2009, BBA-MOL CELL RES, V1793, P154, DOI 10.1016/j.bbamcr.2008.07.008; Stackley KD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025652; Strobel S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2942; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Szafranski JD, 2004, OSTEOARTHR CARTILAGE, V12, P937, DOI 10.1016/j.joca.2004.08.004; Zhou SD, 2004, ARTHRITIS RHEUM-US, V50, P3915, DOI 10.1002/art.20675	58	21	22	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0736-0266	1554-527X		J ORTHOP RES	J. Orthop. Res.	FEB	2018	36	2			SI		739	750		10.1002/jor.23651			12	Orthopedics	Orthopedics	FY3PP	WOS:000426733700022	28696002	Green Accepted			2021-06-18	
J	Novgorodov, SA; Voltin, JR; Gooz, MA; Li, L; Lemasters, JJ; Gudz, TI				Novgorodov, Sergei A.; Voltin, Joshua R.; Gooz, Monika A.; Li, Li; Lemasters, John J.; Gudz, Tatyana I.			Acid sphingomyelinase promotes mitochondrial dysfunction due to glutamate-induced regulated necrosis	JOURNAL OF LIPID RESEARCH			English	Article						brain lipids; ferroptosis; glutamate/cystine antiporter; lipids/peroxidation; mitochondria; sphingolipids; sirtuin; oligodendrocytes	DELTA-MEDIATED PHOSPHORYLATION; ANTIPORTER SYSTEM X(C)(-); NONAPOPTOTIC CELL-DEATH; TRAUMATIC BRAIN-INJURY; PERMEABILITY TRANSITION; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; CYSTINE/GLUTAMATE ANTIPORTER; THERAPEUTIC OPPORTUNITIES; NEUTRAL CERAMIDASE	Inhibiting the glutamate/cystine antiporter system x(c)(-), a key antioxidant defense machinery in the CNS, could trigger a novel form of regulated necrotic cell death, ferroptosis. The underlying mechanisms of system xc. dependent cell demise were elucidated using primary oligodendrocytes (OLs) treated with glutamate to block system xc. function. Pharmacological analysis revealed ferroptosis as a major contributing factor to glutamate-initiated OL death. A sphingolipid profile showed elevations of ceramide species and sphingosine that were preventable by inhibiting of an acid sphingomyelinase (ASM) activity. OL survival was enhanced by both downregulating ASM expression and blocking ASM activity. Glutamate-induced ASM activation seems to involve posttranscriptional mechanisms and was associated with a decreased GSH level. Further investigation of the mechanisms of OL response to glutamate revealed enhanced reactive oxygen species production, augmented lipid peroxidation, and opening of the mitochondrial permeability transition pore that were attenuated by hindering ASM. Of note, knocking down sirtuin 3, a deacetylase governing the mitochondrial antioxidant system, reduced OL survival. The data highlight the importance of the mitochondrial compartment in regulated necrotic cell death and accentuate the novel role of ASM in disturbing mitochondrial functions during OL response to glutamate toxicity, which is essential for pathobiology in stroke and traumatic brain injury.	[Novgorodov, Sergei A.; Voltin, Joshua R.; Gudz, Tatyana I.] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Gooz, Monika A.; Li, Li; Lemasters, John J.] Med Univ South Carolina, Dept Drug Discovery, Charleston, SC 29425 USA; [Gudz, Tatyana I.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Gudz, TI (corresponding author), Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA.; Gudz, TI (corresponding author), Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.	gudz@musc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS083544, R01DK073336, P30 GM103339]; Veterans Affairs Merit AwardUS Department of Veterans Affairs [I01BX002991]; US Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [S10OD018113]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK073336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS083544] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002991] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health Grants R01NS083544 (T.I.G.) and R01DK073336 (J.J.L.), Veterans Affairs Merit Award I01BX002991 (T.I.G.). The Lipidomics Core facility at the Medical University of South Carolina was supported, in part, by National Institutes of Health Grant P30 GM103339. The Cell Imaging Core facility at Medical University of South Carolina was supported, in part, by US Public Health Service Grant S10OD018113. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Albrecht P, 2010, CNS NEUROL DISORD-DR, V9, P373, DOI 10.2174/187152710791292567; Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Bai AP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177805; Beckmann N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00331; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bernardi P, 2015, J MOL CELL CARDIOL, V78, P100, DOI 10.1016/j.yjmcc.2014.09.023; Brennan-Minnella AM, 2015, ANTIOXID REDOX SIGN, V22, P161, DOI 10.1089/ars.2013.5767; Bridges RJ, 2012, BRIT J PHARMACOL, V165, P20, DOI 10.1111/j.1476-5381.2011.01480.x; Canals D, 2011, BRIT J PHARMACOL, V163, P694, DOI 10.1111/j.1476-5381.2011.01279.x; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Chudakova DA, 2008, J BIOL CHEM, V283, P28806, DOI 10.1074/jbc.M803301200; Clarke CJ, 2011, ADV ENZYME REGUL, V51, P51, DOI 10.1016/j.advenzreg.2010.09.016; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2013, CELL DEATH DIFFER, V20, P366, DOI 10.1038/cdd.2012.133; Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Finley LWS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023295; Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95; Gerencser AA, 2009, ANAL CHEM, V81, P6868, DOI 10.1021/ac900881z; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Giorgio V, 2009, J BIOL CHEM, V284, P33982, DOI 10.1074/jbc.M109.020115; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Gulbins E, 2006, AM J PHYSIOL-REG I, V290, pR11, DOI 10.1152/ajpregu.00416.2005; Gulbins E, 2013, NAT MED, V19, P934, DOI 10.1038/nm.3214; Hafner AV, 2010, AGING-US, V2, P914, DOI 10.18632/aging.100252; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Henry Brian, 2013, Handb Exp Pharmacol, P77, DOI 10.1007/978-3-7091-1368-4_4; Herr I, 1999, BRAIN RES, V826, P210, DOI 10.1016/S0006-8993(99)01288-3; Hill BG, 2012, J MOL CELL CARDIOL, V52, P559, DOI 10.1016/j.yjmcc.2011.07.009; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Jenkins RW, 2011, J BIOL CHEM, V286, P3777, DOI 10.1074/jbc.M110.155234; Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341; Kassmann CM, 2008, CURR OPIN NEUROL, V21, P235, DOI 10.1097/WCO.0b013e328300c71f; Kim YA, 2013, BIOMOL THER, V21, P358, DOI 10.4062/biomolther.2013.065; Kincaid B, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00048; Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006; Kolzer M, 2004, FEBS LETT, V559, P96, DOI 10.1016/S0014-5793(04)00033-X; Kornhuber J, 2010, CELL PHYSIOL BIOCHEM, V26, P9, DOI 10.1159/000315101; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lee JK, 2014, J EXP MED, V211, P1551, DOI 10.1084/jem.20132451; Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391; Li X, 2012, CELL PHYSIOL BIOCHEM, V30, P815, DOI 10.1159/000341460; Maldonado EN, 2016, J BIOL CHEM, V291, P19642, DOI 10.1074/jbc.M116.734814; Martinez TN, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-45; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Miller OG, 2015, ARCH TOXICOL, V89, P1439, DOI 10.1007/s00204-015-1496-7; Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Novgorodov AS, 2007, FASEB J, V21, P1503, DOI 10.1096/fj.06-7420com; NOVGORODOV SA, 1991, BIOCHIM BIOPHYS ACTA, V1058, P242, DOI 10.1016/S0005-2728(05)80243-9; Novgorodov SA, 2016, J BIOL CHEM, V291, P1957, DOI 10.1074/jbc.M115.668228; Novgorodov SA, 2014, J BIOL CHEM, V289, P13142, DOI 10.1074/jbc.M113.530311; Novgorodov Sergei A, 2011, Int J Biochem Mol Biol, V2, P347; Novgorodov SA, 2011, J BIOL CHEM, V286, P4644, DOI 10.1074/jbc.M110.164392; Ohtani R, 2004, BRAIN RES, V1023, P31, DOI 10.1016/j.brainres.2004.07.024; OKA A, 1993, J NEUROSCI, V13, P1441; Panov AV, 2005, MOL CELL BIOCHEM, V269, P143, DOI 10.1007/s11010-005-3454-9; Pap EHW, 1999, FEBS LETT, V453, P278, DOI 10.1016/S0014-5793(99)00696-1; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Roth AG, 2009, ANGEW CHEM INT EDIT, V48, P7560, DOI 10.1002/anie.200903288; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Spitzer S, 2016, NEUROPHARMACOLOGY, V110, P574, DOI 10.1016/j.neuropharm.2016.06.014; Stancevic B, 2010, FEBS LETT, V584, P1728, DOI 10.1016/j.febslet.2010.02.026; Sundaram K, 2016, BIOCHEM J, V473, P743, DOI 10.1042/BJ20150586; Tait SWG, 2014, J CELL SCI, V127, P2135, DOI 10.1242/jcs.093575; Tam C, 2010, J CELL BIOL, V189, P1027, DOI 10.1083/jcb.201003053; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yu J, 2007, J BIOL CHEM, V282, P25940, DOI 10.1074/jbc.M701812200; Yu ZF, 2000, J MOL NEUROSCI, V15, P85, DOI 10.1385/JMN:15:2:85; Zeidan YH, 2008, FASEB J, V22, P183, DOI 10.1096/fj.07-8967com; Zeidan YH, 2007, J BIOL CHEM, V282, P11549, DOI 10.1074/jbc.M609424200; Zigdon H, 2013, J BIOL CHEM, V288, P4947, DOI 10.1074/jbc.M112.402719; Zilka O, 2017, ACS CENTRAL SCI, V3, P232, DOI 10.1021/acscentsci.7b00028	84	21	21	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0022-2275	1539-7262		J LIPID RES	J. Lipid Res.	FEB	2018	59	2					312	329		10.1194/jlr.M080374			18	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	FW0IM	WOS:000424977400012	29282302	Other Gold, Green Published			2021-06-18	
J	Silverberg, ND; Panenka, WJ; Iverson, GL				Silverberg, Noah D.; Panenka, William J.; Iverson, Grant L.			Work Productivity Loss After Mild Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Craniocerebral trauma; Occupational health; Post-concussion syndrome; Presenteeism; Rehabilitation; Return to work	HEAD-INJURY; TO-WORK; DSM-IV; RETURN; SYMPTOMS; CONCUSSION; DISABILITY; EMPLOYMENT; PREDICTION; COMPLAINTS	Objectives: To examine the completeness of return to work (RTW) and the degree of productivity loss in individuals who do achieve a complete RTW after mild traumatic brain injury (MTBI). Design: Multisite prospective cohort. Setting: Outpatient concussion clinics. Participants: Patients (N=79; mean age, 41.5y; 55.7% women) who sustained an MTBI and were employed at the time of the injury. Participants were enrolled at their first clinic visit and assessed by telephone 6 to 8 months postinjury. Interventions: Not applicable. Main Outcome Measures: Structured interview of RTW status, British Columbia Postconcussion Symptom Inventory (BC-PSI), Lam Employment Absence and Productivity Scale (LEAPS), Mini International Neuropsychiatric Interview, and brief pain questionnaire. Participants who endorsed symptoms from >= 3 categories with at least moderate severity on the BC-PSI were considered to meet International Classification of Diseases, 10th Revision criteria for postconcussional syndrome. RTW status was classified as complete if participants returned to their preinjury job with the same hours and responsibilities or to a new job that was at least as demanding. Results: Of the 46 patients (58.2%) who achieved an RTW, 33 (71.7%) had a complete RTW. Participants with complete RTW had high rates of postconcussional syndrome (44.5%) and comorbid depression (18.2%), anxiety disorder (24.2%), and bodily pain (30.3%). They also reported productivity loss on the LEAPS, such as "getting less work done" (60.6%) and "making more mistakes" (42.4%). In a regression model, productivity loss was predicted by the presence of postconcussional syndrome and a comorbid psychiatric condition, but not bodily pain. Conclusions: Even in patients who RTW after MTBI, detailed assessment revealed underemployment and productivity loss associated with residual symptoms and psychiatric complications. (C) 2017 by the American Congress of Rehabilitation Medicine	[Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada; [Silverberg, Noah D.; Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Panenka, William J.] British Columbia Neuropsychiat Program, Vancouver, BC, Canada; [Panenka, William J.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] A Red Sox Fdn, Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA	Silverberg, ND (corresponding author), GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570; Panenka, William/0000-0001-7143-6512	WorkSafeBC [RS2014-SP03]; Vancouver Coastal Health Research Institute	Supported by a Specific Priorities Research Grant from WorkSafeBC (grant no. RS2014-SP03), and by a Clinician-Scientist Career Development Award from the Vancouver Coastal Health Research Institute.	Baldwin ML, 1996, AM J IND MED, V29, P632; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BUTLER RJ, 1995, IND LABOR RELAT REV, V48, P452, DOI 10.2307/2524774; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Koning ME, 2017, J NEUROTRAUM, V34, P257, DOI 10.1089/neu.2015.4377; Franche RL, 2005, J OCCUP REHABIL, V15, P607, DOI 10.1007/s10926-005-8038-8; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jackson CE, 2017, BRAIN INJURY, V31, P485, DOI 10.1080/02699052.2017.1280740; Kendrick D, 2012, BRAIN INJURY, V26, P1243, DOI 10.3109/02699052.2012.672787; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Krause N, 1998, J OCCUP REHABIL, V8, P113, DOI 10.1023/A:1023015622987; Kristman VL, 2010, OPEN OCCUP HLTH SAF, V2, P1, DOI DOI 10.2174/1876216601002010001; Lam RW, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-78; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; Lucas S, 2016, HEADACHE, V56, P323, DOI 10.1111/head.12762; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; Ospina MB, 2015, AM J MANAG CARE, V21, pE171; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Schultz AB, 2007, J OCCUP REHABIL, V17, P547, DOI 10.1007/s10926-007-9096-x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vikane E, 2014, BRAIN INJURY, V9052, P1; Vikane E, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/8026414; Waddell G., 2006, IS WORK GOOD YOUR HL; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002	35	21	21	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2018	99	2					250	256		10.1016/j.apmr.2017.07.006			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FU7YX	WOS:000424069800005	28760573				2021-06-18	
J	Allan, V; Vierimaa, M; Gainforth, HL; Cote, J				Allan, Veronica; Vierimaa, Matthew; Gainforth, Heather L.; Cote, Jean			The use of behaviour change theories and techniques in research-informed coach development programmes: a systematic review	INTERNATIONAL REVIEW OF SPORT AND EXERCISE PSYCHOLOGY			English	Article						Sport coaching; coach education; implementation science	MOTIVATIONAL CLIMATE INTERVENTION; FOR-DISEASE-CONTROL; PHYSICAL-ACTIVITY; SOCIAL SUPPORT; SPORTS COACHES; SELF-ESTEEM; EDUCATION; PERFORMANCE; EXPERIENCES; CONCUSSION	Coaches are often targeted in interventions to enhance athlete outcomes. While coach development programmes (CDPs) may change coach behaviour, little is known about theories and techniques used to design and implement effective programmes. Examining the use of behaviour change theories and techniques (BCTs) can aid in understanding and improving CDPs. Adhering to PRISMA guidelines, the purpose of this research was to conduct a systematic review examining the use of behaviour change theories and BCTs in CDPs. In total, 29 CDPs met the inclusion criteria. Data were extracted using the Theory Coding Scheme and Behaviour Change Technique Taxonomy (v1). Only six CDPs were explicitly based on behaviour change theory, and no single theory or combination of theories was used more than once. The number of BCTs used per CDP ranged between one and nine. There was no significant difference between theory-based and non-theory-based CDPs concerning the number of BCTs used per CDP. Theoretical frameworks and techniques that have the potential to effectively change coach behaviours are not being used frequently or consistently in the design and implementation of CDPs. To design CDPs that change coach behaviours and facilitate positive outcomes, further research examining theoretical influences on coach behaviours is needed.	[Allan, Veronica; Cote, Jean] Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada; [Vierimaa, Matthew] Utah State Univ, Dept Kinesiol & Hlth Sci, Logan, UT 84322 USA; [Gainforth, Heather L.] Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada	Allan, V (corresponding author), Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada.	7vra@queensu.ca	Cote, Jean/D-6344-2014				Banack HR, 2012, INT J SPORTS SCI COA, V7, P301, DOI 10.1260/1747-9541.7.2.301; Barnett NP., 1992, SPORT PSYCHOL, V6, P111, DOI DOI 10.1123/TSP.6.2.111; Blom L. C., 2010, ATHLETIC INSIGHT, V12, P187; Bowes I, 2006, SPORT PSYCHOL, V20, P235, DOI 10.1123/tsp.20.2.235; Bruner Mark, 2009, INT REV SPORT EXER P, V2, P23, DOI [10.1080/17509840802687631, DOI 10.1080/17509840802687631]; Bruner MW, 2010, PSYCHOL SPORT EXERC, V11, P133, DOI 10.1016/j.psychsport.2009.05.008; BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V; Callary B, 2014, INT SPORT COACH J, V1, P152, DOI 10.1123/iscj.2014-0094; Callow N, 2010, SPORT PSYCHOL, V24, P277, DOI 10.1123/tsp.24.3.277; Cassidy T., 2009, UNDERSTANDING SPORTS, V3rd ed.; Chambers KL, 2006, SPORT PSYCHOL, V20, P184, DOI 10.1123/tsp.20.2.184; Cheon SH, 2015, PSYCHOL SPORT EXERC, V19, P59, DOI 10.1016/j.psychsport.2015.02.007; Coatsworth JD, 2006, PSYCHOL SPORT EXERC, V7, P173, DOI 10.1016/j.psychsport.2005.08.005; Conroy DE, 2006, SPORT PSYCHOL, V20, P128, DOI 10.1123/tsp.20.2.128; Cushion C., 2010, COACH LEARNING DEV R; Cushion C. J., 2006, INT J SPORTS SCI COA, V1, P247, DOI DOI 10.1260/174795406778604627; Davies P, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-14; Duda JL, 2013, INT J SPORT EXERC PS, V11, P319, DOI 10.1080/1612197X.2013.839413; Duda JL, 2013, INT J SPORT EXERC PS, V11, P311, DOI 10.1080/1612197X.2013.839414; Duncan EM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-86; Edwards J, 2012, INT J SPORTS SCI COA, V7, P317, DOI 10.1260/1747-9541.7.2.317; Evans MB, 2015, BRIT J SPORT MED, V49, P871, DOI 10.1136/bjsports-2015-094634; Franks IM, 1991, J SPORT SCI, V9, P285, DOI 10.1080/02640419108729890; Fraser-Thomas J. L., 2005, Physical Education and Sport Pedagogy, V10, P19, DOI 10.1080/1740898042000334890; Fraser-Thomas J, 2009, SPORT PSYCHOL, V23, P3, DOI 10.1123/tsp.23.1.3; Gainforth HL, 2015, ANN BEHAV MED, V49, P754, DOI 10.1007/s12160-015-9710-7; Gianotti S, 2010, J SCI MED SPORT, V13, P32, DOI 10.1016/j.jsams.2008.07.010; Gilbert WD, 2004, RES Q EXERCISE SPORT, V75, P388, DOI 10.1080/02701367.2004.10609172; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Guagliano JM, 2015, J SCI MED SPORT, V18, P678, DOI 10.1016/j.jsams.2015.05.005; Guagliano JM, 2015, J SCI MED SPORT, V18, P412, DOI 10.1016/j.jsams.2015.01.014; Guagliano JM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-383; Hall C. R., 1989, SPORT PSYCHOL, V3, P142, DOI DOI 10.1123/TSP.3.2.142; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hilland TA, 2015, INT J HEALTH PROMOT, V53, P2, DOI 10.1080/14635240.2014.915758; Jones R. L., 2006, Physical Education and Sport Pedagogy, V11, P181, DOI 10.1080/17408980600708429; Jones RL, 2005, SPORT EDUC SOC, V10, P119, DOI 10.1080/1357332052000308792; Knowles Z., 2001, REFLECTIVE PRACTICE, V2, P185, DOI DOI 10.1080/14623940123820; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langdon J, 2015, J HUM SPORT EXERC, V10, P1, DOI 10.14198/jhse.2015.101.01; Larsen T, 2015, HEALTH EDUC, V115, P570, DOI 10.1108/HE-04-2014-0054; Longshore K, 2015, J CLIN SPORT PSYCHOL, V9, P116, DOI 10.1123/jcsp.2014-0038; Malete L, 2000, SPORT PSYCHOL, V14, P410, DOI 10.1123/tsp.14.4.410; McCullick B. A., 2005, Physical Education and Sport Pedagogy, V10, P121, DOI 10.1080/17408980500105015; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McLaren CD, 2015, SPORT EXERC PERFORM, V4, P113, DOI 10.1037/spy0000026; McSherry LA, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-73; Medical Research Council, 2008, DEV EV COMPL INT NEW; Michie S., 2014, ABC BEHAV CHANGE THE; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10; Michie S, 2010, HEALTH PSYCHOL, V29, P1, DOI 10.1037/a0016939; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Nagel Ernest, 1979, STRUCTURE SCI; Nelson L, 2013, PHYS EDUC SPORT PEDA, V18, P204, DOI 10.1080/17408989.2011.649725; Overton W. F., 2006, THEORETICAL MODELS H, V1, P18; Painter JE, 2008, ANN BEHAV MED, V35, P358, DOI 10.1007/s12160-008-9042-y; Meeus MSP, 2010, J CLIN SPORT PSYCHOL, V4, P323, DOI 10.1123/jcsp.4.4.323; Pensgaard AM, 2000, J SPORT SCI, V18, P191, DOI 10.1080/026404100365090; Pensgaard AM, 2002, SCAND J MED SCI SPOR, V12, P54, DOI 10.1034/j.1600-0838.2002.120110.x; Prestwich A, 2014, HEALTH PSYCHOL, V33, P465, DOI 10.1037/a0032853; Rangeon S, 2012, INT SPORT COACH J, V5, P83, DOI 10.1123/jce.5.1.83; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; SMITH RE, 1995, J APPL DEV PSYCHOL, V16, P125, DOI 10.1016/0193-3973(95)90020-9; Smith RE, 2007, J SPORT EXERCISE PSY, V29, P39, DOI 10.1123/jsep.29.1.39; SMOLL FL, 1993, J APPL PSYCHOL, V78, P602, DOI 10.1037/0021-9010.78.4.602; Smoll FL, 2007, J CLIN SPORT PSYCHOL, V1, P23, DOI 10.1123/jcsp.1.1.23; Sousa C, 2008, J CLIN SPORT PSYCHOL, V2, P258, DOI 10.1123/jcsp.2.3.258; Stebbings J, 2012, J SPORT EXERCISE PSY, V34, P481, DOI 10.1123/jsep.34.4.481; Stebbings J, 2011, J SPORT EXERCISE PSY, V33, P255, DOI 10.1123/jsep.33.2.255; Tavender EJ, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-8; Thompson Neil, 2003, THEORY PRACTICE HUMA; Vella SA, 2013, INT J SPORTS SCI COA, V8, P513, DOI 10.1260/1747-9541.8.3.513; Vella SA, 2013, INT J SPORTS SCI COA, V8, P417, DOI 10.1260/1747-9541.8.2.417; Werthner P, 2006, SPORT PSYCHOL, V20, P198, DOI 10.1123/tsp.20.2.198; Zakrajsek RA, 2008, INT SPORT COACH J, V1, P66, DOI 10.1123/ice.1.1.66	77	21	21	2	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1750-984X	1750-9858		INT REV SPORT EXER P	Int. Rev. Sport Exerc. Psychol.		2018	11	1					47	69		10.1080/1750984X.2017.1286514			23	Hospitality, Leisure, Sport & Tourism; Psychology, Applied	Social Sciences - Other Topics; Psychology	GL1BH	WOS:000436829700003					2021-06-18	
J	Chen, M; Song, HL; Cui, JK; Johnson, CE; Hubler, GK; DePalma, RG; Gu, ZZ; Xia, WM				Chen, Mei; Song, Hailong; Cui, Jiankun; Johnson, Catherine E.; Hubler, Graham K.; DePalma, Ralph G.; Gu, Zezong; Xia, Weiming			Proteomic Profiling of Mouse Brains Exposed to Blast-Induced Mild Traumatic Brain Injury Reveals Changes in Axonal Proteins and Phosphorylated Tau	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; bioinformatics; mild traumatic brain injury; open-field blast; proteomics	NEUROFIBRILLARY TANGLES; MODEL; MICE; EXPRESSION; CSF; ASSOCIATION; BIOMARKERS; CALCIUM; DISEASE; PLASMA	Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by two pathological hallmarks: Tau-containing neurofibrillary tangles and amyloid-beta protein (A beta)-containing neuritic plaques. The goal of this study is to understand mild traumatic brain injury (mTBI)-related brain proteomic changes and tau-related biochemical adaptations that may contribute to AD-like neurodegeneration. We found that both phosphorylated tau (p-tau) and the ratio of p-tau/tau were significantly increased in brains of mice collected at 3 and 24 h after exposure to 82-kPa low-intensity open-field blast. Neurological deficits were observed in animals at 24 h and 7 days after the blast using Simple Neuroassessment of Asymmetric imPairment (SNAP) test, and axon/dendrite degeneration was revealed at 7 days by silver staining. Liquid chromatography-mass spectrometry (LC-MS/MS) was used to analyze brain tissue labeled with isobaric mass tags for relative protein quantification. The results from the proteomics and bioinformatic analysis illustrated the alterations of axonal and synaptic proteins in related pathways, including but not being limited to substantia nigra development, cortical cytoskeleton organization, and synaptic vesicle exocytosis, suggesting a potential axonal damage caused by blast-induced mTBI. Among altered proteins found in brains suffering blast, microtubule-associated protein 1B, stathmin, neurofilaments, actin binding proteins, myelin basic protein, calcium/calmodulin-dependent protein kinase, and synaptotagmin I were representative ones involved in altered pathways elicited by mTBI. Therefore, TBI induces elevated phospho-tau, a pathological feature found in brains of AD, and altered a number of neurophysiological processes, supporting the notion that blast-induced mTBI as a risk factor contributes to AD pathogenesis. LC/MS-based profiling has presented candidate target/pathways that could be explored for future therapeutic development.	[Chen, Mei; Xia, Weiming] Edith Nourse Rogers Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Off Res & Dev, Bedford, MA 01730 USA; [Chen, Mei] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Song, Hailong; Cui, Jiankun; Gu, Zezong] Univ Missouri, Dept Pathol & Anat Sci, Sch Med, Columbia, MO 65212 USA; [Johnson, Catherine E.] Missouri Univ Sci & Technol, Dept Min & Nucl Engn, Rolla, MO USA; [Cui, Jiankun; Gu, Zezong] Truman VA Hosp Res Serv, Columbia, MO USA; [Hubler, Graham K.] Univ Missouri, Sidney Kimmel Inst Nucl Renaissance, Dept Phys & Astron, Columbia, MO 65212 USA; [DePalma, Ralph G.] Dept Vet Affairs, Off Res & Dev, Washington, DC USA; [DePalma, Ralph G.] Uniformed Univ Hlth Sci, Dept Surg, Bethesda, MD USA; [Xia, Weiming] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA	Gu, ZZ (corresponding author), Univ Missouri, Sch Med, Ctr Translat Neurosci, Dept Pathol & Anat Sci, Columbia, MO 65212 USA.; Xia, WM (corresponding author), Edith Nourse Rogers Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Bldg 70,Room 202, Bedford, MA 01730 USA.	guze@health.missouri.edu; weiming.xia@va.gov	DePalma, Ralph/P-1733-2019; Song, Hailong/I-9418-2018	Song, Hailong/0000-0002-4204-6459	Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development [I01BX003527, I21 BX003807]; Cure Alzheimer's Fund; DoD Congressionally Directed Medical Research Programs (CDMRP) for the Peer Reviewed Alzheimer's Research Program Convergence Science Research Award (PRARP-CSRA) [AZ140109]; University of Missouri; Veterans AffairsUS Department of Veterans Affairs [I01BX003527] Funding Source: NIH RePORTER	We thank Dr. Guy Surpris and Benjamin Morris-Eppolito for critical discussions. This study was supported by the award I01BX003527 and I21 BX003807 from the Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development (WX) and the Cure Alzheimer's Fund (WX). This publication-was also made possible by funding from the DoD Congressionally Directed Medical Research Programs (CDMRP) for the Peer Reviewed Alzheimer's Research Program Convergence Science Research Award (PRARP-CSRA; AZ140109) and the research funds of the University of Missouri (ZG). The views expressed in this article are those of the authors and do not represent the views of the US Department of Veterans Affairs or the US Government.	Albayram O, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01068-4; Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bourne JN, 2008, ANNU REV NEUROSCI, V31, P47, DOI 10.1146/annurev.neuro.31.060407.125646; Boutte AM, 2012, ELECTROPHORESIS, V33, P3693, DOI 10.1002/elps.201200196; Chen M, 2018, J PROTEOMICS, V182, P21, DOI 10.1016/j.jprot.2018.04.032; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dieterich DC, 2002, EUR J NEUROSCI, V15, P1433, DOI 10.1046/j.1460-9568.2002.01977.x; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Evans Teresa M, 2014, Transl Proteom, V3, P10; Fagan AM, 2007, ARCH NEUROL-CHICAGO, V64, P343, DOI 10.1001/archneur.64.3.noc60123; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodrich JA, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0395-3; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gupta R, 2005, J ORTHOP RES, V23, P1232, DOI 10.1016/j.orthres.2004.12.010; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hutton M, 2000, ANN NY ACAD SCI, V920, P63; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson MC, 2016, ACS OMEGA, V1, P663, DOI 10.1021/acsomega.6b00220; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Lee HK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163072; Lewis J, 2000, NAT GENET, V25, P402; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Lund LM, 2002, J NEUROSCI RES, V67, P720, DOI 10.1002/jnr.10162; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martinez-Morillo E, 2015, CLIN CHEM LAB MED, V53, P1575, DOI 10.1515/cclm-2014-0908; Menon DK, 2015, NAT REV NEUROL, V11, P71, DOI 10.1038/nrneurol.2014.261; Merriam EB, 2013, J NEUROSCI, V33, P16471, DOI 10.1523/JNEUROSCI.0661-13.2013; Miyasaka T, 2010, FEBS LETT, V584, P3227, DOI 10.1016/j.febslet.2010.06.014; Mouzon B, 2019, J NEUROTRAUM, V36, P576, DOI 10.1089/neu.2018.5720; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Sarkis GA, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0736-z; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; Shaw LM, 2011, ACTA NEUROPATHOL, V121, P597, DOI 10.1007/s00401-011-0808-0; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Song H, 2018, J PROTEOME RES, V17, P858, DOI 10.1021/acs.jproteome.7b00618; Song HL, 2018, BEHAV BRAIN RES, V340, P147, DOI 10.1016/j.bbr.2016.08.037; Song HL, 2018, BEHAV BRAIN RES, V347, P148, DOI 10.1016/j.bbr.2018.03.007; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tortosa E, 2011, J BIOL CHEM, V286, P40638, DOI 10.1074/jbc.M111.271320; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tzekov R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153608; Uchida S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5389; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Yang WJ, 2017, ACTA NEUROL SCAND, V135, P622, DOI 10.1111/ane.12644; Yap YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176997; Zhang MY, 2012, J MOL NEUROSCI, V46, P631, DOI 10.1007/s12031-011-9651-y; Zupanc GKH, 2007, PROTEOM CLIN APPL, V1, P1362, DOI 10.1002/prca.200700420	61	21	21	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2018	66	2					751	773		10.3233/JAD-180726			23	Neurosciences	Neurosciences & Neurology	HB6ZU	WOS:000451224700028	30347620	Green Accepted			2021-06-18	
S	Coleman, LG; Crews, FT		Grant, KA; Lovinger, DM		Coleman, Leon G., Jr.; Crews, Fulton T.			Innate Immune Signaling and Alcohol Use Disorders	NEUROPHARMACOLOGY OF ALCOHOL	Handbook of Experimental Pharmacology		English	Article; Book Chapter						Addiction; Alcohol; Neuroimmune; Treatment	NF-KAPPA-B; INTERMITTENT ETHANOL EXPOSURE; NEURO-IMMUNOLOGICAL FACTORS; TRAUMATIC BRAIN-INJURY; TOLL-LIKE RECEPTOR-3; MICROGLIAL ACTIVATION; NUCLEAR-FACTOR; TNF-ALPHA; INDUCED NEUROINFLAMMATION; INFLAMMATORY MEDIATORS	Innate immune signaling is an important feature in the pathology of alcohol use disorders. Alcohol abuse causes persistent innate immune activation in the brain. This is seen in postmortem human alcoholic brain specimens, as well as in primate and rodent models of alcohol consumption. Further, in vitro models of alcohol exposure in neurons and glia also demonstrate innate immune activation. The activation of the innate immune system seems to be important in the development of alcohol use pathology, as anti-immune therapies reduce pathology and ethanol self-administration in rodent models. Further, innate immune activation has been identified in each of the stages of addiction: binge/ intoxication, withdrawal/negative affect, and preoccupation/craving. This suggests that innate immune activation may play a role both in the development and maintenance of alcoholic pathology. In this chapter, we discuss the known contributions of innate immune signaling in the pathology of alcohol use disorders, and present potential therapeutic interventions that may be beneficial for alcohol use disorders.	[Coleman, Leon G., Jr.; Crews, Fulton T.] Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; [Coleman, Leon G., Jr.; Crews, Fulton T.] Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	Coleman, LG (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA.; Coleman, LG (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.	leon_coleman@med.unc.edu; fulton_crews@med.unc.edu	Crews, Fulton/None	Crews, Fulton/0000-0003-2393-4976; Coleman, Leon/0000-0003-1693-3799	National Institute on Alcohol Abuse and Alcoholism through the Neurobiology of Adolescent Drinking in Adulthood (NADIA) consortium [AA020024, AA020023]; Bowles Center for Alcohol Studies [AA011605]; NCCU [AA019767]; UNC [AA019767]; K08 award program [AA024829]; Monkey Alcohol and Tissue Research Resource [MATRR-R24 AA019431]	We thank the National Institute on Alcohol Abuse and Alcoholism for its support through the Neurobiology of Adolescent Drinking in Adulthood (NADIA) consortium (AA020024, AA020023), the Bowles Center for Alcohol Studies (AA011605), the U54 collaborative partnership between NCCU and UNC (AA019767), the K08 award program (AA024829), and the Monkey Alcohol and Tissue Research Resource (MATRR-R24 AA019431).	Agrawal RG, 2011, BRAIN BEHAV IMMUN, V25, pS165, DOI 10.1016/j.bbi.2011.03.002; Alfonso-Loeches S, 2010, J NEUROSCI, V30, P8285, DOI 10.1523/JNEUROSCI.0976-10.2010; Aloe L, 1999, BRAIN RES, V840, P125, DOI 10.1016/S0006-8993(99)01748-5; Arezoomandan R, 2016, CAN J PHYSIOL PHARM, V94, P257, DOI 10.1139/cjpp-2015-0209; Attarzadeh-Yazdi G, 2014, PROG NEURO-PSYCHOPH, V53, P142, DOI 10.1016/j.pnpbp.2014.04.008; Bachtell R, 2015, CNS NEUROL DISORD-DR, V14, P692, DOI 10.2174/1871527314666150529132503; Badanich KA, 2011, BEHAV NEUROSCI, V125, P879, DOI 10.1037/a0025922; Bai LY, 2014, NEUROSCI BULL, V30, P936, DOI 10.1007/s12264-014-1483-7; Bajo M, 2015, BRAIN BEHAV IMMUN, V45, P189, DOI 10.1016/j.bbi.2014.11.011; Bajo M, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00049; Ballester J, 2017, EXPERT REV CLIN PHAR, V10, P305, DOI 10.1080/17512433.2017.1268916; Banks WA, 1995, NEUROIMMUNOMODULAT, V2, P241, DOI 10.1159/000097202; BANKS WA, 1994, NEUROSCI LETT, V179, P53, DOI 10.1016/0304-3940(94)90933-4; Barbierato M, 2013, CNS NEUROL DISORD-DR, V12, P608; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bell RL, 2015, ADDICT BIOL, V20, P38, DOI 10.1111/adb.12106; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Bhattacharya A, 2017, CURR TOP BEHAV NEURO, V31, P339, DOI 10.1007/7854_2016_43; Bhattacharya A, 2016, PSYCHOPHARMACOLOGY, V233, P1623, DOI 10.1007/s00213-016-4214-0; Bi W, 2011, BRAIN RES, V1395, P12, DOI 10.1016/j.brainres.2011.04.019; Bian C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118842; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Blanc L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081593; Blanco AM, 2005, J IMMUNOL, V175, P6893, DOI 10.4049/jimmunol.175.10.6893; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Blednov YA, 2005, BEHAV BRAIN RES, V165, P110, DOI 10.1016/j.bbr.2005.06.026; Blednov YA, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00129; Blednov YA, 2012, ADDICT BIOL, V17, P108, DOI 10.1111/j.1369-1600.2010.00284.x; Borner C, 2012, MOL PHARMACOL, V81, P587, DOI 10.1124/mol.111.076620; Bose S, 2013, ARCH PHARM RES, V36, P1039, DOI 10.1007/s12272-013-0161-z; Breese GR, 2008, NEUROPSYCHOPHARMACOL, V33, P867, DOI 10.1038/sj.npp.1301468; Breese GR, 2005, PSYCHOPHARMACOLOGY, V178, P367, DOI 10.1007/s00213-004-2016-2; Brombacher TM, 2017, J IMMUNOL, V198, P2681, DOI 10.4049/jimmunol.1601546; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Bsibsi M, 2010, J IMMUNOL, V184, P6929, DOI 10.4049/jimmunol.0902419; Buwitt-Beckmann U, 2006, J BIOL CHEM, V281, P9049, DOI 10.1074/jbc.M512525200; Calu DJ, 2007, CEREB CORTEX, V17, P1342, DOI 10.1093/cercor/bhl045; Cameron JS, 2007, J NEUROSCI, V27, P13033, DOI 10.1523/JNEUROSCI.4290-06.2007; Caraci F, 2015, SCI REP-UK, V5, DOI 10.1038/srep11252; Chen G, 2012, AUTOPHAGY, V8, P1577, DOI 10.4161/auto.21376; Coleman LG, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0799-4; Coleman LG, 2011, ALCOHOL CLIN EXP RES, V35, P671, DOI 10.1111/j.1530-0277.2010.01385.x; Cozzoli DK, 2016, NEUROPHARMACOLOGY, V105, P164, DOI 10.1016/j.neuropharm.2016.01.010; Crews FT, 2011, BRAIN BEHAV IMMUN, V25, pS4, DOI 10.1016/j.bbi.2011.03.003; Crews F, 2006, ALCOHOL CLIN EXP RES, V30, P1938, DOI 10.1111/j.1530-0277.2006.00239.x; Crews FT, 2017, NEUROPHARMACOLOGY, V122, P56, DOI 10.1016/j.neuropharm.2017.01.031; Crews FT, 2016, PHARMACOL REV, V68, P1074, DOI 10.1124/pr.115.012138; Crews FT, 2016, PSYCHOPHARMACOLOGY, V233, P1543, DOI 10.1007/s00213-015-3906-1; Crews FT, 2015, ALCOHOL RES-CURR REV, V37, P331; Crews FT, 2014, INT REV NEUROBIOL, V118, P315, DOI 10.1016/B978-0-12-801284-0.00010-5; Crews FT, 2013, BIOL PSYCHIAT, V73, P602, DOI 10.1016/j.biopsych.2012.09.030; Crews FT, 2009, PHARMACOL BIOCHEM BE, V93, P237, DOI 10.1016/j.pbb.2009.04.018; Cui CH, 2015, ALCOHOL, V49, P435, DOI 10.1016/j.alcohol.2015.04.006; Cui CH, 2014, INT REV NEUROBIOL, V118, P1, DOI 10.1016/B978-0-12-801284-0.00001-4; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Davis RL, 2004, NEUROSCI LETT, V371, P128, DOI 10.1016/j.neulet.2004.08.051; Dawson DA, 2008, ALCOHOL CLIN EXP RES, V32, P2149, DOI 10.1111/j.1530-0277.2008.00806.x; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Di Castro MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep34633; Drew PD, 2015, ALCOHOL CLIN EXP RES, V39, P445, DOI 10.1111/acer.12639; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fernandez-Lizarbe S, 2013, J NEUROCHEM, V126, P261, DOI 10.1111/jnc.12276; Fernandez-Lizarbe S, 2009, J IMMUNOL, V183, P4733, DOI 10.4049/jimmunol.0803590; Fortier CB, 2008, NEUROPSYCHOLOGY, V22, P196, DOI 10.1037/0894-4105.22.2.196; Frank MG, 2007, BRAIN BEHAV IMMUN, V21, P47, DOI 10.1016/j.bbi.2006.03.005; Frank MG, 2016, BRAIN BEHAV IMMUN, V51, P99, DOI 10.1016/j.bbi.2015.08.001; FRANKE H, 1995, ACTA HISTOCHEM, V97, P263, DOI 10.1016/S0065-1281(11)80187-X; Freeman K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-97; GEORGE FR, 1989, ANN NY ACAD SCI, V559, P382; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gorina R, 2011, GLIA, V59, P242, DOI 10.1002/glia.21094; Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004; Grant BF, 1998, J SUBST ABUSE, V10, P163, DOI 10.1016/S0899-3289(99)80131-X; Guo ML, 2015, AUTOPHAGY, V11, P995, DOI 10.1080/15548627.2015.1052205; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Hashioka S, 2015, CNS NEUROL DISORD-DR, V14, P251, DOI 10.2174/1871527314666150217122305; He J, 2008, EXP NEUROL, V210, P349, DOI 10.1016/j.expneurol.2007.11.017; Heberlein A, 2014, ALCOHOL, V48, P671, DOI 10.1016/j.alcohol.2014.08.003; Hoeffel G, 2015, IMMUNITY, V42, P665, DOI 10.1016/j.immuni.2015.03.011; Hu W, 2011, PSYCHOPHARMACOLOGY, V218, P331, DOI 10.1007/s00213-011-2290-8; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Irwin MR, 2009, BIOL PSYCHIAT, V66, P191, DOI 10.1016/j.biopsych.2008.12.004; Izquierdo A, 2016, NEUROSCIENCE, DOI DOI 10.1016/J.NEUR0SCIENCE.2016.03.021.[EPUB; Jackson AC, 2006, J NEUROVIROL, V12, P229, DOI 10.1080/13550280600848399; Jacobsen JHW, 2018, BRAIN BEHAV IMMUN, V67, P181, DOI 10.1016/j.bbi.2017.08.021; Jacobsen JHW, 2016, CURR OPIN PHARMACOL, V26, P131, DOI 10.1016/j.coph.2015.10.010; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Janko C, 2014, ANTIOXID REDOX SIGN, V20, P1075, DOI 10.1089/ars.2013.5179; Jensen CJ, 2013, J NEUROIMMUNE PHARM, V8, P824, DOI 10.1007/s11481-013-9480-6; Serramia MJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17887; Jimenez JL, 2001, J PHARMACOL EXP THER, V299, P753; Jokisch D, 2014, ALCOHOL CLIN EXP RES, V38, P1947, DOI 10.1111/acer.12460; June HL, 2015, NEUROPSYCHOPHARMACOL, V40, P1549, DOI 10.1038/npp.2015.4; Kaltschmidt B, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00069; Kane CJM, 2011, BRAIN BEHAV IMMUN, V25, pS137, DOI 10.1016/j.bbi.2011.02.016; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khairova RA, 2009, INT J NEUROPSYCHOPH, V12, P561, DOI 10.1017/S1461145709009924; Khakh BS, 2015, NAT NEUROSCI, V18, P942, DOI 10.1038/nn.4043; Kim C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2534; Knapp DJ, 1999, ALCOHOL CLIN EXP RES, V23, P633, DOI 10.1097/00000374-199904000-00010; Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Kreisel T, 2014, MOL PSYCHIATR, V19, P699, DOI 10.1038/mp.2013.155; Lawrimore CJ, 2017, ALCOHOL CLIN EXP RES, V41, P939, DOI 10.1111/acer.13368; Leclercq S, 2014, BIOL PSYCHIAT, V76, P725, DOI 10.1016/j.biopsych.2014.02.003; Lee M, 2013, NEUROSCIENCE, V229, P164, DOI 10.1016/j.neuroscience.2012.10.033; Lehmann SM, 2012, J IMMUNOL, V189, P1448, DOI 10.4049/jimmunol.1201078; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Lewohl JM, 2011, ALCOHOL CLIN EXP RES, V35, P1928, DOI 10.1111/j.1530-0277.2011.01544.x; Liang YL, 2014, BRAIN RES, V1590, P75, DOI 10.1016/j.brainres.2014.09.020; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lim SW, 2017, NEUROCRIT CARE, V26, P122, DOI 10.1007/s12028-016-0290-6; Lippai D, 2013, J LEUKOCYTE BIOL, V94, P171, DOI 10.1189/jlb.1212659; Liu JA, 2011, P NATL ACAD SCI USA, V108, P4465, DOI 10.1073/pnas.1019020108; Loftis JM, 2014, INT REV NEUROBIOL, V118, P165, DOI 10.1016/B978-0-12-801284-0.00007-5; Ma YH, 2006, J CELL BIOL, V175, P209, DOI 10.1083/jcb.200606016; Madrigal JLM, 2002, BRAIN RES, V938, P87, DOI 10.1016/S0006-8993(02)02467-8; Mao XRR, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-16; Marciniak E, 2015, SCI REP-UK, V5, DOI 10.1038/srep15862; Maroso M, 2011, J INTERN MED, V270, P319, DOI 10.1111/j.1365-2796.2011.02431.x; Marshall SA, 2017, J NEUROIMMUNE PHARM, V12, P249, DOI 10.1007/s11481-016-9709-2; Marshall SA, 2016, BRAIN BEHAV IMMUN, V51, P258, DOI 10.1016/j.bbi.2015.09.006; Marshall SA, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6020016; Mayfield J, 2013, CURR OPIN NEUROBIOL, V23, P513, DOI 10.1016/j.conb.2013.01.024; McCarthy GM, 2017, ADDICT BIOL; Montesinos J, 2017, ALCOHOL CLIN EXP RES, V41, P1257, DOI 10.1111/acer.13416; Montesinos J, 2016, ALCOHOL CLIN EXP RES, V40, P2260, DOI 10.1111/acer.13208; Montesinos J, 2015, BRAIN BEHAV IMMUN, V45, P233, DOI 10.1016/j.bbi.2014.11.015; Most Dana, 2014, Handb Clin Neurol, V125, P89, DOI 10.1016/B978-0-444-62619-6.00006-9; Muller MM, 2006, P NATL ACAD SCI USA, V103, P14250, DOI 10.1073/pnas.0606668103; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Narayanan KB, 2015, APOPTOSIS, V20, P196, DOI 10.1007/s10495-014-1073-1; Neupane SP, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00655; Northcutt AL, 2015, MOL PSYCHIATR, V20, P1525, DOI 10.1038/mp.2014.177; Nunez YO, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-725; Obernier JA, 2002, PHARMACOL BIOCHEM BE, V72, P521, DOI 10.1016/S0091-3057(02)00715-3; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okun E, 2010, P NATL ACAD SCI USA, V107, P15625, DOI 10.1073/pnas.1005807107; Okvist A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000930; Park CK, 2014, NEURON, V82, P47, DOI 10.1016/j.neuron.2014.02.011; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pascual M, 2007, EUR J NEUROSCI, V25, P541, DOI 10.1111/j.1460-9568.2006.05298.x; Pascual M, 2011, BRAIN BEHAV IMMUN, V25, pS80, DOI 10.1016/j.bbi.2011.02.012; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Periyasamy P, 2017, MOL NEUROBIOL; Periyasamy P, 2016, AUTOPHAGY, V12, P1310, DOI 10.1080/15548627.2016.1183844; Pla A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153097; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Prieto GA, 2017, CYTOKINE GROWTH F R, V34, P27, DOI 10.1016/j.cytogfr.2017.03.005; Prieto GA, 2015, P NATL ACAD SCI USA, V112, pE5078, DOI 10.1073/pnas.1514486112; Qin LY, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-10; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Qin LY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-130; Qin LY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-5; Ray LA, 2014, INT REV NEUROBIOL, V118, P381, DOI 10.1016/B978-0-12-801284-0.00012-9; Reissner KJ, 2010, BEHAV PHARMACOL, V21, P514, DOI 10.1097/FBP.0b013e32833d41b2; Ripley TL, 2015, PSYCHOPHARMACOLOGY, V232, P3431, DOI 10.1007/s00213-015-3995-x; Rostene W, 2007, NAT REV NEUROSCI, V8, P895, DOI 10.1038/nrn2255; Rubio-Araiz A, 2017, ADDICT BIOL, V22, P1103, DOI 10.1111/adb.12376; Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397; Schoenbaum G, 2004, EUR J NEUROSCI, V19, P1997, DOI 10.1111/j.1460-9568.2004.03274.x; Sheng JP, 2015, IMMUNITY, V43, P382, DOI 10.1016/j.immuni.2015.07.016; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Stalnaker TA, 2009, NEUROPHARMACOLOGY, V56, P63, DOI 10.1016/j.neuropharm.2008.07.019; Storer PD, 2005, J NEUROIMMUNOL, V161, P113, DOI 10.1016/j.jneuroim.2004.12.015; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sugimura T, 2015, NEUROSCI RES, V96, P37, DOI 10.1016/j.neures.2015.02.005; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Theberge FR, 2013, BIOL PSYCHIAT, V73, P729, DOI 10.1016/j.biopsych.2012.12.019; Townshend JM, 2003, NEUROPSYCHOLOGIA, V41, P773, DOI 10.1016/S0028-3932(02)00284-1; Tynan RJ, 2010, BRAIN BEHAV IMMUN, V24, P1058, DOI 10.1016/j.bbi.2010.02.001; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Valenta JP, 2016, ALCOHOL CLIN EXP RES, V40, P187, DOI 10.1111/acer.12928; Valles SL, 2004, BRAIN PATHOL, V14, P365; Vetreno R P, 2014, Handb Clin Neurol, V125, P477, DOI 10.1016/B978-0-444-62619-6.00027-6; Vetreno RP, 2012, NEUROSCIENCE, V226, P475, DOI 10.1016/j.neuroscience.2012.08.046; Vetreno RP, 2013, NEUROBIOL DIS, V59, P52, DOI 10.1016/j.nbd.2013.07.002; Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480; Wagley Y, 2013, BBA-MOL CELL RES, V1833, P1476, DOI 10.1016/j.bbamcr.2013.02.017; Walter TJ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0856-z; Wang X, 2016, BRIT J PHARMACOL, V173, P856, DOI 10.1111/bph.13394; Wang XH, 2013, FASEB J, V27, P2713, DOI 10.1096/fj.12-222992; Ward RJ, 1996, FEBS LETT, V389, P119, DOI 10.1016/0014-5793(96)00545-5; Ward RJ, 2009, J NEUROCHEM, V111, P1119, DOI 10.1111/j.1471-4159.2009.06389.x; Weber MD, 2015, J NEUROSCI, V35, P316, DOI 10.1523/JNEUROSCI.3561-14.2015; Weissenborn R, 2003, PSYCHOPHARMACOLOGY, V165, P306, DOI 10.1007/s00213-002-1281-1; Whitman BA, 2013, ALCOHOL CLIN EXP RES, V37, P2086, DOI 10.1111/acer.12189; Wohleb ES, 2011, J NEUROSCI, V31, P6277, DOI 10.1523/JNEUROSCI.0450-11.2011; Worley MJ, 2016, DRUG ALCOHOL DEPEN, V162, P245, DOI 10.1016/j.drugalcdep.2016.02.036; Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512; Yelamanchili SV, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005032; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zhang B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0440-3; Zhu CB, 2010, NEUROPSYCHOPHARMACOL, V35, P2510, DOI 10.1038/npp.2010.116; Zou J, 2006, CELL MOL NEUROBIOL, V26, P385, DOI 10.1007/s10571-006-9045-9; Zou J, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00077; Zou J, 2010, ALCOHOL CLIN EXP RES, V34, P777, DOI 10.1111/j.1530-0277.2010.01150.x; Zou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087915; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	203	21	23	0	1	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	0171-2004		978-3-319-96523-9; 978-3-319-96522-2	HANDB EXP PHARMACOL	Handb. Exp. Pharmacol.		2018	248						369	396		10.1007/164_2018_92	10.1007/978-3-319-96523-9		28	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	BQ3HJ	WOS:000584899800015	29500721	Green Accepted			2021-06-18	
J	Vela, MM; Saez, DG; Simon, AR				Vela, Maria Monteagudo; Saez, Diana Garcia; Simon, Andre R.			Current approaches in retrieval and heart preservation	ANNALS OF CARDIOTHORACIC SURGERY			English	Article						Heart retrieval; heart preservation; Organ Care System (OCS); circulatory determined death (DCD) donors	DONOR HEART; CIRCULATORY DEATH; TRANSPLANTATION; PERFUSION; PROCUREMENT; OUTCOMES	Fifty years after the first successful heart transplantation, despite multiple advances in the treatment of advanced acute and chronic heart failure, there is still no equivalent to heart transplantation as a long-term treatment for end-stage heart failure. Transplantation is, however, limited by the scarcity and quality of heart allografts. Donors are nowadays significantly older, particularly in European countries, and traumatic head injury as the cause of death has been replaced by intracerebral hemorrhage or hypoxic brain damage in the majority of cases. In addition, many donors have undergone extensive resuscitation efforts. Recipient characteristics have progressively changed too within the last couple of decades; recipients are older, often with comorbidities and nearly half of them are bridged to transplant with a wide variety of mechanical circulatory support devices. These developments have resulted in heart transplant surgery becoming significantly more challenging with longer more complex surgery and increased ischemia times for organs that were previously considered to be borderline or non-transplantable in many cases. To address this, several options have been explored within the last years and as a result, novel strategies have been developed and tested in order to optimize graft preservation and potentially increase the donor pool. The two notable developments are the ability to procure hearts from donors after circulatory death and the advent of ex-vivo perfusion of hearts. This technology has made the transplantation of extended criteria organs, including those from circulatory determined death (DCD) donors possible, and allow for out of body time of more than 12 hours in heart transplantation. In this review, we set out the basis of the current practices in organ procurement, and the opportunities for the future as demands for organ transplantation continue to increase.	[Vela, Maria Monteagudo; Saez, Diana Garcia; Simon, Andre R.] Royal Brompton & Harefield NHS Fdn Trust, Harefield Hosp, Dept Cardiothorac Transplantat & Mech Circulatory, London, England	Vela, MM (corresponding author), Royal Brompton & Harefield NHS Fdn Trust, Harefield Hosp, Dept Cardiothorac Transplantat & Mech Circulatory, London, England.	m.monteagudo-vela@rbht.nhs.uk					Ardehali A, 2015, LANCET, V385, P2577, DOI 10.1016/S0140-6736(15)60261-6; Banner NR, 2008, TRANSPLANTATION, V86, P542, DOI 10.1097/TP.0b013e31818149b9; BARNARD C N, 1967, South African Medical Journal, V41, P1271; Bruinsma BG, 2017, CURR OPIN ORGAN TRAN, V22, P281, DOI 10.1097/MOT.0000000000000403; Dhital K, 2015, HEART LUNG CIRC, V24, P1191, DOI 10.1016/j.hlc.2015.05.014; Dhital KK, 2017, CURR OPIN ORGAN TRAN, V22, P189, DOI 10.1097/MOT.0000000000000419; Dhital KK, 2015, LANCET, V385, P2585, DOI 10.1016/S0140-6736(15)60038-1; Fujisaki N, 2016, MED GAS RES, V6, P122, DOI 10.4103/2045-9912.191357; Hamed A, 2009, J HEART LUNG TRANSPL, V28, pS71, DOI 10.1016/j.healun.2008.11.025; Hausenloy DJ, 2015, NEW ENGL J MED, V373, P1408, DOI 10.1056/NEJMoa1413534; Heart Overall Statistics, ISHLT REG 2016; Heart Statistics, ISHLT REG 2016; Heart Statistics, ISHLT REG 2012; Hunt SA, 2006, NEW ENGL J MED, V355, P231, DOI 10.1056/NEJMp068048; Ladowski J S, 1985, J Heart Transplant, V4, P330; Latchana N, 2014, J THORAC DIS, V6, P1143, DOI 10.3978/j.issn.2072-1439.2014.05.14; Messer S, 2015, TRANSPL INT, V28, P634, DOI 10.1111/tri.12361; Messer SJ, 2016, J HEART LUNG TRANSPL, V35, P1443, DOI 10.1016/j.healun.2016.07.004; Saez DG, 2017, J HEART LUNG TRANSPL, V36, pS17; Saez DG, 2016, J HEART LUNG TRANSPL, V35, P1255, DOI 10.1016/j.healun.2016.05.025; Saez DG, 2014, ANN THORAC SURG, V98, P2099, DOI 10.1016/j.athoracsur.2014.06.098; WATSON DC, 1979, SURGERY, V86, P56; WICOMB WN, 1984, ANN THORAC SURG, V37, P243, DOI 10.1016/S0003-4975(10)60333-5; Zimmer HG, 2004, CLIN CARDIOL, V27, P584, DOI 10.1002/clc.4960271013; Zimmer HG, 1998, NEWS PHYSIOL SCI, V13, P203	25	21	21	0	2	AME PUBL CO	SHATIN	FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA	2225-319X	2304-1021		ANN CARDIOTHORAC SUR	Ann. Cardiothorac. Surg.	JAN	2018	7	1					67	74		10.21037/acs.2018.01.06			8	Cardiac & Cardiovascular Systems; Surgery	Cardiovascular System & Cardiology; Surgery	FX2WJ	WOS:000425924700009	29492384	Green Published, Bronze			2021-06-18	
J	Wang, YB; Liu, Y; Lopez, D; Lee, M; Dayal, S; Hurtado, A; Bi, XN; Baudry, M				Wang, Yubin; Liu, Yan; Lopez, Dulce; Lee, Moses; Dayal, Sujay; Hurtado, Alexander; Bi, Xiaoning; Baudry, Michel			Protection against TBI-Induced Neuronal Death with Post-Treatment with a Selective Calpain-2 Inhibitor in Mice	JOURNAL OF NEUROTRAUMA			English	Article						calpain; cell death; neuroprotection; TBI	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; PHARMACOLOGICAL ANALYSIS; SYNAPTIC PLASTICITY; DEGRADATION; PROTEIN; MEMORY; MOUSE; DEGENERATION; SPECTRIN	Traumatic Brain Injury (TBI) is a major cause of death and disability worldwide. The calcium-dependent protease, calpain, has been shown to be involved in TBI-induced neuronal death. However, whereas various calpain inhibitors have been tested in several animal models of TBI, there has not been any clinical trial testing the efficacy of calpain inhibitors in human TBI. One important reason for this could be the lack of knowledge regarding the differential functions of the two major calpain isoforms in the brain, calpain-1 and calpain-2. In this study, we used the controlled cortical impact (CCI) model in mice to test the roles of calpain-1 and calpain-2 in TBI-induced neuronal death. Immunohistochemistry (IHC) with calpain activity markers performed at different time-points after CCI in wild-type and calpain-1 knock-out (KO) mice showed that calpain-1 was activated early in cortical areas surrounding the impact, within 0-8h after CCI, whereas calpain-2 activation was delayed and was predominant during 8-72h after CCI. Calpain-1 KO enhanced cell death, whereas calpain-2 activity correlated with the extent of cell death, suggesting that calpain-1 activation suppresses and calpain-2 activation promotes cell death following TBI. Systemic injection(s) of a calpain-2 selective inhibitor, NA101, at 1h or 4h after CCI significantly reduced calpain-2 activity and cell death around the impact site, reduced the lesion volume, and promoted motor and learning function recovery after TBI. Our data indicate that calpain-1 activity is neuroprotective and calpain-2 activity is neurodegenerative after TBI, and that a selective calpain-2 inhibitor can reduce TBI-induced cell death.	[Wang, Yubin; Liu, Yan; Lopez, Dulce; Lee, Moses; Hurtado, Alexander; Baudry, Michel] Western Univ Hlth Sci, Grad Coll Biomed Sci, 309 E 2nd St, Pomona, CA 91766 USA; [Bi, Xiaoning] Western Univ Hlth Sci, Coll Osteopath Med Pacific, Pomona, CA USA; [Dayal, Sujay] Pitzer Coll, Claremont, CA 91711 USA	Baudry, M (corresponding author), Western Univ Hlth Sci, Grad Coll Biomed Sci, 309 E 2nd St, Pomona, CA 91766 USA.	mbaudry@westernu.edu		Wang, Yubin/0000-0002-8836-9632	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS045260-01, R01NS057128]; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R15MH101703]; Daljit and Elaine Sarkaria Chair; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS090397] Funding Source: NIH RePORTER	This work was supported by grant P01NS045260-01 from NINDS (PI: Dr. C.M. Gall), grant R01NS057128 from NINDS to M.B., and grant R15MH101703 from NIMH to X.B. X.B. is also supported by funds from the Daljit and Elaine Sarkaria Chair.	Bains M, 2013, J NEUROCHEM, V125, P125, DOI 10.1111/jnc.12118; Baudry M, 2016, TRENDS NEUROSCI, V39, P235, DOI 10.1016/j.tins.2016.01.007; Bezprozvanny I, 2009, TRENDS MOL MED, V15, P89, DOI 10.1016/j.molmed.2009.01.001; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Briz V, 2013, J NEUROSCI, V33, P4317, DOI 10.1523/JNEUROSCI.4907-12.2013; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Cagmat E.B., 2015, BRAIN NEUROTRAUMA MO; Coronado VG, 2011, SURVEILLANCE TRAUMAT; Donkor IO, 2011, EXPERT OPIN THER PAT, V21, P601, DOI 10.1517/13543776.2011.568480; Gan-Or Z, 2016, AM J HUM GENET, V98, P1038, DOI 10.1016/j.ajhg.2016.04.002; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; Gupta R, 2016, REV NEUROSCIENCE, V27, P93, DOI 10.1515/revneuro-2015-0017; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Kobeissy FH, 2015, MOL NEUROBIOL, V52, P696, DOI 10.1007/s12035-014-8898-z; Liu J, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.123tr3; Liu S, 2014, BRAIN INJURY, V28, P133, DOI 10.3109/02699052.2013.860479; Liu Y, 2016, NEUROPHARMACOLOGY, V105, P471, DOI 10.1016/j.neuropharm.2016.02.022; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Ono Y, 2012, BBA-PROTEINS PROTEOM, V1824, P224, DOI 10.1016/j.bbapap.2011.08.005; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Schoch KM, 2013, J NEUROCHEM, V125, P909, DOI 10.1111/jnc.12144; Seinfeld J, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0088-15.2016; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sun JD, 2015, CELL REP, V12, P449, DOI 10.1016/j.celrep.2015.06.023; Thompson SN, 2010, J NEUROTRAUM, V27, P2233, DOI 10.1089/neu.2010.1474; Wang YB, 2016, NEUROBIOL DIS, V93, P121, DOI 10.1016/j.nbd.2016.05.007; Wang YB, 2016, CELL REP, V16, P79, DOI 10.1016/j.celrep.2016.05.044; Wang YB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4051; Wang YB, 2013, J NEUROSCI, V33, P18880, DOI 10.1523/JNEUROSCI.3293-13.2013; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yan XX, 2012, CURR GERIATR REP, V1, P85, DOI 10.1007/s13670-012-0009-2; Yin YL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27283	38	21	21	2	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2018	35	1					105	117		10.1089/neu.2017.5024			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FS1WO	WOS:000419569700013	28594313	Green Published			2021-06-18	
J	Yang, LJ; Wang, F; Yang, L; Yuan, YC; Chen, Y; Zhang, GS; Fan, ZZ				Yang, Lijun; Wang, Feng; Yang, Liang; Yuan, Yunchao; Chen, Yan; Zhang, Gengshen; Fan, Zhenzeng			HMGB1 a-Box Reverses Brain Edema and Deterioration of Neurological Function in a Traumatic Brain Injury Mouse Model	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Traumatic brain injury (TBI); High mobility group box-1 (HMGB1)	MOBILITY GROUP BOX-1; CONTROLLED CORTICAL IMPACT; CEREBRAL EDEMA; RECEPTOR 4; RATS; HEMORRHAGE; MICE; MECHANISMS; EXPRESSION; PROTEIN	Background/Aims: Traumatic brain injury (TBI) is a complex neurological injury in young adults lacking effective treatment. Emerging evidences suggest that inflammation contributes to the secondary brain injury following TBI, including breakdown of the blood brain barrier (BBB), subsequent edema and neurological deterioration. High mobility group box-1 (HMGB1) has been identified as a key cytokine in the inflammation reaction following TBI. Here, we investigated the therapeutic efficacy of HMGB1 A-box fragment, an antagonist competing with full-length HMGB1 for receptor binding, against TBI. Methods: TBI was induced by controlled cortical impact (CCI) in adult male mice. HMGB1 A-box fragment was given intravenously at 2 mg/kg/day for 3 days after CCI. HMGB1 A-box-treated CCI mice were compared with saline-treated CCI mice and sham mice in terms of BBB disruption evaluated by Evan's blue extravasation, brain edema by brain water content, cell death by propidium iodide staining, inflammation by Western blot and ELISA assay for cytokine productions, as well as neurological functions by the modified Neurological Severity Score, wire grip and beam walking tests. Results: HMGB1 A-box reversed brain damages in the mice following TBI. It significantly reduced brain edema by protecting integrity of the BBB, ameliorated cell degeneration, and decreased expression of pro-inflammatory cytokines released in injured brain after TBI. These cellular and molecular effects were accompanied by improved behavioral performance in TBI mice. Notably, HMGB1 A-box blocked IL-1 beta-induced HMGB1 release, and preferentially attenuated TLR4, Myd88 and P65 in astrocyte cultures. Conclusion: Our data suggest that HMGB1 is involved in CCI-induced TBI, which can be inhibited by HMGB1 A-box fragment. Therefore, HMGB1 A-box fragment may have therapeutic potential for the secondary brain damages in TBI. (C) 2018 The Author(s) Published by S. Karger AG, Basel	[Yang, Lijun; Wang, Feng; Yang, Liang; Yuan, Yunchao; Chen, Yan; Zhang, Gengshen; Fan, Zhenzeng] Hebei Med Univ, Hosp 2, Dept Neurosurg, 215 Heping Rd, Shijiazhuang 050000, Hebei, Peoples R China; [Yang, Lijun] Hebei Med Univ, Clin Med Postdoctoral Mobile Stn, Shijiazhuang, Hebei, Peoples R China	Fan, ZZ (corresponding author), Hebei Med Univ, Hosp 2, Dept Neurosurg, 215 Heping Rd, Shijiazhuang 050000, Hebei, Peoples R China.	Fanzhenzeng@126.com			Natural Science Foundation of Hebei Province, ChinaNatural Science Foundation of Hebei Province [H2015206201]; foundation of the Second Hospital of Hebei Medical University [2H2201510]	This project is supported by Natural Science Foundation of Hebei Province, China (Grant No. H2015206201) and foundation of the Second Hospital of Hebei Medical University (Grant No. 2H2201510).	Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Bierbach B, 2008, STROKE, V39, P213, DOI 10.1161/STROKEAHA.107.496620; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Guilfoyle MR, 2015, J NEUROTRAUM, V32, P1553, DOI 10.1089/neu.2014.3764; Haruma J, 2016, SCI REP-UK, V6, DOI 10.1038/srep37755; Hidaka S, 2011, J SURG RES, V165, P142, DOI 10.1016/j.jss.2009.05.039; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161; Kong XQ, 2013, J VASC SURG, V57, P194, DOI 10.1016/j.jvs.2012.06.083; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; LeBlanc PM, 2014, J BIOL CHEM, V289, P7777, DOI 10.1074/jbc.M113.541474; Li JH, 2003, MOL MED, V9, P37, DOI 10.1007/BF03402105; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; Musumeci D, 2014, PHARMACOL THERAPEUT, V141, P347, DOI 10.1016/j.pharmthera.2013.11.001; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Urday S, 2015, NAT REV NEUROL, V11, P111, DOI 10.1038/nrneurol.2014.264; Wang DL, 2017, SCI REP-UK, V7, DOI 10.1038/srep46243; WEISSMAN DE, 1988, J NEURO-ONCOL, V6, P339; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yang Xiao-feng, 2005, Chin J Traumatol, V8, P96; Zhang CL, 2008, MED HYPOTHESES, V70, P343, DOI 10.1016/j.mehy.2007.05.024; Zhou C, 2014, EUR J PAIN, V18, P649, DOI 10.1002/j.1532-2149.2013.00416.x; Zhou CY, 2016, J NEUROSCI, V36, P2543, DOI 10.1523/JNEUROSCI.3534-15.2016	38	21	22	1	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2018	46	6					2532	2542		10.1159/000489659			11	Cell Biology; Physiology	Cell Biology; Physiology	GH2SJ	WOS:000433251900029	29742510	DOAJ Gold			2021-06-18	
J	Zhu, YH; Wang, HD; Fang, J; Dai, W; Zhou, J; Wang, XL; Zhou, ML				Zhu, Yihao; Wang, Handong; Fang, Jiang; Dai, Wei; Zhou, Jiang; Wang, Xiaoliang; Zhou, Mengliang			SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article							OXIDATIVE STRESS; COGNITIVE DEFICITS; APOPTOSIS; MODEL; COACTIVATORS; INFLAMMATION; PGC-1-ALPHA; BIOGENESIS; ISCHEMIA; PATHWAY	SS-31, a novel mitochondria-targeted peptide, has been proven to provide neuroprotection in a variety of neurological diseases. Its role as a mitochondrial reactive oxygen species (ROS) scavenger and the underlying pathophysiological mechanisms in traumatic brain injury (TBI) are still not well understood. The aim of the designed study was to investigate the potential neuroprotective effects of SS-31 and fulfill our understanding of the process of the mitochondrial change in the modified Marmarou weight-drop model of TBI. Mice were randomly divided into sham, TBI, TBI + vehicle, and TBI + SS-31 groups in this study. Peptide SS-31 (5 mg/kg) or vehicle was intraperitoneally administrated 30 min after TBI with brain samples harvested 24 h later for further analysis. SS-31 treatment significantly reversed mitochondrial dysfunction and ameliorated secondary brain injury caused by TBI. SS-31 can directly decrease the ROS content, restore the activity of superoxide dismutase (SOD), and decrease the level of malondialdehyde (MDA) and the release of cytochrome c, thus attenuating neurological deficits, brain water content, DNA damage, and neural apoptosis. Moreover, SS-31 restored the expression of SIRT1 and upregulated the nuclear translocation of PGC-1 alpha, which were proved by Western blot and immunohistochemistry. Taken together, these data demonstrate that SS-31 improves the mitochondrial function and provides neuroprotection in mice after TBI potentially through enhanced mitochondrial rebiogenesis. The present study gives us an implication for further clinical research.	[Zhu, Yihao; Wang, Handong; Wang, Xiaoliang; Zhou, Mengliang] Nanjing Univ, Jinling Hosp, Med Sch, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Fang, Jiang] Southeast Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Dai, Wei; Zhou, Jiang] Nanjing Med Univ, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Med Sch, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357]; National Natural Science Foundation for Distinguished Young Scholars of ChinaNational Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars [81401026]	This study was supported by grants from the National Natural Science Foundation of China (no. 81371357) and the National Natural Science Foundation for Distinguished Young Scholars of China (no. 81401026).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Chance B, 1973, Adv Exp Med Biol, V37A, P277; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chen SD, 2011, INT J MOL SCI, V12, P7199, DOI 10.3390/ijms12107199; Chen-Roetling J, 2016, J NEUROCHEM, V139, P586, DOI 10.1111/jnc.13720; CHO DH, 1993, CANCER LETT, V74, P141, DOI 10.1016/0304-3835(93)90235-2; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6; Ding H, 2017, NEUROCHEM RES, V42, P337, DOI 10.1007/s11064-016-2077-8; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Jonckheere AI, 2012, J INHERIT METAB DIS, V35, P211, DOI 10.1007/s10545-011-9382-9; Kim EH, 2015, CNS NEUROSCI THER, V21, P385, DOI 10.1111/cns.12326; Kress GJ, 2002, J NEUROSCI, V22, P5848; Li X, 2018, J CELL MOL MED, V22, P883, DOI 10.1111/jcmm.13313; Negrette-Guzman M, 2013, FREE RADICAL BIO MED, V65, P1078, DOI 10.1016/j.freeradbiomed.2013.08.182; Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010-010-0709-x; Petri S, 2006, J NEUROCHEM, V98, P1141, DOI 10.1111/j.1471-4159.2006.04018.x; Procaccio V, 2014, REV NEUROL-FRANCE, V170, P390, DOI 10.1016/j.neurol.2014.03.005; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Szeto HH, 2008, ANTIOXID REDOX SIGN, V10, P601, DOI 10.1089/ars.2007.1892; Tsai CJ, 2015, STRUCTURE, V23, P139, DOI 10.1016/j.str.2014.10.016; Voigt C, 2012, NEUROPATH APPL NEURO, V38, P354, DOI 10.1111/j.1365-2990.2011.01211.x; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu J, 2015, MOL NEUROBIOL, V52, P783, DOI 10.1007/s12035-014-8918-z; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yonutas HM, 2016, BRAIN RES, V1640, P77, DOI 10.1016/j.brainres.2016.02.007; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhao HS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11779-9; Zhu HR, 2010, NEUROPHARMACOLOGY, V59, P70, DOI 10.1016/j.neuropharm.2010.03.017; Zhu L. L., 2018, CELLULAR PHYSL BIOCH, V44, P388; Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013	40	21	22	2	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.		2018	2018								4783602	10.1155/2018/4783602			12	Cell Biology	Cell Biology	GT0UJ	WOS:000444163800001	30224944	DOAJ Gold, Green Published			2021-06-18	
J	Salman, MM; Kitchen, P; Woodroofe, MN; Bill, RM; Conner, AC; Heath, PR; Conner, MT				Salman, Mootaz M.; Kitchen, Philip; Woodroofe, M. Nicola; Bill, Roslyn M.; Conner, Alex C.; Heath, Paul R.; Conner, Matthew T.			Transcriptome Analysis of Gene Expression Provides New Insights into the Effect of Mild Therapeutic Hypothermia on Primary Human Cortical Astrocytes Cultured under Hypoxia	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						hypothermia; astrocyte; Wnt signaling pathway; p53 signaling; apoptosis; hypoxia; MAPK	ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; STRESS-INDUCED ACTIVATION; WNT SIGNALING PATHWAY; CELL-SURVIVAL; MAP KINASES; INTEGRATIVE ANALYSIS; INDUCIBLE FACTOR-1; CEREBRAL-ISCHEMIA; INDUCED APOPTOSIS	Hypothermia is increasingly used as a therapeutic measure to treat brain injury. However, the cellular mechanisms underpinning its actions are complex and are not yet fully elucidated. Astrocytes are the most abundant cell type in the brain and are likely to play a critical role. In this study, transcriptional changes and the protein expression profile of human primary cortical astrocytes cultured under hypoxic conditions for 6 h were investigated. Cells were treated either with or without a mild hypothermic intervention 2 h post-insult to mimic the treatment of patients following traumatic brain injury (TBI) and/or stroke. Using human gene expression microarrays, 411 differentially expressed genes were identified following hypothermic treatment of astrocytes following a 2 h hypoxic insult. KEGG pathway analysis indicated that these genes were mainly enriched in the Wnt and p53 signaling pathways, which were inhibited following hypothermic intervention. The expression levels of 168 genes involved in Wnt signaling were validated by quantitative real-time-PCR (qPCR). Among these genes, 10 were up-regulated and 32 were down-regulated with the remainder unchanged. Two of the differentially expressed genes (DEGs), p38 and JNK, were selected for validation at the protein level using cell based ELISA. Hypothermic intervention significantly down-regulated total protein levels for the gene products of p38 and JNK. Moreover, hypothermia significantly up-regulated the phosphorylated (activated) forms of JNK protein, while downregulating phosphorylation of p38 protein. Within the p53 signaling pathway, 35 human apoptosis-related proteins closely associated with Wnt signaling were investigated using a Proteome Profiling Array. Hypothermic intervention significantly down-regulated 18 proteins, while upregulating one protein, survivin. Hypothermia is a complex intervention; this study provides the first detailed longitudinal investigation at the transcript and protein expression levels of the molecular effects of therapeutic hypothermic intervention on hypoxic human primary cortical astrocytes. The identified genes and proteins are targets for detailed functional studies, which may help to develop new treatments for brain injury based on an in-depth mechanistic understanding of the astrocytic response to hypoxia and/or hypothermia.	[Salman, Mootaz M.; Woodroofe, M. Nicola] Sheffield Hallam Univ, Biomol Sci Res Ctr, Sheffield, S Yorkshire, England; [Kitchen, Philip; Conner, Alex C.] Univ Birmingham, Inst Clin Sci, Birmingham, W Midlands, England; [Bill, Roslyn M.] Aston Univ, Sch Life & Hlth Sci, Birmingham, W Midlands, England; [Heath, Paul R.] Univ Sheffield, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England; [Conner, Matthew T.] Univ Wolverhampton, Res Inst Hlth Sci, Wolverhampton Sch Sci, Wolverhampton, W Midlands, England	Conner, MT (corresponding author), Univ Wolverhampton, Res Inst Hlth Sci, Wolverhampton Sch Sci, Wolverhampton, W Midlands, England.	m.conner@wlv.ac.uk	Salman, Mootaz M./J-3111-2019; Bill, Roslyn M/D-4554-2012; Kitchen, Philip/J-6936-2019	Salman, Mootaz M./0000-0002-5683-1706; Bill, Roslyn M/0000-0003-1331-0852; Kitchen, Philip/0000-0002-1558-4673	HCED [GD-13-3]; BMRC Sheffield Hallam University; University of Sheffield; RIHS School of Sciences University of Wolverhampton	This work was supported by HCED grant number GD-13-3 (M Salman), BMRC Sheffield Hallam University, University of Sheffield and RIHS School of Sciences University of Wolverhampton.	Andresen M, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0121-3; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Ang SF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013064; Ayakannu T, 2015, MOL HUM REPROD, V21, P723, DOI 10.1093/molehr/gav033; Badawi Y, 2012, ASN NEURO, V4, P231, DOI 10.1042/AN20120006; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bikkavilli Rama Kamesh, 2009, Commun Integr Biol, V2, P46; Blagodatski Artem, 2014, Mol Cell Ther, V2, P28, DOI 10.1186/2052-8426-2-28; Boutilier RG, 2001, J EXP BIOL, V204, P3171; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cenik C, 2015, GENOME RES, V25, P1610, DOI 10.1101/gr.193342.115; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Chenn Anjen, 2008, Organogenesis, V4, P76; Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939; Choudhury GR, 2014, BRAIN RES, V1551, P45, DOI 10.1016/j.brainres.2014.01.013; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dienel GA, 2005, GLIA, V50, P362, DOI 10.1002/glia.20157; Diestel A, 2009, VASC PHARMACOL, V51, P246, DOI 10.1016/j.vph.2009.06.006; Ding ZY, 2010, J CANCER RES CLIN, V136, P1697, DOI 10.1007/s00432-010-0828-5; Frink M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/762840; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Goossens J, 2014, CURR NEUROPHARMACOL, V12, P399, DOI 10.2174/1570159X12666140424233036; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Harrison JG, 2004, BBA-MOL CELL RES, V1644, P17, DOI 10.1016/j.bbamcr.2003.10.008; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jakel S, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00024; Jeong Ji Eun, 2017, Korean J Pediatr, V60, P181, DOI 10.3345/kjp.2017.60.6.181; Ju R, 2010, P NATL ACAD SCI USA, V107, P6906, DOI 10.1073/pnas.1001075107; Karnatovskaia LV, 2014, NEUROHOSPITALIST, V4, P153, DOI 10.1177/1941874413519802; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kim J, 2015, BRAIN CIRC, V1, P14, DOI DOI 10.4103/2394-8108.164997; Kogel D, 2005, CELL DEATH DIFFER, V12, P1, DOI 10.1038/sj.cdd.4401495; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Lazaridis C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0681-2; Lee JH, 2012, RESUSCITATION, V83, P633, DOI 10.1016/j.resuscitation.2011.11.008; Li Y, 2011, NEUROL RES, V33, P583, DOI 10.1179/1743132810Y.0000000013; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Liu AL, 2009, EXP TOXICOL PATHOL, V61, P137, DOI 10.1016/j.etp.2008.06.004; Liu YH, 2010, J NEUROTRAUM, V27, P361, DOI 10.1089/neu.2008.0581; Loor G, 2008, CELL DEATH DIFFER, V15, P686, DOI 10.1038/cdd.2008.13; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Ma H, 2012, CURR MOL MED, V12, P1282, DOI 10.2174/156652412803833517; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Matijasevic Z, 1998, ONCOL RES, V10, P605; Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mimeault M, 2010, PHARMACOL REV, V62, P497, DOI 10.1124/pr.109.002329; Moore EM, 2011, INJURY, V42, P843, DOI 10.1016/j.injury.2011.03.027; Mormile R, 2012, J PEDIATR ENDOCR MET, V25, P1045, DOI 10.1515/jpem-2012-0232; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Munji RN, 2011, J NEUROSCI, V31, P1676, DOI 10.1523/JNEUROSCI.5404-10.2011; Nedergaard M, 2005, GLIA, V50, P281, DOI 10.1002/glia.20205; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Nozari A, 2004, J TRAUMA, V57, P1266, DOI 10.1097/01.TA.0000124268.24159.8B; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Ou LP, 2016, MOL MED REP, V13, P720, DOI 10.3892/mmr.2015.4586; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Podmirseg SR, 2016, ONCOGENE, V35, P4580, DOI 10.1038/onc.2015.524; Previch LE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071146; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenberger J, 2001, J NEUROCHEM, V79, P35, DOI 10.1046/j.1471-4159.2001.00520.x; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Salman MM, 2017, EUR J NEUROSCI, V46, P2121, DOI 10.1111/ejn.13652; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Senchenko VN, 2015, FEBS J, V282, P263; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tan SC, 2017, CANCER INVEST, V35, P163, DOI 10.1080/07357907.2017.1278767; Tanaka T, 2009, BIOCHEM J, V424, P143, DOI 10.1042/BJ20090120; Tollenaere MAX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10075; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vangeison G, 2009, NEUROSCIENTIST, V15, P579, DOI 10.1177/1073858409332405; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Wallace BK, 2012, AM J PHYSIOL-CELL PH, V302, pC505, DOI 10.1152/ajpcell.00261.2011; Walluscheck D, 2013, J CELL MOL MED, V17, P976, DOI 10.1111/jcmm.12071; Yang D, 2010, CARDIOVASC RES, V85, P520, DOI 10.1093/cvr/cvp323; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang H, 2010, NEUROL RES, V32, P384, DOI 10.1179/016164110X12670144526228; ZHANG W, 2004, MICROARRAY QUALITY C; Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51	98	21	22	1	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	DEC 14	2017	11								386	10.3389/fncel.2017.00386			15	Neurosciences	Neurosciences & Neurology	FP9EL	WOS:000417950200001	29311824	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Salberg, S; Yamakawa, G; Christensen, J; Kolb, B; Mychasiuk, R				Salberg, Sabrina; Yamakawa, Glenn; Christensen, Jennaya; Kolb, Bryan; Mychasiuk, Richelle			ASSESSMENT OF A NUTRITIONAL SUPPLEMENT CONTAINING RESVERATROL, PREBIOTIC FIBER, AND OMEGA-3 FATTY ACIDS FOR THE PREVENTION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY IN RATS	NEUROSCIENCE			English	Article						adolescence; concussion; RT-qPCR; Golgi-Cox; prefrontal cortex; primary auditory cortex	POST-CONCUSSION SYMPTOMS; PREFRONTAL CORTEX; PROFESSIONAL FOOTBALL; SEX-DIFFERENCES; POSTCONCUSSION SYNDROME; SYNAPTIC CONNECTIVITY; DENDRITIC MORPHOLOGY; COGNITIVE RESERVE; DNA METHYLATION; GENE-EXPRESSION	Children and adolescents have the highest rates of traumatic brain Injury (TBI), with mild TBI (mTBI) accounting for most of these injuries. Adolescents are particularly vulnerable and often suffer from post-injury symptomologies that may persist for months. We hypothesized that the combination of resveratrol (RES), prebiotic fiber (PBF), and omega-3 fatty acids (docosahexaenoic acid (DHA)) would be an effective therapeutic supplement for the mitigation of mTBI outcomes In the developing brain. Adolescent male and female Sprague-Dawley rats were randomly assigned to the supplement (3S) or control condition, which was followed by a mTBI or sham insult. A behavioral test battery designed to examine symptomologies commonly associated with mTBI was administered. Following the test battery, tissue was collected from the prefrontal cortex (PFC) and primary auditory cortex for Golgi-Cox analysis of spine density, and for changes In expression of 6 genes (Aqp4, Gfap, Igf1, Nfl, Sirt1, and Tau). 3S treatment altered the behavioral performance of sham animals indicating that dietary manipulations modify premorbid characteristics. 3S treatment prevented Injury-related deficits In the longer-term behavior measures, medial prefrontal cortex (mPFC) spine density, and levels of Aqp4, Gfap, Igf1, Nfl, and Sirt1 expression in the PFC. Although not fully protective, treatment with the supplement significantly improved post-mTBI function and warrants further Investigation. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.	[Salberg, Sabrina; Yamakawa, Glenn; Christensen, Jennaya; Mychasiuk, Richelle] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Kolb, Bryan] Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB, Canada	Mychasiuk, R (corresponding author), Alberta Childrens Prov Gen Hosp, Res Inst, Hotchkiss Brain Inst, Heritage Med Res Bldg Room 274,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rmmychas@ucalgary.ca		Yamakawa, Glenn/0000-0003-3079-6532	Alberta Children's Hospital Foundation; Alberta Children's Hospital Research Institute; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); O'Brien Centre Summer Studentships	The authors would like to acknowledge Yilin Li and Kehe Xe for their technical assistance with the Golgi-Cox analysis. They would also like to thank the Alberta Children's Hospital Research Institute, Alberta Children's Hospital Foundation, the O'Brien Centre Summer Studentships, and NSERC for their financial contribution.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2015, PEDIATR NEUROL, V53, P491, DOI 10.1016/j.pediatrneurol.2015.04.011; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cole GM, 2009, PROSTAG LEUKOTR ESS, V81, P213, DOI 10.1016/j.plefa.2009.05.015; Collins MA, 2013, NEUROTOX RES, V23, P105, DOI 10.1007/s12640-012-9360-5; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crews F, 2007, PHARMACOL BIOCHEM BE, V86, P189, DOI 10.1016/j.pbb.2006.12.001; Crombag HS, 2005, CEREB CORTEX, V15, P341, DOI 10.1093/cercor/bhh136; Das Samarjit, 2007, Inflammation & Allergy Drug Targets, V6, P168, DOI 10.2174/187152807781696464; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Eckles-Smith K, 2000, MOL BRAIN RES, V78, P154, DOI 10.1016/S0169-328X(00)00088-7; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Fuentes A, 2010, BRAIN INJURY, V24, P995, DOI 10.3109/02699052.2010.489791; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hehar H, 2016, NEUROBIOL DIS, V87, P11, DOI 10.1016/j.nbd.2015.12.007; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Hudert CA, 2006, P NATL ACAD SCI USA, V103, P11276, DOI 10.1073/pnas.0601280103; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Kamphuis W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042823; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Kolb B, 1990, CEREBRAL CORTEX RAT; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Ladd-Acosta C, 2007, AM J HUM GENET, V81, P1304, DOI 10.1086/524110; Langdon KD, 2011, NEUROSCIENCE, V182, P82, DOI 10.1016/j.neuroscience.2011.03.028; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Mangiola A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/736104; Martin Leslie R, 2005, Ther Clin Risk Manag, V1, P189; Mathias JL, 2015, NEUROSCI BIOBEHAV R, V55, P573, DOI 10.1016/j.neubiorev.2015.06.001; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mychasiuk R, 2016, NEUROSCIENCE, V322, P489, DOI 10.1016/j.neuroscience.2016.02.053; Mychasiuk R, 2015, NEUROSCIENCE, V288, P145, DOI 10.1016/j.neuroscience.2014.12.034; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2016, EUR J NEUROSCI, P1; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2015, NEUROBIOL DIS, V73, P1, DOI 10.1016/j.nbd.2014.09.003; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Mychasiuk R, 2012, SYNAPSE, V66, P308, DOI 10.1002/syn.21512; Mychasiuk R, 2011, BRAIN RES, V1412, P55, DOI 10.1016/j.brainres.2011.07.023; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Parnell J, 2012, GUT MICROBES, V3, P19246; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Rich NJ, 2010, J NEUROSCI RES, V88, P2933, DOI 10.1002/jnr.22443; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Shukla Y, 2011, ANN NY ACAD SCI, V1215, P1, DOI 10.1111/j.1749-6632.2010.05870.x; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Suzuki T, 2012, EUR J NEUROSCI, V36, P3653, DOI 10.1111/j.1460-9568.2012.08280.x; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Welch R, 2016, J NEUROTRAU; Whishaw I. Q., 2005, BEHAV LAB RAT HDB TE; Wright D, 2017, ANN CLIN TRANSL NEUR; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Zhang Z., 2010, METHOD MOL BIOL, V662; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zilles K., 1985, CORTEX RAT STEREOTAX	82	21	22	1	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 4	2017	365						146	157		10.1016/j.neuroscience.2017.09.053			12	Neurosciences	Neurosciences & Neurology	FN4HP	WOS:000415966200013	28988852				2021-06-18	
J	Theus, MH; Brickler, T; Meza, AL; Coutermarsh-Ott, S; Hazy, A; Gris, D; Allen, IC				Theus, Michelle H.; Brickler, Thomas; Meza, Armand L.; Coutermarsh-Ott, Sheryl; Hazy, Amanda; Gris, Denis; Allen, Irving C.			Loss of NLRX1 Exacerbates Neural Tissue Damage and NF-kappa B Signaling following Brain Injury	JOURNAL OF IMMUNOLOGY			English	Article							NOD-LIKE RECEPTOR; NUCLEAR TRANSLOCATION; SUBVENTRICULAR ZONE; NLRP3 INFLAMMASOME; COLON INFLAMMATION; INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; I INTERFERON; EXPRESSION; NEURONS	Traumatic and nontraumatic brain injury results from severe disruptions in the cellular microenvironment leading to massive loss of neuronal populations and increased neuroinflammation. The progressive cascade of secondary events, including ischemia, inflammation, excitotoxicity, and free-radical release, contribute to neural tissue damage. NLRX1 is a member of the NLR family of pattern recognition receptors and is a potent negative regulator of several pathways that significantly modulate many of these events. Thus, we hypothesized that NLRX1 limits immune system signaling in the brain following trauma. To evaluate this hypothesis, we used Nlrx1(-/-) mice in a controlled cortical impact (CCI) injury murine model of traumatic brain injury (TBI). In this article, we show that Nlrx1(-/-) mice exhibited significantly larger brain lesions and increased motor deficits following CCI injury. Mechanistically, our data indicate that the NF-kappa B signaling cascade is significantly upregulated in Nlrx1(-/-) animals. This upregulation is associated with increased microglia and macrophage populations in the cortical lesion. Using a mouse neuroblastoma cell line (N2A), we also found that NLRX1 significantly reduced apoptosis under hypoxic conditions. In human patients, we identify 15 NLRs that are significantly dysregulated, including significant downregulation of NLRX1 in brain injury following aneurysm. We further demonstrate a concurrent increase in NF-kappa B signaling that is correlated with aneurysm severity in these human subjects. Together, our data extend the function of NLRX1 beyond its currently characterized role in host-pathogen defense and identify this highly novel NLR as a significant modulator of brain injury progression.	[Theus, Michelle H.; Brickler, Thomas; Meza, Armand L.; Coutermarsh-Ott, Sheryl; Hazy, Amanda; Allen, Irving C.] Virginia Tech, Dept Biomed Sci & Pathobiol, Virginia Maryland Coll Vet Med, IDRF 140,Duckpond Dr, Blacksburg, VA 24061 USA; [Meza, Armand L.] Virginia Tech, Dept Neurosci, Blacksburg, VA 24061 USA; [Gris, Denis] Univ Sherbrooke, Fac Med & Sci Sante, Programme Immunol, Sherbrooke, PQ J1H 5N4, Canada	Theus, MH; Allen, IC (corresponding author), Virginia Tech, Dept Biomed Sci & Pathobiol, Virginia Maryland Coll Vet Med, IDRF 140,Duckpond Dr, Blacksburg, VA 24061 USA.	mtheus@vt.edu; icallen@vt.edu			National Institute of Neurological Disease and Stroke Awards [NS096281, NS081623]; National Institute of Allergy and Infectious Diseases Animal Model Research for Veterinarians Training Grant [T32-OD010430]; Virginia Tech Initiative for Maximizing Student Development program [GM0727-09]; Virginia Tech Post-Baccalaureate Research and Education Program [GM066534-14]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS096281, R15NS081623] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disease and Stroke Awards NS096281 and NS081623. Student work was supported by National Institute of Allergy and Infectious Diseases Animal Model Research for Veterinarians Training Grant T32-OD010430 (to S.C.-O.). Student support throughout this project was also provided by the Virginia Tech Initiative for Maximizing Student Development program (GM0727-09) and the Virginia Tech Post-Baccalaureate Research and Education Program (GM066534-14). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any other funding agency.	Abdul-Sater AA, 2010, J BIOL CHEM, V285, P41637, DOI 10.1074/jbc.M110.137885; Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012; Allen IC, 2011, IMMUNITY, V34, P854, DOI 10.1016/j.immuni.2011.03.026; Allen IC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00169; Arnoult D, 2009, J CELL SCI, V122, P3161, DOI 10.1242/jcs.051193; Bai X, 2014, NEUROCHEM RES, V39, P1405, DOI 10.1007/s11064-014-1326-y; Baumann G, 2013, EXP BIOL MED, V238, P830, DOI 10.1177/1535370213494558; Boissiere F, 1997, NEUROREPORT, V8, P2849, DOI 10.1097/00001756-199709080-00009; Brickler T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6373506; Coutermarsh-Ott S, 2016, ONCOTARGET, V7, P33096, DOI 10.18632/oncotarget.8861; Coutermarsh-Ott S, 2016, J GEN VIROL, V97, P825, DOI 10.1099/jgv.0.000401; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Eitas TK, 2014, J BIOL CHEM, V289, P4173, DOI 10.1074/jbc.M113.533034; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Gao F, 2013, J SURG RES, V184, P944, DOI 10.1016/j.jss.2013.03.034; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Ghosh A, 2007, P NATL ACAD SCI USA, V104, P18754, DOI 10.1073/pnas.0704908104; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hayman EG, 2017, NEUROCRIT CARE, V26, P301, DOI 10.1007/s12028-016-0354-7; He Y., 2015, INT J POLYM SCI, V2015, P1, DOI DOI 10.1155/2015/685684; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Hwang CJ, 2015, MOL NEUROBIOL, V51, P648, DOI 10.1007/s12035-014-8739-0; Imbeault E, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0090-x; Jaworska J, 2014, P NATL ACAD SCI USA, V111, pE2110, DOI 10.1073/pnas.1322118111; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kang MJ, 2015, J CLIN INVEST, V125, P2458, DOI 10.1172/JCI71747; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Koblansky AA, 2016, CELL REP, V14, P2562, DOI 10.1016/j.celrep.2016.02.064; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; Lei Y, 2016, ONCOGENE, V35, P4698, DOI 10.1038/onc.2016.11; Lei Y, 2013, AUTOPHAGY, V9, P432, DOI 10.4161/auto.23026; Lei Y, 2012, IMMUNITY, V36, P933, DOI 10.1016/j.immuni.2012.03.025; Li HY, 2010, EUR J PHARMACOL, V649, P92, DOI 10.1016/j.ejphar.2010.09.023; Li L, 2009, EUR NEUROL, V62, P330, DOI 10.1159/000236911; Lian H, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-47; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu HQ, 2015, INT J BIOL SCI, V11, P525, DOI 10.7150/ijbs.10927; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lukens JR, 2011, DISCOV MED, V11, P65; Lukens JR, 2015, IMMUNITY, V42, P654, DOI 10.1016/j.immuni.2015.03.006; Lukiw WJ, 1998, J NEUROSCI RES, V53, P583, DOI 10.1002/(SICI)1097-4547(19980901)53:5<583::AID-JNR8>3.0.CO;2-5; Lupfer C, 2013, IMMUNOL REV, V255, P13, DOI 10.1111/imr.12089; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Moore CB, 2008, NATURE, V451, P573, DOI 10.1038/nature06501; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Nakaoka H, 2014, STROKE, V45, P2239, DOI 10.1161/STROKEAHA.114.005851; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Saragoni L, 2000, NEUROCHEM RES, V25, P59, DOI 10.1023/A:1007587315630; Saresella M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0088-1; Schneider M, 2012, NAT IMMUNOL, V13, P823, DOI 10.1038/ni.2378; Sehba FA, 2012, PROG NEUROBIOL, V97, P14, DOI 10.1016/j.pneurobio.2012.02.003; Simmons LJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0703-7; Singh K, 2015, BBA-MOL CELL RES, V1853, P1073, DOI 10.1016/j.bbamcr.2015.01.016; Soares F, 2014, J BIOL CHEM, V289, P19317, DOI 10.1074/jbc.M114.550111; Tattoli I, 2008, EMBO REP, V9, P293, DOI 10.1038/sj.embor.7401161; Theus MH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.165; Theus MH, 2010, STEM CELLS, V28, P1231, DOI 10.1002/stem.449; Tremblay RG, 2010, J NEUROSCI METH, V186, P60, DOI 10.1016/j.jneumeth.2009.11.004; Uchiyama Y, 2004, AM J NEURORADIOL, V25, P1783; Xia XJ, 2011, IMMUNITY, V34, P843, DOI 10.1016/j.immuni.2011.02.022; Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022; Zhou Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0094-3	65	21	24	0	8	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	NOV 15	2017	199	10					3547	3558		10.4049/jimmunol.1700251			12	Immunology	Immunology	FM0MK	WOS:000414660600015	28993512	Bronze, Green Accepted			2021-06-18	
J	Baslet, G; Tolchin, B; Dworetzky, BA				Baslet, Gaston; Tolchin, Benjamin; Dworetzky, Barbara A.			Altered responsiveness in psychogenic nonepileptic seizures and its implication to underlying psychopathology	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						Psychogenic nonepileptic seizures; Semiology; Awareness; Experiential avoidance; Emotion regulation; Resilience	PSYCHOMETRIC PROPERTIES; EXPERIENTIAL AVOIDANCE; EMOTION REGULATION; BECK DEPRESSION; ATTACK DISORDER; CONSCIOUSNESS; DISSOCIATION; DIAGNOSIS; SYMPTOMS; EPILEPSY	Purpose: Altered responsiveness during psychogenic nonepileptic seizures (PNES) is a distinct semiological feature that may signal a psychological vulnerability. We hypothesized that altered responsiveness is related to difficulties with emotion tolerance, experiential avoidance, difficulty coping, dissociation and trauma and prior experiences of loss of awareness. Methods: 71 patients with video-EEG confirmed PNES were divided into two groups based on their responsiveness at the time of the captured event during long-term monitoring. Demographic information, clinical history and self-rated questionnaires highlighting psychopathology were compared between the groups. Results: 47 patients (66%) had altered responsiveness during their captured event. Married or partnered subjects were more represented in the altered responsiveness group. Experiential avoidance, as measured by the Acceptance and Action Questionnaire-II, and affect intolerance, as measured by the Affective Style Questionnaire, were significantly higher in the altered responsiveness group. The Connor Davidson Resilience Scale was significantly higher among intact responsiveness subjects. Subjects with altered responsiveness were more likely to have a family history of seizures, comorbid headaches, and loss of consciousness (LOC) during traumatic brain injury. There were no differences in measures of dissociation, somatization, mood or anxiety, or presence of psychiatric comorbidities, including PTSD or history of trauma. Conclusion: Altered responsiveness during PNES is a marker of lower emotional resilience or ability to tolerate emotions among patients with PNES. Emotion management may be an important therapeutic target for these patients. Prior experiences with LOC also contribute to the presence of altered responsiveness. Trauma and dissociation did not differentiate responsiveness during PNES. (C) 2017 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[Baslet, Gaston] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, 60 Fenwood Rd, Boston, MA 02115 USA; [Tolchin, Benjamin] Yale Univ, Sch Med, Dept Neurol, 15 York St, New Haven, CT 06510 USA; [Dworetzky, Barbara A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, 60 Fenwood Rd, Boston, MA USA	Baslet, G (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, 60 Fenwood Rd, Boston, MA 02115 USA.	gbaslet@bwh.harvard.edu	Baslet, Gaston/AAF-6272-2021	Baslet, Gaston/0000-0002-3039-582X			Ali F, 2010, EPILEPSY BEHAV, V19, P522, DOI 10.1016/j.yebeh.2010.08.014; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Arain AM, 2007, EPILEPSY BEHAV, V11, P409, DOI 10.1016/j.yebeh.2007.07.017; Beck A.T., 1996, MANUAL BECK DEPRESSI; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Benbadis SR, 2004, EPILEPSIA, V45, P1150, DOI 10.1111/j.0013-9580.2004.14504.x; Bernstein E, 1986, J NERV MENT DIS, V185, P491; Bond FW, 2011, BEHAV THER, V42, P676, DOI 10.1016/j.beth.2011.03.007; Brown RJ, 2004, PSYCHOL BULL, V130, P793, DOI 10.1037/0033-2909.130.5.793; Cavanna AE, 2011, BEHAV NEUROL, V24, P107, DOI [10.1155/2011/645159, 10.3233/BEN-2011-0322]; Chen DK, 2012, EPILEPSY BEHAV, V24, P30, DOI 10.1016/j.yebeh.2012.03.009; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Goldstein LH, 2006, J NEUROL NEUROSUR PS, V77, P616, DOI 10.1136/jnnp.2005.066878; Griffith NM, 2008, EPILEPSY BEHAV, V13, P478, DOI 10.1016/j.yebeh.2008.06.005; Griffith NM, 2007, EPILEPSY BEHAV, V11, P105, DOI 10.1016/j.yebeh.2007.04.021; Hayes SC, 2004, PSYCHOL REC, V54, P553, DOI 10.1007/BF03395492; Hofmann SG, 2010, J PSYCHOPATHOL BEHAV, V32, P255, DOI 10.1007/s10862-009-9142-4; Interian A, 2006, PSYCHOSOMATICS, V47, P392, DOI 10.1176/appi.psy.47.5.392; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; LaFrance WC, 2013, EPILEPSIA, V54, P2005, DOI 10.1111/epi.12356; LaFrance WC, 2013, EPILEPSIA, V54, P53, DOI 10.1111/epi.12106; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Lovibond S.H., 1995, MANUAL DEPRESSION AN; PUTNAM FW, 1997, THESIS; Reuber M, 2011, BEHAV NEUROL, V24, P95, DOI [10.1155/2011/327654, 10.3233/BEN-2011-0315]; Reuber M, 2003, ANN NEUROL, V53, P305, DOI 10.1002/ana.3000; Roberts NA, 2014, EPILEPSY BEHAV, V30, P43, DOI 10.1016/j.yebeh.2013.09.035; Selwa LM, 2000, EPILEPSIA, V41, P1330, DOI 10.1111/j.1528-1157.2000.tb04613.x; Uliaszek AA, 2012, EPILEPSY BEHAV, V23, P364, DOI 10.1016/j.yebeh.2012.01.009; van Ijzendoorn MH, 1996, CLIN PSYCHOL REV, V16, P365, DOI 10.1016/0272-7358(96)00006-2; Wong VSS, 2017, PSYCHOGENIC NONEPILE	31	21	21	0	5	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	NOV	2017	52						162	168		10.1016/j.seizure.2017.10.011			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FP9JJ	WOS:000417963000024	29049948	Bronze			2021-06-18	
J	Chen, T; Wu, Y; Wang, YZ; Zhu, JG; Chu, HY; Kong, L; Yin, LW; Ma, HY				Chen, Tao; Wu, Yu; Wang, Yuzi; Zhu, Jigao; Chu, Haiying; Kong, Li; Yin, Liangwei; Ma, Haiying			Brain-Derived Neurotrophic Factor Increases Synaptic Protein Levels via the MAPK/Erk Signaling Pathway and Nrf2/Trx Axis Following the Transplantation of Neural Stem Cells in a Rat Model of Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Brain-derived neurotrophic factor; Traumatic brain injury; Transplantation; Differentiation; TrkB; MAPK/Erk; Thioredoxin; PSD-95; Synaptogenesis	OXIDATIVE STRESS; FUNCTIONAL RECOVERY; DENDRITIC SPINES; BDNF; EXPRESSION; MODULATION; ACTIVATION; RECEPTORS; PHOSPHORYLATION; THIOREDOXIN-1	Brain-derived neurotrophic factor (BDNF) plays an important role in promoting the growth, differentiation, survival and synaptic stability of neurons. Presently, the transplantation of neural stem cells (NSCs) is known to induce neural repair to some extent after injury or disease. In this study, to investigate whether NSCs genetically modified to encode the BDNF gene (BDNF/NSCs) would further enhance synaptogenesis, BDNF/NSCs or naive NSCs were directly engrafted into lesions in a rat model of traumatic brain injury (TBI). Immunohistochemistry, western blotting and RT-PCR were performed to detect synaptic proteins, BDNF-TrkB and its downstream signaling pathways, at 1, 2, 3 or 4 weeks after transplantation. Our results showed that BDNF significantly increased the expression levels of the TrkB receptor gene and the phosphorylation of the TrkB protein in the lesions. The expression levels of Ras, phosphorylated Erk1/2 and postsynaptic density protein-95 were elevated in the BDNF/NSCs-transplanted groups compared with those in the NSCs-transplanted groups throughout the experimental period. Moreover, the nuclear factor (erythroid-derived 2)-like 2/Thioredoxin (Nrf2/Trx) axis, which is a specific therapeutic target for the treatment of injury or cell death, was upregulated by BDNF overexpression. Therefore, we determined that the increased synaptic proteins level implicated in synaptogenesis might be associated with the activation of the MAPK/Erk1/2 signaling pathway and the upregulation of the antioxidant agent Trx modified by BDNF-TrkB following the BDNF/NSCs transplantation after TBI.	[Chen, Tao] Dalian Med Univ, Dept Neurosurg, Affiliated Hosp 1, Dalian 116011, Peoples R China; [Wu, Yu; Wang, Yuzi; Zhu, Jigao; Chu, Haiying; Kong, Li; Ma, Haiying] Dalian Med Univ, Dept Histol & Embryol, Dalian 116044, Peoples R China; [Yin, Liangwei] Dalian Cent Hosp, Dept Oncol, Dalian 116033, Liaoning, Peoples R China	Ma, HY (corresponding author), Dalian Med Univ, Dept Histol & Embryol, Dalian 116044, Peoples R China.; Yin, LW (corresponding author), Dalian Cent Hosp, Dept Oncol, Dalian 116033, Liaoning, Peoples R China.	lwyin2008@163.com; hyma20060602@aliyun.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31300812, 31371218]	We thank Professor Shui Guan and Xuehu Ma from the Stem Cell and Tissue Engineering Laboratory of the Dalian University of Technology for their support in culturing the NSCs. This work was supported by Grant Nos. 31300812 and 31371218 from the National Natural Science Foundation of China.	Aertker BM, 2016, EXP NEUROL, V275, P411, DOI 10.1016/j.expneurol.2015.01.008; Ammar MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep14778; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Androutsellis-Theotokis A, 2009, P NATL ACAD SCI USA, V106, P13570, DOI 10.1073/pnas.0905125106; Aroeira RI, 2016, NEUROCHEM INT, V99, P94, DOI 10.1016/j.neuint.2016.06.007; Bathina S, 2015, ARCH MED SCI, V11, P1164, DOI 10.5114/aoms.2015.56342; Bonnamain V, 2012, FRONT CELL NEUROSCI, V6; Bramham CR, 2014, NEUROPHARMACOLOGY, V76, P601, DOI 10.1016/j.neuropharm.2013.08.012; Caldeira MV, 2007, J BIOL CHEM, V282, P12619, DOI 10.1074/jbc.M700607200; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen ZM, 2008, AM J MED GENET B, V147B, P363, DOI 10.1002/ajmg.b.30607; Cornejo BJ, 2007, ANN NEUROL, V61, P411, DOI 10.1002/ana.21071; Crowther AJ, 2014, NEUROSCI BULL, V30, P542, DOI 10.1007/s12264-014-1453-5; Deinhardt K, 2014, NEUROPHARMACOLOGY, V76, P603, DOI 10.1016/j.neuropharm.2013.04.054; Elias GM, 2006, NEURON, V52, P307, DOI 10.1016/j.neuron.2006.09.012; Elkabetz Y, 2008, COLD SH Q B, V73, P377, DOI 10.1101/sqb.2008.73.052; Fiorin FD, 2016, J NEUROTRAUM, V33, P1317, DOI 10.1089/neu.2015.4068; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Habas A, 2013, P NATL ACAD SCI USA, V110, P18291, DOI 10.1073/pnas.1208764110; Hu XD, 2011, J NEUROSCI, V31, P15597, DOI 10.1523/JNEUROSCI.2445-11.2011; Ichiki H, 2005, BIOCHEM BIOPH RES CO, V334, P1141, DOI 10.1016/j.bbrc.2005.07.007; Itoh T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Li L, 2015, NEUROSCIENCE, V284, P815, DOI 10.1016/j.neuroscience.2014.10.066; Li R, 2013, BRAIN RES, V1523, P1, DOI 10.1016/j.brainres.2013.05.046; Lin H, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00034; Liu Y, 2016, EXP NEUROL, V275, P126, DOI 10.1016/j.expneurol.2015.10.002; Luikart BW, 2008, J NEUROSCI, V28, P7006, DOI 10.1523/JNEUROSCI.0195-08.2008; Luine V, 2013, NEUROSCIENCE, V239, P34, DOI 10.1016/j.neuroscience.2012.10.019; Luo P, 2011, BRAIN RES BULL, V85, P313, DOI 10.1016/j.brainresbull.2011.05.004; Ma DK, 2009, CELL RES, V19, P672, DOI 10.1038/cr.2009.56; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Ma HY, 2011, MOL MED REP, V4, P849, DOI 10.3892/mmr.2011.510; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Moosavi F, 2016, DRUG DES DEV THER, V10, P23, DOI 10.2147/DDDT.S96936; Muthusamy VR, 2012, FREE RADICAL BIO MED, V52, P366, DOI 10.1016/j.freeradbiomed.2011.10.440; Nakajima S, 2015, NEUROCHEM INT, V91, P55, DOI 10.1016/j.neuint.2015.10.009; Niso-Santano M, 2010, FREE RADICAL BIO MED, V48, P1370, DOI 10.1016/j.freeradbiomed.2010.02.024; Park HH, 2016, NEUROTOXICOLOGY, V55, P131, DOI 10.1016/j.neuro.2016.05.022; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Paspala SAB, 2011, NEUROL INDIA, V59, P69, DOI 10.4103/0028-3886.84338; Ratajczak J, 2011, J PHYSIOL PHARMACOL, V62, P3; Sakaguchi M, 2012, DEV NEUROBIOL, V72, P1059, DOI 10.1002/dneu.22023; Santos AR, 2010, PROG NEUROBIOL, V92, P505, DOI 10.1016/j.pneurobio.2010.08.004; Song JS, 2016, TOXICOL APPL PHARM, V307, P138, DOI 10.1016/j.taap.2016.08.003; Stabenfeldt SE, 2011, CURR STEM CELL RES T, V6, P208; Tan J, 2006, AM J PATHOL, V169, P528, DOI 10.2353/ajpath.2006.060122; Tian L, 2014, NEUROPHARMACOLOGY, V77, P453, DOI 10.1016/j.neuropharm.2013.10.027; Yoshii A, 2007, NAT NEUROSCI, V10, P702, DOI 10.1038/nn1903; Yoshii Akira, 2014, Front Synaptic Neurosci, V6, P6, DOI 10.3389/fnsyn.2014.00006; Zagrebelsky M, 2014, NEUROPHARMACOLOGY, V76, P628, DOI 10.1016/j.neuropharm.2013.05.029; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105; Zhou XJ, 2010, J NEUROSCI RES, V88, P1420, DOI 10.1002/jnr.22321; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	54	21	22	1	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	NOV	2017	42	11					3073	3083		10.1007/s11064-017-2340-7			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FK4IR	WOS:000413457000007	28780733				2021-06-18	
J	Minogue, AM				Minogue, Aedin M.			Role of infiltrating monocytes/macrophages in acute and chronic neuroinflammation: Effects on cognition, learning and affective behaviour	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Article						Macrophage; Cognition; M1/M2 polarisation; Neuroinflammation; Alzheimer's disease; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; MARROW-DERIVED MACROPHAGES; CENTRAL-NERVOUS-SYSTEM; BARRIER PERMEABILITY; ALZHEIMERS-DISEASE; INFLAMMATORY STIMULI; A-BETA-PP/PS1 MICE; CELL INFILTRATION; APP/PS1 MICE; ACTIVATION	Peripheral macrophages have limited capacity to gain access to the brain parenchyma under normal physiological conditions. However, accumulating evidence indicates that significant trafficking to the central nervous systems occurs in response to injury or infection and is also apparent under chronic neuroinflammatory conditions. The role of infiltrating macrophages in neuronal function is unclear and confounded by the similarity in morphology and phenotype adopted by both activated macrophages and microglia. Furthermore, the ability of macrophages/microglia to adopt both pro- and anti-inflammatory activation states, along with the fact that these cells display heterogenous expression of molecules associated with both states, has made it difficult to discover their impact upon neuronal injury and cognitive processes. The ability of macrophages to exert a neuroprotective role is influenced by the microenvironment they encounter upon tissue invasion. Upon encountering an inflammatory microenvironment, macrophage polarisation is driven towards a pro-inflammatory (M1) phenotype, a state associated with reduced capacity for restorative processes such as the removal of debris, and enhanced production of pro-inflammatory mediators such as TNF alpha, IL-1 beta and NADPH oxidase. Prolonged production of these inflammatory mediators has been shown to affect neuronal function and health. Thus, macrophage polarisation may be dictated by the inflammatory queues these cells are exposed to upon migration and their subsequent impact on neuronal function may be determined by their ability to resolve the underlying inflammation. (c) 2017 Elsevier Inc. All rights reserved.	[Minogue, Aedin M.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dept Physiol, 152-160 Pearse St, Dublin 2, Ireland; [Minogue, Aedin M.] Trinity Coll Dublin, Trinity Coll, Inst Neurosci, Lloyd Bldg, Dublin 2, Ireland	Minogue, AM (corresponding author), Trinity Coll Dublin, Trinity Coll, Inst Neurosci, Lloyd Bldg, Dublin 2, Ireland.	aminogu@tcd.ie					Barrett JP, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0287-7; Barrett JP, 2015, J ALZHEIMERS DIS, V44, P949, DOI 10.3233/JAD-142076; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Blau CW, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.09.035; Butovsky O, 2012, J CLIN INVEST, V122, P3063, DOI 10.1172/JCI62636; Chung YC, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.100; Costello DA, 2016, NEUROBIOL AGING, V43, P140, DOI 10.1016/j.neurobiolaging.2016.04.001; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Farrall AJ, 2009, NEUROBIOL AGING, V30, P337, DOI 10.1016/j.neurobiolaging.2007.07.015; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Kapellos TS, 2016, BIOCHEM PHARMACOL, V116, P107, DOI 10.1016/j.bcp.2016.07.011; Kelly RJ, 2013, J ALZHEIMERS DIS, V37, P63, DOI 10.3233/JAD-130539; Kiyatkin EA, 2009, NEUROSCIENCE, V161, P926, DOI 10.1016/j.neuroscience.2009.04.004; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Lee W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0324-6; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Luth HJ, 2001, BRAIN RES, V913, P57, DOI 10.1016/S0006-8993(01)02758-5; McKim DB, 2016, J NEUROSCI, V36, P2590, DOI 10.1523/JNEUROSCI.2394-15.2016; McManus RM, 2014, NEUROBIOL AGING, V35, P109, DOI 10.1016/j.neurobiolaging.2013.07.025; Minogue AM, 2014, NEUROBIOL AGING, V35, P1442, DOI 10.1016/j.neurobiolaging.2013.12.026; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Paul J, 2007, J EXP MED, V204, P1999, DOI 10.1084/jem.20070304; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Rawji KS, 2016, BRAIN, V139, P653, DOI 10.1093/brain/awv395; Starr JM, 2009, PSYCHIAT RES-NEUROIM, V171, P232, DOI 10.1016/j.pscychresns.2008.04.003; Ujiie M, 2003, MICROCIRCULATION, V10, P463, DOI 10.1038/sj.mn.7800212; Wohleb ES, 2014, BIOL PSYCHIAT, V75, P970, DOI 10.1016/j.biopsych.2013.11.029; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Zhu D, 2016, J ALZHEIMERS DIS, V52, P483, DOI 10.3233/JAD-151090	34	21	21	2	68	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846	1878-4216		PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	OCT 3	2017	79		A		SI		15	18		10.1016/j.pnpbp.2017.02.008			4	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	EZ9LN	WOS:000405052000003	28189704				2021-06-18	
J	DiMaggio, CJ; Avraham, JB; Lee, DC; Frangos, SG; Wall, SP				DiMaggio, Charles J.; Avraham, Jacob B.; Lee, David C.; Frangos, Spiros G.; Wall, Stephen P.			The Epidemiology of Emergency Department Trauma Discharges in the United States	ACADEMIC EMERGENCY MEDICINE			English	Article							NATIONAL TRAUMA; INJURY; MORTALITY	Objective: Injury-related morbidity and mortality is an important emergency medicine and public health challenge in the United States. Here we describe the epidemiology of traumatic injury presenting to U.S. emergency departments (EDs), define changes in types and causes of injury among the elderly and the young, characterize the role of trauma centers and teaching hospitals in providing emergency trauma care, and estimate the overall economic burden of treating such injuries. Methods: We conducted a secondary retrospective, repeated cross-sectional study of the Nationwide Emergency Department Data Sample (NEDS), the largest all-payer ED survey database in the United States. Main outcomes and measures were survey-adjusted counts, proportions, means, and rates with associated standard errors (SEs) and 95% confidence intervals. We plotted annual age-stratified ED discharge rates for traumatic injury and present tables of proportions of common injuries and external causes. We modeled the association of Level I or II trauma center care with injury fatality using a multivariable survey-adjusted logistic regression analysis that controlled for age, sex, injury severity, comorbid diagnoses, and teaching hospital status. Results: There were 181,194,431 (SE = 4,234) traumatic injury discharges from U.S. EDs between 2006 and 2012. There was a mean year-to-year decrease of 143 (95% CI = -184.3 to -68.5) visits per 100,000 U.S. population during the study period. The all-age, all-cause case-fatality rate for traumatic injuries across U.S. EDs during the study period was 0.17% (SE = 0.001%). The case-fatality rate for the most severely injured averaged 4.8% (SE = 0.001%), and severely injured patients were nearly four times as likely to be seen in Level I or II trauma centers (relative risk = 3.9 [95% CI = 3.7 to 4.1]). The unadjusted risk ratio, based on group counts, for the association of Level I or II trauma centers with mortality was risk ratio = 4.9 (95% CI = 4.5 to 5.3); however, after sex, age, injury severity, and comorbidities were accounted for, Level I or II trauma centers were not associated with an increased risk of fatality (odds ratio = 0.96 [95% CI = 0.79 to 1.18]). There were notable changes at the extremes of age in types and causes of ED discharges for traumatic injury between 2009 and 2012. Age-stratified rates of diagnoses of traumatic brain injury increased 29.5% (SE = 2.6%) for adults older than 85 and increased 44.9% (SE = 1.3%) for children younger than 18. Firearm-related injuries increased 31.7% (SE = 0.2%) in children 5 years and younger. The total inflation-adjusted cost of ED injury care in the United States between 2006 and 2012 was (sic) 99.75 billion (SE = $0.03 billion). Conclusions: Emergency departments are a sensitive barometer of the continuing impact of traumatic injury as an important cause of morbidity and mortality in the United States. Level I or II trauma centers remain a bulwark against the tide of severe trauma in the United States, but the types and causes of traumatic injury in the United States are changing in consequential ways, particularly at the extremes of age, with traumatic brain injuries and firearm-related trauma presenting increased challenges.	[DiMaggio, Charles J.; Avraham, Jacob B.; Frangos, Spiros G.] NYU, Sch Med, Dept Surg, Div Acute Care & Trauma Surg, New York, NY 10003 USA; [Lee, David C.; Wall, Stephen P.] NYU, Sch Med, Ronald O Perelman Dept Emergency Med, New York, NY USA; [DiMaggio, Charles J.; Lee, David C.; Wall, Stephen P.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA	DiMaggio, CJ (corresponding author), NYU, Sch Med, Dept Surg, Div Acute Care & Trauma Surg, New York, NY 10003 USA.; DiMaggio, CJ (corresponding author), NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA.	Charles.DiMaggio@nyumc.org		DiMaggio, Charles/0000-0003-2356-6659; Frangos, Spiros/0000-0003-2860-8969; Wall, Stephen/0000-0003-3965-5074	National Institute of Child Health and Human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01-HD087460]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD087460] Funding Source: NIH RePORTER	This study was funded in part by grant R01-HD087460, awarded by the National Institute of Child Health and Human Development at the National Institutes of Health. The study funders had no role in the study design, analysis, drafting of the manuscript, or decision to submit the study for publication.	Agency for Healthcare Research and Quality, 2012, INTR HCUP NAT EM DEP; Agency for Healthcare Research and Quality, 2011, HCUP METH SER SPEC S; Agency for Healthcare Research and Quality, 2015, INTR HEALTHC COST UT; American Medical Association, 2005, CLIN MOD PHYS ICD 9; [Anonymous], US CONS PROD SAF COM; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bieler GS, 2010, AM J EPIDEMIOL, V171, P618, DOI 10.1093/aje/kwp440; Bonnie R.J., 1999, REDUCING BURDEN INJU; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Calland JF, 2013, J TRAUMA ACUTE CARE, V75, P501, DOI 10.1097/TA.0b013e31829bb75c; CDCP, 2015, WISQARS LEAD CAUS DE; Centers for Disease Control and Prevention, 2013, LEAD CAUS NONF INJ R; Centers for Disease Control and Prevention, 2016, WEB BAS INJ STAT QUE; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DiMaggio C, 2016, INJURY, V47, P1393, DOI 10.1016/j.injury.2016.04.002; Feeney JM, 2017, INJURY, V48, P47, DOI 10.1016/j.injury.2016.08.016; Fingerhut LA, 2002, INJ PREV, V8, P259, DOI 10.1136/ip.8.3.259; Fox J., 2010, R COMPANION APPL REG, V2nd Ed.; Gedeborg R., 2009, JOINT M INT COLL EFF; Haider AH, 2004, J AM COLL SURGEONS, V198, P906, DOI 10.1016/j.jamcollsurg.2004.02.013; Harrell FE., RMS REGRESSION MODEL RMS REGRESSION MODEL RMS REGRESSION MODEL RMS REGRESSION MODEL RMS REGRESSION MODEL RMS REGRESSION MODEL; Hirshon JM, 2009, ACAD EMERG MED, V16, P1103, DOI 10.1111/j.1553-2712.2009.00554.x; Hu GQ, 2010, INJURY PREV, V16, P26, DOI 10.1136/ip.2009.023481; Institute for Social and Preventative Medicine University of Bern, 2007, STROBE STATEMENTCHEC; Jain NB, 2015, JAMA-J AM MED ASSOC, V313, P2236, DOI 10.1001/jama.2015.6250; Kalesan B, 2016, LANCET, V387, P1847, DOI 10.1016/S0140-6736(15)01026-0; Kalesan B, 2016, ANN EPIDEMIOL, V26, P1, DOI 10.1016/j.annepidem.2015.10.009; Kalesan B, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005628; Kauvar DS, 2011, J VASC SURG, V53, P1598, DOI 10.1016/j.jvs.2011.01.056; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; Lumley T, 2004, J STAT SOFTW, V9, DOI DOI 10.18637/JSS.V009.I08; Lumley Thomas, 2014, SQLSURVEY ANAL VERY; Miller Matthew L, 2008, Ann Adv Automot Med, V52, P101; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Ottochian M, 2009, INJURY, V40, P354, DOI 10.1016/j.injury.2008.10.015; Owens PL, 2010, ANN EMERG MED, V56, P150, DOI 10.1016/j.annemergmed.2009.11.022; Palmer Cameron, 2007, Annu Proc Assoc Adv Automot Med, V51, P13; R Development Core Team, 2015, R LANG ENV STAT COMP R LANG ENV STAT COMP MISCELLANEOUS FUNCTI; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Segui-Gomez M, 2012, INJURY RES, P291; Sim J, 2015, ANN SURG TREAT RES, V89, P215, DOI 10.4174/astr.2015.89.4.215; Sise RG, 2014, J TRAUMA ACUTE CARE, V76, P913, DOI 10.1097/TA.0000000000000169; Srinivasan S, 2014, ARCH DIS CHILD, V99, P331, DOI 10.1136/archdischild-2013-304642; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Tashiro J, 2016, J TRAUMA ACUTE CARE, V81, pS54, DOI 10.1097/TA.0000000000001177; Venables W.N., 2002, MODERN APPL STAT S; Venkat A., 2011, EMERG MED NEWS, V33; Wasey J, 2016, ICD9 TOOLS WORKING I; Wood B, 2016, CJEM, V18, pS125; Zafar SN, 2012, BRIT J SURG, V99, P155, DOI 10.1002/bjs.7735; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696	53	21	22	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	OCT	2017	24	10					1244	1256		10.1111/acem.13223			13	Emergency Medicine	Emergency Medicine	FK2YM	WOS:000413349800007	28493608	Bronze, Green Accepted			2021-06-18	
J	Montgomery, S; Hiyoshi, A; Burkill, S; Alfredsson, L; Bahmanyar, S; Olsson, T				Montgomery, Scott; Hiyoshi, Ayako; Burkill, Sarah; Alfredsson, Lars; Bahmanyar, Shahram; Olsson, Tomas			Concussion in adolescence and risk of multiple sclerosis	ANNALS OF NEUROLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; T-CELL; METAANALYSIS; ASSOCIATION; POPULATION; RESPONSES; MEN	ObjectiveTo assess whether concussion in childhood or adolescence is associated with subsequent multiple sclerosis (MS) risk. Previous research suggests an association, but methodological limitations included retrospective data collection and small study populations. MethodsThe national Swedish Patient Register (hospital diagnoses) and MS Register were used to identify all MS diagnoses up to 2012 among people born since 1964, when the Patient Register was established. The 7,292 patients with MS were matched individually with 10 people without MS by sex, year of birth, age/vital status at MS diagnosis, and region of residence (county), resulting in a study population of 80,212. Diagnoses of concussion and control diagnoses of broken limb bones were identified using the Patient Register from birth to age 10 years or from age 11 to 20 years. Conditional logistic regression was used to examine associations with MS. ResultsConcussion in adolescence was associated with a raised risk of MS, producing adjusted odds ratios (95% confidence intervals) of 1.22 (1.05-1.42, p=0.008) and 2.33 (1.35-4.04, p=0.002) for 1 diagnosis of concussion and >1 diagnosis of concussion, respectively, compared with none. No notable association with MS was observed for concussion in childhood, or broken limb bones in childhood and adolescence. InterpretationHead trauma in adolescence, particularly if repeated, is associated with a raised risk of future MS, possibly due to initiation of an autoimmune process in the central nervous system. This further emphasizes the importance of protecting young people from head injuries. Ann Neurol 2017;82:554-561	[Montgomery, Scott; Hiyoshi, Ayako] Orebro Univ, Sch Med Sci, Clin Epidemiol & Biostat, Campus USO, Orebro, Sweden; [Montgomery, Scott; Burkill, Sarah; Bahmanyar, Shahram] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Solna, Sweden; [Montgomery, Scott] UCL, Dept Epidemiol & Publ Hlth, London, England; [Burkill, Sarah; Bahmanyar, Shahram] Karolinska Inst, Dept Med, Ctr Pharmacoepidemiol, Solna, Sweden; [Alfredsson, Lars] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Alfredsson, Lars] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden; [Olsson, Tomas] Karolinska Inst, Dept Clin Neurosci, Ctr Mol Med, Stockholm, Sweden	Montgomery, S (corresponding author), Orebro Univ, Sch Med Sci, Clin Epidemiol & Biostat, Campus USO, Orebro, Sweden.	scott.montgomery@oru.se	Alfredsson, Lars/AAC-9007-2019; Montgomery, Scott/AAN-2546-2020	Alfredsson, Lars/0000-0003-1688-6697; Montgomery, Scott/0000-0001-6328-5494; Olsson, Tomas/0000-0002-2938-1877; Hiyoshi, Ayako/0000-0002-2088-0530; Bahmanyar, Shahram/0000-0002-9205-6540	F. Hoffmann-La RocheHoffmann-La Roche; Novartis Pharma	Funding to obtain and analyze the data was provided by research grants from F. Hoffmann-La Roche and Novartis Pharma.	Ascherio A, 2010, J NEUROIMMUNE PHARM, V5, P271, DOI 10.1007/s11481-010-9201-3; Bahmanyar S, 2009, NEUROLOGY, V72, P1170, DOI 10.1212/01.wnl.0000345366.10455.62; Bjornevik K, 2016, MULT SCLER J, V22, P104, DOI 10.1177/1352458515579444; BOBOWICK AR, 1978, NEUROLOGY, V28, P978, DOI 10.1212/WNL.28.10.978; DisBattista AP, 2016, PLOS ONE, V11; Dokuchaeva NN, 2006, ZH NEVROL PSIKHIATR, P4; Goncharova ZA, 2009, ZH NEVROL PSIKHIATR, V109, P10; Gunnarsson M, 2015, EUR J NEUROL, V22, P1131, DOI 10.1111/ene.12718; Gusev E, 1996, ACTA NEUROL SCAND, V94, P386, DOI 10.1111/j.1600-0404.1996.tb00050.x; Hedstrom AK, 2012, MULT SCLER J, V18, P1334, DOI 10.1177/1352458512436596; Hedstrom AK, 2014, NEUROLOGY, V82, P865, DOI 10.1212/WNL.0000000000000203; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Koch-Henriksen N, 1989, Acta Neurol Scand Suppl, V124, P1; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Lin CW, 2015, J NEUROTRAUM, V32, P655, DOI 10.1089/neu.2014.3723; Lin WS, 2006, BRAIN, V129, P1306, DOI 10.1093/brain/awl044; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Lunny CA, 2014, J NEUROL SCI, V336, P13, DOI 10.1016/j.jns.2013.08.011; National Board of Health and Welfare, PAT REG; Niedziela N, 2014, INT J NEUROSCI, V124, P322, DOI 10.3109/00207454.2013.840618; OLSSON T, 1993, J NEUROL SCI, V117, P130, DOI 10.1016/0022-510X(93)90165-U; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; WANG WZ, 1992, CLIN EXP IMMUNOL, V88, P157; Warren SA, 2013, CAN J NEUROL SCI, V40, P168, DOI 10.1017/S0317167100013688; Yang L, 2017, METAB BRAIN DIS, V32, P1395, DOI 10.1007/s11011-017-9991-6; Zaadstra BM, 2008, MULT SCLER J, V14, P307, DOI 10.1177/1352458507084265; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	31	21	21	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2017	82	4					554	561		10.1002/ana.25036			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FK6AB	WOS:000413584000009	28869671				2021-06-18	
J	Vergara, VM; Mayer, AR; Damaraju, E; Calhoun, VD				Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Calhoun, Vince D.			The effect of preprocessing in dynamic functional network connectivity used to classify mild traumatic brain injury	BRAIN AND BEHAVIOR			English	Article						dynamic functional network connectivity; functional MRI; independent component analysis; traumatic brain injury	STRUCTURAL CONNECTIVITY; CLASSIFICATION; CONSCIOUSNESS; DISRUPTION; DISORDER; STATES; RISK; FMRI	IntroductionDynamic functional network connectivity (dFNC), derived from magnetic resonance imaging (fMRI), is an important technique in the search for biomarkers of brain diseases such as mild traumatic brain injury (mTBI). At the individual level, mTBI can affect cognitive functions and change personality traits. Previous research aimed at detecting significant changes in the dFNC of mTBI subjects. However, one of the main concerns in dFNC analysis is the appropriateness of methods used to correct for subject movement. In this work, we focus on the effect that rearranging movement correction at different points of the processing pipeline has in dFNC analysis utilizing mTBI data. MethodsThe sample cohort consists of 50 mTBI patients and matched healthy controls. A 5-min resting-state run was completed by each participant. Data were preprocessed using different pipeline alternatives varying with the place where motion-related variance was removed. In all pipelines, group-independent component analysis (gICA) followed by dFNC analysis was performed. Additional tests were performed varying the detection of temporal spikes, the number of gICA components, and the sliding-window size. A linear support vector machine was used to test how each pipeline affects classification accuracy. ResultsResults suggest that correction for motion variance before spatial smoothing, but leaving correction for spiky time courses after gICA produced the best mean classification performance. The number of gICA components and the sliding-window size were also important in determining classification performance. Variance in spikes correction affected some pipelines more than others with fewer significant differences than the other parameters. ConclusionThe sequence of preprocessing steps motion regression, smoothing, gICA, and despiking produced data most suitable for differentiating mTBI from healthy subjects. However, the selection of optimal preprocessing parameters strongly affected the final results.	[Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM 87106 USA; [Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychiat, Albuquerque, NM USA	Vergara, VM (corresponding author), Mind Res Network, Albuquerque, NM 87106 USA.	vvergara@mrn.org		Vergara, Victor/0000-0001-9404-0924	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD050836, R21NS064464, 3R21NS064464, P20GM103472, 1R01EB006841, R01REB020407]; NSFNational Science Foundation (NSF) [1539067, 1631819]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER; Office Of The DirectorNational Science Foundation (NSF)NSF - Office of the Director (OD) [1539067] Funding Source: National Science Foundation	NIH, Grant/Award Number: R24HD050836/ R21NS064464/3R21NS064464 to A. R. Mayer, P20GM103472/1R01EB006841/ R01REB020407/P20GM103472 and NSF grants 1539067/1631819 to V. D. Calhoun	Allen EA, 2014, CEREB CORTEX, V24, P663, DOI 10.1093/cercor/bhs352; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 2012, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Cawley GC, 2010, J MACH LEARN RES, V11, P2079; Damaraju E., 2014, BRAIN CONNECTIVITY, V4, pA1; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Friston K. J, 2003, STAT PARAMETRIC MAPP; Grouiller F, 2011, BRAIN, V134, P2867, DOI 10.1093/brain/awr156; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; Lemieux L, 2007, MAGN RESON IMAGING, V25, P894, DOI 10.1016/j.mri.2007.03.009; Levine E, 2001, NEURAL COMPUT, V13, P2573, DOI 10.1162/089976601753196030; Ma S, 2011, IEEE T BIO-MED ENG, V58, P3406, DOI 10.1109/TBME.2011.2167149; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Redelmeier DA, 2003, LANCET, V361, P2177, DOI 10.1016/S0140-6736(03)13770-1; Sakoglu U, 2010, MAGN RESON MATER PHY, V23, P351, DOI 10.1007/s10334-010-0197-8; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shirer WR, 2012, CEREB CORTEX, V22, P158, DOI 10.1093/cercor/bhr099; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P550, DOI 10.1007/s11682-015-9424-2; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; TEASDALE G, 1974, LANCET, V2, P81; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vergara VM, 2017, J NEUROTRAUM, V34, P1045, DOI 10.1089/neu.2016.4526; Vergara VM, 2017, NEUROIMAGE, V145, P365, DOI 10.1016/j.neuroimage.2016.03.038; Vergara VM, 2015, IEEE ENG MED BIO, P5432, DOI 10.1109/EMBC.2015.7319620; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	41	21	21	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	OCT	2017	7	10							e00809	10.1002/brb3.809			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FK5IX	WOS:000413532400016	29075569	DOAJ Gold, Green Published			2021-06-18	
J	Asehnoune, K; Balogh, Z; Citerio, G; Cap, A; Billiar, T; Stocchetti, N; Cohen, MJ; Pelosi, P; Curry, N; Gaarder, C; Gruen, R; Holcomb, J; Hunt, BJ; Juffermans, NP; Maegele, M; Midwinter, M; Moore, FA; O'Dwyer, M; Pittet, JF; Schochl, H; Schreiber, M; Spinella, PC; Stanworth, S; Winfield, R; Brohi, K				Asehnoune, Karim; Balogh, Zsolt; Citerio, Giuseppe; Cap, Andre; Billiar, Timothy; Stocchetti, Nino; Cohen, Mitchell J.; Pelosi, Paolo; Curry, Nicola; Gaarder, Christine; Gruen, Russell; Holcomb, John; Hunt, Beverley J.; Juffermans, Nicole P.; Maegele, Mark; Midwinter, Mark; Moore, Frederick A.; O'Dwyer, Michael; Pittet, Jean-Francois; Schoechl, Herbert; Schreiber, Martin; Spinella, Philip C.; Stanworth, Simon; Winfield, Robert; Brohi, Karim			The research agenda for trauma critical care	INTENSIVE CARE MEDICINE			English	Article						Haemorrhage; Trauma; Shock; Traumatic brain injury; Coagulopathy; Intracranial hypertension	BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HEMOSTATIC RESUSCITATION; MAJOR HEMORRHAGE; TRANEXAMIC ACID; CLINICAL-TRIAL; COAGULOPATHY; TRANSFUSION; THERAPY; IMPROVEMENT	In this research agenda on the acute and critical care management of trauma patients, we concentrate on the major factors leading to death, namely haemorrhage and traumatic brain injury (TBI). In haemostasis biology, the results of randomised controlled trials have led to the therapeutic focus moving away from the augmentation of coagulation factors (such as recombinant factor VIIa) and towards fibrinogen supplementation and administration of antifibrinolytics such as tranexamic acid. Novel diagnostic techniques need to be evaluated to determine whether an individualised precision approach is superior to current empirical practice. The timing and efficacy of platelet transfusions remain in question, while new blood products need to be developed and evaluated, including whole blood variants, lyophilised products and novel red cell storage modalities. The current cornerstones of TBI management are intracranial pressure control, maintenance of cerebral perfusion pressure and avoidance of secondary insults (such as hypotension, hypoxaemia, hyperglycaemia and pyrexia). Therapeutic hypothermia and decompressive craniectomy are controversial therapies. Further research into these strategies should focus on identifying which subgroups of patients may benefit from these interventions. Prediction of the long-term outcome early after TBI remains challenging. Early magnetic resonance imaging has recently been evaluated for predicting the long-term outcome in mild and severe TBI. Novel biomarkers may also help in outcome prediction and may predict chronic neurological symptoms. For trauma in general, rehabilitation is complex and multidimensional, and the optimal timing for commencement of rehabilitation needs investigation. We propose priority areas for clinical trials in the next 10 years.	[Asehnoune, Karim] CHU Nantes, Hotel Dieu, Dept Anesthesiol & Crit Care Med, F-44000 Nantes, France; [Asehnoune, Karim] Univ Nantes, Lab EA 3826, Nantes, France; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy; [Citerio, Giuseppe] ASST Monza, San Gerardo Hosp, Dept Emergency & Intens Care, Neurointens Care Unit, Monza, Italy; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplant, Milan, Italy; [Stocchetti, Nino] Neuro ICU Fdn IRCCS Ca Granda Osped Maggiore Poli, Milan, Italy; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, IRCCS AOU San Martino IST, Genoa, Italy; [Balogh, Zsolt] John Hunter Hosp, Newcastle, NSW, Australia; [Balogh, Zsolt] Univ Newcastle, Newcastle, NSW, Australia; [Billiar, Timothy] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Cap, Andre] US Army Inst Surg Res, San Antonio, TX USA; [Cohen, Mitchell J.] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Aurora, CO USA; [Curry, Nicola] John Radcliffe Hosp, Oxford Univ Hosp NHS Trust, Oxford, England; [Gaarder, Christine] Oslo Univ Hosp, Dept Traumatol, Oslo, Norway; [Gruen, Russell] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Holcomb, John] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX 77030 USA; [Hunt, Beverley J.] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England; [Hunt, Beverley J.] Guys & St Thomas NHS Fdn Trust, Dept Pathol, London, England; [Juffermans, Nicole P.] Acad Med Ctr, Dept Intens Care, Amsterdam, Netherlands; [Maegele, Mark] Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, Cologne, Germany; [Midwinter, Mark] Univ Queensland, Rural Clin Sch Bundaberg, Bundaberg, Qld, Australia; [Moore, Frederick A.] Univ Florida, Dept Surg, Gainesville, FL USA; [O'Dwyer, Michael; Brohi, Karim] Queen Mary Univ London, Ctr Trauma Sci, London, England; [Pittet, Jean-Francois] Univ Alabama Birmingham, Dept Anesthesiol, Crit Care Div, Birmingham, AL USA; [Schoechl, Herbert] Paracelsus Med Univ, Acad Teaching Hosp, AUVA Trauma Ctr Salzburg, Dept Anesthesiol & Intens Care Med, Salzburg, Austria; [Schreiber, Martin] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Spinella, Philip C.] Washington Univ St Louis, Sch Med, Dept Pediat, Washington, DC USA; [Stanworth, Simon] John Radcliffe Hosp, NHS Blood & Transplant, Oxford, England; [Winfield, Robert] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA	Asehnoune, K (corresponding author), CHU Nantes, Hotel Dieu, Dept Anesthesiol & Crit Care Med, F-44000 Nantes, France.; Asehnoune, K (corresponding author), Univ Nantes, Lab EA 3826, Nantes, France.	Karim.Asehnoune@chu-nantes.fr	Stocchetti, Nino/O-7444-2017; Citerio, Giuseppe/B-1839-2015; Balogh, Zsolt J/A-2002-2010	Stocchetti, Nino/0000-0003-3250-6834; Citerio, Giuseppe/0000-0002-5374-3161; Balogh, Zsolt J/0000-0002-0277-4822; O'Dwyer, Michael J/0000-0003-4038-5745; holcomb, john/0000-0001-8312-9157; Pelosi, Paolo/0000-0001-5055-3023			Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Asehnoune K, 2017, ANESTHESIOLOGY, V127, P338, DOI 10.1097/ALN.0000000000001725; Asehnoune K, 2017, INTENS CARE MED, V43, P957, DOI 10.1007/s00134-017-4764-6; Asehnoune K, 2014, LANCET RESP MED, V2, P706, DOI 10.1016/S2213-2600(14)70144-4; Balvers Kirsten, 2015, J Emerg Trauma Shock, V8, P199, DOI 10.4103/0974-2700.166597; Brinck T, 2016, SCAND J SURG, V105, P109, DOI 10.1177/1457496915586650; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cnossen MC, 2021, J NEUROTRAUM, V38, P1072, DOI 10.1089/neu.2015.4121; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Curry N, 2015, BRIT J ANAESTH, V115, P76, DOI 10.1093/bja/aev134; Dewar DC, 2013, J TRAUMA ACUTE CARE, V74, P774, DOI 10.1097/TA.0b013e31827a6e69; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Giancarelli A, 2016, J SURG RES, V202, P182, DOI 10.1016/j.jss.2015.12.036; Gonzalez E, 2016, ANN SURG, V263, P1051, DOI 10.1097/SLA.0000000000001608; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Haghbayan H, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0184-x; Harmsen AMK, 2015, INJURY, V46, P602, DOI 10.1016/j.injury.2015.01.008; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Hughes NT, 2014, PEDIATR EMERG CARE, V30, P651, DOI 10.1097/PEC.0000000000000217; Hunt BJ, 2015, BRIT J HAEMATOL, V170, P788, DOI 10.1111/bjh.13580; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Innerhofer P, 2017, LANCET HAEMATOL, V4, pE258, DOI 10.1016/S2352-3026(17)30077-7; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Khan S, 2014, J TRAUMA ACUTE CARE, V76, P561, DOI 10.1097/TA.0000000000000146; Khan S, 2013, INJURY, V44, P587, DOI 10.1016/j.injury.2012.09.029; Kroes MCW, 2010, J NEUROSCI, V30, P3959, DOI 10.1523/JNEUROSCI.5469-09.2010; Lamb CM, 2014, BRIT J ANAESTH, V113, P242, DOI 10.1093/bja/aeu233; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Makarenko S, 2016, J CLIN NEUROSCI, V26, P8, DOI 10.1016/j.jocn.2015.05.065; Matsumoto J, 2015, DIAGN INTERV IMAG, V96, P687, DOI 10.1016/j.diii.2015.06.001; Moore EE, 2016, TRANSFUSION, V56, pS110, DOI 10.1111/trf.13486; Moore L, 2015, WORLD J SURG, V39, P1397, DOI 10.1007/s00268-015-2977-9; Moreno-Lopez L, 2016, BRAIN INJURY, V30, P1319, DOI 10.1080/02699052.2016.1186839; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NICE, 2016, MAJ TRAUM ASS IN MAN; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Oyeniyi BT, 2017, INJURY, V48, P5, DOI 10.1016/j.injury.2016.10.037; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Roquilly A, 2016, EUR RESPIR J, V47, P1219, DOI 10.1183/13993003.01314-2015; Roquilly A, 2013, AM J RESP CRIT CARE, V188, P958, DOI 10.1164/rccm.201301-0116OC; Roquilly A, 2011, JAMA-J AM MED ASSOC, V305, P1201, DOI 10.1001/jama.2011.360; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Rourke C, 2012, J THROMB HAEMOST, V10, P1342, DOI 10.1111/j.1538-7836.2012.04752.x; Sauaia A, 2017, CRIT CARE CLIN, V33, P167, DOI 10.1016/j.ccc.2016.08.006; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Simmons JW, 2016, BRIT J ANAESTH, V117, P31, DOI 10.1093/bja/aew328; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stanworth SJ, 2016, BRIT J SURG, V103, P357, DOI 10.1002/bjs.10052; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; van Oostendorp SE, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0301-9; Winearls J, 2016, ANESTH ANALG, V123, P910, DOI 10.1213/ANE.0000000000001516	60	21	22	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2017	43	9					1340	1351		10.1007/s00134-017-4895-9			12	Critical Care Medicine	General & Internal Medicine	FE3LF	WOS:000408116700014	28756471				2021-06-18	
J	Bosco, FM; Parola, A; Valentini, MC; Morese, R				Bosco, Francesca M.; Parola, Alberto; Valentini, Maria C.; Morese, Rosalba			Neural correlates underlying the comprehension of deceitful and ironic communicative intentions	CORTEX			English	Article						Communicative intention; Pragmatics; Deceit; Irony; fMRI; Speech act; Comprehension	TRAUMATIC BRAIN-INJURY; MIDDLE TEMPORAL GYRUS; EXECUTIVE FUNCTION; SOCIAL COGNITION; LANGUAGE NETWORK; FRONTAL-LOBE; SPEECH ACTS; MIND; METAANALYSIS; METAPHOR	Neuroimaging studies have shown that a left fronto-temporo-parietal cerebral network is recruited in the comprehension of both deceitful and ironic speech acts. However, no studies to date have directly compared neural activation during the comprehension of these pragmatic phenomena. We used fMRI to investigate the existence of common and specific neural circuits underlying the comprehension of the same speech act, uttered with different communicative intentions, i.e., of being sincere, deceitful or ironic. In particular, the novelty of the present study is that it explores the existence of a specific cerebral area involved in the recognition of irony versus deceit. We presented 23 healthy participants with 48 context stories each followed by a target sentence. For each story we designed different versions eliciting, respectively, different pragmatic interpretations of the same target sentence literal, deceitful or ironic. We kept the semantic and syntactic complexity of the target sentence constant across the conditions. Our results showed that the recognition of ironic communicative intention activated the left temporo-parietal junction (ITPJ), the left inferior frontal gyrus (IIFG), the left middle frontal gyms (IMFG), the left middle temporal gyms (IMTG), and the left dorsolateral prefrontal cortex (IDLPFC). Comprehension of deceitful communicative intention activated the IIFG, the IMFG, and the IDLPFC. fMRI analysis revealed that a left fronto-temporal network including the inferior frontal gyms (IFG), the dorsolateral prefrontal cortex (DLPFC) and the middle frontal gyms (MFG) is activated in both irony and deceit recognition. The original result of the present investigation is that the IMTG was found to be more active in the comprehension of ironic versus deceitful communicative intention, thus suggesting its specific role in irony recognition. To conclude, our results showed that common cerebral areas are recruited in the comprehension of both pragmatic phenomena, while the IMTG has a key role in the recognition of ironic versus deceitful communicative intention. (C) 2017 Elsevier Ltd. All rights reserved.	[Bosco, Francesca M.; Parola, Alberto; Morese, Rosalba] Univ Turin, Dept Psychol, Ctr Cognit Sci, Turin, Italy; [Bosco, Francesca M.; Valentini, Maria C.] Neurosci Inst Turin, Turin, Italy; [Valentini, Maria C.] Hosp Citta Salute & Sci, Dept Neuroradiol, Turin, Italy; [Morese, Rosalba] Univ Svizzera Italiana, Fac Commun Sci, Lugano, Switzerland	Parola, A (corresponding author), Univ Turin, Dept Psychol, Via Po 14, I-10123 Turin, Italy.	alparola@unito.it	Morese, Rosalba/B-5444-2014; bosco, francesca marina/B-6746-2013; Parola, alberto/AAK-3748-2020; Morese, Rosalba/AAI-1008-2019	bosco, francesca marina/0000-0001-6101-8587; Morese, Rosalba/0000-0003-4939-6539; PAROLA, ALBERTO/0000-0002-6039-0907	MIUR PRIN-Progetti di Ricerca di Rilevante Interesse NazionaleMinistry of Education, Universities and Research (MIUR);  [201577HA9M]	The research was funded by MIUR PRIN-Progetti di Ricerca di Rilevante Interesse Nazionale_2017. Project 'The interpretative brain: Understanding and promoting pragmatic abilities across lifespan and in mental illness' project code 201577HA9M. We wish to thank to Luana De Faveri and Giulia Iunco for their precious technical support during fMRI acquisition sessions.	Acheson DJ, 2013, J COGNITIVE NEUROSCI, V25, P1664, DOI 10.1162/jocn_a_00430; Akimoto Y, 2014, HUM BRAIN MAPP, V35, P1167, DOI 10.1002/hbm.22242; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Azim E, 2005, P NATL ACAD SCI USA, V102, P16496, DOI 10.1073/pnas.0408456102; Badre D, 2007, NEUROPSYCHOLOGIA, V45, P2883, DOI 10.1016/j.neuropsychologia.2007.06.015; Bambini V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105634; Bambini V, 2011, BRAIN RES BULL, V86, P203, DOI 10.1016/j.brainresbull.2011.07.015; Bara BG, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00007; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bohrn IC, 2012, NEUROPSYCHOLOGIA, V50, P2669, DOI 10.1016/j.neuropsychologia.2012.07.021; Bosco F. M., 2017, J COMMUN DISORD, V145, P181; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00021; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2014, CONSCIOUS COGN, V24, P84, DOI 10.1016/j.concog.2014.01.003; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Chan YC, 2015, FRONT PSYCHOL, V6, DOI [10.3389/fpgyg.2015.01235, 10.3389/fpsyg.2015.01285]; Ciaramidaro A, 2007, NEUROPSYCHOLOGIA, V45, P3105, DOI 10.1016/j.neuropsychologia.2007.05.011; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Dapretto M, 1999, NEURON, V24, P427, DOI 10.1016/S0896-6273(00)80855-7; Davey J, 2016, NEUROIMAGE, V137, P165, DOI 10.1016/j.neuroimage.2016.05.051; De Smet HJ, 2013, BRAIN LANG, V127, P334, DOI 10.1016/j.bandl.2012.11.001; De Smet HJ, 2011, BRAIN COGNITION, V76, P424, DOI 10.1016/j.bandc.2010.12.006; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Eviatar Z, 2006, NEUROPSYCHOLOGIA, V44, P2348, DOI 10.1016/j.neuropsychologia.2006.05.007; Ferstl EC, 2008, HUM BRAIN MAPP, V29, P581, DOI 10.1002/hbm.20422; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Gabbatore L, 2014, MINERVA PSICHIATR, V55, P45; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; Gobbini MI, 2007, J COGNITIVE NEUROSCI, V19, P1803, DOI 10.1162/jocn.2007.19.11.1803; Grice H., 1975, SYNTAX SEMANTICS; Grice HP., 1991, STUDIES WAY WORDS; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Harada T, 2009, NEUROSCI RES, V63, P24, DOI 10.1016/j.neures.2008.09.010; Hayashi A, 2014, BRAIN RES, V1556, P46, DOI 10.1016/j.brainres.2014.02.011; Honan CA, 2015, BRAIN LANG, V150, P69, DOI 10.1016/j.bandl.2015.08.007; Huber W, 1984, Adv Neurol, V42, P291; Jang G, 2013, NEUROIMAGE, V81, P61, DOI 10.1016/j.neuroimage.2013.05.027; Jung-Beeman M, 2005, TRENDS COGN SCI, V9, P512, DOI 10.1016/j.tics.2005.09.009; Leh SE, 2010, NEUROPSYCHOPHARMACOL, V35, P70, DOI 10.1038/npp.2009.88; Levinson S.C., 1983, PRAGMATICS; Mar RA, 2011, ANNU REV PSYCHOL, V62, P103, DOI 10.1146/annurev-psych-120709-145406; Marien P, 2001, BRAIN LANG, V79, P580, DOI 10.1006/brln.2001.2569; Marien P, 2014, CEREBELLUM, V13, P386, DOI 10.1007/s12311-013-0540-5; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; Masia V, 2017, J NEUROLINGUIST, V42, P31, DOI 10.1016/j.jneuroling.2016.11.005; Mason R.A., 2006, HDB PSYCHOLINGUISTIC, P765, DOI [10.1016/B978-012369374-7/50020-1, DOI 10.1016/B978-012369374-7/50020-1]; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; Menenti L, 2009, J COGNITIVE NEUROSCI, V21, P2358, DOI 10.1162/jocn.2008.21163; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Minzenberg MJ, 2009, ARCH GEN PSYCHIAT, V66, P811, DOI 10.1001/archgenpsychiatry.2009.91; Mo SL, 2008, PSYCHIAT RES, V157, P21, DOI 10.1016/j.psychres.2006.04.002; Murdoch BE, 2010, CORTEX, V46, P858, DOI 10.1016/j.cortex.2009.07.018; Noppeney U, 2004, J COGNITIVE NEUROSCI, V16, P702, DOI 10.1162/089892904323057399; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parola A, 2016, J NEUROLINGUIST, V39, P10, DOI 10.1016/j.jneuroling.2015.12.003; Perner J, 1991, UNDERSTANDING REPRES; Peskin J, 1996, CHILD DEV, V67, P1735, DOI 10.1111/j.1467-8624.1996.tb01824.x; Piemontese M. E., 1996, CAPIRE FARSI CAPIRE; Poldrack RA, 2008, NEUROIMAGE, V40, P409, DOI 10.1016/j.neuroimage.2007.11.048; Premack David, 1978, BEHAV BRAIN SCI, V34, P1401; Rapp AM, 2012, NEUROIMAGE, V63, P600, DOI 10.1016/j.neuroimage.2012.06.022; Rapp AM, 2004, COGNITIVE BRAIN RES, V20, P395, DOI 10.1016/j.cogbrainres.2004.03.017; RUSSELL J, 1994, BRIT J DEV PSYCHOL, V12, P301, DOI 10.1111/j.2044-835X.1994.tb00636.x; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Schnell Z, 2016, J PRAGMATICS, V92, P74, DOI 10.1016/j.pragma.2015.11.004; Schurz M, 2014, NEUROSCI BIOBEHAV R, V42, P9, DOI 10.1016/j.neubiorev.2014.01.009; Searle J., 1979, EXPRESSION MEANING; Shammi P, 1999, BRAIN, V122, P657, DOI 10.1093/brain/122.4.657; Shany-Ur T, 2012, CORTEX, V48, P1329, DOI 10.1016/j.cortex.2011.08.003; Shibata M, 2010, BRAIN RES, V1308, P114, DOI 10.1016/j.brainres.2009.10.030; Spence SA, 2004, PHILOS T R SOC B, V359, P1755, DOI 10.1098/rstb.2004.1555; Sperber D, 2002, MIND LANG, V17, P3, DOI 10.1111/1468-0017.00186; Spotorno N, 2012, NEUROIMAGE, V63, P25, DOI 10.1016/j.neuroimage.2012.06.046; Stoodley CJ, 2009, BRAIN LANG, V110, P149, DOI 10.1016/j.bandl.2009.07.006; Strick M, 2009, EMOTION, V9, P574, DOI 10.1037/a0015951; Strick PL, 2009, ANNU REV NEUROSCI, V32, P413, DOI 10.1146/annurev.neuro.31.060407.125606; SULLIVAN K, 1994, DEV PSYCHOL, V30, P395, DOI 10.1037/0012-1649.30.3.395; Turken AU, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00001; Uchiyama H, 2006, BRAIN RES, V1124, P100, DOI 10.1016/j.brainres.2006.09.088; Uchiyama HT, 2012, CORTEX, V48, P563, DOI 10.1016/j.cortex.2011.01.004; Van Overwalle F, 2009, NEUROIMAGE, V48, P564, DOI 10.1016/j.neuroimage.2009.06.009; Van Overwalle F, 2009, HUM BRAIN MAPP, V30, P829, DOI 10.1002/hbm.20547; Vandenberghe R, 2002, J COGNITIVE NEUROSCI, V14, P550, DOI 10.1162/08989290260045800; Wakusawa K, 2007, NEUROIMAGE, V37, P1417, DOI 10.1016/j.neuroimage.2007.06.013; Walter H, 2004, J COGNITIVE NEUROSCI, V16, P1854, DOI 10.1162/0898929042947838; Walter H, 2009, SOC COGN AFFECT NEUR, V4, P166, DOI 10.1093/scan/nsn047; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Wu DC, 2011, BRAIN RES, V1389, P115, DOI 10.1016/j.brainres.2011.02.084	95	21	22	1	29	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452	1973-8102		CORTEX	Cortex	SEP	2017	94						73	86		10.1016/j.cortex.2017.06.010			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	FH9RB	WOS:000411548300007	28728080				2021-06-18	
J	Neumann, D; Malec, JF; Hammond, FM				Neumann, Dawn; Malec, James F.; Hammond, Flora M.			Reductions in Alexithymia and Emotion Dysregulation After Training Emotional Self-Awareness Following Traumatic Brain Injury: A Phase I Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						affect; aggression; alexithymia; anxiety; brain injury; emotion; emotion regulation	SCALE; VALIDATION; VALIDITY; PREVALENCE; SEVERITY; PROGRAM; SYSTEM; SAMPLE; ADULTS	Objectives: To examine the acceptability and initial efficacy of an emotional self-awareness treatment at reducing alexithymia and emotion dysregulation in participants with traumatic brain injury (TBI). Setting: An outpatient rehabilitation hospital. Participants: Seventeen adults with moderate to severe TBI and alexithymia. Time postinjury ranged 1 to 33 years. Design: Within subject design, with 3 assessment times: baseline, posttest, and 2-month follow-up. Intervention: Eight lessons incorporated psychoeducational information and skill-building exercises teaching emotional vocabulary, labeling, and differentiating self-emotions; interoceptive awareness; and distinguishing emotions from thoughts, actions, and sensations. Measures: Toronto Alexithymia Scale-20 (TAS-20); Levels of Emotional Awareness Scale (LEAS); Trait Anxiety Inventory (TAI); Patient Health Questionnaire-9 (PHQ-9); State-Trait Anger Expression Inventory (STAXI); Difficulty With Emotion Regulation Scale (DERS); and Positive and Negative Affect Scale (PANAS). Results: Thirteen participants completed the treatment. Repeated-measures analysis of variance revealed changes on the TAS-20 (P = .003), LEAS (P < .001), TAI (P = .014), STAXI (P = .015), DERS (P = .020), and positive affect (P < .005). Paired t tests indicated significant baseline to posttest improvements on these measures. Gains were maintained at follow-up for the TAS, LEAS, and positive affect. Treatment satisfaction was high. Conclusion: This is the first study published on treating alexithymia post-TBI. Positive changes were identified for emotional self-awareness and emotion regulation; some changes were maintained several months posttreatment. Findings justify advancing to the next investigational phase for this novel intervention.	[Neumann, Dawn; Malec, James F.; Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA	Neumann, D (corresponding author), Indiana Univ Sch Med, Dept Phys Med & Rehabil, Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA.	dmneuman@iupui.edu			NIH NICHD/NCMRR STTR Phase I grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R41HD077967-01A1]; Indiana University; NIH STTR Phase I grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R41HD077967] Funding Source: NIH RePORTER	This work is supported by NIH NICHD/NCMRR STTR Phase I grant 1R41HD077967-01A1 and the Indiana University Funding Opportunities for Research Commercialization and Economic Success.; Dr Neumann is the owner of a small business funded by an NIH STTR Phase I grant. She was financially compensated for efforts pertaining to this research and has a commercial interest in the training program described in the article. Drs Malec and Hammond, and Mr Langston received funds through Indiana University's subcontract with the business for their work on this project.	Ashman TA, 2006, MT SINAI J MED, V73, P999; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Barchard KA, 2010, BEHAV RES METHODS, V42, P586, DOI 10.3758/BRM.42.2.586; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Cantor J, 2014, ARCH PHYS MED REHAB, V95, P1, DOI 10.1016/j.apmr.2013.08.005; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Etzler SL, 2014, PSYCHOL REST ASSESSM, V56, P178; Fakra E, 2008, SCHIZOPHR RES, V100, P191, DOI 10.1016/j.schres.2007.11.040; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Foland-Ross LC, 2010, J NEUROSCI, V30, P16673, DOI 10.1523/JNEUROSCI.4578-09.2010; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Hammond FM, 2011, J HEAD TRAUMA REHAB, V26, P69, DOI 10.1097/HTR.0b013e318205174d; Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179; Hariri AR, 2000, NEUROREPORT, V11, P43, DOI 10.1097/00001756-200001170-00009; Hart T, 2012, J HEAD TRAUMA REHAB, V27, P113, DOI 10.1097/HTR.0b013e31820e686c; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kokkonen P, 2001, COMPR PSYCHIAT, V42, P471, DOI 10.1053/comp.2001.27892; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LANE RD, 1990, J PERS ASSESS, V55, P124, DOI 10.1207/s15327752jpa5501&2_12; Levant R.F., 2009, J MENS STUDIES, V17, P75, DOI DOI 10.3149/JMS.1701.75; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Neumann D, J HEAD TRAU IN PRESS; Neumann D, 2014, J HEAD TRAUMA REHAB, V29, pE18, DOI 10.1097/HTR.0b013e31827fb0b5; Prince L, 2012, 9 C NEUR REH SPEC IN; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Spielberger C. D, 1999, MANUAL STATE TRAIT A; Spielberger C.D., 1970, STATE TRAIT ANXIETY; SPIELBERGER CD, 1995, ASSESSMENT EMOTIONAL; Torrado M, 2013, ACTA MEDICA PORT, V26, P145; Tsaousides T, 2014, NEUROPSYCHOL REHABIL, V24, P784, DOI 10.1080/09602011.2014.907186; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Wedcliffe T, 2001, S Afr J Commun Disord, V48, P77; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Whyte J, 2009, ARCH PHYS MED REHAB, V90, pS3, DOI 10.1016/j.apmr.2009.07.008; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2013, J HEAD TRAUMA REHAB, V28, P98, DOI 10.1097/HTR.0b013e3182426029	47	21	21	4	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2017	32	5					286	295		10.1097/HTR.0000000000000277			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FG2DW	WOS:000409893800009	28060205	Green Accepted			2021-06-18	
J	Dou, Y; Shen, HT; Feng, DX; Li, HY; Tian, XD; Zhang, J; Wang, Z; Chen, G				Dou, Yang; Shen, Haitao; Feng, Dongxia; Li, Haiying; Tian, Xiaodi; Zhang, Jian; Wang, Zhong; Chen, Gang			Tumor necrosis factor receptor-associated factor 6 participates in early brain injury after subarachnoid hemorrhage in rats through inhibiting autophagy and promoting oxidative stress	JOURNAL OF NEUROCHEMISTRY			English	Article						autophagy; E3 ubiquitin ligase activity; early brain injury; oxidative stress; subarachnoid hemorrhage; TRAF6	DELAYED CEREBRAL-ISCHEMIA; NF-KAPPA-B; ATYPICAL UBIQUITINATION; SIGNAL-TRANSDUCTION; PARKINSONS-DISEASE; ENDOTHELIAL-CELLS; TRAF6; ACTIVATION; MODEL; MECHANISMS	Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a member of the TRAF family and an important multifunctional intracellular adaptin of the tumor necrosis factor superfamily and toll/IL-1 receptor (TIR) superfamily. TRAF6 has been studied in several central nervous system diseases, including ischemic stroke, traumatic brain injury, and neurodegenerative diseases, but its role in subarachnoid hemorrhage (SAH) has not been fully illustrated. This study was designed to explore changes of expression level and potential roles and mechanisms of TRAF6 in early brain injury (EBI) after SAH using a Sprague-Dawley rat model of SAH induced in 0.3 mL nonheparinized autologous arterial blood injected into the prechiasmatic cistern. First, compared with the sham group, we found that the expression levels of TRAF6 increased gradually and peaked at 24 h after SAH. Second, the results showed that application of TRAF6 over-expression plasmid and genetic silencing siRNA could increase or decrease expression of TRAF6, respectively, and severely exacerbate or relieve EBI after SAH, including neuronal death, brain edema, and blood-brain barrier injury. Meanwhile, the levels of autophagy and oxidative stress were reduced and increased separately. Finally, GFP-TRAF6-C70A, which is a TRAF6 mutant that lacks E3 ubiquitin ligase activity, was used to explore the mechanism of TRAF6 in SAH, and the results showed that EBI and oxidative stress were reduced, but the levels of autophagy were increased under this condition. Collectively, these results indicated that TRAF6 affected the degree of EBI after SAH by inhibiting autophagy and promoting oxidative stress.	[Dou, Yang; Shen, Haitao; Li, Haiying; Tian, Xiaodi; Zhang, Jian; Wang, Zhong; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China; [Dou, Yang; Shen, Haitao; Li, Haiying; Tian, Xiaodi; Zhang, Jian; Wang, Zhong; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Brain & Nerve Res Lab, Suzhou, Jiangsu, Peoples R China; [Feng, Dongxia] Scott & White Clin Temple, Temple, TX 76508 USA	Zhang, J (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.	nju_neurosurgery@163.com			Suzhou Key Medical Center [Szzx201501]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571121]; Scientific Department of Jiangsu Province [BL2014045]; Education department of Jiangsu Province [16KJB320008]; Suzhou Government [SZS201413, SYS201608]; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by Suzhou Key Medical Center (Szzx201501), grants from the National Natural Science Foundation of China (No. 81571121), Scientific Department of Jiangsu Province (No. BL2014045), Education department of Jiangsu Province (No. 16KJB320008), Suzhou Government (No. SZS201413 and SYS201608), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions. The authors declare that they have no competing interest.	Ayer RE, 2008, J PINEAL RES, V44, P197, DOI 10.1111/j.1600-079X.2007.00508.x; Brathwaite S, 2014, TRANSL STROKE RES, V5, P207, DOI 10.1007/s12975-013-0316-8; Bruneau S, 2012, BIOCHEM BIOPH RES CO, V419, P66, DOI 10.1016/j.bbrc.2012.01.128; Cabal-Hierro L, 2012, CELL SIGNAL, V24, P1297, DOI 10.1016/j.cellsig.2012.02.006; Cahill J, 2009, STROKE, V40, pS86, DOI 10.1161/STROKEAHA.108.533315; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chen CH, 2013, CNS NEUROSCI THER, V19, P566, DOI 10.1111/cns.12114; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Chen JA, 2011, CELL MOL NEUROBIOL, V31, P269, DOI 10.1007/s10571-010-9617-6; Chen Sheng, 2015, Acta Neurochir Suppl, V120, P39, DOI 10.1007/978-3-319-04981-6_7; Chen S, 2014, PROG NEUROBIOL, V115, P64, DOI 10.1016/j.pneurobio.2013.09.002; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Chong ZZ, 2016, REV NEUROSCIENCE, V27, P745, DOI 10.1515/revneuro-2016-0021; Dang BQ, 2015, CRIT CARE MED, V43, pE369, DOI 10.1097/CCM.0000000000001146; Dawson TM, 2006, J NEURAL TRANSM-SUPP, P209; Driessen S, 2015, AUTOPHAGY, V11, P1458, DOI 10.1080/15548627.2015.1067359; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Etminan N, 2015, TRANSL STROKE RES, V6, P167, DOI 10.1007/s12975-015-0398-6; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Ha H., 2009, CURR PROTOC IMMUNOL; Hansen-Schwartz J, 2007, TRENDS PHARMACOL SCI, V28, P252, DOI 10.1016/j.tips.2007.04.002; He AQ, 2016, INFLAMMATION, V39, P172, DOI 10.1007/s10753-015-0236-8; He SY, 2012, AUTOPHAGY, V8, P1621, DOI 10.4161/auto.21561; He ZH, 2012, STROKE, V43, P484, DOI 10.1161/STROKEAHA.111.626432; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Kang CH, 2008, AUTOPHAGY, V4, P82, DOI 10.4161/auto.5154; Kinsella S, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0099-15.2016; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kooijman E, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-2; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Lee NK, 2002, J BIOCHEM MOL BIOL, V35, P61; Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020; Liu ZJ, 2012, BRAIN RES BULL, V88, P379, DOI 10.1016/j.brainresbull.2012.04.003; Lomaga MA, 2000, J NEUROSCI, V20, P7384; Lu Y, 2014, PAIN, V155, P2618, DOI 10.1016/j.pain.2014.09.027; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Meng ZY, 2017, J IMMUNOL, V198, P820, DOI 10.4049/jimmunol.1600334; Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9; Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708; Puyal J, 2009, AUTOPHAGY, V5, P1060, DOI 10.4161/auto.5.7.9728; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Rahib L, 2009, MOL GENET METAB, V96, P106, DOI 10.1016/j.ymgme.2008.11.163; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rouse Richard J D, 2008, BMC Res Notes, V1, P45, DOI 10.1186/1756-0500-1-45; Rowland MJ, 2012, BRIT J ANAESTH, V109, P315, DOI 10.1093/bja/aes264; Sehba FA, 2011, MOL NEUROBIOL, V43, P27, DOI 10.1007/s12035-010-8155-z; Shen HT, 2015, STROKE, V46, P2607, DOI 10.1161/STROKEAHA.115.009729; Song ZF, 2012, ARTERIOSCL THROM VAS, V32, P50, DOI 10.1161/ATVBAHA.111.238329; Sun SY, 2012, BRAIN RES BULL, V88, P609, DOI 10.1016/j.brainresbull.2012.05.013; Suzuki H, 2015, TRANSL STROKE RES, V6, P1, DOI 10.1007/s12975-014-0380-8; Suzuki H, 2010, STROKE, V41, P1783, DOI 10.1161/STROKEAHA.110.586537; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wang L, 2013, J PHYSIOL-LONDON, V591, P5005, DOI 10.1113/jphysiol.2013.262667; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Wang Z, 2012, J MOL NEUROSCI, V46, P192, DOI 10.1007/s12031-011-9575-6; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Wu HJ, 2016, J CELL MOL MED, V20, P1770, DOI 10.1111/jcmm.12855; Wu J, 2016, STROKE, V47, P1319, DOI 10.1161/STROKEAHA.115.011552; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yao LL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-23; Zapata JM, 2007, ADV EXP MED BIOL, V597, P1; Zhang J, 2013, BRAIN RES, V1528, P80, DOI 10.1016/j.brainres.2013.06.032; Zheng ZL, 2012, CURR NEUROVASC RES, V9, P310, DOI 10.2174/156720212803530663; Zucchelli S, 2011, J BIOL CHEM, V286, P25108, DOI 10.1074/jbc.M110.187591; Zucchelli S, 2010, HUM MOL GENET, V19, P3759, DOI 10.1093/hmg/ddq290	67	21	22	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2017	142	3					478	492		10.1111/jnc.14075			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FA9LZ	WOS:000405768400012	28543180	Bronze			2021-06-18	
J	DuPrey, KM; Webner, DD; Lyons, A; Kucuk, CH; Ellis, JT; Cronholm, PF				DuPrey, Kevin M.; Webner, David; Lyons, Adam; Kucuk, Crystal H.; Ellis, Jeffrey T.; Cronholm, Peter F.			Convergence Insufficiency Identifies Athletes at Risk of Prolonged Recovery From Sport-Related Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries/concussion; eye injuries; clinical assessment/grading scales; pediatric sports medicine	TRAUMATIC BRAIN-INJURY; EMERGENCY-DEPARTMENT; HIGH-SCHOOL; PREDICTORS; NEARPOINT; ADOLESCENTS; RELIABILITY; POPULATION; STATEMENT; SYMPTOMS	Background: Sensitive and specific screening methods are needed to identify athletes at risk of prolonged recovery after sport-related concussion (SRC). Convergence insufficiency (CI) is a common finding in concussed athletes. Purpose: To assess the relationship between CI and recovery after SRC at the initial office visit. Study Design: Case-control study; Level of evidence, 3. Methods: In this retrospective cohort study, 270 athletes (147 male, 123 female), mean +/- SD age 14.7 +/- 2.0 years (range, 10-21 years), with the diagnosis of SRC who presented for initial office visit between January 2014 and January 2016 were evaluated for near point of convergence (NPC). The athletes were categorized into 2 groups: normal near point of convergence (NPC <= 6 cm), and convergence insufficiency (NPC > 6 cm). These athletes were then followed to determine recovery time. Results: Athletes presented for initial office visit at a mean of 5.2 +/- 4.2 days (range, 1-21 days) after SRC. Half of the athletes had CI after SRC (50.4%; n = 136). Athletes with CI (NPC 12.3 +/- 4.7 cm) took significantly longer to recover after SRC, requiring 51.6 +/- 53.9 days, compared with athletes with normal NPC (4.1 +/- 1.3 cm), who required 19.2 +/- 14.7 days (P < .001). After controlling for potential confounding variables, CI significantly increased the odds of prolonged recovery (>= 28 days from injury) by 12.3-fold (P < .001; 95% confidence interval, 6.6-23.0). CI screening correctly classified 75.2% of our sample with 84.2% sensitivity and 70.0% specificity. The positive predictive value for CI and prolonged recovery was 62.5%, and the negative predictive value was 88.1%. Conclusion: CI at the initial office visit identified athletes at increased risk of prolonged recovery after SCR. Clinicians should consider measuring NPC in concussed athletes as a quick and inexpensive prognostic screening method.	[DuPrey, Kevin M.; Webner, David; Lyons, Adam; Kucuk, Crystal H.; Ellis, Jeffrey T.; Cronholm, Peter F.] Crozer Keystone Hlth Syst, Healthplex Sports Med Inst, 196 West Sproul Rd,Suite 110, Springfield, PA 19064 USA; [DuPrey, Kevin M.; Webner, David; Ellis, Jeffrey T.] Crozer Keystone Hlth Syst, Dept Sports Med, Springfield, PA USA; [Lyons, Adam; Cronholm, Peter F.] Univ Penn, Dept Family & Community Hlth, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA; [Kucuk, Crystal H.] Philadelphia Coll Osteopath Med, Philadelphia, PA USA; [Cronholm, Peter F.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	DuPrey, KM (corresponding author), Crozer Keystone Hlth Syst, Healthplex Sports Med Inst, 196 West Sproul Rd,Suite 110, Springfield, PA 19064 USA.	kevin.duprey@crozer.org					Abraham Neethu G, 2015, Oman J Ophthalmol, V8, P14, DOI 10.4103/0974-620X.149856; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Casson IR, 2015, NEUROLOGY, V85, P110, DOI 10.1212/WNL.0000000000001700; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; COOPER J, 1978, J AM OPTOM ASSOC, V49, P673; Cooper J, 2012, OPTOMETRY, V83, P20; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Duke-elder S., 1973, SYSTEM OPHTHALMOLOGY; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Hamed MM, 2013, INDIAN J OPHTHALMOL, V61, P325, DOI 10.4103/0301-4738.97553; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Root JM, 2016, J PEDIATR-US, V174, P39, DOI 10.1016/j.jpeds.2016.03.020; Rosner B., 2011, FUNDAMENTALS BIOSTAT; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Siderov J, 2001, OPHTHAL PHYSL OPT, V21, P356, DOI 10.1046/j.1475-1313.2001.00609.x; Sussman ES, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15610; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Ventura RE, 2016, J NEUROL SCI, V361, P79, DOI 10.1016/j.jns.2015.12.010; Ventura RE, 2015, J NEURO-OPHTHALMOL, V35, P73, DOI 10.1097/WNO.0000000000000223; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Viera AJ, 2005, FAM MED, V37, P360	37	21	21	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2017	45	10					2388	2393		10.1177/0363546517705640			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	FC4VS	WOS:000406839600023	28511593				2021-06-18	
J	Karibe, H; Hayashi, T; Narisawa, A; Kameyama, M; Nakagawa, A; Tominaga, T				Karibe, Hiroshi; Hayashi, Toshiaki; Narisawa, Ayumi; Kameyama, Motonobu; Nakagawa, Atsuhiro; Tominaga, Teiji			Clinical Characteristics and Outcome in Elderly Patients with Traumatic Brain Injury: For Establishment of Management Strategy	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						traumatic brain injury (TBI); elderly; delayed deterioration; antiplatelet; anticoagulant	INTERHEMISPHERIC SUBDURAL-HEMATOMA; SEVERE HEAD-INJURIES; INTRACRANIAL HEMORRHAGE; PREINJURY WARFARIN; GERIATRIC TRAUMA; ANTIPLATELET THERAPY; CEREBRAL-CIRCULATION; MORTALITY; AGE; ANTICOAGULATION	In recent years, instances of neurotrauma in the elderly have been increasing. This article addresses the clinical characteristics, management strategy, and outcome in elderly patients with traumatic brain injury (TBI). Falls to the ground either from standing or from heights are the most common causes of TBI in the elderly, since both motor and physiological functions are degraded in the elderly. Subdural, contusional and intracerebral hematomas are more common in the elderly than the young as the acute traumatic intracranial lesion. High frequency of those lesions has been proposed to be associated with increased volume of the subdural space resulting from the atrophy of the brain in the elderly. The delayed aggravation of intracranial hematomas has been also explained by such anatomical and physiological changes present in the elderly. Delayed hyperemia/hyperperfusion may also be a characteristic of the elderly TBI, although its mechanisms are not fully understood. In addition, widely used pre-injury anticoagulant and antiplatelet therapies may be associated with delayed aggravation, making the management difficult for elderly TBI. It is an urgent issue to establish preventions and treatments for elderly TBI, since its outcome has been remained poor for more than 40 years.	[Karibe, Hiroshi; Hayashi, Toshiaki; Narisawa, Ayumi; Kameyama, Motonobu] Sendai City Hosp, Dept Neurosurg, Sendai, Miyagi, Japan; [Nakagawa, Atsuhiro; Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi, Japan	Karibe, H (corresponding author), Sendai City Hosp, Dept Neurosurg, Taihaku Ku, 1-1-1 Asuto Nagamachi, Sendai, Miyagi 9828502, Japan.	karibe@nsg.med.tohoku.ac.jp					Airoldi F, 2007, CIRCULATION, V116, P745, DOI 10.1161/CIRCULATIONAHA.106.686048; Albeck MJ, 1998, J NEUROSURG, V89, P275, DOI 10.3171/jns.1998.89.2.0275; [Anonymous], 2013, SEV TRAUM HEAD INJ E, P150; Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Biondi-Zoccai GGL, 2006, EUR HEART J, V27, P2667, DOI 10.1093/eurheartj/ehl334; Bonville DJ, 2011, SURGERY, V150, P861, DOI 10.1016/j.surg.2011.07.070; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Cabinet Office, ANN REP AG SOC 2015; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; Chen JJ, 2011, NEUROIMAGE, V55, P468, DOI 10.1016/j.neuroimage.2010.12.032; Chieregato A, 2009, NEUROSURGERY, V64, P705, DOI 10.1227/01.NEU.0000341872.17024.44; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; COHEN TI, 1996, NEUROTRAUMA, P689; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Davis DP, 2007, J TRAUMA, V62, P277, DOI 10.1097/TA.0b013e31802ef4a3; Deiner Stacie, 2004, Curr Opin Anaesthesiol, V17, P165, DOI 10.1097/00001503-200404000-00013; Demetriades D, 2002, BRIT J SURG, V89, P1319, DOI 10.1046/j.1365-2168.2002.02210.x; Di Minno MND, 2009, INTERN EMERG MED, V4, P279, DOI 10.1007/s11739-009-0265-0; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Feeney JM, 2016, J TRAUMA ACUTE CARE, V81, P843, DOI 10.1097/TA.0000000000001245; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gaetani P, 2012, J NEUROSURG SCI, V56, P231; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Hedman AM, 2012, HUM BRAIN MAPP, V33, P1987, DOI 10.1002/hbm.21334; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Inamasu J, 2010, NEUROL MED-CHIR, V50, P1051, DOI 10.2176/nmc.50.1051; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jane J, 1996, NEUROTRAUMA, P793; Kameyama M., 2008, NEUROTRAUMATOLOGY, V31, P49; Kameyama M., 2013, NEUROTRAUMATOLOGY, V36, P10; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Karibe H, 2009, PROGR COMPUTED IMAGI, V31, P255; Karni A, 2001, AM SURGEON, V67, P1098; Katayama Y, 2000, NEUROTRAUMATOLOGY, V23, P6; Kawamata T, 2002, NEUROTRAUMATOLOGY, V25, P205; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; MEYER JS, 1993, CEREBROVAS BRAIN MET, V5, P122; Milos V, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-40; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Moussa ID, 2009, CATHETER CARDIO INTE, V74, P1047, DOI 10.1002/ccd.22167; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Ono Junichi, 1993, Neurological Surgery, V21, P717; Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057; Peisker T, 2010, J NEUROL SCI, V299, P112, DOI 10.1016/j.jns.2010.08.064; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pudelek Barbara, 2002, AACN Clin Issues, V13, P61; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Senft C, 2009, NEUROL RES, V31, P1012, DOI 10.1179/174313209X409034; Takeuchi S, 2010, J CLIN NEUROSCI, V17, P1527, DOI 10.1016/j.jocn.2010.03.055; Tokutomi T, 2005, NEUROTRAUMATOLOGY, V28, P1; Urculo E, 1996, ACTA NEUROCHIR, V138, P776, DOI 10.1007/BF01411487; Vicenzi MN, 2006, BRIT J ANAESTH, V96, P686, DOI 10.1093/bja/ael083; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234; Yilmaz S, 2006, EUR J EMERG MED, V13, P295, DOI 10.1097/00063110-200610000-00010; Yokohori S, 2013, NEUROTRAUMATOLOGY, V36, P76; Yokosuka K, 2015, J NEUROSURG, V123, P1065, DOI 10.3171/2014.10.JNS14915	65	21	21	0	6	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	AUG	2017	57	8					418	425		10.2176/nmc.st.2017-0058			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FG2OC	WOS:000409948800006	28679968	Green Published, Other Gold			2021-06-18	
J	McDonald, BC; Flashman, LA; Arciniegas, DB; Ferguson, RJ; Xing, L; Harezlak, J; Sprehn, GC; Hammond, FM; Maerlender, AC; Kruck, CL; Gillock, KL; Frey, K; Wall, RN; Saykin, AJ; McAllister, TW				McDonald, Brenna C.; Flashman, Laura A.; Arciniegas, David B.; Ferguson, Robert J.; Xing, Li; Harezlak, Jaroslaw; Sprehn, Gwen C.; Hammond, Flora M.; Maerlender, Arthur C.; Kruck, Carrie L.; Gillock, Karen L.; Frey, Kim; Wall, Rachel N.; Saykin, Andrew J.; McAllister, Thomas W.			Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial	NEUROPSYCHOPHARMACOLOGY			English	Article							DOUBLE-BLIND; REHABILITATION; GUIDELINES; INDIVIDUALS; IMPROVEMENT; VALIDATION; DOPAMINE; THERAPY; APHASIA; ADULT	The purpose of this multicenter, prospective, randomized, placebo-controlled study was to evaluate and compare the efficacy of two cognitive rehabilitation interventions (Memory and Attention Adaptation Training (MAAT) and Attention Builders Training (ABT)), with and without pharmacological enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive problems after traumatic brain injury (TBI). Adults with a history of TBI at least 4 months before study enrollment with either objective cognitive deficits or subjective cognitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18). Assessments were conducted pretreatment (baseline) and after 6 weeks of treatment (post treatment). Outcome measures included scores on neuropsychological measures and subjective rating scales. Statistical analyses used linear regression models to predict post-treatment scores for each outcome variable by treatment type, adjusting for relevant covariates. Statistically significant (P<0.05) treatment-related improvements in cognitive functioning were found for word-list learning (MAAT/placebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH),andauditory working memory and divided attention (MAAT/MPH>ABT/MPH). These results suggest that combined treatment with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and working memory, and executive functioning after TBI.	[McDonald, Brenna C.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indiana, PA USA; [McDonald, Brenna C.; Sprehn, Gwen C.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; [McDonald, Brenna C.; Wall, Rachel N.; Saykin, Andrew J.; McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Flashman, Laura A.; Kruck, Carrie L.; Gillock, Karen L.] Geisel Sch Med, Dept Psychiat, Hanover, NH USA; [Arciniegas, David B.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; [Arciniegas, David B.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Arciniegas, David B.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA; [Ferguson, Robert J.] Univ Pittsburgh, Dept Med, Div Hematol Oncol, 930 Scaife Hall, Pittsburgh, PA USA; [Xing, Li; Harezlak, Jaroslaw] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA; [Xing, Li; Harezlak, Jaroslaw] Indiana Univ, Dept Biostat, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Maerlender, Arthur C.] Univ Nebraska, Ctr Brain Biol & Behav, Lincoln, NE USA; [Frey, Kim] Craig Hosp, Dept Speech Language Pathol, Englewood, CO USA; [Saykin, Andrew J.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	McAllister, TW (corresponding author), Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA.; McAllister, TW (corresponding author), Indiana Univ Sch Med, IU Hlth Neurosci Ctr, Dept Psychiat, 355 W 16th St,GH Suite 4800, Indianapolis, IN 46202 USA.	twmcalli@iupui.edu	Saykin, Andrew/A-1318-2007; Harezlak, Jaroslaw/P-8557-2014	Saykin, Andrew/0000-0002-1376-8532; Harezlak, Jaroslaw/0000-0002-3070-7686	Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD047242]; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133A120020, H133A130047]; Department of Veterans AffairsUS Department of Veterans Affairs [CX000239]	This study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (R01 HD047242). The authors declare no conflict of interest. DBA receives research support from the National Institute on Disability, Independent Living, and Rehabilitation Research (H133A120020, H133A130047) and Department of Veterans Affairs (CX000239) and receives compensation from American Psychiatric Association Publishing.	Ahles TA, 2008, BREAST CANCER RES TR, V110, P143, DOI 10.1007/s10549-007-9686-5; APA, 2000, DIAGN STAT MAN MENT; Arciniegas D B, 2013, BEHAV NEUROLOGY NEUR, P225; Arciniegas DB, 2013, BEHAV NEUROLOGY NEUR, P511; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Berthier ML, 2009, ANN NEUROL, V65, P577, DOI 10.1002/ana.21597; Bragoni M, 2000, NEUROL SCI, V21, P19, DOI 10.1007/s100720070114; Brown FC, 2007, CLIN NEUROPSYCHOL, V21, P811, DOI 10.1080/13854040600878777; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Craft S, 1996, NEUROBIOL AGING, V17, P123, DOI 10.1016/0197-4580(95)02002-0; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Ferguson R.J., 1996, SOURCEBOOK PSYCHOL T; Ferguson RJ, 2007, PSYCHO-ONCOL, V16, P772, DOI 10.1002/pon.1133; Ferguson RJ, 2012, PSYCHO-ONCOLOGY, V21, P176, DOI 10.1002/pon.1878; Gordon M., 1996, GORDON DIAGNOSTIC SY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Huang CH, 2016, CURR NEUROPHARMACOL, V14, P272, DOI 10.2174/1570159X13666150514233033; Joensson M, 2015, HUM BRAIN MAPP, V36, P1866, DOI 10.1002/hbm.22742; Johansson B, 2015, BRAIN INJURY, V29, P758, DOI 10.3109/02699052.2015.1004747; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lafayette Instrument, 1989, GROOV PEGB INSTR OWN; McAllister TW, 2016, NEUROPSYCHOPHARMACOL, V41, P1191, DOI 10.1038/npp.2015.282; Palmese CA, 2000, BRAIN INJURY, V14, P535; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Psychological Corporation, 1999, WECHSLER ABBREVIATED; Saykin A J, 1995, Appl Neuropsychol, V2, P79, DOI 10.1207/s15324826an0202_5; SEIDENBERG M, 1994, J CLIN EXP NEUROPSYC, V16, P93, DOI 10.1080/01688639408402620; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Spielberger CD, 1983, STATE TRAIT ANXIETY; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; The Psychological Corporation, 1997, WAIS 3 WECHSL AD INT; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Weathers F, 1993, 9 ANN CONV INT SOC T; Westbrook A, 2016, NEURON, V89, P695, DOI 10.1016/j.neuron.2015.12.029; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Wilkinson G.S., 2006, WRAT4 WIDE RANGE ACH; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Wolfson D., 1993, HALSTEAD REITAN NEUR	50	21	21	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	AUG	2017	42	9					1766	1775		10.1038/npp.2016.261			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	FA3VJ	WOS:000405372200003	27874023	Green Published, Bronze			2021-06-18	
J	Chiluwal, A; Narayan, RK; Chaung, W; Mehan, N; Wang, P; Bouton, CE; Golanov, EV; Li, CY				Chiluwal, Amrit; Narayan, Raj K.; Chaung, Wayne; Mehan, Neal; Wang, Ping; Bouton, Chad E.; Golanov, Eugene V.; Li, Chunyan			Neuroprotective Effects of Trigeminal Nerve Stimulation in Severe Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							CEREBRAL-BLOOD-FLOW; ROSTRAL VENTROLATERAL MEDULLA; ELECTRICAL-STIMULATION; DIVING RESPONSE; HEMORRHAGIC-SHOCK; PATHO-PHYSIOLOGY; CARDIAC REFLEX; NASAL-MUCOSA; RAT; VAGUS	Following traumatic brain injury (TBI), ischemia and hypoxia play a major role in further worsening of the damage, a process referred to as 'secondary injury'. Protecting neurons from causative factors of secondary injury has been the guiding principle of modern TBI management. Stimulation of trigeminal nerve induces pressor response and improves cerebral blood flow (CBF) by activating the rostral ventrolateral medulla. Moreover, it causes cerebrovasodilation through the trigemino-cerebrovascular system and trigemino-parasympathetic reflex. These effects are capable of increasing cerebral perfusion, making trigeminal nerve stimulation (TNS) a promising strategy for TBI management. Here, we investigated the use of electrical TNS for improving CBF and brain oxygen tension (PbrO(2)), with the goal of decreasing secondary injury. Severe TBI was produced using controlled cortical impact (CCI) in a rat model, and TNS treatment was delivered for the first hour after CCI. In comparison to TBI group, TBI animals with TNS treatment demonstrated significantly increased systemic blood pressure, CBF and PbrO(2) at the hyperacute phase of TBI. Furthermore, rats in TNS-treatment group showed significantly reduced brain edema, blood-brain barrier disruption, lesion volume, and brain cortical levels of TNF-alpha and IL-6. These data provide strong early evidence that TNS could be an effective neuroprotective strategy.	[Chiluwal, Amrit; Narayan, Raj K.; Mehan, Neal; Li, Chunyan] Feinstein Inst Med Res, Northwell Neuromonitoring Lab, Manhasset, NY 11030 USA; [Chiluwal, Amrit; Narayan, Raj K.; Mehan, Neal; Li, Chunyan] Hofstra Northwell Sch Med, Dept Neurosurg, Hempstead, NY 11549 USA; [Chaung, Wayne; Wang, Ping] Feinstein Inst Med Res, Ctr Immunol & Inflammat, Manhasset, NY USA; [Golanov, Eugene V.] Houston Methodist Res Inst, Dept Neurosurg, Houston, TX USA; [Narayan, Raj K.; Bouton, Chad E.; Li, Chunyan] Feinstein Inst Med Res, Ctr Bioelect Med, Manhasset, NY 11030 USA	Li, CY (corresponding author), Feinstein Inst Med Res, Northwell Neuromonitoring Lab, Manhasset, NY 11030 USA.; Li, CY (corresponding author), Hofstra Northwell Sch Med, Dept Neurosurg, Hempstead, NY 11549 USA.; Li, CY (corresponding author), Feinstein Inst Med Res, Ctr Bioelect Med, Manhasset, NY 11030 USA.	cli11@northwell.edu	Golanov, Eugene/B-6462-2011	Golanov, Eugene/0000-0003-0220-822X; Wang, Ping/0000-0002-1557-0394	Department of Neurosurgery at Northwell Health; U.S. Department of Defense CDMRP PH/TBI Research Program [PT090526P4 (W81XWH-10-1-0978)]	This work was supported in part by the Department of Neurosurgery at Northwell Health and U.S. Department of Defense CDMRP PH/TBI Research Program under project No. PT090526P4 (W81XWH-10-1-0978).	Atalay B, 2002, J NEUROSURG, V97, P1179, DOI 10.3171/jns.2002.97.5.1179; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Borovikova LV, 2000, NATURE, V405, P458; BOUMA GJ, 1993, ACTA NEUROCHIR, P34; BRANSTON NM, 1995, BRIT J NEUROSURG, V9, P319, DOI 10.1080/02688699550041331; Brown CM, 2003, BRAIN RES BULL, V61, P81, DOI 10.1016/S0361-9230(03)00065-0; Carney N., 2017, NEUROSURGERY, V159, P771; Cook IA, 2016, NEUROMODULATION, V19, P299, DOI 10.1111/ner.12399; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Davies CA, 1998, EXP NEUROL, V154, P199, DOI 10.1006/exnr.1998.6891; DeGiorgio CM, 2013, NEUROLOGY, V80, P786, DOI 10.1212/WNL.0b013e318285c11a; Dutschmann M, 1998, NEUROREPORT, V9, P1053; Englot DJ, 2016, NEUROSURGERY, V79, P345, DOI 10.1227/NEU.0000000000001165; GINSBERG MD, 1994, ANN NEUROL, V36, P553, DOI 10.1002/ana.410360402; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goadsby PJ, 1997, BRAIN RES, V751, P247, DOI 10.1016/S0006-8993(96)01344-3; Golanov EV, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00157; GOLANOV EV, 1994, J CEREBR BLOOD F MET, V14, P492, DOI 10.1038/jcbfm.1994.61; Guarini S, 2003, CIRCULATION, V107, P1189, DOI 10.1161/01.CIR.0000050627.90734.ED; Gulturk S, 2009, INT J NEUROSCI, V119, P1292, DOI 10.1080/00207450802335610; Gurelik M, 2004, NEUROSCI LETT, V365, P210, DOI 10.1016/j.neulet.2004.04.079; Guyenet PG, 1996, PROG BRAIN RES, V107, P127; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Ishii H, 2014, J COMP PHYSIOL B, V184, P385, DOI 10.1007/s00360-014-0807-2; Ito G, 2013, EUR J PAIN, V17, P185, DOI 10.1002/j.1532-2149.2012.00174.x; Jiang M, 2017, MED GAS RES, V7, P48, DOI 10.4103/2045-9912.202910; Kinoshita K, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0138-3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kumaria A, 2012, BRIT J NEUROSURG, V26, P316, DOI 10.3109/02688697.2012.663517; Lapi D, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnuls.2016.00470; Lazaridis C, 2016, NEUROSURG CLIN N AM, V27, P509, DOI 10.1016/j.nec.2016.05.010; Levy G, 2013, SHOCK, V39, P39, DOI 10.1097/SHK.0b013e31827b450d; Li CY, 2017, J CEREBR BLOOD F MET, V37, P1634, DOI 10.1177/0271678X16667131; Li CY, 2016, BIOMED MICRODEVICES, V18, DOI 10.1007/s10544-016-0034-6; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Ma F, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-44; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magis D., 2016, CEPHALALGIA; Mandel M, 2012, FUNCT NEUROL, V27, P207; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Martindale V., 2015, MEDSCAPE; McCulloch P. F., 1998, NEUROSCIENCE, V24, P374; McCulloch PF, 1999, J PHYSIOL-LONDON, V516, P471, DOI 10.1111/j.1469-7793.1999.0471v.x; McCulloch PF, 1999, BRAIN RES, V830, P24, DOI 10.1016/S0006-8993(99)01374-8; McIntosh TK, 1996, LAB INVEST, V74, P315; Meregnani J, 2011, AUTON NEUROSCI-BASIC, V160, P82, DOI 10.1016/j.autneu.2010.10.007; MESSLINGER K, 1995, CAN J PHYSIOL PHARM, V73, P1020; Meuwly C, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000484; MOSKOWITZ MA, 1979, LANCET, V2, P883; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Panneton WM, 2013, PHYSIOLOGY, V28, P284, DOI 10.1152/physiol.00020.2013; Panneton WM, 2000, BRAIN RES, V874, P48, DOI 10.1016/S0006-8993(00)02549-X; Pearn ML, 2016, CELL MOL NEUROBIOL; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROGERS RC, 1980, BRAIN RES BULL, V5, P365, DOI 10.1016/S0361-9230(80)80006-2; Schaller B, 2004, J NEUROL, V251, P658, DOI 10.1007/s00415-004-0458-4; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Shaparin N, 2015, PAIN RES MANAG, V20, P63, DOI 10.1155/2015/482652; Shiflett, 2015, J NEUROLOGY STROKE, V2, P1; SHIOKAWA Y, 1992, BRIT J NEUROSURG, V6, P445, DOI 10.3109/02688699208995034; Shiozawa P, 2014, EPILEPSY BEHAV, V39, P6, DOI 10.1016/j.yebeh.2014.07.021; SUZUKI N, 1990, J CEREBR BLOOD F MET, V10, P399, DOI 10.1038/jcbfm.1990.70; SUZUKI N, 1990, ACTA PHYSIOL SCAND, V138, P307, DOI 10.1111/j.1748-1716.1990.tb08851.x; Svendgaard NA, 1996, NEUROL RES, V18, P394; Toader E, 2011, MINERVA ANESTESIOL, V77, P142; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Underwood M. D., 2016, J CEREB BLOOD FLOW M; Veenith TV, 2016, JAMA NEUROL, V73, P542, DOI 10.1001/jamaneurol.2016.0091; Wang QQ, 2016, J MOL NEUROSCI, V59, P78, DOI 10.1007/s12031-016-0736-5; Weber B, 2003, J CEREBR BLOOD F MET, V23, P1455, DOI 10.1097/01.WCB.0000095799.98378.7D; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Yamakawa K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056728; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Yang YJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0550-6; Yilmaz Adem, 2011, Surg Neurol Int, V2, P77, DOI 10.4103/2152-7806.82084; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZHANG QJ, 1993, NEUROSURGERY, V32, P993, DOI 10.1227/00006123-199306000-00019; Zhou L, 2014, NEURAL REGEN RES, V9, P1585, DOI 10.4103/1673-5374.141783	81	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 28	2017	7								6792	10.1038/s41598-017-07219-3			13	Multidisciplinary Sciences	Science & Technology - Other Topics	FC1PP	WOS:000406610000043	28754973	DOAJ Gold, Green Published			2021-06-18	
J	Du, XP; West, MB; Cai, QF; Cheng, WH; Ewert, DL; Li, W; Floyd, RA; Kopke, RD				Du, Xiaoping; West, Matthew B.; Cai, Qunfeng; Cheng, Weihua; Ewert, Donald L.; Li, Wei; Floyd, Robert A.; Kopke, Richard D.			Antioxidants reduce neurodegeneration and accumulation of pathologic Tau proteins in the auditory system after blast exposure	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Antioxidants; Blast; Oxidative stress; Auditory system; Neurodegeneration; Tau protein	SPIRAL GANGLION NEURONS; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; HEARING-LOSS; INDUCED TINNITUS; IMMUNOCYTOCHEMICAL LOCALIZATION; MOLECULAR-MECHANISMS; NERVE DEGENERATION; NEUROFILAMENT-L; RAT MODEL	Cochlear neurodegeneration commonly accompanies hair cell loss resulting from aging, ototoxicity, or exposures to intense noise or blast overpressures. However, the precise pathophysiological mechanisms that drive this degenerative response have not been fully elucidated. Our laboratory previously demonstrated that non-transgenic rats exposed to blast overpressures exhibited marked somatic accumulation of neurotoxic variants of the microtubule-associated protein, Tau, in the hippocampus. In the present study, we extended these analyses to examine neurodegeneration and pathologic Tau accumulation in the auditory system in response to blast exposure and evaluated the potential therapeutic efficacy of antioxidants on short-circuiting this pathological process. Blast injury induced ribbon synapse loss and retrograde neurodegeneration in the cochlea in untreated animals. An accompanying perikaryal accumulation of neurofilament light chain and pathologic Tau oligomers were observed in neurons from both the peripheral and central auditory system, spanning from the spiral ganglion to the auditory cortex. Due to its coincident accumulation pattern and well-documented neurotoxicity, our results suggest that the accumulation of pathologic Tau oligomers may actively contribute to blast-induced cochlear neurodegeneration. Therapeutic intervention with a combinatorial regimen of 2,4-disulfonyl alpha-phenyl tertiary butyl nitrone (HPN-07) and N-acetylcysteine (NAC) significantly reduced both pathologic Tau accumulation and indications of ongoing neurodegeneration in the cochlea and the auditory cortex. These results demonstrate that a combination of HPN-07 and NAC administrated shortly after a blast exposure can serve as a potential therapeutic strategy for preserving auditory function among military personnel or civilians with blast-induced traumatic brain injuries.	[Du, Xiaoping; West, Matthew B.; Cai, Qunfeng; Cheng, Weihua; Ewert, Donald L.; Li, Wei; Kopke, Richard D.] Hough Ear Inst, 3400 NW 56th St, Oklahoma City, OK 73112 USA; [Floyd, Robert A.; Kopke, Richard D.] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA; [Kopke, Richard D.] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73014 USA; [Kopke, Richard D.] Univ Oklahoma, Hlth Sci Ctr, Dept Otolaryngol, Oklahoma City, OK 73014 USA	Kopke, RD (corresponding author), Hough Ear Inst, 3400 NW 56th St, Oklahoma City, OK 73112 USA.	rkopke@houghear.org			US Department of Navy, Office of Naval Research [N00014-09-1-0999]; Oklahoma Center for the Advancement of Science and Technology (OCAST) [AR14-020]	The authors would like to thank Dr. Rakez Kayed (University of Texas Medical Branch, Galveston, TX) for his kind gift of the oligomeric (T22) Tau antibody and the laboratory of Dr. Charles Liberman (Harvard Medical School, Boston, Massachusetts) for creating the custom NIH ImageJ software plug-in that we used for generating tonotopic maps of rat cochleae. This research was supported by grant N00014-09-1-0999 from the US Department of Navy, Office of Naval Research and The Oklahoma Center for the Advancement of Science and Technology (OCAST) grant AR14-020.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Bae WY, 2008, LARYNGOSCOPE, V118, P1659, DOI 10.1097/MLG.0b013e31817c1303; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; BERGLUND AM, 1991, J COMP NEUROL, V306, P393, DOI 10.1002/cne.903060304; BICHLER E, 1984, ARCH OTO-RHINO-LARYN, V240, P243; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Clavaguera F, 2013, BRAIN PATHOL, V23, P342, DOI 10.1111/bpa.12044; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Cowan CM, 2012, BIOCHEM SOC T, V40, P693, DOI 10.1042/BST20120135; DAU J, 1989, HEARING RES, V42, P253, DOI 10.1016/0378-5955(89)90149-4; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DESPRES G, 1994, ACTA OTO-LARYNGOL, V114, P377, DOI 10.3109/00016489409126073; Dougherty AL, 2013, J REHABIL RES DEV, V50, P893, DOI 10.1682/JRRD.2012.02.0024; Du XP, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4159357; Du XP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080138; Du XP, 2012, HEARING RES, V283, P1, DOI 10.1016/j.heares.2011.11.013; Du XP, 2003, ORL-J OTO-RHIN-LARYN, V65, P7, DOI 10.1159/000068654; ELVERLAND HH, 1980, ACTA OTO-LARYNGOL, V90, P360, DOI 10.3109/00016488009131737; Ewert DL, 2012, HEARING RES, V285, P29, DOI 10.1016/j.heares.2012.01.013; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Furman AC, 2013, J NEUROPHYSIOL, V110, P577, DOI 10.1152/jn.00164.2013; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Gillingwater TH, 2003, J NEUROCYTOL, V32, P863, DOI 10.1023/B:NEUR.0000020629.51673.f5; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; HAFIDI A, 1989, DEV BRAIN RES, V48, P143, DOI 10.1016/0165-3806(89)90098-9; Haroutunian V, 2007, NEUROBIOL AGING, V28, P1, DOI 10.1016/j.neurobiolaging.2005.11.001; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Il Cho S., 2013, PLOS ONE, V8; Iqbal K, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00112; Ishihara T, 2001, J NEUROSCI, V21, P6026; Jensen JB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125160; Kidd AR, 2012, GERONTOLOGY, V58, P490, DOI 10.1159/000338588; Kim NH, 2004, BIOCHIMIE, V86, P553, DOI 10.1016/j.biochi.2004.07.006; Kim NH, 2003, J BIOCHEM MOL BIOL, V36, P488; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; Kril JJ, 2002, ACTA NEUROPATHOL, V103, P370, DOI 10.1007/s00401-001-0477-5; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Lang HN, 2006, J NEUROSCI, V26, P3541, DOI 10.1523/JNEUROSCI.2488-05.2006; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Lee JE, 2004, ACTA OTO-LARYNGOL, V124, P1131, DOI 10.1080/00016480410017521; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lin H, 2006, ANN NEUROL, V60, P399, DOI 10.1002/ana.20965; Lovell MA, 2004, J ALZHEIMERS DIS, V6, P659; Luo H, 2014, J NEUROSCI RES, V92, P1466, DOI 10.1002/jnr.23424; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; Martin L, 2011, NEUROCHEM INT, V58, P458, DOI 10.1016/j.neuint.2010.12.023; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Melov S., 2007, PLOS ONE, V2; Mondragon-Rodriguez S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/940603; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Naini SMA, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/151979; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Noble W, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00083; Olivieri G, 2001, J NEUROCHEM, V76, P224, DOI 10.1046/j.1471-4159.2001.00090.x; OSHIMA T, 1992, BRAIN RES, V590, P53, DOI 10.1016/0006-8993(92)91081-O; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Perez M, 2000, FEBS LETT, V486, P270, DOI 10.1016/S0014-5793(00)02323-1; Phillips Y Y, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P3; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Roberto M, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P23; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; SCHMIDT ML, 1990, AM J PATHOL, V136, P1069; Shi LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081566; Shi L, 2015, ACTA OTO-LARYNGOL, V135, P1093, DOI 10.3109/00016489.2015.1061699; SLEPECKY NB, 1992, HEARING RES, V57, P201, DOI 10.1016/0378-5955(92)90152-D; Spires-Jones T.L., 2014, NEURON; Stankovic K, 2004, J NEUROSCI, V24, P8651, DOI 10.1523/JNEUROSCI.0733-04.2004; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Su B, 2010, NEUROSCI LETT, V468, P267, DOI 10.1016/j.neulet.2009.11.010; Takashima A, 2013, J ALZHEIMERS DIS, V37, P565, DOI 10.3233/JAD-130653; Taniguchi T, 2001, J BIOL CHEM, V276, P10025, DOI 10.1074/jbc.M007427200; Tong MJ, 2013, JARO-J ASSOC RES OTO, V14, P321, DOI 10.1007/s10162-013-0374-3; Usenovic M, 2015, J NEUROSCI, V35, P14234, DOI 10.1523/JNEUROSCI.1523-15.2015; Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684; Valiyaveettil M, 2012, J REHABIL RES DEV, V49, P1153, DOI 10.1682/JRRD.2011.09.0182; VICKERS JC, 1994, NEUROSCIENCE, V62, P1, DOI 10.1016/0306-4522(94)90310-7; Violet M, 2015, NEUROBIOL DIS, V82, P540, DOI 10.1016/j.nbd.2015.09.003; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wan GQ, 2014, ELIFE, V3, DOI 10.7554/eLife.03564; Wang HL, 2015, INT J CLIN EXP PATHO, V8, P8680; Wolfe M.S., 2012, SCIENCE, V2012; Yankaskas K, 2013, HEARING RES, V295, P3, DOI 10.1016/j.heares.2012.04.016	90	21	21	4	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUL	2017	108						627	643		10.1016/j.freeradbiomed.2017.04.343			17	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	EX7XS	WOS:000403463500056	28438658				2021-06-18	
J	Treble-Barna, A; Schultz, H; Minich, N; Taylor, HG; Yeates, KO; Stancin, T; Wade, SL				Treble-Barna, Amery; Schultz, Hanna; Minich, Nori; Taylor, H. Gerry; Yeates, Keith Owen; Stancin, Terry; Wade, Shari L.			Long-Term Classroom Functioning and Its Association With Neuropsychological and Academic Performance Following Traumatic Brain Injury During Early Childhood	NEUROPSYCHOLOGY			English	Article						academic achievement; adaptive function; child development; neuropsychological outcomes; traumatic brain injury	RECOVERY 10 YEARS; COGNITIVE PREDICTORS; YOUNG-CHILDREN; OUTCOMES; BEHAVIOR; ACHIEVEMENT; STUDENTS; INTERVENTIONS; ADOLESCENTS; FLUENCY	Objective: The present study utilized ecobehavioral assessment to examine classroom functioning several years following early childhood traumatic brain injury (TBI) or orthopedic injury (OI) and its association with injury factors, neuropsychological abilities, and academic performance. Method: Participants included 39 children with moderate to severe TBI and 51 children with OI sustained between ages 3 and 7 years. At 7.2 (+/- 1.3) years post injury, ecobehavioral assessment was used to examine classroom functioning. Additional outcomes included neuropsychological tests, parent and teacher ratings of dysexecutive behavior, and teacher ratings of academic performance. Groups were compared on measures controlling for demographic characteristics, and associations among outcomes were examined using linear regression. Results: Children with TBI showed lower academic engagement relative to children with OI, as well as more frequent individual teacher attention for children with more severe injuries. For children with TBI, difficulties in classroom functioning were associated with lower cognitive flexibility and higher parent and teacher ratings of dysexecutive behavior. Lower scores on a test of fluid reasoning and a greater frequency of individual teacher attention were also associated with lower academic performance in children with TBI. Conclusions: Difficulties in classroom functioning are evident several years after early childhood TBI and were associated with greater injury severity, neuropsychological weaknesses, and poorer academic performance. Children with impaired cognitive flexibility and fluid reasoning skills were at greatest risk for these difficulties and associated weaknesses in academic performance. Instructional interactions may be a potential target for intervention to promote academic progress in at- risk children.	[Treble-Barna, Amery; Schultz, Hanna] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Minich, Nori; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat Neuropsychol, Cleveland, OH 44106 USA; [Yeates, Keith Owen] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Stancin, Terry] Case Western Reserve Univ, Dept Pediat Psychol, Cleveland, OH 44106 USA; [Wade, Shari L.] Univ Cincinnati, Dept Phys Med & Rehabil, Cincinnati, OH 45221 USA; [Schultz, Hanna] Univ Alberta, Dept Educ Psychol, Edmonton, AB, Canada	Treble-Barna, A (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202,Kaufman Bldg, Pittsburgh, PA 15213 USA.	amery.treble-barna@pitt.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; Trauma Research grants from the State of Ohio Emergency Medical Services; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8 UL1 TR000077]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER	This research was supported by funding through Grant R01 HD42729 from the National Institute of Child Health and Development (NICHD) and by Trauma Research grants from the State of Ohio Emergency Medical Services. Additional support was provided through Grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences of the National Institutes of Health. We thank Harriet Bannister of the Juniper Gardens Children Project for providing training on the MS-CISSAR.	Abikoff HB, 2002, J ABNORM CHILD PSYCH, V30, P349, DOI 10.1023/A:1015713807297; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Carrow-Woolfolk E., 1999, COMPREHENSIVE ASSESS; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Culbertson WC, 1998, ARCH CLIN NEUROPSYCH, V13, P285, DOI 10.1016/S0887-6177(97)00033-4; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Fulton JB, 2012, NEUROPSYCHOLOGY, V26, P314, DOI 10.1037/a0027973; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gioia G.A., 2000, BEHAV RATING INVENTO; Gonzalez LM, 2007, EPILEPSIA, V48, P124, DOI 10.1111/j.1528-1167.2006.00907.x; GREENWOOD CR, 1994, EXCEPT CHILDREN, V61, P197; Greenwood CR, 2003, J SPEC EDUC, V37, P95, DOI 10.1177/00224669030370020401; GREENWOOD CR, 1991, EXCEPT CHILDREN, V57, P521, DOI 10.1177/001440299105700606; Greenwood CR, 1997, ECOBEHAVIORAL ASSESS; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Junod REV, 2006, J SCHOOL PSYCHOL, V44, P87, DOI 10.1016/j.jsp.2005.12.004; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Logan KR, 1997, EXCEPT CHILDREN, V63, P481; Maggin DM, 2012, J SCHOOL PSYCHOL, V50, P625, DOI 10.1016/j.jsp.2012.06.001; Manly T., 1999, TEA CH TEST EVERYDAY; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Prasad MR, 2017, J HEAD TRAUMA REHAB, V32, pE24, DOI 10.1097/HTR.0000000000000218; Sugai, 2008, EDUC TREAT CHILD, V31, P351, DOI [DOI 10.1353/ETC.0.0007, 10.1353/etc.0.0007]; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; TEASDALE G, 1974, LANCET, V2, P81; Thaler NS, 2012, APPL NEUROPSYCH-CHIL, V1, P30, DOI 10.1080/21622965.2012.665776; Treble-Barna A, 2017, J NEUROTRAUM, V34, P353, DOI 10.1089/neu.2016.4476; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2004, WECHSLER INTELLIGENC; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wong T, 2014, EARLY HUM DEV, V90, P907, DOI 10.1016/j.earlhumdev.2014.09.011; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387	55	21	21	1	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2017	31	5					486	498		10.1037/neu0000325			13	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	EY1GE	WOS:000403713200002	28627915	Bronze, Green Accepted			2021-06-18	
J	Lutton, EM; Razmpour, R; Andrews, AM; Cannella, LA; Son, YJ; Shuvaev, VV; Muzykantov, VR; Ramirez, SH				Lutton, Evan M.; Razmpour, Roshanak; Andrews, Allison M.; Cannella, Lee Anne; Son, Young-Jin; Shuvaev, Vladimir V.; Muzykantov, Vladimir R.; Ramirez, Servio H.			Acute administration of catalase targeted to ICAM-1 attenuates neuropathology in experimental traumatic brain injury	SCIENTIFIC REPORTS			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; OXIDATIVE STRESS; BARRIER PERMEABILITY; INFLAMMATORY RESPONSE; ANTIOXIDANT THERAPIES; SODIUM FLUORESCEIN; ENDOTHELIUM; ACTIVATION	Traumatic brain injury (TBI) contributes to one third of injury related deaths in the US. Treatment strategies for TBI are supportive, and the pathophysiology is not fully understood. Secondary mechanisms of injury in TBI, such as oxidative stress and inflammation, are points at which intervention may reduce neuropathology. Evidence suggests that reactive oxygen species (ROS) propagate blood-brain barrier (BBB) hyperpermeability and inflammation following TBI. We hypothesized that targeted detoxification of ROS may improve the pathological outcomes of TBI. Following TBI, endothelial activation results in a time dependent increase in vascular expression of ICAM-1. We conjugated catalase to anti-ICAM-1 antibodies and administered the conjugate to 8 wk old C57BL/6J mice 30 min after moderate controlled cortical impact injury. Results indicate that catalase targeted to ICAM-1 reduces markers of oxidative stress, preserves BBB permeability, and attenuates neuropathological indices more effectively than non-targeted catalase and anti-ICAM-1 antibody alone. Furthermore, the study of microglia by two-photon microscopy revealed that anti-ICAM-1/catalase prevents the transition of microglia to an activated phenotype. These findings demonstrate the use of a targeted antioxidant enzyme to interfere with oxidative stress mechanisms in TBI and provide a proof-of-concept approach to improve acute TBI management that may also be applicable to other neuroinflammatory conditions.	[Lutton, Evan M.; Razmpour, Roshanak; Andrews, Allison M.; Cannella, Lee Anne; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA; [Andrews, Allison M.; Son, Young-Jin; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Shriners Hosp, Pediat Res Ctr, Philadelphia, PA 19140 USA; [Cannella, Lee Anne; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA; [Shuvaev, Vladimir V.; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA	Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA.; Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Shriners Hosp, Pediat Res Ctr, Philadelphia, PA 19140 USA.; Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA.	servio@temple.edu		ramirez, servio/0000-0002-4609-5653	National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F32 DA041282, P30 DA013429-16]; NIH/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS086570-01]; Shriners Hospitals for Children [85110-PHI-14]; NIH/HLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [1R01 HL126874-01A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL126874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007237, P30DA013429, F32DA041282] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) F32 DA041282 (AMA), P30 DA013429-16 (SHR), NIH/National Institute of Neurological Disorders and Stroke (NINDS) R01 NS086570-01 (SHR), The Shriners Hospitals for Children 85110-PHI-14 (SHR), and NIH/HLBI 1R01 HL126874-01A1 (VRM).	ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; Amenta PS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0191-6; Andrews AM, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00043; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Deng-Bryant Y, 2016, METHODS MOL BIOL, V1462, P89, DOI 10.1007/978-1-4939-3816-2_6; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dietrich JB, 2002, J NEUROIMMUNOL, V128, P58, DOI 10.1016/S0165-5728(02)00114-5; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Frankowski JC, 2015, SCI REP-UK, V5, DOI 10.1038/srep17956; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Hadad N, 2011, J IMMUNOL, V186, P1816, DOI 10.4049/jimmunol.1000193; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hood ED, 2014, BIOMATERIALS, V35, P3708, DOI 10.1016/j.biomaterials.2014.01.023; Howlett J.R., 2016, TRANSLATIONAL RES TR; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kozler P, 2003, PHYSIOL RES, V52, P607; Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806; Kudinov AE, 2016, P NATL ACAD SCI USA, V113, P6955, DOI 10.1073/pnas.1513616113; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; Lochhead JJ, 2010, J CEREBR BLOOD F MET, V30, P1625, DOI 10.1038/jcbfm.2010.29; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; LUSCINSKAS FW, 1994, FASEB J, V8, P929; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mannix R, 2017, J NEUROTRAUM, V34, P495, DOI 10.1089/neu.2016.4457; Margulies S, 2016, J NEUROTRAUM, V33, P101, DOI 10.1089/neu.2014.3855; McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049; Merkel S. F., 2016, CELL TRANSPLANT, DOI [10.3727/096368916X694175, DOI 10.3727/096368916X694175]; Merkel SF, 2017, NEUROSCI BIOBEHAV R, V77, P209, DOI 10.1016/j.neubiorev.2017.03.015; Merkel SF, 2017, J NEUROTRAUM, V34, P165, DOI 10.1089/neu.2015.4275; Merrill JE, 1997, BRAIN BEHAV IMMUN, V11, P245, DOI 10.1006/brbi.1997.0496; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; OISHI R, 1989, N-S ARCH PHARMACOL, V339, P159; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Rochfort KD, 2015, BIOCHEM SOC T, V43, P702, DOI 10.1042/BST20140319; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Scherpereel A, 2001, FASEB J, V15, P416, DOI 10.1096/fj.00-0022com; Shen QH, 2016, WORLDV EVID-BASED NU, V13, P380, DOI 10.1111/wvn.12167; Shuvaev VV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077002; Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789; Shuvaev VV, 2011, J CONTROL RELEASE, V149, P236, DOI 10.1016/j.jconrel.2010.10.026; Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877; Simone E, 2009, CELL TISSUE RES, V335, P283, DOI 10.1007/s00441-008-0676-7; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Soni KS, 2016, J CONTROL RELEASE, V240, P109, DOI 10.1016/j.jconrel.2015.11.009; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; TAKEI F, 1985, J IMMUNOL, V134, P1403; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Tsuhako MH, 2010, FREE RADICAL BIO MED, V48, P704, DOI 10.1016/j.freeradbiomed.2009.12.013; Vialou V, 2012, J NEUROSCI, V32, P7577, DOI 10.1523/JNEUROSCI.1381-12.2012; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zanier Elisa R, 2015, Intensive Care Med Exp, V3, P39, DOI 10.1186/s40635-015-0039-0; Zhang M, 2010, NEUROSCIENCE, V171, P852, DOI 10.1016/j.neuroscience.2010.09.029; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	79	21	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 19	2017	7								3846	10.1038/s41598-017-03309-4			15	Multidisciplinary Sciences	Science & Technology - Other Topics	EY0LT	WOS:000403650300089	28630485	DOAJ Gold, Green Published			2021-06-18	
J	Kaminski, L; Cordemans, V; Cernat, E; M'Bra, KI; Mac-Thiong, JM				Kaminski, Ludovic; Cordemans, Virginie; Cernat, Eduard; M'Bra, Kouame Innocent; Mac-Thiong, Jean-Marc			Functional Outcome Prediction after Traumatic Spinal Cord Injury Based on Acute Clinical Factors	JOURNAL OF NEUROTRAUMA			English	Article						ASIA impairment scale; clinical prediction model; functional outcome; spinal cord injury	INDEPENDENCE MEASURE; SURGICAL DECOMPRESSION; MULTICENTER; RELIABILITY; PROGNOSIS; RECOVERY; VALIDITY; SURGERY; SCI	Spinal cord injury (SCI) is a devastating condition that affects patients on both a personal and societal level. The objective of the study is to improve the prediction of long-term functional outcome following SCI based on the acute clinical findings. A total of 76 patients with acute traumatic SCI were prospectively enrolled in a cohort study in a single Level I trauma center. Spinal Cord Independence Measure (SCIM) at 1 year after the trauma was the primary outcome. Potential predictors of functional outcome were recorded during the acute hospitalization: age, sex, level and type of injury, comorbidities, American Spinal Injury Association (ASIA) Impairment Scale (AIS), ASIA Motor Score (AMS), ASIA Light Touch score (LT), ASIA Pin Prick score (PP), Injury Severity Score (ISS), traumatic brain injury, and delay from trauma to surgery. A linear regression model was created with the primary outcome modeled relative to the acute clinical findings. Only four variables were selected in the model, with performance averaging an R-square value of 0.57. In descending order, the best predictors for SCIM at 1 year were: LT, AIS grade, ISS, and AMS. One-year functional outcome (SCIM) can be estimated by a simple equation that takes into account four parameters of the initial physical examination. Estimating the patient long-term outcome early after traumatic SCI is important in order to define the management strategies that might diminish the costs and to give the patient and family a better view of the long-term expectations.	[Kaminski, Ludovic] Clin Univ St Luc, Serv Orthopedie & Traumatol Appareil Locomoteur, Brussels, Belgium; [Cordemans, Virginie] Catholic Univ Louvain, Inst Rech Expt & Clin, Comp Assisted & Robot Surg CARS, Brussels, Belgium; [Cernat, Eduard] Cent Mil Univ Hosp Dr Carol Davila, Bucharest, Romania; [M'Bra, Kouame Innocent] Ctr Hosp Univ CHU, Serv Orthopedie & Traumatol, Bouake, Bouake, Cote Ivoire; [Mac-Thiong, Jean-Marc] Univ Montreal, Dept Surg, Fac Med, Montreal, PQ, Canada; [Mac-Thiong, Jean-Marc] Hop Sacre Coeur Montreal, Dept Surg, Montreal, PQ, Canada	Kaminski, L (corresponding author), UCL St Luc, Ave Hippocrate 10, B-1200 Brussels, Belgium.	kaminski.ludovic@gmail.com			Department of the Army (United States Army Medical Research Acquisition Activity); Rick Hansen Spinal Cord Injury Registry	The authors would like to thank for their financial support the Department of the Army (United States Army Medical Research Acquisition Activity) and the Rick Hansen Spinal Cord Injury Registry.	Anderson KD, 2011, SPINAL CORD, V49, P880, DOI 10.1038/sc.2011.20; Anderson K, 2008, J SPINAL CORD MED, V31, P133, DOI 10.1080/10790268.2008.11760704; Battistuzzo CR, 2016, J NEUROTRAUM, V33, P1161, DOI 10.1089/neu.2015.4207; Bernhard M, 2005, RESUSCITATION, V66, P127, DOI 10.1016/j.resuscitation.2005.03.005; Bourassa-Moreau E, 2016, J NEUROTRAUM, V33, P301, DOI 10.1089/neu.2015.3957; Bourassa-Moreau E, 2013, J TRAUMA ACUTE CARE, V74, P849, DOI 10.1097/TA.0b013e31827e1381; Burke DA, 2001, SPINAL CORD, V39, P274, DOI 10.1038/sj.sc.3101158; CROZIER KS, 1991, ARCH PHYS MED REHAB, V72, P119; DeVivo M, 2011, TOP SPINAL CORD INJ, V16, P1, DOI DOI 10.1310/SCI1604-1; Furlan JC, 2011, J NEUROTRAUM, V28, P1413, DOI 10.1089/neu.2009.1148; Furlan JC, 2009, J NEUROTRAUM, V26, P1707, DOI [10.1089/neu.2009.0888, 10.1089/neu.2009-0888]; Grant RA, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-014-0334-1; Grassner L, 2016, J NEUROTRAUM, V33, P1658, DOI 10.1089/neu.2015.4325; Itzkovich M, 2007, DISABIL REHABIL, V29, P1926, DOI 10.1080/09638280601046302; Jazayeri SB, 2015, EUR SPINE J, V24, P905, DOI 10.1007/s00586-014-3424-6; Jug M, 2015, J NEUROTRAUM, V32, P1385, DOI 10.1089/neu.2014.3767; Krueger H, 2013, CHRON DIS INJ CAN, V33, P113; National Spinal Cord Injury Statistical Center, 2013, J Spinal Cord Med, V36, P1, DOI 10.1179/1079026813Z.000000000136; Nott Melissa T, 2014, Top Spinal Cord Inj Rehabil, V20, P225, DOI 10.1310/sci2003-225; Sharma B, 2014, J REHABIL MED, V46, P370, DOI 10.2340/16501977-1261; Simpson LA, 2012, J NEUROTRAUM, V29, P1548, DOI 10.1089/neu.2011.2226; Stephan K, 2015, SPINE J, V15, P1994, DOI 10.1016/j.spinee.2015.04.041; van Middendorp JJ, 2009, SPINAL CORD, V47, P555, DOI 10.1038/sc.2008.162; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Vasquez N, 2013, SPINAL CORD, V51, P375, DOI 10.1038/sc.2012.175; Wilson JR, 2014, SPINE J, V14, P1192, DOI 10.1016/j.spinee.2013.08.005; Wilson JR, 2012, J NEUROTRAUM, V29, P2263, DOI 10.1089/neu.2012.2417	27	21	21	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 15	2017	34	12					2027	2033		10.1089/neu.2016.4955			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EX0AN	WOS:000402880600003	28129730				2021-06-18	
J	Zhang, WT; Wang, YF				Zhang, Wei-Tao; Wang, Ya-Fei			Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury	MEDICINE			English	Article						mental sequelae; methylphenidate; randomized controlled trial; traumatic brain injury	REHABILITATION; DEPRESSION; FATIGUE; DISORDERS; SYMPTOMS	Background: This study aimed to evaluate the effect of methylphenidate for treating mental sequelae after traumatic brain injury (TBI). Methods: Thirty-six patients with TBI were randomly divided into the intervention group and placebo group. The participants in the intervention group received methylphenidate, while subjects in the placebo group were administered a placebo. This study was conducted from January 2014 to December 2016. The outcome measurements included Mental Fatigue Scale, Choice Reaction Time, Compensatory Tracking Task, Mental Arithmetic Test, Digit Symbol Substitution Test, Mini-Mental State Examination (MMSE), Beck Depression Inventory (BDI), and Hamilton Rating Scale for Depression. In addition, safety was also recorded and assessed. Results: A total of 33 subjects completed the study. Methylphenidate showed greater efficacy than placebo, with decreased scores on the Mental Fatigue Scale, Choice Reaction Time, and Compensatory Tracking Task in the intervention group compared to the placebo group (P < .01, respectively). Furthermore, increased scores on the Mental Arithmetic Test, Digit Symbol Substitution Test, and MMSE in the intervention group, compared to those in the placebo group (P < .01 respectively), were observed. In addition, a significant difference in the scores on the BDI (P = .04) and Hamilton Rating Scale for Depression (P = .005) was observed between the 2 groups. The safety at the end of the 30 week-treatment was similar between the 2 groups (P > .05). Conclusion: The results of this study demonstrated that methylphenidate could effectively improve mental fatigue and cognitive functions in patients with TBI.	[Zhang, Wei-Tao] Peoples Hosp Yanan, Dept Neurosurg, Yanan 716000, Peoples R China; [Wang, Ya-Fei] Peoples Hosp Ningxia, Dept Neurosurg, 301 Zhengyuan North St, Yinchuan 750001, Peoples R China	Zhang, WT (corresponding author), Peoples Hosp Yanan, Dept Neurosurg, Yanan 716000, Peoples R China.; Wang, YF (corresponding author), Peoples Hosp Ningxia, Dept Neurosurg, 301 Zhengyuan North St, Yinchuan 750001, Peoples R China.	weitao20000@outlook.com; wangds1958@163.com					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Garcia-Baran D, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002886; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HINDMARCH I, 1980, BRIT J CLIN PHARMACO, V10, P189, DOI 10.1111/j.1365-2125.1980.tb01745.x; HINDMARCH I, 1977, BRIT J CLIN PHARMACO, V4, pS167, DOI 10.1111/j.1365-2125.1977.tb05747.x; HINDMARCH I, 1983, ACTA PSYCHIAT SCAND, V68, P141, DOI 10.1111/j.1600-0447.1983.tb11115.x; Huang CH, 2016, CURR NEUROPHARMACOL, V14, P272, DOI 10.2174/1570159X13666150514233033; Jang SH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005009; Jang SH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002628; Johansson B, 2017, ACTA NEUROL SCAND, V135, P100, DOI 10.1111/ane.12587; Johansson B., 2012, BRAIN INJURY FUNCTIO, V1, P3, DOI [10.5772/27042, DOI 10.5772/27042]; Johansson B., 2014, INT J PHYS MED REHAB, V2, P1, DOI [10.4172/2329-9096.1000182, DOI 10.4172/2329-9096.1000182]; Johansson B, 2010, BRAIN INJURY, V24, P2, DOI 10.3109/02699050903452961; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; McAllister Thomas W., 1994, P357; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Sashika H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005968; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shire US Inc WPA, 2009, PROD INF DAYTR TM TR; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Sivan M, 2010, CLIN REHABIL, V24, P110, DOI 10.1177/0269215509343234; Wang Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006458; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Weber P, 2002, PEDIATR NEUROL, V26, P261, DOI 10.1016/S0887-8994(01)00408-8; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003	33	21	22	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUN	2017	96	25							e6960	10.1097/MD.0000000000006960			5	Medicine, General & Internal	General & Internal Medicine	EY6TT	WOS:000404116900005	28640076	DOAJ Gold, Green Published			2021-06-18	
J	Higgins, KL; Denney, RL; Maerlender, A				Higgins, Kathryn L.; Denney, Robert L.; Maerlender, Arthur			Sandbagging on the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) in a high school athlete population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Neuropsychological testing; High school athletes; Baseline; Concussion; Concussion assessment	NEUROCOGNITIVE TEST-PERFORMANCE; TEST-RETEST	The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) is a computerized neuropsychological test battery commonly used to assess cognitive functioning after a concussion. It is recommended that application of ImPACT utilizes a baseline administration so athletes have an individualized baseline with which to compare post-injury results should they sustain a concussion. It has been suggested that athletes may provide suboptimal effort, called "sandbagging," in order to return to their baseline cognitive scores, and thus to play, more quickly. This research examines ImPACT baseline scores when high school athletes were asked to attempt to " sandbag," and compares those scores with scores obtained when they were asked to give their "best effort." Fifty-four high school student athlete volunteers participated in the study. In contrast to previous research that just looked at the cut-score invalidity indicators built into ImPACT, this research developed a regression equation to predict sandbagging. A logistic regression equation developed with four variables that demonstrated the largest effect size between "best effort" and "sandbagged" baselines showed a 99.7% classification accuracy for the " best effort" and "sandbag" groups.	[Higgins, Kathryn L.; Maerlender, Arthur] Univ Nebraska, Ctr Brain Biol & Behav, C76,East Stadium,POB 880156, Lincoln, NE 68588 USA; [Denney, Robert L.] Neuropsychol Associates Southwest Missouri, Springfield, MO USA	Higgins, KL (corresponding author), Univ Nebraska, Ctr Brain Biol & Behav, C76,East Stadium,POB 880156, Lincoln, NE 68588 USA.	khiggins@unl.edu			Forest Institute of Professional Psychology	This work was supported by a Research Grant from Forest Institute of Professional Psychology.	Agresti A., 2007, INTRO CATEGORICAL DA; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT., 1989, MILD HEAD INJURY, P257; Boone K. B., 2007, ASSESSMENT FEIGNED C, P29; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Faure C, 2010, J PHYS EDUC RECREAT, V81, P19, DOI 10.1080/07303084.2010.10598410; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hosmer DW., 2013, APPL LOGISTIC REGRES, V3rd ed.; ImPACT Applications Inc., 2011, TECHN MAN ONL IMPACT; Maerlender AC, 2016, J CLIN EXP NEUROPSYC, V38, P869, DOI 10.1080/13803395.2016.1168781; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Pallant J, 2005, SPSS SURVIVAL MANUAL; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Schatz P, 2014, J ATHL TRAINING, V49, P659, DOI 10.4085/1062-6050-49.3.37; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	21	21	21	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2017	32	3					259	266		10.1093/arclin/acw108			8	Psychology, Clinical; Psychology	Psychology	EU2WN	WOS:000400890700001	28431031	Green Published, Bronze			2021-06-18	
J	McHugo, GJ; Krassenbaum, S; Donley, S; Corrigan, JD; Bogner, J; Drake, RE				McHugo, Gregory J.; Krassenbaum, Sarah; Donley, Sachiko; Corrigan, John D.; Bogner, Jennifer; Drake, Robert E.			The Prevalence of Traumatic Brain Injury Among People With Co-Occurring Mental Health and Substance Use Disorders	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community psychiatry; co-occurring disorders; dual diagnosis; traumatic brain injury	TBI IDENTIFICATION METHOD; PSYCHIATRIC-DISORDERS; POPULATION; ABUSE; RELIABILITY; VALIDITY; ADULTS; RISK; METAANALYSIS; ADOLESCENTS	Objective: To estimate the rate and severity of traumatic brain injury (TBI) among people with co-occurring mental health and substance use disorders and to compare demographic, diagnostic, and institutionalization differences between those who screen positive or negative. Setting: Outpatient community mental health center in Washington, District of Columbia. Participants: A total of 295 people with co-occurring mental health and substance use disorders enrolled in a prospective study of integrated treatment of substance abuse. Design: Cross-sectional baseline assessment. Main Measures: The Ohio State University TBI Identification Method. Standardized measures assessed psychiatric diagnoses, symptom severity, current and lifetime substance use, and history of institutionalization. Results: Eighty percent screened positive for TBI, and 25% reported at least 1 moderate or severe TBI. TBI was associated with current alcohol use and psychiatric symptom severity and with lifetime institutionalization and homelessness. It was more common among participants with posttraumatic stress disorder, borderline personality disorder, and antisocial personality disorder. Men (vs women) and participants with psychotic disorders (vs those with mood disorders) had an earlier age of first TBI with loss of consciousness. Conclusion: TBI is common among people with co-occurring mental health and substance use disorders. Repeated and serious TBIs are common in this population. Failure to detect TBI in people with co-occurring disorders who are seeking integrated treatment could lead to misdiagnosis and inappropriately targeted treatment and rehabilitation.	[McHugo, Gregory J.; Drake, Robert E.] Dartmouth Coll, Dartmouth Psychiat Res Ctr, Hanover, NH 03755 USA; [Krassenbaum, Sarah] Community Connect, Washington, DC USA; [Donley, Sachiko] Univ Calif Irvine, Dept Psychol & Social Behav, Irvine, CA USA; [Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	McHugo, GJ (corresponding author), Dartmouth Psychiat Res Ctr, 46 Centerra Pkwy,Suite 300, Lebanon, NH 03766 USA.	gregory.mchugo@dartmouth.edu	Corrigan, John D./E-2921-2011; Drake, Robert/AAS-3310-2020		West Family Foundation	This research was funded by a gift from the West Family Foundation.	Adams RS, 2012, J SOC WORK PRACT ADD, V12, P28, DOI 10.1080/1533256X.2012.647580; Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Batty R, 2015, J CLIN EXP NEUROPSYC, V37, P917, DOI 10.1080/13803395.2015.1068279; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Boothroyd RA, 2008, ADM POLICY MENT HLTH, V35, P370, DOI 10.1007/s10488-008-0179-6; Brady KT, 2009, J ADDICT MED, V3, P179, DOI 10.1097/ADM.0b013e3181aa244f; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Conrad K J, 2001, Ment Health Serv Res, V3, P141, DOI 10.1023/A:1011571531303; Corrigan J, 2016, 11 WORLD C BRAIN INJ; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Corrigan JD, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1315; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; First M., 1995, STRUCTURED CLIN INTE; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Ilie G, 2015, J NEUROTRAUM, V32, P1130, DOI 10.1089/neu.2014.3619; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Molloy C, 2011, SCHIZOPHRENIA BULL, V37, P1104, DOI 10.1093/schbul/sbr091; Orellana Gricel, 2013, Front Psychiatry, V4, P35, DOI 10.3389/fpsyt.2013.00035; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Sacks JAY, 2003, J NERV MENT DIS, V191, P145, DOI 10.1097/00005053-200303000-00002; Shiroma EJ, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e3182571c14; Shiroma Eric J, 2010, J Correct Health Care, V16, P273, DOI 10.1177/1078345810378253; Sobell M.B., 1980, EVALUATING ALCOHOL D, P129; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE43, DOI 10.1097/HTR.0000000000000141; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005	40	21	21	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2017	32	3					E65	E74		10.1097/HTR.0000000000000249			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EV4GM	WOS:000401716900014	27455436				2021-06-18	
J	Chio, CC; Lin, HJ; Tian, YF; Chen, YC; Lin, MT; Lin, CH; Chang, CP; Hsu, CC				Chio, Chung-Ching; Lin, Hung-Jung; Tian, Yu-Feng; Chen, Yu-Chieh; Lin, Mao-Tsun; Lin, Cheng-Hsien; Chang, Ching-Ping; Hsu, Chien-Chin			Exercise attenuates neurological deficits by stimulating a critical HSP70/NF-kappa B/IL-6/synapsin I axis in traumatic brain injury rats	JOURNAL OF NEUROINFLAMMATION			English	Article						Brain injury; Neuroprotection; Neuroinflammation; Exercise; IL-6; HSP70; Synapsin I	SPINAL-CORD-INJURY; FACTOR-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; HEAT-SHOCK-PROTEIN; CEREBRAL-ISCHEMIA; INFLAMMATORY CYTOKINES; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTOR; NEUROTROPHIC FACTOR; STEM-CELLS	Background: Despite previous evidence for a potent inflammatory response after a traumatic brain injury (TBI), it is unknown whether exercise preconditioning (EP) improves outcomes after a TBI by modulating inflammatory responses. Methods: We performed quantitative real-time PCR (qPCR) to quantify the genes encoding 84 cytokines and chemokines in the peripheral blood and used ELISA to determine both the cerebral and blood levels of interleukin-6 (IL-6). We also performed the chromatin immunoprecipitation (ChIP) assay to evaluate the extent of nuclear factor kappa-B (NF-kappa B) binding to the DNA elements in the IL-6 promoter regions. Also, we adopted the Western blotting assay to measure the cerebral levels of heat shock protein (HSP) 70, synapsin I, and beta-actin. Finally, we performed both histoimmunological and behavioral assessment to measure brain injury and neurological deficits, respectively. Results: We first demonstrated that TBI upregulated nine pro-inflammatory and/or neurodegenerative messenger RNAs (mRNAs) in the peripheral blood such as CXCL10, IL-18, IL-16, Cd-70, Mif, Ppbp, Ltd, Tnfrsf 11b, and Faslg. In addition to causing neurological injuries, TBI also upregulated the following 14 anti-inflammatory and/or neuroregenerative mRNAs in the peripheral blood such as Ccl19, Ccl3, Cxcl19, IL-10, IL-22, IL-6, Bmp6, Ccl22, IL-7, Bmp7, Ccl2, Ccl17, IL-1rn, and Gpi. Second, we observed that EP inhibited both neurological injuries and six proinflammatory and/or neurodegenerative genes (Cxcl10, IL-18, IL-16, Cd70, Mif, and Faslg) but potentiated four antiinflammatory and/or neuroregenerative genes (Bmp6, IL-10, IL-22, and IL-6). Prior depletion of cerebral HSP70 with gene silence significantly reversed the beneficial effects of EP in reducing neurological injuries and altered gene profiles after a TBI. A positive Pearson correlation exists between IL-6 and HSP70 in the peripheral blood or in the cerebral levels. In addition, gene silence of cerebral HSP70 significantly reduced the overexpression of NF-kappa B, IL-6, and synapsin I in the ipsilateral brain regions after an EP in rats. Conclusions: TBI causes neurological deficits associated with stimulating several pro-inflammatory gene profiles but inhibiting several anti-inflammatory gene profiles of cytokines and chemokines. Exercise protects against neurological injuries via stimulating an anti-inflammatory HSP70/NF-kappa B/IL-6/synapsin I axis in the injured brains.	[Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan 710, Taiwan; [Chio, Chung-Ching; Hsu, Chien-Chin] Chi Mei Med Ctr, Dept Emergency Med, Tainan 710, Taiwan; [Lin, Hung-Jung; Chen, Yu-Chieh; Chang, Ching-Ping; Hsu, Chien-Chin] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan 710, Taiwan; [Tian, Yu-Feng] Chi Mei Med Ctr, Dept Surg, Div Gen Surg, Tainan 710, Taiwan; [Tian, Yu-Feng] Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr, Tainan 717, Taiwan; [Lin, Mao-Tsun; Chang, Ching-Ping] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan; [Lin, Cheng-Hsien] Meridigen Biotech Co Ltd, Taipei 11493, Taiwan; [Chang, Ching-Ping] Taipei Med Univ, PhD Program Neural Regenerat Med, Taipei 110, Taiwan	Hsu, CC (corresponding author), Chi Mei Med Ctr, Dept Emergency Med, Tainan 710, Taiwan.; Chang, CP; Hsu, CC (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan 710, Taiwan.; Chang, CP (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan.; Chang, CP (corresponding author), Taipei Med Univ, PhD Program Neural Regenerat Med, Taipei 110, Taiwan.	jessica@stust.edu.tw; nych2525@gmail.com		Chang, Ching-Ping/0000-0003-0890-9414	Ministry of Science and Technology (Taiwan)Ministry of Science and Technology, Taiwan [NSC 102-2628-B-384-001-MY3, MOST 104-2314-B-384-003-MY3, MOST 104-2314-B-218-001-MY3]; Chi Mei Medical Center (Taiwan) [CMFHT 10504]	This work was supported by Ministry of Science and Technology (Taiwan) grants NSC 102-2628-B-384-001-MY3 (to CCC), MOST 104-2314-B-384-003-MY3 (to CCC), MOST 104-2314-B-218-001-MY3 (to CPC) and Chi Mei Medical Center (Taiwan) grants CMFHT 10504 (to CPC).	Archer T, 2012, NEUROTOX RES, V21, P418, DOI 10.1007/s12640-011-9297-0; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; Bielecki B, 2015, ARCH IMMUNOL THER EX, V63, P367, DOI 10.1007/s00005-015-0339-9; Bis JC, 2008, ATHEROSCLEROSIS, V198, P166, DOI 10.1016/j.atherosclerosis.2007.09.031; Bowen KK, 2011, NEUROREPORT, V22, P126, DOI 10.1097/WNR.0b013e3283430a44; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chang CK, 2014, INT J MOL SCI, V15, P19018, DOI 10.3390/ijms151019018; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen YW, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.033829; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chou J, 2006, J NEUROL SCI, V240, P21, DOI 10.1016/j.jns.2005.08.015; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Deola S, 2008, J IMMUNOL, V180, P1362, DOI 10.4049/jimmunol.180.3.1362; Ehrlich DE, 2016, GENES BRAIN BEHAV, V15, P125, DOI 10.1111/gbb.12255; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Fairbanks SL, 2010, BEST PRACT RES-CLIN, V24, P521, DOI 10.1016/j.bpa.2010.10.004; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Fehrenbach E, 2006, SPORTS MED, V36, P373, DOI 10.2165/00007256-200636050-00001; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fujiki M, 2004, BRAIN RES, V1021, P281, DOI 10.1016/j.brainres.2004.06.054; Ghasemzadeh M, 2013, BLOOD, V121, P4555, DOI 10.1182/blood-2012-09-459636; Ghosh CC, 2010, J IMMUNOL, V185, P3685, DOI 10.4049/jimmunol.0902230; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; GURNEY ME, 1986, SCIENCE, V234, P566, DOI 10.1126/science.3764429; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Himi T, 1997, ACTA OTO-LARYNGOL, V117, P123, DOI 10.3109/00016489709118003; Howell JM, 2006, PROTEOMICS, V6, P2050, DOI 10.1002/pmic.200500517; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Inacio AR, 2011, J CEREBR BLOOD F MET, V31, P1093, DOI 10.1038/jcbfm.2010.194; Kittipatarin C, 2007, CYTOKINE, V39, P75, DOI 10.1016/j.cyto.2007.07.183; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Koo JW, 2010, P NATL ACAD SCI USA, V107, P2669, DOI 10.1073/pnas.0910658107; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; KUSHIMA Y, 1992, NEUROSCI RES, V13, P267, DOI 10.1016/0168-0102(92)90039-F; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Liebelt B, 2010, NEUROSCIENCE, V166, P1091, DOI 10.1016/j.neuroscience.2009.12.067; Liu YT, 2001, BRAIN RES, V905, P81, DOI 10.1016/S0006-8993(01)02502-1; Manecka DL, 2013, J BIOL CHEM, V288, P14936, DOI 10.1074/jbc.M112.434597; Martire A, 2003, CARDIOVASC RES, V57, P523, DOI 10.1016/S0008-6363(02)00697-1; Mathy NL, 2000, IMMUNOLOGY, V100, P63, DOI 10.1046/j.1365-2567.2000.00997.x; Mazzeo AT, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0624-5; Michell-Robinson MA, 2015, BRAIN, V138, P1138, DOI 10.1093/brain/awv066; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mortberg E, 2011, ACTA ANAESTH SCAND, V55, P1132, DOI 10.1111/j.1399-6576.2011.02505.x; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; Muramatsu R, 2012, NAT MED, V18, P1658, DOI 10.1038/nm.2943; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakajima H, 2012, J BIOTECHNOL, V157, P326, DOI 10.1016/j.jbiotec.2011.10.003; Neidl R, 2016, J NEUROSCI, V36, P4351, DOI 10.1523/JNEUROSCI.3239-15.2016; Niu J, 2008, J BIOL CHEM, V283, P14542, DOI 10.1074/jbc.M802139200; Okamura H, 1998, ADV IMMUNOL, V70, P281, DOI 10.1016/S0065-2776(08)60389-2; Paxinos G., 2013, RAT BRAIN STEREOTAXI; Pedersen BK, 2007, TRENDS PHARMACOL SCI, V28, P152, DOI 10.1016/j.tips.2007.02.002; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Petersen AMW, 2006, J PHYSIOL PHARMACOL, V57, P43; Phillips C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00170; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; QIAGEN. QIAGEN Redwood City, QIAGENS ING PATHW AN; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; Shih RH, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00077; Shimamura M, 2014, P NATL ACAD SCI USA, V111, P8191, DOI 10.1073/pnas.1400544111; Stamatovic SM, 2006, J IMMUNOL, V177, P2651, DOI 10.4049/jimmunol.177.4.2651; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Tsai MC, 2015, J NEUROIMMUNE PHARM, V10, P45, DOI 10.1007/s11481-014-9570-0; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Vaynman SS, 2006, BRAIN RES, V1070, P124, DOI 10.1016/j.brainres.2005.11.062; Wang XK, 2000, MOL PHARMACOL, V57, P1190; Wang Y, 2001, STROKE, V32, P2170, DOI 10.1161/hs0901.095650; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu MH, 2016, MOL NEUROBIOL, V53, P3702, DOI 10.1007/s12035-015-9305-0; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024; Yu XZ, 2012, INT J CANCER, V131, P1491, DOI 10.1002/ijc.27634; Yu Y, 2007, CIRC RES, V101, P304, DOI 10.1161/CIRCRESAHA.107.148940; Zaremba J, 2006, FOLIA NEUROPATHOL, V44, P282; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144; Zhou ZG, 2009, EXP NEUROL, V220, P183, DOI 10.1016/j.expneurol.2009.08.018; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	92	21	24	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 24	2017	14								90	10.1186/s12974-017-0867-9			18	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	EV3EJ	WOS:000401640300002	28438174	DOAJ Gold, Green Published			2021-06-18	
J	Hanlon, LA; Raghupathi, R; Huh, JW				Hanlon, L. A.; Raghupathi, R.; Huh, J. W.			Differential effects of minocycline on microglial activation and neurodegeneration following closed head injury in the neonate rat	EXPERIMENTAL NEUROLOGY			English	Article						Pediatric TBI; Microglia; Cognition; Axonal injury; Cortex; Thalamus; Subiculum; Corpus callosum	TRAUMATIC BRAIN-INJURY; HYPOXIC-ISCHEMIC INJURY; FOCAL CEREBRAL-ISCHEMIA; WHITE-MATTER INJURY; AXONAL INJURY; CEREBROSPINAL-FLUID; IMMATURE BRAIN; COGNITIVE DEFICITS; UNITED-STATES; JUVENILE RAT	The role of microglia in the pathophysiology of injury to the developing brain has been extensively studied. In children under the age of 4 who have sustained a traumatic brain injury (TBI), markers of microglial/macrophage activation were increased in the cerebrospinal fluid and were associated with worse neurologic outcome. Minocycline is an antibiotic that decreases microglial/macrophage activation following hypoxic-ischemia in neonatal rodents and TBI in adult rodents thereby reducing neurodegeneration and behavioral deficits. In study 1, 11-day-old rats received an impact to the intact skull and were treated for 3 days with minocycline. Immediately following termination of minocycline administration, microglial reactivity was reduced in the cortex and hippo campus (p < 0.001) and was accompanied by an increase in the number of fluoro-Jade B profiles (p < 0.001) suggestive of a reduced clearance of degenerating cells; however, this effect was not sustained at 7 days post-injury. Although microglial reactivity was reduced in the white matter tracts (p < 0.001), minocycline treatment did not reduce axonal injury or degeneration. In the thalamus, minocycline treatment did not affect microglial reactivity, axonal injury and degeneration, and neurodegeneration. Injury-induced spatial learning and memory deficits were also not affected by minocycline. In study 2, to test whether extended dosing of minocycline may be necessary to reduce the ongoing pathologic alterations, a separate group of animals received minocycline for 9 days. Immediately following termination of treatment, microglial reactivity and neurodegeneration in all regions examined were exacerbated in minocycline-treated brain-injured animals compared to brain-injured animals that received vehicle (p < 0.001), an effect that was only sustained in the cortex and hippocampus up to 15 days post-injury (p < 0.001). Whereas injury-induced spatial learning deficits remained unaffected by minocycline treatment, memory deficits appeared to be significantly worse (p < 0.05). Sex had minimal effects on either injury-induced alterations or the efficacy of minocycline treatment. Collectively, these data demonstrate the differential effects of minocycline in the immature brain following impact trauma and suggest that minocycline may not be an effective therapeutic strategy for TBI in the immature brain. (C) 2016 Elsevier Inc. All rights reserved.	[Hanlon, L. A.; Raghupathi, R.] Drexel Univ, Coll Med, Program Neurosci, Philadelphia, PA 19104 USA; [Raghupathi, R.] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA; [Raghupathi, R.] Coatesville Vet Adm Med Ctr, Coatesville, PA USA; [Huh, J. W.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, 7 South Tower 7C06,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA	Huh, JW (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, 7 South Tower 7C06,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	HUH@email.chop.edu			National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 061963]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061963] Funding Source: NIH RePORTER	This study was funded, in part, by a grant from National Institute of Child Health and Human Development (NICHD) (HD 061963). The authors would like to thank Ms. Rupal Prasad and Mr. Douglas Fox for their technical assistance in performing animal surgeries/injuries and histologic analyses, respectively.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Andes D, 2002, INT J ANTIMICROB AG, V19, P261, DOI 10.1016/S0924-8579(02)00022-5; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Buller KM, 2009, J NEUROSCI RES, V87, P599, DOI 10.1002/jnr.21890; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai Z, 2006, NEUROSCIENCE, V137, P425, DOI 10.1016/j.neuroscience.2005.09.023; Carty ML, 2008, INT J DEV NEUROSCI, V26, P477, DOI 10.1016/j.ijdevneu.2008.02.005; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chhor V., 2016, BRAIN BEHAV IMMUN; Cikla U, 2016, J NEUROIMMUNOL, V291, P18, DOI 10.1016/j.jneuroim.2015.12.004; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Denker SP, 2007, J NEUROCHEM, V100, P893, DOI 10.1111/j.1471-4159.2006.04162.x; Duhaime AC, 1999, EXP TOXICOL PATHOL, V51, P172, DOI 10.1016/S0940-2993(99)80091-8; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fan LW, 2006, EUR J NEUROSCI, V24, P341, DOI 10.1111/j.1460-9568.2006.04918.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faustino JV, 2011, J NEUROSCI, V31, P12992, DOI 10.1523/JNEUROSCI.2102-11.2011; Ferrazzano P, 2013, CNS NEUROL DISORD-DR, V12, P338, DOI 10.2174/1871527311312030007; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Ivacko JA, 1996, PEDIATR RES, V39, P39, DOI 10.1203/00006450-199601000-00006; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lam TI, 2013, NEUROREHAB NEURAL RE, V27, P889, DOI 10.1177/1545968313491003; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lechpammer M, 2008, NEUROPATH APPL NEURO, V34, P379, DOI 10.1111/j.1365-2990.2007.00925.x; Leonardo CC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-34; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; MCRAE A, 1995, DEV BRAIN RES, V84, P245, DOI 10.1016/0165-3806(94)00177-2; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Newell E, 2015, PEDIATR CRIT CARE ME, V16, P549, DOI 10.1097/PCC.0000000000000400; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; O'Mara S, 2005, J ANAT, V207, P271, DOI 10.1111/j.1469-7580.2005.00446.x; O'Mara SM, 2009, PROG NEURO-PSYCHOPH, V33, P782, DOI 10.1016/j.pnpbp.2009.03.040; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Potter EG, 2009, J NEUROSCI RES, V87, P1356, DOI 10.1002/jnr.21963; Potts Mathew B, 2006, NeuroRx, V3, P143; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Robertson CL, 2015, J BIOENERG BIOMEMBR, V47, P43, DOI 10.1007/s10863-014-9585-5; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Trofimov A N, 2012, Ross Fiziol Zh Im I M Sechenova, V98, P782; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Wang AL, 2005, NEUROCHEM INT, V47, P152, DOI 10.1016/j.neuint.2005.04.018; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wixey JA, 2011, NEUROSCIENCE, V182, P184, DOI 10.1016/j.neuroscience.2011.03.033; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zhang Z, 2015, J NEUROTRAUM, V32, P1369, DOI 10.1089/neu.2014.3701	78	21	22	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2017	290						1	14		10.1016/j.expneurol.2016.12.010			14	Neurosciences	Neurosciences & Neurology	EM5QR	WOS:000395368000001	28038986	Green Accepted			2021-06-18	
J	Zamproni, LN; Mundim, MV; Porcionatto, MA; des Rieux, A				Zamproni, Laura N.; Mundim, Mayara V.; Porcionatto, Marimelia A.; des Rieux, Anne			Injection of SDF-1 loaded nanoparticles following traumatic brain injury stimulates neural stem cell recruitment	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Neural stem cells; SDF-1; Nanoparticles; Brain injury	FACTOR-I; DELIVERY; PLGA; BIOCOMPATIBILITY; MICROSPHERES; NEUROGENESIS; PROTEIN; REGENERATION; EXPRESSION; PARTICLES	Recruiting neural stem cell (NSC) at the lesion site is essential for central nervous system repair. This process could be triggered by the local delivery of the chemokine SDF-1. We compared two PLGA formulations for local brain SDF-1 delivery: SDF-1 loaded microspheres (MS) and SDF-1 loaded nanoparticles (NP). Both formulations were able to encapsulate more than 80% of SDF-1 but presented different release profiles, with 100% of SDF-1 released after 6 days for the MS and with 25% of SDF-1 released after 2 weeks for NP. SDF-1 bioactivity was demonstrated by a chemotactic assay. When injected in mouse brain after traumatic brain injury, only SDF-1 nanoparticles induced NSC migration to the damage area. More neuroblasts (DCX+ cells) could be visualized around the lesions treated with NP SDF-1 compared to the other conditions. Rostral migratory stream destabilization with massive migration of DCX+ cell toward the perilesional area was observed 2 weeks after NP SDF-1 injection. Local injection of SDF-1-loaded nanoparticles induces recruitment of NSC and could be promising for brain injury lesion. (C) 2017 Elsevier B.V. All rights reserved.	[Zamproni, Laura N.; Mundim, Mayara V.; Porcionatto, Marimelia A.] Univ Fed Sao Paulo, Neurobiol Lab, Res Bldg 2,Rua Pedro de Toledo 669, BR-04039032 Sao Paulo, Brazil; [des Rieux, Anne] Catholic Univ Louvain, Louvain Drug Res Inst, Adv Drug Delivery & Biomat, Ave E Mounier 73, B-1200 Brussels, Belgium; [des Rieux, Anne] Catholic Univ Louvain, Inst Mat & Condensed Matter, B-1348 Louvain La Neuve, Belgium	des Rieux, A (corresponding author), Catholic Univ Louvain, Louvain Drug Res Inst, Adv Drug Delivery & Biomat, Ave E Mounier 73, B-1200 Brussels, Belgium.	anne.desrieux@uclouvain.be	zamproni, laura/K-2422-2016; zamproni, laura/AAC-7271-2019; Porcionatto, Marimelia/C-3322-2012; Mundim, Mayara V/N-9985-2015	zamproni, laura/0000-0003-2219-6676; zamproni, laura/0000-0003-2219-6676; Porcionatto, Marimelia/0000-0001-6287-916X; Mundim, Mayara/0000-0002-9771-977X; des Rieux, Anne/0000-0001-9953-3816	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); UCL (FSR)	Laura Nicoleti Zamproni was a recipient of the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP). We are also grateful to UCL (FSR) for the financial support. Anne des Rieux is a Research Associate at the FRS-FNRS (Fonds de la Recherche Scientifique, Belgique).	Addington CP, 2015, BIOMARK INSIGHTS, V10, P43, DOI [10.4137/BMIMI.S20062, 10.4137/BMI.S20062]; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Berge T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009761; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chereddy KK, 2015, NANOMED-NANOTECHNOL, V11, P1975, DOI 10.1016/j.nano.2015.07.006; Cross DP, 2011, PHARM RES-DORDR, V28, P2477, DOI 10.1007/s11095-011-0474-x; D'Mello SR, 2014, J MICROENCAPSUL, V31, P137, DOI 10.3109/02652048.2013.814728; Dibajnia P, 2013, ACTA PHARMACOL SIN, V34, P78, DOI 10.1038/aps.2012.107; Dunne M, 2000, BIOMATERIALS, V21, P1659, DOI 10.1016/S0142-9612(00)00040-5; Emerich DF, 1999, CELL TRANSPLANT, V8, P47, DOI 10.1177/096368979900800114; Fournier E, 2003, BIOMATERIALS, V24, P3311, DOI 10.1016/S0142-9612(03)00161-3; Fujio M, 2011, BONE, V49, P693, DOI 10.1016/j.bone.2011.06.024; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Gaumet M, 2007, INT J PHARM, V342, P222, DOI 10.1016/j.ijpharm.2007.05.001; Ghassemi AH, 2012, PHARM RES-DORDR, V29, P110, DOI 10.1007/s11095-011-0517-3; Henderson PW, 2011, WOUND REPAIR REGEN, V19, P420, DOI 10.1111/j.1524-475X.2011.00687.x; Hines DJ, 2013, CRIT REV THER DRUG, V30, P257, DOI 10.1615/CritRevTherDrugCarrierSyst.2013006475; Ho CY, 2015, TISSUE ENG PT A, V21, P594, DOI [10.1089/ten.tea.2013.0762, 10.1089/ten.TEA.2013.0762]; Kim DH, 2015, BIOMATERIALS, V61, P115, DOI 10.1016/j.biomaterials.2015.05.025; Knudsen KB, 2014, NANOTOXICOLOGY, V8, P764, DOI 10.3109/17435390.2013.829589; Lee SM, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/208121; Li YN, 2015, STEM CELL TRANSL MED, V4, P1122, DOI 10.5966/sctm.2015-0074; Longmire M, 2008, NANOMEDICINE-UK, V3, P703, DOI 10.2217/17435889.3.5.703; Luker KE, 2009, BIOTECHNIQUES, V47, P625, DOI 10.2144/000113126; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Mao WF, 2014, INT J NEUROSCI, V124, P281, DOI 10.3109/00207454.2013.838236; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Rabbany SY, 2010, CELL TRANSPLANT, V19, P399, DOI 10.3727/096368909X481782; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Segers VFM, 2007, CIRCULATION, V116, P1683, DOI 10.1161/CIRCULATIONAHA.107.718718; Sirianni RW, 2014, BIOCONJUGATE CHEM, V25, P2157, DOI 10.1021/bc500315j; Sun WF, 2014, INFLAMM RES, V63, P287, DOI 10.1007/s00011-013-0699-8; Sun W, 2010, ANAT CELL BIOL, V43, P269, DOI 10.5115/acb.2010.43.4.269; Szebeni J, 2012, NANOMED-NANOTECHNOL, V8, P176, DOI 10.1016/j.nano.2011.06.003; Veziers J, 2001, J NEUROSURG, V95, P489, DOI 10.3171/jns.2001.95.3.0489; Vishwakarma SK, 2014, J ADV RES, V5, P277, DOI 10.1016/j.jare.2013.04.005; Wang LY, 2015, THER CLIN RISK MANAG, V11, P1337, DOI 10.2147/TCRM.S87590; Xue LP, 2014, CELL BIOCHEM BIOPHYS, V70, P1609, DOI 10.1007/s12013-014-0103-5; Yellowley Clare, 2013, Bonekey Rep, V2, P300, DOI 10.1038/bonekey.2013.34; Yoo J, 2012, NEUROSCIENCE, V209, P171, DOI 10.1016/j.neuroscience.2012.02.031; Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06-6558com	41	21	22	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	MAR 15	2017	519	1-2					323	331		10.1016/j.ijpharm.2017.01.036			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EQ3WT	WOS:000398005400032	28115261				2021-06-18	
J	Gardner, AJ; Iverson, GL; Wojtowicz, M; Levi, CR; Kay-Lambkin, F; Schofield, PW; Zafonte, R; Shultz, SR; Lin, AP; Stanwell, P				Gardner, Andrew J.; Iverson, Grant L.; Wojtowicz, Magdalena; Levi, Christopher R.; Kay-Lambkin, Frances; Schofield, Peter W.; Zafonte, Ross; Shultz, Sandy R.; Lin, Alexander P.; Stanwell, Peter			MR Spectroscopy Findings in Retired Professional Rugby League Players	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						concussion; neuroimaging; retired athletes; spectroscopy	MILD COGNITIVE IMPAIRMENT; MAGNETIC-RESONANCE-SPECTROSCOPY; POSTERIOR CINGULATE; USE DISORDERS; CONCUSSION; DISEASE; SYSTEM; INJURY; PET	The aim of this study was to examine brain neurometabolite concentrations in retired rugby league players who had a history of numerous self-reported concussions. Participants were 16 retired professional rugby league players (ages 30-45 years) with an extensive history of concussion and participation in contact sports, and 16 age-and education- matched controls who had no history of neurotrauma or participation in contact sports. All completed a clinical interview, psychological and cognitive testing, and magnetic resonance spectroscopy (MRS) investigation. MRS voxels were placed in posterior cingulate grey matter and parietal white matter. Neurometabolite concentrations were quantified using LCModel. It was hypothesized that retired athletes would differ on N-acetyl aspartate, myo-inositol, choline, glutamate, and glutathione. Retired players had significantly lower concentrations of grey matter glutathione (p = 0.02, d = 0.91). They did not significantly differ in concentrations of other neurometabolites. There were no significant differences between groups on measures of depression, anxiety, or cognitive functioning. The retired athletes reported significantly greater alcohol use (p < 0.01; Cohen's d = 1.49), and they had worse manual dexterity using their non-dominant hand (p = 0.03; d = 1.08). These preliminary findings suggest that MRS might be modestly sensitive to biochemical differences in athletes after their athletic careers have ended in the absence of clinical differences in cognitive performance and self-reported psychological functioning.	[Gardner, Andrew J.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Level 5, Waratah 2298, Australia; [Iverson, Grant L.; Wojtowicz, Magdalena; Zafonte, Ross] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Levi, Christopher R.] Hunter New England Local Hlth Dist, Sports Concuss Program, New Lambton Hts, Australia; [Kay-Lambkin, Frances] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia; [Schofield, Peter W.] Hunter New England Local Hlth Dist, Neuropsychiat Serv, New Lambton, Australia; [Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic, Australia; [Lin, Alexander P.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Ctr Clin Spect, Boston, MA USA; [Stanwell, Peter] Univ Newcastle, Sch Hlth Sci, Callaghan, NSW, Australia	Gardner, AJ (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Level 5, Waratah 2298, Australia.	andrew.gardner@neurogard.com.au	Stanwell, Peter/F-9136-2012	Stanwell, Peter/0000-0002-4780-0393; Schofield, Peter/0000-0001-8298-8590; Iverson, Grant/0000-0001-7348-9570; Levi, Christopher/0000-0002-9474-796X	New South Wales Sporting Injuries Committee - Sports Research & Injury Prevention Scheme Grant; Brain Foundation, Australia - Brain Injury Award; Hunter Medical Research Institute; Harvard Integrated Program to Protect and Improve the Health of NFLPA Members; Mooney-Reed Charitable Foundation; Heniz Family Foundation-Brain Injury Research Fund at Spaulding Rehabilitation Hospital; Australian Football League (AFL); ImPACT Applications, Inc.; CNS Vital Signs; Psychological Assessment Resources (PAR, Inc.); Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Alcohol Beverage Medical Research Council; Rehabilitation Research and Development (RR&D) Service of the US Department of Veterans AffairsUS Department of Veterans Affairs; Vancouver Coastal Health Research Institute; Roche Diagnostics Canada; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	Andrew J. Gardner, Peter Stanwell, Frances Kay-Lambkin, and Christopher R. Levi have been funded to conduct research into concussion in rugby league through a New South Wales Sporting Injuries Committee - Sports Research & Injury Prevention Scheme Grant, and a Brain Foundation, Australia - Brain Injury Award. Andrew J. Gardner acknowledges sport concussion research fellowship funding from Jennie Thomas, Life Governor of the Hunter Medical Research Institute, and Anne Greaves of the Hunter Medical Research Institute. Ross Zafonte was supported in part by the Harvard Integrated Program to Protect and Improve the Health of NFLPA Members. Grant Iverson and Ross Zafonte acknowledge support from the Mooney-Reed Charitable Foundation and the Heniz Family Foundation-Brain Injury Research Fund at Spaulding Rehabilitation Hospital. Author Disclosure/Conflict of Interest Statement Andrew Gardner has a clinical practice in neuropsychology involving the assessment and management of individuals who have sustained sport-related concussion (including current and former athletes). He has received travel funding from the Australian Football League (AFL) to present at the Concussion in Football Conference in 2013. He has served as a concussion consultant to the Australian Rugby Union (ARU) from July 2016. Grant Iverson, PhD has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to mild TBI and sport-related concussion at meetings, scientific conferences, and symposiums. He has a clinical and consulting practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including athletes). He has received research funding from several test publishing companies, including ImPACT Applications, Inc., CNS Vital Signs, and Psychological Assessment Resources (PAR, Inc.). He is a co-investigator, collaborator, or consultant on grants relating to mild TBI funded by several organizations, including, but not limited to, the Canadian Institute of Health Research, Alcohol Beverage Medical Research Council, Rehabilitation Research and Development (RR&D) Service of the US Department of Veterans Affairs, Vancouver Coastal Health Research Institute, and Roche Diagnostics Canada. Frances Kay-Lambkin is supported by a fellowship from the National Health and Medical Research Council of Australia. She is the subject of publishing contracts with multiple companies, including CCBT Ltd in the EU, Magelan, multiple BCBSs and Cobalt Therapeutics LLC in the US, as well as the NHS in the UK. Although she has received no remuneration to date, she may receive royalties in the future. She has not received any equity or payments related to the work discussed in this manuscript.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Benton A., 1994, MULTILINGUAL APHASIA; Bhidayasiri R, 2012, PARKINSONISM RELAT D, V18, P694, DOI 10.1016/j.parkreldis.2012.01.010; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; BOTTOMLEY PA, 1987, ANN NY ACAD SCI, V508, P333, DOI 10.1111/j.1749-6632.1987.tb32915.x; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Crane PK, 2008, J INT NEUROPSYCH SOC, V14, P746, DOI 10.1017/S1355617708081162; DAVIE CA, 1995, J NEUROL NEUROSUR PS, V58, P688, DOI 10.1136/jnnp.58.6.688; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; Duarte JMN, 2012, NEUROIMAGE, V61, P342, DOI 10.1016/j.neuroimage.2011.12.038; Duffy SL, 2014, ALZHEIMERS DEMENT, V10, P67, DOI 10.1016/j.jalz.2013.01.005; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Glodzik L, 2015, J ALZHEIMERS DIS, V43, P939, DOI 10.3233/JAD-140609; Golden C., 1978, STROOP COLOR WORD TE; Guo ZW, 2016, COMPR PSYCHIAT, V69, P179, DOI 10.1016/j.comppsych.2016.06.001; Haga KK, 2009, NEUROBIOL AGING, V30, P353, DOI 10.1016/j.neurobiolaging.2007.07.005; Harriss DJ, 2015, INT J SPORTS MED, V36, P1121, DOI 10.1055/s-0035-1565186; Hellem T, 2015, J AM PSYCHIAT NURSES, V21, P244, DOI 10.1177/1078390315598606; Hong YJ, 2013, NEUROL SCI, V34, P1215, DOI 10.1007/s10072-012-1225-4; Johnson WM, 2012, NUTRIENTS, V4, P1399, DOI 10.3390/nu4101399; King DA, 2010, SPORTS MED, V40, P163, DOI 10.2165/11319740-000000000-00000; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koerte L. N., 2015, J NEUROTRAUMA; Kreis R, 2004, NMR BIOMED, V17, P361, DOI 10.1002/nbm.891; Larroza A, 2014, NEUROLOGIA, V29, P11, DOI 10.1016/j.nrl.2013.02.002; Lin A, 2012, SEMIN NEUROL, V32, P432, DOI 10.1055/s-0032-1331814; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meyers J., 1995, REY COMPLEX FIGURE T; Mitrushina M., 2005, HDB NORMATIVE DATA N; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Mlynarik V, 2001, NMR BIOMED, V14, P325, DOI 10.1002/nbm.713; Mullins PG, 2008, MAGN RESON MED, V60, P964, DOI 10.1002/mrm.21696; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Psychological Corporation, 2009, ADV CLIN SOL WAIS 4; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Riese F, 2015, NEUROBIOL AGING, V36, P53, DOI 10.1016/j.neurobiolaging.2014.07.030; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Seeger U, 2003, MAGNET RESON MED, V49, P19, DOI 10.1002/mrm.10332; Talairach J., 1988, COPLANAR STEREOTACTI; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Weaver KE, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/610605; Wechsler D., 2008, WECHSLET ADULT INTEL; Zimny A, 2015, J ALZHEIMERS DIS, V44, P329, DOI 10.3233/JAD-132138	51	21	21	0	12	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	MAR	2017	38	3					241	252		10.1055/s-0042-120843			12	Sport Sciences	Sport Sciences	EW5JM	WOS:000402541900009	28192828				2021-06-18	
J	Kaushal, M; Oni-Orisan, A; Chen, G; Li, WJ; Leschke, J; Ward, BD; Kalinosky, B; Budde, MD; Schmit, BD; Li, SJ; Muqeet, V; Kurpad, SN				Kaushal, Mayank; Oni-Orisan, Akinwunmi; Chen, Gang; Li, Wenjun; Leschke, Jack; Ward, B. Douglas; Kalinosky, Benjamin; Budde, Matthew D.; Schmit, Brian D.; Li, Shi-Jiang; Muqeet, Vaishnavi; Kurpad, Shekar N.			Evaluation of Whole-Brain Resting-State Functional Connectivity in Spinal Cord Injury: A Large-Scale Network Analysis Using Network-Based Statistic	JOURNAL OF NEUROTRAUMA			English	Article						neural injury; neuroplasticity; traumatic SCI	REORGANIZATION; MRI; CORTEX; RECOVERY; MONKEYS; STROKE; PAIN	Large-scale network analysis characterizes the brain as a complex network of nodes and edges to evaluate functional connectivity patterns. The utility of graph-based techniques has been demonstrated in an increasing number of restingstate functional MRI (rs-fMRI) studies in the normal and diseased brain. However, to our knowledge, graph theory has not been used to study the reorganization pattern of resting-state brain networks in patients with traumatic complete spinal cord injury (SCI). In the present analysis, we applied a graph-theoretical approach to explore changes to global brain network architecture as a result of SCI. Fifteen subjects with chronic (> 2 years) complete (American Spinal Injury Association [ASIA] A) cervical SCI and 15 neurologically intact controls were scanned using rs-fMRI. The data were preprocessed followed by parcellation of the brain into 116 regions of interest (ROI) or nodes. The average time series was extracted at each node, and correlation analysis was performed between every pair of nodes. A functional connectivity matrix for each subject was then generated. Subsequently, the matrices were averaged across groups, and network changes were evaluated between groups using the network-based statistic (NBS) method. Our results showed decreased connectivity in a subnetwork of the whole brain in SCI compared with control subjects. Upon further examination, increased connectivity was observed in a subnetwork of the sensorimotor cortex and cerebellum network in SCI. In conclusion, our findings emphasize the applicability of NBS to study functional connectivity architecture in diseased brain states. Further, we show reorganization of large-scale resting-state brain networks in traumatic SCI, with potential prognostic and therapeutic implications.	[Kaushal, Mayank; Kalinosky, Benjamin; Schmit, Brian D.] Marquette Univ, Dept Biomed Engn, Milwaukee, WI 53233 USA; [Oni-Orisan, Akinwunmi; Kurpad, Shekar N.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Chen, Gang; Li, Wenjun; Ward, B. Douglas; Budde, Matthew D.; Li, Shi-Jiang] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; [Leschke, Jack] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Muqeet, Vaishnavi] Clement J Zablocki Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Milwaukee, WI USA	Kaushal, M (corresponding author), Marquette Univ, Dept Biomed Engn, Milwaukee, WI 53233 USA.; Oni-Orisan, A (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.	mayank.kaushal@marquette.edu	Kaushal, Mayank/AAK-7667-2020; Li, Shi-Jiang/M-2534-2017; Kurpad, Shekar/V-2188-2019	Kaushal, Mayank/0000-0002-4121-6751; 	Marquette University; Bryon Riesch Paralysis Foundation; Falk Foundation	The authors thank Moriah Iverson, MS, and Judeen Richlen, RN, (research coordination); Dana Seslija, MD, MS, William Waring, MD, and Merle Orr, MD, (patient recruitment support); and Yu Liu, MS (MRI technical support). This study was funded by the Research Administration Committee of the Department of Physical Medicine and Rehabilitation at the Medical College of Wisconsin, Marquette University; Bryon Riesch Paralysis Foundation; and The Falk Foundation.	BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Carter AR, 2010, ANN NEUROL, V67, P365, DOI 10.1002/ana.21905; Castellanos NP, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00090; Chen GY, 2011, BRAIN CONNECT, V1, P195, DOI 10.1089/brain.2011.0025; Choe AS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00290; Cox RW, 1999, MAGNET RESON MED, V42, P1014, DOI 10.1002/(SICI)1522-2594(199912)42:6<1014::AID-MRM4>3.0.CO;2-F; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Hou JM, 2014, NEUROSCIENCE, V277, P446, DOI 10.1016/j.neuroscience.2014.07.045; Liu YO, 2011, J NEUROL SCI, V304, P127, DOI 10.1016/j.jns.2011.01.023; Min YS, 2015, J NEUROTRAUM, V32, P1422, DOI 10.1089/neu.2014.3661; Min YS, 2015, ANN REHABIL MED-ARM, V39, P374, DOI 10.5535/arm.2015.39.3.374; Nardone R, 2013, BRAIN RES, V1504, P58, DOI 10.1016/j.brainres.2012.12.034; Oni-Orisan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150351; Park CH, 2011, STROKE, V42, P1357, DOI 10.1161/STROKEAHA.110.596155; Rao JS, 2016, ACTA PHYSIOL, V217, P164, DOI 10.1111/apha.12645; Rao JS, 2015, MAGN RESON IMAGING, V33, P1156, DOI 10.1016/j.mri.2015.06.011; Rao JS, 2014, MAGN RESON IMAGING, V32, P482, DOI 10.1016/j.mri.2014.02.001; Schwab ME, 1996, PHYSIOL REV, V76, P319; Seminowicz DA, 2012, J NEUROSCI, V32, P15843, DOI 10.1523/JNEUROSCI.2927-12.2012; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wrigley PJ, 2009, PAIN, V141, P52, DOI 10.1016/j.pain.2008.10.007; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	24	21	23	4	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2017	34	6					1278	1282		10.1089/neu.2016.4649			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EN7ZR	WOS:000396221200015	27937140	Green Published			2021-06-18	
J	Massenburg, BB; Veetil, DK; Raykar, NP; Agrawal, A; Roy, N; Gerdin, M				Massenburg, Benjamin B.; Veetil, Deepa K.; Raykar, Nakul P.; Agrawal, Amit; Roy, Nobhojit; Gerdin, Martin			A systematic review of quantitative research on traumatic brain injury in India	NEUROLOGY INDIA			English	Article						India; neurotrauma; TBI; traumatic Brain Injury	MODERATE HEAD-INJURY; GLASGOW COMA SCALE; OUTCOME PREDICTION MODEL; PLACEBO-CONTROLLED TRIAL; DECOMPRESSIVE CRANIECTOMY; INTENSIVE-CARE; INTRACEREBRAL HEMORRHAGE; OXIDATIVE CHANGES; CLINICAL ARTICLE; MILD	Introduction: Over a quarter of the world's trauma deaths occur in India, with traumatic brain injury (TBI) as the leading cause of death and disability within trauma. With little known about TBI in India, we set out to do a systematic review to characterize the quantitative literature on TBI in India. Materials and Methods: The following databases were searched from their inception to December 31, 2015: PubMed, Cochrane, Web of Science, and the World Health Organization's Global Health Library, using the keywords: neurotrauma, brain injury, traumatic brain injury, TBI, head injury, and India. Articles were screened by two independent reviewers, with disagreements arbitrated by discussion or a third reviewer. Results: A total of 72 manuscripts were included, encapsulating 19962 patients over 27 years in 14 states of India. The sample-size-weighted mean age was 31.3 years, male-to-female ratio was 3.8: 1, and sample-size-weighted mean in-hospital mortality was 24.6%. Age and mortality did not change significantly over time. Road traffic accidents (55.5%) and falls (29.2%) were the most commonly reported mechanisms of injury for TBI in India. The mean quality of reporting on TBI in India was 65.7%, according to the appropriate EQUATOR guideline score. Conclusion: The quality of reporting of quantitative studies published on TBI in India is low, and future methodological excellence should be ensured. The demographics and outcomes identified can be used as an epidemiological baseline for future research on TBI in India. Future research can build upon this platform to develop and refine context-appropriate policy recommendations and treatment protocols.	[Massenburg, Benjamin B.] Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA; [Massenburg, Benjamin B.; Raykar, Nakul P.] Harvard Med Sch, Program Global Surg & Social Change, Boston, MA USA; [Massenburg, Benjamin B.; Raykar, Nakul P.] Boston Childrens Hosp, Dept Plast & Oral Surg, Boston, MA USA; [Veetil, Deepa K.; Roy, Nobhojit] Bhabha Atom Res Ctr Hosp, Dept Surg, Mumbai, Maharashtra, India; [Raykar, Nakul P.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; [Agrawal, Amit] Narayana Med Coll Hosp, Dept Surg, Nellore, Andhra Pradesh, India; [Roy, Nobhojit] Tata Inst Social Sci, Sch Habitat, Mumbai, Maharashtra, India; [Roy, Nobhojit; Gerdin, Martin] Karolinska Inst, Dept Publ Hlth Sci, Hlth Syst & Policy, Stockholm, Sweden	Massenburg, BB (corresponding author), 50 E 98th St, New York, NY 10029 USA.	Ben.massenburg@mssm.edu	Agrawal, Amit/C-1511-2011; Massenburg, Benjamin B./AAB-9349-2019; Warnberg, Martin Gerdin/D-7482-2019	Agrawal, Amit/0000-0002-3287-5448; Massenburg, Benjamin B./0000-0002-8570-5178; Warnberg, Martin Gerdin/0000-0001-6069-4794; Roy, Nobhojit/0000-0003-2022-7416			Abraham AP, 2014, NEUROL INDIA, V62, P285, DOI 10.4103/0028-3886.136929; Agarwal Ajay, 1999, Indian Journal of Ophthalmology, V47, P233; Agrawal A, 2012, INDIAN J NEUROTRAUM, V9, P87, DOI 10.1016/j.ijnt.2012.11.001; Agrawal D, 2011, NEUROL INDIA, V59, P91, DOI 10.4103/0028-3886.86551; Agrawal M, 2014, BRAIN INJURY, V28, P292, DOI 10.3109/02699052.2013.865266; Ahmad FU, 2006, NEUROL INDIA, V54, P73; Ahmed M, 2015, BRIT J NEUROSURG, V29, P544, DOI 10.3109/02688697.2015.1016892; Amin AP, 2000, SURGERY, V127, P245, DOI 10.1067/msy.2000.104296; Bhattacharjee S, 2014, J NEUROSURG ANESTH, V26, P313, DOI 10.1097/ANA.0000000000000057; Bhole AM, 2007, PAK J MED SCI, V23, P724; Brooke BS, 2009, ANN SURG, V249, P162, DOI 10.1097/SLA.0b013e31819291f9; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Dalvie S S, 1993, J Postgrad Med, V39, P5; Deepika A, 2013, J HEAD TRAUMA REHAB, V28, P442, DOI 10.1097/HTR.0b013e31825e19e5; Dhandapani M, 2014, J CLIN NURS, V23, P1114, DOI 10.1111/jocn.12396; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Dhandapani S, 2015, WORLD NEUROSURG, V84, P1244, DOI 10.1016/j.wneu.2015.05.058; Dhandapani S, 2014, J CLIN NEUROSCI, V21, P745, DOI 10.1016/j.jocn.2013.07.038; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Francis R, 2015, BRIT J NEUROSURG, V29, P655, DOI 10.3109/02688697.2015.1054349; GARDNER JW, 1960, SCIENCE, V131, P633, DOI 10.1126/science.131.3401.633; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Goel RS, 2008, INJURY, V39, P519, DOI 10.1016/j.injury.2007.09.029; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Harish G, 2015, J NEUROCHEM, V134, P156, DOI 10.1111/jnc.13082; Hopewell S, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4178; Horton R, 2012, LANCET, V380, P2053, DOI DOI 10.1016/S0140-6736(12)62133-3.PUBMED; Hunskaar S, 2009, BMC MED EDUC, V9, DOI 10.1186/1472-6920-9-43; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jain A, 2014, ASIAN J PSYCHIATR, V8, P99, DOI 10.1016/j.ajp.2013.12.017; Jain S, 2008, INJURY, V39, P598, DOI 10.1016/j.injury.2007.06.003; Kannan S, 1999, INTENS CARE MED, V25, P855, DOI 10.1007/s001340050965; Kaushal S., 2000, Indian Journal of Pharmacology, V32, P246; Khan A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132229; Kumar R, 2003, MAGN RESON IMAGING, V21, P893, DOI 10.1016/S0730-725X(03)00189-9; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Menon Anand, 2008, J Forensic Leg Med, V15, P75, DOI 10.1016/j.jflm.2007.06.001; Misra UK, 2003, J NEUROL SCI, V208, P25, DOI 10.1016/S0022-510X(02)00415-X; Mohanty S, 2005, MED SCI LAW, V45, P244, DOI 10.1258/rsmmsl.45.3.244; Mukherjee K, 2000, NEUROL INDIA, V48, P43; Munjal SK, 2010, J TRAUMA, V68, P13, DOI 10.1097/TA.0b013e3181c9f274; Mwita CC, 2016, J NEUROSCI RURAL PRA, V7, P97, DOI 10.4103/0976-3147.165390; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nayak C, 2008, NEUROL RES, V30, P461, DOI 10.1179/016164107X251790; Nayak C, 2007, CLIN CHEM LAB MED, V45, P629, DOI 10.1515/CCLM.2007.123; Nayak CD, 2008, NEUROL INDIA, V56, P31, DOI 10.4103/0028-3886.39309; Ng-Kamstra JS, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2015-000011; Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343; Ozcakir A, 2004, TRAUMACARE, V14, P135; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Pillai SV, 2003, NEUROL INDIA, V51, P361; Pillai SV, 2003, NEUROL INDIA, V51, P345; Prasad GL, 2015, BRAIN INJURY, V29, P1717, DOI 10.3109/02699052.2015.1075146; Prasanna KL, 2015, BRAIN INJURY, V29, P336, DOI 10.3109/02699052.2014.955882; Pruthi N, 2012, INDIAN J MED RES, V136, P1039; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Puvanachandra P., 2009, PAK J NEUROL SCI, V4, P27; Puvanachandra P, 2008, SALUD PUBLICA MEXICO, V50, pS3; Ramesh VG, 2008, J CLIN NEUROSCI, V15, P1110, DOI 10.1016/j.jocn.2007.08.033; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Ratan SK, 2001, CLIN PEDIATR, V40, P375, DOI 10.1177/000992280104000702; Ray S, 2016, CURR MED RES PRACT, V6, P49, DOI DOI 10.1016/J.CMRP.2016.04.002; Reddy RP, 2014, INDIAN J PSYCHOL MED, V36, P40, DOI 10.4103/0253-7176.127246; de Almeida CER, 2016, WORLD NEUROSURG, V87, P540, DOI 10.1016/j.wneu.2015.10.020; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Saika A, 2015, ACTA NEUROCHIR, V157, P1323, DOI 10.1007/s00701-015-2469-6; Salunke P, 2015, J NEUROSURG, V122, P602, DOI 10.3171/2014.10.JNS14780; Santhanam R, 2007, NEUROL INDIA, V55, P349; Shanmukhi S, 2003, NEUROL INDIA, V51, P518; Sharma B, 2014, INT OPHTHALMOL, V34, P893, DOI 10.1007/s10792-014-9898-8; Singh AK, 2014, NEUROL INDIA, V62, P169, DOI 10.4103/0028-3886.132364; Singh M, 2006, NEUROL INDIA, V54, P78; Singh P, 2003, NEUROL INDIA, V51, P215; Singh SB, 2013, RES J PHARM BIOL CHE, V4, P420; Sinha S, 2015, NEUROL INDIA, V63, P175, DOI 10.4103/0028-3886.156277; Sinha S, 2013, NEUROL INDIA, V61, P501, DOI 10.4103/0028-3886.121920; Sitsapesan HA, 2013, WORLD NEUROSURG, V79, P568, DOI 10.1016/j.wneu.2012.09.018; Srinivasan US, 2006, NEUROL INDIA, V54, P28, DOI 10.4103/0028-3886.24698; Suresh HS, 2003, NEUROL INDIA, V51, P16; Tabish A, 2006, INJURY, V37, P410, DOI 10.1016/j.injury.2006.01.039; Tandon A, 2009, ACTA NEUROCHIR, V151, P1411, DOI 10.1007/s00701-009-0444-9; TANDON DA, 1994, CLIN OTOLARYNGOL, V19, P98, DOI 10.1111/j.1365-2273.1994.tb01190.x; Thapa A, 2010, SEIZURE-EUR J EPILEP, V19, P211, DOI 10.1016/j.seizure.2010.02.004; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Tran TM, 2015, WORLD NEUROSURG, V83, P269, DOI 10.1016/j.wneu.2014.12.028; Tripathi M, 2014, NEUROL INDIA, V62, P610, DOI 10.4103/0028-3886.149382; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wani AA, 2011, J NEUROSURG-PEDIATR, V7, P276, DOI 10.3171/2010.12.PEDS10241; World Bank, 2018, RUR POP TOT POP; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109; Yousuf A, 2015, J MOL NEUROSCI, V56, P597, DOI 10.1007/s12031-015-0554-1; Yuan Q, 2012, INJURY, V43, P2094, DOI 10.1016/j.injury.2012.03.028	97	21	22	0	11	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	MAR-APR	2017	65	2					305	314		10.4103/neuroindia.NI_719_16			10	Neurosciences	Neurosciences & Neurology	ER2BH	WOS:000398598400019	28290394				2021-06-18	
J	Randall, D; Thomas, M; Whiting, D; McGrath, A				Randall, Diane; Thomas, Matt; Whiting, Diane; McGrath, Andrew			Depression Anxiety Stress Scales (DASS-21): Factor Structure in Traumatic Brain Injury Rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety; confirmatory factor analysis; construct validity; depression; Depression Anxiety Stress Scales (DASS-21); structural equation modeling; traumatic brain injury	CONCUSSION SYMPTOMS QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES; NORMATIVE DATA; PSYCHIATRIC-DISORDERS; HOSPITAL ANXIETY; PERCENTILE NORMS; FIT INDEXES; INDIVIDUALS; VALIDITY; VERSION	Objective: To confirm the construct validity of the Depression Anxiety Stress Scales-21 (DASS-21) by investigating the fit of published factor structures in a sample of adults with moderate to severe traumatic brain injury (posttraumatic amnesia > 24 hours). Participants: Archival data from 504 patient records at the Brain Injury Rehabilitation Unit at Liverpool Hospital, Australia. Participants were aged between 16 and 71 years and were engaged in a specialist rehabilitation program. Main Measure: The DASS-21. Results: Two of the 6 models had adequate fit using structural equation modeling. The data best fit Henry and Crawford's quadripartite model, which comprised a Depression, Anxiety and Stress factor, as well as a General Distress factor. The data also adequately fit Lovibond and Lovibond's original 3-factor model, and the internal consistencies of each factor were very good (alpha = 0.82-0.90). Conclusion: This study confirms the structure and construct validity of the DASS-21 and provides support for its use as a screening tool in traumatic brain injury rehabilitation.	[Randall, Diane; Thomas, Matt; McGrath, Andrew] Charles Sturt Univ, Bathurst, NSW, Australia; [Whiting, Diane] Ingham Inst Appl Med Res, Brain Injury Rehabil Res Grp, Liverpool, Australia	Thomas, M (corresponding author), Charles Sturt Univ, Bathurst, NSW, Australia.	mathomas@csu.edu.au	Whiting, Diane/AAN-2522-2021; McGrath, Andrew/AAJ-1648-2020	McGrath, Andrew/0000-0001-9249-0219; Whiting, Diane/0000-0003-1912-6626			AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Educational Research Association, 2014, STAND ED PSYCH TEST; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Arbuckle JL., 2010, IBM SPSS AMOS 19 USE; Australian Bureau of Statistics, 2007, NAT SURV MENT HLTH W; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Beck AT., 1996, BECK DEPRESSION INVE, V2; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bottesi G, 2015, COMPR PSYCHIAT, V60, P170, DOI 10.1016/j.comppsych.2015.04.005; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Browne M. W., 1992, SOCIOL METHOD RES, V21, P136; Byrne B. M, 2013, STRUCTURAL EQUATION; Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5; Clara IP, 2001, J PSYCHOPATHOL BEHAV, V23, P61, DOI 10.1023/A:1011095624717; Crawford J, 2011, AUST PSYCHOL, V46, P3, DOI 10.1111/j.1742-9544.2010.00003.x; Crawford JR, 2009, BRIT J CLIN PSYCHOL, V48, P163, DOI 10.1348/014466508X377757; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Daza P, 2002, J PSYCHOPATHOL BEHAV, V24, P195, DOI 10.1023/A:1016014818163; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Finney SJ, 2006, QUANT METH EDUC BEHA, P269; First MB, 2002, COMMUNICATION; Fortune N, 1999, DEFINITION INCIDENCE; Gloster AT, 2011, PSYCHOL ASSESSMENT, V23, P970, DOI 10.1037/a0024135; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Helps Y., 2008, HOSP SEPARATIONS DUE; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hillier SL, 1997, BRAIN INJURY, V11, P649; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Joreskog K.G., 1981, ANAL LINEAR STRUCTUR; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kline R.B., 2009, BECOMING BEHAV SCI R; Linhart H, 1986, MODEL SELECTION, V27; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ORance L., 2007, DISABILITY AUSTR ACQ; Osman A, 2012, J CLIN PSYCHOL, V68, P1322, DOI 10.1002/jclp.21908; Ownsworth T, 2008, BRAIN INJURY, V22, P858, DOI 10.1080/02699050802446697; Ownsworth T, 2011, J INT NEUROPSYCH SOC, V17, P112, DOI 10.1017/S1355617710001311; Ponsford J., 2013, TRAUMATIC BRAIN INJU; Psychology Foundation of Australia, 2016, DEPR ANX STRESS SCAL; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Schumacker R. E., 2010, BEGINNERS GUIDE STRU; Sinclair SJ, 2012, EVAL HEALTH PROF, V35, P259, DOI 10.1177/0163278711424282; Skilbeck C, 2011, BRAIN IMPAIR, V12, P22, DOI 10.1375/brim.12.1.22; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; Szabo M, 2010, J ADOLESCENCE, V33, P1, DOI 10.1016/j.adolescence.2009.05.014; Tabachnick B.G., 2013, USING MULTIVARIATE S; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Tully PJ, 2009, J ABNORM CHILD PSYCH, V37, P717, DOI 10.1007/s10802-009-9306-4; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Ullman JB, 2013, USING MULIVARIATE ST; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; West S.G., 1995, STRUCTURAL EQUATION, P56; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wong D, 2013, BRAIN INJURY, V27, P1377, DOI 10.3109/02699052.2013.823662	66	21	22	3	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2017	32	2					134	144		10.1097/HTR.0000000000000250			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EN3YU	WOS:000395944700015	27455437				2021-06-18	
J	Peron, S; Droguerre, M; Debarbieux, F; Ballout, N; Benoit-Marand, M; Francheteau, M; Brot, S; Rougon, G; Jaber, M; Gaillard, A				Peron, Sophie; Droguerre, Marine; Debarbieux, Franck; Ballout, Nissrine; Benoit-Marand, Marianne; Francheteau, Maureen; Brot, Sebastien; Rougon, Genevieve; Jaber, Mohamed; Gaillard, Afsaneh			A Delay between Motor Cortex Lesions and Neuronal Transplantation Enhances Graft Integration and Improves Repair and Recovery	JOURNAL OF NEUROSCIENCE			English	Article						cortical injury; delay; functional recovery; neuroanatomical repair; transplantation	EMBRYONIC STEM-CELLS; SCANNING-ELECTRON-MICROSCOPE; ENDOTHELIAL GROWTH-FACTOR; FRONTAL-CORTEX; SPINAL-CORD; CORTICAL-NEURONS; CEREBRAL-CORTEX; FORELIMB MOVEMENTS; STAIRCASE TEST; ADULT-RATS	We previously reported that embryonic motor cortical neurons transplanted immediately after lesions in the adult mouse motor cortex restored damaged motor cortical pathways. A critical barrier hindering the application of transplantation strategies for a wide range of traumatic injuries is the determination of a suitable time window for therapeutic intervention. Here, we report that a 1 week delay between the lesion and transplantation significantly enhances graft vascularization, survival, and proliferation of grafted cells. More importantly, the delay dramatically increases the density of projections developed by grafted neurons and improves functional repair and recovery as assessed by intravital dynamic imaging and behavioral tests. These findings open new avenues in cell transplantation strategies as they indicate successful brain repair may occur following delayed transplantation.	[Peron, Sophie; Droguerre, Marine; Ballout, Nissrine; Benoit-Marand, Marianne; Francheteau, Maureen; Brot, Sebastien; Jaber, Mohamed; Gaillard, Afsaneh] Univ Poitiers, Cellular Therapies Brain Dis Grp, Expt & Clin Neurosci Lab, IINSERM,U1084, 1 Rue Georges Bonnet,BP 633, F-86022 Poitiers, France; [Peron, Sophie; Droguerre, Marine; Ballout, Nissrine; Benoit-Marand, Marianne; Francheteau, Maureen; Brot, Sebastien; Jaber, Mohamed; Gaillard, Afsaneh] Univ Poitiers, U1084, F-86073 Poitiers, France; [Debarbieux, Franck; Rougon, Genevieve] Fac Med Marseille, Inst Neurosci Timone, CNRS, UMR 7289,ImaPath, F-13005 Marseille, France; [Debarbieux, Franck; Rougon, Genevieve] Aix Marseille Univ, F-13284 Marseille 07, France; [Jaber, Mohamed] CHU Poitiers, F-86021 Poitiers, France	Gaillard, A (corresponding author), Univ Poitiers, Cellular Therapies Brain Dis Grp, Expt & Clin Neurosci Lab, IINSERM,U1084, 1 Rue Georges Bonnet,BP 633, F-86022 Poitiers, France.	afsaneh.gaillard@univ-poitiers.fr	BALLOUT, Nissrine/ABG-2754-2020	Peron, Sophie/0000-0002-7167-4585; Droguerre, Marine/0000-0002-3570-0635; Jaber, Mohamed/0000-0003-2536-1913; BROT, Sebastien/0000-0002-4373-2135; Benoit-Marand, Marianne/0000-0002-1380-5401; ROUGON, Genevieve/0000-0003-1316-8200	Institut pour la Recherche sur la Moelle Epiniere et l'Encephale (IRME); Fonds Europeen de Developpement Regional (FEDER)European Commission [33552]; Contrat de Plan Etat-region (CPER 5); Agence Nationale de la Recherche (ANR)French National Research Agency (ANR)	This work was funded by grants from the Institut pour la Recherche sur la Moelle Epiniere et l'Encephale (IRME), Fonds Europeen de Developpement Regional (FEDER) No 33552 and Contrat de Plan Etat-region (CPER 5) to A.G. and Agence Nationale de la Recherche (ANR) to F.D. We thank the staff of Image'UP platform (University of Poitiers).	[Anonymous], BRAIN RES; [Anonymous], NATURE; Baird AL, 2001, BRAIN RES BULL, V54, P243, DOI 10.1016/S0361-9230(00)00457-3; Ballout N, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00055; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Bessert DA, 1999, J HISTOCHEM CYTOCHEM, V47, P693, DOI 10.1177/002215549904700511; Bouet V, 2007, EXP NEUROL, V203, P555; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Casper D, 2003, EXP NEUROL, V184, P785, DOI 10.1016/S0014-4886(03)00336-4; Chen YJ, 2016, CELL STEM CELL, V18, P817, DOI 10.1016/j.stem.2016.03.014; EBRAHIMIGAILLARD A, 1995, NEUROSCIENCE, V64, P49, DOI 10.1016/0306-4522(94)00396-M; Falkner S, 2016, NATURE, V539, P248, DOI 10.1038/nature20113; Fenrich KK, 2012, J PHYSIOL-LONDON, V590, P3665, DOI 10.1113/jphysiol.2012.230532; FINGER S, 1989, EXP NEUROL, V104, P1, DOI 10.1016/0014-4886(89)90001-0; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Gaillard A, 2000, CEREB CORTEX, V10, P443, DOI 10.1093/cercor/10.5.443; Gaillard A, 1998, ADV ANAT EMBRYOL CEL, V148, P1; Gaillard A, 2007, NAT NEUROSCI, V10, P1294, DOI 10.1038/nn1970; Gaillard A, 2011, TRENDS NEUROSCI, V34, P124, DOI 10.1016/j.tins.2011.01.003; Gaillard A, 2007, CELL ADHES MIGR, V1, P161, DOI 10.4161/cam.1.4.5274; Gaillard A, 2009, NEUROBIOL DIS, V35, P477, DOI 10.1016/j.nbd.2009.07.003; Gaillard F, 2004, NEUROSCIENCE, V126, P631, DOI 10.1016/j.neuroscience.2004.04.011; Gaspard N, 2008, NATURE, V455, P351, DOI 10.1038/nature07287; Gaspard N, 2009, CELL CYCLE, V8, P2491, DOI 10.4161/cc.8.16.9276; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Glock C., 2015, NAT NEUROSCI, V18; Harris NG, 2010, J NEUROTRAUM, V27, P1971, DOI 10.1089/neu.2010.1470; KESSLAK JP, 1986, EXP NEUROL, V94, P615, DOI 10.1016/0014-4886(86)90241-4; KOLB B, 1988, BEHAV NEURAL BIOL, V50, P193, DOI 10.1016/S0163-1047(88)90881-3; KOLB B, 1994, BRAIN RES, V647, P15, DOI 10.1016/0006-8993(94)91393-5; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Lu P, 2012, CELL, V150, P1264, DOI 10.1016/j.cell.2012.08.020; MANTHORPE M, 1983, BRAIN RES, V267, P47, DOI 10.1016/0006-8993(83)91038-7; MAYER E, 1992, EUR J NEUROSCI, V4, P119, DOI 10.1111/j.1460-9568.1992.tb00858.x; Michelsen KA, 2015, NEURON, V85, P982, DOI 10.1016/j.neuron.2015.02.001; MIYOSHI Y, 1995, BRAIN RES, V681, P131, DOI 10.1016/0006-8993(95)00304-9; MIYOSHI Y, 1995, EXP NEUROL, V131, P69, DOI 10.1016/0014-4886(95)90009-8; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nag S, 2002, J NEUROPATH EXP NEUR, V61, P778, DOI 10.1093/jnen/61.9.778; NEAFSEY EJ, 1989, BRAIN RES, V493, P33, DOI 10.1016/0006-8993(89)90997-9; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Olson L, 1982, ADV CELLULAR NEUROBI, V4, P407; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Pinaudeau C, 2000, EUR J NEUROSCI, V12, P2486, DOI 10.1046/j.1460-9568.2000.00148.x; PLUMET J, 1993, RESTOR NEUROL NEUROS, V6, P9, DOI 10.3233/RNN-1993-6102; Riolobos AS, 2001, NEUROBIOL LEARN MEM, V75, P274, DOI 10.1006/nlme.2000.3979; Roome RB, 2014, J NEUROSCI METH, V233, P34, DOI 10.1016/j.jneumeth.2014.05.014; Santos-Torres J, 2009, J NEUROTRAUM, V26, P1593, DOI 10.1089/neu.2008.0702; Senatorov VV, 1991, J NEURAL TRANSPLANT, V2, P125; Skold MK, 2005, J NEUROTRAUMA, V22, P353; Teng H, 2008, J CEREBR BLOOD F MET, V28, P764, DOI 10.1038/sj.jcbfm.9600573; Thompson LH, 2009, EUR J NEUROSCI, V30, P625, DOI 10.1111/j.1460-9568.2009.06878.x; Ueno M, 2011, EXP NEUROL, V230, P280, DOI 10.1016/j.expneurol.2011.05.006; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0	57	21	21	2	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 15	2017	37	7					1820	1834		10.1523/JNEUROSCI.2936-16.2017			15	Neurosciences	Neurosciences & Neurology	EL2DU	WOS:000394431100015	28087762	Bronze, Green Published			2021-06-18	
J	Joseph, B; Azim, A; Haider, AA; Kulvatunyou, N; O'Keeffe, T; Hassan, A; Gries, L; Tran, E; Latifi, R; Rhee, P				Joseph, Bellal; Azim, Asad; Haider, Ansab A.; Kulvatunyou, Narong; O'Keeffe, Terence; Hassan, Ahmed; Gries, Lynn; Tran, Emily; Latifi, Rifat; Rhee, Peter			Bicycle helmets work when it matters the most	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	101st Annual Clinical Congress Scientific Forum of the American-College-of-Surgeons (ACS)	OCT 04-10, 2015	Chicago, IL	Amer Coll Surg		Bicycle; Helmets; Facial fracture; Head injury	SAFETY HELMETS; HEAD-INJURY; FACIAL INJURY; LEGISLATION; PREVENTION; SEVERITY	BACKGROUND: Helmets are known to reduce the incidence of traumatic brain injury (TBI) after bicycle-related accidents. The aim of this study was to assess the association of helmets with severity of TBI and facial fractures after bicycle-related accidents. METHODS: We performed an analysis of the 2012 National Trauma Data Bank abstracted information of all patients with an intracranial hemorrhage after bicycle-related accidents. Regression analysis was also performed. RESULTS: A total of 6,267 patients were included. About 25.1% (n = 1,573) of bicycle riders were helmeted. Overall, 52.4% (n = 3,284) of the patients had severe TBI, and the mortality rate was 2.8% (n = 176). Helmeted bicycle riders had 51% reduced odds of severe TBI (odds ratio [OR].49, 95% confidence interval [CI] .43 to .55, P < .001) and 44% reduced odds of mortality (OR .56, 95% CI .34 to .78, P < .010). Helmet use also reduced the odds of facial fractures by 31% (OR .69, 95% CI .58 to .81, P < .001). CONCLUSION: Bicycle helmet use provides protection against severe TBI, reduces facial fractures, and saves lives even after sustaining an intracranial hemorrhage. (C) 2016 Elsevier Inc. All rights reserved.	[Joseph, Bellal; Azim, Asad; Haider, Ansab A.; Kulvatunyou, Narong; O'Keeffe, Terence; Hassan, Ahmed; Gries, Lynn; Tran, Emily; Latifi, Rifat; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Tucson, AZ 85721 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Tucson, AZ 85721 USA.	bjoseph@surgery.arizona.edu	Hassan, Ahmed/AAB-7241-2019				Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crompton JG, 2012, ARCH SURG-CHICAGO, V147, P674, DOI 10.1001/archsurg.2012.894; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; Hemmila MR, 2007, SURGERY, V142, P439, DOI 10.1016/j.surg.2007.07.002; Joseph B, 2014, EUR J TRAUMA EMERG S, V40, P729, DOI 10.1007/s00068-014-0453-0; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; MCDERMOTT FT, 1995, ANN ROY COLL SURG, V77, P38; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; Moore L, 2009, J AM COLL SURGEONS, V209, P572, DOI 10.1016/j.jamcollsurg.2009.07.004; Rivara FP, 1998, ANNU REV PUBL HEALTH, V19, P293, DOI 10.1146/annurev.publhealth.19.1.293; Schulman J, 2002, INJ PREV, V8, P47, DOI 10.1136/ip.8.1.47; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001855; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101	18	21	22	0	9	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	FEB	2017	213	2					413	417		10.1016/j.amjsurg.2016.05.021			5	Surgery	Surgery	EQ3KH	WOS:000397970400034	27596799				2021-06-18	
J	Sawant-Pokam, PM; Suryavanshi, P; Mendez, JM; Dudek, FE; Brennan, KC				Sawant-Pokam, P. M.; Suryavanshi, P.; Mendez, J. M.; Dudek, F. E.; Brennan, K. C.			Mechanisms of Neuronal Silencing After Cortical Spreading Depression	CEREBRAL CORTEX			English	Article						cortical spreading depression; excitation inhibition balance; somatosensory; whole-cell recording	RAT HIPPOCAMPAL SLICES; LONG-TERM POTENTIATION; INHIBITORY SYNAPTIC-TRANSMISSION; WHOLE-CELL PATCH; PYRAMIDAL CELLS; CEREBRAL-CORTEX; NEOCORTICAL NEURONS; RECEPTOR ACTIVATION; BARREL CORTEX; IN-VIVO	Cortical spreading depression (CSD) is associated with migraine, stroke, and traumatic brain injury, but its mechanisms remain poorly understood. One of the major features of CSD is an hour-long silencing of neuronal activity. Though this silencing has clear ramifications for CSD-associated disease, it has not been fully explained. We used in vivo whole-cell recordings to examine the effects of CSD on layer 2/3 pyramidal neurons in mouse somatosensory cortex and used in vitro recordings to examine their mechanism. We found that CSD caused a reduction in spontaneous synaptic activity and action potential (AP) firing that lasted over an hour. Both pre-and postsynaptic mechanisms contributed to this silencing. Reductions in frequency of postsynaptic potentials were due to a reduction in presynaptic transmitter release probability as well as reduced AP activity. Decreases in postsynaptic potential amplitudewere due to an inhibitory shift in the ratio of excitatory and inhibitory postsynaptic currents. This inhibitory shift in turn contributed to the reduced frequency of APs. Thus, distinct but complementary mechanisms generate the long neuronal silence that follows CSD. These cellular changes could contribute to wider network dysfunction in CSD-associated disease, while the pre-and postsynaptic mechanisms offer separate targets for therapy.	[Sawant-Pokam, P. M.; Suryavanshi, P.; Mendez, J. M.; Brennan, K. C.] Univ Utah, Sch Med, Dept Neurol, 383 Colorow Dr, Salt Lake City, UT 84108 USA; [Dudek, F. E.] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA	Brennan, KC (corresponding author), Univ Utah, Sch Med, Dept Neurol, 383 Colorow Dr, Salt Lake City, UT 84108 USA.	k.c.brennan@hsc.utah.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS085413, R21 NS083010]; Department of DefenseUnited States Department of Defense [CDMRP PR 100060, PR 130373]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS085413] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health (R01 NS085413, R21 NS083010) and the Department of Defense (CDMRP PR 100060, PR 130373).	Aiba I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110849; Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Alle H, 2009, SCIENCE, V325, P1405, DOI 10.1126/science.1174331; Atwood BK, 2014, TRENDS NEUROSCI, V37, P663, DOI 10.1016/j.tins.2014.07.010; Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; BERNANDER O, 1994, J NEUROPHYSIOL, V72, P2743; Brecht M, 2003, J PHYSIOL-LONDON, V553, P243, DOI 10.1113/jphysiol.2003.044222; CALABRESI P, 1995, J CEREBR BLOOD F MET, V15, P1141, DOI 10.1038/jcbfm.1995.142; Cao Y, 1999, ARCH NEUROL-CHICAGO, V56, P548, DOI 10.1001/archneur.56.5.548; Castillo PE, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005728; Chang JC, 2010, BRAIN, V133, P996, DOI 10.1093/brain/awp338; Chevaleyre V, 2006, ANNU REV NEUROSCI, V29, P37, DOI 10.1146/annurev.neuro.29.051605.112834; CZEH G, 1993, BRAIN RES, V632, P195, DOI 10.1016/0006-8993(93)91154-K; De PM, 2015, NEUROSCIENCE, DOI [doi:10.1016/j.neuroscience.2015.04.001., DOI 10.1016/J.NEUROSCIENCE.2015.04.001]; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; El-Hussein AE, 2000, SCIENCE, V290, P1364; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Forti L, 1997, NATURE, V388, P874, DOI 10.1038/42251; FRERKING M, 1995, NEURON, V15, P885, DOI 10.1016/0896-6273(95)90179-5; Gao BX, 1998, J NEUROPHYSIOL, V79, P2277; Ghadiri MK, 2012, CEPHALALGIA, V32, P116, DOI 10.1177/0333102411431308; Gniel HM, 2010, J NEUROPHYSIOL, V104, P3203, DOI 10.1152/jn.00922.2009; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Halabisky B, 2010, J NEUROPHYSIOL, V104, P2214, DOI 10.1152/jn.00147.2010; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Haydon PG, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020438; Heifets BD, 2009, ANNU REV PHYSIOL, V71, P283, DOI 10.1146/annurev.physiol.010908.163149; HERRERAS O, 1993, BRAIN RES, V610, P276, DOI 10.1016/0006-8993(93)91411-K; HIGASHIDA H, 1974, BRAIN RES, V65, P411, DOI 10.1016/0006-8993(74)90232-7; Hille B., 2001, ION CHANNELS EXCITAB; Hughes S, 2013, NAT NEUROSCI, V16, P115, DOI 10.1038/nn.3313; Jia YS, 2010, J NEUROSCI, V30, P14440, DOI 10.1523/JNEUROSCI.3310-10.2010; JING J, 1991, BRAIN RES, V557, P177, DOI 10.1016/0006-8993(91)90132-F; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Jones MV, 1997, J NEUROSCI, V17, P7626; KAKU T, 1994, BRAIN RES, V658, P39, DOI 10.1016/S0006-8993(09)90008-7; Karmazinova M, 2010, PHYSIOL RES, V59, pS1, DOI 10.33549/physiolres.932000; Kawahara N, 1997, NEUROSCI RES, V29, P37, DOI 10.1016/S0168-0102(97)00069-2; Kazemi H, 2012, IRAN J BASIC MED SCI, V15, P926; Kerchner GA, 2008, NAT REV NEUROSCI, V9, P813, DOI 10.1038/nrn2501; Kitamura K, 2008, NAT METHODS, V5, P61, DOI 10.1038/NMETH1150; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Laviv T, 2010, NEURON, V67, P253, DOI 10.1016/j.neuron.2010.06.022; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; Lemieux M, 2015, J NEUROPHYSIOL, V113, P768, DOI 10.1152/jn.00858.2013; Li WC, 2004, J NEUROPHYSIOL, V92, P380, DOI 10.1152/jn.01238.2003; Lindquist BE, 2012, NEUROSCIENCE, V223, P365, DOI 10.1016/j.neuroscience.2012.07.053; Lindquist BE, 2014, J CEREBR BLOOD F MET, V34, P1779, DOI 10.1038/jcbfm.2014.146; Lisman JE, 2007, NAT REV NEUROSCI, V8, P597, DOI 10.1038/nrn2191; Liu GS, 1999, NEURON, V22, P395, DOI 10.1016/S0896-6273(00)81099-5; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; MARSHALL WH, 1959, PHYSIOL REV, V39, P239; McAllister SD, 2002, PROSTAG LEUKOTR ESS, V66, P161, DOI 10.1054/plef.2001.0344; McCormick DA, 2003, CEREB CORTEX, V13, P1219, DOI 10.1093/cercor/bhg104; MODY I, 1987, J NEUROPHYSIOL, V57, P869; Moore CI, 1998, J NEUROPHYSIOL, V80, P2882; Muller M, 2000, J NEUROPHYSIOL, V84, P1869, DOI 10.1152/jn.2000.84.4.1869; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; Petersen CCH, 2003, P NATL ACAD SCI USA, V100, P13638, DOI 10.1073/pnas.2235811100; Pietrobon D, 2013, ANNU REV PHYSIOL, V75, P365, DOI 10.1146/annurev-physiol-030212-183717; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Postlethwaite M, 2007, J PHYSIOL-LONDON, V579, P69, DOI 10.1113/jphysiol.2006.123612; PRINCE DA, 1992, P NATL ACAD SCI USA, V89, P8586, DOI 10.1073/pnas.89.18.8586; Raghavachari S, 2004, J NEUROPHYSIOL, V92, P2456, DOI 10.1152/jn.00258.2004; Rizzoli SO, 2005, NAT REV NEUROSCI, V6, P57, DOI 10.1038/nrn1583; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; Scheckenbach KEL, 2006, EXP NEUROL, V202, P449, DOI 10.1016/j.expneurol.2006.07.007; Shepherd JD, 2007, ANNU REV CELL DEV BI, V23, P613, DOI 10.1146/annurev.cellbio.23.090506.123516; SNOW RW, 1983, J NEUROPHYSIOL, V50, P561; Somjen GG, 2001, PHYSIOL REV, V81, P1065; SPRUSTON N, 1992, J NEUROPHYSIOL, V67, P508; Steriade M, 2006, NEUROSCIENCE, V137, P1087, DOI 10.1016/j.neuroscience.2005.10.029; Steriade M, 1997, CEREB CORTEX, V7, P583, DOI 10.1093/cercor/7.6.583; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Theriot JJ, 2012, J NEUROSCI, V32, P15252, DOI 10.1523/JNEUROSCI.2092-12.2012; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; Timofeev I, 2000, J PHYSIOLOGY-PARIS, V94, P343, DOI 10.1016/S0928-4257(00)01097-4; Tottene A, 2009, NEURON, V61, P762, DOI 10.1016/j.neuron.2009.01.027; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Turrigiano G, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005736; ULRICH D, 1993, J NEUROPHYSIOL, V69, P1769; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wei YN, 2014, J NEUROSCI, V34, P11733, DOI 10.1523/JNEUROSCI.0516-14.2014; Wilson Charles, 2008, Scholarpedia J, V3, P1410; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; YAWO H, 1993, NATURE, V365, P256, DOI 10.1038/365256a0; YOON KW, 1991, J NEUROSCI, V11, P1375; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113; Zhu JJ, 1999, J NEUROPHYSIOL, V81, P1171	104	21	22	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	FEB	2017	27	2					1311	1325		10.1093/cercor/bhv328			15	Neurosciences	Neurosciences & Neurology	EP3BN	WOS:000397257600033	26733536	Green Published, Bronze			2021-06-18	
J	Nitkiewicz, J; Borjabad, A; Morgello, S; Murray, J; Chao, W; Emdad, L; Fisher, PB; Potash, MJ; Volsky, DJ				Nitkiewicz, Jadwiga; Borjabad, Alejandra; Morgello, Susan; Murray, Jacinta; Chao, Wei; Emdad, Luni; Fisher, Paul B.; Potash, Mary Jane; Volsky, David J.			HIV induces expression of complement component C3 in astrocytes by NF-kappa B-dependent activation of interleukin-6 synthesis	JOURNAL OF NEUROINFLAMMATION			English	Article						HIV; HAND; Complement component C3; Astrocytes; IL-6; Neurodegeneration; NF-kappa B; HIV-associated dementia; Brain tissue	HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; SIV-INFECTED MONKEYS; NEUROCOGNITIVE DISORDERS; PRODUCTIVE INFECTION; ALZHEIMERS-DISEASE; GENE-EXPRESSION; MICROGLIA; MICE	Background: Abnormal activation of the complement system contributes to some central nervous system diseases but the role of complement in HIV-associated neurocognitive disorder (HAND) is unclear. Methods: We used real-time PCR and immunohistochemistry to detect complement expression in postmortem brain tissue from HAND patients and controls. To further investigate the basis for viral induction of gene expression in the brain, we studied the effect of HIV on C3 expression by astrocytes, innate immune effector cells, and targets of HIV. Human fetal astrocytes (HFA) were infected with HIV in culture and cellular pathways and factors involved in signaling to C3 expression were elucidated using pharmacological pathway inhibitors, antisense RNA, promoter mutational analysis, and fluorescence microscopy. Results: We found significantly increased expression of complement components including C3 in brain tissues from patients with HAND and C3 was identified by immunocytochemistry in astrocytes and neurons. Exposure of HFA to HIV in culture-induced C3 promoter activity, mRNA expression, and protein production. Use of pharmacological inhibitors indicated that induction of C3 expression by HIV requires NF-kappa B and protein kinase signaling. The relevance of NF-kappa B regulation to C3 induction was confirmed through detection of NF-kappa B translocation into nuclei and inhibition through overexpression of the physiological NF-kappa B inhibitor, I-kappa B alpha. C3 promoter mutation analysis revealed that the NF-kappa B and SP binding sites are dispensable for the induction by HIV, while the proximal IL-1 beta/IL-6 responsive element is essential. HIV-treated HFA secreted IL-6, exogenous IL-6 activated the C3 promoter, and anti-IL-6 antibodies blocked HIV activation of the C3 promoter. The activation of IL-6 transcription by HIV was dependent upon an NF-kappa B element within the IL-6 promoter. Conclusions: These results suggest that HIV activates C3 expression in primary astrocytes indirectly, through NF-kappa B-dependent induction of IL-6, which in turn activates the C3 promoter. HIV induction of C3 and IL-6 in astrocytes may contribute to HIV-mediated inflammation in the brain and cognitive dysfunction.	[Nitkiewicz, Jadwiga; Borjabad, Alejandra; Chao, Wei; Potash, Mary Jane; Volsky, David J.] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA; [Morgello, Susan; Murray, Jacinta] Icahn Sch Med Mt Sinai, Dept Neurol, Manhattan HIV Brain Bank, New York, NY 10029 USA; [Emdad, Luni; Fisher, Paul B.] Virginia Commonwealth Univ, Dept Human & Mol Genet, VCU Massey Canc Ctr, Sch Med,VCU Inst Mol Med, Richmond, VA 23298 USA; [Nitkiewicz, Jadwiga] PSI CRO, Wisniowy Business Pk C,1 Sierpnia 6A, PL-02134 Warsaw, Poland; [Volsky, David J.] Dept Med, Div Infect Dis, 1468 Madison Ave,Annenberg Bldg,21st Floor, New York, NY 10029 USA	Volsky, DJ (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.; Volsky, DJ (corresponding author), Dept Med, Div Infect Dis, 1468 Madison Ave,Annenberg Bldg,21st Floor, New York, NY 10029 USA.	David.Volsky@mssm.edu			PHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R21 MH 086372, R01 MH 083627, R01 DA 017618, R01 DA 037611, R01 MH 104145, U01 MH 100931]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH104145, R01MH083627, U24MH100931, R21MH086372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA017618, R01DA037611] Funding Source: NIH RePORTER	Funding was supplied by PHS grants to DJV: R21 MH 086372, R01 MH 083627, R01 DA 017618, R01 DA 037611, R01 MH 104145 and to SM: U01 MH 100931.	Abassi M, 2017, J NEUROVIROL, V23, P369, DOI 10.1007/s13365-016-0505-9; ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Baccam M, 2003, J IMMUNOL, V170, P3099, DOI 10.4049/jimmunol.170.6.3099; Barnum SR, 1996, GLIA, V18, P107, DOI 10.1002/(SICI)1098-1136(199610)18:2<107::AID-GLIA3>3.0.CO;2-Y; Blatteis CM, 2004, FRONT BIOSCI-LANDMRK, V9, P915, DOI 10.2741/1297; Borjabad A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002213; Brouillette MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155766; Bruder C, 2004, MOL IMMUNOL, V40, P949, DOI 10.1016/j.molimm.2003.10.016; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; Chaudhuri A, 2008, BLOOD, V111, P2062, DOI 10.1182/blood-2007-05-091207; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chu YX, 2010, P NATL ACAD SCI USA, V107, P7975, DOI 10.1073/pnas.0913449107; Clements JE, 2002, J INFECT DIS, V186, P905, DOI 10.1086/343768; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; Depboylu C, 2005, NEUROBIOL DIS, V20, P12, DOI 10.1016/j.nbd.2005.01.030; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fitting S, 2010, J PROTEOME RES, V9, P1795, DOI 10.1021/pr900926n; Harezlak J, 2011, AIDS, V25, P625, DOI 10.1097/QAD.0b013e3283427da7; Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Hong S, 2016, CURR OPIN NEUROBIOL, V36, P128, DOI 10.1016/j.conb.2015.12.004; Hong SZ, 2015, BRAIN BEHAV IMMUN, V45, P1, DOI 10.1016/j.bbi.2014.10.008; Hu WT, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0277-8; Jongen PJH, 2000, ACTA NEUROL SCAND, V101, P116, DOI 10.1034/j.1600-0404.2000.101002116.x; Kamat A, 2012, JAIDS-J ACQ IMM DEF, V60, P234, DOI 10.1097/QAI.0b013e318256f3bc; Kim SY, 2003, J NEUROCHEM, V86, P1458, DOI 10.1046/j.1471-4159.2003.01958.x; Kim SY, 2004, J NEUROIMMUNOL, V157, P17, DOI 10.1016/j.jneuroim.2004.08.032; Komotar RJ, 2008, ADV EXP MED BIOL, V632, P23, DOI 10.1007/978-0-387-78952-1_2; Li JL, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-31; Lian H, 2016, J NEUROSCI, V36, P577, DOI 10.1523/JNEUROSCI.2117-15.2016; Liu FM, 2014, J NEUROVIROL, V20, P184, DOI 10.1007/s13365-014-0243-9; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Mankowski JL, 2004, J NEUROIMMUNOL, V157, P66, DOI 10.1016/j.jneuroim.2004.08.031; Mastellos DC, 2016, IMMUNOBIOLOGY, V221, P1046, DOI 10.1016/j.imbio.2016.06.013; Mateen FJ, 2012, NEUROLOGY, V79, P1873, DOI 10.1212/WNL.0b013e318271f7b8; Mayilyan KR, 2008, DRUG NEWS PERSPECT, V21, P200, DOI 10.1358/dnp.2008.21.4.1213349; Michailidou I, 2015, ANN NEUROL, V77, P1007, DOI 10.1002/ana.24398; Morgan BP, 2015, EXPERT REV CLIN IMMU, V11, P1109, DOI 10.1586/1744666X.2015.1074039; Nookala AR, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0214-3; Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Pendyala G, 2009, J PROTEOME RES, V8, P2253, DOI 10.1021/pr800854t; Potash MJ, 2005, P NATL ACAD SCI USA, V102, P3760, DOI 10.1073/pnas.0500649102; Price RW, 2014, SEMIN NEUROL, V34, P7, DOI 10.1055/s-0034-1372337; Quintana A, 2007, NEUROIMMUNOMODULAT, V14, P139, DOI 10.1159/000110637; REBOUL J, 1989, J NEUROL SCI, V89, P243, DOI 10.1016/0022-510X(89)90026-9; Roberts ES, 2004, J NEUROIMMUNOL, V157, P81, DOI 10.1016/j.jneuroim.2004.08.030; Roberts ES, 2003, AM J PATHOL, V162, P2041, DOI 10.1016/S0002-9440(10)64336-2; Robertson KR, 2007, AIDS, V21, P1915, DOI 10.1097/QAD.0b013e32828e4e27; Rozek W, 2007, J PROTEOME RES, V6, P4189, DOI 10.1021/pr070220c; Ruseva MM, 2015, P NATL ACAD SCI USA, V112, P14319, DOI 10.1073/pnas.1513698112; Sambrook J., 2001, MOL CLONING LAB MANU; Saylor D, 2016, NAT REV NEUROL, V12, P234, DOI 10.1038/nrneurol.2016.27; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Sekar A, 2016, NATURE, V530, P177, DOI 10.1038/nature16549; Shi QQ, 2015, J NEUROSCI, V35, P13029, DOI 10.1523/JNEUROSCI.1698-15.2015; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Sordillo PP, 2016, BRAIN INJURY, V1-11; Speth C, 2004, J NEUROIMMUNOL, V151, P45, DOI 10.1016/j.jneuroim.2004.02.013; Speth C, 2002, J VIROL, V76, P3179, DOI 10.1128/JVI.76.7.3179-3188.2002; Speth C, 2001, J VIROL, V75, P2604, DOI 10.1128/JVI.75.6.2604-2516.2001; Spudich S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007120; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; Thompson KA, 2011, AM J PATHOL, V179, P1623, DOI 10.1016/j.ajpath.2011.06.039; Vasek MJ, 2016, NATURE, V534, P538, DOI 10.1038/nature18283; Winkler JM, 2012, J NEUROIMMUNE PHARM, V7, P372, DOI 10.1007/s11481-012-9344-5; Zink MC, 2002, J NEUROVIROL, V8, P42, DOI 10.1080/13550280290101076	73	21	23	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 26	2017	14								23	10.1186/s12974-017-0794-9			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	EP1LD	WOS:000397145500001	28122624	DOAJ Gold, Green Published			2021-06-18	
J	Elliott, S; Tomita, D; Endre, Z				Elliott, Steve; Tomita, Dianne; Endre, Zoltan			Erythropoiesis stimulating agents and reno-protection: a meta-analysis	BMC NEPHROLOGY			English	Article						AKI (acute kidney injury); Anemia; Clinical trial; EPO; Erythropoietin; ESA; Meta-analysis; Progression of CKD; Reno-protection; Tissue protection; Transplant	RECOMBINANT-HUMAN-ERYTHROPOIETIN; ACUTE KIDNEY INJURY; HIGH-DOSE ERYTHROPOIETIN; ELEVATION MYOCARDIAL-INFARCTION; TRAUMATIC BRAIN-INJURY; BLOOD-PRESSURE CONTROL; LEFT-VENTRICULAR MASS; DOUBLE-BLIND; CARDIAC-SURGERY; RANDOMIZED-TRIAL	Background: Erythropoiesis stimulating agents (ESAs) were proposed to enhance survival of renal tissues through direct effects via activation of EPO receptors on renal cells resulting in reduced cell apoptosis, or indirect effects via increased oxygen delivery due to increased numbers of Hb containing red blood cells. Thus through several mechanisms there may be benefit of ESA administration on kidney disease progression and kidney function in renal patients. However conflicting ESA reno-protection outcomes have been reported in both pre-clinical animal studies and human clinical trials. To better understand the potential beneficial effects of ESAs on renal-patients, meta-analyses of clinical trials is needed. Methods: Literature searches and manual searches of references lists from published studies were performed. Controlled trials that included ESA treatment on renal patients with relevant renal endpoints were selected. Results: Thirty two ESA controlled trials in 3 categories of intervention were identified. These included 7 trials with patients who had a high likelihood of AKI, 7 trials with kidney transplant patients and 18 anemia correction trials with chronic kidney disease (predialysis) patients. There was a trend toward improvement in renal outcomes in the ESA treated arm of AKI and transplant trials, but none reached statistical significance. In 12 of the anemia correction trials, meta-analyses showed no difference in renal outcomes with the anemia correction but both arms received some ESA treatment making it difficult to assess effects of ESA treatment alone. However, in 6 trials the low Hb arm received no ESAs and meta-analysis also showed no difference in renal outcomes, consistent with no benefit of ESA/Hb increase. Conclusions: Most ESA trials were small with modest event rates. While trends tended to favor the ESA treatment arm, these meta-analyses showed no reduction of incidence of AKI, no reduction in DGF or improvement in 1-year graft survival after renal transplantation and no significant delay in progression of CKD. These results do not support significant clinical reno-protection by ESAs.	[Elliott, Steve; Tomita, Dianne] Amgen Inc, One Amgen Ctr,Newbury Pk, Thousand Oaks, CA 91320 USA; [Endre, Zoltan] Univ New South Wales, Prince Wales Hosp, Dept Nephrol, Sydney, NSW 2031, Australia; [Endre, Zoltan] Univ New South Wales, Sch Clin, Sydney, NSW 2031, Australia	Elliott, S (corresponding author), Amgen Inc, One Amgen Ctr,Newbury Pk, Thousand Oaks, CA 91320 USA.	elliottsge@gmail.com					ABRAHAM PA, 1990, AM J NEPHROL, V10, P128, DOI 10.1159/000168067; Abramson JL, 2003, KIDNEY INT, V64, P610, DOI 10.1046/j.1523-1755.2003.00109.x; Akizawa T, 2011, THER APHER DIAL, V15, P431, DOI 10.1111/j.1744-9987.2011.00931.x; Aydin Z, 2012, AM J TRANSPLANT, V12, P1793, DOI 10.1111/j.1600-6143.2012.04019.x; Bahlmann FH, 2009, CURR OPIN NEPHROL HY, V18, P15, DOI 10.1097/MNH.0b013e32831a9dde; Chhabra D, 2008, CLIN J AM SOC NEPHRO, V3, P1168, DOI 10.2215/CJN.04641007; Choukroun G, 2012, J AM SOC NEPHROL, V23, P360, DOI 10.1681/ASN.2011060546; Cianciaruso B, 2008, J NEPHROL, V21, P861; CLYNE N, 1992, NEPHRON, V60, P390, DOI 10.1159/000186797; CODY J, 2005, COCHRANE DB SYST REV, V20; Coupes Beatrice, 2015, BMC Res Notes, V8, P21, DOI 10.1186/s13104-014-0964-0; Covic A, 2014, AM J NEPHROL, V40, P13; Dardashti A, 2014, ANESTHESIOLOGY, V121, P582, DOI 10.1097/ALN.0000000000000321; de Seigneux S, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-132; Desai A, 2010, EUR J HEART FAIL, V12, P936, DOI 10.1093/eurjhf/hfq094; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Elliott S, 2006, BLOOD, V107, P1892, DOI 10.1182/blood-2005-10-4066; Elliott S, 2012, BIOL-TARGETS THER, V6, P163, DOI 10.2147/BTT.S32281; Elliott S, 2012, NEPHROL DIAL TRANSPL, V27, P2733, DOI 10.1093/ndt/gfr698; Endre ZH, 2010, KIDNEY INT, V77, P1020, DOI 10.1038/ki.2010.25; Gouva C, 2004, KIDNEY INT, V66, P753, DOI 10.1111/j.1523-1755.2004.00797.x; Hafer C, 2012, KIDNEY INT, V81, P314, DOI 10.1038/ki.2011.349; Imai E, 2016, NEPHROL DIAL TRANSPL, V31, P447, DOI 10.1093/ndt/gfv272; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kamar N, 2008, TRANSPLANTATION, V85, P1120, DOI 10.1097/TP.0b013e31816a8a1f; Kamar N, 2010, TRANSPL INT, V23, P277, DOI 10.1111/j.1432-2277.2009.00982.x; Kim JH, 2013, CRIT CARE, V17, DOI 10.1186/cc13081; KLEINMAN KS, 1989, AM J KIDNEY DIS, V14, P486, DOI 10.1016/S0272-6386(89)80149-0; Kosiborod M, 2003, AM J MED, V114, P112, DOI 10.1016/S0002-9343(02)01498-5; Koulouridis I, 2013, AM J KIDNEY DIS, V61, P44, DOI 10.1053/j.ajkd.2012.07.014; Kuriyama S, 1997, NEPHRON, V77, P176, DOI 10.1159/000190270; Levin A, 2005, AM J KIDNEY DIS, V46, P799, DOI 10.1053/j.ajkd.2005.08.007; Li J, 2012, EUR J CLIN PHARMACOL, V68, P469, DOI 10.1007/s00228-011-1160-y; Lietz Katarzyna, 2003, Ann Transplant, V8, P17; LIM VS, 1989, ANN INTERN MED, V110, P108, DOI 10.7326/0003-4819-110-2-108; LIM VS, 1990, KIDNEY INT, V37, P131, DOI 10.1038/ki.1990.18; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; Linde T, 2001, TRANSPLANTATION, V71, P79, DOI 10.1097/00007890-200101150-00013; Lucas MF, 1996, NEPHRON, V73, P54; Macdougall IC, 2007, NEPHROL DIAL TRANSPL, V22, P784, DOI 10.1093/ndt/gfl483; Martinez F, 2010, AM J TRANSPLANT, V10, P1695, DOI 10.1111/j.1600-6143.2010.03142.x; Moore E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-3; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Oh SW, 2012, J KOREAN MED SCI, V27, P506, DOI 10.3346/jkms.2012.27.5.506; Ohlsson A, 2014, COCHRANE DB SYST REV, V4; Olweny EO, 2012, WORLD J UROL, V30, P519, DOI 10.1007/s00345-011-0760-6; Palmer SC, 2010, ANN INTERN MED, V153, P23, DOI 10.7326/0003-4819-153-1-201007060-00252; Park J, 2005, AM J KIDNEY DIS, V46, P791, DOI 10.1053/j.ajkd.2005.07.034; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; REVICKI DA, 1995, AM J KIDNEY DIS, V25, P548, DOI 10.1016/0272-6386(95)90122-1; Ritz E, 2007, AM J KIDNEY DIS, V49, P194, DOI 10.1053/j.ajkd.2006.11.032; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Roger SD, 2004, J AM SOC NEPHROL, V15, P148, DOI 10.1097/01.ASN.0000102471.89084.8B; Rossert J, 2006, AM J KIDNEY DIS, V47, P738, DOI 10.1053/j.ajkd.2006.02.170; ROTH D, 1994, AM J KIDNEY DIS, V24, P777, DOI 10.1016/S0272-6386(12)80671-8; Ruggenenti P, 2005, LANCET, V365, P939, DOI 10.1016/S0140-6736(05)71082-5; Sico JJ, 2013, J STROKE CEREBROVASC, V22, P271, DOI 10.1016/j.jstrokecerebrovasdis.2011.09.003; Siedlecki A, 2011, AM J TRANSPLANT, V11, P2279, DOI 10.1111/j.1600-6143.2011.03754.x; Sinclair AM, 2010, BLOOD, V115, P4264, DOI 10.1182/blood-2009-10-248666; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Solling C, 2012, BASIC CLIN PHARMACOL, V110, P113, DOI 10.1111/j.1742-7843.2011.00820.x; Song YR, 2009, AM J NEPHROL, V30, P253, DOI 10.1159/000223229; Sureshkumar KK, 2012, CLIN J AM SOC NEPHRO, V7, P1498, DOI 10.2215/CJN.01360212; Suzuki M, 2012, INT HEART J, V2012, P53; Tasanarong A, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-136; Tie HT, 2015, EUR J CARDIO-THORAC, V48, P32, DOI 10.1093/ejcts/ezu378; Togel FE, 2016, J AM SOC NEPHROL, V27, P3394, DOI 10.1681/ASN.2015091059; Uzu T, 2012, J AM SOC HYPERTENS, V6, P124, DOI 10.1016/j.jash.2011.11.001; Van Biesen W, 2005, TRANSPLANTATION, V79, P367, DOI 10.1097/01.TP.0000150370.51700.99; VanLoo A, 1996, NEPHROL DIAL TRANSPL, V11, P1815; Vasquez EM, 1996, TRANSPLANTATION, V62, P1026, DOI 10.1097/00007890-199610150-00024; Villar E, 2011, J DIABETES COMPLICAT, V25, P237, DOI 10.1016/j.jdiacomp.2011.03.003; Wen YT, 2013, AM J CARDIOVASC DRUG, V13, P435, DOI 10.1007/s40256-013-0042-3; Yoo YC, 2011, ANESTHESIOLOGY, V115, P929, DOI 10.1097/ALN.0b013e318232004b	75	21	21	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2369			BMC NEPHROL	BMC Nephrol.	JAN 11	2017	18								14	10.1186/s12882-017-0438-4			16	Urology & Nephrology	Urology & Nephrology	EH4UJ	WOS:000391765800002	28077085	DOAJ Gold, Green Published			2021-06-18	
J	Degani, AM; Santos, MM; Leonard, CT; Rau, TF; Patel, SA; Mohapatra, S; Danna-dos-Santos, A				Degani, Adriana M.; Santos, Maria M.; Leonard, Charles T.; Rau, Thomas F.; Patel, Sarjubhai A.; Mohapatra, Sambit; Danna-dos-Santos, Alessander			The effects of mild traumatic brain injury on postural control	BRAIN INJURY			English	Article						Traumatic brain injury; concussion; balance; mild brain injury	CEREBRAL CONCUSSION; APPROXIMATE ENTROPY; BALANCE CONTROL; MUSCLE MODES; BODY SWAY; STABILITY; ADULTS; INFORMATION; ADJUSTMENTS; INSTABILITY	Primary objective: The purpose of this study was to investigate the effects of mild traumatic brain injury (mTBI) on multiple postural indices that characterize body sway behaviour. Methods and procedures: The body's centre of pressure (COP) displacement was recorded from 11 individuals with a history of mTBI (29.4 +/- 6.7 years old) and 11 healthy controls (26.8 +/- 3.7 years old) performing bipedal stance on a force platform for 120 seconds. Spatio-temporal (area, amplitude and mean velocity of the COP displacement) and frequency characteristics (frequency containing 80% of the power spectral density) of the body oscillation, as well as its dynamic characteristics (sample entropy estimate of the COP displacement) were extracted from COP signals. Main outcomes and results: All postural indices studied were significantly affected by mTBI (p < 0.010). Participants with a history of mTBI presented a larger, slower, and more random body oscillation compared to controls. Conclusion: The results suggest that (a) balance deficits can be recognized as an effect of mTBI; (b) balance deficits induced by mTBI are multi-dimensional, affecting all three domains included in this study; and (c) the postural indices employed in this study are potential markers to detect changes in postural control following mTBI.	[Degani, Adriana M.; Santos, Maria M.; Leonard, Charles T.; Mohapatra, Sambit; Danna-dos-Santos, Alessander] Univ Montana, Sch Phys Therapy & Rehabil Sci, Motor Control Lab, Missoula, MT 59812 USA; [Leonard, Charles T.; Rau, Thomas F.; Patel, Sarjubhai A.; Mohapatra, Sambit; Danna-dos-Santos, Alessander] Univ Montana, Neural Injury Ctr, Missoula, MT 59812 USA; [Rau, Thomas F.; Patel, Sarjubhai A.] Univ Montana, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA	Degani, AM (corresponding author), Univ Montana Missoula, Sch Phys Therapy & Rehabil Sci, 32 Campus Dr, Missoula, MT 59812 USA.	adriana.degani@umontana.edu	Mohapatra, Sambit/AAJ-6657-2021	Mohapatra, Sambit/0000-0001-7714-5281			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baratto L, 2002, MOTOR CONTROL, V6, P246, DOI 10.1123/mcj.6.3.246; Bizid R, 2009, J SCI MED SPORT, V12, P60, DOI 10.1016/j.jsams.2007.10.006; Bolbecker AR, 2010, PLOS ONE, V6, P1; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Danna-dos-Santos A, 2008, EXP BRAIN RES, V189, P171, DOI 10.1007/s00221-008-1413-x; Danna-dos-Santos A, 2007, EXP BRAIN RES, V179, P533, DOI 10.1007/s00221-006-0812-0; Danna-Dos-Santos A, 2015, EXP BRAIN RES, V233, P657, DOI 10.1007/s00221-014-4145-0; Degani AM, 2007, J APPL BIOMECH, V23, P261, DOI 10.1123/jab.23.4.261; Degani AM, 2016, THESIS; Dehail P, 2007, J REHABIL MED, V39, P531, DOI 10.2340/16501977-0096; Duarte M, 2008, EXP BRAIN RES, V191, P265, DOI 10.1007/s00221-008-1521-7; Duarte M, 2010, REV BRAS FISIOTER, V14, P183, DOI 10.1590/S1413-35552010000300003; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Flanders M, 2011, BIOL CYBERN, V104, P1, DOI 10.1007/s00422-011-0419-9; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Golomer E, 1999, NEUROSCI LETT, V267, P189, DOI 10.1016/S0304-3940(99)00356-0; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; INGLIN B, 1988, J GERONTOL, V43, pM105, DOI 10.1093/geronj/43.4.M105; Johansson B, 2014, INT J PHYS MED REHAB, V2, P2; Kandel E. R., 2000, PRINCIPLES NEURAL SC, P1414; Kanekar N, 2015, J ELECTROMYOGR KINES, V25, P400, DOI 10.1016/j.jelekin.2014.11.002; Kanekar N, 2014, J NEUROSCI METH, V222, P91, DOI 10.1016/j.jneumeth.2013.10.020; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lackner JR, 2005, ANNU REV PSYCHOL, V56, P115, DOI 10.1146/annurev.psych.55.090902.142023; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; Latash M. L., 2008, SYNERGY, P432; Lee D, 1975, J HUMAN MOVEMENT STU, V1, P87, DOI DOI 10.3758/BF03199297; Nagy E, 2004, EUR J APPL PHYSIOL, V92, P407, DOI 10.1007/s00421-004-1157-7; Powers KC, 2014, GAIT POSTURE, V39, P728, DOI 10.1016/j.gaitpost.2013.10.005; Ramdani S, 2009, MED ENG PHYS, V31, P1023, DOI 10.1016/j.medengphy.2009.06.004; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schubert P, 2012, J BIOMED SCI ENG, V5, P496, DOI [10.4236/jbise.2012.59062, DOI 10.4236/JBISE.2012.59062]; Shumway-Cook A, 2011, MOTOR CONTROL TRANSL, P656; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov SM, 1997, J MOTOR BEHAV, V29, P263, DOI 10.1080/00222899709600841; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Tang PF, 1998, J GERONTOL A-BIOL, V53, pM471, DOI 10.1093/gerona/53A.6.M471; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Torres EB, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00039; VANEMMERIK REA, 1993, MOVEMENT DISORD, V8, P305, DOI 10.1002/mds.870080309; WOOLLACOTT M, 1988, ANN NY ACAD SCI, V515, P42, DOI 10.1111/j.1749-6632.1988.tb32964.x; Zatsiorsky VM, 2000, MOTOR CONTROL, V4, P185, DOI 10.1123/mcj.4.2.185	54	21	21	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	1					49	56		10.1080/02699052.2016.1225982			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EJ5KT	WOS:000393257600007	27936960				2021-06-18	
J	Kanser, RJ; Rapport, LJ; Bashem, JR; Billings, NM; Hanks, RA; Axelrod, BN; Miller, JB				Kanser, Robert J.; Rapport, Lisa J.; Bashem, Jesse R.; Billings, Nia M.; Hanks, Robin A.; Axelrod, Bradley N.; Miller, Justin B.			Strategies of successful and unsuccessful simulators coached to feign traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Assessment; performance validity; traumatic brain injury; malingering	SYMPTOM VALIDITY; PERFORMANCE VALIDITY; NEUROPSYCHOLOGICAL ASSESSMENT	Objective: The present study evaluated strategies used by healthy adults coached to simulate traumatic brain injury (TBI) during neuropsychological evaluation. Method: Healthy adults (n=58) were coached to simulate TBI while completing a test battery consisting of multiple performance validity tests (PVTs), neuropsychological tests, a self-report scale of functional independence, and a debriefing survey about strategies used to feign TBI. Results: Successful simulators (n=16) were classified as participants who failed 0 or 1 PVT and also scored as impaired on one or more neuropsychological index. Unsuccessful simulators (n=42) failed2 PVTs or passed PVTs but did not score impaired on any neuropsychological index. Compared to unsuccessful simulators, successful simulators had significantly more years of education, higher estimated IQ, and were more likely to use information provided about TBI to employ a systematic pattern of performance that targeted specific tests rather than performing poorly across the entire test battery. Conclusion: Results contribute to a limited body of research investigating strategies utilized by individuals instructed to feign neurocognitive impairment. Findings signal the importance of developing additional embedded PVTs within standard cognitive tests to assess performance validity throughout a neuropsychological assessment. Future research should consider specifically targeting embedded measures in visual tests sensitive to slowed responding (e.g. response time).	[Kanser, Robert J.; Rapport, Lisa J.; Bashem, Jesse R.; Billings, Nia M.; Miller, Justin B.] Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA; [Hanks, Robin A.] Wayne State Univ, Sch Med, Detroit, MI USA; [Axelrod, Bradley N.] John D Dingell Vet Affairs Med Ctr, Detroit, MI USA; [Miller, Justin B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA	Kanser, RJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	Robert.Kanser@wayne.edu	Billings, Nia/AAG-2001-2021	Miller, Justin B./0000-0002-4439-6604	Wayne State University; Del Harder Foundation; National Institute on Disability and Rehabilitation Research [H133A080044]	This work was supported by Wayne State University, the Del Harder Foundation, and the National Institute on Disability and Rehabilitation Research [grant number H133A080044].	Bashem JR, 2014, CLIN NEUROPSYCHOL, V28, P851, DOI 10.1080/13854046.2014.927927; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cohen J., 1965, HDB CLIN PSYCHOL, P95; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P850, DOI 10.1080/13854046.2012.686631; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis G, 2015, APPL NEUROPSYCH-ADUL, V22, P262, DOI 10.1080/23279095.2014.920842; Green P., 2005, MED SYMPTOM VALIDITY; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Hedges L. V., 1981, J EDUC STAT, V6, P107; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; IVERSON GL, 1995, BRAIN INJURY, V9, P35, DOI 10.3109/02699059509004569; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Pearson Education I, 2008, WECHSL MEM SCAL CLIN; Prigatano G., 1986, PATIENT COMPETENCY R; Psychological Corporation, 2001, WECHSLER TEST ADULT; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reitan RM., 1985, HALSTEAD REITAN NEUR; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER	25	21	21	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	3					644	653		10.1080/13854046.2016.1278040			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EM5FX	WOS:000395338500011	28084893				2021-06-18	
J	Khalili, H; Niakan, A; Ghaffarpasand, F				Khalili, Hosseinali; Niakan, Amin; Ghaffarpasand, Fariborz			Effects of cerebrolysin on functional recovery in patients with severe disability after traumatic brain injury: A historical cohort study	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Traumatic brain injury (TBI); Cerebrolysin; Functional recovery; Prognosis; Severe disability	NEUROTROPHIC TREATMENT; DOUBLE-BLIND; HEAD-INJURY; MODERATE; STROKE; RATS; EPIDEMIOLOGY; MANAGEMENT; APOPTOSIS; CELLS	Objective: To determine the effects of cerebrolysin on functional recovery in patients with severe disability after traumatic brain injury (TBI). Methods: This was a retrospective cohort study being performed during a 2-year period in a level I trauma center in Southern Iran including all the adult patients (>16 years) with severe disability (GOS of 2 and 3) 1-month after trauma. We excluded those with posttraumatic seizures and those with meningitis or current infections. Some patients received cerebrolysin (n = 65) and some did not (n = 64). Cerebrolysin was administered intravenously in 10 mL dosage daily for 30 days. Patients in two study groups were matched regarding the baseline characteristics including age, gender, GCS on admission, pupil reactivity and Rotterdam score. The administered cerebrolysin dosage was 10 mL intravenously daily for 30 days. The 3- and 6-month Glasgow Outcome Scale Extended (GOSE) was recorded. The outcome scales were compared between two study groups. Results: Overall we included 129 patients with severe disability 1-month after TBI. The baseline characteristics were comparable between groups. We found that GOSE at 3-month (p = 0.017) and 6-month (p = 0.009) was significantly higher in those receiving cerebrolysin. Cerebrolysin administration was associated with lower mortality rate, and higher good recovery after 6 month of therapy (p = 0.024). Cerebrolysin administration was also associated with higher favorable and lower unfavorable outcome (p = 0.043). Cerebrolysin was associated with higher seizure rate (p = 0.042). Conclusion: Cerebrolysin administration in patients with severe disability after TBI is associated with improved functional recovery, decreased mortality rate and increased favorable outcome. Seizure is important side effect of cerebrolysin administration in TBI patients. (C) 2016 Elsevier B.V. All rights reserved.	[Khalili, Hosseinali] Shiraz Univ Med Sci, Shiraz Trauma Res Ctr, Shiraz, Iran; [Niakan, Amin] Shiraz Univ Med Sci, Dept Neurosurg, Shiraz, Iran; [Ghaffarpasand, Fariborz] Shiraz Univ Med Sci, Student Res Comm, Dept Neurosurg, Shiraz, Iran	Ghaffarpasand, F (corresponding author), Shiraz Univ Med Sci, Namazi Hosp, Neurosurg Dept Off, Namazi Sq, Shiraz 7197311351, Iran.	fariborz.ghaffarpasand@gmail.com	niakan, amin/A-6818-2019; Khalili, Hosseinali/I-1087-2016; Ghaffarpasand, Fariborz/I-4204-2019	niakan, amin/0000-0003-2644-8543; Khalili, Hosseinali/0000-0002-3390-4212; Ghaffarpasand, Fariborz/0000-0002-1721-9987	Shiraz University of Medical Sciences	We would like to acknowledge all the patients and their families who participated in this family with patience and fortitude. The study was supported by a grant from trauma research center of Shiraz University of Medical Sciences.	Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209; Alvarez XA, 2008, J NEURAL TRANSM, V115, P683, DOI 10.1007/s00702-008-0024-9; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Bornstein N, 2012, DRUG TODAY, V48, P43, DOI 10.1358/dot.2012.48(Suppl.A).1739723; Boyce Vanessa S, 2014, Handb Exp Pharmacol, V220, P443, DOI 10.1007/978-3-642-45106-5_16; Chen CC, 2013, BRIT J NEUROSURG, V27, P803, DOI 10.3109/02688697.2013.793287; Coronado VG, 2011, MMWR SURVEILL SUMM, V60, P1; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Formichi P, 2012, J CELL MOL MED, V16, P2840, DOI 10.1111/j.1582-4934.2012.01615.x; Gauthier S, 2015, DEMENT GERIATR COGN, V39, P332, DOI 10.1159/000377672; Heydari ST, 2013, PUBLIC HEALTH, V127, P704, DOI 10.1016/j.puhe.2013.05.003; Heydari ST, 2013, CHIN J TRAUMATOL, V16, P84, DOI 10.3760/cma.j.issn.1008-1275.2013.02.003; Khalili H, 2016, WORLD NEUROSURG, V94, P120, DOI 10.1016/j.wneu.2016.06.122; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Masliah E, 2012, DRUG TODAY, V48, P3, DOI 10.1358/dot.2012.48(Suppl.A).1739716; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Muresanu DF, 2016, STROKE, V47, P151, DOI 10.1161/STROKEAHA.115.009416; Muresanu DF, 2015, CNS NEUROL DISORD-DR, V14, P587, DOI 10.2174/1871527314666150430162531; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Taghipour M, 2006, J RES MED SCI, V11, P248; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Wong GKC, 2005, ACTA NEUROCHIR SUPPL, V95, P59; Zhang L, 2013, STROKE, V44, P1965, DOI 10.1161/STROKEAHA.111.000831; Zhang YL, 2015, J NEUROSURG, V122, P843, DOI 10.3171/2014.11.JNS14271; Zhang YL, 2013, J NEUROSURG, V118, P1343, DOI 10.3171/2013.3.JNS122061	32	21	22	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JAN	2017	152						34	38		10.1016/j.clineuro.2016.11.011			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EJ2AB	WOS:000393010900007	27871029				2021-06-18	
J	Yeh, PH; Guan Koay, C; Wang, BQ; Morissette, J; Sham, E; Senseney, J; Joy, D; Kubli, A; Yeh, CH; Eskay, V; Liu, W; French, LM; Oakes, TR; Riedy, G; Ollinger, J				Yeh, Ping-Hong; Guan Koay, Cheng; Wang, Binquan; Morissette, John; Sham, Elyssa; Senseney, Justin; Joy, David; Kubli, Alex; Yeh, Chen-Haur; Eskay, Victora; Liu, Wei; French, Louis M.; Oakes, Terrence R.; Riedy, Gerard; Ollinger, John			Compromised Neurocircuitry in Chronic Blast-Related Mild Traumatic Brain Injury	HUMAN BRAIN MAPPING			English	Article						mild traumatic brain injury; blast injury; cognition; concussion; post-traumatic stress disorder; diffusion tensor imaging; tractography; neurocircuitry	WHITE-MATTER INTEGRITY; DIFFUSE AXONAL INJURY; TENSOR; MEMORY; MRI; TRACTOGRAPHY; SYMPTOMS; EXPOSURE; CONCUSSION; COMPLAINTS	The aim of this study was to apply recently developed automated fiber segmentation and quantification methods using diffusion tensor imaging (DTI) and DTI-based deterministic and probabilistic tractography to access local and global diffusion changes in blast-induced mild traumatic brain injury (bmTBI). Two hundred and two (202) male active US service members who reported persistent post-concussion symptoms for more than 6 months after injury were recruited. An additional forty (40) male military controls were included for comparison. DTI results were examined in relation to post-concussion and post-traumatic stress disorder (PTSD) symptoms. No significant group difference in DTI metrics was found using voxel-wise analysis. However, group comparison using tract profile analysis and tract specific analysis, as well as single subject analysis using tract profile analysis revealed the most prominent white matter microstructural injury in chronic bmTBI patients over the frontal fiber tracts, that is, the front-limbic projection fibers (cingulum bundle, uncinate fasciculus), the fronto-parieto-temporal association fibers (superior longitudinal fasciculus), and the fronto-striatal pathways (anterior thalamic radiation). Effects were noted to be sensitive to the number of previous blast exposures, with a negative association between fractional anisotropy (FA) and time since most severe blast exposure in a subset of the multiple blast-exposed group. However, these patterns were not observed in the subgroups classified using macrostructural changes (T2 white matter hyperintensities). Moreover, post-concussion symptoms and PTSD symptoms, as well as neuropsychological function were associated with low FA in the major nodes of compromised neurocircuitry. Hum Brain Mapp 38:352-369, 2017. (c) 2016 Wiley Periodicals, Inc.	[Yeh, Ping-Hong; Wang, Binquan] Henry Jackson Fdn Adv Mil Med, Rockledge, MD USA; [Yeh, Ping-Hong; Guan Koay, Cheng; Morissette, John; Sham, Elyssa; Senseney, Justin; Joy, David; Kubli, Alex; Yeh, Chen-Haur; Eskay, Victora; Liu, Wei; French, Louis M.; Oakes, Terrence R.; Riedy, Gerard; Ollinger, John] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [French, Louis M.; Riedy, Gerard] Uniformed Serv Univ Hlth Sci, CNRM, Bethesda, MD 20814 USA	Yeh, PH (corresponding author), Walter Reed Natl Mil Med Ctr, 8901 Wisconsin Ave,Bldg 51,Room 1128, Bethesda, MD 20889 USA.	pinghongyeh@gmail.com	french, louis/AAB-2083-2020; Koay, Cheng Guan/AAH-8017-2020	Koay, Cheng Guan/0000-0002-4343-8040; french, louis/0000-0002-9451-0604; Joy, David/0000-0001-9941-9538	CDMRPUnited States Department of Defense [PT074437]; NARSAD, Brain Behavior Research Fund [18317]	Contract grant sponsors: CDMRP to USUHS (CNRM) Grant PT074437 (G.R.) and NARSAD, Brain Behavior Research Fund Grant 18317 (P-H. Y.).	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Ashley MJ, 2004, TRAUMATIC BRAIN INJU; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Battaglini M, 2008, NEUROIMAGE, V40, P583, DOI 10.1016/j.neuroimage.2007.10.067; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Charlton RA, 2010, CORTEX, V46, P474, DOI 10.1016/j.cortex.2009.07.005; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Connell S, 2011, J NEUROTRAUM, V28, P1229, DOI 10.1089/neu.2011.1832; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI 10.1002/da.22044; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; French LM, 2014, J REHABIL RES DEV, V51, P933, DOI 10.1682/JRRD.2013.10.0226; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Gouw AA, 2011, J NEUROL NEUROSUR PS, V82, P126, DOI 10.1136/jnnp.2009.204685; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Heilbronner SR, 2014, J NEUROSCI, V34, P10041, DOI 10.1523/JNEUROSCI.5459-13.2014; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jbabdi S, 2007, NEUROIMAGE, V37, P116, DOI 10.1016/j.neuroimage.2007.04.039; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubicki M, 2009, BRAIN IMAGING BEHAV, V3, P191, DOI 10.1007/s11682-009-9061-8; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Kvickstrom P, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-13; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Nestor PG, 2004, NEUROPSYCHOLOGY, V18, P629, DOI 10.1037/0894-4105.18.4.629; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Ruff Robert L, 2010, F1000 Med Rep, V2, P64, DOI 10.3410/M2-64; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Skranes J, 2007, BRAIN, V130, P654, DOI 10.1093/brain/awm001; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Teipel SJ, 2009, J ALZHEIMERS DIS, V17, P571, DOI 10.3233/JAD-2009-1077; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038; Widjaja E, 2013, EPILEPSIA, V54, P1065, DOI 10.1111/epi.12208; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yeatman JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049790; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023; YLIKOSKI A, 1995, STROKE, V26, P1171, DOI 10.1161/01.STR.26.7.1171; Yushkevich PA, 2008, NEUROIMAGE, V41, P448, DOI 10.1016/j.neuroimage.2008.01.013; Zhang H, 2005, LECT NOTES COMPUT SC, V3749, P172	97	21	22	0	46	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JAN	2017	38	1					352	369		10.1002/hbm.23365			18	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EF3XY	WOS:000390259700025	27629984	Green Published			2021-06-18	
J	Merchant-Borna, K; Asselin, P; Narayan, D; Abar, B; Jones, CMC; Bazarian, JJ				Merchant-Borna, Kian; Asselin, Patrick; Narayan, Darren; Abar, Beau; Jones, Courtney M. C.; Bazarian, Jeffrey J.			Novel Method of Weighting Cumulative Helmet Impacts Improves Correlation with Brain White Matter Changes After One Football Season of Sub-concussive Head Blows	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Mild traumatic brain injury; Subconcussive head trauma; Diffusion tensor imaging; Football; Sensors; Biomechanics	CHRONIC TRAUMATIC ENCEPHALOPATHY; TENSOR IMAGING FINDINGS; AXONAL INJURY; EXPOSURE; ACCELERATION; INTEGRITY; DAMAGE; RISK; VULNERABILITY; DEFORMATION	One football season of sub-concussive head blows has been shown to be associated with subclinical white matter (WM) changes on diffusion tensor imaging (DTI). Prior research analyses of helmet-based impact metrics using mean and peak linear and rotational acceleration showed relatively weak correlations to these WM changes; however, these analyses failed to account for the emerging concept that neuronal vulnerability to successive hits is inversely related to the time between hits (TBH). To develop a novel method for quantifying the cumulative effects of sub-concussive head blows during a single season of collegiate football by weighting helmet-based impact measures for time between helmet impacts. We further aim to compare correlations to changes in DTI after one season of collegiate football using weighted cumulative helmet-based impact measures to correlations using non-weighted cumulative helmet-based impact measures and non-cumulative measures. We performed a secondary analysis of DTI and helmet impact data collected on ten Division III collegiate football players during the 2011 season. All subjects underwent diffusion MR imaging before the start of the football season and within 1 week of the end of the football season. Helmet impacts were recorded at each practice and game using helmet-mounted accelerometers, which computed five helmet-based impact measures for each hit: linear acceleration (LA), rotational acceleration (RA), Gadd Severity Index (GSI), Head Injury Criterion (HIC15), and Head Impact Technology severity profile (HITsp). All helmet-based impact measures were analyzed using five methods of summary: peak and mean (non-cumulative measures), season sum-totals (cumulative unweighted measures), and season sum-totals weighted for time between hits (TBH), the interval of time from hit to post-season DTI assessment (TUA), and both TBH and TUA combined. Summarized helmet-based impact measures were correlated to statistically significant changes in fractional anisotropy (FA) using bivariate and multivariable correlation analyses. The resulting R (2) values were averaged in each of the five summary method groups and compared using one-way ANOVA followed by Tukey post hoc tests for multiple comparisons. Total head hits for the season ranged from 431 to 1850. None of the athletes suffered a clinically evident concussion during the study period. The mean R (2) value for the correlations using cumulative helmet-based impact measures weighted for both TUA and TBH combined (0.51 +/- A 0.03) was significantly greater than the mean R (2) value for correlations using non-cumulative HIMs (vs. 0.19 +/- A 0.04, p < 0.0001), unweighted cumulative helmet-based impact measures (vs. 0.27 + 0.03, p < 0.0001), and cumulative helmet-based impact measures weighted for TBH alone (vs. 0.34 +/- A 0.02, p < 0.001). R (2) values for weighted cumulative helmet-based impact measures ranged from 0.32 to 0.77, with 60% of correlations being statistically significant. Cumulative GSI weighted for TBH and TUA explained 77% of the variance in the percent of white matter voxels with statistically significant (PWMVSS) increase in FA from pre-season to post-season, while both cumulative GSI and cumulative HIC15 weighted for TUA accounted for 75% of the variance in PWMVSS decrease in FA. A novel method for weighting cumulative helmet-based impact measures summed over the course of a football season resulted in a marked improvement in the correlation to brain WM changes observed after a single football season of sub-concussive head blows. Our results lend support to the emerging concept that sub-concussive head blows can result in sub-clinical brain injury, and this may be influenced by the time between hits. If confirmed in an independent data set, our novel method for quantifying the cumulative effects of sub-concussive head blows could be used to develop threshold-based countermeasures to prevent the accumulation of WM changes with multiple seasons of play.	[Merchant-Borna, Kian; Asselin, Patrick; Abar, Beau; Jones, Courtney M. C.; Bazarian, Jeffrey J.] Univ Rochester, Dept Emergency Med, Sch Med & Dent, 265 Crittenden Blvd,Box 655C, Rochester, NY 14642 USA; [Narayan, Darren] Rochester Inst Technol, Sch Math Sci, Rochester, NY 14623 USA	Merchant-Borna, K (corresponding author), Univ Rochester, Dept Emergency Med, Sch Med & Dent, 265 Crittenden Blvd,Box 655C, Rochester, NY 14642 USA.	kian.merchant-borna@rochester.edu		Abar, Beau/0000-0003-1536-220X; Merchant-Borna, Kian/0000-0002-6643-1597	National Football League Charities	This study was supported by funds from the National Football League Charities https://www.nflcharities.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Duma SM, 2014, J BIOMECH, V47, P1557, DOI 10.1016/j.jbiomech.2013.08.022; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Effgen G. W., 2012, P 2012 INT IRCOBI C, P455; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gons RAR, 2013, NEUROLOGY, V81, P971, DOI 10.1212/WNL.0b013e3182a43e33; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Stern RA, 2015, NEUROLOGY, V85, P1008; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Wu L. C., 2015, ENG ANN BIOMED; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhu T, 2008, NEUROIMAGE, V40, P1144, DOI 10.1016/j.neuroimage.2008.01.016	51	21	21	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2016	44	12					3679	3692		10.1007/s10439-016-1680-9			14	Engineering, Biomedical	Engineering	EC4MB	WOS:000388103900020	27350072				2021-06-18	
J	Yu, YW; Hsieh, TH; Chen, KY; Wu, JCC; Hoffer, BJ; Greig, NH; Li, YZ; Lai, JH; Chang, CF; Lin, JW; Chen, YH; Yang, LY; Chiang, YH				Yu, Yu-Wen; Hsieh, Tsung-Hsun; Chen, Kai-Yun; Wu, John Chung-Che; Hoffer, Barry J.; Greig, Nigel H.; Li, Yazhou; Lai, Jing-Huei; Chang, Cheng-Fu; Lin, Jia-Wei; Chen, Yu-Hsin; Yang, Liang-Yo; Chiang, Yung-Hsiao			Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats	JOURNAL OF NEUROTRAUMA			English	Article						amyloid-beta precursor protein; BMX; cognitive dysfunction; controlled cortical impact; GFAP; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; mild traumatic brain injury; neuroinflammation	GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; CENTRAL-NERVOUS-SYSTEM; CLOSED HEAD-INJURY; ALZHEIMERS-DISEASE; GENE-EXPRESSION; NEURODEGENERATIVE DISEASE; SYNAPTIC PLASTICITY; DIABETES-MELLITUS; SIGNALING PATHWAY	Mild traumatic brain injury (mTBI) is a major public health issue, representing 75-90% of all cases of TBI. In clinical settings, mTBI, which is defined as a Glascow Coma Scale (GCS) score of 13-15, can lead to various physical, cognitive, emotional, and psychological-related symptoms. To date, there are no pharmaceutical-based therapies to manage the development of the pathological deficits associated with mTBI. In this study, the neurotrophic and neuroprotective properties of glucose-dependent insulinotropic polypeptide (GIP), an incretin similar to glucagon-like peptide-1 (GLP-1), was investigated after its steady-state subcutaneous administration, focusing on behavior after mTBI in an in vivo animal model. The mTBI rat model was generated by a mild controlled cortical impact (mCCI) and used to evaluate the therapeutic potential of GIP. We used the Morris water maze and novel object recognition tests, which are tasks for spatial and recognition memory, respectively, to identify the putative therapeutic effects of GIP on cognitive function. Further, beam walking and the adhesive removal tests were used to evaluate locomotor activity and somatosensory functions in rats with and without GIP administration after mCCI lesion. Lastly, we used immunohistochemical (IHC) staining and Western blot analyses to evaluate the inflammatory markers, glial fibrillary acidic protein (GFAP), amyloid-beta precursor protein (APP), and bone marrow tyrosine kinase gene in chromosome X (BMX) in animals with mTBI. GIP was well tolerated and ameliorated mTBI-induced memory impairments, poor balance, and sensorimotor deficits after initiation in the post-injury period. In addition, GIP mitigated mTBI-induced neuroinflammatory changes on GFAP, APP, and BMX protein levels. These findings suggest GIP has significant benefits in managing mTBI-related symptoms and represents a novel strategy for mTBI treatment.	[Yu, Yu-Wen; Hsieh, Tsung-Hsun; Chen, Kai-Yun; Hoffer, Barry J.; Chiang, Yung-Hsiao] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Neural Regenerat Med, Taipei, Taiwan; [Yu, Yu-Wen; Hsieh, Tsung-Hsun; Chen, Kai-Yun; Hoffer, Barry J.; Chiang, Yung-Hsiao] Natl Hlth Res Inst, Taipei, Taiwan; [Hsieh, Tsung-Hsun; Chen, Kai-Yun; Lai, Jing-Huei; Chiang, Yung-Hsiao] Taipei Med Univ, Ctr Neurotrauma & Neuroregenerat, Taipei, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Coll Med, Dept Phys Therapy, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Coll Med, Grad Inst Rehabil Sci, Taoyuan, Taiwan; [Wu, John Chung-Che; Lai, Jing-Huei; Chang, Cheng-Fu; Lin, Jia-Wei; Chiang, Yung-Hsiao] Taipei Med Univ, Coll Med, Dept Surg, Taipei, Taiwan; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Greig, Nigel H.; Li, Yazhou] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Chen, Yu-Hsin; Yang, Liang-Yo] Taipei Med Univ, Sch Med, Dept Physiol, Coll Med, Taipei, Taiwan; [Chen, Yu-Hsin] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Yang, Liang-Yo] Taipei Med Univ, Res Ctr Biomed Devices & Prototyping Prod, Taipei, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ Hosp, Dept Med Res, Translat Lab, Taipei, Taiwan; [Yang, Liang-Yo] China Med Univ, Sch Med, Coll Med, Taichung, Taiwan	Yang, LY (corresponding author), China Med Univ, Sch Med, Coll Med, Taichung, Taiwan.; Chiang, YH (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Neural Regenerat Med, 250 Wu Hsing St, Taipei 11031, Taiwan.	ychiang@tmu.edu.tw	Hsieh, Tung-Hsun/AAZ-5010-2020	Hsieh, Tung-Hsun/0000-0002-1794-7941; YU, YU-WEN/0000-0002-7279-2532	Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [MOST 103-2321-B-038-003, NSC 101-2321-B-038-004, NSC 102-2321-B-038-004, NSC 101-2632-B-038-001-MY3, MOST 103-2314-B-038-038]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER	This study was supported by the Ministry of Science and Technology, grant number MOST 103-2321-B-038-003, NSC 101-2321-B-038-004, NSC 102-2321-B-038-004 and NSC 101-2632-B-038-001-MY3, MOST 103-2314-B-038-038 and the Intramural Research Program of the National Institute on Aging.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081585; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Buhren BA, 2009, J NEUROSCI RES, V87, P1858, DOI 10.1002/jnr.22001; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Cerecedo-Lopez CD, 2014, MED HYPOTHESES, V82, P171, DOI 10.1016/j.mehy.2013.11.028; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Darsalia V, 2015, J CEREBR BLOOD F MET, V35, P718, DOI 10.1038/jcbfm.2015.17; Deacon CF, 2000, J CLIN ENDOCR METAB, V85, P3575, DOI 10.1210/jc.85.10.3575; Ding KH, 2006, PEPTIDES, V27, P2750, DOI 10.1016/j.peptides.2006.05.011; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Elahi D., 2015, ENDOCR RES, P1; Faivre E, 2011, J NEUROPHYSIOL, V105, P1574, DOI 10.1152/jn.00866.2010; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Figueiredo CP, 2010, BEHAV PHARMACOL, V21, P394, DOI 10.1097/FBP.0b013e32833c8544; Finan B, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007218; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Funato H, 1998, AM J PATHOL, V152, P983; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Gault VA, 2008, BIOCHEM PHARMACOL, V75, P2325, DOI 10.1016/j.bcp.2008.03.011; Gault VA, 2008, J NEUROPHYSIOL, V99, P1590, DOI 10.1152/jn.01161.2007; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Hakon J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120074; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Herman GA, 2006, J CLIN ENDOCR METAB, V91, P4612, DOI 10.1210/jc.2006-1009; Holscher C, 2014, ALZHEIMERS DEMENT, V10, pS47, DOI 10.1016/j.jalz.2013.12.009; Howard PK, 2011, ADV EMERG NURS J, V33, P274, DOI 10.1097/TME.0b013e318233d43c; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Irwin N, 2005, J MED CHEM, V48, P1244, DOI 10.1021/jm049262s; Janus C, 2001, Curr Neurol Neurosci Rep, V1, P451, DOI 10.1007/s11910-001-0105-8; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kamoi K, 2012, ENDOCR J, V59, P353, DOI 10.1507/endocrj.EJ11-0245; Kim SJ, 2008, MOL CELL BIOL, V28, P1644, DOI 10.1128/MCB.00325-07; Kobori N, 2015, J NEUROTRAUM, V32, P139, DOI 10.1089/neu.2014.3487; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lennox RR, 2015, MOL MED REP, V12, P1544, DOI 10.3892/mmr.2015.3447; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Li YZ, 2015, J NEUROCHEM, V135, P1203, DOI 10.1111/jnc.13169; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Lin CM, 2009, SURG NEUROL, V72, P50, DOI 10.1016/j.wneu.2009.09.004; Lindsay J.S., 2014, IMMUNOENDOCRINOL, V1, pe391; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Martin CMA, 2013, BBA-GEN SUBJECTS, V1830, P3407, DOI 10.1016/j.bbagen.2013.03.011; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Meier JJ, 2004, DIABETES, V53, P654, DOI 10.2337/diabetes.53.3.654; Meneilly GS, 2003, DIABETES CARE, V26, P2835, DOI 10.2337/diacare.26.10.2835; Monami M, 2009, EUR J ENDOCRINOL, V160, P909, DOI 10.1530/EJE-09-0101; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nyberg J, 2005, J NEUROSCI, V25, P1816, DOI 10.1523/jneurosci.4920-04.2005; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Okawa T, 2014, J DIABETES INVEST, V5, P31, DOI 10.1111/jdi.12129; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Paavonen K, 2004, MOL BIOL CELL, V15, P4226, DOI 10.1091/mbc.E04-03-0241; Palmer CD, 2008, BLOOD, V111, P1781, DOI 10.1182/blood-2007-07-102343; Paratore Sabrina, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P210; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Prusky GT, 2000, BEHAV BRAIN RES, V116, P135, DOI 10.1016/S0166-4328(00)00267-9; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Spielman L. J., 2014, IMMUNOENDOCRINOLOGY, V1, P1, DOI [10.14800/Immunoendocrinology.391, DOI 10.1016/J.JNEUR0IM.2014.06.004]; Taglialatela G, 2009, BEHAV BRAIN RES, V200, P95, DOI 10.1016/j.bbr.2008.12.034; Tan T, 2013, CURR OPIN PHARMACOL, V13, P996, DOI 10.1016/j.coph.2013.09.005; Tatarkiewicz K, 2014, DIABETES OBES METAB, V16, P75, DOI 10.1111/dom.12181; Tian JQ, 2010, SCAND J IMMUNOL, V72, P1, DOI 10.1111/j.1365-3083.2010.02400.x; Titus DJ, 2013, NEUROSCIENCE, V231, P182, DOI 10.1016/j.neuroscience.2012.12.002; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; Verkhratsky A, 2010, NEUROTHERAPEUTICS, V7, P399, DOI 10.1016/j.nurt.2010.05.017; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wenk Gary L, 2004, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0805as26; Wu JCC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039226; Wu TZ, 2016, HANDB EXP PHARMACOL, V233, P137, DOI 10.1007/164_2015_9; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838	107	21	21	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2016	33	22					2044	2054		10.1089/neu.2015.4229			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EC4OL	WOS:000388112300008	26972789	Green Published, Other Gold			2021-06-18	
J	Lv, YN; Qian, YS; Ou-yang, AJ; Fu, LS				Lv, Yanni; Qian, Yisong; Ou-yang, Aijun; Fu, Longsheng			Hydroxysafflor Yellow A Attenuates Neuron Damage by Suppressing the Lipopolysaccharide-Induced TLR4 Pathway in Activated Microglial Cells	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Hydroxysafflor yellow A; Toll-like receptor 4; Neuroprotective effect; Microglia; Neurons; Co-culture system; Anti-inflammatory; Neurotrophic	TRAUMATIC BRAIN-INJURY; CEREBRAL ISCHEMIA/REPERFUSION INJURY; INFLAMMATORY RESPONSE; NEUROTROPHIC FACTOR; SIGNALING PATHWAYS; INNATE IMMUNITY; DOWN-REGULATION; SAFFLOR YELLOW; BV2 MICROGLIA; RECEPTOR 4	Microglia activation initiates a neurological deficit cascade that contributes to substantial neuronal damage and impairment following ischemia stroke. Toll-like receptor 4 (TLR4) has been demonstrated to play a critical role in this cascade. In the current study, we tested the hypothesis that hydroxysafflor yellow A (HSYA), an active ingredient extracted from Flos Carthami tinctorii, alleviated inflammatory damage, and mediated neurotrophic effects in neurons by inducing the TLR4 pathway in microglia. A non-contact Transwell co-culture system comprised microglia and neurons was treated with HSYA followed by a 1 mg/mL lipopolysaccharide (LPS) stimulation. The microglia were activated prior to neuronal apoptosis, which were induced by increasing TLR4 expression in the activated microglia. However, HSYA suppressed TLR4 expression in the activated microglia, resulting in less neuronal damage at the early stage of LPS stimulation. Western blot analysis and immunofluorescence indicated that dose-dependently HSYA down-regulated TLR4-induced downstream effectors myeloid differentiation factor 88 (MyD88), nuclear factor kappa b (NF-kappa B), and the mitogen-activated protein kinases (MAPK)-regulated proteins c-Jun NH2-terminal protein kinase (JNK), protein kinase (ERK) 1/2 (ERK1/2), p38 MAPK (p38), as well as the LPS-induced inflammatory cytokine release. However, HSYA up-regulated brain-derived neurotrophic factor (BDNF) expression. Our data suggest that HSYA could exert neurotrophic and anti-inflammatory functions in response to LPS stimulation by inhibiting TLR4 pathway-mediated signaling.	[Lv, Yanni; Ou-yang, Aijun; Fu, Longsheng] Nanchang Univ, Dept Pharm, Affiliated Hosp 1, Yongwai St 17, Nanchang 330006, Peoples R China; [Qian, Yisong] Nanchang Univ, Inst Translat Med, Nanchang 330001, Peoples R China	Lv, YN (corresponding author), Nanchang Univ, Dept Pharm, Affiliated Hosp 1, Yongwai St 17, Nanchang 330006, Peoples R China.	lvyanni@126.com					Barbierato M, 2015, CNS NEUROL DISORD-DR, P608; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bozic I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118372; Buchanan MM, 2010, J NEUROCHEM, V114, P13, DOI 10.1111/j.1471-4159.2010.06736.x; Chen L, 2013, NEUROCHEM RES, V38, P2268, DOI 10.1007/s11064-013-1135-8; Chen L, 2015, BRAIN RES, V1624, P433, DOI 10.1016/j.brainres.2015.08.007; de Bernardo S, 2003, J NEUROSCI RES, V73, P818, DOI 10.1002/jnr.10704; Doeppner TR, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.359; He Y, 2013, NEURAL REGEN RES, V8, P2744, DOI 10.3969/j.issn.1673-5374.2013.29.006; Hines DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060388; Ji DB, 2009, VASC PHARMACOL, V50, P137, DOI 10.1016/j.vph.2008.11.009; Jiang ZL, 2014, IMMUNOL LETT, V160, P17, DOI 10.1016/j.imlet.2014.03.006; Kawamura K, 2012, ENDOCRINOLOGY, V153, P3972, DOI 10.1210/en.2012-1167; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Klintworth H, 2009, NEUROSCI LETT, V462, P1, DOI 10.1016/j.neulet.2009.06.065; Kraft AD, 2011, INT J ENV RES PUB HE, V8, P2980, DOI 10.3390/ijerph8072980; Kurpius D, 2006, GLIA, V54, P58, DOI 10.1002/glia.20355; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; Lee EJ, 2015, MOL NEURODEGENER, V10, P61; Lee KM, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0652-1; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2008, J NEUROSCI, V28, P2320, DOI 10.1523/JNEUROSCI.4760-07.2008; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li J, 2013, NEUROSCI LETT, V535, P51, DOI 10.1016/j.neulet.2012.12.056; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; Lv YN, 2015, EUR J PHARMACOL, V769, P324, DOI 10.1016/j.ejphar.2015.11.036; Madeddu F, 2004, NEUROREPORT, V15, P2045, DOI 10.1097/00001756-200409150-00010; Morrison HW, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-4; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Pardo B, 1997, BRAIN RES PROTOC, V1, P127, DOI 10.1016/S1385-299X(96)00020-7; Park J, 2015, NEUROSCI LETT, V584, P191, DOI 10.1016/j.neulet.2014.10.016; Prathab B.S., 2015, PHARM BIOCH BEHAV, V137, P60, DOI DOI 10.1016/J.PBB.2015.08.007; Shulga A, 2009, MOL CELL NEUROSCI, V42, P408, DOI 10.1016/j.mcn.2009.09.002; Song J, 2014, INT J MOL SCI, V15, P15512, DOI 10.3390/ijms150915512; Song M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-92; Sun CY, 2010, PHYTOTHER RES, V24, P1788, DOI 10.1002/ptr.3166; Tanaka S, 2006, J NEUROSCI RES, V83, P557, DOI 10.1002/jnr.20752; Tao XF, 2015, FREE RADICAL BIO MED, V84, P103, DOI 10.1016/j.freeradbiomed.2015.03.003; Tian JW, 2008, PHARMACOLOGY, V82, P121, DOI 10.1159/000141653; Umschweif G, 2014, J CEREBR BLOOD F MET, V34, P1381, DOI 10.1038/jcbfm.2014.93; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wang W, 2014, NEUROSCI RES, V81-82, P21, DOI 10.1016/j.neures.2014.01.005; Wang XY, 2009, J IMMUNOL, V183, P7471, DOI 10.4049/jimmunol.0900762; Wu B, 2015, J NEUROINFLAMM, V12, P133; Wu Y, 2012, BIOL PHARM BULL, V35, P515, DOI 10.1248/bpb.35.515; Yao LL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-23; Yoo KY, 2011, NEUROCHEM RES, V36, P2417, DOI 10.1007/s11064-011-0569-0; Zhang L, 2015, J NEUROCHEM, V132, P713, DOI 10.1111/jnc.13021; Zhang X, 2014, CELL PHYSIOL BIOCHEM, V34, P715, DOI 10.1159/000363036; Zhang ZH, 2014, BRAIN RES, V1563, P72, DOI 10.1016/j.brainres.2014.03.036; Zhang ZH, 2014, NEUROSCI LETT, V562, P39, DOI 10.1016/j.neulet.2014.01.005; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59	54	21	22	1	16	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	NOV	2016	36	8					1241	1256		10.1007/s10571-015-0322-3			16	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	DY5VX	WOS:000385173600003	26754542				2021-06-18	
J	Myrga, JM; Juengst, SB; Failla, MD; Conley, YP; Arenth, PM; Grace, AA; Wagner, AK				Myrga, John M.; Juengst, Shannon B.; Failla, Michelle D.; Conley, Yvette P.; Arenth, Patricia M.; Grace, Anthony A.; Wagner, Amy K.			COMT and ANKK1 Genetics Interact With Depression to Influence Behavior Following Severe TBI: An Initial Assessment	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						DRD2; ANKK1; COMT; TBI; behavior; rehabilomics; frontal lobe	TRAUMATIC BRAIN-INJURY; DOPAMINE D2 RECEPTOR; POSTTRAUMATIC-STRESS-DISORDER; O-METHYLTRANSFERASE COMT; MEDIAL PREFRONTAL CORTEX; SERIOUS LIFE EVENTS; A1 ALLELE; COGNITIVE PERFORMANCE; CHALLENGING BEHAVIOR; IMPULSIVE AGGRESSION	Objective. Genetic variations in the dopamine (DA) system are associated with cortical-striatal behavior in multiple populations. This study assessed associations of functional polymorphisms in the ankyrin repeat and kinase domain (ANKK1; Taq1a) and catechol-O-methyltransferase (COMT; Val158Met) genes with behavioral dysfunction following traumatic brain injury (TBI). Participants. This was a prospective study of 90 survivors of severe TBI recruited from a level 1 trauma center. Main measures. The Frontal Systems Behavior Scale, a self- or family report questionnaire evaluating behavior associated with frontal lobe dysfunction, was completed 6 and 12 months postinjury. Depression was measured concurrently with the Patient Health Questionnaire-9. Study participants were genotyped for Val158Met and Taq1a polymorphisms. Results. No statistically significant behavioral differences were observed by Taq1a or Val158Met genotype alone. At 12 months, among those with depression, Met homozygotes (Val158Met) self-reported worse behavior than Val carriers (P = .015), and A2 homozygotes (Taq1a) self-reported worse behavior than A1 carriers (P = .028) in bivariable analysis. Multivariable models suggest an interaction between depression and genetic variation with behavior at 12 months post-TBI, and descriptive analysis suggests that carriage of both risk alleles may contribute to worse behavioral performance than carriage of either risk allele alone. Conclusion. In the context of depression, Val158Met and Taq1a polymorphisms are individually associated with behavioral dysfunction 12 months following severe TBI, with preliminary evidence suggesting cumulative, or perhaps epistatic, effects of COMT and ANKK1 on behavioral dysfunction.	[Myrga, John M.; Juengst, Shannon B.; Arenth, Patricia M.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Failla, Michelle D.] Vanderbilt Univ, Dept Psychiat, 221 Kirkland Hall, Nashville, TN 37235 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA; [Grace, Anthony A.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Grace, Anthony A.; Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Wagner, AK (corresponding author), Univ Pittsburgh, Phys Med & Rehabil, Kaufmann Bldg,Suite 202,3471 Fifth Ave, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Juengst, Shannon B/AAC-5891-2019; Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067; Juengst, Shannon/0000-0003-4709-545X	National Institute For Disability, Independent Living, and Rehabilitation Research (NIDILRR) [90DP0041]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162]; Department of Defense (DoD)United States Department of Defense [W81XWH-071-0701]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH101180] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Institute For Disability, Independent Living, and Rehabilitation Research (NIDILRR): 90DP0041, National Institutes of Health (NIH): R01 HD048162; Department of Defense (DoD): W81XWH-071-0701.	Amat J, 2005, NAT NEUROSCI, V8, P365, DOI 10.1038/nn1399; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Arnsten AFT, 2009, NAT REV NEUROSCI, V10, P410, DOI 10.1038/nrn2648; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Baune BT, 2008, NEUROPSYCHOPHARMACOL, V33, P924, DOI 10.1038/sj.npp.1301462; Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642; Benedetti F, 2010, EUR PSYCHIAT, V25, P476, DOI 10.1016/j.eurpsy.2009.12.007; Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542; Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006; BLUM K, 1995, PHARMACOGENETICS, V5, P121, DOI 10.1097/00008571-199506000-00001; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bosia M, 2007, NEUROSCI LETT, V417, P271, DOI 10.1016/j.neulet.2007.02.076; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carvalho JO, 2013, ASSESSMENT, V20, P632, DOI 10.1177/1073191113492845; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chang CH, 2014, BIOL PSYCHIAT, V76, P223, DOI 10.1016/j.biopsych.2013.09.020; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; CILIAX BJ, 1995, J NEUROSCI, V15, P1714; Cools R, 2003, NEUROPSYCHOLOGIA, V41, P1431, DOI 10.1016/S0028-3932(03)00117-9; Dalley JW, 2008, PHARMACOL BIOCHEM BE, V90, P250, DOI 10.1016/j.pbb.2007.12.021; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Economidou D, 2012, NEUROPSYCHOPHARMACOL, V37, P2057, DOI 10.1038/npp.2012.53; Eisenberg DTA, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-2; Failla MD, 2015, J HEAD TRAUMA REHAB, V30, pE54, DOI 10.1097/HTR.0000000000000118; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Ferrari PF, 2003, EUR J NEUROSCI, V17, P371, DOI 10.1046/j.1460-9568.2003.02447.x; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Gilbert SJ, 2008, CURR BIOL, V18, pR110, DOI 10.1016/j.cub.2007.12.014; GOLDMAN D, 1993, ALCOHOL CLIN EXP RES, V17, P199, DOI 10.1111/j.1530-0277.1993.tb00749.x; Goto Y, 2005, NAT NEUROSCI, V8, P805, DOI 10.1038/nn1471; Guedes VA, 2016, EXPERT REV NEUROTHER, V16, P61, DOI 10.1586/14737175.2016.1126180; HALL H, 1994, NEUROPSYCHOPHARMACOL, V11, P245, DOI 10.1038/sj.npp.1380111; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hosak L, 2007, EUR PSYCHIAT, V22, P276, DOI 10.1016/j.eurpsy.2007.02.002; Hygen BW, 2015, DEV PSYCHOL, V51, P1098, DOI 10.1037/dev0000020; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Juengst S, 2014, ARCH PHYS MED REHAB, V95, pE71, DOI [10.1016/j.apmr.2014.07.227, DOI 10.1016/J.APMR.2014.07.227]; Juengst SB, 2015, ARCH PHYS MED REHAB, V96, pe7; Kandel ER, 1998, AM J PSYCHIAT, V155, P457, DOI 10.1176/ajp.155.4.457; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Lawford BR, 2006, EUR PSYCHIAT, V21, P180, DOI 10.1016/j.eurpsy.2005.01.006; Lee FJS, 2007, EMBO J, V26, P2127, DOI 10.1038/sj.emboj.7601656; Lisman JE, 2005, NEURON, V46, P703, DOI 10.1016/j.neuron.2005.05.002; Liu Y, 2011, J NEUROTRAUM, V28, pA105; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Mannisto PT, 1999, PHARMACOL REV, V51, P593; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; Miczek KA, 2002, PSYCHOPHARMACOLOGY, V163, P434, DOI 10.1007/s00213-002-1139-6; Mier D, 2010, MOL PSYCHIATR, V15, P918, DOI 10.1038/mp.2009.36; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Myrga JM, J HEAD TRAUMA REHABI; Pardini M, 2014, CNS SPECTRUMS, V19, P382, DOI 10.1017/S1092852914000108; Patton MH, 2013, J NEUROSCI, V 33, P16865, DOI 10.1523/JNEUROSCI.2449-13.2013; Pohjalainen T, 1998, MOL PSYCHIATR, V3, P256, DOI 10.1038/sj.mp.4000350; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Robbins TW, 2005, NAT NEUROSCI, V8, P261, DOI 10.1038/nn0305-261; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Savitz J, 2013, INT J NEUROPSYCHOPH, V16, P2095, DOI 10.1017/S146114571300045X; Seo DJ, 2008, AGGRESS VIOLENT BEH, V13, P383, DOI 10.1016/j.avb.2008.06.003; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Simpson EH, 2014, LEARN MEMORY, V21, P205, DOI 10.1101/lm.032094.113; Solanto MV, 2002, BEHAV BRAIN RES, V130, P65, DOI 10.1016/S0166-4328(01)00431-4; Strous RD, 2003, AM J MED GENET B, V120B, P29, DOI 10.1002/ajmg.b.20021; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wagner S, 2010, ACTA PSYCHIAT SCAND, V122, P110, DOI 10.1111/j.1600-0447.2009.01501.x; Wanger AK, 2009, J NEUROCHEM, V110, P801, DOI 10.1111/j.1471-4159.2009.06155.x; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Weintraub D, 2006, ARCH NEUROL-CHICAGO, V63, P969, DOI 10.1001/archneur.63.7.969; Winkler EA, 2016, NEUROGENETICS, V17, P31, DOI 10.1007/s10048-015-0467-8; Young RM, 2002, ALCOHOL ALCOHOLISM, V37, P451, DOI 10.1093/alcalc/37.5.451; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Zai CC, 2012, WORLD J BIOL PSYCHIA, V13, P65, DOI 10.3109/15622975.2010.543431	83	21	22	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV-DEC	2016	30	10					920	930		10.1177/1545968316648409			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DZ0HD	WOS:000385517400002	27154305	Green Accepted, Bronze			2021-06-18	
J	Russell, K; Hutchison, MG; Selci, E; Leiter, J; Chateau, D; Ellis, MJ				Russell, Kelly; Hutchison, Michael G.; Selci, Erin; Leiter, Jeff; Chateau, Daniel; Ellis, Michael J.			Academic Outcomes in High-School Students after a Concussion: A Retrospective Population-Based Analysis	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; 4TH INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; RECOVERY-TIME; SPORT HELD; CHILDREN; MANAGEMENT; SYMPTOMS; ZURICH; IMPACT	Background Many concussion symptoms, such as headaches, vision problems, or difficulty remembering or concentrating may deleteriously affect school functioning. Our objective was to determine if academic performance was lower in the academic calendar year that students sustain a concussion compared to the previous year when they did not sustain a concussion. Methods Using Manitoba Health and Manitoba Education data, we conducted a population-based, controlled before-after study from 2005-2006 to 2010-2011 academic years. Grade 9-12 students with an ICD9/10 code for concussion were matched to non-concussed controls. Overall changes in grade point average (GPA) were compared for the academic year prior to the concussion to the academic year the concussion occurred (or could have occurred among non-concussed matched students). Results Overall, 8240 students (1709 concussed, 6531 non-concussed students) were included. Both concussed and non-concussed students exhibited a lower overall GPA from one year to the next. Having sustained a concussion resulted in a -0.90% (95% CI: -1.88, 0.08) reduction in GPA. Over the same period, non-concussed matched students' GPA reduced by -0.57% (95% CI: -1.32, 0.19). Students who sustained a concussion during high school were just as likely to graduate within four years as their non-concussed peers (ORadj: 0.84; 95% CI: 0.73, 1.02). Conclusions We found that, at a population level, a concussion had minimal long-term effects on academic performance during high school. While academic accommodations and Return-to-Learn programs are an important component of pediatric concussion management, research is needed to identify risk factors for poor academic performance after a concussion and who should receive these programs.	[Russell, Kelly; Selci, Erin] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [Russell, Kelly; Selci, Erin; Ellis, Michael J.] Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada; [Russell, Kelly; Leiter, Jeff; Ellis, Michael J.] Canada North Concuss Network, Winnipeg, MB, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON M5S 1A1, Canada; [Leiter, Jeff] Univ Manitoba, Dept Surg, Winnipeg, MB, Canada; [Chateau, Daniel] Univ Manitoba, Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Sect Neurosurg, Dept Surg, Winnipeg, MB, Canada; [Russell, Kelly] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada	Russell, K (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada.; Russell, K (corresponding author), Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada.; Russell, K (corresponding author), Canada North Concuss Network, Winnipeg, MB, Canada.; Russell, K (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada.	krussell@chrim.ca		chateau, Dan/0000-0002-2215-820X; Russell, Kelly/0000-0002-9159-9201	Manitoba Medical Services Foundation; Winnipeg Foundation; Population Health Research Data Repository [2014011, 2013/2014-56]	This study was funded by the Manitoba Medical Services Foundation (KR) and The Winnipeg Foundation (KR). The funders had no role in the study design, data collection, and analysis, decision to publish, or manuscript preparation.; We thank Mr Mingming (Milton) Hu (MSc in Statistics, Manitoba Center for Health Policy) for conducting the data analysis. He was paid for this work from the aforementioned funders. The authors acknowledge the Manitoba Centre for Health Policy for use of data contained in the Population Health Research Data Repository under project # 2014011 (HIPC# 2013/2014-56). The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, or other data providers is intended or should be inferred. Data used in this study are from the Population Health Research Data Repository housed at the Manitoba Centre for Health Policy, University of Manitoba and were derived from data provided by Manitoba Health and Manitoba Education.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Chouinard R, 2008, BRIT J EDUC PSYCHOL, V78, P31, DOI 10.1348/000709907X197993; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ellis MJ, 2015, J NEUROSURG PEDIAT, P1; FARKAS G, 1990, AM EDUC RES J, V27, P807, DOI 10.3102/00028312027004807; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hox JJ, 1998, MULTILEVEL MODELING, P147, DOI DOI 10.1007/978-3-642-72087-1_17; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Manitoba Education, 2015, GRADUATION REQUIREME; Manitoba Government, STUD REC SYST PROF S; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Patel DR, 2010, PEDIATR CLIN N AM, V57, P795, DOI 10.1016/j.pcl.2010.03.002; Purcell LK, 2014, PAED CHILD HEALT-CAN, V19, P153, DOI 10.1093/pch/19.3.153; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; SAS Institute Inc, 1976, SAS VERS 9 3 TS1M0; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220	46	21	21	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2016	11	10							e0165116	10.1371/journal.pone.0165116			12	Multidisciplinary Sciences	Science & Technology - Other Topics	DZ9NZ	WOS:000386204500118	27764223	DOAJ Gold, Green Published			2021-06-18	
J	Elkin, BS; Elliott, JM; Siegmund, GP				Elkin, Benjamin S.; Elliott, James M.; Siegmund, Gunter P.			Whiplash Injury or Concussion? A Possible Biomechanical Explanation for Concussion Symptoms in Some Individuals Following a Rear-End Collision	JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY			English	Article						brain; car crash; cervical spine; finite element model; football	CLINICAL-PREDICTION RULE; HEAD IMPACT SEVERITY; MODERATE/SEVERE DISABILITY; PROFESSIONAL FOOTBALL; PROGNOSTIC-FACTORS; FULL RECOVERY; BRAIN-DAMAGE; RISK-FACTORS; MODEL; PHYSIOTHERAPY	STUDY DESIGN: Finite element modeling of experimental data. BACKGROUND: The clinical presentations of whiplash injury and concussion have considerable overlap. Both diagnoses are generally based on presenting signs and symptoms, and a history of neck or head trauma. With incomplete knowledge of the trauma, differentiating between whiplash injury and concussion can be clinically challenging. OBJECTIVES: To estimate the brain strains that develop during rear-end car crashes, evaluate how these strains vary with different head kinematic parameters, and compare these strains to those generated during potentially concussive football helmet impacts. METHODS: Head kinematic data were analyzed from 2 prior studies, one that focused on head restraint impacts in rear-end crash tests and another that focused on football helmet impacts. These data were used as inputs to a finite element model of the human brain. Brain strains were calculated and compared to different peak kinematic parameters and between the 2 impact conditions. RESULTS: Brain strains correlated best with the head's angular velocity change for both impact conditions. The 4 crashes with head angular velocity changes greater than 30 rad/s (greater than 1719 degrees/s) generated the highest brain stains. One crash, in which the head wrapped onto the top of the head restraint, generated brain strains similar to a 9.3-m/s rear football helmet impact, a level previously associated with concussion. CONCLUSION: This work provides new insight into a potential biomechanical link between whiplash injury and concussion, and advances our understanding of how head restraint interaction during a rear-end crash may cause an injury more typically associated with sports-related head impacts.	[Elkin, Benjamin S.] MEA Forens Engineers & Scientists, Toronto, ON, Canada; [Elliott, James M.] Northwestern Univ, Feinberg Sch Med, Dept Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA; [Siegmund, Gunter P.] MEA Forens Engineers & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada; [Siegmund, Gunter P.] Univ British Columbia, Sch Kinesiol, Vancouver, BC, Canada	Siegmund, GP (corresponding author), MEA Forens Engineers & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada.	gunter.siegmund@meaforensic.com	Siegmund, Gunter P/B-7003-2013				Alexander MP, 1998, NEUROLOGY, V51, P336, DOI 10.1212/WNL.51.2.336; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Berglund A, 2001, J CLIN EPIDEMIOL, V54, P851, DOI 10.1016/S0895-4356(00)00369-3; Borchgrevink GE, 1998, SPINE, V23, P25, DOI 10.1097/00007632-199801010-00006; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2008, SPINE, V33, pS83, DOI 10.1097/BRS.0b013e3181643eb8; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Davidsson J., 1999, BIORID II FINAL REPO; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Elliott JM, 2009, J ORTHOP SPORT PHYS, V39, P312, DOI 10.2519/jospt.2009.2826; Erichsen JE., 1867, ON RAILWAY AND OTHER; FRANKEL CJ, 1959, JAMA-J AM MED ASSOC, V169, P216, DOI 10.1001/jama.1959.03000200014004; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; GAY JR, 1953, JAMA-J AM MED ASSOC, V152, P1698, DOI 10.1001/jama.1953.03690180020006; Gennarelli T.A., 1972, SAE TECHNICAL PAPER; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Ivancic PC, 2013, ACCIDENT ANAL PREV, V50, P323, DOI 10.1016/j.aap.2012.05.008; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; Jakobsson L, 2000, ACCIDENT ANAL PREV, V32, P307, DOI 10.1016/S0001-4575(99)00107-4; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Jull G, 2013, PAIN, V154, P1798, DOI 10.1016/j.pain.2013.05.041; Kamper SJ, 2008, PAIN, V138, P617, DOI 10.1016/j.pain.2008.02.019; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lamb SE, 2013, LANCET, V381, P546, DOI 10.1016/S0140-6736(12)61304-X; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Marshall CM, 2015, PHYSICIAN SPORTSMED, V43, P274, DOI 10.1080/00913847.2015.1064301; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Michaleff ZA, 2014, LANCET, V384, P133, DOI 10.1016/S0140-6736(14)60457-8; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1967, SAE TECHNICAL PAPER, DOI http://dx.doi.org/10.4271/670906; Ommaya AK, 1966, SAE TECHNICAL PAPER; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pan J, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15607; Panzer MB, 2016, INT J AUTOMOT ENG, V7, P37, DOI 10.20485/jsaeijae.7.1_37; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PETTERSSON K, 1994, ACTA ORTHOP SCAND, V65, P525, DOI 10.3109/17453679409000906; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Ritchie C, 2015, J ORTHOP SPORT PHYS, V45, P242, DOI 10.2519/jospt.2015.5642; Ritchie C, 2013, PAIN, V154, P2198, DOI 10.1016/j.pain.2013.07.001; Ronnen HR, 1996, RADIOLOGY, V201, P93, DOI 10.1148/radiology.201.1.8816527; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Siegmund G. P, 1997, P 41 STAPP CAR CRASH, P357; Siegmund GP, 2008, SPINE, V33, P1643, DOI 10.1097/BRS.0b013e31817b5bcf; Siegmund Gunter P, 2005, Traffic Inj Prev, V6, P267, DOI 10.1080/15389580590969427; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Siegmund GP, 2014, ANN BIOMED ENG, V42, P1834, DOI 10.1007/s10439-014-1052-2; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; STURZENEGGER M, 1994, NEUROLOGY, V44, P688, DOI 10.1212/WNL.44.4.688; STURZENEGGER M, 1995, J NEUROL, V242, P443, DOI 10.1007/BF00873547; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Voyvodic F, 1997, NEURORADIOLOGY, V39, P35, DOI 10.1007/s002340050363; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Walton DM, 2013, J ORTHOP SPORT PHYS, V43, P31, DOI 10.2519/jospt.2013.4507; Walton DM, 2009, J ORTHOP SPORT PHYS, V39, P334, DOI 10.2519/jospt.2009.2765; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950; Zumsteg D, 2006, CAN J NEUROL SCI, V33, P379, DOI 10.1017/S0317167100005333	63	21	21	0	14	J O S P T	ALEXANDRIA	1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA	0190-6011	1938-1344		J ORTHOP SPORT PHYS	J. Orthop. Sports Phys. Ther.	OCT	2016	46	10					874	885		10.2519/jospt.2016.7049			12	Orthopedics; Rehabilitation; Sport Sciences	Orthopedics; Rehabilitation; Sport Sciences	DX5CW	WOS:000384398400009	27690834	Bronze			2021-06-18	
J	Fino, PC; Nussbaum, MA; Brolinson, PG				Fino, Peter C.; Nussbaum, Maury A.; Brolinson, Per Gunnar			Decreased high-frequency center-of-pressure complexity in recently concussed asymptomatic athletes	GAIT & POSTURE			English	Article						mTBI; Concussion; Brain injury; Postural stability; Entropy	SPORT-RELATED CONCUSSION; POSTURAL-CONTROL DYNAMICS; TRAUMATIC BRAIN-INJURY; TIME-TO-CONTACT; APPROXIMATE ENTROPY; CEREBRAL CONCUSSION; MULTISCALE ENTROPY; OLDER-ADULTS; INTRACORTICAL INHIBITION; SWAY	Two experiments compared multiple methods of estimating postural stability entropy to address: 1) if postural complexity differences exist between concussed and healthy athletes immediately following return-to-play; 2) which methods best detect such differences; and 3) what is an appropriate interpretation of such differences. First, center of pressure (COP) data were collected from six concussed athletes over the six weeks immediately following their concussion and from 24 healthy athletes. Second, 25 healthy non-athletes performed four quiet standing tasks: normal, co-contracting their lower extremity muscles, performing a cognitive arithmetic task, and voluntarily manipulating their sway. Postural complexity was calculated using approximate, sample, multi-variate sample, and multi-variate composite multi-scale (MV-CompMSE) entropy methods for both high-pass filtered and low-pass filtered COP data. MV-CompMSE of the high-pass filtered COP signal identified the most consistent differences between groups, with concussed athletes exhibiting less complexity over the high frequency COP time series. Among healthy non-athletes, high-pass filtered MV-CompMSE increased only in the co-contraction condition, suggesting the decrease in high frequency MV-CompMSE found in concussed athletes may be due to more relaxed muscles or less complex muscle contractions. This decrease in entropy may associate with reported increases in intra-cortical inhibition. Furthermore, a single-case study suggested high frequency MV-CompMSE may be a useful clinical tool for concussion management. (C) 2016 Elsevier B.V. All rights reserved.	[Fino, Peter C.] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97239 USA; [Fino, Peter C.] Virginia Tech, Dept Mech Engn, Blacksburg, VA USA; [Nussbaum, Maury A.] Virginia Tech, Dept Ind & Syst Engn, Blacksburg, VA USA; [Brolinson, Per Gunnar] Virginia Tech, Dept Sports Med, Blacksburg, VA USA; [Brolinson, Per Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA	Fino, PC (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97239 USA.	fino@ohsu.edu; nussbaum@vt.edu; pbrolins@vcom.vt.edu	Nussbaum, Maury A/A-9655-2008	Nussbaum, Maury A/0000-0002-1887-8431; Fino, Peter/0000-0002-8621-3706	National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF) [DGE 0822220]	The authors would like to thank Dr. Thurmon Lockhart for assistance in the initial stages of this work, and Lauren Becker and Brett Griesemer for contributing to data collection. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 0822220. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.	ALLUM JHJ, 1984, J NEUROPHYSIOL, V52, P797; Bottaro A, 2005, HUM MOVEMENT SCI, V24, P588, DOI 10.1016/j.humov.2005.07.006; Cantello R, 2007, NEUROSCIENCE, V150, P64, DOI 10.1016/j.neuroscience.2007.08.033; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Costa M, 2007, EPL-EUROPHYS LETT, V77, DOI 10.1209/0295-5075/77/68008; Coxon JP, 2006, J NEUROPHYSIOL, V95, P3371, DOI 10.1152/jn.01334.2005; Dault MC, 2003, COGNITIVE BRAIN RES, V16, P434, DOI 10.1016/S0926-6410(03)00058-2; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Dorman JC, 2015, J SCI MED SPORT, V18, P2, DOI 10.1016/j.jsams.2013.11.010; Duarte M, 2008, EXP BRAIN RES, V191, P265, DOI 10.1007/s00221-008-1521-7; Dubose DF, 2017, MED SCI SPORT EXER, V49, P167, DOI 10.1249/MSS.0000000000001067; EVANS CM, 1983, J PHYSIOL-LONDON, V344, P483, DOI 10.1113/jphysiol.1983.sp014953; Fino P., 2015, ANN BIOMED ENG, P1; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Gow B, 2015, ENTROPY, V17, P7849; Gruber AH, 2011, GAIT POSTURE, V34, P13, DOI 10.1016/j.gaitpost.2011.02.015; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; King L. A., 2013, ARCH PHYS MED REHABI; Kuznetsov N, 2013, ANN BIOMED ENG, V41, P1646, DOI 10.1007/s10439-012-0646-9; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Liepert J, 1998, EXP BRAIN RES, V118, P421, DOI 10.1007/s002210050296; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Loram ID, 2009, J NEUROPHYSIOL, V102, P460, DOI 10.1152/jn.00007.2009; Loram ID, 2005, J PHYSIOL-LONDON, V564, P281, DOI 10.1113/jphysiol.2004.073437; Loram ID, 2005, J PHYSIOL-LONDON, V564, P295, DOI 10.1113/jphysiol.2004.076307; Manor B, 2010, J APPL PHYSIOL, V109, P1786, DOI 10.1152/japplphysiol.00390.2010; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Mihalik JP, 2014, J SPORT HEALTH SCI, V3, P307, DOI 10.1016/j.jshs.2014.07.005; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Quatman-Yates CC, 2015, PEDIATR PHYS THER, V27, P316, DOI 10.1097/PEP.0000000000000193; Ramdani S, 2009, MED ENG PHYS, V31, P1023, DOI 10.1016/j.medengphy.2009.06.004; Rehman N., 2009, P ROYAL SOC LOND MAT; Rhea CK, 2015, GAIT POSTURE, V41, P731, DOI 10.1016/j.gaitpost.2015.01.008; Rhea CK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017696; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Roerdink M, 2011, HUM MOVEMENT SCI, V30, P203, DOI 10.1016/j.humov.2010.04.005; Schillings AM, 1999, BRAIN RES, V816, P480, DOI 10.1016/S0006-8993(98)01198-6; Singh NB, 2012, J ELECTROMYOGR KINES, V22, P131, DOI 10.1016/j.jelekin.2011.10.007; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stins JF, 2009, GAIT POSTURE, V30, P106, DOI 10.1016/j.gaitpost.2009.04.001; Tinazzi M, 2005, NEUROSCI LETT, V378, P55, DOI 10.1016/j.neulet.2004.12.015; Wei Q, 2012, ENTROPY-SWITZ, V14, P2157, DOI 10.3390/e14112157; Winter D. A., 2009, BIOMECHANICS MOTOR C, V4th; Wu SD, 2013, ENTROPY-SWITZ, V15, P1069, DOI 10.3390/e15031069; Zatsiorsky VM, 1999, MOTOR CONTROL, V3, P28, DOI 10.1123/mcj.3.1.28; Zhang HB, 2015, J ELECTROMYOGR KINES, V25, P937, DOI 10.1016/j.jelekin.2015.10.011; Zhou DG, 2015, EXP BRAIN RES, V233, P2401, DOI 10.1007/s00221-015-4310-0	57	21	21	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	OCT	2016	50						69	74		10.1016/j.gaitpost.2016.08.026			6	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	EB2LC	WOS:000387192600012	27580081	Bronze			2021-06-18	
J	Gale, SC; Kocik, JF; Creath, R; Crystal, JS; Dombrovskiy, VY				Gale, Stephen C.; Kocik, Jurek F.; Creath, Robert; Crystal, Jessica S.; Dombrovskiy, Viktor Y.			A comparison of initial lactate and initial base deficit as predictors of mortality after severe blunt trauma	JOURNAL OF SURGICAL RESEARCH			English	Article						Lactate; Base deficit; Blunt trauma; Metabolic acidosis; Shock; Resuscitation	INTENSIVE-CARE-UNIT; SERUM LACTATE; ARTERIAL LACTATE; BLOOD LACTATE; CLEARANCE; ACIDOSIS; UTILITY; INJURY; SEPSIS; SHOCK	Background: After injury, base deficit (BD) and lactate are common measures of shock. Lactate directly measures anaerobic byproducts, whereas BD is calculated and multifactorial. Although recent studies suggest superiority for lactate in predicting mortality, most were small or analyzed populations with heterogeneous injury severity. Our objective was to compare initial BD with lactate as predictors of inhospital mortality in a large cohort of blunt trauma patients all presenting with hemorrhagic shock. Materials and methods: The Glue Grant multicenter prospective cohort database was queried; demographic, injury, and physiologic parameters were compiled. Survivors, early deaths (<= 24 h), and late deaths were compared. Profound shock (lactate >= 4 mmol/L) and severe traumatic brain injury subgroups were identified a priori. Chi-square, t-test, and analysis of variance were used as appropriate for analysis. Multivariable logistic regression and area under the receiver operating characteristic curve analysis assessed survival predictors. P < 0.05 was significant. Results: A total of 1829 patients met inclusion; 289 (15.8%) died. Both BD and lactate were higher for nonsurvivors (P < 0.00001). After multivariable regression, both lactate (odds ratio [OR] 1.17; 95% confidence interval [CI]: 1.12-1.23; P < 0.00001) and BD (OR 1.04; 95% CI: 1.01-1.07; P < 0.005) predicted overall mortality. However, when excluding early deaths (n = 77), only lactate (OR 1.12 95% CI: 1.06-1.19; P < 0.0001) remained predictive but not BD (OR 1.00 95% CI: 0.97-1.04; P = 0.89). For the shock subgroup, (n = 915), results were similar with lactate, but not BD, predicting both early and late deaths. Findings also appear independent of traumatic brain injury severity. Conclusions: After severe blunt trauma, initial lactate better predicts inhospital mortality than initial BD. Initial BD does not predict mortality for patients who survive > 24 h. (C) 2016 Elsevier Inc. All rights reserved.	[Gale, Stephen C.; Kocik, Jurek F.] East Texas Med Ctr, Trauma Serv, Dept Surg, Tyler, TX USA; [Creath, Robert] East Texas Med Ctr, Dept Emergency Med, Tyler, TX USA; [Crystal, Jessica S.; Dombrovskiy, Viktor Y.] Rutgers RWJMS, Dept Surg, New Brunswick, NJ USA	Gale, SC (corresponding author), East Texas Med Ctr, Ctr Trauma, Elmer G Ellis Level 1,1020 E Idel St, Tyler, TX 75701 USA.	scgale@etmc.org		Gale, Stephen/0000-0002-6454-4686	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM062119]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM062119] Funding Source: NIH RePORTER	The authors would like to acknowledge the contribution of Inflammation and the Host Response to Injury investigators in the Large-Scale Collaborative Research Program, supported by the National Institute of General Medical Sciences (U54GM062119). Also, they are grateful for the influence and mentorship of Ms. Susette Coyle, RN, and Drs Stephen Lowry (deceased), Siobhan Corbett, and Steven Calvano-all from the Robert Wood Johnson Medical School, a Glue Grant "participating institution." They were instrumental in understanding the potential that this data set holds for clinical investigation and in helping formulate the questions investigated in this and other studies. Finally, they thank Mr Elmer G. Ellis for institutional support at East Texas Medical Center in Tyler, Texas.	ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Callaway DW, 2009, J TRAUMA, V66, P1040, DOI 10.1097/TA.0b013e3181895e9e; Casserly B, 2015, CRIT CARE MED, V43, P567, DOI 10.1097/CCM.0000000000000742; Davis JW, 2006, J TRAUMA, V60, P587; Davis JW, 1998, J TRAUMA, V44, P114, DOI 10.1097/00005373-199801000-00014; Dezman ZDW, 2015, J TRAUMA ACUTE CARE, V79, P580, DOI 10.1097/TA.0000000000000810; Galkova K, 2013, BRATISL MED J, V114, P637, DOI 10.4149/BLL_2013_136; Husain FA, 2003, AM J SURG, V185, P485, DOI 10.1016/S0002-9610(03)00044-8; Kincaid EH, 1998, J AM COLL SURGEONS, V187, P384, DOI 10.1016/S1072-7515(98)00202-6; Lavery RF, 2000, J AM COLL SURGEONS, V190, P656, DOI 10.1016/S1072-7515(00)00271-4; Li K, 2015, INT J CLIN EXP MED, V8, P6578; Martin MJ, 2006, AM J SURG, V191, P625, DOI 10.1016/j.amjsurg.2006.02.014; Marty P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-3; McNelis J, 2001, AM J SURG, V182, P481, DOI 10.1016/S0002-9610(01)00755-3; Mikulaschek A, 1996, J TRAUMA, V40, P218, DOI 10.1097/00005373-199602000-00008; Neville AL, 2011, AM SURGEON, V77, P1337; Odom SR, 2013, J TRAUMA ACUTE CARE, V74, P999, DOI 10.1097/TA.0b013e3182858a3e; Ouellet JF, 2012, J TRAUMA ACUTE CARE, V72, P1532, DOI 10.1097/TA.0b013e318256dd5a; Pal JD, 2006, J TRAUMA, V60, P583, DOI 10.1097/01.ta.0000205858.82575.55; Paladino L, 2008, RESUSCITATION, V77, P363, DOI 10.1016/j.resuscitation.2008.01.022; Regnier MA, 2012, ANESTHESIOLOGY, V117, P1276, DOI 10.1097/ALN.0b013e318273349d; Trauma Related Database (TRDB), 2011, INFL HOST RESP INJ	22	21	22	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2016	205	2					446	455		10.1016/j.jss.2016.06.103			10	Surgery	Surgery	EC2VG	WOS:000387981700025	27664895				2021-06-18	
J	Kamins, J; Giza, CC				Kamins, Joshua; Giza, Christopher C.			Concussion-Mild Traumatic Brain Injury Recoverable Injury with Potential for Serious Sequelae	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Concussion; Mild TBI; Sequalae of concussion	MINOR HEAD TRAUMA; SPORADIC HEMIPLEGIC MIGRAINE; SPORTS-RELATED CONCUSSION; DELAYED CEREBRAL EDEMA; POSTCONCUSSION SYNDROME; EARLY INTERVENTION; CONTROLLED-TRIAL; UNITED-STATES; EXERCISE; EPIDEMIOLOGY	Concussion is increasingly recognized as a major public health issue. Most patients will return to baseline and experience full recovery, although a subset experiences persistent symptoms. Newer animal models and imaging studies are beginning to demonstrate that metabolic and neurovascular resolution may actually take longer than symptomatic recovery. Repeat traumatic brain injury within the metabolic window of dysfunction may result in worsened symptoms and prolonged recovery. The true risk for second impact syndrome appears to be small, and development of cerebral edema after a mild impact may be related to genetic risks rather than serial impacts.	[Kamins, Joshua] Univ Calif Los Angeles, Dept Neurol, 710 Westwood Plaza,Suite 1-240, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Dept Neurosurg, Room 531 Wasserman,300 Stein Plaza, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp UCLA, Dept Pediat, Room 531 Wasserman,300 Stein Plaza, Los Angeles, CA 90095 USA	Giza, CC (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, Room 531 Wasserman,300 Stein Plaza, Los Angeles, CA 90095 USA.; Giza, CC (corresponding author), Univ Calif Los Angeles, Mattel Childrens Hosp UCLA, Dept Pediat, Room 531 Wasserman,300 Stein Plaza, Los Angeles, CA 90095 USA.	cgiza@mednet.ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NCAA; DODUnited States Department of Defense; NFL-GE; Today's and Tomorrow's Children Fund; UCLA BIRC; UCLA FGP; UCLA Steve Tisch BrainSPORT program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER	For full transparency, all funding sources are listed. Grants/Research Support: NIH, NCAA, DOD, NFL-GE, Today's and Tomorrow's Children Fund, UCLA BIRC, UCLA FGP, UCLA Steve Tisch BrainSPORT program; Consultant: NFL-NCP, NHLPA, Neural Analytics; Advisory Panel: LoveYourBrain, MLS, NBA, NCAA, Neural Analytics, USSF; Medicolegal: One or 2 cases annually; Speaker's Bureau: Medical Education Speakers Network; Stock Shareholder: None; Other Financial or Material Support: None; Other: Commissioner California State Athletic Commission (end 2/2015).	Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2981, DOI 10.1073/pnas.1508756112; Bey T, 2009, WEST J EMERG MED, V10, P6; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Bruner JS, 1960, PROCESS ED; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Clark PJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141898; Curtain RP, 2006, PEDIATR NEUROL, V34, P329, DOI 10.1016/j.pediatrneurol.2005.08.033; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Eckner JT, 2011, MED SCI SPORT EXER, V43, P382, DOI 10.1249/MSS.0b013e3181f1cc51; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Gage N. L., 1963, HDB RES TEACHING; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Giesser BS, 2015, THER ADV NEUROL DISO, V8, P123, DOI 10.1177/1756285615576663; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greco T, 2013, J NEUROTRAUM, V30, P1983, DOI 10.1089/neu.2013.2990; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Groot C, 2016, AGEING RES REV, V25, P13, DOI 10.1016/j.arr.2015.11.005; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heyer GL, 2014, PEDIATR NEUROL, V50, P464, DOI 10.1016/j.pediatrneurol.2014.01.040; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Iverson GL, 2015, BRAIN INJURY, V29, P263, DOI 10.3109/02699052.2014.965214; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kavalci C, 2014, WORLD J EMERG SURG, V9, DOI 10.1186/1749-7922-9-31; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lewis MS, 2011, NEUROUROL URODYNAM, V30, P183, DOI 10.1002/nau.20963; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Malmivaara A, 1995, Duodecim, V111, P2101; Malpas TJ, 2010, DEV MED CHILD NEUROL, V52, P103, DOI 10.1111/j.1469-8749.2009.03493.x; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Salmon P, 2001, CLIN PSYCHOL REV, V21, P33, DOI 10.1016/S0272-7358(99)00032-X; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	76	21	21	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					441	+		10.1016/j.nec.2016.05.005			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800006	27637394	Green Accepted, Bronze			2021-06-18	
J	Potter, SDS; Brown, RG; Fleminger, S				Potter, Sebastian D. S.; Brown, Richard G.; Fleminger, Simon			Randomised, waiting list controlled trial of cognitive-behavioural therapy for persistent postconcussional symptoms after predominantly mild-moderate traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC AMNESIA; RISK-FACTORS; QUESTIONNAIRE; REHABILITATION; RECOVERY; PREVENTION; FATIGUE; SCALE	Background Persistent postconcussional symptoms (PCS) can be a source of distress and disability following traumatic brain injury (TBI). Such symptoms have been viewed as difficult to treat but may be amenable to psychological approaches such as cognitive-behavioural therapy (CBT). Objectives To evaluate the effectiveness of a 12-session individualised, formulation-based CBT programme. Method Two-centre randomised waiting list controlled trial with 46 adults with persistent PCS after predominantly mild-to-moderate TBI (52% with post-traumatic amnesia (PTA)<= 24 hours), but including some with severe TBIs (20% with PTA>7 days). Results Improvements associated with CBT were found on the primary outcome measures relating to quality of life (using the Quality of Life Assessment Schedule and the Brain Injury Community Rehabilitation Outcome Scale). Treatment effects after covarying for treatment duration were also found for PCS and several secondary outcomes, including measures of anxiety and fatigue (but not depression or post-traumatic stress disorder (PTSD)). Improvements were more apparent for those completing CBT sessions over a shorter period of time, but were unrelated to medicolegal status, injury severity or length of time since injury. Conclusions This study suggests that CBT can improve quality of life for adults with persistent PCS and potentially reduce symptoms for some, in the context of outpatient brain injury rehabilitation services.	[Potter, Sebastian D. S.; Brown, Richard G.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, London, England; [Fleminger, Simon] Kings Coll London, Inst Psychiat Psychol & Neurosci, Sect Cognit Neuropsychiat, London, England; [Potter, Sebastian D. S.; Brown, Richard G.; Fleminger, Simon] South London & Maudsley NHS Fdn Trust, Maudsley Hosp, Lishman Unit, London, England	Potter, SDS (corresponding author), Inst Psychiat Psychol & Neurosci PO77, Dept Psychol, De Crespigny Pk, London SE5 8AZ, England.	sebastian.potter@kcl.ac.uk		Brown, Richard/0000-0001-9021-0172; Potter, Sebastian/0000-0002-2173-9870	National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London	RGB acknowledges salary support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Andersson EE, 2011, J REHABIL MED, V43, P323, DOI 10.2340/16501977-0666; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beurskens AJHM, 2000, OCCUP ENVIRON MED, V57, P353, DOI 10.1136/oem.57.5.353; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010; Davies R, 2005, BRAIN INJURY, V19, P941, DOI 10.1080/02699050400000565; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; FETTES PA, 1992, INT J EAT DISORDER, V11, P97, DOI 10.1002/1098-108X(199203)11:2&lt;97::AID-EAT2260110202&gt;3.0.CO;2-H; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frank J. D., 1982, PSYCHOTHERAPY RES BE, P5; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Gurr B, 2005, BRAIN INJURY, V19, P481, DOI 10.1080/02699050400005176; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kraft S, 2006, CLIN PSYCHOL PSYCHOT, V13, P397, DOI 10.1002/cpp.505; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MAHONEY F I, 1965, Md State Med J, V14, P61; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Selai CE, 2001, NEUROPSYCHOL REHABIL, V11, P219, DOI 10.1080/09602010042000033; Selai CE, 2000, EPILEPSY RES, V38, P67; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Spielberger C.D., 1999, STATE TRAIT ANGER EX; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Weiss DS., 1997, ASSESSING PSYCHOL TR, P399, DOI DOI 10.1037/T12199-000; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; World Health Organization, 1992, ICD 10 CLASS MENT BE; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	55	21	21	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2016	87	10					1075	1083		10.1136/jnnp-2015-312838			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	DW9OU	WOS:000383991400007	27496149				2021-06-18	
J	Sherman, SA; Phillips, JK; Costa, JT; Cho, FS; Oungoulian, SR; Finan, JD				Sherman, Sydney A.; Phillips, Jack K.; Costa, J. Tighe; Cho, Frances S.; Oungoulian, Sevan R.; Finan, John D.			Stretch Injury of Human Induced Pluripotent Stem Cell Derived Neurons in a 96 Well Format	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; HIPPOCAMPAL SLICE CULTURES; MECHANICAL STRETCH; AXONAL INJURY; STRAIN-RATE; MEMBRANE-PERMEABILITY; CALCIUM INFLUX; NEURAL TRAUMA; ION CHANNELS	Traumatic brain injury (TBI) is a major cause of mortality and morbidity with limited therapeutic options. Traumatic axonal injury (TAI) is an important component of TBI pathology. It is difficult to reproduce TAI in animal models of closed head injury, but in vitro stretch injury models reproduce clinical TAI pathology. Existing in vitro models employ primary rodent neurons or human cancer cell line cells in low throughput formats. This in vitro neuronal stretch injury model employs human induced pluripotent stem cell-derived neurons (hiPSCNs) in a 96 well format. Silicone membranes were attached to 96 well plate tops to create stretchable, culture substrates. A custom-built device was designed and validated to apply repeatable, biofidelic strains and strain rates to these plates. A high content approach was used to measure injury in a hypothesis-free manner. These measurements are shown to provide a sensitive, dose-dependent, multi-modal description of the response to mechanical insult. hiPSCNs transition from healthy to injured phenotype at approximately 35% Lagrangian strain. Continued development of this model may create novel opportunities for drug discovery and exploration of the role of human genotype in TAI pathology.	[Sherman, Sydney A.; Phillips, Jack K.; Finan, John D.] NorthShore Univ HealthSyst, Dept Neurosurg, Evanston, IL 60201 USA; [Costa, J. Tighe; Cho, Frances S.] Columbia Univ, Dept Biomed Engn, New York, NY USA	Finan, JD (corresponding author), NorthShore Univ HealthSyst, Dept Neurosurg, Evanston, IL 60201 USA.	jfinan@northshore.org		Finan, John/0000-0003-4626-9702			Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Alhebshi AH, 2014, NEUROSCI LETT, V570, P126, DOI 10.1016/j.neulet.2013.09.049; Amin H, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00121; Becker N, 2013, J PHARMACOL TOX MET, V68, P82, DOI 10.1016/j.vascn.2013.03.009; Berry BJ, 2015, BIOTECHNOL PROGR, V31, P1613, DOI 10.1002/btpr.2160; Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Dage JL, 2014, PSYCHOPHARMACOLOGY, V231, P1105, DOI 10.1007/s00213-013-3384-2; Di Pietro V, 2015, NEUROCHEM RES, V40, P991, DOI 10.1007/s11064-015-1554-9; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P83, DOI 10.1177/1545968315586465; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Haythornthwaite A, 2012, J BIOMOL SCREEN, V17, P1264, DOI 10.1177/1087057112457821; Holbourn A.H.S, 1943, LANCET, V243, P483; HUNG CT, 1994, J BIOMECH, V27, P227, DOI 10.1016/0021-9290(94)90212-7; Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Lai W.M., 1993, INTRO CONTINUUM MECH, V134; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Lang P, 2006, NAT REV DRUG DISCOV, V5, P343, DOI 10.1038/nrd2008; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Lee AA, 1996, AM J PHYSIOL-CELL PH, V271, pC1400; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Magou GC, 2011, J NEUROTRAUM, V28, P2203, DOI 10.1089/neu.2010.1596; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; Markos SM, 2017, J HEAD TRAUMA REHAB, V32, pE24, DOI 10.1097/HTR.0000000000000224; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister Thomas W, 2015, Handb Clin Neurol, V128, P723, DOI 10.1016/B978-0-444-63521-1.00045-5; Meneghello G, 2015, NEUROSCIENCE, V301, P204, DOI 10.1016/j.neuroscience.2015.05.071; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Morrison G, 2016, STEM CELL RES, V16, P140, DOI 10.1016/j.scr.2015.12.025; Odawara A, 2014, BIOCHEM BIOPH RES CO, V443, P1176, DOI 10.1016/j.bbrc.2013.12.142; Padmanabhan K, 2010, J NEUROSCI METH, V193, P380, DOI 10.1016/j.jneumeth.2010.08.031; Peterson C, 2015, CHILD MALTREATMENT, V20, P162, DOI 10.1177/1077559515583549; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Ryan KR, 2016, NEUROTOXICOLOGY, V53, P271, DOI 10.1016/j.neuro.2016.02.003; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SCHAFFER JL, 1994, J ORTHOP RES, V12, P709, DOI 10.1002/jor.1100120514; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Sirenko O, 2014, ASSAY DRUG DEV TECHN, V12, P536, DOI 10.1089/adt.2014.592; Smith DH, 1999, J NEUROSCI, V19, P4263; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Sunkara V, 2011, LAB CHIP, V11, P962, DOI 10.1039/c01c00272k; Tukker A. M., 2016, ALTEX, DOI 10.14573/altex.1510091; Ursekar CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090665; Usenovic M, 2015, J NEUROSCI, V35, P14234, DOI 10.1523/JNEUROSCI.1523-15.2015; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; Wheeler HE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118020; WILLIAMS JL, 1992, J BIOMECH ENG-T ASME, V114, P377, DOI 10.1115/1.2891398; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	60	21	21	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 27	2016	6								34097	10.1038/srep34097			12	Multidisciplinary Sciences	Science & Technology - Other Topics	DX0VY	WOS:000384085500001	27671211	DOAJ Gold, Green Published			2021-06-18	
J	Kuriakose, M; Skotak, M; Misistia, A; Kahali, S; Sundaramurthy, A; Chandra, N				Kuriakose, Matthew; Skotak, Maciej; Misistia, Anthony; Kahali, Sudeepto; Sundaramurthy, Aravind; Chandra, Namas			Tailoring the Blast Exposure Conditions in the Shock Tube for Generating Pure, Primary Shock Waves: The End Plate Facilitates Elimination of Secondary Loading of the Specimen	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; INDUCED NEUROTRAUMA; NERVOUS-SYSTEM; PRESSURE; IMPACT; MODEL; RAT	The end plate mounted at the mouth of the shock tube is a versatile and effective implement to control and mitigate the end effects. We have performed a series of measurements of incident shock wave velocities and overpressures followed by quantification of impulse values (integral of pressure in time domain) for four different end plate configurations (0.625, 2, 4 inches, and an open end). Shock wave characteristics were monitored by high response rate pressure sensors allocated in six positions along the length of 6 meters long 229 mm square cross section shock tube. Tests were performed at three shock wave intensities, which was controlled by varying the Mylar membrane thickness (0.02, 0.04 and 0.06 inch). The end reflector plate installed at the exit of the shock tube allows precise control over the intensity of reflected waves penetrating into the shock tube. At the optimized distance of the tube to end plate gap the secondary waves were entirely eliminated from the test section, which was confirmed by pressure sensor at T4 location. This is pronounced finding for implementation of pure primary blast wave animal model. These data also suggest only deep in the shock tube experimental conditions allow exposure to a single shock wave free of artifacts. Our results provide detailed insight into spatiotemporal dynamics of shock waves with Friedlander waveform generated using helium as a driver gas and propagating in the air inside medium sized tube. Diffusion of driver gas (helium) inside the shock tube was responsible for velocity increase of reflected shock waves. Numerical simulations combined with experimental data suggest the shock wave attenuation mechanism is simply the expansion of the internal pressure. In the absence of any other postulated shock wave decay mechanisms, which were not implemented in the model the agreement between theory and experimental data is excellent.	[Kuriakose, Matthew; Skotak, Maciej; Misistia, Anthony; Kahali, Sudeepto; Sundaramurthy, Aravind; Chandra, Namas] New Jersey Inst Technol, Ctr Injury Biomech Mat & Med CIBM3, Dept Biomed Engn, Newark, NJ 07102 USA	Chandra, N (corresponding author), New Jersey Inst Technol, Ctr Injury Biomech Mat & Med CIBM3, Dept Biomed Engn, Newark, NJ 07102 USA.	namas.chandra@njit.edu	Skotak, Maciej/H-4769-2019; Kahali, Sudeepto/G-9413-2018; Sundaramurthy, Aravind/O-2047-2019	Skotak, Maciej/0000-0003-2584-7294; Kahali, Sudeepto/0000-0001-8675-7466; Sundaramurthy, Aravind/0000-0002-0359-8680	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [14059001]	This work was supported by grant no. 14059001 entitled "Primary Blast Injury Criteria for Animal/Human TBI Models using Field Validated Shock Tubes" received from the U.S. Army Medical Research and Materiel Command.	BECKER H, 1965, J APPL POLYM SCI, V9, P911, DOI 10.1002/app.1965.070090309; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Burnside R, 1965, J AUSTRALIAN MATH SO, V5, P258; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I., 2015, FRONTIERS NEUROENGIN; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cullis I G, 2001, J R Army Med Corps, V147, P16; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DRYER M, 1967, J GEOPHYS RES, V72, P2955, DOI 10.1029/JZ072i011p02955; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; EMRICH RJ, 1953, J APPL PHYS, V24, P360, DOI 10.1063/1.1721279; GLASS II, 1955, J AERONAUT SCI, V22, P73, DOI 10.2514/8.3282; Gould KE, 1981, DTIC DOCUMENT; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOOKER WJ, 1963, J CHEM PHYS, V38, P214, DOI 10.1063/1.1733464; Hyde D., 2004, CONWEP 2 1 0 8; KIEFER JH, 1985, J PHYS CHEM-US, V89, P2013, DOI 10.1021/j100256a043; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; MIURA H, 1990, FLUID DYN RES, V6, P251, DOI 10.1016/0169-5983(90)90015-Q; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Needham C. E., 2010, BLAST WAVE PROPAGATI; Needham CE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00072; Newman AJ, 2010, J FLUID ENG-T ASME, V132, DOI 10.1115/1.4002183; PARK C, 1973, COMBUST FLAME, V20, P369, DOI 10.1016/0010-2180(73)90029-1; Rafaels KA, 2010, BLAST BRAIN INJURY R; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; SLEPICKA F, 1966, PHYS FLUIDS, V9, P1865, DOI 10.1063/1.1761946; SOMMERFELD M, 1985, EXP FLUIDS, V3, P197; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vieille P., 1899, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, V129, P1228; Yattoo Gh, 2008, J Trauma Manag Outcomes, V2, P5, DOI 10.1186/1752-2897-2-5; Zajtchuk R, 1991, CONVENTIONAL WARFARE, P241; Zel'dovlch YB, 1965, PHYS SHOCK WAVES HIG, P1966	44	21	21	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2016	11	9							e0161597	10.1371/journal.pone.0161597			19	Multidisciplinary Sciences	Science & Technology - Other Topics	DV9IX	WOS:000383255200019	27603017	DOAJ Gold, Green Published			2021-06-18	
J	Spencer, NG; Schilling, T; Miralles, F; Eder, C				Spencer, Nicholas G.; Schilling, Tom; Miralles, Francesc; Eder, Claudia			Mechanisms Underlying Interferon-gamma-Induced Priming of Microglial Reactive Oxygen Species Production	PLOS ONE			English	Article							MEDIATED NEUROTOXICITY; SUPEROXIDE-PRODUCTION; ION CHANNELS; K+ CHANNEL; PROTEIN; ACTIVATION; CELLS; NOX2; PHOSPHORYLATION; PROLIFERATION	Microglial priming and enhanced reactivity to secondary insults cause substantial neuronal damage and are hallmarks of brain aging, traumatic brain injury and neurodegenerative diseases. It is, thus, of particular interest to identify mechanisms involved in microglial priming. Here, we demonstrate that priming of microglia with interferon-gamma(IFN gamma) substantially enhanced production of reactive oxygen species (ROS) following stimulation of microglia with ATP. Priming of microglial ROS production was substantially reduced by inhibition of p38 MAPK activity with SB203580, by increases in intracellular glutathione levels with N-Acetyl-L-cysteine, by blockade of NADPH oxidase subunit NOX2 activity with gp91ds-tat or by inhibition of nitric oxide production with L-NAME. Together, our data indicate that priming of microglial ROS production involves reduction of intracellular glutathione levels, upregulation of NADPH oxidase subunit NOX2 and increases in nitric oxide production, and suggest that these simultaneously occurring processes result in enhanced production of neurotoxic peroxynitrite. Furthermore, IFN gamma-induced priming of microglial ROS production was reduced upon blockade of Kir2.1 inward rectifier K+ channels with ML133. Inhibitory effects of ML133 on microglial priming were mediated via regulation of intracellular glutathione levels and nitric oxide production. These data suggest that microglial Kir2.1 channels may represent novel therapeutic targets to inhibit excessive ROS production by primed microglia in brain pathology.	[Spencer, Nicholas G.; Schilling, Tom; Eder, Claudia] St Georges Univ London, Infect & Immun Res Inst, London, England; [Miralles, Francesc] St Georges Univ London, Mol & Clin Sci Res Inst, London, England; [Miralles, Francesc] St Georges Univ London, Inst Med & Biomed Educ, London, England	Eder, C (corresponding author), St Georges Univ London, Infect & Immun Res Inst, London, England.	ceder@sgul.ac.uk		Miralles, Francesc/0000-0003-3069-2725; Schilling, Tom/0000-0002-0274-5482	European Union FP7 grant "TargetBraIn" [279017]	This work was supported by European Union FP7 grant "TargetBraIn" (#279017) to CE.	Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; BEIS I, 1975, BIOCHEM J, V152, P23, DOI 10.1042/bj1520023; Bhattacharya A, 2016, GLIA, V64, P1772, DOI 10.1002/glia.23001; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65; Dale E, 2016, GLIA, V64, P1733, DOI 10.1002/glia.22992; Diebold BA, 2015, ANTIOXID REDOX SIGN, V23, P375, DOI 10.1089/ars.2014.5862; Eder C, 2010, J NEUROIMMUNOL, V224, P51, DOI 10.1016/j.jneuroim.2010.05.008; El-Benna J, 2008, SEMIN IMMUNOPATHOL, V30, P279, DOI 10.1007/s00281-008-0118-3; Franciosi S, 2002, J NEUROSCI RES, V69, P607, DOI 10.1002/jnr.10331; HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2; Haslund-Vinding J, 2017, BRIT J PHARMACOL, V174, P1733, DOI 10.1111/bph.13425; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796; Klegeris A, 1997, J NEUROSCI RES, V49, P229, DOI 10.1002/(SICI)1097-4547(19970715)49:2<229::AID-JNR11>3.0.CO;2-W; Lam D, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00185; LOWRY OH, 1964, J BIOL CHEM, V239, P18; Mangano EN, 2012, NEUROBIOL AGING, V33, P1411, DOI 10.1016/j.neurobiolaging.2011.02.016; McLarnon JG, 1997, NEUROSCIENCE, V78, P1217, DOI 10.1016/S0306-4522(96)00680-X; McManus RM, 2014, NEUROBIOL AGING, V35, P109, DOI 10.1016/j.neurobiolaging.2013.07.025; Milton RH, 2008, J NEUROSCI, V28, P11488, DOI 10.1523/JNEUROSCI.2431-08.2008; Minogue AM, 2014, NEUROBIOL AGING, V35, P1442, DOI 10.1016/j.neurobiolaging.2013.12.026; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nayernia Z, 2014, ANTIOXID REDOX SIGN, V20, P2815, DOI 10.1089/ars.2013.5703; Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Park YC, 1996, IMMUNOLOGY, V87, P296, DOI 10.1046/j.1365-2567.1996.456544.x; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Rojo AI, 2014, ANTIOXID REDOX SIGN, V21, P1766, DOI 10.1089/ars.2013.5745; Schilling T, 2015, GLIA, V63, P664, DOI 10.1002/glia.22776; Schilling T, 2014, J CELL SCI, V127, P4561, DOI 10.1242/jcs.151068; Schilling T, 2011, J CELL PHYSIOL, V226, P3295, DOI 10.1002/jcp.22675; Schilling T, 2010, J NEUROIMMUNOL, V225, P190, DOI 10.1016/j.jneuroim.2010.05.024; Schilling T, 2009, J NEUROIMMUNOL, V216, P118, DOI 10.1016/j.jneuroim.2009.07.008; Schmitz M, 2015, NEUROBIOL AGING, V36, P2597, DOI 10.1016/j.neurobiolaging.2015.05.013; Steinert JR, 2010, NEUROSCIENTIST, V16, P435, DOI 10.1177/1073858410366481; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Thomas MP, 2007, J NEUROCHEM, V100, P503, DOI 10.1111/j.1471-4159.2006.04315.x; vanMuiswinkel FL, 1996, J NEUROCHEM, V66, P2468; Vilhardt F, 2002, J BIOL CHEM, V277, P42136, DOI 10.1074/jbc.M200862200; Wu LJ, 2012, NAT NEUROSCI, V15, P565, DOI 10.1038/nn.3059; Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965	46	21	21	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2016	11	9							e0162497	10.1371/journal.pone.0162497			17	Multidisciplinary Sciences	Science & Technology - Other Topics	DV9IT	WOS:000383254800071	27598576	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Consistency and cost of dual-task gait balance measure in healthy adolescents and young adults	GAIT & POSTURE			English	Article						Gait; Balance; Concussion; Mild traumatic brain injury	ERROR SCORING SYSTEM; CONCUSSION; MANAGEMENT; STABILITY; RECOVERY	Matched control data are commonly used to examine recovery from concussion. Limited data exist, however, examining dual-task gait data consistency collected over time in healthy individuals. The study purposes were to: 1) assess the consistency of single-task and dual-task gait balance control measures, 2) determine the minimal detectable change (MDC) of gait balance control measures, and 3) examine the extent to which age and task complexity affect dual-task walking costs in healthy adolescents and young adults. Twenty-four adolescent (mean age = 15.5 +/- 1.1 years) and 21 young adult (mean age = 21.2 +/- 4.5 years) healthy participants completed 5 testing sessions across a two-month period, which involved analyses of gait balance control and temporal-distance variables during single-task and dual-task walking conditions in a motion analysis laboratory. Cronbach's alpha and MDCs were used to determine the consistency of the gait balance control variables and the smallest amount of change required to distinguish true performance from change due to the performance/measurement variability, respectively. Dual-task costs were evaluated to determine the effect of task complexity and age across time using 3-way ANOVAs. Good to excellent test-retest consistency was found for all single-task and dual-task walking (Cronbach's a range: 0.764-0.970), with a center-of-mass medial-lateral displacement MDC range of 0.835-0.948 cm. Greater frontal plane dual-task costs were observed during more complex secondary tasks (p < 0.001). The results revealed good-excellent consistency across testing sessions for all variables and indicated dual-task costs are affected by task complexity. Thus, healthy controls can be effective comparators when assessing injured subjects. (C) 2016 Elsevier B.V. All rights reserved.	[Howell, David R.] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA; [Howell, David R.] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, 319 Longwood Ave, Boston, MA 02115 USA; [Howell, David R.] Boston Childrens Hosp, Brain Injury Ctr, 319 Longwood Ave, Boston, MA 02115 USA; [Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA	Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, 122 Esslinger Hall, Eugene, OR 97403 USA.	chou@uoregon.edu		Howell, David/0000-0002-2955-0191; Chou, Li-Shan/0000-0002-2777-7034	Veterans Administration subcontract awards [A4842C8, A4843C]; Translational Research Award from the University of Oregon; Department of Defense-TATRC Award [W81XWH-11-1-0717]; Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology; Peace Health Oregon Region	Funding for the data collection of this work was supported by Veterans Administration subcontract awards [A4842C8 & A4843C], Translational Research Award from the University of Oregon and Peace Health Oregon Region, the Department of Defense-TATRC Award (W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology. The authors would also like to acknowledge Mr. Quinn Peterson, Mr. Michael Kado, Ms. Madison Murray, and Ms. Rachel Klas for their assistance with data collection.	Amin DJ, 2014, J SPORTS SCI, V2, P200, DOI DOI 10.17265/2332-7839/2014.04.005; Buckley T. A., 2015, J SPORT HLTH SCI; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Godde B, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00139; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kim S, 2008, J EDUC MEAS, V45, P179, DOI 10.1111/j.1745-3984.2008.00059.x; Kline P., 2013, HDB PSYCHOL TESTING, P13; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P., 2012, CONS STAT CONC SPORT, p[482013, 554]; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Ries JD, 2009, PHYS THER, V89, P569, DOI 10.2522/ptj.20080258; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; SUTHERLAND DH, 1980, J BONE JOINT SURG AM, V62, P336, DOI 10.2106/00004623-198062030-00004; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Winter D. A., 2009, BIOMECHANICS MOTOR C, P86; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	27	21	21	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	SEP	2016	49						176	180		10.1016/j.gaitpost.2016.07.008			5	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	DY1MF	WOS:000384858400030	27427835	Bronze			2021-06-18	
J	Hutchinson, EB; Schwerin, SC; Radomski, KL; Irfanoglu, MO; Juliano, SL; Pierpaoli, CM				Hutchinson, Elizabeth B.; Schwerin, Susan C.; Radomski, Kryslaine L.; Irfanoglu, Mustafa O.; Juliano, Sharon L.; Pierpaoli, Carlo M.			QUANTITATIVE MRI AND DTI ABNORMALITIES DURING THE ACUTE PERIOD FOLLOWING CCI IN THE FERRET	SHOCK			English	Article						Anisotropy; diffusion tensor imaging; microgliosis; T2 relaxometry; traumatic axonal injury	TRAUMATIC BRAIN-INJURY; COMMON DATA ELEMENTS; WHITE-MATTER INJURY; AXONAL INJURY; DIFFEOMORPHIC REGISTRATION; MOUSE MODEL; DIFFUSION; RAT	During the acute time period following traumatic brain injury (TBI), noninvasive brain imaging tools such as magnetic resonance imaging (MRI) can provide important information about the clinical and pathological features of the injury and may help predict long-term outcomes. In addition to standard imaging approaches, several quantitative MRI techniques including relaxometry and diffusion MRI have been identified as promising reporters of cellular alterations after TBI and may provide greater sensitivity and specificity for identifying brain abnormalities especially in mild TBI. However, for these imaging tools to be useful, it is crucial to define their relationship with the neurophysiological response to brain injury. Recently, a model of controlled cortical impact (CCI) has been developed in the ferret which has many advantages compared with rodent models (e.g., gyrencephalic cortex and high white matter volume). The objective of this study was to evaluate quantitative MRI metrics in the ferret CCI model, including T2 values and diffusion tensor imaging (DTI) metrics, during the acute time period. Longitudinal quantitative comparisons of in vivo MRI and DTI metrics were evaluated to identify abnormalities and characterize their spatial patterns in the ferret brain. Ex vivo MRI and DTI maps were then compared with histological staining for glial and neuronal abnormalities. The main findings of this article describe T2, diffusivity, and anisotropy markers of tissue change during the acute time period following mild TBI, and ex vivo analyses suggest that MRI and DTI markers are sensitive to subtle cellular alterations in this model. This was confirmed by comparison with immunohistochemistry, also showing altered markers in regions of MRI and DTI change.	[Hutchinson, Elizabeth B.; Irfanoglu, Mustafa O.; Pierpaoli, Carlo M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bldg 13,Room 3W16,13 South Dr, Bethesda, MD 20892 USA; [Schwerin, Susan C.; Radomski, Kryslaine L.; Juliano, Sharon L.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Hutchinson, Elizabeth B.; Schwerin, Susan C.; Radomski, Kryslaine L.; Irfanoglu, Mustafa O.] Henry M Jackson Fdn Adv Mil Med Inc, Bethesda, MD USA	Hutchinson, EB (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bldg 13,Room 3W16,13 South Dr, Bethesda, MD 20892 USA.	elizabeth.hutchinson@nih.gov	Juliano, Sharon/AAO-1030-2020; Pierpaoli, Carlo/E-1672-2011	Pierpaoli, Carlo/0000-0001-8558-4428; Schwerin, Susan/0000-0001-5435-2448; Radomski, Kryslaine/0000-0001-9624-623X; Hutchinson, Elizabeth/0000-0002-3374-5469	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIHEB000088, ZIAEB000089] Funding Source: NIH RePORTER		Arfanakis K, 2002, MAGN RESON IMAGING, V20, P511, DOI 10.1016/S0730-725X(02)00509-X; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Irfanoglu MO, 2016, NEUROIMAGE, V132, P439, DOI 10.1016/j.neuroimage.2016.02.066; Irfanoglu MO, 2015, NEUROIMAGE, V106, P284, DOI 10.1016/j.neuroimage.2014.11.042; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.0.CO;2-J; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; PIERPAOLI C, 1993, RADIOLOGY, V189, P439, DOI 10.1148/radiology.189.2.8210373; Pierpaoli C, 2010, ISMRM 19 ANN M STOCK; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Schwerin S, 2014, 44 ANN M SOC NEUR WA; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	23	21	21	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	SEP	2016	46	3		1			167	176		10.1097/SHK.0000000000000659			10	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	DX3HG	WOS:000384263600024	27294688	Green Published			2021-06-18	
J	Wang, Q; Fan, WJ; Cai, Y; Wu, QL; Mo, LD; Huang, ZW; Huang, HL				Wang, Qin; Fan, Weijia; Cai, Ying; Wu, Qiaoli; Mo, Lidong; Huang, Zhenwu; Huang, Huiling			Protective effects of taurine in traumatic brain injury via mitochondria and cerebral blood flow	AMINO ACIDS			English	Article						Traumatic brain injury; Taurine; Mitochondrion; Cerebral blood flow	ENDOPLASMIC-RETICULUM STRESS; ANTIOXIDANT ACTIVITY; DYSFUNCTION; METABOLISM; RESUSCITATION; INFLAMMATION; MORPHOLOGY; MECHANISM; APOPTOSIS; CALCIUM	In mammalian tissues, taurine is an important natural component and the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. This study is to examine the taurine's protective effects on neuronal ultrastructure, the function of the mitochondrial respiratory chain complex, and on cerebral blood flow (CBF). The model of traumatic brain injury (TBI) was made for SD rats by a fluid percussion device, with taurine (200 mg/kg) administered by tail intravenous injection once daily for 7 days after TBI. It was found that CBF was improved for both left and right brain at 30 min and 7 days post-injury by taurine. Reaction time was prolonged relative to the TBI-only group. Neuronal damage was prevented by 7 days taurine. Mitochondrial electron transport chain complexes I and II showed greater activity with the taurine group. The improvement by taurine of CBF may alleviate edema and elevation in intracranial pressure. Importantly taurine improved the hypercoagulable state.	[Wang, Qin; Huang, Zhenwu] Chinese Ctr Dis Control & Prevent, Natl Inst Nutr & Hlth, 27 Nanwei Rd, Beijing 100050, Peoples R China; [Wang, Qin; Fan, Weijia; Cai, Ying; Wu, Qiaoli; Mo, Lidong; Huang, Huiling] Tianjin Huanhu Hosp, Tianjin Neurol Inst, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, 6 Jizhao Rd, Tianjin 300350, Peoples R China	Huang, HL (corresponding author), Tianjin Huanhu Hosp, Tianjin Neurol Inst, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, 6 Jizhao Rd, Tianjin 300350, Peoples R China.	huanghuiling@126.com		, Qin/0000-0002-5891-9621	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973089, 81571216]	The authors would like to thank support from the National Natural Science Foundation of China (Grant Nos. 30973089 and 81571216).	Aly HAA, 2014, FOOD CHEM TOXICOL, V64, P1, DOI 10.1016/j.fct.2013.11.007; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Curtis L, 2014, J NEUROSURG SCI, V58, P151; Dagal A, 2011, CURR OPIN ANESTHESIO, V24, P131, DOI 10.1097/ACO.0b013e3283445898; El Idrissi A, 2008, AMINO ACIDS, V34, P321, DOI 10.1007/s00726-006-0396-9; Gharibani PM, 2013, ADV EXP MED BIOL, V776, P241, DOI 10.1007/978-1-4614-6093-0_23; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; Guan WH, 2011, TRANSL STROKE RES, V2, P80, DOI 10.1007/s12975-010-0050-4; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155; Johansson PI, 2013, TRANSFUSION, V53, P3088, DOI 10.1111/trf.12214; Jong CJ, 2015, AMINO ACIDS, V47, P2609, DOI 10.1007/s00726-015-2053-7; Jong CJ, 2012, AMINO ACIDS, V42, P2223, DOI 10.1007/s00726-011-0962-7; Kallakuri S, 2015, J CLIN IMAG SCI, V5, DOI 10.4103/2156-7514.166354; Keelan J, 1999, BRAIN RES, V821, P124, DOI 10.1016/S0006-8993(99)01084-7; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kim C, 2014, AMINO ACIDS, V46, P89, DOI 10.1007/s00726-013-1545-6; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Luddington RJ, 2005, CLIN LAB HAEMATOL, V27, P81, DOI 10.1111/j.1365-2257.2005.00681.x; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Menzie J, 2014, AMINO ACIDS, V46, P31, DOI 10.1007/s00726-012-1382-z; Nakajima Y, 2010, J NEUROTRAUM, V27, P403, DOI 10.1089/neu.2009.1044; Pan CL, 2012, AMINO ACIDS, V43, P845, DOI 10.1007/s00726-011-1141-6; Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1; Peterson EC, 2011, INT J VASC MED, V2011, DOI 10.1155/2011/823525; Prentice H, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964518; Rak K, 2014, NEUROREPORT, V25, P1250, DOI 10.1097/WNR.0000000000000254; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Rosca AE, 2013, BLOOD COAGUL FIBRIN, V24, P256, DOI 10.1097/MBC.0b013e32835b7611; Schaffer S, 2000, AMINO ACIDS, V19, P527, DOI 10.1007/s007260070004; Schaffer S, 2016, AMINO ACIDS, V48, P549, DOI 10.1007/s00726-015-2110-2; Schaffer SW, 2014, AMINO ACIDS, V46, P1147, DOI 10.1007/s00726-014-1708-0; Schaffer SW, 2014, AMINO ACIDS, V46, P21, DOI 10.1007/s00726-012-1378-8; Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6; Setyarani M, 2014, EUR J NUTR, V53, P929, DOI 10.1007/s00394-013-0596-5; Shimada K, 2015, ADV EXP MED BIOL, V803, P581, DOI 10.1007/978-3-319-15126-7_47; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Sun M, 2015, J NEUROTRAUM, V32, P66, DOI 10.1089/neu.2012.2432; Sun M, 2012, AMINO ACIDS, V42, P1735, DOI 10.1007/s00726-011-0885-3; Sun M, 2011, AMINO ACIDS, V40, P1419, DOI 10.1007/s00726-010-0751-8; Sun QR, 2014, BIOCHEM BIOPH RES CO, V447, P485, DOI 10.1016/j.bbrc.2014.04.019; Tapia NM, 2013, J TRAUMA ACUTE CARE, V74, P378, DOI 10.1097/TA.0b013e31827e20e0; Vlodavsky E, 2017, J CEREBR BLOOD F MET, V37, P166, DOI 10.1177/0271678X15621068; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang YJ, 2013, ACTA BIOCH BIOPH SIN, V45, P359, DOI 10.1093/abbs/gmt034; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zhou F, 2006, ADV EXP MED BIOL, V583, P353; Zhu KJ, 2014, WORLD J GASTROENTERO, V20, P9585, DOI 10.3748/wjg.v20.i28.9585	57	21	23	0	11	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0939-4451	1438-2199		AMINO ACIDS	Amino Acids	SEP	2016	48	9					2169	2177		10.1007/s00726-016-2244-x			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DU1XR	WOS:000382004500007	27156064				2021-06-18	
J	Wang, P; Li, H; Barde, S; Zhang, MD; Sun, J; Wang, T; Zhang, P; Luo, HJ; Wang, YJ; Yang, YT; Wang, CY; Svenningsson, P; Theodorsson, E; Hokfelt, TGM; Xu, ZQD				Wang, Peng; Li, Hui; Barde, Swapnali; Zhang, Ming-Dong; Sun, Jing; Wang, Tong; Zhang, Pan; Luo, Hanjiang; Wang, Yongjun; Yang, Yutao; Wang, Chuanyue; Svenningsson, Per; Theodorsson, Elvar; Hokfelt, Tomas G. M.; Xu, Zhi-Qing David			Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						dorsal raphe; neuropeptide; siRNA; stress; transmitter coexistence	DORSAL RAPHE NUCLEUS; CENTRAL-NERVOUS-SYSTEM; NONSEROTONERGIC PROJECTION NEURONS; GAMMA-AMINOBUTYRIC-ACID; PHASEOLUS-VULGARIS-LEUKOAGGLUTININ; SINGLE-CELL TRANSCRIPTOMICS; PREPROGALANIN MESSENGER-RNA; UNPREDICTABLE MILD STRESS; MEDIAL PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY	The neuropeptide galanin coexists in rat brain with serotonin in the dorsal raphe nucleus and with noradrenaline in the locus coeruleus (LC), and it has been suggested to be involved in depression. We studied rats exposed to chronic mild stress (CMS), a rodent model of depression. As expected, these rats showed several endophenotypes relevant to depression-like behavior compared with controls. All these endophenotypes were normalized after administration of a selective serotonin reuptake inhibitor. The transcripts for galanin and two of its receptors, galanin receptor 1 (GALR1) and GALR2, were analyzed with quantitative real-time PCR using laser capture microdissection in the following brain regions: the hippocampal formation, LC, and ventral periaqueductal gray (vPAG). Only Galr1 mRNA levels were significantly increased, and only in the latter region. After knocking down Galr1 in the vPAG with an siRNA technique, all parameters of the depressive behavioral phenotype were similar to controls. Thus, the depression-like behavior in rats exposed to CMS is likely related to an elevated expression of Galr1 in the vPAG, suggesting that a GALR1 antagonist could have antidepressant effects.	[Wang, Peng; Li, Hui; Sun, Jing; Wang, Tong; Zhang, Pan; Luo, Hanjiang; Yang, Yutao; Xu, Zhi-Qing David] Capital Med Univ, Beijing Inst Brain Disorders, Minist Sci & Technol, Beijing Lab Brain Disorders,Dept Neurobiol,Beijin, Beijing 100069, Peoples R China; [Barde, Swapnali; Zhang, Ming-Dong; Hokfelt, Tomas G. M.] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; [Zhang, Ming-Dong] Karolinska Inst, Dept Biochem & Biophys, Div Mol Neurobiol, SE-17177 Stockholm, Sweden; [Wang, Yongjun; Wang, Chuanyue] Capital Med Univ, Anding Hosp, Beijing 100088, Peoples R China; [Svenningsson, Per] Karolinska Inst, Dept Neurol & Clin Neurosci, Ctr Mol Med, SE-17176 Stockholm, Sweden; [Svenningsson, Per] Karolinska Univ Hosp, SE-17176 Stockholm, Sweden; [Theodorsson, Elvar] Linkoping Univ, Dept Clin Chem, SE-58183 Linkoping, Sweden; [Theodorsson, Elvar] Linkoping Univ, Dept Clin & Expt Med, SE-58183 Linkoping, Sweden; [Wang, Peng] Logist Univ Peoples Armed Police Force, Dept Anat & Histoembryol, Tianjin 300309, Peoples R China	Xu, ZQD (corresponding author), Capital Med Univ, Beijing Inst Brain Disorders, Minist Sci & Technol, Beijing Lab Brain Disorders,Dept Neurobiol,Beijin, Beijing 100069, Peoples R China.; Hokfelt, TGM (corresponding author), Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden.	tomas.hokfelt@ki.se; zhiqingx@ccmu.edu.cn	Theodorsson, Elvar/H-2096-2011; Wang, Chuan-Yue/C-9369-2015; Xu, Zhi-Qing David/H-9757-2013	Theodorsson, Elvar/0000-0003-0756-7723; Wang, Chuan-Yue/0000-0001-6549-3713; Xu, Zhi-Qing David/0000-0002-0387-7559; Zhang, Mingdong/0000-0002-6348-1994	National Natural Sciences Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30870815, 31171032]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7091002]; National Basic Research Program of China 973 ProgramNational Basic Research Program of China [2010CB912003]; Beijing Talent Project [PHR20100510]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [4X-2887]; Seed Grant of the International Alliance of Translational Neuroscience [PXM2014_014226_000006]; Beijing Brain Project [Z161100000216142]; KI	We thank Prof. Staffan Cullheim [Karolinska Institutet (KI)] for critical support and Professor Kathryn Commons (Childrens Hospital, Harvard University) for valuable advice. Laser-scanning microscopy was made available by the center for Live Imaging of Cells at the KI, an imaging core facility supported by the Knut and Alice Wallenberg Foundation. This study was supported by the National Natural Sciences Foundation of China (Grants 30870815 and 31171032), Beijing Natural Science Foundation (Key Project 7091002), National Basic Research Program of China 973 Program (Grant 2010CB912003), Beijing Talent Project (Grant PHR20100510), Swedish Research Council (Grant 4X-2887), Seed Grant PXM2014_014226_000006 of the International Alliance of Translational Neuroscience, and Beijing Brain Project (Grant Z161100000216142), as well as by funds from the KI.	Abrams JK, 2004, ANN NY ACAD SCI, V1018, P46, DOI 10.1196/annals.1296.005; AGHAJANIAN GK, 1977, BRAIN RES, V122, P229, DOI 10.1016/0006-8993(77)90291-8; Bang SJ, 2012, J COMP NEUROL, V520, P4157, DOI 10.1002/cne.23146; BARABAN JM, 1981, BRAIN RES, V204, P1, DOI 10.1016/0006-8993(81)90646-6; BARBARESI P, 1988, NEUROSCIENCE, V27, P183, DOI 10.1016/0306-4522(88)90229-1; Barr AM, 2006, NEUROSCI LETT, V405, P111, DOI 10.1016/j.neulet.2006.06.033; Barrera G, 2005, NEUROPEPTIDES, V39, P289, DOI 10.1016/j.npep.2004.12.008; Bartfai T, 2012, TRENDS PHARMACOL SCI, V33, P9, DOI 10.1016/j.tips.2011.09.006; BELIN MF, 1983, BRAIN RES, V275, P329, DOI 10.1016/0006-8993(83)90994-0; BELIN MF, 1979, BRAIN RES, V170, P279, DOI 10.1016/0006-8993(79)90107-0; BING O, 1993, NEUROSCI LETT, V164, P17, DOI 10.1016/0304-3940(93)90846-D; Borroto-Escuela DO, 2010, BIOCHEM BIOPH RES CO, V393, P767, DOI 10.1016/j.bbrc.2010.02.078; Branchek TA, 2000, TRENDS PHARMACOL SCI, V21, P109, DOI 10.1016/S0165-6147(00)01446-2; Brown RE, 2008, EUR J NEUROSCI, V27, P352, DOI 10.1111/j.1460-9568.2008.06024.x; Burazin TCD, 2000, EUR J NEUROSCI, V12, P2901, DOI 10.1046/j.1460-9568.2000.00184.x; Burbach JPH, 2010, EUR J PHARMACOL, V626, P27, DOI 10.1016/j.ejphar.2009.10.015; Calizo LH, 2011, NEUROPHARMACOLOGY, V61, P524, DOI 10.1016/j.neuropharm.2011.04.008; Celada P, 2001, J NEUROSCI, V21, P9917, DOI 10.1523/JNEUROSCI.21-24-09917.2001; Celada P, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00025; Chandler DJ, 2013, BRAIN RES, V1522, P38, DOI 10.1016/j.brainres.2013.04.057; Cheung CC, 2001, NEUROSCIENCE, V103, P423, DOI 10.1016/S0306-4522(01)00012-4; Commons KG, 2009, J CHEM NEUROANAT, V38, P273, DOI 10.1016/j.jchemneu.2009.05.005; Commons KG, 2015, J COMP NEUROL, V523, P1488, DOI 10.1002/cne.23748; Commons KG, 2005, EUR J NEUROSCI, V21, P1577, DOI 10.1111/j.1460-9568.2005.03991.x; Coppen A J, 1968, Adv Pharmacol, V6, P283; Crawford LK, 2010, J NEUROPHYSIOL, V103, P2652, DOI 10.1152/jn.01132.2009; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DESCARRIES L, 1982, J COMP NEUROL, V207, P239, DOI 10.1002/cne.902070305; Dorocic IP, 2014, NEURON, V83, P663, DOI 10.1016/j.neuron.2014.07.002; Eberwine J, 2011, PHARMACOL THERAPEUT, V129, P241, DOI 10.1016/j.pharmthera.2010.09.010; FORD B, 1995, J COMP NEUROL, V363, P177, DOI 10.1002/cne.903630203; FRITSCHY JM, 1990, J COMP NEUROL, V293, P616, DOI 10.1002/cne.902930407; Fu WY, 2010, J COMP NEUROL, V518, P3464, DOI 10.1002/cne.22407; Fuxe K, 1998, ANN NY ACAD SCI, V863, P274, DOI 10.1111/j.1749-6632.1998.tb10702.x; FUXE K, 1990, SEROTONIN, P169; Fuxe K, 1991, GALANIN NEW MULTIFUN, DOI [DOI 10.1007/978-1-349-12664-4_16, 10.1007/978-1-349-12664-4_16]; Fuxe Kjell, 2012, Front Endocrinol (Lausanne), V3, P127, DOI 10.3389/fendo.2012.00127; Fuxe K, 2010, PROG NEUROBIOL, V90, P82, DOI 10.1016/j.pneurobio.2009.10.012; Gabbott PLA, 2005, J COMP NEUROL, V492, P145, DOI 10.1002/cne.20738; Gervasoni D, 2000, J NEUROSCI, V20, P4217; Gras C, 2002, J NEUROSCI, V22, P5442; Griebel G, 2013, NAT REV DRUG DISCOV, V12, P667, DOI 10.1038/nrd4075; Griebel G, 2012, NAT REV DRUG DISCOV, V11, P462, DOI 10.1038/nrd3702; GUNDLACH AL, 1990, EUR J PHARMACOL, V184, P163, DOI 10.1016/0014-2999(90)90677-X; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; Hajos M, 1998, NEUROSCIENCE, V87, P95, DOI 10.1016/S0306-4522(98)00157-2; HARANDI M, 1987, NEUROSCIENCE, V21, P237, DOI 10.1016/0306-4522(87)90336-8; HEDLUND PB, 1992, EUR J PHARMACOL, V224, P203, DOI 10.1016/0014-2999(92)90806-F; Hioki H, 2010, J COMP NEUROL, V518, P668, DOI 10.1002/cne.22237; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hokfelt T, 2003, LANCET NEUROL, V2, P463, DOI 10.1016/S1474-4422(03)00482-4; Hokfelt T., 1984, CLASSICAL NEUROTRA 1, V2, P157; Hokfelt T, 1984, CLASSICAL TRANSMITTE, P157; HOLETS VR, 1988, NEUROSCIENCE, V24, P893, DOI 10.1016/0306-4522(88)90076-0; Holmes A, 2005, PSYCHOPHARMACOLOGY, V178, P276, DOI 10.1007/s00213-004-1997-1; Holmes A, 2003, TRENDS PHARMACOL SCI, V24, P580, DOI 10.1016/j.tips.2003.09.011; Holmes A., 2006, CNS & Neurological Disorders-Drug Targets, V5, P225, DOI 10.2174/187152706776359600; Holmes A, 2003, NEUROPSYCHOPHARMACOL; HOLMES PV, 1995, PHARMACOL BIOCHEM BE, V50, P655, DOI 10.1016/0091-3057(94)00334-3; Iismaa T P, 1999, Results Probl Cell Differ, V26, P257; Jackson J, 2009, SYNAPSE, V63, P31, DOI 10.1002/syn.20581; JACOBS BL, 1992, PHYSIOL REV, V72, P165; Jankowski MP, 2004, J COMP NEUROL, V468, P518, DOI 10.1002/cne.10976; Johnson PL, 2008, J PSYCHOPHARMACOL, V22, P642, DOI 10.1177/0269881107082900; Johnson PL, 2004, ANN NY ACAD SCI, V1018, P58, DOI 10.1196/annals.1296.006; Jolas T, 1997, BRAIN RES, V755, P229, DOI 10.1016/S0006-8993(97)00103-0; Juhasz G, 2014, P NATL ACAD SCI USA, V111, pE1666, DOI 10.1073/pnas.1403649111; Kalueff AV, 2007, DEPRESS ANXIETY, V24, P495, DOI 10.1002/da.20262; Karlsson RM, 2006, AMINO ACIDS, V31, P231, DOI 10.1007/s00726-006-0336-8; Kawa L, 2016, EXP NEUROL, V279, P159, DOI 10.1016/j.expneurol.2016.02.019; Kendell SF, 2005, EXPERT OPIN THER TAR, V9, P153, DOI 10.1517/14728222.9.1.153; Khoshbouei H, 2002, PHARMACOL BIOCHEM BE, V71, P407, DOI 10.1016/S0091-3057(01)00683-9; Kim MA, 2004, BRAIN RES, V1026, P56, DOI 10.1016/j.brainres.2004.08.022; Kirby LG, 2003, NEUROSCIENCE, V116, P669, DOI 10.1016/S0306-4522(02)00584-5; Kuteeva E, 2008, NEUROPSYCHOPHARMACOL, V33, P2573, DOI 10.1038/sj.npp.1301660; Kuteeva E, 2010, EXPERIENTIA SUPPL, V102, P163, DOI 10.1007/978-3-0346-0228-0_12; Lang R, 2015, PHARMACOL REV, V67, P118, DOI 10.1124/pr.112.006536; Larm JA, 2003, EUR J NEUROSCI, V17, P481, DOI 10.1046/j.1460-9568.2003.02471.x; Le Maitre E, 2013, P NATL ACAD SCI USA, V110, pE536, DOI 10.1073/pnas.1221378110; Lee HS, 2003, BRAIN RES, V963, P57, DOI 10.1016/S0006-8993(02)03841-6; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Li YQ, 2001, BRAIN RES, V900, P110, DOI 10.1016/S0006-8993(01)02272-7; LLOYD KG, 1989, PROG NEURO-PSYCHOPH, V13, P341, DOI 10.1016/0278-5846(89)90123-1; Lu Xiaoying, 2007, CNS & Neurological Disorders-Drug Targets, V6, P183, DOI 10.2174/187152707780619335; Lu XY, 2005, P NATL ACAD SCI USA, V102, P874, DOI 10.1073/pnas.0408891102; Machado-Vieira R, 2009, PHARMACOL THERAPEUT, V123, P143, DOI 10.1016/j.pharmthera.2009.02.010; Maes Michael, 1995, P933; MAGOUL R, 1986, J HISTOCHEM CYTOCHEM, V34, P735, DOI 10.1177/34.6.2422252; Marinelli S, 2004, J NEUROPHYSIOL, V92, P3532, DOI 10.1152/jn.00437.2004; Maubach KA, 1999, CURR OPIN CHEM BIOL, V3, P481, DOI 10.1016/S1367-5931(99)80070-2; MELANDER T, 1986, J COMP NEUROL, V248, P475, DOI 10.1002/cne.902480404; Melander T, 1988, J Chem Neuroanat, V1, P213; Melander T., 1986, GABA NEUROPEPTIDES R, V6, P3640; Mennicken F, 2002, J CHEM NEUROANAT, V24, P257, DOI 10.1016/S0891-0618(02)00068-6; Millan MJ, 2006, PHARMACOL THERAPEUT, V110, P135, DOI 10.1016/j.pharmthera.2005.11.006; Millon C, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu064; Mohler H, 2012, NEUROPHARMACOLOGY, V62, P42, DOI 10.1016/j.neuropharm.2011.08.040; Moller C, 1999, NEUROPSYCHOPHARMACOL, V21, P507, DOI 10.1016/S0893-133X(98)00102-X; MOORE RY, 1981, SEROTONIN NEUROTRANS, P35; Moreau J L, 1992, Eur Neuropsychopharmacol, V2, P43; NANOPOULOS D, 1982, BRAIN RES, V232, P375, DOI 10.1016/0006-8993(82)90281-5; Nemeroff CB, 2005, J CLIN PSYCHIAT, V66, P5; O'Donnell D, 1999, J COMP NEUROL, V409, P469; O'Leary OF, 2007, EUR NEUROPSYCHOPHARM, V17, P215, DOI 10.1016/j.euroneuro.2006.06.012; ODONNELL D, 2003, HAND CHEM N, V20, P195; Ogren SO, 2006, CNS DRUGS, V20, P633; OTTERSEN OP, 1984, J COMP NEUROL, V229, P374, DOI 10.1002/cne.902290308; Paul IA, 2003, ANN NY ACAD SCI, V1003, P250, DOI 10.1196/annals.1300.016; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Perez SE, 2001, J COMP NEUROL, V434, P158, DOI 10.1002/cne.1171; Petschner P, 2016, NEUROPEPTIDES, V57, P65, DOI 10.1016/j.npep.2016.01.010; Peyron C, 1998, NEUROSCIENCE, V82, P443; Peyron C, 1996, J COMP NEUROL, V364, P402; Picciotto MR, 2010, BRAIN RES, V1314, P206, DOI 10.1016/j.brainres.2009.08.033; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; Pittenger Christopher, 2007, CNS & Neurological Disorders-Drug Targets, V6, P101, DOI 10.2174/187152707780363267; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; PRIESTLEY JV, 1993, J NEUROSCI METH, V48, P99, DOI 10.1016/S0165-0270(05)80011-1; Puig MV, 2005, CEREB CORTEX, V15, P1, DOI 10.1093/cercor/bhh104; Rovin ML, 2012, NEUROPEPTIDES, V46, P81, DOI 10.1016/j.npep.2012.01.001; Saar I, 2013, J NEUROCHEM, V127, P114, DOI 10.1111/jnc.12274; Saar I, 2013, NEUROCHEM RES, V38, P398, DOI 10.1007/s11064-012-0933-8; Sajdyk TJ, 2004, NEUROPEPTIDES, V38, P225, DOI 10.1016/j.npep.2004.05.006; Schafer MKH, 2002, J BIOL CHEM, V277, P50734, DOI 10.1074/jbc.M206738200; Schatzberg Alan F., 1995, P911; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; Sciolino NR, 2012, NEUROSCI BIOBEHAV R, V36, P1965, DOI 10.1016/j.neubiorev.2012.06.005; Sciolino NR, 2012, BEHAV BRAIN RES, V233, P191, DOI 10.1016/j.bbr.2012.05.001; Sergeyev V, 2005, PSYCHOPHARMACOLOGY, V178, P115, DOI 10.1007/s00213-004-2015-3; SESACK SR, 1989, J COMP NEUROL, V290, P213, DOI 10.1002/cne.902900205; Sharkey LM, 2008, NEUROCHEM RES, V33, P285, DOI 10.1007/s11064-007-9524-5; Sharp T, 2007, TRENDS PHARMACOL SCI, V28, P629, DOI 10.1016/j.tips.2007.10.009; Sharp T, 2011, CURR OPIN PHARMACOL, V11, P45, DOI 10.1016/j.coph.2011.02.003; Shi TJS, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-80; Shikanai H, 2012, J NEUROSCI, V32, P14415, DOI 10.1523/JNEUROSCI.5929-11.2012; Shutoh F, 2008, NEUROSCI LETT, V432, P132, DOI 10.1016/j.neulet.2007.12.050; SKOFITSCH G, 1985, PEPTIDES, V6, P509, DOI 10.1016/0196-9781(85)90118-4; SKOFITSCH G, 1986, PEPTIDES, V7, P1029, DOI 10.1016/0196-9781(86)90133-6; SMITH GST, 1994, J COMP NEUROL, V350, P23, DOI 10.1002/cne.903500103; Soiza-Reilly M, 2011, J CHEM NEUROANAT, V41, P247, DOI 10.1016/j.jchemneu.2011.04.004; Spaethling JM, 2014, FASEB J, V28, P771, DOI 10.1096/fj.13-240267; STAMP JA, 1995, BRAIN RES, V677, P39, DOI 10.1016/0006-8993(95)00119-B; Steckler T, 2008, HBK BEHAV NEUROSCI, V17, P157, DOI 10.1016/S1569-7339(07)00010-0; STEINBUSCH HWM, 1982, J HISTOCHEM CYTOCHEM, V30, P756, DOI 10.1177/30.8.6749970; STEINBUSCH HWM, 1981, NEUROSCIENCE, V6, P557, DOI 10.1016/0306-4522(81)90146-9; Swanson CJ, 2005, P NATL ACAD SCI USA, V102, P17489, DOI 10.1073/pnas.0508970102; Sweerts BW, 1999, MOL BRAIN RES, V69, P113, DOI 10.1016/S0169-328X(99)00095-9; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; Taylor M, 2003, PSYCHOL MED, V33, P387, DOI 10.1017/S0033291702006876; Templin JS, 2012, BRAIN RES, V1457, P1, DOI 10.1016/j.brainres.2012.03.066; Theodorsson E, 2000, SCAND J CLIN LAB INV, V60, P411; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; TRULLAS R, 1990, EUR J PHARMACOL, V185, P1, DOI 10.1016/0014-2999(90)90204-J; Valentino RJ, 2005, NEUROPEPTIDES, V39, P1, DOI 10.1016/j.npep.2004.09.005; Varga V, 2001, NEUROSCIENCE, V106, P783, DOI 10.1016/S0306-4522(01)00294-9; Wang P, 2011, EXPRESSION GALANIN I, pS; WANG QP, 1992, BRAIN RES BULL, V29, P943; Waters SM, 2000, NEUROSCIENCE, V95, P265; Weiss JM, 2005, NEUROPEPTIDES, V39, P281, DOI 10.1016/j.npep.2004.12.028; Weiss JM, 1998, ANN NY ACAD SCI, V863, P364, DOI 10.1111/j.1749-6632.1998.tb10707.x; Weissbourd B, 2014, NEURON, V83, P645, DOI 10.1016/j.neuron.2014.06.024; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Wu G, 2011, EXPERT OPIN THER TAR, V15, P1317, DOI 10.1517/14728222.2011.628314; Xu ZQD, 1998, NEUROSCIENCE, V87, P79, DOI 10.1016/S0306-4522(98)00151-1; Xu ZQD, 1998, J COMP NEUROL, V392, P227, DOI 10.1002/(SICI)1096-9861(19980309)392:2<227::AID-CNE6>3.0.CO;2-4; Xu ZQD, 2005, NEUROPEPTIDES, V39, P269, DOI 10.1016/j.npep.2005.02.003; Xu ZQD, 1997, J CHEM NEUROANAT, V13, P169, DOI 10.1016/S0891-0618(97)00043-4; Xu ZQD, 1999, P NATL ACAD SCI USA, V96, P14583, DOI 10.1073/pnas.96.25.14583; Yilmaz A, 2002, PHARMACOL BIOCHEM BE, V71, P341, DOI 10.1016/S0091-3057(01)00693-1; Zarate CA, 2004, AM J PSYCHIAT, V161, P171, DOI 10.1176/appi.ajp.161.1.171	171	21	22	0	8	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 9	2016	113	32					E4726	E4735		10.1073/pnas.1609198113			10	Multidisciplinary Sciences	Science & Technology - Other Topics	DT2EJ	WOS:000381293300021	27457954	Bronze, Green Published			2021-06-18	
J	Liu, LY; Song, HF; Duan, HJ; Chai, JK; Yang, J; Li, X; Yu, YH; Zhang, XL; Hu, XH; Xiao, MJ; Feng, R; Yin, HN; Hu, Q; Yang, LL; Du, JD; Li, TR				Liu, Lingying; Song, Huifeng; Duan, Hongjie; Chai, Jiake; Yang, Jing; Li, Xiao; Yu, Yonghui; Zhang, Xulong; Hu, Xiaohong; Xiao, Mengjing; Feng, Rui; Yin, Huinan; Hu, Quan; Yang, Longlong; Du, Jundong; Li, Tianran			TSG-6 secreted by human umbilical cord-MSCs attenuates severe burn-induced excessive inflammation via inhibiting activations of P38 and JNK signaling	SCIENTIFIC REPORTS			English	Article							MESENCHYMAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; ANTIINFLAMMATORY PROTEIN TSG-6; COLLAGEN-INDUCED ARTHRITIS; BV2 MICROGLIAL CELLS; OXIDATIVE STRESS; IN-VIVO; SYSTEMIC INFLAMMATION; IMMUNE-RESPONSES; DBA/1J MICE	The hMSCs have become a promising approach for inflammation treatment in acute phase. Our previous study has demonstrated that human umbilical cord-MSCs could alleviate the inflammatory reaction of severely burned wound. In this study, we further investigated the potential role and mechanism of the MSCs on severe burn-induced excessive inflammation. Wistar rats were randomly divided into following groups: Sham, Burn, Burn+ MSCs, Burn+ MAPKs inhibitors, and Burn, Burn+ MSCs, Burn+ Vehicle, Burn+ siTSG-6, Burn+ rhTSG-6 in the both experiments. It was found that MSCs could only down-regulate P38 and JNK signaling, but had no effect on ERK in peritoneal macrophages of severe burn rats. Furthermore, suppression of P38 and JNK activations significantly reduced the excessive inflammation induced by severe burn. TSG-6 was secreted by MSCs using different inflammatory mediators. TSG-6 from MSCs and recombinant human (rh) TSG-6 all significantly reduced activations of P38 and JNK signaling induced by severe burn and then attenuated excessive inflammations. On the contrary, knockdown TSG-6 in the cells significantly increased phosphorylation of P38 and JNK signaling and reduced therapeutic effect of the MSCs on excessive inflammation. Taken together, this study suggested TSG-6 from MSCs attenuated severe burn-induced excessive inflammation via inhibiting activation of P38 and JNK signaling.	[Liu, Lingying; Song, Huifeng; Duan, Hongjie; Chai, Jiake; Yang, Jing; Li, Xiao; Yu, Yonghui; Zhang, Xulong; Hu, Xiaohong; Xiao, Mengjing; Feng, Rui; Yin, Huinan; Hu, Quan; Yang, Longlong; Du, Jundong; Li, Tianran] Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Burn & Plast Surg, Beijing, Peoples R China	Chai, JK (corresponding author), Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Burn & Plast Surg, Beijing, Peoples R China.	cjk304@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81372052, 81501694, 81471873]; Nursery Fund of PLA General Hospital [14KMM22]	This work was supported by four research projects of National Natural Science Foundation of China (81372052), (81501694), (81471873) and the Nursery Fund of PLA General Hospital (14KMM22).	Arno A, 2011, PHARMACEUTICALS, V4, P1355, DOI 10.3390/ph4101355; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Beltran SR, 2015, J PERIODONTOL, V86, P62, DOI 10.1902/jop.2014.140187; Bettaieb A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113019; Chen X, 2012, BIOMET BIOSTAT S, V2012, P1, DOI DOI 10.1002/LDR.2366; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Chu Wan-li, 2012, Zhonghua Yi Xue Za Zhi, V92, P853; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; Costantini TW, 2009, J SURG RES, V156, P64, DOI 10.1016/j.jss.2009.03.066; Dahiya P, 2009, FRONT BIOSCI, V14, P4962, DOI 10.2741/3580; Eynott PR, 2004, IMMUNOLOGY, V112, P446, DOI 10.1111/j.1365-2567.2004.01887.x; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Gu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep08733; Guo SX, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0548-3; Hatakeyama N, 2014, CURR PHARM DESIGN, V20, P5766, DOI 10.2174/138161282036140912122809; Hocking AM, 2010, EXP CELL RES, V316, P2213, DOI 10.1016/j.yexcr.2010.05.009; Ipaktchi K, 2006, J IMMUNOL, V177, P8065, DOI 10.4049/jimmunol.177.11.8065; Kim DS, 2015, AM J CHINESE MED, V43, P731, DOI 10.1142/S0192415X15500457; Kott M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112323; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee MJ, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-40; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Li BS, 2015, NAT MED, V21, P563, DOI 10.1038/nm.3840; Liu LY, 2013, J TRAUMA ACUTE CARE, V75, P789, DOI 10.1097/TA.0b013e3182a6862b; Liu LY, 2015, INT J CLIN EXP PATHO, V8, P6367; Liu LY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088348; Liu Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-135; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Milner CM, 2006, BIOCHEM SOC T, V34, P446, DOI 10.1042/BST0340446; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; Nemoto W, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-38; Noone C, 2013, STEM CELLS DEV, V22, P3003, DOI 10.1089/scd.2013.0028; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Qiu JL, 2015, NEUROCHEM INT, V85-86, P46, DOI 10.1016/j.neuint.2015.04.007; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Sheikh AM, 2011, NEUROBIOL DIS, V41, P717, DOI 10.1016/j.nbd.2010.12.009; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Sun T, 2015, AM J TRANSL RES, V7, P891; Sun X, 2015, J ETHNOPHARMACOL, V170, P81, DOI 10.1016/j.jep.2015.05.001; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Wang N, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt142; Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043768; Wang S, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0019-z; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; Xu Jiajun, 2014, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V26, P405, DOI 10.3760/cma.j.issn.2095-4352.2014.06.008; Xue LA, 2013, INT J CLIN EXP PATHO, V6, P1327; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	50	21	22	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 22	2016	6								30121	10.1038/srep30121			13	Multidisciplinary Sciences	Science & Technology - Other Topics	DR6OQ	WOS:000380021600001	27444207	DOAJ Gold, Green Published			2021-06-18	
J	You, WD; Feng, JF; Tang, QL; Cao, J; Wang, L; Lei, J; Mao, Q; Gao, GY; Jiang, JY				You, Wendong; Feng, Junfeng; Tang, Qilin; Cao, Jun; Wang, Lei; Lei, Jin; Mao, Qing; Gao, Guoyi; Jiang, Jiyao			Intraventricular intracranial pressure monitoring improves the outcome of older adults with severe traumatic brain injury: an observational, prospective study	BMC ANESTHESIOLOGY			English	Article						Intraventricular intracranial pressure monitoring; Severe traumatic brain injury; Older adults	SEVERE HEAD-INJURY; INCREASED MORTALITY; INTENSIVE-CARE; MANAGEMENT; TRIAL; MULTICENTER; HYPOXIA; AGE	Background: Intracranial pressure (ICP) monitoring is widely used in the management of patients with severe traumatic brain injury (TBI). However, there is limited evidence about the efficacy of ICP monitoring in older subjects (aged >= 65 years). This study evaluated the effect of intraventricular ICP monitoring on the outcome of older adults suffering from a severe TBI. Methods: This prospective, observational study included 166 older TBI patients (aged >= 65 years) with Glasgow Coma scale (GCS) scores lower than 9 at admission. The study cohort was divided into two groups, intraventricular ICP monitoring and non-ICP monitoring. The primary outcome was in-hospital mortality. The secondary outcomes included the Glasgow Outcome Scale (GOS) score 6 months after injury, the ICU and total hospital lengths of stay, and mechanical ventilation days. Results: There were 80 patients in the intraventricular ICP monitoring group and 86 patients in non-ICP monitoring group. There was no statistical difference between groups in demographics and severity of head injury. Patients treated with intraventricular ICP monitoring had lower in-hospital mortality (33.8 % vs 51.2 %, P < 0.05), a higher 6-month GOS score (3.0 +/- 1.4 vs 2.5 +/- 1.2 P < 0.05), and a lower dosage (514 +/- 246 g vs 840 +/- 323 g, P < 0.0001) and shorter duration (7.2 +/- 3.6 days vs 8.4 +/- 4.3 days, P < 0.01) of mannitol use. However, the ICU length of stay (14.3 +/- 6.4 days vs 11.6 +/- 5.8 days, P < 0.01) and mechanical ventilation days (6.7 +/- 3.5 days vs 5.6 +/- 2.4 days, P < 0.05) were longer in the ICP monitoring group. The total length of hospital stay did not differ between the two groups (28.5 +/- 12.1 days vs 26.1 +/- 13.5 days, P = 0.23). Conclusions: Intraventricular ICP monitoring may have beneficial effects on the decreased in-hospital mortality and improved 6-month outcome of older patients with severe TBI. However, given that this was an observational study conducted in a single institution, further well-designed randomized control trials are needed to evaluate the effect of intraventricular ICP monitoring on the outcome of older severe TBI patients.	[You, Wendong; Feng, Junfeng; Tang, Qilin; Cao, Jun; Wang, Lei; Lei, Jin; Mao, Qing; Gao, Guoyi; Jiang, Jiyao] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurosurg, Shanghai 200127, Peoples R China; [You, Wendong; Feng, Junfeng; Tang, Qilin; Cao, Jun; Wang, Lei; Lei, Jin; Mao, Qing; Gao, Guoyi; Jiang, Jiyao] Shanghai Inst Head Trauma, Shanghai 200127, Peoples R China	Gao, GY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurosurg, Shanghai 200127, Peoples R China.; Gao, GY (corresponding author), Shanghai Inst Head Trauma, Shanghai 200127, Peoples R China.	gao3@sina.com					Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kasotakis G, 2012, J AM COLL SURGEONS, V214, P950, DOI 10.1016/j.jamcollsurg.2012.03.004; Lane PL, 2000, CAN J SURG, V43, P442; Liu H, 2015, WORLD NEUROSURG, V83, P794, DOI 10.1016/j.wneu.2014.12.040; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; Melhem S, 2014, CRIT CARE, V18, DOI 10.1186/cc13713; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Perez-Perez AJ, 2002, AM J NEPHROL, V22, P573, DOI 10.1159/000065279; Procaccio F, 2000, J Neurosurg Sci, V44, P1; Sarrafzadeh AS, 2014, WORLD NEUROSURG, V82, pE393, DOI 10.1016/j.wneu.2013.07.012; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tang A, 2015, J SURG RES, V194, P565, DOI 10.1016/j.jss.2014.11.017; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965; Zeng JS, 2013, J NEUROSURG, V119, P1228, DOI 10.3171/2013.7.JNS122131	34	21	23	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	JUL 11	2016	16								35	10.1186/s12871-016-0199-9			8	Anesthesiology	Anesthesiology	DR3UX	WOS:000379829200003	27401211	DOAJ Gold, Green Published			2021-06-18	
J	Dong, H; Ma, YF; Ren, ZX; Xu, B; Zhang, YH; Chen, J; Yang, B				Dong, Hui; Ma, Yunfu; Ren, Zengxi; Xu, Bin; Zhang, Yunhe; Chen, Jing; Yang, Bo			Sigma-1 Receptor Modulates Neuroinflammation After Traumatic Brain Injury	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Sigma-1 receptor; Nitrosative stress; Oxidative stress	MACROPHAGE SUBSETS; SPINAL-CORD; MICROGLIA; MICE; ACTIVATION; NEUROTOXICITY; INFLAMMATION; SURVIVAL; TISSUE; RAT	Traumatic brain injury (TBI) remains a significant clinical problem and contributes to one-third of all injury-related deaths. Activated microglia-mediated inflammatory response is a distinct characteristic underlying pathophysiology of TBI. Here, we evaluated the effect and possible mechanisms of the selective Sigma-1 receptor agonist 2-(4-morpholinethyl)-1-phenylcyclohexanecarboxylate (PRE-084) in mice TBI model. A single intraperitoneal injection 10 mu g/g PRE-084, given 15 min after TBI significantly reduced lesion volume, lessened brain edema, attenuated modified neurological severity score, increased the latency time in wire hang test, and accelerated body weight recovery. Moreover, immunohistochemical analysis with Iba1 staining showed that PRE-084 lessened microglia activation. Meanwhile, PRE-084 reduced nitrosative and oxidative stress to proteins. Thus, Sigma-1 receptors play a major role in inflammatory response after TBI and may serve as useful target for TBI treatment in the future.	[Dong, Hui; Yang, Bo] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou 450052, Henan, Peoples R China; [Dong, Hui; Ma, Yunfu; Zhang, Yunhe; Chen, Jing] Zhengzhou Univ, Affiliated Hosp 3, Dept Pediat Neurosurg, Zhengzhou 450052, Henan, Peoples R China; [Ren, Zengxi] Pingdingshan Second Peoples Hosp, Dept Neurosurg, Pingdingshan 467000, Henan, Peoples R China; [Xu, Bin] Shanxi Dayi Hosp, Dept Neurosurg, Taiyuan 030000, Shanxi, Peoples R China	Yang, B (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou 450052, Henan, Peoples R China.	dr_yangbo@126.com			Chinese Academy of SciencesChinese Academy of Sciences [XDA01030300]; 211 Project-phase III of Zhengzhou University-the basic and clinical research of stem cells; Excellent Youth Foundation of Henan Scientific Committee [114100510005]; Henan Province; Bureau of Science and Technology Development Project from Henan Province [200902310250]	This study was supported by Strategic Priority Research Program of the Chinese Academy of Sciences (XDA01030300), 211 Project-phase III of Zhengzhou University-the basic and clinical research of stem cells, Excellent Youth Foundation of Henan Scientific Committee (114100510005), Young Excellent Teachers in University Funded Projects of Henan Province, and Bureau of Science and Technology Development Project from Henan Province (200902310250).	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Chen ZZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092133; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Girgis H, 2013, BRAIN RES, V1491, P78, DOI 10.1016/j.brainres.2012.10.049; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kimura Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075760; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mancuso R, 2012, NEUROTHERAPEUTICS, V9, P814, DOI 10.1007/s13311-012-0140-y; Maurice T, 2009, PHARMACOL THERAPEUT, V124, P195, DOI 10.1016/j.pharmthera.2009.07.001; Opara J A, 2014, J Med Life, V7, P124; Pabba M, 2014, J NEUROSCI, V34, P11325, DOI 10.1523/JNEUROSCI.0458-14.2014; Peviani M, 2014, NEUROBIOL DIS, V62, P218, DOI 10.1016/j.nbd.2013.10.010; Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Xie CC, 2015, BRAIN RES, V1602, P1, DOI 10.1016/j.brainres.2014.03.021; Yang Y, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-108; Yuan YM, 2015, BRAIN BEHAV IMMUN, V48, P287, DOI 10.1016/j.bbi.2015.04.008; Zhao J, 2014, INVEST OPHTH VIS SCI, V55, P3375, DOI 10.1167/iovs.13-12823; Zhao S, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-67	37	21	21	0	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUL	2016	36	5					639	645		10.1007/s10571-015-0244-0			7	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	DN9LP	WOS:000377401400001	26228028				2021-06-18	
J	Moghieb, A; Bramlett, HM; Das, JH; Yang, ZH; Selig, T; Yost, RA; Wang, MS; Dietrich, WD; Wang, KKW				Moghieb, Ahmed; Bramlett, Helen M.; Das, Jyotirmoy H.; Yang, Zhihui; Selig, Tyler; Yost, Richard A.; Wang, Michael S.; Dietrich, W. Dalton; Wang, Kevin K. W.			Differential Neuroproteomic and Systems Biology Analysis of Spinal Cord Injury	MOLECULAR & CELLULAR PROTEOMICS			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; INFLAMMATORY CYTOKINES; REVERSED-PHASE; BIOMARKERS; PROTEIN; PROTEOMICS; CALPAIN; SEPARATION	Acute spinal cord injury (SCI) is a devastating condition with many consequences and no known effective treatment. Although it is quite easy to diagnose traumatic SCI, the assessment of injury severity and projection of disease progression or recovery are often challenging, as no consensus biomarkers have been clearly identified. Here rats were subjected to experimental moderate or severe thoracic SCI. At 24h and 7d postinjury, spinal cord segment caudal to injury center versus sham samples was harvested and subjected to differential proteomic analysis. Cationic/anionic-exchange chromatography, followed by 1D polyacrylamide gel electrophoresis, was used to reduce protein complexity. A reverse phase liquid chromatography-tandem mass spectrometry proteomic platform was then utilized to identify proteome changes associated with SCI. Twenty-two and 22 proteins were up-regulated at 24 h and 7 day after SCI, respectively; whereas 19 and 16 proteins are down-regulated at 24 h and 7 day after SCI, respectively, when compared with sham control. A subset of 12 proteins were identified as candidate SCI biomarkers -TF (Transferrin), FASN (Fatty acid synthase), NME1 (Nucleoside diphosphate kinase 1), STMN1 (Stathmin 1), EEF2 (Eukaryotic translation elongation factor 2), CTSD (Cathepsin D), ANXA1 (Annexin A1), ANXA2 (Annexin A2), PGM1 (Phosphoglucomutase 1), PEA15 (Phosphoprotein enriched in astrocytes 15), GOT2 (Glutamic-oxaloacetic transaminase 2), and TPI-1 (Triosephosphate isomerase 1), data are available via ProteomeXchange with identifier PXD003473. In addition, Transferrin, Cathepsin D, and TPI-1 and PEA15 were further verified in rat spinal cord tissue and/or CSF samples after SCI and in human CSF samples from moderate/severe SCI patients. Lastly, a systems biology approach was utilized to determine the critical biochemical pathways and interactome in the pathogenesis of SCI. Thus, SCI candidate biomarkers identified can be used to correlate with disease progression or to identify potential SCI therapeutic targets.	[Moghieb, Ahmed; Das, Jyotirmoy H.; Yang, Zhihui; Selig, Tyler] Univ Florida, Program Neurotrauma Neuroprote & Biomarkres Res, Gainesville, FL 32611 USA; [Moghieb, Ahmed; Yang, Zhihui; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, 1149 Newell Dr, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA; [Moghieb, Ahmed; Yost, Richard A.] Univ Florida, Dept Chem, Gainesville, FL 32611 USA; [Bramlett, Helen M.; Wang, Michael S.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace LPLC 3-18, Miami, FL 33136 USA; [Bramlett, Helen M.; Wang, Michael S.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace LPLC 3-18, Miami, FL 33136 USA; [Das, Jyotirmoy H.] Washington Univ, Sch Med, St Louis, MO 63110 USA	Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, 1149 Newell Dr, Gainesville, FL 32611 USA.	kwang@ufl.edu		Wang, Kevin/0000-0002-9343-6473	DODUnited States Department of Defense [W81XWH-12-1-0276]; United States ArmyUnited States Department of Defense [W81XWH-12-1-0277]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U24DK097209] Funding Source: NIH RePORTER	This study is supported in part by the DOD grant W81XWH-12-1-0276 (WDD, MSW) and W81XWH-12-1-0277 (KKW) from the United States Army.	Agrawal G, 2010, SPINE, V35, P1122, DOI 10.1097/BRS.0b013e3181be5fa7; Allard L, 2005, CLIN CHEM, V51, P2043, DOI 10.1373/clinchem.2005.053942; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Boja ES, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-22; Cao F, 2008, J CLIN NEUROSCI, V15, P541, DOI 10.1016/j.jocn.2007.05.014; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cortez R., 2008, CURR TREAT OPTION NE, V9, P115; Davidsson P, 2005, DIS MARKERS, V21, P81, DOI 10.1155/2005/848676; Ding QX, 2006, PROTEOMICS, V6, P505, DOI 10.1002/pmic.200500296; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Fekete T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085190; Gil-Dones F, 2009, BIOMARK INSIGHTS, V4, P135; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Holly LT, 2009, J NEUROSURG-SPINE, V10, P194, DOI 10.3171/2008.12.SPINE08367; Issaq HJ, 2005, J CHROMATOGR B, V817, P35, DOI 10.1016/j.jchromb.2004.07.042; Johann DJ, 2004, ANN NY ACAD SCI, V1022, P295, DOI 10.1196/annals.1318.045; Kang SK, 2006, PROTEOMICS, V6, P2797, DOI 10.1002/pmic.200500621; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kobeissy FH, 2008, EXPERT REV PROTEOMIC, V5, P293, DOI 10.1586/14789450.5.2.293; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Kotelnikova E, 2015, MULT SCLER J, V21, P138, DOI 10.1177/1352458514543339; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2; Lubieniecka JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019247; Ma JJ, 2001, SCAND J PLAST RECONS, V35, P355; Okon EB, 2013, J NEUROTRAUM, V30, P1564, DOI 10.1089/neu.2013.2956; Paul D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/783131; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Pinzon A, 2008, EXP NEUROL, V213, P129, DOI 10.1016/j.expneurol.2008.05.018; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Pouw MH, 2009, SPINAL CORD, V47, P519, DOI 10.1038/sc.2008.176; Qian JC, 2010, J NEUROTRAUM, V27, P599, DOI 10.1089/neu.2009.1145; Reis FM, 2011, SPINAL CORD, V49, P361, DOI 10.1038/sc.2010.121; Sajja BR, 2009, NEUROIMAG CLIN N AM, V19, P45, DOI 10.1016/j.nic.2008.08.002; Sharif A, 2004, NEUROSCIENCE, V126, P263, DOI 10.1016/j.neuroscience.2004.02.039; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Sheng S, 2006, MOL CELL PROTEOMICS, V5, P26, DOI 10.1074/mcp.T500019-MCP200; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Stammers AT, 2012, J NEUROSCI RES, V90, P782, DOI 10.1002/jnr.22820; The Christopher & Dana Reeve Foundation, 2008, PARALYSIS, V2008, P1; Tissot Lion J. D. N., 2008, PROTEOMICS, V8, P1945; Tsai MC, 2008, MOL CELL PROTEOMICS, V7, P1668, DOI 10.1074/mcp.M800076-MCP200; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Wang E, 2013, CANCER LETT, V340, P261, DOI 10.1016/j.canlet.2012.11.050; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yan XD, 2010, NEUROCHEM INT, V56, P971, DOI 10.1016/j.neuint.2010.04.007; Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4; Yu WJ, 2006, ELECTROPHORESIS, V27, P2100, DOI 10.1002/elps.200500820; Zhang B, 2011, J TRAUMA, V71, P1680, DOI 10.1097/TA.0b013e318231bce7; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287; Zhang ZQ, 2010, METHODS MOL BIOL, V662, P317, DOI 10.1007/978-1-60761-800-3_16	57	21	21	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	1535-9476	1535-9484		MOL CELL PROTEOMICS	Mol. Cell. Proteomics	JUL	2016	15	7					2379	2395		10.1074/mcp.M116.058115			17	Biochemical Research Methods	Biochemistry & Molecular Biology	DQ9SS	WOS:000379550200014	27150525	Other Gold, Green Published			2021-06-18	
J	Moro, N; Ghavim, SS; Harris, NG; Hovda, DA; Sutton, RL				Moro, Nobuhiro; Ghavim, Sima S.; Harris, Neil G.; Hovda, David A.; Sutton, Richard L.			Pyruvate treatment attenuates cerebral metabolic depression and neuronal loss after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						C-14-2DG; Controlled cortical impact; Fluoro-Jade B; Pyruvate; Rat	CONTROLLED CORTICAL IMPACT; CYTOCHROME-OXIDASE HISTOCHEMISTRY; PENTOSE-PHOSPHATE PATHWAY; CLOSED-HEAD INJURY; ETHYL PYRUVATE; HEMORRHAGIC-SHOCK; KETOGENIC DIET; EXTRACELLULAR GLUCOSE; SPREADING DEPRESSION; COGNITIVE DEFICITS	Experimental traumatic brain injury (TBI) is known to produce an acute increase in cerebral glucose utilization, followed rapidly by a generalized cerebral metabolic depression. The current studies determined effects of single or multiple treatments with sodium pyruvate (SP; 1000 mg/kg, i.p.) or ethyl pyruvate (EP; 40 mg/kg, i.p.) on cerebral glucose metabolism and neuronal injury in rats with unilateral controlled cortical impact (CCI) injury. In Experiment 1 a single treatment was given immediately after CCI. SP significantly improved glucose metabolism in 3 of 13 brain regions while EP improved metabolism in 7 regions compared to saline-treated controls at 24 h post-injury. Both SP and EP produced equivalent and significant reductions in dead/dying neurons in cortex and hippocampus at 24 h post-CCI. In Experiment 2 SP or EP were administered immediately (time 0) and at 1, 3 and 6 h post-CCI. Multiple SP treatments also significantly attenuated TBI-induced reductions in cerebral glucose metabolism (in 4 brain regions) 24 h post-CCI, as did multiple injections of EP (in 4 regions). The four pyruvate treatments produced significant neuroprotection in cortex and hippocampus 1 day after CCI, similar to that found with a single SP or EP treatment. Thus, early administration of pyruvate compounds enhanced cerebral glucose metabolism and neuronal survival, with 40 mg/kg of EP being as effective as 1000 mg/kg of SP, and multiple treatments within 6 h of injury did not improve upon outcomes seen following a single treatment. (C) 2016 Elsevier B.V. All rights reserved.	[Moro, Nobuhiro; Ghavim, Sima S.; Harris, Neil G.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Moro, Nobuhiro; Ghavim, Sima S.; Harris, Neil G.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 956901, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Sutton, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 956901, Los Angeles, CA 90095 USA.	moro.nobuhiro@nihon-u.ac.jp; sghavim@mednet.ucla.edu; ngharris@mednet.ucla.edu; dhovda@mednet.ucla.edu; rsutton@ucla.edu		Harris, Neil/0000-0002-1965-6750	UCLA Brain Injury Research Center; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [PO1NS058489, NS091222, NS27544, U54HD087101]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD087101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, R01NS091222, P01NS058489] Funding Source: NIH RePORTER	This work was supported by the UCLA Brain Injury Research Center and Awards PO1NS058489, NS091222, NS27544 and U54HD087101 from the National Institutes of Health (NIH). The content is the sole responsibility of the authors and does not necessarily represent official views of the NIH. NGH is a fellow of The Center for Neuroskills, Bakersfield, California.	Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; Alvarez G, 2003, J NEUROSCI RES, V73, P260, DOI 10.1002/jnr.10648; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Conejo NM, 2007, NEUROSCIENCE, V145, P403, DOI 10.1016/j.neuroscience.2006.11.057; Das UN, 2006, MED SCI MONITOR, V12, pRA79; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1987, EXP NEUROL, V97, P391, DOI 10.1016/0014-4886(87)90099-9; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Izumi Y, 2010, NEUROSCI LETT, V478, P131, DOI 10.1016/j.neulet.2010.04.078; Kao KK, 2010, BIOCHEM PHARMACOL, V80, P151, DOI 10.1016/j.bcp.2010.03.007; Kashiwagi A, 1997, DIABETES, V46, P2088, DOI 10.2337/diabetes.46.12.2088; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kim JB, 2005, BRAIN RES, V1060, P188, DOI 10.1016/j.brainres.2005.08.029; Kim TY, 2007, EXP NEUROL, V208, P159, DOI 10.1016/j.expneurol.2007.08.013; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lee J. E., 2001, INSECTA KOREANA S, V21, P1; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Lee YJ, 2004, J APPL PHYSIOL, V96, P793, DOI 10.1152/japplphysiol.00797.2003; Mongan PD, 2003, J SURG RES, V112, P180, DOI 10.1016/S0022-4804(03)00148-3; Mongan PD, 2002, AM J PHYSIOL-HEART C, V283, pH1634, DOI 10.1152/ajpheart.01073.2001; Mongan PD, 2001, AM J PHYSIOL-HEART C, V281, pH854; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Moro N, 2013, BRAIN RES, V1535, P124, DOI 10.1016/j.brainres.2013.08.044; Moro N, 2011, NEUROSCI LETT, V491, P158, DOI 10.1016/j.neulet.2011.01.029; Moro N, 2010, EXP NEUROL, V225, P391, DOI 10.1016/j.expneurol.2010.07.013; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sharma P, 2003, BRAIN RES, V992, P104, DOI 10.1016/j.brainres.2003.08.043; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; Shi H, 2015, CNS NEUROSCI THER, V21, P374, DOI 10.1111/cns.12366; Shijo K, 2015, BRAIN RES, V1614, P94, DOI 10.1016/j.brainres.2015.04.022; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Sutton RL, 2000, NEURAL PLAST, V7, P109, DOI 10.1155/NP.2000.109; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tokumaru O, 2009, NEUROCHEM RES, V34, P775, DOI 10.1007/s11064-008-9871-x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wrubel KM, 2007, PHARMACOL BIOCHEM BE, V86, P712, DOI 10.1016/j.pbb.2007.02.018; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu YM, 2005, STROKE, V36, P2238, DOI 10.1161/01.STR.0000181779.83472.35; Zeng JY, 2007, ANESTHESIOLOGY, V107, P630, DOI 10.1097/01.anes.0000281898.01966.1e; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2012, ANESTHESIOLOGY, V116, P73, DOI 10.1097/ALN.0b013e31823d7731	63	21	21	2	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						270	277		10.1016/j.brainres.2016.04.005			8	Neurosciences	Neurosciences & Neurology	DP7EI	WOS:000378661600031	27059390	Green Accepted			2021-06-18	
J	Rowe, RK; Rumney, BM; May, HG; Permana, P; Adelson, PD; Harman, SM; Lifshitz, J; Thomas, TC				Rowe, Rachel K.; Rumney, Benjamin M.; May, Hazel G.; Permana, Paska; Adelson, P. David; Harman, S. Mitchell; Lifshitz, Jonathan; Thomas, Theresa C.			Diffuse traumatic brain injury affects chronic corticosterone function in the rat	ENDOCRINE CONNECTIONS			English	Article						TBI; concussion; corticosterone; stress	PITUITARY DYSFUNCTION; PARAVENTRICULAR NUCLEUS; BEHAVIORAL MORBIDITY; GROWTH-HORMONE; LATE-ONSET; HYPOPITUITARISM; NEURONS; TBI; DEXAMETHASONE; STRESS	As many as 20-55% of patients with a history of traumatic brain injury (TBI) experience chronic endocrine dysfunction, leading to impaired quality of life, impaired rehabilitation efforts and lowered life expectancy. Endocrine dysfunction after TBI is thought to result from acceleration-deceleration forces to the brain within the skull, creating enduring hypothalamic and pituitary neuropathology, and subsequent hypothalamic-pituitary endocrine (HPE) dysfunction. These experiments were designed to test the hypothesis that a single diffuse TBI results in chronic dysfunction of corticosterone (CORT), a glucocorticoid released in response to stress and testosterone. We used a rodent model of diffuse TBI induced by midline fluid percussion injury (mFPI). At 2 months postinjury compared with uninjured control animals, circulating levels of CORT were evaluated at rest, under restraint stress and in response to dexamethasone, a synthetic glucocorticoid commonly used to test HPE axis regulation. Testosterone was evaluated at rest. Further, we assessed changes in injury-induced neuron morphology (Golgi stain), neuropathology (silver stain) and activated astrocytes (GFAP) in the paraventricular nucleus (PVN) of the hypothalamus. Resting plasma CORT levels were decreased at 2 months postinjury and there was a blunted CORT increase in response to restraint induced stress. No changes in testosterone were measured. These changes in CORT were observed concomitantly with altered complexity of neuron processes in the PVN over time, devoid of neuropathology or astrocytosis. Results provide evidence that a single moderate diffuse TBI leads to changes in CORT function, which can contribute to the persistence of symptoms related to endocrine dysfunction. Future experiments aim to evaluate additional HP-related hormones and endocrine circuit pathology following diffuse TBI.	[Rowe, Rachel K.; Permana, Paska; Harman, S. Mitchell; Lifshitz, Jonathan; Thomas, Theresa C.] Phoenix Vet Affairs Hlth Care Syst, Phoenix, AZ 85012 USA; [Rowe, Rachel K.; Rumney, Benjamin M.; May, Hazel G.; Adelson, P. David; Lifshitz, Jonathan; Thomas, Theresa C.] Phoenix Childrens Hosp, BARROW Neurol Inst, Phoenix, AZ 85016 USA; [Rowe, Rachel K.; Rumney, Benjamin M.; May, Hazel G.; Adelson, P. David; Lifshitz, Jonathan; Thomas, Theresa C.] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ 85004 USA; [Rumney, Benjamin M.; May, Hazel G.] Univ Bath, Dept Biol & Biochem, Bath, Avon, England; [Adelson, P. David] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85287 USA	Thomas, TC (corresponding author), Phoenix Vet Affairs Hlth Care Syst, Phoenix, AZ 85012 USA.; Thomas, TC (corresponding author), Phoenix Childrens Hosp, BARROW Neurol Inst, Phoenix, AZ 85016 USA.; Thomas, TC (corresponding author), Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ 85004 USA.	theresathomas@email.arizona.edu	Thomas, Theresa Currier/K-1979-2019; Adelson, David/W-2083-2019	Thomas, Theresa Currier/0000-0002-9619-7666; Rowe, Rachel/0000-0002-9034-3159	Phoenix VA Health Care System; Arizona Biomedical Research Commission through the Arizona Department of Health Services [ADHS14-00003606]; National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-065052]; Phoenix Children's Hospital Leadership Circle; Phoenix Children's Hospital Mission Support Funds; Bisgrove Scholar award - Science Foundation Arizona	Research reported in this manuscript was supported, in part, by Phoenix VA Health Care System, Arizona Biomedical Research Commission as made available through the Arizona Department of Health Services under award number ADHS14-00003606, National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01 NS-065052, Phoenix Children's Hospital Leadership Circle and Phoenix Children's Hospital Mission Support Funds. Dr Rowe was supported by the Bisgrove Scholar award funded by Science Foundation Arizona.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; BARRY J, 1975, CR SOC BIOL, V169, P978; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Berg C, 2010, EXP CLIN ENDOCR DIAB, V118, P139, DOI 10.1055/s-0029-1225611; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Cole Chad D, 2004, Neurosurg Focus, V16, pE9; Crenn P, 2014, CLIN NUTR, V33, P348, DOI 10.1016/j.clnu.2013.06.003; Dabrowska J, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00156; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Dubourg J, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11182; Dziedzic N, 2014, DEV NEUROSCI-BASEL, V36, P261, DOI 10.1159/000362873; FRANZONI MF, 1984, CELL TISSUE RES, V236, P357, DOI 10.1007/BF00214239; Gasco V, 2012, PITUITARY, V15, P20, DOI 10.1007/s11102-010-0235-6; Glynn N, 2013, CLIN ENDOCRINOL, V78, P17, DOI 10.1111/cen.12010; Gomez F, 1998, AM J PHYSIOL-REG I, V274, pR420; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Hoffman AN, 2017, J NEUROTRAUM, V34, P213, DOI 10.1089/neu.2015.4339; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Javed Zeeshan, 2015, Indian J Endocrinol Metab, V19, P753, DOI 10.4103/2230-8210.167561; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kleindienst A, 2016, J NEUROTRAUM, V33, P615, DOI 10.1089/neu.2015.3981; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kopczak A, 2014, J NEUROTRAUM, V31, P99, DOI 10.1089/neu.2013.3002; Lafrenaye AD, 2014, J CEREBR BLOOD F MET, V34, P1628, DOI 10.1038/jcbfm.2014.122; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Mangiola A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/736104; Marina D, 2015, EUR J ENDOCRINOL, V172, P813, DOI 10.1530/EJE-14-1152; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Mikics E, 2008, PHYSIOL BEHAV, V94, P341, DOI 10.1016/j.physbeh.2008.01.023; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Munoz A, 1999, J COMP NEUROL, V409, P549; Nemes O, 2015, HORM-INT J ENDOCRINO, V14, P383, DOI 10.14310/horm.2002.1564; Newman CB, 2015, PITUITARY, V18, P297, DOI 10.1007/s11102-014-0571-z; Pillai AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038971; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; RHO JH, 1989, J NEUROSCI, V9, P1375; Richmond E, 2014, ENDOCRINE, V45, P3, DOI 10.1007/s12020-013-0049-1; Rosario ER, 2013, J HEAD TRAUMA REHAB, V28, P390, DOI 10.1097/HTR.0b013e318250eac6; Schneider Harald J, 2007, Pediatr Endocrinol Rev, V4, P205; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tanriverdi F, 2015, J CLIN MED, V4, P847, DOI 10.3390/jcm4050847; Tanriverdi F, 2015, NEUROPSYCH DIS TREAT, V11, P1835, DOI 10.2147/NDT.S65814; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; TASKER JG, 1991, J PHYSIOL-LONDON, V434, P271, DOI 10.1113/jphysiol.1991.sp018469; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Thomas TC, 2015, BRAIN NEUROTRAUMA MO; Thomas TC, 2012, J NEUROTRAUM, V29, P187, DOI 10.1089/neu.2011.2091; Tripodi M, 2008, PLOS BIOL, V6, P2172, DOI 10.1371/journal.pbio.0060260; VANDENPOL AN, 1982, J COMP NEUROL, V206, P317, DOI 10.1002/cne.902060402; VANDENPOL AN, 1990, J COMP NEUROL, V296, P654, DOI 10.1002/cne.902960410; VandeVord PJ, 2016, J NEUROTRAUM, V33, P82, DOI 10.1089/neu.2014.3786; Wamsteeker Cusulin JI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064943; Webb NE, 2014, NEUROREHABILITATION, V34, P625, DOI 10.3233/NRE-141074; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Yin J, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00439; Zaben M, 2013, DISABIL REHABIL, V35, P522, DOI 10.3109/09638288.2012.697252; Zhu H, 2013, BRAIN RES, V1541, P69, DOI 10.1016/j.brainres.2013.10.002; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	74	21	21	0	11	BIOSCIENTIFICA LTD	BRISTOL	STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND	2049-3614			ENDOCR CONNECT	Endocr. Connect.	JUL 1	2016	5	4					152	166		10.1530/EC-16-0031			15	Endocrinology & Metabolism	Endocrinology & Metabolism	DV9MU	WOS:000383265500003	27317610	DOAJ Gold, Green Published			2021-06-18	
J	Fahlstedt, M; Halldin, P; Kleiven, S				Fahlstedt, Madelen; Halldin, Peter; Kleiven, Svein			The protective effect of a helmet in three bicycle accidents-A finite element study	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Helmet; Head injuries; Bicycle; Accident reconstruction; Finite element analysis; Injury prevention	TRAUMATIC BRAIN-INJURIES; HEAD-INJURY; DAMAGE; RISK; EFFICACY; MODEL	There is some controversy regarding the effectiveness of helmets in preventing head injuries among cyclists. Epidemiological, experimental and computer simulation studies have suggested that helmets do indeed have a protective effect, whereas other studies based on epidemiological data have argued that there is no evidence that the helmet protects the brain. The objective of this study was to evaluate the protective effect of a helmet in single bicycle accident reconstructions using detailed finite element simulations. Strain in the brain tissue, which is associated with brain injuries, was reduced by up to 43% for the accident cases studied when a helmet was included. This resulted in a reduction of the risk of concussion of up to 54%. The stress to the skull bone went from fracture level of 80 MPa down to 13-16 MPa when a helmet was included and the skull fracture risk was reduced by up to 98% based on linear acceleration. Even with a 10% increased riding velocity for the helmeted impacts, to take into account possible increased risk taking, the risk of concussion was still reduced by up to 46% when compared with the unhelmeted impacts with original velocity. The results of this study show that the brain injury risk and risk of skull fracture could have been reduced in these three cases if a helmet had been worn. (C) 2016 Elsevier Ltd. All rights reserved.	[Fahlstedt, Madelen; Halldin, Peter; Kleiven, Svein] KTH Royal Inst Technol, Sch Technol & Hlth, Neuron Engn, Stockholm, Sweden	Fahlstedt, M (corresponding author), Alfred Nobels Alle 10, SE-14152 Huddinge, Sweden.	madelenf@kth.se			Lansforsakringarnas Cooperation Research fund	This study was partly financed by Lansforsakringarnas Cooperation Research fund.	Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; Adams J, 2001, Inj Prev, V7, P343, DOI 10.1136/ip.7.4.343; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Amoros Emmanuelle, 2011, BMC Public Health, V11, P653, DOI 10.1186/1471-2458-11-653; [Anonymous], 2012, EN1078; [Anonymous], 2001, 327 COST EUR COMM; [Anonymous], 2008, 20632008 ASNZS; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Beusenberg M, 2001, P INT RES COUNC BIOM; Bourdet N, 2014, INT J CRASHWORTHINES, V19, P222, DOI 10.1080/13588265.2013.805293; Bourdet N, 2012, P I MECH ENG P-J SPO, V226, P282, DOI 10.1177/1754337112442326; Chan P., 2007, J CHEM INF MODEL, V53, P1689; Ching RP, 1997, ACCIDENT ANAL PREV, V29, P555, DOI 10.1016/S0001-4575(97)00008-0; CPSC, 1998, FED REGISTER, V63, P11711; Curnow WJ, 2007, ACCIDENT ANAL PREV, V39, P433, DOI 10.1016/j.aap.2006.09.013; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Ebrahimi I, 2015, TRAFFIC INJ PREV, V16, P404, DOI 10.1080/15389588.2014.937804; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Fahlstedt M., 2015, J BIOMECH; Fahlstedt M., 2014, P INT CYCL SAF C 201; Forero Rueda M. A., 2009, THESIS U COLL DUBLIN; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; Ghajari M, 2013, ACCIDENT ANAL PREV, V50, P263, DOI 10.1016/j.aap.2012.04.016; Giordano C., 2014, STAPP CAR CRASH J, V58, p14S; Holbourn AHS, 1943, LANCET, V2, P438; Ito D., 2014, P INT RES COUNC BIOM, P119; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Klug C. F., 2015, INT RES COUNC BIOM I, P136; Livermore Software Technology Corporation (LSTC), 2014, LS DYNA KEYW US MAN, VII; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; McIntosh A, 1998, ACCIDENT ANAL PREV, V30, P161, DOI 10.1016/S0001-4575(97)00089-4; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; McNally DS, 2013, ACCIDENT ANAL PREV, V60, P15, DOI 10.1016/j.aap.2013.07.011; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; OECD/ITF, 2014, ROAD SAF ANN REP 201; Otte D, 2014, SAE INT J TRANSP SAF, V2, P257, DOI 10.4271/2014-01-0517; Povey LJ, 1999, ACCIDENT ANAL PREV, V31, P763, DOI 10.1016/S0001-4575(99)00033-0; Pucher J, 2011, TRANSPORT RES A-POL, V45, P451, DOI 10.1016/j.tra.2011.03.001; Rizzi M., 2013, 2013 IRCOBI C P INT, P412; Robinson DL, 2006, BMJ-BRIT MED J, V332, P722, DOI 10.1136/bmj.332.7543.722-a; Scholten AC, 2015, ACCIDENT ANAL PREV, V81, P51, DOI 10.1016/j.aap.2015.04.022; SMITH TA, 1994, ACCIDENT ANAL PREV, V26, P795, DOI 10.1016/0001-4575(94)90055-8; Thompson D., 1999, COCHRANE DB SYST REV, P1; Verschueren P., 2009, THESIS KU LEUVEN LEU; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5	51	21	23	0	30	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JUN	2016	91						135	143		10.1016/j.aap.2016.02.025			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	DK8FP	WOS:000375162900015	26974030				2021-06-18	
J	Williams, JA; Bartoshuk, LM; Fillingim, RB; Dotson, CD				Williams, Johnny A.; Bartoshuk, Linda M.; Fillingim, Roger B.; Dotson, Cedrick D.			Exploring Ethnic Differences in Taste Perception	CHEMICAL SENSES			English	Article						epidemiology; gustation; methods; psychophysics; sex differences; spatial testing	TRAUMATIC BRAIN-INJURY; CHORDA TYMPANI NERVE; BITTER-TASTE; FOOD PREFERENCES; 6-N-PROPYLTHIOURACIL PROP; INTENSITY PERCEPTION; GENETIC SENSITIVITY; GUSTATORY FUNCTION; NUTRITIONAL-STATUS; INSULIN-RELEASE	It is well known that nutritional intake can vary substantially as a function of demographic variables such as ethnicity and/or sex. Although a variety of factors are known to underlie the relationship between these demographic variables and nutritional intake, it is interesting to speculate that variation in food intake associated with ethnicity or sex may result, in part, from differences in the perceived taste of foods in these different populations. Thus, we initiated a study to evaluate taste responsiveness in different ethnic groups. Moreover, because of the known differences in taste responsiveness between males and females, analyses were stratified by sex. The ethnic groups tested differed significantly from one another in reported perceived taste intensity. Our results showed that Hispanics and African Americans rated taste sensations higher than non-Hispanic Whites and that these differences were more pronounced in males. Understanding the nature of these differences in taste perception is important, because taste perception may contribute to dietary health risk. When attempting to modify diet, individuals of different ethnicities may require personalized interventions that take into account the different sensory experience that these individuals may have when consuming foods.	[Williams, Johnny A.] Univ Florida, Coll Dent, Gainesville, FL 32610 USA; [Bartoshuk, Linda M.] Univ Florida, Inst Food & Agr Sci, Dept Food Sci & Human Nutr, Gainesville, FL 32610 USA; [Bartoshuk, Linda M.; Dotson, Cedrick D.] Univ Florida, Ctr Smell & Taste, Gainesville, FL 32611 USA; [Fillingim, Roger B.] Univ Florida, Coll Dent, Dept Community Dent & Behav Sci, Gainesville, FL 32610 USA; [Dotson, Cedrick D.] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32611 USA; [Dotson, Cedrick D.] Univ Florida, Coll Med, Dept Psychiat, Div Addict Med, Gainesville, FL 32611 USA	Dotson, CD (corresponding author), Univ Florida, Dept Neurosci, McKnight Brain Inst, 1149 Newell Dr,Box 100244, Gainesville, FL 32611 USA.	c.dotson@mbi.ufl.edu	Fillingim, Roger/K-3569-2019	Dotson, Cedrick/0000-0003-0992-1191; Fillingim, Roger/0000-0002-7699-8183	National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DC283, P30DC010763, R01NS042754]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30DC010763, R01DC000283] Funding Source: NIH RePORTER	This work was supported by National Institute of Health (NIH) [R01DC283, P30DC010763 and R01NS042754].	Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Ahne G, 2000, LARYNGOSCOPE, V110, P1396, DOI 10.1097/00005537-200008000-00033; Bartoshuk LM, 2006, PHILOS T R SOC B, V361, P1137, DOI 10.1098/rstb.2006.1853; Bartoshuk LM, 2012, PHYSIOL BEHAV, V107, P516, DOI 10.1016/j.physbeh.2012.06.013; BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1; Bartoshuk LM, 2005, CHEM SENSES, V30, pI218, DOI 10.1093/chemse/bjh192; Bartoshuk LM, 2005, CURR DIR PSYCHOL SCI, V14, P122, DOI 10.1111/j.0963-7214.2005.00346.x; Bartoshuk LM, 2004, PHYSIOL BEHAV, V82, P109, DOI 10.1016/j.physbeh.2004.02.033; BERNSTEIN IL, 1980, PHYSIOL BEHAV, V24, P529, DOI 10.1016/0031-9384(80)90247-4; BERTHOUD HR, 1980, AM J PHYSIOL, V238, pE336; Bertoli S, 2014, WORLD J DIABETES, V5, P717, DOI 10.4239/wjd.v5.i5.717; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Choi SE, 2014, J ACAD NUTR DIET, V114, P938, DOI 10.1016/j.jand.2013.11.015; Coldwell SE, 2013, NEUROLOGY, V80, pS20, DOI 10.1212/WNL.0b013e3182872e38; Coronado VG, 2012, BRAIN INJURY MED PRI, P91; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daradkeh Ghazi, 2014, Pak J Biol Sci, V17, P1089, DOI 10.3923/pjbs.2014.1089.1097; Dinehart ME, 2006, PHYSIOL BEHAV, V87, P304, DOI 10.1016/j.physbeh.2005.10.018; Drewnowski A, 1997, AM J CLIN NUTR, V66, P391; Drewnowski A, 1998, ANN NY ACAD SCI, V855, P797, DOI 10.1111/j.1749-6632.1998.tb10661.x; DREWNOWSKI A, 1985, PHYSIOL BEHAV, V35, P617, DOI 10.1016/0031-9384(85)90150-7; Drewnowski A, 2000, J AM DIET ASSOC, V100, P191, DOI 10.1016/S0002-8223(00)00061-4; Drewnowski A, 2007, J AM DIET ASSOC, V107, P1340, DOI 10.1016/j.jada.2007.05.013; Drewnowski A, 1999, PUBLIC HEALTH NUTR, V2, P513, DOI 10.1017/S1368980099000695; Duffy VB, 2004, APPETITE, V43, P5, DOI 10.1016/j.appet.2004.02.007; Finsterer J, 2015, J NEUROSCI RURAL PRA, V6, P377, DOI 10.4103/0976-3147.158768; Fischer ME, 2014, J ACAD NUTR DIET, V114, P1195, DOI 10.1016/j.jand.2014.04.013; FISCHER R, 1961, NATURE, V191, P1328, DOI 10.1038/1911328a0; Fox AL, 1932, P NATL ACAD SCI USA, V18, P115, DOI 10.1073/pnas.18.1.115; FRIJTERS JER, 1982, J GEN PSYCHOL, V107, P233, DOI 10.1080/00221309.1982.9709931; Gemousakakis T, 2011, J INTEGR NEUROSCI, V10, P537, DOI 10.1142/S0219635211002828; GLANVILL.EV, 1965, NATURE, V205, P851, DOI 10.1038/205851a0; Goldstein GL, 2005, OBES RES, V13, P1017, DOI 10.1038/oby.2005.119; GREEN BG, 1993, CHEM SENSES, V18, P683, DOI 10.1093/chemse/18.6.683; GRINKER J, 1978, AM J CLIN NUTR, V31, P1078; Gudziol H, 2007, ACTA OTO-LARYNGOL, V127, P658, DOI 10.1080/00016480600951491; Haase L, 2011, APPETITE, V57, P421, DOI 10.1016/j.appet.2011.06.009; Habib SS, 2015, JCPSP-J COLL PHYSICI, V25, pS132, DOI 10.2015/JCPSP.S132133; JERZSALATTA M, 1990, APPETITE, V15, P127, DOI 10.1016/0195-6663(90)90045-A; Kalva JJ, 2014, J FOOD SCI, V79, pS238, DOI [10.1111/1750-3841.12342, 10.1111/1750-3841.1]; Kaminski LC, 2000, PHYSIOL BEHAV, V68, P691, DOI 10.1016/S0031-9384(99)00240-1; Keast RSJ, 2014, APPETITE, V80, P1, DOI 10.1016/j.appet.2014.04.022; Kim UK, 2003, SCIENCE, V299, P1221, DOI 10.1126/science.1080190; Kokrashvili Z, 2009, CHEM SENSES, V34, pA77; Kumanyika SK, 2008, PHYSIOL BEHAV, V94, P61, DOI 10.1016/j.physbeh.2007.11.019; Landis BN, 2006, ADV OTO-RHINO-LARYNG, V63, P242, DOI 10.1159/000093763; Landis BN, 2009, J NEUROL, V256, P242, DOI 10.1007/s00415-009-0088-y; LEHMAN CD, 1995, PHYSIOL BEHAV, V57, P943, DOI 10.1016/0031-9384(95)91121-R; Marks LE, 2012, PHYSIOL BEHAV, V105, P443, DOI 10.1016/j.physbeh.2011.08.039; MATTES R, 1989, J AM DIET ASSOC, V89, P692; Mennella JA, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-60; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; Moser RP, 2005, J NUTR EDUC BEHAV, V37, P306, DOI 10.1016/S1499-4046(06)60161-9; Nahab F, 2011, NEUROLOGY, V76, P154, DOI 10.1212/WNL.0b013e3182061afb; NIEWIND A, 1988, NUTR RES, V8, P13, DOI 10.1016/S0271-5317(88)80083-6; Penniston KL, 2008, J ENDOUROL, V22, P567, DOI 10.1089/end.2007.0304; Pingel J, 2010, EUR ARCH OTO-RHINO-L, V267, P1911, DOI 10.1007/s00405-010-1276-1; Rankin KM, 2000, CHEM SENSES, V25, P747, DOI 10.1093/chemse/25.6.747; RANKIN KM, 1992, PERCEPT PSYCHOPHYS, V52, P479, DOI 10.3758/BF03206709; Reifsnider E, 2008, J SPEC PEDIATR NURS, V13, P154, DOI 10.1111/j.1744-6155.2008.00150.x; Reineccius G, 1994, SOURCE BOOK FLAVORS, P626; Salbe AD, 2004, AM J CLIN NUTR, V79, P372; Skrandies W, 2015, PHYSIOL BEHAV, V142, P1, DOI 10.1016/j.physbeh.2015.01.024; Teff KL, 2010, PHYSIOL BEHAV, V99, P317, DOI 10.1016/j.physbeh.2009.11.009; TEFF KL, 1995, PHYSIOL BEHAV, V57, P1089, DOI 10.1016/0031-9384(94)00373-D; Tepper BJ, 2008, OBESITY, V16, P2289, DOI 10.1038/oby.2008.357; Tepper BJ, 2009, INT J FOOD SCI NUTR, V60, P35, DOI 10.1080/09637480802304499; Tepper BJ, 2002, PHYSIOL BEHAV, V75, P305, DOI 10.1016/S0031-9384(01)00664-3; Tepper BJ, 1999, APPETITE, V32, P422, DOI 10.1006/appe.1999.0240; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tonkin AM, 2010, CIRCULATION, V122, P850, DOI 10.1161/CIRCULATIONAHA.110.960112; Wang JC, 2007, ALCOHOL CLIN EXP RES, V31, P209, DOI 10.1111/j.1530-0277.2006.00297.x; WOODS SC, 1980, PHYSIOL BEHAV, V24, P485, DOI 10.1016/0031-9384(80)90241-3; Yackinous CA, 2002, APPETITE, V38, P201, DOI 10.1006/appe.2001.0481; Yanagisawa K, 1998, PHYSIOL BEHAV, V63, P329, DOI 10.1016/S0031-9384(97)00423-X	75	21	21	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0379-864X	1464-3553		CHEM SENSES	Chem. Senses	JUN	2016	41	5					449	456		10.1093/chemse/bjw021			8	Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology	Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology	DR2MU	WOS:000379739400008	26994473	Green Published			2021-06-18	
J	Zhang, S; Kojic, L; Tsang, M; Grewal, P; Liu, J; Namjoshi, D; Wellington, CL; Tetzlaff, W; Cynader, MS; Jia, W				Zhang, Si; Kojic, Luba; Tsang, Michelle; Grewal, Parampal; Liu, Jie; Namjoshi, Dhananjay; Wellington, Cheryl L.; Tetzlaff, Wolfram; Cynader, Max S.; Jia, William			Distinct roles for metalloproteinases during traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Closed and open head injury; Mice model; Metalloproteinases; Gelatinase activity; Immunohistochemistry	CONTROLLED CORTICAL IMPACT; ALPHA-CONVERTING-ENZYME; FOCAL CEREBRAL-ISCHEMIA; MATRIX METALLOPROTEINASES; CELL-DEATH; INTRACEREBRAL HEMORRHAGE; MULTIPLE ROLES; HEAD-INJURY; MODEL; BLOOD	Background: Significant protease activations have been reported after traumatic brain injury (TBI). These proteases are responsible for cleavage of transmembrane proteins in neurons, glial, and endothelial cells and this results in the release of their extracellular domains (ectodomains). Methods: Two TBI models were employed here, representing both closed head injury (CHI) and open head injury (OHI). In situ zymography, immunohistochemistry, bright field and confocal microscopy, quantification of immunopositive cells and statistical analysis were applied. Results: We found, using in situ zymography, that gelatinase activity of matrix metalloproteinases (MMP)-2 and MMP-9 was upregulated in cortex of both injury models. Using immunohistochemistry for several MPPs (Matrix metalloproteinases) and ADAMs (disintegrin and metalloproteinases), including MMP-2, -9, ADAM-10, -17, distinct patterns of induction were observed in the two TBI models. In closed head injury, an early increase in protein expression of MMP-2, -9 and ADAM -17 was found as early as 10 min post injury in cortex and peaked at 1 h for all 4 proteases examined. In contrast, after OHI the maximal expression was observed locally neighboring the impact site, at a later time-point, as long as 24 h after the injury for MMP-2 and MMP-9. Confocal microscopy revealed colocalization of the 4 proteases with the neuronal marker NeuN in CHI, but only MMP2 colocalized with NeuN in OHI. Conclusions: The findings may lead to a trauma-induced therapeutic strategy triggered soon after a primary insult to improve survival and to reduce brain damage following TBI. (C) 2016 Published by Elsevier Ltd.	[Zhang, Si; Kojic, Luba; Tsang, Michelle; Grewal, Parampal; Cynader, Max S.; Jia, William] Univ British Columbia, Brain Res Ctr, Vancouver, BC V5Z 1M9, Canada; [Liu, Jie; Tetzlaff, Wolfram] Univ British Columbia, ICORD, Vancouver, BC V5Z 1M9, Canada; [Namjoshi, Dhananjay; Wellington, Cheryl L.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	Jia, W (corresponding author), Univ British Columbia, Dept Surg, Fac Med, Div Neurosurg, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	zhang.si@hotmail.com; lkojic@mail.ubc.ca; myt1@sfu.ca; parampal.grewal@gmail.com; jliu@icord.org; dnamjoshi@cmmt.ubc.ca; cheryl@cmmt.ubc.ca; tetzlaff@icord.org; cynader@brain.ubc.ca; w.jia@ubc.ca	JIA, WILLIAM/AAE-4322-2020; Tetzlaff, Wolfram/AAY-4430-2020				Alexander JS, 2002, J ANAT, V200, P561, DOI 10.1046/j.1469-7580.2002.00057.x; Amantea D, 2008, NEUROSCIENCE, V152, P8, DOI 10.1016/j.neuroscience.2007.12.030; [Anonymous], 2015, J CEREB BLOOD FLOW M; [Anonymous], 2015, MOL NEUROBIOL; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Barzo P, 1997, ACT NEUR S, V70, P119; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Goddard DR, 2001, GLIA, V34, P267, DOI 10.1002/glia.1060; Gold MS, 2009, BIOL PSYCHIAT, V66, P118, DOI 10.1016/j.biopsych.2009.02.021; Grossetete M, 2008, J CEREBR BLOOD F MET, V28, P752, DOI 10.1038/sj.jcbfm.9600572; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Haddad M, 2008, EUR J PHARMACOL, V588, P52, DOI 10.1016/j.ejphar.2008.04.013; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Katakowski M, 2007, J CEREBR BLOOD F MET, V27, P669, DOI 10.1038/sj.jcbfm.9600390; Kolar M, 2008, ACTA NEUROCHIR SUPPL, V102, P373, DOI 10.1007/978-3-211-85578-2_71; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee P, 2012, EXP NEUROL, V234, P50, DOI 10.1016/j.expneurol.2011.12.016; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Postina R, 2008, CURR ALZHEIMER RES, V5, P179, DOI 10.2174/156720508783954668; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siao CJ, 2002, CELL MOL BIOL, V48, P151; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Skovronsky DM, 2001, J NEUROBIOL, V49, P40, DOI 10.1002/neu.1064; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vilalta A, 2008, ACTA NEUROCHIR SUPPL, V102, P415, DOI 10.1007/978-3-211-85578-2_81; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Walker EJ, 2009, EXP NEUROL, V216, P122, DOI 10.1016/j.expneurol.2008.11.022; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Xue MZ, 2009, BRAIN, V132, P26, DOI 10.1093/brain/awn215; Yang P, 2006, PROG NEUROBIOL, V79, P73, DOI 10.1016/j.pneurobio.2006.05.001; Yang Y, 2010, J NEUROCHEM, V112, P134, DOI 10.1111/j.1471-4159.2009.06433.x; Yong VW, 2007, J NEUROL SCI, V259, P79, DOI 10.1016/j.jns.2006.11.021; Yong VW, 2007, NEUROTHERAPEUTICS, V4, P580, DOI 10.1016/j.nurt.2007.07.005; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Zhang S., 2012, DISTINCT PATTERNS PR; Zhang S., 2013, TREATMENT ISCHEMIC S	59	21	22	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUN	2016	96						46	55		10.1016/j.neuint.2016.02.013			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DN1DO	WOS:000376806700005	26939762				2021-06-18	
J	Cherian, I; Bernardo, A; Grasso, G				Cherian, Iype; Bernardo, Antonio; Grasso, Giovanni			Cisternostomy for Traumatic Brain Injury: Pathophysiologic Mechanisms and Surgical Technical Notes	WORLD NEUROSURGERY			English	Article						Cisternostomy; Decompressive hemicraniectomy; Traumatic brain injury	ISCHEMIA; EDEMA; DECRA; MODEL; TIME	OBJECTIVE: Traumatic brain injury (TBI) is one of the major challenges in health care, representing the third most frequent cause of death. Current optimal management is based on a progressive, target-driven approach combining both medical and surgical treatment strategies. Here we describe cisternostomy, an emerging surgical treatment for the treatment of TBI. METHODS: Cisternostomy is a novel technique that incorporates knowledge of skull base and microvascular surgery. By opening the brain cisterns to atmospheric pressure, the technique could decrease the intracranial pressure due to a backshift of the cerebrospinal fluid (CSF) from the swollen brain to the cisterns through the Virchow-Robin spaces. RESULTS: An increasing number of evidence has demonstrated a paravascular pathway that facilitates CSF flow from the subarachnoid space through the brain parenchyma. This network of paravascular channels, termed as the "glymphatic" pathway, reduces considerably its activity after TBI, thus participating in the development of brain edema formation. Cisternostomy, by opening the brain cisterns to atmospheric pressure, could decrease the intracerebral pressure due to a backshift of CSF through the Virchow-Robin spaces. CONCLUSIONS: In the current common practice, the surgical measures for TBI include external ventricular drainage insertion and decompressive craniectomy. There is evidence that both of these measures reduce intracranial pressure but the effect on the outcome, particularly in the long term, is equivocal. A new line of evidence supports cisternostomy as an emerging surgical treatment for TBI.	[Cherian, Iype] Coll Med Sci, Dept Neurosurg, Bharatpur, Nepal; [Bernardo, Antonio] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Grasso, Giovanni] Univ Palermo, Dept Expt Biomed & Clin Neurosci BIONEC, Neurosurg Sect, Palermo, Italy	Grasso, G (corresponding author), Univ Palermo, Dept Expt Biomed & Clin Neurosci BIONEC, Neurosurg Sect, Palermo, Italy.	giovanni.grasso@unipa.it	bernardo, Antonio/AAB-9474-2020; grasso, giovanni/K-3774-2018	bernardo, Antonio/0000-0002-2751-2626; grasso, giovanni/0000-0001-5362-0092			Baethmann A, 1998, Curr Opin Anaesthesiol, V11, P193, DOI 10.1097/00001503-199804000-00013; Cherian Iype, 2013, Asian J Neurosurg, V8, P132, DOI 10.4103/1793-5482.121684; Chi JH, 2011, NEUROSURGERY, V68, pN19, DOI [10.1227/01.neu.0000398210.58112.7e, 10.1227/01.neu.0000393594.53816.33]; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doubal FN, 2010, STROKE, V41, P450, DOI 10.1161/STROKEAHA.109.564914; Fukuda H, 2014, J NEUROL SURG PART B, V75, P125, DOI 10.1055/s-0033-1359302; Grasso G, 2015, WORLD NEUROSURG, V84, P1491, DOI 10.1016/j.wneu.2015.05.056; Grasso G, 2015, WORLD NEUROSURG, V84, P594, DOI 10.1016/j.wneu.2015.01.043; Iaccarino C, 2013, WORLD NEUROSURG, V79, P78, DOI 10.1016/j.wneu.2012.10.061; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McIntosh TK, 1996, LAB INVEST, V74, P315; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang MH, 2012, J NEUROSCI, V32, P17948, DOI 10.1523/JNEUROSCI.1860-12.2012; Zhang XA, 2014, J NEUROSURG, V121, P390, DOI 10.3171/2014.3.JNS132206	21	21	23	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2016	89						51	57		10.1016/j.wneu.2016.01.072			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DM6GM	WOS:000376448700009	26851743				2021-06-18	
J	Dyer, JR; Williams, R; Bombardier, CH; Vannoy, S; Fann, JR				Dyer, Joshua R.; Williams, Ryan; Bombardier, Charles H.; Vannoy, Steven; Fann, Jesse R.			Evaluating the Psychometric Properties of 3 Depression Measures in a Sample of Persons With Traumatic Brain Injury and Major Depressive Disorder	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; depression; outcomes research; patient outcomes; traumatic brain injuries	PATIENT HEALTH QUESTIONNAIRE-9; RANDOMIZED CONTROLLED-TRIAL; RATING-SCALE; HOSPITAL ANXIETY; DSM-IV; VALIDITY; SYMPTOMS; SEVERITY; SENSITIVITY; SERTRALINE	Objectives: To explore the psychometric properties of 3 widely used measures of depression in a sample of individuals with traumatic brain injury (TBI) and major depressive disorder and refine them to maximize efficiency. Design: Secondary analysis of data from a randomized controlled trial of cognitive-behavioral therapy for depression after TBI. Setting: Nationwide recruitment from community and clinical settings. Participants: One hundred adults within 10 years of complicated mild to severe TBI. Intervention: Telephone and in-person cognitive-behavioral therapy. Main Measures: Patient Health Questionnaire-9 (PHQ-9), Symptom Checklist-20, and Hamilton Depression Rating Scale. Results: We used Rasch rating scale analysis and multilevel modeling to investigate the 3 measures. Measurement properties of each of the depression measures were strong. We explored modifications to the rating scales to improve efficiency while retaining strong psychometric characteristics. Correlations among these revised measures were high. Treatment effects of each revised depression measure were compared using a multilevel model, and effect size estimates were comparable among the revised PHQ-9, Symptom Checklist-20, and Hamilton Depression Rating Scale. Conclusions: Although each of the 3 measures demonstrated adequate reliability, the efficiency of all 3 instruments was improved with rating scale analysis. The PHQ-9 required the fewest modifications and functions well as a measure of depression among those with TBI.	[Dyer, Joshua R.; Bombardier, Charles H.] Univ Washington, Sch Med, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA; [Fann, Jesse R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA; [Williams, Ryan] Amer Inst Res, Chicago, IL USA; [Vannoy, Steven] Univ Massachusetts, Dept Counseling, Boston, MA USA; [Vannoy, Steven] Univ Massachusetts, Sch Psychol, Boston, MA USA	Dyer, JR (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	jdyer@u.washington.edu	vannoy, steven/W-2737-2019		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21HD53736]; Department of Education, National Institute on Disability and Rehabilitation Research [H133G070016]	This study was supported by the National Institutes of Health (grant R21HD53736) and the Department of Education, National Institute on Disability and Rehabilitation Research (grant H133G070016). Trial registration: clinicaltrials.gov identifier: NCT00878150.	Aben I, 2002, PSYCHOSOMATICS, V43, P386, DOI 10.1176/appi.psy.43.5.386; Al-Adawi S, 2007, BRAIN INJURY, V21, P385, DOI 10.1080/02699050701311059; American Psychiatric Association, 2001, DIAGN STAT MAN MENT; ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; Arundine A, 2012, J HEAD TRAUMA REHAB, V27, P104, DOI 10.1097/HTR.0b013e3182125591; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Bagby RM, 2004, AM J PSYCHIAT, V161, P2163, DOI 10.1176/appi.ajp.161.12.2163; BECH P, 1975, ACTA PSYCHIAT SCAND, V51, P161, DOI 10.1111/j.1600-0447.1975.tb00002.x; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bush BA, 2004, J CLIN PSYCHOL MED S, V11, P195, DOI 10.1023/B:JOCS.0000037613.69367.d4; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; de Coster L, 2005, INT J GERIATR PSYCH, V20, P358, DOI 10.1002/gps.1290; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Faries D, 2000, J PSYCHIAT RES, V34, P3, DOI 10.1016/S0022-3956(99)00037-0; First Michael B, 2001, USERS GUIDE STRUCTUR; Guy, 1976, ECDEU ASSESSMENT MAN; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Khan A, 2002, J CLIN PSYCHOPHARM, V22, P40, DOI 10.1097/00004714-200202000-00007; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Linacre M, 2014, WINSTEPS RASCH MEASU; MAIER W, 1985, PHARMACOPSYCHIATRY, V18, P114, DOI 10.1055/s-2007-1017335; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Pinheiro JBD, 2015, NLME LINEAR NONLINEA; Ramanathan DM, 2011, BRAIN INJURY, V25, P328, DOI 10.3109/02699052.2011.554336; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2010, J CLIN PSYCHIAT, V71, P1125, DOI 10.4088/JCP.09m05086blu; Ruhe HG, 2005, COMPR PSYCHIAT, V46, P417, DOI 10.1016/j.comppsych.2005.03.001; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Schwarzbold ML, 2014, REV BRAS PSIQUIATR, V36, P206, DOI 10.1590/1516-4446-2013-1308; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Westcott MC, 2005, BRAIN INJURY, V19, P1261, DOI 10.1080/02699050500150104; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Williams RT, 2009, REHABIL PSYCHOL, V54, P198, DOI 10.1037/a0015529	46	21	21	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2016	31	3					225	232		10.1097/HTR.0000000000000177			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DR3FK	WOS:000379787800014	26291629				2021-06-18	
J	Kerr, ZY; Dalton, SL; Roos, KG; Djoko, A; Phelps, J; Dompier, TP				Kerr, Zachary Y.; Dalton, Sara L.; Roos, Karen G.; Djoko, Aristarque; Phelps, Jennifer; Dompier, Thomas P.			Comparison of Indiana High School Football Injury Rates by Inclusion of the USA Football "Heads Up Football" Player Safety Coach	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; pediatrics; prevention	SPORTS-RELATED INJURIES; UNITED-STATES; EPIDEMIOLOGY; CONCUSSION	Background: In Indiana, high school football coaches are required to complete a coaching education course with material related to concussion awareness, equipment fitting, heat emergency preparedness, and proper technique. Some high schools have also opted to implement a player safety coach (PSC). The PSC, an integral component of USA Football's Heads Up Football (HUF) program, is a coach whose primary responsibility is to ensure that other coaches are implementing proper tackling and blocking techniques alongside other components of the HUF program. Purpose: To compare injury rates in Indiana high school football teams by their usage of a PSC or online coaching education only. Study Design: Cohort study; Level of evidence, 2. Methods: Athletic trainers (ATs) evaluated and tracked injuries at each practice and game during the 2015 high school football season. Players were drawn from 6 teams in Indiana. The PSC group, which used the PSC component, was comprised of 204 players from 3 teams. The education only group (EDU), which utilized coaching education only, was composed of 186 players from 3 teams. Injury rates and injury rate ratios (IRRs) were reported with 95% confidence intervals (CIs). Results: During 25,938 athlete-exposures (AEs), a total of 149 injuries were reported, of which 54 (36.2%) and 95 (63.8%) originated from the PSC and EDU groups, respectively. The practice injury rate was lower in the PSC group than the EDU group (2.99 vs 4.83/1000 AEs; IRR, 0.62; 95% CI, 0.40-0.95). The game injury rate was also lower in the PSC group than the EDU group (11.37 vs 26.37/1000 AEs; IRR, 0.43; 95% CI, 0.25-0.74). When restricted to concussions only, the rate was lower in the PSC group (0.09 vs 0.73/1000 AEs; IRR, 0.12; 95% CI, 0.01-0.94), although only 1 concussion was reported in the PSC group. No differences were found in game concussion rates (0.60 vs 4.39/1000 AEs; IRR, 0.14; 95% CI, 0.02-1.11). Conclusion: Findings support the PSC as an effective method of injury mitigation in high school football. Future research should seek to replicate this study using larger samples from additional states.	[Kerr, Zachary Y.; Dalton, Sara L.; Roos, Karen G.; Djoko, Aristarque; Phelps, Jennifer; Dompier, Thomas P.] Sports Injury Res & Prevent Inc, Datalys Ctr, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA; [Phelps, Jennifer] USA Football, Indianapolis, IN USA	Kerr, ZY (corresponding author), Sports Injury Res & Prevent Inc, Datalys Ctr, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org		Kerr, Zachary/0000-0003-1423-1259	NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01CE002885, U01CE002880] Funding Source: NIH RePORTER		[Anonymous], 2014, 2014 15 HIGH SCH ATH; Badgeley MA, 2013, J PHYS ACT HEALTH, V10, P160, DOI 10.1123/jpah.10.2.160; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Comstock RD, CONVENIENCE SAMPLE S; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Institute of Medicine, SPORTS RELATED CONCU; Kerr ZY, 2016, J ATHL TRAINING, V51, P70, DOI 10.4085/1062-6050-51.3.02; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; National Federation of High Schools, IND FOOTB SEA 222, V222; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Thackston L., INDIANA 1 STATE CONC; USA Football, HEADS UP FOOTB; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	21	21	21	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	MAY	2016	4	5								10.1177/2325967116648441			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DQ2MT	WOS:000379037100010	27275000	DOAJ Gold, Green Published			2021-06-18	
J	Sufrinko, A; Johnson, EW; Henry, LC				Sufrinko, Alicia; Johnson, Eric W.; Henry, Luke C.			The Influence of Sleep Duration and Sleep-Related Symptoms on Baseline Neurocognitive Performance Among Male and Female High School Athletes	NEUROPSYCHOLOGY			English	Article						sleep; neurocognition; sex; concussion	SPORTS-RELATED CONCUSSION; GENDER-DIFFERENCES; ADOLESCENTS; PATTERNS; METAANALYSIS; DIFFERENCE; IMPACT; NEED; SEX	Typically, the effects of sleep duration on cognition are examined in isolation. Objective: This study examined the effects of restricted sleep and related symptoms on neurocognitive performance. Method: Baseline Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and postconcussion symptom scale (PCSS) were administered to athletes (N = 7,150) ages 14-17 (M = 15.26, SD = 1.09) prior to sport participation. Three groups of athletes were derived from total sleep duration: sleep restriction (<= 5 hours), typical sleep (5.5-8.5 hours), and optimal sleep (>= 9 hours). A MANCOVA (age and sex as covariates) was conducted to examine differences across ImPACT/PCSS. Follow-up MANOVA compared ImPACT/PCSS performance among symptomatic (e.g., trouble falling asleep, sleeping less than usual) adolescents from the sleep restriction group (n = 78) with asymptomatic optimal sleepers (n = 99). Results: A dose-response effect of sleep duration on ImPACT performance and PCSS was replicated (Wilk's lambda = .98, F-2,F-7145 = 17.25, p < .001, eta(2) = .01). The symptomatic sleep restricted adolescents (n = 78) had poorer neurocognitive performance: verbal memory, F = 11.60, p = .001, visual memory, F = 6.57, p = .01, visual motor speed, F = 6.19, p = .01, and reaction time (RT), F = 5.21, p = .02, compared to demographically matched controls (n = 99). Girls in the sleep problem group performed worse on RT (p = .024). Conclusion: Examining the combination of sleep-related symptoms and reduced sleep duration effectively identified adolescents at risk for poor neurocognitive performance than sleep duration alone.	[Sufrinko, Alicia; Johnson, Eric W.; Henry, Luke C.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Sports Med Concuss Program, Pittsburgh, PA 15203 USA; [Johnson, Eric W.; Henry, Luke C.] Univ Pittsburgh, Sch Med, 3200 South Water St, Pittsburgh, PA 15203 USA	Henry, LC (corresponding author), Univ Pittsburgh, Sch Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	lch32@pitt.edu		Henry, Luke/0000-0003-4557-0309			Alfano CA, 2009, DEPRESS ANXIETY, V26, P503, DOI 10.1002/da.20443; Arnett P., 2014, CONCUSSION ATHLETICS, P35; Beijamini F, 2008, BRAZ J MED BIOL RES, V41, P734, DOI 10.1590/S0100-879X2008000800016; Belenky G, 2003, J SLEEP RES, V12, P1, DOI 10.1046/j.1365-2869.2003.00337.x; Blatter K, 2006, BEHAV BRAIN RES, V168, P312, DOI 10.1016/j.bbr.2005.11.018; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; CARSKADON MA, 1980, SLEEP, V2, P453; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Dewald JF, 2010, SLEEP MED REV, V14, P179, DOI 10.1016/j.smrv.2009.10.004; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P81, DOI 10.1017/S1355617713001288; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gradisar M, 2011, SLEEP MED, V12, P110, DOI 10.1016/j.sleep.2010.11.008; Henry LC, 2015, APPL NEUROPSYCH-CHIL, V4, P266, DOI 10.1080/21622965.2014.911094; Jenni OG, 2007, SLEEP MED CLIN, V2, P321, DOI 10.1016/j.jsmc.2007.05.001; Klein JD, 2002, J ADOLESCENT HEALTH, V30, P190, DOI 10.1016/S1054-139X(01)00342-1; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Laberge L, 2001, J SLEEP RES, V10, P59, DOI 10.1046/j.1365-2869.2001.00242.x; Lee KA, 1999, J ADOLESCENT HEALTH, V24, P16, DOI 10.1016/S1054-139X(98)00074-3; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; McClure D. J., 2013, ORTHOPAEDIC J SPO S1, V1; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mercer PW, 1998, J ADOLESCENT HEALTH, V23, P259, DOI 10.1016/S1054-139X(98)00037-8; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; MORRISON DN, 1992, J AM ACAD CHILD PSY, V31, P94, DOI 10.1097/00004583-199201000-00014; Moser RS, 2015, APPL NEUROPSYCH-CHIL, V4, P41, DOI 10.1080/21622965.2013.791825; National Sleep Foundation, 2006, SLEEP AM POLL; Noland H, 2009, J SCHOOL HEALTH, V79, P224, DOI 10.1111/j.1746-1561.2009.00402.x; Pennebaker JW, 2000, SCIENCE OF SELF-REPORT, P299; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Roberts RE, 2002, J PSYCHOSOM RES, V53, P561, DOI 10.1016/S0022-3999(02)00446-4; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Tonetti L, 2008, CHRONOBIOL INT, V25, P745, DOI 10.1080/07420520802394191; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	37	21	21	1	27	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2016	30	4					484	491		10.1037/neu0000250			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	DK2XM	WOS:000374777700009	26569029				2021-06-18	
J	Hasanin, A; Kamal, A; Amin, S; Zakaria, D; El Sayed, R; Mahmoud, K; Mukhtar, A				Hasanin, Ahmed; Kamal, Amr; Amin, Shereen; Zakaria, Dina; El Sayed, Riham; Mahmoud, Kareem; Mukhtar, Ahmed			Incidence and outcome of cardiac injury in patients with severe head trauma	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Severe head injury; Cardiac injury; Echocardiography; Tsroponin	SYMPATHETIC NERVOUS ACTIVITY; LEFT-VENTRICULAR DYSFUNCTION; TROPONIN-I; SUBARACHNOID HEMORRHAGE; MYOCARDIAL DYSFUNCTION; WALL-MOTION; ABNORMALITIES; PREDICTORS; INFARCTION; STROKE	Background: Although cardiac injury has been reported in patients with various neurological conditions, few data report cardiac injury in patients with traumatic brain injury (TBI). The aim of this work is to report the incidence of cardiac injury in patients with TBI and its impact on patient outcome. Methods: A prospective observational study was conducted on a cohort of 50 patients with severe TBI. Only patients with isolated severe TBI defined as Glascow coma scale (GCS) < 8 were included in the study. Acute physiology and chronic health evaluation (APACHE) II score, GCS, hemodynamic data, serum Troponin I, electrocardiogram (ECG), and echocardiographic examination, and patients' outcome were recorded. A neurogenic cardiac injury score (NCIS) was calculated for all patients (rising troponin = 1, abnormal echocardiography = 1, hypotension = 1). Univariate and multivariate analyses for risk factors for mortality were done for all risk factors. Results and discussion: Fifty patients were included; age was 31 +/- 12, APACHE II was 21 +/- 5, and male patients were 45 (90 %). Troponin I was elevated in 27 (54 %) patients, abnormal echocardiography and hypotension were documented in 14 (28 %) and 16 (32 %) patients, respectively. The in-hospital mortality was 36 %. Risk factors for mortality by univariate analysis were age, GCS, APACHE II score, serum troponin level, NCIS, and hypotension. However, in multivariate analysis, the only two independent risk factors for mortality were APACHE II score (OR = 1.25, 95 % confidence interval: 1.02-1.54, P = 0.03) and NCIS score (OR = 8.38, 95 % confidence interval: 1.44-48.74, P = 0.018). Conclusions: Cardiac injury is common in patients with TBI and is associated with increased mortality. The association of high NCIS and poor outcome in these patients warrants a further larger study.	[Hasanin, Ahmed; Kamal, Amr; Amin, Shereen; Zakaria, Dina; Mukhtar, Ahmed] Cairo Univ, Dept Anesthesia & Crit Care Med, Fac Med, Cairo, Egypt; [El Sayed, Riham] Cairo Univ, Dept Clin & Chem Pathol, Fac Med, Cairo, Egypt; [Mahmoud, Kareem] Cairo Univ, Dept Cardiol, Fac Med, Cairo, Egypt	Hasanin, A (corresponding author), Cairo Univ, Dept Anesthesia & Crit Care Med, Fac Med, Cairo, Egypt.	ahmedmohamedhasanin@gmail.com	Hasanin, Ahmed/H-3378-2018; Mahmoud, Kareem/AAP-5921-2021; Mukhtar, Ahmed/C-7916-2015	Mukhtar, Ahmed/0000-0002-0504-274X; hasanin, ahmed/0000-0001-9947-5863; Mahmoud, Kareem/0000-0002-2398-0000			Bahloul M, 2006, AM J CRIT CARE, V15, P462; Banki N, 2006, J NEUROSURG, V105, P15, DOI 10.3171/jns.2006.105.1.15; Bergenzaun L, 2011, CRIT CARE, V15, DOI 10.1186/cc10368; Bulsara KR, 2003, J NEUROSURG, V98, P524, DOI 10.3171/jns.2003.98.3.0524; Cheung Raymond T.F., 2004, Curr Treat Options Cardiovasc Med, V6, P199, DOI 10.1007/s11936-996-0014-x; Chew MS, 2012, CARDIOL RES PRACT, V2012, DOI 10.1155/2012/139537; Coghlan LA, 2009, STROKE, V40, P412, DOI 10.1161/STROKEAHA.108.528778; Di Angelantonio E, 2005, J NEUROL NEUROSUR PS, V76, P76, DOI 10.1136/jnnp.2004.041491; Gelow J, 2009, AM J MED, V122, P583, DOI 10.1016/j.amjmed.2008.12.016; Horowitz MB, 1998, ACTA NEUROCHIR, V140, P87, DOI 10.1007/s007010050063; James P, 2000, BRIT MED J, V320, P1502, DOI 10.1136/bmj.320.7248.1502; KOEPP M, 1995, ARCH NEUROL-CHICAGO, V52, P152, DOI 10.1001/archneur.1995.00540260056016; Masuda T, 2002, STROKE, V33, P1671, DOI 10.1161/01.STR.0000016327.74392.02; MAYER SA, 1995, J NEUROSURG, V83, P889, DOI 10.3171/jns.1995.83.5.0889; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; Okabe T, 2013, NEUROCRIT CARE, V18, P271, DOI 10.1007/s12028-012-9804-z; Parekh N, 2000, J AM COLL CARDIOL, V36, P1328, DOI 10.1016/S0735-1097(00)00857-3; Prathep S, 2014, CRIT CARE MED, V42, P142, DOI 10.1097/CCM.0b013e318298a890; Riera Maria, 2010, J Trauma, V68, pE13, DOI 10.1097/TA.0b013e3181469d5b; Serri K, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0217-4; Song HS, 2008, J CLIN NEUROL, V4, P75, DOI 10.3988/jcn.2008.4.2.75; Stollberger C, 2009, EUR J NEUROL, V16, pe116, DOI 10.1111/j.1468-1331.2009.02619.x; Sugimoto K, 2008, INT HEART J, V49, P75, DOI 10.1536/ihj.49.75; Temes RE, 2010, NEUROCRIT CARE, V13, P359, DOI 10.1007/s12028-010-9447-x; Tung P, 2004, STROKE, V35, P548, DOI 10.1161/01.STR.0000114874.96688.54; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046; Zaroff JG, 2012, NEUROCRIT CARE, V17, P374, DOI 10.1007/s12028-011-9592-x	28	21	21	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	APR 27	2016	24								58	10.1186/s13049-016-0246-z			6	Emergency Medicine	Emergency Medicine	DM1AI	WOS:000376077000003	27121183	DOAJ Gold, Green Published			2021-06-18	
J	Lee, S; Mattingly, A; Lin, A; Sacramento, J; Mannent, L; Castel, MN; Canolle, B; Delbary-Gossart, S; Ferzaz, B; Morganti, JM; Rosi, S; Ferguson, AR; Manley, GT; Bresnahan, JC; Beattie, MS				Lee, Sangmi; Mattingly, Aaron; Lin, Amity; Sacramento, Jeffrey; Mannent, Leda; Castel, Marie-Noelle; Canolle, Benoit; Delbary-Gossart, Sandrine; Ferzaz, Badia; Morganti, Josh M.; Rosi, Susanna; Ferguson, Adam R.; Manley, Geoffrey T.; Bresnahan, Jacqueline C.; Beattie, Michael S.			A novel antagonist of p75NTR reduces peripheral expansion and CNS trafficking of pro-inflammatory monocytes and spares function after traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury (TBI); p75 neurotrophin receptor (p75NTR); Inflammatory responses; Pro-inflammatory monocytes; Neuroprotection; Therapeutic target	NF-KAPPA-B; NERVE GROWTH-FACTOR; NEUROTROPHIN RECEPTOR; BONE-MARROW; MICROGLIAL ACTIVATION; HIPPOCAMPAL-NEURONS; OUTCOME PREDICTION; DENDRITIC CELLS; TNF-ALPHA; RECOVERY	Background: Traumatic brain injury (TBI) results in long-term neurological deficits, which may be mediated in part by pro-inflammatory responses in both the injured brain and the circulation. Inflammation may be involved in the subsequent development of neurodegenerative diseases and post-injury seizures. The p75 neurotrophin receptor (p75NTR) has multiple biological functions, affecting cell survival, apoptotic cell death, axonal growth, and degeneration in pathological conditions. We recently found that EVT901, a novel piperazine derivative that inhibits p75NTR oligomerization, is neuroprotective, reduces microglial activation, and improves outcomes in two models of TBI in rats. Since TBI elicits both CNS and peripheral inflammation, we used a mouse model of TBI to examine whether EVT901 would affect peripheral immune responses and trafficking to the injured brain. Methods: Cortical contusion injury (CCI)-TBI of the sensory/motor cortex was induced in C57Bl/6 wild-type mice and CCR2+/RFP heterozygote transgenic mice, followed by treatment with EVT901, a selective antagonist of p75NTR, or vehicle by i.p. injection at 4 h after injury and then daily for 7 days. Brain and blood were collected at 1 and 6 weeks after injury. Flow cytometry and histological analysis were used to determine peripheral immune responses and trafficking of peripheral immune cells into the lesion site at 1 and 6 weeks after TBI. A battery of behavioral tests administered over 6 weeks was used to evaluate neurological outcome, and stereological estimation of brain tissue volume at 6 weeks was used to assess tissue damage. Finally, multivariate principal components analysis (PCA) was used to evaluate the relationships between inflammatory events, EVT901 treatment, and neurological outcomes. Results: EVT901 is neuroprotective in mouse CCI-TBI and dramatically reduced the early trafficking of CCR2+ and pro-inflammatory monocytes into the lesion site. EVT901 reduced the number of CD45(high)CD11b+ and CD45(high)F4/80 + cells in the injured brain at 6 weeks. TBI produced a significant increase in peripheral pro-inflammatory monocytes (Ly6C(int-high) pro-inflammatory monocytes), and this peripheral effect was also blocked by EVT901 treatment. Further, we found that blocking p75NTR with EVT901 reduces the expansion of pro-inflammatory monocytes, and their response to LPS in vitro, supporting the idea that there is a peripheral EVT901 effect that blunts inflammation. Further, 1 week of EVT901 blocks the expansion of pro-inflammatory monocytes in the circulation after TBI, reduces the number of multiple subsets of pro-inflammatory monocytes that enter the injury site at 1 and 6 weeks post-injury, and is neuroprotective, as it was in the rat. Conclusions: Together, these findings suggest that p75NTR signaling participates in the production of the peripheral pro-inflammatory response to CNS injury and implicates p75NTR as a part of the pro-inflammatory cascade. Thus, the neuroprotective effects of p75NTR antagonists might be due to a combination of central and peripheral effects, and p75NTR may play a role in the production of peripheral inflammation in addition to its many other biological roles. Thus, p75NTR may be a therapeutic target in human TBI.	[Lee, Sangmi; Lin, Amity; Sacramento, Jeffrey; Morganti, Josh M.; Rosi, Susanna; Ferguson, Adam R.; Manley, Geoffrey T.; Bresnahan, Jacqueline C.; Beattie, Michael S.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, Box 08991001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94143 USA; [Mattingly, Aaron; Rosi, Susanna; Ferguson, Adam R.; Beattie, Michael S.] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Mannent, Leda; Castel, Marie-Noelle; Canolle, Benoit; Ferzaz, Badia] Sanofi Rech, Early Candidate, 195 Route Espagne, Chilly Mazarin, France; [Delbary-Gossart, Sandrine] Evotec, 195 Route Espagne, F-31036 Toulouse, France	Beattie, MS (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, Box 08991001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94143 USA.; Beattie, MS (corresponding author), Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA.	michael.beattie@ucsf.edu	Beattie, Michael S/A-8953-2009; Morganti, Josh/AAL-9727-2020	Morganti, Josh/0000-0002-4183-0049; Ferguson, Adam/0000-0001-7102-1608	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038079]; UCSF/BASIC pilot funds; Sanofi R and D; UCSF; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038079, R21NS087458, R01NS067092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016] Funding Source: NIH RePORTER	We would like to thank Dr. Jenny Haefeli and Pavan Upadhyayula for the PCA syndromic plots and software development and Dr. Xiaokui Ma for the technical support in the tissue sectioning. Thanks to Dr. Noah Saederup and Dr. Israel F. Charo at Gladstone Institute, UCSF, for providing the CCR2<SUP>+/RFP</SUP> Tg mice [ 50] to Dr. Rosi who provided them for the current experiment. This work was supported by NIH NS038079, with the statistical support from NS067092, UCSF/BASIC pilot funds, and a sponsored research agreement (SRA) between Sanofi R and D and UCSF.	Alabanza LM, 2013, J IMMUNOL, V191, P3764, DOI 10.4049/jimmunol.1202556; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Beattie MS, 2010, EUR J NEUROSCI, V32, P290, DOI 10.1111/j.1460-9568.2010.07343.x; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen CY, 2013, DEV NEUROSCI-BASEL, V35, P474, DOI 10.1159/000355874; Chen QY, 2013, J IMMUNOL, V190, P1048, DOI 10.4049/jimmunol.1202455; Choi S, 2014, NEUROSCIENCE, V257, P11, DOI 10.1016/j.neuroscience.2013.10.058; Choi S, 2009, ASN NEURO, V1, DOI 10.1042/AN20090009; Croft M, 2013, NAT REV DRUG DISCOV, V12, P147, DOI 10.1038/nrd3930; Delbary-Gossart S, 2016, BRAIN; Fleming SM, 2013, JOVE-J VIS EXP, DOI 10.3791/50303; Flores-Torales E, 2010, FOLIA HISTOCHEM CYTO, V48, P682, DOI 10.2478/v10042-010-0063-6; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; Gao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096741; Gardiner E, 2012, MOL PSYCHIATR, V17, P827, DOI 10.1038/mp.2011.78; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Ibanez CF, 2012, TRENDS NEUROSCI, V35, P431, DOI 10.1016/j.tins.2012.03.007; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Inoue T, 2013, EXP NEUROL, V248, P136, DOI 10.1016/j.expneurol.2013.06.006; Irvine K -A., 2010, J VIS EXP; Irvine KA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00116; Jiang YM, 2008, MOL IMMUNOL, V45, P1557, DOI 10.1016/j.molimm.2007.10.008; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kuci S, 2010, HAEMATOL-HEMATOL J, V95, P651, DOI 10.3324/haematol.2009.015065; Lee SM, 2011, J NEUROTRAUM, V28, P1893, DOI 10.1089/neu.2011.1860; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Longo FM, 2013, NAT REV DRUG DISCOV, V12, P507, DOI 10.1038/nrd4024; Meeker R, 2014, J NEUROIMMUNE PHARM, V9, P615, DOI 10.1007/s11481-014-9566-9; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nassenstein C, 2006, EXP TOXICOL PATHOL, V57, P55, DOI 10.1016/j.etp.2006.02.008; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Poulsen KL, 2014, J PHARMACOL EXP THER, V350, P164, DOI 10.1124/jpet.114.214189; Qu CF, 2004, J EXP MED, V200, P1231, DOI 10.1084/jem.20032152; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rogers ML, 2010, J NEUROIMMUNOL, V226, P93, DOI 10.1016/j.jneuroim.2010.05.040; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Saiwai H, 2013, J NEUROCHEM, V125, P74, DOI 10.1111/jnc.12135; Schachtrup C, 2015, NAT NEUROSCI, V18, P1077, DOI 10.1038/nn.4054; Schor NF, 2005, PROG NEUROBIOL, V77, P201, DOI 10.1016/j.pneurobio.2005.10.006; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Sebastiani A, 2015, J NEUROTRAUM, V32, P1599, DOI 10.1089/neu.2014.3751; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Shames BD, 1999, J SURG RES, V83, P69, DOI 10.1006/jsre.1998.5564; Sharif O, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-1; Shen WY, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-137; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Shi J, 2013, STEM CELLS, V31, P2561, DOI 10.1002/stem.1516; Skeldal S, 2011, BIOESSAYS, V33, P614, DOI 10.1002/bies.201100036; Srinivasan B, 2004, J BIOL CHEM, V279, P41839, DOI 10.1074/jbc.M402872200; Staniszewska I, 2008, J CELL SCI, V121, P504, DOI 10.1242/jcs.000232; Szaflarski JP, 2014, NEUROPSYCH DIS TREAT, V10, P1469, DOI 10.2147/NDT.S50421; Takatsuru Y, 2009, BRAIN RES, V1294, P45, DOI 10.1016/j.brainres.2009.07.092; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Terry RL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-270; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Verbeke S, 2013, FEBS LETT, V587, P2591, DOI 10.1016/j.febslet.2013.06.039; Volosin M, 2008, J NEUROSCI, V28, P9870, DOI 10.1523/JNEUROSCI.2841-08.2008; Wensink AC, 2015, J IMMUNOL, V194, P491, DOI 10.4049/jimmunol.1401214; YAN Q, 1988, J NEUROSCI, V8, P3481; Yang Y, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-108; Yuan FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090463; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang HQ, 2011, J NEUROSCI, V31, P15894, DOI 10.1523/JNEUROSCI.3943-11.2011	99	21	21	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	APR 22	2016	13								88	10.1186/s12974-016-0544-4			21	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DJ9KB	WOS:000374531300001	27102880	DOAJ Gold, Green Published			2021-06-18	
J	Tzekov, R; Dawson, C; Orlando, M; Mouzon, B; Reed, J; Evans, J; Crynen, G; Mullan, M; Crawford, F				Tzekov, Radouil; Dawson, Clint; Orlando, Megan; Mouzon, Benoit; Reed, Jon; Evans, James; Crynen, Gogce; Mullan, Michael; Crawford, Fiona			Sub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain Injury	PLOS ONE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; MICROTUBULE-ASSOCIATED PROTEINS; RETINAL GANGLION-CELLS; HEAT-SHOCK PROTEINS; OPTIC-NERVE LESION; AXONAL-TRANSPORT; BASIC-PROTEIN; ALTERED EXPRESSION; APOLIPOPROTEIN-E; CATHEPSIN-D	Repetitive mild traumatic brain injury (r-mTBI) results in neuropathological and biochemical consequences in the human visual system. Using a recently developed mouse model of r-mTBI, with control mice receiving repetitive anesthesia alone (r-sham) we assessed the effects on the retina and optic nerve using histology, immunohistochemistry, proteomic and lipidomic analyses at 3 weeks post injury. Retina tissue was used to determine retinal ganglion cell (RGC) number, while optic nerve tissue was examined for cellularity, myelin content, protein and lipid changes. Increased cellularity and areas of demyelination were clearly detectable in optic nerves in r-mTBI, but not in r-sham. These changes were accompanied by a similar to 25% decrease in the total number of Brn3a-positive RGCs. Proteomic analysis of the optic nerves demonstrated various changes consistent with a negative effect of r-mTBI on major cellular processes like depolymerization of microtubules, disassembly of filaments and loss of neurons, manifested by decrease of several proteins, including neurofilaments (NEFH, NEFM, NEFL), tubulin (TUBB2A, TUBA4A), microtubule-associated proteins (MAP1A, MAP1B), collagen (COL6A1, COL6A3) and increased expression of other proteins, including heat shock proteins (HSP90B1, HSPB1), APOE and cathepsin D. Lipidomic analysis showed quantitative changes in a number of phospholipid species, including a significant increase in the total amount of lysophosphatidylcholine (LPC), including the molecular species 16:0, a known demyelinating agent. The overall amount of some ether phospholipids, like ether LPC, ether phosphatidylcholine and ether lysophosphatidylethanolamine were also increased, while the majority of individual molecular species of ester phospholipids, like phosphatidylcholine and phosphatidylethanolamine, were decreased. Results from the biochemical analysis correlate well with changes detected by histological and immunohistochemical methods and indicate the involvement of several important molecular pathways. This will allow future identification of therapeutic targets for improving the visual consequences of r-mTBI.	[Tzekov, Radouil; Dawson, Clint; Orlando, Megan; Mouzon, Benoit; Reed, Jon; Evans, James; Crynen, Gogce; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Sarasota, FL USA; [Tzekov, Radouil] Univ S Florida, Dept Ophthalmol, Tampa, FL USA; [Tzekov, Radouil; Mouzon, Benoit; Evans, James; Crawford, Fiona] James A Haley Vet Adm, Tampa, FL USA	Tzekov, R (corresponding author), Roskamp Inst, Sarasota, FL USA.; Tzekov, R (corresponding author), Univ S Florida, Dept Ophthalmol, Tampa, FL USA.; Tzekov, R (corresponding author), James A Haley Vet Adm, Tampa, FL USA.	rtzekov@roskampinstitute.net	Dawson, Clint/AAH-3213-2021	Dawson, Clint/0000-0001-7273-0684; Tzekov, Radouil/0000-0002-3662-9818	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation	This work was supported by Department of Defense award W81XWH-10-1-0759 (to Fiona Crawford), and the Roskamp Foundation.	Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; ADAMCZEWSKAGONCERZEWICZ Z, 1981, J NEUROCHEM, V36, P1378, DOI 10.1111/j.1471-4159.1981.tb00575.x; Agudo-Barriuso M, 2011, MYSTERY GLAUCOMA, P91; Aquino DA, 1997, J NEUROPATH EXP NEUR, V56, P664; Atkins Edward J, 2008, Rev Neurol Dis, V5, P73; Beaulieu JM, 1999, BIOCHEM CELL BIOL, V77, P41, DOI 10.1139/bcb-77-1-41; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bilyk J R, 1994, Semin Ophthalmol, V9, P200, DOI 10.3109/08820539409060016; Blondeau N, 2002, J CEREBR BLOOD F MET, V22, P821, DOI 10.1097/00004647-200207000-00007; Bocquet A, 2009, J NEUROSCI, V29, P11043, DOI 10.1523/JNEUROSCI.1924-09.2009; CAMMER W, 1986, BRAIN RES, V364, P91, DOI 10.1016/0006-8993(86)90990-X; Carroll W M, 1983, Clin Exp Neurol, V19, P17; Chen H, 2014, SURV OPHTHALMOL, V59, P64, DOI 10.1016/j.survophthal.2013.02.005; Chidlow G, 2005, MOL VIS, V11, P387; Chidlow G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114838; Cho Y, 2015, J BIOL CHEM, V290, P22759, DOI 10.1074/jbc.M115.638445; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Cwiklinska H, 2003, INT IMMUNOL, V15, P241, DOI 10.1093/intimm/dxg022; DAS SK, 1978, LIPIDS, V13, P679, DOI 10.1007/BF02533745; de Monasterio-Schrader P, 2012, CELL MOL LIFE SCI, V69, P2879, DOI 10.1007/s00018-012-0958-9; Dieterich DC, 2002, EUR J NEUROSCI, V15, P1433, DOI 10.1046/j.1460-9568.2002.01977.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Galindo-Romero C, 2011, EXP EYE RES, V92, P377, DOI 10.1016/j.exer.2011.02.008; GOTO K, 1990, NEUROSCI LETT, V117, P269, DOI 10.1016/0304-3940(90)90675-Y; Greenwald BD, 2012, BRAIN INJURY, V26, P1338, DOI 10.3109/02699052.2012.706356; Grzelczyk A, 2013, BIOCHIMIE, V95, P667, DOI 10.1016/j.biochi.2012.10.009; Gupta R, 2005, J ORTHOP RES, V23, P1232, DOI 10.1016/j.orthres.2004.12.010; Hensley K, 2011, MOL NEUROBIOL, V43, P180, DOI 10.1007/s12035-011-8166-4; HERRMANN H, 1985, J BIOL CHEM, V260, P5797; Hsieh CC, 2000, ATHEROSCLEROSIS, V151, P481, DOI 10.1016/S0021-9150(00)00453-6; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Ikeno Y, 2009, J NEUROSCI RES, V87, P190, DOI 10.1002/jnr.21821; Jacobs SM, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0389-5; Joachim SC, 2011, INVEST OPHTH VIS SCI, V52, P3468, DOI 10.1167/iovs.10-5763; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Kim H, 2011, FEBS LETT, V585, P18, DOI 10.1016/j.febslet.2010.11.033; Kubo T, 2002, J NEUROCHEM, V82, P1129, DOI 10.1046/j.1471-4159.2002.01060.x; Kuhlmann T, 2002, J NEUROSCI RES, V67, P185, DOI 10.1002/jnr.10104; Lachapelle F, 2005, BRAIN PATHOL, V15, P198; Lavi S, 2007, CIRCULATION, V115, P2715, DOI 10.1161/CIRCULATIONAHA.106.671420; Levkovitch-Verbin H, 2000, INVEST OPHTH VIS SCI, V41, P4169; Li Y, 2011, J CELL BIOCHEM, V112, P1930, DOI 10.1002/jcb.23113; Lin PC, 2011, J BIOL CHEM, V286, P41466, DOI 10.1074/jbc.M111.283580; LIU KM, 1985, CELL TISSUE RES, V242, P245; Martin A, 2003, J NEUROSCI, V23, P5416; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; MCKERRACHER L, 1990, J NEUROSCI, V10, P2834; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nagai J, 2011, J NEUROCHEM, V118, P256, DOI 10.1111/j.1471-4159.2011.07297.x; Nguyen JV, 2011, P NATL ACAD SCI USA, V108, P1176, DOI 10.1073/pnas.1013965108; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; NIXON RA, 1990, J CELL BIOL, V110, P437, DOI 10.1083/jcb.110.2.437; Padilla ND, 2003, IMMUNOLOGY, V109, P564, DOI 10.1046/j.1365-2567.2003.01681.x; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Petratos S, 2012, BRAIN, V135, P1794, DOI 10.1093/brain/aws100; Prilloff S, 2012, INVEST OPHTH VIS SCI, V53, P1460, DOI 10.1167/iovs.11-8306; Raasakka A, 2014, NEUROSCI BULL, V30, P956, DOI 10.1007/s12264-013-1437-5; Rodemer C, 2003, HUM MOL GENET, V12, P1881, DOI 10.1093/hmg/ddg191; Rosenberger TA, 2002, J LIPID RES, V43, P59; Saab S, 2014, BIOCHIMIE, V107, P58, DOI 10.1016/j.biochi.2014.07.023; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Salinas-Navarro M, 2009, VISION RES, V49, P637, DOI 10.1016/j.visres.2009.01.010; Saunders LL, 2009, ARCH PHYS MED REHAB, V90, P1853, DOI 10.1016/j.apmr.2009.05.020; Schilling T, 2009, J CELL PHYSIOL, V221, P325, DOI 10.1002/jcp.21857; SCHMIDTKASTNER R, 1994, RESTOR NEUROL NEUROS, V6, P145, DOI 10.3233/RNN-1994-6208; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Sherafat MA, 2011, NEUROCHEM RES, V36, P1887, DOI 10.1007/s11064-011-0510-6; SNYDER DS, 1985, J NEUROCYTOL, V14, P579, DOI 10.1007/BF01200799; STOLL G, 1989, GLIA, V2, P170, DOI 10.1002/glia.440020306; Surgucheva I, 2002, J NEUROSCI RES, V68, P97, DOI 10.1002/jnr.10198; Surguchov A, 2001, J NEUROSCI RES, V65, P68, DOI 10.1002/jnr.1129; Takahashi M, 2002, ATHEROSCLEROSIS, V161, P387, DOI 10.1016/S0021-9150(01)00674-8; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Teigler A, 2009, HUM MOL GENET, V18, P1897, DOI 10.1093/hmg/ddp110; Thukkani AK, 2003, CIRCULATION, V108, P3128, DOI 10.1161/01.CIR.0000104564.01539.6A; Tytell M, 2005, INT J HYPERTHER, V21, P445, DOI 10.1080/02656730500041921; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wender M, 1981, Acta Neuropathol Suppl, V7, P36; Wong EV, 2003, J NEUROSCI, V23, P3112; Xu K, 2013, SCIENCE, V339, P452, DOI 10.1126/science.1232251; You YY, 2011, INVEST OPHTH VIS SCI, V52, P6911, DOI 10.1167/iovs.11-7434; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Yuan AD, 2006, J NEUROSCI, V26, P10006, DOI 10.1523/JNEUROSCI.2580-06.2006; Zhao J, 2016, METHOD ENZYMOL, V568, P477, DOI 10.1016/bs.mie.2015.09.012; Zhou ZG, 2011, LIPIDS, V46, P879, DOI 10.1007/s11745-011-3575-8; Zhu XD, 2007, AM J RESP CELL MOL, V36, P585, DOI 10.1165/rcmb.2006-0391OC	92	21	21	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2016	11	4							e0153608	10.1371/journal.pone.0153608			29	Multidisciplinary Sciences	Science & Technology - Other Topics	DJ9IK	WOS:000374527000029	27088355	DOAJ Gold, Green Published			2021-06-18	
J	Abogresha, NM; Greish, SM; Abdelaziz, EZ; Khalil, WF				Abogresha, Noha M.; Greish, Sahar Mansour; Abdelaziz, Eman Z.; Khalil, Waleed F.			Remote effect of kidney ischemia-reperfusion injury on pancreas: role of oxidative stress and mitochondrial apoptosis	ARCHIVES OF MEDICAL SCIENCE			English	Article						kidney ischemia-reperfusion; pancreatic apoptosis; oxidative stress	ISCHEMIA/REPERFUSION; EXPRESSION; THYMUS; BLOOD; RATIO	Introduction: Recent studies have demonstrated remote effects of renal ischemia/reperfusion (IR) injury on some organs such as brain, liver, and lungs. Oxidative stress is reported to be the cornerstone in such ischemic conditions. Associated apoptosis is also reported in remote lung, liver and myocardial injury after acute kidney injury. So, we postulated that renal IR may affect the pancreas by its remote effect. Oxidative stress and mitochondria) mediated apoptosis may play a crucial role in this injury. We investigated the effects of kidney IR on pancreatic exocrine and endocrine functions, antioxidant enzyme activity, and apoptosis. Material and methods: The protective effect of vitamin C was also investigated. The animals were submitted to non-traumatic bilateral renal IR, sham operation or treatment with vitamin C after IR. Rats were sacrificed on the 1st, 3rd, and 7th days of the experiment to evaluate the parameters of oxidative stress (catalase, lipid peroxidase, reduced glutathione and superoxide dismutase), pancreatic endocrine and exocrine function (amylase, insulin and fasting blood glucose), renal functions (serum creatinine and blood urea nitrogen), cellular injury and apoptotic markers (Bcl-2, Bax and caspase-3). Results: Kidney I/R significantly increased the renal and pancreatic functions at 1, 3 and 7 days, while fasting insulin was significantly increased at day 3 after ischemia. Moreover, I/R significantly increased the studied oxidative stress markers and decreased the antioxidant capacity in pancreatic tissues. In addition, renal I/R induced numerous histopatological lesions in pancreatic tissues and increased the apoptosis-related genes. Treating the rats with vitamin C (100 mg/kg) significantly restored the renal and pancreatic functions, improved the pancreatic antioxidant capacity and protected the pancreatic tissues from apoptotic necrosis. Conclusions: The results suggested that bilateral renal ischemia for 45 min caused significant impairment of pancreatic function and structure as indicators of acute pancreatitis. While IR enhances oxidative stress and apoptosis, vitamin C appears to play a cytoprotective role.	[Abogresha, Noha M.; Greish, Sahar Mansour] Suez Canal Univ, Fac Med, Dept Physiol, Ismaileya 41522, Egypt; [Abdelaziz, Eman Z.] Suez Canal Univ, Fac Med, Dept Pharmacol, Ismaileya, Egypt; [Khalil, Waleed F.] Suez Canal Univ, Fac Vet Med, Dept Pharmacol, Ismaileya, Egypt	Greish, SM (corresponding author), Suez Canal Univ, Fac Med, Dept Physiol, Ismaileya 41522, Egypt.	saharmg@yahoo.com	Abdelaziz, Eman Z/ABG-6634-2020; khalil, Waleed/AAJ-7724-2020	Abdelaziz, Eman Z/0000-0002-6120-5048; khalil, Waleed/0000-0003-2198-6406; Greish, Sahar/0000-0002-6729-9006; Abogresha, Noha/0000-0001-7548-6349			Abdollahzad H, 2009, INT J VITAM NUTR RES, V79, P281, DOI 10.1024/0300-9831.79.56.281; AEBI H, 1984, METHOD ENZYMOL, V105, P121; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Bulent G, ISCHEMIA REPERFUSION; Chambial S, 2013, INDIAN J CLIN BIOCHE, V28, P314, DOI 10.1007/s12291-013-0375-3; Chang BJ, 2002, ARCH BIOCHEM BIOPHYS, V405, P55, DOI 10.1016/S0003-9861(02)00342-9; Chappel JB, 1969, SUBCELLULAR COMPONEN; Chen CC, 2004, ACTA PHARMACOL SIN, V25, P1334; Doustar Y, 2012, J ANIM VET ADV, V11, P108; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Fujimoto K, 1997, J SURG RES, V71, P127, DOI 10.1006/jsre.1997.5151; Hengartner M O, 2000, Symp Soc Exp Biol, V52, P1; Hussein AM, 2014, PHYSIOL RES, V63, P47, DOI 10.33549/physiolres.932497; Kockar C, 2012, NOBEL MED, V8, P49; Laura E, 2012, INTERN J NEPHROL, V2012; Munoz-Casares FC, 2006, J PINEAL RES, V40, P195, DOI 10.1111/j.1600-079X.2005.00291.x; Obermaier R, 2001, CLIN EXP MED, V1, P51, DOI 10.1007/PL00012237; Philchenkov A, 2004, EXP ONCOL, V26, P82; Rodrigo R, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-192; Salakou S, 2001, EUR J CARDIO-THORAC, V20, P712, DOI 10.1016/S1010-7940(01)00776-X; Salakou S, 2007, IN VIVO, V21, P123; Sambrook J., 2001, MOL CLONING LAB MANU; Scopa CD, 2001, APPL IMMUNOHISTO M M, V9, P329, DOI 10.1097/00022744-200112000-00007; TAMURA K, 1993, HEPATO-GASTROENTEROL, V40, P452; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Warzecha Z, 2004, J PHYSIOL PHARMACOL, V55, P791; WOOLLIAMS JA, 1983, RES VET SCI, V34, P253, DOI 10.1016/S0034-5288(18)32219-7; Yildirim A, 2009, INT J MORPHOL, V27, P519, DOI 10.4067/S0717-95022009000200036	28	21	28	0	5	TERMEDIA PUBLISHING HOUSE LTD	POZNAN	KLEEBERGA ST 2, POZNAN, 61-615, POLAND	1734-1922	1896-9151		ARCH MED SCI	Arch. Med. Sci.	APR	2016	12	2					252	262		10.5114/aoms.2015.48130			11	Medicine, General & Internal	General & Internal Medicine	DJ9BY	WOS:000374510200003	27186168	DOAJ Gold, Green Published			2021-06-18	
J	O'Donnell, ML; Alkemade, N; Creamer, MC; McFarlane, AC; Silove, D; Bryant, RA; Forbes, D				O'Donnell, Meaghan L.; Alkemade, Nathan; Creamer, Mark C.; McFarlane, Alexander C.; Silove, Derrick; Bryant, Richard A.; Forbes, David			The Long-Term Psychiatric Sequelae of Severe Injury: A 6-Year Follow-Up Study	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; DISABILITY; DEPRESSION; BURDEN; FEAR; US	Objective: The impact of mental health on disease burden associated with injury represents a major public health issue, yet almost no information is available on the associated long-term mental health outcomes. The primary aim of this study was to assess the psychiatric outcomes 6 years after a severe injury and their subsequent impact on long-term disability. The secondary aim was to investigate the relationship between a mild traumatic brain injury (mTBI) and long-term psychiatric disorder and its impact on disability. Methods: From April 2004 to February 2006, randomly selected injury patients admitted to 4 hospitals across Australia were assessed during hospitalization and at 72 months after trauma (N = 592). Injury characteristics, the presence of an mTBI (ICD-9 criteria), and previous psychiatric history were assessed during hospitalization. Structured clinical interviews for psychiatric disorders (DSM-IV and DSM-5) and a self-report measure of disability (WHODAS II) were administered at 72 months. Results: At 72 months after a severe injury, 28% of patients met criteria for at least 1 psychiatric disorder, with 45% of those presenting with comorbid diagnoses. The most prevalent psychiatric disorder was a major depressive episode (11%) followed by substance use disorder (9%), agoraphobia (9%), posttraumatic stress disorder (6%), and generalized anxiety disorder (6%). The presence of any psychiatric disorder was found to increase the risk for disability (P<.001, odds ratio = 6.04). An mTBI was found to increase the risk for having some anxiety disorders but not to increase disability by itself. Conclusions: The long-term psychiatric consequences of severe injury are substantial and represent a significant contributor to long-term disability. This study points to an important intersection between injury and psychiatric disorder as a leading contributor to disease burden and suggests this growing burden will impose new challenges on health systems. (C) Copyright 2016 Physicians Postgraduate Press, Inc.	[O'Donnell, Meaghan L.; Alkemade, Nathan; Forbes, David] Phoenix Australia, Ctr Posttraumat Mental Hlth, Level 3,Alan Gilbert Bldg,161 Barry St, Carlton, Vic 3053, Australia; [O'Donnell, Meaghan L.; Alkemade, Nathan; Creamer, Mark C.; Forbes, David] Univ Melbourne, Dept Psychiat, Parkville, Vic, Australia; [Bryant, Richard A.] Univ New South Wales, Sch Psychol, Sydney, NSW, Australia; [Silove, Derrick] Univ New South Wales, Sch Psychiat, Sydney, NSW, Australia; [McFarlane, Alexander C.] Univ Adelaide, Ctr Traumat Stress, Adelaide, SA, Australia; [Silove, Derrick] Mental Hlth Ctr, Psychiat Res & Teaching Unit, Liverpool, NSW, Australia	O'Donnell, ML (corresponding author), Phoenix Australia, Ctr Posttraumat Mental Hlth, Level 3,Alan Gilbert Bldg,161 Barry St, Carlton, Vic 3053, Australia.	mod@unimelb.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; Forbes, David/0000-0001-9145-1605; O'Donnell, Meaghan/0000-0003-4349-0022	National Health and Medical Research Council Program GrantNational Health and Medical Research Council of Australia [568970]	This study was supported by a National Health and Medical Research Council Program Grant (568970).	Andrews G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008343; Andruszkow H, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-26; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bonanno GA, 2012, PSYCHOL TRAUMA-US, V4, P74, DOI 10.1037/a0017829; Bryant RA, 2008, PSYCHOL MED, V38, P555, DOI 10.1017/S0033291707002231; Bryant RA, 2015, BRIT J PSYCHIAT, V206, P417, DOI 10.1192/bjp.bp.114.145516; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Findley PA, 2011, DISABIL REHABIL, V33, P1608, DOI 10.3109/09638288.2010.540294; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Kenardy J, 2015, ARCH PHYS MED REHAB, V96, P410, DOI 10.1016/j.apmr.2014.10.007; Levin HS, 1995, NEUROTRAUMA, P749; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; McAllister TW, 2010, PSYCHIAT ANN, V40, P533, DOI 10.3928/00485713-20101018-04; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; O'Donnell ML, 2013, J CLIN PSYCHIAT, V74, pE137, DOI 10.4088/JCP.12m08011; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schweininger S, 2015, DEPRESS ANXIETY, V32, P64, DOI 10.1002/da.22288; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Slade T, 2009, AUST NZ J PSYCHIAT, V43, P594, DOI 10.1080/00048670902970882; TEASDALE G, 1974, LANCET, V2, P81; WHO, 2009, GLOB HLTH RISKS MORT; WHODAS Group, 2000, WHO DIS ASS SCHED 2; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zhang Y, 2007, BIOMETRICS, V63, P865, DOI 10.1111/j.1541-0420.2006.00735.x; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zoellner LA, 2014, DEPRESS ANXIETY, V31, P97, DOI 10.1002/da.22133	35	21	21	0	9	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry	APR	2016	77	4					E473	E479		10.4088/JCP.14m09721			7	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	DQ5LU	WOS:000379247700013	27137435				2021-06-18	
J	Vera-Estay, E; Seni, AG; Champagne, C; Beauchamp, MH				Vera-Estay, Evelyn; Seni, Anne G.; Champagne, Caroline; Beauchamp, Miriam H.			All for One: Contributions of Age, Socioeconomic Factors, Executive Functioning, and Social Cognition to Moral Reasoning in Childhood	FRONTIERS IN PSYCHOLOGY			English	Article						moral reasoning; executive functions; affect recognition; theory of mind; childhood	TRAUMATIC BRAIN-INJURY; FACIAL EXPRESSIONS; EFFORTFUL CONTROL; NEURAL BASIS; CHILDRENS; EMOTION; EMPATHY; MIND; RECOGNITION; BEHAVIOR	Moral reasoning (MR) is a socio-cognitive skill essential to appropriate social functioning in childhood, and evolves in quality and complexity during ontogenetic development. Past research suggests that MR is related to age, socioeconomic factors, as well as some social and cognitive skills, such as executive functioning (EF), theory of mind (ToM), empathy, and affect recognition. However, their contributions have been studied in silos rather than comprehensively, with little integration of the relative and combined contribution of these skills to MR. Furthermore, few studies have addressed the putative links between these factors in childhood, a period during which these skills are in maturation. The aim of this study was to explore what factors predict moral maturity in typically developing children (n = 76, 47.4% males, M = 9.2, SD = 1.67 years), explore the potential moderating and mediating role of executive functions and social cognition in the relationship between age and MR maturity, and identify the specific contributions of age, socioeconomic factors, EF, and social cognition, using an innovative visual MR assessment tool (So-Moral). The results indicate that MR maturity was correlated with age, EF (inhibition, verbal fluency, and attentional control), and social cognition (ToM and affect recognition). Neither EF nor social cognition moderated the effect of age on MR maturity. However, verbal fluency and third-order false beliefs had a moderating role in this link. MR maturity in children was predicted by three variables from each of the three domains: age, verbal fluency, and third-order ToM. These results contribute to a better understanding of the underpinnings of MR during childhood, suggesting that MR is not reducible to general developmental factors such as age, but that higher order skills, such EF and social cognition also contribute to moral maturity. The findings have relevance for both typically developing and clinical populations in which social skills may be reduced, as well as for the identification of potential loci for intervention in children at-risk for socially maladaptive behaviors.	[Vera-Estay, Evelyn; Seni, Anne G.; Champagne, Caroline; Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, CP 6128, Montreal, PQ H3C 3J7, Canada; [Vera-Estay, Evelyn; Beauchamp, Miriam H.] Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada	Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP 6128, Montreal, PQ H3C 3J7, Canada.; Beauchamp, MH (corresponding author), Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada.	miriam.beauchamp@umontreal.ca			Social Sciences and Humanities Research Council of CanadaSocial Sciences and Humanities Research Council of Canada (SSHRC); Government of Chile (CONICYT)	This study was funded by the Social Sciences and Humanities Research Council of Canada and a scholarship to EV-E from the Government of Chile (CONICYT). The funding body was not involved in the study design, collection, analysis or interpretation of data, nor in the writing of the manuscript and the decision to submit the article for publication.	Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Arsenio WF, 2006, COGNITIVE DEV, V21, P388, DOI 10.1016/j.cogdev.2006.06.005; Baird JA, 2004, NEW DIR CHILD ADOLES, V103, P37, DOI 10.1002/cd.96; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Beauchamp M, 2012, ADM CODING MANUAL SO; Beauchamp MH, 2013, BRAIN INJURY, V27, P896, DOI 10.3109/02699052.2013.775486; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bechi M, 2012, PSYCHIAT RES, V198, P371, DOI 10.1016/j.psychres.2012.02.004; BERKOWITZ MW, 1983, MERRILL PALMER QUART, V29, P399; Birch SAJ, 2004, TRENDS COGN SCI, V8, P255, DOI 10.1016/j.tics.2004.04.011; Blair RJR, 2001, PERS INDIV DIFFER, V31, P799, DOI 10.1016/S0191-8869(00)00181-1; Blair RJR, 2001, J ABNORM CHILD PSYCH, V29, P491, DOI 10.1023/A:1012225108281; Bowen KL, 2014, J PSYCHOPATHOL BEHAV, V36, P60, DOI 10.1007/s10862-013-9368-z; Bradley RH, 2002, ANNU REV PSYCHOL, V53, P371, DOI 10.1146/annurev.psych.53.100901.135233; Brune M, 2005, PSYCHIAT RES, V133, P135, DOI 10.1016/j.psychres.2004.10.007; BRYANT BK, 1982, CHILD DEV, V53, P413, DOI 10.1111/j.1467-8624.1982.tb01331.x; Caravita SCS, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00262; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; Cohen J, 1988, STAT POWER ANAL BEHA; Couper E, 2002, BRAIN IMPAIR, V3, P105, DOI DOI 10.1375/BRIM.3.2.105; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Cui LX, 2016, J ABNORM CHILD PSYCH, V44, P663, DOI 10.1007/s10802-015-0079-7; Cushman F, 2013, COGNITION, V127, P6, DOI 10.1016/j.cognition.2012.11.008; Dadds MR, 2008, CHILD PSYCHIAT HUM D, V39, P111, DOI 10.1007/s10578-007-0075-4; Daniel E, 2014, J ADOLESCENCE, V37, P1201, DOI 10.1016/j.adolescence.2014.08.009; Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221; Decety J, 2015, MORAL BRAIN: A MULTIDISCIPLINARY PERSPECTIVE, P279; Decety J, 2014, TRENDS COGN SCI, V18, P337, DOI 10.1016/j.tics.2014.04.008; Decety J, 2013, CHILD DEV PERSPECT, V7, P49, DOI 10.1111/cdep.12020; Decety J, 2012, CEREB CORTEX, V22, P209, DOI 10.1093/cercor/bhr111; Devine RT, 2014, CHILD DEV, V85, P1777, DOI 10.1111/cdev.12237; Dooley JJ, 2010, BRAIN IMPAIR, V11, P152, DOI 10.1375/brim.11.2.152; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Dunn J, 2000, BRIT J DEV PSYCHOL, V18, P159, DOI 10.1348/026151000165625; Eisenberg N, 2004, CHILD DEV, V75, P25, DOI 10.1111/j.1467-8624.2004.00652.x; Eisenberg N, 2003, CROSS CONT, P253; Eisenberg N, 2002, J PERS SOC PSYCHOL, V82, P993, DOI 10.1037//0022-3514.82.6.993; EISENBERG N, 1990, MOTIV EMOTION, V14, P131, DOI 10.1007/BF00991640; EISENBERGBERG N, 1978, DEV PSYCHOL, V14, P185; Gibbs J. C., 2013, MORAL DEV REALITY TH; Gibbs J.C., 2010, MORAL DEV REALITY TH; HAIDT J, 1993, J PERS SOC PSYCHOL, V65, P613, DOI 10.1037/0022-3514.65.4.613; Hastings ME, 2008, PERS INDIV DIFFER, V44, P1474, DOI 10.1016/j.paid.2008.01.004; Hayes A.F., 2018, INTRO MEDIATION MODE, V2nd ed.; Hayes AF., 2012, PROCESS VERSATILE CO; Herba CM, 2006, J CHILD PSYCHOL PSYC, V47, P1098, DOI 10.1111/j.1469-7610.2006.01652.x; Hinnant JB, 2013, COGNITION EMOTION, V27, P1460, DOI 10.1080/02699931.2013.789792; Hoffman Martin L., 2001, EMPATHY MORAL DEV IM, DOI [10.1017/cbo9780511805851, 10.1017/CBO9780511805851, DOI 10.1017/CBO9780511805851]; Hooper SR, 2010, SCHOOL PSYCHOL QUART, V25, P1, DOI 10.1037/a0018329; Janus M., 2007, EARLY EDUC DEV, V18, P375, DOI DOI 10.1080/10409280701610796A; Johnson M. H., 1991, BIOL COGNITIVE DEV C; Kerr A, 2004, BRAIN COGNITION, V55, P148, DOI 10.1016/s0278-2626(03)00275-6; Killen M., 2011, EMERGENCE MORALITY C, P9; Killen M, 2011, COGNITION, V119, P197, DOI 10.1016/j.cognition.2011.01.006; Kochanska G, 2000, DEV PSYCHOL, V36, P220, DOI 10.1037//0012-1649.36.2.220; Kohlberg L., 1983, MORAL STAGES CURRENT; Korkman M., 2007, NEPSY 2 CLIN TNTERPR; Korkmaz B, 2011, PEDIATR RES, V69, p101R, DOI 10.1203/PDR.0b013e318212c177; Kretschmer A, 2014, INT J DEV DISABIL, V60, P174, DOI 10.1179/2047387714Y.0000000045; Lagattuta KH, 2005, CHILD DEV, V76, P713, DOI 10.1111/j.1467-8624.2005.00873.x; Lane JD, 2010, BRIT J DEV PSYCHOL, V28, P871, DOI 10.1348/026151009X483056; Malti T, 2013, SOC DEV, V22, P773, DOI 10.1111/sode.12031; Malti T, 2010, NEW DIR CHILD ADOLES, V129, P1, DOI 10.1002/cd.272; Martel MM, 2007, DEV PSYCHOPATHOL, V19, P541, DOI 10.1017/S0954579407070265; Mathersul D, 2009, J CLIN EXP NEUROPSYC, V31, P278, DOI 10.1080/13803390802043619; Miller M, 2010, J ABNORM CHILD PSYCH, V38, P315, DOI 10.1007/s10802-009-9369-2; Miller PA, 1996, DEV PSYCHOL, V32, P210, DOI 10.1037/0012-1649.32.2.210; Moll J, 2005, NAT REV NEUROSCI, V6, P799, DOI 10.1038/nrn1768; Nettle, 2006, J CULTURAL EVOLUTION, V4, P231, DOI [10.1556/JCEP.4.2006.3-4.3, DOI 10.1556/JCEP.4.2006.3-4.3]; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Preacher KJ, 2011, PSYCHOL METHODS, V16, P93, DOI 10.1037/a0022658; Rhodes M, 2013, PSYCHOL SCI, V24, P999, DOI 10.1177/0956797612466267; Roberts W, 1996, CHILD DEV, V67, P449, DOI 10.2307/1131826; Rosenqvist J, 2014, CHILD NEUROPSYCHOL, V20, P281, DOI 10.1080/09297049.2013.778235; Sharp C, 2008, SOCIAL COGNITION DEV; Smetana JG, 2012, DEV PSYCHOL, V48, P1144, DOI 10.1037/a0025891; Statistics Canada, 2015, MED TOT INC FAM TYP; Stevens D, 2001, J GENET PSYCHOL, V162, P201, DOI 10.1080/00221320109597961; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tappan MB, 1997, DEV REV, V17, P78, DOI 10.1006/drev.1996.0422; Thomas LA, 2007, DEVELOPMENTAL SCI, V10, P547, DOI 10.1111/j.1467-7687.2007.00614.x; Turiel E., 1983, DEV SOCIAL KNOWLEDGE; Turiel E., 2002, CULTURE MORALITY SOC; Vera-Estay E, 2015, J MORAL EDUC, V44, P17, DOI 10.1080/03057240.2014.986077; Wainryb C, 2006, ADV CHILD DEV BEHAV, V34, P131, DOI 10.1016/S0065-2407(06)80006-6; Walker LJ, 2000, CHILD DEV, V71, P1033, DOI 10.1111/1467-8624.00207; WALKER LJ, 1991, CHILD DEV, V62, P264, DOI 10.2307/1131002; Wechsler D., 2005, ECHELLE INTELLIGENCE, V4th; Wechsler D., 2011, WECHLSER ABBREVIATED; Young L, 2007, P NATL ACAD SCI USA, V104, P8235, DOI 10.1073/pnas.0701408104	90	21	21	2	63	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.	MAR 8	2016	7								277	10.3389/fpsyg.2016.00227			13	Psychology, Multidisciplinary	Psychology	DF5MY	WOS:000371397300001	27014110	DOAJ Gold, Green Published			2021-06-18	
J	Posti, JP; Piitulainen, JM; Hupa, L; Fagerlund, S; Frantzen, J; Aitasalo, KMJ; Vuorinen, V; Serlo, W; Syrjanen, S; Vallittu, PK				Posti, Jussi P.; Piitulainen, Jaakko M.; Hupa, Leena; Fagerlund, Susanne; Frantzen, Janek; Aitasalo, Kalle M. J.; Vuorinen, Ville; Serlo, Willy; Syrjanen, Stina; Vallittu, Pekka K.			A glass fiber-reinforced composite - bioactive glass cranioplasty implant: A case study of an early development stage implant removed due to a late infection	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Bioactive glass; Fiber-reinforced composite; Cranioplasty; Decompressive craniectomy; Calvarial reconstruction; Traumatic brain injury	BIOCOMPATIBLE GLASSES; AUTOGENOUS BONE; RECONSTRUCTION; S53P4; SPONDYLODESIS; BEHAVIOR; REPAIR	This case study describes the properties of an early development stage bioactive glass containing fiber-reinforced composite calvarial implant with histology that has been in function for two years and three months. The patient is a 33-year old woman with a history of substance abuse, who sustained a severe traumatic brain injury later unsuccessfully treated with an autologous bone flap and a custom-made porous polyethylene implant. She was thereafter treated with developmental stage glass fiber-reinforced composite - bioactive glass implant. After two years and three months, the implant was removed due to an implant site infection. The implant was analyzed histologically, mechanically, and in terms of chemistry and dissolution of bioactive glass. Mechanical integrity of the load bearing fiber-reinforced composite part of the implant was not affected by the in vivo period. Bioactive glass particles demonstrated surface layers of hydroxyapatite like mineral and dissolution, and related increase of pH was considerably less after two and three months period than that for fresh bioactive glass. There was a difference in the histology of the tissues inside the implant areas near to the margin of the implant that absorbed blood during implant installation surgery, showed fibrous tissue with blood vessels, osteoblasts, collagenous fibers with osteoid formation, and tiny clusters of more mature hard tissue. In the center of the implant, where there was less absorbed blood, only fibrous tissue was observed. This finding is in line with the combined positron emission tomography - computed tomography examination with (18F)-fluoride marker, which demonstrated activity of the mineralizing bone by osteoblasts especially at the area near to the margin of the implant 10 months after implantation. Based on these promising reactions found in the bioactive glass containing fiber reinforced composite implant that has been implanted for two years and three months, calvarial reconstruction with the presented material appears to be a feasible method. (C) 2015 Elsevier Ltd. All rights reserved.	[Posti, Jussi P.; Frantzen, Janek; Vuorinen, Ville] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, POB 52, Turku 20521, Finland; [Posti, Jussi P.; Frantzen, Janek] Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, POB 52, Turku 20521, Finland; [Posti, Jussi P.] Univ Turku, Dept Neurol, Turku 20014, Finland; [Posti, Jussi P.; Piitulainen, Jaakko M.; Aitasalo, Kalle M. J.] Univ Turku, Inst Dent, Dept Biomat Sci, Lemminkaisenkatu 2, FIN-20520 Turku, Finland; [Posti, Jussi P.; Piitulainen, Jaakko M.; Aitasalo, Kalle M. J.] Univ Turku, Inst Dent, TCBC, Lemminkaisenkatu 2, FIN-20520 Turku, Finland; [Piitulainen, Jaakko M.; Aitasalo, Kalle M. J.; Vallittu, Pekka K.] Turku Univ Hosp, Div Surg & Canc Dis, Dept Otorhinolaryngol Head & Neck Surg, POB 52, Turku 20521, Finland; [Hupa, Leena; Fagerlund, Susanne] Abo Akad Univ, Johan Gadolin Proc Chem Ctr, Piispankatu 9, SF-20500 Turku, Finland; [Serlo, Willy] Oulu Univ Hosp, Dept Children & Adolescents, Oys 90029, Finland; [Serlo, Willy] Oulu Univ, MRC Oulu, POB 23, Oulu, Finland; [Serlo, Willy] Oulu Univ, PEDEGO Res Ctr, POB 23, Oulu, Finland; [Syrjanen, Stina] Univ Turku, Inst Dent, Dept Oral Pathol & Radiol, Turku 20014, Finland; [Syrjanen, Stina] Turku Univ Hosp, Dept Pathol, POB 52, Turku 20521, Finland; [Vallittu, Pekka K.] City Turku Welf Div, POB 670, Turku 20101, Finland	Posti, JP (corresponding author), Turku Univ Hosp, Dept Neurosurg, Clin Neurosci, POB 52, Turku 20521, Finland.	jussi.posti@utu.fi	Posti, Jussi P./Y-2908-2019; Hupa, Leena/A-5774-2016	Posti, Jussi P./0000-0002-5925-5193; Syrjanen, Stina/0000-0003-0738-5698; Piitulainen, Jaakko/0000-0001-9788-8904; Hupa, Leena/0000-0001-7745-7779	Personal EVO Funding (Finland); Maire Taponen Foundation	This work was partially funded by the Personal EVO Funding (Finland) and grant from Maire Taponen Foundation (JPP).	Aitasalo KMJ, 2014, HEAD NECK-J SCI SPEC, V36, P722, DOI 10.1002/hed.23370; Azenha MR, 2012, ORAL MAXILLOFAC SURG, V16, P393, DOI 10.1007/s10006-011-0308-3; Bhaskar IP, 2014, WORLD NEUROSURG, V82, pE531, DOI 10.1016/j.wneu.2013.01.013; Boccaccini A. R., 2012, BIOGLASSES INTRO, P121; Bouillaguet S, 2006, J BIOMED MATER RES B, V76B, P98, DOI 10.1002/jbm.b.30349; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Fagerlund S, 2013, ACTA BIOMATER, V9, P5400, DOI 10.1016/j.actbio.2012.08.051; Frantzen J, 2011, J SPINAL DISORD TECH, V24, P455, DOI 10.1097/BSD.0b013e31822a20c6; Honeybul S, 2013, J NEUROSURG, V119, P1566, DOI 10.3171/2013.8.JNS13857; Hupa L., 2015, J NONCRYSOL IN PRESS; Hupa L, 2010, GLASS TECHNOL-PART A, V51, P89; Klinger DR, 2014, WORLD NEUROSURG, V82, pE525, DOI 10.1016/j.wneu.2013.08.005; Lee EI, 2014, PLAST RECONSTR SURG, V133, P675, DOI 10.1097/01.prs.0000438061.46290.33; Lindfors NC, 2010, J BIOMED MATER RES B, V94B, P157, DOI 10.1002/jbm.b.31636; Mylonas AI, 2007, J CRANIO MAXILL SURG, V35, P63, DOI 10.1016/j.jcms.2006.10.004; Pernaa K, 2011, J Long Term Eff Med Implants, V21, P139; Piitulainen JM, 2015, WORLD NEUROSURG, V83, P708, DOI 10.1016/j.wneu.2015.01.014; Piitulainen JM, 2015, ACTA NEUROCHIR, V157, P681, DOI 10.1007/s00701-015-2363-2; Rantakokko J, 2012, SCAND J SURG, V101, P66, DOI 10.1177/145749691210100113; Stoor P, 2001, J BIOMED MATER RES, V58, P113, DOI 10.1002/1097-4636(2001)58:1<113::AID-JBM170>3.0.CO;2-V; Stoor P, 1998, ACTA ODONTOL SCAND, V56, P161, DOI 10.1080/000163598422901; Sundseth J, 2014, ACTA NEUROCHIR, V156, P805, DOI 10.1007/s00701-013-1992-6; Truntzer Jeremy, 2015, Eur J Orthop Surg Traumatol, V25, P211, DOI 10.1007/s00590-014-1488-y; Tunkel A.R., 2010, PRINCIPLES PRACTICE, V1, P1279; Tuusa SMR, 2008, J BIOMED MATER RES B, V84B, P510, DOI 10.1002/jbm.b.30898; Ullmark G, 2013, ACTA ORTHOP, V84, P138, DOI 10.3109/17453674.2013.786632; Vallittu PK, 2007, INT J PROSTHODONT, V20, P43; Varila L, 2012, J MATER SCI-MATER M, V23, P2425, DOI 10.1007/s10856-012-4693-4; Zhang D, 2010, J BIOMED MATER RES A, V93A, P475, DOI 10.1002/jbm.a.32564	29	21	22	2	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	MAR	2016	55						191	200		10.1016/j.jmbbm.2015.10.030			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	DE8LD	WOS:000370886600017	26594779				2021-06-18	
J	Schober, ME; Requena, DF; Abdullah, OM; Casper, TC; Beachy, J; Malleske, D; Pauly, JR				Schober, Michelle E.; Requena, Daniela F.; Abdullah, Osama M.; Casper, T. Charles; Beachy, Joanna; Malleske, Daniel; Pauly, James R.			Dietary Docosahexaenoic Acid Improves Cognitive Function, Tissue Sparing, and Magnetic Resonance Imaging Indices of Edema and White Matter Injury in the Immature Rat after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; DTI; Morris water maze; pediatric	CONTROLLED CORTICAL IMPACT; MORRIS WATER MAZE; IN-VIVO; AXON DIAMETER; DIFFUSION; EXPRESSION; SUPPLEMENTATION; MODEL; TERM; VULNERABILITY	Traumatic brain injury (TBI) is the leading cause of acquired neurologic disability in children. Specific therapies to treat acute TBI are lacking. Cognitive impairment from TBI may be blunted by decreasing inflammation and oxidative damage after injury. Docosahexaenoic acid (DHA) decreases cognitive impairment, oxidative stress, and white matter injury in adult rats after TBI. Effects of DHA on cognitive outcome, oxidative stress, and white matter injury in the developing rat after experimental TBI are unknown. We hypothesized that DHA would decrease early inflammatory markers and oxidative stress, and improve cognitive, imaging and histologic outcomes in rat pups after controlled cortical impact (CCI). CCI or sham surgery was delivered to 17 d old male rat pups exposed to DHA or standard diet for the duration of the experiments. DHA was introduced into the dam diet the day before CCI to allow timely DHA delivery to the pre-weanling pups. Inflammatory cytokines and nitrates/nitrites were measured in the injured brains at post-injury Day (PID) 1 and PID2. Morris water maze (MWM) testing was performed at PID41-PID47. T2-weighted and diffusion tensor imaging studies were obtained at PID12 and PID28. Tissue sparing was calculated histologically at PID3 and PID50. DHA did not adversely affect rat survival or weight gain. DHA acutely decreased oxidative stress and increased anti-inflammatory interleukin 10 in CCI brains. DHA improved MWM performance and lesion volume late after injury. At PID12, DHA decreased T2-imaging measures of cerebral edema and decreased radial diffusivity, an index of white matter injury. DHA improved short- and long-term neurologic outcomes after CCI in the rat pup. Given its favorable safety profile, DHA is a promising candidate therapy for pediatric TBI. Further studies are needed to explore neuroprotective mechanisms of DHA after developmental TBI.	[Schober, Michelle E.; Requena, Daniela F.; Casper, T. Charles] Univ Utah, Dept Pediat, Div Crit Care, Salt Lake City, UT 84158 USA; [Abdullah, Osama M.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84158 USA; [Beachy, Joanna; Malleske, Daniel] Univ Utah, Dept Pediat, Div Neonatol, Salt Lake City, UT 84158 USA; [Pauly, James R.] Univ Kentucky, Coll Pharm, Lexington, KY USA; [Pauly, James R.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA	Schober, ME (corresponding author), Univ Utah, Sch Med, POB 581289, Salt Lake City, UT 84158 USA.	michelle.schober@hsc.utah.edu					Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Adelson PD, 1998, ACT NEUR S, V71, P104; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Alexander DC, 2010, NEUROIMAGE, V52, P1374, DOI 10.1016/j.neuroimage.2010.05.043; Anderson V, 2006, AM J PHYS MED REHAB, V85, P767, DOI 10.1097/01.phm.0000233176.08480.22; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Barazany D, 2009, BRAIN, V132, P1210, DOI 10.1093/brain/awp042; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Bendszus M, 2002, J NEUROSURG, V97, P1419, DOI 10.3171/jns.2002.97.6.1419; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Bockhorst KH, 2008, J NEUROSCI RES, V86, P1520, DOI 10.1002/jnr.21607; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Card JP, 2005, J NEUROTRAUM, V22, P989, DOI 10.1089/neu.2005.22.989; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Chang CY, 2013, J NUTR BIOCHEM, V24, P2127, DOI 10.1016/j.jnutbio.2013.08.004; Chang PKY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0244-5; Colombo J, 2013, AM J CLIN NUTR, V98, P403, DOI 10.3945/ajcn.112.040766; Corser-Jensen CE, 2014, EXP NEUROL, V256, P7, DOI 10.1016/j.expneurol.2014.03.008; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fleith M, 2005, CRIT REV FOOD SCI, V45, P205, DOI 10.1080/10408690590956378; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Huang Z, 2012, NEUROSCI LETT, V526, P138, DOI 10.1016/j.neulet.2012.08.018; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Innis SM, 2008, BRAIN RES, V1237, P35, DOI 10.1016/j.brainres.2008.08.078; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kinnavane L, 2015, BEHAV BRAIN RES, V285, P67, DOI 10.1016/j.bbr.2014.07.049; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Krafft PR, 2012, INT J STROKE, V7, P398, DOI 10.1111/j.1747-4949.2012.00838.x; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lauritzen L, 2002, LIPIDS, V37, P237, DOI 10.1007/s11745-002-0886-2; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lewis M, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2012.05.014; Lien EL, 2009, PROSTAG LEUKOTR ESS, V81, P125, DOI 10.1016/j.plefa.2009.05.004; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Massaro AN, 2015, DEV MED CHILD NEUROL, V57, P441, DOI 10.1111/dmcn.12646; Mayer D, 2007, NEUROIMAGE, V35, P1077, DOI 10.1016/j.neuroimage.2007.01.006; McQuillen PS, 2004, PEDIATR NEUROL, V30, P227, DOI 10.1016/j.pediatrneurol.2003.10.001; Meola D., 2013, J ALZHEIMER DIS PA S, P10; Miller SL, 2012, NEUROENDOCRINOLOGY, V96, P13, DOI 10.1159/000336378; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Paterniti I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-6; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Potts Mathew B, 2006, NeuroRx, V3, P143; R Core Team, 2012, R LANG ENV STAT COMP; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schober ME, 2014, J NEUROTRAUM, V31, pA65; Schober ME, 2014, J NEUROTRAUM, V31, P358, DOI 10.1089/neu.2013.2922; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Schwarzmaier SM, 2015, J NEUROTRAUM, V32, P990, DOI 10.1089/neu.2014.3775; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031; Stonehouse W, 2014, NUTRIENTS, V6, P2730, DOI 10.3390/nu6072730; Tajuddin N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101223; Tuor UI, 2014, NEUROIMAGE-CLIN, V6, P32, DOI 10.1016/j.nicl.2014.08.003; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wainwright PE, 1999, J NUTR, V129, P1079; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2014, NEUROREHAB NEURAL RE, V28, P75, DOI 10.1177/1545968313498650; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	88	21	21	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2016	33	4					390	402		10.1089/neu.2015.3945			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DD2NH	WOS:000369758800008	26247583	Green Published			2021-06-18	
J	Gulsen, I; Ak, H; Colcimen, N; Alp, HH; Akyol, ME; Demir, I; Atalay, T; Balahroglu, R; Ragbetli, MC				Gulsen, Ismail; Ak, Hakan; Colcimen, Nese; Alp, Hamit H.; Akyol, Mehmet E.; Demir, Ismail; Atalay, Tugay; Balahroglu, Ragip; Ragbetli, Murat C.			Neuroprotective Effects of Thymoquinone on the Hippocampus in a Rat Model of Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Malondialdehyde; Neuron density; Thymoquinone; Traumatic brain injury; Stereology	ISCHEMIA-REPERFUSION; COENZYME Q(10); NIGELLA-SATIVA; DNA; DAMAGE; NEURONS; GINSENG; DYSFUNCTION; MELATONIN; EDEMA	BACKGROUND: Traumatic brain injury is a leading cause of morbidity and mortality worldwide. We evaluated the neuroprotective effects of thymoquinone (TQ) in a rat model of traumatic brain injury by using biochemical and histopathologic methods for the first time. MATERIALS AND METHODS: Twenty-four rats were divided into sham (n = 8), trauma (n = 8), and TQ-treated (n = 8) groups. A moderate degree of head trauma was induced with the use of Feeney's falling weight technique, and TQ (5 mg/kg/day) was administered to the TQ-treated group for 7 days. All animals were killed after cardiac perfusion. Brain tissues were extracted immediately after perfusion without damaging the tissues. Biochemical procedures were performed with the serum, and a histopathologic evaluation was performed on the brain tissues. Biochemical experiments included malondialdehyde (MDA), reduced and oxidized coenzyme Q10 analysis, DNA isolation and hydroylazation, and glutathione peroxidase, and superoxide dismutase analyses. RESULTS: Neuron density in contralateral hippocampal regions (CA1, CA2-3, and CA4) 7 days after the trauma decreased significantly in the trauma and TQ-treated groups, compared with that in the control group. Neuron densities in contralateral hippocampal regions (CA1, CA2-3, and CA4) were greater in the TQ-treated group than in the trauma group. TQ did not increase superoxide dismutase or glutathione peroxidase antioxidant levels. However, TQ decreased the MDA levels. CONCLUSIONS: These results indicate that TQ has a healing effect on neural cells after head injury and this effect is mediated by decreasing MDA levels in the nuclei and mitochondrial membrane of neurons.	[Gulsen, Ismail; Akyol, Mehmet E.] Yuzuncu Yil Univ, Dept Neurosurg, Van, Turkey; [Ak, Hakan; Atalay, Tugay] Bozok Univ, Sch Med, Dept Neurosurg, Yozgat, Turkey; [Colcimen, Nese; Ragbetli, Murat C.] Yuzuncu Yil Univ, Sch Med, Dept Histol & Embryol, Yozgat, Turkey; [Alp, Hamit H.; Balahroglu, Ragip] Yuzuncu Yil Univ, Sch Med, Dept Biochem, Yozgat, Turkey; [Demir, Ismail] Pamukkale Univ, Sch Med, Dept Neurosurg, Denizli, Turkey	Ak, H (corresponding author), Bozok Univ, Sch Med, Dept Neurosurg, Yozgat, Turkey.	nrsdrhakanak@yahoo.com	Ragbetli, Murat/Q-5060-2017; Atalay, Tugay/AAY-2265-2020; ALP, Hamit Hakan/U-2671-2018	Ragbetli, Murat/0000-0002-8189-264X; Atalay, Tugay/0000-0003-0243-9132; alp, hamit hakan/0000-0002-9202-4944			AARABI B, 1979, J NEUROSURG, V51, P779, DOI 10.3171/jns.1979.51.6.0779; ADELI K, 1990, CLIN CHEM, V36, P261; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Al-Majed AA, 2006, EUR J PHARMACOL, V543, P40, DOI 10.1016/j.ejphar.2006.05.046; Ammar ESM, 2011, INT IMMUNOPHARMACOL, V11, P2232, DOI 10.1016/j.intimp.2011.10.013; Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; Awad AS, 2011, J PHARM PHARMACOL, V63, P1037, DOI 10.1111/j.2042-7158.2011.01303.x; Badary OA, 2003, DRUG CHEM TOXICOL, V26, P87, DOI 10.1081/DCT-120020404; BEAL MF, 1994, ANN NEUROL, V36, P882, DOI 10.1002/ana.410360613; Bonnefont-Rousselot D, 2000, DIABETES METAB, V26, P163; DEJONG AMP, 1994, EUR J BIOCHEM, V222, P975; Demir I, 2013, ACTA NEUROCHIR, V155, P913, DOI 10.1007/s00701-013-1672-6; EDLUND C, 1994, J NEUROCHEM, V63, P634; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FAVIT A, 1992, J CEREBR BLOOD F MET, V12, P638, DOI 10.1038/jcbfm.1992.88; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fouda AMM, 2008, BASIC CLIN PHARMACOL, V103, P109, DOI 10.1111/j.1742-7843.2008.00260.x; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; Halliwell B, 2007, FREE RADICALS BIOL M, V4th; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kanter M, 2006, HUM EXP TOXICOL, V25, P127, DOI 10.1191/0960327106ht608oa; Kaur H, 1996, BIOCHEM J, V318, P21, DOI 10.1042/bj3180021; Khoschsorur GA, 2000, CHROMATOGRAPHIA, V52, P181, DOI 10.1007/BF02490453; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; Koc PK, 1999, RES EXP MED, V199, P21, DOI 10.1007/s004330050129; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Landi L, 1997, FREE RADICAL BIO MED, V22, P329, DOI 10.1016/S0891-5849(96)00294-8; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; Liao BS, 2002, EXP NEUROL, V173, P224, DOI 10.1006/exnr.2001.7841; Littarru GP, 2004, METHOD ENZYMOL, V378, P170; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mehri S, 2014, IRAN J BASIC MED SCI, V17, P1007; Naval MV, 2007, J ETHNOPHARMACOL, V112, P262, DOI 10.1016/j.jep.2007.03.010; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Padhye Subhash, 2008, Cancer Ther, V6, P495; Rausch WD, 2006, ACTA NEUROBIOL EXP, V66, P369; Reed M.G., 1998, UNBIASED STEREOLOGY, V1, P39; Silver J, 2005, TXB TRAUMATIC BRAIN, P27; SUN Y, 1988, CLIN CHEM, V34, P497; Takizawa Y, 2009, PEDIATR RES, V65, P636, DOI 10.1203/PDR.0b013e3181a16a9f; Tarng DG, 2000, AM J KIDNEY DIS, V36, P934, DOI 10.1053/ajkd.2000.19086; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Ustun N, 2014, ULUS TRAVMA ACIL CER, V20, P328, DOI 10.5505/tjtes.2014.05021; Wang XY, 2001, BIOL NEONATE, V79, P172; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; Weissman L, 2007, NEUROSCIENCE, V145, P1318, DOI 10.1016/j.neuroscience.2006.08.061; Woo CC, 2012, BIOCHEM PHARMACOL, V83, P443, DOI 10.1016/j.bcp.2011.09.029; Yao XF, 2005, MUTAT RES-GEN TOX EN, V587, P38, DOI 10.1016/j.mrgentox.2005.07.010; Yildiz F, 2010, RENAL FAILURE, V32, P126, DOI 10.3109/08860220903367577	53	21	22	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	FEB	2016	86						243	249		10.1016/j.wneu.2015.09.052			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DD0QU	WOS:000369625300057	26428323				2021-06-18	
J	Yu, P; Zhang, ZF; Li, SJ; Wen, XL; Quan, W; Tian, QL; Chen, JL; Zhang, JN; Jiang, RC				Yu, Peng; Zhang, Zhifei; Li, Shengjie; Wen, Xiaolong; Quan, Wei; Tian, Qilong; Chen, Jieli; Zhang, Jianning; Jiang, Rongcai			Progesterone modulates endothelial progenitor cell (EPC) viability through the CXCL12/CXCR4/PI3K/Akt signalling pathway	CELL PROLIFERATION			English	Article							TRAUMATIC BRAIN-INJURY; ENDOMETRIAL STROMAL CELLS; MEMBRANE COMPONENT 1; NEUROTROPHIC FACTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; GROWTH-FACTOR; CANCER CELLS; TUMOR-GROWTH; IN-VITRO	ObjectivesProgesterone treatment can effectively increase levels of circulating endothelial progenitor cells (EPCs) and improve neurological functional outcome in a traumatic brain injury (TBI) rat model. However, the mechanisms of progesterone's effects on EPC viability remain elusive. The CXCL12/CXCR4 (CXC chemokine ligand 12/CXC chemokine receptor 4) signalling pathway regulates cell proliferation; we hypothesize that it mediates progesterone-induced EPC viability. Materials and methodsEPCs were isolated from bone marrow-derived mononuclear cells (BM-MNCs) and treated with progesterone (5, 10 and 100 nm). MTS assay was used to investigate EPC viability. Protein expression was examined by Western blotting, ELISA assay and flow cytometry. Cell membrane and cytoplasm proteins were extracted with membrane and cytoplasm protein extraction kits. CXCR4 antagonist (AMD3100) and phosphatidylinositol 3-kinases (PI3K) antagonist (LY294002) were used to characterize underlying mechanisms. ResultsProgesterone-induced EPC viability was time- and dose-dependent. Administration of progesterone facilitated EPC viability and increased expression of CXCL12 and phosphorylated Akt (also known as protein kinase B, pAkt) activity (P < 0.05). Progesterone did not regulate CXCR4 protein expression in cultured EPC membranes or cytoplasm. However, progesterone-induced EPC viability was significantly attenuated by AMD3100 or LY294002. Inhibition of the signalling pathway with AMD3100 and LY294002 subsequently reduced progesterone-induced CXCL12/CXCR4/PI3K/pAkt signalling activity. ConclusionsThe CXCL12/CXCR4/PI3K/pAkt signalling pathway increased progesterone-induced EPC viability.	[Yu, Peng; Zhang, Zhifei; Li, Shengjie; Wen, Xiaolong; Quan, Wei; Tian, Qilong; Zhang, Jianning; Jiang, Rongcai] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China; [Yu, Peng; Zhang, Zhifei; Li, Shengjie; Wen, Xiaolong; Quan, Wei; Tian, Qilong; Zhang, Jianning; Jiang, Rongcai] Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Yu, Peng; Zhang, Zhifei; Li, Shengjie; Wen, Xiaolong; Quan, Wei; Tian, Qilong; Zhang, Jianning; Jiang, Rongcai] Minist Educ & Tianjin City, Key Lab Postneurotrauma Neurorepair & Regenerat C, Tianjin 300052, Peoples R China; [Chen, Jieli] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	Zhang, JN; Jiang, RC (corresponding author), Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, Tianjin 300052, Peoples R China.	jiang116216@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271359]; Ontario-China Research and Innovation Fund (OCRIF) [2011DFG33430]; Tianjin Research Program of Application Foundation and Advanced Technology [11JCZDJC18100]	This work was financially supported by the National Natural Science Foundation of China (grant 81271359), The Ontario-China Research and Innovation Fund (OCRIF, 2011DFG33430) and Tianjin Research Program of Application Foundation and Advanced Technology (grant 11JCZDJC18100).	Ahn Jee-Yin, 2014, Exp Neurobiol, V23, P200, DOI 10.5607/en.2014.23.3.200; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Atluri P, 2006, ANN THORAC SURG, V81, P1728, DOI 10.1016/j.athoracsur.2005.12.015; Basso FG, 2015, ARCH ORAL BIOL, V60, P1117, DOI 10.1016/j.archoralbio.2015.04.010; Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brandl A, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-12; Briasoulis A, 2011, CARDIOVASC THER, V29, P125, DOI 10.1111/j.1755-5922.2009.00131.x; Carr AN, 2006, CARDIOVASC RES, V69, P925, DOI 10.1016/j.cardiores.2005.12.005; Colombo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066734; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Frontczak-Baniewicz M, 2003, ACTA NEUROBIOL EXP, V63, P65; Gatti M, 2013, TOXICOLOGY, V314, P209, DOI 10.1016/j.tox.2013.10.003; Gong XM, 2006, CELL BIOL INT, V30, P466, DOI 10.1016/j.cellbi.2006.01.007; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Heeschen C, 2004, CIRCULATION, V109, P1615, DOI 10.1161/01.CIR.0000124476.32871.E3; Herbrig K, 2006, ANN RHEUM DIS, V65, P157, DOI 10.1136/ard.2005.035378; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Ishihara Y, 2013, J STEROID BIOCHEM, V135, P1, DOI 10.1016/j.jsbmb.2012.12.013; Jiang JX, 2015, ONCOTARGET, V6, P6359, DOI 10.18632/oncotarget.3438; Juarez J, 2004, HISTOL HISTOPATHOL, V19, P299, DOI 10.14670/HH-19.299; Kang H, 2005, INT J ONCOL, V26, P1429; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Khan MZ, 2003, J NEUROVIROL, V9, P300, DOI 10.1080/13550280390201010; Kucia M, 2004, J MOL HISTOL, V35, P233; Li B, 2014, J INTERFERON CYTOKIN, V35, P23; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Liu B, 2009, J NEUROENDOCRINOL, V21, P993, DOI 10.1111/j.1365-2826.2009.01920.x; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Loomans CJM, 2004, DIABETES, V53, P195, DOI 10.2337/diabetes.53.1.195; Mayol JM, 2002, WORLD J SURG, V26, P652, DOI 10.1007/s00268-001-0284-0; Moll NM, 2010, EXPERT REV HEMATOL, V3, P315, DOI 10.1586/EHM.10.16; Okada H, 2011, FERTIL STERIL, V96, P786, DOI 10.1016/j.fertnstert.2011.06.048; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Peluso JJ, 2008, J CLIN ENDOCR METAB, V93, P1592, DOI 10.1210/jc.2007-2771; Peluso JJ, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.103036; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Scioli MG, 2014, INT J MOL SCI, V15, P6517, DOI 10.3390/ijms15046517; Shiah YJ, 2015, STEM CELL REP, V4, P313, DOI 10.1016/j.stemcr.2015.01.011; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Spratte J, 2015, FERTIL STERIL, V103, P1363, DOI 10.1016/j.fertnstert.2015.02.023; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Su C, 2012, ENDOCRINOLOGY, V153, P4389, DOI 10.1210/en.2011-2177; Suh KS, 2005, CURR PHARM DESIGN, V11, P2753, DOI 10.2174/1381612054546806; Swiatek-De Lange M, 2007, GLIA, V55, P1061, DOI 10.1002/glia.20523; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Tsukada S, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt168; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546; Wang H, 2014, ENVIRON SCI ENG, P11, DOI 10.1007/978-3-319-00867-7_2; Wang L, 2015, ACTA BIOCH BIOPH SIN, V47, P663, DOI 10.1093/abbs/gmv064; Wei L, 2014, J RECEPT SIG TRANSD, V35, P329; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu YM, 2009, J NEUROCHEM, V109, P1157, DOI 10.1111/j.1471-4159.2009.06043.x; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu JB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1386; Xu QH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/546353; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035; Zhao LR, 2014, INT J MOL MED, V34, P1025, DOI 10.3892/ijmm.2014.1852; Zheng SH, 2012, J CELL MOL MED, V16, P296, DOI 10.1111/j.1582-4934.2011.01305.x; Zhou ZZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100372	63	21	26	0	13	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0960-7722	1365-2184		CELL PROLIFERAT	Cell Prolif.	FEB	2016	49	1					48	57		10.1111/cpr.12231			10	Cell Biology	Cell Biology	DD8DP	WOS:000370155400005	26818151	Green Published			2021-06-18	
J	Fu, TS; Jing, RW; Fu, WW; Cusimano, MD				Fu, Terence S.; Jing, Ruwei; Fu, Wayne W.; Cusimano, Michael D.			Epidemiological Trends of Traumatic Brain Injury Identified in the Emergency Department in a Publicly-Insured Population, 2002-2010	PLOS ONE			English	Article							UNITED-STATES; VISITS; CONCUSSIONS; ADMISSION	Objectives To examine epidemiological trends of Traumatic Brain Injury (TBI) treated in the Emergency Department (ED), identify demographic groups at risk of TBI, and determine the factors associated with hospitalization following an ED visit for TBI. Methods A province-wide database was used to identify all ED visits for TBI in Ontario, Canada between April 2002 and March 2010. Trends were analyzed using linear regression, and predictors of hospital admission were evaluated using logistic regression. Results There were 986,194 ED visits for TBI over the eight-year study period, resulting in 49,290 hospitalizations and 1,072 deaths. The age- and sex-adjusted rate of TBI decreased by 3%, from 1,013.9 per 100,000 (95% CI 1,008.3-1,010.6) to 979.1 per 100,000 (95% CI 973.7-984.4; p = 0.11). We found trends towards increasing age, comorbidity level, length of stay, and ambulatory transport use. Children and young adults (ages 5-24) sustained peak rates of motor vehicle crash (MVC) and bicyclist-related TBI, but also experienced the greatest decline in these rates (p = 0.003 and p = 0.005). In contrast, peak rates of fall-related TBI occurred among the youngest (ages 0-4) and oldest (ages 85+) segments of the population, but rates remained stable over time (p = 0.52 and 0.54). The 5-24 age group also sustained the highest rates of sports-related TBI but rates remained stable (p = 0.80). On multivariate analysis, the odds of hospital admission decreased by 1% for each year over the study period (OR = 0.991, 95% CI = 0.987-0.995). Increasing age and comorbidity, male sex, and ambulatory transport were significant predictors of hospital admission. Conclusions ED visits for TBI are involving older populations with increasingly complex comorbidities. While TBI rates are either stable or declining among vulnerable groups such as young drivers, youth athletes, and the elderly, these populations remain key targets for focused injury prevention and surveillance. Clinicians in the ED setting should be cognizant of factors associated with hospitalization following TBI.	[Fu, Terence S.; Jing, Ruwei; Fu, Wayne W.; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Dept Surg, Toronto, ON, Canada; [Fu, Terence S.; Jing, Ruwei; Fu, Wayne W.; Cusimano, Michael D.] Univ Toronto, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Injury Prevent Res Off, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg, Dept Surg, Toronto, ON, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019		Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research (#TIR-103946), and the Ontario Neurotrauma Foundation.	Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; Cameron ID, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005465.pub3; Canadian Institute of Health Information (CIHI), 2008, DAT QUAL STUD EM DEP, VII; Canadian Institute of Health Information (CIHI), 2006, HEAD INJ CAN DEC CHA; Centers for Disease Control and Prevention, 2014, DAT STAT WISQARS COS; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CIHI, 2007, BURD NEUR DIS DIS IN; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Fingerhut L, 2002, EXTERNAL CAUSES INJU; Fu TS, 2015, J TRAUMA ACUTE CARE, V79, P449, DOI 10.1097/TA.0000000000000733; Fu TS, 2015, CAN J NEURO IN PRESS; Gillespie LD, 2012, COCHRANE DB SYST REV; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hanson HR, 2013, PEDIATRICS, V132, pE859, DOI 10.1542/peds.2013-1704; Klein KS, 2005, INJURY PREV, V11, P288, DOI 10.1136/ip.2004.007013; Macpherson A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub2; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mayhew D.R., 2005, BEST PRACTICES GRADU; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Russell KF, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003300.pub3; Schull MJ, 2012, ACAD EMERG MED, V19, P828, DOI 10.1111/j.1553-2712.2012.01396.x; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Simniceanu A, 2014, TRAFFIC INJ PREV, V15, P734, DOI 10.1080/15389588.2013.867483; Solomon R, 2014, CAN PUBLIC POL, V40, P15, DOI 10.3138/cpp.2012-102; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	33	21	23	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2016	11	1							e0145469	10.1371/journal.pone.0145469			13	Multidisciplinary Sciences	Science & Technology - Other Topics	DA8CX	WOS:000368033100017	26760779	DOAJ Gold, Green Published			2021-06-18	
J	Shu, LF; Wang, CL; Wang, JB; Zhang, YM; Zhang, X; Yang, YY; Zhuo, JW; Liu, JC				Shu, Longfei; Wang, Chunlin; Wang, Jinbiao; Zhang, Yongming; Zhang, Xing; Yang, Yanyan; Zhuo, Jianwei; Liu, Jiachuan			The neuroprotection of hypoxic preconditioning on rat brain against traumatic brain injury by up-regulated transcription factor Nrf2 and HO-1 expression	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Hypoxic preconditioning; Nuclear factor erythroid 2-related factor 2p; Heme oxygenase-1	POSTTRAUMATIC-STRESS-DISORDER; CONTROLLED CORTICAL IMPACT; ANTIOXIDANT THERAPIES; CEREBRAL-ISCHEMIA; PATHWAY; AFGHANISTAN; MICE	Hypoxic preconditioning (HPC) increases the inherent tolerance of brain tissue suffering from severe hypoxia or ischemia insult by stimulating the protective ability of the brain. However, little is known concerning the effect of HPC on traumatic brain injury (TBI). We designed this study to investigate the effect of HPC on TBI and explore its underlying mechanisms. We found that HPC significantly alleviates neurological dysfunction, lessens brain edema, reduces cell apoptosis, increases neuronal survival, up regulates the expressions of Nrf2 and HO-1, and decreases the inducer of protein carbonyls, 4-hydroxy2-nonenal, and 8-hydroxy-2-deoxyguanosine in the brain tissue of rats 24 h after brain injury. However, no influence was observed in normal rats after only 3 d of hypoxic training. Results further indicated that HPC protects the brain against traumatic damage. This protective effect may be achieved by up-regulating Nrf2 and HO-1 expression and alleviating oxidative stress damage. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Shu, Longfei; Wang, Chunlin; Wang, Jinbiao; Zhang, Yongming; Zhang, Xing; Yang, Yanyan; Zhuo, Jianwei; Liu, Jiachuan] Anhui Med Univ, PLA, Hosp 105, Dept Neurosurg,Clin Coll, Hefei 230031, Anhui, Peoples R China	Liu, JC (corresponding author), PLA, Hosp 105, Dept Neurosurg, Changjiang Rd 424, Beijing, Peoples R China.	ljc571017@sina.com			Military "Twelfth Five" Medical Scientific Research of China [CWS11J262]; Nanjing Military Medical Technology Innovation Pre-program of China [09Z009]	This work was supported by the following grants: Military "Twelfth Five" Medical Scientific Research of China (CWS11J262) and Nanjing Military Medical Technology Innovation Pre-program of China (09Z009).	Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Cheng ZG, 2013, ASIAN PAC J TROP MED, V6, P305, DOI 10.1016/S1995-7645(13)60061-9; Das RR, 2005, NEW ENGL J MED, V353, P633; Deshane J, 2005, ACTA BIOCHIM POL, V52, P273; Dubinina EE, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1069, DOI 10.1134/S0006297910090014; Galle AA, 2013, BRAIN RES, V1498, P1, DOI 10.1016/j.brainres.2012.12.026; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Huang XS, 2014, MOL CELL BIOCHEM, V385, P33, DOI 10.1007/s11010-013-1812-6; Jones NM, 2008, PEDIATR RES, V63, P620, DOI 10.1203/PDR.0b013e31816d9117; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Orman JA, 2012, J TRAUMA ACUTE CARE, V73, pS496, DOI 10.1097/TA.0b013e318275473c; Rybnikova E, 2012, NEUROSCI LETT, V513, P100, DOI 10.1016/j.neulet.2012.02.019; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Shen XF, 2013, INT J MOL SCI, V14, P21598, DOI 10.3390/ijms141121598; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Wacker BK, 2012, J NEUROCHEM, V123, P954, DOI 10.1111/jnc.12047; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Zhan LX, 2013, MOL NEUROBIOL, V48, P109, DOI 10.1007/s12035-013-8436-4; Zhang N, 2011, NEUROCHEM INT, V58, P684, DOI 10.1016/j.neuint.2011.02.007; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	28	21	23	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 12	2016	611						74	80		10.1016/j.neulet.2015.11.012			7	Neurosciences	Neurosciences & Neurology	DC1BO	WOS:000368952000013	26590328				2021-06-18	
J	Alder, J; Fujioka, W; Giarratana, A; Wissocki, J; Thakkar, K; Vuong, P; Patel, B; Chakraborty, T; Elsabeh, R; Parikh, A; Girn, HS; Crockett, D; Thakker-Varia, S				Alder, Janet; Fujioka, Wendy; Giarratana, Anna; Wissocki, Jenna; Thakkar, Keya; Vuong, Phung; Patel, Bijal; Chakraborty, Trisha; Elsabeh, Rami; Parikh, Ankit; Girn, Hartaj S.; Crockett, David; Thakker-Varia, Smita			Genetic and pharmacological intervention of the p75NTR pathway alters morphological and behavioural recovery following traumatic brain injury in mice	BRAIN INJURY			English	Article						Animal models; neurotrophic factors; learning and memory; locomotor function	MIDDLE CEREBRAL-ARTERY; NERVE GROWTH-FACTOR; TRKB MESSENGER-RNA; MOLECULE P75(NTR) LIGAND; REDUCES INFARCT SIZE; NEUROTROPHIC FACTOR; CELL-DEATH; DOPAMINERGIC-NEURONS; INCREASED EXPRESSION; FUNCTIONAL RECOVERY	Primary objective: Neurotrophin levels are elevated after TBI, yet there is minimal regeneration. It was hypothesized that the pro-neurotrophin/p75NTR pathway is induced more than the mature neurotrophin/Trk pathway and that interfering with p75 signalling improves recovery following TBI. Research design: Lateral Fluid Percussion (LFP) injury was performed on wildtype and p75 mutant mice. In addition, TrkB agonist 7,8 Dihydroxyflavone or p75 antagonist TAT-Pep5 were tested. Western blot and immunohistochemistry revealed biochemical and cellular changes. Morris Water Maze and Rotarod tests demonstrated cognitive and vestibulomotor function. Main outcomes and results: p75 was up-regulated and TrkB was down-regulated 1 day post-LFP. p75 mutant mice as well as mice treated with the p75 antagonist or the TrkB agonist exhibited reduced neuronal death and degeneration and less astrocytosis. The cells undergoing apoptosis appear to be neurons rather than glia. There was improved motor function and spatial learning in p75 mutant mice and mice treated with the p75 antagonist. Conclusions: Many of the pathological and behavioural consequences of TBI might be due to activation of the pro-neurotrophin/p75 toxic pathway overriding the protective mechanisms of the mature neurotrophin/Trk pathway. Targeting p75 can be a novel strategy to counteract the damaging effects of TBI.	[Alder, Janet; Fujioka, Wendy; Giarratana, Anna; Wissocki, Jenna; Thakkar, Keya; Vuong, Phung; Patel, Bijal; Chakraborty, Trisha; Elsabeh, Rami; Parikh, Ankit; Girn, Hartaj S.; Crockett, David; Thakker-Varia, Smita] Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA	Thakker-Varia, S (corresponding author), Rutgers Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, 675 Hoes Lane West,Res Bldg 357A, Piscataway, NJ 08854 USA.	varia@rutgers.edu		Chakraborty, Trisha/0000-0003-4050-0600	New Jersey Commission on Brain Injury Research [08-3205 BIR-E-1]; Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship	The authors report no conflicts of interest. This study was supported by the New Jersey Commission on Brain Injury Research (08-3205 BIR-E-1) and an Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship.	Agrawal R, 2015, BBA-MOL BASIS DIS, V1852, P862, DOI 10.1016/j.bbadis.2015.01.018; Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Andero R, 2011, AM J PSYCHIAT, V168, P163, DOI 10.1176/appi.ajp.2010.10030326; Ariza M, 2006, BRAIN INJURY, V20, P1053, DOI 10.1080/02699050600909862; Beattie EC, 1996, COLD SPRING HARB SYM, V61, P389; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bourikas D, 2010, MOL CELL NEUROSCI, V45, P363, DOI 10.1016/j.mcn.2010.07.009; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Catts VS, 2008, EUR J NEUROSCI, V28, P883, DOI 10.1111/j.1460-9568.2008.06390.x; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Choi DC, 2010, P NATL ACAD SCI USA, V107, P2675, DOI 10.1073/pnas.0909359107; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cragnolini AB, 2008, TRENDS NEUROSCI, V31, P99, DOI 10.1016/j.tins.2007.11.005; Cragnolini AB, 2012, DEV NEUROBIOL, V72, P766, DOI 10.1002/dneu.20981; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Domeniconi M, 2005, NEURON, V46, P849, DOI 10.1016/j.neuron.2005.05.029; Domeniconi M, 2007, MOL CELL NEUROSCI, V34, P271, DOI 10.1016/j.mcn.2006.11.005; Edalat Houri, 2013, Iranian Biomedical Journal, V17, P140, DOI 10.6091/ibj.1193.2013; Enomoto M, 2013, EXP NEUROL, V248, P170, DOI 10.1016/j.expneurol.2013.06.013; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Failla MD, 2015, NEUROREHABILITATION; Ferrer I, 1998, BRAIN PATHOL, V8, P253; Grabenstatter HL, 2014, J NEUROSCI RES, V92, P1307, DOI 10.1002/jnr.23402; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Gu Q, 2014, TOXICOL IN VITRO, V28, P469, DOI 10.1016/j.tiv.2014.01.007; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Higashi H, 2002, J NEUROSURG, V96, P117, DOI 10.3171/jns.2002.96.1.0117; Houweling DA, 1998, NEUROSCI LETT, V251, P193, DOI 10.1016/S0304-3940(98)00536-9; HOVDA DA, 1990, ACT NEUR S, V51, P331; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ibanez CF, 2012, TRENDS NEUROSCI, V35, P431, DOI 10.1016/j.tins.2012.03.007; Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362; Irmady K, 2014, J NEUROSCI, V34, P3419, DOI 10.1523/JNEUROSCI.1982-13.2014; Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Jiang ML, 2013, HUM MOL GENET, V22, P2462, DOI 10.1093/hmg/ddt098; Kim DH, 2005, NEUROCRIT CARE, V3, P71, DOI 10.1385/NCC:3:1:071; KNUSEL B, 1992, J NEUROSCI, V12, P4391; KOKAIA Z, 1994, NEUROREPORT, V5, P1241, DOI 10.1097/00001756-199406020-00021; Koshimizu H, 2010, NEUROSCI LETT, V473, P229, DOI 10.1016/j.neulet.2010.02.055; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lemkuil BP, 2011, ANESTHESIOLOGY, V114, P49, DOI 10.1097/ALN.0b013e318201dcb3; Levivier M, 1995, J NEUROSCI, V15, P7810, DOI 10.1523/jneurosci.15-12-07810.1995; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Liu Y, 1999, J NEUROSCI, V19, P4370; Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706; Loh NK, 2001, EXP NEUROL, V170, P72, DOI 10.1006/exnr.2001.7692; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.3.CO;2-S; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; Mamounas LA, 1995, J NEUROSCI, V15, P7929; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; MASANA Y, 1993, J NEUROSCI RES, V35, P468, DOI 10.1002/jnr.490350503; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; McKay SE, 1996, DEVELOPMENT, V122, P715; McTigue DM, 1998, J NEUROSCI, V18, P5354; Meng YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106238; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Montazeri F, 2013, J SPINAL CORD MED, V36, P231, DOI 10.1179/2045772312Y.0000000077; MUDO G, 1993, NEUROSCIENCE, V57, P901, DOI 10.1016/0306-4522(93)90036-F; Nygren J, 2006, J NEUROSCI RES, V84, P626, DOI 10.1002/jnr.20956; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1111/j.1530-0277.2002.tb02573.x; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pedraza CE, 2005, AM J PATHOL, V166, P533, DOI 10.1016/S0002-9440(10)62275-4; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Ramos A, 2007, J NEUROSCI, V27, P1498, DOI 10.1523/JNEUROSCI.4806-06.2007; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200; Schabitz WR, 2004, STROKE, V35, P992, DOI 10.1161/01.STR.0000119754.85848.0D; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sebastiani A, 2015, J NEUROTRAUM, V32, P1599, DOI 10.1089/neu.2014.3751; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Shi J, 2013, STEM CELLS, V31, P2561, DOI 10.1002/stem.1516; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Shulga A, 2012, J NEUROSCI, V32, P1757, DOI 10.1523/JNEUROSCI.3282-11.2012; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tauris J, 2011, EUR J NEUROSCI, V33, P622, DOI 10.1111/j.1460-9568.2010.07556.x; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; Volosin M, 2006, J NEUROSCI, V26, P7756, DOI 10.1523/JNEUROSCI.1560-06.2006; Whiting M.D., 2006, COGNITIVE IMPAIRMENT; Woo NH, 2005, NAT NEUROSCI, V8, P1069, DOI 10.1038/nn1510; Xie YY, 2003, DEV NEUROSCI-BASEL, V25, P65, DOI 10.1159/000071469; Yamashita K, 1997, METAB BRAIN DIS, V12, P271, DOI 10.1007/BF02674671; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YOUNG SL, 1994, BEHAV NEUROSCI, V108, P19, DOI 10.1037/0735-7044.108.1.19; Zhang Y, 2006, BRAIN RES, V1111, P227, DOI 10.1016/j.brainres.2006.07.005	117	21	21	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	1					48	65		10.3109/02699052.2015.1088963			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DJ8YT	WOS:000374501200008	26579945				2021-06-18	
J	Du, GL; Zhao, ZM; Chen, YH; Li, ZH; Tian, YH; Liu, ZF; Liu, B; Song, JQ				Du, Guoliang; Zhao, Zongmao; Chen, Yonghan; Li, Zonghao; Tian, Yaohui; Liu, Zhifeng; Liu, Bin; Song, Jianqiang			Quercetin attenuates neuronal autophagy and apoptosis in rat traumatic brain injury model via activation of PI3K/Akt signaling pathway	NEUROLOGICAL RESEARCH			English	Article						Quercetin; Autophagy; Apoptosis; PI3K/Akt; Traumatic brain injury	INDUCED OXIDATIVE STRESS; CELL-DEATH; PATHOPHYSIOLOGY; NEUROPROTECTION; RESVERATROL; FLAVONOIDS; DAMAGE; EDEMA	Objective: Neuronal autophagy and apoptosis play an irreplaceable role in brain injury pathogenesis and may represent a hopeful target for treatment. Previous studies have demonstrated that administration of quercetin-attenuated brain damage in a variety of brain injury models including traumatic brain injury (TBI). However, whether PI3K/Akt signaling pathway mediates the neuroprotection of quercetin following TBI is not well clarified. We sought to propose a hypothesis that quercetin could attenuate neuronal autophagy and apoptosis via enhancing PI3K/Akt signaling. Methods: All rats were randomly arranged into four groups as follows: sham group (n = 25), TBI group (n = 25), TBI + quercetin group (n = 25), TBI + quercetin + LY294002 group (n = 25). Quercetin (Sigma, USA, dissolved in 0.9% saline solution) was administered intraperitoneally at a dose of 50 mg/kg at 30 min, 12 h, and 24 h after TBI. The neurological impairment and spatial cognitive function was assessed by the neurologic severity score and Morris water maze, respectively. Immunohistochemistry staining and western blotting was used to evaluate the expression of LC3, p-Akt, caspase-3, Bcl-2, and Bax. Results: Quercetin treatment significantly attenuated TBI-induced neurological impairment (1-3 days, p < 0.05) and improved cognitive function (5-8 days, p < 0.05). Double immunolabeling demonstrated that quercetin significantly reduced the LC3-positive cells co-labeled with NeuN, whereas significantly enhanced p-Akt-positive cells co-labeled with NeuN. Furthermore, quercetin treatment reduced the expression of LC3. caspase-3 and Bax levels induced following TBI (p < 0.05), and increased the expression of p-Akt and Bcl-2 at 48 h (p < 0.05). Conclusion: In conclusion, our observations indicate that post-injury treatment with quercetin could inhibit neuronal autophagy and apoptosis in the hippocampus in a rat model of TBI. The neuroprotective effects of quercetin may be related to modulation of PI3K/Akt signaling pathway.	[Du, Guoliang; Chen, Yonghan; Li, Zonghao; Tian, Yaohui; Liu, Zhifeng; Liu, Bin; Song, Jianqiang] Cent Hosp Cangzhou, Dept Neurosurg, Cangzhou 061001, Hebei, Peoples R China; [Zhao, Zongmao] Hebei Med Univ, Dept Neurosurg, Hosp 2, Shijiazhuang, Peoples R China	Du, GL (corresponding author), Cent Hosp Cangzhou, Dept Neurosurg, Cangzhou 061001, Hebei, Peoples R China.	guoliangdu2001@163.com					Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Cao XJ, 2014, DEV PSYCHOBIOL, V56, P1102, DOI 10.1002/dev.21130; Cordaro M, 2016, J NEUROTRAUM, V33, P132, DOI 10.1089/neu.2014.3460; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Dajas F, 2012, J ETHNOPHARMACOL, V143, P383, DOI 10.1016/j.jep.2012.07.005; de Oliveira MR, 2016, BIOTECHNOL ADV, V34, P532, DOI 10.1016/j.biotechadv.2015.12.014; Dok-Go H, 2003, BRAIN RES, V965, P130, DOI 10.1016/S0006-8993(02)04150-1; Dong YS, 2014, INT J MED SCI, V11, P282, DOI 10.7150/ijms.7634; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; Erlund I, 2004, NUTR RES, V24, P851, DOI 10.1016/j.nutres.2004.07.005; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Larson AJ, 2012, ADV NUTR, V3, P39, DOI 10.3945/an.111.001271; Li N, 2014, MOL MED REP, V10, P2299, DOI 10.3892/mmr.2014.2502; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Nabavi SF, 2015, FOOD CHEM, V179, P305, DOI 10.1016/j.foodchem.2015.02.006; Nabavi SF, 2012, FOOD FUNCT, V3, P437, DOI 10.1039/c2fo10264a; Nabavi SM, 2012, FOOD CHEM, V132, P931, DOI 10.1016/j.foodchem.2011.11.070; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Ossola B, 2009, EXPERT OPIN DRUG SAF, V8, P397, DOI 10.1517/14740330903026944; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Singh P, 2003, NEUROL INDIA, V51, P215; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Wang JW, 2014, J SURG RES, V186, P328, DOI 10.1016/j.jss.2013.08.027; Wang XQ, 2011, BRAIN RES BULL, V86, P277, DOI 10.1016/j.brainresbull.2011.07.014; Yao RQ, 2012, NEUROCHEM RES, V37, P2777, DOI 10.1007/s11064-012-0871-5; Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	35	21	23	1	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.		2016	38	11					1012	1019		10.1080/01616412.2016.1240393			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EA1CQ	WOS:000386330500010	27690831				2021-06-18	
J	Du, XP; West, MB; Cheng, WH; Ewert, DL; Li, W; Saunders, D; Towner, RA; Floyd, RA; Kopke, RD				Du, Xiaoping; West, Matthew B.; Cheng, Weihua; Ewert, Donald L.; Li, Wei; Saunders, Debra; Towner, Rheal A.; Floyd, Robert A.; Kopke, Richard D.			Ameliorative Effects of Antioxidants on the Hippocampal Accumulation of Pathologic Tau in a Rat Model of Blast-Induced Traumatic Brain Injury	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article							FOCAL CEREBRAL-ISCHEMIA; RADICAL-TRAPPING AGENT; N-ACETYL-CYSTEINE; ALZHEIMERS-DISEASE; DENTATE GYRUS; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; MITOCHONDRIAL DYSFUNCTION; MOLECULAR-MECHANISMS; CEREBROSPINAL-FLUID	Traumatic brain injury (TBI) can lead to early onset dementia and other related neurodegenerative diseases. We previously demonstrated that damage to the central auditory pathway resulting from blast-induced TBI (bTBI) could be significantly attenuated by a combinatorial antioxidant treatment regimen. In the current study, we examined the localization patterns of normal Tau and the potential blast-induced accumulation of neurotoxic variants of this microtubule-associated protein that are believed to potentiate the neurodegenerative effects associated with synaptic dysfunction in the hippocampus following three successive blast overpressure exposures in nontransgenic rats. We observed a marked increase in the number of both hyperphosphorylated and oligomeric Tau-positive hilar mossy cells and somatic accumulation of endogenous Tau in oligodendrocytes in the hippocampus. Remarkably, a combinatorial regimen of 2,4-disulfonyl alpha-phenyl tertiary butyl nitrone (HPN-07) and N-acetylcysteine (NAC) resulted in striking reductions in the numbers of both mossy cells and oligodendrocytes positively labeled for these pathological Tau immunoreactivity patterns in response to bTBI. This treatment strategy represents a promising therapeutic approach for simultaneously reducing or eliminating both primary auditory injury and nonauditory changes associated with bTBI-induced hippocampal neurodegeneration.	[Du, Xiaoping; West, Matthew B.; Cheng, Weihua; Ewert, Donald L.; Li, Wei; Kopke, Richard D.] Hough Ear Inst, Oklahoma City, OK 73112 USA; [Saunders, Debra; Towner, Rheal A.; Floyd, Robert A.; Kopke, Richard D.] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA; [Kopke, Richard D.] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA; [Kopke, Richard D.] Univ Oklahoma, Hlth Sci Ctr, Dept Otolaryngol, Oklahoma City, OK 73104 USA	Kopke, RD (corresponding author), Hough Ear Inst, Oklahoma City, OK 73112 USA.; Kopke, RD (corresponding author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.; Kopke, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.; Kopke, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Otolaryngol, Oklahoma City, OK 73104 USA.	rkopke@houghear.org		Towner, Rheal/0000-0001-7368-8983	United States Department of Navy, Office of Naval Research [N00014-09-1-0999]	This research was supported by Grant N00014-09-1-0999 from the United States Department of Navy, Office of Naval Research. The authors would like to thank Dr. Rakez Kayed (University of Texas Medical Branch, Galveston, TX) for his kind gift of the oligomeric (T22) Tau antibody.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Clausen F, 2008, J NEUROTRAUM, V25, P1449, DOI 10.1089/neu.2008.0585; Clavaguera F, 2013, BRAIN PATHOL, V23, P342, DOI 10.1111/bpa.12044; Cowan CM, 2012, BIOCHEM SOC T, V40, P693, DOI 10.1042/BST20120135; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DEWAR D, 1995, BRAIN RES, V684, P70, DOI 10.1016/0006-8993(95)00417-O; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Du X., 2013, PLOS ONE, V8; Du XP, 2012, HEARING RES, V283, P1, DOI 10.1016/j.heares.2011.11.013; Duffy AM, 2013, HIPPOCAMPUS, V23, P649, DOI 10.1002/hipo.22138; Ewert DL, 2012, HEARING RES, V285, P29, DOI 10.1016/j.heares.2012.01.013; Floyd RA, 2006, AGING CELL, V5, P51, DOI 10.1111/j.1474-9726.2006.00189.x; Floyd RA, 2008, FREE RADICAL BIO MED, V45, P1361, DOI 10.1016/j.freeradbiomed.2008.08.017; Floyd RA, 2013, FREE RADICAL BIO MED, V62, P145, DOI 10.1016/j.freeradbiomed.2013.01.033; Folmer RL, 2011, INT J PSYCHOPHYSIOL, V82, P4, DOI 10.1016/j.ijpsycho.2011.03.005; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gerson JE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00093; Golarai G, 2001, J NEUROSCI, V21, P8523; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gresle MM, 2006, BRAIN RES, V1110, P13, DOI 10.1016/j.brainres.2006.06.111; GULYAS AI, 1992, NEUROSCIENCE, V48, P1, DOI 10.1016/0306-4522(92)90334-X; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; Han M, 2003, CELL MOL BIOL, V49, P1249; Haroutunian V, 2007, NEUROBIOL AGING, V28, P1, DOI 10.1016/j.neurobiolaging.2005.11.001; Hart AM, 2004, NEUROSCIENCE, V125, P91, DOI 10.1016/j.neuroscience.2003.12.040; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hirokawa N, 1996, J CELL BIOL, V132, P667, DOI 10.1083/jcb.132.4.667; HSU M, 1993, J NEUROSCI, V13, P3964; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hughes PM, 2003, J NEUROPATH EXP NEUR, V62, P1276, DOI 10.1093/jnen/62.12.1276; Imai H, 2001, STROKE, V32, P2149, DOI 10.1161/hs0901.095725; Irving EA, 1996, NEUROSCI LETT, V213, P189; Irving EA, 1997, J CEREBR BLOOD F MET, V17, P612; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Kopeikina KJ, 2011, AM J PATHOL, V179, P2071, DOI 10.1016/j.ajpath.2011.07.004; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kril JJ, 2002, ACTA NEUROPATHOL, V103, P370, DOI 10.1007/s00401-001-0477-5; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Lee DC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-56; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Lu JZ, 2014, JARO-J ASSOC RES OTO, V15, P353, DOI 10.1007/s10162-014-0441-4; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Maphis N., 2015, FRONTIERS NEUROSCIEN, V9, P1; Maphis N, 2015, BRAIN, V138, P1738, DOI 10.1093/brain/awv081; Marshall JWB, 2001, STROKE, V32, P190, DOI 10.1161/01.STR.32.1.190; McCracken E, 2002, J CEREBR BLOOD F MET, V22, P1090, DOI 10.1097/00004647-200209000-00006; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; MIETTINEN R, 1992, NEUROSCIENCE, V48, P29, DOI 10.1016/0306-4522(92)90335-Y; Miller G, 2012, SCIENCE, V336, P790, DOI 10.1126/science.336.6083.790; Mondragon-Rodriguez S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/940603; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Noble W, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00083; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Papa L, 2007, APOPTOSIS, V12, P1389, DOI 10.1007/s10495-007-0069-5; Peeling J, 2001, NEUROPHARMACOLOGY, V40, P433, DOI 10.1016/S0028-3908(00)00170-2; Perez M, 2000, FEBS LETT, V486, P270, DOI 10.1016/S0014-5793(00)02323-1; Prasanthi JRP, 2010, FREE RADICAL BIO MED, V49, P1212, DOI 10.1016/j.freeradbiomed.2010.07.007; Rajasekar N, 2013, EUR J PHARMACOL, V715, P381, DOI 10.1016/j.ejphar.2013.04.033; Rapoport SI, 2003, NEUROTOX RES, V5, P385, DOI 10.1007/BF03033167; Ratzliff ADH, 2004, J NEUROSCI, V24, P2259, DOI 10.1523/JNEUROSCI.5191-03.2004; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; SAEZ G, 1982, BIOCHIM BIOPHYS ACTA, V719, P24, DOI 10.1016/0304-4165(82)90302-6; Sagara JI, 2010, NEUROREPORT, V21, P416, DOI 10.1097/WNR.0b013e328337765c; Sajja VSSS, 2014, NEUROSCI LETT, V570, P33, DOI 10.1016/j.neulet.2014.03.072; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Scharfman HE, 2013, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00106; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; Shi TY, 2013, NEUROTHERAPEUTICS, V10, P340, DOI 10.1007/s13311-012-0168-z; SHIN RW, 1991, LAB INVEST, V64, P693; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Stephenson AP, 2013, TOXICOL LETT, V218, P299, DOI 10.1016/j.toxlet.2012.12.024; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Su B, 2010, NEUROSCI LETT, V468, P267, DOI 10.1016/j.neulet.2009.11.010; Sy M, 2011, AM J PATHOL, V178, P2811, DOI 10.1016/j.ajpath.2011.02.012; Takeda A, 2000, J NEUROCHEM, V75, P1234, DOI 10.1046/j.1471-4159.2000.0751234.x; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Taniguchi T, 2001, J BIOL CHEM, V276, P10025, DOI 10.1074/jbc.M007427200; Valiyaveettil M, 2012, J REHABIL RES DEV, V49, P1153, DOI 10.1682/JRRD.2011.09.0182; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wang JZ, 2013, J ALZHEIMERS DIS, V33, pS123, DOI 10.3233/JAD-2012-129031; Wolfe MS, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/796024; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528; Xiao F, 2008, NEUROCHEM RES, V33, P1735, DOI 10.1007/s11064-008-9617-9; Yeung MSY, 2014, CELL, V159, P766, DOI 10.1016/j.cell.2014.10.011; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zhao ZG, 2001, BRAIN RES, V909, P46, DOI 10.1016/S0006-8993(01)02618-X	109	21	21	0	9	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.		2016	2016								4159357	10.1155/2016/4159357			15	Cell Biology	Cell Biology	DD1GF	WOS:000369668600001	27034735	DOAJ Gold, Green Published			2021-06-18	
J	Houston, MN; Bay, RC; McLeod, TCV				Houston, Megan N.; Bay, R. Curtis; McLeod, Tamara C. Valovich			The relationship between post-injury measures of cognition, balance, symptom reports and health-related quality-of-life in adolescent athletes with concussion	BRAIN INJURY			English	Article						Brain injury; assessment; patient-reported outcome measures; paediatric	MULTIDIMENSIONAL FATIGUE SCALE; CLINICAL-OUTCOMES ASSESSMENT; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; GENERIC CORE SCALES; STATES HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; STANDARDIZED ASSESSMENT; CONSENSUS STATEMENT; RELIABILITY	Background: Little is known about the relationship between post-concussion impairments and health-related quality-of-life (HRQoL). The primary purpose of this study was to determine the relationship between traditional concussion assessments and HRQoL in adolescent athletes post-concussion. The secondary purpose was to determine the association between HRQoL deficits and time lost. Methods: In total, 1134 athletes completed a baseline assessment battery. HRQoL measures included the Pediatric Quality of Life Inventory (PedsQL), Multidimensional Fatigue Scale (MFS) and Headache Impact Test-6. In total, 122 athletes sustained a concussion and underwent follow-up testing at 3 and 10 days post-injury. Results: The strongest relationships were between symptom severity and HRQoL. For concurrent regression analyses at Day 3, PedsQL-Physical accounted for 17.9% of the variance in time lost beyond that accounted for by traditional measures. At Day 10, PedsQL-School accounted for 15.2% and symptom severity for 7.1% of this variance. In predictive analyses, at Day 3, PedsQL-Physical accounted for 3.9% and MFS-General for 3.3% of the variance in time lost beyond that accounted for by traditional measures. At Day 10, MFS-Cognitive accounted for 12.0% of this variance. Conclusions: HRQoL appears to play a role in time lost post-concussion and should be measured in combination with traditional concussion assessments.	[Houston, Megan N.] Keller Army Hosp, West Point, NY 10996 USA; [Bay, R. Curtis; McLeod, Tamara C. Valovich] AT Still Univ, Dept Interdisciplinary Hlth Sci, Mesa, AZ USA; [McLeod, Tamara C. Valovich] AT Still Univ, Sch Osteopath Med, Mesa, AZ USA	Houston, MN (corresponding author), Keller Army Hosp, West Point, NY 10996 USA.	megan.n.houston.ctr@mail.mil	McLeod, Tamara/AAU-9435-2020; Meijer, Anna/K-5118-2016	Bay, Ralph/0000-0003-3525-9269	National Operating Committee on Standards for Athletic Equipment (NOCSAE)	The authors report no conflicts of interest. This study was funded by a grant from the National Operating Committee on Standards for Athletic Equipment (NOCSAE).	Bayliss MS, 2002, HIT 6 USERS GUIDE; Boyce SH, 2003, SCOT MED J, V48, P88, DOI 10.1177/003693300304800308; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cohen J., 2003, APPL MULTIPLE CORREL; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; D'Amico D, 2003, NEUROL SCI, V24, pS97; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Jette AM, 2006, PHYS THER, V86, P726, DOI 10.1093/ptj/86.5.726; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2011, J SPORT REHABIL, V20, P46, DOI 10.1123/jsr.20.1.46; Piebes SK, 2011, J SPORT REHABIL, V20, P129, DOI 10.1123/jsr.20.1.129; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Snyder AR, 2008, J ATHL TRAINING, V43, P428, DOI 10.4085/1062-6050-43.4.428; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; Valovich McLeod TC, 2010, ATHLETIC TRAINING SP, V2, P219, DOI DOI 10.3928/19425864-20100630-02; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-9; Varni James W, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P705, DOI 10.1586/14737167.5.6.705; Varni JW, 2010, INT J PEDIATR OBES, V5, P34, DOI 10.3109/17477160903111706; Varni JW, 2009, PEDIATR DIABETES, V10, P321, DOI 10.1111/j.1399-5448.2008.00482.x; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2004, J RHEUMATOL, V31, P2494; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Williams RM, 2015, J ATHL TRAINING, V50, P262, DOI 10.4085/1062-6050-49.3.81; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59	44	21	21	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	7					891	898		10.3109/02699052.2016.1146960			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DP2MI	WOS:000378322400008	27088297				2021-06-18	
J	Papa, L; Mittal, MK; Ramirez, J; Ramia, M; Kirby, S; Silvestri, S; Giordano, P; Weber, K; Braga, CF; Tan, CN; Ameli, NJ; Lopez, M; Zonfrillo, M				Papa, Linda; Mittal, Manoj K.; Ramirez, Jose; Ramia, Michelle; Kirby, Sara; Silvestri, Salvatore; Giordano, Philip; Weber, Kurt; Braga, Carolina F.; Tan, Ciara N.; Ameli, Neema J.; Lopez, Marco; Zonfrillo, Mark			In Children and Youth with Mild and Moderate Traumatic Brain Injury, Glial Fibrillary Acidic Protein Out-Performs S100b in Detecting Traumatic Intracranial Lesions on Computed Tomography	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography (CT); glial fibrillary acidic protein (GFAP); head trauma; mild traumatic brain injury; S100B	SERUM S-100B LEVELS; HEAD-INJURY; GFAP; BIOMARKERS	In adults, glial fibrillary acidic protein (GFAP) has been shown to out-perform S100 in detecting intracranial lesions on computed tomography (CT) in mild traumatic brain injury (TBI). This study examined the ability of GFAP and S100 to detect intracranial lesions on CT in children and youth involved in trauma. This prospective cohort study enrolled a convenience sample of children and youth at two pediatric and one adult Level 1 trauma centers following trauma, including both those with and without head trauma. Serum samples were obtained within 6h of injury. The primary outcome was the presence of traumatic intracranial lesions on CT scan. There were 155 pediatric trauma patients enrolled, 114 (74%) had head trauma and 41 (26%) had no head trauma. Out of the 92 patients who had a head CT, eight (9%) had intracranial lesions. The area under the receiver operating characteristic curve (AUC) for distinguishing head trauma from no head trauma for GFAP was 0.84 (0.77-0.91) and for S100 was 0.64 (0.55-0.74; p<0.001). Similarly, the AUC for predicting intracranial lesions on CT for GFAP was 0.85 (0.72-0.98) versus 0.67 (0.50-0.85) for S100 (p=0.013). Additionally, we assessed the performance of GFAP and S100 in predicting intracranial lesions in children ages 10 years or younger and found the AUC for GFAP was 0.96 (95% confidence interval [CI] 0.86-1.00) and for S100 was 0.72 (0.36-1.00). In children younger than 5 years old, the AUC for GFAP was 1.00 (95% CI 0.99-1.00) and for S100 0.62 (0.15-1.00). In this population with mild TBI, GFAP out-performed S100 in detecting head trauma and predicting intracranial lesions on head CT. This study is among the first published to date to prospectively compare these two biomarkers in children and youth with mild TBI.	[Papa, Linda; Ramia, Michelle; Silvestri, Salvatore; Giordano, Philip; Weber, Kurt; Braga, Carolina F.; Tan, Ciara N.; Ameli, Neema J.; Lopez, Marco] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA; [Papa, Linda; Ramirez, Jose; Silvestri, Salvatore; Giordano, Philip; Weber, Kurt] Arnold Palmer Hosp Children, Dept Pediat Emergency Med, Orlando, FL USA; [Mittal, Manoj K.; Kirby, Sara; Zonfrillo, Mark] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Mittal, Manoj K.; Zonfrillo, Mark] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood S-200, Orlando, FL 32806 USA.	lpstat@aol.com	Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	The project described was supported in part by Award Number R01NS057676 from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders And Stroke or the National Institutes of Health.	Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Herrmann M, 2001, NEUROSURGERY, V49, P1272, DOI 10.1097/00006123-200111000-00058; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Olsson B, 2011, PROG NEUROBIOL, V95, P520, DOI 10.1016/j.pneurobio.2011.04.006; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Rothoerl RD, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00054; Swanson CA, 2010, J TRAUMA, V68, P1072, DOI 10.1097/TA.0b013e3181d7a6f2; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vajtr D., 2013, SOUD LEK, V57, P7; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	26	21	22	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					58	64		10.1089/neu.2015.3869			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200007	25752485	Green Published			2021-06-18	
J	Winter, L; Moriarty, HJ; Robinson, K; Piersol, CV; Vause-Earland, T; Newhart, B; Iacovone, DB; Hodgson, N; Gitlin, LN				Winter, Laraine; Moriarty, Helene J.; Robinson, Keith; Piersol, Catherine V.; Vause-Earland, Tracey; Newhart, Brian; Iacovone, Delores Blazer; Hodgson, Nancy; Gitlin, Laura N.			Efficacy and acceptability of a home-based, family-inclusive intervention for veterans with TBI: A randomized controlled trial	BRAIN INJURY			English	Article						Community reintegration; family; in-home service; rehabilitation; traumatic brain injury; veterans	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; COMMUNITY REINTEGRATION; SERVICE MEMBERS; CAREGIVER; MILITARY; OUTCOMES; NEUROREHABILITATION; INTEGRATION; DEMENTIA	Objective: Traumatic brain injury (TBI) often undermines community re-integration, impairs functioning and produces other symptoms. This study tested an innovative programme for veterans with TBI, the Veterans' In-home Programme (VIP), delivered in veterans' homes, involving a family member and targeting the environment (social and physical) to promote community re-integration, mitigate difficulty with the most troubling TBI symptoms and facilitate daily functioning. Setting: Interviews and intervention sessions were conducted in homes or by telephone. Participants: Eighty-one veterans with TBI at a VA polytrauma programme and a key family member. Design: This was a 2-group randomized controlled trial. Control-group participants received usual-care enhanced by two attention-control telephone calls. Follow-up interviews occurred up to 4 months after baseline interview. Main measures: VIP's efficacy was evaluated using measures of community re-integration, target outcomes reflecting veterans' self-identified problems and self-rated functional competence. Results: At follow-up, VIP participants had significantly higher community re-integration scores and less difficulty managing targeted outcomes, compared to controls. Self-rated functional competence did not differ between groups. In addition, VIP's acceptability was high. Conclusion: A home-based, family-inclusive service for veterans with TBI shows promise for improving meaningful outcomes and warrants further research and clinical application.	[Winter, Laraine] Philadelphia Res & Educ Fdn, Philadelphia, PA 19104 USA; [Winter, Laraine; Moriarty, Helene J.] Dept Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA 19104 USA; [Moriarty, Helene J.] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA; [Robinson, Keith; Newhart, Brian; Iacovone, Delores Blazer] Dept Vet Affairs Med Ctr, Med Rehabil Serv, Philadelphia, PA 19104 USA; [Robinson, Keith] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Piersol, Catherine V.; Vause-Earland, Tracey] Thomas Jefferson Univ, Sch Hlth Profess, Philadelphia, PA 19107 USA; [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Ctr Innovat Care Aging, Baltimore, MD USA	Winter, L (corresponding author), Philadelphia Res & Educ Fdn, Philadelphia VA Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA.	laraine.winter@gmail.com		Piersol, Catherine/0000-0003-4992-8988			ANDRESEN EM, 1994, AM J PREV MED, V10, P77; Asher I. E., 2007, OCCUPATIONAL THERAPY; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; BATTLE CC, 1966, AM J PSYCHOTHER, V20, P184; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Blais AR, 2009, MIL PSYCHOL, V21, P365, DOI 10.1080/08995600902914727; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Bovend'Eerdt TJ, 2010, ARCH PHYS MED REHAB, V91, P939, DOI 10.1016/j.apmr.2010.03.008; Brown M, 2004, J HEAD TRAUMA REHAB, V46, P469; Centers for Disease Control and Prevention, 2014, TRAUMATIC BRAIN INJU; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KA, 2009, ARCH PHYS MED REHAB, V90, pS52, DOI 10.1016/j.apmr.2009.05.019; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cifu DX, 2010, AM J PHYS MED REHAB, V89, P688, DOI 10.1097/PHM.0b013e3181e722ad; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Davis T, 2015, ARCH DIS CHILDHOOD-E, V100, P97, DOI 10.1136/archdischild-2014-306797; Defense and Veterans Brain Injury Center, 2014, DOD WORLDW NUMB TBI; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Florian V, 1989, INT DISABILITY STUDI, V13, P150; Gitlin LN, 2008, AM J GERIAT PSYCHIAT, V16, P229, DOI 10.1097/JGP.0b013e318160da72; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2010, JAMA-J AM MED ASSOC, V304, P983, DOI 10.1001/jama.2010.1253; Gitlin LN, 2010, J AM GERIATR SOC, V58, P1465, DOI 10.1111/j.1532-5415.2010.02971.x; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; Glynn SM, 2013, CLIN CHILD FAM PSYCH, V16, P410, DOI 10.1007/s10567-013-0153-z; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Josman N, 1999, Can J Occup Ther, V66, P33; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kazis LE., 2000, MED OUTCOMES TRUST M, V5, P1; Kim EC, 2007, J NEUROPSYCHIATRY CL, V19; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Lawton M.P., 1973, PSYCHOL ADULT DEV AG, P619, DOI DOI 10.1037/10044-020; LAWTON MP, 1983, GERONTOLOGIST, V23, P349, DOI 10.1093/geront/23.4.349; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lewin K., 1935, DYNAMIC THEORY PERSO; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; McCulloch KL, 2015, J HEAD TRAUMA REHAB, V30, P56, DOI 10.1097/HTR.0000000000000104; MILDERS MV, 1995, NEUROPSYCHOL REHABIL, V5, P223, DOI 10.1080/09602019508401468; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Oddy M, 2003, NEUROPSYCHOL REHABIL, V13, P259, DOI 10.1080/09602010244000345; Pace GM, 1999, BRAIN INJURY, V13, P535; Park HY, 2015, OCCUP THER INT, V22, P104, DOI 10.1002/oti.1389; Pollard D, 2005, ALLENS COGNITIVE LEV; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP, 1986, NEUROSPYCHOLOGICAL R; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Resnik L, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-145; Resnik L, 2011, J REHABIL RES DEV, V48, P89, DOI 10.1682/JRRD.2010.04.0070; Resnik L, 2009, J REHABIL RES DEV, V46, P469, DOI 10.1682/JRRD.2008.07.0082; Roitman DM, 1996, PHYS OCCUPATIONAL TH, V14, P43; Salter K, 2008, BRAIN INJURY, V22, P820, DOI 10.1080/02699050802425428; Sander AM, 2010, J HEAD TRAUMA REHAB, V25, P121, DOI 10.1097/HTR.0b013e3181cd1635; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2011, J TRAUMA STRESS, V24, P660, DOI 10.1002/jts.20706; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Stejskal TM, 2012, NEUROREHABILITATION, V31, P75, DOI 10.3233/NRE-2012-0776; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Williamson GM, 1998, HEALTH PSYCHOL, V17, P152, DOI 10.1037/0278-6133.17.2.152; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375; Zasler ND, 2003, NEUROPSYCHOL REHABIL, V13, P31, DOI 10.1080/09602010	69	21	21	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	4					373	387		10.3109/02699052.2016.1144080			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DK1BF	WOS:000374646200002	26983578				2021-06-18	
J	Sarvghad-Moghaddam, H; Jazi, MS; Rezaei, A; Karami, G; Ziejewski, M				Sarvghad-Moghaddam, Hesam; Jazi, Mehdi Salimi; Rezaei, Asghar; Karami, Ghodrat; Ziejewski, Mariusz			Examination of the protective roles of helmet/faceshield and directionality for human head under blast waves	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						shear stress; intracranial pressure (ICP); fluid-structure interaction (FSI).; blast traumatic brain injury (bTBI); finite elements (FEs)	BRAIN; MITIGATION; HELMET; RESPONSES; POLYUREA	A parametric study was conducted to delineate the efficacy of personal protective equipment (PPE), such as ballistic faceshields and advanced combat helmets, in the case of a blast. The propagations of blast waves and their interactions with an unprotected head, a helmeted one, and a fully protected finite element head model (FEHM) were modeled. The biomechanical parameters of the brain were recorded when the FEHM was exposed to shockwaves from the front, back, top, and bottom. The directional dependent tissue response of the brain and the variable efficiency of PPE with respect to the blast orientation were two major results of this study.	[Sarvghad-Moghaddam, Hesam; Jazi, Mehdi Salimi; Rezaei, Asghar; Karami, Ghodrat; Ziejewski, Mariusz] N Dakota State Univ, Dept Mech Engn, Fargo, ND 58108 USA	Karami, G (corresponding author), N Dakota State Univ, Dept Mech Engn, Fargo, ND 58108 USA.	g.karami@ndsu.edu					[Anonymous], 2011, ALT HYP VERS 11 0; Bowen LG, 1968, 2113 DEF AT SUPP AG; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Ganpule S, 2012, COMPUT METHOD BIOMEC, V15, P1233, DOI 10.1080/10255842.2011.597353; Grujicic A, 2012, J MATER ENG PERFORM, V21, P1562, DOI 10.1007/s11665-011-0065-3; Grujicic M, 2012, MULTIDISCIP MODEL MA, V8, P297, DOI 10.1108/15736101211269122; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Jazi MS, 2014, COMPUT METHOD BIOMEC, V17, P1368, DOI 10.1080/10255842.2012.748755; LSTC, 2007, LS DYNA KEYW US MAN; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Rezaei A, 2014, INT J NUMER METH BIO, V30, P69, DOI 10.1002/cnm.2590; Salimi Jazi M, 2013, ASME 2013 INT MECH E; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; van Hoof J, 2001, P 19 INT S BALL MAY; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	20	21	21	1	120	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.	DEC 10	2015	18	16					1846	1855		10.1080/10255842.2014.977878			10	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Computer Science; Engineering	CB2HK	WOS:000349447600013	25413615				2021-06-18	
J	Delye, H; Clijmans, T; Mommaerts, MY; Sloten, JV; Goffin, J				Delye, Hans; Clijmans, Tim; Mommaerts, Maurice Yves; Sloten, Jos Vander; Goffin, Jan			Creating a normative database of age-specific 3D geometrical data, bone density, and bone thickness of the developing skull: a pilot study	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						finite element model; normative database; skull geometry; skull properties; craniosynostosis; trauma; technique; craniofacial	HALO-PIN PLACEMENT; BEAM COMPUTED-TOMOGRAPHY; VALIDATION IN-VITRO; FETAL CRANIAL BONE; KOREAN ADULTS; 3-DIMENSIONAL CEPHALOMETRY; INTERORBITAL DISTANCE; PEDIATRIC SKULL; PARIETAL BONE; ACCURACY	OBJECT Finite element models (FEMs) of the head are used to study the biomechanics of traumatic brain injury and depend heavily on the use of accurate material properties and head geometry. Any FEM aimed at investigating traumatic head injury in children should therefore use age-specific dimensions of the head, as well as age-specific material properties of the different tissues. In this study, the authors built a database of age-corrected skull geometry, skull thickness, and bone density of the developing skull to aid in the development of an age-specific FEM of a child's head. Such a database, containing age-corrected normative skull geometry data, can also be used for preoperative surgical planning and postoperative long-term follow-up of craniosynostosis surgery results. METHODS Computed tomography data were processed for 187 patients (age range 0-20 years old). A 3D surface model was calculated from segmented skull surfaces. Skull models, reference points, and sutures were processed into a MATLAB-supported database. This process included automatic calculation of 2D measurements as well as 3D measurements: length of the coronal suture, length of the lambdoid suture, and the 3D anterior-posterior length, defined as the sum of the metopic and sagittal suture. Skull thickness and skull bone density calculations were included. RESULTS Cephalic length, cephalic width, intercoronal distance, lateral orbital distance, intertemporal distance, and 3D measurements were obtained, confirming the well-established general growth pattern of the skull. Skull thickness increases rapidly in the first year of life, slowing down during the second year of life, while skull density increases with a fast but steady pace during the first 3 years of life. Both skull thickness and density continue to increase up to adulthood. CONCLUSIONS This is the first report of normative data on 2D and 3D measurements, skull bone thickness, and skull bone density for children aged 0-20 years. This database can help build an age-specific FEM of a child's head. It can also help to tailor preoperative virtual planning in craniosynostosis surgery toward patient-specific normative target values and to perform objective long-term follow-up in craniosynostosis surgery.	[Delye, Hans; Goffin, Jan] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands; [Delye, Hans] Katholieke Univ Leuven, Div Expt Neurosurg & Neuroanat, Brussels, Belgium; [Clijmans, Tim; Sloten, Jos Vander] Katholieke Univ Leuven, Biomech Sect BMe, Brussels, Belgium; [Mommaerts, Maurice Yves] UZ Brussel, Dept Craniomaxillofacial Surg, Brussels, Belgium	Delye, H (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, Huispost 636,Postbus 9101, NL-6500 HB Nijmegen, Netherlands.	hans.delye@radboudumc.nl	Delye, H.H.K./L-4265-2015; Mommaerts, Maurice/N-9287-2014	Mommaerts, Maurice/0000-0002-3522-8879	Flemish FWO-Levenslijn grant of the Levenslijn-Kinderfonds - King Baudouin Foundation, Belgium	This work was funded by the Flemish FWO-Levenslijn grant of the Levenslijn-Kinderfonds governed by the King Baudouin Foundation, Belgium.	Axelsson S, 2003, EUR J ORTHODONT, V25, P185, DOI 10.1093/ejo/25.2.185; BROWN WAB, 1984, ANN HUM BIOL, V11, P221, DOI 10.1080/03014468400007091; Cavalcanti MGP, 2004, DENTOMAXILLOFAC RAD, V33, P170, DOI 10.1259/dmfr/13603271; Cavalcanti MGP, 1999, J ORAL MAXIL SURG, V57, P690, DOI 10.1016/S0278-2391(99)90434-2; Citardi MJ, 2001, SKULL BASE-INTERD AP, V11, P5, DOI 10.1055/s-2001-12781; Clumans T, 2008, J CRANIO MAXILL SURG, V36, P66, DOI 10.1016/j.jcms.2007.08.003; Coates D, 1989, J ORAL MAXILLOFAC S1, V47, P124; Connor SEJ, 2007, DENTOMAXILLOFAC RAD, V36, P270, DOI 10.1259/dmfr/90016954; COSTARAS M, 1982, J CRAN GENET DEV BIO, V2, P5; CURREY JD, 1969, J BIOMECH, V2, P1, DOI 10.1016/0021-9290(69)90036-0; Delye H, 2007, J NEUROTRAUM, V24, P1576, DOI 10.1089/neu.2007.0283; Desantis Klinich Kathleen, 2002, Stapp Car Crash J, V46, P165; Ebraheim NA, 2007, SPINE J, V7, P689, DOI 10.1016/j.spinee.2006.09.007; Farkas LG., 1987, ANTHROPOMETRIC FACIA; GARFIN SR, 1986, J PEDIATR ORTHOPED, V6, P434, DOI 10.1097/01241398-198607000-00008; Gelaude F, 2007, COMPUT AIDED SURG, V12, P286, DOI 10.1080/10929080701684762; HILDEBOLT CF, 1990, AM J PHYS ANTHROPOL, V82, P283, DOI 10.1002/ajpa.1330820307; HILDEBOLT CF, 1988, AM J PHYS ANTHROPOL, V76, P497, DOI 10.1002/ajpa.1330760409; Hwang K, 1999, J CRANIOFAC SURG, V10, P395, DOI 10.1097/00001665-199909000-00004; Hwang K, 2000, J CRANIOFAC SURG, V11, P17, DOI 10.1097/00001665-200011010-00004; Hwang K, 1997, J CRANIOFAC SURG, V8, P208, DOI 10.1097/00001665-199705000-00013; Jung YS, 2003, INT J ORAL MAX SURG, V32, P638, DOI 10.1054/ijom.2002.0415; KALENDER WA, 1995, EUR J RADIOL, V20, P83, DOI 10.1016/0720-048X(95)00631-Y; Khechoyan DY, 2014, J PLAST RECONSTR AES, V67, P9, DOI 10.1016/j.bjps.2013.09.009; KRIEWALL TJ, 1981, J BIOMECH, V14, P73, DOI 10.1016/0021-9290(81)90166-4; KRIEWALL TJ, 1982, AM J OBSTET GYNECOL, V143, P707, DOI 10.1016/0002-9378(82)90119-3; LETTS M, 1988, J BONE JOINT SURG BR, V70, P277; Lo L J, 2000, Chang Gung Med J, V23, P354; Lo Lun-Jou, 2003, Chang Gung Med J, V26, P1; Loder RT, 1996, J PEDIATR ORTHOPED, V16, P340, DOI 10.1097/01241398-199605000-00009; Lynnerup N, 2001, FORENSIC SCI INT, V117, P45, DOI 10.1016/S0379-0738(00)00447-3; Lynnerup Niels, 2005, Head Face Med, V1, P13, DOI 10.1186/1746-160X-1-13; MAFEE MF, 1986, AM J NEURORADIOL, V7, P265; Marcus JR, 2009, PLAST RECONSTR SURG, V124, P2076, DOI 10.1097/PRS.0b013e3181bf7e1b; Marcus Jeffrey R, 2008, Eplasty, V8, pe20; Mardini S, 2014, J PLAST RECONSTR AES, V67, P336, DOI 10.1016/j.bjps.2013.11.004; MAVES MD, 1986, OTOLARYNG HEAD NECK, V95, P464, DOI 10.1177/019459988609500408; Moerenhout BAMML, 2009, J CRANIO MAXILL SURG, V37, P18, DOI 10.1016/j.jcms.2008.07.006; Mommaerts MY, 2001, J CRANIOFAC SURG, V12, P547, DOI 10.1097/00001665-200111000-00008; Moreira-Gonzalez A, 2006, PLAST RECONSTR SURG, V117, P1964, DOI 10.1097/01.prs.0000209933.78532.a7; Motherway JA, 2009, J BIOMECH, V42, P2129, DOI 10.1016/j.jbiomech.2009.05.030; Olszewski R, 2008, DENTOMAXILLOFAC RAD, V37, P261, DOI 10.1259/dmfr/33343444; Olszewski R, 2007, INT J ORAL MAX SURG, V36, P828, DOI 10.1016/j.ijom.2007.05.022; Olszewski R, 2006, NEURORADIOLOGY, V48, P853, DOI 10.1007/s00234-006-0140-x; Pereira Inês Minniti Rodrigues, 2008, Radiol Bras, V41, P229, DOI 10.1590/S0100-39842008000400006; Roelants M, 2009, ANN HUM BIOL, V36, P680, DOI 10.3109/03014460903049074; ROSS MD, 1976, S AFR MED J, V50, P635; Saber NR, 2012, CHILD NERV SYST, V28, P405, DOI 10.1007/s00381-011-1630-7; Slovis T, 2007, CAFFEYS PEDIAT DIAGN, V11; Swennen GRJ, 2006, AM J ORTHOD DENTOFAC, V130, P410, DOI 10.1016/j.ajodo.2005.11.035; Thilander B, 2005, EUR J ORTHODONT, V27, P370, DOI 10.1093/ejo/cji033; Togashi K, 2002, ANGLE ORTHOD, V72, P513; van Lindert EJ, 2013, CHILD NERV SYST, V29, P1007, DOI 10.1007/s00381-013-2059-y; WAITZMAN AA, 1992, CLEFT PALATE-CRAN J, V29, P118, DOI 10.1597/1545-1569(1992)029<0118:CSMBOC>2.3.CO;2; WONG WB, 1994, SPINE, V19, P1451, DOI 10.1097/00007632-199407000-00005	55	21	21	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2015	16	6					687	702		10.3171/2015.4.PEDS1493			16	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CX0FM	WOS:000365372300011	26339957	Bronze			2021-06-18	
J	Jayaram, H; Cepurna, WO; Johnson, EC; Morrison, JC				Jayaram, Hari; Cepurna, William O.; Johnson, Elaine C.; Morrison, John C.			MicroRNA Expression in the Glaucomatous Retina	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						microRNA; glaucoma model; retina	NEURONAL CELL-DEATH; ELEVATED INTRAOCULAR-PRESSURE; OPTIC-NERVE DAMAGE; LARGE GENE LISTS; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA LEVELS; OPEN-ANGLE GLAUCOMA; SPINAL-CORD-INJURY; GANGLION-CELL	PURPOSE. MicroRNAs are small, endogenous noncoding RNAs that modulate posttranscriptional gene expression. Although the contribution of microRNAs to the pathogenesis of glaucomatous damage is unknown, supporting evidence from central nervous system (CNS) research suggests they may play a role. It was therefore hypothesized that microRNAs known to be altered in CNS injury are also altered in experimental glaucoma. METHODS. Intraocular pressure (IOP) was elevated in rats by unilateral injection of hypertonic saline and IOP monitored for 5 weeks. After rats were killed, retrobulbar optic nerve sections were graded for damage. MicroRNA was extracted from whole retinae of eyes with advanced nerve damage (n = 8) and from normal, noninjected control eyes (n = 8). Quantitative PCRs were performed using a panel of 17 microRNAs, reported from CNS research to be implicated in mechanisms also linked to glaucomatous damage. Computationally and experimentally derived gene targets were identified for the differentially expressed microRNAs. These were then integrated with existing gene array data. Functional interpretation was performed using the Molecular Signatures Database and DAVID Functional Annotation Clustering. RESULTS. Eight microRNAs were significantly downregulated in glaucomatous retinae compared with controls (miR-181c, miR-497, miR-204, let-7a, miR-29b, miR-16, miR106b, and miR-25); miR-27a was significantly upregulated. Enrichment of targets associated with extracellular matrix/cell proliferation, immune system, and regulation of apoptosis were observed. Cholesterol homeostasis and mTORC-1 pathways showed reduced expression. CONCLUSIONS. MicroRNAs are differentially expressed in retinae of eyes with advanced glaucomatous damage compared with normal controls. Integrating microRNA with gene expression data may improve understanding of the complex biological responses produced by chronically elevated IOP.	[Jayaram, Hari; Cepurna, William O.; Johnson, Elaine C.; Morrison, John C.] Oregon Hlth & Sci Univ, Casey Eye Inst, Kenneth C Swan Ocular Neurobiol Lab, Portland, OR 97239 USA	Morrison, JC (corresponding author), Oregon Hlth & Sci Univ, Casey Eye Inst, Kenneth C Swan Ocular Neurobiol Lab, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.	morrisoj@ohsu.edu		Jayaram, Hari/0000-0003-1998-0670	US-UK Fulbright Commission; Fight for Sight; Special Trustees of Moorfields Eye Hospital; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EY010145, P30EY010572]; Research to Prevent Blindness, Inc (RPB)Research to Prevent Blindness (RPB); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY010145, P30EY010572] Funding Source: NIH RePORTER	Supported by the US-UK Fulbright Commission in conjunction with Fight for Sight, The Special Trustees of Moorfields Eye Hospital (HJ), National Institutes of Health Grants R01EY010145 (JCM) and P30EY010572 (OHSU Core Grant), and an unrestricted grant from Research to Prevent Blindness, Inc (RPB). JCM is an RPB Senior Investigator.	Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P1247, DOI 10.1167/iovs.03-1123; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Buckingham BP, 2008, J NEUROSCI, V28, P2735, DOI 10.1523/JNEUROSCI.4443-07.2008; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Burgos KL, 2013, RNA, V19, P712, DOI 10.1261/rna.036863.112; Chang CY, 2014, ARCH TOXICOL, DOI [10.1007/s00204-014-1364-x, DOI 10.1007/S00204-014-1364-X]; Cheng HYM, 2007, CELL CYCLE, V6, P3034, DOI 10.4161/cc.6.24.5106; Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111; De Santis G, 2010, J NEUROIMMUNOL, V226, P165, DOI 10.1016/j.jneuroim.2010.06.009; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Guo L, 2005, INVEST OPHTH VIS SCI, V46, P175, DOI 10.1167/iovs.04-0832; Guo Y, 2011, INVEST OPHTH VIS SCI, V52, P1460, DOI 10.1167/iovs.10-5930; Guo Y, 2010, INVEST OPHTH VIS SCI, V51, P3003, DOI 10.1167/iovs.09-4663; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hanninen VA, 2002, CURR EYE RES, V25, P389; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Hong PW, 2014, GLIA, V62, P2044, DOI 10.1002/glia.22725; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Howell GR, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-429; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hutchison ER, 2013, GLIA, V61, P1018, DOI 10.1002/glia.22483; Jadhav SP, 2014, J NEUROCHEM, V130, P388, DOI 10.1111/jnc.12731; Jakobs TC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a020636; Jia LJ, 2000, INVEST OPHTH VIS SCI, V41, P1380; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson EC, 2000, INVEST OPHTH VIS SCI, V41, P431; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Jovicic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054222; Khanna S, 2013, J CEREBR BLOOD F MET, V33, P1197, DOI 10.1038/jcbfm.2013.68; Kinoshita C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4823; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu G, 2010, EXP NEUROL, V226, P200, DOI 10.1016/j.expneurol.2010.08.032; Lozano DC, 2015, CHRONOBIOL INT, V32, P513, DOI 10.3109/07420528.2015.1008135; McMahon DG, 2014, PROG RETIN EYE RES, V39, P58, DOI 10.1016/j.preteyeres.2013.12.001; Meza-Sosa KF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00175; Miyahara T, 2003, INVEST OPHTH VIS SCI, V44, P4347, DOI 10.1167/iovs.02-1032; Moon JM, 2013, J CEREBR BLOOD F MET, V33, P1976, DOI 10.1038/jcbfm.2013.157; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; Morrison JC, 2005, PROG RETIN EYE RES, V24, P217, DOI 10.1016/j.preteyeres.2004.08.003; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; Murray AR, 2013, INVEST OPHTH VIS SCI, V54, P1689, DOI 10.1167/iovs.12-10921; Nickells RW, 2007, CAN J OPHTHALMOL, V42, P278, DOI 10.3129/canjophthalmol.i07-036; Ouyang YB, 2013, GLIA, V61, P1784, DOI 10.1002/glia.22556; Ouyang YB, 2012, NEUROBIOL DIS, V45, P555, DOI 10.1016/j.nbd.2011.09.012; Peng ZF, 2013, J NEUROSCI RES, V91, P1349, DOI 10.1002/jnr.23255; Quigley HA, 1999, PROG RETIN EYE RES, V18, P39, DOI 10.1016/S1350-9462(98)00014-7; QUIGLEY HA, 1983, AM J OPHTHALMOL, V95, P673, DOI 10.1016/0002-9394(83)90389-6; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Reichstein D, 2007, EXP EYE RES, V84, P13, DOI 10.1016/j.exer.2006.08.009; Roshan R, 2014, RNA, V20, P1287, DOI 10.1261/rna.044008.113; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sarkar S, 2008, MOL BIOSYST, V4, P895, DOI 10.1039/b804606a; Selles-Navarro I, 2001, EXP NEUROL, V167, P282, DOI 10.1006/exnr.2000.7573; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shi GD, 2012, EXP BRAIN RES, V216, P225, DOI 10.1007/s00221-011-2925-3; Shibata Chikako, 2013, Mol Cell Ther, V1, P5, DOI 10.1186/2052-8426-1-5; Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269; Steele MR, 2006, INVEST OPHTH VIS SCI, V47, P977, DOI 10.1167/iovs.05-0865; Stein JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123682; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787; Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X; Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013; Wang CY, 2015, GLIA, V63, P194, DOI 10.1002/glia.22743; Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856; Wang HL, 2010, BRAIN RES, V1357, P166, DOI 10.1016/j.brainres.2010.08.023; Wang Q, 2014, INVEST OPHTH VIS SCI, V55, P3986, DOI 10.1167/iovs.13-13076; Wang Y, 2015, BRAIN RES BULL, V117, P1, DOI 10.1016/j.brainresbull.2015.06.001; Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0; Yang ZY, 2007, INVEST OPHTH VIS SCI, V48, P5539, DOI 10.1167/iovs.07-0542; Ye EA, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0265-0; Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021; Zhang L, 2015, J NEUROCHEM, V132, P713, DOI 10.1111/jnc.13021; Zhang L, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-211; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404; Zhang Y, 2010, J INTEGR BIOINFORMAT, V7, DOI 10.2390/biecoll-jib-2010-127; Zhao HP, 2013, STROKE, V44, P1706, DOI 10.1161/STROKEAHA.111.000504	93	21	23	0	7	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404	1552-5783		INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	DEC	2015	56	13					7971	7982		10.1167/iovs.15-18088			12	Ophthalmology	Ophthalmology	DB1BU	WOS:000368243800044	26720444	Green Published			2021-06-18	
J	Liu, XX; Niethammer, M; Kwitt, R; Singh, N; McCormick, M; Aylward, S				Liu, Xiaoxiao; Niethammer, Marc; Kwitt, Roland; Singh, Nikhil; McCormick, Matt; Aylward, Stephen			Low-Rank Atlas Image Analyses in the Presence of Pathologies	IEEE TRANSACTIONS ON MEDICAL IMAGING			English	Article						Low-rank and sparse decomposition; sparse images; unbiased atlas; atlas-based segmentation	BRAIN; REGISTRATION	We present a common framework, for registering images to an atlas and for forming an unbiased atlas, that tolerates the presence of pathologies such as tumors and traumatic brain injury lesions. This common framework is particularly useful when a sufficient number of protocol-matched scans from healthy subjects cannot be easily acquired for atlas formation and when the pathologies in a patient cause large appearance changes. Our framework combines a low-rank-plus-sparse image decomposition technique with an iterative, diffeomorphic, group-wise image registration method. At each iteration of image registration, the decomposition technique estimates a "healthy" version of each image as its low-rank component and estimates the pathologies in each image as its sparse component. The healthy version of each image is used for the next iteration of image registration. The low-rank and sparse estimates are refined as the image registrations iteratively improve. For unbiased atlas formation, at each iteration, the average of the low-rank images from the patients is used as the atlas image for the next iteration, until convergence. Since each iteration's atlas is comprised of low-rank components, it provides a population-consistent, pathology-free appearance. Evaluations of the proposed methodology are presented using synthetic data as well as simulated and clinical tumor MRI images from the brain tumor segmentation (BRATS) challenge from MICCAI 2012.	[Liu, Xiaoxiao] Allen Inst Brain Sci, Seattle, WA 98103 USA; [Niethammer, Marc; Singh, Nikhil] Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA; [Kwitt, Roland] Salzburg Univ, Dept Comp Sci, A-5020 Salzburg, Austria; [McCormick, Matt] Kitware Inc, Clifton Pk, NY 12065 USA; [Aylward, Stephen] Kitware Inc, Carrboro, NC 27510 USA	Liu, XX (corresponding author), Allen Inst Brain Sci, Seattle, WA 98103 USA.	liuxiaoxiao@gmail.com	singh, Nikhil/AAX-5380-2020	McCormick, Matthew/0000-0001-9475-3756	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R44CA143234, R41EB015775, R43EB016621, R41NS081792, R43CA165621]; NSFNational Science Foundation (NSF) [EECS-1148870, EECS-0925875]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R43CA143234, R44CA165621, R44CA143234, R43CA165621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R41EB015775, R43EB016621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R41NS081792, R44NS081792] Funding Source: NIH RePORTER	This work was supported, in part, by the National Institutes of Health under grants R44CA143234, R41EB015775, R43EB016621, R41NS081792, R43CA165621, and by NSF under grants EECS-1148870 and EECS-0925875.	Atkinson D, 1997, IEEE T MED IMAGING, V16, P903, DOI 10.1109/42.650886; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Chitphakdithai N, 2010, LECT NOTES COMPUT SC, V6361, P367; Collins DL, 1998, IEEE T MED IMAGING, V17, P463, DOI 10.1109/42.712135; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Joshi S, 2004, NEUROIMAGE, V23, pS151, DOI 10.1016/j.neuroimage.2004.07.068; Lin Z., 2010, ARXIV; Liu XX, 2014, LECT NOTES COMPUT SC, V8675, P97, DOI 10.1007/978-3-319-10443-0_13; Menze BH, 2015, IEEE T MED IMAGING, V34, P1993, DOI 10.1109/TMI.2014.2377694; Niethammer M, 2011, LECT NOTES COMPUT SC, V6892, P639, DOI 10.1007/978-3-642-23629-7_78; Peng YG, 2012, IEEE T PATTERN ANAL, V34, P2233, DOI 10.1109/TPAMI.2011.282; Prastawa M, 2009, MED IMAGE ANAL, V13, P297, DOI 10.1016/j.media.2008.11.002; Ramus L, 2010, LECT NOTES COMPUT SC, V6363, P155; Rohlfing T, 2010, HUM BRAIN MAPP, V31, P798, DOI 10.1002/hbm.20906; Wang B, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P1152, DOI 10.1109/ISBI.2012.6235764	15	21	22	1	6	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0062	1558-254X		IEEE T MED IMAGING	IEEE Trans. Med. Imaging	DEC	2015	34	12					2583	2591		10.1109/TMI.2015.2448556			9	Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging	Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging	CY0OD	WOS:000366104500014	26111390	Green Accepted, Green Published			2021-06-18	
J	Lucke-Wold, BP; Naser, ZJ; Logsdon, AF; Turner, RC; Smith, KE; Robson, MJ; Bailes, JE; Lee, JM; Rosen, CL; Huber, JD				Lucke-Wold, Brandon P.; Naser, Zachary J.; Logsdon, Aric F.; Turner, Ryan C.; Smith, Kelly E.; Robson, Matthew J.; Bailes, Julian E.; Lee, John M.; Rosen, Charles L.; Huber, Jason D.			Amelioration of nicotinamide adenine dinucleotide phosphate-oxidase mediated stress reduces cell death after blast-induced traumatic brain injury	TRANSLATIONAL RESEARCH			English	Article							ALPHA-LIPOIC ACID; ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; NADPH OXIDASES; NOX FAMILY; PATHWAY; EXPRESSION; APOPTOSIS; TAU; ENCEPHALOPATHY	A total of 1.7 million traumatic brain injuries (TBIs) occur each year in the United States, but available pharmacologic options for the treatment of acute neurotrauma are limited. Oxidative stress is an important secondary mechanism of injury that can lead to neuronal apoptosis and subsequent behavioral changes. Using a clinically relevant and validated rodent blast model, we investigated how nicotinamide adenine dinucleotide phosphate oxidase (Nox) expression and associated oxidative stress contribute to cellular apoptosis after single and repeat blast injuries. Nox4 forms a complex with p22phox after injury, forming free radicals at neuronal membranes. Using immunohistochemical-staining methods, we found a visible increase in Nox4 after single blast injury in Sprague Dawley rats. Interestingly, Nox4 was also increased in postmortem human samples obtained from athletes diagnosed with chronic traumatic encephalopathy. Nox4 activity correlated with an increase in superoxide formation. Alpha-lipoic acid, an oxidative stress inhibitor, prevented the development of superoxide acutely and increased antiapoptotic markers B-cell lymphoma 2 (t = 3.079, P < 0.05) and heme oxygenase 1 (t = 8.169, P < 0.001) after single blast. Subacutely, alpha-lipoic acid treatment reduced proapoptotic markers Bax (t = 4.483, P < 0.05), caspase 12 (t = 6.157, P < 0.001), and caspase 3 (t = 4.573, P < 0.01) after repetitive blast, and reduced tau hyperphosphorylation indicated by decreased CP-13 and paired helical filament staining. Alpha-lipoic acid ameliorated impulsive-like behavior 7 days after repetitive blast injury (t = 3.573, P < 0.05) compared with blast exposed animals without treatment. TBI can cause debilitating symptoms and psychiatric disorders. Oxidative stress is an ideal target for neuropharmacologic intervention, and alpha-lipoic acid warrants further investigation as a therapeutic for prevention of chronic neurodegeneration.	W Virginia Univ, Sch Pharm, Dept Neurosurg, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA; W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; Drexel Univ, Coll Med, Dept Med, Profess Studies Hlth Sci, Philadelphia, PA 19104 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA; Univ Chicago, Pritzker Sch Med, NorthShore Univ HealthSyst, Dept Neurosurg, Evanston, IL USA; Univ Chicago, Pritzker Sch Med, NorthShore Univ HealthSyst, Dept Pathol, Evanston, IL USA	Huber, JD (corresponding author), W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Hlth Sci Ctr, One Med Ctr Dr,POB 9530, Morgantown, WV 26506 USA.	jdhuber@hsc.wvu.edu	Robson, Matthew/H-3127-2013	Robson, Matthew/0000-0002-3277-3062; Fraser, Kelly/0000-0003-1563-050X; Turner, Ryan/0000-0001-5523-0645; Lucke-Wold, Brandon/0000-0001-6577-4080	West Virginia University Research and Development Grant; American Medical Association Foundation Seed Grant; American Foundation of Pharmaceutical Education Pre-doctoral Fellowship; Neurosurgery Research and Education Foundation Medical Student Summer Research Fellowship; American Foundation of Pharmaceutical Education Predoctoral Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942] Funding Source: NIH RePORTER	A West Virginia University Research and Development Grant funded the current project. An American Medical Association Foundation Seed Grant, an American Foundation of Pharmaceutical Education Pre-doctoral Fellowship, and a Neurosurgery Research and Education Foundation Medical Student Summer Research Fellowship were awarded to support B. Lucke-Wold. A. Logsdon also received an American Foundation of Pharmaceutical Education Predoctoral Fellowship.	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Badaut J, 2015, NEUROSCIENCE, V285, P215, DOI 10.1016/j.neuroscience.2014.10.035; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Booth-Kewley S, 2010, J NERV MENT DIS, V198, P91, DOI 10.1097/NMD.0b013e3181cc45e9; Borza Liana Rada, 2014, Rev Med Chir Soc Med Nat Iasi, V118, P19; Bramlett H. M., 2014, J NEUROTRAUMA; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen WJ, 2013, INT J ONCOL, V42, P963, DOI 10.3892/ijo.2013.1774; Cheng ZG, 2013, ASIAN PAC J TROP MED, V6, P305, DOI 10.1016/S1995-7645(13)60061-9; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Curtis L, 2014, J NEUROSURG SCI, V58, P151; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Freeman LC, 2015, J NEUROCHEM; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Ghadiri T, 2014, J NEUROSCI METH, V233, P18, DOI 10.1016/j.jneumeth.2014.05.035; Giraldo E, 2014, REDOX BIOL, V2, P873, DOI 10.1016/j.redox.2014.03.002; Gomes MB, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-80; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Ho YH, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0157-8; Indharty Rr Suzy, 2013, Asian J Neurosurg, V8, P83, DOI 10.4103/1793-5482.116381; James LM, 2014, MIL MED, V179, P357, DOI 10.7205/MILMED-D-13-00241; Kates SA, 2014, BASIC CLIN PHARMACOL, V115, P456, DOI 10.1111/bcpt.12254; Kim P, 2012, BIOMOL THER, V20, P125, DOI 10.4062/biomolther.2012.20.1.125; Leeds PR, 2014, ACS CHEM NEUROSCI, V5, P422, DOI 10.1021/cn500040g; Li HY, 2014, J PINEAL RES, V57, P110, DOI 10.1111/jpi.12148; Li Z, 2015, NEUROL SCI, V36, P61, DOI 10.1007/s10072-014-1909-z; Liu XR, 2014, TRANSL STROKE RES, V5, P692, DOI 10.1007/s12975-014-0359-5; Liu XA, 2010, J ALZHEIMERS DIS, V19, P953, DOI 10.3233/JAD-2010-1294; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Lobo V, 2010, Pharmacogn Rev, V4, P118, DOI 10.4103/0973-7847.70902; Lopez-Castroman J, 2014, PSYCHOL MED, V44, P3059, DOI 10.1017/S0033291714000646; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Uranga RM, 2009, TOXICOL SCI, V111, P331, DOI 10.1093/toxsci/kfp152; Meyerhoff JL, 2004, BRAIN RES, V1016, P139, DOI 10.1016/j.brainres.2004.03.019; O'Callaghan JP, 2004, J NEUROSCI METH, V135, P159, DOI 10.1016/j.jneumeth.2003.12.006; Okubo Shuichi, 2013, Acta Neurochir Suppl, V118, P83, DOI 10.1007/978-3-7091-1434-6_14; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Ozbal S, 2015, BIOTECH HISTOCHEM, V90, P206, DOI 10.3109/10520295.2014.977950; Park S, 2014, CURR MED CHEM, V21, P3636, DOI 10.2174/0929867321666140706141806; Peng H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058339; Reljanovic M, 1999, FREE RADICAL RES, V31, P171, DOI 10.1080/10715769900300721; Rocamonde B, 2012, NEUROSCIENCE, V224, P102, DOI 10.1016/j.neuroscience.2012.08.028; Rocamonde B, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/521939; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Steimer T, 2003, STRESS, V6, P87, DOI 10.1080/1025389031000111320; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Tajes M, 2014, NEUROSCI LETT, V580, P78, DOI 10.1016/j.neulet.2014.07.047; Teichert J, 2005, J CLIN PHARMACOL, V45, P313, DOI 10.1177/0091270004270792; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Wagener FADTG, 2013, CURR PHARM DESIGN, V19, P2698; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang ZF, 2010, J ALZHEIMERS DIS, V20, P145, DOI 10.3233/JAD-2010-1351; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Xu SL, 2013, AM J PHYSIOL-HEART C, V305, pH1484, DOI 10.1152/ajpheart.00382.2013; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang R, 2009, HYPERTENSION, V53, P556, DOI 10.1161/HYPERTENSIONAHA.108.124594	68	21	22	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1931-5244	1878-1810		TRANSL RES	Transl. Res.	DEC	2015	166	6					509	528		10.1016/j.trsl.2015.08.005			20	Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental	Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine	CY5JR	WOS:000366444400001	26414010				2021-06-18	
J	Poulsen, MB; Damgaard, B; Zerahn, B; Overgaard, K; Rasmussen, RS				Poulsen, Mai Bang; Damgaard, Bodil; Zerahn, Bo; Overgaard, Karsten; Rasmussen, Rune Skovgaard			Modafinil May Alleviate Poststroke Fatigue A Randomized, Placebo-Controlled, Double-Blinded Trial	STROKE			English	Article						clinical trial; fatigue; randomized controlled trial; rehabilitation; stroke	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; MONTREAL COGNITIVE ASSESSMENT; EXCESSIVE DAYTIME SLEEPINESS; STROKE PATIENTS; MULTIPLE-SCLEROSIS; STATE-EXAMINATION; MENTAL FATIGUE; SEVERITY SCALE; METHYLPHENIDATE	Background and Purpose-Poststroke fatigue is common and reduces quality of life. Current evidence for intervention is limited, and this is the first placebo-controlled trial to investigate treatment of poststroke fatigue with the wakefulness promoting drug modafinil. Methods-The trial was randomized, double-blinded, and placebo-controlled. Patients were treated with 400-mg modafinil or placebo for 90 days. Assessments were done at inclusion, 30, 90, and 180 days. The primary end point was fatigue at 90 days measured by the Multidimensional Fatigue Inventory-20 general fatigue domain. Secondary end points included the Fatigue Severity Scale, the Montreal Cognitive Assessment, the modified Rankin Scale and the Stroke-specific quality of Life questionnaire. Adult patients with a recent stroke achieving a score of >= 12 on the Multidimensional Fatigue Inventory-20 general fatigue domain were consecutively included. Exclusion criteria were severe cognitive disabilities and contraindications for modafinil treatment. Results-One thousand one hundred twenty-one patients with stroke were screened and 41 patients included, 21 received modafinil. The primary end point, the Multidimensional Fatigue Inventory-20 general fatigue score, did not differ between groups. Patients in the modafinil group obtained better scores on the Fatigue Severity Scale (P=0.02) and in some subscales of the stroke-specific quality of life questionnaire (0.001<P<0.05), which were secondary outcomes. No serious adverse reactions were observed and there was no difference in blood pressure between groups. Conclusions-There were no significant differences between the 2 groups with regard to the primary end point. There were secondary significant outcomes that should be explored in future trials.	[Poulsen, Mai Bang; Overgaard, Karsten; Rasmussen, Rune Skovgaard] Herlev Univ Hosp, Dept Neurol, DK-2730 Herlev, Denmark; [Damgaard, Bodil] Herlev Univ Hosp, Dept Radiol, DK-2730 Herlev, Denmark; [Zerahn, Bo] Herlev Univ Hosp, Dept Clin Physiol, DK-2730 Herlev, Denmark; [Damgaard, Bodil] Hilleroed Univ Hosp, Dept Radiol, Hillerod, Denmark	Poulsen, MB (corresponding author), Herlev Hosp, Dept Neurol, Herlev Ringvej 75, DK-2730 Herlev, Denmark.	maibang@gmail.com		Zerahn, Bo/0000-0002-3457-6249; Poulsen, Mai Bang/0000-0002-5525-0678; Rasmussen, Rune/0000-0002-5630-122X	Danish Ministry of Higher Education and Science; Department of Neurology at Herlev Hospital; Health Foundation; Research Council at Herlev Hospital; Merchant L.F. Foghts Foundation; Director Emil Hertz and wife Inger Hertz Foundation; Else and Mogens Wedell-Wedelsborgs Foundation; Boerge and Marie Kroghs Foundation; Soeren and Helene Hempels grant; Linex Foundation	The trial was supported by the Danish Ministry of Higher Education and Science, the Department of Neurology at Herlev Hospital, The Health Foundation, The Research Council at Herlev Hospital, Merchant L.F. Foghts Foundation, Director Emil Hertz and wife Inger Hertz Foundation, Else and Mogens Wedell-Wedelsborgs Foundation, Boerge and Marie Kroghs Foundation, Soeren and Helene Hempels grant and the Linex Foundation. The drugs used was not supplied by the manufacturer but bought from an independent pharmacy.	Andersen G, 2012, ACTA NEUROL SCAND, V125, P248, DOI 10.1111/j.1600-0404.2011.01557.x; Awudu GAH, 2014, DRUG SAFETY, V37, P661, DOI 10.1007/s40264-014-0201-8; Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406; Bech P, 2001, J AFFECT DISORDERS, V66, P159, DOI 10.1016/S0165-0327(00)00309-8; Brioschi A, 2009, EUR NEUROL, V62, P243, DOI 10.1159/000232927; Choi-Kwon S, 2005, CEREBROVASC DIS, V19, P84, DOI 10.1159/000082784; Choi-Kwon S, 2007, CEREBROVASC DIS, V23, P103, DOI 10.1159/000097045; Cumming TB, 2013, ACTA NEUROL SCAND, V128, P122, DOI 10.1111/ane.12084; Duncan F, 2012, J PSYCHOSOM RES, V73, P18, DOI 10.1016/j.jpsychores.2012.04.001; Glader EL, 2002, STROKE, V33, P1327, DOI 10.1161/01.STR.0000014248.28711.D6; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Johansson B, 2015, BRAIN INJURY, V29, P758, DOI 10.3109/02699052.2015.1004747; Johansson B, 2012, ACTA NEUROPSYCHIATR, V24, P266, DOI 10.1111/j.1601-5215.2012.00678.x; Jones CJ, 1999, RES Q EXERCISE SPORT, V70, P113, DOI 10.1080/02701367.1999.10608028; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Karaiskos D, 2012, J NEUROPSYCH CLIN N, V24, P349, DOI 10.1176/appi.neuropsych.11110325; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kumar R, 2008, DRUGS, V68, P1803, DOI 10.2165/00003495-200868130-00003; Kutlubaev MA, 2015, INT J STROKE, V10, P280, DOI 10.1111/ijs.12428; Lerdal A, 2013, NEUROLOGY, V81, P1581, DOI 10.1212/WNL.0b013e3182a9f471; Lerdal A, 2011, INT J NURS STUD, V48, P1258, DOI 10.1016/j.ijnurstu.2011.02.019; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; Maribo Thomas, 2006, Ugeskr Laeger, V168, P2790; MEYER DE, 1988, BIOL PSYCHOL, V26, P3, DOI 10.1016/0301-0511(88)90013-0; Minzenberg MJ, 2008, NEUROPSYCHOPHARMACOL, V33, P1477, DOI 10.1038/sj.npp.1301534; Mucke M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006788.pub3; Muus I, 2007, CLIN REHABIL, V21, P620, DOI 10.1177/0269215507075504; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Pollock A, 2012, LANCET NEUROL, V11, P209, DOI 10.1016/S1474-4422(12)70029-7; Rush CR, 2002, BEHAV PHARMACOL, V13, P105, DOI 10.1097/00008877-200203000-00002; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Simon P, 1995, EUR NEUROPSYCHOPHARM, V5, P509, DOI 10.1016/0924-977X(95)00041-M; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Tseng BY, 2010, STROKE, V41, P2908, DOI 10.1161/STROKEAHA.110.596064; Urban KR, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00038; van de Port IGL, 2007, CEREBROVASC DIS, V23, P40, DOI 10.1159/000095757; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wesensten NJ, 2005, J SLEEP RES, V14, P255, DOI 10.1111/j.1365-2869.2005.00468.x; Williams LS, 1999, STROKE, V30, P1362, DOI 10.1161/01.STR.30.7.1362; Wu SM, 2015, STROKE, V46, P893, DOI 10.1161/STROKEAHA.114.006647	42	21	21	2	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	2015	46	12					3470	3477		10.1161/STROKEAHA.115.010860			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CX2NS	WOS:000365534400018	26534969	Bronze			2021-06-18	
J	Sokol, KK; Black, GE; Azarow, KS; Long, W; Martin, MJ; Eckert, MJ				Sokol, Kyle K.; Black, George E.; Azarow, Kenneth S.; Long, William; Martin, Matthew J.; Eckert, Matthew J.			Prehospital interventions in severely injured pediatric patients: Rethinking the ABCs	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	45th Annual Meeting of the Western-Trauma-Association	MAR 01-06, 2015	Telluride, CO	Western Trauma Assoc		Prehospital; pediatric; trauma; tourniquet; intubation	EMERGENCY MEDICAL-SERVICES; ADVANCED LIFE-SUPPORT; COMBAT CASUALTY CARE; TRAUMATIC BRAIN-INJURY; ENDOTRACHEAL INTUBATION; HEMOSTATIC DRESSINGS; TOURNIQUET USE; SURVIVAL; NEEDS; FIELD	BACKGROUND The current conflict in Afghanistan has resulted in a high volume of significantly injured pediatric patients. The austere environment has demanded emphasis on prehospital interventions (PHIs) to sustain casualties during transport. METHODS The Department of Defense Trauma Registry was queried for all pediatric patients (18 years) treated at Camp Bastion from 2004 to 2012. PHIs were grouped by Advanced Trauma Life Support categories into (1) airway (A)intubation or surgical airway; 2) breathing (B)chest tube or needle thoracostomy; and 3) circulation (C)tourniquet or hemostatic dressing. Outcomes were assessed based on injury severity, hemodynamics, blood products and fluids, as well as mortality rates. RESULTS There were 766 injured children identified with 20% requiring one or more PHIs, most commonly circulation (C, 51%) followed by airway (A, 40%) and breathing (B, 8.7%). The majority of C interventions were tourniquets (85%) and hemostatic dressings (15%). Only 38% of patients with extremity vascular injury or amputation received a C intervention, with a significant reduction in blood products and intravenous fluids associated with receiving a C PHI (both p < 0.05). A interventions consisted of endotracheal intubation for depressed mental status (Glasgow Coma Scale [GCS] score < 8). Among patients with traumatic brain injury, A interventions were associated with higher unadjusted mortality (56% vs. 20%, p < 0.01) and remained independently associated with increased mortality after multivariate adjustment (odds ratio, 5.9; p = 0.001). B interventions were uncommon and performed in only 2% of patients with no recorded adverse outcomes. CONCLUSION There is a high incidence of PHIs among pediatric patients with severe wartime injuries. The most common and effective were C PHI for hemorrhage control, which should remain a primary focus of equipment and training. A interventions were most commonly performed in the setting of severe traumatic brain injury but were associated with worse outcomes. B interventions seem safe and effective and may be underused. LEVEL OF EVIDENCE Care management/therapeutic study, level IV.	[Sokol, Kyle K.; Black, George E.; Martin, Matthew J.; Eckert, Matthew J.] Madigan Army Med Ctr, Dept Surg, Tacoma, WA 98431 USA; [Azarow, Kenneth S.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Long, William; Martin, Matthew J.] Legacy Emanuel Hosp, Trauma & Acute Care Surg Serv, Portland, OR USA	Eckert, MJ (corresponding author), Madigan Army Med Ctr, Dept Surg, 9040-A Fitzsimmons Ave, Tacoma, WA 98431 USA.	matthew.j.eckert.mil@mail.mil	Martin, Matthew/B-2676-2014	Martin, Matthew/0000-0002-9169-9069; Black, George/0000-0002-4046-100X			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS9; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Ali J, 1997, J TRAUMA, V42, P786, DOI 10.1097/00005373-199705000-00006; APPLEBAUM D, 1985, ANN EMERG MED, V14, P656, DOI 10.1016/S0196-0644(85)80882-9; Aylwin CJ, 2008, ANN ROY COLL SURG, V90, P54, DOI 10.1308/003588408X242286; Bankole S, 2011, PEDIATR CRIT CARE ME, V12, pE166, DOI 10.1097/PCC.0b013e3181f36f6e; Barton Erik D., 1995, Journal of Emergency Medicine, V13, P155, DOI 10.1016/0736-4679(94)00135-9; Bennett BL, 2014, MIL MED, V179, P497, DOI 10.7205/MILMED-D-13-00199; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Borgman M, 2012, J TRAUMA ACUTE CARE, V73, pS509, DOI 10.1097/TA.0b013e318275477c; Butler FK, 2010, J TRAUMA, V69, pS10, DOI 10.1097/TA.0b013e3181e4220c; Butler FK, 2012, J TRAUMA ACUTE CARE, V73, pS395, DOI 10.1097/TA.0b013e3182754850; Cascio AN, 2004, J TRAUMA, V56, P454, DOI 10.1097/01.TA.0000109686.44485.14; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; DiRusso SM, 2005, J TRAUMA, V59, P84, DOI 10.1097/01.TA.0000171462.28379.F3; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Floccare DJ, 2003, J TRAUMA, V55, P1184, DOI 10.1097/01.TA.0000097177.08594.4B; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Granville-Chapman J, 2011, INJURY, V42, P447, DOI 10.1016/j.injury.2010.09.037; Johansson J, 2012, RESUSCITATION, V83, P1259, DOI 10.1016/j.resuscitation.2012.02.018; Kheirabadi Bijan, 2011, US Army Med Dep J, P25; Kotwal Russ S, 2011, J Spec Oper Med, V11, P127; Kragh JF, 2015, PREHOSP EMERG CARE, V19, P184, DOI 10.3109/10903127.2014.964892; Kragh JF, 2013, AM J EMERG MED, V31, P873, DOI 10.1016/j.ajem.2012.11.030; Kragh JF, 2012, PEDIATR EMERG CARE, V28, P1361, DOI 10.1097/PEC.0b013e318276c260; LAVERY RF, 1992, PEDIATR EMERG CARE, V8, P9, DOI 10.1097/00006565-199202000-00004; Loiselle J M, 2001, Ann Emerg Med, V38, P352; Long E, 2014, PEDIATR ANESTH, V24, P1204, DOI 10.1111/pan.12490; MacIntyre AD, 2011, AM SURGEON, V77, P162; Martinon C, 2011, PEDIATR CRIT CARE ME, V12, P65, DOI 10.1097/PCC.0b013e3181e2a244; McGuigan R, 2007, J PEDIATR SURG, V42, P207, DOI 10.1016/j.jpedsurg.2006.09.020; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; Ordonez C, 2012, WORLD J SURG, V36, P2761, DOI 10.1007/s00268-012-1745-3; Perron A D, 2001, Prehosp Emerg Care, V5, P6, DOI 10.1080/10903120190940245; RAMENOFSKY ML, 1984, J TRAUMA, V24, P818, DOI 10.1097/00005373-198409000-00007; Schmidt U, 2002, UNFALLCHIRURG, V105, P1000, DOI 10.1007/s00113-002-0520-6; Schmidt U, 1998, J TRAUMA, V44, P98, DOI 10.1097/00005373-199801000-00010; Seamon MJ, 2013, INJURY, V44, P634, DOI 10.1016/j.injury.2012.12.020; Seid Terrence, 2012, Int J Crit Illn Inj Sci, V2, P114, DOI 10.4103/2229-5151.100887; SEIDEL JS, 1986, CIRCULATION, V74, P129; SEIDEL JS, 1986, PEDIATRICS, V78, P808; SEIDEL JS, 1984, PEDIATRICS, V73, P769; Spinella PC, 2008, CRIT CARE MED, V36, pS293, DOI 10.1097/CCM.0b013e31817da99f; Suominen P, 1998, J PEDIATR SURG, V33, P1388, DOI 10.1016/S0022-3468(98)90014-8; Svenson JE, 1996, PEDIATR EMERG CARE, V12, P173, DOI 10.1097/00006565-199606000-00007; Tien Homer C, 2009, J Spec Oper Med, V9, P65; van Olden GDJ, 2004, J TRAUMA, V57, P381, DOI 10.1097/01.TA.0000096645.13484.E6; Vavilala MS, 2011, PEDIATR CRIT CARE ME, V12, P477, DOI 10.1097/PCC.0b013e3181e8b729; Wilson KL, 2013, AM SURGEON, V79, P257	50	21	21	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2015	79	6					983	989		10.1097/TA.0000000000000706			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CX4TD	WOS:000365692300023	26680137				2021-06-18	
J	Galindo, AN; Kussmann, M; Dayon, L				Galindo, Antonio Nunez; Kussmann, Martin; Dayon, Loic			Proteomics of Cerebrospinal Fluid: Throughput and Robustness Using a Scalable Automated Analysis Pipeline for Biomarker Discovery	ANALYTICAL CHEMISTRY			English	Article							PROTEIN DEPLETION METHODS; ALZHEIMERS-DISEASE; PLASMA-PROTEINS; CSF; IDENTIFICATION; QUANTITATION; DIAGNOSIS; WORKFLOW	Cerebrospinal fluid (CSF) is a body fluid of high clinical relevance and an important source of potential biomarkers for brain-associated damages, such as traumatic brain injury and stroke, and for brain diseases, such as Alzheimer's and Parkinson's. Herein, we have implemented, evaluated, and validated a scalable automated proteomic pipeline (ASAP(2)) for the sample preparation and proteomic analysis of CSF, enabling increased throughput and robustness for biomarker discovery. Human CSF samples were depleted from abundant proteins and subjected to automated reduction, alkylation, protein digestion, tandem mass tag (TMT) 6-plex labeling, pooling, and sample cleanup in a 96-well-plate format before reversed-phase liquid chromatography tandem mass spectrometry (RP-LC MS/MS). We showed the impact on the CSF proteome coverage of applying the depletion of abundant proteins, which is usually performed on blood plasma or serum samples. Using ASAP(2) to analyze 96 identical CSF samples, we determined the analytical figures of merit of our shotgun proteomic approach regarding proteome coverage consistency (i.e., 387 proteins), quantitative accuracy, and individual protein variability. We demonstrated that, as for human plasma samples, ASAP(2) is efficient in analyzing large numbers of human CSF samples and is a valuable tool for biomarker discovery. The data has been deposited to the ProteomeXchange with identifier PXD003024.	[Galindo, Antonio Nunez; Kussmann, Martin; Dayon, Loic] Nestle Inst Hlth Sci SA, Mol Biomarkers Core, Lausanne, Switzerland	Dayon, L (corresponding author), Nestle Inst Hlth Sci SA, Mol Biomarkers Core, EPFL Innovat Pk,Batiment H, Lausanne, Switzerland.	loic.dayon@rd.nestle.com	Dayon, Loic/J-2499-2019	Dayon, Loic/0000-0002-8499-270X			Abdi F, 2006, J ALZHEIMERS DIS, V9, P293; Borg Jacques, 2011, Clin Proteomics, V8, P6, DOI 10.1186/1559-0275-8-6; Carrasquillo MM, 2009, NAT GENET, V41, P192, DOI 10.1038/ng.305; Choe L, 2007, PROTEOMICS, V7, P3651, DOI 10.1002/pmic.200700316; Cominetti O., 2015, UNPUB; Dayon L, 2008, ANAL CHEM, V80, P2921, DOI 10.1021/ac702422x; Dayon L, 2014, J PROTEOME RES, V13, P3837, DOI 10.1021/pr500635f; De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179; Griggs R. C., 2012, GOLDMANS CECIL MED, P2228; Guldbrandsen A, 2014, MOL CELL PROTEOMICS, V13, P3152, DOI 10.1074/mcp.M114.038554; Hirabayashi Takahiro, 2014, Adv Neurobiol, V8, P293; Holtta M, 2015, J PROTEOME RES, V14, P654, DOI 10.1021/pr501076j; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jedrychowski MP, 2015, CELL METAB, V22, P734, DOI 10.1016/j.cmet.2015.08.001; Liu GY, 2012, J NEUROCHEM, V120, P190, DOI 10.1111/j.1471-4159.2011.07547.x; Liu YS, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145728; Maurer MH, 2010, MASS SPECTROM REV, V29, P17, DOI 10.1002/mas.20213; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Ogata Y, 2005, J PROTEOME RES, V4, P837, DOI 10.1021/pr049750o; Percy AJ, 2014, J PROTEOME RES, V13, P3733, DOI 10.1021/pr500317d; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Roche S, 2008, PROTEOM CLIN APPL, V2, P428, DOI 10.1002/prca.200780040; Rosenberg G. A., 2012, BRADLEYS NEUROLOGY C; Schutzer SE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010980; Shores KS, 2007, J PROTEOME RES, V6, P3739, DOI 10.1021/pr070293w; Tu CJ, 2010, J PROTEOME RES, V9, P4982, DOI 10.1021/pr100646w; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Yadav AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024442; Yuan XL, 2005, J CHROMATOGR B, V815, P179, DOI 10.1016/j.jchromb.2004.06.044	31	21	21	1	26	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	NOV 3	2015	87	21					10755	10761		10.1021/acs.analchem.5b02748			7	Chemistry, Analytical	Chemistry	CV6BE	WOS:000364354900018	26452177				2021-06-18	
J	Dahm, J; Ponsford, J				Dahm, Jane; Ponsford, Jennie			LONG-TERM EMPLOYMENT OUTCOMES FOLLOWING TRAUMATIC BRAIN INJURY AND ORTHOPAEDIC TRAUMA: A TEN-YEAR PROSPECTIVE STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; orthopaedics; employment; prospective studies	QUALITY-OF-LIFE; HEAD-INJURY; DISABILITY; WORK; PREDICTORS; MODERATE; RETURN; SEVERITY; ADULTS	Objective: To investigate the trajectory and predictors of employment over a period of 10 years following traumatic brain injury and traumatic orthopaedic injury. Design: Prospective follow-up at 1, 2, 5 and 10 years postinjury. Participants: Seventy-nine individuals with traumatic brain injury and 79 with traumatic orthopaedic injury recruited from Epworth HealthCare in Melbourne, Australia during inpatient rehabilitation. Methods: Information was obtained from medical files and self-report questionnaires. Results: Individuals with traumatic brain injury were less likely to be competitively employed during the period up to 10 years post-injury compared with individuals with traumatic orthopaedic injury, although there was evidence of increasing employment participation during that time. More severe traumatic brain injury, older age, pre-injury psychological treatment, and studying or having a blue-collar occupation at time of injury were associated with poorer employment outcomes. Individuals with traumatic brain injury had spent less time with their current employer and were less likely to have increased responsibility since the injury than those with traumatic orthopaedic injury. At least half of each group reported difficulty at work due to fatigue. Conclusion: Given the potential for gains in employment participation over an extended time-frame, there may be benefit in ongoing access to individualized vocational rehabilitation. Particular areas of focus would include managing fatigue and psychiatric disorders, and exploring supported occupational activity for all levels of injury severity.	[Dahm, Jane; Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia; [Ponsford, Jennie] Epworth HealthCare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Dahm, J (corresponding author), Monash Univ, Sch Psychol Sci, Bldg 17, Clayton, Vic 3800, Australia.	janedahm@bigpond.com			Transport Accident Commission (TAC) through the Institute for Safety, Compensation and Recovery Research (ISCRR)	Information for individuals with TBI was accessed from data collected for the Longitudinal Head Injury Study funded by the Transport Accident Commission (TAC; www.tac.vic.gov.au), through the Institute for Safety, Compensation and Recovery Research (ISCRR; www.iscrr.com.au).	Airey CM, 2001, DISABIL REHABIL, V23, P509; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andruszkow H, 2013, CLIN ORTHOP RELAT R, V471, P2899, DOI 10.1007/s11999-013-3031-6; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Australian Bureau of Statistics, 2014, LAB FORC AUSTR; Australian Bureau of Statistics; Statistics New Zealand, 2013, ANZSCO AUSTR NZ STAN; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Braithwaite IJ, 1998, INJURY, V29, P55; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Forslund MV, 2014, BRAIN INJURY, V28, P980, DOI 10.3109/02699052.2014.888770; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jennett B, 1981, MANAGEMENT HEAD INJU; Kelley E, 2014, J HEAD TRAUMA REHAB, V29, P147, DOI 10.1097/HTR.0b013e31826db6b9; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; MacKenzie EJ, 2006, J TRAUMA, V61, P688, DOI 10.1097/01.ta.0000195985.56153.68; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ouellet MC, 2009, J HEAD TRAUMA REHAB, V24, P262, DOI 10.1097/HTR.0b013e3181a68b73; Overgaard M, 2011, J TRAUMA, V71, P435, DOI 10.1097/TA.0b013e31820e7ec3; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Redmill DA, 2006, INJURY, V37, P243, DOI 10.1016/j.injury.2005.11.014; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; Satz P, 2011, J CLIN EXP NEUROPSYC, V33, P121, DOI 10.1080/13803395.2010.493151; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Soberg HL, 2011, J TRAUMA, V71, P425, DOI 10.1097/TA.0b013e3181eff54f; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; World Health Organization, 2001, INT CLASS FUNCT DIS	40	21	21	0	11	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV	2015	47	10					932	940		10.2340/16501977-2016			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CW3XE	WOS:000364924900006	26550768	DOAJ Gold			2021-06-18	
J	Dematteo, C; Volterman, KA; Breithaupt, PG; Claridge, EA; Adamich, J; Timmons, BW				Dematteo, Carol; Volterman, Kimberly A.; Breithaupt, Peter G.; Claridge, Everett A.; Adamich, John; Timmons, Brian W.			Exertion Testing in Youth with Mild Traumatic Brain Injury/Concussion	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						RETURN TO PLAY; HEAD INJURY; BRAIN CONCUSSION; POSTCONCUSSION SYNDROME; CHILDREN; ADOLESCENTS	COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; POSTCONCUSSION SYNDROME; CHILDREN; RETURN; REHABILITATION; ADOLESCENTS; DEPRESSION; STATEMENT	Purpose The decision regarding return to activity (RTA) after mild traumatic brain injuries/concussion is one of the most difficult and controversial areas in concussion management, particularly for youth. This study investigated how youth with postconcussion syndrome (PCS) are affected by exertion and whether standardized exertion testing using the McMaster All-Out Progressive Continuous Cycling Test can contribute to clinical decision making for safe RTA. Methods Fifty-four youth (8.5-18.3 yr) with a previously confirmed concussion participated in the study. Each participant performed exertion testing on a cycle ergometer and completed a Postconcussion Symptom scale at the following time points: before exertion (baseline), 5 and 30 min, and 24 h after exertion. A modified Postconcussion Symptom scale was administered at 2-min intervals during exertion. Results Participants had a mean SD symptom duration of 6.3 +/- 6.9 months after the most recent concussive injury, with a median of 4.1 months (range, 0.7-35 months). Sixty-three percent of participants had symptoms during exertion testing. Symptom profile (number and severity) significantly affected perception of exertion at 50% peak mechanical power. During acute assessment of symptoms (30-min after exertion), headache (P = 0.39), nausea (P = 0.63), and dizziness (P = 0.35) did not change. However, both the number and severity of symptoms significantly improved over 24 h, with 56.8% of youth showing improvements. The time from the most recent injury had a significant effect on the symptom score at baseline, 30 min after exertion, and 24 h after exertion. Conclusions Exertion testing has an important role in the evaluation of symptoms and readiness to RTA, particularly in youth who are slow to recover. Overall, controlled exertion seemed to lesson symptoms for most youth.	[Dematteo, Carol; Claridge, Everett A.; Adamich, John; Timmons, Brian W.] McMaster Univ, CanChild Ctr Childhood Disabil Res, Hamilton, ON L8S 1C7, Canada; [Dematteo, Carol] McMaster Univ, Sch Rehabil Sci, Hamilton, ON L8S 1C7, Canada; [Volterman, Kimberly A.; Breithaupt, Peter G.; Timmons, Brian W.] McMaster Univ, Dept Pediat, Child Hlth & Exercise Med Program, Hamilton, ON L8S 1C7, Canada	Dematteo, C (corresponding author), McMaster Univ, Sch Rehabil Sci, 1400 Main St West,IAHS 433, Hamilton, ON L8S 1C7, Canada.	dematteo@mcmaster.ca			Pollock Foundation through McMaster's CanChild Centre for Childhood Disability Research; Pollock Foundation through CanChild Centre for Childhood Disability and Research	We offer our gratitude to the children and their families who participated in this study. This study was funded by the Pollock Foundation through McMaster's CanChild Centre for Childhood Disability Research.; Carol DeMatteo and Brian Timmons received a $7000 grant from the Pollock Foundation through CanChild Centre for Childhood Disability and Research.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DeMatteo C, 2015, DISABIL REHABIL, V37, P1107, DOI 10.3109/09638288.2014.952452; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Emery CA, 2010, BRIT J SPORT MED, V44, P64, DOI 10.1136/bjsm.2009.068353; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnson LSM, 2012, J SCHOOL HEALTH, V82, P180, DOI 10.1111/j.1746-1561.2011.00684.x; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Ploeger HE, 2011, J PEDIATR-US, V158, P814, DOI 10.1016/j.jpeds.2010.10.020; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	39	21	21	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	NOV	2015	47	11					2283	2290		10.1249/MSS.0000000000000682			8	Sport Sciences	Sport Sciences	CT6RU	WOS:000362940900005	25871465				2021-06-18	
J	Littleton, AC; Schmidt, JD; Register-Mihalik, JK; Gioia, GA; Waicus, KM; Mihalik, JP; Guskiewicz, KM				Littleton, Ashley C.; Schmidt, Julianne D.; Register-Mihalik, Johna K.; Gioia, Gerard A.; Waicus, Kelly M.; Mihalik, Jason P.; Guskiewicz, Kevin M.			Effects of Attention Deficit Hyperactivity Disorder and Stimulant Medication on Concussion Symptom Reporting and Computerized Neurocognitive Test Performance	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						ADHD; Concussion vital signs; Psychometrics; Reliability; Neuropsychology; Traumatic brain injury	TEST-RETEST RELIABILITY; SPORT-RELATED CONCUSSION; CNS VITAL SIGNS; DEFICIT/HYPERACTIVITY DISORDER; NEUROPSYCHOLOGICAL PERFORMANCE; PREADOLESCENT CHILDREN; RESPONSE VARIABILITY; COGNITIVE CONTROL; PHYSICAL-ACTIVITY; COLLEGE-STUDENTS	Effects of attention deficit hyperactivity disorder (ADHD) and stimulant medications on concussion measures are unclear. The objectives of this study were to (i) examine consistency of performance in an unmedicated ADHD group and a control group on concussion measures, (ii) assess performance differences between the two groups, and (iii) assess the effect of stimulant medication on performance in the ADHD group. College-aged participants (22 ADHD and 22 matched controls) were administered a symptom checklist and a computerized neurocognitive test (CNS Vital Signs, CNSVS) 3 times (1 week apart): Sessions 1 and 2 were unmedicated for all participants; Session 3 was medicated for the ADHD group. The reliability of the measures (intraclass correlation coefficients, ICC2,1) was consistent for both groups. When unmedicated, the ADHD group performed worse than controls on psychomotor speed [F(1,40) = 15.19, p < 0.001], and worse than when medicated on reaction time [F(1,39) = 6.34, p = 0.02]. The ADHD group performed better and comparable with controls when medicated. Clinicians should take medication status into account when interpreting scores.	[Littleton, Ashley C.] Univ N Carolina, Human Movement Sci & Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Schmidt, Julianne D.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA; [Register-Mihalik, Johna K.; Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Gioia, Gerard A.] Childrens Natl Med Ctr, Div Pediat Neuropsychol, Washington, DC 20010 USA; [Waicus, Kelly M.] Univ N Carolina, Campus Hlth Serv, Chapel Hill, NC 27599 USA	Littleton, AC (corresponding author), 209 Fetzer Hall,CB 8700, Chapel Hill, NC 27599 USA.	alittlet@live.unc.edu	Meijer, Anna/K-5118-2016				Advokat C, 2010, NEUROSCI BIOBEHAV R, V34, P1256, DOI 10.1016/j.neubiorev.2010.03.006; Agay N, 2010, PSYCHOPHARMACOLOGY, V210, P511, DOI 10.1007/s00213-010-1853-4; Alosco ML, 2014, BRAIN INJURY, V28, P472, DOI 10.3109/02699052.2014.887145; Brams M, 2010, CURR MED RES OPIN, V26, P1809, DOI 10.1185/03007995.2010.488553; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Brown Thomas E, 2008, Curr Psychiatry Rep, V10, P407, DOI 10.1007/s11920-008-0065-7; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Chang Z, 2014, J CHILD PSYCHOL PSYC, V55, P878, DOI 10.1111/jcpp.12164; CHELUNE GJ, 1991, NEUROLOGY, V41, P399, DOI 10.1212/WNL.41.3.399; Choi JW, 2015, MED SCI SPORT EXER, V47, P33, DOI 10.1249/MSS.0000000000000373; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Connor DF, 2005, CONTEMPORARY CLIN NE, P487; Cornforth C, 2010, CURR PHARM DESIGN, V16, P2424, DOI 10.2174/138161210791959827; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Fisher BC, 2014, PSYCHOL REP, V114, P404, DOI 10.2466/15.10.PR0.114k23w0; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Gropper RJ, 2009, J ATTEN DISORD, V12, P574, DOI 10.1177/1087054708320390; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hautmann C, 2017, J ATTEN DISORD, V21, P120, DOI 10.1177/1087054713502233; Hervey AS, 2006, CHILD NEUROPSYCHOL, V12, P125, DOI 10.1080/09297040500499081; Hinton-Bayre A, 2000, J INT NEUROPSYCH SOC, V6, P362, DOI 10.1017/S1355617700633118; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Huang YS, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-194; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2014, APPL NEUROPSYCH-ADUL, V21, P36, DOI 10.1080/09084282.2012.721149; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Kinsbourne M, 2001, ANN NY ACAD SCI, V931, P287; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leckie RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00985; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2013, J PEDIATR-US, V163, P1192, DOI 10.1016/j.jpeds.2013.05.061; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; Mikami AY, 2009, J CLIN PSYCHOL MED S, V16, P233, DOI 10.1007/s10880-009-9165-8; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; National Institute for Health and Clinical Excellence (NICE), 2008, ATTENTION DEFICIT HY; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Nielsen NP, 2011, INT J PSYCHIAT CLIN, V15, P219, DOI 10.3109/13651501.2011.582538; Nikolas MA, 2013, NEUROPSYCHOLOGY, V27, P107, DOI 10.1037/a0030685; Pasini A, 2013, EUR J PAEDIATR NEURO, V17, P407, DOI 10.1016/j.ejpn.2013.02.002; Patel AV, 2007, J ATHL TRAINING, V42, P66; Pietrzak RH, 2006, NEUROSCI BIOBEHAV R, V30, P1225, DOI 10.1016/j.neubiorev.2006.10.002; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Pontifex MB, 2013, J PEDIATR-US, V162, P543, DOI 10.1016/j.jpeds.2012.08.036; Register-Mihalik JK, 2012, J ATHL TRAINING, V47, P297, DOI 10.4085/1062-6050-47.3.13; Riordan HJ, 1999, ARCH CLIN NEUROPSYCH, V14, P217, DOI 10.1016/S0887-6177(98)00015-8; Robinson AM, 2014, BEHAV NEUROSCI, V128, P703, DOI 10.1037/bne0000015; Rowe DL, 2005, CLIN NEUROPHYSIOL, V116, P324, DOI 10.1016/j.clinph.2004.08.001; Ruiz JR, 2010, J PEDIATR-US, V157, P917, DOI 10.1016/j.jpeds.2010.06.026; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schwartz K, 2008, PSYCHOL MED, V38, P1607, DOI 10.1017/S003329170700267X; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Tamm L, 2012, NEUROTHERAPEUTICS, V9, P500, DOI 10.1007/s13311-012-0138-5; Valera EM, 2007, BIOL PSYCHIAT, V61, P1361, DOI 10.1016/j.biopsych.2006.06.011; Vaurio RG, 2009, NEUROPSYCHOLOGIA, V47, P2389, DOI 10.1016/j.neuropsychologia.2009.01.022; Voss MW, 2011, NEUROSCIENCE, V199, P166, DOI 10.1016/j.neuroscience.2011.10.009; White RD, 2014, SPORTS HEALTH, V6, P149, DOI 10.1177/1941738113484679; Wolf LE, 2001, ANN NY ACAD SCI, V931, P385; Wu CT, 2011, NEUROPSYCHOLOGY, V25, P333, DOI 10.1037/a0022167; Ziereis S, 2015, RES DEV DISABIL, V38, P181, DOI 10.1016/j.ridd.2014.12.005; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	67	21	21	1	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2015	30	7					683	693		10.1093/arclin/acv043			11	Psychology, Clinical; Psychology	Psychology	CY4GQ	WOS:000366367000009	26310392	Bronze			2021-06-18	
J	Loov, C; Mitchell, CH; Simonsson, M; Erlandsson, A				Loov, Camilla; Mitchell, Claire H.; Simonsson, Martin; Erlandsson, Anna			Slow degradation in phagocytic astrocytes can be enhanced by lysosomal acidification	GLIA			English	Article						phagocytosis; lysosome; digestion; glia; Rab27a; Nox2; pHrodo; nanoparticle	TRAUMATIC BRAIN-INJURY; B7 COSTIMULATORY MOLECULES; T-CELL-ACTIVATION; DENDRITIC CELLS; NADPH OXIDASE; ANTIGEN PRESENTATION; ALZHEIMERS-DISEASE; PHAGOSOME MATURATION; APOPTOTIC CELLS; STEM-CELL	Inefficient lysosomal degradation is central in the development of various brain disorders, but the underlying mechanisms and the involvement of different cell types remains elusive. We have previously shown that astrocytes effectively engulf dead cells, but then store, rather than degrade the ingested material. In the present study we identify reasons for the slow digestion and ways to accelerate degradation in primary astrocytes. Our results show that actin-rings surround the phagosomes for long periods of time, which physically inhibit the phago-lysosome fusion. Furthermore, astrocytes express high levels of Rab27a, a protein known to reduce the acidity of lysosomes by Nox2 recruitment, in order to preserve antigens for presentation. We found that Nox2 colocalizes with the ingested material, indicating that it may influence antigen processing also in astrocytes, as they express MHC class II. By inducing long-time acidification of astrocytic lysosomes using acidic nanoparticles, we could increase the digestion of astrocyte-ingested, dead cells. The degradation was, however, normalized over time, indicating that inhibitory pathways are up-regulated in response to the enhanced acidification.	[Loov, Camilla; Erlandsson, Anna] Uppsala Univ, Uppsala Univ Hosp Ent 85, Dept Neurosci, Uppsala, Sweden; [Mitchell, Claire H.] Univ Penn, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; [Mitchell, Claire H.] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; [Simonsson, Martin] Lulea Univ Technol, SciLifeLab, S-95187 Lulea, Sweden; [Simonsson, Martin] Lulea Univ Technol, Dept Comp Sci Elect & Space Engn, S-95187 Lulea, Sweden; [Erlandsson, Anna] Uppsala Univ, Dept Publ Hlth & Caring Sci, Rudbeck Lab, Uppsala, Sweden	Erlandsson, A (corresponding author), Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden.	anna.erlandsson@pubcare.uu.se			Magnus Bergwall Foundation; Ahlen Foundation; Swedish Medical Society; Tore Nilsson Foundation; Alzheimer Foundation	Grant sponsors: Magnus Bergwall Foundation, Ahlen Foundation, the Swedish Medical Society, the Tore Nilsson Foundation, and the Alzheimer Foundation.	Abramov AY, 2005, J NEUROSCI, V25, P9176, DOI 10.1523/JNEUROSCI.1632-05.2005; Abramov AY, 2005, PHILOS T R SOC B, V360, P2309, DOI 10.1098/rstb.2005.1766; Allan ERO, 2014, J IMMUNOL, V192, P4989, DOI 10.4049/jimmunol.1302896; Aloisi F, 1998, J IMMUNOL, V160, P4671; Appelqvist H, 2013, J MOL CELL BIOL, V5, P214, DOI 10.1093/jmcb/mjt022; Avila-Munoz E, 2014, AGEING RES REV, V18, P29, DOI 10.1016/j.arr.2014.07.004; Aziz Monowar, 2013, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1431s100; Baltazar GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049635; Bryant P, 2004, CURR OPIN IMMUNOL, V16, P96, DOI 10.1016/j.coi.2003.11.011; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chang GHF, 2000, NEURO-ONCOLOGY, V2, P174, DOI 10.1093/neuonc/2.3.174; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; Cornet A, 2000, J NEUROIMMUNOL, V106, P69, DOI 10.1016/S0165-5728(99)00215-5; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Di Malta C, 2012, AUTOPHAGY, V8, P1871, DOI 10.4161/auto.22184; Di Malta C, 2012, P NATL ACAD SCI USA, V109, pE2334, DOI 10.1073/pnas.1209577109; Dolman Nick J, 2013, Curr Protoc Cytom, VChapter 12, DOI 10.1002/0471142956.cy1230s65; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Fellner L, 2013, GLIA, V61, P349, DOI 10.1002/glia.22437; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Guenette SY, 2003, TRENDS MOL MED, V9, P279, DOI 10.1016/S1471-4914(03)00112-6; Hiltbold EM, 2002, CURR OPIN IMMUNOL, V14, P30, DOI 10.1016/S0952-7915(01)00295-3; Hoffmann E, 2012, P NATL ACAD SCI USA, V109, P14556, DOI 10.1073/pnas.1203912109; Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511; Jancic C, 2007, NAT CELL BIOL, V9, P367, DOI 10.1038/ncb1552; Jensen MD, 2009, NEUROCHEM INT, V55, P362, DOI 10.1016/j.neuint.2009.04.002; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jones RS, 2013, J NEUROIMMUNE PHARM, V8, P301, DOI 10.1007/s11481-012-9427-3; Kim SH, 2008, INFECT IMMUN, V76, P5373, DOI 10.1128/IAI.01044-08; Kinchen JM, 2008, NAT REV MOL CELL BIO, V9, P781, DOI 10.1038/nrm2515; Krysko DV, 2006, APOPTOSIS, V11, P1709, DOI 10.1007/s10495-006-9527-8; Liebl D, 2009, J CELL SCI, V122, P2935, DOI 10.1242/jcs.048355; Loov C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033090; Ma D, 2013, J NEUROIMMUNOL, V254, P10, DOI 10.1016/j.jneuroim.2012.08.010; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magnus T, 2002, J NEUROPATH EXP NEUR, V61, P760, DOI 10.1093/jnen/61.9.760; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Miksa M, 2009, J IMMUNOL METHODS, V342, P71, DOI 10.1016/j.jim.2008.11.019; Nagele RG, 2003, BRAIN RES, V971, P197, DOI 10.1016/S0006-8993(03)02361-8; Nicoll JAR, 2003, TRENDS MOL MED, V9, P281, DOI 10.1016/S1471-4914(03)00109-6; Nielsen HM, 2010, GLIA, V58, P1235, DOI 10.1002/glia.21004; Nielsen HM, 2009, GLIA, V57, P978, DOI 10.1002/glia.20822; Nikcevich KM, 1997, J IMMUNOL, V158, P614; Nixon RA, 2008, AUTOPHAGY, V4, P590, DOI 10.4161/auto.6259; Platt FM, 2012, J CELL BIOL, V199, P723, DOI 10.1083/jcb.201208152; Poon IKH, 2010, CELL DEATH DIFFER, V17, P381, DOI 10.1038/cdd.2009.195; Ravin R, 2008, CELL STEM CELL, V3, P670, DOI 10.1016/j.stem.2008.09.012; Romao S, 2013, J CELL BIOL, V203, P757, DOI 10.1083/jcb.201308173; Savina A, 2007, IMMUNOL REV, V219, P143, DOI 10.1111/j.1600-065X.2007.00552.x; Savina A, 2006, CELL, V126, P205, DOI 10.1016/j.cell.2006.05.035; Savina A, 2009, IMMUNITY, V30, P544, DOI 10.1016/j.immuni.2009.01.013; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Shafer LE, 2001, CHARGING AHEAD INTRO, P81; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sokolowski JD, 2011, BRAIN BEHAV IMMUN, V25, P915, DOI 10.1016/j.bbi.2010.09.021; Soos JM, 1999, INT IMMUNOL, V11, P1169, DOI 10.1093/intimm/11.7.1169; SZABO AG, 1986, PHOTOCHEM PHOTOBIOL, V44, P143, DOI 10.1111/j.1751-1097.1986.tb03578.x; Vardjan N, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-144; Yokoyama K, 2011, J BIOL CHEM, V286, P5375, DOI 10.1074/jbc.M110.171702; Zeinstra E, 2003, J NEUROIMMUNOL, V135, P166, DOI 10.1016/S0165-5728(02)00462-9; Zhou Z, 2008, TRENDS CELL BIOL, V18, P474, DOI 10.1016/j.tcb.2008.08.002; Zhu DH, 2009, BIOCHEM J, V421, P201, DOI 10.1042/BJ20090356	68	21	21	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	NOV	2015	63	11					1997	2009		10.1002/glia.22873			13	Neurosciences	Neurosciences & Neurology	CR2UB	WOS:000361185000008	26095880	Green Accepted			2021-06-18	
J	Bartels, RHMA; Meijer, FJA; van der Hoeven, H; Edwards, M; Prokop, M				Bartels, Ronald H. M. A.; Meijer, Frederick J. A.; van der Hoeven, Hans; Edwards, Michael; Prokop, Mathias			Midline shift in relation to thickness of traumatic acute subdural hematoma predicts mortality	BMC NEUROLOGY			English	Article						Acute subdural hematoma; Survival; Prediction; CT	BRAIN-INJURY; PROGNOSTIC MODELS; VALIDATION; ADMISSION; CRITERIA; MODERATE; IMPACT	Background: Traumatic acute subdural hematoma has a high mortality despite intensive treatment. Despite the existence of several prediction models, it is very hard to predict an outcome. We investigated whether a specific combination of initial head CT-scan findings is a factor in predicting outcome, especially non-survival. Methods: We retrospectively studied admission head CT scans of all adult patients referred for a traumatic acute subdural hematoma between April 2009 and April 2013. Chart review was performed for every included patient. Midline shift and thickness of the hematoma were measured by two independent observers. The difference between midline shift and thickness of the hematoma was calculated. These differences were correlated with outcome. IRB has approved the study. Results: A total of 59 patients were included, of whom 29 died. We found a strong correlation between a midline shift exceeding the thickness of the hematoma by 3 mm or more, and subsequent mortality. For each evaluation, specificity was 1.0 ( 95 % CI: 0.85-1 for all evaluations), positive predictive value 1.0 ( 95 % CI between 0.31-1 and 0.56-1), while sensitivity ranged from 0.1 to 0.23 ( 95 % CI between 0.08-0.39 and 0.17-0.43), and negative predictive value varied from 0.52 to 0.56 ( 95 % CI between 0.38-0.65 and 0.41-0.69). Conclusions: In case of a traumatic acute subdural hematoma, a difference between the midline shift and the thickness of the hematoma >= 3 mm at the initial CT predicted mortality in all cases. This is the first time that such a strong correlation was reported. Especially for the future development of prediction models, the relation between midline shift and thickness of the hematoma could be included as a separate factor.	[Bartels, Ronald H. M. A.] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6525 ED Nijmegen, Netherlands; [Meijer, Frederick J. A.; Prokop, Mathias] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6525 ED Nijmegen, Netherlands; [van der Hoeven, Hans] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, NL-6525 ED Nijmegen, Netherlands; [Edwards, Michael] Radboud Univ Nijmegen, Med Ctr, Dept Trauma & Emergency Surg, NL-6525 ED Nijmegen, Netherlands	Bartels, RHMA (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6525 ED Nijmegen, Netherlands.	ronald.bartels@radboudumc.nl	Bartels, Ronald HMA/L-4184-2015; Edwards, M.J.R./H-8026-2014; Prokop, W.M./H-8081-2014; Meijer, Frederick/L-4516-2015	Bartels, Ronald HMA/0000-0002-8638-4660; Meijer, Frederick/0000-0001-5921-639X; Prokop, Mathias/0000-0001-8157-8055			Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; D'Amato L, 2007, J Neurosurg Sci, V51, P107; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011; Zumkeller M, 1996, NEUROSURGERY, V39(, P712	11	21	23	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	OCT 24	2015	15								220	10.1186/s12883-015-0479-x			6	Clinical Neurology	Neurosciences & Neurology	CU1WA	WOS:000363311500002	26496765	DOAJ Gold, Green Published			2021-06-18	
J	Boyd, BJ; Galle, A; Daglas, M; Rosenfeld, JV; Medcalf, R				Boyd, Ben J.; Galle, Adam; Daglas, Maria; Rosenfeld, Jeffrey V.; Medcalf, Robert			Traumatic brain injury opens blood-brain barrier to stealth liposomes via an enhanced permeability and retention (EPR)-like effect	JOURNAL OF DRUG TARGETING			English	Article						Albumin; blood-brain barrier; extravasation; stealth liposomes; traumatic brain injury	SERUM-ALBUMIN; MOLECULAR-WEIGHT; MICE; PHARMACOKINETICS; DENDRIMER; FASUDIL; EDEMA; MODEL	The opening of the tight junctions in the blood-brain barrier (BBB) following traumatic brain injury (TBI) is hypothesized to be sufficient to enable accumulation of large drug carriers, such as stealth liposomes, in a similar manner to the extravasation seen in tumor tissue via the enhanced permeability and retention (EPR) effect. The controlled cortical impact model of TBI was used to evaluate liposome accumulation in mice. Dual-radiolabeled PEGylated liposomes were administered either immediately after induction of TBI or at increasing times post-TBI to mimic the likely clinical scenario. The accumulation of radiolabel in the brain tissue ipsilateral and contralateral to the site of trauma, as well as in other organs, was evaluated. Selective influx of liposomes occurred at 0-8h after injury, while the barrier closed between 8 and 24hr after injury, consistent with reports on albumin infiltration. Significantly enhanced accumulation of liposomes occurred in mice subjected to TBI compared to anaesthetized controls, and accumulation was greater in the injured versus the contralateral side of the brain. Thus, stealth liposomes show potential to enhance drug delivery to the site of brain injury with a wide range of encapsulated therapeutic candidates.	[Boyd, Ben J.] Monash Univ, Monash Inst Pharmaceut Sci, Drug Delivery Disposit & Dynam, Parkville Campus,381 Royal Parade, Parkville, Vic 3052, Australia; [Boyd, Ben J.] Monash Univ, Monash Inst Pharmaceut Sci, ARC Ctr Excellence Convergent Bionano Sci & Techn, Parkville, Vic 3052, Australia; [Galle, Adam; Daglas, Maria; Medcalf, Robert] Monash Univ, Alfred Hosp, Australian Ctr Blood Dis, Melbourne, Vic, Australia; [Galle, Adam; Daglas, Maria; Medcalf, Robert] Monash Univ, Cent Clin Sch, Mol Neurotrauma & Haemostasis, Parkville, Vic 3052, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Alfred Hosp, Dept Surg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD 20814 USA; [Rosenfeld, Jeffrey V.] Monash Univ, Monash Inst Med Engn, Melbourne, Vic, Australia	Boyd, BJ (corresponding author), Monash Univ, Monash Inst Pharmaceut Sci, Drug Delivery Disposit & Dynam, Parkville Campus,381 Royal Parade, Parkville, Vic 3052, Australia.	ben.boyd@monash.edu; robert.medcalf@monash.edu	Medcalf, Robert L/E-9632-2011	Boyd, Ben/0000-0001-5434-590X	Faculty of Medicine, Nursing and Health Sciences, Monash UniversityMonash University [SPG-L 016]; John and Joan Power Charitable Trust; Australian Research CouncilAustralian Research Council	The authors report no declarations of interest. The authors acknowledge the Faculty of Medicine, Nursing and Health Sciences, Monash University for funding Strategic Grant (SPG-L 016) and the John and Joan Power Charitable Trust awarded to JVR. B.J.B. acknowledges the Australian Research Council for a Future Fellowship.	ALLEN TM, 1993, BIOCHIM BIOPHYS ACTA, V1150, P9, DOI 10.1016/0005-2736(93)90115-G; BOYD BJ, 2006, MOL PHARMACEUT, V3, P614, DOI DOI 10.1021/MP060032E; Caraglia M, 2012, CURR DRUG METAB, V13, P4, DOI 10.2174/138920012798356871; Gillies ER, 2005, MOL PHARMACEUT, V2, P129, DOI 10.1021/mp049886u; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Ishida T, 2002, INT J PHARMACEUT, V232, P59, DOI 10.1016/S0378-5173(01)00896-1; Kaminskas LM, 2008, MOL PHARMACEUT, V5, P449, DOI 10.1021/mp7001208; Kaminskas LM, 2012, NANOMED-NANOTECHNOL, V8, P103, DOI 10.1016/j.nano.2011.05.013; Kaminskas LM, 2011, J PHARM SCI-US, V100, P5069, DOI 10.1002/jps.22682; Kaminskas LM, 2009, MOL PHARMACEUT, V6, P1190, DOI 10.1021/mp900049a; Kiselev MA, 2001, BIOFIZIKA+, V46, P423; KITAGAWA K, 1991, ACTA NEUROPATHOL, V82, P164, DOI 10.1007/BF00294441; Lee CC, 2006, P NATL ACAD SCI USA, V103, P16649, DOI 10.1073/pnas.0607705103; Liddelow SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106592; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Rashid H, 1998, BIOCHEM MOL BIOL INT, V44, P165; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Takanashi Y, 2001, NEUROL MED-CHIR, V41, P107, DOI 10.2176/nmc.41.107; Thorne RG, 2006, P NATL ACAD SCI USA, V103, P5567, DOI 10.1073/pnas.0509425103; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiao Guangqing, 2013, Int J Cell Biol, V2013, P703545, DOI 10.1155/2013/703545	26	21	21	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1061-186X	1029-2330		J DRUG TARGET	J. Drug Target.	OCT 21	2015	23	9					847	853		10.3109/1061186X.2015.1034280			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DD2RK	WOS:000369769700008	26079716				2021-06-18	
J	Bonsall, DR; Kim, H; Tocci, C; Ndiaye, A; Petronzio, A; McKay-Corkum, G; Molyneux, PC; Scammell, TE; Harrington, ME				Bonsall, David R.; Kim, Hyunji; Tocci, Catherine; Ndiaye, Awa; Petronzio, Abbey; McKay-Corkum, Grace; Molyneux, Penny C.; Scammell, Thomas E.; Harrington, Mary E.			Suppression of Locomotor Activity in Female C57Bl/6J Mice Treated with Interleukin-1 beta: Investigating a Method for the Study of Fatigue in Laboratory Animals	PLOS ONE			English	Article							MESSENGER-RNA; DOUBLE-BLIND; BEHAVIORAL DEPRESSION; INFLAMMATORY MARKERS; BRAIN IL-1-BETA; CANCER PATIENTS; BASAL GANGLIA; MOUSE MODEL; SLEEP; METHYLPHENIDATE	Fatigue is a disabling symptom in patients with multiple sclerosis and Parkinson's Disease, and is also common in patients with traumatic brain injury, cancer, and inflammatory disorders. Little is known about the neurobiology of fatigue, in part due to the lack of an approach to induce fatigue in laboratory animals. Fatigue is a common response to systemic challenge by pathogens, a response in part mediated through action of the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). We investigated the behavioral responses of mice to IL-1 beta. Female C57Bl/6J mice of 3 ages were administered IL-1 beta at various doses i.p. Interleukin-1 beta reduced locomotor activity, and sensitivity increased with age. Further experiments were conducted with middle-aged females. Centrally administered IL-1 beta dose-dependently reduced locomotor activity. Using doses of IL-1 beta that caused suppression of locomotor activity, we measured minimal signs of sickness, such as hyperthermia, pain or anhedonia (as measured with abdominal temperature probes, pre-treatment with the analgesic buprenorphine and through sucrose preference, respectively), all of which are responses commonly reported with higher doses. We found that middle-aged orexin(-/-) mice showed equivalent effects of IL-1 beta on locomotor activity as seen in wild-type controls, suggesting that orexins are not necessary for IL-1 beta-induced reductions in wheel-running. Given that the availability and success of therapeutic treatments for fatigue is currently limited, we examined the effectiveness of two potential clinical treatments, modafinil and methylphenidate. We found that these treatments were variably successful in restoring locomotor activity after IL-1 beta administration. This provides one step toward development of a satisfactory animal model of the multidimensional experience of fatigue, a model that could allow us to determine possible pathways through which inflammation induces fatigue, and could lead to novel treatments for reversal of fatigue.	[Bonsall, David R.; Kim, Hyunji; Tocci, Catherine; Ndiaye, Awa; Petronzio, Abbey; McKay-Corkum, Grace; Molyneux, Penny C.; Harrington, Mary E.] Smith Coll, Neurosci Program, Northampton, MA 01063 USA; [Scammell, Thomas E.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA	Harrington, ME (corresponding author), Smith Coll, Neurosci Program, Northampton, MA 01063 USA.	mharring@smith.edu		Bonsall, David/0000-0002-2542-7559	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21NR012845-01A1]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R21NR012845] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grant to MEH R21NR012845-01A1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anforth HR, 1998, EUR CYTOKINE NETW, V9, P279; Anisman H, 2008, PSYCHOPHARMACOLOGY, V199, P231, DOI 10.1007/s00213-008-1166-z; Antle MC, 2012, NEUROPSYCHOPHARMACOL, V37, P2446, DOI 10.1038/npp.2012.103; Baker FC, 2005, AM J PHYSIOL-REG I, V288, pR998, DOI 10.1152/ajpregu.00615.2004; BARRETT J, 1993, SLEEP, V16, P93; Bluthe RM, 1997, PSYCHONEUROENDOCRINO, V22, P1, DOI 10.1016/S0306-4530(96)00042-X; Bower JE, 2015, ADV EXP MED BIOL, V862, P53, DOI 10.1007/978-3-319-16366-6_5; Bower JE, 2011, BRAIN BEHAV IMMUN, V25, P147, DOI 10.1016/j.bbi.2010.09.010; Bower JE, 2009, CLIN CANCER RES, V15, P5534, DOI 10.1158/1078-0432.CCR-08-2584; Cambras T, 2007, P NATL ACAD SCI USA, V104, P7634, DOI 10.1073/pnas.0702424104; Capuron L, 2012, ARCH GEN PSYCHIAT, V69, P1044, DOI 10.1001/archgenpsychiatry.2011.2094; Carmichael MD, 2006, AM J PHYSIOL-REG I, V291, pR1344, DOI 10.1152/ajpregu.00141.2006; CHAO CC, 1992, CLIN IMMUNOL IMMUNOP, V64, P161, DOI 10.1016/0090-1229(92)90194-S; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Ching S, 2007, J NEUROSCI, V27, P10476, DOI 10.1523/JNEUROSCI.3357-07.2007; Chou TC, 2001, J NEUROSCI, V21; Clevenger L, 2012, BRAIN BEHAV IMMUN, V26, P1037, DOI 10.1016/j.bbi.2012.04.003; Dobryakova E, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00052; Donohue KD, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-14; DUNN AJ, 1991, BRAIN RES BULL, V26, P539, DOI 10.1016/0361-9230(91)90092-X; Eldadah BA, 2010, PM&R, V2, P406, DOI 10.1016/j.pmrj.2010.03.022; Espana RA, 2007, SLEEP, V30, P1417, DOI 10.1093/sleep/30.11.1417; Felger JC, 2013, BRAIN BEHAV IMMUN, V31, P153, DOI 10.1016/j.bbi.2012.10.010; Felger JC, 2012, FRONT NEUROENDOCRIN, V33, P315, DOI 10.1016/j.yfrne.2012.09.003; Finsterer J, 2014, AM J HOSP PALLIAT ME, V31, P562, DOI 10.1177/1049909113494748; Fletcher MA, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-96; Franceschi C, 2003, BIOCHEM SOC T, V31, P457, DOI 10.1042/BST0310457; Gaykema RPA, 2008, NEUROSCIENCE, V152, P273, DOI 10.1016/j.neuroscience.2007.10.042; Gaykema RPA, 2009, BRAIN BEHAV IMMUN, V23, P926, DOI 10.1016/j.bbi.2009.03.005; Gong S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084391; Grossberg AJ, 2011, J NEUROSCI, V31, P11376, DOI 10.1523/JNEUROSCI.2311-11.2011; Harden LM, 2011, PSYCHONEUROENDOCRINO, V36, P608, DOI 10.1016/j.psyneuen.2010.09.003; Harrington ME, 2012, PROG NEUROBIOL, V99, P93, DOI 10.1016/j.pneurobio.2012.07.004; Ifuku M, 2014, EUR J NEUROSCI, V40, P3253, DOI 10.1111/ejn.12668; Ishizuka T, 2008, EUR J PHARMACOL, V578, P209, DOI 10.1016/j.ejphar.2007.09.009; Jean-Pierre P, 2010, CANCER-AM CANCER SOC, V116, P3513, DOI 10.1002/cncr.25083; Katafuchi T, 2003, NEUROSCIENCE, V120, P837, DOI 10.1016/S0306-4522(03)00365-8; Katafuchi T, 2006, ANN NY ACAD SCI, V1088, P230, DOI 10.1196/annals.1366.020; KENT S, 1992, P NATL ACAD SCI USA, V89, P9117, DOI 10.1073/pnas.89.19.9117; Kerr CW, 2012, J PAIN SYMPTOM MANAG, V43, P68, DOI 10.1016/j.jpainsymman.2011.03.026; Konsman JP, 2008, EUR J NEUROSCI, V28, P2499, DOI 10.1111/j.1460-9568.2008.06549.x; Konsman JP, 2000, EUR J NEUROSCI, V12, P4434, DOI 10.1046/j.0953-816X.2000.01319.x; Lattie EG, 2012, BRAIN BEHAV IMMUN, V26, P849, DOI 10.1016/j.bbi.2012.02.008; LAYE S, 1995, AM J PHYSIOL-REG I, V268, pR1327; Lindqvist D, 2013, BRAIN BEHAV IMMUN, V33, P183, DOI 10.1016/j.bbi.2013.07.007; Liu LQ, 2012, BRAIN BEHAV IMMUN, V26, P706, DOI 10.1016/j.bbi.2012.02.001; MASOTTO C, 1992, BRAIN RES BULL, V28, P161, DOI 10.1016/0361-9230(92)90175-W; Matsuwaki T, 2014, BRAIN BEHAV IMMUN, V40, P166, DOI 10.1016/j.bbi.2014.03.015; McCusker RH, 2013, J EXP BIOL, V216, P84, DOI 10.1242/jeb.073411; Mendonca DA, 2007, MOVEMENT DISORD, V22, P2070, DOI 10.1002/mds.21656; Minton O, 2011, J PAIN SYMPTOM MANAG, V41, P761, DOI 10.1016/j.jpainsymman.2010.06.020; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Nunes EJ, 2014, PSYCHOPHARMACOLOGY, V231, P727, DOI 10.1007/s00213-013-3285-4; Opp MR, 1998, LIFE SCI, V62, P923, DOI 10.1016/S0024-3205(98)00010-1; Ottenweller JE, 1998, PHYSIOL BEHAV, V63, P795, DOI 10.1016/S0031-9384(97)00539-8; Prommer E, 2012, AM J HOSP PALLIAT ME, V29, P483, DOI 10.1177/1049909111427029; Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020; Ricci JA, 2007, J OCCUP ENVIRON MED, V49, P1, DOI 10.1097/01.jom.0000249782.60321.2a; Ridder DA, 2011, J EXP MED, V208, P2615, DOI 10.1084/jem.20110398; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; SALAMONE JD, 1994, BEHAV BRAIN RES, V65, P221, DOI 10.1016/0166-4328(94)90108-2; Schoene C, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00081; Schrepf A, 2013, BRAIN BEHAV IMMUN, V30, pS126, DOI 10.1016/j.bbi.2012.07.022; Schwartz N, 2014, SCIENCE, V345, P535, DOI 10.1126/science.1253994; Sheng P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081802; Skelly DT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069123; Smith LB, 2014, BRAIN BEHAV IMMUN, V38, P66, DOI 10.1016/j.bbi.2013.12.022; Sorge RE, 2015, NAT NEUROSCI, V18, P1081, DOI 10.1038/nn.4053; SPADARO F, 1990, BRAIN BEHAV IMMUN, V4, P308, DOI 10.1016/0889-1591(90)90034-N; Spath-Schwalbe E, 1998, J CLIN ENDOCR METAB, V83, P1573, DOI 10.1210/jc.83.5.1573; Spathis A, 2014, J CLIN ONCOL, V32, P1882, DOI 10.1200/JCO.2013.54.4346; Stringer EA, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-93; Trotti LM, 2014, NEUROTHERAPEUTICS, V11, P68, DOI 10.1007/s13311-013-0236-z; Volkow N D, 2001, J Neurosci, V21, pRC121; Wang XS, 2008, CANCER, V113, P2102, DOI 10.1002/cncr.23820; Wang XS, 2015, GYNECOL ONCOL, V136, P446, DOI 10.1016/j.ygyno.2014.10.013; Weymann KB, 2014, BRAIN BEHAV IMMUN, V37, P84, DOI 10.1016/j.bbi.2013.11.003; Wood LJ, 2006, BIOL RES NURS, V8, P157, DOI 10.1177/1099800406290932; Worden LT, 2009, PSYCHOPHARMACOLOGY, V203, P489, DOI 10.1007/s00213-008-1396-0; Yamato M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090950; Zolkowska D, 2009, J PHARMACOL EXP THER, V329, P738, DOI 10.1124/jpet.108.146142; Zombeck JA, 2013, COMPARATIVE MED, V63, P491	82	21	21	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2015	10	10							e0140678	10.1371/journal.pone.0140678			18	Multidisciplinary Sciences	Science & Technology - Other Topics	CU0CX	WOS:000363184600095	26469939	DOAJ Gold, Green Published			2021-06-18	
J	Park, JM; Josan, S; Mayer, D; Hurd, RE; Chung, YR; Bendahan, D; Spielman, DM; Jue, T				Park, Jae Mo; Josan, Sonal; Mayer, Dirk; Hurd, Ralph E.; Chung, Youngran; Bendahan, David; Spielman, Daniel M.; Jue, Thomas			Hyperpolarized C-13 NMR observation of lactate kinetics in skeletal muscle	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						Muscle metabolism; Lactate bioenergetics; Hyperpolarized C-13; Pyruvate	PYRUVATE-DEHYDROGENASE ACTIVITY; TRAUMATIC BRAIN-INJURY; IN-VIVO; METABOLIC-RESPONSE; GLYCOGEN-SYNTHESIS; INTENSE EXERCISE; ACID CYCLE; TRANSPORT; ONSET; MITOCHONDRIAL	The production of glycolytic end products, such as lactate, usually evokes a cellular shift from aerobic to anaerobic ATP generation and O-2 insufficiency. In the classical view, muscle lactate must be exported to the liver for clearance. However, lactate also forms under well-oxygenated conditions, and this has led investigators to postulate lactate shuttling from non-oxidative to oxidative muscle fiber, where it can serve as a precursor. Indeed, the intracellular lactate shuttle and the glycogen shunt hypotheses expand the vision to include a dynamic mobilization and utilization of lactate during a muscle contraction cycle. Testing the tenability of these provocative ideas during a rapid contraction cycle has posed a technical challenge. The present study reports the use of hyperpolarized [1-C-13] lactate and [2-C-13] pyruvate in dynamic nuclear polarization (DNP) NMR experiments to measure the rapid pyruvate and lactate kinetics in rat muscle. With a 3 s temporal resolution, C-13 DNP NMR detects both [1-C-13] lactate and [2-C-13] pyruvate kinetics in muscle. Infusion of dichloroacetate stimulates pyruvate dehydrogenase activity and shifts the kinetics toward oxidative metabolism. Bicarbonate formation from [1-C-13] lactate increases sharply and acetyl-L-carnitine, acetoacetate and glutamate levels also rise. Such a quick mobilization of pyruvate and lactate toward oxidative metabolism supports the postulated role of lactate in the glycogen shunt and the intracellular lactate shuttle models. The study thus introduces an innovative DNP approach to measure metabolite transients, which will help delineate the cellular and physiological role of lactate and glycolytic end products.	[Park, Jae Mo; Josan, Sonal; Spielman, Daniel M.] Stanford Univ, Radiol, Stanford, CA 94305 USA; [Josan, Sonal; Mayer, Dirk] SRI Int, Program Neurosci, Menlo Pk, CA 94025 USA; [Mayer, Dirk] Univ Maryland, Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Hurd, Ralph E.] GE Healthcare, Appl Sci Lab, Hyderabad, Andhra Pradesh, India; [Chung, Youngran; Jue, Thomas] Univ Calif Davis, Biochem & Mol Med, Davis, CA 95616 USA; [Bendahan, David] Aix Marseille Univ, Ctr Resonance Magnet Biol & Med, F-13385 Marseille, France	Jue, T (corresponding author), Univ Calif Davis, Biochem & Mol Med, Davis, CA 95616 USA.	TJue@ucdavis.edu	Mayer, Dirk/AAJ-5906-2020; Park, Jae Mo/H-6470-2019; Bendahan, David/AAU-1420-2020	Mayer, Dirk/0000-0001-7557-9019; Park, Jae Mo/0000-0002-7404-6971; 	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41 EB015891, AA05965, AA018681, AA13521-INIA, CA176836, OD012283, EB009070]; Department of DefenseUnited States Department of Defense [PC100427]; Lucas Foundation; France Berkeley Fund; GE HealthcareGE Healthcare; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA176836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015891, R01EB009070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA005965, R37AA005965, R01AA018681, U01AA013521] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD012283] Funding Source: NIH RePORTER	The project received funding support from the National Institutes of Health [P41 EB015891, AA05965, AA018681, AA13521-INIA, CA176836, OD012283 and EB009070], The Department of Defense [PC100427], The Lucas Foundation, France Berkeley Fund and GE Healthcare. Deposited in PMC for release after 12 months.	Ardenkjaer-Larsen JH, 2003, P NATL ACAD SCI USA, V100, P10158, DOI 10.1073/pnas.1733835100; Atherton HJ, 2011, NMR BIOMED, V24, P201, DOI 10.1002/nbm.1573; Bangsbo J, 2002, AM J PHYSIOL-REG I, V282, pR273; Bangsbo J, 2006, PFLUG ARCH EUR J PHY, V452, P737, DOI 10.1007/s00424-006-0075-4; Bastiaansen JAM, 2014, METABOLOMICS, V10, P986, DOI 10.1007/s11306-014-0630-5; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684; Bertocci LA, 1999, J APPL PHYSIOL, V86, P2077; Bertocci LA, 1997, J APPL PHYSIOL, V83, P32; BOCK HG, 1975, J BIOL CHEM, V250, P5774; BONEN A, 1990, AM J PHYSIOL, V258, pC693; Boron W.F., 2003, MED PHYSL CELLULAR M; Brooks G., 2000, EXERCISE PHYSL HUMAN, V3rd ed.; Brooks GA, 1998, AM J PHYSIOL-REG I, V275, pR1192; BROOKS GA, 1986, MED SCI SPORT EXER, V18, P360, DOI 10.1249/00005768-198606000-00019; BROOKS GA, 1986, FASEB J, V45, P2924; Brooks GA, 2000, MED SCI SPORT EXER, V32, P790, DOI 10.1097/00005768-200004000-00011; Brooks GEA, 2007, J PHYSIOL-LONDON, V584, P705, DOI 10.1113/jphysiol.2007.142992; Brooks GA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00408; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; Chung YR, 2005, AM J PHYSIOL-CELL PH, V288, pC730, DOI 10.1152/ajpcell.00138.2004; Chung YR, 1998, AM J PHYSIOL-CELL PH, V274, pC846; Day SE, 2007, NAT MED, V13, P1382, DOI 10.1038/nm1650; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Glenn TC, 2015, J NEUROTRAUM, V32, P811, DOI 10.1089/neu.2014.3482; GOODMAN MN, 1978, DIABETES, V27, P1065, DOI 10.2337/diab.27.11.1065; Grassi B, 1998, J APPL PHYSIOL, V85, P1394; Grieshaber M K, 1994, Rev Physiol Biochem Pharmacol, V125, P43, DOI 10.1007/BFb0030909; Howlett RA, 2003, AM J PHYSIOL-REG I, V284, pR481, DOI 10.1152/ajpregu.00078.2002; Howlett RA, 1999, AM J PHYSIOL-ENDOC M, V277, pE18; JOHNSON JL, 1988, J APPL PHYSIOL, V64, P1591; Juel C, 1999, J PHYSIOL-LONDON, V517, P633, DOI 10.1111/j.1469-7793.1999.0633s.x; JUEL C, 1991, BIOCHIM BIOPHYS ACTA, V1065, P15, DOI 10.1016/0005-2736(91)90004-R; KARK RAP, 1970, NEUROLOGY, V20, P404; Kettunen MI, 2010, MAGN RESON MED, V63, P872, DOI 10.1002/mrm.22276; KREUTZER U, 1995, AM J PHYSIOL-HEART C, V268, pH1675; Kreutzer U, 1997, EUR J BIOCHEM, V243, P233, DOI 10.1111/j.1432-1033.1997.0233a.x; LANOUE KF, 1973, J BIOL CHEM, V248, P7171; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; Li YJ, 2009, AM J PHYSIOL-CELL PH, V296, pC25, DOI 10.1152/ajpcell.00094.2008; Mayer D, 2009, MAGN RESON MED, V62, P557, DOI 10.1002/mrm.22041; MCDERMOTT JC, 1993, MOL CELL BIOCHEM, V122, P113, DOI 10.1007/BF01076095; MCDERMOTT JC, 1992, CAN J PHYSIOL PHARM, V70, P142, DOI 10.1139/y92-021; MCLANE JA, 1979, J BIOL CHEM, V254, P6548; Park JM, 2013, NMR BIOMED, V26, P1197, DOI 10.1002/nbm.2935; Park JM, 2013, NEURO-ONCOLOGY, V15, P433, DOI 10.1093/neuonc/nos319; Passarella S, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00407; PILEGAARD H, 1993, AM J PHYSIOL, V264, pE156; POOLE RC, 1993, AM J PHYSIOL, V264, pC761; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P386, DOI 10.1016/0003-9861(90)90506-T; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P377, DOI 10.1016/0003-9861(90)90505-S; Sahlin K, 2002, J PHYSIOL-LONDON, V541, P569, DOI 10.1113/jphysiol.2002.016683; SCHNEIDER SH, 1981, METABOLISM, V30, P590, DOI 10.1016/0026-0495(81)90137-2; Schroeder MA, 2013, P NATL ACAD SCI USA, V110, pE958, DOI 10.1073/pnas.1213471110; Schroeder MA, 2013, EUR J HEART FAIL, V15, P130, DOI 10.1093/eurjhf/hfs192; Shulman RG, 2005, EXERC SPORT SCI REV, V33, P157, DOI 10.1097/00003677-200510000-00002; Shulman RG, 2001, P NATL ACAD SCI USA, V98, P457, DOI 10.1073/pnas.98.2.457; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; STANLEY WC, 1986, J APPL PHYSIOL, V60, P1116; STANLEY WC, 1985, AM J PHYSIOL, V249, pE595; STANLEY WC, 1987, AM J PHYSIOL, V253, pE472; Tschakovsky ME, 1999, J APPL PHYSIOL, V86, P1101; WASSERMAN K, 1987, CIRCULATION, V76, P29; Whipp B. J., 1994, MED SCI SPORTS EXERC, V26, P1297; White AT, 2012, AM J PHYSIOL-ENDOC M, V303, pE308, DOI 10.1152/ajpendo.00054.2012; Yoshida Y, 2007, J PHYSIOL-LONDON, V582, P1317, DOI 10.1113/jphysiol.2007.135095	68	21	21	0	6	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0022-0949	1477-9145		J EXP BIOL	J. Exp. Biol.	OCT	2015	218	20					3308	3318		10.1242/jeb.123141			11	Biology	Life Sciences & Biomedicine - Other Topics	CU3UO	WOS:000363451300021	26347554	Green Published, Bronze			2021-06-18	
J	Ditty, BJ; Omar, NB; Foreman, PM; Patel, DM; Pritchard, PR; Okor, MO				Ditty, Benjamin J.; Omar, Nidal B.; Foreman, Paul M.; Patel, Daxa M.; Pritchard, Patrick R.; Okor, Mamerhi O.			The nonsurgical nature of patients with subarachnoid or intraparenchymal hemorrhage associated with mild traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						mild traumatic brain injury; subarachnoid hemorrhage; intraparenchymal hemorrhage; contusion; vascular disorders	NEUROSURGICAL CONSULTATION; INTRACRANIAL INJURY; HEAD-INJURY; MANAGEMENT; DETERIORATION	OBJECT Mild traumatic brain injury (mTBI), as defined by Glasgow Coma Scale (GCS) score of 13 or higher, is a common problem in the United States and worldwide, estimated to affect more than 1 million patients yearly. When associated with intracranial hemorrhage, it is a common reason for neurosurgical consultation and transfer to tertiary care centers. The authors set out to investigate the clinical implications of subarachnoid hemorrhage (SAH) and/or intraparenchymal hemorrhage (IPH) associated with mTBI in hopes of standardization of mTBI clinical care and optimization of resource allocation. METHODS The authors performed a retrospective review of 500 consecutively treated patients with mTBI and SAH and/or IPH admitted to a Level I trauma center in Alabama between May 2003 and May 2013. They performed a review of medical records to confirm the diagnosis, determine neurological condition at admission, and assess for episodes of neurological decline or brain injury related complications including altered mental status, seizures, and hyponatremia. RESULTS Of the 500 patients for whom data were reviewed, 304(60.8%) were male and 196 (39.2%) were female. Average age was 46.3 years. Overall, 63 patients (12.6%) had isolated IPH, 411 (82.2%) had isolated SAH, and 26 (5.2%) had radiographic evidence of both IPH and SAH. One hundred forty-five patients (29%) were transferred an average distance of 64.5 miles. The authors identified no patients who experienced neurological worsening during their hospital course. Two patients experienced hyponatremia that required treatment with sodium supplementation. CONCLUSIONS Patients with the constellation of SAH and/or IPH and mTBI do not require neurosurgical consultation, and these findings should not be used as the sole criteria to justify transfer to tertiary referral centers.	[Ditty, Benjamin J.; Foreman, Paul M.; Patel, Daxa M.; Pritchard, Patrick R.; Okor, Mamerhi O.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA; [Omar, Nidal B.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA	Okor, MO (corresponding author), Dept Neurosurg, 510 20th St S,FOT 1034, Birmingham, AL 35294 USA.	mookor@uabmc.edu					AbdelFattah KR, 2012, J TRAUMA ACUTE CARE, V73, P685, DOI 10.1097/TA.0b013e318265ccd9; Almenawer SA, 2013, NEUROSURGERY, V72, P56, DOI 10.1227/NEU.0b013e318276f899; Borczuk P, 2013, J TRAUMA ACUTE CARE, V74, P1504, DOI 10.1097/TA.0b013e31829215cf; Carlson AP, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10182; Fabbri A, 2013, CRIT CARE, V17, DOI 10.1186/cc12575; Haydel Micelle, 2012, Emerg Med Pract, V14, P1; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Klein Y, 2010, J TRAUMA, V69, P544, DOI 10.1097/TA.0b013e3181c99936; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Quigley MR, 2013, J TRAUMA ACUTE CARE, V74, P581, DOI 10.1097/TA.0b013e31827d6088; Tavender EJ, 2011, ACAD EMERG MED, V18, P880, DOI 10.1111/j.1553-2712.2011.01134.x; van Essen TA, 2010, CLIN NEUROL NEUROSUR, V112, P775, DOI 10.1016/j.clineuro.2010.06.012; Wu C, 2012, J TRAUMA ACUTE CARE, V73, P1247, DOI 10.1097/TA.0b013e318265d24e	15	21	21	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2015	123	3					649	653		10.3171/2014.10.JNS132713			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CP6VZ	WOS:000360027600019	25526270	Bronze			2021-06-18	
J	Bogner, J; Barrett, RS; Hammond, FM; Horn, SD; Corrigan, JD; Rosenthal, J; Beaulieu, CL; Waszkiewicz, M; Shea, T; Reddin, CJ; Cullen, N; Giuffrida, CG; Young, J; Garmoe, W				Bogner, Jennifer; Barrett, Ryan S.; Hammond, Flora M.; Horn, Susan D.; Corrigan, John D.; Rosenthal, Joseph; Beaulieu, Cynthia L.; Waszkiewicz, Margaret; Shea, Timothy; Reddin, Christopher J.; Cullen, Nora; Giuffrida, Clare G.; Young, James; Garmoe, William			Predictors of Agitated Behavior During Inpatient Rehabilitation for Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Confusion; Rehabilitation	FUNCTIONAL INDEPENDENCE MEASURE; GOOD ANTISEIZURE PROPHYLAXIS; DECREASE SEIZURE RATES; OF-THE-LITERATURE; RECOVERY; SCALE; METHYLPHENIDATE; RELIABILITY; MANAGEMENT; CONFUSION	Objective: To identify predictors of the severity of agitated behavior during inpatient traumatic brain injury (TBI) rehabilitation. Design: Prospective, longitudinal observational study. Setting: Inpatient rehabilitation centers. Participants: Consecutive patients enrolled between 2008 and 2011, admitted for inpatient rehabilitation after index TBI, who exhibited agitation during their stay (n=555, N=2130). Interventions: Not applicable. Main Outcome Measure: Daytime Agitated Behavior Scale scores. Results: Infection and lower FIM cognitive scores predicted more severe agitation. The medication classes associated with more severe agitation included sodium channel antagonist anticonvulsants, second-generation antipsychotics, and gamma-aminobutyric acid-A anxiolytics/hypnotics. Medication classes associated with less severe agitation included antiasthmatics, statins, and norepinephrine-dopamine-5 hydroxytryptamine (serotonin) agonist stimulants. Conclusions: Further support is provided for the importance of careful serial monitoring of both agitation and cognition to provide early indicators of Possible beneficial or adverse effects of pharmacologic interventions used for any purpose and for giving careful consideration to the effects of any intervention on underlying cognition when attempting to control agitation. Cognitive functioning was found to predict agitation, medications that have been found in previous studies to enhance cognition were associated with less agitation, and medications that can potentially suppress cognition were associated with more agitation. There could be factors other than the interventions that account for these relations. In addition, the study provides support for treatment of underlying disorders as a possible first step in management of agitation. Although the results of this study cannot be used to draw causal inferences, the associations that were found can be used to generate hypotheses about the most viable interventions that should be tested in future controlled trials. (C) 2015 by the American Congress of Rehabilitation Medicine	[Bogner, Jennifer; Corrigan, John D.; Rosenthal, Joseph; Shea, Timothy] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Barrett, Ryan S.; Horn, Susan D.] Int Sever Informat Syst, Inst Clin Outcomes Res, Salt Lake City, UT USA; [Hammond, Flora M.] Indiana Univ Sch Med, Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Hammond, Flora M.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Beaulieu, Cynthia L.] Brooks Rehabil Hosp, Jacksonville, FL USA; [Waszkiewicz, Margaret; Giuffrida, Clare G.; Young, James] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Reddin, Christopher J.] Naval Med Ctr, San Diego, CA USA; [Cullen, Nora] Toronto Rehabil Inst, Toronto, ON, Canada; [Garmoe, William] MedStar Natl Rehabil Hosp, Washington, DC USA	Bogner, J (corresponding author), 480 Med Ctr Dr, Columbus, OH 43210 USA.	Jennifer.Bogner@osumc.edu		Cullen, Nora/0000-0001-6359-9418	National Institutes of Health, National Center for Medical Rehabilitation ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD050439-01]; National Institute on Disability and Rehabilitation Research [H133A080023]; Ontario Neurotrauma Foundation [2007-ABI-ISIS-525]; American Congress of Rehabilitation Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	Supported by the National Institutes of Health, National Center for Medical Rehabilitation Research (grant no. 1R01HD050439-01); National Institute on Disability and Rehabilitation Research (grant no. H133A080023); and Ontario Neurotrauma Foundation (grant no. 2007-ABI-ISIS-525).; Publication of this article was supported by the American Congress of Rehabilitation Medicine.	Beaulieu C, 2008, J HEAD TRAUMA REHAB, V23, P304, DOI 10.1097/01.HTR.0000336843.60961.b7; Bhullar IS, 2014, J TRAUMA ACUTE CARE, V76, P54, DOI 10.1097/TA.0b013e3182aafd15; BOGNER J, 1995, NEUROREHABILITATION, V5, P293, DOI 10.3233/NRE-1995-5403; Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DIKMEN S, 1984, EPILEPSIA, V25, P741, DOI 10.1111/j.1528-1157.1984.tb03485.x; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Flanagan SR, 2009, PM&R, V1, P76, DOI 10.1016/j.pmrj.2008.10.013; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Horn SD, 2015, ARCH PHYS MED REHAB, V96, pS178, DOI 10.1016/j.apmr.2014.09.042; Inaba K, 2014, J TRAUMA ACUTE CARE, V76, P60; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; Levy M, 2005, NEUROREHABILITATION, V20, P279; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; McNett M, 2012, BRAIN INJURY, V26, P1155, DOI 10.3109/02699052.2012.667587; Peng WJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/261409; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Silva MA, 2012, AM J PHYS MED REHAB, V91, P890, DOI 10.1097/PHM.0b013e31825a1648; Singh R, 2014, BRAIN INJURY, V28, P336, DOI 10.3109/02699052.2013.873142; SMITH KR, 1994, ARCH NEUROL-CHICAGO, V51, P653, DOI 10.1001/archneur.1994.00540190029012; Tang V, 2007, J HEAD TRAUMA REHAB, V22, P409, DOI 10.1097/01.HTR.0000300236.21114.bc; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632	37	21	21	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2015	96	8		3			S274	S281		10.1016/j.apmr.2015.04.020			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CO3CV	WOS:000359035100009	26212403				2021-06-18	
J	Zhao, W; Ruan, SJ; Ji, SB				Zhao, Wei; Ruan, Shijie; Ji, Songbai			Brain pressure responses in translational head impact: a dimensional analysis and a further computational study	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury; Finite element model; Linear acceleration; Rotational acceleration; Dartmouth Head Injury Model	FINITE-ELEMENT MODELS; INTRACRANIAL-PRESSURE; INJURY; ACCELERATION; BIOMECHANICS; PREDICTORS; MOTION; SKULL	Brain pressure responses resulting from translational head impact are typically related to focal injuries at the coup and contrecoup sites. Despite significant efforts characterizing brain pressure responses using experimental and modeling approaches, a thorough investigation of the key controlling parameters appears lacking. In this study, we identified three parameters specific and important for brain pressure responses induced by isolated linear acceleration via a dimensional analysis: itself (magnitude and directionality), brain size and shape. These findings were verified using our recently developed Dartmouth Head Injury Model (DHIM). Applying to the rigid skull, we found that the temporal profile of the given directly determined that of pressure. Brain pressure was also found to be linearly proportional to brain size and dependent on impact direction. In addition, we investigated perturbations to brain pressure responses as a result of non-rigid skull deformation. Finally, DHIM pressure responses were quantitatively validated against two representative cadaveric head impacts (categorized as "good" to "excellent" in performance). These results suggest that both the magnitude and directionality of as well as brain size and shape should be considered when interpreting brain pressure responses. Further, a model validated against pressure responses alone is not sufficient to ensure its fidelity in strain-related responses. These findings provide important insights into brain pressure responses in translational head impact and the resulting risk of pressure-induced injury. In addition, they establish the feasibility of creating a pre-computed atlas for real-time tissue-level pressure responses without a direct simulation in the future.	[Zhao, Wei; Ji, Songbai] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Ruan, Shijie] Tianjin Univ Sci & Technol, Tianjin 300222, Peoples R China; [Ji, Songbai] Dartmouth Coll, Geisel Sch Med, Dept Surg, Hanover, NH 03755 USA; [Ji, Songbai] Dartmouth Coll, Geisel Sch Med, Dept Orthopaed Surg, Hanover, NH 03755 USA	Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Hanover, NH 03755 USA.	Songbai.Ji@Dartmouth.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS078607]; Dartmouth Hitchcock Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078607, R21NS088781] Funding Source: NIH RePORTER	This work was sponsored, in part, by the NIH Grant R21 NS078607 and the Dartmouth Hitchcock Foundation.	Abaqus, 2012, ABAQUS, V6, P12; ARUN KS, 1987, IEEE T PATTERN ANAL, V9, P699, DOI 10.1109/TPAMI.1987.4767965; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; de Lange Ronald, 2005, Stapp Car Crash J, V49, P457; Gibson LJ, 2006, J ZOOL, V270, P462, DOI 10.1111/j.1469-7998.2006.00166.x; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, V113, P185; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Ji S, 2014, ANN BIOMED IN PRESS; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kang HS, 1997, P 41 STAPP CAR CRASH; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King A.I., 2003, IRCOBI C LISB PORT, P1; KING AI, 1995, J NEUROTRAUM, V12, P651, DOI 10.1089/neu.1995.12.651; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Libertiaux V, 2011, J MECH BEHAV BIOMED, V4, P1177, DOI 10.1016/j.jmbbm.2011.03.028; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Morse JD, 2014, ANN BIOMED ENG, V42, P2501, DOI 10.1007/s10439-014-1091-8; Nahum A. M., 1977, 770922 SAE; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J A, 2000, Stapp Car Crash J, V44, P215; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Ruan J, 2001, Stapp Car Crash J, V45, P395; Ruan J, 2006, INT J VEH SAF, V1, P281, DOI [10. 1504/IJVS. 2006. 011230, DOI 10.1504/IJVS.2006.011230]; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; Sonin AA, 2001, PHYS BASIS DIMENSION; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; Trosseille X., 1992, P 36 STAPP CAR CRASH, DOI 10.4271/922527; Tse KM, 2014, INT J NUMER METH BIO, V30, P397, DOI 10.1002/cnm.2609; Ward C., 1980, 801304 SAE, DOI [10.4271/801304, DOI 10.4271/801304]; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Yoganandan N, 2014, J BIOMECH, V47, P1749, DOI 10.1016/j.jbiomech.2014.03.010; Yoganandan N, 2009, J TRAUMA, V66, P309, DOI 10.1097/TA.0b013e3181692104; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	53	21	23	0	10	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	AUG	2015	14	4					753	766		10.1007/s10237-014-0634-0			14	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CL9ZZ	WOS:000357339300006	25412925	Green Accepted			2021-06-18	
J	Abbaszadeh, HA; Tiraihi, T; Noori-Zadeh, A; Delshad, AR; Sadeghizade, M; Taheri, T				Abbaszadeh, Hojjat-Allah; Tiraihi, Taki; Noori-Zadeh, Ali; Delshad, Ali Reza; Sadeghizade, Majid; Taheri, Taher			Human ciliary neurotrophic factor-overexpressing stable bone marrow stromal cells in the treatment of a rat model of traumatic spinal cord injury	CYTOTHERAPY			English	Article						BMSCs; CNS regeneration; CNS traumatic injury; CNTF	RESTRICTED PRECURSOR CELLS; FUNCTIONAL RECOVERY; AXON REGENERATION; BRAIN-INJURY; CNTF; TRANSECTION	Background aims. Traumatic injury to the central nervous system (CNS) often causes motor dysfunctions. However, because of the CNS complexity and variability in the clinical presentations, efforts to repair damaged CNS tissue and restoring its functions are particularly demanding. On the other hand, recent progress in the regenerative therapy field have led to novel approaches for the treatment of traumatic CNS injury and renewed hopes to overcome the obstacles. It appears that the balance between neurite re-growth inhibiting and neurite re-growth inducing molecules determines the axonal re-growth fate. Neurotrophic factors can tilt this balance and indeed promote cell survival and axonal re-growth over neuro-degeneration. One of the promising neurotrophic factors in this field is ciliary neurotrophic factor (CNTF). Methods. We transfected rat bone marrow stromal cells with a mammalian expression vector inserted human CNTF gene through the use of a non-viral method to prepare human CNTF-overexpressing stem cells under ex vivo conditions. We transplanted these modified cells to the rat model of spinal cord traumatic injury to,explore functional recovery after contusion induction. Results. Our data from immunocytochemistry and behavioral tests showed that such cells can act as a powerful potential approach to treat traumatic CNS injuries because these modified cells improved the behavioral test scores in the rat model of spinal cord injury. Conclusions. CNTF-overexpressing bone marrow stromal cells can ameliorate spinal cord traumatic injury and can be used in the treatment of traumatic CNS injuries in the near future.	[Abbaszadeh, Hojjat-Allah] Shahid Beheshti Univ Med Sci, Sch Med, Dept Biol & Anat Sci, Tehran, Iran; [Tiraihi, Taki] Tarbiat Modares Univ, Fac Med Sci, Dept Anat Sci, Tehran, Iran; [Tiraihi, Taki; Taheri, Taher] Khatam Al Anbia Hosp, Shefa Neurosci Res Ctr, Tehran, Iran; [Noori-Zadeh, Ali] Tarbiat Modares Univ, Fac Med Sci, Dept Clin Biochem, Tehran, Iran; [Delshad, Ali Reza] Shahed Univ, Sch Med Sci, Dept Anat Sci, Tehran, Iran; [Sadeghizade, Majid] Tarbiat Modares Univ, Dept Genet, Fac Sci, Tehran, Iran	Taheri, T (corresponding author), Tarbiat Modares Univ, Fac Med Sci, Dept Anat, Intersect Shaheed Chamran & Jalal El Ahmad, POB 14122-3155, Tehran, Iran.	takialtr@modares.ac.ir	Noori-Zadeh, Ali/Q-4998-2017; Abbaszadeh, Hojjat Allah/R-6726-2019	Noori-Zadeh, Ali/0000-0002-4897-7684; Abbaszadeh, Hojjat Allah/0000-0002-7157-1834	Shefa Neurosciences Research Center at Khatam Al-Anbia Hospital, Tehran, Iran [86-N-105]; Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran	The project was funded by the Shefa Neurosciences Research Center at Khatam Al-Anbia Hospital, Tehran, Iran (grant No. 86-N-105). We are grateful for the support of the Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewin SL, 1997, LARYNGOSCOPE, V107, P992, DOI 10.1097/00005537-199707000-00029; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Morganti-Kossman C, 2012, SPINAL CORD INJURY P, P242; Muller A, 2009, MOL CELL NEUROSCI, V41, P233, DOI 10.1016/j.mcn.2009.03.002; Naumann T, 2003, BRAIN PATHOL, V13, P309; Noori-Zadeh A, 2014, J NEUROL SCI, V339, P81, DOI 10.1016/j.jns.2014.01.025; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Ohta S, 2005, SPINE, V30, P1154, DOI 10.1097/01.brs.0000162402.79482.fd; Rothaeusler K, 2007, CURR PROTOC CYTOM, V7, P31; Shichinohe H, 2015, NEUROREHAB NEURAL RE, V29, P80, DOI 10.1177/1545968314525856; Stankoff B, 2002, J NEUROSCI, V22, P9221; Xie F, 2008, EXP NEUROL, V209, P302, DOI 10.1016/j.expneurol.2007.07.005	21	21	23	2	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	JUL	2015	17	7					912	921		10.1016/j.jcyt.2015.03.689			10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	CL0KS	WOS:000356632200008	25939801				2021-06-18	
J	Bodanapally, UK; Sours, C; Zhuo, JC; Shanmuganathan, K				Bodanapally, Uttam K.; Sours, Chandler; Zhuo, Jiachen; Shanmuganathan, Kathirkamanathan			Imaging of Traumatic Brain Injury	RADIOLOGIC CLINICS OF NORTH AMERICA			English	Article						Trauma; Brain injury; Computed tomography; MR imaging	CLOSED-HEAD INJURY; DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; WORKING-MEMORY; FUNCTIONAL CONNECTIVITY; STEM LESIONS; SUBARACHNOID HEMORRHAGE; COGNITIVE IMPAIRMENT; OUTCOME PREDICTION; CLINICAL-EFFICACY	Imaging plays an important role in the management of patients with traumatic brain injury (TBI). Computed tomography (CT) is the first-line imaging technique allowing rapid detection of primary structural brain lesions that require surgical intervention. CT also detects various deleterious secondary insults allowing early medical and surgical management. Serial imaging is critical to identifying secondary injuries. MR imaging is indicated in patients with acute TBI when CT fails to explain neurologic findings. However, MR imaging is superior in patients with mild TBI and also predicts neurocognitive outcome.	[Bodanapally, Uttam K.; Sours, Chandler; Zhuo, Jiachen; Shanmuganathan, Kathirkamanathan] Univ Maryland, Med Ctr, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA	Shanmuganathan, K (corresponding author), Univ Maryland, Med Ctr, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	ksahnrriuganathan@umm.edu					Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Ahmadi J, 1989, Top Magn Reson Imaging, V2, P17; Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Al-Nakshabandi NA, 2001, RADIOLOGY, V218, P433, DOI 10.1148/radiology.218.2.r01fe09433; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P30; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Biffl WL, 2001, WORLD J SURG, V25, P1036, DOI 10.1007/s00268-001-0056-x; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bodanapally UK, 2013, NEURORADIOLOGY, V55, P771, DOI 10.1007/s00234-013-1166-5; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Bryer EJ, 2013, J INT NEUROPSYCH SOC, V19, P751, DOI 10.1017/S1355617713000490; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; Chen CJ, 2012, RADIOLOGY, V264, P844, DOI 10.1148/radiol.12112154; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; FELDMANN E, 1988, NEUROLOGY, V38, P697, DOI 10.1212/WNL.38.5.697; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gean AD, 2010, RADIOLOGY, V257, P212, DOI 10.1148/radiol.10092075; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gentry LR, 1991, NEUROIMAG CLIN N AM, V1, P411; George EO, 2014, J NEUROTRAUM, V31, P1018, DOI 10.1089/neu.2013.3224; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Glauser J, 2004, CLEV CLIN J MED, V71, P353, DOI 10.3949/ccjm.71.4.353; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; HAHN FJ, 1985, AM J NEURORADIOL, V6, P844; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson PL, 2002, NEUROIMAG CLIN N AM, V12, P217, DOI 10.1016/S1052-5149(02)00008-4; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kubal WS, 2012, RADIOL CLIN N AM, V50, P15, DOI 10.1016/j.rcl.2011.08.010; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lee Bruce, 2005, NeuroRx, V2, P372; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lee Kyeong-Seok, 1997, Journal of Korean Medical Science, V12, P353; Leestma JE, 1988, FORENSIC NEUROPATHOL, P409; Lowenhielm P, 1973, P INT C BIOKINETICS, P423; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MACPHERSON BCM, 1990, CLIN RADIOL, V42, P321, DOI 10.1016/S0009-9260(05)82145-2; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; NOGUCHI K, 1995, RADIOLOGY, V196, P773, DOI 10.1148/radiology.196.3.7644642; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; REED D, 1986, AM J NEURORADIOL, V7, P417; Reichle ME, 2010, TRENDS COGN SCI, V14, P180, DOI 10.1016/j.tics.2010.01.008; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; SCHNEIDER R, 1961, JAMA-J AM MED ASSOC, V177, P362, DOI 10.1001/jama.1961.03040320006002; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 2000, NEUROSURGERY, V46, P70; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Study Group on Head Injury of the Italian Society for Neurosurgery, 1996, J NEUROSURG SCI, V40, P11; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; UK National Institute for Health and Clinical Excellence, 2003, HEAD INJ TRIAG ASS I; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; WERNICK S, 1989, J COMPUT ASSIST TOMO, V13, P323, DOI 10.1097/00004728-198903000-00027; WEST OC, 1993, RADIOLOGY, V188, P329, DOI 10.1148/radiology.188.2.8327674; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	147	21	22	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0033-8389	1557-8275		RADIOL CLIN N AM	Radiol. Clin. N. Am.	JUL	2015	53	4					695	+		10.1016/j.rcl.2015.02.011			22	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CL5GF	WOS:000356987100006	26046506				2021-06-18	
J	Pang, CH; Lee, SE; Kim, CH; Kim, JE; Kang, HS; Park, CK; Paek, SH; Kim, CH; Jahng, TA; Kim, JW; Kim, YH; Kim, DG; Chung, CK; Jung, HW; Yoo, H				Pang, Chang Hwan; Lee, Soo Eon; Kim, Chang Hyeun; Kim, Jeong Eun; Kang, Hyun-Seung; Park, Chul-Kee; Paek, Sun Ha; Kim, Chi Heon; Jahng, Tae-Ahn; Kim, Jin Wook; Kim, Yong Hwy; Kim, Dong Gyu; Chung, Chun Kee; Jung, Hee-Won; Yoo, Heon			Acute intracranial bleeding and recurrence after bur hole craniostomy for chronic subdural hematoma	JOURNAL OF NEUROSURGERY			English	Article						acute intracranial bleeding; bur hole craniostomy; chronic subdural hematoma; recurrence; traumatic brain injury	CLOSED-SYSTEM DRAINAGE; RETROSPECTIVE ANALYSIS; SURGICAL-MANAGEMENT; INTERVENTION; ANTIPLATELET; CRANIOTOMY; THERAPY; INJURY; SINGLE; ADULTS	OBJECT There is inconsistency among the perioperative management strategies currently used for chronic subdural hematoma (cSDH). Moreover, postoperative complications such as acute intracranial bleeding and cSDH recurrence affect clinical outcome of cSDH surgery. This study evaluated the risk factors associated with acute intracranial bleeding and cSDH recurrence and identified an effective perioperative strategy for cSDH patients. METHODS A retrospective study of patients who underwent bur hole craniostomy for cSDH between 2008 and 2012 was performed. RESULTS A consecutive series of 303 cSDH patients (234 males and 69 females; mean age 67.17 years) was analyzed. Postoperative acute intracranial bleeding developed in 14 patients (4.57%) within a mean of 3.07 days and recurrence was observed in 37 patients (12.21%) within a mean of 31.69 days (range 10-104 days) after initial bur hole craniostomy. The comorbidities of hematological disease and prior shunt surgery were clinical factors associated with acute bleeding. There was a significant risk of recurrence in patients with diabetes mellitus, but recurrence did not affect the final neurological outcome (p = 0.776). Surgical details, including the number of operative bur holes, saline irrigation of the hematoma cavity, use of a drain, and type of postoperative ambulation, were not significantly associated with outcome. However, a large amount of drainage was associated with postoperative acute bleeding. CONCLUSIONS Bur hole craniostomy is an effective surgical procedure for initial and recurrent cSDH. Patients with hematological disease or a history of prior shunt surgery are at risk for postoperative acute bleeding; therefore, these patients should be carefully monitored to avoid overdrainage. Surgeons should consider informing patients with diabetes mellitus that this comorbidity is associated with an increased likelihood of recurrence.	[Pang, Chang Hwan; Lee, Soo Eon; Kim, Chang Hyeun; Kim, Jeong Eun; Kang, Hyun-Seung; Park, Chul-Kee; Paek, Sun Ha; Kim, Chi Heon; Kim, Yong Hwy; Kim, Dong Gyu; Chung, Chun Kee; Jung, Hee-Won] Seoul Natl Univ Hosp, Dept Neurosurg, Seoul 110744, South Korea; [Jahng, Tae-Ahn; Kim, Jin Wook] Bundang Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea; [Kim, Jeong Eun; Kang, Hyun-Seung; Park, Chul-Kee; Paek, Sun Ha; Kim, Chi Heon; Jahng, Tae-Ahn; Kim, Dong Gyu; Chung, Chun Kee; Jung, Hee-Won] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea; [Yoo, Heon] Natl Canc Ctr, Dept Neurosurg, Seoul, South Korea	Yoo, H (corresponding author), Natl Canc Ctr, Specif Organs Canc Ctr, Dept Neurosurg, 323 Ilsan Ro, Goyang Si 410769, Gyeonggi Do, South Korea.	heonyoo@ncc.re.kr	Park, Chul-Kee/O-7842-2019; Park, Chul-Kee/J-5499-2012; Kim, Yong Hwy/L-8289-2019	Park, Chul-Kee/0000-0002-2350-9876; Pang, Chang hwan/0000-0002-9017-9336	Korean Brain and Spinal Cord Research Foundation	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This work was supported by the Korean Brain and Spinal Cord Research Foundation.	Adeolu AA, 2012, BRIT J NEUROSURG, V26, P743, DOI 10.3109/02688697.2012.690912; Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255; Aspegren OP, 2013, CLIN NEUROL NEUROSUR, V115, P981, DOI 10.1016/j.clineuro.2012.10.008; Bergsneider M, 2005, NEUROSURGERY SUPPL, V57, pii; Carmel P W, 1999, Neurosurg Focus, V7, pe7; Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y; Erol FS, 2005, J CLIN NEUROSCI, V12, P261, DOI 10.1016/j.jocn.2003.09.012; Gokmen M, 2008, ZBL NEUROCHIR, V69, P129, DOI 10.1055/s-2007-1004587; HAMILTON MG, 1993, NEUROSURGERY, V33, P67; Kansal R, 2010, J CLIN NEUROSCI, V17, P428, DOI 10.1016/j.jocn.2009.07.109; Karibe Hiroshi, 2011, No Shinkei Geka, V39, P1149; Lega BC, 2010, J NEUROSURG, V113, P615, DOI 10.3171/2009.9.JNS08825; Lindvall P, 2009, J CLIN NEUROSCI, V16, P1287, DOI 10.1016/j.jocn.2009.01.001; Markwalder TM, 2000, NEUROSURG CLIN N AM, V11, P541, DOI 10.1016/S1042-3680(18)30120-7; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; MCCULLOUGH DC, 1974, J NEUROSURG, V40, P372, DOI 10.3171/jns.1974.40.3.0372; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298; Mizutani K, 2014, CLIN NEUROL NEUROSUR, V117, P100, DOI 10.1016/j.clineuro.2013.11.035; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Pahatouridis D, 2013, NEUROSURG REV, V36, P151, DOI 10.1007/s10143-012-0412-3; Reinges MHT, 2000, J NEUROL NEUROSUR PS, V69, P40, DOI 10.1136/jnnp.69.1.40; Rohde V, 2002, NEUROSURG REV, V25, P89, DOI 10.1007/s101430100182; Sambasivan M, 1997, SURG NEUROL, V47, P418, DOI 10.1016/S0090-3019(97)00188-2; Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6; Van der Veken J, 2014, ACTA NEUROCHIR, V156, P981, DOI 10.1007/s00701-014-2042-8	26	21	24	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2015	123	1					65	74		10.3171/2014.12.JNS141189			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CL5DY	WOS:000356981200009	25679282				2021-06-18	
J	Sayer, NA; Orazem, RJ; Noorbaloochi, S; Gravely, A; Frazier, P; Carlson, KF; Schnurr, PP; Oleson, H				Sayer, Nina A.; Orazem, Robert J.; Noorbaloochi, Siamak; Gravely, Amy; Frazier, Patricia; Carlson, Kathleen F.; Schnurr, Paula P.; Oleson, Heather			Iraq and Afghanistan War Veterans with Reintegration Problems: Differences by Veterans Affairs Healthcare User Status	ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH			English	Article						Veterans; Healthcare service needs; Mental health; Posttraumatic stress disorder; Traumatic brain injury; Department of Veterans Affairs Healthcare	TRAUMATIC BRAIN-INJURY; BINGE DRINKING; DEPLOYMENT; MILITARY; SERVICES; FREEDOM; RISK	We studied 1,292 Iraq and Afghanistan War veterans who participated in a clinical trial of expressive writing to estimate the prevalence of perceived reintegration difficulty and compare Veterans Affairs (VA) healthcare users to nonusers in terms of demographic and clinical characteristics. About half of participants perceived reintegration difficulty. VA users and nonusers differed in age and military background. Levels of mental and physical problems were higher in VA users. In multivariate analysis, military service variables and probable traumatic brain injury independently predicted VA use. Findings demonstrate the importance of research comparing VA users to nonusers to understand veteran healthcare needs.	[Sayer, Nina A.; Orazem, Robert J.; Noorbaloochi, Siamak; Gravely, Amy; Oleson, Heather] Minneapolis VA Healthcare Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA; [Sayer, Nina A.; Noorbaloochi, Siamak] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Frazier, Patricia] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA; [Carlson, Kathleen F.] Portland VA Med Ctr, Ctr Improve Vet Involvement Care, Portland, OR USA; [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Schnurr, Paula P.] Natl Ctr PTSD, White River Jct, VT USA; [Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH USA	Sayer, NA (corresponding author), Minneapolis VA Healthcare Syst, Ctr Chron Dis Outcomes Res, One Vet Dr, Minneapolis, MN 55417 USA.	nina.sayer@va.gov	Sayer, Nina/E-3249-2016; Noorbaloochi, Siamak/ABB-5817-2020		Department of Veterans Affairs (VA)US Department of Veterans Affairs; Health Services Research and Development (HSRD) Service [DHI-07-150]; Department of Defense (DoD)United States Department of Defense [08-2-0045]	This research was supported by the Department of Veterans Affairs (VA), Health Services Research and Development (HSR&D) Service (Grant No. DHI-07-150) and the Department of Defense (DoD) (Grant No. 08-2-0045). The sponsors were not involved in any aspect of the study's design and conduct; data collection, management, analysis, or interpretation of data; or in the preparation, review or approval of the manuscript. The findings and conclusions presented in this manuscript are those of the authors and do not necessarily represent the views of the VA, HSR&D, or DoD.	Agha Z, 2000, ARCH INTERN MED, V160, P3252, DOI 10.1001/archinte.160.21.3252; Baikie KA, 2012, J AFFECT DISORDERS, V136, P310, DOI 10.1016/j.jad.2011.11.032; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Derogatis L., 2000, BRIEF SYMPTOM INVENT; Derogatis L, 1993, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dillman D.A., 2000, MAIL INTERNET SURVEY; Foa E.B., 1995, POSTTRAUMATIC STRESS; Frazier P, 2003, CONT T VOC, P251; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hynes DM, 2007, MED CARE, V45, P214, DOI 10.1097/01.mlr.0000244657.90074.b7; King DW, 2003, MANUAL DEPLOYMENT RI; Koepsell TD, 2009, PREV MED, V48, P267, DOI 10.1016/j.ypmed.2009.01.008; Kovac SH, 2002, SUICIDE LIFE-THREAT, V32, P428, DOI 10.1521/suli.32.4.428.22335; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Littman Alyson J, 2012, Prev Chronic Dis, V9, pE99; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70; Nelson KM, 2007, PUBLIC HEALTH REP, V122, P93, DOI 10.1177/003335490712200113; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Pennebaker J.W., 1982, PSYCHOL PHYS SYMPTOM; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Sayer NA, 2014, SOC ISS POLICY REV, V8, P33, DOI 10.1111/sipr.12001; Sayer NA, 2011, J TRAUMA STRESS, V24, P660, DOI 10.1002/jts.20706; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI 10.1002/jts.20493; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; U. S. Department of Veterans Affairs, 2010, NAT CTR VET AN STAT; U.S. Department of Veterans Affairs Epidemiology Program, 2014, AN VA HLTH CAR UT OP; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers FW, 1995, PTSD CHECKLIST MILIT; WECHSLER H, 1995, AM J PUBLIC HEALTH, V85, P982, DOI 10.2105/AJPH.85.7.982	39	21	21	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0894-587X	1573-3289		ADM POLICY MENT HLTH	Adm. Policy. Ment. Health	JUL	2015	42	4					493	503		10.1007/s10488-014-0564-2			11	Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	CJ7EC	WOS:000355656100012	24913102	Green Published, Other Gold			2021-06-18	
J	Garcia-Ovejero, D; Arevalo-Martin, A; Paniagua-Torija, B; Florensa-Vila, J; Ferrer, I; Grassner, L; Molina-Holgado, E				Garcia-Ovejero, Daniel; Arevalo-Martin, Angel; Paniagua-Torija, Beatriz; Florensa-Vila, Jose; Ferrer, Isidro; Grassner, Lukas; Molina-Holgado, Eduardo			The ependymal region of the adult human spinal cord differs from other species and shows ependymoma-like features	BRAIN			English	Article						neural stem cells; spinal cord injury; ependymoma; regeneration; central canal	NEURAL STEM-CELLS; GENE-EXPRESSION; GLIAL-CELLS; SYRINGOMYELIA; BRAIN; PROLIFERATION; MODEL; DIFFERENTIATION; CLASSIFICATION; IDENTIFICATION	Several laboratories have described the existence of undifferentiated precursor cells that may act like stem cells in the ependyma of the rodent spinal cord. However, there are reports showing that this region is occluded and disassembled in humans after the second decade of life, although this has been largely ignored or interpreted as a post-mortem artefact. To gain insight into the patency, actual structure, and molecular properties of the adult human spinal cord ependymal region, we followed three approaches: (i) with MRI, we estimated the central canal patency in 59 control subjects, 99 patients with traumatic spinal cord injury, and 26 patients with non-traumatic spinal cord injuries. We observed that the central canal is absent from the vast majority of individuals beyond the age of 18 years, gender-independently, throughout the entire length of the spinal cord, both in healthy controls and after injury; (ii) with histology and immunohistochemistry, we describe morphological properties of the non-lesioned ependymal region, which showed the presence of perivascular pseudorosettes, a common feature of ependymoma; and (iii) with laser capture microdissection, followed by TaqMan (R) low density arrays, we studied the gene expression profile of the ependymal region and found that it is mainly enriched in genes compatible with a low grade or quiescent ependymoma (53 genes); this region is enriched only in 14 genes related to neurogenic niches. In summary, we demonstrate here that the central canal is mainly absent in the adult human spinal cord and is replaced by a structure morphologically and molecularly different from that described for rodents and other primates. The presented data suggest that the ependymal region is more likely to be reminiscent of a low-grade ependymoma. Therefore, a direct translation to adult human patients of an eventual therapeutic potential of this region based on animal models should be approached with caution.	[Garcia-Ovejero, Daniel; Arevalo-Martin, Angel; Paniagua-Torija, Beatriz; Molina-Holgado, Eduardo] Hosp Nacl Paraplej SESCAM, Lab Neuroinflammat, Toledo, Spain; [Florensa-Vila, Jose] Hosp Nacl Paraplej SESCAM, Radiol Unit, Toledo, Spain; [Ferrer, Isidro] IDIBELL Hosp Univ Bellvitge, Inst Neuropatol, Serv Anat Patol, Lhospitalet De Llobregat, Spain; [Grassner, Lukas] Trauma Ctr Murnau, Ctr Spinal Cord Injuries, Murnau, Germany; [Grassner, Lukas] Paracelsus Med Univ, Inst Mol Regenerat Med, SCI TReCS Spinal Cord Injury & Tissue Regenerat C, Salzburg, Austria	Garcia-Ovejero, D (corresponding author), Hosp Nacl Paraplej, Lab Neuroinflammat, Finca La Peraleda S-N, Toledo 45071, Spain.	dgarciao@sescam.jccm.es	Florensa-Vila, Jose/AAA-5194-2019; Molina-Holgado, Eduardo/C-2714-2008	Molina-Holgado, Eduardo/0000-0001-6693-1682; Garcia-Ovejero, Daniel/0000-0002-7479-5104; Arevalo-Martin, Angel/0000-0002-0549-6098	Wings For Life Foundation; Instituto de Salud Carlos III (Ministry of Economy and Competitiveness of Spain); Fundacion Mutua-Madrilena (Madrid, Spain)	This work was funded by Wings For Life Foundation. Laboratory of Neuroinflammation has been supported by Instituto de Salud Carlos III (Ministry of Economy and Competitiveness of Spain) and Fundacion Mutua-Madrilena (Madrid, Spain).	Abematsu M, 2010, J CLIN INVEST, V120, P3255, DOI 10.1172/JCI42957; Alelu-Paz R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003378; Alfaro-Cervello C, 2014, J COMP NEUROL, V522, P1800, DOI 10.1002/cne.23501; Alfaro-Cervello C, 2012, J COMP NEUROL, V520, P3528, DOI 10.1002/cne.23104; Andreiuolo F, 2010, NEURO-ONCOLOGY, V12, P1126, DOI 10.1093/neuonc/noq074; Auguste KI, 2006, NEUROSURG CLIN N AM, V17, P51, DOI 10.1016/j.nec.2005.10.004; Barnabe-Heider F, 2010, CELL STEM CELL, V7, P470, DOI 10.1016/j.stem.2010.07.014; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Brodbelt AR, 2003, J CLIN NEUROSCI, V10, P401, DOI 10.1016/S0967-5868(02)00326-0; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Cavanee WK., 2007, WHO CLASSIFICATION T; Ceruti S, 2009, BRAIN, V132, P2206, DOI 10.1093/brain/awp147; Clarke J. L., 1859, PHILOS T ROY SOC LON, V149, P437; Cornil L, 1933, REV NEUROL-FRANCE, V59, P749; Dromard C, 2008, J NEUROSCI RES, V86, P1916, DOI 10.1002/jnr.21646; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Ellison DLS, 2004, NEUROPATHOLOGY REFER; Fandel D, 2013, BRAIN RES, V1535, P89, DOI 10.1016/j.brainres.2013.08.022; Fu H, 2003, J COMP NEUROL, V456, P237, DOI 10.1002/cne.10481; Garcia-Ovejero D, 2013, J COMP NEUROL, V521, P233, DOI 10.1002/cne.23184; Goritz C, 2012, CELL STEM CELL, V10, P657, DOI 10.1016/j.stem.2012.04.005; Horner PJ, 2000, J NEUROSCI, V20, P2218; Hu ZZ, 2008, CLIN CHEM, V54, P824, DOI 10.1373/clinchem.2007.096164; Hugnot JP, 2011, FRONT BIOSCI-LANDMRK, V16, P1044, DOI 10.2741/3734; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; KASANTIKUL V, 1979, J NEUROSURG, V51, P85, DOI 10.3171/jns.1979.51.1.0085; Kelly TK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004213; Klekamp J, 2002, J NEUROSURG, V97, P317, DOI 10.3171/spi.2002.97.3.0317; Ko HY, 2012, SPINAL CORD, V50, P695, DOI 10.1038/sc.2012.35; Koelliker A., 1893, HDB GEWEBELEHRE MENS; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu P, 2014, NEURON, V83, P789, DOI 10.1016/j.neuron.2014.07.014; Mamaeva D, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-99; Mamber C, 2013, PROG NEUROBIOL, V111, P1, DOI 10.1016/j.pneurobio.2013.07.003; McDonough A, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/387513; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Milde T, 2012, BRAIN PATHOL, V22, P848, DOI 10.1111/j.1750-3639.2012.00600.x; MILHORAT TH, 1994, J NEUROSURG, V81, P103, DOI 10.3171/jns.1994.81.1.0103; MILHORAT TH, 1994, J NEUROSURG, V80, P716, DOI 10.3171/jns.1994.80.4.0716; MILHORAT TH, 1995, J NEUROSURG, V82, P802, DOI 10.3171/jns.1995.82.5.0802; Modena P, 2006, J CLIN ONCOL, V24, P5223, DOI 10.1200/JCO.2006.06.3701; Namimatsu S, 2005, J HISTOCHEM CYTOCHEM, V53, P3, DOI 10.1369/jhc.4C6466.2005; NETSKY MG, 1953, AMA ARCH NEUROL PSY, V70, P741, DOI 10.1001/archneurpsyc.1953.02320360056006; Obermair FJ, 2010, STEM CELL RES, V5, P131, DOI 10.1016/j.scr.2010.05.001; Palm T, 2009, CANCER-AM CANCER SOC, V115, P3955, DOI 10.1002/cncr.24476; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; Petit A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024538; Peyre M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012932; Pfenninger CV, 2011, GLIA, V59, P68, DOI 10.1002/glia.21077; Puget S, 2009, J CLIN ONCOL, V27, P1884, DOI 10.1200/JCO.2007.15.4195; R DEVELOPMENT CORE TEAM, 2014, R LANG ENV STAT COMP; Radojicic M, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-30; Ramon y Cajal S., 1899, TEXTURA SISTEMA NERV; Retzius G, 1893, BIOL UNTERSUCH, V5, P2; Ritter AM, 1998, J NEURO-ONCOL, V40, P51, DOI 10.1023/A:1006082622699; ROSSIER AB, 1985, BRAIN, V108, P439, DOI 10.1093/brain/108.2.439; Sabelstrom H, 2014, EXP NEUROL, V260, P44, DOI 10.1016/j.expneurol.2013.01.026; Sabourin JC, 2009, STEM CELLS, V27, P2722, DOI 10.1002/stem.226; Sakakibara A, 2007, PATHOL INT, V57, P358, DOI 10.1111/j.1440-1827.2007.02108.x; Scheithauer BW, 2008, BRAIN PATHOL, V18, P307, DOI 10.1111/j.1750-3639.2008.00179.x; Schiffer D, 1997, BRAIN TUMOURS BIOL P; Shihabuddin LS, 1997, EXP NEUROL, V148, P577, DOI 10.1006/exnr.1997.6697; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Tetzlaff W, 2011, J NEUROTRAUM, V28, P1611, DOI 10.1089/neu.2009.1177; Tysseling VM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-16; von Lenhossek M, 1895, FEINERE BAU NERVENSS; Wagshul ME, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-5; Wani K, 2012, ACTA NEUROPATHOL, V123, P727, DOI 10.1007/s00401-012-0941-4; Weigert K, 1895, BEITRAGE KENNTNIS NO; Weiss S, 1996, J NEUROSCI, V16, P7599; Wippold FJ, 2006, AM J NEURORADIOL, V27, P488; Witt H, 2011, CANCER CELL, V20, P143, DOI 10.1016/j.ccr.2011.07.007; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Yang H, 2006, J NEUROSCI, V26, P2157, DOI 10.1523/JNEUROSCI.4070-05.2005; Yasui K, 1999, ACTA NEUROPATHOL, V97, P253, DOI 10.1007/s004010050982	79	21	21	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN 1	2015	138		6				1583	1597		10.1093/brain/awv089			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CM9BD	WOS:000357999300023	25882650	Bronze, Green Published			2021-06-18	
J	Smith, AL; Garbus, H; Rosenkrantz, TS; Fitch, RH				Smith, Amanda L.; Garbus, Haley; Rosenkrantz, Ted S.; Fitch, Roslyn Holly			Sex Differences in Behavioral Outcomes Following Temperature Modulation During Induced Neonatal Hypoxic Ischemic Injury in Rats	BRAIN SCIENCES			English	Article						Temperature modulation; hypoxia ischemia; rodent model; rapid auditory processing; motor; learning/memory; preterm; neuroprotection; neurobehavioral; hypothermia	LOW-BIRTH-WEIGHT; AUDITORY PROCESSING DEFICITS; DEVELOPMENTAL COORDINATION DISORDER; SPATIAL MEMORY DEFICITS; TRAUMATIC BRAIN-INJURY; PRETERM MALE INFANTS; CEREBRAL-ISCHEMIA; TERM INFANT; POSTISCHEMIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA	Neonatal hypoxia ischemia (HI; reduced oxygen and/or blood flow to the brain) can cause various degrees of tissue damage, as well as subsequent cognitive/behavioral deficits such as motor, learning/memory, and auditory impairments. These outcomes frequently result from cardiovascular and/or respiratory events observed in premature infants. Data suggests that there is a sex difference in HI outcome, with males being more adversely affected relative to comparably injured females. Brain/body temperature may play a role in modulating the severity of an HI insult, with hypothermia during an insult yielding more favorable anatomical and behavioral outcomes. The current study utilized a postnatal day (P) 7 rodent model of HI injury to assess the effect of temperature modulation during injury in each sex. We hypothesized that female P7 rats would benefit more from lowered body temperatures as compared to male P7 rats. We assessed all subjects on rota-rod, auditory discrimination, and spatial/non-spatial maze tasks. Our results revealed a significant benefit of temperature reduction in HI females as measured by most of the employed behavioral tasks. However, HI males benefitted from temperature reduction as measured on auditory and non-spatial tasks. Our data suggest that temperature reduction protects both sexes from the deleterious effects of HI injury, but task and sex specific patterns of relative efficacy are seen.	[Smith, Amanda L.; Garbus, Haley; Fitch, Roslyn Holly] Univ Connecticut, Dept Psychol, 406 Babbidge Rd,Unit 1020, Storrs, CT 06269 USA; [Rosenkrantz, Ted S.] Univ Connecticut, Sch Med, Dept Pediat, Farmington, CT 06030 USA	Smith, AL (corresponding author), Univ Connecticut, Dept Psychol, 406 Babbidge Rd,Unit 1020, Storrs, CT 06269 USA.	amanda.l.smith@uconn.edu; haley.garbus@uconn.edu; rosenkrant@uchc.edu; Roslyn.h.fitch@uconn.edu	Fitch, Roslyn Holly/A-2562-2014		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD049792]	The authors would like to thank all undergraduates who assisted with behavioral testing. The research was supported by NIH grant HD049792.	Alexander M, 2014, BEHAV BRAIN RES, V259, P85, DOI 10.1016/j.bbr.2013.10.038; Alexander ML, 2012, DEV NEUROSCI-BASEL, V34, P515, DOI 10.1159/000345645; Alexander M, 2013, BRAIN SCI, V3, P177, DOI 10.3390/brainsci3010177; Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Arteni NS, 2003, BRAIN RES, V973, P171, DOI 10.1016/S0006-8993(03)02436-3; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Barrett Robert D., 2007, Birth Defects Research, V81, P163, DOI 10.1002/bdrc.20095; Benasich AA, 2006, NEUROPSYCHOLOGIA, V44, P396, DOI 10.1016/j.neuropsychologia.2005.06.004; Billiards SS, 2006, CLIN PERINATOL, V33, P915, DOI 10.1016/j.clp.2006.10.003; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Choudhury N, 2007, DEVELOPMENTAL SCI, V10, P213, DOI 10.1111/j.1467-7687.2007.00546.x; Corbett D, 2000, BRAIN PATHOL, V10, P145; Curtis WJ, 2006, DEV NEUROPSYCHOL, V29, P341, DOI 10.1207/s15326942dn2902_4; de Kleine MJK, 2003, ARCH DIS CHILD, V88, P870, DOI 10.1136/adc.88.10.870; de Vries LS, 2009, SEMIN PEDIATR NEUROL, V16, P216, DOI 10.1016/j.spen.2009.09.001; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Downie ALS, 2002, BRAIN LANG, V80, P208, DOI 10.1006/brln.2001.2594; Drury PP, 2010, SEMIN FETAL NEONAT M, V15, P287, DOI 10.1016/j.siny.2010.05.005; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Elsmen E, 2004, ACTA PAEDIATR, V93, P529, DOI 10.1080/08035250410024998; Fan XY, 2013, PEDIATR RES, V73, P18, DOI 10.1038/pr.2012.139; Fang AY, 2013, PEDIATR RES, V73, P12, DOI 10.1038/pr.2012.138; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Fitch RH, 2008, BRAIN RES BULL, V76, P1, DOI 10.1016/j.brainresbull.2007.07.013; Fitch RH, 2013, FRONT SYST NEUROSCI, V7, DOI [10.3389/fnsys.2013.00058, 10.3389/fusys.2013.00058]; Gadian DG, 2000, BRAIN, V123, P499, DOI 10.1093/brain/123.3.499; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Hack M, 2008, CLIN OBSTET GYNECOL, V51, P763, DOI 10.1097/GRF.0b013e3181870922; Hill CA, 2011, DEV NEUROSCI-BASEL, V33, P494, DOI 10.1159/000331651; Hill CA, 2011, INT J DEV NEUROSCI, V29, P381, DOI 10.1016/j.ijdevneu.2011.03.005; Hindmarsh GJ, 2000, EARLY HUM DEV, V60, P115, DOI 10.1016/S0378-3782(00)00105-5; Howe TH, 2011, AM J PHYS MED REHAB, V90, P667, DOI 10.1097/PHM.0b013e31821a703f; Huang BY, 2008, RADIOGRAPHICS, V28, P417, DOI 10.1148/rg.282075066; Huang ZH, 2009, BRAIN RES, V1301, P100, DOI 10.1016/j.brainres.2009.09.006; Inder TE, 1999, ANN NEUROL, V46, P755, DOI 10.1002/1531-8249(199911)46:5<755::AID-ANA11>3.0.CO;2-0; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; Kent AL, 2012, PEDIATRICS, V129, P124, DOI 10.1542/peds.2011-1578; Kerenyi A, 2012, PEDIATR RES, V71, P573, DOI 10.1038/pr.2012.8; Kesler SR, 2008, J PEDIATR-US, V152, P513, DOI 10.1016/j.jpeds.2007.08.009; Knickmeyer RC, 2006, J CHILD NEUROL, V21, P825, DOI 10.1177/08830738060210101601; Kono Y, 2011, PEDIATR INT, V53, P930, DOI 10.1111/j.1442-200X.2011.03424.x; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Lang JT, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-33; Laptook AR, 2013, ANN NEUROL, V73, P520, DOI 10.1002/ana.23843; LAPTOOK AR, 1995, STROKE, V26, P1240, DOI 10.1161/01.STR.26.7.1240; LAPTOOK AR, 1994, PEDIATR RES, V35, P436, DOI 10.1203/00006450-199404000-00010; Laptook AR, 2001, PEDIATRICS, V108, P1103, DOI 10.1542/peds.108.5.1103; Lauterbach MD, 2001, NEUROPSYCHOLOGY, V15, P411, DOI 10.1037/0894-4105.15.3.411; Lee BS, 2010, PEDIATR RES, V68, P303, DOI 10.1203/00006450-201011001-00592; Liu FD, 2009, STROKE, V40, P1842, DOI 10.1161/STROKEAHA.108.538686; Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019; Luu TM, 2009, PEDIATRICS, V123, P1037, DOI 10.1542/peds.2008-1162; Ma H, 2012, CURR MOL MED, V12, P1282, DOI 10.2174/156652412803833517; Mansson J, 2015, ACTA PAEDIATR, V104, P514, DOI 10.1111/apa.12937; Manwani B, 2011, WOMENS HEALTH, V7, P319, DOI [10.2217/WHE.11.22, 10.2217/whe.11.22]; Massaro AN, 2015, DEV MED CHILD NEUROL, V57, P441, DOI 10.1111/dmcn.12646; Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007; McClure MM, 2007, BRAIN RES, V1132, P203, DOI 10.1016/j.brainres.2006.11.006; McClure MM, 2006, BRAIN RES, V1087, P190, DOI 10.1016/j.brainres.2006.03.016; McClure MM, 2005, INT J DEV NEUROSCI, V23, P351, DOI 10.1016/j.ijdevneu.2004.12.008; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; McGettigan C, 2011, J COGNITIVE NEUROSCI, V23, P961, DOI 10.1162/jocn.2010.21491; MEDEN P, 1994, BRAIN RES, V647, P131, DOI 10.1016/0006-8993(94)91407-9; Moreira RS, 2014, J PEDIAT-BRAZIL, V90, P119, DOI 10.1016/j.jped.2013.05.010; Ohmura A, 2005, BRAIN DEV-JPN, V27, P517, DOI 10.1016/j.braindev.2005.01.004; Ortiz-Mantilia S, 2008, DEV PSYCHOBIOL, V50, P107, DOI 10.1002/dev.20278; Patel SD, 2014, BIOCHEM SOC T, V42, P564, DOI 10.1042/BST20130247; Peacock JL, 2012, PEDIATR RES, V71, P305, DOI 10.1038/pr.2011.50; Peiffer AM, 2004, DEV BRAIN RES, V148, P53, DOI 10.1016/j.devbrainres.2003.09.020; Peiffer AM, 2002, NEUROREPORT, V13, P2277, DOI 10.1097/00001756-200212030-00021; Piek JP, 2008, HUM MOVEMENT SCI, V27, P668, DOI 10.1016/j.humov.2007.11.002; Potharst ES, 2013, DEV MED CHILD NEUROL, V55, P178, DOI 10.1111/dmcn.12018; Raz N, 2004, NEUROBIOL AGING, V25, P377, DOI 10.1016/S0197-4580(03)00118-0; Raz S, 2010, J INT NEUROPSYCH SOC, V16, P169, DOI 10.1017/S1355617709991147; Renolleau S, 2007, J NEUROCHEM, V100, P1062, DOI 10.1111/j.1471-4159.2006.04269.x; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Rutter M, 2003, J CHILD PSYCHOL PSYC, V44, P1092, DOI 10.1111/1469-7610.00194; Smith AL, 2015, DEV NEUROSCI-BASEL, V37, P440, DOI 10.1159/000375487; Smith AL, 2014, BRAIN SCI, V4, P240, DOI 10.3390/brainsci4020240; Smith AL, 2014, EXP NEUROL, V254, P54, DOI 10.1016/j.expneurol.2014.01.003; Spittle AJ, 2014, SEMIN FETAL NEONAT M, V19, P84, DOI 10.1016/j.siny.2013.11.005; Tsuji M, 2010, EXP NEUROL, V226, P285, DOI 10.1016/j.expneurol.2010.09.002; Van Hus JW, 2014, DEV MED CHILD NEUROL, V56, P587, DOI 10.1111/dmcn.12295; Van Lierde KM, 2009, FOLIA PHONIATR LOGO, V61, P296, DOI 10.1159/000238401; Vannucci RC, 2000, AM J PERINAT, V17, P113, DOI 10.1055/s-2000-9293; Vannucci RC, 1999, J NEUROSCI RES, V55, P158, DOI 10.1002/(SICI)1097-4547(19990115)55:2<158::AID-JNR3>3.0.CO;2-1; Vannucci RC, 1997, ANN NY ACAD SCI, V835, P234, DOI 10.1111/j.1749-6632.1997.tb48634.x; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Wagner BP, 2002, PEDIATR RES, V51, P354, DOI 10.1203/00006450-200203000-00015; Wang RH, 2001, EUR J PHARMACOL, V433, P73, DOI 10.1016/S0014-2999(01)01498-4; Xiong M, 2013, EXP NEUROL, V247, P720, DOI 10.1016/j.expneurol.2013.03.015; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Zhu CL, 2006, EUR J NEUROSCI, V23, P387, DOI 10.1111/j.1460-9568.2005.04581.x; Zwicker JG, 2013, ARCH DIS CHILD, V98, P118, DOI 10.1136/archdischild-2012-302268	95	21	21	0	3	MDPI AG	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2076-3425	2976-3425		BRAIN SCI	Brain Sci.	JUN	2015	5	2					220	240		10.3390/brainsci5020220			21	Neurosciences	Neurosciences & Neurology	CT9HB	WOS:000363126600009	26010486	DOAJ Gold, Green Published			2021-06-18	
J	Wade, NG; Vogel, DL; Armistead-Jehle, P; Meit, SS; Heath, PJ; Strass, HA				Wade, Nathaniel G.; Vogel, David L.; Armistead-Jehle, Patrick; Meit, Scott S.; Heath, Patrick J.; Strass, Haley A.			Modeling Stigma, Help-Seeking Attitudes, and Intentions to Seek Behavioral Healthcare in a Clinical Military Sample	PSYCHIATRIC REHABILITATION JOURNAL			English	Article						public stigma; self-stigma; help seeking; attitudes; military	NATIONAL-GUARD SOLDIERS; SELF-STIGMA; PSYCHOLOGICAL HELP; COMMITMENT THERAPY; PUBLIC STIGMA; ACTIVE-DUTY; BARRIERS; IMPACT; COMBAT; IRAQ	Objective: This study examined the relationship between public and self-stigma of seeking behavioral health services, and help-seeking attitudes and intent in a sample of active duty military personnel currently being assessed for traumatic brain injuries in a military health center. Although it has been suggested that many military personnel in need of care do not seek services due to concerns with stigma it is not fully clear what role different types of stigma play in the process. Method: Using previously collected data from a clinical sample of 97 military personnel, we conducted path analyses to test the mediation effects of self-stigma on the relationship between public stigma and attitudes toward and intentions to seek behavioral health care. Results: In contrast to a model of military stigma but in line with research with civilian samples, results from this study indicate that self-stigma fully mediates the relationship between public stigma and help-seeking attitudes and intentions. Conclusions and Implications for Practice: These results indicate that programming aimed at increasing mental health care use in the military might best focus on reducing self-stigma associated with seeking mental health services.	[Wade, Nathaniel G.; Vogel, David L.; Heath, Patrick J.; Strass, Haley A.] Iowa State Univ, Dept Psychol, Ames, IA USA; [Armistead-Jehle, Patrick; Meit, Scott S.] Munson Army Hlth Ctr, Dept Behav Hlth, Ft Leavenworth, KS USA	Wade, NG (corresponding author), Iowa State Univ Sci & Technol, Dept Psychol, W112 Lagomarcino Hall, Ames, IA 50011 USA.	nwade@iastate.edu	Heath, Patrick/S-2713-2019; Armistead-Jehle, Patrick/AAU-5741-2020	Heath, Patrick/0000-0002-7939-4916; Armistead-Jehle, Patrick/0000-0002-6784-1432			AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Britt TW, 2007, MIL MED, V172, P157, DOI 10.7205/MILMED.172.2.157; CASH TF, 1975, J COUNS PSYCHOL, V22, P273, DOI 10.1037/h0076730; Cornish M. A., 2012, ANN CONV AM PSYCH AS; Corrigan P, 2004, AM PSYCHOL, V59, P614, DOI 10.1037/0003-066X.59.7.614; Corrigan PW, 2009, WORLD PSYCHIATRY, V8, P75; Efron B., 1993, MONOGRAPHS STAT APPL, V57; FISCHER EH, 1995, J COLL STUDENT DEV, V36, P368; FISCHER EH, 1970, J CONSULT CLIN PSYCH, V35, P79, DOI 10.1037/h0029636; Gould M, 2010, J ROY SOC MED, V103, P148, DOI 10.1258/jrsm.2010.090426; Hammer JH, 2013, PSYCHOL MEN MASCULIN, V14, P65, DOI 10.1037/a0026813; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Kehle SM, 2010, J TRAUMA STRESS, V23, P33, DOI 10.1002/jts.20480; Kim PY, 2010, PSYCHIAT SERV, V61, P582, DOI 10.1176/ps.2010.61.6.582; Komiya N, 2000, J COUNS PSYCHOL, V47, P138, DOI 10.1037/0022-0167.47.1.138; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Lannin D. G., THE COUNSELING PSYCH; Lannin DG, 2013, J COUNS PSYCHOL, V60, P508, DOI 10.1037/a0033789; Ludwikowski WMA, 2009, J COUNS PSYCHOL, V56, P408, DOI 10.1037/a0016180; Luoma JB, 2008, ADDICT RES THEORY, V16, P149, DOI 10.1080/16066350701850295; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Martens MP, 2005, COUNS PSYCHOL, V33, P375, DOI 10.1177/0011000005274598; Masuda A, 2007, BEHAV RES THER, V45, P2764, DOI 10.1016/j.brat.2007.05.008; Mental Health Advisory Team Six, 2009, OP IR FREED 07 09; Mittal D, 2012, PSYCHIAT SERV, V63, P974, DOI 10.1176/appi.ps.201100459; Nash W. P., 2007, COMBAT STRESS INJURY, P70; Nash WP, 2009, PSYCHIAT ANN, V39, P789, DOI 10.3928/00485713-20090728-05; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shrout PE, 2002, PSYCHOL METHODS, V7, P422, DOI 10.1037//1082-989X.7.4.422; Skopp NA, 2012, J CLIN PSYCHOL, V68, P1036, DOI 10.1002/jclp.21889; Stecker T, 2007, PSYCHIAT SERV, V58, P1358, DOI 10.1176/appi.ps.58.10.1358; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Vogel DL, 2007, J COUNS PSYCHOL, V54, P40, DOI 10.1037/0022-0167.54.1.40; Vogel DL, 2006, J COUNS PSYCHOL, V53, P325, DOI 10.1037/0022-0167.53.3.325; Vogel DL, 2013, J COUNS PSYCHOL, V60, P311, DOI 10.1037/a0031889; Vogel DL, 2010, COUNS PSYCHOL, V38, P904, DOI 10.1177/0011000010368297; Wade N. G., 2013, ANN CONV AM PSYCH AS; Warner CH, 2008, MIL MED, V173, P563, DOI 10.7205/MILMED.173.6.563; Westphal RJ, 2007, MIL MED, V172, P1138, DOI 10.7205/MILMED.172.11.1138; Zinzow HM, 2013, MIL PSYCHOL, V25, P514, DOI 10.1037/mil0000015	42	21	21	0	11	CENTER PSYCHIATRIC REHABILITATION	BOSTON	BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA	1095-158X	1559-3126		PSYCHIATR REHABIL J	Psychiatr. Rehabil. J.	JUN	2015	38	2			SI		135	141		10.1037/prj0000131			7	Psychiatry; Rehabilitation	Psychiatry; Rehabilitation	DE1NE	WOS:000370392900007	25821982				2021-06-18	
J	Pistoia, F; Sacco, S; Franceschini, M; Sara, M; Pistarini, C; Cazzulani, B; Simonelli, I; Pasqualetti, P; Carolei, A				Pistoia, Francesca; Sacco, Simona; Franceschini, Marco; Sara, Marco; Pistarini, Caterina; Cazzulani, Benedetta; Simonelli, Ilaria; Pasqualetti, Patrizio; Carolei, Antonio			Comorbidities: A Key Issue in Patients with Disorders of Consciousness	JOURNAL OF NEUROTRAUMA			English	Article						vegetative state; comorbidities; minimally conscious state; outcome; brain injury	TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; PAROXYSMAL SYMPATHETIC HYPERACTIVITY; REVISED CRS-R; MEDICAL COMPLICATIONS; ITALIAN VERSION; RECOVERY; OUTCOMES; SCALE; REHABILITATION	The aim of this study was to identify the impact of comorbidities on outcomes of patients with vegetative state (VS) or minimally conscious state (MCS). All patients in VS or MCS consecutively admitted to two postacute care units within a 1-year period were evaluated at baseline and at 6 months through the Coma Recovery Scale-Revised Version and the Disability Rating Scale (DRS). Comorbidities were also recorded for each patient along the same period. Six-month outcomes included death, full recovery of consciousness, and functional improvement. One hundred and thirty-nine patients (88 male and 51 female; median age, 59 years) were included. Ninety-seven patients were in VS (70%) and 42 in MCS (30%). At 6 months, 33 patients were dead (24%), 39 had a full recovery of consciousness (28%), and 67 remained in VS or MCS (48%). According to DRS scores, 40% of patients (n=55) showed a functional improvement in the level of disability. One hundred and thirty patients (94%) showed at least one comorbidity. Severity of comorbidities (hazard ratio [HR]=2.8; 95% confidence interval [CI], 1.71-4.68; p<0.001) and the presence of ischemic or organic heart diseases (HR=2.6; 95% CI, 1.21-5.43; p=0.014) were the strongest predictors of death, together with increasing age (HR=1.0; 95% CI, 1.0-1.06; p=0.033). Respiratory diseases and arrhythmias without organic heart diseases were negative predictors of full recovery of consciousness (odds ratio [OR]=0.3; 95% CI, 0.12-0.7; p=0.006; OR=0.2; 95% CI, 0.07-0.43; p<0.001) and functional improvement (OR=0.4; 95% CI, 0.15-0.85, p=0.020; OR=0.2; 95% CI, 0.08-0.45; p<0.001). Our data show that comorbidities are common in these patients and some of them influence recovery of consciousness and outcomes.	[Pistoia, Francesca; Sacco, Simona; Carolei, Antonio] Univ Aquila, Neurol Inst, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy; [Franceschini, Marco] IRCCS San Raffaele Pisana, Dept Neurorehabil, Rome, Italy; [Sara, Marco] Hosp San Raffaele, Postcoma & Rehabil Care Unit, Cassino, Italy; [Pistarini, Caterina; Cazzulani, Benedetta] IRCCS Maugeri Fdn, Postcoma & Rehabil Care Unit, Pavia, Italy; [Simonelli, Ilaria; Pasqualetti, Patrizio] Fatebenefratelli Fdn Hlth Res & Educ, Med Stat & Informat Technol, AFaR Div, Rome, Italy; [Simonelli, Ilaria; Pasqualetti, Patrizio] IRCCS San Raffaele Pisana, Unit Clin & Mol Epidemiol, Rome, Italy	Pistoia, F (corresponding author), Univ Aquila, Neurol Inst, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.	francesca.pistoia@univaq.it	Sacco, Simona/I-5253-2012; Sara, Marco/AAB-3651-2019; Pistoia, Francesca/AAC-1027-2019; Cazzulani, Benedetta/AAC-1818-2020; Pistarini, CATERINA/K-5234-2018; Simonelli, Ilaria/K-5968-2016; Pasqualetti, Patrizio/D-4496-2013	Sacco, Simona/0000-0003-0651-1939; Cazzulani, Benedetta/0000-0002-1219-9163; Pistarini, CATERINA/0000-0001-8925-0484; Simonelli, Ilaria/0000-0002-6172-1317; Pasqualetti, Patrizio/0000-0001-5560-1979; PISTOIA, Francesca/0000-0003-0790-4240; Franceschini, Marco/0000-0002-2131-1583			ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Dolce G, 2008, J NEUROTRAUM, DOI [10.1089/neu.2008.0536, DOI 10.1089/NEU.2008.0536, 10.1089/neu.2008.0536.]; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; FEINSTEIN AR, 1970, J CHRON DIS, V23, P455, DOI 10.1016/0021-9681(70)90054-8; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Ganesh S, 2013, ARCH PHYS MED REHAB, V94, P1899, DOI 10.1016/j.apmr.2012.12.026; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Greenfield S., 1987, CLIN RES A, V35, P346; Lombardi F, 2007, FUNCT NEUROL, V22, P47; Luce JM, 2013, CHEST, V144, P1381, DOI 10.1378/chest.13-0395; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1861, DOI 10.1016/j.apmr.2013.05.027; Oppenheimer S, 2006, CLIN AUTON RES, V16, P6, DOI 10.1007/s10286-006-0276-0; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Pistoia F, 2012, J NEUROTRAUM, V29, P2328, DOI 10.1089/neu.2009.1257; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Sacco S, 2011, BRAIN INJURY, V25, P488, DOI 10.3109/02699052.2011.558043; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Sara M, 2008, BRAIN INJURY, V22, P33, DOI 10.1080/02699050701810670; Sara M, 2011, NEUROREHAB NEURAL RE, V25, P35, DOI 10.1177/1545968310378508; Sara M, 2010, NONLIN DYNAM PSYCHOL, V14, P1; Sara M, 2010, J NEUROTRAUM, V27, P771, DOI [10.1089/neu.2008.0804, 10.1089/neu.2008-0804]; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Schiff Nicholas D, 2010, Cleve Clin J Med, V77 Suppl 3, pS27, DOI 10.3949/ccjm.77.s3.05; Seel RT, 2013, ARCH PHYS MED REHAB, V94, P1908, DOI 10.1016/j.apmr.2012.11.052; StataCorp, 2007, STAT STAT SOFTW REL; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1851, DOI 10.1016/j.apmr.2013.07.003; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1877, DOI 10.1016/j.apmr.2012.12.027	32	21	22	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2015	32	10					682	688		10.1089/neu.2014.3659			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CH3ZP	WOS:000353970200003	25333386				2021-06-18	
J	Theadom, A; Parmar, P; Jones, K; Barker-Collo, S; Starkey, NJ; McPherson, KM; Ameratunga, S; Feigin, VL				Theadom, Alice; Parmar, Priya; Jones, Kelly; Barker-Collo, Suzanne; Starkey, Nicola J.; McPherson, Kathryn M.; Ameratunga, Shanthi; Feigin, Valery L.		BIONIC Res Grp	Frequency and Impact of Recurrent Traumatic Brain Injury in a Population-Based Sample	JOURNAL OF NEUROTRAUMA			English	Article						repetitive injury; cognitive functioning; recurrent injury; postconcussion symptoms; traumatic brain injury	CONCUSSION SYMPTOMS QUESTIONNAIRE; MILD HEAD-INJURY; RELIABILITY; SCALE; DIAGNOSIS; VALIDITY; AMNESIA; PLAYERS; RETURN	The aim of this study was to determine the frequency, mechanism(s), and impact of recurrent traumatic brain injury (TBI) over a 1-year period. Population-based TBI incidence and 1-year outcomes study with embedded case-control analysis. All participants (adults and children) who experienced a recurrent TBI (more than one) in the 12 months after an index injury and matched controls who sustained one TBI within the same period were enrolled in a population-based TBI incidence and outcomes study. Details of all recurrent TBIs sustained within 12 months of the initial index injury were recorded. Each recurrent TBI case was matched to a case sustaining one TBI based on age (+/- 2 years), gender, and index TBI severity. Cognitive ability, disability, and postconcussion symptoms (PCS) were assessed 1 year after the index injury. Overall, 9.9% (n=72) of TBI cases experienced at least one recurrent TBI within the year after initial index injury. Males, people <35 years of age, and those who had experienced a TBI before their index injury were at highest risk of recurrent TBI. Recurrent TBI cases reported significantly increased PCS at 1 year, compared to the matched controls (n=72) sustaining one TBI. There was no difference in overall cognitive ability and disability between the two groups. People experiencing recurrent TBIs are more likely to experience increased frequency and severity of PCS. Greater public awareness of the potential effects of recurrent brain injury is needed.	[Theadom, Alice; Parmar, Priya; Jones, Kelly; Feigin, Valery L.] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland 1142, New Zealand; [Barker-Collo, Suzanne] Univ Auckland, Dept Psychol, Auckland, New Zealand; [Starkey, Nicola J.] Univ Waikato, Sch Psychol, Hamilton, New Zealand; [McPherson, Kathryn M.] Auckland Univ Technol, Person Ctr Res Ctr, Hlth & Rehabil Inst, Auckland 1142, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand	Theadom, A (corresponding author), Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Fac Hlth & Environm Studies, AA254C,90 Akoranga Dr,Northcote 0627, Auckland 1142, New Zealand.	alice.theadom@aut.ac.nz	Jones, Kelly/I-5199-2019; Feigin, Valery/AAF-2313-2019; Starkey, Nicola/AAJ-3795-2020	Starkey, Nicola/0000-0002-4370-8186; McPherson, Kathryn/0000-0003-1240-8882; Feigin, Valery L./0000-0002-6372-1740; Ameratunga, Shanthi/0000-0001-8042-2251; Theadom, Alice/0000-0003-0351-6216; Parmar, Priya/0000-0001-6001-9326; McPherson, Kath/0000-0003-0487-8497	Health Research Council of New ZealandHealth Research Council of New Zealand [09/063A, 11/192]; ABI Management Rehabilitation	This work was funded by the Health Research Council of New Zealand (09/063A, 11/192). A.T. was cofunded by ABI Management Rehabilitation, and K.M. holds the Laura Fergusson Trust Chair. The authors thank the research team for their dedication and performance; the staff at the coroner's office in Hamilton; the staff of the New Zealand Accident Compensation Corporation and Health Information Service; Waikato District Health Board; Waikato University Staff; the many doctors, nurses, and rehabilitation professionals and service providers, such as ABI Management and administrative staff within and outside Hamilton; and the BIONIC participants and their families and friends. The authors also thank Helen McDonald for her administrative support for the study and CNS Vital Signs for their support with the neuropsychological assessment.	[Anonymous], 2010, NAT METHODS, V7, P331, DOI 10.1038/nmeth0510-331; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chapman RCG, 2010, BRAIN INJURY, V24, P797, DOI 10.3109/02699051003709607; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gualtieri C. T., 2004, AM NEUR ASS ANN M FE; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/316575; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Silverberg ND, 2013, J NEUROTRAUM, V30, P1398, DOI 10.1089/neu.2012.2827; Statistics New Zealand, 2006, REG SUMM TABL TERR A; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Winqvist S, 2008, BRAIN INJURY, V22, P780, DOI 10.1080/02699050802339397; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	40	21	21	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2015	32	10					674	681		10.1089/neu.2014.3579			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CH3ZP	WOS:000353970200002	25334048				2021-06-18	
J	Geng, CK; Cao, HH; Ying, X; Zhang, HT; Yu, HL				Geng, Cheng-Kui; Cao, Hong-Hua; Ying, Xiong; Zhang, Hong-Tian; Yu, Hua-Lin			The effects of hyperbaric oxygen on macrophage polarization after rat spinal cord injury	BRAIN RESEARCH			English	Article						Spinal cord injury; Hyperbaric oxygen therapy; Secondary damage; Macrophage polarization; Inflammation	TRAUMATIC BRAIN-INJURY; ALTERNATIVE ACTIVATION; FUNCTIONAL RECOVERY; INTERFERON-GAMMA; THERAPY; MICROGLIA; NEUROPROTECTION; INFLAMMATION; ANTAGONIST; EXPRESSION	The immunoreactive responses are a two-edged sword after spinal cord injury (SCI). Macrophages are the predominant inflammatory cells responsible for this response. However, the mechanism underlying the effects of HBOT on the immunomodulation following SCI is unclear now. The present study was performed to examine the effects of hyperbaric oxygen therapy (HBOT) on macrophage polarization after the rat compressive injury of the spinal cord. HBOT was associated with significant increases in IL-4 and IL-13 levels, and reductions in TNF-alpha and IFN-gamma levels. This was associated simultaneously with the levels of alternatively activated macrophages (M2 phenotype: arginase-1- or CD206-positive), and decreased levels of classically activated macrophages (M1 phenotype: iNOS- or CD16/32-positive). These changes were associated with functional recovery in the HBOT-transplanted group, which correlated with preserved axons and increased myelin sparing. Our results suggested that HBOT after SCI modified the inflammatory environment by shifting the macrophage phenotype from M1 to M2, which may further promote the axonal extension and functional recovery. (C) 2015 Elsevier B.V. All rights reserved.	[Geng, Cheng-Kui; Ying, Xiong] Kunming Med Univ, Affiliated Hosp 1, Yanan Hosp Kunming, Dept Orthoped, Kunming 650032, Peoples R China; [Geng, Cheng-Kui; Zhang, Hong-Tian; Yu, Hua-Lin] Kunming Med Univ, Affiliated Hosp 1, Dept Minimally Invas Neurosurg, Kunming 650032, Peoples R China; [Cao, Hong-Hua] Tumor Hosp Yunnan Prov, Dept Hematol, Kunming 650118, Peoples R China; [Cao, Hong-Hua] Kunming Med Univ, Affiliated Hosp 3, Kunming 650118, Peoples R China; [Zhang, Hong-Tian] Gen Hosp Beijing PLA, Affiliated Bayi Brain Hosp, Beijing 100700, Peoples R China	Zhang, HT (corresponding author), Kunming Med Univ, Affiliated Hosp 1, Dept Minimally Invas Neurosurg, 295 Xichang Rd, Kunming 650032, Peoples R China.	xiaohaijun_neu@126.com; zhanghongtian007@126.com			Natural Scientific Research funds of China [81371345]; Beijing Nova programBeijing Municipal Science & Technology Commission [XX2013059]	This work was supported by the Natural Scientific Research funds of China (No. 81371345) for Dr. Hong-Tian Zhang and Beijing Nova program (XX2013059) for Dr. Hong-Tian Zhang.	Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Asamoto S, 2000, SPINAL CORD, V38, P538, DOI 10.1038/sj.sc.3101023; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Chen KB, 2011, SPINE, V36, P1350, DOI 10.1097/BRS.0b013e3181f014ec; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Dayan K, 2012, LIFE SCI, V90, P360, DOI 10.1016/j.lfs.2011.12.005; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; Efrati S, 2014, EXPERT REV NEUROTHER, V14, P233, DOI 10.1586/14737175.2014.884928; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Ethuin F, 2004, LAB INVEST, V84, P1363, DOI 10.1038/labinvest.3700148; Genovese T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-58; Gertsch-Lapcevic Y, 1991, SCI Nurs, V8, P97; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Huang H, 2013, INT J CLIN EXP PATHO, V6, P1337; Huang L, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-21; Huang LX, 2003, J NEUROSURG, V99, P198, DOI 10.3171/spi.2003.99.2.0198; Kahraman S, 2007, NEUROCHEM RES, V32, P1547, DOI 10.1007/s11064-007-9354-5; Kigerl K. A., 2009, J NEUROSCI, V29, P13435; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; KNIGHTON DR, 1981, SURGERY, V90, P262; Li J, 2011, SPINAL CORD, V49, P777, DOI 10.1038/sc.2011.8; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; Makela J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011091; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; RAWE SE, 1981, NEUROSURGERY, V9, P40, DOI 10.1227/00006123-198107000-00007; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Shin WH, 2004, GLIA, V46, P142, DOI 10.1002/glia.10357; Suzuki Y, 2005, INT J PARASITOL, V35, P83, DOI 10.1016/j.ijpara.2004.10.020; Tai PA, 2010, J NEUROTRAUM, V27, P1121, DOI 10.1089/neu.2009.1162; Tompach PC, 1997, INT J ORAL MAX SURG, V26, P82, DOI 10.1016/S0901-5027(05)80632-0; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Tuna M, 2001, J NEUROSURG, V95, P64, DOI 10.3171/spi.2001.95.1.0064; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Yang J., 2013, LIFE SCI; Yang J, 2013, SPINE, V38, pE1641, DOI 10.1097/BRS.0000000000000005; Yeo J D, 1984, Cent Nerv Syst Trauma, V1, P161; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; Zhang YK, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-67	46	21	28	4	27	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 5	2015	1606						68	76		10.1016/j.brainres.2015.01.029			9	Neurosciences	Neurosciences & Neurology	CH0XR	WOS:000353746200007	25724144				2021-06-18	
J	Benromano, T; Defrin, R; Ahn, AH; Zhao, J; Pick, CG; Levy, D				Benromano, T.; Defrin, R.; Ahn, A. H.; Zhao, J.; Pick, C. G.; Levy, D.			Mild closed head injury promotes a selective trigeminal hypernociception: Implications for the acute emergence of post-traumatic headache	EUROPEAN JOURNAL OF PAIN			English	Article							TRAUMATIC BRAIN-INJURY; FORMALIN TEST; SENSORY INNERVATION; COGNITIVE DEFICITS; PAIN; PREVALENCE; RATS; MICE	BackgroundHeadache is one of the most common symptoms following traumatic head injury. The mechanisms underlying the emergence of such post-traumatic headache (PTH) remain unknown but may be related to injury of deep cranial tissues or damage to central pain processing pathways, as a result of brain injury. MethodsA mild closed head injury in mice combined with the administration of cranial or hindpaw formalin tests was used to examine post-traumatic changes in the nociceptive processing from deep cranial tissues or the hindpaw. Histological analysis was used to examine post-traumatic pro-inflammatory changes in the calvarial periosteum, a deep cranial tissue. ResultsAt 48h after head injury, mice demonstrated enhanced nociceptive responses following injection of formalin into the calvarial periosteum, a deep cranial tissue, but no facilitation of the nociceptive responses following injection of formalin into an extracranial tissue, the hindpaw. Mice also showed an increase in the number of activated periosteal mast cells 48h following mild head trauma, suggesting an inflammatory response. ConclusionOur study demonstrates that mild closed head injury is associated with enhanced processing of nociceptive information emanating from trigeminal-innervated deep cranial tissues, but not from non-cranial tissues. Based on these finding as well as the demonstration of head injury-evoked degranulation of calvarial periosteal mast cells, we propose that inflammatory-evoked enhancement of peripheral cranial nociception, rather than changes in supraspinal pain mechanisms play a role in the initial emergence of PTH. Peripheral targeting of nociceptors that innervate the calvaria may be used to ameliorate PTH pain.	[Benromano, T.; Pick, C. G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Defrin, R.] Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel; [Defrin, R.; Pick, C. G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Ahn, A. H.] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA; [Zhao, J.; Levy, D.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA	Levy, D (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA.	dlevy1@bidmc.harvard.edu	Pick, Chaim/D-4789-2009; Levy, Dan/AAF-1871-2021		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS077882, NS078263, AA020305]; National Headache Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078263, R01NS086830, R21NS077882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21AA020305] Funding Source: NIH RePORTER	This work is supported by NIH grants NS077882, NS078263 and AA020305 and the National Headache Foundation to Dr Levy.	Ahn A. H., 2008, NEUROSCIENCE M PLANN; CLAVELOU P, 1995, PAIN, V62, P295, DOI 10.1016/0304-3959(94)00273-H; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Fischer M, 2014, PAIN, V155, P511, DOI 10.1016/j.pain.2013.11.015; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Keidel M, 2006, HEADACHES, P863; Kosaras B, 2009, J COMP NEUROL, V515, P331, DOI 10.1002/cne.22049; Levy D, 2007, PAIN, V130, P166, DOI 10.1016/j.pain.2007.03.012; Levy D, 2009, CURR PAIN HEADACHE R, V13, P237, DOI 10.1007/s11916-009-0040-y; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; McCall WD, 1996, NEUROSCI LETT, V208, P45, DOI 10.1016/0304-3940(96)12552-0; McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scher AI, 2014, CEPHALALGIA, V34, P83, DOI 10.1177/0333102413499644; Schueler M, 2013, PAIN, V154, P1622, DOI 10.1016/j.pain.2013.04.040; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; VOS BP, 1994, J NEUROSCI, V14, P2708; Zhao J, 2014, PAIN, V155, P1392, DOI 10.1016/j.pain.2014.04.019; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	24	21	21	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAY	2015	19	5					621	628		10.1002/ejp.583			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	CF6FW	WOS:000352653500005	25168788	Green Accepted			2021-06-18	
J	Halaweish, I; Bambakidis, T; He, W; Linzel, D; Chang, ZG; Srinivasan, A; Dekker, SE; Liu, BL; Li, YQ; Alam, HB				Halaweish, Ihab; Bambakidis, Ted; He, Wei; Linzel, Durk; Chang, Zhigang; Srinivasan, Ashok; Dekker, Simone E.; Liu, Baoling; Li, Yongqing; Alam, Hasan B.			Early Resuscitation with Fresh Frozen Plasma for Traumatic Brain Injury Combined with Hemorrhagic Shock Improves Neurologic Recovery	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							LARGE-ANIMAL-MODEL; EMERGENCY-DEPARTMENT THORACOTOMY; SEVERE HEAD-INJURY; NORMAL SALINE; ENDOTHELIAL PERMEABILITY; PLATELET DYSFUNCTION; INDUCED COAGULOPATHY; MASSIVE TRANSFUSION; INDUCED HYPOTHERMIA; LYOPHILIZED PLASMA	BACKGROUND: We have shown that early administration of fresh frozen plasma (FFP) reduces the size of brain lesions 6 hours after injury in a large animal model of traumatic brain injury (TBI) and hemorrhagic shock (HS). To examine long-term outcomes, we hypothesized that early treatment with FFP would result in faster neurologic recovery and better long-term outcomes in a combined TBI and HS model. STUDY DESIGN: Anesthetized Yorkshire swine underwent combined TBI and volume-controlled hemorrhage (40% blood volume). After 2 hours of shock, animals were randomized (n = 5/group) to normal saline (3 x shed blood) or FFP (1 x shed blood) treatment. A neurologic severity score was assessed for 30 days. Magnetic resonance imaging of the brain was performed at days 3, 10, and 24. Cognitive function was tested by training animals to retrieve food from color-coded boxes. RESULTS: Neurologic impairment was lower and speed of recovery was considerably faster in the FFPtreated animals. There was a trend toward a smaller lesion size in FFP-treated animal at days 3 and 10, but this did not reach statistical significance. Both groups reached baseline performance on the cognitive testing; however, FFP-treated animals were able to participate, on average, 8 days earlier due to quicker recovery. CONCLUSIONS: This is the first study to demonstrate the beneficial effects of FFP treatment in a long-term survival model of combined TBI and HS. Our data show that early treatment with FFP substantially attenuates the degree of neurologic impairment, improves the rate of recovery, and preserves the cognitive functions. (C) 2015 by the American College of Surgeons	[Halaweish, Ihab; Bambakidis, Ted; Liu, Baoling; Li, Yongqing; Alam, Hasan B.] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA; [Srinivasan, Ashok] Univ Michigan Hosp, Neuroradiol Sect, Dept Radiol, Ann Arbor, MI 48109 USA; [He, Wei] Southeast Univ, Sch Med, Zhongda Hosp, Dept Cardiothorac Surg, Nanjing, Peoples R China; [Chang, Zhigang] Beijing Hosp Minist Hlth, Beijing, Peoples R China; [Linzel, Durk] Flevoziekenhuis Hosp, Dept Emergency Med, Almere, Netherlands; [Dekker, Simone E.] Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Dept Anesthesiol, Amsterdam, Netherlands	Alam, HB (corresponding author), Univ Michigan Hosp, Dept Surg, 2920 Taubman Ctr 5331,1500 Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]	Dr Alam received a grant from the US Army Medical Research and Materiel Command (GRANTT00521959).	Alam HB, 2002, SURGERY, V132, P278, DOI 10.1067/msy.2002.125787; [Anonymous], 2007, J NEUROTRAUM, V24, pS1, DOI 10.1089/neu.2007.9997; [Anonymous], 1999, JAMA, V282, P974; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Baker AJ, 2008, J TRAUMA, V64, P348, DOI 10.1097/01.ta.0000245973.71929.db; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Cao YN, 2014, J TRAUMA ACUTE CARE, V77, P28, DOI 10.1097/TA.0000000000000276; Cardenas JC, 2014, CURR OPIN HEMATOL, V21, P404, DOI 10.1097/MOH.0000000000000063; Centers for Disease Control and Prevention, INJ PREV CONTR LEAD; Centers for Disease Control and Prevention, INJ PREV CONTR WEB B; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Dardiotis E, 2012, BRAIN INJURYEPATHOGE; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Dekker SE, 2014, SURGERY, V156, P556, DOI 10.1016/j.surg.2014.04.016; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Difede J, 2010, ANN NY ACAD SCI, V1208, P1, DOI 10.1111/j.1749-6632.2010.05795.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gentilello L, 2000, J TRAUMA, V48, P447; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Gonzalez EA, 2006, J TRAUMA, V61, P66, DOI 10.1097/01.ta.0000224190.65542.e2; Hartog CS, 2011, ANESTH ANALG, V112, P156, DOI 10.1213/ANE.0b013e3181eaff91; HOFFMAN M, 1990, AM J CLIN PATHOL, V93, P694, DOI 10.1093/ajcp/93.5.694; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Hwabejire JO, 2013, J TRAUMA ACUTE CARE, V75, P968, DOI 10.1097/TA.0b013e31829a021a; Imam AM, 2013, J TRAUMA ACUTE CARE, V75, P976, DOI 10.1097/TA.0b013e31829e2186; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Matijevic N, 2013, J TRAUMA ACUTE CARE, V74, P84, DOI 10.1097/TA.0b013e3182788e32; McCully SP, 2013, SEMIN THROMB HEMOST, V39, P896, DOI 10.1055/s-0033-1357484; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Moore EE, 2014, SHOCK, V41, P35, DOI 10.1097/SHK.0000000000000110; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nichol AD, 2009, INJURY, V40, P471, DOI 10.1016/j.injury.2009.01.002; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Sailliol A, 2013, TRANSFUSION, V53, p65S, DOI 10.1111/trf.12038; Schenk S, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-41; Schrieber M, 2007, J TRAUMA, V63, P1261; Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P998, DOI 10.1097/TA.0000000000000193; Sillesen M, 2013, SURGERY, V154, P197, DOI 10.1016/j.surg.2013.04.002; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Spinella PC, 2009, J TRAUMA, V66, pS69, DOI 10.1097/TA.0b013e31819d85fb; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012	51	21	22	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	MAY	2015	220	5					809	819		10.1016/j.jamcollsurg.2015.01.057			11	Surgery	Surgery	CG5OP	WOS:000353342200010	25907868				2021-06-18	
J	Reid, MW; Velez, CS				Reid, Matthew W.; Velez, Carmen S.			Discriminating military and civilian traumatic brain injuries	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Military; Blast exposure; Polytrauma; Comorbidity	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; OEF/OIF SERVICE MEMBERS; CHRONIC PAIN; BLAST EXPOSURES; WAR VETERAN; PREVALENCE; IRAQ; AFGHANISTAN; HEALTH	Traumatic brain injury (TBI) occurs at higher rates among service members than civilians. Explosions from improvised explosive devices and mines are the leading cause of TBI in the military. As such, TBI is frequently accompanied by other injuries, which makes its diagnosis and treatment difficult. In addition to postconcussion symptoms, those who sustain a TBI commonly report chronic pain and posttraumatic stress symptoms. This combination of symptoms is so typical they have been referred to as the "polytrauma clinical triad" among injured service members. We explore whether these symptoms discriminate civilian occurrences of TBI from those of service members, as well as the possibility that repeated blast exposure contributes to the development of chronic traumatic encephalopathy (CTE). This article is part of a Special Issue entitled 'Traumatic Brain Injury'. (C) 2015 Elsevier Inc. All rights reserved.	[Reid, Matthew W.] Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Reid, Matthew W.; Velez, Carmen S.] San Antonio Mil Med Ctr, San Antonio, TX USA	Reid, MW (corresponding author), Def & Vet Brain Injury Ctr, Washington, DC 20307 USA.	matthew.w.reid2.ctr@mail.mil					Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Adler NE, 2010, ANN NY ACAD SCI, V1186, P1, DOI 10.1111/j.1749-6632.2009.05385.x; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Alfano DP, 2006, BRAIN COGNITION, V60, P194; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bosco MA, 2013, HEADACHE, V53, P1518, DOI 10.1111/head.12172; Braveman P, 2011, ANNU REV PUBL HEALTH, V32, P381, DOI 10.1146/annurev-publhealth-031210-101218; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Casscells S., 2007, HLTH AFFAIRS MEMORAN; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; DVBIC, 2014, DOD WORLDW TBI NUMB; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Gill IJ, 2014, BRAIN INJURY, V28, P1, DOI 10.3109/02699052.2013.851416; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald C.L, 2015, BRAIN; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; Norris JN, 2014, BRAIN INJURY, V28, P1052, DOI 10.3109/02699052.2014.891761; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; PITMAN RK, 1989, AM J PSYCHIAT, V146, P667; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Turk DC, 2010, HDB PAIN ASSESSMENT; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Winterstein CE, 1937, LANCET, V230, P719; Zhu F, 2013, J MECH MED BIOL, V13, DOI 10.1142/S0219519413500656; Zou YY, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-79	70	21	21	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		123	128		10.1016/j.mcn.2015.03.014			6	Neurosciences	Neurosciences & Neurology	CK7FT	WOS:000356398900008	25827093				2021-06-18	
J	Lim, YW; Meyer, NP; Shah, AS; Budde, MD; Stemper, BD; Olsen, CM				Lim, Yi Wei; Meyer, Nathan P.; Shah, Alok S.; Budde, Matthew D.; Stemper, Brian D.; Olsen, Christopher M.			Voluntary Alcohol Intake following Blast Exposure in a Rat Model of Mild Traumatic Brain Injury	PLOS ONE			English	Article							SUBSTANCE-ABUSE; ETHANOL-CONSUMPTION; PREFRONTAL CORTEX; ANIMAL-MODELS; DRINKING; OVERPRESSURE; PREFERENCE; RESISTANT; ADDICTION; BEHAVIOR	Alcoholism is a frequent comorbidity following mild traumatic brain injury (mTBI), even in patients without a previous history of alcohol dependence. Despite this correlational relationship, the extent to which the neurological effects of mTBI contribute to the development of alcoholism is unknown. In this study, we used a rodent blast exposure model to investigate the relationship between mTBI and voluntary alcohol drinking in alcohol naive rats. We have previously demonstrated in Sprague Dawley rats that blast exposure leads to microstructural abnormalities in the medial prefrontal cortex (mPFC) and other brain regions that progress from four to thirty days. The mPFC is a brain region implicated in alcoholism and drug addiction, although the impact of mTBI on drug reward and addiction using controlled models remains largely unexplored. Alcohol naive Sprague Dawley rats were subjected to a blast model of mTBI (or sham conditions) and then tested in several common measures of voluntary alcohol intake. In a seven-week intermittent two-bottle choice alcohol drinking test, sham and blast exposed rats had comparable levels of alcohol intake. In a short access test session at the conclusion of the two-bottle test, blast rats fell into a bimodal distribution, and among high intake rats, blast treated animals had significantly elevated intake compared to shams. We found no effect of blast when rats were tested for an alcohol deprivation effect or compulsive drinking in a quinine adulteration test. Throughout the experiment, alcohol drinking was modest in both groups, consistent with other studies using Sprague Dawley rats. In conclusion, blast exposure had a minimal impact on overall alcohol intake in Sprague Dawley rats, although intake was increased in a subpopulation of blast animals in a short access session following intermittent access exposure.	[Lim, Yi Wei; Meyer, Nathan P.; Budde, Matthew D.; Stemper, Brian D.; Olsen, Christopher M.] Med Coll Wisconsin, Neurosci Res Ctr, Milwaukee, WI 53226 USA; [Lim, Yi Wei; Meyer, Nathan P.; Olsen, Christopher M.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Shah, Alok S.; Budde, Matthew D.; Stemper, Brian D.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Shah, Alok S.; Budde, Matthew D.; Stemper, Brian D.] Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA	Olsen, CM (corresponding author), Med Coll Wisconsin, Neurosci Res Ctr, Milwaukee, WI 53226 USA.	colsen@mcw.edu	Olsen, Christopher/G-9595-2013; Stemper, Brian/AAX-7611-2020	Olsen, Christopher/0000-0003-2700-0310; 	Neuroscience Research Center at the Medical College of Wisconsin; Research and Education Initiative Fund , a component of the Advancing a Healthier Wisconsin Endowment at the Medical College of Wisconsin; United States (U.S.) Department of Veterans AffairsUS Department of Veterans Affairs [I01 RX000380]; Veterans Health Administration, Rehabilitation Research and Development Service Program, and Veterans Affairs Medical Research; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R21DA039276] Funding Source: NIH RePORTER	This work was supported by the Neuroscience Research Center at the Medical College of Wisconsin (CMO), the Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin Endowment at the Medical College of Wisconsin (CMO), Merit Review Award I01 RX000380 from the United States (U.S.) Department of Veterans Affairs (MDB), Veterans Health Administration, Rehabilitation Research and Development Service Program, and Veterans Affairs Medical Research (BDS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abernathy K, 2010, INT REV NEUROBIOL, V91, P289, DOI 10.1016/S0074-7742(10)91009-X; Adams RS, 2012, J HEAD TRAUMA REHAB, V27, P349, DOI 10.1097/HTR.0b013e318268db94; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; AMIT Z, 1970, PSYCHOPHARMACOLOGIA, V17, P367, DOI 10.1007/BF00403808; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; Beck A, 2012, ARCH GEN PSYCHIAT, V69, P842, DOI 10.1001/archgenpsychiatry.2011.2026; Becker HC, 2013, CURR TOP BEHAV NEURO, V13, P355, DOI 10.1007/7854_2012_203; Bito-Onon JJ, 2011, ADDICT BIOL, V16, P440, DOI 10.1111/j.1369-1600.2010.00309.x; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Camicella S, 2009, ALCOHOL, V43, P35, DOI 10.1016/j.alcohol.2008.12.001; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Control NcfIPa, 2003, REP C MILD TRAUM BRA; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Edwards S, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.70; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fein G, 2002, ALCOHOL CLIN EXP RES, V26, P558, DOI 10.1111/j.1530-0277.2002.tb02574.x; Fetzner MG, 2011, DEPRESS ANXIETY, V28, P632, DOI 10.1002/da.20852; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119; Grant BF, 2004, DRUG ALCOHOL DEPEN, V74, P223, DOI 10.1016/j.drugalcdep.2004.02.004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holmes A, 2012, NAT NEUROSCI, V15, P1359, DOI 10.1038/nn.3204; Hopf FW, 2010, ALCOHOL CLIN EXP RES, V34, P1565, DOI 10.1111/j.1530-0277.2010.01241.x; KHANNA JM, 1990, ALCOHOL, V7, P429, DOI 10.1016/0741-8329(90)90027-A; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Li J, 2011, BRAIN RES BULL, V86, P428, DOI 10.1016/j.brainresbull.2011.08.013; LINSEMAN MA, 1987, PSYCHOPHARMACOLOGY, V92, P254; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lowing JL, 2014, J NEUROTRAUMA; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayeux JP, 2015, BEHAV BRAIN RES, V279, P22, DOI 10.1016/j.bbr.2014.10.053; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; Moorman DE, 2009, ALCOHOL, V43, P379, DOI 10.1016/j.alcohol.2009.07.002; Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Samson HH, 2003, INT REV NEUROBIOL, V54, P109; Seif T, 2013, NAT NEUROSCI, V16, P1094, DOI 10.1038/nn.3445; Shah Ms Alok S, 2012, Biomed Sci Instrum, V48, P393; Simms JA, 2008, ALCOHOL CLIN EXP RES, V32, P1816, DOI 10.1111/j.1530-0277.2008.00753.x; SINCLAIR JD, 1968, Q J STUD ALCOHOL, V29, P863; Stemper BD, 2014, ANN BIOMED ENG; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teng SX, 2014, BRAIN BEHAV IMMUN; Tiffany ST, 2000, ADDICTION, V95, pS145, DOI 10.1046/j.1360-0443.95.8s2.3.x; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vengeliene V, 2014, ALCOHOL, V48, P313, DOI 10.1016/j.alcohol.2014.03.002; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; WISE RA, 1973, PSYCHOPHARMACOLOGIA, V29, P203, DOI 10.1007/BF00414034; Yoneyama N, 2008, ALCOHOL, V42, P149, DOI 10.1016/j.alcohol.2007.12.006; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	66	21	22	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2015	10	4							e0125130	10.1371/journal.pone.0125130			15	Multidisciplinary Sciences	Science & Technology - Other Topics	CG6AH	WOS:000353376800130	25910266	DOAJ Gold, Green Published			2021-06-18	
J	Iordens, GIT; Den Hartog, D; Van Lieshout, EMM; Tuinebreijer, WE; De Haan, J; Patka, P; Verhofstad, MHJ; Schep, NWL				Iordens, Gijs I. T.; Den Hartog, Dennis; Van Lieshout, Esther M. M.; Tuinebreijer, Wim E.; De Haan, Jeroen; Patka, Peter; Verhofstad, Michael H. J.; Schep, Niels W. L.		Dutch Elbow Collaborative	Good Functional Recovery of Complex Elbow Dislocations Treated With Hinged External Fixation: A Multicenter Prospective Study	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							ULNAR COLLATERAL LIGAMENT; FRACTURE-DISLOCATIONS; RADIAL HEAD; CORONOID FRACTURES; PRIMARY REPAIR; INSTABILITY; MANAGEMENT; INJURIES; JOINT; COMPLICATIONS	After a complex dislocation, some elbows remain unstable after closed reduction or fracture treatment. Function after treatment with a hinged external fixator theoretically allows collateral ligaments to heal without surgical reconstruction. However, there is a lack of prospective studies that assess functional outcome, pain, and ROM. We asked: (1) In complex elbow fracture-dislocations, does treatment with a hinged external fixator result in reduction of disability and pain, and in improvement in ROM, function, and quality of life? (2) Does delayed treatment (7 days or later) have a negative effect on ROM after 1 year? (3) What are the complications seen after external fixator treatment? During a 2-year period, 11 centers recruited 27 patients 18 years or older who were included and evaluated at 2 and 6 weeks and at 3, 6, and 12 months after surgery as part of this prospective case series. During the study period, the participating centers agreed on general indications for use of the hinged external fixator, which included persistent instability after closed reduction alone or closed reduction combined with surgical treatment of associated fracture(s), when indicated. Functional outcome was evaluated using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH; primary outcome) score, the Mayo Elbow Performance Index (MEPI), the Oxford Elbow Score, and the level of pain (VAS). ROM, adverse events, secondary interventions, and radiographs also were evaluated. A total of 26 of the 27 patients (96%) were available for followup at 1 year. All functional and pain scores improved. The median QuickDASH score decreased from 30 (25(th)-75(th) percentiles [P-25-P-75], 23-40) at 6 weeks to 7 (P-25-P-75, 2-12) at 1 year with a median difference of -25 (p < 0.001). The median MEPI score increased from 80 (P-25-P-75, 64-85) at 6 weeks to 100 (P-25-P-75, 85-100) at 1 year with a median difference of 15 (p < 0.001). The median Oxford Elbow Score increased from 60 (P-25-P-75, 44-68) at 6 weeks to 90 (P-25-P-75, 73-96) at 1 year with a median difference of 29 (p < 0.001). The median VAS decreased from 2.8 (P-25-P-75, 1.0-5.0) at 2 weeks to 0.5 (P-25-P-75, 0.0-1.9) at 1 year with a median difference of -2.1 (p = 0.001). ROM also improved. The median flexion-extension arc improved from 50A degrees (P-25-P-75, 33A degrees-80A degrees) at 2 weeks to 118A degrees (P-25-P-75, 105A degrees-138A degrees) at 1 year with a median difference of 63A degrees (p < 0.001). Similarly, the median pronation-supination arc improved from 90A degrees (P-25-P-75, 63A degrees-124A degrees) to 160A degrees (P-25-P-75, 138A degrees-170A degrees) with a median difference of 75A degrees (p < 0.001). At 1 year, the median residual deficit compared with the uninjured side was 30A degrees (P-25-P-75, 5A degrees-35A degrees) for the flexion-extension arc, and 3A degrees (P-25-P-75, 0A degrees-25A degrees) for the pronation-supination arc. Ten patients (37%) experienced a fixator-related complication, and seven patients required secondary surgery (26%). One patient reported recurrent instability. A hinged external elbow fixator provides enough stability to start early mobilization after an acute complex elbow dislocation and residual instability. This was reflected in good functional outcome scores and only slight disability despite a relatively high complication rate. Level IV, therapeutic study.	[Iordens, Gijs I. T.; Den Hartog, Dennis; Van Lieshout, Esther M. M.; Tuinebreijer, Wim E.; Patka, Peter; Verhofstad, Michael H. J.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg, Trauma Res Unit, NL-3000 CA Rotterdam, Netherlands; [De Haan, Jeroen] Westfriesgasthuis, Dept Surg, Hoorn, Netherlands; [Schep, Niels W. L.] Univ Amsterdam, Acad Med Ctr, Dept Surg, Trauma Unit, NL-1105 AZ Amsterdam, Netherlands	Den Hartog, D (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg, Trauma Res Unit, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.denhartog@erasmusmc.nl			Osteosynthesis and Trauma Care (OTC) Foundation (Zuchwil, Switzerland) [2009-NSPP]; Orthofix SRL (Bussolengo, Italy)	The institution of one or more of the authors (GITI, DDH, EMMVL, PP, MHJV) has received, during the study period, funding from the Osteosynthesis and Trauma Care (OTC) Foundation (Zuchwil, Switzerland) (No. 2009-NSPP) and from Orthofix SRL (Bussolengo, Italy).	Anakwe RE, 2011, J BONE JOINT SURG AM, V93A, P1220, DOI 10.2106/JBJS.J.00860; Beaton D E, 2001, J Hand Ther, V14, P128; Cheung EV, 2008, J SHOULDER ELB SURG, V17, P447, DOI 10.1016/j.jse.2007.10.006; Dawson J, 2008, J BONE JOINT SURG BR, V90B, P466, DOI 10.1302/0301-620X.90B4.20290; Duckworth AD, 2008, J SHOULDER ELB SURG, V17, P281, DOI 10.1016/j.jse.2007.06.007; Egol KA, 2007, BULL HOSP JT DIS, V65, P263; Floor S, 2006, Ned Tijdschr Geneeskd, V150, P1724; Forthman C, 2007, J HAND SURG-AM, V32A, P1200, DOI 10.1016/j.jhsa.2007.06.019; Foruria Antonio M, 2013, J Bone Joint Surg Am, V95, pe66, DOI 10.2106/JBJS.K.01533; Garrigues GE, 2011, J BONE JOINT SURG AM, V93A, P1873, DOI 10.2106/JBJS.I.01673; HEFTI F, 1995, ORTHOPADE, V24, P237; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Ivo R, 2009, STRATEG TRAUMA LIMB, V4, P49, DOI 10.1007/s11751-009-0064-1; JOHNSTON G W, 1962, Ulster Med J, V31, P51; JOSEFSSON PO, 1987, J BONE JOINT SURG AM, V69A, P605, DOI 10.2106/00004623-198769040-00018; Jupiter JB, 2002, J BONE JOINT SURG AM, V84A, P1630, DOI 10.2106/00004623-200209000-00017; Maripuri SN, 2007, INJURY, V38, P1254, DOI 10.1016/j.injury.2007.02.040; McKee MD, 1998, J BONE JOINT SURG BR, V80B, P1031, DOI 10.1302/0301-620X.80B6.8536; McKee Michael D, 2005, J Bone Joint Surg Am, V87 Suppl 1, P22, DOI 10.2106/JBJS.D.02933; MEHLHOFF TL, 1988, J BONE JOINT SURG AM, V70A, P244, DOI 10.2106/00004623-198870020-00013; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; MORREY BF, 1995, J BONE JOINT SURG AM, V77A, P316, DOI 10.2106/00004623-199502000-00019; Morrey BF, ELBOW ITS DISORDERS, P2; Mughal M, 2013, J HAND SURG-EUR VOL, V38, P686, DOI 10.1177/1753193412449579; ODRISCOLL SW, 1991, J BONE JOINT SURG AM, V73A, P440, DOI 10.2106/00004623-199173030-00015; Pollock JW, 2009, J SHOULDER ELB SURG, V18, P408, DOI 10.1016/j.jse.2009.01.009; PROTZMAN RR, 1978, J BONE JOINT SURG AM, V60, P539, DOI 10.2106/00004623-197860040-00019; Pugh DMW, 2004, J BONE JOINT SURG AM, V86A, P1122, DOI 10.2106/00004623-200406000-00002; Rafai M, 1999, Chir Main, V18, P272; REGAN W, 1989, J BONE JOINT SURG AM, V71A, P1348, DOI 10.2106/00004623-198971090-00011; Ring D, 2002, J BONE JOINT SURG AM, V84A, P547, DOI 10.2106/00004623-200204000-00006; Ring D, 2004, J HAND SURG-AM, V29A, P470, DOI 10.1016/j.jhsa.2004.01.005; Ring D, 2014, CLIN ORTHOP RELAT R, V472, P2044, DOI 10.1007/s11999-014-3510-4; Ruch D S, 2001, Injury, V32 Suppl 4, pSD70; Savoie FH, 2008, AM J SPORT MED, V36, P1066, DOI 10.1177/0363546508315201; Schep NWL, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-130; Schippinger G, 1999, LANGENBECK ARCH SURG, V384, P294, DOI 10.1007/s004230050206; Sorensen AKB, 2011, J SHOULDER ELB SURG, V20, P1300, DOI 10.1016/j.jse.2011.06.002; Stavlas P, 2004, INJURY, V35, P1158, DOI 10.1016/j.injury.2003.09.002; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yu JR, 2007, J SHOULDER ELB SURG, V16, P60, DOI 10.1016/j.jse.2006.01.008; Zeiders GJ, 2008, J BONE JOINT SURG AM, V90A, P75, DOI 10.2106/JBJS.H.00893	42	21	24	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	APR	2015	473	4					1451	1461		10.1007/s11999-014-3959-1			11	Orthopedics; Surgery	Orthopedics; Surgery	CD2DY	WOS:000350885600041	25352259	Green Published			2021-06-18	
J	Wiley, CA; Bonneh-Barkay, D; Dixon, CE; Lesniak, A; Wang, GJ; Bissel, SJ; Kochanek, PM				Wiley, Clayton A.; Bonneh-Barkay, Dafna; Dixon, C. Edward; Lesniak, Andrew; Wang, Guoji; Bissel, Stephanie J.; Kochanek, Patrick M.			Role for mammalian chitinase 3-like protein 1 in traumatic brain injury	NEUROPATHOLOGY			English	Article						BRP-39; chitinase 3-like protein 1; controlled cortical impact; neuroinflammation; traumatic brain injury	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; REACTIVE ASTROCYTES; TRANSGENIC INHIBITION; YKL-40 EXPRESSION; INFLAMMATION; TISSUE; DEGENERATION; MICE; EVOLUTION; CHI3L1	Traumatic brain injury (TBI) is accompanied by inflammatory infiltrates and CNS tissue response. The astrocytosis associated with TBI has been proposed to have both beneficial and detrimental effects on surviving neural tissue. We recently observed prominent astrocytic expression of YKL-40/chitinase 3-like protein 1 (CHI3L1) associated with severity of brain injury. The physiological role of CHI3L1 in the CNS is unknown; however, its distribution at the perimeter of contusions and temporal course of expression suggested that in TBI it might be an important component of the astrocytic response to modulate CNS inflammation. To address this hypothesis, we used serially sectioned brains to quantitatively compare the neuropathological outcomes of TBI produced by controlled cortical impact in wild type (WT) and chi3l1 knockout (KO) mice where the murine YKL-40 homologue, breast regression protein 39 (BRP-39/CHI3l1), had been homozygously disrupted. At 21 days post-injury, chi3l1KO mice displayed greater astrocytosis (increased GFAP staining) in the hemispheres ipsilateral and contralateral to impact compared with WT mice. Similarly, Iba1 expression as a measure of microglial/macrophage response was significantly increased in chi3l1KO compared with WT in the hemisphere contralateral to impact. We conclude that astrocytic expression of CHI3L1 limits the extent of both astrocytic and microglial/macrophage facets of neuroinflammation and suggests a novel potential therapeutic target for modulating neuroinflammation.	[Wiley, Clayton A.; Bonneh-Barkay, Dafna; Lesniak, Andrew; Wang, Guoji; Bissel, Stephanie J.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Dept Neurosurg Anesthesiol, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurosurg Anesthesiol, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Dixon, C. Edward; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Anesthesiol & Pediat, Pittsburgh, PA 15213 USA	Wiley, CA (corresponding author), Univ Pittsburgh, Dept Pathol, S701 Scaife Hall 200 Lothrop, Pittsburgh, PA 15213 USA.	wiley1@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 070003, NS079061, NS 30318, K24 MH01717]; Pittsburgh Foundation Emmerling funds	We thank Mark Stauffer, Arlene Carbone-Wiley and Advait Salgarkar for valuable technical assistance. This work was supported, partly by funds from NIH NINDS NS 070003 to PMK; NS079061 to CED; NS 30318 to CED and PMK; K24 MH01717 to CAW, and Pittsburgh Foundation Emmerling funds to DB-B.	Bonneh-Barkay D, 2008, AM J PATHOL, V173, P130, DOI 10.2353/ajpath.2008.080045; Bonneh-Barkay D, 2012, J NEUROPATH EXP NEUR, V71, P948, DOI 10.1097/NEN.0b013e31826eaee7; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; Bonneh-Barkay D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-34; Brambilla R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-213; Brambilla R, 2009, J IMMUNOL, V182, P2628, DOI 10.4049/jimmunol.0802954; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Bussink AP, 2007, GENETICS, V177, P959, DOI 10.1534/genetics.107.075846; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Foley LM, 2009, J NEUROTRAUM, V26, P1509, DOI 10.1089/neu.2008.0747; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Haroon F, 2011, J IMMUNOL, V186, P6521, DOI 10.4049/jimmunol.1001135; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Hoffman GE, 2004, PEPTIDES, V25, P425, DOI 10.1016/j.peptides.2004.02.004; Isse K, 2012, AM J TRANSPLANT, V12, P27, DOI 10.1111/j.1600-6143.2011.03797.x; Johansen JS, 2006, DAN MED BULL, V53, P172; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kirkpatrick RB, 1997, EXP CELL RES, V237, P46, DOI 10.1006/excr.1997.3764; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kular L, 2011, BIOCHIMIE, V93, P377, DOI 10.1016/j.biochi.2010.11.010; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Ober C, 2009, CURR OPIN ALLERGY CL, V9, P401, DOI 10.1097/ACI.0b013e3283306533; Rehli M, 2003, J BIOL CHEM, V278, P44058, DOI 10.1074/jbc.M306792200; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Voskuhl RR, 2009, J NEUROSCI, V29, P11511, DOI 10.1523/JNEUROSCI.1514-09.2009	38	21	22	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	APR	2015	35	2					95	106		10.1111/neup.12158			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CF5WV	WOS:000352628900001	25377763				2021-06-18	
J	Lorente, L; Martin, MM; Gonzalez-Rivero, AF; Argueso, M; Ramos, L; Sole-Violan, J; Caceres, JJ; Jimenez, A; Borreguero-Leon, JM				Lorente, Leonardo; Martin, Maria M.; Gonzalez-Rivero, Agustin F.; Argueso, Monica; Ramos, Luis; Sole-Violan, Jordi; Caceres, Juan J.; Jimenez, Alejandro; Borreguero-Leon, Juan M.			Serum Levels of Caspase-Cleaved Cytokeratin-18 in Patients with Severe Traumatic Brain Injury Are Associated with Mortality: A Pilot Study	PLOS ONE			English	Article							CELL APOPTOSIS; BCL-2 FAMILY; DEATH; BIOMARKERS; EXPRESSION; FRAGMENTS; THERAPY; LIVER	Objective There have been found apoptotic changes in brain tissue samples from animals and humans after a traumatic brain injury (TBI). The protein cytokeratin 18 (CK-18), present in epithelial cells, is cleaved by the action of caspases during apoptosis, and the resulting fragments are released into the blood as caspase-cleaved CK (CCCK)-18. Circulating levels of CCCK-18, as biomarker of apoptosis, have been determined in patients with different processes; however, it has not been explored in TBI patients. Thus, the objective of this study was to determine whether there is an association between serum CCCK-18 levels and mortality and whether such levels could be used as a biomarker to predict outcomes in TBI patients. Methods A prospective, observational, multicenter study carried out in six Spanish Intensive Care Units. We included patients with severe TBI defined as Glasgow Coma Scale (GCS) lower than 9; and were excluded those patients with Injury Severity Score (ISS) in non-cranial aspects higher than 9. We measured serum CCCK-18 levels at admission. The end-point of the study was 30-day mortality. Results Surviving patients (n = 73) showed lower serum CCCK-18 levels (P = 0.003) than non-survivors (n = 27). On ROC analysis, the area under the curve (AUC) for serum CCCK-18 levels as predictor of 30-day mortality was 0.69 (95% CI = 0.59-0.78; P = 0.006). We found in survival analysis that patients with serum CCCK-18 higher than 201 u/L had higher 30-day mortality than patients with lower levels (Hazard ratio = 3.9; 95% CI = 1.81-8.34; P< 0.001). Regression analyses showed that serum CCCK-18 levels higher than 201 u/L were associated with 30-day mortality (OR = 8.476; 95% CI = 2.087-34.434; P = 0.003) after controlling for age and GCS. Conclusions The novel finding of our study was that serum CCCK-18 levels are associated with 30-day mortality and could be used as a prognostic biomarker in patients with severe TBI.	[Lorente, Leonardo] Hosp Univ Canarias, Intens Care Unit, Tenerife, Spain; [Martin, Maria M.] Hosp Univ Nuestra Senora de Candelaria, Intens Care Unit, Santa Cruz De Tenerife, Spain; [Gonzalez-Rivero, Agustin F.; Borreguero-Leon, Juan M.] Hosp Univ Canarias, Lab Deparment, Tenerife, Spain; [Argueso, Monica] Univ Valencia, Hosp Clin, Intens Care Unit, Valencia, Spain; [Ramos, Luis] Hosp Gen La Palma, Intens Care Unit, Brena Alta, La Palma, Spain; [Sole-Violan, Jordi] Hosp Univ Dr Negrin, CIBERES, Intens Care Unit, Las Palmas Gran Canaria, Spain; [Caceres, Juan J.] Hosp Insular, Intens Care Unit, Las Palmas Gran Canaria, Spain; [Jimenez, Alejandro] Hosp Univ Canarias, Res Unit, Tenerife, Spain	Lorente, L (corresponding author), Hosp Univ Canarias, Intens Care Unit, Tenerife, Spain.	lorentemartin@msn.com		Borreguero Leon, Juan Maria/0000-0001-7414-5278; Argueso, Monica/0000-0001-5917-1056	Fundacion Canaria de Investigacion Sanitaria (FUNCANIS) (La Laguna, Tenerife, Spain)	This study was supported by fundings from Fundacion Canaria de Investigacion Sanitaria (FUNCANIS) (La Laguna, Tenerife, Spain). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bantel H, 2004, HEPATOLOGY, V40, P1078, DOI 10.1002/hep.20411; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Cavallucci V, 2011, CURR PHARM DESIGN, V17, P215, DOI 10.2174/138161211795049705; Chen R, 2013, EXP THER MED, V6, P1463, DOI 10.3892/etm.2013.1342; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Greystoke A, 2011, BRIT J CANCER, V104, P719, DOI 10.1038/sj.bjc.6606082; Hagg M, 2002, INVEST NEW DRUG, V20, P253, DOI 10.1023/A:1016249728664; Hofer S, 2009, CRIT CARE, V13, DOI 10.1186/cc7923; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Lorente L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094370; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Luft T, 2007, BLOOD, V110, P4535, DOI 10.1182/blood-2006-10-049817; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Moore DJ, 2012, CLIN DRUG INVEST, V32, P179, DOI 10.2165/11598610-000000000-00000; Parfieniuk-Kowerda A, 2014, LIVER INT, V34, P544, DOI 10.1111/liv.12297; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Roth GA, 2004, SHOCK, V22, P218, DOI 10.1097/01.shk.0000136098.49672.0e; Sgier C, 2010, J VIRAL HEPATITIS, V17, P845, DOI 10.1111/j.1365-2893.2009.01251.x; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Sumer S, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.10106; TEASDALE G, 1974, LANCET, V2, P81; Ueno T, 2003, EUR J CANCER, V39, P769, DOI 10.1016/S0959-8049(02)00865-1; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wesche-Soldato DE, 2007, CURR DRUG TARGETS, V8, P493, DOI 10.2174/138945007780362764	31	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2015	10	3							e0121739	10.1371/journal.pone.0121739			10	Multidisciplinary Sciences	Science & Technology - Other Topics	CE9AD	WOS:000352134700124	25822281	DOAJ Gold, Green Published			2021-06-18	
J	Carr, W; Yarnell, AM; Ong, R; Walilko, T; Kamimori, GH; da Silva, U; McCarron, RM; LoPresti, ML				Carr, Walter; Yarnell, Angela M.; Ong, Ricardo; Walilko, Timothy; Kamimori, Gary H.; da Silva, Uade; McCarron, Richard M.; LoPresti, Matthew L.			Ubiquitin carboxy-terminal hydrolase-L1 as a serum neurotrauma biomarker for exposure to occupational low-level blast	FRONTIERS IN NEUROLOGY			English	Article						biomarker; blast; military; neurotrauma; breacher	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; CONCUSSION; MILD; SYMPTOMS; RECOVERY; L1	Repeated exposure to low-level blast is a characteristic of a few select occupations and there is concern that such occupational exposures present risk for traumatic brain injury. These occupations include specialized military and law enforcement units that employ controlled detonation of explosive charges for the purpose of tactical entry into secured structures. The concern for negative effects from blast exposure is based on rates of operator self-reported headache, sleep disturbance, working memory impairment, and other concussion-like symptoms. A challenge in research on this topic has been the need for improved assessment tools to empirically evaluate the risk associated with repeated exposure to blast overpressure levels commonly considered to be too low in magnitude to cause acute injury. Evaluation of serum-based neurotrauma biomarkers provides an objective measure that is logistically feasible for use in field training environments. Among candidate biomarkers, ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) has some empirical support and was evaluated in this study. We used daily blood draws to examine acute change in UCH-L1 among 108 healthy military personnel who were exposed to repeated low-level blast across a 2-week period. These research volunteers also wore pressure sensors to record blast exposures, wrist actigraphs to monitor sleep patterns, and completed daily behavioral assessments of symptomology, postural stability, and neurocognitive function. UCH-L1 levels were elevated as a function of participating in the 2-week training with explosives, but the correlation of UCH-L1 elevation and blast magnitude was weak and inconsistent. Also, UCH-L1 elevations did not correlate with deficits in behavioral measures. These results provide some support for including UCH-L1 as a measure of central nervous system effects from exposure to low-level blast. However, the weak relation observed suggests that additional indicators of blast effect are needed.	[Carr, Walter; Yarnell, Angela M.; Kamimori, Gary H.; LoPresti, Matthew L.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Ong, Ricardo] US Army Special Forces Command, Ft Bragg, NC USA; [Walilko, Timothy] Appl Res Associates Inc, Littleton, CO USA; [da Silva, Uade; McCarron, Richard M.] Walter Reed Army Inst Res, NeuroTrauma Dept, Silver Spring, MD 20910 USA	Carr, W (corresponding author), Walter Reed Army Inst Res, Dept Behav Biol, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	walter.s.carr.mil@mail.mil		Olaghere da Silva, Uade/0000-0003-1755-4985	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); US Navy Bureau of Medicine; US Army Special Operations Command; US Army Engineer School	This work was supported by the US Army Medical Research and Materiel Command and the US Navy Bureau of Medicine. We thank the members of the study team who helped collect and process the data: SGT Ashlie Strickland-Mangano, SGT Benjamin Joiner, SPC George Adams, SSG Kelly McWhirter, SGT Shawn McLoughlin, SSG Dominic Prankienas, SGT Robert Catalano, SGT Reginald Acklin, HM3 Eric Cho, Luke Aurich, Dan Welsh, Brandon Peterson, Zach Gates, Stephanie Eonta, Carmen Contreras-Sesvold, and David Miles. We also thank the leadership from the US Army Special Operations Command and US Army Engineer School for their support and the Soldiers of the units studied for their service to our nation and their participation in the study.	Baker AJ, 2011, J TRAUMA, V71, pS472, DOI 10.1097/TA.0b013e318232e7da; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Carr W, 2015, J HEAD TRAUMA REHAB, V30, P47, DOI 10.1097/HTR.0000000000000064; Chen FJ, 2010, P NATL ACAD SCI USA, V107, P1636, DOI 10.1073/pnas.0911516107; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; El-Maraghi S, 2013, EGYPT J CRIT CARE ME, V1, P25, DOI 10.1016/j.ejccm.2012.12.002; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Eonta SE, 2011, AVIAT SPACE ENVIR MD, V82, P34, DOI 10.3357/ASEM.2799.2011; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Goemaere J, 2012, J COMP NEUROL, V520, P258, DOI 10.1002/cne.22689; Guingab-Cagmat JD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00061; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Heinzelmann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00198; Ichikawa T, 2010, BIOCHEM BIOPH RES CO, V391, P852, DOI 10.1016/j.bbrc.2009.11.151; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS3, DOI 10.1016/j.acn.2006.10.001; Kelley A., 2010, 201016 US ARM AER RE; Kelly MP, 2012, ARCH CLIN NEUROPSYCH, V27, P375, DOI 10.1093/arclin/acs036; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Lathan C, 2013, MIL MED, V178, P365, DOI 10.7205/MILMED-D-12-00438; Manevich Y, 2014, FREE RADICAL BIO MED, V72, P210, DOI 10.1016/j.freeradbiomed.2014.04.002; McLeod TCV, 2009, J ATHL TRAINING, V44, P663, DOI 10.4085/1062-6050-44.6.663; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; Needham CE, 2010, SHOCK WAVE HIGH PRES, P1, DOI 10.1007/978-3-642-05288-0; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Norris JN, 2013, MIL MED, V178, P767, DOI 10.7205/MILMED-D-12-00493; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Schmid Kara E, 2012, Front Neurol, V3, P90, DOI 10.3389/fneur.2012.00090; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Tator CH, 2002, INJURY PREV, V8, pIV33, DOI 10.1136/ip.8.suppl_4.iv33; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	39	21	21	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAR 16	2015	6								49	10.3389/fneur.2015.00049			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU8CX	WOS:000363769900002	25852633	DOAJ Gold, Green Published			2021-06-18	
J	Lang, EW; Kasprowicz, M; Smielewski, P; Santos, E; Pickard, J; Czosnyka, M				Lang, Erhard W.; Kasprowicz, Magdalena; Smielewski, Peter; Santos, Edgar; Pickard, John; Czosnyka, Marek			Short pressure reactivity index versus long pressure reactivity index in the management of traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain monitoring; cerebral autoregulation; cerebrovascular reactivity; severe head injury; outcome; cerebral perfusion pressure; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW-VELOCITY; CAROTID-ARTERY-DISEASE; SEVERE HEAD-INJURY; CEREBROVASCULAR AUTOREGULATION; SPONTANEOUS OSCILLATIONS; INTRACRANIAL-PRESSURE; B-WAVES; HUMANS; CLASSIFICATION	OBJECT The pressure reactivity index (PRx) correlates with outcome after traumatic brain injury (TBI) and is used to calculate optimal cerebral perfusion pressure (CPPopt). The PRx is a correlation coefficient between slow, spontaneous changes (0.003-0.05 Hz) in intracranial pressure (ICP) and arterial blood pressure (ABP). A novel index the so-called long PRx (L-PRx)-that considers ABP and ICP changes (0.0008-0.008 Hz) was proposed. METHODS The authors compared PRx and L-PRx for 6-month outcome prediction and CPPopt calculation in 307 patients with TBI. The PRx- and L-PRx based CPPopt were determined and the predictive power and discriminant abilities were compared. RESULTS The PRx and L-PRx correlation was good (R = 0.7, p < 0.00001; Spearman test). The PRx, age, CPP, and Glasgow Coma Scale score but not L-PRx were significant fatal outcome predictors (death and persistent vegetative state). There was a significant difference between the areas under the receiver operating characteristic curves calculated for PRx and L-PRx (0.61 +/- 0.04 vs 0.51 +/- 0.04; z-statistic = -3.26, p = 0.011), which indicates a better ability by PRx than L-PRx to predict fatal outcome. The CPPopt was higher for L-PRx than for PRx, without a statistical difference (median CPPopt for L-PRx: 76.9 mm Hg, interquartile range [IQR] +/- 10.1 mm Hg; median CPPopt for PRx: 74.7 mm Hg, IQR +/- 8.2 mm Hg). Death was associated with CPP below CPPopt for PRx (chi(2) = 30.6, p < 0.00001), and severe disability was associated with CPP above CPPopt for PRx (chi(2) = 7.8, p = 0.005). These relationships were not statistically significant for CPPopt for L-PRx. CONCLUSIONS The PRx is superior to the L-PRx for TBI outcome prediction. Individual CPPopt for L-PRx and PRx are not statistically different. Deviations between CPP and CPPopt for PRx are relevant for outcome prediction; those between CPP and CPPopt for L-PRx are not. The PRx uses the entire B-wave spectrum for index calculation, whereas the L-PRX covers only one-third of it. This may explain the performance discrepancy.	[Lang, Erhard W.] Red Cross Hosp, Neurosurg Associates, D-34121 Kassel, Germany; [Kasprowicz, Magdalena] Heidelberg Univ, Dept Neurosurg, D-69115 Heidelberg, Germany; [Smielewski, Peter; Pickard, John; Czosnyka, Marek] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, PL-50370 Wroclaw, Poland; [Santos, Edgar] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 1TN, England	Lang, EW (corresponding author), Red Cross Hosp, Neurosurg Associates, Bergmannstr 30, D-34121 Kassel, Germany.	keeflang@online.de		Smielewski, Peter/0000-0001-5096-3938; Santos, Edgar/0000-0002-8976-5549; Kasprowicz, Magdalena/0000-0002-2271-7737	Polish Ministry of Science and Higher EducationMinistry of Science and Higher Education, Poland; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	DISCLOSURE The software for brain monitoring (ICM+) is licensed by the University of Cambridge (Cambridge Enterprise), and Drs. Smielewski and Czosnyka have financial interests in a part of the licensing fee. Dr. Czosnyka is a consultant for Codman J & J. Dr. Lang is a consultant for GMS Integra. Dr. Kasprowicz is the recipient of a scholarship funded by the Polish Ministry of Science and Higher Education.	AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; DIEHL RR, 1991, NEUROSCI LETT, V127, P5, DOI 10.1016/0304-3940(91)90880-3; Diehl RR, 1997, STROKE, V28, P1289; DIEHL RR, 1996, FUNKTIONELLE DOPPLER; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Haubrich C, 2004, ACTA NEUROL SCAND, V109, P210, DOI 10.1034/j.1600-0404.2003.00210.x; Jaeger M, 2012, STROKE, V43, P2097, DOI 10.1161/STROKEAHA.112.659888; Johnson U, 2014, NEUROCRIT CARE, V21, P259, DOI 10.1007/s12028-014-9954-2; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lang EW, 1999, NEUROL RES, V21, P665, DOI 10.1080/01616412.1999.11740995; Lewis PM, 2008, ACTA NEUROCHIR, V150, P139, DOI 10.1007/s00701-007-1447-z; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mayer S., 1876, SITZ KAISER AKAD WIS, V74, P281; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Oehm E, 2006, CEREBROVASC DIS, V22, P204, DOI 10.1159/000093810; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Sanchez-Porras R, 2012, ACTA NEUROCHIR, V154, P1575, DOI 10.1007/s00701-012-1423-0; Santos E, 2011, ACTA NEUROCHIR, V153, P2189, DOI 10.1007/s00701-011-1148-5; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; Strege RJ, 2003, NEUROL RES, V25, P510, DOI 10.1179/016164103101201742; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014	32	21	23	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2015	122	3					588	594		10.3171/2014.10.JNS14602			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CC3RJ	WOS:000350266600014	25423266	Bronze			2021-06-18	
J	Perrin, PB; Niemeier, JP; Mougeot, JL; Vannoy, CH; Hirsch, MA; Watts, JA; Rossman, W; Grafton, LM; Guerrier, TD; Pershad, R; Kingsbury, CA; Bartel, SW; Whitney, MP				Perrin, Paul B.; Niemeier, Janet P.; Mougeot, Jean-Luc; Vannoy, Charles H.; Hirsch, Mark A.; Watts, John A.; Rossman, Whitney; Grafton, Lori M.; Guerrier, Tami D.; Pershad, Rashmi; Kingsbury, Carla A.; Bartel, Sheri W.; Whitney, Marybeth P.			Measures of Injury Severity and Prediction of Acute Traumatic Brain Injury Outcomes	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; inpatient; outcomes; traumatic brain injury	GLASGOW COMA SCALE; POSTTRAUMATIC AMNESIA DURATION; MILD HEAD-INJURY; FUNCTIONAL OUTCOMES; PRACTICAL SCALE; REHABILITATION; MODERATE; CLASSIFICATION; CONSCIOUSNESS; MULTICENTER	Objective: To examine the comparative efficacy of 3 common measures of traumatic brain injury (TBI) severity for predicting inpatient outcomes upon hospital discharge. Setting: Acute brain injury rehabilitation unit at level 1 trauma center. Participants: 100 patients with TBI. Design: Retrospective analysis of injury severity, demographic, and outcome data. Main Measures: Glasgow Coma Scale (GCS) at admission, time to follow commands (TTC), duration of posttraumatic amnesia (PTA), and Functional Independence Measure at hospital discharge. Results: A hierarchal multiple regression revealed that duration of PTA was a significant and powerful unique predictor of Functional Independence Measure scores at discharge (beta = -0.46, P = .001), while TTC (beta = 0.26, P = .056) and GCS (beta = 0.16, P = .143) were not. These effects were present even after controlling for age, gender, educational level, racial/ethnic minority status, cause of injury, history of substance abuse, and neurosurgical intervention. Conclusion: Although clinicians often use GCS scores and TTC when assessing acute TBI severity and during treatment formulation, this study provides evidence that duration of PTA may be a more meaningful predictor of patients' functional levels at discharge.	[Perrin, Paul B.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Niemeier, Janet P.; Hirsch, Mark A.; Guerrier, Tami D.; Pershad, Rashmi; Kingsbury, Carla A.; Bartel, Sheri W.; Whitney, Marybeth P.] Carolinas Rehabil, Charlotte, NC USA; [Mougeot, Jean-Luc; Vannoy, Charles H.; Rossman, Whitney] Cannon Res Ctr, Charlotte, NC USA; [Watts, John A.] Dept Emergency Med, Charlotte, NC USA; [Grafton, Lori M.] Carolinas Rehabil, Brain Injury Unit, Charlotte, NC USA; [Whitney, Marybeth P.] Carolinas Healthcare Syst, Charlotte, NC 28203 USA	Niemeier, JP (corresponding author), Carolinas Healthcare Syst, Carolinas Rehabil, 1100 Blythe Ave, Charlotte, NC 28203 USA.	Janet.niemeier@carolinashealthcare.org	Hirsch, Mark A./D-2798-2016; Perrin, Paul/L-5373-2015	Hirsch, Mark A./0000-0002-8997-7971; Perrin, Paul/0000-0003-2070-215X; Vannoy, Charles/0000-0003-3617-8081	National Center for Medical Rehabilitation Research (NCMRR); Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R01HD052922-01A2]; NIH CTSA AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR00058]; National Center for Medical Rehabilitation Research (NCMRR) [1RO1HD052922-01A2]; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH/NICHD); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD052922] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000058] Funding Source: NIH RePORTER	This research was supported by the National Center for Medical Rehabilitation Research (NCMRR), The Eunice Kennedy Shriver National Institute of Child Health and Human Development, 1R01HD052922-01A2 and, in part, by NIH CTSA Award UL1 TR00058; Dr Niemeier is currently receiving a grant 1RO1HD052922-01A2 from National Center for Medical Rehabilitation Research (NCMRR), The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH/NICHD).	BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLOMERT DM, 1974, CAN PSYCHIAT ASSOC J, V19, P185, DOI 10.1177/070674377401900215; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Eastvold AD, 2013, J HEAD TRAUMA REHAB, V28, P48, DOI 10.1097/HTR.0b013e31823c9317; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frey KL, 2007, BRAIN INJURY, V21, P513, DOI 10.1080/02699050701311026; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; Jennett B, 1975, Ciba Found Symp, P309; Jennett B, 1972, Scand J Rehabil Med, V4, P16; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Ketchum JM, 2012, NEUROREHABILITATION, V30, P23, DOI 10.3233/NRE-2012-0724; Kevric J, 2011, EMERG MED J, V28, P486, DOI 10.1136/emj.2009.085845; Kosch Y, 2010, BRAIN INJURY, V24, P479, DOI 10.3109/02699051003610417; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; PONSFORD J, J NEUROTRAUM, DOI DOI 10.1089/NEU.2012.2843; Preece MHW, 2013, BRAIN INJURY, V27, P83, DOI 10.3109/02699052.2012.722260; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sandhaug M, 2010, BRAIN INJURY, V24, P740, DOI 10.3109/02699051003652849; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; SICHEZ JP, 1983, NEUROCHIRURGIE, V29, P21; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; Sveen U, 2010, SCAND J OCCUP THER, V17, P225, DOI 10.3109/11038120903171295; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Walker WC, 2011, PM&R, V3, P6, DOI 10.1016/j.pmrj.2010.11.001; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581	43	21	22	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2015	30	2					136	142		10.1097/HTR.0000000000000026			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CF1MG	WOS:000352309300016	24590151				2021-06-18	
J	Sinha, S; Raheja, A; Garg, M; Moorthy, S; Agrawal, D; Gupta, DK; Satyarthee, GD; Singh, PK; Borkar, SA; Gurjar, H; Tandon, V; Pandey, RM; Sharma, BS				Sinha, Sumit; Raheja, Amol; Garg, Mayank; Moorthy, Skanda; Agrawal, Deepak; Gupta, Deepak K.; Satyarthee, Guru D.; Singh, Pankaj K.; Borkar, Sachin A.; Gurjar, Hitesh; Tandon, Vivek; Pandey, Ravindra M.; Sharma, Bhawani S.			Decompressive craniectomy in traumatic brain injury: A single-center, multivariate analysis of 1,236 patients at a tertiary care hospital in India	NEUROLOGY INDIA			English	Article						Decompressive craniectomy; outcome; predictors of outcome; traumatic brain injury	SEVERE HEAD-INJURIES; INTRACRANIAL HYPERTENSION; MULTICENTER; MANAGEMENT; SURGERY; AGE	Object: To evaluate the outcome of patients undergoing a decompressive craniectomy (DC) in traumatic brain injury (TBI) and the factors predicting outcome. Materials and Methods: A total of 1,236 patients with TBI operated with a DC from January 2008 to December 2013 at a tertiary care hospital were included in the study. The data from the hospital computerized database was retrospectively analyzed and 324 (45%) patients were followed-up for a mean duration of 25.3 months (range 3-42 months) among the cohort of 720 alive patients. The institute's ethical committee clearance was obtained before the start of the study. Results: There were 81% males with a median age [interquartile range (IQR)] of 32 (23-45) years. The mortality rate and median (IQR) Glasgow outcome score (GOS) at discharge in patients presenting with minor, moderate, and severe head injury were 18%, 5 (4-5); 28%, 4 (1-5); and 47.4%, 2 (1-4), respectively. An overall favorable outcome (GOS 4 and 5) at discharge was observed in 46.5% patients and in 39% patients who presented with severe TBI. Only 7.5% patients were in a persistent vegetative state (PVS), while 78% had an overall favorable outcome at the last follow-up of surviving patients (P < 0.001). On multivariate analysis, the factors predictive of a favorable GOS at discharge were: a younger age (odds ratio (OR) 1.03, confidence interval (CI) = 1.02-1.04; P < 0.001), no pupillary abnormalities at admission (OR 2.28, CI = 1.72-3.02; P < 0.001), absence of preoperative hypotension (OR 1.91, CI = 1.08-3.38; P = 0.02), an isolated TBI (OR 1.42, CI = 1.08-1.86; P=0.01), absence of a preoperative infarct (OR 3.68, CI = 1.74-7.81; P=0.001), presence of a minor head injury (OR 6.33, CI = 4.07-9.86; P <0.001), performing a duraplasty (OR 1.86, CI = 1.20-2.87; P = 0.005) rather than a slit durotomy (OR 3.95, CI = 1.67-9.35; P = 0.002), and, avoidance of a contralateral DC (OR 3.58, CI = 1.90-6.73; P < 0.001) Conclusions: The severity of head injury, performing a duraplasty rather than a slit durotomy, avoidance of a contralateral DC, and the presence of preoperative hypotension, infarct, and/or pupillary asymmetry have the highest odds of predicting the short term GOS at the time of discharge, after a DC in patients with TBI. Although DC carries a high risk of mortality, the probability of the survivors having a favorable outcome is significantly more as compared to those who remain in a PVS.	[Sinha, Sumit; Raheja, Amol; Garg, Mayank; Moorthy, Skanda; Agrawal, Deepak; Gupta, Deepak K.; Satyarthee, Guru D.; Singh, Pankaj K.; Borkar, Sachin A.; Gurjar, Hitesh; Tandon, Vivek; Sharma, Bhawani S.] All India Inst Med Sci, Dept Neurosurg & Gamma Knife, New Delhi 110029, India; [Pandey, Ravindra M.] All India Inst Med Sci, Dept Biostat, New Delhi 110029, India	Sinha, S (corresponding author), All India Inst Med Sci, Dept Neurosurg & Gamma Knife, New Delhi 110029, India.	sumitneuro@gmail.com	/AAG-3032-2021; GARG, RAKESH/H-4591-2011	/0000-0002-5499-0746; GARG, RAKESH/0000-0001-5842-8024			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agrawal Deepak, 2012, J Emerg Trauma Shock, V5, P217, DOI 10.4103/0974-2700.99685; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Eberle BM, 2010, INJURY, V41, P894, DOI 10.1016/j.injury.2010.02.023; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Hofman K, 2005, AM J PUBLIC HEALTH, V95, P13, DOI 10.2105/AJPH.2004.039354; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Khan SA, 2014, CHILD NERV SYST, V30, P277, DOI 10.1007/s00381-013-2225-2; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Lemcke J, 2010, ACTA NEUROCHIR SUPPL, V106, P231, DOI 10.1007/978-3-211-98811-4_43; Munch E, 2000, NEUROSURGERY, V47, P315; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; Peng R, 1998, AM SURGEON, V64, P950; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	27	21	21	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	MAR-APR	2015	63	2					175	183		10.4103/0028-3886.156277			9	Neurosciences	Neurosciences & Neurology	CH9WN	WOS:000354387200010	25947980				2021-06-18	
J	Wang, D; Zhang, JJ				Wang, Dong; Zhang, Jianjun			Effects of hypothermia combined with neural stem cell transplantation on recovery of neurological function in rats with spinal cord injury	MOLECULAR MEDICINE REPORTS			English	Article						spinal cord injury; neural stem cells; transplantation; hypothermia; rat	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; MARROW STROMAL CELLS; PROTEIN-KINASE-II; MILD HYPOTHERMIA; BLOOD-FLOW; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; FLUID-PERCUSSION	The microenvironment of the injured spinal cord is hypothesized to be involved in driving the differentiation and survival of engrafted neural stem cells (NSCs). Hypothermia is known to improve the microenvironment of the injured spinal cord in a number of ways. To investigate the effect of NSC transplantation in combination with hypothermia on the recovery of rat spinal cord injury, 60 Sprague-Dawley female rats were used to establish a spinal cord hemisection model. They were divided randomly into three groups: A, spinal cord injury group; B, NSC transplantation group; and C, NSC transplantation + hypothermia group. At 1, 2, 4, 6 and 8 weeks post-injury, the motor function of all animals was evaluated using the Basso, Beattie and Besnaham locomotor scoring system and the inclined plane test. At 4 weeks post-transplantation, histological analysis and immunocytochemistry were performed. At 8 weeks post-transplantation, horseradish peroxidase nerve tracing and transmission electron microscopy were conducted to observe axonal regeneration. The outcome of hind limb motor function recovery in group C significantly surpassed that in group B at 4 weeks post-injury (P<0.05). Recovery was also observed in group A, but to a lesser degree. For the pathological sections no neural axonal were observed in group A. A few axon-like structures were observed in group B and more in group C. Horseradish peroxidase-labeled neurofibers and bromodeoxyuridine-positive cells were observed in the spinal cords of group C. Fewer of these cells were found in group B and fewer still in group A. The differences among the three groups were significant (P<0.05). Using transmission electron microscopy, newly formed nerve fibers and myelinated nerve fibers were observed in the central transverse plane in groups B and C, although these nerve fibers were not evident in group A. In conclusion, NSC transplantation promoted the recovery of hind limb function in rats, and combination treatment with hypothermia produced synergistic effects.	[Wang, Dong; Zhang, Jianjun] Tianjin Med Univ, Ctr Clin Coll 4, Dept Neurosurg, Tianjin 300140, Peoples R China; [Wang, Dong; Zhang, Jianjun] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China	Wang, D (corresponding author), Tianjin Med Univ, Ctr Clin Coll 4, Dept Neurosurg, 3 Zhongshan Rd, Tianjin 300140, Peoples R China.	dewangdong@163.com			Application Basis and Front Technology Projects of Tianjin (Science and Technology Foundation of Tianjin) [12JCYBJC18000]	This study was sponsored by the Application Basis and Front Technology Projects of Tianjin (Science and Technology Foundation of Tianjin, No. 12JCYBJC18000.	Arican N, 2006, INT J NEUROSCI, V116, P1249, DOI 10.1080/00207450600550303; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bae JS, 2007, STEM CELLS, V25, P1307, DOI 10.1634/stemcells.2006-0561; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Beggs KJ, 2006, CELL TRANSPLANT, V15, P711, DOI 10.3727/000000006783981503; Bhang SH, 2007, BIOCHEM BIOPH RES CO, V359, P40, DOI 10.1016/j.bbrc.2007.05.046; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; Carvalho KAT, 2008, TRANSPL P, V40, P845, DOI 10.1016/j.transproceed.2008.02.054; Chen G, 2010, CHINESE MED J-PEKING, V123, P2424, DOI 10.3760/cma.j.issn.0366-6999.2010.17.025; CHURN SB, 1990, STROKE, V21, P1715, DOI 10.1161/01.STR.21.12.1715; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; Fukui O, 2006, BRAIN RES, V1121, P35, DOI 10.1016/j.brainres.2006.08.121; Furuya T, 2009, BRAIN RES, V1295, P192, DOI 10.1016/j.brainres.2009.07.087; Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959; Gressens P, 2008, BRAIN PATHOL, V18, P10, DOI 10.1111/j.1750-3639.2007.00095.x; Gu Y, 2010, J MOL NEUROSCI, V40, P332, DOI 10.1007/s12031-009-9304-6; Ha KY, 2008, SPINE, V33, P2059, DOI 10.1097/BRS.0b013e31818018f6; HANSEBOUT RR, 1985, CAN J NEUROL SCI, V12, P83, DOI 10.1017/S0317167100046758; Harrop JS, 2001, SPINE, V26, P340, DOI 10.1097/00007632-200102150-00008; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Huang ZG, 1999, CAN J NEUROL SCI, V26, P298, DOI 10.1017/S0317167100000421; Hwang DH, 2014, J NEUROSCI, V34, P12788, DOI 10.1523/JNEUROSCI.5359-13.2014; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; Jori FP, 2005, J CELL BIOCHEM, V94, P645, DOI 10.1002/jcb.20315; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Kobayashi MS, 2008, BRAIN RES REV, V58, P171, DOI 10.1016/j.brainresrev.2008.03.001; Kobbe P, 2009, UNFALLCHIRURG, V112, P1055, DOI 10.1007/s00113-009-1711-1; Ku JH, 2006, BJU INT, V98, P739, DOI 10.1111/j.1464-410X.2006.06395.x; KULUZ JW, 1993, AM J PHYSIOL, V265, pH824; Kwon BK, 2008, SPINE J, V8, P859, DOI 10.1016/j.spinee.2007.12.006; Le Blanc K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118; Li XH, 2014, ZHONGHUA CHUANG SHAN, V30, P500; LO EH, 1992, STROKE, V23, P889, DOI 10.1161/01.STR.23.6.889; Lyden PD, 2006, INT J STROKE, V1, P9, DOI 10.1111/j.1747-4949.2005.00011.x; Mazzini L, 2008, J NEUROL SCI, V265, P78, DOI 10.1016/j.jns.2007.05.016; Morino T, 2008, SPINAL CORD, V46, P425, DOI 10.1038/sj.sc.3102163; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Nguyen HP, 2010, ANESTHESIOLOGY, V113, P327, DOI 10.1097/ALN.0b013e3181dfd4f7; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Papadopoulos SM, 2002, J TRAUMA, V52, P323, DOI 10.1097/00005373-200202000-00019; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Shen LH, 2008, GLIA, V56, P1747, DOI 10.1002/glia.20722; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Shimohata T, 2007, J CEREBR BLOOD F MET, V27, P1463, DOI 10.1038/sj.jcbfm.9600450; Shimohata T, 2007, STROKE, V38, P375, DOI 10.1161/01.STR.0000254616.78387.ee; Sun Zhengang, 2010, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V24, P165; SUTTON LN, 1991, STROKE, V22, P1567, DOI 10.1161/01.STR.22.12.1567; Theus MH, 2008, EXP NEUROL, V210, P656, DOI 10.1016/j.expneurol.2007.12.020; Tohyama Y, 1998, EXP BRAIN RES, V122, P333, DOI 10.1007/s002210050521; Zausinger S, 2003, STROKE, V34, P1526, DOI 10.1161/01.STR.0000070841.31224.29; Zhao H, 2004, STROKE, V35, P572, DOI 10.1161/01.STR.0000110787.42083.58; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zhao H, 2007, J NEUROSURG, V107, P636, DOI 10.3171/JNS-07/09/0636; Zhu HD, 2005, EXP NEUROL, V193, P361, DOI 10.1016/j.expneurol.2005.01.022	63	21	25	0	24	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	MAR	2015	11	3					1759	1767		10.3892/mmr.2014.2905			9	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CD2OA	WOS:000350917700028	25385306	Green Published, Other Gold			2021-06-18	
J	Pham, N; Akonasu, H; Shishkin, R; Taghibiglou, C				Nam Pham; Akonasu, Hungbo; Shishkin, Rhonda; Taghibiglou, Changiz			Plasma Soluble Prion Protein, a Potential Biomarker for Sport-Related Concussions: A Pilot Study	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; CELLULAR ISOFORM; EXPRESSION; EPIDEMIOLOGY; PRPC; PATHOPHYSIOLOGY; DIAGNOSIS; HEALTHY	Sport-related mild traumatic brain injury (mTBI) or concussion is a significant health concern to athletes with potential long-term consequences. The diagnosis of sport concussion and return to sport decision making is one of the greatest challenges facing health care clinicians working in sports. Blood biomarkers have recently demonstrated their potential in assisting the detection of brain injury particularly, in those cases with no obvious physical injury. We have recently discovered plasma soluble cellular prion protein (PrPC) as a potential reliable biomarker for blast induced TBI (bTBI) in a rodent animal model. In order to explore the application of this novel TBI biomarker to sport-related concussion, we conducted a pilot study at the University of Saskatchewan (U of S) by recruiting athlete and non-athlete 18 to 30 year-old students. Using a modified quantitative ELISA method, we first established normal values for the plasma soluble PrPC in male and female students. The measured plasma soluble PrPC in confirmed concussion cases demonstrated a significant elevation of this analyte in post-concussion samples. Data collected from our pilot study indicates that the plasma soluble PrPC is a potential biomarker for sport-related concussion, which may be further developed into a clinical diagnostic tool to assist clinicians in the assessment of sport concussion and return-to-play decision making.	[Nam Pham; Akonasu, Hungbo; Taghibiglou, Changiz] Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 0W0, Canada; [Shishkin, Rhonda] Univ Saskatchewan, Coll Kinesiol & Huskies Athlet, Saskatoon, SK, Canada	Taghibiglou, C (corresponding author), Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 0W0, Canada.	changiz.taghibiglou@usask.ca	Taghibiglou, Changiz/H-4590-2019				Aguzzi A, 2009, PHYSIOL REV, V89, P1105, DOI 10.1152/physrev.00006.2009; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Banks WA, 2009, EXP NEUROL, V218, P162, DOI 10.1016/j.expneurol.2009.04.025; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Breitling LP, 2012, EXP GERONTOL, V47, P919, DOI 10.1016/j.exger.2012.08.001; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guingab-Cagmat JD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00061; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Haddon DJ, 2009, J INFECT DIS, V200, P827, DOI 10.1086/605022; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Jeon Jae-Won, 2013, Immune Netw, V13, P148, DOI 10.4110/in.2013.13.4.148; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Krupinski J, 2008, ACTA NEUROPATHOL, V116, P537, DOI 10.1007/s00401-008-0427-6; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meehan WP, 2011, CLIN SPORT MED, V30, pXVII, DOI 10.1016/j.csm.2010.09.008; Megra B, 2013, J NEUROIMMUNE PHARM, V8, P1159, DOI 10.1007/s11481-013-9458-4; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Meyne F, 2009, J ALZHEIMERS DIS, V17, P863, DOI 10.3233/JAD-2009-1110; Mitsios N, 2007, J NEUROSCI RES, V85, P602, DOI 10.1002/jnr.21142; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Parsons MP, 2014, NEURON, V82, P279, DOI 10.1016/j.neuron.2014.03.030; Pham N, 2015, J NEUROTRAUM, V32, P58, DOI 10.1089/neu.2014.3471; Pham N, 2014, BIOCHEM BIOPH RES CO, V448, P151, DOI 10.1016/j.bbrc.2014.04.071; Picard-Hagen N, 2006, J GEN VIROL, V87, P3723, DOI 10.1099/vir.0.81859-0; Politopoulou G, 2000, HAEMATOLOGICA, V85, P580; Ritchie AJ, 2013, BRIT J HAEMATOL, V163, P678, DOI 10.1111/bjh.12543; Roberts TK, 2010, AM J PATHOL, V177, P1848, DOI 10.2353/ajpath.2010.091006; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Simak J, 2002, TRANSFUSION, V42, P334, DOI 10.1046/j.1537-2995.2002.00072.x; Starke R, 2002, BRIT J HAEMATOL, V119, P863, DOI 10.1046/j.1365-2141.2002.03847.x; Stewart TC, 2013, J TRAUMA ACUTE CARE, V76, P736; Strathmann FG, 2014, CLIN BIOCHEM, DOI [10.1016/j.clinbiochem.2014.12.017, DOI 10.1016/J.CLINBIOCHEM.2014.12.017]; Torres M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036159; Volkel D, 2001, TRANSFUSION, V41, P441, DOI 10.1046/j.1537-2995.2001.41040441.x; Wang Kevin K W, 2012, Front Neurol, V3, P147, DOI 10.3389/fneur.2012.00147; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Yusa S, 2012, VIRUSES-BASEL, V4, P3109, DOI 10.3390/v4113109; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	48	21	21	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2015	10	2							e0117286	10.1371/journal.pone.0117286			12	Multidisciplinary Sciences	Science & Technology - Other Topics	CA3QK	WOS:000348821200036	25643046	DOAJ Gold, Green Published			2021-06-18	
J	Bivona, U; Formisano, R; De Laurentiis, S; Accetta, N; Di Cosimo, MR; Massicci, R; Ciurli, P; Azicnuda, E; Silvestro, D; Sabatini, U; Caravasso, CF; Carlesimo, GA; Caltagirone, C; Costa, A				Bivona, Umberto; Formisano, Rita; De Laurentiis, Sara; Accetta, Natascia; Di Cosimo, Maria Rita; Massicci, Roberta; Ciurli, Paola; Azicnuda, Eva; Silvestro, Daniela; Sabatini, Umberto; Caravasso, Chiara Falletta; Carlesimo, Giovanni Augusto; Caltagirone, Carlo; Costa, Alberto			Theory of mind impairment after severe traumatic brain injury and its relationship with caregivers' quality of life	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Traumatic brain injury; theory of mind; self-awareness; quality of life; psychological support; neuropsychotherapeutic approach	COMPETENCE RATING-SCALE; SELF-AWARENESS; SOCIAL COGNITION; REHABILITATION; QOLIBRI; REPRESENTATION; PERSPECTIVE; VALIDATION; DEFICITS; BELIEFS	Purpose: Theory of mind (ToM) deficits are common consequences of severe Traumatic Brain Injury (sTBI), but little is known about their impact on patients' and their caregivers' quality of life. This study aimed (i) to examine the presence of ToM difficulties in individuals with sTBI and adequate levels of self-awareness (SA); (ii) to investigate their relationship with perceived Health Related Quality of Life (HRQoL) in patients and their caregivers. Methods: Twenty individuals with sTBI and adequate levels of SA, and 20 healthy controls (HCs) were recruited. ToM was examined by the Faux-pas Recognition paradigm. The QOLIBRI questionnaire was administered to patients and their caregivers to assess their HRQoL. Cognitive functioning and psychopathology were evaluated. Results: Individuals with sTBI were less accurate than HCs on the Faux-pas Recognition paradigm. Patients' satisfaction of HRQoL was related to their performance on the Wisconsin Card Sorting Test. Caregivers' satisfaction was significantly predicted by patients' score on the Faux-pas paradigm. Conclusions: ToM is impaired in individuals with sTBI and adequate levels of SA. Moreover, their ToM performance predicted HRQoL in the caregivers. From a clinical perspective, these results provide understanding of the potential impact of ToM impairment in subjects with sTBI and their social system.	[Bivona, Umberto; Formisano, Rita; De Laurentiis, Sara; Accetta, Natascia; Di Cosimo, Maria Rita; Massicci, Roberta; Ciurli, Paola; Azicnuda, Eva; Silvestro, Daniela; Sabatini, Umberto; Caravasso, Chiara Falletta; Carlesimo, Giovanni Augusto; Caltagirone, Carlo; Costa, Alberto] Fdn Santa Lucia, Rome, Italy; [Carlesimo, Giovanni Augusto; Caltagirone, Carlo] Univ Roma Tor Vergata, Rome, Italy	Bivona, U (corresponding author), IRCCS, Fdn Santa Lucia, Via Ardeatina 306, I-00100 Rome, Italy.	u.bivona@hsantalucia.it	Massicci, Roberta/J-5596-2018; Costa, Alberto/AAA-7038-2019; Azicnuda, Eva/K-9010-2016; Sabatini, Umberto/K-4659-2016	Massicci, Roberta/0000-0003-2154-6822; Sabatini, Umberto/0000-0001-5321-8626; Falletta Caravasso, Chiara/0000-0003-3389-2853; COSTA, Alberto/0000-0002-4784-5524			BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Bagby RM, 1997, DISORDERS AFFECT REG, P26, DOI DOI 10.1017/CBO9780511526831.005; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S., 2000, UNDERSTANDING OTHER; Basso A, 1987, Funct Neurol, V2, P189; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; BROTHERS L, 1992, J COGNITIVE NEUROSCI, V4, P107, DOI 10.1162/jocn.1992.4.2.107; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Ciurli P, 2010, J INT NEUROPSYCH SOC, V16, P360, DOI 10.1017/S135561770999141X; Costa A, 2008, BEHAV NEUROL, V19, P71, DOI 10.1155/2008/694632; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Fett AKJ, 2011, NEUROSCI BIOBEHAV R, V35, P573, DOI 10.1016/j.neubiorev.2010.07.001; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Frith U, 2001, CURR DIR PSYCHOL SCI, V10, P151, DOI 10.1111/1467-8721.00137; Giustini M, 2014, FUNCT NEUROL, V29, P167, DOI 10.11138/FNeur/2014.29.3.167; Hagen C., 2005, LEVELS COGNITIVE FUN; Hamilton H., J NEUROL NEUROSURG P, V23, P56; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Heaton RK, 2000, FORMA COMPLETA REVIS, P1; Hoofien D, 2006, ISR J PSYCHIATR REL, V43, P296; JENNETT B, 1975, LANCET, V1, P480; Keenan J.P., 2003, FACE MIRROR SEARCH O; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Maat A, 2012, SCHIZOPHR RES, V137, P212, DOI 10.1016/j.schres.2012.02.017; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; Moriguchi Y, 2006, NEUROIMAGE, V32, P1472, DOI 10.1016/j.neuroimage.2006.04.186; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Neumann D, 2014, J HEAD TRAUMA REHAB, V29, pE18, DOI 10.1097/HTR.0b013e31827fb0b5; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; Orsini A., 2003, B PSICOL APPL, V239, P73; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sasse N, 2013, J HEAD TRAUMA REHAB, V28, P464, DOI 10.1097/HTR.0b013e318263977d; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Soberg HL, 2013, J REHABIL MED, V45, P785, DOI 10.2340/16501977-1158; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; SPIERS MV, 1994, BRAIN INJURY, V8, P463, DOI 10.3109/02699059409150998; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; TEASDALE G, 1974, LANCET, V2, P81; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5	60	21	22	0	22	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2015	33	3					335	345		10.3233/RNN-140484			11	Neurosciences	Neurosciences & Neurology	CK9CU	WOS:000356538900008	25720542				2021-06-18	
J	Diwakar, M; Harrington, DL; Maruta, J; Ghajar, J; El-Gabalawy, F; Muzzatti, L; Corbetta, M; Huang, MX; Lee, RR				Diwakar, Mithun; Harrington, Deborah L.; Maruta, Jun; Ghajar, Jamshid; El-Gabalawy, Fady; Muzzatti, Laura; Corbetta, Maurizio; Huang, Ming-Xiong; Lee, Roland R.			Filling in the gaps: Anticipatory control of eye movements in chronic mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Mild traumatic brain injury; Visual tracking; Anticipatory control; Attention; Magnetoencephalography	SIGNAL SPACE SEPARATION; POST-CONCUSSION SYNDROME; DIFFUSION-TENSOR; SMOOTH-PURSUIT; IMAGING APPROACH; TARGET BLANKING; CORTICAL MECHANISMS; HEAD-INJURY; MEG; ATTENTION	A barrier in the diagnosis of mild traumatic brain injury (mTBI) stems from the lack of measures that are adequately sensitive in detecting mild head injuries. MRI and CT are typically negative in mTBI patients with persistent symptoms of post-concussive syndrome (PCS), and characteristic difficulties in sustaining attention often go undetected on neuropsychological testing, which can be insensitive to momentary lapses in concentration. Conversely, visual tracking strongly depends on sustained attention over time and is impaired in chronic mTBI patients, especially when tracking an occluded target. This finding suggests deficient internal anticipatory control in mTBI, the neural underpinnings of which are poorly understood. The present study investigated the neuronal bases for deficient anticipatory control during visual tracking in 25 chronic mTBI patients with persistent PCS symptoms and 25 healthy control subjects. The task was performed while undergoing magnetoencephalography (MEG), which allowed us to examine whether neural dysfunction associated with anticipatory control deficits was due to altered alpha, beta, and/or gamma activity. Neuropsychological examinations characterized cognition in both groups. During MEG recordings, subjects tracked a predictably moving target that was either continuously visible or randomly occluded (gap condition). MEG source-imaging analyses tested for group differences in alpha, beta, and gamma frequency bands. The results showed executive functioning, information processing speed, and verbal memory deficits in the mTBI group. Visual tracking was impaired in the mTBI group only in the gap condition. Patients showed greater error than controls before and during target occlusion, and were slower to resynchronize with the target when it reappeared. Impaired tracking concurred with abnormal beta activity, which was suppressed in the parietal cortex, especially the right hemisphere, and enhanced in left caudate and frontal-temporal areas. Regional beta-amplitude demonstrated high classification accuracy (92%) compared to eye-tracking (65%) and neuropsychological variables (80%). These findings show that deficient internal anticipatory control in mTBI is associated with altered beta activity, which is remarkably sensitive given the heterogeneity of injuries. Published by Elsevier Inc.	[Diwakar, Mithun; Harrington, Deborah L.; El-Gabalawy, Fady; Muzzatti, Laura; Huang, Ming-Xiong; Lee, Roland R.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92121 USA; [Harrington, Deborah L.; Huang, Ming-Xiong; Lee, Roland R.] VA San Diego Healthcare Syst, Radiol & Res Serv, San Diego, CA USA; [Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA; [Ghajar, Jamshid] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Corbetta, Maurizio] Washington Univ, Dept Neurol, St Louis, MO USA	Huang, MX (corresponding author), Univ Calif San Diego, Radiol Imaging Lab, 3510 Dunhill St, San Diego, CA 92121 USA.	mxhuang@ucsd.edu; rrlee@ucsd.edu	Maruta, Jun/I-3790-2019; Corbetta, maurizio/AAZ-5219-2020	Maruta, Jun/0000-0002-5054-6605; CORBETTA, MAURIZIO/0000-0001-8295-3304	McDonnell Foundation [220020185]; Department of Veterans AffairsUS Department of Veterans Affairs [NURC-022-10F, CX000146-05A1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095741] Funding Source: NIH RePORTER	This work was supported by grants from the McDonnell Foundation (220020185 to JG) and the Department of Veterans Affairs (NURC-022-10F to MXH; CX000146-05A1 to DLH).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assmus A, 2003, NEUROIMAGE, V20, pS82, DOI 10.1016/j.neuroimage.2003.09.025; Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brookes MJ, 2011, P NATL ACAD SCI USA, V108, P16783, DOI 10.1073/pnas.1112685108; Brookes MJ, 2011, NEUROIMAGE, V56, P1082, DOI 10.1016/j.neuroimage.2011.02.054; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burgess PW, 2007, PHILOS T R SOC B, V362, P887, DOI 10.1098/rstb.2007.2095; Burke MR, 2008, CEREB CORTEX, V18, P126, DOI 10.1093/cercor/bhm038; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030; de Xivry JJO, 2008, J VISION, V8, DOI 10.1167/8.15.6; Delis DC, 1987, CALIFORNIA VERBAL LE; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ding JH, 2009, HUM BRAIN MAPP, V30, P3541, DOI 10.1002/hbm.20777; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Elsinger CL, 2006, NEUROIMAGE, V31, P1177, DOI 10.1016/j.neuroimage.2006.01.041; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Genovesio A, 2014, TRENDS COGN SCI, V18, P72, DOI 10.1016/j.tics.2013.11.007; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Gross J, 1999, PHYS MED BIOL, V44, P2081, DOI 10.1088/0031-9155/44/8/317; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Harrington DL, 1998, J NEUROSCI, V18, P1085; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P408, DOI 10.1016/j.nicl.2014.08.004; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2014, NEUROIMAGE, V84, P585, DOI 10.1016/j.neuroimage.2013.09.022; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jakobs O, 2009, NEUROIMAGE, V47, P667, DOI 10.1016/j.neuroimage.2009.04.065; Kawawaki D, 2006, NEUROSCI RES, V54, P112, DOI 10.1016/j.neures.2005.10.015; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kopell N, 2000, P NATL ACAD SCI USA, V97, P1867, DOI 10.1073/pnas.97.4.1867; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lencer R, 2004, EUR J NEUROSCI, V19, P1430, DOI 10.1111/j.1460-9568.2004.03229.x; Lencer R, 2008, BRAIN COGNITION, V68, P219, DOI 10.1016/j.bandc.2008.08.013; Lewine J D, 1995, Neuroimaging Clin N Am, V5, P575; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Loonstra A S, 2001, Appl Neuropsychol, V8, P161, DOI 10.1207/S15324826AN0803_5; Makin ADJ, 2009, NEUROPSYCHOLOGIA, V47, P1128, DOI 10.1016/j.neuropsychologia.2009.01.010; Maris E, 2007, J NEUROSCI METH, V164, P177, DOI 10.1016/j.jneumeth.2007.03.024; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; Merchant H, 2013, ANNU REV NEUROSCI, V36, P313, DOI 10.1146/annurev-neuro-062012-170349; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MIZUKI Y, 1992, INT J PSYCHOPHYSIOL, V12, P169, DOI 10.1016/0167-8760(92)90008-Y; MIZUKI Y, 1980, CLIN NEUROPHYSIOL, V49, P345; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Mosher JC, 1999, IEEE T BIO-MED ENG, V46, P245, DOI 10.1109/10.748978; Nagel M, 2006, NEUROIMAGE, V29, P1319, DOI 10.1016/j.neuroimage.2005.08.050; Nagel M, 2008, NEUROIMAGE, V41, P483, DOI 10.1016/j.neuroimage.2008.02.058; Niedermeyer E, 2005, ELECTROENCEPHALOGRAP; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; O'Driscoll GA, 2000, NEUROREPORT, V11, P1335, DOI 10.1097/00001756-200004270-00037; Pascual B, 2015, CEREB CORTEX, V25, P680, DOI 10.1093/cercor/bht260; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Sekihara K, 2001, IEEE T BIO-MED ENG, V48, P760, DOI 10.1109/10.930901; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; SMITH MB, 1995, AM PSYCHOL, V50, P393; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song T, 2008, MED BIOL ENG COMPUT, V46, P923, DOI 10.1007/s11517-007-0290-y; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Takahashi N, 1997, CLIN ELECTROENCEPHAL, V28, P49, DOI 10.1177/155005949702800109; Taulu S, 2006, PHYS MED BIOL, V51, P1759, DOI 10.1088/0031-9155/51/7/008; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; Taulu S., 2004, NEUROL CLIN NEUROPHY, V2004; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VanVeen BD, 1997, IEEE T BIO-MED ENG, V44, P867, DOI 10.1109/10.623056; Vieth JB, 1996, BRAIN TOPOGR, V8, P215, DOI 10.1007/BF01184772; Wechsler D, 1997, WAIS 3 ADM SCORING M; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	97	21	21	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	8						210	223		10.1016/j.nicl.2015.04.011			14	Neuroimaging	Neurosciences & Neurology	DI0LE	WOS:000373187100022	26106545	DOAJ Gold, Green Published			2021-06-18	
J	Geeraedts, LMG; Pothof, LAH; Caldwell, E; de Lange-de Klerk, ESM; D'Amours, SK				Geeraedts, Leo M. G., Jr.; Pothof, Leonie A. H.; Caldwell, Erica; de Lange-de Klerk, Elly S. M.; D'Amours, Scott K.			Prehospital fluid resuscitation in hypotensive trauma patients: Do we need a tailored approach?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Trauma; Haemorrhage; Prehospital; Fluid resuscitation; Blood transfusion	SHOCK INDEX; INTRAVENOUS FLUID; GUIDELINES; MANAGEMENT; SURVIVAL; INJURY	Aim: The ideal strategy for prehospital intravenous fluid resuscitation in trauma remains unclear. Fluid resuscitation may reverse shock but aggravate bleeding by raising blood pressure and haemodilution. We examined the effect of prehospital i.v. fluid on the physiologic status and need for blood transfusion in hypotensive trauma patients after their arrival in the emergency department (ED). Methods: Retrospective analysis of trauma patients (n = 941) with field hypotension presenting to a level 1 trauma centre. Regression models were used to investigate associations between prehospital fluid volumes and shock index and blood transfusion respectively in the emergency department and mortality at 24 h. Results: A 1 L increase of prehospital i.v. fluid was associated with a 7% decrease of shock index in the emergency department (p < 0.001). Volumes of 0.5-1 L and 1-2 L were associated with reduced likelihood of shock as compared to volumes of 0-0.5 L: OR 0.61 (p = 0.03) and OR 0.54 (p = 0.02), respectively. Volumes of 1-2 L were also associated with an increased likelihood of receiving blood transfusion in ED: OR 3.27 (p < 0.001). Patients who had received volumes of > 2 L have a much greater likelihood of receiving blood transfusion in ED: OR 9.92 (p < 0.001). Mortality at 24 h was not associated with prehospital i.v. fluids. Conclusion: In hypotensive trauma patients, prehospital i.v. fluids were associated with a reduction of likelihood of shock upon arrival in ED. However, volumes of > 1 L were associated with a markedly increased likelihood of receiving blood transfusion in ED. Therefore, decision making regarding prehospital i.v. fluid resuscitation is critical and may need to be tailored to the individual situation. Further research is needed to clarify whether a causal relationship exists between prehospital i.v. fluid volume and blood transfusion. Also, prospective trials on prehospital i.v. fluid resuscitation strategies in specific patient subgroups (e.g. traumatic brain injury and concomitant haemorrhage) are warranted. (C) 2014 Elsevier Ltd. All rights reserved.	[Geeraedts, Leo M. G., Jr.] Vrije Univ Amsterdam Med Ctr, Dept Surg, NL-1007 MB Amsterdam, Netherlands; [Geeraedts, Leo M. G., Jr.] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, NL-1007 MB Amsterdam, Netherlands; [Geeraedts, Leo M. G., Jr.] Vrije Univ Amsterdam Med Ctr, Helicopter Emergency Med Serv, Northwestern Netherlands Trauma Area, NL-1007 MB Amsterdam, Netherlands; [Pothof, Leonie A. H.] Canisius Wilhelmina Hosp, Dept Surg, NL-6500 GS Nijmegen, Netherlands; [Caldwell, Erica; D'Amours, Scott K.] Liverpool Hosp, Dept Trauma Serv, Liverpool Bc, NSW 1871, Australia; [de Lange-de Klerk, Elly S. M.] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Geeraedts, LMG (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Surg ZH 7F,POB 7057, NL-1007 MB Amsterdam, Netherlands.	l.geeraedts@vumc.nl; leoniepothof@hotmail.com; erica.caldwell@sswahs.nsw.gov.au; esm.delange@vumc.nl; scott.damours@sswahs.nsw.gov.au					American College of Surgeons Committee on Trauma, 2008, ADV TRAUM LIF SUPP D; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Birkhahn RH, 2005, AM J EMERG MED, V23, P323, DOI 10.1016/j.ajem.2005.02.029; Cotton BA, 2009, J TRAUMA, V67, P389, DOI 10.1097/TA.0b013e3181a8b26f; Dula David J, 2002, Prehosp Emerg Care, V6, P417, DOI 10.1080/10903120290938058; Geeraedts LMG, 2009, INJURY, V40, P11, DOI 10.1016/j.injury.2008.10.007; Hampton DA, 2013, J TRAUMA ACUTE CARE, V75, pS9, DOI 10.1097/TA.0b013e318290cd52; Haut ER, 2011, ANN SURG, V253, P371, DOI 10.1097/SLA.0b013e318207c24f; Holcomb JB, 2011, J TRAUMA, V71, pS315, DOI 10.1097/TA.0b013e318227ed13; Hubetamann Bjorn, 2011, J Emerg Trauma Shock, V4, P465, DOI 10.4103/0974-2700.86630; Hussmann B, 2013, INJURY, V44, P611, DOI 10.1016/j.injury.2012.02.004; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; KAWESKI SM, 1990, J TRAUMA, V30, P1215, DOI 10.1097/00005373-199010000-00005; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; KWAN I, 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858; McSwain NE, 2011, J TRAUMA, V70, pS2, DOI 10.1097/TA.0b013e31821b201d; Mutschler M, 2013, CRIT CARE, V17, DOI 10.1186/cc12851; Nolan J, 2001, RESUSCITATION, V48, P57, DOI 10.1016/S0300-9572(00)00318-X; RADY MY, 1992, RESUSCITATION, V23, P227, DOI 10.1016/0300-9572(92)90006-X; Revell M, 2002, EMERG MED J, V19, P494, DOI 10.1136/emj.19.6.494; Sampalis JS, 1997, J TRAUMA, V43, P608, DOI 10.1097/00005373-199710000-00008; SHIRES G T, 1964, Int Anesthesiol Clin, V2, P435, DOI 10.1097/00004311-196402000-00016; Soar J, 2010, RESUSCITATION, V81, P1400, DOI 10.1016/j.resuscitation.2010.08.015; Soreide E, 2005, INJURY, V36, P1001, DOI 10.1016/j.injury.2005.01.002; Sumann G, 2009, HIGH ALT MED BIOL, V10, P71, DOI 10.1089/ham.2008.1067; Talving P, 2005, PREHOSP DISASTER MED, V20, P228, DOI 10.1017/S1049023X00002582; Yaghoubian A, 2007, AM SURGEON, V73, P1027	28	21	22	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2015	46	1					4	9		10.1016/j.injury.2014.08.001			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AX1YJ	WOS:000346739600002	25173671				2021-06-18	
J	Newsome, MR; Durgerian, S; Mourany, L; Scheibel, RS; Lowe, MJ; Beall, EB; Koenig, KA; Parsons, M; Troyanskaya, M; Reece, C; Wilde, E; Fischer, BL; Jones, SE; Agarwal, R; Levin, HS; Rao, SM				Newsome, Mary R.; Durgerian, Sally; Mourany, Lyla; Scheibel, Randall S.; Lowe, Mark J.; Beall, Erik B.; Koenig, Katherine A.; Parsons, Michael; Troyanskaya, Maya; Reece, Christine; Wilde, Elisabeth; Fischer, Barbara L.; Jones, Stephen E.; Agarwal, Rajan; Levin, Harvey S.; Rao, Stephen M.			Disruption of caudate working memory activation in chronic blast-related traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; fMRI; Cortical plasticity; Working memory; Concussion; Veteran	POSTTRAUMATIC-STRESS-DISORDER; BASAL GANGLIA; RESPONSE-INHIBITION; PARKINSONS-DISEASE; HEAD-INJURY; INDIVIDUAL-DIFFERENCES; INDUCED NEUROTRAUMA; MILITARY PERSONNEL; COGNITIVE FUNCTION; TEMPORAL DYNAMICS	Mild to moderate traumatic brain injury (TBI) due to blast exposure is frequently diagnosed in veterans returning from the wars in Iraq and Afghanistan. However, it is unclear whether neural damage resulting from blast TBI differs from that found in TBI due to blunt-force trauma (e.g., falls and motor vehicle crashes). Little is also known about the effects of blast TBI on neural networks, particularly over the long term. Because impairment in working memory has been linked to blunt-force TBI, the present functional magnetic resonance imaging (fMRI) study sought to investigate whether brain activation in response to a working memory task would discriminate blunt-force from blast TBI. Twenty-five veterans (mean age=29.8 years, standard deviation=6.01 years, 1 female) who incurred TBI due to blast an average of 4.2 years prior to enrollment and 25 civilians (mean age = 27.4 years, standard deviation=6.68 years, 4 females) with TBI due to blunt-force trauma performed the Sternberg Item Recognition Task while undergoing fMRI. The task involved encoding 1, 3, or 5 items in working memory. A group of 25 veterans (mean age=29.9 years, standard deviation=5.53 years, 0 females) and a group of 25 civilians (mean age = 27.3 years, standard deviation = 5.81 years, 0 females) without history of TBI underwent identical imaging procedures and served as controls. Results indicated that the civilian TBI group and both control groups demonstrated a monotonic relationship between working memory set size and activation in the right caudate during encoding, whereas the blast TBI group did not (p < 0.05, corrected for multiple comparisons using False Discovery Rate). Blast TBI was also associated with worse performance on the Sternberg Item Recognition Task relative to the other groups, although no other group differences were found on neuropsychological measures of episodic memory, inhibition, and general processing speed. These results could not be attributed to caudate atrophy or the presence of PTSD symptoms. Our results point to a specific vulnerability of the caudate to blast injury. Changes in activation during the Sternberg Item Recognition Task, and potentially other tasks that recruit the caudate, may serve as biomarkers for blast TBI. (C) 2015 The Authors. Published by Elsevier Inc.	[Newsome, Mary R.; Scheibel, Randall S.; Troyanskaya, Maya; Wilde, Elisabeth; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Res Serv Line, Houston, TX USA; [Newsome, Mary R.; Scheibel, Randall S.; Troyanskaya, Maya; Wilde, Elisabeth; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Durgerian, Sally] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Mourany, Lyla; Parsons, Michael; Reece, Christine; Rao, Stephen M.] Cleveland Clin, Neurol Inst, Schey Ctr Cognit Neuroimaging, 9500 Euclid Ave U10, Cleveland, OH 44195 USA; [Lowe, Mark J.; Beall, Erik B.; Koenig, Katherine A.; Jones, Stephen E.] Cleveland Clin, Imaging Inst, Cleveland, OH 44106 USA; [Fischer, Barbara L.] Wm S Middleton Mem Vet Affairs Hosp, GRECC, Madison, WI USA; [Agarwal, Rajan] Michael E DeBakey VA Med Ctr, Diagnost & Therapeut Care, Houston, TX USA; [Agarwal, Rajan] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA	Rao, SM (corresponding author), Cleveland Clin, Neurol Inst, Schey Ctr Cognit Neuroimaging, 9500 Euclid Ave U10, Cleveland, OH 44195 USA.	raos2@ccf.org	Koenig, Katherine/K-1564-2019; Rao, Stephen M/A-2460-2010	Rao, Stephen M/0000-0002-6463-7460; Koenig, Katherine/0000-0002-1504-7130; Durgerian, Sally/0000-0003-3931-9679	U.S Department of DefenseUnited States Department of Defense [W81XWH-08-2-0124, W81XWH-10-1-0609]; Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development, Traumatic Brain Injury Center of Excellence [B6812C]; Veterans AffairsUS Department of Veterans Affairs [I21RX001608] Funding Source: NIH RePORTER	This study was supported by grants from the U.S Department of Defense (W81XWH-08-2-0124, W81XWH-10-1-0609) and was supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development, Project #B6812C Traumatic Brain Injury Center of Excellence. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs. There are no potential conflicts of interest, including financial, between any of the authors and the work presented in this manuscript. We are grateful to the veterans taking part in the research. Thanks to laboratory members who provided helpful contributions: Gregory Vogt, Xiaodi Lin, Tricia Merkley, Rebecca Marsh, Brian Taylor, and Mark Walker.	Acheson DJ, 2009, PSYCHOL BULL, V135, P50, DOI 10.1037/a0014411; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Ashby FG, 2005, J COGNITIVE NEUROSCI, V17, P1728, DOI 10.1162/089892905774589271; Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Baddeley A. D., 1986, WORKING MEMORY; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benton AL, 1983, MULTILINGUAL APHASIA; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cairo TA, 2004, COGNITIVE BRAIN RES, V21, P377, DOI 10.1016/j.cogbrainres.2004.06.014; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chang C, 2007, NEUROIMAGE, V34, P1253, DOI 10.1016/j.neuroimage.2006.08.056; Chein JM, 2001, CEREB CORTEX, V11, P1003, DOI 10.1093/cercor/11.11.1003; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cools R, 2006, NEUROSCI BIOBEHAV R, V30, P1, DOI 10.1016/j.neubiorev.2005.03.024; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Delis DC, 2000, CALIFORNIA VERBAL LE; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dretsch M. N., 2014, J NEUROTRAUMA; Erpelding N, 2013, PAIN, V154, P2060, DOI 10.1016/j.pain.2013.06.030; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Ghahremani DG, 2012, J NEUROSCI, V32, P7316, DOI 10.1523/JNEUROSCI.4284-11.2012; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gordon EM, 2015, CEREB CORTEX, V25, P336, DOI 10.1093/cercor/bht229; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; JOHNSONLAIRD PN, 1994, COGNITION, V50, P189, DOI 10.1016/0010-0277(94)90028-0; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kreitzer AC, 2008, NEURON, V60, P543, DOI 10.1016/j.neuron.2008.11.005; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Levy R, 1997, J NEUROSCI, V17, P3870; Lewis SJG, 2004, EUR J NEUROSCI, V19, P755, DOI 10.1111/j.1460-9568.2004.03108.x; Li CSR, 2008, NEUROIMAGE, V41, P1352, DOI 10.1016/j.neuroimage.2008.04.023; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Marklund P, 2009, BRAIN, V132, P336, DOI 10.1093/brain/awn309; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; Murty VP, 2011, NEUROIMAGE, V57, P1264, DOI 10.1016/j.neuroimage.2011.05.006; Ness V, 2013, NEUROPSYCHOLOGIA, V51, P2562, DOI 10.1016/j.neuropsychologia.2013.09.032; Nikolaidis A, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00169; Postle BR, 1999, COGNITIVE BRAIN RES, V8, P107, DOI 10.1016/S0926-6410(99)00010-5; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Robinson JL, 2012, NEUROIMAGE, V60, P117, DOI 10.1016/j.neuroimage.2011.12.010; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Shahaduzzaman M, 2013, MED HYPOTHESES, V81, P675, DOI 10.1016/j.mehy.2013.07.025; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Talairach J., 1988, COPLANAR STEREOTAXIC; Tanelian T., 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; TEASDALE G, 1974, LANCET, V2, P81; Tian FH, 2014, NEUROIMAGE-CLIN, V4, P808, DOI 10.1016/j.nicl.2014.05.005; van Wingen GA, 2012, MOL PSYCHIATR, V17, P116, DOI 10.1038/mp.2011.110; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Weathers F.W., 1993, 9 ANN C ISTSS SAN AN; Wishart HA, 2011, J INT NEUROPSYCH SOC, V17, P174, DOI 10.1017/S1355617710001402; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	86	21	21	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	8						543	553		10.1016/j.nicl.2015.04.024			11	Neuroimaging	Neurosciences & Neurology	DI0LE	WOS:000373187100058	26110112	DOAJ Gold, Green Published			2021-06-18	
J	Norup, A; Perrin, PB; Cuberos-Urbano, G; Anke, A; Andelic, N; Doyle, ST; Quijano, MC; Caracuel, A; Sosa, DMD; Jove, IGE; Arango-Lasprilla, JC				Norup, Anne; Perrin, Paul B.; Cuberos-Urbano, Gustavo; Anke, Audny; Andelic, Nada; Doyle, Sarah T.; Cristina Quijano, Maria; Caracuel, Alfonso; Diaz Sosa, Dulce Maria; Espinosa Jove, Irma Guadalupe; Carlos Arango-Lasprilla, Juan			Family needs after brain injury: A cross cultural study	NEUROREHABILITATION			English	Article						Traumatic brain injury; caregivers; family needs; cultural differences; global regions	QUALITY-OF-LIFE; CAREGIVER BURDEN; REHABILITATION; HEALTH; TBI; INDIVIDUALS; IMPACT; MODERATE; COMMUNICATION; SATISFACTION	OBJECTIVE: The objective of this study was to explore differences by country in the importance of family needs after traumatic brain injury (TBI), as well as differences in met/unmet needs. METHOD: Two hundred and seventy-one family members of an individual with TBI in Mexico, Colombia, Spain, Denmark, and Norway completed the Family Needs Questionnaire. RESULTS: Eight of the ten needs rated as most important globally were from the Health Information subscale. Importance ratings on the Health Information, Professional Support, and Involvement With Care subscales were similar across countries, but Mexican family members rated Instrumental Support needs as less important than Colombian, Spanish, and Danish family members, and also rated their Community Support needs as less important than Danish and Spanish family members. Mexican family member's rated emotional support needs as less important than Colombian, Spanish, and Danish family members. Globally, the needs rated as most often met were from the Health Information subscale, and the most unmet needs were from the Emotional Support subscale. CONCLUSION: Despite some similarities across countries several differences were identified, and these can help professionals to provide more culturally appropriate rehabilitation services for family members in order to improve informal care for TBI.	[Norup, Anne] Copenhagen Univ Hosp, Traumat Brain Injury Unit, Dept Neurorehabil, RUBRIC Res Unit Brain Injury Rehabil Copenhagen, Glostrup, Denmark; [Perrin, Paul B.; Doyle, Sarah T.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Caracuel, Alfonso] Univ Granada, Mind Brain & Behav Res Ctr, Dept Dev & Educ Psychol, Granada, Spain; [Anke, Audny] Univ Hosp North Norway, Dept Rehabil, Tromso, Norway; [Anke, Audny] Univ Tromso, Dept Clin Med, Fac Hlth Sci, N-9001 Tromso, Norway; [Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Cristina Quijano, Maria] Javeriana Univ, Cali, Colombia; [Andelic, Nada] Univ Oslo, Fac Med, Inst Hlth & Soc, CHARM Res Ctr Habilitat & Rehabil Models & Serv, Oslo, Norway; [Cuberos-Urbano, Gustavo] Univ Granada, Dept Personal Assessment & Psychol Treatment, Granada, Spain; [Diaz Sosa, Dulce Maria] Univ Nacl Autonoma Mexico, Dept Psychol, Mexico City 04510, DF, Mexico; [Espinosa Jove, Irma Guadalupe] Inst Nacl Rehabil Mexico, Mexico City, DF, Mexico; [Carlos Arango-Lasprilla, Juan] Univ Deusto, Ikerbasque, Basque Fdn Sci, Bilbao, Spain	Arango-Lasprilla, JC (corresponding author), Univ Deusto, Ikerbasque, Basque Fdn Sci, Dept Psychol, Bilbao, Spain.	jcarango@deusto.es	Caracuel, Alfonso/V-3695-2019; Perrin, Paul/L-5373-2015	Caracuel, Alfonso/0000-0002-9738-8456; Anke, Audny/0000-0002-2491-2560; Perrin, Paul/0000-0003-2070-215X; Norup, Anne/0000-0002-5598-6116; Quijano Martinez, Maria Cristina/0000-0003-3548-1628; Andelic, Nada/0000-0002-3719-4406			Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andelic N., 2012, LANCET NEUROLOGY; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arango-Lasprilla JC, 2011, J REHABIL MED, V43, P983, DOI 10.2340/16501977-0883; Arango-Lasprilla JC, 2010, NEUROREHABILITATION, V27, P83, DOI 10.3233/NRE-2010-0583; Arango-Lasprilla JC, 2010, BRAIN INJURY, V24, P1017, DOI 10.3109/02699052.2010.490516; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Gorn SB, 2013, REV PANAM SALUD PUBL, V33, P252, DOI 10.1590/S1020-49892013000400003; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Engberg Aase Worsaae, 2007, Ugeskr Laeger, V169, P204; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Galanti Geri-Ann, 2003, J Transcult Nurs, V14, P180, DOI 10.1177/1043659603014003004; Gamboa AM, 2006, NEUROREHABILITATION, V21, P327; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Kolakowsky-Hayner SA, 2000, ARCH CLIN NEUROPSYCH, V15, P810; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehan TJ, 2012, NEUROREHABILITATION, V30, P75, DOI 10.3233/NRE-2012-0729; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Leibach GG, 2014, NEUROREHABILITATION, V34, P167, DOI 10.3233/NRE-131013; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037/0033-295X.98.2.224; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Moules S, 1999, BRAIN INJURY, V13, P983; Norup A., 2013, SEVERE BRAIN INJURY; Norup A, 2012, BRAIN INJURY, V26, P1192, DOI 10.3109/02699052.2012.672790; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wright J. D., 2009, PERCEPTIONS MENTAL H	52	21	21	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2015	36	2					203	214		10.3233/NRE-151208			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CK9CW	WOS:000356539100006	26410614				2021-06-18	
J	Olivecrona, Z; Bobinski, L; Koskinen, LOD				Olivecrona, Zandra; Bobinski, Lukas; Koskinen, Lars-Owe D.			Association of ICP, CPP, CT findings and S-100B and NSE in severe traumatic head injury. Prognostic value of the biomarkers	BRAIN INJURY			English	Article						CPP; CT classification; ICP targeted therapy; ICP; NSE; prognostication; S-100B; severe traumatic brain injury	NEURON-SPECIFIC ENOLASE; LOW-DOSE PROSTACYCLIN; SERUM S100B LEVELS; BRAIN-INJURY; COMPUTED-TOMOGRAPHY; CEREBROSPINAL-FLUID; OUTCOME PREDICTION; PROTEIN; MARKER; DAMAGE	Objective: The association was studied of intracranial pressure (ICP) and cerebral perfusion pressure (CPP) on S-100B and neuron-specific enolase (NSE) in severe traumatic brain injury (sTBI). The relationship was explored between biomarkers, ICP, CPP, CT-scan classifications and the clinical outcome. Materials and methods: Data were collected prospectively and consecutively in 48 patients with Glasgow Coma Scale score <= 8, age 15-70 years. NSE and S-100B were analysed during 5 consecutive days. The initial and follow-up CT-scans were classified according to the Marshall, Rotterdam and Morris-Marshall classifications. Outcome was evaluated with extended Glasgow outcome scale at 3 months. Results: Maximal ICP and minimal CPP correlated with S-100B and NSE levels. Complex relations between biomarkers and CT classifications were observed. S-100B bulk release (AUC = 0.8333, p = 0.0009), and NSE at 72 hours (AUC = 0.8476, p = 0.0045) had the highest prediction power of mortality. Combining Morris-Marshall score and S-100B bulk release improved the prediction of clinical outcome (AUC = 0.8929, p = 0.0008). Conclusion: Biomarker levels are associated with ICP and CPP and reflect different aspects of brain injury as evaluated by CT-scan. The biomarkers might predict mortality. There are several pitfalls influencing the interpretation of biomarker data in respect to ICP, CPP, CT-findings and clinical outcome.	[Olivecrona, Zandra; Bobinski, Lukas; Koskinen, Lars-Owe D.] Umea Univ, Dept Neurosurg, Inst Pharmacol & Clin Neurosci, SE-90185 Umea, Sweden	Koskinen, LOD (corresponding author), Umea Univ, Dept Neurosurg, Inst Pharmacol & Clin Neurosci, SE-90185 Umea, Sweden.	lars-owe.koskinen@neuro.umu.se	Koskinen, Lars-Owe/AAQ-8957-2020		Department of Pharmacology and Clinical Neuroscience, Umea University; Tore Nilsson Found; Kempe Found; Capio Research Found	The authors report no conflicts of interest. Financial support from the Department of Pharmacology and Clinical Neuroscience, Umea University, Tore Nilsson Found, Kempe Found, and Capio Research Found is acknowledged.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Babcock L, 2012, BRAIN INJURY, V26, P1372, DOI 10.3109/02699052.2012.694565; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Bobinski L, 2012, ACTA NEUROCHIR, V154, P1069, DOI 10.1007/s00701-012-1345-x; Bouzat P, 2009, ANN FR ANESTH, V28, P135, DOI 10.1016/j.annfar.2008.12.019; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; Guan Wei, 2003, Chin J Traumatol, V6, P218; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jung CS, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/560305; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kirchhoff C, 2008, EUR J MED RES, V13, P511; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kofke WA, 2004, ANESTH ANALG, V99, P1323, DOI 10.1213/01.ANE.0000135345.03635.6A; Koskinen LOD, 2015, NEUROCRIT CARE, V22, P26, DOI 10.1007/s12028-014-0030-8; Lesko MM, 2014, BRAIN INJURY, V28, P987, DOI 10.3109/02699052.2014.890743; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marmarou A, 2000, ACT NEUR S, V76, P349; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Moller AD, 1997, AM J PHYSIOL-HEART C, V273, pH200; Morris GF, 1997, CLIN NEUROL NEURO S1, V99, pS16; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Olivecrona M, 2012, BRAIN INJURY, V26, P67, DOI 10.3109/02699052.2011.635351; Olivecrona M, 2009, J NEUROTRAUM, V26, P1251, DOI [10.1089/neu.2008.0605, 10.1089/neu.2008-0605]; Olivecrona Z, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-33; Olivecrona Z, 2012, ACTA NEUROCHIR, V154, P675, DOI 10.1007/s00701-012-1292-6; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Unden J, 2007, NEUROCRIT CARE, V6, P94, DOI 10.1007/s12028-007-0005-0; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vos PE, 2006, EUR J NEUROL, V13, P632, DOI 10.1111/j.1468-1331.2006.01332.x; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Ytrebo LM, 2000, SCAND J GASTROENTERO, V35, P546	65	21	22	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	4					446	454		10.3109/02699052.2014.989403			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CF8JE	WOS:000352803300005	25518864				2021-06-18	
J	Prasanna, KL; Mittal, RS; Gandhi, A				Prasanna, K. L.; Mittal, R. S.; Gandhi, Ashok			Neuroendocrine dysfunction in acute phase of moderate-to-severe traumatic brain injury: A prospective study	BRAIN INJURY			English	Article						Endocrine; pituitary; traumatic brain injury	GROWTH-HORMONE DEFICIENCY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; HEAD-INJURY; PITUITARY DYSFUNCTION; PLASMA-CORTISOL; ADULT PATIENTS; FACTOR-I; HYPOPITUITARISM; ABNORMALITIES; REHABILITATION	Objectives: Most of the retrospective studies have demonstrated that traumatic brain injury mediated hypopituitarism could be more frequent than previously known. Therefore, this study has prospectively investigated pituitary function and their correlation with severity, pressure effect and Glasgow Outcome Scale in the acute phase of moderate-to-severe traumatic brain injury. Patients and methods: One hundred consecutive moderate-to-severe traumatic brain injury patients from August 2012 to November 2013 formed the study group. Apart from clinical assessment, non-contrast computed tomography of the head was performed on all patients on admission. The hormonal analysis (fT3, fT4, TSH, GH, Cortisol, Prolactin) was performed within 24 hours of traumatic brain injury and was repeated on the 7th day amongst the patients who survived. Results: Growth hormone was the most common hormone to decrease. Cortisol was the most common hormone to increase. Risk of pituitary insufficiency was increased in patients with severe traumatic brain injury, patients with increased intracranial pressure and who had low Glasgow Outcome Scale. Conclusion: Neuroendocrine dysfunction occurs often in the acute phase of moderate-to-severe traumatic brain injury, more commonly in patients with severe traumatic brain injury, patients with pressure effects and low Glasgow Outcome Scale. Hormonal analysis should be considered in patients with moderate-to-severe traumatic brain injury, so that appropriate hormonal replacement can be done to optimize the clinical outcome.	[Prasanna, K. L.; Mittal, R. S.; Gandhi, Ashok] SMS Med Coll & Hosp, Dept Neurosurg, Jaipur 302004, Rajasthan, India	Prasanna, KL (corresponding author), SMS Med Coll & Hosp, Dept Neurosurg, JLN Marg, Jaipur 302004, Rajasthan, India.	drprasannakl@yahoo.co.in					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Beshyah SA, 1999, CLIN ENDOCRINOL, V50, P1, DOI 10.1046/j.1365-2265.1999.00682.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; DESAI D, 1989, J TRAUMA, V29, P719, DOI 10.1097/00005373-198906000-00003; EDWARDS OM, 1986, MEDICINE, V65, P281; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mahapatra A K, 2014, TXB HEAD INJURY, P1; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2004, DTSCH ARZTEBL, V101, pA712; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; SOULES MR, 1979, SOUTHERN MED J, V72, P1592, DOI 10.1097/00007611-197912000-00029; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Tandon A, 2009, ACTA NEUROCHIR, V151, P1411, DOI 10.1007/s00701-009-0444-9; TEASDALE G, 1974, LANCET, V2, P81; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; ZIEGLER MG, 1990, CRIT CARE MED, V18, P253, DOI 10.1097/00003246-199003000-00001	47	21	22	0	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	3					336	342		10.3109/02699052.2014.955882			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CB0HQ	WOS:000349307000008	25671810				2021-06-18	
J	Sambasivan, K; Grilli, L; Gagnon, I				Sambasivan, Krithika; Grilli, Lisa; Gagnon, Isabelle			Balance and mobility in clinically recovered children and adolescents after a mild traumatic brain injury	JOURNAL OF PEDIATRIC REHABILITATION MEDICINE			English	Article						Balance; mobility or gait; children and adolescents; Mild Traumatic Brain Injury; concussion		PURPOSE: To compare the ability of clinical balance measures to detect differences between children recovered from a mild Traumatic Brain Injury (mTBI) and healthy controls. METHODS: A cross-sectional study, with twenty-six children with mTBI and twenty-two age-matched controls was conducted. Balance was evaluated on three scales: Bruininks-Osteresky Test-second edition; Balance Error Scoring System and Community Balance and Mobility Scale, along with gait analysis of three paradigms (self-selected paced walking, obstacle crossing and tandem walking), under single and dual-task conditions, using GAITRite (R) walkway. Independent sample t-tests (alpha = 0.05) were used to identify group differences. Dual-Task Cost (DTC) was analyzed using repeated measures ANOVA and t-tests. Discriminant analysis predicted which balance measure best identified the groups. RESULTS: Children with mTBI performed worse on all balance scales (p < 0.05). Gait parameters were significantly better for the controls. There were no group differences on the motor and cognitive DTC. The Community Balance and Mobility Scale and gait parameters including velocity at obstacle crossing and parameters for tandem walking, best discriminated the groups. CONCLUSION: Clinical balance assessments may need to include static and dynamic measures, to capture possible performance difficulties. The inclusion of these measures will enhance clinical decision making and prevent premature return to physical activities in children with mTBI.	[Sambasivan, Krithika] McGill Univ, Sch Phys & Occupat Therapy, 3654 Promenade Sir William Osler, Montreal, PQ H3G 1Y5, Canada; [Grilli, Lisa; Gagnon, Isabelle] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada	Gagnon, I (corresponding author), McGill Univ, Sch Phys & Occupat Therapy, 3654 Promenade Sir William Osler, Montreal, PQ H3G 1Y5, Canada.	isabelle.gagnon8@mcgill.ca			Fonds de la recherche du Quebec-SanteFonds de la Recherche en Sante du Quebec; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); McGill University Health Center Research Institute	Programme de partenariat OPPQ/REPAR, 2012-2014. IG is supported by the Fonds de la recherche du Quebec-Sante, the Canadian Institutes of Health Research and by the McGill University Health Center Research Institute.	Alderson L, 2007, PHYS THER REV, V12, P3, DOI 10.1179/108331907X174943; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bruininks R., 2005, OSTERESKY TEST MOTOR; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cherng RJ, 2009, GAIT POSTURE, V29, P204, DOI 10.1016/j.gaitpost.2008.08.003; Clegg H, 2009, COMMUNITY BALANCE MO; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Deitz Jean C, 2007, Phys Occup Ther Pediatr, V27, P87, DOI 10.1300/J006v27n04_06; Draganich LF, 2004, J BIOMECH, V37, P889, DOI 10.1016/j.jbiomech.2003.11.002; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Geuze Reint H., 2005, Neural Plasticity, V12, P183, DOI 10.1155/NP.2005.183; Greene BR, 2012, J APPL BIOMECHANICS, V28; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Horak FB, 1997, PHYS THER, V77, P517, DOI 10.1093/ptj/77.5.517; Howe JA, 2006, CLIN REHABIL, V20, P885, DOI 10.1177/0269215506072183; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Katz-Leurer M, 2011, NEUROREHABILITATION, V29, P45, DOI 10.3233/NRE-2011-0676; Kontos AP, 2012, AM J SPORTS MED; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lowrey CR, 2007, EXP BRAIN RES, V182, P289, DOI 10.1007/s00221-007-0986-0; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McFadyen BJ, 2001, GAIT POSTURE, V13, P7, DOI 10.1016/S0966-6362(00)00090-4; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Montero-Odasso M, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-35; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Piek JP, 1999, DEV MED CHILD NEUROL, V41, P159, DOI 10.1017/S0012162299000341; Rinehart NJ, 2006, DEV MED CHILD NEUROL, V48, P819, DOI 10.1017/S0012162206001769; SALLIS JF, 1988, AM J EPIDEMIOL, V127, P933, DOI 10.1093/oxfordjournals.aje.a114896; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Thorpe DE, 2005, ARCH PHYS MED REHAB, V86, P2342, DOI 10.1016/j.apmr.2005.07.301; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wright FV, 2010, BRAIN INJURY, V24, P1585, DOI 10.3109/02699052.2010.523045; Wright MJ, 2012, PHYS OCCUP THER PEDI, V32, P416, DOI 10.3109/01942638.2012.705418	46	21	21	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1874-5393	1875-8894		J PEDIATR REHAB MED	J. Pediatr. Rehab. Med.		2015	8	4					335	344		10.3233/PRM-150351			10	Pediatrics	Pediatrics	VG7LK	WOS:000448290900007	26684073				2021-06-18	
J	Sun, M; Zhao, YM; Gu, Y; Zhang, YZ				Sun, Ming; Zhao, Yumei; Gu, Yi; Zhang, Yazhuo			Protective Effects of Taurine against Closed Head Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						oxidative stress; closed head injury; neuroprotection; taurine	TRAUMATIC BRAIN-INJURY; DOWN-REGULATING CALPAIN; FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; LIPID-PEROXIDATION; CELL-DAMAGE; PATHOPHYSIOLOGY; ANTIOXIDANTS; STROKE; MODEL	Taurine, an abundant amino acid in the nervous system, is reported to reduce ischemic brain injury in a dose-dependent manner. This study was designed to investigate whether taurine protected the brain against closed head injury (CHI) in rats. Taurine was administered intravenously 30 min after CHI. It was found that taurine lessened body-weight loss and improved neurological functions at 7 days after CHI. Moreover, it lowered brain edema and blood-brain barrier permeability, enhanced activity of superoxide dismutase and the level of glutathione, and reduced levels of malondialdehyde and lactic acid in traumatic tissue 24 h after CHI. In addition, it attenuated neuronal cell death in hippocampal CA1 and CA3 subfields 7 days after CHI. All of these effects were dose dependent. These data demonstrated the dose-dependent protection of taurine against experimental CHI and suggest that taurine treatment might be beneficial in reducing trauma-induced oxidative damage to the brain, thus showing the potential for clinical implications.	[Sun, Ming; Zhao, Yumei; Gu, Yi] Beijing Neurosurg Inst, Dept Neuropharmacol, Beijing 100050, Peoples R China; [Zhang, Yazhuo] Beijing Neurosurg Inst, Dept Cytobiol, Beijing 100050, Peoples R China	Zhang, YZ (corresponding author), Beijing Neurosurg Inst, Dept Cytobiol, 6 Tiantan Xili, Beijing 100050, Peoples R China.	yazhuozhang@yahoo.com					Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Birdsall T C, 1998, Altern Med Rev, V3, P128; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRALET J, 1991, BRAIN RES, V539, P175, DOI 10.1016/0006-8993(91)90703-X; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; CARRUTHERSJONES DI, 1978, NEUROCHEM RES, V3, P115, DOI 10.1007/BF00964364; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chao PK, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-121; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; El Idrissi A, 2008, AMINO ACIDS, V34, P321, DOI 10.1007/s00726-006-0396-9; El Idrissi A, 2003, ADV EXP MED BIOL, V526, P515; Furukawa S., 1991, J JPN PHARM THER, V19, P275; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hanna J, 2004, EXP TOXICOL PATHOL, V56, P189, DOI 10.1016/j.etp.2004.08.004; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101; JACOBSON I, 1985, J NEUROSCI METH, V15, P263, DOI 10.1016/0165-0270(85)90107-4; Lallemand F, 2004, AMINO ACIDS, V26, P111, DOI 10.1007/s00726-003-0058-0; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Louzada PR, 2004, FASEB J, V18, P511, DOI 10.1096/fj.03-0739com; Mankovskaya I N, 2000, High Alt Med Biol, V1, P105, DOI 10.1089/15270290050074242; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Messina SA, 2000, ADV EXP MED BIOL, V483, P355; Michalk DV, 1996, ADV EXP MED BIOL, V403, P223; Nishizawa Y., 1991, JPN PHARMACOL THER, V19, P307; PASANTESMORALES H, 1981, J NEUROSCI RES, V6, P465, DOI 10.1002/jnr.490060404; Pushpakiran G, 2004, AMINO ACIDS, V27, P91, DOI 10.1007/s00726-004-0066-8; RASCHKE P, 1995, FREE RADICAL BIO MED, V19, P461, DOI 10.1016/0891-5849(95)00044-X; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; SANBERG PR, 1980, NEUROSCI LETT, V16, P297, DOI 10.1016/0304-3940(80)90014-2; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Saransaari P, 2000, AMINO ACIDS, V19, P509, DOI 10.1007/s007260070003; Schaffer SW, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S2; Schuller-Levis GB, 2004, NEUROCHEM RES, V29, P117, DOI 10.1023/B:NERE.0000010440.37629.17; Shao A, 2008, REGUL TOXICOL PHARM, V50, P376, DOI 10.1016/j.yrtph.2008.01.004; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smith SL, 1996, J NEUROSURG, V84, P229, DOI 10.3171/jns.1996.84.2.0229; Sun M, 2008, CELL MOL NEUROBIOL, V28, P593, DOI 10.1007/s10571-007-9183-8; Sun M, 2012, AMINO ACIDS, V42, P1735, DOI 10.1007/s00726-011-0885-3; Sun M, 2011, AMINO ACIDS, V40, P1419, DOI 10.1007/s00726-010-0751-8; Sun M, 2009, NEUROCHEM INT, V54, P339, DOI 10.1016/j.neuint.2008.12.017; Tamai I, 1995, BIOCHEM PHARMACOL, V50, P1783, DOI 10.1016/0006-2952(95)02046-2; URQUHART N, 1974, J NEUROCHEM, V22, P871, DOI 10.1111/j.1471-4159.1974.tb04309.x; Ustun ME, 2001, J NEUROSURG ANESTH, V13, P227; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wojcik OP, 2010, ATHEROSCLEROSIS, V208, P19, DOI 10.1016/j.atherosclerosis.2009.06.002; Yildirim ZL, 2007, ANN NY ACAD SCI, V1100, P553, DOI 10.1196/annals.1395.061	53	21	21	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2015	32	1					66	74		10.1089/neu.2012.2432			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AX4JX	WOS:000346900100009	23327111				2021-06-18	
J	Towns, SJ; Silva, MA; Belanger, HG				Towns, Stephanie J.; Silva, Marc A.; Belanger, Heather G.			Subjective sleep quality and postconcussion symptoms following mild traumatic brain injury	BRAIN INJURY			English	Article						Concussion; mood; postconcussive syndrome; psychological distress	DISTURBANCE; INDEX; INVENTORY-18; RELIABILITY; PREVALENCE; COMPLAINTS; INSOMNIA; VALIDITY	Primary objective: The goal of this investigation is to examine the prevalence of poor subjective sleep in patients with a history of mild traumatic brain injury (mTBI) and examine the relationship between subjective sleep quality and postconcussive symptoms (PCS), above and beyond the typical demographic and psychological distress variables. Research design: Individuals with a history of mTBI completed online questionnaires. Regression analysis was utilized to determine if subjective sleep quality would predict PCS severity, above and beyond demographic variables and psychological distress. Methods and procedures: Individuals with a history of mTBI (n = 158) completed surveys online. Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) and PCS with the Neurobehavioral Symptom Inventory (NSI). Demographic information was collected and psychological distress was measured using the Brief Symptom Inventory-18 (BSI-18). Main outcomes and results: In this sample, 92% of patients with mTBI reported poor sleep. Sleep quality significantly accounted for the variance in PCS, above and beyond demographics, time since injury and psychological distress (p < 0.001), although only a small amount of the variance in PCS was explained. Conclusions: Results indicate that poor subjective sleep quality is a significant problem in those with mTBI. While sleep is associated with PCS severity, psychological distress is a more potent predictor.	[Towns, Stephanie J.; Silva, Marc A.; Belanger, Heather G.] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Belanger, Heather G.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA; [Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Belanger, Heather G.] Def & Vet Brain Injury Ctr, Tampa, FL USA; [Belanger, Heather G.] James A Haley Vet Hosp, Hlth Serv Res & Dev, Rehabil Res & Dev RR&D Ctr Excellence Maximizing, Tampa, FL 33612 USA	Towns, SJ (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Psychiat HB7750, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	stephanie.j.towns@dartmouth.edu	Towns, Stephanie/AAF-2035-2020; Silva, Marc A./J-1874-2019	Silva, Marc A./0000-0002-3879-6054	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0719]; Department of Veterans Affairs, Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; James A. Haley Veterans' HospitalUS Department of Veterans Affairs	The research reported here was supported in part by the Department of Defense (W81XWH-10-1-0719), Department of Veterans Affairs, Veterans Health Administration (VHA) and the Defense and Veterans Brain Injury Center (DVBIC). Further support was provided by the James A. Haley Veterans' Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Army, Department of Defense, Department of Veterans Affairs or US Government.	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Belanger HG, 2015, MIL MED, V180, P186; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; Centers for Disease Control, RAT TBI REL EM DEP V; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Derogatis LR, 2000, BSI 18 ADM SCOR PROC; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Mild Traumatic Brain Injury Committee American Congress of Rehabilitation Medicine Head Injury Interdisciplinary Special Interest Group, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Mittenberg W, 2008, TXB CLIN NEUROPSYCHO, P430; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Silva MA, 2013, CLIN NEUROPSYCHOL, V27, P601; World Health Organization, 1992, ICD 10 CLASS MENT BE	27	21	21	1	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	11					1337	1341		10.3109/02699052.2015.1045030			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CR4MF	WOS:000361306100008	26288022				2021-06-18	
J	Li, SJ; Tian, Y; Huang, XT; Zhang, YQ; Wang, DH; Wei, HJ; Dong, JF; Jiang, RC; Zhang, JN				Li, Shengjie; Tian, Ye; Huang, Xintao; Zhang, Yongqiang; Wang, Dehui; Wei, Huijie; Dong, Jingfei; Jiang, Rongcai; Zhang, Jianning			Intravenous transfusion of endothelial colony-forming cells attenuates vascular degeneration after cerebral aneurysm induction	BRAIN RESEARCH			English	Article						Cerebral aneurysm; Endothelial colony-forming cells; Transfusion; Inflammation; Macrophage; Apoptosis	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; PROGENITOR CELLS; INTRACRANIAL ANEURYSMS; BONE-MARROW; INFLAMMATORY RESPONSE; HEMODYNAMIC-CHANGES; MOUSE MODEL	Cerebral aneurysm (CA) rupture is a major cause of subarachnoid hemorrhage with high morbidity and mortality. Using an animal model, we examined the potential of endothelial colony-forming cells (ECFCs) transfusion on vascular degeneration after CA induction and underlying mechanisms. CA was induced in the right anterior cerebral artery-olfactory artery (ACA/OA) bifurcations in Sprague-Dawley rats with or without ECFCs transfusion. The degeneration of internal elastic lamina (IEL), media thickness and CA size were evaluated. Expression of matrix metalloproteinase-2 and 9 (MMP-2 and 9), tissue inhibitor of metalloproteinase-1 (TIMP-1), macrophage chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), nuclear factor kappa B (NF-kappa B), endothelial nitric oxide synthase (eNOS), B-cell leukemia/lymphoma-2 (Bcl-2), and inducible nitric oxide synthase (iNOS) were analyzed by quantitative real-time polymerase chain reaction. The macrophages infiltration and apoptosis of smooth muscle cells (SMCs) were examined immunohistologically. Rats in CA+ECFCs transfusion group showed a notable reduction in IEL degeneration, media thinning and CA size compared with those in CA+saline group. ECFCs transfusion inhibited the MMP-driven wall destruction by downregulating MMP-2, MMP-9 expression and upregulating TIMP-1. ECFCs transfusion dramatically decreased VCAM-1 and NF-kappa B expression, increased eNOS expression and caused no change in MCP-1 expression, which was accompanied by reduced macrophages infiltration. Moreover, ECFCs transfusion reversed downregulation of Bcl-2 expression and upregulation of iNOS expression, and decreased SMCs apoptosis. Collectively, these findings suggest that ECFCs transfusion confers protection against degeneration of aneurysmal wall by inhibiting inflammatory cascades and SMCs apoptosis. (C) 2014 Elsevier B.V. All rights reserved.	[Li, Shengjie; Tian, Ye; Huang, Xintao; Zhang, Yongqiang; Wang, Dehui; Wei, Huijie; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Li, Shengjie; Tian, Ye; Huang, Xintao; Zhang, Yongqiang; Wang, Dehui; Wei, Huijie; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Li, Shengjie; Tian, Ye; Huang, Xintao; Zhang, Yongqiang; Wang, Dehui; Wei, Huijie; Jiang, Rongcai; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Li, Shengjie; Tian, Ye; Huang, Xintao; Zhang, Yongqiang; Wang, Dehui; Wei, Huijie; Jiang, Rongcai; Zhang, Jianning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin 300052, Peoples R China; [Dong, Jingfei] Puget Sound Blood Res Inst, Seattle, WA 98102 USA	Jiang, RC (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	jianghope@gmail.com; jianningzhang@hotmail.com		Huang, Xintao/0000-0002-9683-9518	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81200907]; Tianjin Research Program of Application Foundation and Advanced Technology [12JCQNJC6800]	This work was financially supported by the National Natural Science Foundation of China (Grants 81200907) and Tianjin Research Program of Application Foundation and Advanced Technology (Grants 12JCQNJC6800).	Aoki T, 2008, STROKE, V39, P1276, DOI 10.1161/STROKEAHA.107.503086; Aoki T, 2008, CURR NEUROVASC RES, V5, P37, DOI 10.2174/156720208783565663; Aoki T, 2007, CIRCULATION, V116, P2830, DOI 10.1161/CIRCULATIONAHA.107.728303; Aoki T, 2007, STROKE, V38, P162, DOI 10.1161/01.STR.0000252129.18605.c8; Aoki T, 2009, STROKE, V40, P942, DOI 10.1161/STROKEAHA.108.532556; Cao JP, 2012, ANESTHESIOLOGY, V116, P1278, DOI 10.1097/ALN.0b013e3182567f84; Chyatte D, 1997, STROKE, V28, P799, DOI 10.1161/01.STR.28.4.799; Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859; Fang XG, 2012, J CLIN NEUROSCI, V19, P1283, DOI 10.1016/j.jocn.2011.09.038; Fukuda S, 2000, CIRCULATION, V101, P2532, DOI 10.1161/01.CIR.101.21.2532; Gao L, 2008, STROKE, V39, P2085, DOI 10.1161/STROKEAHA.107.509422; Gill M, 2001, CIRC RES, V88, P167; Hara A, 1998, NEUROL RES, V20, P127; HASHIMOTO N, 1984, Neurological Research, V6, P33; HASHIMOTO N, 1978, SURG NEUROL, V10, P3; Hashimoto T, 2006, NEUROL RES, V28, P372, DOI 10.1179/016164106X14973; HAZAMA F, 1986, AM J PATHOL, V124, P399; Hermansen SE, 2011, AM J PHYSIOL-CELL PH, V300, pC783, DOI 10.1152/ajpcell.00044.2010; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Jamous MA, 2007, J NEUROSURG, V107, P405, DOI 10.3171/JNS-07/08/0405; Jin D, 2007, SURG NEUROL S2, V68, pS16; Jin Dianshi, 2007, Surg Neurol, V68 Suppl 2, pS11, DOI 10.1016/j.surneu.2007.02.060; Kadirvel R, 2010, AM J NEURORADIOL, V31, P165, DOI 10.3174/ajnr.A1781; Kanematsu Y, 2011, STROKE, V42, P173, DOI 10.1161/STROKEAHA.110.590976; Kataoka K, 1999, STROKE, V30, P1396, DOI 10.1161/01.STR.30.7.1396; Khurana VG, 2003, STROKE, V34, P2555, DOI 10.1161/01.STR.0000096994.53810.59; KIM C, 1992, SURG NEUROL, V38, P331, DOI 10.1016/0090-3019(92)90017-H; Kim SC, 1997, NEUROSURGERY, V41, P642, DOI 10.1097/00006123-199709000-00027; Kondo S, 1998, STROKE, V29, P181, DOI 10.1161/01.STR.29.1.181; Lavergne M, 2011, CELL PROLIFERAT, V44, P44, DOI 10.1111/j.1365-2184.2010.00722.x; Leone AM, 2009, EUR HEART J, V30, P890, DOI 10.1093/eurheartj/ehp078; Li ZF, 2013, CNS NEUROSCI THER, V19, P352, DOI 10.1111/cns.12086; LOSCALZO J, 1995, NEW ENGL J MED, V333, P251, DOI 10.1056/NEJM199507273330410; Makino H, 2012, STROKE, V43, P2450, DOI 10.1161/STROKEAHA.112.659821; Melero-Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood-2006-12-062471; Morimoto M, 2002, STROKE, V33, P1911, DOI 10.1161/01.STR.0000021000.19637.3D; Muhs A, 2003, HUM GENE THER, V14, P375, DOI 10.1089/104303403321208970; Nuki Y, 2009, HYPERTENSION, V54, P1337, DOI 10.1161/HYPERTENSIONAHA.109.138297; Nuki Y, 2009, J CEREBR BLOOD F MET, V29, P495, DOI 10.1038/jcbfm.2008.136; OKADA Y, 1993, CELL BIOL INT, V17, P863, DOI 10.1006/cbir.1993.1149; Ota R, 2009, J CEREBR BLOOD F MET, V29, P1547, DOI 10.1038/jcbfm.2009.77; Piatkowski A, 2013, INT REV CEL MOL BIO, V306, P43, DOI 10.1016/B978-0-12-407694-5.00002-X; Qiu J, 2013, INT J MOL MED, V31, P91, DOI 10.3892/ijmm.2012.1180; Richardson MR, 2011, J MOL CELL CARDIOL, V50, P266, DOI 10.1016/j.yjmcc.2010.07.009; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rouhl RPW, 2008, STROKE, V39, P2158, DOI 10.1161/STROKEAHA.107.507251; Sadamasa N, 2003, STROKE, V34, P2980, DOI 10.1161/01.STR.0000102556.55600.3B; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Sencer A, 2006, NEUROL RES, V28, P415, DOI 10.1179/016164106X115017; Shantsila E, 2007, J AM COLL CARDIOL, V49, P741, DOI 10.1016/j.jacc.2006.09.050; Southgate KM, 1999, ARTERIOSCL THROM VAS, V19, P1640, DOI 10.1161/01.ATV.19.7.1640; Tamura T, 2009, J HYPERTENS, V27, P1284, DOI 10.1097/HJH.0b013e328329d1a7; Tulamo R, 2010, J NEUROINTERV SURG, V2, P120, DOI 10.1136/jnis.2009.002055; Venugopal SK, 2002, CIRCULATION, V106, P1439, DOI 10.1161/01.CIR.0000033116.22237.F9; Wei HJ, 2011, NEUROSCI LETT, V498, P114, DOI 10.1016/j.neulet.2011.04.061; Wei HJ, 2011, J NEUROSCI RES, V89, P1822, DOI 10.1002/jnr.22696; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3; Xu Y, 2011, NEUROSCIENCE, V181, P292, DOI 10.1016/j.neuroscience.2011.02.051; Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081; Zhang YM, 2009, AM J PHYSIOL-HEART C, V296, pH1675, DOI 10.1152/ajpheart.00665.2008; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073	62	21	21	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 17	2014	1593						65	75		10.1016/j.brainres.2014.09.077			11	Neurosciences	Neurosciences & Neurology	AX5FJ	WOS:000346951900007	25316629				2021-06-18	
J	Falciglia, F; Giordano, M; Aulisa, AG; Di Lazzaro, A; Guzzanti, V				Falciglia, Francesco; Giordano, Marco; Aulisa, Angelo G.; Di Lazzaro, Antonio; Guzzanti, Vincenzo			Radial Neck Fractures in Children: Results When Open Reduction Is Indicated	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						radial neck fractures; children; open reduction	PERCUTANEOUS REDUCTION; FIXATION; HEAD; MANAGEMENT	Background: Radial neck fractures in children are rare, representing 5% of all elbow pediatric fractures. Most are minimally displaced or nondisplaced. Severely displaced or angulated radial neck fractures often have poor outcomes, even after open reduction, and case series reported in literature are limited. The aim of the study is to analyze the outcomes of patients with a completely displaced and angulated fracture who underwent open reduction when closed reduction failed. Methods: Between 2000 and 2009, 195 patients with radial neck fractures were treated in our institute. Twenty-four cases satisfied all the inclusion criteria and were evaluated clinically and radiologically at a mean follow-up of 7 years. At follow-up, the carrying angle in full elbow extension and the range of motion of the elbow and forearm were measured bilaterally. We recorded clinical results as good, fair, or poor according to the range of movement and the presence of pain. Radiographic evaluation documented the size of the radial head, the presence of avascular necrosis, premature physeal closure, and cubitus valgus. Results: Statistical analysis showed that fair and poor results are directly correlated with loss of pronation-supination (P = 0.001), reduction of elbow flexion-extension (P = 0.001), increase of elbow valgus angle (P = 0.002), necrosis of the radial head (P = 0.001), premature physeal closure (P = 0.01), and associated lesions (olecranon fracture with or without dislocation of the elbow) (P = 0.002). Discussion: In our cases, residual radial head deformity due to premature closure of the growth plate and avascular necrosis were correlated with a functional deficit. Associated elbow injury was coupled with a negative prognosis. In our series, about 25% of patients had fair and 20% had poor results. Outcomes were good in 55% and felt to represent a better outcome than if the fracture remained nonanatomically reduced with residual angulation and/or displacement of the radial head. This study reports the largest series of these fractures with a combination of significant angulation and displacement of the fracture requiring open reduction. We feel that open reduction is indicated when the head of the radius is completely displaced and without contact with the rim of the metaphysis.	[Falciglia, Francesco; Giordano, Marco; Aulisa, Angelo G.; Di Lazzaro, Antonio; Guzzanti, Vincenzo] Childrens Hosp Bambino Gesu, Inst Sci Res, Dept Orthopaed & Traumatol, I-00165 Rome, Italy; [Guzzanti, Vincenzo] Univ Cassino, I-03043 Cassino, FR, Italy	Falciglia, F (corresponding author), Childrens Hosp Bambino Gesu, Inst Sci Res, Dept Orthopaed & Traumatol, Pzza S Onofrio 4, I-00165 Rome, Italy.	francesco.falciglia@opbg.net	Aulisa, Angelo gabriele/AAH-9244-2019; Giordano, Marco/AAH-9404-2019; Falciglia, Francesco/AAI-2543-2019	Aulisa, Angelo gabriele/0000-0003-2917-9385; Giordano, Marco/0000-0002-9646-8892; Falciglia, Francesco/0000-0002-2028-6611; Guzzanti, Vincenzo/0000-0002-7694-8995			Al-Aubaidi Z, 2012, INJURY, V43, P301, DOI 10.1016/j.injury.2011.08.001; Cha SM, 2012, INT ORTHOP, V36, P803, DOI 10.1007/s00264-011-1387-3; Chotel F, 2004, J PEDIATR ORTHOP B, V13, P268, DOI 10.1097/01.bpb.0000111050.85604.f1; DORMANS JP, 1990, ORTHOP CLIN N AM, V21, P257; DSOUZA S, 1993, J PEDIATR ORTHOPED, V13, P232; Klitscher D, 2009, J PEDIATR ORTHOPED, V29, P698, DOI 10.1097/BPO.0b013e3181b76895; METAIZEAU JP, 1980, REV CHIR ORTHOP, V66, P47; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; NEWMAN JH, 1977, INJURY, V9, P114, DOI 10.1016/0020-1383(77)90004-3; O'Brien P I, 1965, Clin Orthop Relat Res, V41, P51; Pring Maya E, 2012, J Pediatr Orthop, V32 Suppl 1, pS14, DOI 10.1097/BPO.0b013e31824b251d; Radomisli TE, 1998, CLIN ORTHOP RELAT R, P30; REIDY JA, 1963, J BONE JOINT SURG AM, V45, P1355, DOI 10.2106/00004623-196345070-00002; Rodriguez-Merchan EC, 1991, ORTHOPEDICS, V14, P697; SALTER RB, 1963, J BONE JOINT SURG AM, V45, P587, DOI 10.2106/00004623-196345030-00019; Schmittenbecher PP, 2005, J PEDIATR ORTHOPED, V25, P45; STEELE JA, 1992, J BONE JOINT SURG BR, V74, P760; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; Tan Bryan Hsi Ming, 2011, J Orthop Surg (Hong Kong), V19, P209; Tarallo L, 2013, J ORTHOP TRAUMATOL, V14, P291, DOI 10.1007/s10195-013-0252-0; TIBONE JE, 1981, J BONE JOINT SURG AM, V63, P100, DOI 10.2106/00004623-198163010-00013; Ugutmen E, 2010, J PEDIATR ORTHOP B, V19, P289, DOI 10.1097/BPB.0b013e32833918a0; Ursei Monica, 2006, Acta Orthop Belg, V72, P131; Vocke AK, 1998, J PEDIATR ORTHOP B, V7, P217, DOI 10.1097/01202412-199807000-00007; Waters PM, 2001, J PEDIATR ORTHOPED, V21, P570, DOI 10.1097/00004694-200109000-00003; Wilkins KE, 1996, FRACTURES CHILDREN, P586; Zimmerman RM, 2013, J BONE JOINT SURG AM, V95A, P1825, DOI 10.2106/JBJS.L.01130	27	21	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-6798	1539-2570		J PEDIATR ORTHOPED	J. Pediatr. Orthop.	DEC	2014	34	8					756	762					7	Orthopedics; Pediatrics	Orthopedics; Pediatrics	AT5TI	WOS:000345004600006	25171679	Green Published			2021-06-18	
J	Munce, TA; Dorman, JC; Odney, TO; Thompson, PA; Valentine, VD; Bergeron, MF				Munce, Thayne A.; Dorman, Jason C.; Odney, Tryg O.; Thompson, Paul A.; Valentine, Verle D.; Bergeron, Michael F.			Effects of Youth Football on Selected Clinical Measures of Neurologic Function: A Pilot Study	JOURNAL OF CHILD NEUROLOGY			English	Article						balance; oculomotor; neurocognitive; subconcussive	SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; VISUAL SCREENING TOOL; HIGH-SCHOOL FOOTBALL; VOLLEYBALL PLAYERS; NCAA CONCUSSION; UNITED-STATES; COLLEGIATE; IMPACT; BALANCE	We assessed 10 youth football players (13.4 +/- 0.7 y) immediately before and after their season to explore the effects of football participation on selected clinical measures of neurologic function. Postseason postural stability in a closed-eye condition was improved compared to preseason (P = .017). Neurocognitive testing with the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) battery revealed that reaction time was significantly faster at postseason (P = .015). There were no significant preseason versus postseason differences in verbal memory (P = .507), visual memory (P = .750), or visual motor speed (P = .087). Oculomotor performance assessed by the King-Devick test was moderately to significantly improved (P = .047-.115). A 12-week season of youth football did not impair the postural stability, neurocognitive function, or oculomotor performance measures of the players evaluated. Though encouraging, continued and more comprehensive investigations of this at-risk population are warranted.	[Munce, Thayne A.; Dorman, Jason C.; Valentine, Verle D.; Bergeron, Michael F.] Sanford Hlth, Natl Inst Athlet Hlth & Performance, Sioux Falls, SD 57104 USA; [Munce, Thayne A.; Bergeron, Michael F.] Univ S Dakota, Sanford Sch Med, Dept Pediat, Sioux Falls, SD USA; [Munce, Thayne A.; Dorman, Jason C.; Valentine, Verle D.; Bergeron, Michael F.] Sanford Res, Sioux Falls, SD USA; [Odney, Tryg O.; Valentine, Verle D.] Sanford Hlth, Sanford Orthoped & Sports Med, Sioux Falls, SD 57104 USA; [Thompson, Paul A.] Sanford Res, Methodol & Data Anal Div, Sioux Falls, SD USA; [Valentine, Verle D.] Univ S Dakota, Sanford Sch Med, Dept Family Med, Sioux Falls, SD USA	Munce, TA (corresponding author), Sanford Hlth, Natl Inst Athlet Hlth & Performance, 1210 W 18th St,Suite 204, Sioux Falls, SD 57104 USA.	thayne.munce@sanfordhealth.org			Sanford Research, Sioux Falls, South Dakota	The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The authors received financial support for this study from Sanford Research, Sioux Falls, South Dakota.	Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; HASCELIK Z, 1989, J SPORT MED PHYS FIT, V29, P234; Hrysomallis C, 2011, SPORTS MED, V41, P221, DOI 10.2165/11538560-000000000-00000; Jafarzadehpur E, 2007, SCAND J MED SCI SPOR, V17, P186, DOI 10.1111/j.1600-0838.2005.00535.x; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mulligan I, 2012, J ORTHOP SPORT PHYS, V42, P625, DOI 10.2519/jospt.2012.3798; Nakamoto H, 2008, PERCEPT MOTOR SKILL, V106, P163, DOI 10.2466/PMS.106.1.163-170; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Talavage TM, 2013, J NEUROTRAUMA; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Valentine VD, 2012, MED SCI SPORTS EXERC, p[44, S264]	35	21	21	1	23	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	DEC	2014	29	12					1601	1607		10.1177/0883073813509887			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	AX4NB	WOS:000346908000011	24272520				2021-06-18	
J	Perrin, PB; Krch, D; Sutter, M; Snipes, DJ; Arango-Lasprilla, JC; Kolakowsky-Hayner, SA; Wright, J; Lequerica, A				Perrin, Paul. B.; Krch, Denise; Sutter, Megan; Snipes, Daniel. J.; Carlos Arango-Lasprilla, Juan; Kolakowsky-Hayner, Stephanie A.; Wright, Jerry; Lequerica, Anthony			Racial/Ethnic Disparities in Mental Health Over the First 2 Years After Traumatic Brain Injury: A Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Mental health; Minority health; Rehabilitation	QUALITY-OF-LIFE; MAJOR DEPRESSIVE DISORDER; PERCEIVED DISCRIMINATION; ETHNIC DISPARITIES; UNITED-STATES; RACIAL DISPARITIES; SATISFACTION; RACE/ETHNICITY; OUTCOMES; ADULTS	Objective: To determine whether racial/ethnic disparities occur in depression, anxiety, and satisfaction with life at 1 and 2 years postdischarge. Design: A prospective, longitudinal, multicenter study of individuals with traumatic brain injury (TBI) participating in the National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems project. Medical, demographic, and outcome data were obtained from the Model Systems database at baseline, as well as 1 and 2 years postdischarge. Setting: A total of 16 TBI Model Systems hospitals in the United States. Participants: Individuals with moderate or severe TBI (N=1662) aged 16 years or older consecutively discharged between January 2008 and June 2011 from acute care and comprehensive inpatient rehabilitation at a Model Systems hospital. Intervention: Not applicable. Main Outcome Measures: The Patient Health Questionnaire-9, Generalized Anxiety Disorder 7-item scale, and Satisfaction with Life Scale assessed depression, anxiety, and satisfaction with life at 1 and 2-year follow-ups. Results: After controlling for all possible covariates, hierarchal linear models found that black individuals had elevated depression across the 2 time points relative to white individuals Asian/Pacific Islanders' depression increased over time in comparison to the decreasing depression in those of Hispanic origin, which was a greater decrease than in white individuals. Black individuals had lower life satisfaction than did white and Hispanic individuals, but only marginally greater anxiety over time than did white individuals and similar levels of anxiety as did Asian/Pacific Islanders and Hispanic individuals. Conclusions: Mental health trajectories of individuals with TBI differed as a function of race/ethnicity across the first 2 years postdischarge, providing the first longitudinal evidence of racial/ethnic disparities in mental health after TBI during this time period. Further research will be required to understand the complex factors underlying these differences. (C) 2014 by the American Congress of Rehabilitation Medicine	[Perrin, Paul. B.; Sutter, Megan; Snipes, Daniel. J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Krch, Denise; Lequerica, Anthony] Kessler Fdn, W Orange, NJ USA; [Krch, Denise; Lequerica, Anthony] Rutgers, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [Carlos Arango-Lasprilla, Juan] Univ Deusto, Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Kolakowsky-Hayner, Stephanie A.; Wright, Jerry] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA	Perrin, PB (corresponding author), Virginia Commonwealth Univ, Dept Psychol, 808 W Franklin St,Rm 201,POB 842018, Richmond, VA 23284 USA.	pperrin@vcu.edu	Kolakowsky-Hayner, Stephanie A./I-9858-2019; Sutter, Megan/L-9770-2019; Perrin, Paul/L-5373-2015	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Sutter, Megan/0000-0001-9816-9549; Perrin, Paul/0000-0003-2070-215X			ALSTON RJ, 1994, J COUNS DEV, V72, P378, DOI 10.1002/j.1556-6676.1994.tb00953.x; Arango-Lasprilla JC, 2012, BRAIN INJURY, V26, P814, DOI 10.3109/02699052.2012.655360; Arango-Lasprilla JC, 2011, PM&R, V3, P1083, DOI 10.1016/j.pmrj.2011.05.023; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Arango-Lasprilla JC, 2009, NEUROREHABILITATION, V24, P5, DOI 10.3233/NRE-2009-0449; Ayalon L, 2001, AGING MENT HEALTH, V15, P587; Barger SD, 2009, QUAL LIFE RES, V18, P179, DOI 10.1007/s11136-008-9426-2; Blendon RJ, 2007, HEALTH AFFAIR, V26, P1437, DOI 10.1377/hlthaff.26.5.1437; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borowsky SJ, 2000, J GEN INTERN MED, V15, P381, DOI 10.1046/j.1525-1497.2000.12088.x; Borrell LN, 2008, J IMMIGR MINOR HEALT, V10, P229, DOI 10.1007/s10903-007-9074-6; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Chowdhury PR, 2008, ETHNIC DIS, V18, P483; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2013, J HEAD TRAUMA REHAB, V28, P489, DOI 10.1097/HTR.0000000000000004; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Egede LE, 2012, AM J PUBLIC HEALTH, V102, pS266, DOI 10.2105/AJPH.2011.300176; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Finch BK, 2000, J HEALTH SOC BEHAV, V41, P295, DOI 10.2307/2676322; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581; Gee GC, 2007, AM J PUBLIC HEALTH, V97, P1275, DOI 10.2105/AJPH.2006.091827; Hankerson SH, 2011, J NATL MED ASSOC, V103, P576, DOI 10.1016/S0027-9684(15)30383-7; Hines P. M., 1982, ETHNICITY FAMILY THE, P84; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JONES C, 1979, AM J NURS, V79, P1551; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Keppel Kenneth, 2008, Healthy People Stat Notes, P1; Kessler RC, 1999, J HEALTH SOC BEHAV, V40, P208, DOI 10.2307/2676349; Kim HS, 2008, AM PSYCHOL, V63, P518, DOI 10.1037/0003-066X; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Landale N. S., 2006, NATL RES COUNCIL US; MCADOO H, 1983, STRESS FAMILY, V1, P178; Myaskovsky L, 2011, ARCH PHYS MED REHAB, V92, P441, DOI 10.1016/j.apmr.2010.10.007; Noh S, 2003, AM J PUBLIC HEALTH, V93, P232, DOI 10.2105/AJPH.93.2.232; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pamuk E, 1998, SOCIOECONOMIC STATUS; Paradies Y, 2006, INT J EPIDEMIOL, V35, P888, DOI 10.1093/ije/dyl056; Pascoe EA, 2009, PSYCHOL BULL, V135, P531, DOI 10.1037/a0016059; Pavot W, 2009, SOC INDIC RES SER, V39, P101, DOI 10.1007/978-90-481-2354-4_5; Pieterse AL, 2012, J COUNS PSYCHOL, V59, P1, DOI 10.1037/a0026208; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Satcher D, 2001, MENTAL HLTH CULTURE; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shim RS, 2012, ETHNIC DIS, V22, P15; Skaer TL, 2000, CLIN THER, V22, P1575, DOI 10.1016/S0149-2918(00)83055-6; Smedley BD., 2002, UNEQUAL TREATMENT CO; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stam R, 2007, NEUROSCI BIOBEHAV R, V31, P530, DOI 10.1016/j.neubiorev.2006.11.010; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Stockdale SE, 2008, MED CARE, V46, P668, DOI 10.1097/MLR.0b013e3181789496; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Williams David R., 2001, Ethnicity and Disease, V11, P800; Williams DR, 2009, J BEHAV MED, V32, P20, DOI 10.1007/s10865-008-9185-0; Williams DR, 2000, ETHNIC HEALTH, V5, P243, DOI 10.1080/713667453; Wyatt SB, 2003, AM J MED SCI, V325, P315, DOI 10.1097/00000441-200306000-00003	60	21	21	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2014	95	12					2288	2295		10.1016/j.apmr.2014.07.409			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AW0AY	WOS:000345954000008	25128715				2021-06-18	
J	Sun, YJ; Lin, YF; Cao, XL; Xiang, L; Qi, JH				Sun, Yujuan; Lin, Yanfei; Cao, Xueli; Xiang, Lan; Qi, Jianhua			Sterols from Mytilidae Show Anti-Aging and Neuroprotective Effects via Anti-Oxidative Activity	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						neuroprotection; anti-aging; anti-oxidative stress; Mytilidae; sterols; UTH1; SOD; Alzheimer's disease	TRAUMATIC BRAIN-INJURY; OXIDATIVE-STRESS; ALZHEIMERS-DISEASE; LIFE-SPAN; PATHWAY; YEAST; NEURODEGENERATION; CRINOSTEROL; RAPAMYCIN; SOD	For screening anti-aging samples from marine natural products, K6001 yeast strain was employed as a bioassay system. The active mussel extract was separated to give an active sterol fraction (SF). SF was further purified, and four sterol compounds were obtained. Their structures were determined to be cholesterol (CHOL), brassicasterol, crinosterol, and 24-methylenecholesterol. All compounds showed similar anti-aging activity. To understand the action mechanism involved, anti-oxidative experiments, reactive oxygen species (ROS) assays, and malondialdehyde (MDA) tests were performed on the most abundant compound, CHOL. Results indicated that treatment with CHOL increases the survival rate of yeast under oxidative stress and decreases ROS and MDA levels. In addition, mutations of uth1, skn7, sod1, and sod2, which feature a K6001 background, were employed and the lifespans of the mutations were not affected by CHOL. These results demonstrate that CHOL exerts anti-aging effects via anti-oxidative stress. Based on the connection between neuroprotection and anti-aging, neuroprotective experiments were performed in PC12 cells. Paraquat was used to induce oxidative stress and the results showed that the CHOL and SF protect the PC12 cells from the injury induced by paraquat. In addition, these substance exhibited nerve growth factor (NGF) mimic activities again confirmed their neuroprotective function.	[Sun, Yujuan; Lin, Yanfei; Cao, Xueli; Xiang, Lan; Qi, Jianhua] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China	Xiang, L (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Yu Hang Tang Rd 866, Hangzhou 310058, Zhejiang, Peoples R China.	11119014@zju.edu.cn; 11219008@zju.edu.cn; 11319006@zju.edu.cn; lxiang@zju.edu.cn; qijianhua@zju.edu.cn			Key Construction Program of the National "985" Project [2012HY017B]; International Science and Technology Cooperation Program of China [2014DFG32690]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81273385]	This work was financially supported by Key Construction Program of the National "985" Project (Grant No. 2012HY017B); International Science and Technology Cooperation Program of China (Grant No. 2014DFG32690); and National Natural Science Foundation of China (Grant No. 81273385). We are grateful to Michael Breitenbach (Salzburg University, Austria) for gifts of K6001 yeast strain and also grateful to Akira Matsuura (Chiba University, Japan) for gifts of strain BY4741 and all mutations with the K6001 background.	[Anonymous], 2008, SPSS BIOST SOFTW VER; Bandara PDS, 1998, CURR GENET, V34, P259, DOI 10.1007/s002940050395; BERGMANN W, 1949, J ORG CHEM, V14, P1078, DOI 10.1021/jo01158a016; Blagosklonny MV, 2009, AGING-US, V1, P281, DOI 10.18632/aging.100034; BOLKER HI, 1967, NATURE, V213, P905, DOI 10.1038/213905a0; Chen W, 2014, NEUROCHEM INT, V68, P28, DOI 10.1016/j.neuint.2014.01.015; Hamaguchi T, 2010, CNS NEUROSCI THER, V16, P285, DOI 10.1111/j.1755-5949.2010.00147.x; Hughes KA, 2005, ANNU REV ENTOMOL, V50, P421, DOI 10.1146/annurev.ento.50.071803.130409; Jiang T, 2014, BRIT J PHARMACOL, V171, P3146, DOI 10.1111/bph.12655; Kickstein E, 2010, P NATL ACAD SCI USA, V107, P21830, DOI 10.1073/pnas.0912793107; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kiyoshi S., 1963, CHEM PHARM BULL, V11, P650; LANG RW, 1982, HELV CHIM ACTA, V65, P407, DOI 10.1002/hlca.19820650144; Lu WG, 2004, STEROIDS, V69, P803, DOI 10.1016/j.steroids.2004.09.010; Mulford KE, 2011, EUKARYOT CELL, V10, P761, DOI 10.1128/EC.00328-10; Olsher M, 2005, BIOCHEMISTRY-US, V44, P2080, DOI 10.1021/bi047710s; Orr ME, 2014, NEUROBIOL AGING, V35, P1233, DOI 10.1016/j.neurobiolaging.2013.12.006; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Prince M., 2013, WORLD ALZHEIMER REPO; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Roberti G, 2014, J CELL PHYSIOL, V229, P1130, DOI 10.1002/jcp.24573; SMITH LL, 1991, FREE RADICAL BIO MED, V11, P47, DOI 10.1016/0891-5849(91)90187-8; Sun KY, 2013, INT J MOL SCI, V14, P4461, DOI 10.3390/ijms14034461; Thapa A, 2013, LANGMUIR, V29, P11713, DOI 10.1021/la4020459; Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003; Turton HE, 1997, J BACTERIOL, V179, P1096, DOI 10.1128/jb.179.4.1096-1101.1997; Walhovd KB, 2014, SCAND J PSYCHOL, V55, P244, DOI 10.1111/sjop.12120; Weng YF, 2010, BIOORGAN MED CHEM, V18, P999, DOI 10.1016/j.bmc.2009.12.070; Wu WQ, 2014, FOOD FUNCT, V5, P158, DOI 10.1039/c3fo60400d; Xiang L, 2011, BIOSCI BIOTECH BIOCH, V75, P854, DOI 10.1271/bbb.100774; [杨若林 Yang Ruolin], 2003, [中国海洋药物, Chinese Journal of Marine Drugs], V22, P31; Yang W, 2013, INT J MOL SCI, V14, P24200, DOI 10.3390/ijms141224200; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074	33	21	23	2	46	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1661-6596	1422-0067		INT J MOL SCI	Int. J. Mol. Sci.	DEC	2014	15	12					21660	21673		10.3390/ijms151221660			14	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	AX2TM	WOS:000346797400005	25429428	DOAJ Gold, Green Published			2021-06-18	
J	Papoutsis, J; Stargatt, R; Catroppa, C				Papoutsis, Jennifer; Stargatt, Robyn; Catroppa, Cathy			Long-Term Executive Functioning Outcomes for Complicated and Uncomplicated Mild Traumatic Brain Injury Sustained in Early Childhood	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							BEHAVIOR RATING INVENTORY; PEDIATRIC HEAD-INJURY; YOUNG-CHILDREN; FOLLOW-UP; TBI	This study investigated long-term executive functioning following early mild traumatic brain injury (TBI), differentiating between complicated (n = 34) and uncomplicated injuries (n = 18). Children post mild TBI were compared to 33 controls at least 7-years post-injury. The complicated mild TBI group performed significantly worse on divided attention compared to both groups, with younger age at injury and neurological symptoms predictors of outcome. No significant group differences existed on speed of information processing, selective attention, working memory, or goal setting. These findings indicate that specific aspects of executive function are compromised by early complicated mild TBI and argue for a stratified definition of mild TBI.	[Papoutsis, Jennifer; Stargatt, Robyn; Catroppa, Cathy] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Papoutsis, Jennifer; Stargatt, Robyn] La Trobe Univ, Dept Psychol, Bundoora, Vic 3083, Australia	Papoutsis, J (corresponding author), Murdoch Childrens Res Inst, Flemmington Rd, Parkville, Vic 3052, Australia.	jennifer.papoutsis@mcri.edu.au					Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; De Luca CR, 2010, STUD NEUROPSYCHOL NE, P23; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gioia G.A., 2000, BEHAV RATING INVENTO; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Kolb B., 1995, BRAIN PLASTICITY BEH; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	25	21	21	0	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	NOV 17	2014	39	8					638	645		10.1080/87565641.2014.979926			8	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	AU6AS	WOS:000345685100004	25470225				2021-06-18	
J	Kane, WG; Wright, DA; Fu, RW; Carlson, KF				Kane, Wendy G.; Wright, Dagan A.; Fu, Rongwei; Carlson, Kathleen F.			Racial/Ethnic and Insurance Status Disparities in Discharge to Posthospitalization Care for Patients With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						discharge disposition; ethnicity; healthcare disparities; insurance; race; traumatic brain injury	UNITED-STATES; LEVEL I; DISPOSITION; OUTCOMES; RACE; MODERATE; LIFE	Objectives: Professional, posthospitalization care (PHC) can improve outcomes among patients with traumatic brain injury. We examined disparities in discharge to PHC by patients' race/ethnicity and insurance type. Participants: A total of 6061 adults hospitalized for unintentional traumatic brain injury in Oregon, 2008 to 2011. Main Outcome Measure: Posthospitalization care was assessed on the basis of discharge disposition. Multivariable logistic regression was used to estimate effects of race/ethnicity and insurance on referral to PHC while controlling for potential confounders. Generalized estimating equations were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs), accounting for clustering of data by hospital. Results: 28% of patients were discharged to PHC. While controlling for potential confounders, Hispanics were less likely to be discharged to PHC (OR, 0.62; CI, 0.40-0.96) than non-Hispanic whites. Compared with patients with private insurance, uninsured patients were less likely to be discharged to PHC (OR, 0.19; CI, 0.11-0.32) whereas patients with public insurance (OR, 1.65; CI, 1.33-2.05) and worker's compensation (OR, 1.66; CI, 1.09-2.52) were more likely to be discharged to PHC. Conclusions: Results suggest that racial/ethnic and insurance disparities exist in discharge to postacute care after hospitalization for traumatic brain injury. Future research should examine factors that might contribute to and reduce these inequities in care.	[Kane, Wendy G.; Wright, Dagan A.; Fu, Rongwei; Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Wright, Dagan A.] Oregon Hlth Author, Injury & Violence Prevent Sect, Ctr Prevent & Hlth Promot, Portland, OR USA; [Carlson, Kathleen F.] Portland VA Med Ctr R&D 66, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97239 USA	Carlson, KF (corresponding author), Portland VA Med Ctr R&D 66, Portland Ctr Study Chron Comorbid Mental & Phys D, 3715 SW US Vet Hosp Rd, Portland, OR 97239 USA.	kathleen.carlson@va.gov			Veterans Health Administration Health Services Research and Development ServiceUS Department of Veterans Affairs [CDA 08-025]	Funds were not received for this study. Dr Carlson's effort was supported by a career development grant from the Veterans Health Administration Health Services Research and Development Service (CDA 08-025). The opinions expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.	*AG HEALTHC RES QU, 2003, NAT HEALTHC DISP REP; Agency for Healthcare Research and Quality (AHRQ), 2012, MULT POST REH MOD SE; Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project, COM SOFTW VERS 3 7; Alkhoury F, 2011, AM SURGEON, V77, P277; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bergman Karen, 2010, J Trauma Nurs, V17, P102, DOI 10.1097/JTN.0b013e3181ecc452; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Cifu DX, GERIATRIC REHABILITA; Coronado VG, EPIDEMIOLOGY PREVENT; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Duncan GJ, 2002, AM J PUBLIC HEALTH, V92, P1151, DOI 10.2105/AJPH.92.7.1151; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Emergency Medical Services and Trauma Systems Program, 2012, OR TRAUM REG REP 201; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Hardin JW, 2008, GEN ESTIMATING EQUAT, P1; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Laurence B, 2013, MADICARE COVERAGE IN; Laurence B., 2013, MEDICARE COVERAGE IN; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Research Council, 2008, GULF WAR HLTH, V7, P65; Newhouse JP, 2013, NEW ENGL J MED, V368, P1465, DOI 10.1056/NEJMp1302981; Oregon Health Authority; Public Health Division, OR TRAUM HOSP DES; Sacks GD, 2011, J TRAUMA, V71, P1011, DOI 10.1097/TA.0b013e3182092c27; Salim A, 2010, J TRAUMA, V68, P211, DOI 10.1097/TA.0b013e3181a0e659; Scheetz LJ, 2005, J NURS SCHOLARSHIP, V37, P361, DOI 10.1111/j.1547-5069.2005.00062.x; Sears JM, 2014, INJURY, V45, P16, DOI 10.1016/j.injury.2012.12.024; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; SMEDLEY BD, 2003, UNEQUAL TREATMENT CO, P80; Young JS, 1998, J TRAUMA, V45, P800, DOI 10.1097/00005373-199810000-00033; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zasler ND, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1	41	21	21	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2014	29	6					E10	E17		10.1097/HTR.0000000000000028			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT7LI	WOS:000345117800002	24590153				2021-06-18	
J	Larrabee, GJ				Larrabee, Glenn J.			Test Validity and Performance Validity: Considerations in Providing a Framework for Development of an Ability-Focused Neuropsychological Test Battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Test construction; Meta-analysis; Head injury; Traumatic brain injury; Alzheimer's disease; Cerebrovascular disease/accident and stroke	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; MILD COGNITIVE IMPAIRMENT; ADULT INTELLIGENCE SCALE; CARD SORTING TEST; ALZHEIMERS-DISEASE; SYMPTOM VALIDITY; CONSTRUCT-VALIDITY; RESPONSE BIAS; HEAD-INJURY	Literature on test validity and performance validity is reviewed to propose a framework for specification of an ability-focused battery (AFB). Factor analysis supports six domains of ability: first, verbal symbolic; secondly, visuoperceptual and visuospatial judgment and problem solving; thirdly, sensorimotor skills; fourthly, attention/working memory; fifthly, processing speed; finally, learning and memory (which can be divided into verbal and visual subdomains). The AFB should include at least three measures for each of the six domains, selected based on various criteria for validity including sensitivity to presence of disorder, sensitivity to severity of disorder, correlation with important activities of daily living, and containing embedded/derived measures of performance validity. Criterion groups should include moderate and severe traumatic brain injury, and Alzheimer's disease. Validation groups should also include patients with left and right hemisphere stroke, to determine measures sensitive to lateralized cognitive impairment and so that the moderating effects of auditory comprehension impairment and neglect can be analyzed on AFB measures.		Larrabee, GJ (corresponding author), 2650 Bahia Vista St,308, Sarasota, FL 34242 USA.	glarrabee@aol.com					American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Backman L, 2005, NEUROPSYCHOLOGY, V19, P520, DOI 10.1037/0894-4105.19.4.520; Baddeley A, 2007, WORKING MEMORY THOUG; Barbey AK, 2013, NEUROPSYCHOLOGIA, V51, P1361, DOI 10.1016/j.neuropsychologia.2012.05.017; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Bauer RM, 2000, CLIN GUIDE NEUROPSYC, P419; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Ben-Porath Y.S., 2012, INTERPRETING MMPI 2; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benton A., 1994, MULTILINGUAL APHASIA; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Borenstein M., 2009, INTRO METAANALYSIS; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P124; Brandt J., 2001, HOPKINS VERBAL LEARN; Brown FC, 2007, CLIN NEUROPSYCHOL, V21, P811, DOI 10.1080/13854040600878777; Brown FC, 2010, EPILEPSY BEHAV, V17, P215, DOI 10.1016/j.yebeh.2009.11.026; Brown LB, 2005, ARCH CLIN NEUROPSYCH, V20, P209, DOI 10.1016/j.acn.2004.06.003; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll J. B., 1993, HUMAN COGNITIVE ABIL; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Chelune GJ, 2010, CLIN NEUROPSYCHOL, V24, P454, DOI 10.1080/13854040802360574; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crook TH, 1988, NEUROPSYCHOLOGY, V2, P1, DOI 10.1037//0894-4105.2.1.1; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P1397, DOI 10.1080/13854046.2012.728627; Delis D, 2000, CALIFORNIA VERBAL LE; Delis DC, 2003, J INT NEUROPSYCH SOC, V9, P936, DOI 10.1017/S1355617703960139; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2002, PSYCHOL ASSESSMENT, V14, P360, DOI 10.1037//1040-3590.14.3.360; Earnst KS, 2001, AGING NEUROPSYCHOL C, V8, P109, DOI 10.1076/anec.8.2.109.839; Evans JD, 2004, SCHIZOPHR RES, V70, P331, DOI 10.1016/j.schres.2004.01.011; Fawcett T., 2003, ROC GRAPHS NOTES PRA; Frazier TW, 2004, J INT NEUROPSYCH SOC, V10, P578, DOI 10.1017/S1355617704104049; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Golden C., 1978, STROOP COLOR WORD TE; GOLDEN CJ, 1985, MANUAL LURIA NEBRASK; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Griffith HR, 2006, J INT NEUROPSYCH SOC, V12, P166, DOI 10.1017/S1355617706060267; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heilman K. M., 2012, INT J CLIN NEUROPSYC, P296; Hill B. D., 2013, 41 ANN C INT NEUR SO; Hill BD, 2013, ARCH CLIN NEUROPSYCH, V28, P640, DOI 10.1093/arclin/act045; Holdnack JA, 2013, PRACT RESOUR MENT, P331, DOI 10.1016/B978-0-12-386934-0.00007-9; Holdnack JA, 2011, ASSESSMENT, V18, P178, DOI 10.1177/1073191110393106; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Houston C. M., 2007, CLIN NEUROPSYCHOL, V20, P145; HSIAO JK, 1989, ARCH GEN PSYCHIAT, V46, P664; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Iverson G L, 2001, Appl Neuropsychol, V8, P167, DOI 10.1207/S15324826AN0803_6; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Jastak J., 1984, WIDE RANGE ACHIEVEME; Kaplan E., 1983, BOSTON NAMING TEST; Keifer E, 2013, J CLIN EXP NEUROPSYC, V35, P1048, DOI 10.1080/13803395.2013.854319; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Larrabee, 2012, FORENSIC NEUROPSYCHO, P116; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee G. J., 1992, J CLIN EXPT NEUROPSY, V14, P65; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P497, DOI 10.1080/01688638508401281; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2003, J INT NEUROPSYCH SOC, V9, P947, DOI 10.1017/S1355617703960140; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P239, DOI 10.1080/01688638508401257; LARRABEE GJ, 1986, INT J NEUROSCI, V29, P141, DOI 10.3109/00207458608985644; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P139, DOI 10.1076/1385-4046(200002)14:1;1-8;FT139; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P813, DOI 10.1080/13854040701625846; Larrabee GJ, 1988, NEUROPSYCHOLOGY, V2, P173, DOI 10.1037//0894-4105.2.3-4.173; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Leonberger F. T., 1992, NEUROPSYCHOLOGY, V6, P239, DOI DOI 10.1037/0894-4105.6.3.239; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Loewenstein D. A., 1999, HDB ASSESSMENT CLIN, P529; Loring DW, 2008, J INT NEUROPSYCH SOC, V14, P394, DOI 10.1017/S1355617708080582; Loring DW, 2006, CLIN NEUROPSYCHOL, V20, P221, DOI 10.1080/13854040590947443; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P949, DOI 10.1001/archneur.1995.00540340029010; McGrew KS, 2009, INTELLIGENCE, V37, P1, DOI 10.1016/j.intell.2008.08.004; McGurk SR, 2003, PSYCHIAT SERV, V54, P1129, DOI 10.1176/appi.ps.54.8.1129; Meyers J., 1995, MEYERS SCORING SYSTE; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 2004, ARCH CLIN NEUROPSYCH, V19, P637, DOI 10.1016/j.acn.2003.08.007; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2014, APPL NEUROPSYCH-ADUL, V21, P60, DOI 10.1080/09084282.2012.737881; Meyers JE, 2014, ARCH CLIN NEUROPSYCH, V29, P224, DOI 10.1093/arclin/acu001; Miller JB, 2010, CLIN NEUROPSYCHOL, V24, P678, DOI 10.1080/13854041003601493; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mitrushina M., 2005, HDB NORMATIVE DATA N; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Morgan J. E., 2009, NEUROPSYCHOLOGY MALI; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; Pearson, 2009, ADV CLIN SOLUTIONS U; Powell J B, 1991, Arch Clin Neuropsychol, V6, P241, DOI 10.1016/0887-6177(91)90001-P; Purves D., 2008, PRINCIPLES COGNITIVE; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rice ME, 2005, LAW HUMAN BEHAV, V29, P615, DOI 10.1007/s10979-005-6832-7; Rohling M. L., 2008, 6 ANN C AM AC CLIN N; Rohling ML, 2011, PSYCHOL BULL, V137, P708, DOI 10.1037/a0023327; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2004, NEUROPSYCHOL REV, V14, P155, DOI 10.1023/B:NERV.0000048182.55980.4b; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Russell E. W., 1993, HALSTEAD RUSSEL NEUR; Salmon DP, 1999, J INT NEUROPSYCH SOC, V5, P692, DOI 10.1017/S1355617799577126; Salthouse TA, 2005, NEUROPSYCHOLOGY, V19, P532, DOI 10.1037/0894-4105.19.4.532; Salthouse TA, 2010, PRACT RESOUR MENT, P217, DOI 10.1016/B978-0-12-375035-8.10008-4; Schmidt M., 1996, REY AUDITORY VERBAL; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherod MG, 2009, J INT NEUROPSYCH SOC, V15, P258, DOI 10.1017/S1355617709090365; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith A, 1983, SYMBOL DIGIT MODALIT; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2011, CLIN NEUROPSYCHOL, V25, P12, DOI 10.1080/13854046.2010.544165; SWETS JA, 1973, SCIENCE, V182, P990, DOI 10.1126/science.182.4116.990; Tabachnick B.G., 2005, USING MULTIVARIATE S; Tellegen A., 2008, MMPI2RF; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Trahan D, 1988, CONTINUOUS VISUAL ME; TRAHAN DE, 1990, J CLIN EXP NEUROPSYC, V12, P857, DOI 10.1080/01688639008401027; TRAHAN DE, 1989, CLIN NEUROPSYCHOL, V3, P169, DOI DOI 10.1080/13854048908403290; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Tulsky DS, 2003, PSYCHOL ASSESSMENT, V15, P149, DOI 10.1037/1040-3590.15.2.149; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Volbrecht ME, 2000, ARCH CLIN NEUROPSYCH, V15, P251, DOI 10.1016/S0887-6177(99)00016-5; Wechsler, 1997, WAIS 3 WMS 3 TECHNIC; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 2008, WAIS 4; Wechsler D., 2009, WMS 4 TECHNICAL INTE; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; Whelihan WM, 2005, ARCH CLIN NEUROPSYCH, V20, P217, DOI 10.1016/j.acn.2004.07.002; Wilkinson G.S., 1993, WRAT 3 WIDE RANGE AC; Wilkinson G. S., 2006, WIDE RANGE ACHIEVMEN; Williams MW, 2013, CLIN NEUROPSYCHOL, V27, P356, DOI 10.1080/13854046.2013.765507; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Wolfson D., 1993, HALSTEAD REITAN NEUR; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	177	21	21	0	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2014	29	7					695	714		10.1093/arclin/acu049			20	Psychology, Clinical; Psychology	Psychology	AU9DA	WOS:000345890600012	25280794	Green Published			2021-06-18	
J	Das, M; Wang, CY; Bedi, R; Mohapatra, SS; Mohapatra, S				Das, Mahasweta; Wang, Chunyan; Bedi, Raminder; Mohapatra, Shyam S.; Mohapatra, Subhra			Magnetic micelles for DNA delivery to rat brains after mild traumatic brain injury	NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE			English	Article						TBI; LFPI; Brain; Magnetic micelle; Bio-distribution; Theranostic; DNA delivery	NUCLEIC-ACID DELIVERY; GENE DELIVERY; STEALTH LIPOSOMES; ZOLEDRONIC ACID; DRUG-DELIVERY; FLUORO-JADE; MAGNETOFECTION; NANOPARTICLES; CELLS; TRANSFECTION	Traumatic brain injury (TBI) causes significant mortality, long term disability and psychological symptoms. Gene therapy is a promising approach for treatment of different pathological conditions. Here we tested chitosan and polyethyleneimine (PEI)-coated magnetic micelles (CP-mag micelles or CPMMs), a potential MRI contrast agent, to deliver a reporter DNA to the brain after mild TBI (mTBI). CPMM-tomato plasmid (ptd) conjugate expressing a red-fluorescent protein (RFP) was administered intranasally immediately after mTBI or sham surgery in male SD rats. Evans blue extravasation following mTBI suggested CPMM-ptd entry into the brain via the compromised blood-brain barrier. Magnetofection increased the concentration of CPMMs in the brain. RFP expression was observed in the brain (cortex and hippocampus), lung and liver 48 h after mTBI. CPMM did not evoke any inflammatory response by themselves and were excreted from the body. These results indicate the possibility of using intranasally administered CPMM as a theranostic vehicle for mTBI. From the Clinical Editor: In this study, chitosan and PEI-coated magnetic micelles (CPMM) were demonstrated as potentially useful vehicles in traumatic brain injury in a rodent model. Magnetofection increased the concentration of CPMMs in the brain and, after intranasal delivery, CPMM did not evoke any inflammatory response and were excreted from the body. (C) 2014 Elsevier Inc. All rights reserved.	[Das, Mahasweta; Wang, Chunyan; Mohapatra, Shyam S.; Mohapatra, Subhra] Univ S Florida, Coll Med, Nanomed Res Ctr, Tampa, FL USA; [Das, Mahasweta; Bedi, Raminder; Mohapatra, Shyam S.] Univ S Florida, Dept Internal Med, Coll Med, Tampa, FL 33612 USA; [Wang, Chunyan; Mohapatra, Subhra] Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA	Mohapatra, SS (corresponding author), Univ S Florida, Tampa, FL 33620 USA.	smohapat@health.usf.edu; smohapa2@health.usf.edu	Mohapatra, Shyam/C-2500-2012		Office of Naval Research grantOffice of Naval Research [N000140810914]; VA reintegration grant; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA152005] Funding Source: NIH RePORTER	The Office of Naval Research grant (N000140810914) to SSM and VA reintegration grant to SM.	Al-Deen FN, 2013, COLLOID SURFACE B, V102, P492, DOI 10.1016/j.colsurfb.2012.09.026; Brix G, 2008, MICROCIRCULATION, V15, P15, DOI 10.1080/10739680701410850; Caraglia M, 2012, CURR CANCER DRUG TAR, V12, P186, DOI 10.2174/156800912799277421; Caraglia M, 2013, MOL PHARMACEUT, V10, P1111, DOI 10.1021/mp3006215; Castillo B, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/218940; Cho Y, 2010, J EXP BIOL, V213, P1513, DOI 10.1242/jeb.035162; Dalby B, 2004, METHODS, V33, P95, DOI 10.1016/j.ymeth.2003.11.023; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; Dobson J, 2006, GENE THER, V13, P283, DOI 10.1038/sj.gt.3302720; Duckworth EAM, 2005, BRAIN RES, V1042, P29, DOI 10.1016/j.brainres.2005.02.021; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gersting SW, 2004, J GENE MED, V6, P913, DOI 10.1002/jgm.569; Guerra-Crespo M, 2003, J NEUROSCI METH, V127, P179, DOI 10.1016/S0165-0270(03)00125-0; Halldorsson JG, 2012, BRAIN INJURY, V26, P1, DOI 10.3109/02699052.2011.635359; Leavey JA, CORNELL U ENV HLTH S; Lou YL, 2009, J BIOMED MATER RES A, V88A, P1058, DOI 10.1002/jbm.a.31961; Marra M, 2012, BIOTECHNOL ADV, V30, P302, DOI 10.1016/j.biotechadv.2011.06.018; McBain SC, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/40/405102; Nasongkla N, 2006, NANO LETT, V6, P2427, DOI 10.1021/nl061412u; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Plank C, 2003, EXPERT OPIN BIOL TH, V3, P745, DOI 10.1517/eobt.3.5.745.21225; Plank C, 2003, BIOL CHEM, V384, P737, DOI 10.1515/BC.2003.082; Plank C, 2011, THER DELIV, V2, P717, DOI 10.4155/TDE.11.37; Repacholi MH, 1996, ELECTROMAGNETIC FIEL; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schwerdt JI, 2012, CURR GENE THER, V12, P116; Vainauska D, 2012, MEDICINA-LITHUANIA, V48, P324; Wang CY, 2012, J CONTROL RELEASE, V163, P82, DOI 10.1016/j.jconrel.2012.04.030; Yang SY, 2008, ARTIF ORGANS, V32, P195, DOI 10.1111/j.1525-1594.2007.00526.x; Yun J, 2012, J CLIN NEUROSCI, V19, P875, DOI 10.1016/j.jocn.2011.12.016	32	21	21	1	29	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1549-9634	1549-9642		NANOMED-NANOTECHNOL	Nanomed.-Nanotechnol. Biol. Med.	OCT	2014	10	7					1539	1548		10.1016/j.nano.2014.01.003			10	Nanoscience & Nanotechnology; Medicine, Research & Experimental	Science & Technology - Other Topics; Research & Experimental Medicine	AR1AU	WOS:000343312100018	24486465	Green Accepted			2021-06-18	
J	Gilbert, M; Snyder, C; Corcoran, C; Norton, MC; Lyketsos, CG; Tschanz, JT				Gilbert, Mac; Snyder, Christine; Corcoran, Chris; Norton, Maria C.; Lyketsos, Constantine G.; Tschanz, JoAnn T.			The association of traumatic brain injury with rate of progression of cognitive and functional impairment in a population-based cohort of Alzheimer's disease: the Cache County Dementia Progression Study	INTERNATIONAL PSYCHOGERIATRICS			English	Article						traumatic brain injury; dementia progression; functional ability; Alzheimer's disease	A-BETA DEPOSITION; HEAD-INJURY; VASCULAR FACTORS; RISK; COST	Background: There is limited research on factors that influence the rate of progression in Alzheimer's disease (AD). A history of traumatic brain injury (TBI) is associated with an increased risk for AD, but its role on the rate of dementia progression after the onset of AD has not been examined. Methods: A population-based cohort of 325 persons with incident AD was followed for up to 11 years. The sample was 65% female with a mean (SD) age of dementia onset = 84.4 (6.4) years. History of TBI was categorized as number, severity (with or without loss of consciousness), and timing in relation to dementia onset (within ten years or more than ten years). Cognition was assessed by the Consortium to Establish a Registry of AD battery, and functional ability was assessed by the Clinical Dementia Rating Sum of Boxes. Results: In linear mixed models, a history of TBI within ten years of onset showed faster progression of functional impairment (LR x(2) = 10.27, p = 0.006), while those with TBI more than ten years before dementia onset had higher scores on a measure of list learning (beta = 1.61, p = 0.003) and semantic memory (beta = 0.75, p = 0.0035). Conclusions: History of TBI and its recency may be a useful factor to predict functional progression in the course of AD.	[Gilbert, Mac; Snyder, Christine; Norton, Maria C.; Tschanz, JoAnn T.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA; [Corcoran, Chris] Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA; [Corcoran, Chris; Norton, Maria C.; Tschanz, JoAnn T.] Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA; [Norton, Maria C.] Utah State Univ, Dept Family Consumer & Human Dev, Logan, UT 84322 USA; [Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Dept Psychiat, Baltimore, MD USA	Tschanz, JT (corresponding author), Utah State Univ, Ctr Epidemiol Studies, 4450 Old Main Hill, Logan, UT 84322 USA.	joann.tschanz@usu.edu			NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG21136, R01AG11380]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021136, R01AG011380] Funding Source: NIH RePORTER	This project was supported by NIA grants R01AG21136 and R01AG11380. The authors are indebted to Dr. Ronald Munger for his unqualified support of the DPS. We also acknowledge the contributions of the following individuals whose activities have helped to ensure the success of the project: John C. S. Breitner, MD, MPH, Cara Brewer, BA, Tony Calvert, RN, BA, Michelle Carlson, PhD, Kimberly Graham, BA, Robert C. Green, MD, MPH, Hochang Ben Lee, MD, Jeanne-Marie Leoutsakos, PhD, Carol Leslie, MS, Lawrence S. Mayer, PhD, Michelle M. Mielke, PhD, Chiadi U. Onyike, MD, Roxane Pfister, MS, Georgiann Sanborn, MS, Nancy Sassano, PhD, Sarah Schwartz, MS, Ingmar Skoog, MD, Martin Steinberg, MD, Katherine Treiber, PhD, Yorghos Tripodis, PhD, Kathleen A. Welsh-Bohmer, PhD, Heidi Wengreen, PhD, RD, James Wyatt, and Peter P. Zandi, PhD, MPH. Finally, we thank the participants and their families for their participation and support.	American Psychiatric Association, 1987, DIAGNOSTIC AND STATI; Amieva H, 2008, ANN NEUROL, V64, P492, DOI 10.1002/ana.21509; Breitner JCS, 1999, NEUROLOGY, V53, P321, DOI 10.1212/WNL.53.2.321; Coduras A, 2010, J ALZHEIMERS DIS, V19, P601, DOI 10.3233/JAD-2010-1258; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Helzner EP, 2009, ARCH NEUROL-CHICAGO, V66, P343, DOI 10.1001/archneur.66.3.343; Herrmann N, 2010, CAN J PSYCHIAT, V55, P768, DOI 10.1177/070674371005501204; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; Leoutsakos JMS, 2012, INT PSYCHOGERIATR, V24, P1561, DOI 10.1017/S104161021200049X; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mielke MM, 2007, NEUROLOGY, V69, P1850, DOI 10.1212/01.wnl.0000279520.59792.fe; Mielke MM, 2011, J ALZHEIMERS DIS, V26, P127, DOI 10.3233/JAD-2011-110086; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P166, DOI 10.1176/appi.neuropsych.22.2.166; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Singer J. D., 2003, APPLIED LONGITUDINAL; Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003; Tschanz JT, 2011, AM J GERIAT PSYCHIAT, V19, P532, DOI 10.1097/JGP.0b013e3181faec23; Tschanz JT, 2002, NEUROPSY NEUROPSY BE, V15, P28; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; Werner CA, 2011, THE OLDER POPULATION	34	21	21	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1041-6102	1741-203X		INT PSYCHOGERIATR	Int. Psychogeriatr.	OCT	2014	26	10					1593	1601		10.1017/S1041610214000842			9	Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology	Psychology; Geriatrics & Gerontology; Psychiatry	AP0UZ	WOS:000341782100004	24831798	Green Accepted			2021-06-18	
J	Hewitt, J; Williams, M; Pearce, L; Black, A; Benson, E; Tarrant, M; Chakrabati, M; Stechman, MJ; Moug, SJ; McCarthy, K				Hewitt, Jonathan; Williams, Matthew; Pearce, Lyndsay; Black, Amy; Benson, Emily; Tarrant, Madelaine; Chakrabati, Mahua; Stechman, Michael J.; Moug, Susan J.; McCarthy, Kathryn			The prevalence of cognitive impairment in emergency general surgery	INTERNATIONAL JOURNAL OF SURGERY			English	Article						Cognitive impairment; Acute general surgery; MoCA; Older people; Elderly	TRAUMATIC BRAIN-INJURY; POSTOPERATIVE DELIRIUM; VALIDATION; MOCA; VERSION	Objectives: Rates of all surgical procedures are increasing at a faster rate than the population is ageing. However, this encouraging statistic, necessitates a robust evidence base. The epidemiological evidence base in acute general surgery in the older person is sparse. This is the first assessment of the prevalence of cognitive impairment measured using the Montreal Cognitive Assessment tool (MoCA) in acute general surgery. Methods: In three sites in Wales, England and Scotland comprising rural and urban populations, we studied consecutive patients aged over 65 years. We considered any older person admitted to the acute general surgical unit. We assessed them for baseline demographic data. They each underwent a MoCA assessment. Results: We collected data on 245 people, mean age 76.9 years (8.1, standard deviation), 136 (55.5%) were women. Of these 201 completed the MoCA test, mean score of 18.9 and median score 20 (range 0-30). There were 37 (15.1%) MoCA scores in the normal range (>= 26) and 44 (18%) people were unable to attempt (or complete) the MoCA. Increasing age (p < 0.01) but not sex (p = 0.14) predicted an abnormal MoCA. Considering only the 44 people who were unable to attempt the MoCA assessment, 11 (25%) were known to have a diagnosis of dementia, 9 (20.5%) were too unwell and the remainder unable to complete the assessment to due pre-existing disability. Conclusions: In a representative UK wide population, a high proportion of older people admitted with an acute general surgical problem had cognitive impairment when assessed using the MoCA. (C) 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.	[Hewitt, Jonathan; Williams, Matthew; Black, Amy] Cardiff Univ, Cardiff CF10 3AX, S Glam, Wales; [Pearce, Lyndsay] North West Surg Rotat, Liverpool, Merseyside, England; [Benson, Emily; Tarrant, Madelaine; McCarthy, Kathryn] North Bristol NHS Trust, Bristol, Avon, England; [Stechman, Michael J.] Univ Hosp, Cardiff, S Glam, Wales; [Moug, Susan J.] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland	Hewitt, J (corresponding author), Univ Hosp Llandough, Cardiff CF64 2XX, S Glam, Wales.	hewittj2@cardiff.ac.uk	HEWITT, JONATHAN/AAC-9713-2019	HEWITT, JONATHAN/0000-0002-7924-1792	Cardiff University Research Opportunity Program (CUROP) [pound1340]	One author, Matthew Williams, a medical student, obtained a competitive grant for a living allowance over his summer holiday to help support he undertakes part of this project. Grant 1340 pound Cardiff University Research Opportunity Program (CUROP).	Boos Gustavo Luchi, 2005, Rev. Bras. Anestesiol., V55, P517, DOI 10.1590/S0034-70942005000500006; de Guise E, 2013, BRAIN INJURY, V27, P1428, DOI 10.3109/02699052.2013.835867; Evered LA, 2011, ANESTHESIOLOGY, V114, P1297, DOI 10.1097/ALN.0b013e31821b1aab; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Ismail Z, 2010, INT J GERIATR PSYCH, V25, P111, DOI 10.1002/gps.2306; Lee JY, 2008, J GERIATR PSYCH NEUR, V21, P104, DOI 10.1177/0891988708316855; Lifshitz M, 2012, J GERIATR PSYCH NEUR, V25, P155, DOI 10.1177/0891988712457047; Luis CA, 2009, INT J GERIATR PSYCH, V24, P197, DOI 10.1002/gps.2101; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Newman JC, 2011, NEW ENGL J MED, V365, P2447, DOI 10.1056/NEJMp1110652; Ni Chonchubhair A., 1995, BRIT J ANAESTH, V75, P481; Osborne RA, 2014, J NEUROL SCI, V336, P191, DOI 10.1016/j.jns.2013.10.038; Partridge JSL, 2013, INT J GERIATR PSYCH, V28, P804, DOI 10.1002/gps.3900; Partridge JSL, 2012, AGE AGEING, V41, P142, DOI 10.1093/ageing/afr182; Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923; Sasajima Y, 2012, EUR J VASC ENDOVASC, V44, P411, DOI 10.1016/j.ejvs.2012.06.028; Sweet L, 2011, INT PSYCHOGERIATR, V23, P1582, DOI 10.1017/S1041610211001451; Wong GKC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059946; Wong GKC, 2013, BRAIN INJURY, V27, P394, DOI 10.3109/02699052.2012.750746	20	21	21	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1743-9191	1743-9159		INT J SURG	Int. J. Surg.	OCT	2014	12	10					1031	1035		10.1016/j.ijsu.2014.07.020			5	Surgery	Surgery	AR4XG	WOS:000343588800002	25128866	Bronze			2021-06-18	
J	Petrini, K; Piwek, L; Crabbe, F; Pollick, FE; Garrod, S				Petrini, Karin; Piwek, Lukasz; Crabbe, Frances; Pollick, Frank E.; Garrod, Simon			Look at Those Two!: The Precuneus Role in Unattended Third-Person Perspective of Social Interactions	HUMAN BRAIN MAPPING			English	Article						biological motion; fMRI; granger causality; precuneus; social interaction	BIOLOGICAL MOTION PERCEPTION; DEFAULT MODE NETWORK; TRAUMATIC BRAIN-INJURY; FUNCTIONAL-ANATOMY; CINGULATE CORTEX; BASE-LINE; FMRI; SELF; CONNECTIVITY; COGNITION	Human beings often observe other people's social interactions without being a part of them. Whereas the implications of some brain regions (e.g. amygdala) have been extensively examined, the implication of the precuneus remains yet to be determined. Here we examined the implication of the precuneus in third-person perspective of social interaction using functional magnetic resonance imaging (fMRI). Participants performed a socially irrelevant task while watching the biological motion of two agents acting in either typical (congruent to social conventions) or atypical (incongruent to social conventions) ways. When compared to typical displays, the atypical displays elicited greater activation in the central and posterior bilateral precuneus, and in frontoparietal and occipital regions. Whereas the right precuneus responded with greater activation also to upside down than upright displays, the left precuneus did not. Correlations and effective connectivity analysis added consistent evidence of an interhemispheric asymmetry between the right and left precuneus. These findings suggest that the precuneus reacts to violations of social expectations, and plays a crucial role in third-person perspective of others' interaction even when the social context is unattended. Hum Brain Mapp 35:5190-5203, 2014. (c) 2014 Wiley Periodicals, Inc.	[Petrini, Karin] UCL, Inst Ophthalmol, London EC1V 9EL, England; [Piwek, Lukasz; Crabbe, Frances; Pollick, Frank E.; Garrod, Simon] Univ Glasgow, Sch Psychol, Glasgow, Lanark, Scotland	Petrini, K (corresponding author), UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.	k.petrini@ucl.ac.uk	Pollick, Frank/F-3186-2011; garrod, simon c/C-6837-2009	Pollick, Frank/0000-0002-7212-4622; Petrini, Karin/0000-0001-5354-5600	ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [RES-060-25-0010]	Contract grant sponsor: ESRC; Contract grant number: RES-060-25-0010	Aalto S, 2002, NEUROREPORT, V13, P67, DOI 10.1097/00001756-200201210-00018; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Becchio C., 2011, J NEUROSCI PSYCHOL E, V4, P1; Belin P, 2004, TRENDS COGN SCI, V8, P129, DOI 10.1016/j.tics.2004.01.008; Bluhm RL, 2007, SCHIZOPHRENIA BULL, V33, P1004, DOI 10.1093/schbul/sbm052; Bluhm RL, 2009, J PSYCHIATR NEUROSCI, V34, P187; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Brass M, 2007, CURR BIOL, V17, P2117, DOI 10.1016/j.cub.2007.11.057; Bruneau EG, 2010, NEUROIMAGE, V52, P1704, DOI 10.1016/j.neuroimage.2010.05.057; Buchel C, 1998, BRAIN, V121, P1281, DOI 10.1093/brain/121.7.1281; Calvo-Merino B, 2006, CURR BIOL, V16, P1905, DOI 10.1016/j.cub.2006.07.065; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Centelles L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015749; Cherkassky VL, 2006, NEUROREPORT, V17, P1687, DOI 10.1097/01.wnr.0000239956.45448.4c; Cloutier J, 2011, NEUROIMAGE, V57, P583, DOI 10.1016/j.neuroimage.2011.04.051; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Cross ES, 2009, EUR J NEUROSCI, V30, P1383, DOI 10.1111/j.1460-9568.2009.06941.x; Cross ES, 2009, CEREB CORTEX, V19, P315, DOI 10.1093/cercor/bhn083; de Gelder B, 2010, NEUROSCI BIOBEHAV R, V34, P513, DOI 10.1016/j.neubiorev.2009.10.008; De Lange FP, 2008, CURR BIOL, V18, P454, DOI 10.1016/j.cub.2008.02.057; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; den Ouden HEM, 2005, NEUROIMAGE, V28, P787, DOI 10.1016/j.neuroimage.2005.05.001; Farrer C, 2002, NEUROIMAGE, V15, P596, DOI 10.1006/nimg.2001.1009; Fecteau S, 2007, NEUROIMAGE, V36, P480, DOI 10.1016/j.neuroimage.2007.02.043; Fink GR, 1996, J NEUROSCI, V16, P4275; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Frankenstein UN, 2001, NEUROIMAGE, V14, P827, DOI 10.1006/nimg.2001.0883; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Gallese V, 2004, TRENDS COGN SCI, V8, P396, DOI 10.1016/j.tics.2004.07.002; Gitelman DR, 2002, NEUROIMAGE, V15, P970, DOI 10.1006/nimg.2001.1006; Goebel R, 2006, HUM BRAIN MAPP, V27, P392, DOI 10.1002/hbm.20249; Grafton ST, 2009, ANN NY ACAD SCI, V1156, P97, DOI 10.1111/j.1749-6632.2009.04425.x; GRANGER CWJ, 1969, ECONOMETRICA, V37, P424, DOI 10.2307/1912791; Groen WB, 2010, CEREB CORTEX, V20, P1937, DOI 10.1093/cercor/bhp264; Henke K, 2003, NEUROPSYCHOLOGIA, V41, P863, DOI 10.1016/S0028-3932(03)00035-6; Iacoboni M, 2005, PLOS BIOL, V3, P529, DOI 10.1371/journal.pbio.0030079; Iacoboni M, 2004, NEUROIMAGE, V21, P1167, DOI 10.1016/j.neuroimage.2003.11.013; Jabbi M, 2008, EMOTION, V8, P775, DOI 10.1037/a0014194; JOHANSSON G, 1973, PERCEPT PSYCHOPHYS, V14, P201, DOI 10.3758/BF03212378; Kennedy DP, 2008, SOC COGN AFFECT NEUR, V3, P177, DOI 10.1093/scan/nsn011; Kennedy DP, 2006, P NATL ACAD SCI USA, V103, P8275, DOI 10.1073/pnas.0600674103; Kircher TTJ, 2000, COGNITIVE BRAIN RES, V10, P133, DOI 10.1016/S0926-6410(00)00036-7; Kjaer TW, 2002, NEUROIMAGE, V17, P1080, DOI 10.1006/nimg.2002.1230; Kobayashi Y, 2007, J COMP NEUROL, V502, P810, DOI 10.1002/cne.21346; Kriegeskorte N, 2009, NAT NEUROSCI, V12, P535, DOI 10.1038/nn.2303; Kujala MV, 2012, HUM BRAIN MAPP, V33, P1753, DOI 10.1002/hbm.21317; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Lou HC, 2004, P NATL ACAD SCI USA, V101, P6827, DOI 10.1073/pnas.0400049101; Margulies DS, 2009, P NATL ACAD SCI USA, V106, P20069, DOI 10.1073/pnas.0905314106; McDermott KB, 1999, MEMORY, V7, P661; McKay LS, 2012, NEUROIMAGE, V59, P1524, DOI 10.1016/j.neuroimage.2011.08.033; Mitchell JP, 2008, CEREB CORTEX, V18, P262, DOI 10.1093/cercor/bhm051; Neri P, 2006, NAT NEUROSCI, V9, P1186, DOI 10.1038/nn1759; Parvizi J, 2006, P NATL ACAD SCI USA, V103, P1563, DOI 10.1073/pnas.0507729103; Pavlova M, 2000, PERCEPT PSYCHOPHYS, V62, P889, DOI 10.3758/BF03212075; Pavlova MA, 2012, CEREB CORTEX, V22, P981, DOI 10.1093/cercor/bhr156; Petrini K, 2010, J VISION, V10, DOI 10.1167/10.5.2; Puce A, 2003, PHILOS T R SOC B, V358, P435, DOI 10.1098/rstb.2002.1221; Reid VM, 2009, DEV PSYCHOL, V45, P620, DOI 10.1037/a0015209; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Roebroeck A, 2005, NEUROIMAGE, V25, P230, DOI 10.1016/j.neuroimage.2004.11.017; Rose D, 2009, PERCEPTION, V38, P153, DOI 10.1068/p6279; Ruby P, 2001, NAT NEUROSCI, V4, P546; Saygin AP, 2004, J NEUROSCI, V24, P6181, DOI 10.1523/JNEUROSCI.0504-04.2004; Schilbach L, 2006, NEUROPSYCHOLOGIA, V44, P718, DOI 10.1016/j.neuropsychologia.2005.07.017; Schilbach L, 2013, BEHAV BRAIN SCI, V36, P393, DOI 10.1017/S0140525X12000660; Schilbach Leonhard, 2010, Nat Rev Neurosci, V11, P449, DOI 10.1038/nrn2805-c1; Schippers MB, 2011, NEUROIMAGE, V57, P22, DOI 10.1016/j.neuroimage.2011.02.008; Schippers MB, 2010, P NATL ACAD SCI USA, V107, P9388, DOI 10.1073/pnas.1001791107; Sevdalis V, 2011, BRAIN COGNITION, V77, P231, DOI 10.1016/j.bandc.2011.08.005; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shipley TF, 2003, PSYCHOL SCI, V14, P377, DOI 10.1111/1467-9280.24471; Sinke CBA, 2010, NEUROIMAGE, V49, P1717, DOI 10.1016/j.neuroimage.2009.09.065; Smith SM, 2012, NEUROIMAGE, V59, P1228, DOI 10.1016/j.neuroimage.2011.08.015; SUMI S, 1984, PERCEPTION, V13, P283, DOI 10.1068/p130283; Troje NF, 2006, CURR BIOL, V16, P821, DOI 10.1016/j.cub.2006.03.022; Tsukiura T, 2002, J COGNITIVE NEUROSCI, V14, P922, DOI 10.1162/089892902760191144; Uddin LQ, 2007, TRENDS COGN SCI, V11, P153, DOI 10.1016/j.tics.2007.01.001; Van Overwalle F, 2009, NEUROIMAGE, V48, P564, DOI 10.1016/j.neuroimage.2009.06.009; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Vogeley K, 2004, J COGNITIVE NEUROSCI, V16, P817, DOI 10.1162/089892904970799; Vogeley K, 2003, TRENDS COGN SCI, V7, P38, DOI 10.1016/S1364-6613(02)00003-7; Zhang S, 2012, NEUROIMAGE, V59, P3548, DOI 10.1016/j.neuroimage.2011.11.023	84	21	22	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	OCT	2014	35	10					5190	5203		10.1002/hbm.22543			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AQ3CV	WOS:000342667400018	24824165	Green Published, Green Accepted			2021-06-18	
J	Hu, BY; Liu, XJ; Qiang, R; Jiang, ZL; Xu, LH; Wang, GH; Li, X; Peng, B				Hu, Bao-Ying; Liu, Xian-Jin; Qiang, Ren; Jiang, Zheng-Lin; Xu, Li-Hua; Wang, Guo-Hua; Li, Xia; Peng, Bin			Treatment with ginseng total saponins improves the neurorestoration of rat after traumatic brain injury	JOURNAL OF ETHNOPHARMACOLOGY			English	Article						Ginseng total saponins; Neuroprotection; Neural stem/progenitor cell; Neurorestoration; Rat; Traumatic brain injury	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; ADULT NEUROGENESIS; DENTATE GYRUS; HIPPOCAMPAL-NEURONS; AXON REGENERATION; MOTOR-PERFORMANCE; PANAX-NOTOGINSENG; RG1	Ethnopharmacological relevance: Ginseng, the root of Panax ginseng CA. Meyer, is a traditional medicinal herb that has been widely used in Asia for the treatment of many diseases through its effects of reinforcing vitality, strengthening the bodily resistance to pathogenic factors, engendering body liquids and allaying thirst, relieving uneasiness of the body and mind and benefiting intelligence, reducing body weight and prolonging life. Ginsenosides are the most important biologically active substances in ginseng. Many reports have suggested that ginsenosides could exert prominent neuroprotective and neurotrophic effects, promote neural stem/progenitor cell (NSC) proliferation and promote neurite outgrowth and neuronal network formation. The present study aimed to investigate whether treatment with ginsenosides could facilitate NSC proliferation in the hippocampal formation after traumatic brain injury (TBI) and contribute to the recovery of neurological functions including learning and memory. Materials and methods: The modified Feeney's method was used to induce a TBI in rats. Ginseng total saponins (GTS) were treated intraperitoneally twice a day for 1 week after the TBI. The neurological functions, morphology of the hippocampus, expression of nerve growth-related factors and number of NSCs in the hippocampal formation ipsilateral to the trauma were determined. Results: We determined 1) GTS (5-80 mg/kg) treatment after a TBI improved the recovery of neurological functions, including learning and memory, and reduced cell loss in the hippocampal area. The effects of GTS at 20,40,60, and 80 mg/kg were better than the effects of GTS at 5 and 10 mg/kg. 2) GTS treatment (20 mg/kg) after a TBI increased the expression of NGF, GDNF and NCAM, inhibited the expression of Nogo-A, Nogo-B, TN-C, and increased the number of BrdU/nestin positive NSCs in the hippocampal formation. Conclusions: GTS treatment in rats after a TBI alleviated the secondary brain injury and ameliorated the neurological functions with an effective dose limit of 5-80 mg/kg. GTS regulated the expression of nerve growth-related factors and improved the proliferation of neural stem/progenitor cells, which might facilitate neural regeneration and tissue repair, and might contribute to the recovery of neurological functions, including learning and memory. These effects of GTS might provide a foundation for the use of ginseng as a medicinal herb to enhance intelligence, reduce the aging process and prolong life in the traditional medicine. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Hu, Bao-Ying; Jiang, Zheng-Lin; Xu, Li-Hua; Wang, Guo-Hua; Li, Xia; Peng, Bin] Nantong Univ, Inst Naut Med, Dept Neuropharmacol, Nantong 226001, Jiangsu, Peoples R China; [Liu, Xian-Jin; Qiang, Ren] Third Peoples Hosp Nantong, Dept Infect Dis, Nantong 226001, Jiangsu, Peoples R China	Qiang, R (corresponding author), Third Peoples Hosp Nantong, Dept Infect Dis, 99 Cent Qingnian Rd, Nantong 226001, Jiangsu, Peoples R China.	ntqiangren@gmail.com; jiangzl@ntu.edu.cn			Administration of Science and Technology of Nantong [BK2012086]; Priority Academic Program Development of Jiangsu Higher Education Institutions; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81071614, 81372131, 81000497]	This study was supported by a grant from the Administration of Science and Technology of Nantong (Project no. BK2012086) and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions. Zheng-Lin Jiang is supported by the National Natural Science Foundation of China (Grant nos. 81071614, 81372131 and 81000497).	Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Boutin C, 2009, EUR J NEUROSCI, V30, P1209, DOI 10.1111/j.1460-9568.2009.06928.x; Cafferty WBJ, 2006, J NEUROSCI, V26, P12242, DOI 10.1523/JNEUROSCI.3827-06.2006; Chen CF, 2008, ACTA PHARMACOL SIN, V29, P1103, DOI 10.1111/j.1745-7254.2008.00868.x; Chiu SC, 2009, J MOL MED, V87, P1179, DOI 10.1007/s00109-009-0528-2; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DEGRABA TJ, 1994, J CEREBR BLOOD F MET, V14, P262, DOI 10.1038/jcbfm.1994.33; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Gong L, 2011, PHARM BIOL, V49, P501, DOI 10.3109/13880209.2010.521514; Hannila SS, 1999, J NEUROBIOL, V39, P51, DOI 10.1002/(SICI)1097-4695(199904)39:1<51::AID-NEU5>3.3.CO;2-K; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jablonska A, 2011, ACTA NEUROBIOL EXP, V71, P74; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Ji YC, 2005, J KOREAN MED SCI, V20, P291, DOI 10.3346/jkms.2005.20.2.291; JIANG S, 2003, J APOPLEXY NERVOUS D, V20, P415; Jiang Z.L., 2001, CHIN J APPL PHYSL, V17, P105; Joset A, 2010, J CELL BIOL, V188, P271, DOI 10.1083/jcb.200906089; Kempermann G, 2002, EUR J NEUROSCI, V16, P129, DOI 10.1046/j.1460-9568.2002.02042.x; Leker RR, 2009, EXPERT OPIN BIOL TH, V9, P1117, DOI 10.1517/14712590903130558; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Liang W, 2010, BRAIN RES, V1357, P19, DOI 10.1016/j.brainres.2010.07.091; Liao BS, 2002, EXP NEUROL, V173, P224, DOI 10.1006/exnr.2001.7841; Lim JH, 1997, NEUROSCI RES, V28, P191, DOI 10.1016/S0168-0102(97)00041-2; Liu JW, 2007, J NAT PROD, V70, P1329, DOI 10.1021/np070135j; Liu L, 2011, BRAIN RES, V1382, P147, DOI 10.1016/j.brainres.2011.01.051; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mook-Jung I, 2001, J NEUROSCI RES, V63, P509, DOI 10.1002/jnr.1045; Ng TB, 2006, J PHARM PHARMACOL, V58, P1007, DOI 10.1211/jpp.58.8.0001; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Rovegno M, 2012, MED INTENSIVA, V36, P37, DOI 10.1016/j.medin.2011.06.008; Rudakewich M, 2001, PLANTA MED, V67, P533, DOI 10.1055/s-2001-16488; Schmid RS, 2008, CURR OPIN NEUROBIOL, V18, P245, DOI 10.1016/j.conb.2008.07.015; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shen LH, 2004, NEUROL RES, V26, P422, DOI 10.1179/016164104225016047; Shen LH, 2003, NEUROSCI LETT, V344, P1, DOI 10.1016/S0304-3940(03)00318-5; Shi Q, 2005, LIFE SCI, V76, P983, DOI 10.1016/j.lfs.2004.07.026; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Tohda C, 2005, NEUROSIGNALS, V14, P34, DOI 10.1159/000085384; Vaquero J, 2011, PROG NEUROBIOL, V93, P341, DOI 10.1016/j.pneurobio.2010.12.002; Walsh GS, 1999, J NEUROSCI, V19, P4155; Wang ZJ, 2006, CHEM-BIOL INTERACT, V159, P58, DOI 10.1016/j.cbi.2005.09.003; WINSTON SR, 1979, J IOWA MED SOC, V69, P393; Xia L, 2012, J NEUROSCI RES, V90, P1424, DOI 10.1002/jnr.22811; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yoneyama M, 2011, J PHARMACOL SCI, V115, P425, DOI 10.1254/jphs.11R02CP; Zhao HF, 2011, NEUROSCIENCE, V183, P189, DOI 10.1016/j.neuroscience.2011.03.048; Zhao HF, 2009, BRAIN RES, V1256, P111, DOI 10.1016/j.brainres.2008.12.031; Zheng GQ, 2011, J ETHNOPHARMACOL, V133, P724, DOI 10.1016/j.jep.2010.01.064; 姜正林, 2000, 中华航海医学杂志, V7, P28	63	21	22	1	42	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-8741			J ETHNOPHARMACOL	J. Ethnopharmacol.	SEP 11	2014	155	2					1243	1255		10.1016/j.jep.2014.07.009			13	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	AP2JE	WOS:000341897700030	25046825				2021-06-18	
J	Gaither, JB; Spaite, DW; Stolz, U; Ennis, J; Mosier, J; Sakles, JJ				Gaither, Joshua B.; Spaite, Daniel W.; Stolz, Uwe; Ennis, Joshua; Mosier, Jarrod; Sakles, John J.			PREVALENCE OF DIFFICULT AIRWAY PREDICTORS IN CASES OF FAILED PREHOSPITAL ENDOTRACHEAL INTUBATION	JOURNAL OF EMERGENCY MEDICINE			English	Article						prehospital; airway management; endotracheal intubation; complications; difficult; failure; success	TRAUMATIC BRAIN-INJURY; RAPID-SEQUENCE INTUBATION; EMERGENCY-DEPARTMENT; TRACHEAL INTUBATION; LARYNGOSCOPE; MANAGEMENT; SURVIVAL; MEDICINE; TRIAL	Background: Difficult airway predictors (DAPs) are associated with failed endotracheal intubation (ETI) in the emergency department (ED). However, little is known about the relationship between DAPs and failed prehospital ETI. Objective: Our aim was to determine the prevalence of common DAPs among failed prehospital intubations. Methods: We reviewed a quality-improvement database, including all cases of ETI in a single ED, over 3 years. Failed prehospital (FP) ETI was defined as a case brought to the ED after attempted prehospital ETI, but bag-valve-mask ventilation, need for a rescue airway (supraglottic device, cricothyrotomy, etc.), or esophageal intubation was discovered at the ED. Physicians performing ETI evaluated each case for the presence of DAPs, including blood/emesis, facial/neck trauma, airway edema, spinal immobilization, short neck, and tongue enlargement. Results: There were a total of 1377 ED ETIs and 161 had an FP-ETI (11.8%). Prevalence of DAPs in cases with FP-ETI was obesity 13.0%, large tongue 18.0%, short neck 13%, small mandible 4.3%, cervical immobility 49.7%, blood in airway 57.8%, vomitus in airway 23.0%, airway edema 12.4%, and facial or neck trauma 32.9%. The number of cases with FP-ETI and 0, 1, 2, 3, or 4 or more DAPs per case was 22 (13.6%), 43 (26.7%), 23 (24.3%), 42 (26.1%), and 31 (19.3%), respectively. Conclusions: DAPs are common in cases of FP-ETI. Some of these factors may be associated with FP-ETI. Additional study is needed to determine if DAPs can be used to identify patients that are difficult to intubate in the field. (C) 2014 Elsevier Inc.	[Gaither, Joshua B.; Spaite, Daniel W.; Stolz, Uwe; Ennis, Joshua; Mosier, Jarrod; Sakles, John J.] Univ Arizona, Dept Emergency Med, Coll Med, Arizona Emergency Med Res Ctr, Tucson, AZ 85714 USA	Gaither, JB (corresponding author), Univ Arizona, Dept Emergency Med, 3950 S Country Club Rd,2254, Tucson, AZ 85714 USA.			Spaite, Daniel/0000-0003-2601-6476			Berlac P, 2008, ACTA ANAESTH SCAND, V52, P897, DOI 10.1111/j.1399-6576.2008.01673.x; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Clemency BM, 2014, PREHOSP EMERG CARE, V18, P239, DOI 10.3109/10903127.2013.864352; Davis DP, 2007, PREHOSP EMERG CARE, V11, P1, DOI 10.1080/10903120601021093; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Freund Y, 2012, EUR J EMERG MED, V19, P304, DOI 10.1097/MEJ.0b013e32834d3e4f; Gaither JB, 2012, ANN EMERG MED, V60, P732, DOI 10.1016/j.annemergmed.2012.06.017; Garza Alex G, 2005, Prehosp Emerg Care, V9, P163, DOI 10.1080/10903120590924654; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Germann C, 2009, PREHOSP EMERG CARE, V13, P44, DOI 10.1080/10903120802474505; Jabre P, 2007, ANN EMERG MED, V50, P258, DOI 10.1016/j.annemergmed.2007.04.022; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Kim YM, 2011, PREHOSP EMERG CARE, V15, P98, DOI 10.3109/10903127.2010.514087; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; Mosier JM, 2012, J EMERG MED, V42, P629, DOI 10.1016/j.jemermed.2011.06.007; O'Shea Jeremiah K, 2005, Prehosp Emerg Care, V9, P167, DOI 10.1080/10903120590924663; Prunty H, 2012, PREHOSP EMERG CARE, V16, P156; Sakles JC, 2012, ANN EMERG MED, V60, P739, DOI 10.1016/j.annemergmed.2012.03.031; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Walls R, 2008, MANUAL EMERGENCY AIR; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2003, ACAD EMERG MED, V10, P717, DOI 10.1111/j.1553-2712.2003.tb00065.x; Wang Henry E, 2005, Prehosp Emerg Care, V9, P145; Wang HE, 2009, RESUSCITATION, V80, P50, DOI 10.1016/j.resuscitation.2008.08.016	25	21	21	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	SEP	2014	47	3					294	300		10.1016/j.jemermed.2014.04.021			7	Emergency Medicine	Emergency Medicine	AO6ET	WOS:000341443300015	24906900				2021-06-18	
J	Irimia, A; Goh, SYM; Torgerson, CM; Vespa, PM; Van Horn, JD				Irimia, A.; Goh, S-Y M.; Torgerson, C. M.; Vespa, P. M.; Van Horn, J. D.			Structural and connectomic neuroimaging for the personalized study of longitudinal alterations in cortical shape, thickness and connectivity after traumatic brain injury	JOURNAL OF NEUROSURGICAL SCIENCES			English	Article						Brain injuries; Neuroimaging; Magnetic resonance imaging; Connectome	MRI TISSUE CHARACTERIZATION; WHITE-MATTER INTEGRITY; SURFACE-BASED ANALYSIS; FLAIR PULSE SEQUENCES; CLOSED HEAD-INJURY; DIFFUSION-TENSOR; QUANTITATIVE-ANALYSIS; MULTIPLE-SCLEROSIS; COORDINATE SYSTEM; SEGMENTATION	The integration of longitudinal brain structure analysis with neurointensive care strategies continues to be a substantial difficulty facing the traumatic brain injury (TBI) research community. For patient-tailored case analysis, it remains challenging to establish how lesion profile modulates longitudinal changes in cortical structure and connectivity, as well as how these changes lead to behavioral, cognitive and neural dysfunction. Additionally, despite the clinical potential of morphometric and connectomic studies, few analytic tools are available for their study in TBI. Here we review the state of the art in structural and connectomic neuroimaging for the study of TBI and illustrate a set of recently-developed, patient-tailored approaches for the study of TBI-related brain atrophy and alterations in morphometry as well as inter-regional connectivity. The ability of such techniques to quantify how injury modulates longitudinal changes in cortical shape, structure and circuitry is highlighted. Quantitative approaches such as these can be used to assess and monitor the clinical condition and evolution of TBI victims, and can have substantial translational impact, especially when used in conjunction with measures of neuropsychological function.	[Irimia, A.; Goh, S-Y M.; Torgerson, C. M.; Van Horn, J. D.] Univ So Calif, Keck Sch Med, Inst Neuroimaging & Informat, Dept Neurol, Los Angeles, CA 90032 USA; [Vespa, P. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Van Horn, JD (corresponding author), Univ So Calif, Keck Sch Med, Inst Neuroimaging & Informat, Los Angeles, CA 90032 USA.	jvanhorn@usc.edu	Irimia, Andrei/B-8275-2008	Irimia, Andrei/0000-0002-9254-9388; Van Horn, John/0000-0003-1537-0816	National Alliance for Medical Image Computing (NA-MIC) under NIH Roadmap Initiative [2U54EB005149]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489, R41NS081792]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB005149, P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R41NS081792, P01NS058489] Funding Source: NIH RePORTER	This work was supported by the National Alliance for Medical Image Computing (NA-MIC; www.na-mic.org), under NIH Roadmap Initiative grant 2U54EB005149, sub-award to J. D. V. H., by the NINDS, grant P01NS058489 to P. V., and R41NS081792, sub-award to J. D. V. H.	Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; Ashikaga R, NEURORAIOLOGY, V7, P239; Atlas SW, ADIOLOGY, V88, P803; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; Defense_Centers_of_ Excellence, 2013, NEUROIMAGING FOLLOWI; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Hajnal JV, J COMPUT ASSST TOMO, V92, P841; Hamann P, 2008, PLOS BIOL, V6, P1479; Hillary FG, 2009, IMAGING BEHAV, V3, P1122; Irimia A, NEUROIMAGE CIN, V201, P1; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Irimia A, 2011, J NEUROTRAUM, V28, P2287, DOI 10.1089/neu.2011.1920; Itti L, 2001, J NEUROIMAGING, V11, P412, DOI 10.1111/j.1552-6569.2001.tb00071.x; Jacobs MA, 2001, STROKE, V32, P950, DOI 10.1161/01.STR.32.4.950; Jacobs MA, 2001, STROKE, V32, P943, DOI 10.1161/01.STR.32.4.943; Johnston B, 1996, IEEE T MED IMAGING, V15, P154, DOI 10.1109/42.491417; JONES KM, 1992, AM J ROENTGENOL, V158, P1313, DOI 10.2214/ajr.158.6.1590133; Kaas JH, 2008, EXP NEUROL, V209, P407, DOI 10.1016/j.expneurol.2007.06.014; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kirkby BS, 1934, NEUROPSYCHOOGIA, P689; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krzywnski M, GENOME RES, V20919; Kuzma BB, 2000, SRG NEURO, V53, P400; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Liao CC, 2009, COMPUT MED IMAG GRAP, V33, P423, DOI 10.1016/j.compmedimag.2009.04.001; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mitsias PD, 2002, STROKE, V33, P2839, DOI 10.1161/01.STR.0000043072.76353.7C; MUGLER JP, 1990, MAGNET RESON MED, V15, P152, DOI 10.1002/mrm.1910150117; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77; Niethammer M, 2011, LECT NOTES COMPUT SC, V6892, P639, DOI 10.1007/978-3-642-23629-7_78; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Prataa M.W., 2012, P SOC PHOTO-OPT INS; Raff U, 2000, ACAD RADIOL, V7, P237, DOI 10.1016/S1076-6332(00)80473-0; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Schlaug G, 2009, STROKE, V40, pE123; Seghier ML, 2008, NEUROIMAGE, V41, P1253, DOI 10.1016/j.neuroimage.2008.03.028; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spaos GK, 2007, AM J NEURORADIOL, V28, P537; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; van Horn JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037454; Warach S, AN EUROL, V1, P231; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wn B, IEEE INT S BIOM ENG; Xie K, 2005, EUR J RADIOL, V56, P12, DOI 10.1016/j.ejrad.2005.03.028; Zakaria N, 2007, J NEUROTRAUM, V24, P1233	71	21	22	0	9	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0390-5616	1827-1855		J NEUROSURG SCI	J. Neurosurg. Sci.	SEP	2014	58	3					129	144					16	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AR1XH	WOS:000343377400001	24844173				2021-06-18	
J	Liu, SF; Mok, K; Neelavalli, J; Cheng, YCN; Tang, J; Ye, YQ; Haacke, EM				Liu, Saifeng; Mok, Karen; Neelavalli, Jaladhar; Cheng, Yu-Chung N.; Tang, Jin; Ye, Yongquan; Haacke, E. Mark			Improved MR Venography Using Quantitative Susceptibility-Weighted Imaging	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						susceptibility-weighted imaging; quantitative susceptibility mapping; phase imaging	MAGNETIC-SUSCEPTIBILITY; OXYGEN-SATURATION; PHASE DATA; BRAIN; FIELD; MAP; RECONSTRUCTION; MULTIPLE	Purpose: To remove the geometry dependence of phase-based susceptibility weighting masks in susceptibility-weighted imaging (SWI) and to improve the visualization of the veins and microbleeds. Materials and Methods: True SWI (tSWI) was generated using susceptibility-based masks. Simulations were used to evaluate the influence of the characteristic parameters defining the mask. In vivo data from three healthy adult human volunteers were used to compare the contrast-to-noise-ratios (CNRs) of the right septal vein and the left internal cerebral vein as measured from both tSWI and SWI data. A traumatic brain injury (TBI) patient dataset was used to illustrate qualitatively the proper visualization of microbleeds using tSWI. Results: Compared with conventional SWI, tSWI improved the CNR of the two selected veins by a factor of greater than three for datasets with isotropic resolution and greater than 30% for datasets with anisotropic resolution. Veins with different orientations can be properly enhanced in tSWI. Furthermore, the blooming artifact due to the strong dipolar phase of microbleeds in conventional SWI was reduced in tSWI for the TBI case. Conclusion: The use of tSWI overcomes the geometric limitations of using phase and provides better visualization of the venous system, especially for data collected with isotropic resolution.	[Liu, Saifeng; Mok, Karen; Haacke, E. Mark] McMaster Univ, Sch Biomed Engn, Hamilton, ON, Canada; [Neelavalli, Jaladhar; Cheng, Yu-Chung N.; Ye, Yongquan; Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI USA; [Tang, Jin; Haacke, E. Mark] MRI Inst Biomed Res, Detroit, MI USA	Neelavalli, J (corresponding author), HUH MR Res G030 Radiol,3990 John R St, Detroit, MI 48201 USA.	jaladhar@wayne.edu	Liu, Saifeng/I-1242-2019	NEELAVALLI, JALADHAR/0000-0002-9513-337X; Liu, Saifeng/0000-0002-3642-8282; Cheng, Yu-Chung/0000-0001-5870-6653	National Institutes of Health (NIH) (STTR) [1R42HL112580-01A1]; Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0522]; Perinatal Research Initiative of the Wayne State University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R42HL112580] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health (NIH) (STTR); Contract grant number: 1R42HL112580-01A1; Contract grant sponsor: Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC); Contract grant number: W81XWH-12-1-0522; Contract grant sponsor: Perinatal Research Initiative of the Wayne State University. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official government position, policy, or decision unless so designated by other documentation.	Abdul-Rahman HS, 2007, APPL OPTICS, V46, P6623, DOI 10.1364/AO.46.006623; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke E.M., 1999, MAGNETIC RESONANCE I; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haacke EM, 2011, SUSCEPTIBILIY WEIGHT; Jain V, 2012, MAGN RESON MED, V68, P863, DOI 10.1002/mrm.23282; Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082; Liu T, 2011, NMR BIOMED, V24, P1129, DOI 10.1002/nbm.1670; Liu T, 2009, MAGN RESON MED, V61, P196, DOI 10.1002/mrm.21828; Marques JP, 2005, CONCEPT MAGN RESON B, V25B, P65, DOI 10.1002/cmr.b.20034; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Schweser F, 2012, NEUROIMAGE, V62, P2083, DOI 10.1016/j.neuroimage.2012.05.067; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Shmueli K, 2009, MAGN RESON MED, V62, P1510, DOI 10.1002/mrm.22135; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Wharton S, 2010, NEUROIMAGE, V53, P515, DOI 10.1016/j.neuroimage.2010.06.070; Xu YB, 2006, MAGN RESON IMAGING, V24, P155, DOI 10.1016/j.mri.2005.10.030; Xu YB, 2008, MAGN RESON IMAGING, V26, P1406, DOI 10.1016/j.mri.2008.04.008; Zwanenburg JJM, 2011, NEUROIMAGE, V56, P1902, DOI 10.1016/j.neuroimage.2011.03.046	21	21	23	1	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	SEP	2014	40	3					698	708		10.1002/jmri.24413			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AN4DQ	WOS:000340538200025	24923249	Green Accepted			2021-06-18	
J	Niemeier, JP; Perrin, PB; Holcomb, MG; Rolston, CD; Artman, LK; Lu, J; Nersessova, KS				Niemeier, Janet P.; Perrin, Paul B.; Holcomb, Megan G.; Rolston, Cynthia D.; Artman, Laura K.; Lu, Juan; Nersessova, Karine S.			Gender Differences in Awareness and Outcomes During Acute Traumatic Brain Injury Recovery	JOURNAL OF WOMENS HEALTH			English	Article							SYSTEMS BEHAVIOR SCALE; COMPETENCE RATING-SCALE; HEAD-INJURY; PROGESTERONE; TBI; SEX; REHABILITATION; PERSPECTIVE; COGNITION; PARTICIPATION	Background: Recent literature on traumatic brain injury (TBI), though mixed when reporting outcomes, seems collectively to suggest possible gender advantage for women in postinjury recovery, especially in executive functions. Hormonal neuroprotection, through female reproductive hormones, is often proposed as an underlying factor in these results. We explored potential gender differences in an aspect of executive functions, self-awareness (SA), which is often impaired after TBI, limits patient effort in critical rehabilitation, and increases caregiver burden. Methods: Within a prospective survey, repeated-measures design, 121 patients with moderate or severe TBI undergoing acute rehabilitation in a Level 1 trauma center, a family member or caregiver informant, and a treating clinician were asked to complete the Patient Competency Rating Scale (PCRS) and the Frontal Systems Behavior Scale (FrSBe) at admission and discharge. Results: Although overall, women and men with TBI showed generally similar levels of SA, women had significantly better awareness of their injury-related deficits at acute rehabilitation discharge, even when controlling for age, education, and injury severity. Conclusions: Mixed findings in this study mirror the pattern of results that dominate the published literature on gender and TBI. Gender differences in executive dysfunction may not be as large or robust as some researchers argue. In addition, complex interplays of socialization, gender-role expectations, naturally occurring male and female ability differences, and differences in access to postinjury rehabilitation are understudied potential moderators.	[Niemeier, Janet P.] Carolinas Rehabil, Dept Phys Med & Rehabil, Charlotte, NC 28203 USA; [Perrin, Paul B.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Holcomb, Megan G.] Vet Hosp, Dept Psychol, Pensacola, FL USA; [Rolston, Cynthia D.; Artman, Laura K.; Nersessova, Karine S.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Lu, Juan] Virginia Commonwealth Univ, Dept Epidemiol, Richmond, VA USA	Niemeier, JP (corresponding author), Carolinas Rehabil, Dept Phys Med & Rehabil, 1100 Blythe Blvd, Charlotte, NC 28203 USA.	janet.niemeier@carolinashealthcare.org	; Perrin, Paul/L-5373-2015	Lu, Juan/0000-0002-5389-7603; Perrin, Paul/0000-0003-2070-215X	National Center for Medical Rehabilitation Research (NCMRR); Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R01HD052922-01A2]; NIH CTSA AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR00058]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD052922] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000058] Funding Source: NIH RePORTER	This research was supported by the National Center for Medical Rehabilitation Research (NCMRR), the Eunice Kennedy Shriver National Institute of Child Health and Human Development, 1R01HD052922-01A2, and, in part, by NIH CTSA Award UL1 TR00058.	Addis ME, 2003, AM PSYCHOL, V58, P5, DOI 10.1037/0003-066X.58.1.5; Alston M, 2012, AUST SOC WORK, V65, P39, DOI 10.1080/0312407X.2011.594898; BASDEVANT A, 1986, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V15, P147; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Bingefors K, 2004, EUR J PAIN, V8, P435, DOI 10.1016/j.ejpain.2004.01.005; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Colantonio A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-102; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; de Abreu PMJE, 2014, MEMORY, V22, P323, DOI 10.1080/09658211.2013.781186; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Drapeau A, 2009, J BEHAV HEALTH SER R, V36, P372, DOI 10.1007/s11414-009-9168-0; Farace E, 2000, Neurosurg Focus, V8, pe6; Fleming J., 2010, INT ENCY REHABILITAT; Fritz MA, 2011, CLIN GYNECOLOGIC END, P193; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Heaton R., 1993, WISCONSIN CARD SORTI; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; JOHNSON WS, 1971, J AM CHEM SOC, V93, P4332, DOI 10.1021/ja00746a062; Katz Noomi, 2002, Can J Occup Ther, V69, P281; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Kolakowsky-Hayner SA, 2012, J HEAD TRAUMA REHAB, V27, P83, DOI 10.1097/HTR.0b013e31823645db; Komesaroff P A, 2001, Climacteric, V4, P144; Kraus J F, 2000, Neurosurg Focus, V8, pe5; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lane-Brown AT, 2009, BRAIN INJURY, V23, P999, DOI 10.3109/02699050903379347; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M., 2010, J HEAD TRAUMA REHAB, V8, P24; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Mauritz W, 2009, EUR J EMERG MED, V16, P153, DOI 10.1097/MEJ.0b013e32832a0864; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Munro CA, 2012, AGING NEUROPSYCHOL C, V19, P759, DOI 10.1080/13825585.2012.690366; Murre JMJ, 2013, ACTA PSYCHOL, V142, P96, DOI 10.1016/j.actpsy.2012.10.005; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Niemeier JP, 2013, NEUROPSYCHOL REHABIL, V23, P363, DOI 10.1080/09602011.2012.761944; Olga NK, 2006, BEHAV BRAIN RES, V170, P233, DOI 10.1016/j.bbr.2006.02.026; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P359, DOI 10.1097/00001199-200507000-00007; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Razmjou H, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-66; Redpath SJ, 2010, BRAIN INJURY, V24, P802, DOI 10.3109/02699051003709623; Soules M R, 2001, Menopause, V8, P402, DOI 10.1097/00042192-200111000-00004; Soules MR, 2005, MENOPAUSE, V12, P117, DOI 10.1097/00042192-200512020-00001; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; TAYLOR J, 1987, J PERS, V55, P139, DOI 10.1111/j.1467-6494.1987.tb00432.x; VanHeest Jaci L, 2007, Curr Sports Med Rep, V6, P190, DOI 10.1007/s11932-007-0027-6; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wood W, 1997, J PERS SOC PSYCHOL, V73, P523, DOI 10.1037/0022-3514.73.3.523; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yeung JHH, 2011, ARCH SURG-CHICAGO, V146, P436, DOI 10.1001/archsurg.2011.46	68	21	21	2	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	JUL	2014	23	7					573	580		10.1089/jwh.2013.4535			8	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	AL5KK	WOS:000339172300003	24932911	Green Published			2021-06-18	
J	Rabin, J; Harris, DG; Crews, GA; Ho, M; Taylor, BS; Sarkar, R; O'Connor, JV; Scalea, TM; Crawford, RS				Rabin, Joseph; Harris, Donald G.; Crews, Gordon A.; Ho, Michelle; Taylor, Bradley S.; Sarkar, Rajabrata; O'Connor, James V.; Scalea, Thomas M.; Crawford, Robert S.			Early Aortic Repair Worsens Concurrent Traumatic Brain Injury	ANNALS OF THORACIC SURGERY			English	Article							EARLY FRACTURE FIXATION; AMERICAN-ASSOCIATION; THORACIC AORTA; NONOPERATIVE MANAGEMENT; NATURAL-HISTORY; DELAYED REPAIR; BLUNT TRAUMA; RUPTURE; SURGERY; PROGRESSION	Background. Blunt thoracic aortic injury (BTAI) and traumatic brain injury (TBI) are the leading causes of death after blunt trauma, and TBI is common among patients with BTAI. Although aspects of aortic management, such as repair timing and procedural anticoagulation therapy, may complicate TBI, the optimal management of these patients is undefined. Methods. Adults with BTAI and moderate to severe TBI admitted to a level I trauma center over 12 years were retrospectively analyzed; patients presenting in extremis were excluded. The primary outcome was neurologic progression within 48 hours of aortic repair. Patients undergoing nonoperative aortic management served as controls for baseline TBI progression. Secondary outcomes were aortic morbidity and mortality and overall inpatient survival. Results. Of 309 patients with BTAI, 138 had concurrent TBI, and 75 were included for analysis. Twenty-two (29%) were treated nonoperatively, 29 (39%) had early aortic repair (17 open, 12 endovascular), and 24 (32%) had delayed repair (3 open, 21 endovascular). The severity of TBI was similar between groups. Early aortic repair within 24 hours of admission was independently associated with worsening TBI, regardless of repair modality or anticoagulation use. In contrast, patients undergoing delayed repair had no perioperative neurologic progression despite procedural anticoagulation therapy. Early aortic repair was also associated with increased aortic morbidity and mortality. Conclusions. For patients with BTAI and TBI, early aortic intervention is associated with progressive TBI regardless of repair modality, as well as increased aortic morbidity and mortality. Patients not requiring emergent intervention can undergo delayed repair with full anticoagulation therapy. (C) 2014 by The Society of Thoracic Surgeons	Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Div Vasc Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Aort Dis, Baltimore, MD 21201 USA	Harris, DG (corresponding author), Univ Maryland, Med Ctr, Div Gen Surg, 22 S Greene St, Baltimore, MD 21201 USA.	dharris@smail.umaryland.edu		Harris, Donald/0000-0002-5059-5597			Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Caffarelli AD, 2010, J THORAC CARDIOV SUR, V140, P598, DOI 10.1016/j.jtcvs.2010.02.056; Cardarelli MG, 2002, ANN SURG, V236, P465, DOI 10.1097/00000658-200210000-00009; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; de Mestral C, 2013, J AM COLL SURGEONS, V216, P1110, DOI 10.1016/j.jamcollsurg.2013.01.005; Demetriades D, 2008, J TRAUMA, V64, P561, DOI 10.1097/TA.0b013e3181641bb3; Demetriades D, 2009, J TRAUMA, V66, P967, DOI 10.1097/TA.0b013e31817dc483; Di Eusanio M, 2013, ANN THORAC SURG, V95, P1591, DOI 10.1016/j.athoracsur.2013.02.033; Estrera AL, 2010, ANN THORAC SURG, V90, P64, DOI 10.1016/j.athoracsur.2010.03.053; Fabian TC, 1998, ANN SURG, V227, P666, DOI 10.1097/00000658-199805000-00007; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; Hemmila MR, 2004, J TRAUMA, V56, P13, DOI 10.1097/01.TA.0000108634.15989.07; Holmes JH, 2002, ANN THORAC SURG, V73, P1149, DOI 10.1016/S0003-4975(01)03585-8; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; Kepros J, 2002, J TRAUMA, V52, P475, DOI 10.1097/00005373-200203000-00010; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Nagy K, 2000, J TRAUMA, V48, P1128, DOI 10.1097/00005373-200006000-00021; Neschis DG, 2008, NEW ENGL J MED, V359, P1708, DOI 10.1056/NEJMra0706159; Neschis DG, 2009, ANN SURG, V250, P377, DOI 10.1097/SLA.0b013e3181b3b5c9; Nguyen D, 2009, AM J ROENTGENOL, V192, P3, DOI 10.2214/AJR.07.3702; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Osgood MJ, 2013, J VASC SURG, V57, p30S, DOI 10.1016/j.jvs.2013.02.141; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Pate JW, 1999, WORLD J SURG, V23, P59, DOI 10.1007/s002689900565; Paul JS, 2011, J TRAUMA, V71, P1519, DOI 10.1097/TA.0b013e31823b9811; Peterson BG, 2005, J TRAUMA, V59, P1062, DOI 10.1097/01.ta.0000188634.72008.d5; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Rabin J, 2014, J THORAC CARDIOV SUR, V147, P143, DOI 10.1016/j.jtcvs.2013.08.053; Scalea TM, 1999, J TRAUMA, V46, P839, DOI 10.1097/00005373-199905000-00012; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; STROMHOLM T, 1995, EUR J VASC ENDOVASC, V10, P36, DOI 10.1016/S1078-5884(05)80196-0; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f	40	21	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0003-4975	1552-6259		ANN THORAC SURG	Ann. Thorac. Surg.	JUL	2014	98	1					46	51		10.1016/j.athoracsur.2014.04.025			6	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	AK4ZF	WOS:000338432600019	24857854				2021-06-18	
J	Neselius, S; Brisby, H; Marcusson, J; Zetterberg, H; Blennow, K; Karlsson, T				Neselius, Sanna; Brisby, Helena; Marcusson, Jan; Zetterberg, Henrik; Blennow, Kaj; Karlsson, Thomas			Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; DIFFUSE AXONAL INJURY; WORD-ASSOCIATION TEST; CLOSED-HEAD-INJURY; COGNITIVE IMPAIRMENT; WORKING-MEMORY; FOOTBALL PLAYERS; HIGH-SCHOOL; INDIVIDUAL-DIFFERENCES	Background: Mild traumatic brain injury (TBI) or concussion is common in many sports. Today, neuropsychological evaluation is recommended in the monitoring of a concussion and in return-to-play considerations. To investigate the sensitivity of neuropsychological assessment, we tested amateur boxers post bout and compared with controls. Further the relationship between neuropsychological test results and brain injury biomarkers in the cerebrospinal fluid (CSF) were investigated. Method: Thirty amateur boxers on high elite level with a minimum of 45 bouts and 25 non-boxing matched controls were included. Memory tests (Rey Osterrieth Complex Figure, Listening Span, Digit Span, Controlled Word Association Test, and computerized testing of episodic memory), tests of processing speed and executive functions (Trail Making, Reaction Time, and Finger Tapping) were performed and related to previously published CSF biomarker results for the axonal injury marker neurofilament light (NFL). Results: The neurological assessment showed no significant differences between boxers and controls, although elevated CSF NFL, as a sign of axonal injury, was detected in about 80% of the boxers 1-6 days post bout. The investigation of the relationship between neuropsychological evaluation and CSF NFL concentrations revealed that boxers with persisting NFL concentration elevation after at least 14 days resting time post bout, had a significantly poorer performance on Trail Making A (p = 0.041) and Simple Reaction Time (p = 0.042) compared to other boxers. Conclusion: This is the first study showing traumatic axonal brain injury can be present without measureable cognitive impairment. The repetitive, subconcussive head trauma in amateur boxing causes axonal injury that can be detected with analysis of CSF NFL, but is not sufficient to produce impairment in memory tests, tests of processing speed, or executive functions. The association of prolonged CSF NFL increase in boxers with impairment of processing speed is an interesting observation, which needs to be verified in larger studies.	[Neselius, Sanna; Brisby, Helena] Sahlgrens Univ Hosp, Dept Orthopaed, Gothenburg, Sweden; [Neselius, Sanna; Brisby, Helena] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden; [Marcusson, Jan] Linkoping Univ Hosp, Geriatr Sect, S-58185 Linkoping, Sweden; [Marcusson, Jan] Linkoping Univ, Inst Clin & Expt Med, Linkoping, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, London, England; [Karlsson, Thomas] Linkoping Univ, Dept Behav Sci & Learning, Linkoping, Sweden; [Karlsson, Thomas] Linkoping Univ, Linnaeus Ctr HEAD, Linkoping, Sweden	Neselius, S (corresponding author), Sahlgrens Univ Hosp, Dept Orthopaed, Gothenburg, Sweden.	sanna.neselius@vgregion.se			ALF Grants, County Council of Vastra Gotaland, Sweden; Gothenburg Medical Society, Sweden; ALF Grants, County Council of Ostergotland	This work was supported by ALF Grants, County Council of Vastra Gotaland, Sweden; Gothenburg Medical Society, Sweden; and ALF Grants, County Council of Ostergotland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Benton A., 1994, MULTILINGUAL APHASIA; Bianco M, 2013, BRIT J SPORT MED, V47, P452, DOI 10.1136/bjsports-2012-091771; BIGLER ED, 1989, J CLIN PSYCHOL, V45, P277, DOI 10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; CORNELL DG, 1997, ARCH CLIN NEUROPSYCH, V12, P47; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Halstead WC., 1947, BRAIN INTELLIGENCE Q; Hannay HJ, 1986, EXPT TECHNIQUES HUMA; Haut M W, 2000, Appl Neuropsychol, V7, P237, DOI 10.1207/S15324826AN0704_5; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; Kane MJ, 2002, PSYCHON B REV, V9, P637, DOI 10.3758/BF03196323; KASTE M, 1982, LANCET, V2, P1186; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Lezak MD, 1984, SCANDINAVIAN J WO S1, V10, P25; Loring DW, 1990, NEUROLOGY, V74, P685; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Malek-Ahmadi M, 2011, DEMENT GERIATR COGN, V32, P235, DOI 10.1159/000334525; Malm J, 1998, NEUROLOGY, V51, P433, DOI 10.1212/WNL.51.2.433; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Mayers LB, 2011, J CLIN EXP NEUROPSYC, V33, P532, DOI 10.1080/13803395.2010.535506; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mitrushina M., 2005, HDB NORMATIVE DATA N; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Prigatano GP, 2003, J INT NEUROPSYCH SOC, V9, P128, DOI 10.1017/S1355617703000134; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; Reitan R.M., 1992, NEUROPSYCHOLOGICAL E; REITAN RM, 1994, J CLIN PSYCHOL, V50, P47, DOI 10.1002/1097-4679(199401)50:1<47::AID-JCLP2270500106>3.0.CO;2-X; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rosen VM, 2002, NEUROPSYCHOLOGIA, V40, P2226, DOI 10.1016/S0028-3932(02)00132-X; Ross TP, 2003, ARCH CLIN NEUROPSYCH, V18, P153, DOI 10.1016/S0887-6177(01)00192-5; Spreen O., 1998, COMPENDIUM NEUROPSYC; Thomas JR, 1999, RES Q EXERCISE SPORT, V70, P11, DOI 10.1080/02701367.1999.10607726; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Tulving E., 1985, CAN PSYCHOL, V1, P1; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wright MJ, 2010, J CLIN EXP NEUROPSYC, V32, P728, DOI 10.1080/13803390903512652; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	65	21	21	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2014	9	6							e99870	10.1371/journal.pone.0099870			8	Multidisciplinary Sciences	Science & Technology - Other Topics	AK6AC	WOS:000338508200048	24941067	DOAJ Gold, Green Published			2021-06-18	
J	Fei, F; Rao, W; Zhang, L; Chen, BG; Li, J; Fei, Z; Chen, Z				Fei, F.; Rao, W.; Zhang, L.; Chen, B. -G.; Li, J.; Fei, Z.; Chen, Z.			DOWNREGULATION OF HOMER1B/C IMPROVES NEURONAL SURVIVAL AFTER TRAUMATIC NEURONAL INJURY	NEUROSCIENCE			English	Article						neurons; injury; receptors; glutamic acid; Homer1; RNAi	METABOTROPIC GLUTAMATE RECEPTORS; INDUCED OXIDATIVE STRESS; SPINAL DORSAL-HORN; BRAIN-INJURY; GENE-EXPRESSION; INDUCED APOPTOSIS; CORTICAL-NEURONS; LOOSE LIGATION; CELL-DEATH; IN-VITRO	Homer protein, a member of the post-synaptic density protein family, plays an important role in the neuronal synaptic activity and is extensively involved in neurological disorders. The present study investigates the role of Homer1b/c in modulating neuronal survival by using an in vitro traumatic neuronal injury model, which was achieved by using a punch device that consisted of 28 stainless steel blades joined together and produced 28 parallel cuts. Downregulation of Homer1b/c by specific siRNA significantly (p < 0.05) alleviated the cytoplasmic calcium levels and neuron lactate dehydrogenase release, and ultimately decreased the apoptotic rate after traumatic neuronal injury compared with non-targeting siRNA control treatment in cultured rat cortical neurons. Moreover, the expression of metabotropic glutamate receptor 1a (mGluR1a) was significantly (p < 0.05) reduced in the Homer1b/c siRNA-transfected neurons after injury. Therefore, Homer1b/c not only modulated the mGluR1a-inositol 1,4,5-triphosphate receptors-Ca2+ signal transduction pathway, but also regulated the expression of mGluR1a in mechanical neuronal injury. These findings indicate that the suppression of Homer1b/c expression potentially protects neurons from glutamate excitotoxicity after injury and might be an effective intervention target in traumatic brain injury. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Fei, F.; Chen, Z.] Fourth Mil Med Univ, Coll Basic Med, Dept Cell Biol, Xian 710032, Peoples R China; [Rao, W.; Zhang, L.; Li, J.; Fei, Z.] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China; [Chen, B. -G.] Tongji Univ, Affiliated Shanghai East Hosp, Cent Lab, Shanghai 200120, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 127 Changle Xi Rd, Xian 710032, Peoples R China.	feizhou@fmmu.edu.cn; znchen@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093]; research funds from the government [AWS11J008, 2012BAI11B02]; Program for Changjiang Scholars and Innovative Research Team in UniversityProgram for Changjiang Scholars & Innovative Research Team in University (PCSIRT) [IRT1053]	This work was supported by the National Natural Science Foundation of China (No. 30930093), research funds from the government (Nos. AWS11J008 and 2012BAI11B02), and Program for Changjiang Scholars and Innovative Research Team in University (No. IRT1053).	Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; Bottai D, 2002, J NEUROSCI, V22, P167, DOI 10.1523/JNEUROSCI.22-01-00167.2002; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Ciruela F, 2000, MOL CELL NEUROSCI, V15, P36, DOI 10.1006/mcne.1999.0808; COPANI A, 1995, J NEUROCHEM, V64, P101; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fei Z, 2005, NEUROSCI LETT, V380, P280, DOI 10.1016/j.neulet.2005.01.063; Foa L, 2009, J NEUROCHEM, V108, P1, DOI 10.1111/j.1471-4159.2008.05726.x; Ha JS, 2006, NEUROSCI LETT, V393, P165, DOI 10.1016/j.neulet.2005.09.056; Hegde AN, 2010, LEARN MEMORY, V17, P314, DOI 10.1101/lm.1504010; Hiroaki Y, 2002, BIOCHEM BIOPH RES CO, V295, P756, DOI 10.1016/S0006-291X(02)00738-6; Hu JH, 2010, NEURON, V68, P1128, DOI 10.1016/j.neuron.2010.11.008; Huang WD, 2005, NEUROSCI LETT, V389, P46, DOI 10.1016/j.neulet.2005.07.014; Irie K, 2002, J MOL BIOL, V318, P1117, DOI 10.1016/S0022-2836(02)00170-5; Kammermeier PJ, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-1; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lapanantasin S, 2006, SYNAPSE, V60, P406, DOI 10.1002/syn.20308; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lobner D, 2000, J NEUROSCI METH, V96, P147, DOI 10.1016/S0165-0270(99)00193-4; Luo P, 2012, APOPTOSIS, V17, P975, DOI 10.1007/s10495-012-0736-z; Luo P, 2012, FREE RADICAL RES, V46, P766, DOI 10.3109/10715762.2012.678340; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Mikoshiba K, 2006, J NEUROCHEM, V97, P1627, DOI 10.1111/j.1471-4159.2006.03985.x; Miletic G, 2005, NEUROSCI LETT, V386, P189, DOI 10.1016/j.neulet.2005.06.007; Miletic G, 2009, ANESTH ANALG, V109, P2000, DOI 10.1213/ANE.0b013e3181beea9b; Miyabe T, 2006, NEUROSCI LETT, V398, P296, DOI 10.1016/j.neulet.2006.01.011; Mukhin A, 1996, J NEUROSCI, V16, P6012; Obara I, 2013, PAIN, V154, P1932, DOI 10.1016/j.pain.2013.03.035; Obara Ilona, 2013, Front Psychiatry, V4, P39, DOI 10.3389/fpsyt.2013.00039; Rezvani K, 2012, J NEUROCHEM, V122, P24, DOI 10.1111/j.1471-4159.2012.07752.x; Ronesi JA, 2012, NAT NEUROSCI, V15, P431, DOI 10.1038/nn.3033; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; Shiraishi-Yamaguchi Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-206; Soloviev MM, 2000, J MOL BIOL, V295, P1185; Szumlinski KK, 2004, NEURON, V43, P401, DOI 10.1016/j.neuron.2004.07.019; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tappe A, 2006, NAT MED, V12, P677, DOI 10.1038/nm1406; Tappe-Theodor A, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-38; Wagner KV, 2013, J NEUROSCI, V33, P3857, DOI 10.1523/JNEUROSCI.4333-12.2013; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yao YX, 2011, ANESTH ANALG, V113, P1501, DOI 10.1213/ANE.0b013e31822c0b98	50	21	24	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 16	2014	267						187	194		10.1016/j.neuroscience.2014.02.037			8	Neurosciences	Neurosciences & Neurology	AF0KM	WOS:000334402700018	24607348				2021-06-18	
J	Hue, CD; Cao, SQ; Bass, CR; Meaney, DF; Morrison, B				Hue, Christopher D.; Cao, Siqi; Bass, Cameron R Dale; Meaney, David F.; Morrison, Barclay, III			Repeated Primary Blast Injury Causes Delayed Recovery, but not Additive Disruption, in an In Vitro Blood-Brain Barrier Model	JOURNAL OF NEUROTRAUMA			English	Article						shock tube; repeated blast injury; traumatic brain injury; endothelial cells; blood-brain barrier	POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE FUNCTION; TEMPORAL WINDOW; HEAD-INJURY; RAT MODEL; EXPOSURE; PERMEABILITY; MECHANISMS; PATHOPHYSIOLOGY; VULNERABILITY	Recent studies have demonstrated increased susceptibility to breakdown of the cerebral vasculature associated with repetitive traumatic brain injury. We hypothesized that exposure to two consecutive blast injuries would result in exacerbated damage to an in vitro model of the blood-brain barrier (BBB) compared with exposure to a single blast of the same severity. Contrary to our hypothesis, however, repeated mild or moderate primary blast delivered with a 24 or 72 h interval between injuries did not significantly exacerbate reductions in transendothelial electrical resistance (TEER) across a brain endothelial monolayer compared with sister cultures receiving a single exposure of the same intensity. Permeability of the barrier to a range of different-sized solutes remained unaltered after single and repeated blast, supporting that the effects of repeated blast on BBB integrity were not additive. Single blast exposure significantly reduced immunostaining of ZO-1 and claudin-5 tight junction proteins, but subsequent exposure did not cause additional damage to tight junctions. Although repeated blast did not further reduce TEER, the second exposure delayed TEER recovery in BBB cultures. Similarly, recovery of hydraulic conductivity through the BBB was delayed by a second exposure. Extending the interinjury interval to 72 h, the effects of multiple injuries on the BBB were found to be independent given sufficient recovery time between consecutive exposures. Careful investigation of the effects of repeated blast on the BBB will help identify injury levels and a temporal window of vulnerability associated with BBB dysfunction, ultimately leading to improved strategies for protecting warfighters against repeated blast-induced disruption of the cerebral vasculature.	[Hue, Christopher D.; Cao, Siqi; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Bass, Cameron R Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Morrison, B (corresponding author), Columbia Univ, 351 Engn Terrace,MC8904,1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; , Siqi/0000-0001-9779-4174; Meaney, David/0000-0002-0954-4122	Multidisciplinary University Research Initiative from the Army Research Office [W911MF 10 1-0526]; National Science FoundationNational Science Foundation (NSF) [DGE-07-07425]	This work was supported by a Multidisciplinary University Research Initiative from the Army Research Office (W911MF 10 1-0526), and a National Science Foundation Graduate Research Fellowship (C.D.H.; DGE-07-07425). The authors would like to acknowledge Gwen B. Effgen and Edward W. Vogel III for helpful discussions and insightful suggestions pertaining to experimental design and development of the blast injury model. We also thank Dr. Scott A. Banta for providing access to a microplate reader.	Abbott NJ, 2012, EPILEPSIA, V53, P1, DOI 10.1111/j.1528-1167.2012.03696.x; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Brown RC, 2007, BRAIN RES, V1130, P17, DOI 10.1016/j.brainres.2006.10.083; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greish K, 2007, J DRUG TARGET, V15, P457, DOI 10.1080/10611860701539584; Gumbleton M, 2001, J PHARM SCI-US, V90, P1681, DOI 10.1002/jps.1119; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Li GL, 2010, ANN BIOMED ENG, V38, P2499, DOI 10.1007/s10439-010-0023-5; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Omidi Y, 2003, BRAIN RES, V990, P95, DOI 10.1016/S0006-8993(03)03443-7; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SILL HW, 1995, AM J PHYSIOL-HEART C, V268, pH535; Simon MJ, 2011, ANN BIOMED ENG, V39, P394, DOI 10.1007/s10439-010-0144-x; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Valiyaveettil M, 2013, NEUROSCI LETT, V539, P1, DOI 10.1016/j.neulet.2013.01.028; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7	54	21	22	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					951	960		10.1089/neu.2013.3149			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200007	24372353				2021-06-18	
J	Honeybul, S; Ho, KM; Lind, CRP; Gillett, GR				Honeybul, Stephen; Ho, Kwok M.; Lind, Christopher R. P.; Gillett, Grant R.			Validation of the CRASH model in the prediction of 18-month mortality and unfavorable outcome in severe traumatic brain injury requiring decompressive craniectomy	JOURNAL OF NEUROSURGERY			English	Article						corticosteroid randomization after significant head injury prediction model; decompressive craniectomy; outcome; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL MICRODIALYSIS; PATHOPHYSIOLOGY; CORTICOSTEROIDS; CALIBRATION; PLOTS	Object. The goal in this study was to assess the validity of the corticosteroid randomization after significant head injury (CRASH) collaborators prediction model in predicting mortality and unfavorable outcome at 18 months in patients with severe traumatic brain injury (TBI) requiring decompressive craniectomy. In addition, the authors aimed to assess whether this model was well calibrated in predicting outcome across a wide spectrum of severity of TBI requiring decompressive craniectomy. Methods. This prospective observational cohort study included all patients who underwent a decompressive craniectomy following severe TBI at the two major trauma hospitals in Western Australia between 2004 and 2012 and for whom 18-month follow-up data were available. Clinical and radiological data on initial presentation were entered into the Web-based model and the predicted outcome was compared with the observed outcome. In validating the CRASH model, the authors used area under the receiver operating characteristic curve to assess the ability of the CRASH model to differentiate between favorable and unfavorable outcomes. Results. The ability of the CRASH 6-month unfavorable prediction model to differentiate between unfavorable and favorable outcomes at 18 months after decompressive craniectomy was good (area under the receiver operating characteristic curve 0.85, 95% CI 0.80-0.90). However, the model's calibration was not perfect. The slope and the intercept of the calibration curve were 1.66 (SE 0.21) and -1.11 (SE 0.14), respectively, suggesting that the predicted risks of unfavorable outcomes were not sufficiently extreme or different across different risk strata and were systematically too high (or overly pessimistic), respectively. Conclusions. The CRASH collaborators prediction model can be used as a surrogate index of injury severity to stratify patients according to injury severity. However, clinical decisions should not be based solely on the predicted risks derived from the model, because the number of patients in each predicted risk stratum was still relatively small and hence the results were relatively imprecise. Notwithstanding these limitations, the model may add to a clinician's ability to have better-informed conversations with colleagues and patients' relatives about prognosis.	[Honeybul, Stephen; Lind, Christopher R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6009, Australia; [Honeybul, Stephen; Lind, Christopher R. P.] Royal Perth Hosp, Perth, WA 6001, Australia; Univ Western Australia, Dept Intens Care Med, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Lind, Christopher R. P.] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia; [Gillett, Grant R.] Univ Otago, Dunedin Hosp, Dunedin, New Zealand; [Gillett, Grant R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010; Lind, Christopher/K-3629-2012	Ho, Kwok M./0000-0002-6705-6004; Lind, Christopher/0000-0001-9991-1725			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Cooper DJ, 2011, NEW ENGL J MED, V365, P2040; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Diedler J, 2010, NEUROCRIT CARE, V12, P313, DOI 10.1007/s12028-010-9350-5; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2011, BRIT J ANAESTH, V106, P528, DOI 10.1093/bja/aeq417; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Ho KM, 2007, J CLIN EPIDEMIOL, V60, P746, DOI 10.1016/j.jclinepi.2006.10.017; Honeybul S, 2012, J MED ETHICS, V38, P657, DOI 10.1136/medethics-2012-100672; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Hutchinson PJ, 2011, BRIT J NEUROSURG, V25, P441, DOI 10.3109/02688697.2011.583366; JENNETT B, 1975, LANCET, V1, P480; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nelson DW, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-21; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Puetz V, 2007, LANCET NEUROL, V6, P580, DOI 10.1016/S1474-4422(07)70160-6; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vergouwe Y, 2005, J CLIN EPIDEMIOL, V58, P475, DOI 10.1016/j.jclinepi.2004.06.017	35	21	21	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2014	120	5					1131	1137		10.3171/2014.1.JNS131559			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AF7OD	WOS:000334903500016	24605836				2021-06-18	
J	Jin, W; Ming, X; Hou, XS; Zhu, TS; Yuan, BY; Wang, J; Ni, HB; Jiang, J; Wang, HD; Liang, WB				Jin, Wei; Ming, Xing; Hou, Xiaoshan; Zhu, Tiansheng; Yuan, Baoyu; Wang, Jing; Ni, Hongbin; Jiang, Jian; Wang, Handong; Liang, Weibang			Protective effects of erythropoietin in traumatic spinal cord injury by inducing the Nrf2 signaling pathway activation	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Erythropoietin; nuclear factor erythroid 2-related factor 2; spinal cord injury; rats	HEME OXYGENASE-1 EXPRESSION; RESPONSE ELEMENT PATHWAY; BRAIN-INJURY; POSSIBLE INVOLVEMENT; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; RAT MODEL; DAMAGE	BACKGROUND: Erythropoietin has demonstrated neuroprotective effects against traumatic spinal cord injury (SCI), but the underlying mechanisms remain unclear. The signaling pathway of an antioxidant transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2), has been shown to play an important role in protecting SCI-induced secondary spinal cord damage. This study was undertaken to explore the effect of recombinant human erythropoietin (rhEPO) on the activation of Nrf2 signaling pathway and secondary spinal cord damage in rats after SCI. METHODS: Adultmale Sprague-Dawley rats were subjected to laminectomy at T8-T9 and compression with avascular clip. Three groups were analyzed: (1) sham group, (2) SCI group, and (3) SCI + rhEPO group (n = 16 per group). In the SCI + rhEPO group, rhEPO was administered at a dose of 5,000 IU/kg at 30 minutes after SCI. Spinal cord samples were extracted at 72 hours after the trauma. RESULTS: As a result, we found that the treatment with rhEPO markedly up-regulated the messenger RNA expressions and activities of Nrf2 signaling pathway-related agents, including Nrf2, NAD(P) H: quinone oxidoreductase 1(NQO1), and glutathione S-transferase. The administration of rhEPO also significantly ameliorated the secondary spinal cord damage, as shown by a decreased severity of locomotion deficit, spinal cord edema, and apoptosis. CONCLUSION: Post-SCI rhEPO administration induces Nrf2-mediated cytoprotective response in the injured spinal cord, and this may be a mechanism whereby rhEPO improves the outcome following SCI. (J Trauma Acute Care Surg. 2014; 76: 1228-1234. Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Jin, Wei; Ming, Xing; Hou, Xiaoshan; Zhu, Tiansheng; Yuan, Baoyu; Wang, Jing; Ni, Hongbin; Jiang, Jian; Liang, Weibang] Drum Tower Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Wang, Handong] Nanjing Univ, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Wang, Handong] Nanjing Univ, Sch Med, Jingling Hosp, Nanjing 210008, Jiangsu, Peoples R China	Liang, WB (corresponding author), Drum Tower Hosp, Dept Neurosurg, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.	hdwang_jw@163.com; njneurosurgery@163.com			Medical Science and Technology Development Foundation, Nanjing Department of Health [QYK10148]	This work was supported by a grant from Medical Science and Technology Development Foundation, Nanjing Department of Health (QYK10148).	Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cadotte DW, 2011, CLIN ORTHOP RELAT R, V469, P732, DOI 10.1007/s11999-010-1674-0; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Choo AM, 2008, EXP NEUROL, V212, P490, DOI 10.1016/j.expneurol.2008.04.038; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Genc K, 2010, CELL BIOCHEM FUNCT, V28, P197, DOI 10.1002/cbf.1639; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Jin W, 2011, J TRAUMA, V71, P680, DOI 10.1097/TA.0b013e3181f6b984; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Jin W, 2011, ANN CLIN LAB SCI, V41, P25; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kasper C., 2003, CYTOKINE HDB, VI, P149; Katavetin P, 2007, BIOCHEM BIOPH RES CO, V359, P928, DOI 10.1016/j.bbrc.2007.05.207; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Liang WB, 2010, BIOMATERIALS, V31, P8634, DOI 10.1016/j.biomaterials.2010.07.084; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Matis GK, 2009, EUR SPINE J, V18, P314, DOI 10.1007/s00586-008-0829-0; Ning B, 2011, NEUROSCI LETT, V490, P57, DOI 10.1016/j.neulet.2010.12.025; Okutan O, 2007, J CLIN NEUROSCI, V14, P364, DOI 10.1016/j.jocn.2006.01.022; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Ozturk Erdogan, 2005, Prog Neuropsychopharmacol Biol Psychiatry, V29, P922, DOI 10.1016/j.pnpbp.2005.04.028; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stammers AT, 2012, J NEUROSCI RES, V90, P782, DOI 10.1002/jnr.22820; Vitellaro-Zuccarello L, 2008, NEUROSCIENCE, V151, P452, DOI 10.1016/j.neuroscience.2007.11.004; Wang XL, 2012, J NEUROTRAUM, V29, P936, DOI 10.1089/neu.2011.1922; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yazihan N, 2008, INJURY, V39, P1408, DOI 10.1016/j.injury.2008.03.010; Zhang J, 2010, CYTOKINE, V52, P252, DOI 10.1016/j.cyto.2010.08.011; Zhu L, 2009, BRAIN RES, V1289, P96, DOI 10.1016/j.brainres.2009.07.015	35	21	24	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2014	76	5					1228	1234		10.1097/TA.0000000000000211			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AG6YA	WOS:000335563800016	24747453				2021-06-18	
J	Leunissen, I; Coxon, JP; Caeyenberghs, K; Michiels, K; Sunaert, S; Swinnen, SP				Leunissen, Inge; Coxon, James P.; Caeyenberghs, Karen; Michiels, Karla; Sunaert, Stefan; Swinnen, Stephan P.			Task switching in traumatic brain injury relates to cortico-subcortical integrity	HUMAN BRAIN MAPPING			English	Article						executive function; diffusion tensor imaging; traumatic brain injury; basal ganglia	BLUNT HEAD-INJURY; BASAL GANGLIA; COGNITIVE CONTROL; AXONAL INJURY; FOCAL LESIONS; DIFFUSION TRACTOGRAPHY; EXECUTIVE FUNCTION; FUNCTIONAL-ROLE; NEUROPSYCHOLOGY; DYSFUNCTION	Suppressing and flexibly adapting actions are a critical part of our daily behavioral repertoire. Traumatic brain injury (TBI) patients show clear impairments in this type of action control; however, the underlying mechanisms are poorly understood. Here, we tested whether white matter integrity of cortico-subcortical pathways could account for impairments in task switching, an important component of executive functioning. Twenty young adults with TBI and eighteen controls performed a switching task requiring attention to global versus local stimulus features. Diffusion weighted images were acquired and whole brain tract-based spatial statistics (TBSS) were used to explore where white matter damage was associated with switching impairment. A crossing fiber model and probabilistic tractography further identified the specific fiber populations. Relative to controls, patients with a history of TBI had a higher switch cost and were less accurate. The TBI group showed a widespread decline in fractional anisotropy (FA) throughout the TBSS skeleton. FA in the superior corona radiata showed a negative relationship with switch cost. More specifically, this involved cortico-subcortical loops with the (pre-)supplementary motor area and superior frontal gyrus. These findings provide evidence for damage to frontal-subcortical projections in TBI, which is associated with task switching impairments. Hum Brain Mapp 35:2459-2469, 2014. (c) 2013 Wiley Periodicals, Inc.	[Leunissen, Inge; Caeyenberghs, Karen; Swinnen, Stephan P.] Katholieke Univ Leuven, Movement Control & Neuroplast Res Grp, Dept Kinesiol, Grp Biomed Sci, Louvain, Belgium; [Coxon, James P.] Univ Auckland, Movement Neurosci Lab, Dept Sport & Exercise Sci, Auckland 1, New Zealand; [Michiels, Karla] Univ Hosp, Dept Phys Med & Rehabil, Louvain, Belgium; [Sunaert, Stefan] Katholieke Univ Leuven, Med Imaging Res Ctr, Grp Biomed Sci, Louvain, Belgium	Leunissen, I (corresponding author), Tervuursevest 101, B-3001 Heverlee, Belgium.	inge.leunissen@faber.kuleuven.be	Coxon, James/S-1286-2019	Coxon, James/0000-0003-2351-8489; Leunissen, Inge/0000-0002-3977-3620; Caeyenberghs, Karen/0000-0001-7009-6843	Research Program of the Research Foundation-Flanders (FWO)FWO [G.0483.10, Levenslijn G.0482.10, G.A114.11]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P7/11]; PhD fellowship of the Research Foundation-Flanders (FWO)FWO	Contract grant sponsor: Research Program of the Research Foundation-Flanders (FWO); Contract grant number: G.0483.10; Levenslijn G.0482.10; and G.A114.11; Contract grant sponsor: Interuniversity Attraction Poles program of the Belgian federal government [P7/11]; Contract grant sponsor: PhD fellowship of the Research Foundation-Flanders (FWO).	ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Bianchi L., 1895, BRAIN, V18, P497, DOI DOI 10.1093/BRAIN/18.4.497; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; BRANDT J, 1996, NEUROPSYCHOLOGICAL A, P312; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Carrera E, 2006, NEUROLOGY, V66, P1817, DOI 10.1212/01.wnl.0000219679.95223.4c; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Forstmann BU, 2011, J NEUROSCI, V31, P17242, DOI 10.1523/JNEUROSCI.0309-11.2011; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gold BT, 2010, NEUROBIOL AGING, V31, P512, DOI 10.1016/j.neurobiolaging.2008.04.005; Graybiel AM, 2005, CURR OPIN NEUROBIOL, V15, P638, DOI 10.1016/j.conb.2005.10.006; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Hellyer PJ, 2012, ANN NEUROL; Hikosaka O, 2010, TRENDS COGN SCI, V14, P154, DOI 10.1016/j.tics.2010.01.006; HOLM S, 1979, SCAND J STAT, V6, P65; Jbabdi S, 2011, BRAIN CONNECT, V1, P169, DOI 10.1089/brain.2011.0033; Jbabdi S, 2010, NEUROIMAGE, V49, P247, DOI 10.1016/j.neuroimage.2009.08.039; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Johansen-Berg H, 2010, CURR OPIN NEUROL, V23, P351, DOI 10.1097/WCO.0b013e32833b7631; Kanai R, 2011, NAT REV NEUROSCI, V12, P231, DOI 10.1038/nrn3000; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krause M, 2012, CORTEX, V48, P97, DOI 10.1016/j.cortex.2011.03.014; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lowenstein Daniel H, 2009, Ann Neurol, V66, pA7, DOI 10.1002/ana.21876; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mansfield EL, 2011, J NEUROSCI, V31, P14688, DOI 10.1523/JNEUROSCI.2390-11.2011; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Nachev P, 2008, NAT REV NEUROSCI, V9, P856, DOI 10.1038/nrn2478; Nambu A, 2002, NEUROSCI RES, V43, P111, DOI 10.1016/S0168-0102(02)00027-5; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rushworth MFS, 2004, TRENDS COGN SCI, V8, P410, DOI 10.1016/j.tics.2004.07.009; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAYLOR AE, 1995, BRAIN COGNITION, V28, P281, DOI 10.1006/brcg.1995.1258; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	66	21	21	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2014	35	5					2459	2469		10.1002/hbm.22341			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AE5FB	WOS:000334012100048	23913872	Green Published			2021-06-18	
J	Lippa, SM; Pastorek, NJ; Romesser, J; Linck, J; Sim, AH; Wisdom, NM; Miller, BI				Lippa, Sara M.; Pastorek, Nicholas J.; Romesser, Jennifer; Linck, John; Sim, Anita H.; Wisdom, Nick M.; Miller, Brian I.			Ecological Validity of Performance Validity Testing	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Performance validity test; Mild traumatic brain injury; Response bias; Veterans; Mayo-Portland Adaptability Inventory Participation Index	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; FAKE-BAD SCALE; SYMPTOM VALIDITY; NEUROPSYCHOLOGICAL ASSESSMENT; HEAD-INJURY; MMPI-2; COMPENSATION; EXAGGERATION; INCENTIVES	Performance validity tests (PVTs) have been shown to relate to neuropsychological performance, but no studies have looked at the ecological validity of these measures. Data from 131 veterans with a history of mild traumatic brain injury from a multicenter Veterans Administration consortium were examined to determine the relation between scores on a self-report version of the Mayo-Portland Adaptability Inventory Participation Index, a measure of community participation, and the Word Memory Test, a PVT. A restricted regression model, including education, age, history of loss of consciousness, cognitive measures, and a measure of symptom validity test performance, was not significantly associated with self-reported community reintegration. Adding PVT results to the restricted model, however, did significantly improve the prediction of community reintegration as PVT failure was associated with lower self-reported community participation. The results of this study indicate that PVTs may also serve as an indicator of patients' functioning in the community.	[Lippa, Sara M.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders, Boston, MA 02130 USA; [Pastorek, Nicholas J.; Wisdom, Nick M.; Miller, Brian I.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Romesser, Jennifer] George E Wahlen Dept Vet Affairs Med Ctr, Salt Lake City, UT 84148 USA; [Linck, John] Oklahoma City VA Med Ctr, Oklahoma City, OK 73104 USA; [Sim, Anita H.] Minneapolis VA Hlth Care Syst, Minneapolis, MN 55417 USA; [Wisdom, Nick M.; Miller, Brian I.] Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA	Pastorek, NJ (corresponding author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd RECL 117, Houston, TX 77030 USA.	nicholas.pastorek@va.gov			Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs; VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks [B6812C]; Minnesota Veterans Medical Research & Education Foundation	No pharmaceutical or corporate funding was used in the preparation of this manuscript or collection of data. This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; B6812C (PI-Levin HS) VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks, as well as the Minnesota Veterans Medical Research & Education Foundation.	Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone, 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2010, CLIN NEUROPSYCHOL, V24, P759, DOI 10.1080/13854041003712951; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Centers for Disease Control and Prevention, 2003, MILD TRAUM BRAIN INJ; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Diehr MC, 2003, J CLIN EXP NEUROPSYC, V25, P571, DOI 10.1076/jcen.25.4.571.13876; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P., 2005, GREENS WORD MEMORY T; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; Greiffenstein MF, 2004, CLIN NEUROPSYCHOL, V18, P573, DOI 10.1080/13854040490888512; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; LOFTUS EF, 1992, APPL COGNITIVE PSYCH, V6, P93, DOI 10.1002/acp.2350060202; Malec JF., 2005, The Mayo-Portland Adaptability Inventory; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Poyner G, 2010, PSYCHOL INJ LAW, V3, P130, DOI 10.1007/s12207-010-9076-x; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Van Dyke SA, 2010, MIL MED, V175, P947, DOI 10.7205/MILMED-D-10-00337; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X	48	21	21	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2014	29	3					236	244		10.1093/arclin/acu002			9	Psychology, Clinical; Psychology	Psychology	AG9WC	WOS:000335769700003	24681945	Bronze			2021-06-18	
J	Theus, MH; Ricard, J; Glass, SJ; Travieso, LG; Liebl, DJ				Theus, M. H.; Ricard, J.; Glass, S. J.; Travieso, L. G.; Liebl, D. J.			EphrinB3 blocks EphB3 dependence receptor functions to prevent cell death following traumatic brain injury	CELL DEATH & DISEASE			English	Article						ephrins; Eph receptors; controlled cortical impact (CCI) injury; traumatic brain injury (TBI)	SPINAL-CORD-INJURY; CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; UP-REGULATION; AXONAL REGENERATION; COMMISSURAL AXONS; WHITE-MATTER; LUNG-CANCER; ADULT CNS; RAT	Eph receptor tyrosine kinases and their membrane-bound ligands, ephrins, have a variety of roles in the developing and adult central nervous system that require direct cell-cell interactions; including regulating axon path finding, cell proliferation, migration and synaptic plasticity. Recently, we identified a novel pro-survival role for ephrins in the adult subventricular zone, where ephrinB3 blocks Eph-mediated cell death during adult neurogenesis. Here, we examined whether EphB3 mediates cell death in the adult forebrain following traumatic brain injury and whether ephrinB3 infusion could limit this effect. We show that EphB3 co-labels with microtubule-associated protein 2-positive neurons in the adult cortex and is closely associated with ephrinB3 ligand, which is reduced following controlled cortical impact (CCI) injury. In the complete absence of EphB3 (EphB3(-/-)), we observed reduced terminal deoxynucleotidyl transferase-dUTP nick end labeling (TUNEL), and functional improvements in motor deficits after CCI injury as compared with wild-type and ephrinB3(-/)-mice. We also demonstrated that EphB3 exhibits dependence receptor characteristics as it is cleaved by caspases and induces cell death, which is not observed in the presence of ephrinB3. Following trauma, infusion of pre-clustered ephrinB3-Fc molecules (eB3-Fc) into the contralateral ventricle reduced cortical infarct volume and TUNEL staining in the cortex, dentate gyrus and CA3 hippocampus of wild-type and ephrinB3(-/)-mice, but not EphB3(-/)-mice. Similarly, application of eB3-Fc improved motor functions after CCI injury. We conclude that EphB3 mediates cell death in the adult cortex through a novel dependence receptor-mediated cell death mechanism in the injured adult cortex and is attenuated following ephrinB3 stimulation.	[Theus, M. H.] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA; [Ricard, J.; Glass, S. J.; Travieso, L. G.; Liebl, D. J.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Liebl, DJ (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	dliebl@med.miami.edu		Ricard, Jerome/0000-0002-9019-4165	Miami Project to Cure Paralysis; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049545, NS30291]; Department of DefenseUnited States Department of Defense [W81XWH-05-1-0061, NS064699]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049545, F32NS064699, P50NS030291] Funding Source: NIH RePORTER	We thank Dr. Mark Henkemeyer for his generous gift of the mutant mice. We also thank Jose Mier for assistance with animal husbandry. This work was supported by the Miami Project to Cure Paralysis, NIH/NINDS NS049545 (DJL), NS30291 (DJL), Department of Defense W81XWH-05-1-0061 (DJL) and NS064699 (MHT).	Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Blits-Huizinga CT, 2004, IUBMB LIFE, V56, P257, DOI 10.1080/15216540412331270076; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Cruz-Orengo L, 2006, EXP NEUROL, V202, P421, DOI 10.1016/j.expneurol.2006.07.005; del Rio G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000463; Duffy P, 2012, P NATL ACAD SCI USA, V109, P5063, DOI 10.1073/pnas.1113953109; Figueroa JD, 2006, J NEUROSCI RES, V84, P1438, DOI 10.1002/jnr.21048; Furne C, 2009, BBA-MOL CELL RES, V1793, P231, DOI 10.1016/j.bbamcr.2008.09.009; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Howard MA, 2003, HEARING RES, V178, P118, DOI 10.1016/S0378-5955(03)00068-6; Ji XD, 2011, CANCER RES, V71, P1156, DOI 10.1158/0008-5472.CAN-10-0717; Kang JQ, 2003, MOL PHARMACOL, V64, P557, DOI 10.1124/mol.64.3.557; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Li G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1675; Liebl DJ, 2003, J NEUROSCI RES, V71, P7, DOI 10.1002/jnr.10457; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mehlen P, 2004, CELL MOL LIFE SCI, V61, P1854, DOI 10.1007/s00018-004-3467-7; Mehlen P, 2004, APOPTOSIS, V9, P37, DOI 10.1023/B:APPT.0000012120.66221.b2; Mehlen P, 1998, NATURE, V395, P801; Mendes SW, 2006, J NEUROSCI, V26, P882, DOI 10.1523/JNEUROSCI.3162-05.2006; Miranda JD, 1999, EXP NEUROL, V156, P218, DOI 10.1006/exnr.1998.7012; Omoto S, 2011, NEUROSCI RES, V69, P187, DOI 10.1016/j.neures.2010.12.004; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Rodenas-Ruano A, 2006, DEV BIOL, V292, P34, DOI 10.1016/j.ydbio.2006.01.004; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sobel RA, 2005, BRAIN PATHOL, V15, P35; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tauszig-Delamasure S, 2007, P NATL ACAD SCI USA, V104, P13361, DOI 10.1073/pnas.0701243104; Theus MH, 2010, STEM CELLS, V28, P1231, DOI 10.1002/stem.449; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Willson CA, 2003, CELL TRANSPLANT, V12, P279, DOI 10.3727/000000003108746830; Willson CA, 2002, CELL TRANSPLANT, V11, P229; Yokoyama N, 2001, NEURON, V29, P85, DOI 10.1016/S0896-6273(01)00182-9; Zhuang ZY, 2010, J NEUROSCI, V30, P16015, DOI 10.1523/JNEUROSCI.0481-10.2010	46	21	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	MAY	2014	5				SI				e1207	10.1038/cddis.2014.165			11	Cell Biology	Cell Biology	AI9DN	WOS:000337229300007	24810043	DOAJ Gold, Green Published			2021-06-18	
J	Liu, F; Liao, F; Li, W; Han, YF; Liao, DG				Liu, Feng; Liao, Fan; Li, Wei; Han, Yongfeng; Liao, Daguang			Progesterone alters Nogo-A, GFAP and GAP-43 expression in a rat model of traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						Nogo-A; GFAP; GAP-43; progesterone; traumatic brain injury	INHIBITS NEURITE OUTGROWTH; CERVICAL-SPINAL CORD; AXON REGENERATION; CONTUSION INJURY; MESSENGER-RNA; FEMALE RATS; CNS INJURY; RECOVERY; NEURONS; GROWTH	Previous studies have demonstrated that progesterone has neuroprotective effects in the central nervous system (CNS) following traumatic brain injury (TBI). Numerous cellular mechanisms have been reported to be important in the neuroprotective effects of progesterone, including the reduction of edema, inflammation and apoptosis, and the inhibition of oxidative stress. However, the effect of progesterone on neuronal protection following TBI remains unclear. The present study aimed to investigate the effects of progesterone on the expression of Nogo-A, an inhibitor of axonal growth, glial fibrillary acidic protein (GFAP), a main component of the glial scar and growth-associated protein-43 (GAP-43), a signaling molecule in neuronal growth in TBI rats. The TBI model was produced by the weight drop method. In total, 75 rats were assigned to three groups: the sham group, TBI group with vehicle treatment and TBI group with progesterone treatment. The protein expression of Nogo-A, GFAP and GAP-43 in the cortex and the hippocampus was examined by immunocytochemistry. TBI rats significantly increased the expression of Nogo-A, GFAP, and GAP-43 at 1, 3, 7 and 14 days post-injury. Progesterone significantly decreased the expression of Nogo-A and GFAP, and upregulated the GAP-43 protein. Our findings suggested that progesterone promotes neuroprotection following TBI by inhibiting the expression of Nogo-A and GFAP, and increasing GAP-43 expression.	[Liu, Feng; Liao, Fan; Liao, Daguang] Cent S Univ, Xiangya Hosp 3, Dept Neurosurg, Changsha 410013, Hunan, Peoples R China; [Li, Wei] First Hosp Changsha, Dept Neurosurg, Changsha 410013, Hunan, Peoples R China; [Han, Yongfeng] First Hosp Shijiazhuang City, Shijiazhuang 050000, Hebei, Peoples R China	Liao, DG (corresponding author), Cent S Univ, Xiangya Hosp 3, Dept Neurosurg, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	daguangliao@hotmail.com					Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Brenneman MM, 2008, BEHAV BRAIN RES, V187, P262, DOI 10.1016/j.bbr.2007.09.018; CLAYTON GH, 1994, J COMP NEUROL, V347, P470, DOI 10.1002/cne.903470312; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Deniselle MCG, 2001, CELL MOL NEUROBIOL, V21, P237, DOI 10.1023/A:1010943104315; Denny JB, 2006, CURR NEUROPHARMACOL, V4, P293, DOI 10.2174/157015906778520782; Donovan SL, 2008, SOMATOSENS MOT RES, V25, P33, DOI 10.1080/08990220701830696; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Garay L, 2009, BRAIN RES, V1283, P177, DOI 10.1016/j.brainres.2009.04.057; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hsieh SHK, 2006, J NEUROSCI, V26, P1006, DOI 10.1523/JNEUROSCI.2806-05.2006; Hughes-Davis EJ, 2005, NEUROSCIENCE, V135, P1231, DOI 10.1016/j.neuroscience.2005.07.017; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Mueller BK, 2009, BRIT J PHARMACOL, V157, P675, DOI 10.1111/j.1476-5381.2009.00220.x; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Nguyen L, 2009, MOL CELL NEUROSCI, V41, P62, DOI 10.1016/j.mcn.2009.01.011; Oertle T, 2003, J NEUROSCI, V23, P5393; Pajovic SB, 1999, GEN PHYSIOL BIOPHYS, V18, P35; Pierson RC, 2005, MOL BRAIN RES, V138, P105, DOI 10.1016/j.molbrainres.2004.10.047; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Santoro B, 2004, NEUROBIOL DIS, V17, P349, DOI 10.1016/j.nbd.2004.07.003; SchmidtKastner R, 1997, CELL TISSUE RES, V288, P225, DOI 10.1007/s004410050808; SCHREYER DJ, 1993, J NEUROBIOL, V24, P959, DOI 10.1002/neu.480240709; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Udvadia AJ, 2001, DEVELOPMENT, V128, P1175; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang Hua, 2006, Zhonghua Er Ke Za Zhi, V44, P792; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Nan-Xiang, 2007, Neurosci Bull, V23, P41, DOI 10.1007/s12264-007-0006-1; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956	46	21	21	0	15	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	APR	2014	9	4					1225	1231		10.3892/mmr.2014.1967			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	AE9RD	WOS:000334345300020	24567055	Bronze			2021-06-18	
J	Rowe, RK; Harrison, JL; O'Hara, BF; Lifshitz, J				Rowe, Rachel K.; Harrison, Jordan L.; O'Hara, Bruce F.; Lifshitz, Jonathan			Diffuse brain injury does not affect chronic sleep patterns in the mouse	BRAIN INJURY			English	Article						Chronic; concussion; diffuse; mouse; sleep; TBI	OXIDATIVE STRESS; HEAD-INJURY; DISTURBANCES; RAT; WAKEFULNESS; WAKE; FRAGMENTATION; DEPRIVATION; HIPPOCAMPUS; PERFORMANCE	Primary objective: To test if the current model of diffuse brain injury produces chronic sleep disturbances similar to those reported by TBI patients. Methods and procedures: Adult male C57BL/6 mice were subjected to moderate midline fluid percussion injury (n = 7; 1.4 atm; 6-10 minutes righting reflex time) or sham injury (n = 5). Sleep-wake activity was measured post-injury using a non-invasive, piezoelectric cage system. Chronic sleep patterns were analysed weekly for increases or decreases in percentage sleep (hypersomnia or insomnia) and changes in bout length (fragmentation). Main outcomes and results: During the first week after diffuse TBI, brain-injured mice exhibited increased mean percentage sleep and mean bout length compared to sham-injured mice. Further analysis indicated the increase in mean percentage sleep occurred during the dark cycle. Injury-induced changes in sleep, however, did not extend beyond the first week post-injury and were not present in weeks 2-5 post-injury. Conclusions: Previously, it has been shown that the midline fluid percussion model used in this study immediately increased post-traumatic sleep. The current study extended the timeline of investigation to show that sleep disturbances extended into the first week post-injury, but did not develop into chronic sleep disturbances. However, the clinical prevalence of TBI-related sleep-wake disturbances warrants further experimental investigation.	[Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Rowe, Rachel K.] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Rowe, Rachel K.; O'Hara, Bruce F.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA; [Harrison, Jordan L.; Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Program Neurosci, Phoenix, AZ USA; [O'Hara, Bruce F.] Univ Kentucky, Coll Arts & Sci, Dept Biol, Lexington, KY USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA	Lifshitz, J (corresponding author), Phoenix Childrens Hosp, Translat Neurotrauma Res Program, Barrow Neurol Inst, Phoenix, AZ 85016 USA.	jlifshitz@email.arizona.edu		Rowe, Rachel/0000-0002-9034-3159	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, R01NS065052-S, R21NS072611, KSCHIRT 10-5A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072611, R01NS065052] Funding Source: NIH RePORTER	Research reported in this publication was supported, in part, by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS065052, R01NS065052-S, R21NS072611 and KSCHIRT 10-5A. Dr O'Hara is a primary owner of Signal Solutions, LLC (Lexington, KY). All other authors had no conflicts of interest.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Bhalerao U, 2013, BRAIN INJURY, V27, P767, DOI 10.3109/02699052.2013.793396; Billiard M, 2013, SLEEP MED, V14, P462, DOI 10.1016/j.sleep.2013.01.009; BONNET MH, 1985, SLEEP, V8, P11, DOI 10.1093/sleep/8.1.11; BONNET MH, 1986, PHYSIOL BEHAV, V37, P915, DOI 10.1016/S0031-9384(86)80012-9; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chikahisa S, 2011, FRONTIERS NEUROLOGY, V2, P863; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Donohue KD, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-14; Dworak M, 2010, J NEUROSCI, V30, P9007, DOI 10.1523/JNEUROSCI.1423-10.2010; FAN L, 1995, MOL BRAIN RES, V30, P125; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; Gopalakrishnan A, 2004, SLEEP, V27, P27, DOI 10.1093/sleep/27.1.27; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Kalinchuk AV, 2003, EUR J NEUROSCI, V17, P863, DOI 10.1046/j.1460-9568.2003.02532.x; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Krueger JM, 2007, SLEEP MED CLIN, V2, P161, DOI 10.1016/j.jsmc.2007.03.003; KRUEGER JM, 1995, INT ARCH ALLERGY IMM, V106, P97, DOI 10.1159/000236827; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McShane BB, 2010, J NEUROSCI METH, V193, P321, DOI 10.1016/j.jneumeth.2010.08.024; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; REIMUND E, 1994, MED HYPOTHESES, V43, P231, DOI 10.1016/0306-9877(94)90071-X; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Rowe RK, 2014, SLEEP IN PRESS; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; STEPANSKI E, 1984, SLEEP, V7, P18, DOI 10.1093/sleep/7.1.18; Stepanski EJ, 2002, SLEEP, V25, P268, DOI 10.1093/sleep/25.3.268; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willie JT, 2012, J NEUROTRAUM, V29, P1908, DOI 10.1089/neu.2012.2404	49	21	22	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2014	28	4					504	510		10.3109/02699052.2014.888768			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AF5GL	WOS:000334741900015	24702469	Green Accepted			2021-06-18	
J	Guise, BJ; Thompson, MD; Greve, KW; Bianchini, KJ; West, L				Guise, Brian J.; Thompson, Matthew D.; Greve, Kevin W.; Bianchini, Kevin J.; West, Laura			Assessment of performance validity in the Stroop Color and Word Test in mild traumatic brain injury patients: A criterion-groups validation design	JOURNAL OF NEUROPSYCHOLOGY			English	Article							MALINGERED NEUROCOGNITIVE DYSFUNCTION; CARD SORTING TEST; INCOMPLETE EFFORT; MMPI-2; SCALE; NAN	The current study assessed performance validity on the Stroop Color and Word Test (Stroop) in mild traumatic brain injury (TBI) using criterion-groups validation. The sample consisted of 77 patients with a reported history of mild TBI. Data from 42 moderate-severe TBI and 75 non-head-injured patients with other clinical diagnoses were also examined. TBI patients were categorized on the basis of Slick, Sherman, and Iverson (1999) criteria for malingered neurocognitive dysfunction (MND). Classification accuracy is reported for three indicators (Word, Color, and Color-Word residual raw scores) from the Stroop across a range of injury severities. With false-positive rates set at approximately 5%, sensitivity was as high as 29%. The clinical implications of these findings are discussed.	[Guise, Brian J.; Greve, Kevin W.; Bianchini, Kevin J.; West, Laura] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Thompson, Matthew D.; Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA 70002 USA; [Thompson, Matthew D.] Grayson & Associates, Birmingham, AL USA	Greve, KW (corresponding author), Jefferson Neurobehav Grp, 2901 N 1-10 Serv Rd East, Metairie, LA 70002 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Boyle PA, 2004, CLIN NEUROPSYCHOL, V18, P75, DOI 10.1080/13854040490507172; British Psychological Society Professional Practice Board, 2009, ASS EFF CLIN TEST CO; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; GOLDEN CJ, 1976, J CLIN PSYCHOL, V32, P654, DOI 10.1002/1097-4679(197607)32:3<654::AID-JCLP2270320336>3.0.CO;2-Z; Golden CJ, 2002, STROOP COLOR WORD TE; Gouvier WD, 1998, CRIT ISS NE, P55; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Heaton R., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hennekens CH, 1987, EPIDEMIOLOGY MED; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P334; Larrabee G.J., 2007, ASSESSMENT MALINGERE; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J, 2000, TELEPHONY, V239, P7; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Moritz S, 2002, ARCH CLIN NEUROPSYCH, V17, P477, DOI 10.1016/S0887-6177(01)00130-5; Nigg JT, 2002, J AM ACAD CHILD PSY, V41, P59, DOI 10.1097/00004583-200201000-00012; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spieler DH, 1996, J EXP PSYCHOL HUMAN, V22, P461, DOI 10.1037/0096-1523.22.2.461; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh TN, 1996, TEST MEMORY MALINGER; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1	45	21	21	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	MAR	2014	8	1					20	33		10.1111/jnp.12002			14	Psychology; Psychology, Experimental	Psychology	AA9YD	WOS:000331448100002	23253228				2021-06-18	
J	Lin, KH; Shiao, JSC; Guo, NW; Liao, SC; Kuo, CY; Hu, PY; Hsu, JH; Hwang, YH; Guo, YL				Lin, Kuan-Han; Shiao, Judith Shu-Chu; Guo, Nai-Wen; Liao, Shih-Cheng; Kuo, Chun-Ya; Hu, Pei-Yi; Hsu, Jin-Huei; Hwang, Yaw-Huei; Guo, Yue Leon			Long-Term Psychological Outcome of Workers After Occupational Injury: Prevalence and Risk Factors	JOURNAL OF OCCUPATIONAL REHABILITATION			English	Article						Major depression; Occupational injury; Partial post-traumatic stress disorder (PPTSD); Post-traumatic stress disorder (PTSD); Risk factor	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; 1999 TAIWAN EARTHQUAKE; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; SURVIVORS; COMORBIDITY; MORBIDITY; VICTIMS; COMMUNITY	Introduction This study aimed to examine the prevalence rates of both post-traumatic stress disorder (PTSD) and major depression at 12 months in workers experiencing different types of occupational injury in Taiwan. Demographic and injury-related risk factors for psychological symptoms were also evaluated. Methods Our study candidates were injured workers in Taiwan who were hospitalized for 3 days or longer and received hospitalization benefits from the Labor Insurance program. A two-staged survey study was conducted. A self-reported questionnaire including the Brief Symptom Rating Scale and Post-traumatic Symptom Checklist was sent to workers at 12 months after injury. Those who met the criteria were recruited for the second-stage phone interview with a psychiatrist using the Mini-international Neuropsychiatric Interview (MINI). Results A total of 1,233 workers completed the questionnaire (response rate 28.0 %). Among them, 167 (13.5 %) fulfilled the criteria for the MINI interview and were invited. A total of 106 (63.5 %) completed the phone interview. The estimated rate of either PTSD/PPTSD or major depression was 5.2 %. The risk factors for psychological symptoms were female gender, lower education level, loss of consciousness after occupational injury, injury affecting physical appearance, occupational injury experience before this event, life experience before and after this injury, length of hospital stay, self-rated injury severity, and percentage of income to the family. Conclusions These results showed that occupational injury can cause long-term psychological impact in workers. Key demographic and injury characteristics may enhance the identification of at-risk occupational injured workers who would benefit from targeted screening and early intervention efforts.	[Lin, Kuan-Han; Hwang, Yaw-Huei; Guo, Yue Leon] Natl Taiwan Univ, Inst Occupat Med & Ind Hyg, Sch Publ Hlth, Taipei 10764, Taiwan; [Shiao, Judith Shu-Chu] Natl Taiwan Univ, Coll Med, Dept Nursing, Taipei, Taiwan; [Shiao, Judith Shu-Chu] NTU Hosp, Taipei, Taiwan; [Guo, Yue Leon] Natl Cheng Kung Univ, Inst Behav Med, Tainan 70101, Taiwan; [Liao, Shih-Cheng] Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan; [Kuo, Chun-Ya] Chung Shan Med Univ Hosp, Dept Psychiat, Taichung, Taiwan; [Hu, Pei-Yi; Hsu, Jin-Huei] Councils Labor Affairs, Inst Occupat Safety & Hlth, Taipei, Taiwan; [Guo, Yue Leon] Natl Taiwan Univ, Coll Med, Dept Environm & Occupat Med, Taipei 100, Taiwan; [Guo, Yue Leon] Natl Taiwan Univ, NTU Hosp, Taipei 100, Taiwan	Guo, YL (corresponding author), Natl Taiwan Univ, Coll Med, Dept Environm & Occupat Med, Rm 339,17 Xuzhou Rd, Taipei 100, Taiwan.	leonguo@ntu.edu.tw	Guo, Yue-Liang Leon/ABF-2314-2020; Lin, Kuan-Han/AAF-7584-2020; LIAO, SHIH-CHENG/C-5665-2017	GUO, Yue Leon/0000-0002-8530-4809; LIAO, SHIH-CHENG/0000-0003-4129-0879; Lin, Kuan-Han/0000-0003-2047-6025; HWANG, YAW-HUEI/0000-0003-1817-8969; SHIAO, JUDITH SHU-CHU/0000-0002-6725-0034			American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P427; Armenian HK, 2002, J URBAN HEALTH, V79, P373, DOI 10.1093/jurban/79.3.373; Asmundson GJG, 1998, J ANXIETY DISORD, V12, P57, DOI 10.1016/S0887-6185(97)00049-2; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Bland SH, 1996, PSYCHOSOM MED, V58, P18, DOI 10.1097/00006842-199601000-00004; Breslau N, 2004, PSYCHOL MED, V34, P889, DOI 10.1017/S0033291703001612; Chang CM, 2005, J NERV MENT DIS, V193, P40, DOI 10.1097/01.nmd.0000149217.67211.ab; Chen CH, 2007, COMPR PSYCHIAT, V48, P269, DOI 10.1016/j.comppsych.2006.12.003; CHEN CN, 1993, ARCH GEN PSYCHIAT, V50, P125; Chien IC, 2004, PSYCHIAT SERV, V55, P691, DOI 10.1176/appi.ps.55.6.691; Chou FHC, 2007, PSYCHIAT CLIN NEUROS, V61, P370, DOI 10.1111/j.1440-1819.2007.01688.x; COMPTON WM, 1991, AM J PSYCHIAT, V148, P1697; Dersh J, 2002, J OCCUP ENVIRON MED, V44, P459, DOI 10.1097/00043764-200205000-00014; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; GARRISON CZ, 1995, J AM ACAD CHILD PSY, V34, P1193, DOI 10.1097/00004583-199509000-00017; GOENJIAN A, 1993, BRIT J PSYCHIAT, V163, P230, DOI 10.1192/bjp.163.2.230; Goenjian AK, 2000, AM J PSYCHIAT, V157, P911, DOI 10.1176/appi.ajp.157.6.911; GOENJIAN AK, 1994, AM J PSYCHIAT, V151, P895; Guo NW, 2012, J OCCUP HLTH; Guo YJ, 2004, PSYCHIAT RES, V127, P35, DOI 10.1016/j.psychres.2004.03.009; Hsu CC, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00022; Jeon HJ, 2007, DEPRESS ANXIETY, V24, P577, DOI 10.1002/da.20270; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kuo HW, 2007, J PSYCHOSOM RES, V62, P495, DOI 10.1016/j.jpsychores.2004.11.012; Lai TJ, 2004, J PSYCHIATR RES, V38, P313, DOI 10.1016/j.jpsychires.2003.08.005; Lee M B, 1990, J Formos Med Assoc, V89, P1081; Lee MB, 1990, CHINESE PSYCHIAT, V4, P10; MacDonald HA, 2003, J OCCUP REHABIL, V13, P63, DOI 10.1023/A:1022563930482; Maes M, 2000, EUR ARCH PSY CLIN N, V250, P156, DOI 10.1007/s004060070034; MAJ M, 1989, ACTA PSYCHIAT SCAND, V79, P544, DOI 10.1111/j.1600-0447.1989.tb10301.x; Marshall RD, 2001, AM J PSYCHIAT, V158, P1467, DOI 10.1176/appi.ajp.158.9.1467; Mason S, 2002, J TRAUMA, V53, P98, DOI 10.1097/00005373-200207000-00019; Norris FH, 2002, PSYCHIATRY, V65, P240, DOI 10.1521/psyc.65.3.240.20169; North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI 10.1001/jama.282.8.755; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Pincus HA, 2001, J CLIN PSYCHIAT, V62, P5; RUBONIS AV, 1991, PSYCHOL BULL, V109, P384, DOI 10.1037/0033-2909.109.3.384; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; Wu HC, 2006, AUST NZ J PSYCHIAT, V40, P355, DOI 10.1111/j.1440-1614.2006.01802.x; Yang YK, 2003, GEN HOSP PSYCHIAT, V25, P253, DOI 10.1016/S0163-8343(03)00022-7; Zasler N. D., 2007, BRAIN INJURY MED PRI, P779	44	21	22	0	20	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1053-0487	1573-3688		J OCCUP REHABIL	J. Occup. Rehabil.	MAR	2014	24	1					1	10		10.1007/s10926-013-9431-3			10	Rehabilitation; Social Issues	Rehabilitation; Social Issues	AB8DJ	WOS:000332020000001	23504486				2021-06-18	
J	Ponsford, JL; Sinclair, KL				Ponsford, Jennie L.; Sinclair, Kelly L.			Sleep and Fatigue Following Traumatic Brain Injury	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Fatigue; Sleep disturbance; Depression; Attention; Treatment	1ST 2 YEARS; EXCESSIVE DAYTIME SLEEPINESS; WAKE DISTURBANCES; OBJECTIVE MEASURES; MENTAL FATIGUE; QUALITY INDEX; HEAD INJURY; INSOMNIA; DISORDERS; MELATONIN	This article reviews literature relating to sleep disturbance and fatigue after traumatic brain injury. It discusses the nature and prevalence of sleep disturbances associated with traumatic brain injury and the measures used to assess them. Potential causes are discussed, including damage to sleep-wake regulating centers, disruption of circadian timing of sleep, and secondary causes, such as pain, depression, and anxiety. The nature and assessment of fatigue are discussed, followed by a review of evidence regarding causes. Evidence is reviewed of the consequences of sleep disturbance and fatigue. Potential treatments of nonpharmacologic and pharmacologic natures are reviewed.	[Ponsford, Jennie L.; Sinclair, Kelly L.] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Ponsford, Jennie L.; Sinclair, Kelly L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Sci, Bldg 17,Clayton Campus, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu					Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; De La Rue-Evans L, 2013, REHABIL NURS, V38, P2, DOI 10.1002/rnj.66; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Johansson B, 2012, BRAIN INJURY, V26, P1621, DOI 10.3109/02699052.2012.700082; Johansson B, 2012, ACTA NEUROPSYCHIATR, V24, P266, DOI 10.1111/j.1601-5215.2012.00678.x; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Juengst S, 2013, ARCH PHYS MED REHAB, V94, P74, DOI 10.1016/j.apmr.2012.07.025; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leavitt VM, 2010, PM&R, V2, P332, DOI 10.1016/j.pmrj.2010.03.027; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mollayeya T, 2013, SLEEP MED REV, V17, P411, DOI 10.1016/j.smrv.2013.02.001; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Olver J, J NEUROTRAUMA; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Schnieders J, 2012, J HEAD TRAUMA REHAB, V27, P404, DOI 10.1097/HTR.0b013e3182306341; Schonberger M, J HEAD TRAUMA REHABI; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Sherer M, 2009, ARCH PHYS MED REHAB, V90, P1749, DOI 10.1016/j.apmr.2009.05.011; Sinclair K, BEHAV SLEEP MED; Sinclair K, NEUROREHABIL NEURAL; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Willmott C, J HEAD TRAU IN PRESS; Zhdanova IV, 2001, J CLIN ENDOCR METAB, V86, P4727, DOI 10.1210/jc.86.10.4727; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	76	21	22	0	24	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2014	37	1					77	+		10.1016/j.psc.2013.10.001			14	Psychiatry	Psychiatry	AD8UM	WOS:000333541200006	24529424				2021-06-18	
J	Sivak, S; Bittsansky, M; Grossmann, J; Nosal', V; Kantorova, E; Sivakova, J; Demkova, A; Hnilicova, P; Dobrota, D; Kurca, E				Sivak, S.; Bittsansky, M.; Grossmann, J.; Nosal', V.; Kantorova, E.; Sivakova, J.; Demkova, A.; Hnilicova, P.; Dobrota, D.; Kurca, E.			Clinical correlations of proton magnetic resonance spectroscopy findings in acute phase after mild traumatic brain injury	BRAIN INJURY			English	Article						Magnetic resonance spectroscopy; mild traumatic brain injury; neuropsychological testing	SPORT-RELATED CONCUSSION; MR SPECTROSCOPY; ABNORMALITIES; RECOVERY	Introduction: Standard brain magnetic resonance imaging (MRI) is typically normal in most patients after mild traumatic brain injury (MTBI). Proton magnetic resonance spectroscopy (H-1-MRS) is more sensitive to detect subtle post-traumatic changes. The aim of the study was to evaluate the clinical correlations of these changes in the acute phase (within 3 days) after MTBI. Methods: Twenty-one patients with MTBI and 22 controls were studied. Both groups underwent neuropsychological testing and single-voxel H-1-MRS examination of both frontal lobes and upper brainstem. Results: Significant decrease in NAA was found in both frontal lobes and in NAA/Cre ratio in the right frontal lobe (p < 0.05). Correlation analysis showed a correlation of NAA in the left frontal lobe with Backward Digit Span (p = 0.022) and Stroop test A (p = 0.0034) and a weak correlation with TMT B time (p = 0.046). The NAA/Cre in the right frontal lobe correlated with Stroop test A (p = 0.007) and with the total score of Digit Span (p = 0.016). Lower NAA was found in the upper brainstem (p = 0.0157) in the sub-group of patients with post-traumatic unconsciousness. Conclusions: This study found a correlation of H-1-MRS metabolite changes with cognitive decline and presence or absence of loss of consciousness in the acute phase after MTBI.	[Sivak, S.; Grossmann, J.; Nosal', V.; Kantorova, E.; Demkova, A.; Kurca, E.] Comenius Univ, Neurol Clin, Martin 03659, Slovakia; [Bittsansky, M.; Hnilicova, P.; Dobrota, D.] Comenius Univ, Dept Med Biochem, Martin 03659, Slovakia; [Sivakova, J.] Comenius Univ, Jessenius Fac Med, Clin Gynecol & Obstet, Martin 03659, Slovakia	Sivak, S (corresponding author), Comenius Univ, Jessenius Fac Med, Neurol Clin, Kollarova 2, Martin 03659, Slovakia.	sivak@jfmed.uniba.sk	Hnilicova, Petra/X-8588-2018; Nosal, Vladimir/X-7567-2018; Bittsansky, Michal/N-6680-2018; Sivak, Stefan/O-4237-2018	Nosal, Vladimir/0000-0001-6044-8294; Bittsansky, Michal/0000-0002-6372-7165; Sivak, Stefan/0000-0002-0348-3082; Hnilicova, Petra/0000-0003-1529-1675	EU resources and European social fund-ITMS [26110230067, 2012/31-UKMA-8]	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This work was supported by the grants co-financed from EU resources and European social fund-ITMS 26110230067 and 2012/31-UKMA-8.	Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Aubry M., 2002, BRIT J SPORT MED, V36, P3, DOI [DOI 10.1136/BJSM.36.1.6, 10.1136/bjsm.36.1.6]; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BROWN WJ, 1972, AM J PATHOL, V67, P41; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gonzalez PG, 2011, PM&R, V3, pS413, DOI 10.1016/j.pmrj.2011.08.536; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kuera M., 1980, TEST KONCENTRACE POZ; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; McCullough BJ, 2011, PHYS MED REH CLIN N, V22, P635, DOI 10.1016/j.pmr.2011.08.005; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; WECHSLER D, 1999, WECHSLER MEMORY SCAL; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	34	21	22	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2014	28	3					341	346		10.3109/02699052.2013.865270			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AC0RI	WOS:000332202100012	24377396				2021-06-18	
J	Agarwalla, PK; Stapleton, CJ; Ogilvy, CS				Agarwalla, Pankaj K.; Stapleton, Christopher J.; Ogilvy, Christopher S.			Craniectomy in Acute Ischemic Stroke	NEUROSURGERY			English	Article						Decompressive craniectomy; Edema; Ischemic stroke; Suboccipital decompression	MIDDLE CEREBRAL-ARTERY; AGGRESSIVE DECOMPRESSIVE SURGERY; OCCUPYING HEMISPHERIC INFARCTION; TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; CEREBELLAR INFARCTION; SURGICAL DECOMPRESSION; MALIGNANT INFARCTION; INTRACRANIAL-PRESSURE; TERRITORY INFARCTION	Anterior and posterior circulation acute ischemic stroke carries significant morbidity and mortality as a result of malignant cerebral edema. Decompressive craniectomy has evolved as a viable neurosurgical intervention in the armamentarium of treatment options for this life-threatening edema. In this review, we highlight the history of craniectomy for stroke and discuss recent data relevant to its efficacy in modern neurosurgical practice.	[Ogilvy, Christopher S.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Ogilvy, CS (corresponding author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,ACC 745, Boston, MA 02114 USA.	cogilvy@partners.org	Mingmei, Zhao/N-7178-2014	Mingmei, Zhao/0000-0002-0047-5220			Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Amar AP, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS11369; Poca MA, 2010, J NEUROSURG, V112, P648, DOI 10.3171/2009.7.JNS081677; Bardutzky J, 2007, STROKE, V38, P3084, DOI 10.1161/STROKEAHA.107.490193; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; CHEN HJ, 1992, STROKE, V23, P957, DOI 10.1161/01.STR.23.7.957; Cho DY, 2003, SURG NEUROL, V60, P227, DOI 10.1016/S0090-3019(03)00266-0; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Curry WT, 2005, NEUROSURGERY, V56, P681, DOI 10.1227/01.NEU.0000156604.41886.62; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; Doerfler A, 2001, STROKE, V32, P813, DOI 10.1161/01.STR.32.3.813; FAIRBURN B, 1956, BMJ-BRIT MED J, V1, P1335, DOI 10.1136/bmj.1.4979.1335; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9; Gerriets T, 2001, STROKE, V32, P442, DOI 10.1161/01.STR.32.2.442; Geurts M, 2013, STROKE, V44, P2506, DOI 10.1161/STROKEAHA.113.002014; GREENWOOD J, 1968, JOHNS HOPKINS MED J, V122, P254; Guresir E, 2011, J NEUROSURG, V114, P954, DOI 10.3171/2009.12.JNS091065; Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HACKE W, 1995, INTENS CARE MED, V21, P856, DOI 10.1007/BF01700973; HEROS RC, 1992, STROKE, V23, P937, DOI 10.1161/01.STR.23.7.937; Hofmeijer J, 2007, J NEUROL NEUROSUR PS, V78, P1124, DOI 10.1136/jnnp.2006.110726; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; HORNIG CR, 1994, STROKE, V25, P372, DOI 10.1161/01.STR.25.2.372; Huttner HB, 2009, LANCET NEUROL, V8, P949, DOI 10.1016/S1474-4422(09)70224-8; IVAMOTO HS, 1974, STROKE, V5, P365, DOI 10.1161/01.STR.5.3.365; Jauss M, 1999, J NEUROL, V246, P257, DOI 10.1007/s004150050344; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; Juttler E, 2009, STROKE, V40, P3060, DOI 10.1161/STROKEAHA.109.550913; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; Kasner SE, 2001, STROKE, V32, P2117, DOI 10.1161/hs0901.095719; Kidwell CS, 2003, STROKE, V34, P2729, DOI 10.1161/01.STR.0000097608.38779.CC; Kilincer C, 2005, ACTA NEUROCHIR, V147, P587, DOI 10.1007/s00701-005-0493-7; Kimberly WT, 2011, NEUROLOGY, V76, pS50, DOI 10.1212/WNL.0b013e31820c35f4; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Klein A, 2012, NEUROCRIT CARE, V16, P456, DOI 10.1007/s12028-012-9677-1; Koh MS, 2000, SURG NEUROL, V53, P225, DOI 10.1016/S0090-3019(00)00163-4; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Krieger DW, 1999, STROKE, V30, P287, DOI 10.1161/01.STR.30.2.287; Kudo Hiroshi, 2007, J Stroke Cerebrovasc Dis, V16, P259, DOI 10.1016/j.jstrokecerebrovasdis.2007.09.001; LEHRICH JR, 1970, ARCH NEUROL-CHICAGO, V22, P490, DOI 10.1001/archneur.1970.00480240010002; Leonhardt G, 2002, J NEUROL, V249, P1433, DOI 10.1007/s00415-002-0875-1; LINDGREN SO, 1956, J NEUROSURG, V13, P575, DOI 10.3171/jns.1956.13.6.0575; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MATHEW P, 1995, J NEUROL NEUROSUR PS, V59, P287, DOI 10.1136/jnnp.59.3.287; Mori K, 2001, ACTA NEUROCHIR, V143, P483, DOI 10.1007/s007010170078; Mori K, 2001, ACTA NEUROCHIR, V143, P491; Mostofi Keyvan, 2013, Surg Neurol Int, V4, P28, DOI 10.4103/2152-7806.107906; Mumert ML, 2012, J CLIN NEUROSCI, V19, P455, DOI 10.1016/j.jocn.2011.09.004; Neugebauer H, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-115; Oladunjoye AO, 2013, J NEUROSURG, V118, P776, DOI 10.3171/2013.1.JNS121475; Pfefferkorn T, 2009, STROKE, V40, P3045, DOI 10.1161/STROKEAHA.109.550871; Piedra MP, 2013, J NEUROSURG, V118, P109, DOI 10.3171/2012.10.JNS121037; Pullicino PM, 1997, NEUROLOGY, V49, P1090, DOI 10.1212/WNL.49.4.1090; Qureshi AI, 2003, CRIT CARE MED, V31, P272, DOI 10.1097/00003246-200301000-00043; Raco A, 2003, NEUROSURGERY, V53, P1061, DOI 10.1227/01.NEU.0000088766.34559.3E; Ramaswamy V, 2008, J CHILD NEUROL, V23, P889, DOI 10.1177/0883073808314960; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; Sakai K, 1998, NEUROL MED-CHIR, V38, P131, DOI 10.2176/nmc.38.131; SCARCELLA G, 1956, J NEUROSURG, V13, P366; Schwab S, 1996, NEUROLOGY, V47, P393, DOI 10.1212/WNL.47.2.393; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Shah S, 2013, WORLD NEUROSURG, V80, P126, DOI 10.1016/j.wneu.2013.06.001; Sims JR, 2009, NEUROLOGY, V72, P2104, DOI 10.1212/WNL.0b013e3181aa5329; Staykov D, 2011, STROKE, V42, P513, DOI 10.1161/STROKEAHA.110.605642; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Takeuchi S, 2013, J CLIN NEUROSCI, V20, P377, DOI 10.1016/j.jocn.2012.03.035; TANEDA M, 1982, J NEUROSURG, V57, P83, DOI 10.3171/jns.1982.57.1.0083; TOMSICK TA, 1994, AM J NEURORADIOL, V15, P16; Tsitsopoulos PP, 2011, ACTA NEUROL SCAND, V123, P345, DOI 10.1111/j.1600-0404.2010.01404.x; Tsitsopoulos PP, 2011, ACTA NEUROCHIR, V153, P2075, DOI 10.1007/s00701-011-1120-4; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANLOON J, 1993, ACTA NEUROCHIR, V122, P187, DOI 10.1007/BF01405527; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; Wagner S, 2001, J NEUROSURG, V94, P693, DOI 10.3171/jns.2001.94.5.0693; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Walz B, 2002, J NEUROL, V249, P1183, DOI 10.1007/s00415-002-0798-x; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wirtz C R, 1997, Neurosurg Focus, V2, pE3; YOUNG PH, 1982, SOUTHERN MED J, V75, P473, DOI 10.1097/00007611-198204000-00025; Zhao JW, 2012, NEUROCRIT CARE, V17, P161, DOI 10.1007/s12028-012-9703-3	90	21	21	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2014	74			1			S151	S162		10.1227/NEU.0000000000000226			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AL3VU	WOS:000339059800018	24402484				2021-06-18	
J	Dickert, NW; Mah, VA; Biros, MH; Harney, DM; Silbergleit, R; Sugarman, J; Veledar, E; Weinfurt, KP; Wright, DW; Pentz, RD				Dickert, Neal W.; Mah, Victoria A.; Biros, Michelle H.; Harney, Deneil M.; Silbergleit, Robert; Sugarman, Jeremy; Veledar, Emir; Weinfurt, Kevin P.; Wright, David W.; Pentz, Rebecca D.			Consulting Communities When Patients Cannot Consent: A Multicenter Study of Community Consultation for Research in Emergency Settings	CRITICAL CARE MEDICINE			English	Article						bioethics; community consultation; ethics; informed consent; research in emergency settings	INFORMED-CONSENT; RESUSCITATION RESEARCH; GLUCOSE CONTROL; EXCEPTION; TRIALS; CARE; EXPERIENCE; MEDICINE; NETWORK; ILL	Objectives: To assess the range of responses to community consultation efforts conducted within a large network and the impact of different consultation methods on acceptance of exception from informed consent research and understanding of the proposed study. Design: A cognitively pretested survey instrument was administered to 2,612 community consultation participants at 12 U.S. centers participating in a multicenter trial of treatment for acute traumatic brain injury. Setting: Survey nested within community consultation for a phase III randomized controlled trial of treatment for acute traumatic brain injury conducted within a multicenter trial network and using exception from informed consent. Subjects: Adult participants in community consultation events. Interventions: Community consultation efforts at participating sites. Measurements and Main Results: Acceptance of exception from informed consent in general, attitude toward personal exception from informed consent enrollment, and understanding of the study content were assessed. Fifty-four percent of participants agreed exception from informed consent enrollment was acceptable in general in the proposed study; 71% were accepting of personal exception from informed consent enrollment. Participants in interactive versus noninteractive community consultation events were more accepting of exception from informed consent in general (63% vs 49%) and personal exception from informed consent inclusion (77% vs 67%). Interactive community consultation participants had high-level recall of study content significantly more often than noninteractive consultation participants (77% vs 67%). Participants of interactive consultation were more likely to recall possible study benefits (61% vs 45%) but less likely to recall potential risks (56% vs 69%). Conclusions: Interactive community consultation methods were associated with increased acceptance of exception from informed consent and greater overall recall of study information but lower recall of risks. There was also significant variability in exception from informed consent acceptance among different interactive consultation events. These findings have important implications for institutional review board and investigators conducting exception from informed consent research and for community engagement efforts in research more generally.	[Dickert, Neal W.] Emory Univ, Div Cardiol, Rollins Sch Publ Hlth, Sch Med,Dept Epidemiol, Atlanta, GA 30322 USA; [Dickert, Neal W.] Atlanta VA Med Ctr, Atlanta, GA USA; [Mah, Victoria A.] Emory Univ, Div Cardiol, Sch Med, Emory Clin Cardiovasc Res Inst, Atlanta, GA 30322 USA; [Biros, Michelle H.] Univ Minnesota, Sch Med, Dept Emergency Med, Minneapolis, MN 55455 USA; [Harney, Deneil M.; Silbergleit, Robert] Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI USA; [Sugarman, Jeremy] Johns Hopkins Univ, Sch Med, Berman Inst Bioeth, Baltimore, MD USA; [Sugarman, Jeremy] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Veledar, Emir] Emory Univ, Sch Med, Div Cardiol, Emory Clin Cardiovasc Inst, Atlanta, GA 30322 USA; [Veledar, Emir] Baptist Hlth South Florida, Ctr Res Grants, Miami, FL USA; [Weinfurt, Kevin P.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Dept Psychol & Neurosci,Duke Clin Res Inst, Durham, NC USA; [Wright, David W.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA; [Pentz, Rebecca D.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA	Dickert, NW (corresponding author), Emory Univ, Div Cardiol, Rollins Sch Publ Hlth, Sch Med,Dept Epidemiol, Atlanta, GA 30322 USA.	njr@emory.edu	Veledar, Emir/K-2808-2012; Veledar, Emir/L-6637-2019; Wright, David/F-1209-2013	Veledar, Emir/0000-0002-3831-5433; Sugarman, Jeremy/0000-0001-7022-8332; Wright, David/0000-0002-7145-9105	ProTECT III [5U01NS062778]; Neurological Emergencies Treatment Trial Network [5U01NS056975-07]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [F32HL095358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS056975, U10NS058994, U01NS062778] Funding Source: NIH RePORTER	This project was supported, in part, by the ProTECT III (5U01NS062778) and the Neurological Emergencies Treatment Trial Network (5U01NS056975-07) awards from the National Institute of Neurological Disorders and Stroke.	Baren JM, 2007, ACAD EMERG MED, V14, P346, DOI 10.1197/j.aem.2007.01.002; Biros M, 2007, ACAD EMERG MED, V14, P344, DOI 10.1197/j.aem.2006.12.007; Biros MH, 2009, RESUSCITATION, V80, P1382, DOI 10.1016/j.resuscitation.2009.08.019; Bulger EM, 2009, ANN EMERG MED, V53, P341, DOI 10.1016/j.annemergmed.2008.07.021; Cearnal L, 2006, ANN EMERG MED, V48, P726, DOI 10.1016/j.annemergmed.2006.10.010; Clinical and Translational Science Awards Consortium, 2011, NIH PUBL, V11-7782; Contant C, 2006, CRIT CARE MED, V34, P2049, DOI 10.1097/01.CCM.0000227649.72651.F1; DeIorio NM, 2007, J EMPIR RES HUM RES, V2, P23, DOI 10.1525/jer.2007.2.3.23; Dickert N, 2005, AM J PUBLIC HEALTH, V95, P1123, DOI 10.2105/AJPH.2004.058933; Dickert NW, 2013, RESUSCITATION, V84, P1416, DOI 10.1016/j.resuscitation.2013.04.006; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Govindarajan P, 2013, ACAD EMERG MED, V20, P98, DOI 10.1111/acem.12039; Holloway KFC, 2006, AM J BIOETHICS, V6, P7, DOI 10.1080/15265160600685556; Kasner SE, 2011, ANN EMERG MED, V57, P346, DOI 10.1016/j.annemergmed.2010.07.009; Lewis RJ, 2009, ANN EMERG MED, V53, P351, DOI 10.1016/j.annemergmed.2008.09.020; Lo B, 2006, CRIT CARE MED, V34, P2236, DOI 10.1097/01.CCM.0000229632.85246.3A; McClure KB, 2003, ACAD EMERG MED, V10, P352, DOI 10.1197/aemj.10.4.352; McCullough LB, 2008, CRIT CARE MED, V36, P993, DOI 10.1097/CCM.0B013E318164E9AC; Merchant RM, 2008, ACAD EMERG MED, V15, P581, DOI 10.1111/j.1553-2712.2008.00134.x; Morrison CA, 2009, J SURG RES, V157, P115, DOI 10.1016/j.jss.2009.03.051; Nelson M, 2008, PREHOSP EMERG CARE, V12, P417, DOI 10.1080/10903120802290885; Nichol G, 2004, RESUSCITATION, V62, P3, DOI 10.1016/j.resuscitation.2004.02.013; Potter JE, 2013, INTENS CARE MED, V39, P472, DOI 10.1007/s00134-012-2732-8; Ragin DF, 2008, SOC SCI MED, V66, P1379, DOI 10.1016/j.socscimed.2007.10.022; Ramsey CA, 2011, ACAD EMERG MED, V18, P733, DOI 10.1111/j.1553-2712.2011.01102.x; Richardson LD, 2005, ACAD EMERG MED, V12, P1064, DOI 10.1197/j.aem.2005.06.018; Schmidt TA, 2003, ANN EMERG MED, V41, P79, DOI 10.1067/mem.2003.17; Silbergleit R, 2012, ACAD EMERG MED, V19, P448, DOI 10.1111/j.1553-2712.2012.01328.x; Silbergleit R, 2012, NEW ENGL J MED, V366, P591, DOI 10.1056/NEJMoa1107494; Sugarman J, 2009, RESUSCITATION, V80, P644, DOI 10.1016/j.resuscitation.2009.03.015; US Department of Health & Human Services, 2011, GUID I REV BOARDS CL; Willis G. B., 1999, COGNITIVE INTERVIEWI; Wright DW, 2008, ANN EMERG MED, V51, P355, DOI 10.1016/j.annemergmed.2007.08.021	33	21	21	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2014	42	2					272	280		10.1097/CCM.0b013e3182a27759			9	Critical Care Medicine	General & Internal Medicine	291WS	WOS:000329863400022	24145834	Green Accepted			2021-06-18	
J	Jeffcote, T; Hinzman, JM; Jewell, SL; Learney, RM; Pahl, C; Tolias, C; Walsh, DC; Hocker, S; Zakrzewska, A; Fabricius, ME; Strong, AJ; Hartings, JA; Boutelle, MG				Jeffcote, Toby; Hinzman, Jason M.; Jewell, Sharon L.; Learney, Robert M.; Pahl, Clemens; Tolias, Christos; Walsh, Daniel C.; Hocker, Sara; Zakrzewska, Agnieszka; Fabricius, Martin E.; Strong, Anthony J.; Hartings, Jed A.; Boutelle, Martyn G.			Detection of Spreading Depolarization with Intraparenchymal Electrodes in the Injured Human Brain	NEUROCRITICAL CARE			English	Article						Cortical spreading depolarization; Traumatic brain injury; Secondary brain injury	UNITED-STATES; ISCHEMIA; DEPRESSION; STROKE; VASOSPASM	Spreading depolarization events following ischemic and traumatic brain injury are associated with poor patient outcome. Currently, monitoring these events is limited to patients in whom subdural electrodes can be placed at open craniotomy. This study examined whether these events can be detected using intra-cortical electrodes, opening the way for electrode insertion via burr hole. Animal work was carried out on adult Sprague-Dawley rats in a laboratory setting to investigate the feasibility of recording depolarization events. Subsequently, 8 human patients requiring craniotomy for traumatic brain injury or aneurysmal subarachnoid hemorrhage were monitored for depolarization events in an intensive care setting with concurrent strip (subdural) and depth (intra-parenchymal) electrode recordings. (1) Depolarization events can be reliably detected from intra-cortically placed electrodes. (2) A reproducible slow potential change (SPC) waveform morphology was identified from intra-cortical electrodes on the depth array. (3) The depression of cortical activity known to follow depolarization events was identified consistently from both intra-cortical and sub-cortical electrodes on the depth array. Intra-parenchymally sited electrodes can be used to consistently identify depolarization events in humans. This technique greatly extends the capability of monitoring for spreading depolarization events in injured patients, as electrodes can be sited without the need for craniotomy. The method provides a new investigative tool for the evaluation of the contribution of these events to secondary brain injury in human patients.	[Jeffcote, Toby; Tolias, Christos; Walsh, Daniel C.; Zakrzewska, Agnieszka] Kings Coll Hosp London, Dept Neurosurg, London, England; [Jeffcote, Toby; Learney, Robert M.; Boutelle, Martyn G.] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England; [Hinzman, Jason M.; Hartings, Jed A.] Univ Cincinnati, UC Coll Med, Inst Neurosci, Dept Neurosurg, Cincinnati, OH USA; [Jewell, Sharon L.] Kings Coll Hosp London, Dept Neurophysiol, London, England; [Pahl, Clemens] Kings Coll Hosp London, Dept Intens Care Med, London, England; [Hocker, Sara] Mayo Clin, Div Crit Care Neurol, Rochester, MN USA; [Fabricius, Martin E.] Rigshosp, Dept Clin Neurophysiol, DK-2100 Copenhagen, Denmark; [Strong, Anthony J.] Kings Coll London, Inst Psychiat, Dept Acad Neurosurg, London, England	Boutelle, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England.	jed.hartings@uc.edu; m.boutelle@imperial.ac.uk	Walsh, Daniel/AAZ-1875-2020; Jeffcote, Toby/AAP-7945-2021	Learney, Robert/0000-0003-2870-6120; Hartings, Jed/0000-0001-8583-3471	Wellcome Trust/Department of Health Healthcare Innovation Challenge Fund [HICF-1010-080]; U.S. Army CDMRP PH/TBI Research Program [W81XWH-08-2-0016]; Mayfield Education and Research Foundation	This work was funded in part by a Wellcome Trust/Department of Health Healthcare Innovation Challenge Fund (Grant HICF-1010-080) and in part by the U.S. Army CDMRP PH/TBI Research Program (contract number W81XWH-08-2-0016) and the Mayfield Education and Research Foundation. We thank Chi Leng Leong for help with the figures. All animal work was carried out at the University of Cincinnati. All human clinical investigations were carried out at Kings College Hospital, London, UK.	Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROPHYSIOL, V102, P2563, DOI 10.1152/jn.00345.2009; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Kudo C, 2008, EXP NEUROL, V212, P201, DOI 10.1016/j.expneurol.2008.03.026; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2005, CRIT CARE MED, V33, P2147, DOI 10.1097/01.CCM.0000179029.95415.51; Stuart RM, 2010, NEUROCRIT CARE, V13, P355, DOI 10.1007/s12028-010-9414-6; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Valadka AB, 2007, NEUROSURGERY, V61, P203, DOI 10.1227/01.NEU.0000255497.26440.01; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Woitzik J, 2012, J CEREBR BLOOD F MET, V32, P203, DOI 10.1038/jcbfm.2011.169	29	21	21	0	13	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2014	20	1					21	31		10.1007/s12028-013-9938-7			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AB2RI	WOS:000331639400004	24343564				2021-06-18	
J	Chen, Y; Garcia, GE; Huang, W; Constantini, S				Chen, Yun; Garcia, Gregory E.; Huang, Wei; Constantini, Shlomi			The involvement of secondary neuronal damage in the development of neuropsychiatric disorders following bra insults	FRONTIERS IN NEUROLOGY			English	Article						neuropsychiatric disorders; secondary neuronal damage; brain insults; traumatic brain injury; neurodegenerative diseases; clinical manifestations; histomotphology; pathophysiology		Neuropsychiatric disorders are one of the leading causes of disability worldwide and affect the health of billions of people. Previous publications have demonstrated that neuropsychiatric disorders can cause histomorphological damage in particular regions of the brain. By using a clinical symptom-comparing approach, 55 neuropsychiatric signs or symptoms related usually to 14 types of acute and chronic brain insults were identified and categorized in the present study. Forty percent of the 55 neuropsychiatric signs and symptoms have been found to be commonly shared by the 14 brain insults. A meta-analysis supports existence of the same neuropsychiatric signs or symptoms in all brain insults. The results suggest that neuronal damage might be occurring in the same or similar regions or structures of the brain. Neuronal cell death, neural loss, and axonal degeneration in some parts of the brain (the limbic system, basal ganglia system, brainstem, cerebellum, and cerebral cortex) might be the histomorphological basis that is responsible for the neuropsychiatric symptom clusters. These morphological alterations may be the result of secondary neuronal damage (a cascade of progressive neural injury and neuronal cell death that is triggered by the initial insult). Secondary neuronal damage causes neuronal cell death and neural injury in not only the initial injured site but also remote brain regions. It may be a major contributor to subsequent neuropsychiatric disorders following brain insults.	[Chen, Yun] BrightstarTech Inc, 23102 Meadow Mist Rd, Clarksburg, MD 20871 USA; [Garcia, Gregory E.] US Army Med Res Inst Chem Def, Aberdeen, MD USA; [Huang, Wei] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Constantini, Shlomi] Tel Aviv Univ, Tel Aviv Med Ctr, Dana Childrens Hosp, Dept Pediat Neurosurg, IL-69978 Tel Aviv, Israel	Chen, Y (corresponding author), BrightstarTech Inc, 23102 Meadow Mist Rd, Clarksburg, MD 20871 USA.	yun.chen@brightstartechinc.com					Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Agrawal SK, 1996, J NEUROSCI, V16, P545; Ahn WK, 2009, COGNITIVE SCI, V33, P147, DOI 10.1111/j.1551-6709.2009.01008.x; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; [Anonymous], 2000, Bull World Health Organ, V78, P413; [Anonymous], 2012, NSDUH SER H, V44; Arnone D, 2009, BRIT J PSYCHIAT, V195, P194, DOI 10.1192/bjp.bp.108.059717; Bellows J G, 1979, Compr Ther, V5, P3; BERENT S, 1988, ANN NEUROL, V23, P541, DOI 10.1002/ana.410230603; Blair RJR, 2013, NAT REV NEUROSCI, V14, P786, DOI 10.1038/nrn3577; Bolla KI, 2002, NEUROLOGY, V59, P1337, DOI 10.1212/01.WNL.0000031422.66442.49; Bolla KI, 1999, J NEUROPSYCH CLIN N, V11, P361, DOI 10.1176/jnp.11.3.361; Bolla KI, 2000, NEUROLOGY, V54, P2285, DOI 10.1212/WNL.54.12.2285; Bolla KI, 2005, NEUROIMAGE, V26, P480, DOI 10.1016/j.neuroimage.2005.02.012; Bolla KI, 1998, NEUROLOGY, V51, P1532, DOI 10.1212/WNL.51.6.1532; BOTHE HW, 1984, ACTA NEUROPATHOL, V64, P37, DOI 10.1007/BF00695604; BOWEN DM, 1989, P NATL ACAD SCI USA, V86, P9504, DOI 10.1073/pnas.86.23.9504; Bruce M, 2011, CHILD CARE HLTH DEV, V37, P244, DOI 10.1111/j.1365-2214.2010.01164.x; Buttner A, 2011, NEUROPATH APPL NEURO, V37, P118, DOI 10.1111/j.1365-2990.2010.01131.x; Busser J, 1998, J NEUROSCI, V18, P2801; Buttner A, 2005, DRUG ALCOHOL DEPEN, V79, P63, DOI 10.1016/j.drugalcdep.2004.12.010; Chen J, 2003, J BIOL CHEM, V278, P28089, DOI 10.1074/jbc.M303094200; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen Y, 2013, J NEUROPSYCH CLIN N, V25, P103, DOI 10.1176/appi.neuropsych.12030058; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00119; Chen Y, 2012, NEUROTOXICOLOGY, V33, P391, DOI 10.1016/j.neuro.2012.03.011; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Chio A, 2011, J NEUROL NEUROSUR PS, V82, P740, DOI 10.1136/jnnp.2010.235952; CLEMENT JG, 1993, NEUROTOXICOLOGY, V14, P485; CONSTANTINI S, 1993, NEUROSURGERY, V33, P204, DOI 10.1097/00006123-199308000-00004; Conti AC, 1998, J NEUROSCI, V18, P5663; Cullen J, 1996, Nurs N Z, V2, P20; Darke S, 2008, DRUG ALCOHOL REV, V27, P253, DOI 10.1080/09595230801923702; de Courten-Myers GM, 1999, J NEUROPATH EXP NEUR, V58, P217; de la Torre R, 2004, THER DRUG MONIT, V26, P137, DOI 10.1097/00007691-200404000-00009; de Oliveira Sheila Knupp Feitosa, 2010, Curr Infect Dis Rep, V12, P103, DOI 10.1007/s11908-010-0082-7; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; ECKERT WG, 1991, AM J FOREN MED PATH, V12, P119, DOI 10.1097/00000433-199106000-00007; Farrugia D, 2009, J MENT HLTH COUNS, V31, P189, DOI 10.17744/mehc.31.3.f2l6hk4834p82483; Fattore L, 2009, NEUROPSYCHOPHARMACOL, V34, P1091, DOI 10.1038/npp.2008.43; Fine EJ, 2002, SEMIN NEUROL, V22, P375, DOI 10.1055/s-2002-36759; Fix James D., 2008, BOARD REV SERIES, P274; FRACKOWIAK RSJ, 1991, CIBA F SYMP, V163, P235; Frank MG, 2012, J NEUROIMMUNOL, V252, P33, DOI 10.1016/j.jneuroim.2012.07.010; Franzen CA, 2009, MOL CANCER RES, V7, P1045, DOI 10.1158/1541-7786.MCR-09-0017; Garcia-Campayo J, 2009, CURR OPIN PSYCHIATR, V22, P224, DOI 10.1097/YCO.0b013e3283252d43; Gil-Bea FJ, 2005, NEUROSCI LETT, V375, P37, DOI 10.1016/j.neulet.2004.10.062; Gold Carl A, 2008, Expert Rev Neurother, V8, P1879, DOI 10.1586/14737175.8.12.1879; Gordon HW, 2002, PSYCHONEUROENDOCRINO, V27, P115, DOI 10.1016/S0306-4530(01)00039-7; Grossberg S, 2012, NEURAL NETWORKS, V27, P1, DOI [10.1016/j.neunet.2012.09.017, 10.1016/j.neunet.2011.10.011]; HILL DL, 1981, PHYSIOL BEHAV, V26, P269, DOI 10.1016/0031-9384(81)90022-6; Holleran L, 2014, NEUROPSYCHOPHARMACOL, V39, P944, DOI 10.1038/npp.2013.294; Hyman S, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P605; Ishizawa Y, 2000, J PHARMACOL EXP THER, V293, P845; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Jarquin-Valdivia AA, 2004, ARCH NEUROL-CHICAGO, V61, P1800, DOI 10.1001/archneur.61.11.1800; Jellinger KA, 2009, NEUROPSYCHIATRIE, V23, P115; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORDAN WP, 1983, BEHAV NEUROSCI, V97, P710, DOI 10.1037/0735-7044.97.5.710; Katzer A, 2012, J ABNORM PSYCHOL, V121, P530, DOI 10.1037/a0026536; Kawana N, 2001, Mil Med, V166, P23; Kempton MJ, 2008, ARCH GEN PSYCHIAT, V65, P1017, DOI 10.1001/archpsyc.65.9.1017; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KHAN T, 1993, EUR J CELL BIOL, V62, P406; Kinderman P, 2005, HARVARD REV PSYCHIAT, V13, P206, DOI 10.1080/10673220500243349; KING DJ, 1994, ACTA PSYCHIAT SCAND, V89, P53, DOI 10.1111/j.1600-0447.1994.tb05833.x; Kreipe Richard E, 2006, Adolesc Med Clin, V17, P1; Kronish IM, 2012, STROKE, V43, P2192, DOI 10.1161/STROKEAHA.112.655209; Lim HK, 2013, INT PSYCHOGERIATR, V25, P1929, DOI 10.1017/S104161021300149X; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lopez-Neblina F, 2005, J INVEST SURG, V18, P335, DOI 10.1080/08941930500328862; Malenka R.C, 2009, MOL NEUROPHARMACOLOG; Martino D, 2009, J PSYCHOSOM RES, V67, P547, DOI 10.1016/j.jpsychores.2009.07.004; Matthews PR, 2012, J AFFECT DISORDERS, V137, P125, DOI 10.1016/j.jad.2011.10.043; MERRILL JE, 1991, FASEB J, V5, P2391; Miczek KA, 2008, PHARMACOL THERAPEUT, V120, P102, DOI 10.1016/j.pharmthera.2008.07.006; Montoya A, 2006, J PSYCHIATR NEUROSCI, V31, P21; Moretti Germana, 2008, Clin Pract Epidemiol Ment Health, V4, P13, DOI 10.1186/1745-0179-4-13; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morimoto K, 1996, P NATL ACAD SCI USA, V93, P13345, DOI 10.1073/pnas.93.23.13345; Nagatsu T, 2007, J NEURAL TRANSM-SUPP, P113; NAIL RL, 1976, DRUG ALCOHOL DEPEN, V1, P429, DOI 10.1016/0376-8716(76)90007-7; Neumann MA, 2005, ANESTH ANALG, V100, P1003, DOI 10.1213/01.ANE.0000146516.35921.1A; Neyeloff Jeruza L, 2012, BMC Res Notes, V5, P52, DOI 10.1186/1756-0500-5-52; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Ostman M, 2002, BRIT J PSYCHIAT, V181, P494, DOI 10.1192/bjp.181.6.494; Oyama O, 2007, AM FAM PHYSICIAN, V76, P1333; Parent A, 1995, CARPENTERS HUMAN NEU, P186; Passarotti AM, 2011, PSYCHOPHARMACOLOGY, V216, P485, DOI 10.1007/s00213-011-2243-2; Paulsen JS, 2013, J NEUROL NEUROSUR PS, V84, P1233, DOI 10.1136/jnnp-2013-305114; Phukan J, 2007, LANCET NEUROL, V6, P994, DOI 10.1016/S1474-4422(07)70265-X; Pier MPBI, 2004, J AFFECT DISORDERS, V81, P73, DOI 10.1016/j.jad.2003.08.002; Planeta CS, 2013, BRAZ J MED BIOL RES, V46, P909, DOI 10.1590/1414-431X20133379; Pucak Michele L, 2007, Dialogues Clin Neurosci, V9, P125; PULLIAM L, 1994, ADV NEUROIMMUNOL, V4, P195, DOI 10.1016/S0960-5428(06)80257-3; REINVANG I, 1991, ACTA NEUROL SCAND, V83, P289, DOI 10.1111/j.1600-0404.1991.tb04703.x; RICHARDS M, 1993, ANN NEUROL, V33, P267, DOI 10.1002/ana.410330307; Roth J, 2012, J NEUROSURG-PEDIATR, V10, P168, DOI 10.3171/2012.6.PEDS11451; Rothwell JC, 2011, J INTEGR NEUROSCI, V10, P303, DOI 10.1142/S0219635211002798; Rutter M, 2005, BRIT J PSYCHIAT, V186, P4, DOI 10.1192/bjp.186.1.4; Samii A, 2004, LANCET, V363, P1783, DOI 10.1016/S0140-6736(04)16305-8; Satterthwaite TD, 2010, AM J PSYCHIAT, V167, P418, DOI 10.1176/appi.ajp.2009.09060808; SCHAUMBURG HH, 1987, NEUROLOGY, V37, P276, DOI 10.1212/WNL.37.2.276; Schmidt CW, 2007, ENVIRON HEALTH PERSP, V115, pA404, DOI 10.1289/ehp.115-a404; Schulden JD, 2012, PSYCHIAT CLIN N AM, V35, P411, DOI 10.1016/j.psc.2012.03.007; Seifert T, 2011, PROG NEUROBIOL, V95, P406, DOI 10.1016/j.pneurobio.2011.09.008; Sharma R, 2010, ALCOHOL CLIN EXP RES, V34, P813, DOI 10.1111/j.1530-0277.2010.01153.x; Sherer R, 2002, PSYCHIAT TIMES, VXIX, P1; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; SLEDZIK PS, 1994, AM J PHYS ANTHROPOL, V94, P269, DOI 10.1002/ajpa.1330940210; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Snyder Howard, 1993, Journal of Emergency Medicine, V11, P253, DOI 10.1016/0736-4679(93)90042-6; Stein DJ, 2008, CNS SPECTRUMS, V13, P379, DOI 10.1017/S1092852900016540; STERN Y, 1993, ARCH NEUROL-CHICAGO, V50, P1040, DOI 10.1001/archneur.1993.00540100035011; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Strakowski SM, 2012, BIPOLAR DISORD, V14, P313, DOI 10.1111/j.1399-5618.2012.01022.x; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; SUMITOMO I, 1967, TOHOKU J EXP MED, V91, P13, DOI 10.1620/tjem.91.13; SZYMUSIAK R, 1986, EXP NEUROL, V94, P598, DOI 10.1016/0014-4886(86)90240-2; Takada Y, 2006, J BIOL CHEM, V281, P5612, DOI 10.1074/jbc.M507213200; Takei Y, 2013, J PSYCHIATR RES, V47, P1581, DOI 10.1016/j.jpsychires.2013.07.029; Tang Dean G, 1996, Pathol Oncol Res, V2, P117; Tilson HA, 1998, TOXICOL LETT, V103, P631, DOI 10.1016/S0378-4274(98)00271-9; Tiraboschi P, 2004, NEUROLOGY, V62, P1984, DOI 10.1212/01.WNL.0000129697.01779.0A; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van der Stelt M, 2003, EUR J PHARMACOL, V480, P133, DOI 10.1016/j.ejphar.2003.08.101; Vertes RP, 2006, NEUROSCIENCE, V142, P1, DOI 10.1016/j.neuroscience.2006.06.027; Walker FO, 2007, LANCET, V369, P218, DOI 10.1016/S0140-6736(07)60111-1; Ward RJ, 2009, ALCOHOL ALCOHOLISM, V44, P128, DOI 10.1093/alcalc/agn100; WHO, 2001, WORLD HLTH REPORT 20; WIDLOCHER DJ, 1983, PSYCHIAT CLIN N AM, V6, P27; Willard SL, 2013, BIOL PSYCHIAT, V74, P890, DOI 10.1016/j.biopsych.2013.03.013; Wilson JMB, 2003, NEUROMOL MED, V3, P105, DOI 10.1385/NMM:3:2:105; Wolf U, 2009, J NEUROPSYCH CLIN N, V21, P245, DOI 10.1176/appi.neuropsych.21.3.245; Yoshihara Yujiro, 2008, Ann Gen Psychiatry, V7, P25, DOI 10.1186/1744-859X-7-25; YOUNG AB, 1993, RES P ARNMD, V71, P175; Young AB, 1997, REV NEUROL-FRANCE, V153, P496; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	139	21	21	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								22	10.3389/fneur.2014.00022			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QW	WOS:000209629300022	24653712	DOAJ Gold, Green Published			2021-06-18	
J	DeFazio, MV; Rammo, RA; Robles, JR; Bramlett, HM; Dietrich, WD; Bullock, MR				DeFazio, Michael V.; Rammo, Richard A.; Robles, Jaime R.; Bramlett, Helen M.; Dietrich, W. Dalton; Bullock, M. Ross			The Potential Utility of Blood-Derived Biochemical Markers as Indicators of Early Clinical Trends Following Severe Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Biomarkers; D-dimer; MMP-9; S-100B; Trauma; Traumatic brain injury	NEUROTROPHIC PROTEIN S100B; D-DIMER; HEAD-INJURY; OUTCOME PREDICTION; ISCHEMIC-STROKE; S-100B PROTEIN; SERUM S-100B; DAMAGE; BARRIER; MATRIX-METALLOPROTEINASE-9	OBJECTIVE: Severe traumatic brain injury (TBI) is a dynamic neuropathologic process in which a substantial proportion of patients die within the first 48-hours. The assessment of injury severity and prognosis are of primary concern in the initial management of severe TBI. Supplemental testing that aids in the stratification of patients at high risk for deterioration may significantly improve posttraumatic management in the acute setting. METHODS: This retrospective study assessed the utility of both single-marker and multimarker models as predictive indicators of acute clinical status after severe TBI. Forty-four patients who sustained severe TBI (admission Glasgow Coma Scale [GCS] score <= 8) were divided into two cohorts according to a dichotomized clinical outcome at 72 hours after admission: Poor status (death or GCS score <= 8) and improved status (GCS score improved to >8). Threshold values for clinical status prediction were calculated for serum S-100B, matrix metalloproteinase-9, and plasma D-dimer, upon admission and at 24 hours after TBI by the use of receiver operating characteristic analysis. Performance characteristics of these single-marker predictors were compared with those derived from a multimarker logistic regression analysis. RESULTS: Biomarkers with the greatest predictive value for poor status at 72 hours included serum S-100B on admission, as well as plasma D-dimer and serum S-100B at 24 hours, for which, associations were strongly significant. Multimarker analysis indicated no substantial improvement in prediction accuracy over the best single predictors during this time frame. CONCLUSION: In conjunction with other clinical, physical, and radiologic evidence, blood-derived biochemical markers may serve to enhance prediction of early clinical trends after severe TBI.	[DeFazio, Michael V.; Rammo, Richard A.; Bramlett, Helen M.; Dietrich, W. Dalton; Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Robles, Jaime R.] Virginia Commonwealth Univ, Sch Pharm, Richmond, VA USA	Bullock, MR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.	rbullock@med.miami.edu			Miami Project to Cure Paralysis, State of Florida; Ryder Trauma Center, Neurosurgical Intensive Care Unit at Jackson Memorial Hospital, and Biosite, Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133] Funding Source: NIH RePORTER	This work was supported by The Miami Project to Cure Paralysis, State of Florida, Ryder Trauma Center, Neurosurgical Intensive Care Unit at Jackson Memorial Hospital, and Biosite, Inc.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Asahi M, 2001, J NEUROSCI, V21, P7724; Barber M, 2004, STROKE, V35, P1421, DOI 10.1161/01.STR.0000126890.63512.41; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Delgado P, 2006, NEUROLOGY, V67, P94, DOI 10.1212/01.wnl.0000223349.97278.e0; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Dunn KL, 2002, J AM COLL CARDIOL, V40, P1475, DOI 10.1016/S0735-1097(02)02172-1; Gibler W Brian, 2003, Rev Cardiovasc Med, V4 Suppl 4, pS47; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Juvela S, 2006, STROKE, V37, P1451, DOI 10.1161/01.STR.0000221710.55467.33; Kai HK, 1998, J AM COLL CARDIOL, V32, P368, DOI 10.1016/S0735-1097(98)00250-2; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kuo JR, 2007, EUR J NEUROL, V14, P1073, DOI 10.1111/j.1468-1331.2007.01908.x; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Montaner J, 2008, STROKE, V39, P2280, DOI 10.1161/STROKEAHA.107.505354; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Williams MT, 2003, CRIT CARE CLIN, V19, P185, DOI 10.1016/S0749-0704(02)00048-9; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807	44	21	24	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2014	81	1					151	158		10.1016/j.wneu.2013.01.015			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AC2DV	WOS:000332309200046	23313262	Green Accepted			2021-06-18	
J	Middleton, A; Fritz, SL; Liuzzo, DM; Newman-Norlund, R; Herter, TM				Middleton, Addie; Fritz, Stacy L.; Liuzzo, Derek M.; Newman-Norlund, Roger; Herter, Troy M.			Using clinical and robotic assessment tools to examine the feasibility of pairing tDCS with upper extremity physical therapy in patients with stroke and TBI: A consideration-of-concept pilot study	NEUROREHABILITATION			English	Article						tDCS; stroke; TBI; upper extremity; rehabilitation	DIRECT-CURRENT STIMULATION; INDUCED MOVEMENT THERAPY; FUGL-MEYER ASSESSMENT; BRAIN-STIMULATION; IMPACT SCALE-16; MOTOR RECOVERY; REHABILITATION; PEOPLE; RELIABILITY; NORMS	BACKGROUND: Transcranial direct current stimulation (tDCS) may provide a safe, non-invasive technique for modulating neural excitability during neurorehabilitation. OBJECTIVE: 1) Assess feasibility and potential effectiveness of tDCS as an adjunct to standard upper extremity (UE) physical therapy (PT) for motor impairments resulting from neurological insult. 2) Determine sustainability of improvements over a six month period. METHODS: Five participants with chronic neurologic insult (stroke or traumatic brain injury > 6 months prior) completed 24 sessions (40 minutes, three times/week) of UE-PT combined with bihemispheric tDCS delivered at 1.5 mA over the motor cortex during the first 15 minutes of each PT session. Outcomes were assessed using clinical (UE Fugl-Meyer, Purdue Pegboard, Box and Block, Stroke Impact Scale) and robotic (unimanual and bimanual motor control) measures. Change in scores and associated effects sizes from Pre-test to Post-test and a six month Follow-up were calculated for each participant and group as a whole. RESULTS: Scores on UE Fugl-Meyer, Box and Block, Purdue Pegboard, Stroke Impact Scale, and robotic measures improved from Pre- to Post-test. Improvements on UE Fugl-Meyer, Box and Block, and robotic measures were largely sustained at six months. CONCLUSIONS: Combining bihemispheric tDCS with UE-PT in individuals with neurological insult warrants further investigation.	[Middleton, Addie; Fritz, Stacy L.; Liuzzo, Derek M.; Newman-Norlund, Roger; Herter, Troy M.] Univ S Carolina, Dept Exercise Sci, Div Rehabil Sci, Columbia, SC 29208 USA	Middleton, A (corresponding author), Univ S Carolina, Dept Exercise Sci, Phys Therapy Program, 921 Assembly St,3rd Floor PHRC, Columbia, SC 29208 USA.	middletj@email.sc.edu		Middleton, Addie/0000-0001-8970-3703	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM081740] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM081740, T32 GM081740] Funding Source: Medline		Ang KK, 2012, IEEE ENG MED BIO, P4128, DOI 10.1109/EMBC.2012.6346875; Balasubramanian Sivakumar, 2012, Am J Phys Med Rehabil, V91, pS255, DOI 10.1097/PHM.0b013e31826bcdc1; Birkenmeier RL, 2010, NEUROREHAB NEURAL RE, V24, P620, DOI 10.1177/1545968310361957; Bolognini N, 2011, NEUROREHAB NEURAL RE, V25, P819, DOI 10.1177/1545968311411056; Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Chang JJ, 2007, ARCH PHYS MED REHAB, V88, P1332, DOI 10.1016/j.apmr.2007.07.016; Chen HM, 2009, NEUROREHAB NEURAL RE, V23, P435, DOI 10.1177/1545968308331146; Coderre AM, 2010, NEUROREHAB NEURAL RE, V24, P528, DOI 10.1177/1545968309356091; Debert CT, 2012, J NEUROL PHYS THER, V36, P58, DOI 10.1097/NPT.0b013e318254bd4f; DESROSIERS J, 1995, DISABIL REHABIL, V17, P217, DOI 10.3109/09638289509166638; DICKSTEIN R, 1986, PHYS THER, V66, P1233, DOI 10.1093/ptj/66.8.1233; Dobkin BH, 2009, NEUROREHAB NEURAL RE, V23, P197, DOI 10.1177/1545968309331863; Duncan PW, 2003, NEUROLOGY, V60, P291, DOI 10.1212/01.WNL.0000041493.65665.D6; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; Einav O, 2011, TOP STROKE REHABIL, V18, P587, DOI 10.1310/tsr18s01-587; Feng WW, 2013, TOP STROKE REHABIL, V20, P68, DOI 10.1310/tsr2001-68; Fulk GD, 2010, TOP STROKE REHABIL, V17, P477, DOI 10.1310/tsr1706-477; Fusco A, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/837595; Giacobbe V, 2013, NEUROREHABILITATION, V33, P49, DOI 10.3233/NRE-130927; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; Khedr EM, 2013, NEUROREHAB NEURAL RE, V27, P592, DOI 10.1177/1545968313484808; Kidgell DJ, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-64; Kimberley TJ, 2010, J REHABIL RES DEV, V47, P851, DOI 10.1682/JRRD.2010.02.0019; Lang Catherine E, 2007, J Neurol Phys Ther, V31, P3; Lefebvre S, 2013, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00343; Lefebvre S, 2014, NEUROREHAB NEURAL RE, V28, P100, DOI 10.1177/1545968313478485; Lin JH, 2009, PHYS THER, V89, P840, DOI 10.2522/ptj.20080285; Lin KC, 2010, J REHABIL RES DEV, V47, P563, DOI 10.1682/JRRD.2009.09.0155; Lindenberg R, 2010, NEUROLOGY, V75, P2176, DOI 10.1212/WNL.0b013e318202013a; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Nair DG, 2011, RESTOR NEUROL NEUROS, V29, P411, DOI 10.3233/RNN-2011-0612; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nowak DA, 2009, NEUROREHAB NEURAL RE, V23, P641, DOI 10.1177/1545968309336661; O'Shea J, 2014, NEUROIMAGE, V85, P924, DOI 10.1016/j.neuroimage.2013.05.096; Ochi M, 2013, J REHABIL MED, V45, P137, DOI 10.2340/16501977-1099; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; Page SJ, 2012, PHYS THER, V92, P791, DOI 10.2522/ptj.20110009; Pellicciari MC, 2013, NEUROIMAGE, V83, P569, DOI 10.1016/j.neuroimage.2013.06.076; Russo R, 2013, BRAIN STIMUL, V6, P946, DOI 10.1016/j.brs.2013.05.009; Scott SH, 2011, J REHABIL RES DEV, V48, P335, DOI 10.1682/JRRD.2010.04.0057; Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266; Tyryshkin K, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-47; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Wang Q, 2011, J REHABIL MED, V43, P619, DOI 10.2340/16501977-0819; Wu DY, 2013, ARCH PHYS MED REHAB, V94, P1, DOI 10.1016/j.apmr.2012.07.022; Zollo L, 2011, EUR J PHYS REHAB MED, V47, P223	48	21	22	1	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2014	35	4					741	754		10.3233/NRE-141178			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AW4HK	WOS:000346241600012	25323084	Green Accepted			2021-06-18	
J	Sun, LQ; Gao, JL; Cui, CM; Cui, Y; Jing, XB; Zhao, MM; Wang, YC; Tian, YX; Wang, KJ; Cui, JZ				Sun, Li-Qian; Gao, Jun-Ling; Cui, Chang-Men; Cui, Ying; Jing, Xiao-Bin; Zhao, Man-Man; Wang, Yong-Chao; Tian, Yan-Xia; Wang, Kai-Jie; Cui, Jian-Zhong			Astrocytic p-connexin 43 regulates neuronal autophagy in the hippocampus following traumatic brain injury in rats	MOLECULAR MEDICINE REPORTS			English	Article						CX43; CBX; autophagy; LC3; TBI	GAP-JUNCTION COMMUNICATION; INDUCED CELL-DEATH; CEREBRAL-ISCHEMIA; COGNITIVE IMPAIRMENT; GLUTAMATE TRANSPORT; MODEL; MICE; GLIA; PROTEIN; PATHOPHYSIOLOGY	Gap junctions are conductive channels formed by membrane proteins termed connexins, which permit the intercellular exchange of metabolites, ions and small molecules. Previous data demonstrated that traumatic brain injury (TBI) activates autophagy and increases microtubule-associated protein 1 light chain 3 (LC3) immunostaining predominantly in neurons. Although previous studies have identified several extracellular factors that modulate LC3 expression, knowledge of the regulatory network controlling LC3 in health and disease remains incomplete. The aim of the present study was to assess whether gap junctions control the in vivo expression of LC3 in TBI. Using a modified weight-drop device, adult male Sprague-Dawley rats (weight, 350-375 g) were subjected to TBI. Phosphorylated gap junction protein levels and LC3-II levels were quantified using western blot analysis. The spatial distribution of immunoreactivity for phosphorylated connexin 43 (p-CX43) and LC3-II was analyzed by immunofluorescence. The results showed that p-CX43 expression in the hippocampus reached a maximum level 6 h following injury. In addition, the immunoreactivity of p-CX43 was localized in the astrocytes surrounding pyramidal neurons. The LC3-II protein content remained at high levels 24 h following injury. Double immunolabeling demonstrated that LC3-II dots colocalized with the hippocampus pyramidal neurons. Furthermore, inhibition of p-CX43 reduced TBI-induced autophagy, according to western blot analysis. As astrocytic gap junction coupling is affected in various forms of brain injury, the results suggest that point gap junctions/connexins are important regulators of autophagy in the hippocampal neurons following TBI.	[Sun, Li-Qian; Cui, Chang-Men; Cui, Jian-Zhong] Hebei Med Univ, Dept Surg, Shijiazhuang 050017, Hebei, Peoples R China; [Gao, Jun-Ling; Zhao, Man-Man; Wang, Yong-Chao; Tian, Yan-Xia] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Cui, Ying; Wang, Kai-Jie; Cui, Jian-Zhong] Tangshan Gongren Hosp, Tangshan 063000, Hebei, Peoples R China; [Jing, Xiao-Bin] Tangshan Ophthalmol Hosp, Tangshan 063000, Hebei, Peoples R China	Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China.	cjz20000@tom.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2012401071]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (grant no. H2012401071).	Anderson CM, 2000, GLIA, V32, P1; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Chew SSL, 2010, EXP NEUROL, V225, P250, DOI 10.1016/j.expneurol.2010.07.014; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cotrina ML, 2009, PURINERG SIGNAL, V5, P223, DOI 10.1007/s11302-009-9138-2; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; Dermietzel R, 1998, GLIA, V24, P1, DOI 10.1002/(SICI)1098-1136(199809)24:1<1::AID-GLIA1>3.0.CO;2-A; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; Giaume C, 1997, GLIA, V21, P114; Hansson E, 2000, NEUROCHEM INT, V37, P317, DOI 10.1016/S0197-0186(00)00033-4; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Khorasani MZ, 2009, PAK J PHARM SCI, V22, P349; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Magistretti PJ, 2000, BRAIN RES, V886, P108, DOI 10.1016/S0006-8993(00)02945-0; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meijer AJ, 2009, CRIT REV CL LAB SCI, V46, P210, DOI 10.1080/10408360903044068; Milad MR, 2004, BEHAV NEUROSCI, V118, P389, DOI 10.1037/0735-7044.118.2.389; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Nakase T, 2003, STROKE, V34, P1987, DOI 10.1161/01.STR.0000079814.72027.34; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Pozuelo-Rubio M, 2011, CELL DEATH DIFFER, V18, P479, DOI 10.1038/cdd.2010.118; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Rozental R, 2001, METH MOL B, V154, P447; Song SX, 2012, MOL MED REP, V327, P331; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	40	21	21	0	12	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	JAN	2014	9	1					77	82		10.3892/mmr.2013.1787			6	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	AA0KJ	WOS:000330783700013	24220542	Bronze			2021-06-18	
J	Wilkins, SA; Shannon, CN; Brown, ST; Vance, EH; Ferguson, D; Gran, K; Crowther, M; Wellons, JC; Johnston, JM				Wilkins, Sara Anne; Shannon, Chevis N.; Brown, Steven T.; Vance, E. Haley; Ferguson, Drew; Gran, Kimberly; Crowther, Marshall; Wellons, John C., III; Johnston, James M., Jr.			Establishment of a multidisciplinary concussion program: impact of standardization on patient care and resource utilization Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; standardization; implementation analysis; trauma	SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; MANAGEMENT; STATEMENT	Object. Recent legislation and media coverage have heightened awareness of concussion in youth sports. Previous work by the authors' group defined significant variation of care in management of children with concussion. To address this variation, a multidisciplinary concussion program was established based on a uniform management protocol, with emphasis on community outreach via traditional media sources and the Internet. This retrospective study evaluates the impact of standardization of concussion care and resource utilization before and after standardization in a large regional pediatric hospital center. Methods. This retrospective study included all patients younger than 18 years of age evaluated for sports-related concussion between January 1, 2007, and December 31, 2011. Emergency department, sports medicine, and neurosurgery records were reviewed. Data collected included demographics, injury details, clinical course, Sports Concussion Assessment Tool-2 (SCAT2) scores, imaging, discharge instructions, and referral for specialty care. The cohort was analyzed comparing patients evaluated before and after standardization of care. Results. Five hundred eighty-nine patients were identified, including 270 before standardization (2007-2011) and 319 after standardization (2011-2012). Statistically significant differences (p < 0.0001) were observed between the 2 groups for multiple variables: there were more girls, more first-time concussions, fewer initial presentations to the emergency department, more consistent administration of the SCAT2, and more consistent supervision of return to play and return to think after adoption of the protocol. Conclusions. A combination of increased public awareness and legislation has led to a 5-fold increase in the number of youth athletes presenting for concussion evaluation at the authors' center. Establishment of a multidisciplinary clinic with a standardized protocol resulted in significantly decreased institutional resource utilization and more consistent concussion care for this growing patient population.	[Wilkins, Sara Anne; Brown, Steven T.; Johnston, James M., Jr.] Univ Alabama Birmingham, Dept Neurosurg, Div Neurosurg, Birmingham, AL 35233 USA; [Ferguson, Drew; Crowther, Marshall] Univ Alabama Birmingham, Dept Orthoped Surg, Div Sports Med, Birmingham, AL 35233 USA; [Gran, Kimberly] Vanderbilt Univ, Dept Emergency Med, Nashville, TN 37235 USA; [Shannon, Chevis N.; Vance, E. Haley; Wellons, John C., III] Vanderbilt Univ, Dept Neurosurg, Nashville, TN 37235 USA	Johnston, JM (corresponding author), Univ Alabama Birmingham, Childrens Alabama, Div Neurosurg, Sect Pediat Neurosurg, 1600 7th Ave S,Lowder 400, Birmingham, AL 35233 USA.	james.johnston@childrensal.org		Johnston, James/0000-0001-8564-1808			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Comstock RD, 2006, HIGH SCH RIO REPORTI; Comstock RD, 2011, HIGH SCH RIO REPORTI; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Toporek B, 2013, ED WEEK	15	21	21	0	14	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JAN	2014	13	1					82	89		10.3171/2013.10.PEDS13241			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	281GM	WOS:000329088000014	24236447				2021-06-18	
J	Kramer, AH; Zygun, DA; Doig, CJ; Zuege, DJ				Kramer, Andreas H.; Zygun, David A.; Doig, Christopher J.; Zuege, Danny J.			Incidence of neurologic death among patients with brain injury: a cohort study in a Canadian health region	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							HOSPITAL CARDIAC-ARREST; POTENTIAL ORGAN DONORS; NEUROCRITICAL CARE; HEAD-INJURIES; UNITED-STATES; CASE-FATALITY; MORTALITY; DONATION; STROKE; DIAGNOSIS	Background: Hospital mortality has decreased over time for critically ill patients with various forms of brain injury. We hypothesized that the proportion of patients who progress to neurologic death may have also decreased. Methods: We performed a prospective cohort study involving consecutive adult patients with traumatic brain injury, subarachnoid hemorrhage, intracerebral hemorrhage or anoxic brain injury admitted to regional intensive care units in southern Alberta over a 10.5-year period. We used multivariable logistic regression to adjust for patient age and score on the Glasgow Coma Scale at admission, and to assess whether the proportion of patients who progress to neurologic death has changed over time. Results: The cohort consisted of 2788 patients. The proportion of patients who progressed to neurologic death was 8.1% at the start of the study period, and the adjusted odds of progressing to neurologic death decreased over the study period (odds ratio [OR] per yr 0.92, 95% confidence interval [CI] 0.87-0.98, p = 0.006). This change was most pronounced among patients with traumatic brain injury (OR per yr 0.87, 95% CI 0.78-0.96, p = 0.005); there was no change among patients with anoxic injury (OR per yr 0.96, 95% CI 0.85-1.09, p = 0.6). A review of the medical records suggests that missed cases of neurologic death were rare ( 0.5% of deaths). Interpretation: The proportion of patients with brain injury who progress to neurologic death has decreased over time, especially among those with head trauma. This finding may reflect positive developments in the prevention and care of brain injury. However, organ donation after neurologic death represents the major source of organs for transplantation. Thus, these findings may help explain the relatively stagnant rates of deceased organ donation in some regions of Canada, which in turn has important implications for the care of patients with end-stage organ failure.	[Kramer, Andreas H.; Zygun, David A.; Doig, Christopher J.; Zuege, Danny J.] Univ Calgary, Foothills Med Ctr, Dept Crit Care Med, Calgary, AB, Canada; [Kramer, Andreas H.; Zygun, David A.] Univ Calgary, Foothills Med Ctr, Dept Clin Neurosci, Calgary, AB, Canada; [Doig, Christopher J.] Univ Calgary, Foothills Med Ctr, Dept Community Hlth Sci, Calgary, AB, Canada; [Zuege, Danny J.] Univ Calgary, Foothills Med Ctr, Dept Med, Calgary, AB, Canada	Kramer, AH (corresponding author), Univ Calgary, Foothills Med Ctr, Dept Crit Care Med, Calgary, AB, Canada.	andreas.kramer@albertahealthservices.ca	Doig, Christopher/AAC-7949-2020; Zuege, Danny J./L-5368-2017	Doig, Christopher/0000-0002-8576-9139; Zuege, Danny J./0000-0003-2033-5847			Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; [Anonymous], 2010, ALB TRAFF COLL STAT; Barnieh L, 2006, CAN J ANAESTH, V53, P727, DOI 10.1007/BF03021633; Beaulieu MA, 1999, CAN J NEUROL SCI, V26, P64; Canadian Institute for Health Information, 2013, E STAT REP TRANSPL W; Canadian Institute for Health Information, 2006, HEAD INJ CAN DEC CHA; Canadian Institute for Health Information, CAN ORG REPL REG ANN; Champagne P, 2012, CAN J CARDIOL, V28, pS161, DOI 10.1016/j.cjca.2012.07.186; Cloutier R, 2006, CAN J ANAESTH, V53, P716, DOI 10.1007/BF03021631; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; de Keizer NF, 2000, INTENS CARE MED, V26, P577, DOI 10.1007/s001340051207; Dennis J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2674; Downie J, 2009, CAN J ANAESTH, V56, P851, DOI 10.1007/s12630-009-9130-x; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Haider AH, 2012, J TRAUMA ACUTE CARE, V73, P1340, DOI 10.1097/TA.0b013e318270bbca; Hernadez-Alejandro R, 2011, CAN J ANESTH, V58, P599, DOI 10.1007/s12630-011-9511-9; JENNETT B, 1975, LANCET, V1, P480; Jochmans I, 2012, TRANSPL INT, V25, P857, DOI 10.1111/j.1432-2277.2012.01510.x; Karkhaneh M, 2011, ACCIDENT ANAL PREV, V43, P788, DOI 10.1016/j.aap.2010.10.026; Kitamura T, 2012, CIRCULATION, V126, P2834, DOI 10.1161/CIRCULATIONAHA.112.109496; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kramer AH, 2013, CAN J ANESTH, V60, P966, DOI 10.1007/s12630-013-0001-0; Kramer AH, 2011, NEUROCRIT CARE, V14, P329, DOI 10.1007/s12028-011-9530-y; Kumar R, 2012, ANAESTH INTENS CARE, V40, P517, DOI 10.1177/0310057X1204000319; Lindsay MP, 2009, TRACKING HEART DIS S; Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3; Mayo NE, 2007, NEUROLOGY, V68, P1122, DOI 10.1212/01.wnl.0000258664.12423.4c; Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rea TD, 2003, CIRCULATION, V108, P1196, DOI 10.1161/01.CIR.0000087403.24467.A4; Russell K, 2010, CAN MED ASSOC J, V182, P333, DOI 10.1503/cmaj.091080; Saidi RF, 2012, WORLD J SURG, V36, P2909, DOI 10.1007/s00268-012-1748-0; Shahpori R, 2009, ST HEAL T, V143, P81, DOI 10.3233/978-1-58603-979-0-81; Shemie SD, 2006, CAN MED ASSOC J, V175, pS1, DOI 10.1503/cmaj.060895; Shemie SD, 2006, CAN MED ASSOC J, V174, pS1, DOI 10.1503/cmaj.045142; Stewart TC, 2003, J TRAUMA, V54, P266, DOI 10.1097/01.TA.0000038699.47295.2D; Summers DM, 2010, TRANSPLANTATION, V90, P1506, DOI 10.1097/TP.0b013e3182007b33; Tenn-Lyn NA, 2006, CAN J ANAESTH, V53, P732, DOI 10.1007/BF03021634; Transport Canada, 2010, CAN MOT VEH TRAFF CO; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wijdicks EFM, 2004, CRIT CARE MED, V32, P2332, DOI 10.1097/01.CCM.0000145949.34618.E1	42	21	21	0	1	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	DEC 10	2013	185	18					E838	E845		10.1503/cmaj.130271			8	Medicine, General & Internal	General & Internal Medicine	264TC	WOS:000327902600015	24167208	Green Published, Bronze			2021-06-18	
J	Kurtz, P; Claassen, J; Schmidt, JM; Helbok, R; Hanafy, KA; Presciutti, M; Lantigua, H; Connolly, ES; Lee, KW; Badjatia, N; Mayer, SA				Kurtz, Pedro; Claassen, Jan; Schmidt, J. Michael; Helbok, Raimund; Hanafy, Khalid A.; Presciutti, Mary; Lantigua, Hector; Connolly, E. Sander; Lee, Kiwon; Badjatia, Neeraj; Mayer, Stephan A.			Reduced Brain/Serum Glucose Ratios Predict Cerebral Metabolic Distress and Mortality After Severe Brain Injury	NEUROCRITICAL CARE			English	Article						Brain injury; Coma; Cerebral microdialysis; Glucose; Metabolism; Glucose transport	INTENSIVE INSULIN THERAPY; LACTATE/PYRUVATE RATIO; COMBINED MICRODIALYSIS; COMATOSE PATIENTS; GLYCEMIC CONTROL; BLOOD-GLUCOSE; HYPERGLYCEMIA; IMPACT; PRESSURE; HYPERGLYCOLYSIS	The brain is dependent on glucose to meet its energy demands. We sought to evaluate the potential importance of impaired glucose transport by assessing the relationship between brain/serum glucose ratios, cerebral metabolic distress, and mortality after severe brain injury. We studied 46 consecutive comatose patients with subarachnoid or intracerebral hemorrhage, traumatic brain injury, or cardiac arrest who underwent cerebral microdialysis and intracranial pressure monitoring. Continuous insulin infusion was used to maintain target serum glucose levels of 80-120 mg/dL (4.4-6.7 mmol/L). General linear models of logistic function utilizing generalized estimating equations were used to relate predictors of cerebral metabolic distress (defined as a lactate/pyruvate ratio [LPR] a parts per thousand yen 40) and mortality. A total of 5,187 neuromonitoring hours over 300 days were analyzed. Mean serum glucose was 133 mg/dL (7.4 mmol/L). The median brain/serum glucose ratio, calculated hourly, was substantially lower (0.12) than the expected normal ratio of 0.40 (brain 2.0 and serum 5.0 mmol/L). In addition to low cerebral perfusion pressure (P = 0.05) and baseline Glasgow Coma Scale score (P < 0.0001), brain/serum glucose ratios below the median of 0.12 were independently associated with an increased risk of metabolic distress (adjusted OR = 1.4 [1.2-1.7], P < 0.001). Low brain/serum glucose ratios were also independently associated with in-hospital mortality (adjusted OR = 6.7 [1.2-38.9], P < 0.03) in addition to Glasgow Coma Scale scores (P = 0.029). Reduced brain/serum glucose ratios, consistent with impaired glucose transport across the blood brain barrier, are associated with cerebral metabolic distress and increased mortality after severe brain injury.	[Kurtz, Pedro; Claassen, Jan; Schmidt, J. Michael; Helbok, Raimund; Hanafy, Khalid A.; Presciutti, Mary; Lantigua, Hector; Connolly, E. Sander; Lee, Kiwon; Badjatia, Neeraj; Mayer, Stephan A.] Columbia Univ Coll Phys & Surg, Milstein Hosp Ctr 8, Dept Neurol, Neurol Intens Care Unit, New York, NY 10032 USA	Mayer, SA (corresponding author), Columbia Univ Coll Phys & Surg, Milstein Hosp Ctr 8, Dept Neurol, Neurol Intens Care Unit, 177 Ft Washington Ave, New York, NY 10032 USA.	sam14@columbia.edu	Helbok, Raimund/AAA-8361-2021; Claassen, Jan/AAA-5451-2020	Schmidt, J. Michael/0000-0001-8141-2944	Charles A. Dana Foundation; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024156]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024156] Funding Source: NIH RePORTER	This work was supported in part by a grant from the Charles A. Dana Foundation. The project described was also supported by Grant UL1 RR024156 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. The authors were solely responsible for the study design, data collection, analysis and interpretation of the data, writing the manuscript, and in the decision to submit for publication.	Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Badjatia N, 2009, CRIT CARE MED, V37, P1893, DOI 10.1097/CCM.0b013e31819fffd3; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Choi HA, 2011, NEUROCRIT CARE, V14, P389, DOI 10.1007/s12028-010-9474-7; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Helbok R, 2010, NEUROCRIT CARE, V12, P317, DOI 10.1007/s12028-009-9327-4; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Ko SB, 2011, STROKE, V42, P3087, DOI 10.1161/STROKEAHA.111.623165; Magnoni S, 2012, CRIT CARE MED, V40, P1785, DOI 10.1097/CCM.0b013e318246bd45; MAHER F, 1994, FASEB J, V8, P1003; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Nilsson OG, 2006, NEUROSURGERY, V59, P521, DOI 10.1227/01.NEU.0000227521.58701.E5; Nordmark J, 2009, ACTA ANAESTH SCAND, V53, P289, DOI 10.1111/j.1399-6576.2008.01885.x; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pan W, 2001, BIOMETRICS, V57, P529, DOI 10.1111/j.0006-341X.2001.00529.x; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; PRENTICE RL, 1991, BIOMETRICS, V47, P825, DOI 10.2307/2532642; Qaseem A, 2011, ANN INTERN MED, V154, P260, DOI 10.7326/0003-4819-154-4-201102150-00007; Schlenk F, 2008, INTENS CARE MED, V34, P1200, DOI 10.1007/s00134-008-1044-5; Schlenk F, 2008, CRIT CARE, V12, DOI 10.1186/cc6776; Schmidt JM, 2010, STROKE, V42, P1531; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Zazulia AR, 2009, STROKE, V40, P1638, DOI 10.1161/STROKEAHA.108.536037	47	21	22	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2013	19	3					311	319		10.1007/s12028-013-9919-x			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	257OB	WOS:000327393200009	24081837				2021-06-18	
J	McCormick, CL; Yoash-Gantz, RE; McDonald, SD; Campbell, TC; Tupler, LA				McCormick, Cortney L.; Yoash-Gantz, Ruth E.; McDonald, Scott D.; Campbell, Thomas C.; Tupler, Larry A.			Performance on the Green Word Memory Test Following Operation Enduring Freedom/Operation Iraqi Freedom-Era Military Service: Test Failure is Related to Evaluation Context	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Symptom validity tests; Effort; Neuropsychology; Military veterans; Traumatic brain injury; Posttraumatic stress disorder; Major depressive disorder; Service connection	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SYMPTOM VALIDITY TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; MENTAL-HEALTH PROBLEMS; POSTCONCUSSIVE SYMPTOMS; COMPLAINTS INVENTORY; DEPRESSIVE SYMPTOMS; PREFRONTAL CORTEX	This study investigates prior reports of high neuropsychological symptom validity test (SVT) failure rates in post-deployed Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) active and veteran military personnel, using a large, multi-site sample (N 214) drawn from three levels of the Department of Defense/Department of Veterans Affairs (VA) Polytrauma System of Care. The sample failure rate and its relationship to research versus dual research/clinical context of evaluation were examined, in addition to secondary variables explored in prior studies. Results yielded an overall failure rate of 25, lower than prior reports describing OEF/OIF active-duty and veteran military personnel. Findings also supported the hypothesis that SVT failure rates would differ by context (dual research). Participants with traumatic brain injury (TBI) failed more frequently than those without TBI in the dual context but not in the research context. Secondary analyses revealed that failure rates increased in the presence of depression, posttraumatic stress disorder, and male sex but were unrelated to active versus veteran military status, service connection (SC) or percentage of SC, age, education, or ethnicity. Further research is required to elucidate the underpinnings of these findings in light of the limited literature and variability between OEF/OIF-related SVT studies, as well as the substantial diagnostic and treatment implications for VA.	[McCormick, Cortney L.; Yoash-Gantz, Ruth E.; McDonald, Scott D.; Campbell, Thomas C.; Tupler, Larry A.] Midatlantic Mental Illness Res Educ & Clin Ctr, Durham, NC USA; [McCormick, Cortney L.; Yoash-Gantz, Ruth E.] Hefner Vet Affairs Med Ctr, Salisbury, NC USA; [Yoash-Gantz, Ruth E.] Wake Forest Univ, Dept Psychiat & Behav Sci, Winston Salem, NC 27109 USA; [McDonald, Scott D.; Campbell, Thomas C.] McGuire Vet Affairs Med Ctr, Richmond, VA USA; [McDonald, Scott D.; Campbell, Thomas C.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [McDonald, Scott D.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Tupler, Larry A.] Durham Vet Affairs Med Ctr, Durham, NC USA; [Tupler, Larry A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA	McCormick, CL (corresponding author), James A Haley VAMC, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	cortney.mccormick@va.gov			Department of Veterans Affairs Mid-Atlantic Mental Illness Research, Education, and Clinical Center (MIRECC) for the Study of Post-Deployment Mental Health; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and TreatmentUS Department of Veterans Affairs; Department of Veterans Affairs Rehabilitation Research and Development Career Development Award-2US Department of Veterans Affairs [1IK2RX000703-01]	Preparation of this manuscript was supported in part by the Department of Veterans Affairs Mid-Atlantic Mental Illness Research, Education, and Clinical Center (MIRECC) for the Study of Post-Deployment Mental Health, the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, and a Department of Veterans Affairs Rehabilitation Research and Development Career Development Award-2 (1IK2RX000703-01 to S.D.M.).	Allen MD, 2007, BRAIN INJURY, V21, P1425, DOI 10.1080/02699050701769819; Ansari TL, 2011, BIOL PSYCHOL, V86, P337, DOI 10.1016/j.biopsycho.2010.12.013; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P725, DOI 10.1093/arclin/acs071; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P101, DOI 10.1093/arclin/acr081; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Aupperle RL, 2012, ARCH GEN PSYCHIAT, V69, P360, DOI 10.1001/archgenpsychiatry.2011.1539; Barnes A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006626; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Boyko EJ, 2000, AM J EPIDEMIOL, V151, P307, DOI 10.1093/oxfordjournals.aje.a010207; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brinkmann K, 2009, INT J PSYCHOPHYSIOL, V74, P250, DOI 10.1016/j.ijpsycho.2009.09.009; Browndyke JN, 2008, BRAIN INJURY, V22, P481, DOI 10.1080/02699050802084894; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Burriss L, 2008, DEPRESS ANXIETY, V25, P149, DOI 10.1002/da.20291; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 2010, AM J PHYS MED REHAB, V89, P688, DOI 10.1097/PHM.0b013e3181e722ad; Cote Murray J, 2007, Health Care Manag Sci, V10, P253, DOI 10.1007/s10729-007-9018-7; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dedert EA, 2009, J PSYCHIATR RES, V43, P830, DOI 10.1016/j.jpsychires.2009.01.004; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Everaert J, 2012, CLIN PSYCHOL REV, V32, P413, DOI 10.1016/j.cpr.2012.04.003; First M., 1995, STRUCTURED CLIN INTE; Foland-Ross LC, 2013, PSYCHOL SCI, V24, P334, DOI 10.1177/0956797612457380; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Frueh BC, 2007, AM J PUBLIC HEALTH, V97, P2143, DOI 10.2105/AJPH.2007.115436; Golding H, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0081; Gorissen M, 2005, SCHIZOPHR RES, V78, P199, DOI 10.1016/j.schres.2005.02.016; Green, 2004, GREENS MED SYMPTOM V; Green P., 2005, GREENS WORD MEMORY T; Green P., 2007, ASSESSMENT FEIGNED C; Guez J, 2011, J TRAUMA STRESS, V24, P260, DOI 10.1002/jts.20635; Hampton T, 2011, JAMA-J AM MED ASSOC, V306, P477, DOI 10.1001/jama.2011.1092; Heilbronner RL, 2010, CLIN NEUROPSYCHOL, V24, P1267, DOI 10.1080/13854046.2010.526785; Hess TM, 2012, J GERONTOL B-PSYCHOL, V67, P447, DOI 10.1093/geronb/gbr129; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoerger M, 2012, COGNITION EMOTION, V26, P1098, DOI 10.1080/02699931.2011.631985; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Jones A, 2012, CLIN NEUROPSYCHOL, V26, P790, DOI 10.1080/13854046.2012.693202; Kahneman D., 1973, ATTENTION EFFORT; Karatekin C, 2010, SCHIZOPHRENIA BULL, V36, P1167, DOI 10.1093/schbul/sbp035; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Kessels RPC, 2007, CLIN NEUROL NEUROSUR, V109, P323, DOI 10.1016/j.clineuro.2006.12.009; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Mackin RS, 2012, INT J GERIATR PSYCH, V27, P637, DOI 10.1002/gps.2763; Manning JR, 2012, J NEUROSCI, V32, P8871, DOI 10.1523/JNEUROSCI.5321-11.2012; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCormick C. L., 2011, 5 ANN VHA MENT HLTH; McCormick C. L., 2009, MCCORMICK TBI UNPUB; McHugh PR, 2007, J ANXIETY DISORD, V21, P211, DOI 10.1016/j.janxdis.2006.09.003; Mernoff Stephen T, 2010, Med Health R I, V93, P16; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Nelson N. W., 2012, J INT NEUROPSYCH SOC, V18, P1, DOI DOI 10.1017/S1355617711001548; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Raposo A, 2009, NEUROPSYCHOLOGIA, V47, P2261, DOI 10.1016/j.neuropsychologia.2008.10.024; Riviere LA, 2011, BRIT J PSYCHIAT, V198, P136, DOI 10.1192/bjp.bp.110.084863; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Rosen GM, 2007, J ANXIETY DISORD, V21, P201, DOI 10.1016/j.janxdis.2006.09.011; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruocco AC, 2008, CLIN NEUROPSYCHOL, V22, P547, DOI 10.1080/13854040701336444; Russo AC, 2012, ARCH CLIN NEUROPSYCH, V27, P840, DOI 10.1093/arclin/acs090; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2011, J HEAD TRAUMA REHAB, V26, P454, DOI 10.1097/HTR.0b013e3181ff393c; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Telling AL, 2010, BRAIN COGNITION, V73, P203, DOI 10.1016/j.bandc.2010.05.004; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Tylee Andre, 2005, Prim Care Companion J Clin Psychiatry, V7, P167; Van Dyke SA, 2010, MIL MED, V175, P947, DOI 10.7205/MILMED-D-10-00337; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004	118	21	21	0	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2013	28	8					808	823		10.1093/arclin/act050			16	Psychology, Clinical; Psychology	Psychology	262FC	WOS:000327718700008	23877970	Bronze			2021-06-18	
J	Anderson, MI; Simpson, GK; Morey, PJ				Anderson, Malcolm I.; Simpson, Grahame K.; Morey, Peter J.			The Impact of Neurobehavioral Impairment on Family Functioning and the Psychological Well-Being of Male Versus Female Caregivers of Relatives With Severe Traumatic Brain Injury: Multigroup Analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregiver gender; family functioning; neurobehavioral impairment; psychological distress; traumatic brain injury	LIFE SATISFACTION; DISTRESS; PREDICTORS; MODEL; STRESS; TBI; REHABILITATION; INDIVIDUALS; SYMPTOMS; SPOUSES	Objective: To examine the differential effect of neurobehavioral impairments (cognitive, behavioral, and social) on family functioning, family roles, and psychological distress in male versus female caregivers of relatives with severe traumatic brain injury (TBI). Design: Structural equation modeling with multigroup analysis conducted in a cross-sectional sample to test an established theoretical model. Participants: An aggregated sample of 122 caregivers (46 male, 76 female) of people with severe TBI. The sample comprised 64 spouses and 58 parents (29 parental couples) of 93 persons with TBI. Measures: Neurobehavioral Problem Checklist; Family Assessment Device; and Brief Symptom Inventory. Results: Structural equation modeling showed that the proposed model had acceptable fit indices for the combined sample. Multigroup analysis indicated that both male and female caregivers (i) responded similarly to the neurobehavioral impairments experienced by the injured relative and (ii) reported behavior having a direct effect on family functioning, which, in turn, increased psychological distress. However, the effect of disrupted family functioning was more influential on the level of distress in male caregivers than in female caregivers. Conclusion: Evidence was found for gender-specific pathways underlying the psychological distress of male versus female caregivers. Such findings can assist in tailoring family support strategies so that they cater for caregivers of both genders.	[Anderson, Malcolm I.] Avondale Coll Higher Educ, Fac Nursing & Hlth, Sydney, NSW, Australia; [Simpson, Grahame K.] Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Simpson, Grahame K.] Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Morey, Peter J.] Avondale Coll Higher Educ, Fac Business, Cooranbong, NSW, Australia	Anderson, MI (corresponding author), Avondale Coll Higher Educ, Fac Nursing & Hlth, Sydney, NSW, Australia.	malcolm.anderson@avondale.edu.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Anderson, Malcolm/0000-0003-2963-7497	Avondale College of Higher Education Foundation; Australasian Research Institute [050301]	This work was supported by the Avondale College of Higher Education Foundation and the Australasian Research Institute (grant 050301). The authors acknowledge the contributions made by the staff from the Brain Injury Rehabilitation Programmes in New South Wales in facilitating this project. The authors declare no conflicts of interest.	AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Anderson M. I., 2006, STRESS ITS IMPACT SO, P23; Anderson MI, 2009, BRAIN INJURY, V23, P931, DOI 10.3109/02699050903302336; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Arbuckle J. L., 2009, AMOS 18 COMPUTER SOF; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Blake H, 2008, INT J THER REHABIL, V15, P263, DOI 10.12968/ijtr.2008.15.6.29878; Camplair PS, 1989, THESIS UMI ANN ARBOR, P153; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Derogatis L, 1993, BRIEF SYMPTOM INVENT; Derogatis LD, 1983, SCL 90R  ADM SCORING; Elliott G.R., 1982, STRESS HUMAN HLTH; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FRISTAD MA, 1989, J MARITAL FAM THER, V15, P259, DOI 10.1111/j.1752-0606.1989.tb00808.x; Frosch S, 1997, BRAIN INJURY, V11, P891; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Ho R., 2006, HDB UNIVARIATE MULTI; Hobfoll S.E., 1992, J FAM PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; HOBFOLL SE, 1989, AM PSYCHOL, V44, P513, DOI 10.1037/0003-066X.44.3.513; Hoofien D, 2001, BRAIN INJURY, V15, P189; Joreskog KG., 1993, LISREL 8 USERS REFER; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Klose M, 2004, Arch Womens Ment Health, V7, P133, DOI 10.1007/s00737-004-0047-7; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kreutzer J., 1987, GEN HLTH HIST QUESTI; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEATHAM J, 1996, BRAIN INJURY, V10, P543; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; MacCullum RC, 1980, PSYCHOL METHODS, V88, p[588, 130]; Munck IME., 1979, MODEL BUILDING COMP; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SOLOMON C R, 1991, Brain Injury, V5, P253, DOI 10.3109/02699059109008096; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001	50	21	22	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2013	28	6					453	463		10.1097/HTR.0b013e31825d6087			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	299AA	WOS:000330365200010	22832371				2021-06-18	
J	Chen, BX; Grothe, C; Schaller, K				Chen, Bixia; Grothe, Christoph; Schaller, Karl			Validation of a new neurological score (FOUR Score) in the assessment of neurosurgical patients with severely impaired consciousness	ACTA NEUROCHIRURGICA			English	Article						Assessment; Coma; Consciousness; FOUR score; Glasgow coma scale; Outcome	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; BRAIN-STEM REFLEXES; PROGNOSTIC VALUE; PRACTICAL SCALE; MOTOR RESPONSE; PREDICTION; INNSBRUCK; SURVIVAL; TRAUMA	The Glasgow coma scale (GCS) was introduced as a scoring system for patients with impaired consciousness after traumatic brain injury (TBI). Since, it has become the worldwide standard in TBI assessment. The GCS has repeatedly been criticized for its several failures to reflect verbal reaction in intubated patients, and to test brain stem reflexes. Recently, the full outline of unresponsiveness (FOUR) score was introduced, which is composed of four clinically distinct categories of evaluation: eye reaction, motor function, brainstem reflexes and respiratory pattern. This study aims to validate the FOUR score in neurosurgical patients. FOUR score and GCS were assessed in a consecutive series of neurosurgical patients with severely impaired consciousness (GCS < 9). Their correlation with the 30-day Glasgow outcome score (GOS) was compared. Patients admitted for TBI, spontaneous intracranial hemorrhage (intracerebral hemorrhage, aneurysmal subarachnoid hemorrhage, cerebellar hemorrhage), or malignant middle cerebral artery infarction were included. We assessed a total of 101 patients (mean age = 64y, SD = 36.1y). The area under the curve (AUC) for mortality was 0.768 (P = 0.0001) for the FOUR Score, and 0.699 (P = 0.001) for the GCS. For poor outcome (GOS = 2-3) the FOUR score AUC was 0.683 (P = 0.018), the GCS AUC was 0.682 (P = 0.019). The FOUR score value for favorable outcome (GOS = 4-5) was 0.748 (P = 0.001), the corresponding GCS value was 0.704 (P = 0.002). The FOUR score was more robust than the GCS in predicting mortality after 30 days in neurosurgical patients with severely impaired consciousness. There was no relevant difference in predicting poor and good outcome.	[Chen, Bixia; Grothe, Christoph; Schaller, Karl] Univ Bonn, Med Ctr, Dept Neurosurg, Bonn, Germany; [Chen, Bixia] Univ Duisburg Essen, Med Ctr, Dept Neurosurg, Essen, Germany; [Schaller, Karl] Univ Geneva, Med Ctr, Dept Neurosurg, CH-1211 Geneva, Switzerland; [Schaller, Karl] Fac Med, Geneva, Switzerland; [Schaller, Karl] Univ Med Ctr, Dept Neurosurg, Fac Med, CH-1211 Geneva 4, Switzerland	Schaller, K (corresponding author), Univ Med Ctr, Dept Neurosurg, Fac Med, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 4, Switzerland.	karl.schaller@hcuge.ch					Akavipat P, 2009, NEUROL MED-CHIR, V49, P565, DOI 10.2176/nmc.49.565; Alexandre A, 1982, J Neurosurg Sci, V26, P187; BENESCH CG, 1993, ARCH NEUROL-CHICAGO, V50, P1309, DOI 10.1001/archneur.1993.00540120024008; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Chan Betty, 1993, Journal of Emergency Medicine, V11, P579, DOI 10.1016/0736-4679(93)90312-U; de Sousa LCA, 2007, OTOL NEUROTOL, V28, P426; Diringer MN, 1997, ARCH NEUROL-CHICAGO, V54, P606, DOI 10.1001/archneur.1997.00550170078017; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Hirai S, 1996, NEUROSURGERY, V39, P441, DOI 10.1097/00006123-199609000-00002; JENNETT B, 1975, LANCET, V1, P480; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; Parry-Jones AR, 2013, STROKE, V44, P1840, DOI 10.1161/STROKEAHA.113.001009; ROUT MW, 1971, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5765.7; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Schefold JC, 2009, RESUSCITATION, V80, P658, DOI 10.1016/j.resuscitation.2009.03.006; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; SUGIURA K, 1983, NEUROSURGERY, V12, P411, DOI 10.1227/00006123-198304000-00007; TEASDALE G, 1974, LANCET, V2, P81; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Wijdicks Eelco F M, 2010, Pract Neurol, V10, P51, DOI 10.1136/jnnp.2009.200097; WIJDICKS EFM, 1994, ANN NEUROL, V35, P239, DOI 10.1002/ana.410350219; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 1998, J NEUROL NEUROSUR PS, V64, P117, DOI 10.1136/jnnp.64.1.117; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435; ZENTNER J, 1994, NEUROL RES, V16, P89	32	21	21	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2013	155	11					2133	2139		10.1007/s00701-013-1854-2			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	236QZ	WOS:000325815600018	24013867	Green Published			2021-06-18	
J	Elkin, BS; Morrison, B				Elkin, Benjamin S.; Morrison, Barclay			Viscoelastic Properties of the P17 and Adult Rat Brain From Indentation in the Coronal Plane	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						rat brain; heterogeneous mechanical properties; age-dependence; viscoelasticity; indentation; TBI; neurosurgery	INJURY; BEHAVIOR; IMPACT; TESTS	This technical brief serves as an update to our previous work characterizing the region-dependence of viscoelastic mechanical properties of the P17 and adult rat brain in the coronal plane (Elkin et al., 2011, "A Detailed Viscoelastic Characterization of the P17 and Adult Rat Brain," J. Neurotrauma, 28, pp. 2235-2244.). Here, modifications to the microindentation device provided for the reliable measurement of load during the ramp portion of load relaxation microindentation tests. In addition, a correction factor for finite sample thickness was incorporated to more accurately assess the intrinsic mechanical properties of the tissue. The shear relaxation modulus was significantly dependent on the anatomic region and developmental age, with a general increase in stiffness with age and increased stiffness in the hippocampal and cortical regions compared with the white matter and cerebellar regions of the brain. The shear modulus ranged from similar to 0.2 kPa to similar to 2.6 kPa depending on region, age, and time scale. Best-fit Prony series parameters from least squares fitting to the indentation data from each region are reported, which describe the shear relaxation behavior for each anatomic region within each age group at both short (<10 ms) and long (similar to 20 s) time scales. These data will be useful for improving the biofidelity of finite element models of rat brain deformation at short time scales, such as models of traumatic brain injury.	[Elkin, Benjamin S.; Morrison, Barclay] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Elkin, Benjamin S.] MEA Forens Engineers & Scientists, Mississauga, ON L4Z 1S6, Canada	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.	ben.elkin@meaforensic.com; bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864	National Highway Traffic Safety Administration (NHTSA) [DTNH22-08-C-00088]; Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by the National Highway Traffic Safety Administration (NHTSA; Project No. DTNH22-08-C-00088) and a Natural Sciences and Engineering Research Council of Canada (NSERC) postgraduate scholarship (BSE).	Allen MP, 1997, UNDERSTANDING REGRES, P113; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; Bonferroni C.E., 1935, STUDI ONORE PROFESSO, P13; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cheng L, 2000, J POLYM SCI POL PHYS, V38, P10, DOI 10.1002/(SICI)1099-0488(20000101)38:1<10::AID-POLB2>3.0.CO;2-6; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; Clayton EH, 2011, PHYS MED BIOL, V56, P2391, DOI 10.1088/0031-9155/56/8/005; Elias PZ, 2012, J MECH BEHAV BIOMED, V12, P63, DOI 10.1016/j.jmbbm.2012.03.014; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; Elkin BS, 2011, J NEUROTRAUM, V28, P2235, DOI 10.1089/neu.2010.1604; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Finan J. D., 2012, P IRCOBI C; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; HAYES WC, 1972, J BIOMECH, V5, P541, DOI 10.1016/0021-9290(72)90010-3; Lee E.H., 1960, J APPL MECH, V27, P438, DOI DOI 10.1115/1.3644020; Lee SJ, 2011, J BIOMED MATER RES B, V97B, P84, DOI 10.1002/jbm.b.31789; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Mao HJ, 2011, J NEUROTRAUM, V28, P2263, DOI 10.1089/neu.2010.1600; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; Sakai M, 2002, PHILOS MAG A, V82, P1841, DOI 10.1080/01418610210134738; Shulyakov AV, 2011, J MECH BEHAV BIOMED, V4, P484, DOI 10.1016/j.jmbbm.2010.12.012; Takhounts EG, 2008, STAPP CAR C, V52, P1; Vappou J, 2008, J BIOMECH, V41, P2954, DOI 10.1016/j.jbiomech.2008.07.034; Vappou J, 2007, MAGN RESON MATER PHY, V20, P273, DOI 10.1007/s10334-007-0098-7; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zamir EA, 2004, J BIOMECH ENG-T ASME, V126, P276, DOI 10.1115/1.1695573	29	21	21	1	21	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	NOV	2013	135	11							114507	10.1115/1.4025386			5	Biophysics; Engineering, Biomedical	Biophysics; Engineering	240IF	WOS:000326088100016	24026193				2021-06-18	
J	Macciocchi, SN; Seel, RT; Thompson, N				Macciocchi, Stephen N.; Seel, Ronald T.; Thompson, Nicole			The Impact of Mild Traumatic Brain Injury on Cognitive Functioning Following Co-occurring Spinal Cord Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Forensic neuropsychology; Rehabilitation	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; SPORTS-RELATED CONCUSSION; CLOSED HEAD-INJURY; METAANALYSIS; RECOVERY; ELDERS; SCORES	Meta-analytic studies have shown that mild traumatic brain injury (MTBI) has relatively negligible effects on cognitive functioning at 90 or more days post-injury. Few studies have prospectively examined the effects of MTBI in acute physical trauma populations. This prospective, cohort study compared the cognitive performance of persons who sustained a spinal cord injury (SCI) and a co-occurring MTBI (N 53) to persons who sustained an SCI alone (N 64) between 26 and 76 days (mean 46) post-injury. The presence of MTBI was determined based on acute medical record review using a standardized algorithm. Primary outcome measures were seven neuropsychological tests that evaluated visual, verbal, and working memory, perceptual reasoning, and processing speed that controlled for potential upper extremity impairment. Persons who sustained SCI with or without MTBI had lower than expected performance across all neuropsychological tests, on average about 1 SD below the mean. Analysis of covariance indicated that persons with MTBI did not evidence greater impairment on any neuropsychological test. The aggregated effect size (Cohens d) was 0.16. The strongest predictors of neuropsychological test scores were education, race, history of learning problems, and days from injury to rehabilitation admission. MTBI did not predict performance on any neuropsychological test. These findings are consistent with other controlled studies that indicate a single MTBI has negligible long-term impacts on cognition.	[Macciocchi, Stephen N.; Seel, Ronald T.; Thompson, Nicole] Shepherd Ctr, Atlanta, GA 30309 USA; [Macciocchi, Stephen N.] Univ Georgia, Athens, GA 30602 USA	Macciocchi, SN (corresponding author), Shepherd Ctr, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.	stephen_macciocchi@shepherd.org			National Institute of Disability and Rehabilitation Research [H113G03004]	Funding for this study was provided by National Institute of Disability and Rehabilitation Research: H113G03004.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brandt J., 2001, HOPKINS VERBAL LEARN; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dotson VM, 2008, CLIN NEUROPSYCHOL, V22, P989, DOI 10.1080/13854040701679017; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein MF, 2003, CLIN NEUROPSYCHOL, V17, P561, DOI 10.1076/clin.17.4.561.27937; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Manly JJ, 2005, J GERIATR PSYCH NEUR, V18, P213, DOI 10.1177/0891988705281868; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; Mapou R. L., 2008, ADULT LEARNING DISAB; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sipski ML, 2006, AM J PHYS MED REHAB, V85, P310, DOI 10.1097/01.phm.0000202105.87011.bf; Smith A, 1995, SYMBOL DIGIT MODALIT; Trahan D, 1988, CONTINUOUS VISUAL ME; Wechsler D., 1997, ADM SCORING MANUAL W; Wetzel L., 2000, SHORT CATEGORY TEST	32	21	23	1	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2013	28	7					684	691		10.1093/arclin/act049			8	Psychology, Clinical; Psychology	Psychology	243AS	WOS:000326289300006	24055885	Bronze, Green Published			2021-06-18	
J	McKeon, JMM; Livingston, SC; Reed, A; Hosey, RG; Black, WS; Bush, HM				McKeon, Jennifer M. Medina; Livingston, Scott C.; Reed, Ashley; Hosey, Robert G.; Black, Williams S.; Bush, Heather M.			Trends in Concussion Return-to-Play Timelines Among High School Athletes From 2007 Through 2009	JOURNAL OF ATHLETIC TRAINING			English	Article						injury incidence; time to event; survival probability	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; SPORTS-RELATED CONCUSSION; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; POSTURAL STABILITY; NCAA CONCUSSION; EPIDEMIOLOGY; RECOVERY; PREVENTION	Context: Whereas guidelines about return-to-play (RTP) after concussion have been published, actual prognoses remain elusive. Objective: To develop probability estimates for time until RTP after sport-related concussion. Design: Descriptive epidemiology study. Setting: High school. Patients or Other Participants: Injured high school varsity, junior varsity, or freshman athletes who participated in 1 of 13 interscholastic sports at 7 area high schools during the 20072009 academic years. Intervention(s): Athletic trainers employed at each school collected concussion data. The athletic trainer or physician on site determined the presence of a concussion. Athlete-exposures for practices and games also were captured. Main Outcome Measure(s): Documented concussions were categorized by time missed from participation using severity outcome intervals (same-day return, 1- to 2-day return, 3- to 6-day return, 7- to 9-day return, 10- to 21-day return, >21-day return, no return [censored data]). We calculated Kaplan-Meier time-to-event probabilities that included censored data to determine the probability of RTP at each of these time intervals. Results: A total of 81 new concussions were documented in 478 775 athlete-exposures during the study period. After a new concussion, the probability of RTP (95% confidence interval) was 2.5% (95% confidence interval = 0.3, 6.9) for a 1- to 2-day return, 71.3% (95% confidence interval = 59.0, 82.9) for a 7-to 9-day return, and 88.8% (95% confidence interval = 72.0, 97.2) for a 10- to 21-day return. Conclusions: For high school athletes, RTP within the first 2 days after concussion was unlikely. After 1 week, the probability of return rose substantially (approximately 71%). Prognostic indicators are used to educate patients about the likely course of disease. Whereas individual symptoms and recovery times vary, prognostic time-to-event probabilities allow clinicians to provide coaches, parents, and athletes with a prediction of the likelihood of RTP within certain timeframes after a concussion.	[McKeon, Jennifer M. Medina] Ithaca Coll, Dept Exercise & Sport Sci, Ithaca, NY 14850 USA; [McKeon, Jennifer M. Medina; Livingston, Scott C.] Univ Kentucky, Coll Hlth Sci, Lexington, KY 40506 USA; [Reed, Ashley] Kent State Univ, Coll Educ Hlth & Human Sci, Kent, OH USA; [Hosey, Robert G.] Univ Kentucky, Coll Med, Lexington, KY 40506 USA; [Black, Williams S.] UK Healthcare, Univ Hlth Serv, Lexington, KY USA; [Bush, Heather M.] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA	McKeon, JMM (corresponding author), Ithaca Coll, Dept Exercise & Sport Sci, Ctr Hlth Sci 309A, Ithaca, NY 14850 USA.	jmckeon@ithaca.edu					ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Borowski LA, 2008, AM J SPORT MED, V36, P2328, DOI 10.1177/0363546508322893; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chong A, 2010, ASIAN PAC J CANCER P, V11, P953; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fernandez WG, 2007, ACAD EMERG MED, V14, P641, DOI [10.1197/j.aem.2007.03.1354, 10.1111/j.1553-2712.2007.tb01851.x]; Fuller CW, 2007, BRIT J SPORT MED, V41, pI20, DOI 10.1136/bjsm.2007.037267; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hootman JM, 2007, J ATHL TRAINING, V42, P311; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Ingram JG, 2008, AM J SPORT MED, V36, P1116, DOI 10.1177/0363546508314400; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kentucky High School Athletic Association and KHSAA Member Schools, IMPL NFHS PLAYING RU; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mather FJ, 2003, BRAIN INJURY, V17, P1077, DOI 10.1080/0269905031000114045; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Patel DR, 2006, PRIMARY CARE, V33, P545, DOI 10.1016/j.pop.2006.02.001; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Sallis RE, 2001, INT J SPORTS MED, V22, P420, DOI 10.1055/s-2001-16246; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Swenson DM, 2009, AM J SPORT MED, V37, P1586, DOI 10.1177/0363546509332500; Talamini R, 2008, INT J CANCER, V122, P1624, DOI 10.1002/ijc.23205; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	68	21	21	0	22	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2013	48	6					836	843		10.4085/1062-6050-48.6.17			8	Sport Sciences	Sport Sciences	268AW	WOS:000328141200014	24143901	Green Published, Bronze			2021-06-18	
J	Meekes, J; Braams, O; Braun, KPJ; Jennekens-Schinkel, A; van Nieuwenhuizen, O				Meekes, Joost; Braams, Olga; Braun, Kees P. J.; Jennekens-Schinkel, Aag; van Nieuwenhuizen, Onno		Dutch Collaborative Epilepsy Surg	Verbal memory after epilepsy surgery in childhood	EPILEPSY RESEARCH			English	Article						Child; Epilepsy surgery; Temporal/extra-temporal resection; Verbal memory; SRB analysis	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; SEMANTIC MEMORY; EFFECT SIZE; CHILDREN; DECLINE; LOBECTOMY; STATISTICS; SCLEROSIS; RESECTION	Purpose: To investigate verbal memory after epilepsy surgery both group-wise and at the level of individual children, and to assess associations with side of surgery and removal of the temporal lobe. Methods: A prospective controlled study in a consecutive sample of 21 children undergoing epilepsy surgery, with comprehensive assessments of verbal memory before surgery and six, 12 and 24 months after surgery. For each patient, two age- and gender-matched controls were tested at similar intervals. Standardized regression-based (SRB) analysis was applied to compare post-surgical change in individual patients with change in controls. Results: Group-wise, average normed scores on verbal memory tests were higher after epilepsy surgery than before, corroborating earlier reports. By dint of empirically based SRB analysis, however, considerable individual differences in post-surgical change were revealed. Children with resections that included the left temporal lobe functioned significantly poorer than predicted on the basis of their pre-surgical performance. In contrast, verbal memory performance after surgery was consistent with pre-surgical baseline in the majority of children with resections that spared the left temporal lobe. Conclusions: Despite cessation of epileptic seizures, verbal memory remains vulnerable in children who required surgery including the left temporal lobe. In most - but not all - children with other types of surgery, post-surgical verbal memory is consistent with their individual pre-surgical base level. (C) 2013 Elsevier B.V. All rights reserved.	[Meekes, Joost; Braams, Olga; Jennekens-Schinkel, Aag] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Sect Neuropsychol Children & Adolescents, NL-3508 AB Utrecht, Netherlands; [Meekes, Joost; Braams, Olga; Jennekens-Schinkel, Aag; van Nieuwenhuizen, Onno] Bio Res Ctr Children, NL-6816 VS Arnhem, Netherlands; [Braun, Kees P. J.; van Nieuwenhuizen, Onno] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Child Neurol, NL-3508 AB Utrecht, Netherlands	Meekes, J (corresponding author), Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Sect Neuropsychol Children & Adolescents, Room KG 01-327-1,POB 85090, NL-3508 AB Utrecht, Netherlands.	meekes.joost@gmail.com; o.b.braams@umcutrecht.nl; k.braun@umcutrecht.nl; a.jennekens@umcutrecht.nl; OnnovanNieuwenhuizen@umcutrecht.nl		Meekes, Joost/0000-0001-6902-8958	Bio Foundation; Epilepsies of Childhood Foundation	This work was supported by grants from Bio Foundation and the Epilepsies of Childhood Foundation. These sponsors had no involvement in the design of the study; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the manuscript.	Alexander AI, 2005, ARCH CLIN NEUROPSYCH, V20, P587, DOI 10.1016/j.acn.2004.12.005; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; Baxendale S, 2006, EPILEPSIA, V47, P1887, DOI 10.1111/j.1528-1167.2006.00810.x; Bell B, 2011, NAT REV NEUROL, V7, P154, DOI 10.1038/nrneurol.2011.3; Berg AT, 2012, NEUROLOGY, V79, P1384, DOI 10.1212/WNL.0b013e31826c1b55; Binder JR, 2008, EPILEPSIA, V49, P1377, DOI 10.1111/j.1528-1167.2008.01625.x; Busch RM, 2011, ARCH CLIN NEUROPSYCH, V26, P739, DOI 10.1093/arclin/acr067; CHELUNE GJ, 1995, ARCH CLIN NEUROPSYCH, V10, P413; Duff K, 2012, ARCH CLIN NEUROPSYCH, V27, P248, DOI 10.1093/arclin/acr120; Dulay MF, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11340; Engel Jerome Jr., 1993, P609; Geerts A, 2010, EPILEPSIA, V51, P1189, DOI 10.1111/j.1528-1167.2010.02546.x; Helmstaedter C, 2011, EPILEPSIA, V52, P1402, DOI 10.1111/j.1528-1167.2011.03157.x; HERMANN BP, 1995, EPILEPSIA, V36, P137, DOI 10.1111/j.1528-1157.1995.tb00972.x; Jambaque I, 2007, NEUROPSYCHOLOGIA, V45, P2850, DOI 10.1016/j.neuropsychologia.2007.05.008; KAUFMAN AS, 1993, MANUAL KAUFMAN ADOLE; Kort W., 2005, WISC 3 NL HANDLEIDIN; Lah S, 2004, EPILEPSY BEHAV, V5, P804, DOI 10.1016/j.yebeh.2004.08.005; Langfitt JT, 2007, NEUROLOGY, V68, P1988, DOI 10.1212/01.wnl.0000264000.11511.30; Lawrence MA, 2012, EZ EASY ANAL VISUALI; Lendt M, 1999, EPILEPSIA, V40, P1543, DOI 10.1111/j.1528-1157.1999.tb02038.x; Lendt M, 2002, EPILEPSY BEHAV, V3, P51, DOI 10.1006/ebeh.2001.0296; Loring DW, 2007, NEUROPSYCHOL REV, V17, P413, DOI 10.1007/s11065-007-9043-9; Mabbott DJ, 2003, NEUROPSYCHOLOGIA, V41, P995, DOI 10.1016/S0028-3932(02)00318-4; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McSweeny A., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; Messas CS, 2008, EPILEPSY BEHAV, V12, P311, DOI 10.1016/j.yebeh.2007.10.014; Mulder J.L., 2004, KAUFMAN INTELLIGENTI; Olejnik S, 2003, PSYCHOL METHODS, V8, P434, DOI 10.1037/1082-989X.8.4.434; R Development Core Team, 2011, R LANG ENV STAT COMP; Race E, 2012, NEUROPSYCHOL REV, V22, P105, DOI 10.1007/s11065-012-9197-y; Reynolds C. R., 2007, TEST MEMORY LEARNING; Rzezak P, 2011, EPILEPSY BEHAV, V21, P242, DOI 10.1016/j.yebeh.2011.03.032; Sherman EMS, 2011, EPILEPSIA, V52, P857, DOI 10.1111/j.1528-1167.2011.03022.x; Skirrow C, 2011, NEUROLOGY, V76, P1330, DOI 10.1212/WNL.0b013e31821527f0; Stroup E, 2003, NEUROLOGY, V60, P1266, DOI 10.1212/01.WNL.0000058765.33878.0D; Thaler NS, 2011, APPL NEUROPSYCHOL, V18, P168, DOI 10.1080/09084282.2011.595443; Van Schooneveld MMJ, 2013, BRAIN DEV-JPN, V35, P721, DOI 10.1016/j.braindev.2013.01.011; Venables W.N., 2002, MODERN APPL STAT S; Wechsler D., 2002, WECHSLER INTELLIGENC; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501	41	21	22	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	NOV	2013	107	1-2					146	155		10.1016/j.eplepsyres.2013.08.017			10	Clinical Neurology	Neurosciences & Neurology	273HB	WOS:000328524800017	24042124				2021-06-18	
J	Van Cleve, W; Kernic, MA; Ellenbogen, RG; Wang, J; Zatzick, DF; Bell, MJ; Wainwright, MS; Groner, JI; Mink, RB; Giza, CC; Boyle, LN; Mitchell, PH; Rivara, FP; Vavilala, MS				Van Cleve, William; Kernic, Mary A.; Ellenbogen, Richard G.; Wang, Jin; Zatzick, Douglas F.; Bell, Michael J.; Wainwright, Mark S.; Groner, Jonathan I.; Mink, Richard B.; Giza, Christopher C.; Boyle, Linda Ng; Mitchell, Pamela H.; Rivara, Frederick P.; Vavilala, Monica S.		PEGASUS Pediat Guideline Adherence	National Variability in Intracranial Pressure Monitoring and Craniotomy for Children With Moderate to Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Decompressive craniectomy; Intracranial pressure monitoring	GLASGOW COMA SCALE; UNITED-STATES; OUTCOMES; PROGRAM; VOLUME; SCORE; CARE	BACKGROUND: Traumatic brain injury (TBI) is a significant cause of mortality and disability in children. Intracranial pressure monitoring (ICPM) and craniotomy/craniectomy (CRANI) may affect outcomes. Sources of variability in the use of these interventions remain incompletely understood. OBJECTIVE: To analyze sources of variability in the use of ICPM and CRANI. METHODS: Retrospective cross-sectional study of patients with moderate/severe pediatric TBI with the use of data submitted to the American College of Surgeons National Trauma Databank. RESULTS: We analyzed data from 7140 children at 156 US hospitals during 7 continuous years. Of the children, 27.4% had ICPM, whereas 11.7% had a CRANI. Infants had lower rates of ICPM and CRANI than older children. A lower rate of ICPM was observed among children hospitalized at combined pediatric/adult trauma centers than among children treated at adult-only trauma centers (relative risk = 0.80; 95% confidence interval 0.66-0.97). For ICPM and CRANI, 18.5% and 11.6%, respectively, of residual model variance was explained by between-hospital variation in care delivery, but almost no correlation was observed between within-hospital tendency toward performing these procedures. CONCLUSION: Infants received less ICPM than older children, and children hospitalized at pediatric trauma centers received less ICPM than children at adult-only trauma centers. In addition, significant between-hospital variability existed in the delivery of ICPM and CRANI to children with moderate-severe TBI.	[Van Cleve, William; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA; [Kernic, Mary A.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA; [Ellenbogen, Richard G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Ellenbogen, Richard G.] Univ Washington, Dept Global Hlth Med, Seattle, WA 98104 USA; [Wang, Jin] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Zatzick, Douglas F.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA; [Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; [Groner, Jonathan I.] Ohio State Univ, Coll Med, Dept Surg, Columbus, OH 43210 USA; [Mink, Richard B.] Los Angeles BioMed Res Inst, Harbor UCLA Med Ctr, Los Angeles, CA USA; [Mink, Richard B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Div Pediat Neurol, Los Angeles, CA USA; [Boyle, Linda Ng] Univ Washington, Coll Engn, Seattle, WA 98104 USA; [Mitchell, Pamela H.] Univ Washington, Sch Nursing, Seattle, WA 98104 USA	Vavilala, MS (corresponding author), Univ Washington, 325 Ninth Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu		Groner, Jonathan/0000-0002-0998-593X	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS072308 to 03]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER	The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. This study was funded by the National Institutes of Health (NIH) 1R01NS072308 to 03.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Bates D, LME4 LINEAR MIXED EF LME4 LINEAR MIXED EF; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clark DE., 2010, ICDPIC STATA MODULE; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Durbin D R, 2001, Inj Prev, V7, P96, DOI 10.1136/ip.7.2.96; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Gelman A., 2007, DATA ANAL USING REGR; Honaker J, 2011, J STAT SOFTW, V45, P1; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Lumley T, 2006, UW BIOSTATISTICS WOR; MacKenzie EJ, 2003, JAMA-J AM MED ASSOC, V289, P1515, DOI 10.1001/jama.289.12.1515; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Pineda JA, 2013, LANCET NEUROL, V12, P45, DOI 10.1016/S1474-4422(12)70269-7; R Core Team, 2012, R LANG ENV STAT COMP; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120	25	21	21	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2013	73	5					746	752		10.1227/NEU.0000000000000097			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	300MH	WOS:000330467500011	23863766	Bronze, Green Accepted			2021-06-18	
J	Yang, M; Kosterin, P; Salzberg, BM; Milovanova, TN; Bhopale, VM; Thom, SR				Yang, Ming; Kosterin, Paul; Salzberg, Brian M.; Milovanova, Tatyana N.; Bhopale, Veena M.; Thom, Stephen R.			Microparticles generated by decompression stress cause central nervous system injury manifested as neurohypophysial terminal action potential broadening	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						decompression sickness; nitric oxide synthase; NADPH oxidase; leukocytes; platelets	TRAUMATIC BRAIN-INJURY; INDUCED NEUTROPHIL ACTIVATION; GAS CAVITATION NUCLEI; ENDOTHELIAL MICROPARTICLES; VASCULAR INJURIES; OXIDASE ACTIVITY; SICKNESS; AIR; DYSFUNCTION; PEROXIDASE	The study goal was to use membrane voltage changes during neurohypophysial action potential (AP) propagation as an index of nerve function to evaluate the role that circulating microparticles (MPs) play in causing central nervous system injury in response to decompression stress in a murine model. Mice studied 1 h following decompression from 790 kPa air pressure for 2 h exhibit a 45% broadening of the neurohypophysial AP. Broadening did not occur if mice were injected with the MP lytic agent polyethylene glycol telomere B immediately after decompression, were rendered thrombocytopenic, or were treated with an inhibitor of nitric oxide synthase-2 (iNOS) prior to decompression, or in knockout (KO) mice lacking myeloperoxidase or iNOS. If MPs were harvested from control (no decompression) mice and injected into naive mice, no AP broadening occurred, but AP broadening was observed with injections of equal numbers of MPs from either wild-type or iNOS KO mice subjected to decompression stress. Although not required for AP broadening, MPs from decompressed mice, but not control mice, exhibit NADPH oxidase activation. We conclude that inherent differences in MPs from decompressed mice, rather than elevated MPs numbers, mediate neurological injury and that a component of the perivascular response to MPs involves iNOS. Additional study is needed to determine the mechanism of AP broadening and also mechanisms for MP generation associated with exposure to elevated gas pressure.	[Yang, Ming; Milovanova, Tatyana N.; Bhopale, Veena M.; Thom, Stephen R.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kosterin, Paul; Salzberg, Brian M.] Univ Penn, Dept Neurosci, Perelman Sch Med, Philadelphia, PA 19104 USA; [Salzberg, Brian M.] Univ Penn, Dept Physiol, Perelman Sch Med, Philadelphia, PA 19104 USA	Thom, SR (corresponding author), Univ Maryland, Dept Emergency Med, 110 South Paca St, Baltimore, MD 21201 USA.	sthom@smail.umaryland.edu			Office of Naval ResearchOffice of Naval Research; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-40966]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040966, R01NS060703] Funding Source: NIH RePORTER	Funding was provided by grants from the Office of Naval Research and the National Institutes of Health (NS-40966).	Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Altman PL, 1964, BIOLOGY DATA BOOK, P264; BROADWELL RD, 1976, J COMP NEUROL, V166, P257, DOI 10.1002/cne.901660302; Brown CM, 2008, EXP NEUROL, V210, P782, DOI 10.1016/j.expneurol.2007.11.021; Csanyi G, 2011, FREE RADICAL BIO MED, V51, P1116, DOI 10.1016/j.freeradbiomed.2011.04.025; Erdem I, 2009, AVIAT SPACE ENVIR MD, V80, P2, DOI 10.3357/ASEM.2234.2009; FOX FE, 1954, J ACOUST SOC AM, V26, P984, DOI 10.1121/1.1907466; FRANCIS TJR, 1988, J NEUROPATH EXP NEUR, V47, P475, DOI 10.1097/00005072-198807000-00008; Frontczak-Baniewicz M, 2001, NEUROENDOCRINOL LETT, V22, P81; Ganong WF, 2000, CLIN EXP PHARMACOL P, V27, P422, DOI 10.1046/j.1440-1681.2000.03259.x; Gao GK, 2009, UNDERSEA HYPERBAR M, V36, P33; HATTON GI, 1984, PEPTIDES, V5, P121, DOI 10.1016/0196-9781(84)90271-7; Janiszewski M, 2004, CRIT CARE MED, V32, P818, DOI 10.1097/01.CCM.0000114829.17746.19; Jansen F, 2013, CARDIOVASC RES, V98, P94, DOI 10.1093/cvr/cvt013; Jersey SL, 2010, AVIAT SPACE ENVIR MD, V81, P64, DOI 10.3357/ASEM.2303.2010; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Koch AE, 2008, UNDERSEA HYPERBAR M, V35, P197; Kohshi Kiyotaka, 2003, Sangyo Eiseigaku Zasshi, V45, P97; Kosterin P, 2005, J MEMBRANE BIOL, V208, P113, DOI 10.1007/s00232-005-0824-x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Madden LA, 2010, AVIAT SPACE ENVIR MD, V81, P41, DOI 10.3357/ASEM.2610.2010; Mayo L, 2008, J IMMUNOL, V181, P92, DOI 10.4049/jimmunol.181.1.92; Obaid AL, 2004, J NEUROSCI METH, V134, P179, DOI 10.1016/j.jneumeth.2003.11.011; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Pontier JM, 2012, APPL PHYSIOL NUTR ME, V37, P1; REAVES TA, 1982, NEUROSCIENCE, V7, P1545, DOI 10.1016/0306-4522(82)90263-9; SALZBERG BM, 1983, NATURE, V306, P36, DOI 10.1038/306036a0; Schmiegelow M, 2000, HORM RES, V54, P53, DOI 10.1159/000053232; SENSEMAN DM, 1983, J GEN PHYSIOL, V81, P887, DOI 10.1085/jgp.81.6.887; Tashiro T, 2002, ENDOCR PATHOL, V13, P183, DOI 10.1385/EP:13:3:183; Thom SR, 2013, J APPL PHYSIOL, V114, P1396, DOI 10.1152/japplphysiol.00106.2013; Thom SR, 2013, J APPL PHYSIOL, V114, P550, DOI 10.1152/japplphysiol.01386.2012; Thom SR, 2012, J APPL PHYSIOL, V112, P1268, DOI 10.1152/japplphysiol.01305.2011; Thom SR, 2011, J APPL PHYSIOL, V110, P340, DOI 10.1152/japplphysiol.00811.2010; Vann RD, 2011, LANCET, V377, P153, DOI 10.1016/S0140-6736(10)61085-9; Vince RV, 2009, EUR J APPL PHYSIOL, V105, P507, DOI 10.1007/s00421-008-0927-z; Vorbrodt AW, 1996, J NEUROCYTOL, V25, P645, DOI 10.1007/BF02284831; Yang M, 2012, J APPL PHYSIOL, V112, P204, DOI 10.1152/japplphysiol.00953.2011; YOUNT DE, 1977, AVIAT SPACE ENVIR MD, V48, P185; Yount DE, 1997, J COLLOID INTERF SCI, V193, P50, DOI 10.1006/jcis.1997.5048	40	21	21	0	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587	1522-1601		J APPL PHYSIOL	J. Appl. Physiol.	NOV	2013	115	10					1481	1486		10.1152/japplphysiol.00745.2013			6	Physiology; Sport Sciences	Physiology; Sport Sciences	257PW	WOS:000327398600009	24052032	Green Published			2021-06-18	
J	Moro, N; Ghavim, S; Harris, NG; Hovda, DA; Sutton, RL				Moro, Nobuhiro; Ghavim, Sima; Harris, Neil G.; Hovda, David A.; Sutton, Richard L.			Glucose administration after traumatic brain injury improves cerebral metabolism and reduces secondary neuronal injury	BRAIN RESEARCH			English	Article						C-14-2DG; Controlled cortical impact; Fluoro-Jade B; Hyperglycemia; Rat	CORTICAL IMPACT INJURY; PENTOSE-PHOSPHATE PATHWAY; INTENSIVE INSULIN THERAPY; FLUID PERCUSSION INJURY; TIGHT GLYCEMIC CONTROL; CLOSED-HEAD TRAUMA; 5-PERCENT DEXTROSE; BLOOD-FLOW; 0.9-PERCENT SALINE; ENERGY-METABOLISM	Clinical studies have indicated an association between acute hyperglycemia and poor outcomes in patients with traumatic brain injury (TBI), although optimal blood glucose levels needed to maximize outcomes for these patients remain under investigation. Previous results from experimental animal models suggest that post-TBI hyperglycemia may be harmful, neutral, or beneficial. The current studies determined the effects of single or multiple episodes of acute hyperglycemia on cerebral glucose metabolism and neuronal injury in a rodent model of unilateral controlled cortical impact (CCI) injury. In Experiment 1, a single episode of hyperglycemia (50% glucose at 2 g/kg, i.p.) initiated immediately after CCI was found to significantly attenuate a TBI-induced depression of glucose metabolism in cerebral cortex (4 of 6 regions) and subcortical regions (2 of 7) as well as to significantly reduce the number of dead/dying neurons in cortex and hippocampus at 24 h post-CCI. Experiment 2 examined effects of more prolonged and intermittent hyperglycemia induced by glucose administrations (2 g/kg, i.p.) at 0, 1,3 and 6 h post-CCI. The latter study also found significantly improved cerebral metabolism (in 3 of 6 cortical and 3 of 7 subcortical regions) and significant neuroprotection in cortex and hippocampus 1 day after CCI and glucose administration. These results indicate that acute episodes of post-TBI hyperglycemia can be beneficial and are consistent with other recent studies showing benefits of providing exogenous energy substrates during periods of increased cerebral metabolic demand. (C) 2013 Elsevier B.V. All rights reserved.	[Moro, Nobuhiro; Ghavim, Sima; Harris, Neil G.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Moro, Nobuhiro; Ghavim, Sima; Harris, Neil G.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Sutton, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	moro.nobuhiro@nihon-u.ac.jp; sghavim@mednet.ucla.edu; ngharris@mednet.ucla.edu; dhovda@mednet.ucla.edu; rsutton@mednet.ucla.edu		Harris, Neil/0000-0002-1965-6750	UCLA Brain Injury Research Center; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [PO1NS058489]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER	This work was supported by the UCLA Brain Injury Research Center and award PO1NS058489 from the National Institute of Neurological Disorders and Stroke (NINDS). The content is the sole responsibility of the authors and does not necessarily represent official views of the NINDS or the National Institutes of Health.	Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik-Olson BL, 2010, J NEUROTRAUM, V27, P2191, DOI 10.1089/neu.2010.1508; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; DUCKROW RB, 1987, J NEUROCHEM, V48, P989, DOI 10.1111/j.1471-4159.1987.tb05614.x; Duckrow RB, 1995, BRAIN RES, V703, P145, DOI 10.1016/0006-8993(95)01077-7; Duelli R, 2000, BRAIN RES, V858, P338, DOI 10.1016/S0006-8993(00)01942-9; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Fanne Rami Abu, 2011, J Neurosurg, V114, P85, DOI 10.3171/2010.4.JNS10263; FELDMAN Z, 1995, J NEUROSURG, V83, P1060, DOI 10.3171/jns.1995.83.6.1060; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Gurevich B, 1997, ANESTH ANALG, V84, P554, DOI 10.1097/00000539-199703000-00016; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hill J, 2010, J NEUROTRAUM, V27, P1439, DOI 10.1089/neu.2010.1328; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kokiko-Cochran ON, 2008, NEUROSCI LETT, V436, P27, DOI 10.1016/j.neulet.2008.02.046; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Lin AL, 2010, P NATL ACAD SCI USA, V107, P8446, DOI 10.1073/pnas.0909711107; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Marion Donald W, 2009, F1000 Med Rep, V1, DOI 10.3410/M1-42; Moro N, 2010, EXP NEUROL, V225, P391, DOI 10.1016/j.expneurol.2010.07.013; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Payne RS, 2003, BRAIN RES, V971, P9, DOI 10.1016/S0006-8993(03)02276-5; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Perner A, 2003, INTENS CARE MED, V29, P642, DOI 10.1007/s00134-002-1628-4; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHUIER F, 1990, J CEREBR BLOOD F MET, V10, P765, DOI 10.1038/jcbfm.1990.134; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Takahashi S, 2012, ASN NEURO, V4, P71, DOI 10.1042/AN20120002; Talmor D, 1998, ANESTH ANALG, V86, P1225, DOI 10.1097/00000539-199806000-00017; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yang M, 2009, INT J NURS STUD, V46, P753, DOI 10.1016/j.ijnurstu.2009.01.004; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	86	21	24	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 16	2013	1535						124	136		10.1016/j.brainres.2013.08.044			13	Neurosciences	Neurosciences & Neurology	236WY	WOS:000325831400012	23994447	Green Accepted			2021-06-18	
J	Arun, P; Abu-Taleb, R; Oguntayo, S; Wang, Y; Valiyaveettil, M; Long, JB; Nambiar, MP				Arun, Peethambaran; Abu-Taleb, Rania; Oguntayo, Samuel; Wang, Ying; Valiyaveettil, Manojkumar; Long, Joseph B.; Nambiar, Madhusoodana P.			Acute Mitochondrial Dysfunction after Blast Exposure: Potential Role of Mitochondrial Glutamate Oxaloacetate Transaminase	JOURNAL OF NEUROTRAUMA			English	Article						adenosine triphosphate; blast exposure; glutamate oxaloacetate transaminase; mini citric acid cycle; mitochondrial dysfunction; pyruvate dehydrogenase; traumatic brain injury	TRAUMATIC BRAIN-INJURY; N-ACETYLASPARTATE; RAT-BRAIN; INDUCED NEUROTRAUMA; OVERPRESSURE; METABOLISM; SEVERITY; MODEL	Use of improvised explosive devices has significantly increased the incidence of traumatic brain injury (TBI) and associated neuropsychiatric deficits in the recent wars in Iraq and Afghanistan. Acute deleterious effects of single and repeated blast exposure can lead to long-term neurobiological effects and neuropsychiatric deficits. Using in vitro and in vivo shock tube models of blast-induced TBI, we studied changes in mitochondrial energy metabolism after blast exposure. Single and repeated blast exposures in vitro resulted in significant decreases in neuronal adenosine triphosphate (ATP) levels at 6h post-blast that returned towards normal levels by 24h. Similar changes in ATP also were observed in the cerebral cortices of mice subjected to single and repeated blast exposures. In neurons, mitochondrial glutamate oxaloacetate transaminase (GOT(2)) plays a critical role in metabolism and energy production. Proteomic analysis of brain cortices showed a significant decrease in GOT(2) levels 6h after repeated blast exposures, which was further confirmed by Western blotting. Western blot analysis of GOT(2) and pyruvate dehydrogenase in the cortex showed direct correlation only between GOT(2) and ATP levels. Activity of GOT(2) in the isolated cortical mitochondria also showed significant decrease at 6h supporting the results of proteomic and Western blot analyses. Knowing the significant role of GOT(2) in the neuronal mitochondrial energy metabolism, it is quite likely that the down regulation of GOT(2) after blast exposure is playing a significant role in mitochondrial dysfunction after blast exposure.	[Arun, Peethambaran; Abu-Taleb, Rania; Oguntayo, Samuel; Wang, Ying; Valiyaveettil, Manojkumar; Long, Joseph B.; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Blast Induced Neurotrauma Branch, Silver Spring, MD 20910 USA	Arun, P (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Blast Induced Neurotrauma Branch, Silver Spring, MD 20910 USA.	peethambaran.arun.ctr@mail.mil					Arun P, 2012, INTERV MED APPL SCI, V4, P125, DOI 10.1556/IMAS.4.2012.3.2; Arun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033798; Arun P, 2012, NEUROREPORT, V23, P342, DOI 10.1097/WNR.0b013e328351b58d; Arun P, 2011, NEUROREPORT, V22, P379, DOI 10.1097/WNR.0b013e328346b138; Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Duckworth Josh L, 2013, Pathophysiology, V20, P23, DOI 10.1016/j.pathophys.2012.03.001; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Madhavarao CN, 2006, ADV EXP MED BIOL, V576, P49; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; Madhavarao CN, 2003, J NEUROCHEM, V86, P824, DOI 10.1046/j.1471-4159.2003.01905.x; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Xing GQ, 2012, EXP NEUROL, V234, P31, DOI 10.1016/j.expneurol.2011.12.007; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; YUDKOFF M, 1994, J BIOL CHEM, V269, P27414	30	21	22	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT 1	2013	30	19					1645	1651		10.1089/neu.2012.2834			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	227WQ	WOS:000325146800005	23600763				2021-06-18	
J	Yan, EB; Johnstone, VPA; Alwis, DS; Morganti-Kossmann, MC; Rajan, R				Yan, E. B.; Johnstone, V. P. A.; Alwis, D. S.; Morganti-Kossmann, M. -C.; Rajan, R.			CHARACTERISING EFFECTS OF IMPACT VELOCITY ON BRAIN AND BEHAVIOUR IN A MODEL OF DIFFUSE TRAUMATIC AXONAL INJURY	NEUROSCIENCE			English	Article						traumatic brain injury; impact velocity; diffuse axonal injury; behaviour deficit; electrophysiology; sensory cortex	LATERAL FLUID PERCUSSION; PROFESSIONAL FOOTBALL; MOUSE MODEL; ACCELERATION; MOTOR; BIOMECHANICS; PERFORMANCE; CONCUSSION; SEVERITY; CHILDREN	The velocity of impact between an object and the human head is a critical factor influencing brain injury outcomes but has not been explored in any detail in animal models. Here we provide a comprehensive overview of the interplay between impact velocity and injury severity in a well-established weight-drop impact acceleration (WDIA) model of diffuse brain injury in rodents. We modified the standard WDIA model to produce impact velocities of 5.4, 5.85 and 6.15 m/s while keeping constant the weight and the drop height. Gradations in impact velocity produced progressive degrees of injury severity measured behaviourally, electrophysiologically and anatomically, with the former two methods showing greater sensitivity to changes in impact velocity. There were impact velocity-dependent reductions in sensorimotor performance and in cortical depth-related depression of sensory cortex responses; however axonal injury (demonstrated by immunohistochemistry for beta-amyloid precursor protein and neurofilament heavy-chain) was discernible only at the highest impact velocity. We conclude that the WDIA model is capable of producing graded axonal injury in a repeatable manner, and as such will prove useful in the study of the biomechanics, pathophysiology and potential treatment of diffuse axonal injury. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Yan, E. B.; Johnstone, V. P. A.; Alwis, D. S.; Rajan, R.] Monash Univ, Dept Physiol, Monash, Vic 3800, Australia; [Morganti-Kossmann, M. -C.] Monash Univ, Dept Epidemiol & Prevent Med, Monash, Vic 3800, Australia; [Morganti-Kossmann, M. -C.] Australian New Zealand Ctr Intens Care Res, Carlton, Vic, Australia	Rajan, R (corresponding author), Monash Univ, Dept Physiol, Monash, Vic 3800, Australia.	Ramesh.rajan@monash.edu	Johnstone, Victoria/B-5083-2015; rajan, ramesh/L-4842-2019	Johnstone, Victoria/0000-0001-9885-3607; Rajan, Ramesh/0000-0001-9862-0520; Morganti-Kossmann, Cristina/0000-0002-0807-2063	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [APP1029311]	This study was funded by Grant No. APP1029311 from the National Health and Medical Research Council of Australia.	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Alwis DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052169; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Brands DWA, 2002, PRED BRAIN MECH CLOS, P155; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Davidsson Johan, 2011, Front Neurol, V2, P41, DOI 10.3389/fneur.2011.00041; Dischinger PC, 1998, ACCIDENT ANAL PREV, V30, P831, DOI 10.1016/S0001-4575(98)00036-0; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gilchrist MD, 2004, STRAIN, V40, P180, DOI 10.1111/j.1475-1305.2004.00168.x; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Han Y, 2012, TRAFFIC INJ PREV, V13, P507, DOI 10.1080/15389588.2012.661111; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Helps Y., 2008, HOSP SEPARATIONS DUE; Hendricks S, 2012, J SPORT SCI, V30, P1215, DOI 10.1080/02640414.2012.707328; Johnstone VPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063454; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; MAIC, 2012, STAT INF 1 JAN 30 JU; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nance ML, 2006, ANN SURG, V243, P121, DOI 10.1097/01.sla.0000193838.11102.56; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Rajan R, 2007, EUR J NEUROSCI, V25, P2383, DOI 10.1111/j.1460-9568.2007.05481.x; Rajan R, 2006, J NEUROSCI METH, V157, P103, DOI 10.1016/j.jneumeth.2006.04.008; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Tencer AF, 2005, ACCIDENT ANAL PREV, V37, P287, DOI 10.1016/j.aap.2004.09.005; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wood DP, 2005, P I MECH ENG D-J AUT, V219, P183, DOI 10.1243/095440705X6703; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yan WY, 2011, COMPUT METHOD BIOMEC, V14, P1049, DOI 10.1080/10255842.2010.506435; Ydenius A, 2010, TRAFFIC INJ PREV, V11, P526, DOI 10.1080/15389588.2010.492053; Yuelin Zhang, 2011, Journal of Biomechanical Science and Engineering, V6, P191, DOI 10.1299/jbse.6.191; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhao H, 2010, INT J CRASHWORTHINES, V15, P313, DOI 10.1080/13588260903335290	54	21	22	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	SEP 17	2013	248						17	29		10.1016/j.neuroscience.2013.05.045			13	Neurosciences	Neurosciences & Neurology	299UV	WOS:000330422100002	23735754				2021-06-18	
J	Andrews, PJD; Sinclair, LH; Harris, B; Baldwin, MJ; Battison, CG; Rhodes, JKJ; Murray, G; De Backer, D				Andrews, Peter J. D.; Sinclair, Louise H.; Harris, Bridget; Baldwin, Melissa J.; Battison, Claire G.; Rhodes, Jonathan K. J.; Murray, Gordon; De Backer, Daniel		Eurotherm3235Trial Collaborators	Study of therapeutic hypothermia (32 to 35 C) for intracranial pressure reduction after traumatic brain injury (the Eurotherm3235Trial): outcome of the pilot phase of the trial	TRIALS			English	Article						Traumatic brain injury; Therapeutic hypothermia; Randomized controlled trial; Feasibility	MILD HYPOTHERMIA; HEAD-INJURY; ADULTS; IMPACT; HYPERTENSION; PREVENTION; EFFICACY	Background: Clinical trials in traumatic brain injury (TBI) are challenging. Previous trials of complex interventions were conducted in high-income countries, reported long lead times for site setup and low screened-to-recruitment rates. In this report we evaluate the internal pilot phase of an international, multicentre TBI trial of a complex intervention to assess: design and implementation of an online case report form; feasibility of recruitment (sites and patients); feasibility and effectiveness of delivery of the protocol. Methods: All aspects of the pilot phase of the trial were conducted as for the main trial. The pilot phase had oversight by independent Steering and Data Monitoring committees. Results: Forty sites across 12 countries gained ethical approval. Thirty seven of 40 sites were initiated for recruitment. Of these, 29 had screened patients and 21 randomized at least one patient. Lead times to ethics approval (6.8 weeks), hospital approval (18 weeks), interest to set up (61 weeks), set up to screening (11 weeks), and set up to randomization (31.6 weeks) are comparable with other international trials. Sixteen per cent of screened patients were eligible. We found 88% compliance rate with trial protocol. Conclusion: The pilot data demonstrated good feasibility for this large international multicentre randomized controlled trial of hypothermia to control intracranial pressure. The sample size was reduced to 600 patients because of homogeneity of the patient group and we showed an optimized cooling intervention could be delivered.	[Andrews, Peter J. D.; Sinclair, Louise H.; Harris, Bridget; Battison, Claire G.; Rhodes, Jonathan K. J.] Univ Edinburgh, Dept Anaesthesia & Pain Management, Edinburgh, Midlothian, Scotland; [Baldwin, Melissa J.] NHS Lothian, Edinburgh EH1 3EG, Midlothian, Scotland; [Murray, Gordon] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [De Backer, Daniel] Univ Libre Brussels, Erasme Univ Hosp, B-1070 Brussels, Belgium	Andrews, PJD (corresponding author), Univ Edinburgh, Dept Anaesthesia & Pain Management, Edinburgh, Midlothian, Scotland.	p.andrews@ed.ac.uk	De Backer, Daniel/AAF-4177-2020; Forbes, John F/L-2558-2013	De Backer, Daniel/0000-0001-9841-5762; Forbes, John F/0000-0002-8255-3762; Murray, Gordon/0000-0001-9866-4734	European Society of Intensive Care Medicine (Pilot Phase); University of Edinburgh; NHS Lothian; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [11/01/30] Funding Source: researchfish	Funded by The European Society of Intensive Care Medicine (Pilot Phase) and sponsored by The University of Edinburgh and NHS Lothian.	Andrews PJD, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-8; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Edwards P, 2005, LANCET, V365, P1957; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; Klingmann I, 2009, IMPACT CLIN RES EURO; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Nilsson P, 2005, ACTA NEUROCHIR SUPPL, V95, P51; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300	20	21	27	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1745-6215			TRIALS	Trials	SEP 3	2013	14								277	10.1186/1745-6215-14-277			7	Medicine, Research & Experimental	Research & Experimental Medicine	213AI	WOS:000324024700001	24004918	DOAJ Gold, Green Published			2021-06-18	
J	Godbolt, AK; DeBoussard, CN; Stenberg, M; Lindgren, M; Ulfarsson, T; Borg, J				Godbolt, Alison K.; DeBoussard, Catharine Nygren; Stenberg, Maud; Lindgren, Marie; Ulfarsson, Trandur; Borg, Jorgen			DISORDERS OF CONSCIOUSNESS AFTER SEVERE TRAUMATIC BRAIN INJURY: A SWEDISH ICELANDIC STUDY OF INCIDENCE, OUTCOMES AND IMPLICATIONS FOR OPTIMIZING CARE PATHWAYS	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; prognosis; vegetative state; minimally conscious state; outcome; care pathways	REACTION LEVEL SCALE; GLASGOW COMA SCALE; PROLONGED POSTTRAUMATIC UNAWARENESS; PERSISTENT VEGETATIVE STATE; LATE RECOVERY; HEAD-INJURY; REHABILITATION; STIMULATION; GUIDELINES; RLS85	Background: Very severe traumatic brain injury may cause disorders of consciousness in the form of coma, unresponsive wakefulness syndrome (also known as vegetative state) or minimally conscious state. Previous studies of outcome for these patients largely pre-date the 2002 definition of minimally conscious state. Objectives: To establish the numbers of patients with disorder of consciousness at 3 weeks, 3 months and 1 year after severe traumatic brain injury, and to relate conscious state 3 weeks after injury to outcomes at 1 year. Design: Multi-centre, prospective, observational study of severe traumatic brain injury. Inclusion criteria: lowest (non-sedated) Glasgow Coma Scale 3-8 during the first 24 h; requirement for neurosurgical intensive care; age 18-65 years; alive 3 weeks after injury. Diagnosis of coma, unresponsive wakefulness syndrome, minimally conscious state or emerged from minimally conscious state was based on clinical and Coma Recovery Scale Revised assessments 3 weeks, 3 months and 1 year after injury. One-year outcome was measured with Glasgow Outcome Scale Extended (GOSE). Results: A total of 103 patients was included in the study. Of these, 81% were followed up to 1 year (76% alive, 5% dead). Three weeks after injury 36 were in coma, unresponsive wakefulness syndrome or minimally conscious state and 11 were anaesthetized. Numbers of patients who had emerged from minimally conscious state 1 year after injury, according to status at 3 weeks were: coma (0/6), unresponsive wakefulness syndrome (9/17), minimally conscious state (13/13), anaesthetized (9/11). Outcome at 1 year was good (GOSE>4) for half of patients in minimally conscious state or anaesthetized at 3 weeks, but for none of the patients in coma or unresponsive wakefulness syndrome. These differences in outcome were not revealed by prognostic predictions based on acute data. Conclusion: Patients in minimally conscious state or anaesthetized 3 weeks after injury have a better prognosis than patients in coma or unresponsive wakefulness syndrome, which could not be explained by acute prognostic models.	[Godbolt, Alison K.; DeBoussard, Catharine Nygren; Borg, Jorgen] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden; [Godbolt, Alison K.; DeBoussard, Catharine Nygren; Borg, Jorgen] Danderyd Hosp, Univ Dept Rehabil Med Stockholm, Stockholm, Sweden; [Godbolt, Alison K.] Univ Uppsala Hosp, Dept Rehabil Med, Uppsala, Sweden; [Godbolt, Alison K.] Uppsala Univ, Uppsala, Sweden; [Stenberg, Maud] Norrlands Univ Hosp, Dept Rehabil Med, Umea, Sweden; [Lindgren, Marie] Cty Council Ostergotland, Clin Dept Rehabil Med, Linkoping, Sweden; [Ulfarsson, Trandur] Sahlgrens Univ Hosp, Dept Rehabil Med, S-41345 Gothenburg, Sweden	Godbolt, AK (corresponding author), Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden.	alison.godbolt@ki.se		Borg, Jorgen/0000-0002-2372-7478; Godbolt, Alison/0000-0003-4511-6181	AFA insurance [060833]; ALF-grants from Uppsala University Hospital; Danderyd Hospital	The authors would like to thank the patients and their relatives, the PROBRAIN collaborators*, the clinical staff of our units, and our neurosurgical colleagues for allowing recruitment of their patients. This study was supported by grant 060833 from AFA insurance. The funders had no access to data and no input to study design or data analysis. AKG has received support from ALF-grants from Uppsala University Hospital and Danderyd Hospital. We also thank Dr Anna Tolli, Danderyd Hospital and Karolinska Institute, Dr Kristina Lindgren, Karlstad Hospital, Dr Bjorn Johansson, University Hospital Uppsala and Dr Christer Tengvar, University Hospital Uppsala, who assisted in assessment of patients. Paramedical staff contributing to the study included Stina Gunnarsson and Marina Bystrom Odhe, (Linkoping), Anna-Lisa Nilsson (Lima), Marie Sandgren (Stockholm), Steffan Stenson (Uppsala), and Siv Svensson (Gothenburg). Seija Lund was nurse coordinator in Stockholm and Ingrid Morberg in Gothenburg. Lisbet Broman gave advice on statistical aspects.	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; [Anonymous], 2001, BMC EMERG MED, V1, P1; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Godbolt AK, 2011, AM J PHYS MED REHAB, V90, P482, DOI 10.1097/PHM.0b013e31820f9768; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; INGVAR DH, 1973, ACTA NEUROL SCAND, V49, P233; JENNETT B, 1972, LANCET, V1, P734; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Krakau K, 2007, NUTRITION, V23, P308, DOI 10.1016/j.nut.2007.01.010; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; NHS Scotland, 2009, TRAUM BRAIN INJ TBI; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TESSERIS J, 1991, ACTA NEUROCHIR, V110, P65, DOI 10.1007/BF01402050; the Multi-Society Task Force on PVS, 1994, N ENGL J MED, V330, P1572; Walther SM, 2003, INTENS CARE MED, V29, P933, DOI 10.1007/s00134-003-1757-4; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yamamoto T, 2010, EUR J NEUROSCI, V32, P1145, DOI 10.1111/j.1460-9568.2010.07412.x	29	21	21	0	9	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					741	748		10.2340/16501977-1167			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500008	24002309	DOAJ Gold, Green Published			2021-06-18	
J	Klein, AM; Howell, K; Vogler, J; Grill, E; Straube, A; Bender, A				Klein, Anke-Maria; Howell, Kaitlen; Vogler, Jana; Grill, Eva; Straube, Andreas; Bender, Andreas			Rehabilitation Outcome of Unconscious Traumatic Brain Injury Patients	JOURNAL OF NEUROTRAUMA			English	Article						clinical course; recovery of consciousness; rehabilitation outcome; TBI	NEUROLOGIC PROGNOSIS; TERM OUTCOMES; LIFE; RESUSCITATION; CONSCIOUSNESS; EPIDEMIOLOGY; VALIDATION; PREDICTION; WITHDRAWAL; RECOVERY	Outcome prediction of traumatic brain injury (TBI) patients with severe disorders of consciousness (DOC) at the end of their time in an intensive care setting is important for clinical decision making and counseling of relatives, and constitutes a major challenge. Even the question of what constitutes an improved outcome is controversially discussed. We have conducted a retrospective cohort study for the rehabilitation dynamics and outcome of TBI patients with DOC. Out of 188 patients, 37.2% emerged from a minimally conscious state (MCS) and 16.5% achieved at least partial functional independence after a mean observation period of 107 days (range 1-399 days). This reflects that emergence from MCS is much easier to achieve than functional independence. Logistic regression analysis identified age and level of consciousness upon admission to neurorehabilitation as independent prognostic factors for both outcomes. The group who reached at least partial functional independence started to improve significantly more than the corresponding outcome group by post-injury week 7, and the average time to reach this functional status was 18 weeks. In contrast, the group who emerged from MCS started to improve after 6 weeks. The longest delay between brain injury and the beginning of functional improvement (measured by biweekly Functional Independence Measure [FIM] scores) still compatible with reaching at least partial functional independence was 18 weeks. In conclusion, despite a strong negative selection, a substantial proportion of severe TBI patients with DOC achieve functional improvements or at least emerge from MCS within the inpatient rehabilitation phase. In order to avoid self-fulfilling prophecies in decision making, it is important to be aware of the fact that the beginning of clinical improvement may take several months after brain injury. In this study, separation of both of the functional outcome groups started by 7 weeks post-injury.	[Klein, Anke-Maria; Howell, Kaitlen; Vogler, Jana; Straube, Andreas; Bender, Andreas] Univ Munich, Dept Neurol, D-81377 Munich, Germany; [Grill, Eva] Univ Munich, Inst Med Informat Biometry & Epidemiol, D-81377 Munich, Germany; [Grill, Eva] Univ Munich, Integrated Ctr Res & Treatment Vertigo Balance &, D-81377 Munich, Germany; [Bender, Andreas] Therapiezentrum Burgau, Dept Neurol, Burgau, Germany	Bender, A (corresponding author), Univ Munich, Dept Neurol, Marchioninistr 15, D-81377 Munich, Germany.	anbender@med.uni-muenchen.de	Grill, Eva/AAF-8104-2020; Grill, Eva/D-1875-2010	Grill, Eva/0000-0002-0273-7984; Grill, Eva/0000-0002-0273-7984; Bender, Andreas/0000-0002-6328-7104	ZNS Hannelore Kohl Stiftung foundation [2011013]	This study was supported by a grant (#2011013) of the ZNS Hannelore Kohl Stiftung foundation.	Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bender A, 2012, J NEUROL, V259, P2481, DOI 10.1007/s00415-012-6573-8; Beninato M, 2006, ARCH PHYS MED REHAB, V87, P32, DOI 10.1016/j.apmr.2005.08.130; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DUBROJA I, 1995, J NEUROL NEUROSUR PS, V58, P465, DOI 10.1136/jnnp.58.4.465; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Gabbe BJ, 2008, ANN SURG, V247, P854, DOI 10.1097/SLA.0b013e3181656d1e; Gabbe BJ, 2005, ACAD EMERG MED, V12, P751, DOI 10.1197/j.aem.2005.03.527; Geocadin RG, 2006, NEUROLOGY, V67, P105, DOI 10.1212/01.wnl.0000223335.86166.b4; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Grill E., 2013, ARCH PHYS MED REHABI; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hemphill JC, 2009, EMERG MED CLIN N AM, V27, P27, DOI 10.1016/j.emc.2008.08.009; Houlden DA, 2010, CRIT CARE MED, V38, P167, DOI 10.1097/CCM.0b013e3181c031b3; JENNETT B, 1975, LANCET, V1, P480; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Lule D, 2009, PROG BRAIN RES, V177, P339, DOI 10.1016/S0079-6123(09)17723-3; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Voss A, 1993, SPECTRUM NEUROREHABI, P112; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Woischneck D, 1998, ACT NEUR S, V71, P138; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466; Yuan F, 2012, J TRAUMA ACUTE CARE, V73, P137, DOI 10.1097/TA.0b013e31824b00ac; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88	35	21	21	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1476	1483		10.1089/neu.2012.2735			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800002	23477301	Green Published			2021-06-18	
J	Smith, BA; Harmatys, KM; Xiao, SZ; Cole, EL; Plaunt, AJ; Wolter, W; Suckow, MA; Smith, BD				Smith, Bryan A.; Harmatys, Kara M.; Xiao, Shuzhang; Cole, Erin L.; Plaunt, Adam J.; Wolter, William; Suckow, Mark A.; Smith, Bradley D.			Enhanced Cell Death Imaging Using Multivalent Zinc(II)-bis(dipicolylamine) Fluorescent Probes	MOLECULAR PHARMACEUTICS			English	Article						cell death imaging; multivalency; zinc(II)-bis(dipicolylamine); in vivo fluorescence imaging; phosphatidylserine; squaraine rotaxane	COORDINATION-COMPLEXES; INDUCED APOPTOSIS; MOLECULAR PROBES; BRAIN-INJURY; FIND-ME; DEXAMETHASONE; CANCER; MICE; PHOSPHATIDYLSERINE; MECHANISMS	There is a clinical need for imaging technologies that can accurately detect cell death in a multitude of pathological conditions. Zinc(II)-bis(dipicolylamine) (Zn(2)BDPA) Coordination complexes are known to associate with the anionic phosphatidylserine that is exposed on the surface Of dead and dying : cells; and fluorescent Monovalent Zn(2)BDPA probes are :successful cell death imaging agents. This present study compared the membrane targeting ability of two structurally related deep red fluorescent probes, bis-Zn(2)BDPA-SR and tetra-Zn(2)BDPA-SR, with two and four appended Za(2)BDPA units, respectively. Vesicle and cell microscopy studies. indicated that a higher number Zn(2)BDPA targeting units improved probe, selectivity for phosphatidylserine-rich Vesicles, and increased probe localization at the plasma membrane of dead and dying cells. The fluorescent probes were also tested in three separate animal models, (1) necrotic prostate tumor rat model, (2) thymus atrophy mouse model, and (3) traumatic brain injury mouse model. In each case, there was more tetra-Zn(2)BDPA-SR accumulation at the site of cell death than bis-Zn(2)BDPA-SR. The results indicate that multivalent Zn(2)BDPA probes are promising molecules for effective imaging of cell death processes in cell culture and in living subjects.	[Smith, Bryan A.; Harmatys, Kara M.; Xiao, Shuzhang; Cole, Erin L.; Plaunt, Adam J.; Smith, Bradley D.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Wolter, William; Suckow, Mark A.] Univ Notre Dame, Freimann Life Sci Ctr, Notre Dame, IN 46556 USA	Smith, BD (corresponding author), Univ Notre Dame, Dept Chem & Biochem, 236 Nieuwland Sci Hall, Notre Dame, IN 46556 USA.	smith.115@nd.edu	Suckow, Mark/C-2696-2014	Suckow, Mark/0000-0001-7317-697X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01GM059078, T32GM075762]; Notre Dame Integrated Imaging Facility; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM075762, R01GM059078] Funding Source: NIH RePORTER	We are grateful for funding support from NIH grants R01GM059078 (to B.D.S.) and T32GM075762 (to B.A.S.) and the Notre Dame Integrated Imaging Facility. We thank Sarah Chapman in the NDIIF for technical assistance.	AHMED SA, 1994, IMMUNOPHARMACOLOGY, V28, P55; Blankenberg FG, 2012, J NUCL MED, V53, P1659, DOI 10.2967/jnumed.112.108944; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Cole EL, 2012, ORG BIOMOL CHEM, V10, P5769, DOI 10.1039/c2ob06783h; Collins BE, 2004, CURR OPIN CHEM BIOL, V8, P617, DOI 10.1016/j.cbpa.2004.10.004; Englund EA, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1629; Frey B, 2009, J IMMUNOTOXICOL, V6, P209, DOI 10.3109/15476910903204058; Gassensmith JJ, 2009, CHEM COMMUN, P6329, DOI 10.1039/b911064j; Hanshaw RG, 2005, CHEMBIOCHEM, V6, P2214, DOI 10.1002/cbic.200500149; Ichiyoshi H, 2003, EXP MOL PATHOL, V75, P178, DOI 10.1016/S0014-4800(03)00050-9; Jiang H, 2005, ORG LETT, V7, P3013, DOI 10.1021/ol0510421; Johnson JR, 2007, ANGEW CHEM INT EDIT, V46, P5528, DOI 10.1002/anie.200701491; Kawahara S, 2001, EUR J INORG CHEM, P2437; Konstantinidis K, 2012, ARTERIOSCL THROM VAS, V32, P1552, DOI 10.1161/ATVBAHA.111.224915; Krachler AM, 2011, P NATL ACAD SCI USA, V108, P11614, DOI 10.1073/pnas.1102360108; Lakshmi C, 2004, TETRAHEDRON, V60, P11307, DOI 10.1016/j.tet.2004.08.052; Lambert TN, 2003, COORDIN CHEM REV, V240, P129, DOI 10.1016/S0010-8545(02)00257-6; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Munoz LE, 2007, J LEUKOCYTE BIOL, V81, P6, DOI 10.1189/jlb.0306166; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Smith BA, 2012, BIOCONJUGATE CHEM, V23, P1989, DOI 10.1021/bc3003309; Smith BA, 2012, ACS CHEM NEUROSCI, V3, P530, DOI 10.1021/cn3000197; Smith BA, 2011, APOPTOSIS, V16, P722, DOI 10.1007/s10495-011-0601-5; Smith BA, 2011, MOL PHARMACEUT, V8, P583, DOI 10.1021/mp100395u; Smith BA, 2010, J AM CHEM SOC, V132, P67, DOI 10.1021/ja908467y; Stoffel M, 2004, J NEUROTRAUM, V21, P733, DOI 10.1089/0897715041269678; SUN XM, 1992, BIOCHEM PHARMACOL, V44, P2131; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; White AG, 2012, BIOORG MED CHEM LETT, V22, P2833, DOI 10.1016/j.bmcl.2012.02.078; White AG, 2010, BIOCONJUGATE CHEM, V21, P1297, DOI 10.1021/bc1000998; Xiao SZ, 2013, TETRAHEDRON LETT, V54, P861, DOI 10.1016/j.tetlet.2012.11.103; Xiao SZ, 2010, ORG LETT, V12, P140, DOI 10.1021/ol902546m	37	21	21	0	67	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1543-8384	1543-8392		MOL PHARMACEUT	Mol. Pharm.	SEP	2013	10	9					3296	3303		10.1021/mp300720k			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	240WP	WOS:000326128700003	23915311	Green Accepted			2021-06-18	
J	Zimmer, A; Piecora, K; Schuster, D; Webbe, F				Zimmer, Adam; Piecora, Kyle; Schuster, Danielle; Webbe, Frank			Sport and Team Differences on Baseline Measures of Sport-Related Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						traumatic brain injuries; baseline assessment; Concussion Resolution Index; Standardized Assessment of Concussion; Balance Error Scoring System	NEUROPSYCHOLOGICAL TEST PROTOCOL; ERROR SCORING SYSTEM; POSTURAL STABILITY; BALANCE; MANAGEMENT; SYMPTOMS; RELIABILITY; DIAGNOSIS; ATHLETE; INJURY	Context: With the advent of the National Collegiate Athletic Association's (NCAA's) mandating the presence and practice of concussion-management plans in collegiate athletic programs, institutions will consider potential approaches for concussion management, including both baseline and normative comparison approaches. Objective: To examine sport and team differences in baseline performance on a computer-based neurocognitive measure and 2 standard sideline measures of cognition and balance and to determine the potential effect of premorbid factors sex and height on baseline performance. Design: Cross-sectional study. Setting: University laboratory. Patients or Other Participants: A total of 437 NCAA Division II student-athletes (males = 273, females = 164; age = 19.61 +/- 1.64 years, height = 69.89 +/- 4.04 inches [177.52 +/- 10.26 cm]) were recruited during mandatory preseason testing conducted in a concussion-management program. Main Outcome Measure(s): The computerized Concussion Resolution Index (CRI), the Standardized Assessment of Concussion (Form A; SAC), and the Balance Error Scoring System (BESS). Results: Players on the men's basketball team tended to perform worse on the baseline measures, whereas soccer players tended to perform better. We found a difference in total BESS scores between these sports (P = .002). We saw a difference between sports on the hard-surface portion of the BESS (F-6,F-347 = 3.33, P = .003, eta(2)(p) = 0.05). No sport, team, or sex differences were found with SAC scores (P > .05). We noted differences between sports and teams in the CRI indices, with basketball, particularly the men's team, performing worse than soccer (P < .001) and softball/baseball (P = .03). When sex and height were considered as possible sources of variation in BESS and CRI team or sport differences, height was a covariate for the team (F-1,F-385 = 5.109, P = .02, eta(2)(p) = 0.013) and sport (F1,326 = 11.212, P = .001, eta(2)(p) = 0.033) analyses, but the interaction of sex and sport on CRI indices was not significant in any test (P > .05). Conclusions: Given that differences in neurocognitive functioning and performance among sports and teams exist, the comparison of posttraumatic and baseline assessment may lead to more accurate diagnoses of concussion and safer return-to- participation decision making than the use of normative comparisons.	[Zimmer, Adam; Piecora, Kyle; Schuster, Danielle; Webbe, Frank] Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA	Webbe, F (corresponding author), Florida Inst Technol, 150 W Univ Blvd, Melbourne, FL 32901 USA.	webbe@fit.edu		Webbe, Frank/0000-0002-4370-5698			Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT., 1989, MILD HEAD INJURY, P257; Bressel E, 2007, J ATHL TRAINING, V42, P42; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cohen J., 1988, STAT POWER ANAL BEHA, P284; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Lovell MR, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P111, DOI 10.1007/0-387-32565-4_6; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M., 1997, STANDARDIZED ASSESSM; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; PARDINI JE, 2010, HDB SPORT NEUROPSYCH, P209; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ryan JP, 2004, CLIN J SPORT MED, V14, P18, DOI 10.1097/00042752-200401000-00004	27	21	21	0	16	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2013	48	5					659	667		10.4085/1062-6050-48.5.06			9	Sport Sciences	Sport Sciences	268AR	WOS:000328140600010	23952044	Green Published			2021-06-18	
J	Cripps, MW; Kutcher, ME; Daley, A; McCreery, RC; Greenberg, MD; Cachola, LM; Redick, BJ; Nelson, MF; Cohen, MJ				Cripps, Michael W.; Kutcher, Matthew E.; Daley, Aaron; McCreery, Ryan C.; Greenberg, Molly D.; Cachola, Leslie M.; Redick, Brittney J.; Nelson, Mary F.; Cohen, Mitchell Jay			Cause and timing of death in massively transfused trauma patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	Military Health Systems Research Symposium (MHSRS)	AUG 13-16, 2012	Fort Lauderdale, FL			Massive transfusion; cause of death; epidemiology of trauma	BLOOD-CELL RATIOS; EARLY COAGULOPATHY; EPIDEMIOLOGY; PLASMA; INJURY; IMPACT; HEMORRHAGE; MORTALITY; PLATELET	BACKGROUND: The purpose of this study was to characterize the cause of death in severely injured trauma patients to define potential responses to resuscitation. METHODS: Prospective analysis of 190 critically injured patients who underwent massive transfusion protocol (MTP) activation or received massive transfusion (910 U of packed red blood cells [RBC] per 24 hours). Cause of death was adjudicated into one of four categories as follows: (1) exsanguination, (2) early physiologic collapse, (3) late physiologic collapse, and (4) nonsurvivable injury. RESULTS: A total 190 patients underwent massive transfusion or MTP with 76 deaths (40% mortality), of whom 72 deaths were adjudicated to one of four categories: 33.3% died of exsanguination, 16.6% died of early physiologic collapse, 11.1% died of late physiologic collapse, while 38.8% died of nonsurvivable injuries. Patients who died of exsanguination were younger and had the highest RBC/fresh frozen plasma ratio (2.97 [2.24]), although the early physiologic collapse group survived long enough to use the most blood products (p < 0.001). The late physiologic collapse group had significantly fewer penetrating injuries, was older, and had significantly more crystalloid use but received a lower RBC/fresh frozen plasma ratio (1.50 [0.42]). Those who were determined to have a nonsurvivable injury had a lower presenting Glasgow Coma Scale (GCS) score, fewer penetrating injuries, and higher initial blood pressure reflecting a preponderance of nonsurvivable traumatic brain injury. The average survival time for patients with potentially survivable injuries was 2.4 hours versus 18.4 hours for nonsurvivable injuries (p < 0.001). CONCLUSION: Severely injured patients requiring MTP have a high mortality rate. However, no studies to date have addressed the cause of death after MTP. Characterization of cause of death will allow targeting of surgical and resuscitative conduct to allow extension of the physiologic reserve time, therefore rendering previously nonsurvivable injury potentially survivable. (J Trauma Acute Care Surg. 2013; 75: S255YS262. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Cripps, Michael W.] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn Trauma Crit Care, Dallas, TX 75390 USA; [Kutcher, Matthew E.; McCreery, Ryan C.; Greenberg, Molly D.; Cachola, Leslie M.; Redick, Brittney J.; Nelson, Mary F.; Cohen, Mitchell Jay] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Surg, San Francisco, CA USA	Cripps, MW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn Trauma Crit Care, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	michael.cripps@utsouthwestern.edu		Kutcher, Matthew/0000-0003-4566-5359; Cripps, Michael/0000-0002-1263-1876	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08 GM085689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM085689] Funding Source: NIH RePORTER		BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Cothren CC, 2007, WORLD J SURG, V31, P1507, DOI 10.1007/s00268-007-9087-2; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Evans JA, 2010, WORLD J SURG, V34, P158, DOI 10.1007/s00268-009-0266-1; Flaherty S, 2003, J TRAUMA, V54, P70; Ho AMH, 2012, BRIT J SURG, V99, P132, DOI 10.1002/bjs.7732; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Pang JM, 2008, INJURY, V39, P102, DOI 10.1016/j.injury.2007.05.022; Perkins JG, 2011, TRANSFUSION, V51, P242, DOI 10.1111/j.1537-2995.2010.02818.x; Potenza BM, 2004, J TRAUMA, V56, P68, DOI 10.1097/01.TA.0000101490.32972.9F; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Teixeira PGR, 2009, J TRAUMA, V66, P693, DOI 10.1097/TA.0b013e31817e5c77; Tien HC, 2007, J TRAUMA, V62, P142, DOI 10.1097/01.ta.0000251558.38388.47; Zehtabchi S, 2009, ACAD EMERG MED, V16, P371, DOI 10.1111/j.1553-2712.2009.00386.x	26	21	22	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2013	75			2			S255	S262		10.1097/TA.0b013e31829a24b4			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300JV	WOS:000330461100028	23883917	Green Accepted			2021-06-18	
J	Hwabejire, JO; Jin, G; Imam, AM; Duggan, M; Sillesen, M; Deperalta, D; Jepsen, CH; Lu, J; Li, YQ; deMoya, MA; Alam, HB				Hwabejire, John O.; Jin, Guang; Imam, Ayesha M.; Duggan, Michael; Sillesen, Martin; Deperalta, Danielle; Jepsen, Cecilie H.; Lu, Jennifer; Li, Yongqing; deMoya, Marc A.; Alam, Hasan B.			Pharmacologic modulation of cerebral metabolic derangement and excitotoxicity in a porcine model of traumatic brain injury and hemorrhagic shock	SURGERY			English	Article							MEMBRANE PHOSPHOLIPID DEGRADATION; PERMEABILITY TRANSITION PORE; CRITICALLY-ILL PATIENTS; OXYGEN DELIVERY; CELL-DEATH; RAT-BRAIN; K+-ATPASE; GLUTAMATE; GLYCEROL; INHIBITION	Background. Cerebral metabolic derangement and excitotoxicity play critical roles in the evolution of traumatic brain injury (TBI). We have shown previously that treatment with large doses of valproic acid (VPA) decreases the size of brain lesion. The goal of this experiment was to determine whether this effect was owing to metabolic modulation. Methods. Yorkshire swine (n = 9) underwent a protocol of computer-controlled TBI and 40% hemorrhage and were resuscitated randomly with either fresh frozen plasma equal to the volume of shed blood (FFP; n = 4) or VPA (300 mg/kg) and FFP (FFP+VPA; n = 5). Hemodynamics, brain oxygenation, and blood glucose were monitored continuously for 6 hours after resuscitation. Cerebral microdialysis was used to measure glucose, lactate, pyruvate, glutamate, and glycerol levels at baseline, 1 and 2 hours post-shock, post-resuscitation (PR), and at 2, 4, and 6 hours PR. Brain samples from the injured side were then separated into mitochondrial and cytosolic fractions, and activity of pyruvate dehydrogenase complex (PDH) was measured using a dipstick assay kit. Results. At baseline, there was no difference in brain lactate, pyruvate, glycerol, and glutamate concentrations between the groups. At all time points, there were no differences between the groups in brain oxygenation, cerebral perfusion pressure, or blood and brain glucose concentrations. After VPA infusion (PR time point), however, there was sustained decrease in lactate (0.91 +/- 0.47 vs 2.54 +/- 0.59 mmol/L; P < .01) and pyruvate (12.80 +/- 4.89 vs 46.25 +/- 9.22; P < .001) concentrations compared with the FFP alone group, implying superior glucose utilization for ATP production. There was also a decrease in concentrations of glutamate (6.64 +/- 3.68 vs 42.25 +/- 27.07 mmol/L; P = .02) and glycerol (19.20 +/- 6.76 vs 69.75 +/- 30.07 mmol/L; P = .01), in the FFP+VPA group, signifying lesser degree of excitotoxicity and brain damage, respectively. Brain PDH activity was greater in the mitochondrial fractions (5,984 +/- 504 adjusted volume intensity [INT] X mm(2) vs 4,332 +/- 1,055 INT X mm(2); P = .04) and lower in cytosolic fractions in the FFP+VPA group (1,597 +/- 1,395 vs 4,026 +/- 1,067 INT X mm(2); P = .03), indicating better mitochondrial membrane function and enhanced mitochondrial PDH retention. Conclusion. VPA treatment attenuates perturbation of post-traumatic cerebral metabolism by mitigating mitochondrial dysfunction, and decreases glutamate-mediated excitotoxic damage. These properties could explain its effectiveness in decreasing lesion size and post-traumatic cerebral edema.	[Hwabejire, John O.; Jin, Guang; Imam, Ayesha M.; Duggan, Michael; Sillesen, Martin; Deperalta, Danielle; Jepsen, Cecilie H.; Lu, Jennifer; Li, Yongqing; deMoya, Marc A.; Alam, Hasan B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care,Dept S, Boston, MA USA; [Jin, Guang; Alam, Hasan B.] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA	Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 5331 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Sillesen, Martin/0000-0001-9494-5475	US Army Medical Research Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]	Funded by a grant from the US Army Medical Research Material Command GRANTT00521959 (to HBA).	Anderson TR, 2010, J PHYSIOL-LONDON, V588, P4401, DOI 10.1113/jphysiol.2010.191858; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; BROWN GK, 1994, J MED GENET, V31, P875, DOI 10.1136/jmg.31.11.875; Butt MU, 2009, J SURG RES, V156, P290, DOI 10.1016/j.jss.2009.04.012; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fei Zhou, 2003, Chin J Traumatol, V6, P270; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Frye RE, PYRUVATE DEHYDROGENA; Guyton A.C., 2006, TXB MED PHYSL; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Howarth C, 2012, J CEREBR BLOOD F MET, V32, P1222, DOI 10.1038/jcbfm.2012.35; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Li YQ, 2012, ADV EXP MED BIOL, V710, P107, DOI 10.1007/978-1-4419-5638-5_11; Mark LP, 2001, AM J NEURORADIOL, V22, P1813; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Mellergard P, 2012, J NEUROTRAUM, V29, P112, DOI 10.1089/neu.2010.1732; Mitosciences, PYR DEH PDH ENZ ACT; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Mukhin A, 1996, J NEUROSCI, V16, P6012; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Qu MY, 2012, NEUROSCI RES, V72, P94, DOI 10.1016/j.neures.2011.09.009; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; US Centers for Disease Control and Prevention, INJ PREV CONTR TRAUM; US Centers for Disease Control and Prevention, SURV TRAUM BRAIN INJ; US Centers for Disease Control and Prevention, TRAUM BRAIN INJ US; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wang XQ, 2003, J CELL SCI, V116, P2099, DOI 10.1242/jcs.00420; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YU MH, 1993, CRIT CARE MED, V21, P830, DOI 10.1097/00003246-199306000-00009; Yu SP, 2003, BIOCHEM PHARMACOL, V66, P1601, DOI 10.1016/S0006-2952(03)00531-8; Zacharias N, 2011, RESUSCITATION, V82, P105, DOI 10.1016/j.resuscitation.2010.09.469; Zorov DB, 2009, CARDIOVASC RES, V83, P213, DOI 10.1093/cvr/cvp151	39	21	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	AUG	2013	154	2					234	243		10.1016/j.surg.2013.04.008			10	Surgery	Surgery	196UB	WOS:000322801800012	23889951				2021-06-18	
J	Mullen, MT; Kasner, SE; Messe, SR				Mullen, Michael T.; Kasner, Scott E.; Messe, Steven R.			Seizures Do Not Increase In-Hospital Mortality After Intracerebral Hemorrhage in the Nationwide Inpatient Sample	NEUROCRITICAL CARE			English	Article						Intracerebral hemorrhage; Seizures; Anti-epileptic drugs; Outcomes; Classifications: ICH; Seizures; Stroke	ADMINISTRATIVE DATA; ANTIEPILEPTIC DRUG; ACUTE STROKE; PREDICTORS; MULTICENTER; ICH	Seizures are common after intracerebral hemorrhage (ICH) but their impact on outcome is uncertain and prophylactic anti-convulsant use is controversial. We hypothesized that seizures would not increase the risk of in-hospital mortality in a large administrative database. The study population included patients in the 2006 Nationwide Inpatient Sample over the age of 18 with a principal diagnosis of ICH (ICD9 = 431). Subjects with a secondary diagnosis of aneurysm, arterio-venous malformation, brain tumor, or traumatic brain injury were excluded. Seizures were defined by ICD9 codes (345.0x-345.5x, 345.7x-345.9x, 780.39). Logistic regression was used to quantify the relationship between seizures and in-hospital mortality. Pre-specified subgroups included age strata, length of stay, and invasive procedures. 13,033 subjects met all eligibility criteria, of which 1,430 (11.0 %) had a secondary diagnosis of seizure. Subjects with seizure were younger (64 vs. 70 years, p < 0.001), more likely to get craniectomy (2.1 vs. 1.2 %, p = 0.006), ventriculostomy (8.5 vs. 6.0 %, p < 0.001), intubation (32.2 vs. 25.9 %, p < 0.001), and tracheostomy (6.4 vs. 4.2 %, p < 0.001). Seizure patients had lower in-hospital mortality (24.3 vs. 28.0 %, p = 0.003). In a multivariable model incorporating patient and hospital level variables, seizures were associated with reduced odds of in-hospital death (OR = 0.62, 95 % CI 0.52-0.75). A secondary diagnosis of seizure after ICH was not associated with increased in-hospital death overall or in any of the pre-specified subgroups; however, there may be residual confounding by severity. These findings do not support a need for routine prophylactic anti-epileptic drug use after ICH.	[Mullen, Michael T.; Kasner, Scott E.; Messe, Steven R.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	Mullen, MT (corresponding author), Univ Penn, Dept Neurol, 3400 Spruce St,3 W Gates Bldg, Philadelphia, PA 19104 USA.	michael.mullen@uphs.upenn.edu					[Anonymous], 2011, OV NAT INP SAMPL NIS; Arboix A, 1997, STROKE, V28, P1590, DOI 10.1161/01.STR.28.8.1590; Averill Richard F, 2002, J AHIMA, V73, P46; Battey TW, 2012, NEUROCRIT CARE; BERGER AR, 1988, NEUROLOGY, V38, P1363, DOI 10.1212/WNL.38.9.1363; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Burneo JG, 2010, EUR J NEUROL, V17, P52, DOI 10.1111/j.1468-1331.2009.02739.x; Castellanos M, 2005, J NEUROL NEUROSUR PS, V76, P691, DOI 10.1136/jnnp.2004.044347; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; De Herdt V, 2011, NEUROLOGY, V77, P1794, DOI 10.1212/WNL.0b013e31823648a6; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Gilad R, 2011, EPILEPSY RES, V95, P227, DOI 10.1016/j.eplepsyres.2011.04.002; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Jette N, 2010, EPILEPSIA, V51, P62, DOI 10.1111/j.1528-1167.2009.02201.x; KILPATRICK CJ, 1990, ARCH NEUROL-CHICAGO, V47, P157, DOI 10.1001/archneur.1990.00530020053014; Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1; Labovitz DL, 2001, NEUROLOGY, V57, P200, DOI 10.1212/WNL.57.2.200; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Messe S, 2009, NEUROCRIT CARE, V11, P38, DOI 10.1007/s12028-009-9207-y; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; Passero S, 2002, EPILEPSIA, V43, P1175, DOI 10.1046/j.1528-1157.2002.00302.x; Reddig RT, 2011, CLIN NEUROL NEUROSUR, V113, P895, DOI 10.1016/j.clineuro.2011.07.008; Reith J, 1997, STROKE, V28, P1585, DOI 10.1161/01.STR.28.8.1585; Szaflarski JP, 2008, EPILEPSIA, V49, P974, DOI 10.1111/j.1528-1167.2007.01513.x; Taylor S, 2011, NEUROCRIT CARE, V15, P80, DOI 10.1007/s12028-010-9341-6; Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4	28	21	22	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	AUG	2013	19	1					19	24		10.1007/s12028-012-9791-0			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	187SP	WOS:000322140000004	23138543				2021-06-18	
J	Sitruk-Ware, R; El-Etr, M				Sitruk-Ware, R.; El-Etr, M.			Progesterone and related progestins: potential new health benefits	CLIMACTERIC			English	Article						PROGESTERONE; PROGESTIN; NESTORONE; NEUROREGENERATION; MYELIN REPAIR; STROKE; HORMONE REPLACEMENT THERAPY; LACTATION; PROGESTERONE VAGINAL RING	HORMONE REPLACEMENT THERAPY; TRAUMATIC BRAIN-INJURY; MEDROXYPROGESTERONE ACETATE; PRETERM BIRTH; VAGINAL RING; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; RECEPTORS; NESTORONE; ESTRADIOL	Progesterone is a steroid hormone that is essential for the regulation of reproductive function. The main physiological roles of this hormone have been widely described. Progesterone and progestins have been approved for a number of indications including the treatment of irregular and anovulatory menstrual cycles and, when combined with estrogen, for contraception, and the prevention of endometrial hyperplasia in postmenopausal hormonal replacement therapy (HRT) regimens. Lack of understanding between the differences in categories of the progestins as well as with the physiological hormone has resulted in considerable controversy surrounding the use of progestins for HRT regimens. Newer evidence suggests that there are distinct differences between the molecules and there is no progestin class effect, with regard to benefits or side-effects. In addition to its role in reproduction, progesterone regulates a number of biologically distinct processes in other tissues, particularly in the nervous system and the vessels. Recently, it has been shown in animal experiments that progesterone and the progestin Nestorone (R) have positive effects on neuroregeneration and repair of brain damage, as well as myelin repair. The potential benefits of natural progesterone and its related derivatives warrant further investigation. It is hoped that a better understanding of the mechanism of action of progesterone and selected progestins will help in defining better therapies for men and women.	[Sitruk-Ware, R.] Populat Council, New York, NY 10065 USA; [Sitruk-Ware, R.] Rockefeller Univ, New York, NY 10021 USA; [El-Etr, M.] INSERM, UMR 788, Le Kremlin Bicetre, France	Sitruk-Ware, R (corresponding author), Populat Council, 1230 York Ave, New York, NY 10065 USA.				USAIDUnited States Agency for International Development (USAID); NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Barrus Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5 ROI HD061106-04, 5U54HD029990]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD029990, R01HD061106] Funding Source: NIH RePORTER	Some results described in this review were obtained under grants from USAID, NICHD and the Barrus Foundation. R. S. W. received support from the NIH for the work on the progesterone vaginal ring during lactation (5 ROI HD061106-04) and for the work on the action of progesterone and Nestorone on the brain (5U54HD029990).	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Canonico M, 2010, ARTERIOSCL THROM VAS, V30, P340, DOI 10.1161/ATVBAHA.109.196022; Chabbert-Buffet N, 2012, MOL CELL ENDOCRINOL, V358, P232, DOI 10.1016/j.mce.2012.02.021; CHI IC, 1995, CLIN OBSTET GYNECOL, V38, P872, DOI 10.1097/00003081-199538040-00022; Cicinelli E, 2000, OBSTET GYNECOL, V95, P403, DOI 10.1016/S0029-7844(99)00542-6; Conneely OM, 2000, STEROIDS, V65, P571, DOI 10.1016/S0039-128X(00)00115-X; da Fonseca EB, 2003, AM J OBSTET GYNECOL, V188, P419, DOI 10.1067/mob.2003.41; de Villiers TJ, 2013, CLIMACTERIC, V16, P203, DOI 10.3109/13697137.2013.771520; Di Renzo GC, 2012, GYNECOL ENDOCRINOL, V28, P925, DOI 10.3109/09513590.2012.730576; DIAZ S, 1991, J CLIN ENDOCR METAB, V72, P196, DOI 10.1210/jcem-72-1-196; DIAZ S, 1991, ANN NY ACAD SCI, V626, P11; Edwards HE, 2000, NEUROSCIENCE, V101, P895, DOI 10.1016/S0306-4522(00)00439-5; Fournier A, 2008, J CLIN ONCOL, V26, P1260, DOI 10.1200/JCO.2007.13.4338; Fournier A, 2008, BREAST CANCER RES TR, V107, P103, DOI 10.1007/s10549-007-9523-x; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Fraser IS, 2007, CONTRACEPTION, V76, P432, DOI 10.1016/j.contraception.2007.08.006; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Fu XD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-166; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Gaussem P, 2011, THROMB HAEMOSTASIS, V105, P560, DOI 10.1160/TH10-05-0327; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gofflot F, 2007, CELL, V131, P405, DOI 10.1016/j.cell.2007.09.012; Gravett MG, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-S1-S2; Hassan SS, 2011, ULTRASOUND OBST GYN, V38, P18, DOI 10.1002/uog.9017; Herkert O, 2001, CIRCULATION, V104, P2826, DOI 10.1161/hc4801.099737; Hermsmeyer RK, 2008, NAT CLIN PRACT CARD, V5, P387, DOI 10.1038/ncpcardio1234; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Klipping C, 2011, DRUGS R&D, V11, P159, DOI 10.2165/11591200-000000000-00000; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kumar N, 2000, STEROIDS, V65, P629, DOI 10.1016/S0039-128X(00)00119-7; Levy T, 2000, STEROIDS, V65, P645, DOI 10.1016/S0039-128X(00)00121-5; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu LF, 2010, ENDOCRINOLOGY, V151, P5782, DOI 10.1210/en.2010-0005; Luo GY, 2010, REPROD SCI, V17, P532, DOI 10.1177/1933719110363618; MACLUSKY NJ, 1978, NATURE, V274, P276, DOI 10.1038/274276a0; Massai MR, 2001, CONTRACEPTION, V64, P369, DOI 10.1016/S0010-7824(01)00259-1; Massai R, 2005, CONTRACEPTION, V72, P352, DOI 10.1016/j.contraception.2005.05.004; Meis PJ, 2003, NEW ENGL J MED, V348, P2379, DOI 10.1056/NEJMoa035140; MILES RA, 1994, FERTIL STERIL, V62, P485; Nath A, 2009, CLIMACTERIC, V12, P96, DOI 10.1080/13697130902905757; Nath A, 2009, EUR J CONTRACEP REPR, V14, P88, DOI 10.1080/13625180902747425; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; PARSONS B, 1982, J NEUROSCI, V2, P1446; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Sandstrom NJ, 2001, BEHAV NEUROSCI, V115, P384, DOI 10.1037//0735-7044.115.2.384; Sasagawa S, 2008, STEROIDS, V73, P222, DOI 10.1016/j.steroids.2007.10.003; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schierbeck LL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6409; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; SHAABAN MM, 1991, J STEROID BIOCHEM, V40, P705, DOI 10.1016/0960-0760(91)90294-F; Simoncini T, 2007, HUM REPROD, V22, P2325, DOI 10.1093/humrep/dem109; Sitruk-Ware R, 2007, CLIMACTERIC, V10, P358, DOI 10.1080/13697130701609121; Sitruk-Ware R, 2010, CONTRACEPTION, V82, P410, DOI 10.1016/j.contraception.2010.04.004; Sitruk-Ware R, 2008, MATURITAS, V61, P151, DOI 10.1016/j.maturitas.2004.01.001; Sivin I, 1997, CONTRACEPTION, V55, P225, DOI 10.1016/S0010-7824(97)00008-5; Smith C, 2012, INT J STROKE, DOI [10.1111/j.1747-4949.2012.00924, DOI 10.1111/J.1747-4949.2012.00924]; Stanczyk FZ, 2013, ENDOCR REV, V34, P171, DOI 10.1210/er.2012-1008; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stuenkel CA, 2012, J CLIN ENDOCR METAB, V97, P2617, DOI 10.1210/jc.2012-2403; Tavaniotou A, 2000, HUM REPROD UPDATE, V6, P139, DOI 10.1093/humupd/6.2.139; Toner JP, 2000, HUM REPROD, V15, P166, DOI 10.1093/humrep/15.suppl_1.166; Valore EV, 2002, AM J OBSTET GYNECOL, V187, P561, DOI 10.1067/mob.2002.125280; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8; Williams JK, 1998, AM J OBSTET GYNECOL, V179, P1288, DOI 10.1016/S0002-9378(98)70149-8; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zegers-Hochschild F, 2000, HUM REPROD, V15, P2093, DOI 10.1093/humrep/15.10.2093; Zegers-Hochschild F, 1996, HUM REPROD, V11, P53; Zerr-Fouineau M, 2007, FASEB J, V21, P265, DOI 10.1096/fj.06-6840com	81	21	28	0	29	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1369-7137	1473-0804		CLIMACTERIC	Climacteric	AUG	2013	16			1			69	78		10.3109/13697137.2013.802556			10	Obstetrics & Gynecology	Obstetrics & Gynecology	183BB	WOS:000321787500010	23647429				2021-06-18	
J	Tam, JW; Schmitter-Edgecombe, M				Tam, Joyce W.; Schmitter-Edgecombe, Maureen			The Role of Processing Speed in the Brief Visuospatial Memory Test - Revised	CLINICAL NEUROPSYCHOLOGIST			English	Article						BVMT-R; Visuospatial memory; Speed of processing; Executive function	TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; WORKING-MEMORY; MULTIPLE-SCLEROSIS; OLDER-ADULTS; PERFORMANCE; BATTERY; SCHIZOPHRENIA; VALIDATION; DEMENTIA	The Brief Visuospatial Memory Test - Revised (BVMT-R) is a commonly used, commercialized, assessment tool to measure visuospatial learning and memory abilities across research and clinical settings. In this study we evaluated the influence of processing speed and executive functioning on BVMT-R learning, memory, and percent retention scores. A total of 141 cognitively healthy older adults completed the BVMT-R along with measures of visuoconstructional abilities (BVMT-R copy), speeded processing (Symbol Digit Modalities Test-oral), and executive function (FAS). After controlling for age and visuoconstructional abilities, hierarchical regression models showed that the processing speed measure was a unique predictor of both BVMT-R learning and memory performances, while the executive function measure was not. The visuoconstructional measure was the only unique predictor of BVMT-R percent retention. The findings suggest that, when interpreting the BVMT-R learning and memory scores of patients who exhibit speeded processing deficits, the impact of slowed processing speed on performance should be considered.	[Tam, Joyce W.; Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			Life Science Discovery Fund of Washington State; NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB009675]; NSFNational Science Foundation (NSF) [DGE-0900781]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009675] Funding Source: NIH RePORTER	We would like to thank the members of the WSU Aging and Dementia Research Laboratory for their help in coordinating, collecting, and scoring the data. Portions of this research were presented at the 40th annual conference of the International Neuropsychological Society, Montreal, Quebec, Canada. This research was funded in part by grants from the Life Science Discovery Fund of Washington State; NIBIB (Grant #R01 EB009675); and NSF (Grant DGE-0900781). No financial or other relationships exist that could be interpreted as a conflict of interest pertaining to this manuscript.	Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 2006, J INT NEUROPSYCH SOC, V12, P549, DOI 10.1017/S1355617706060723; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; BRANDT J, 2003, TELEPHONE INTERVIEW; Brown LA, 2012, EXP AGING RES, V38, P1, DOI 10.1080/0361073X.2012.636722; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Duff K, 2005, ARCH CLIN NEUROPSYCH, V20, P111, DOI 10.1016/j.acn.2004.03.003; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Foster PS, 2010, COGN BEHAV NEUROL, V23, P19, DOI 10.1097/WNN.0b013e3181c20de7; Green MF, 2004, BIOL PSYCHIAT, V56, P301, DOI 10.1016/j.biopsych.2004.06.023; Groninger L, 1995, CLIN NEUROPSYCHOL, V9, P11; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Johnson AM, 2004, NEUROPSYCHOLOGIA, V42, P577, DOI 10.1016/j.neuropsychologia.2003.10.011; Lee T, 2012, NEUROPSYCHOLOGY, V26, P776, DOI 10.1037/a0030053; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Nuechterlein K. H, 2006, MATRIS CONSENSUS BAT; Perrotin A, 2006, ACTA PSYCHOL, V122, P58, DOI 10.1016/j.actpsy.2005.10.003; SACCUZZO DP, 1981, ARCH GEN PSYCHIAT, V38, P175; Salthouse T. A., 1993, J GERONTOL B-PSYCHOL, V48, P245; SALTHOUSE TA, 1991, PSYCHOL SCI, V2, P179, DOI 10.1111/j.1467-9280.1991.tb00127.x; SALTHOUSE TA, 1992, ACTA PSYCHOL, V79, P155, DOI 10.1016/0001-6918(92)90030-H; SALTHOUSE TA, 1992, J GERONTOL, V47, P121, DOI DOI 10.1093/GER0NJ/47.3.P121; Schmitter-Edgecombe M, 2011, J INT NEUROPSYCH SOC, V17, P853, DOI 10.1017/S1355617711000865; SLIWINSKI M, 1997, J GERONTOL B-PSYCHOL, V52, P308; Smerbeck AM, 2011, MULT SCLER J, V17, P449, DOI 10.1177/1352458510391689; Smith A., 1991, SYMBOL DIGIT MODALIT; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P83, DOI 10.1016/j.acn.2005.07.008; Yatham LN, 2010, BIPOLAR DISORD, V12, P351, DOI 10.1111/j.1399-5618.2010.00830.x; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	35	21	22	1	21	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG 1	2013	27	6					962	972		10.1080/13854046.2013.797500			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	197RA	WOS:000322867100005	23682755	Green Accepted			2021-06-18	
J	Osorio, MB; Kurowski, BG; Beebe, D; Taylor, HG; Brown, TM; Kirkwood, MW; Wade, SL				Osorio, Marisa B.; Kurowski, Brad G.; Beebe, Dean; Taylor, H. Gerry; Brown, Tanya M.; Kirkwood, Michael W.; Wade, Shari L.			Association of Daytime Somnolence With Executive Functioning in the First 6 Months After Adolescent Traumatic Brain Injury	PM&R			English	Article							BEHAVIOR RATING INVENTORY; SLEEP LATENCY TEST; SUBSTANCE USE; HEAD INJURY; SHORT-TERM; CHILDREN; DISORDERS; CONSEQUENCES; DISTURBANCES; PREVALENCE	Objective: To determine the relationship between severity of injury and self-reports and parent reports of daytime somnolence in adolescents after traumatic brain injury (TBI), and to determine the relationship between daytime somnolence and self-report and parent report of executive functioning in daily life. Design: Cross-sectional study conducted within the first 6 months (mean standard deviation 14.97 +/- 7.51 weeks) after injury. Partial correlation controlling for injury severity was used to examine the associations of TBI severity with daytime somnolence and the association of daytime somnolence with executive functioning. Setting: Outpatient visits at 3 children's hospitals and 2 general hospitals with pediatric trauma commitment. Participants: A total of 102 adolescents, 12-18 years old, who sustained moderate-to-severe TBI (n = 60) or complicated mild TBI (n = 42). Main Outcome Measurements: Parent-report Sleepiness Scale, Epworth Sleepiness Scale (youth report), Behavior Rating Inventory of Executive Function (BRIEF) (self-report and maternal report). Results: Adolescents who sustained moderate-to-severe TBI had increased daytime somnolence compared with those with complicated mild injuries in the parent report but not in the youth report. Based on the parent report, 51% of adolescents with moderate-to-severe TBI showed significant daytime somnolence compared with 22% of those with complicated mild TBI. The parent report of daytime somnolence was associated with executive dysfunction on both the BRIEF self-report and parent report; however, the youth report of daytime somnolence was associated only with the BRIEF self-report. Conclusions: The parent report of daytime somnolence correlated with TB I severity and predicted executive functioning difficulties of the teens in everyday circumstances. Although a correlation between daytime somnolence and executive dysfunction were also apparent on self-report, this did not differ based on injury severity. Teens tended to report fewer difficulties with executive function, which suggests that the teens have decreased awareness of their impairments.	[Osorio, Marisa B.] Univ Washington, Dept Phys Med & Rehabil, Div Pediat Rehabil Med, Seattle, WA 98145 USA; [Osorio, Marisa B.] Seattle Childrens Hosp, Seattle, WA 98145 USA; [Kurowski, Brad G.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Kurowski, Brad G.; Beebe, Dean; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Beebe, Dean] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Brown, Tanya M.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA	Osorio, MB (corresponding author), Univ Washington, Dept Phys Med & Rehabil, Div Pediat Rehabil Med, POB 5371,M-S W-6847, Seattle, WA 98145 USA.	marisa.osorio@sealtlechildrens.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-MH073764]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); Colorado Traumatic Brain Injury Trust Fund Research Program; Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	Supported in part by National Institutes of Health grant R01-MH073764 from the National Institute of Mental Health and by a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program.	Anderson B, 2009, PEDIATRICS, V123, pE701, DOI 10.1542/peds.2008-1182; Babcock DA, 2011, PEDIATR CLIN N AM, V58, P543, DOI 10.1016/j.pcl.2011.03.001; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beebe DW, 2008, J CHILD PSYCHOL PSYC, V49, P915, DOI 10.1111/j.1469-7610.2008.01885.x; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beebe DW, 2006, SLEEP, V29, P1115, DOI 10.1093/sleep/29.9.1115; Beebe DW, 2012, CHILD NEUROPSYCHOL, V18, P313, DOI 10.1080/09297049.2011.602014; Beebe DW, 2011, PEDIATR CLIN N AM, V58, P649, DOI 10.1016/j.pcl.2011.03.002; Beebe DW, 2010, J ADOLESCENT HEALTH, V47, P523, DOI 10.1016/j.jadohealth.2010.03.005; Beebe DW, 2002, J SLEEP RES, V11, P1, DOI 10.1046/j.1365-2869.2002.00289.x; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Campbell IG, 2007, SLEEP, V30, P1677, DOI 10.1093/sleep/30.12.1677; Carskadon MA, 2004, ANN NY ACAD SCI, V1021, P276, DOI 10.1196/annals.1308.032; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Clark DB, 2012, ADDICTION, V107, P206, DOI 10.1111/j.1360-0443.2011.03566.x; Dagys N, 2012, J CHILD PSYCHOL PSYC, V53, P660, DOI 10.1111/j.1469-7610.2011.02502.x; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; Fallone G, 2002, SLEEP MED REV, V6, P287, DOI 10.1053/smrv.2001.0192; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Grant JE, 2012, DRUG ALCOHOL DEPEN, V121, P159, DOI 10.1016/j.drugalcdep.2011.08.015; Gromov I, 2009, CHILD ADOL PSYCH CL, V18, P929, DOI 10.1016/j.chc.2009.04.004; Hanson KL, 2011, J CHILD ADOLES SUBST, V20, P135, DOI 10.1080/1067828X.2011.555272; Hasler BP, 2012, SLEEP MED REV, V16, P67, DOI 10.1016/j.smrv.2011.03.004; HODGES K, 1999, J CHILD FAM STUD, V8, P109; Hodges K., 1996, J CHILD FAM STUD, V5, P445, DOI [10.1007/BF02233865, DOI 10.1007/BF02233865]; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; James JE, 2011, J ADOLESCENCE, V34, P665, DOI 10.1016/j.adolescence.2010.09.006; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Moore M, 2008, PAEDIATR RESPIR REV, V9, P114, DOI 10.1016/j.prrv.2008.01.001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Owens JA, 2005, SLEEP MED, V6, P63, DOI 10.1016/j.sleep.2004.07.015; Peterson RL, 2012, J HEAD TRAUMA REHABI; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Redline S, 2007, AM J RESP CRIT CARE, V176, P401, DOI 10.1164/rccm.200703-375OC; ROEHRS T, 1992, J CLIN NEUROPHYSIOL, V9, P63, DOI 10.1097/00004691-199201000-00007; Sadeh A, 2009, SLEEP, V32, P1602, DOI 10.1093/sleep/32.12.1602; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Talbot LS, 2010, EMOTION, V10, P831, DOI 10.1037/a0020138; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wechsler D., 2003, WECHSLER INTELLIGENC; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Wilson KR, 2011, REHABIL PSYCHOL, V56, P100, DOI 10.1037/a0023446; Wolfson AR, 2003, SLEEP MED REV, V7, P491, DOI 10.1016/S1087-0792(03)90003-7; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763	64	21	21	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUL	2013	5	7					554	562		10.1016/j.pmrj.2012.11.006			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	190PC	WOS:000322351700002	23375631	Green Accepted			2021-06-18	
J	Cabrera, V; Ramos, E; Gonzalez-Arenas, A; Cerbon, M; Camacho-Arroyo, I; Morales, T				Cabrera, V.; Ramos, E.; Gonzalez-Arenas, A.; Cerbon, M.; Camacho-Arroyo, I.; Morales, T.			Lactation Reduces Glial Activation Induced by Excitotoxicity in the Rat Hippocampus	JOURNAL OF NEUROENDOCRINOLOGY			English	Article						astrocytes; kainate; GFAP; Iba-1; microglial; reproduction	FIBROBLAST-GROWTH-FACTOR; PROLACTIN-INDUCED EXPRESSION; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; CINGULATE CORTEX; FEMALE RATS; NEUROPROTECTIVE ACTIONS; AROMATASE EXPRESSION; CULTURED ASTROCYTES; CELL-PROLIFERATION	Motherhood induces a series of adaptations in the physiology of the female, including an increase of maternal brain plasticity and a reduction of cell damage in the hippocampus caused by kainic acid (KA) excitotoxicity. We analysed the role of lactation in glial activation in the hippocampal fields of virgin and lactating rats after i.c.v. application of 100ng of KA. Immunohistochemical analysis for glial fibrillary acidic protein (GFAP) and ionised calcium binding adaptor molecule 1 (Iba-1), which are markers for astrocytes and microglial cell-surface proteins, respectively, revealed differential cellular responses to KA in lactating and virgin rats. A significant astrocyte and microglial response in hippocampal areas of virgin rats was observed 24h and 72h after KA. By contrast, no increase in either GFAP- or Iba-1-positive cells was observed in response to KA in the hippocampus of lactating rats. Western blot analysis of GFAP showed an initial decrease at 24h after KA treatment, with an increase at 72h in the whole hippocampus of virgin but not of lactating rats. The number of GFAP-positive cells was increased by lactation in the dentate gyrus of the hippocampus but not in CA1 and CA3 areas. The present results indicate that lactating rats exhibit diminished responses of astrocyte and microglial cells in the hippocampus to damage induced by KA, supporting the notion that the maternal hippocampus is resistant to excitotoxic insults.	[Cabrera, V.; Ramos, E.; Morales, T.] Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Celular & Mol, Queretaro, Mexico; [Gonzalez-Arenas, A.; Cerbon, M.; Camacho-Arroyo, I.] Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Queretaro, Mexico	Morales, T (corresponding author), UNAM, Inst Neurobiol, Blvd Juriquilla 3001, Queretaro 76230, Qro, Mexico.	marter@unam.mx	Morales, Teresa/I-2941-2019; Morales, Teresa/E-5927-2012; Camacho-Arroyo, Ignacio/AAM-6757-2021; Camacho-Arroyo, Ignacio/AAM-4654-2021	Morales, Teresa/0000-0003-1539-2070; Morales, Teresa/0000-0003-1539-2070; Camacho-Arroyo, Ignacio/0000-0003-2978-1253; Camacho-Arroyo, Ignacio/0000-0003-2978-1253	PAPIIT-DGAPA, UNAMPrograma de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico [IN204709, IN202812]; CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [51044, 128090, 233854]	The present study was supported by PAPIIT-DGAPA, UNAM IN204709, IN202812; CONACYT 51044, 128090. Part of this work was the master's dissertation of VC, who received CONACyT fellowship No. 233854. The authors thank Dr Dorothy Pless for grammatical review, as well as Nydia Hernandez (Digital Imaging), Martin Garcia (Animal Care) and Ana Gabriela Pina-Medina Bsc (Western blot) for technical assistance.	AKWA Y, 1993, J CELL BIOL, V121, P135, DOI 10.1083/jcb.121.1.135; ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; Arias C, 2009, HORM BEHAV, V55, P257, DOI 10.1016/j.yhbeh.2008.10.016; Aschner M, 1999, ANNU REV PHARMACOL, V39, P151, DOI 10.1146/annurev.pharmtox.39.1.151; Azcoitia I, 2001, Prog Brain Res, V132, P469; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; Azcoitia I, 2010, EUR J NEUROSCI, V32, P1995, DOI 10.1111/j.1460-9568.2010.07516.x; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Cabrera V, 2009, NEUROSCI LETT, V461, P136, DOI 10.1016/j.neulet.2009.06.017; DEVITO WJ, 1993, J NEUROCHEM, V60, P835, DOI 10.1111/j.1471-4159.1993.tb03227.x; DEVITO WJ, 1992, ENDOCRINOLOGY, V130, P2549, DOI 10.1210/en.130.5.2549; DEVITO WJ, 1995, J CELL BIOCHEM, V57, P290, DOI 10.1002/jcb.240570213; DEVITO WJ, 1995, MOL CELL ENDOCRINOL, V108, P125, DOI 10.1016/0303-7207(94)03465-6; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Estrada FS, 2012, NEUROSCI LETT, V514, P51, DOI 10.1016/j.neulet.2012.02.055; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Featherstone RE, 2000, BEHAV NEUROSCI, V114, P158, DOI 10.1037/0735-7044.114.1.158; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Furuta M, 2005, DEV BRAIN RES, V156, P61, DOI 10.1016/j.devbrainres.2005.01.008; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Gomora-Arrati P, 2010, NEUROSCI LETT, V484, P197, DOI 10.1016/j.neulet.2010.08.052; Haraguchi S, 2010, ENDOCRINOLOGY, V151, P2211, DOI 10.1210/en.2009-1229; Jordan CL, 1999, J NEUROBIOL, V40, P434, DOI 10.1002/(SICI)1097-4695(19990915)40:4<434::AID-NEU2>3.0.CO;2-T; Kinsley CH, 2006, HORM BEHAV, V49, P131, DOI 10.1016/j.yhbeh.2005.05.017; Kinsley CH, 2008, HORM BEHAV, V54, P1, DOI 10.1016/j.yhbeh.2008.01.001; Leuner B, 2007, HIPPOCAMPUS, V17, P434, DOI 10.1002/hipo.20278; Moderscheim TAE, 2007, NEUROSCIENCE, V145, P963, DOI 10.1016/j.neuroscience.2006.12.053; Morales T, 2011, J NEUROENDOCRINOL, V23, P994, DOI 10.1111/j.1365-2826.2011.02141.x; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Oliet Stephane H R, 2006, Novartis Found Symp, V276, P238; Panatier A, 2006, NEURON GLIA BIOL, V2, P51, DOI 10.1017/S1740925X06000019; Pawluski JL, 2006, HORM BEHAV, V49, P143, DOI 10.1016/j.yhbeh.2005.05.016; Pawluski JL, 2009, FRONT NEUROENDOCRIN, V30, P343, DOI 10.1016/j.yfrne.2009.03.007; REPRESA A, 1993, J NEUROCYTOL, V22, P299, DOI 10.1007/BF01187128; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Russell J A, 2001, Prog Brain Res, V133, P1; Salmaso N, 2008, NEUROSCIENCE, V154, P932, DOI 10.1016/j.neuroscience.2008.03.063; Salmaso N, 2006, HORM BEHAV, V50, P448, DOI 10.1016/j.yhbeh.2006.05.006; Salmaso N, 2005, NEUROSCIENCE, V134, P1431, DOI 10.1016/j.neuroscience.2005.05.038; Salmaso N, 2009, EUR J NEUROSCI, V29, P786, DOI 10.1111/j.1460-9568.2009.06627.x; SAWCHENKO PE, 1990, J COMP NEUROL, V291, P269, DOI 10.1002/cne.902910209; Shapiro LA, 2008, EPILEPSIA, V49, P33, DOI 10.1111/j.1528-1167.2008.01491.x; Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647; Simard AR, 2007, J COMP NEUROL, V504, P716, DOI 10.1002/cne.21469; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Takahashi DK, 2010, NEUROBIOL DIS, V40, P573, DOI 10.1016/j.nbd.2010.07.018; Tejadilla D, 2010, NEUROSCIENCE, V169, P1178, DOI 10.1016/j.neuroscience.2010.05.074; Theodosis D T, 2001, Prog Brain Res, V133, P49; Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023; Torner L, 2009, J NEUROSCI, V29, P1826, DOI 10.1523/JNEUROSCI.3178-08.2009; TORRE ER, 1993, BRAIN RES, V631, P256, DOI 10.1016/0006-8993(93)91543-2; Vanoye-Carlo A, 2008, HORM BEHAV, V53, P112, DOI 10.1016/j.yhbeh.2007.09.004; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Yague JG, 2010, BRAIN RES, V1315, P41, DOI 10.1016/j.brainres.2009.09.111; Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100	57	21	21	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	JUN	2013	25	6					519	527		10.1111/jne.12028			9	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	152FE	WOS:000319515400001	23356710				2021-06-18	
J	Crepeau, AZ; Kerrigan, JF; Gerber, P; Parikh, G; Jahnke, H; Nakaji, P; Little, A; Chapmank, KE				Crepeau, Amy Z.; Kerrigan, John F.; Gerber, Paula; Parikh, Gunjan; Jahnke, Heidi; Nakaji, Peter; Little, Andrew; Chapmank, Kevin E.			Rhythmical and Periodic EEG Patterns Do Not Predict Short-term Outcome in Critically Ill Patients With Subarachnoid Hemorrhage	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						Continuous EEG; ICU monitoring; Subarachnoid hemorrhage; Seizure	NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; ELECTROGRAPHIC SEIZURES; INTRACEREBRAL HEMORRHAGE; INTEROBSERVER AGREEMENT; SUBCOMMITTEE; DISCHARGES; MORTALITY; PRESSURE	Introduction: Nonconvulsive seizures and nonconvulsive status epilepticus commonly occur in patients with aneurysmal subarachnoid hemorrhages. When continuous EEG is used in patients in the neuro-intensive care unit, rhythmical and periodic patterns of uncertain significance are frequently encountered. It is unknown how these findings impact patient outcome. Methods: Patients were enrolled from a single tertiary care center with subarachnoid hemorrhages secondary to ruptured intracranial aneurysm, and either a witnessed seizure or significantly impaired mental status. Prospective clinical, laboratory, imaging, and short-term outcome data were collected. Continuous EEG monitoring was performed and scored according to American Clinical Neurophysiology Society (ACNS) Subcommittee on Research Terminology for Continuous EEG Monitoring. Results: Sixty-eight patients were enrolled. Fifty-four had a poor-grade subarachnoid hemorrhage upon admission. Fifty-one patients had rhythmical or periodic patterns: 33 with periodic discharges and 38 with rhythmic delta activity. Four patients had unequivocal electrographic seizures. Patients did poorly in the short term: 14 died and 42 were severely disabled at discharge. In hospital, mortality was 19.6% in patients with rhythmical or periodic patterns and 23.5% in patients without. Age, female gender, and endovascular treatment had a positive correlation with the occurrence of periodic discharges. However, there was no correlation between rhythmical and periodic patterns and outcome. Discussion: Using the ACNS Research Terminology, it is shown that rhythmical and periodic patterns are very common in critically ill patients with subarachnoid hemorrhage. However, the presence and the abundance of these patterns did not predict short-term outcome in this prospective, single-center observational study. We were unable to show that rhythmical and periodic EEG patterns are an independent predictor for outcome relative to other clinical features. Large multicenter studies will be required to determine if these patterns independently predict outcome and to demonstrate the impact of treatment interventions that are directed at rhythmical and periodic continuous EEG patterns.	[Crepeau, Amy Z.; Kerrigan, John F.; Parikh, Gunjan; Jahnke, Heidi] St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ USA; [Kerrigan, John F.] St Josephs Hosp, Barrow Neurol Inst, Clin Neurophysiol Sect, Phoenix, AZ USA; [Gerber, Paula] Providence Hosp, Neurodiagnost Lab, Portland, OR USA; [Jahnke, Heidi; Nakaji, Peter; Little, Andrew] St Josephs Hosp, Div Neurosurg, Barrow Neurol Inst, Phoenix, AZ USA; [Chapmank, Kevin E.] Childrens Hosp Colorado, Sect Pediat Neurol, Aurora, CO 80045 USA	Chapmank, KE (corresponding author), Childrens Hosp Colorado, 13123 East 16th Ave,B155, Aurora, CO 80045 USA.	kevin.chapman@childrenscolorado.org	Parikh, Gunjan/AAS-1375-2020; Viani, Rafael/V-1196-2018	Parikh, Gunjan/0000-0002-8447-1349; 			Aronica E, 2010, EUR J NEUROSCI, V31, P1100, DOI 10.1111/j.1460-9568.2010.07122.x; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2007, NEUROSURGERY, V61, P60, DOI 10.1227/01.neu.0000279724.05898.e7; DeGiorgio CM, 1996, EPILEPSIA, V37, P606, DOI 10.1111/j.1528-1157.1996.tb00623.x; Fountain NB, 2001, J CLIN NEUROPHYSIOL, V18, P345, DOI 10.1097/00004691-200107000-00006; Gerber PA, 2008, J CLIN NEUROPHYSIOL, V25, P241, DOI 10.1097/WNP.0b013e318182ed67; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Kaplan PW, 2000, NEUROPHYSIOL CLIN, V30, P377, DOI 10.1016/S0987-7053(00)00238-0; Little AS, 2007, J NEUROSURG, V106, P805, DOI 10.3171/jns.2007.106.5.805; Maganti R, 2008, EPILEPSY BEHAV, V12, P572, DOI 10.1016/j.yebeh.2007.12.002; Mocco J, 2006, NEUROSURGERY, V59, P529, DOI 10.1227/01.NEU.0000228680.22550.A2; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Sutter R, 2011, EPILEPSIA, V52, P453, DOI 10.1111/j.1528-1167.2010.02888.x; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; WILLIAMS GW, 1985, NEUROLOGY, V35, P1714, DOI 10.1212/WNL.35.12.1714; Young GB, 1996, NEUROLOGY, V47, P83	27	21	21	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258	1537-1603		J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	JUN	2013	30	3					247	254		10.1097/WNP.0b013e3182933d2f			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	298TN	WOS:000330347500004	23733088				2021-06-18	
J	Macdonald, RL; Jaja, B; Cusimano, MD; Etminan, N; Hanggi, D; Hasan, D; Ilodigwe, D; Lantigua, H; Le Roux, P; Lo, B; Louffat-Olivares, A; Mayer, S; Molyneux, A; Quinn, A; Schweizer, TA; Schenk, T; Spears, J; Todd, M; Torner, J; Vergouwen, MDI; Wong, GKC; Singh, J				Macdonald, R. Loch; Jaja, Blessing; Cusimano, Michael D.; Etminan, Nima; Hanggi, Daniel; Hasan, David; Ilodigwe, Don; Lantigua, Hector; Le Roux, Peter; Lo, Benjamin; Louffat-Olivares, Ada; Mayer, Stephan; Molyneux, Andrew; Quinn, Audrey; Schweizer, Tom A.; Schenk, Thomas; Spears, Julian; Todd, Michael; Torner, James; Vergouwen, Mervyn D. I.; Wong, George K. C.; Singh, Jeff		SAHIT Collaboration	SAHIT Investigators-on the Outcome of Some Subarachnoid Hemorrhage Clinical Trials	TRANSLATIONAL STROKE RESEARCH			English	Article						Clinical trial; Outcome; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; ACUTE STROKE TRIALS; COMMUNICATING ARTERY ANEURYSM; CEREBRAL INFARCTION; MAGNESIUM-SULFATE; COOPERATIVE ANEURYSM; STATISTICAL-ANALYSIS; RANDOMIZED-TRIAL; GRADE PATIENTS; DOUBLE-BLIND	Outcome of patients with aneurysmal subarachnoid hemorrhage (SAH) has improved over the last decades. Yet, case fatality remains nearly 40 % and survivors often have permanent neurological, cognitive and/or behavioural sequelae. Other than nimodipine drug or clinical trials have not consistently improved outcome. We formed a collaboration of SAH investigators to create a resource for prognostic analysis and for studies aimed at optimizing the design and analysis of phase 3 trials in aneurysmal SAH. We identified investigators with data from randomized, clinical trials of patients with aneurysmal SAH or prospectively collected single- or multicentre databases of aneurysmal SAH patients. Data are being collected and proposals to use the data and to design future phase 3 clinical trials are being discussed. This paper reviews some issues discussed at the first meeting of the SAH international trialists (SAHIT) repository meeting. Investigators contributed or have agreed to contribute data from several phase 3 trials including the tirilazad trials, intraoperative hypothermia for aneurysmal SAH trial, nicardipine clinical trials, international subarachnoid aneurysm trial, intravenous magnesium sulphate for aneurysmal SAH, magnesium for aneurysmal SAH and from prospectively-collected data from four institutions. The number of patients should reach 15,000. Some industry investigators refused to provide data and others reported that their institutional research ethics boards would not permit even deidentified or anonymized data to be included. Others reported conflict of interest that prevented them from submitting data. The problems with merging data were related to lack of common definitions and coding of variables, differences in outcome scales used, and times of assessment. Some questions for investigation that arose are discussed. SAHIT demonstrates the possibility of SAH investigators to contribute data for collaborative research. The problems are similar to those already documented in other similar collaborative efforts such as in head injury research. We encourage clinical trial and registry investigators to contact us and participate in SAHIT. Key issues moving forward will be to use common definitions (common data elements), outcomes analysis, and to prioritize research questions, among others.	[Macdonald, R. Loch; Jaja, Blessing; Cusimano, Michael D.; Ilodigwe, Don; Lo, Benjamin; Louffat-Olivares, Ada; Schweizer, Tom A.; Spears, Julian] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Etminan, Nima; Hanggi, Daniel] Univ Dusseldorf, Fac Med, Dept Neurosurg, D-40225 Dusseldorf, Germany; [Hasan, David; Todd, Michael; Torner, James] Univ Iowa, Iowa City, IA USA; [Lantigua, Hector; Mayer, Stephan] Columbia Univ, New York, NY USA; [Le Roux, Peter] Univ Penn, Philadelphia, PA 19104 USA; [Molyneux, Andrew] Univ Oxford, Oxford, England; [Quinn, Audrey] Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; [Schenk, Thomas] Kings Coll London, London WC2R 2LS, England; [Vergouwen, Mervyn D. I.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Wong, George K. C.] Chinese Univ Hong Kong, Ma Liu Shui, Hong Kong, Peoples R China; [Macdonald, R. Loch] Univ Toronto, St Michaels Hosp, Div Neurosurg,Labatt Family Ctr Excellence Brain, Keenan Res Ctr,Li Ka Shing Knowledge Inst,Dept Su, Toronto, ON M5B 1W8, Canada; [Singh, Jeff] Univ Toronto, Univ Hlth Network, Toronto, ON M5B 1W8, Canada	Macdonald, RL (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg,Labatt Family Ctr Excellence Brain, Keenan Res Ctr,Li Ka Shing Knowledge Inst,Dept Su, 30 Bond St, Toronto, ON M5B 1W8, Canada.	MacdonaldLo@smh.ca	Wong, George Kwok Chu/L-4344-2016; Wong, George KC/A-6378-2011; Cusimano, Michael/X-4059-2019	Wong, George KC/0000-0002-6078-2548; Singh, Jeffrey/0000-0003-3499-574X; hasan, david/0000-0002-8335-5442; Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Physicians Services Incorporated Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Brain Aneurysm Foundation; Integra; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Canadian Stroke Network; Medical Research Council UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Cerecyte Coil Trial; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Ontario Ministry of Research and InnovationMinistry of Research and Innovation, Ontario; Netherlands Thrombosis Foundation; Netherlands Heart FoundationNetherlands Heart Foundation; Hong Kong Food and Health Bureau; Hong Kong University Grant Committee	Funded by a grant from the Canadian Institutes for Health Research.; Michael D. Cusimano receives grant support from the Canadian Institutes for Health Research. Nima Etminan receives grant support from Physicians Services Incorporated Foundation. David Hasan receives grant funding from National Institutes of Health and Brain Aneurysm Foundation. Peter Le Roux receives research funding from the National Institutes of Health and Integra and is a consultant for Codman, Integra and Edge Therapeutics. R. Loch Macdonald receives grant funding from the Canadian Institutes for Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, Brain Aneurysm Foundation and Physicians Services Incorporated Foundation. He is a consultant for Actelion Pharmaceuticals, Ltd. and Chief Scientific Officer of Edge Therapeutics, Inc. Stephan Mayer is a consultant for Actelion Pharmaceuticals, Ltd. Andrew Molyneux is a consultant for Micrus Endovascular and receives grant support from the Medical Research Council UK and Cerecyte Coil Trial. Tom A. Schweizer receives grant support from the Heart and Stroke Foundation of Canada, the Canadian Institutes of Health Research and the Ontario Ministry of Research and Innovation. Michael Todd receives grant support from the National Institutes of Health. James Torner receives grant support from the National Institutes of Health. Mervyn D. I. Vergouwen receives grant support from the Netherlands Thrombosis Foundation and Netherlands Heart Foundation. George K. C. Wong receives grant support from the Hong Kong Food and Health Bureau and the Hong Kong University Grant Committee.	Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Ali M, 2007, STROKE, V38, P1905, DOI 10.1161/STROKEAHA.106.473579; Ali M, 2012, INT J STROKE, V7, P133, DOI 10.1111/j.1747-4949.2011.00735.x; [Anonymous], 2012, MMWR-MORBID MORTAL W, V61, P379; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Bellebaum C, 2004, J CLIN EXP NEUROPSYC, V26, P1081, DOI 10.1080/13803390490515342; Bendel P, 2009, NEURORADIOLOGY, V51, P711, DOI 10.1007/s00234-009-0552-5; Broderick JP, 2011, JAMA-J AM MED ASSOC, V306, P2026, DOI 10.1001/jama.2011.1622; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Cook DJ, 2012, CURR NEUROVASC RES, V9, P139; Dachs RJ, 2008, PLOS MED, V5, P705, DOI 10.1371/journal.pmed.0050113; de Rooij NK, 2007, J NEUROL NEUROSUR PS, V78, P1365, DOI 10.1136/jnnp.2007.117655; Deans KJ, 2007, CRIT CARE MED, V35, P1509, DOI 10.1097/01.CCM.0000266584.40715.A6; Di Vergouwen M, 2007, J CEREBR BLOOD F MET, V27, P1293, DOI 10.1038/sj.jcbfm.9600431; DISNEY L, 1989, CAN J NEUROL SCI, V16, P299, DOI 10.1017/S0317167100029127; Dorhout Mees SM, 2007, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000277.PUB3; Dreier JP, 2002, NEUROSURGERY, V51, P1457, DOI 10.1097/00006123-200212000-00017; Duncan PW, 2000, STROKE, V31, P1429, DOI 10.1161/01.STR.31.6.1429; Etminan N, 2011, J CEREBR BLOOD F MET, V31, P1443, DOI 10.1038/jcbfm.2011.7; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Fisher M, 2005, STROKE, V36, P1808, DOI 10.1161/01.STR.0000173403.60553.27; Fontanella M, 2003, ACTA NEUROCHIR, V145, P867, DOI 10.1007/s00701-003-0111-5; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; Hadjivassiliou M, 2001, NEUROLOGY, V56, P1672, DOI 10.1212/WNL.56.12.1672; HALEY EC, 1993, J NEUROSURG, V78, P537, DOI 10.3171/jns.1993.78.4.0537; HALEY EC, 1994, J NEUROSURG, V80, P788, DOI 10.3171/jns.1994.80.5.0788; Hall CE, 2012, NEUROCRIT CARE, V16, P6, DOI 10.1007/s12028-011-9608-6; Hillis AE, 2000, J NEUROL NEUROSUR PS, V69, P608, DOI 10.1136/jnnp.69.5.608; Ilodigwe D, 2012, J NEUROSURG; Jaja BNR, 2013, NEUROCRIT CARE, V18, P143, DOI 10.1007/s12028-012-9792-z; Jang YG, 2009, NEUROCRIT CARE, V10, P141, DOI 10.1007/s12028-008-9147-y; JENNETT B, 1975, LANCET, V1, P480; KASUYA H, 2011, ACTA NEUROCHIR SUPPL, V2, P165, DOI DOI 10.1007/978-3-7091-0356-2_30; Khatri P, 2008, INT J STROKE, V3, P130, DOI 10.1111/j.1747-4949.2008.00151.x; King JT, 2006, NEUROSURGERY, V59, P803, DOI 10.1227/01.NEU.0000232666.67779.41; Kreiter KT, 2002, STROKE, V33, P200, DOI 10.1161/hs0102.101080; Kreiter KT, 2009, STROKE, V40, P2362, DOI 10.1161/STROKEAHA.109.547331; Lees KR, 2012, STROKE, V43, P1163, DOI 10.1161/STROKEAHA.111.641423; LeRoux PD, 1996, J NEUROSURG, V85, P39, DOI 10.3171/jns.1996.85.1.0039; Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Macdonald RL, 2012, STROKE, V43, P1463, DOI 10.1161/STROKEAHA.111.648980; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Macdonald RL, 2010, NEUROCRIT CARE, V13, P416, DOI 10.1007/s12028-010-9433-3; Manning L, 2005, EUR J NEUROL, V12, P466, DOI 10.1111/j.1468-1331.2005.01012.x; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Mavaddat N, 1999, J NEUROSURG, V91, P402, DOI 10.3171/jns.1999.91.3.0402; Mees SM, 2012, LANCET; Meinert C.L., 1986, CLIN TRIALS DESIGN C; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Muroi C, 2008, SURG NEUROL, V69, P33, DOI 10.1016/j.surneu.2007.07.015; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; OHMAN J, 1991, J NEUROSURG, V74, P14, DOI 10.3171/jns.1991.74.1.0014; Otawara Y, 2009, SURG NEUROL, V72, P592, DOI 10.1016/j.surneu.2009.06.016; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Pluta RM, 2009, NEUROL RES, V31, P151, DOI 10.1179/174313209X393564; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Sahs AL, 1969, INTRACRANIAL ANEURYS; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Scales DC, 2005, J CRIT CARE, V20, P6, DOI 10.1016/j.jcrc.2005.02.002; Schellinger PD, 2012, INT J STROKE, V7, P227, DOI 10.1111/j.1747-4949.2012.00773.x; Sehba FA, 2006, NEUROL RES, V28, P381, DOI 10.1179/016164106X114991; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; Tobin MJ, 2008, CHEST, V133, P1071, DOI 10.1378/chest.08-0077; van den Bergh WM, 2003, ACTA NEUROCHIR, V145, P195, DOI 10.1007/s00701-002-1064-9; van der Schaaf IC, 2002, STROKE, V33, P2043, DOI 10.1161/01.STR.0000024110.82735.5A; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vergouwen MDI, 2012, STROKE, V43, P2671, DOI 10.1161/STROKEAHA.112.666693; Vergouwen MDI, 2011, J CEREBR BLOOD F MET, V31, P1545, DOI 10.1038/jcbfm.2011.56; Veyna RS, 2002, J NEUROSURG, V96, P510, DOI 10.3171/jns.2002.96.3.0510; Vincent JL, 2010, CRIT CARE MED, V38, pS534, DOI 10.1097/CCM.0b013e3181f208ac; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong GKC, 2010, STROKE, V41, P921, DOI 10.1161/STROKEAHA.109.571125; Zhang S., 2010, COCHRANE DB SYST REV, V2	79	21	23	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	JUN	2013	4	3					286	296		10.1007/s12975-012-0242-1			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	136XU	WOS:000318397800002	24323299				2021-06-18	
J	Salido, EM; Dorfman, D; Bordone, M; Chianelli, M; Fleitas, MFG; Rosenstein, RE				Salido, Ezequiel M.; Dorfman, Damian; Bordone, Melina; Chianelli, Monica; Gonzalez Fleitas, Maria Florencia; Rosenstein, Ruth E.			Global and Ocular Hypothermic Preconditioning Protect the Rat Retina from Ischemic Damage	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; GANGLION-CELLS; GLUTAMINE-SYNTHETASE; CIRCULATORY ARREST; LOCAL HYPOTHERMIA; NMDA RECEPTORS; NEURONS; MECHANISMS; INDUCTION; TOLERANCE	Retinal ischemia could provoke blindness. At present, there is no effective treatment against retinal ischemic damage. Strong evidence supports that glutamate is implicated in retinal ischemic damage. We investigated whether a brief period of global or ocular hypothermia applied 24 h before ischemia (i.e. hypothermic preconditioning, HPC) protects the retina from ischemia/reperfusion damage, and the involvement of glutamate in the retinal protection induced by HPC. For this purpose, ischemia was induced by increasing intraocular pressure to 120 mm Hg for 40 min. One day before ischemia, animals were submitted to global or ocular hypothermia (33 degrees C and 32 degrees C for 20 min, respectively) and fourteen days after ischemia, animals were subjected to electroretinography and histological analysis. Global or ocular HPC afforded significant functional (electroretinographic) protection in eyes exposed to ischemia/reperfusion injury. A marked alteration of the retinal structure and a decrease in retinal ganglion cell number were observed in ischemic retinas, whereas global or ocular HPC significantly preserved retinal structure and ganglion cell count. Three days after ischemia, a significant decrease in retinal glutamate uptake and glutamine synthetase activity was observed, whereas ocular HPC prevented the effect of ischemia on these parameters. The intravitreal injection of supraphysiological levels of glutamate induced alterations in retinal function and histology which were significantly prevented by ocular HPC. These results support that global or ocular HPC significantly protected retinal function and histology from ischemia/reperfusion injury, probably through a glutamate-dependent mechanism.	[Salido, Ezequiel M.; Dorfman, Damian; Bordone, Melina; Chianelli, Monica; Gonzalez Fleitas, Maria Florencia; Rosenstein, Ruth E.] Univ Buenos Aires, Dept Human Biochem, CEFyBO,CONICET, Lab Retinal Neurochem & Expt Ophthalmol,Sch Med, Buenos Aires, DF, Argentina	Rosenstein, RE (corresponding author), Univ Buenos Aires, Dept Human Biochem, CEFyBO,CONICET, Lab Retinal Neurochem & Expt Ophthalmol,Sch Med, Buenos Aires, DF, Argentina.	ruthr@fmed.uba.ar	Salido, Ezequiel Martin/AAF-7166-2021	Salido, Ezequiel Martin/0000-0003-3741-3389; Gonzalez Fleitas, Maria Florencia/0000-0001-5795-8365; Bordone, Melina/0000-0003-4912-228X	Agencia Nacional de Promocion Cientifica y TecnologicaANPCyT; University of Buenos AiresUniversity of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas, ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	This research was supported by grants from the Agencia Nacional de Promocion Cientifica y Tecnologica; The University of Buenos Aires; and Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi K, 1998, EUR J PHARMACOL, V350, P53, DOI 10.1016/S0014-2999(98)00317-3; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Bhagatte Y, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.84; Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P3784, DOI 10.1167/iovs.09-4894; Birnbaum Y, 1997, CIRCULATION, V96, P1641, DOI 10.1161/01.CIR.96.5.1641; BUCHAN A, 1992, NEUROL CLIN, V10, P49; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Cambria RP, 1997, J VASC SURG, V25, P234, DOI 10.1016/S0741-5214(97)70365-3; Cazevieille C, 1997, BRAIN RES, V755, P91, DOI 10.1016/S0006-8993(97)00090-5; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Dave KR, 2006, NEUROSCI LETT, V404, P170, DOI 10.1016/j.neulet.2006.05.037; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; FABEROWSKI N, 1989, INVEST OPHTH VIS SCI, V30, P2309; Faridar Alireza, 2011, Front Neurol, V2, P80, DOI 10.3389/fneur.2011.00080; Fernandez DC, 2009, J NEUROCHEM, V111, P488, DOI 10.1111/j.1471-4159.2009.06334.x; Franco PJ, 2008, INVEST OPHTH VIS SCI, V49, P4604, DOI 10.1167/iovs.08-2054; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; IKEDA H, 1992, EXP EYE RES, V55, P435, DOI 10.1016/0014-4835(92)90116-A; IVERSEN L L, 1991, Eye (London), V5, P194; Izumi Y, 2003, VISUAL NEUROSCI, V20, P97, DOI 10.1017/S0952523803202017; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KATO H, 1992, NEUROSCI LETT, V139, P118, DOI 10.1016/0304-3940(92)90871-4; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kwong JMK, 2003, BRAIN RES, V970, P119, DOI 10.1016/S0006-8993(03)02298-4; Leben J, 1997, ANN NY ACAD SCI, V813, P807, DOI 10.1111/j.1749-6632.1997.tb51785.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Moore EM, 2011, INJURY, V42, P843, DOI 10.1016/j.injury.2011.03.027; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NAKATA N, 1993, NEUROREPORT, V4, P695, DOI 10.1097/00001756-199306000-00023; NAYAK MS, 1995, CURR EYE RES, V14, P81, DOI 10.3109/02713689508999918; NEAL MJ, 1994, J NEUROCHEM, V62, P1025; Ning XH, 1998, AM J PHYSIOL-HEART C, V274, pH786; Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237; Nishio S, 2000, J NEUROSURG, V93, P845, DOI 10.3171/jns.2000.93.5.0845; Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001; Poitry S, 2000, J NEUROSCI, V20, P1809; Quina LA, 2005, J NEUROSCI, V25, P11595, DOI 10.1523/JNEUROSCI.2837-05.2005; Quinones-Hinojosa A, 2003, NEUROSURGERY, V52, P1178, DOI 10.1227/01.NEU.0000057836.64972.A0; RIEPE RE, 1977, NATURE, V268, P654, DOI 10.1038/268654a0; Roth S, 2004, BRAIN RES BULL, V62, P461, DOI 10.1016/j.brainresbull.2003.07.006; Roth S, 1998, INVEST OPHTH VIS SCI, V39, P777; Sakamoto K, 2004, BRAIN RES, V1015, P154, DOI 10.1016/j.brainres.2004.04.074; SARTHY PV, 1978, J CELL BIOL, V78, P675, DOI 10.1083/jcb.78.3.675; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SOLOMON RA, 1991, NEUROSURGERY, V29, P732, DOI 10.1227/00006123-199111000-00015; Sumioka K, 2000, INVEST OPHTH VIS SCI, V41, P29; Tamai K, 1997, EXP EYE RES, V65, P733, DOI 10.1006/exer.1997.0386; THARION J, 1982, J THORAC CARDIOV SUR, V84, P66; Thoreson WB, 1999, PROG RETIN EYE RES, V18, P765, DOI 10.1016/S1350-9462(98)00031-7; Wang RB, 2010, J NEUROTRAUM, V27, P763, DOI 10.1089/neu.2009.1005; Wang XD, 2002, NEUROL RES, V24, P730, DOI 10.1179/016164102101200663; Yunoki M, 2002, J NEUROSURG, V97, P650, DOI 10.3171/jns.2002.97.3.0650	54	21	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e61656	10.1371/journal.pone.0061656			13	Multidisciplinary Sciences	Science & Technology - Other Topics	131QH	WOS:000318008400075	23626711	DOAJ Gold, Green Published			2021-06-18	
J	Adamson, C; Yuan, WH; Babcock, L; Leach, JL; Seal, ML; Holland, SK; Wade, SL				Adamson, Chris; Yuan, Weihong; Babcock, Lynn; Leach, James L.; Seal, Marc L.; Holland, Scott K.; Wade, Shari L.			Diffusion tensor imaging detects white matter abnormalities and associated cognitive deficits in chronic adolescent TBI	BRAIN INJURY			English	Article						Traumatic brain injury; adolescents; executive functioning; diffusion tensor imaging; diffuse axonal injury	TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; EXECUTIVE FUNCTION; AXONAL INJURY; STRUCTURAL EVENTS; CHILDREN; RECOVERY; DAMAGE; PREDICTORS; PLASTICITY	Primary objective: This study examined long-term alterations in white matter microstructure following TBI in adolescence using diffusion tensor imaging (DTI). It was hypothesized that white matter integrity would be compromised in adolescents with TBI and would correlate with measures of executive functioning and cognitive abilities. Research design: This study employed whole-brain, voxel-wise, statistical comparison of DTI indices in youth of 12-17 years old (mean = 15.06) with TBI vs an age-and gender-matched cohort (mean age = 15.37). Methods and procedures: This study scanned 17 adolescents with complicated-mild-to-severe TBI, 1-3 years after injury, and 13 healthy adolescents. Tract-Based Spatial Statistics (TBSS) was employed for DTI analysis. Main outcomes and results: Overall diffusivity elevations were found in the TBI group with increases in axial diffusivity in the right hemisphere. White matter integrity was associated with word reading, planning and processing times in the TBI group, but not healthy controls. Conclusions: The detected abnormalities in axial diffusivity may reflect neuronal regeneration and cerebral reorganization after injury. These findings provide tentative evidence of persistent white matter alteration following TBI in adolescence. Associations of DTI indices with cognitive performance following TBI provide tentative support for links between white matter integrity and performance post-TBI.	[Adamson, Chris; Seal, Marc L.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Yuan, Weihong; Holland, Scott K.] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, Cincinnati, OH USA; [Yuan, Weihong; Babcock, Lynn; Leach, James L.; Holland, Scott K.; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Babcock, Lynn; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Div, Cincinnati, OH USA; [Leach, James L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Seal, Marc L.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia	Wade, SL (corresponding author), Cincinnati Childrens Hosp, ML, 3333 Burnet Ave, Cincinnati, OH 45243 USA.	shari.wade@cchmc.org	Seal, Marc L/J-9290-2019	Seal, Marc L/0000-0002-8396-140X; Babcock, Lynn/0000-0002-2658-6893; Holland, Scott/0000-0003-3719-0875	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000077] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH073764] Funding Source: Medline		Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Andersson J.L.R., 2007, NONLINEAR REGISTRATI; ANDERSSON JLR, 2007, NONLINEAR OPTIMISATI; [Anonymous], 2009, EC COST SPINAL CORD, P1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Guy S.C., 2004, BRIEF SR BEHAV RATIN; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jeurissen B, 2010, ESTIMATING NUMBER FI; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Langlois JA, 2006, TBI US EMERGENCY DEP; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; Schmithorst VJ, 2008, HUM BRAIN MAPP, V29, P696, DOI 10.1002/hbm.20431; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P181, DOI 10.1017/S1355617710001414; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wechsler D., 2004, WECHSLER INTELLIGENC; Westlye LT, 2010, CEREB CORTEX, V20, P2055, DOI 10.1093/cercor/bhp280; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	52	21	22	0	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					454	463		10.3109/02699052.2012.750756			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300010	23472581	Green Accepted			2021-06-18	
J	Babcock, L; Byczkowski, T; Wade, SL; Ho, M; Bazarian, JJ				Babcock, Lynn; Byczkowski, Terri; Wade, Shari L.; Ho, Mona; Bazarian, Jeffrey J.			Inability of S100B to Predict Postconcussion Syndrome in Children Who Present to the Emergency Department With Mild Traumatic Brain Injury A Brief Report	PEDIATRIC EMERGENCY CARE			English	Article						mild traumatic brain injury; postconcussion syndrome; S100B; biomarker	MINOR HEAD-INJURY; NEURON-SPECIFIC ENOLASE; CONCUSSION SYMPTOMS QUESTIONNAIRE; SERUM-LEVELS; COMPUTED-TOMOGRAPHY; S-100B PROTEIN; MULTICENTER; RELIABILITY; BIOMARKERS; MANAGEMENT	Objective: This study aimed to explore the ability of the serum marker S100B to predict the development and severity of postconcussion syndrome (PCS) at 3 months in children after mild traumatic brain injury (mTBI). Methods: This is a retrospective analysis of a prospective observational study conducted in a pediatric emergency department (ED). Children were eligible for the study if they were between the ages 5 and 18 years, presented within 6 hours of injury, met the case definition of mTBI from American Congress of Rehabilitation Medicine, had a Glasgow Coma Scale score of greater than 13, consented to have blood drawn for S100B levels, and completed the 3-month telephone follow-up. At the follow-up, the Rivermead Postconcussion Questionnaire was conducted to determine the development and severity of PCS. Results: A total of 76 children were included in this cohort. The children had a mean (SD) age of 14.0 (3.1) years, 60.5% were male, and 89.5% had a Glasgow Coma Scale of 15. Twenty-eight (36.8%) developed PCS. For the children who developed PCS, the mean (SD) S100B level was 0.092 (0.376) mu g/L. For children who did not develop PCS (n = 48), the mean (SD) S100B level was 0.022 (0.031) mu g/L. The analyses did not support an association between initial S100B levels measured in the ED and development of PCS or severity of PCS symptoms. Conclusions: In this small sample, S100B, measured immediately after injury in the ED, did not seem to predict those children with mTBI who will go on to develop PCS.	[Babcock, Lynn; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Babcock, Lynn; Byczkowski, Terri; Ho, Mona] Cincinnati Childrens Hosp Med Ctr, Div Pediat Emergency Med, Cincinnati, OH 45229 USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA	Babcock, L (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pediat Emergency Med, 3333 Burnet Ave,ML 2008, Cincinnati, OH 45229 USA.	lynn.babcock@cchmc.org		Babcock, Lynn/0000-0002-2658-6893	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NIH/NINDS K23 NS41952-02]; New York State Department of Health [NYS DOH C806001]; University of Cincinnati Center for Clinical and Translational Science and Training; Division of Emergency Medicine at Cincinnati Children's Hospital Medical Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD064754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER	This study was in part funded by Dr Jeffrey Bazarian's Career Development K23 Award from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS K23 NS41952-02). S100B analysis was funded through a grant from the New York State Department of Health (NYS DOH C806001). This analysis was funded in part by Dr Babcock's KL2 Mentored Career Development Program in Clinical and Translational Research from the University of Cincinnati Center for Clinical and Translational Science and Training, as well as the Division of Emergency Medicine at Cincinnati Children's Hospital Medical Center.	Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Akhtar Javed I, 2003, Pediatr Crit Care Med, V4, P322; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babcock L, 2012, BRAIN INJURY, V26, P1372, DOI 10.3109/02699052.2012.694565; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2001, K23NS4195202 NIHNIND; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bergman DA, 1999, PEDIATRICS, V104, P1407; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Filippidis AS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10185; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0	41	21	21	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	APR	2013	29	4					458	461		10.1097/PEC.0b013e31828a202d			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	119NC	WOS:000317103300009	23528506	Green Accepted			2021-06-18	
J	Bains, M; Cebak, JE; Gilmer, LK; Barnes, CC; Thompson, SN; Geddes, JW; Hall, ED				Bains, Mona; Cebak, John E.; Gilmer, Lesley K.; Barnes, Colleen C.; Thompson, Stephanie N.; Geddes, James W.; Hall, Edward D.			Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model	JOURNAL OF NEUROCHEMISTRY			English	Article						alpha-spectrin; calpain; neuroprotection; SNJ-1945; traumatic brain injury	ACID 5-METHOXY-3-OXAPENTYL ESTER; CEREBROSPINAL-FLUID; CORPUS-CALLOSUM; HEAD-INJURY; PROTEOLYSIS; NEURODEGENERATION; BREAKDOWN; DEGRADATION; MECHANISMS; RATS	The efficacy of the amphipathic ketoamide calpain inhibitor SNJ-1945 in attenuating calpain-mediated degradation of the neuronal cytoskeletal protein -spectrin was examined in the controlled cortical impact (CCI) traumatic brain injury (TBI) model in male CF-1 mice. Using a single early (15min after CCI-TBI) i.p. bolus administration of SNJ-1945 (6.25, 12.5, 25, or 50-mg/kg), we identified the most effective dose on -spectrin degradation in the cortical tissue of mice at its 24h peak after severe CCI-TBI. We then investigated the effects of a pharmacokinetically optimized regimen by examining multiple treatment paradigms that varied in dose and duration of treatment. Finally, using the most effective treatment regimen, the therapeutic window of -spectrin degradation attenuation was assessed by delaying treatment from 15min to 1 or 3h post-injury. The effect of SNJ-1945 on -spectrin degradation exhibited a U-shaped doseresponse curve when treatment was initiated 15min post-TBI. The most effective 12.5mg/kg dose of SNJ-1945 significantly reduced -spectrin degradation by similar to 60% in cortical tissue. Repeated dosing of SNJ-1945 beginning with a 12.5mg/kg dose did not achieve a more robust effect compared with a single bolus treatment, and the required treatment initiation was less than 1h. Although calpain has been firmly established to play a major role in post-traumatic secondary neurodegeneration, these data suggest that even brain and cell-permeable calpain inhibitors, when administered alone, do not show sufficient cytoskeletal protective efficacy or a practical therapeutic window in a mouse model of severe TBI. Such conclusions need to be verified in the human clinical situation.	[Bains, Mona; Cebak, John E.; Gilmer, Lesley K.; Barnes, Colleen C.; Thompson, Stephanie N.; Geddes, James W.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Med Ctr, SCoBIRC, Room B477,Biomed & Biol Sci Res Bldg,741 S Limest, Lexington, KY 40536 USA.	edhall@uky.edu	Thompson, Stephanie/AAB-8272-2020; Hall, Edward D/F-8930-2013		National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P01 NS058484, 2P30 NS051220]; Kentucky Spinal Cord & Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058484, P30NS051220] Funding Source: NIH RePORTER	This study was supported by funding from the National Institute of Neurological Disorders and Stroke (2P01 NS058484, 2P30 NS051220) and the Kentucky Spinal Cord & Head Injury Research Trust. The authors have no conflicts of interest to declare in relation to the contents of this manuscript.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; Mellgren RL, 2007, J BIOL CHEM, V282, P2567, DOI 10.1074/jbc.M604560200; Mellgren RL, 2009, BBA-MOL CELL RES, V1793, P1886, DOI 10.1016/j.bbamcr.2009.09.013; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Oka T, 2006, NEUROSCIENCE, V141, P2139, DOI 10.1016/j.neuroscience.2006.05.060; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Shirasaki Y, 2008, BIOORG MED CHEM LETT, V18, P5174, DOI 10.1016/j.bmcl.2008.08.089; Shirasaki Y, 2006, J OCUL PHARMACOL TH, V22, P417, DOI 10.1089/jop.2006.22.417; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thompson SN, 2010, J NEUROTRAUM, V27, P2233, DOI 10.1089/neu.2010.1474; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yoshikawa Y, 2010, AM J PHYSIOL-HEART C, V298, pH643, DOI 10.1152/ajpheart.00849.2009	29	21	21	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	APR	2013	125	1					125	132		10.1111/jnc.12118			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	112YR	WOS:000316631900013	23216523	Bronze			2021-06-18	
J	Bell, MJ; Kochanek, PM				Bell, Michael J.; Kochanek, Patrick M.			Pediatric Traumatic Brain Injury in 2012 The Year with New Guidelines and Common Data Elements	CRITICAL CARE CLINICS			English	Article						Pediatric TBI guidelines; Pediatric TBI common data elements; Evidenced-based medicine; Children; Severe traumatic brain injury	SEVERE HEAD-INJURY; ENDOTRACHEAL INTUBATION; DEXAMETHASONE THERAPY; HYPERTONIC SALINE; CLINICAL-TRIAL; CHILDREN; RECOMMENDATIONS; SURVIVAL; HYPERVENTILATION; HYPOTHERMIA	Pediatric Traumatic Brain Injury in 2012:The Year with New Guidelines and Common Data Elements Michael J. Bell and Patrick M. Kochanek Traumatic brain injury (TBI) remains the leading cause of death of children in the developing world. In 2012, several international efforts were completed to aid clinicians and researchers in advancing the field of pediatric TBI. The second edition of the Guidelines for the Medical Management of Traumatic Brain Injury in Infants, Children and Adolescents updated those published in 2003. This article highlights the processes involved in developing the Guidelines, contrasts the new guidelines with the previous edition, and delineates new research efforts needed to advance knowledge. The impact of common data elements within these potential new research fields is reviewed.	[Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Bell, Michael J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Bell, Michael J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA	Bell, MJ (corresponding author), Safar Ctr Resuscitat Res, Pediat Neurotrauma Ctr, 3434 5th Ave, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U44 NS070324, T32HD040686, U01 HD049981, R01 NS069247, R01 NS072308]; US ArmyUnited States Department of Defense [W81XWH-09-2-0187, W81XWH-10-0623]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686, UG1HD049981, U10HD049981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087, R01NS069247, U44NS070324, R01NS072308] Funding Source: NIH RePORTER	Both Drs Bell and Kochanek were selected by the Brain Trauma Foundation to develop the Guidelines for the Medical Management of Severe Traumatic Brain Injury for Infants, Children and Adolescents but were not compensated for their work. In addition, Dr Bell was selected by the National Institute of Neurological Disorders and Stroke to participate in development of the Common Data Elements for Pediatric TBI, but he was not compensated for his work. Dr Kochanek is supported by several Federal grants (U44 NS070324, T32HD040686 from the NIH and W81XWH-09-2-0187 and W81XWH-10-0623 from the US Army), as is Dr Bell (U01 HD049981, R01 NS069247, R01 NS072308 from the NIH).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS68; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS53; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS5; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS9; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS34; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS49; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS56; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS60; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS38; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Briassoulis G, 2006, PEDIATR CRIT CARE ME, V7, P56, DOI 10.1097/01.PCC.0000192339.44871.26; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; FANCONI S, 1988, INTENS CARE MED, V14, P163; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Hulka F, 1997, J TRAUMA, V42, P514, DOI 10.1097/00005373-199703000-00020; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Johnson DL, 1996, PEDIATR NEUROSURG, V25, P309, DOI 10.1159/000121145; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475	50	21	22	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	APR	2013	29	2					223	+		10.1016/j.ccc.2012.11.004			17	Critical Care Medicine	General & Internal Medicine	125JJ	WOS:000317535800007	23537673	Green Accepted			2021-06-18	
J	Carpenter, SL; Abshire, TC; Anderst, JD				Carpenter, Shannon L.; Abshire, Thomas C.; Anderst, James D.		Sect Hematology Oncology; Comm Child Abuse Neglect	Evaluating for Suspected Child Abuse: Conditions That Predispose to Bleeding	PEDIATRICS			English	Article						intracranial hemorrhage; inherited coagulation disorders; bruising; nonaccidental trauma	EHLERS-DANLOS-SYNDROME; VON-WILLEBRAND-DISEASE; FACTOR-XIII DEFICIENCY; FACTOR-V DEFICIENCY; INTRACRANIAL HEMORRHAGE SECONDARY; CHRONIC SUBDURAL-HEMATOMA; TRAUMATIC BRAIN-INJURY; FACTOR-VII DEFICIENCY; SYNDROME TYPE-IV; OSTEOGENESIS IMPERFECTA	Child abuse might be suspected when children present with cutaneous bruising, intracranial hemorrhage, or other manifestations of bleeding. In these cases, it is necessary to consider medical conditions that predispose to easy bleeding/bruising. When evaluating for the possibility of bleeding disorders and other conditions that predispose to hemorrhage, the pediatrician must consider the child's presenting history, medical history, and physical examination findings before initiating a laboratory investigation. Many medical conditions can predispose to easy bleeding. Before ordering laboratory tests for a disease, it is useful to understand the biochemical basis and clinical presentation of the disorder, condition prevalence, and test characteristics. This technical report reviews the major medical conditions that predispose to bruising/bleeding and should be considered when evaluating for abusive injury.					Sege, Robert/0000-0003-1260-4787			Acharya SS, 2008, HAEMOPHILIA, V14, P1151, DOI 10.1111/j.1365-2516.2008.01831.x; Acharya SS, 2004, J THROMB HAEMOST, V2, P248, DOI 10.1111/j.1538-7836.2003.t01-1-00553.x; Akhavan S, 2003, BRIT J HAEMATOL, V120, P142, DOI 10.1046/j.1365-2141.2003.03986.x; Alamelu J, 2010, BRIT J HAEMATOL, V149, P813, DOI 10.1111/j.1365-2141.2010.08191.x; Albanese A, 2005, J NEUROSURG, V102, P1130, DOI 10.3171/jns.2005.102.6.1130; ALFAWAZ IM, 1992, ACTA HAEMATOL-BASEL, V88, P194; ALMAANI WS, 1986, SURG NEUROL, V26, P457, DOI 10.1016/0090-3019(86)90258-2; Barabas G M, 1967, Br Dent J, V123, P473; Barkovich AJ, 2005, PEDIAT NEUROIMAGING, P190; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.0.CO;2-O; Bick RL, 1992, DISORDERS THROMBOSIS; Bolton-Maggs PHB, 2006, BRIT J HAEMATOL, V135, P603, DOI 10.1111/j.1365-2141.2006.06343.x; Bolton-Maggs PHB, 2004, HAEMOPHILIA, V10, P593, DOI 10.1111/j.1365-2516.2004.00944.x; Boshkov LK, 2001, DISORDERS HEMOSTASIS, P495; Brenner B, 2000, THROMB HAEMOSTASIS, V84, P935; Brown DL, 2008, HAEMOPHILIA, V14, P1176, DOI 10.1111/j.1365-2516.2008.01856.x; Carpenter RF, 1999, ARCH DIS CHILD, V80, P363, DOI 10.1136/adc.80.4.363; Carpenter SL, 2008, HAEMOPHILIA, V14, P1250, DOI 10.1111/j.1365-2516.2008.01766.x; Clemetson C. A. B., 2004, J AM PHYS SURG, V9, P78; Clemetson CAB, 2004, MED HYPOTHESES, V62, P533, DOI 10.1016/j.mehy.2003.12.023; De Paepe A, 2004, BRIT J HAEMATOL, V127, P491, DOI 10.1111/j.1365-2141.2004.05220.x; Dean JA, 2000, THROMB HAEMOSTASIS, V84, P401; Devaussuzenet VMP, 1998, PEDIATR RADIOL, V28, P978, DOI 10.1007/s002470050513; Di Michele DM, 2001, DISORDERS HEMOSTASIS, P127; Di Minno G, 2009, THROMB HAEMOSTASIS, V102, P1157, DOI 10.1160/TH09-04-0225; Duga S, 2009, SEMIN THROMB HEMOST, V35, P416, DOI 10.1055/s-0029-1225764; Dunstan FD, 2002, ARCH DIS CHILD, V86, P330, DOI 10.1136/adc.86.5.330; Ellestad SC, 2007, HAEMOPHILIA, V13, P432, DOI 10.1111/j.1365-2516.2007.01469.x; EVENSEN SA, 1984, SCAND J HAEMATOL, V33, P177; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Farah RA, 2007, J THROMB HAEMOST, V5, P433, DOI 10.1111/j.1538-7836.2007.02318.x; Favaloro EJ, 2008, SEMIN THROMB HEMOST, V34, P709, DOI 10.1055/s-0029-1145254; Favier R, 2001, BRIT J HAEMATOL, V114, P4, DOI 10.1046/j.1365-2141.2001.02845.x; Fay WP, 1997, BLOOD, V90, P204; FELDMAN KW, 1992, PEDIATRICS, V90, P633; Franchini M, 2010, J THROMB HAEMOST, V8, P421, DOI 10.1111/j.1538-7836.2009.03717.x; Fressinaud E, 1998, BLOOD, V91, P1325, DOI 10.1182/blood.V91.4.1325; Ganesh A, 2004, OPHTHALMOLOGY, V111, P1428, DOI 10.1016/j.ophtha.2003.10.028; Gardner HB, 2005, MED HYPOTHESES, V64, P663, DOI 10.1016/j.mehy.2004.09.009; Girolami A, 2006, HAEMOPHILIA, V12, P345, DOI 10.1111/j.1365-2516.2006.01299.x; Goddeau RP, 2010, ARCH NEUROL-CHICAGO, V67, P236, DOI 10.1001/archneurol.2009.319; Gomez K, 2008, HAEMOPHILIA, V14, P1183, DOI 10.1111/j.1365-2516.2008.01667.x; Goodnight SH, 2001, DISORDERS HEMOSTASIS, P184; Goodnight SH, 2001, DISORDERS HEMOSTASIS, P52; Gordon M, 2008, CLIN PEDIATR, V47, P385, DOI 10.1177/0009922807309065; Groninger A, 2005, PEDIATR NEUROL, V32, P140, DOI 10.1016/j.pediatrneurol.2004.07.011; Harrison P, 2009, SEMIN THROMB HEMOST, V35, P150, DOI 10.1055/s-0029-1220323; Hassan Amy A, 2005, Hematology Am Soc Hematol Educ Program, P403; HATHAWAY WE, 1972, BLOOD-J HEMATOL, V39, P500, DOI 10.1182/blood.V39.4.500.500; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hayward CPM, 2006, HAEMOPHILIA, V12, P128, DOI 10.1111/j.1365-2516.2006.01270.x; Herrmann FH, 2006, HAEMOPHILIA, V12, P479, DOI 10.1111/j.1365-2516.2006.01303.x; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Hill M, 2008, HAEMOPHILIA, V14, P889, DOI 10.1111/j.1365-2516.2008.01795.x; Hsieh L, 2008, HAEMOPHILIA, V14, P1190, DOI 10.1111/j.1365-2516.2008.01857.x; Huang JN, 2008, HAEMOPHILIA, V14, P1164, DOI 10.1111/j.1365-2516.2008.01785.x; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Hymel KP, 2010, PEDIATRICS, V125, P712, DOI 10.1542/peds.2009-2133; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Ivaskevicius V, 2007, THROMB HAEMOSTASIS, V97, P914, DOI 10.1160/TH07-01-0034; Jenny C, 2006, PEDIATRICS, V118, P1299, DOI 10.1542/peds.2006-1795; Karimi M, 2009, SEMIN THROMB HEMOST, V35, P426, DOI 10.1055/s-0029-1225765; Kasper CK, 2007, HAEMOPHILIA, V13, P90, DOI 10.1111/j.1365-2516.2006.01397.x; Kasper CK, 2009, HAEMOPHILIA, V15, P1181, DOI 10.1111/j.1365-2516.2009.02003.x; Kulkarni R, 2009, HAEMOPHILIA, V15, P1281, DOI 10.1111/j.1365-2516.2009.02074.x; Kumar S, 2002, MAYO CLIN PROC, V77, P181; Kuurila K, 2002, ANN OTO RHINOL LARYN, V111, P939, DOI 10.1177/000348940211101014; Lak M, 1999, BRIT J HAEMATOL, V107, P204; Lancellotti S, 2009, SEMIN THROMB HEMOST, V35, P367, DOI 10.1055/s-0029-1225759; Lapecorella M, 2008, HAEMOPHILIA, V14, P1170, DOI 10.1111/j.1365-2516.2008.01844.x; Lee JH, 2009, BLOOD COAGUL FIBRIN, V20, P161, DOI 10.1097/MBC.0b013e3283258028; Lieder HS, 2005, AACN ADV CRIT CARE, V16, P178, DOI 10.1097/00044067-200504000-00009; Maguire S, 2005, ARCH DIS CHILD, V90, P182, DOI 10.1136/adc.2003.044065; Maguire S, 2009, ARCH DIS CHILD, V94, P860, DOI 10.1136/adc.2008.150110; Malfait F, 2009, BLOOD REV, V23, P191, DOI 10.1016/j.blre.2009.06.001; Mansouritorgabeh H, 2004, HAEMOPHILIA, V10, P271, DOI 10.1111/j.1365-2516.2004.00890.x; Mariani G, 2005, THROMB HAEMOSTASIS, V93, P481, DOI 10.1160/TH04-10-0650; McIntosh N, 2007, PEDIATRICS, V120, P1074, DOI 10.1542/peds.2007-2097; McKay H, 2004, BLOOD, V104, P159, DOI 10.1182/blood-2003-11-4077; McLean LA, 2012, AM J NEURORADIOL, V33, P1281, DOI 10.3174/ajnr.A2967; Meeks SL, 2008, HAEMOPHILIA, V14, P1159, DOI 10.1111/j.1365-2516.2008.01832.x; Mehta R, 2008, HAEMOPHILIA, V14, P1255, DOI 10.1111/j.1365-2516.2008.01834.x; Menegatti M, 2009, SEMIN THROMB HEMOST, V35, P407, DOI 10.1055/s-0029-1225763; Millar DS, 2000, HUM GENET, V106, P249, DOI 10.1007/s004390051035; Mishra P, 2008, HAEMOPHILIA, V14, P952, DOI 10.1111/j.1365-2516.2008.01814.x; Miyasaka M, 2007, EMERG RADIOL, V14, P323, DOI 10.1007/s10140-007-0632-y; MIZOI K, 1984, SURG NEUROL, V22, P495, DOI 10.1016/0090-3019(84)90310-0; National Heart Lung and Blood Institute/National Asthma Education and Prevention Program, 2007, NIH PUBLICATION, V07-4051; Nelson MD, 1999, HAEMOPHILIA, V5, P306; Neunert C, 2011, BLOOD, V117, P4190, DOI 10.1182/blood-2010-08-302984; Newman RS, 2002, AM J HEMATOL, V71, P328, DOI 10.1002/ajh.10225; Nichols WL, 2008, HAEMOPHILIA, V14, P171, DOI 10.1111/j.1365-2516.2007.01643.x; Nuss R, 2001, AM J HEMATOL, V68, P37, DOI 10.1002/ajh.1146; Offiah A, 2009, PEDIATR RADIOL, V39, P461, DOI 10.1007/s00247-009-1157-1; OHARE AE, 1984, ARCH DIS CHILD, V59, P860, DOI 10.1136/adc.59.9.860; OWEN SM, 1984, ARCH DERMATOL, V120, P97, DOI 10.1001/archderm.120.1.97; Paranjothy S, 2009, ARCH DIS CHILD, V94, P421, DOI 10.1136/adc.2008.144881; Parmar CD, 2007, J NEUROSURG, V106, P57, DOI 10.3171/ped.2007.106.1.57; Pepin M, 2000, NEW ENGL J MED, V342, P673, DOI 10.1056/NEJM200003093421001; Pepin MG, EHLERS DANLOS SYNDRO; Peyvandi F, 2002, HAEMOPHILIA, V8, P308, DOI 10.1046/j.1365-2516.2002.00633.x; Peyvandi F, 1998, BRIT J HAEMATOL, V100, P773; Peyvandi F, 1999, THROMB HAEMOSTASIS, V82, P1207; POZZATI E, 1983, NEUROSURGERY, V13, P66, DOI 10.1227/00006123-198307000-00014; Remacha PPO, 2000, REV CLIN ESP, V200, P181; ReverdiauMoalic P, 1996, BLOOD, V88, P900, DOI 10.1182/blood.V88.3.900.bloodjournal883900; ROBERTS DLL, 1984, BRIT J DERMATOL, V111, P341, DOI 10.1111/j.1365-2133.1984.tb04733.x; Roberts HR, 1995, WILLIAMS HEMATOLOGY, P1413; Rughani AI, 2009, NEUROSURGERY, V64, P1192, DOI 10.1227/01.NEU.0000345650.60160.07; Sadler JE, 2000, THROMB HAEMOSTASIS, V84, P160; Salooja N, 2000, HAEMOPHILIA, V6, P44; Sasaki-Adams D, 2008, J NEUROSURG-PEDIATR, V1, P229, DOI 10.3171/PED/2008/1/3/229; SCHIEVINK WI, 1990, STROKE, V21, P626, DOI 10.1161/01.STR.21.4.626; Shearer MJ, 2009, BLOOD REV, V23, P49, DOI 10.1016/j.blre.2008.06.001; Sirotnak AP, 2006, ABUSIVE HEAD TRAUMA, P191; Spreafico M, 2008, HAEMOPHILIA, V14, P1201, DOI 10.1111/j.1365-2516.2008.01845.x; Steiner RD, OSTEOGENESIS IMPERFE; Steinmann B, 2002, CONNECTIVE TISSUE IT, P431; Stray-Pedersen A, 2011, FORENSIC SCI MED PAT, V7, P37, DOI 10.1007/s12024-010-9176-7; Stricker T, 2002, J PAEDIATR CHILD H, V38, P528, DOI 10.1046/j.1440-1754.2002.00049.x; Strijks E, 1999, NEUROPEDIATRICS, V30, P320, DOI 10.1055/s-2007-973512; Sugar NF, 1999, ARCH PEDIAT ADOL MED, V153, P399, DOI 10.1001/archpedi.153.4.399; Sullivan PM, 2000, CHILD ABUSE NEGLECT, V24, P1257, DOI 10.1016/S0145-2134(00)00190-3; TAKAHASHI Y, 1991, HAEMOSTASIS, V21, P321; Talving P, 2011, J TRAUMA, V71, P1205, DOI 10.1097/TA.0b013e31820d151d; TOKORO K, 1988, NEUROSURGERY, V22, P595, DOI 10.1227/00006123-198803000-00029; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; Ulinski T, 2004, PEDIATR NEPHROL, V19, P798, DOI 10.1007/s00467-004-1461-9; Vasileiadis I, 2009, BLOOD COAGUL FIBRIN, V20, P309, DOI 10.1097/MBC.0b013e328329e485; Verhovsek M, 2008, AM J HEMATOL, V83, P928, DOI 10.1002/ajh.21293; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Vinchon M, 2010, CHILD NERV SYST, V26, P637, DOI 10.1007/s00381-009-1048-7; Walton LJ, 2010, ARCH DIS CHILD, V95, P53, DOI 10.1136/adc.2009.160978; Wetzstein Viola, 2006, Haematologica, V91, pECR60; Witmer CM, 2007, HAEMOPHILIA, V13, P560, DOI 10.1111/j.1365-2516.2007.01546.x; Wong AYK, 2006, J THROMB HAEMOST, V4, P2623, DOI 10.1111/j.1538-7836.2006.02235.x; Wong WY, 2000, HAEMOPHILIA, V6, P50; WYNNEDAVIES R, 1981, CLIN ORTHOP RELAT R, P26; Zipursky A, 1999, BRIT J HAEMATOL, V104, P430, DOI 10.1046/j.1365-2141.1999.01104.x; Ziv O, 2004, HAEMOPHILIA, V10, P162, DOI 10.1111/j.1365-2516.2003.00871.x	142	21	22	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2013	131	4					E1357	E1373		10.1542/peds.2013-0196			17	Pediatrics	Pediatrics	135EF	WOS:000318269500039	23530171	Bronze			2021-06-18	
J	Lakis, N; Corona, RJ; Toshkezi, G; Chin, LS				Lakis, Nelli; Corona, Robert J.; Toshkezi, Gentian; Chin, Lawrence S.			Chronic traumatic encephalopathy - neuropathology in athletes and war veterans	NEUROLOGICAL RESEARCH			English	Article						Chronic traumatic encephalopathy; Tau proteinopathy; Neurofibrillary tangles; Concussion; Traumatic brain injury; Dementia	PROGRESSIVE SUPRANUCLEAR PALSY; BRAIN-INJURY; HEAD-INJURY; DEMENTIA-PUGILISTICA; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; CONCUSSION; CORTEX	Objective: The neuropathologic findings of chronic traumatic encephalopathy (CTE) were first described almost 40 years after the first clinical reports. We reviewed the literature and describe the neuropathological findings seen primarily in professional athletes and more recently, in war veterans. Methods: We reviewed the literature of CTE concentrating on references that focused on the correlation of clinical findings with the neuropathologic changes. The pathobiology and proposed mechanisms of injury are described. Diagnostic modalities and various diagnostic criteria of CTE are reviewed. Results: We are beginning to understand the neuropathologic basis of CTE, which appears to be a consequence of repetitive mild brain injuries. There appear to be reproducible criteria for the post-mortem diagnosis of CTE and the neuropathologic findings are becoming more widely accepted. More research is required to elucidate the risk factors that predispose athletes and war veterans to CTE. There is also a need for more diagnostic markers and a method to assess CTE in patients prior to death. The neuropathologic findings of a progressive tauopathy including the presence of numerous neurofibrillary tangles (NFTs), rare neuritic plaques, and widespread expression of TDP-43 (transactive response [TAR] DNA binding protein 43) also require further study. Discussion: The potential prevalence of CTE, as well as the vulnerable populations involved, makes research into this topic crucial. Currently, a comprehensive neurological exam, neuropsychiatric assessment, and standard radiographic techniques such as conventional MRI are the mainstay of diagnosis. There is a pressing need for the prevention of CTE and the development of non-invasive diagnostic tests in order to develop therapies that may be of clinical use to athletes and blast injury veterans during their lifetimes.	[Lakis, Nelli; Corona, Robert J.] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13078 USA; [Toshkezi, Gentian; Chin, Lawrence S.] SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13078 USA	Chin, LS (corresponding author), SUNY Upstate Med Univ, Dept Neurosurg, 750 E,Adams St, Syracuse, NY 13078 USA.	chinl@upstate.edu					Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Areza-Fegyveres R, 2007, ARQ NEURO-PSIQUIAT, V65, P830, DOI 10.1590/S0004-282X2007000500019; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bird CM, 2008, NAT REV NEUROSCI, V9, P182, DOI 10.1038/nrn2335; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; COURVILLE CYRIL B., 1962, BULL LOS ANGELES NEUROL SOC, V27, P160; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Eggers AE, 2007, MED HYPOTHESES, V69, P852, DOI 10.1016/j.mehy.2007.01.074; Feany MB, 1996, J NEUROPATH EXP NEUR, V55, P53, DOI 10.1097/00005072-199601000-00006; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Galvin JE, 2011, NEUROLOGY, V76, P1797, DOI 10.1212/WNL.0b013e31821ccc83; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; HOF PR, 1992, ACTA NEUROPATHOL, V84, P45, DOI 10.1007/BF00427214; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Ludolph AC, 2009, EUR J NEUROL, V16, P297, DOI 10.1111/j.1468-1331.2008.02513.x; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller G, 2012, SCIENCE, V336, P790, DOI 10.1126/science.336.6083.790; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Morris JC, 2001, J MOL NEUROSCI, V17, P101, DOI 10.1385/JMN:17:2:101; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPEZ JW, 1995, J NEUROPSYCH CLIN N, V7, P103; Perl DP, 2003, J NEUROPATH EXP NEUR, V62, P381, DOI 10.1093/jnen/62.4.381; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Talavage T. M., 2010, J NEUROTRAUMA; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Troncoso JC, 1996, NEUROBIOL AGING, V17, P365, DOI 10.1016/0197-4580(96)00028-0; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	77	21	21	0	46	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	APR	2013	35	3					290	299		10.1179/1743132813Y.0000000177			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	104QW	WOS:000316010700010	23485056				2021-06-18	
J	Li, XG; vot Holst, H; Kleiven, S				Li, Xiaogai; von Holst, Hans; Kleiven, Svein			Decompressive craniectomy causes a significant strain increase in axonal fiber tracts	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Axonal fiber tracts; Decompressive craniectomy; Diffusion-weighted image; Lagrangian finite strain tensor	TRAUMATIC BRAIN-INJURY; DYNAMIC STRETCH INJURY; SERIES	Decompressive craniectomy (DC) allows for the expansion of a swollen brain outside the skull and has the potential to reduce intracranial pressure. However, the stretching of axons may contribute to an unfavorable outcome in patients treated with DC. In this study, we present a method for quantifying and visualizing axonal fiber deformation during both the pre-craniectomy and post-craniectomy periods to provide more insight into the mechanical effects of this treatment on axonal fibers. The deformation of the brain tissue in the form of a Lagrangian finite strain tensor for the entire brain was obtained by a non-linear image registration method based on the CT scanning data sets of the patient. Axonal fiber tracts were extracted from diffusion-weighted images. Based on the calculated brain tissue strain tensor and the observed axonal fiber tracts, the deformation of axonal fiber tracts in the form of a first principal strain, axonal strain and axonal shear strain were quantified. The greatest axonal fiber displacement was predominantly located in the treated region of the craniectomy, accompanied by a large axonal deformation close to the skull edge of the craniectomy. The distortion (stretching or shearing) of axonal fibers in the treated area of the craniectomy may influence the axonal fibers in such a way that neurochemical events are disrupted. A quantitative model may clarify some of the potential problems with this treatment. (C) 2012 Elsevier Ltd. All rights reserved.	[Li, Xiaogai; von Holst, Hans; Kleiven, Svein] Royal Inst Technol KTH, Sch Technol & Hlth, Div Neuron Engn, SE-14152 Stockholm, Sweden; [von Holst, Hans] Karolinska Inst, Neurosurg Sect, Div Clin Neurosci, Stockholm, Sweden	Li, XG (corresponding author), Royal Inst Technol KTH, Sch Technol & Hlth, Div Neuron Engn, Alfred Nobels Alle 10, SE-14152 Stockholm, Sweden.	xiaogai@kth.se		Li, Xiaogai/0000-0001-8522-4705	Swedish Research CouncilSwedish Research CouncilEuropean Commission [621-2008-3400]; Swedish Governmental Agency for Innovation systems (VINNOVA)Vinnova; Chinese Council Scholarship (CSC)	This study was supported by Swedish Research Council D.nr. 621-2008-3400, the Swedish Governmental Agency for Innovation systems (VINNOVA), and the Chinese Council Scholarship (CSC) for the first author. We thank Professor Tieqiang Li (Karolinska Institute, Stockholm, Sweden) for providing the diffusion-weighted images and the MRI in this study.	Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Fowler SS, 2001, OTOLARYNG HEAD NECK, V124, P641, DOI 10.1067/mhn.2001.115908; Hill DLG, 2002, LECT NOTES COMPUT SC, V2488, P532; Holzapfel G., 2000, NONLINEAR SOLID MECH; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Joseph R.G., 1996, NEUROPSYCHIATRY NEUR; Li X, 2012, FINITE ELEMENT NEURO; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Pieper S, 2004, 2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 and 2, P632; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Smith DH, 1999, J NEUROSCI, V19, P4263; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Vashu R, 2011, ACTA NEUROCHIR, V153, P2065, DOI 10.1007/s00701-011-1101-7; Vercauteren T, 2009, NEUROIMAGE, V45, pS61, DOI 10.1016/j.neuroimage.2008.10.040; Wagner S, 2001, J NEUROSURG, V94, P693, DOI 10.3171/jns.2001.94.5.0693; Winter CD, 2005, J CLIN NEUROSCI, V12, P619, DOI 10.1016/j.jocn.2005.02.002; Wirtz C R, 1997, Neurosurg Focus, V2, pE3; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	26	21	21	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2013	20	4					509	513		10.1016/j.jocn.2012.04.019			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	126PF	WOS:000317632500004	23403173				2021-06-18	
J	Oladunjoye, AO; Schrot, RJ; Zwienenberg-Lee, M; Muizelaar, JP; Shahlaie, K				Oladunjoye, Azeem O.; Schrot, Rudolph J.; Zwienenberg-Lee, Marike; Muizelaar, J. Paul; Shahlaie, Kiarash			Decompressive craniectomy using gelatin film and future bone flap replacement	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; cranioplasty; stroke; peridural scarring; traumatic brain injury; surgical technique	TRAUMATIC BRAIN-INJURY; ADHESION PREVENTIVE MATERIAL; CEREBRAL-ARTERY INFARCTION; SEVERE HEAD-INJURY; SURGICAL DECOMPRESSION; COLLAGEN MATRIX; TECHNICAL NOTE; CRANIOPLASTY; COMPLICATIONS; MULTICENTER	Object. Decompressive craniectomy plays an important role in the management of patients with traumatic brain injury (TBI) and stroke. Risks of decompressive craniectomy include those associated with cranioplasty, and may be related to adhesions that develop between the brain surface and overlying scalp and temporalis muscle. The authors report their institutional experience using a multilayered technique (collagen and gelatin film barriers) to facilitate safe and rapid cranioplasty following decompressive craniectomy. Methods. The authors conducted a retrospective chart review of 62 consecutive adult and pediatric patients who underwent decompressive craniectomy and subsequent cranioplasty between December 2007 and January 2011. Diagnoses included TBI, ischemic stroke, intraparenchymal hemorrhage, or subarachnoid hemorrhage. A detailed review of clinical charts was performed, including anesthesia records and radiographic study results. Results. The majority of patients underwent unilateral hemicraniectomy (n = 56), with indications for surgery including midline shift (n = 37) or elevated intracranial pressure (n = 25). Multilayered decompressive craniectomy was safe and easy to perform, and was associated with a low complication rate, minimal operative time, and limited blood loss. Conclusions. Decompressive craniectomy repair using an absorbable gelatin film barrier facilitates subsequent cranioplasty by preventing adhesions between intracranial contents and the overlying galea aponeurotica and temporalis muscle fascia. This technique makes cranioplasty dissection faster and potentially safer, which may improve clinical outcomes. The indications for gelatin film should be expanded to include placement in the epidural space after craniectomy. (http://thejns.org/doi/abs/10.3171/2013.1.JNS121475)	[Oladunjoye, Azeem O.; Schrot, Rudolph J.; Zwienenberg-Lee, Marike; Muizelaar, J. Paul; Shahlaie, Kiarash] Univ Calif Davis, Dept Neurol Surg, Sch Med, Sacramento, CA 95817 USA	Shahlaie, K (corresponding author), Univ Calif Davis, Dept Neurol Surg, Sch Med, 4860 Y St,Suite 3740, Sacramento, CA 95817 USA.	kiarash.shahlaie@ucdmc.ucdavis.edu					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bulters D, 2010, BRIT J NEUROSURG, V24, P75, DOI 10.3109/02688690903506135; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Danish SF, 2006, J NEUROSURG, V104, P16, DOI 10.3171/ped.2006.104.1.16; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guresir E, 2012, NEUROSURGERY, V70, P881, DOI 10.1227/NEU.0b013e318237a6a6; Guresir E, 2011, J NEUROSURG, V114, P954, DOI 10.3171/2009.12.JNS091065; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Horaczek JA, 2008, NEUROSURGERY, V63, P176, DOI 10.1227/01.NEU.0000312707.25073.CB; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Huang X, 2010, INT J MED SCI, V7, P385; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Lee CH, 2007, CLIN NEUROL NEUROSUR, V109, P667, DOI 10.1016/j.clineuro.2007.05.015; Marion DW, 2006, NEUROSURGERY, V58, P655; Matsumura Goki, 2008, Asian Cardiovasc Thorac Ann, V16, P309; McCall TD, 2008, SURG NEUROL, V70, P92, DOI 10.1016/j.surneu.2007.04.007; McGhee MA, 1999, AM J OTOL, V20, P712; Missori P, 2008, SURG NEUROL, V70, P437, DOI 10.1016/j.surneu.2007.03.029; Miyake S, 2006, NEUROL MED-CHIR, V46, P104, DOI 10.2176/nmc.46.104; Munch E, 2000, NEUROSURGERY, V47, P315; Nakagawa S, 2003, NEUROL MED-CHIR, V43, P120, DOI 10.2176/nmc.43.120; Narotam PK, 2004, SPINE, V29, P2861, DOI 10.1097/01.brs.0000148049.69541.ad; Nishizawa S, 1998, J Clin Neurosci, V5 Suppl, P78, DOI 10.1016/S0967-5868(98)90019-4; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Quinn TM, 2011, ACTA NEUROL SCAND, V123, P239, DOI 10.1111/j.1600-0404.2010.01397.x; Ragel BT, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1028; Sade B, 2011, J NEUROSURG, V114, P714, DOI 10.3171/2010.7.JNS10460; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vakis A, 2006, CLIN NEUROL NEUROSUR, V108, P798, DOI 10.1016/j.clineuro.2005.11.026; Wirtz C R, 1997, Neurosurg Focus, V2, pE3; Yamagata Sen, 1993, Neurologia Medico-Chirurgica, V33, P582, DOI 10.2176/nmc.33.582; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99	41	21	21	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2013	118	4					776	782		10.3171/2013.1.JNS121475			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	114BT	WOS:000316715700015	23394343				2021-06-18	
J	Purushothuman, S; Marotte, L; Stowe, S; Johnstone, DM; Stone, J				Purushothuman, Sivaraman; Marotte, Lauren; Stowe, Sally; Johnstone, Daniel M.; Stone, Jonathan			The Response of Cerebral Cortex to Haemorrhagic Damage: Experimental Evidence from a Penetrating Injury Model	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; BETA-OLIGOMER FORMATION; ALZHEIMERS-DISEASE; SENILE PLAQUES; HEAD-INJURY; RISK-FACTORS; MOUSE MODEL; CELL-DEATH; HYPOTHESIS	Understanding the response of the brain to haemorrhagic damage is important in haemorrhagic stroke and increasingly in the understanding the cerebral degeneration and dementia that follow head trauma and head-impact sports. In addition, there is growing evidence that haemorrhage from small cerebral vessels is important in the pathogenesis of age-related dementia (Alzheimer's disease). In a penetration injury model of rat cerebral cortex, we have examined the neuropathology induced by a needlestick injury, with emphasis on features prominent in the ageing and dementing human brain, particularly plaque-like depositions and the expression of related proteins. Needlestick lesions were made in neo- and hippocampal cortex in Sprague Dawley rats aged 3-5 months. Brains were examined after 1-30 d survival, for haemorrhage, for the expression of hyperphosphorylated tau, Ab, amyloid precursor protein (APP), for gliosis and for neuronal death. Temporal cortex from humans diagnosed with Alzheimer's disease was examined with the same techniques. Needlestick injury induced long-lasting changes-haem deposition, cell death, plaque-like deposits and glial invasion-along the needle track. Around the track, the lesion induced more transient changes, particularly upregulation of A beta, APP and hyperphosporylated tau in neurons and astrocytes. Reactions were similar in hippocampus and neocortex, except that neuronal death was more widespread in the hippocampus. In summary, experimental haemorrhagic injury to rat cerebral cortex induced both permanent and transient changes. The more permanent changes reproduced features of human senile plaques, including the formation of extracellular deposits in which haem and Ab-related proteins co-localised, neuronal loss and gliosis. The transient changes, observed in tissue around the direct lesion, included the upregulation of A beta, APP and hyperphosphorylated tau, not associated with cell death. The findings support the possibility that haemorrhagic damage to the brain can lead to plaque-like pathology.	[Purushothuman, Sivaraman; Stowe, Sally; Johnstone, Daniel M.; Stone, Jonathan] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Purushothuman, Sivaraman; Stowe, Sally; Johnstone, Daniel M.; Stone, Jonathan] Univ Sydney, Discipline Physiol, Sydney, NSW 2006, Australia; [Marotte, Lauren; Stowe, Sally] Australian Natl Univ, Res Sch Biol, Div Biomed Sci & Biochem, Canberra, ACT, Australia	Stone, J (corresponding author), Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia.	jonstone@eye.usyd.edu.au	Johnstone, Daniel/E-9929-2013	Johnstone, Daniel/0000-0003-2876-3299; Purushothuman, Sivaraman/0000-0002-0880-5060	Sir Zelman Cowen Universities Fund; Bluesand Foundation; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R28AA012725] Funding Source: NIH RePORTER	This work was supported by the Sir Zelman Cowen Universities Fund, and by the Bluesand Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Braak H, 1998, J NEURAL TRANSM-SUPP, P127; Braak H, 2004, NEUROBIOL AGING, V25, P713, DOI 10.1016/j.neurobiolaging.2003.12.015; Castellani RJ, 2011, J PATHOL, V224, P147, DOI 10.1002/path.2885; Chuang JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033120; Cordonnier C, 2006, NEUROLOGY, V66, P1356, DOI 10.1212/01.wnl.0000210535.20297.ae; Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016; Cullen KM, 2005, J CEREBR BLOOD F MET, V25, P1656, DOI 10.1038/sj.jcbfm.9600155; de la Torre JC, 2010, NEURODEGENER DIS, V7, P116, DOI 10.1159/000285520; de la Torre JC, 2004, NEUROL RES, V26, P517, DOI 10.1179/016164104225016254; de la Torre JC, 2000, ANN NY ACAD SCI, V924, P136; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; Decker H, 2010, J NEUROSCI, V30, P9166, DOI 10.1523/JNEUROSCI.1074-10.2010; delaTorre JC, 1997, ANN NY ACAD SCI, V826, P75; Deshpande A, 2009, J NEUROSCI, V29, P4004, DOI 10.1523/JNEUROSCI.5980-08.2009; DOWSON JH, 1992, NEUROBIOL AGING, V13, P493, DOI 10.1016/0197-4580(92)90077-B; DOWSON JH, 1981, HISTOPATHOLOGY, V5, P305, DOI 10.1111/j.1365-2559.1981.tb01789.x; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HARDY JA, 1986, NEUROBIOL AGING, V7, P489, DOI 10.1016/0197-4580(86)90086-2; Hossmann KA, 2009, TXB STROKE MED, P1; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jolkkonen J, 2007, NEUROSCI LETT, V428, P99, DOI 10.1016/j.neulet.2007.09.043; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Kumar-Singh S, 2005, AM J PATHOL, V167, P527, DOI 10.1016/S0002-9440(10)62995-1; Kumar-Singh S, 2002, AM J PATHOL, V161, P507, DOI 10.1016/S0002-9440(10)64207-1; Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; Lee JS, 2011, NEUROSCI LETT, V489, P84, DOI 10.1016/j.neulet.2010.11.071; MacKenzie JM, 1996, J CLIN PATHOL, V49, P360, DOI 10.1136/jcp.49.5.360; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; Meadowcroft MD, 2009, J MAGN RESON IMAGING, V29, P997, DOI 10.1002/jmri.21731; Micheva KD, 2007, NEURON, V55, P25, DOI 10.1016/j.neuron.2007.06.014; Mikula S, 2007, NEUROIMAGE, V35, P9, DOI 10.1016/j.neuroimage.2006.11.053; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Miyakawa T, 2000, ANN NY ACAD SCI, V903, P46, DOI 10.1111/j.1749-6632.2000.tb06349.x; Morrison JH, 2002, PROG BRAIN RES, V136, P467; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Park A, 2010, TIME MAGAZINE, P30; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Poels MMF, 2010, STROKE, V41, pS103, DOI 10.1161/STROKEAHA.110.595181; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; Quintana C, 2007, J ALZHEIMERS DIS, V12, P157; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Salminen A, 2008, J CELL MOL MED, V12, P2255, DOI 10.1111/j.1582-4934.2008.00496.x; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith MA, 2002, FREE RADICAL BIO MED, V33, P1194, DOI 10.1016/S0891-5849(02)01021-3; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Thal DR, 2002, CLIN NEUROPATHOL, V21, P35; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Tomiyama T, 2010, J NEUROSCI, V30, P4845, DOI 10.1523/JNEUROSCI.5825-09.2010; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; van Groen T, 2005, STROKE, V36, P1551, DOI 10.1161/01.STR.0000169933.88903.cf; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; WEN R, 1995, J NEUROSCI, V15, P7377; Wu CW, 2004, NEUROBIOL DIS, V17, P367, DOI 10.1016/j.nbd.2004.08.014; Yates PA, 2011, NEUROLOGY, V77, P48, DOI 10.1212/WNL.0b013e318221ad36	74	21	21	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2013	8	3							e59740	10.1371/journal.pone.0059740			18	Multidisciplinary Sciences	Science & Technology - Other Topics	111UM	WOS:000316546400060	23555765	DOAJ Gold, Green Published			2021-06-18	
J	Takeuchi, S; Takasato, Y; Masaoka, H; Hayakawa, T; Yatsushige, H; Nagatani, K; Osada, H; Otani, N; Wada, K; Nawashiro, H				Takeuchi, Satoru; Takasato, Yoshio; Masaoka, Hiroyuki; Hayakawa, Takanori; Yatsushige, Hiroshi; Nagatani, Kimihiro; Osada, Hideo; Otani, Naoki; Wada, Kojiro; Nawashiro, Hiroshi			Hydrocephalus after decompressive craniectomy for hemispheric cerebral infarction	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Complication; Decompressive craniectomy; Hydrocephalus; lschemic stroke	TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; ARTERY INFARCTION; MALIGNANT INFARCTION; EVANS INDEX; HEMICRANIECTOMY; MANAGEMENT; HYPERTENSION	The aim of the present study was to investigate the risk factors for hydrocephalus after decompressive craniectomy (DC) for hemispheric cerebral infarction. This study selected 28 patients who underwent DC for malignant hemispheric cerebral infarction. The patients' clinical and radiologic findings were retrospectively reviewed. Fourteen of the 28 patients were male and 14 were female, with an age range from 34 to 80 years (mean, 63.5 years). Eighteen patients (64.3%) underwent DC within 48 hours of stroke onset. The superior limit of DC was <25 mm from the midline in 16 patients (57.1%). Twenty-two patients underwent cranioplasty, and the interval from DC to cranioplasty was within 60 days in 14 patients. Pre- and post-cranioplasty hydrocephalus were observed in 13 and nine patients, respectively. Two patients required shunt procedures for post-cranioplasty hydrocephalus. Patients with DC whose superior limit was <25 mm from the midline had a significantly increased risk of developing not only pre-cranioplasty but also post-cranioplasty hydrocephalus (p = 0.008, p = 0.010, respectively). In addition, the presence of pre-cranioplasty hydrocephalus was significantly associated with the development of post-cranioplasty hydrocephalus (p = 0.001). The presence of pre- and post-cranioplasty hydrocephalus was significantly associated with a poor outcome (p = 0.031, p = 0.049, respectively). DC with a superior limit <25 mm from the midline should be avoided to prevent the development of hydrocephalus. (C) 2012 Elsevier Ltd. All rights reserved.	[Takeuchi, Satoru; Nagatani, Kimihiro; Osada, Hideo; Otani, Naoki; Wada, Kojiro; Nawashiro, Hiroshi] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan; [Takasato, Yoshio; Masaoka, Hiroyuki; Hayakawa, Takanori; Yatsushige, Hiroshi] Natl Hosp Org Disaster Med Ctr, Dept Neurosurg, Tokyo, Japan	Takeuchi, S (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	s.takeuchi@room.ocn.ne.jp					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Ambarki K, 2010, NEUROSURGERY, V67, P94, DOI 10.1227/01.NEU.0000370939.30003.D1; Ban SP, 2010, J KOREAN NEUROSURG S, V48, P244, DOI 10.3340/jkns.2010.48.3.244; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; D'Ambrosio AL, 2005, NEUROSURGERY, V56, P12, DOI 10.1227/01.NEU.0000144820.38439.63; Danish SF, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS945; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Johnson RD, 2011, J CLIN NEUROSCI, V18, P1018, DOI 10.1016/j.jocn.2010.12.021; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Munch E, 2000, NEUROSURGERY, V47, P315; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Otani N, 2008, CEREBROVASC DIS, V26, P612, DOI 10.1159/000165115; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Rahme R, 2010, NEUROSURGERY, V67, P675, DOI 10.1227/01.NEU.0000383142.10103.0B; Schaller B, 2003, BRAIN RES, V982, P31, DOI 10.1016/S0006-8993(03)02900-7; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Takeuchi S, 2011, NEUROSURGERY, V68, pE1509, DOI 10.1227/NEU.0b013e3182124403; Toma AK, 2011, NEUROSURGERY, V68, P939, DOI 10.1227/NEU.0b013e318208f5e0; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	29	21	23	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2013	20	3					377	382		10.1016/j.jocn.2012.03.035			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	115VL	WOS:000316839900008	23266079				2021-06-18	
J	Theodore, N; Aarabi, B; Dhall, SS; Gelb, DE; Hurlbert, RJ; Rozzelle, CJ; Ryken, TC; Walters, BC; Hadley, MN				Theodore, Nicholas; Aarabi, Bizhan; Dhall, Sanjay S.; Gelb, Daniel E.; Hurlbert, R. John; Rozzelle, Curtis J.; Ryken, Timothy C.; Walters, Beverly C.; Hadley, Mark N.			Occipital Condyle Fractures	NEUROSURGERY			English	Article						Cervical immobilization; CT imaging; Occipital condyle fracture	HYPOGLOSSAL NERVE PALSY; COLLET-SICARD SYNDROME; CLOSED-HEAD-INJURY; AVULSION FRACTURE; FORGOTTEN CONDYLE; CT; IMPAIRMENT; MANAGEMENT; MORPHOLOGY; DIAGNOSIS		[Theodore, Nicholas] Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ 85013 USA; [Aarabi, Bizhan] Univ Maryland, Dept Neurosurg, Baltimore, MD 21201 USA; [Gelb, Daniel E.] Univ Maryland, Dept Orthopaed, Baltimore, MD 21201 USA; [Dhall, Sanjay S.] Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA; [Hurlbert, R. John] Univ Calgary, Fac Med, Univ Calgary Spine Program, Dept Clin Neurosci, Calgary, AB, Canada; [Rozzelle, Curtis J.; Walters, Beverly C.; Hadley, Mark N.] Univ Alabama Birmingham, Childrens Hosp Alabama, Div Neurol Surg, Birmingham, AL USA; [Ryken, Timothy C.] Univ Iowa, Iowa Spine & Brain Inst, Waterloo, ON, Canada; [Walters, Beverly C.] Inova Hlth Syst, Dept Neurosci, Falls Church, VA USA	Hadley, MN (corresponding author), UAB Div Neurol Surg, 510 20th St S,FOT 1030, Birmingham, AL 35294 USA.	mhadley@uabmc.edu	Walters, Beverly/R-8411-2019	Walters, Beverly/0000-0002-5244-4282; Theodore, Nicholas/0000-0001-5355-2683			ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; [Anonymous], 2002, NEUROSURGERY S, V50, pS114; Aulino JM, 2005, EMERG RADIOL, V11, P342, DOI 10.1007/s10140-005-0425-0; BETTINI N, 1993, SKELETAL RADIOL, V22, P187; Bloom AI, 1997, CLIN RADIOL, V52, P198, DOI 10.1016/S0009-9260(97)80273-5; BOLENDER N, 1978, AM J ROENTGENOL, V131, P729, DOI 10.2214/ajr.131.4.729; BOZBOGA M, 1992, SPINE, V17, P1119, DOI 10.1097/00007632-199209000-00019; BRIDGMAN SA, 1992, SURG NEUROL, V38, P152, DOI 10.1016/0090-3019(92)90094-4; Capuano C, 2004, ACTA NEUROCHIR, V146, P779, DOI 10.1007/s00701-004-0289-1; Caroli E, 2005, EUR SPINE J, V14, P487, DOI 10.1007/s00586-004-0832-z; CASTLING B, 1995, BRIT J ORAL MAX SURG, V33, P171, DOI 10.1016/0266-4356(95)90292-9; Cottalorda J, 1996, J PEDIATR ORTHOP B, V5, P61, DOI 10.1097/01202412-199605010-00013; Curri D, 1988, J Neurosurg Sci, V32, P157; DEEB ZL, 1988, CT-J COMPUT TOMOGR, V12, P261; Demisch S, 1998, CLIN NEUROL NEUROSUR, V100, P44, DOI 10.1016/S0303-8467(97)00111-X; DESAI SS, 1990, J TRAUMA, V30, P240, DOI 10.1097/00005373-199002000-00023; Emery E, 1995, Eur Spine J, V4, P191, DOI 10.1007/BF00298245; GOLDSTEIN SJ, 1982, SURG NEUROL, V17, P350, DOI 10.1016/0090-3019(82)90308-1; Hanson JA, 2002, AM J ROENTGENOL, V178, P1261, DOI 10.2214/ajr.178.5.1781261; HARDINGSMITH J, 1981, J BONE JOINT SURG AM, V63, P1170, DOI 10.2106/00004623-198163070-00016; HASHIMOTO T, 1988, NEUROSURGERY, V23, P367, DOI 10.1227/00006123-198809000-00015; Ide C, 1998, J NEUROSURG, V88, P773, DOI 10.3171/jns.1998.88.4.0773; JONES DN, 1990, AM J NEURORADIOL, V11, P1181; Lam CH, 1996, CAN J NEUROL SCI, V23, P145, DOI 10.1017/S0317167100038890; Legros B, 2000, J TRAUMA, V48, P342, DOI 10.1097/00005373-200002000-00031; Leone A, 2000, RADIOLOGY, V216, P635, DOI 10.1148/radiology.216.3.r00se23635; LEVENTHAL MR, 1992, ORTHOPEDICS, V15, P944; LINK TM, 1995, RADIOLOGY, V196, P741, DOI 10.1148/radiology.196.3.7644638; Malham GM, 2009, EMERG RADIOL, V16, P291, DOI 10.1007/s10140-008-0789-z; MANN FA, 1994, AM J ROENTGENOL, V163, P193, DOI 10.2214/ajr.163.1.8010212; MARIANI PJ, 1990, ANN EMERG MED, V19, P1447, DOI 10.1016/S0196-0644(05)82618-6; Maserati MB, 2009, J NEUROSURG-SPINE, V11, P388, DOI 10.3171/2009.5.SPINE08866; MASSARO F, 1993, INJURY, V24, P419, DOI 10.1016/0020-1383(93)90110-R; Maughan PH, 2005, NEUROSURGERY, V57, P600, DOI 10.1227/01.NEU.0000170989.90325.04; MODY BS, 1992, INJURY, V23, P350, DOI 10.1016/0020-1383(92)90194-W; Noble ER, 1996, AM J NEURORADIOL, V17, P507; OLSSON R, 1994, ACTA RADIOL, V35, P90; ORBAY T, 1989, SURG NEUROL, V31, P402, DOI 10.1016/0090-3019(89)90076-1; PALEY MD, 1995, BRIT J ORAL MAX SURG, V33, P239, DOI 10.1016/0266-4356(95)90008-X; RAILA FA, 1993, SKELETAL RADIOL, V22, P269; Savolaine E R, 1989, J Orthop Trauma, V3, P71, DOI 10.1097/00005131-198903010-00014; SHARMA BS, 1994, CLIN NEUROL NEUROSUR, V96, P197, DOI 10.1016/0303-8467(94)90063-9; SPENCER JA, 1984, NEUROSURGERY, V15, P101, DOI 10.1227/00006123-198407000-00019; STROOBANTS J, 1994, J NEUROSURG, V81, P137, DOI 10.3171/jns.1994.81.1.0137; Tuli S, 1997, NEUROSURGERY, V41, P368, DOI 10.1097/00006123-199708000-00006; Urculo E, 1996, J NEUROSURG, V84, P522, DOI 10.3171/jns.1996.84.3.0522; VALASKATZIS EP, 1990, S AFR MED J, V77, P47; WANI MA, 1991, J TRAUMA, V31, P1437, DOI 10.1097/00005373-199110000-00025; WASSERBERG J, 1995, NEURORADIOLOGY, V37, P370; WESSELS LS, 1990, S AFR J SURG, V28, P155; YOUNG WF, 1994, NEUROSURGERY, V34, P257, DOI 10.1227/00006123-199402000-00008; Young WF, 1994, NEUROSURGERY, V34, P260	52	21	21	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAR	2013	72			2			106	113		10.1227/NEU.0b013e3182775527			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	103TP	WOS:000315942300012	23417183				2021-06-18	
J	Wang, H; Anderson, LG; Lascola, CD; James, ML; Venkatraman, TN; Bennett, ER; Acheson, SK; Vitek, MP; Laskowitz, DT				Wang, Haichen; Anderson, Lauren G.; Lascola, Christopher D.; James, Michael L.; Venkatraman, Talaignair N.; Bennett, Ellen R.; Acheson, Shawn K.; Vitek, Michael P.; Laskowitz, Daniel T.			ApolipoproteinE mimetic peptides improve outcome after focal ischemia	EXPERIMENTAL NEUROLOGY			English	Article						Apolipoprotein E; Ischemic stroke; Reperfusion; Brain edema; Microglia; Inflammation	GLOBAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; D-ASPARTATE RECEPTOR; GLIAL CELL-CULTURES; CLOSED-HEAD INJURY; INTRACEREBRAL HEMORRHAGE; APOE GENOTYPE; MURINE MODEL; E-DEFICIENT; E PROTECTS	Growing clinical evidence implicates isoform-specific effects of apolipoprotein E (apoE) in reducing neuroinflammation and mediating adaptive responses following ischemic and traumatic brain injury. However, the intact apoE holoprotein does not cross the blood-brain barrier and thus has limited therapeutic potential. We have created a small peptide, COG1410 (acetyl-AS-Aib-LRKL-Aib-KRLL-amide), derived from the apoE receptor-binding region. COG1410 retains the anti-inflammatory and neuroprotective biological properties of the intact holoprotein and penetrates the blood-brain barrier. In the current study, we utilized a murine model of transient focal cerebral ischemia and reperfusion to demonstrate that intravenous (IV) administration of COG1410 reduces infarct volume and radiographic progression of infarct, and improves functional outcome as assessed by rotarod when delivered up to 4 h after ischemia onset. (c) 2012 Elsevier Inc. All rights reserved.	[Wang, Haichen; Anderson, Lauren G.; James, Michael L.; Bennett, Ellen R.; Vitek, Michael P.; Laskowitz, Daniel T.] Duke Univ, Sch Med, Dept Med Neurol, Durham, NC 27710 USA; [Lascola, Christopher D.; Venkatraman, Talaignair N.] Duke Univ, Sch Med, Dept Radiol, Durham, NC 27710 USA; [Lascola, Christopher D.; Vitek, Michael P.; Laskowitz, Daniel T.] Duke Univ, Sch Med, Dept Neurobiol, Durham, NC 27710 USA; [James, Michael L.; Laskowitz, Daniel T.] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC 27710 USA; [Acheson, Shawn K.] Duke Univ, Sch Med, Dept Psychiatiy, Durham, NC 27710 USA; [Acheson, Shawn K.] Durham VA Med Ctr, Neurobiol Res Lab, Durham, NC 27705 USA; [Vitek, Michael P.] Cognosci Inc, Res Triangle Pk, NC 27709 USA	Laskowitz, DT (corresponding author), Duke Univ, Sch Med, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu	Acheson, Shawn/A-3299-2016; James, Michael L./AAJ-5592-2020; Lascola, Christopher D/B-9126-2017	James, Michael L./0000-0002-8715-5210; Lascola, Christopher D/0000-0002-8031-782X; Vitek, Michael/0000-0001-8140-8048	BLRD VA [IK2 BX001267] Funding Source: Medline; Veterans AffairsUS Department of Veterans Affairs [IK2BX001267] Funding Source: NIH RePORTER		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Bart RD, 1998, NEUROREPORT, V9, P2615, DOI 10.1097/00001756-199808030-00035; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2012, NEUROCRIT CARE, V16, P316, DOI 10.1007/s12028-011-9641-5; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; MARSHALL GR, 1990, P NATL ACAD SCI USA, V87, P487, DOI 10.1073/pnas.87.1.487; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; Mesis Rachel G, 2006, Neurosurg Focus, V21, pE4; Pocivavsek A, 2009, J NEUROIMMUNOL, V214, P25, DOI 10.1016/j.jneuroim.2009.06.010; Ratnaparkhi GS, 2000, PROTEIN ENG, V13, P697, DOI 10.1093/protein/13.10.697; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Sheng ZY, 2008, NEUROPHARMACOLOGY, V55, P204, DOI 10.1016/j.neuropharm.2008.05.016; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Tsuchiya D, 2003, BRAIN RES, V970, P131, DOI 10.1016/S0006-8993(03)02300-X; Tukhovskaya EA, 2009, J NEUROSCI RES, V87, P677, DOI 10.1002/jnr.21874; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Zhang XJ, 2006, NEUROL INDIA, V54, P402	42	21	25	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2013	241						67	74		10.1016/j.expneurol.2012.11.027			8	Neurosciences	Neurosciences & Neurology	095DV	WOS:000315315800009	23219883				2021-06-18	
J	Ma, GM; Dennis, M; Rose, K; Spratt, D; Spielman, D				Ma, Gemma; Dennis, Michelle; Rose, Karrie; Spratt, David; Spielman, Derek			Tawny frogmouths and brushtail possums as sentinels for Angiostrongylus cantonensis, the rat lungworm	VETERINARY PARASITOLOGY			English	Article						Angiostrongylosis; Angiostrongylus cantonensis; Podargus strigoides; Trichosurus vulpecula	NEURAL ANGIOSTRONGYLOSIS; PODARGUS-STRIGOIDES; INFECTION; FUSCIPES; SYDNEY; BLACK; DOGS	The objective of this study was to determine the prevalence of angiostrongylosis in tawny frogmouths (Podargus strigoides) and brushtail possums (Trichosurus vulpecula) with signs of neurological disease, and to describe the clinicopathological features of angiostrongylosis in both species. Tawny frogmouths and brushtail possums with signs of neurological disease were sampled from the Sydney metropolitan area between October 1998 and June 2010. Samples from 100 tawny frogmouths and 31 brushtail possums from the Australian Registry of Wildlife Health (ARWH), the Wildlife Assistance and Information Foundation (WAIF) and Wildlife Health and Conservation Centre (WHCC), University of Sydney were examined. Histological examinations of the brain, spinal cord and other available tissues were used to characterize the disease responsible for each animal's clinical signs. Of the 100 tawny frogmouths with neurological disease examined, angiostrongylosis was considered responsible in 80(80%), traumatic injury in 17(17%), protozoal infection in 3(3%) and other diseases in 2 (2%) and the cause of clinical signs was unknown in 10 (10%). Eleven tawny frogmouths presenting with neurological signs associated with head trauma had concurrent angiostrongylosis. Of the 31 brushtail possums, Wobbly Possum Syndrome (WPS) was diagnosed in 21 (68%), angiostrongylosis in 4(13%) and other diseases in the remaining 6 (19%). Angiostrongylosis was overrepresented in hand reared juvenile possums. Cases of angiostrongylosis in tawny frogmouths followed a strong seasonal pattern peaking through late summer and autumn. The results confirm that Angiostrongylus cantonensis is endemic in Sydney, Australia and that tawny frogmouths could be important sentinels for this zoonotic parasite. Crown Copyright (C) 2012 Published by Elsevier B.V. All rights reserved.	[Ma, Gemma] RSPCA NSW, Yagoona, NSW 2199, Australia; [Dennis, Michelle] QML Pathol Vetnost Serv, Mansfield, Qld 4122, Australia; [Rose, Karrie] Taronga Conservat Soc Australia, Australian Registry Wildlife Hlth, Mosman, NSW 2088, Australia; [Spratt, David] CSIRO Ecosyst Sci, Acton, ACT 2601, Australia; [Spielman, Derek] Univ Sydney, Fac Vet Sci, Camperdown, NSW 2006, Australia	Spielman, D (corresponding author), Univ Sydney, Fac Vet Sci, Camperdown, NSW 2006, Australia.	derek.spielman@sydney.edu.au	Spratt, David M/D-4954-2011	Dennis, Michelle M./0000-0002-9075-2032	Australian Biosecurity Intelligence Network (ABIN)	We wish to thank the Taronga Wildlife Hospital, Drs. Cheryl Sangster and Richard Montali, Ms. Jane Hall, the WAIF Wildlife Clinic and the Wildlife Health and Conservation Centre for contributing case material and pathology services and Profs Paul Canfield and Richard Malik for helpful comments on the manuscript. The Australian Registry of Wildlife Health acknowledges the Australian Biosecurity Intelligence Network (ABIN) for information management and communication systems that contributed to this research. ABIN is a project of the National Collaborative Research Infrastructure Strategy (NCRIS).	Barrett JL, 2002, AUST VET J, V80, P554, DOI 10.1111/j.1751-0813.2002.tb11039.x; BHAIBULAYA M, 1975, INT J PARASITOL, V5, P7, DOI 10.1016/0020-7519(75)90091-0; BHAIBULAYA M, 1968, PARASITOLOGY, V58, P789, DOI 10.1017/S0031182000069572; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; Britton P., 2011, PAEDIAT ANGIOSTRONGY; Carlisle MS, 1998, AUST VET J, V76, P167, DOI 10.1111/j.1751-0813.1998.tb10121.x; Charles J., 1995, ANN C AUSTR COMM ASS; Chotmongkol Verajit, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P231; COLLINS GH, 1992, AUST VET J, V69, P170, DOI 10.1111/j.1751-0813.1992.tb07505.x; FREEDMAN LS, 1979, J EPIDEMIOL COMMUN H, V33, P223, DOI 10.1136/jech.33.3.223; Gelis S, 2011, AUST VET J, V89, P47, DOI 10.1111/j.1751-0813.2010.00660.x; Graeff-Teixeira C, 2009, CLIN MICROBIOL REV, V22, P322, DOI 10.1128/CMR.00044-08; Hartley W J, 1991, J Vet Diagn Invest, V3, P167; Hartley W.J., 1993, NZ VET J, V33, P44; Higgins DP, 1997, AUST VET J, V75, P564, DOI 10.1111/j.1751-0813.1997.tb14194.x; JINDRAK K, 1970, AM J VET RES, V31, P449; JINDRAK K, 1968, J COMP PATHOL, V78, P371, DOI 10.1016/0021-9975(68)90015-7; Kwek G., 2010, HARD SWALLOW TRUE SA; Ladds P., 2009, PATHOLOGY AUSTR NATI; MACKERRAS M. JOSEPHINE, 1955, AUSTRALIAN JOUR ZOOL, V3, P1, DOI 10.1071/ZO9550001; MASON KV, 1987, AUST VET J, V64, P201, DOI 10.1111/j.1751-0813.1987.tb15181.x; Mason KV, 1983, THESIS U QUEENSLAND; MCKENZIE RA, 1978, AUST VET J, V54, P86, DOI 10.1111/j.1751-0813.1978.tb00354.x; Monks DJ, 2005, J AVIAN MED SURG, V19, P289, DOI 10.1647/2004-024.1; OWEN HJ, 1995, BIOL CONSERV, V71, P339, DOI 10.1016/0006-3207(94)00058-X; Prociv P, 2000, INT J PARASITOL, V30, P1295, DOI 10.1016/S0020-7519(00)00133-8; Reddacliff LA, 1999, AUST VET J, V77, P466, DOI 10.1111/j.1751-0813.1999.tb12095.x; Senanayake SN, 2003, MED J AUSTRALIA, V179, P430, DOI 10.5694/j.1326-5377.2003.tb05623.x; Spratt DM, 2005, MICROBIOL AUST, V26, P63; Spratt DM, 2005, INT J PARASITOL, V35, P717, DOI 10.1016/j.ijpara.2005.01.014; Stokes VL, 2007, AUST J ZOOL, V55, P177, DOI 10.1071/ZO06061	31	21	21	1	44	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-4017			VET PARASITOL	Vet. Parasitol.	FEB 18	2013	192	1-3					158	165		10.1016/j.vetpar.2012.11.009			8	Parasitology; Veterinary Sciences	Parasitology; Veterinary Sciences	078DP	WOS:000314078900019	23218219				2021-06-18	
J	Hoerold, D; Pender, NP; Robertson, IH				Hoerold, Doreen; Pender, Niall P.; Robertson, Ian H.			Metacognitive and online error awareness deficits after prefrontal cortex lesions	NEUROPSYCHOLOGIA			English	Article						Deficit awareness; Insight; Error monitoring; Error awareness; Brain lesions	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; SUSTAINED ATTENTION; ANOSOGNOSIA; HEMIPLEGIA; REHABILITATION; INSIGHT; STROKE; TASK	Awareness of deficits after brain injury represents a significant clinical and theoretical challenge, but relatively little is known about the neuroanatomical correlates of specific types of deficit awareness. We examined the awareness correlates of left versus right prefrontal cortex lesions in comparison to left and right posterior lesions including two types of awareness measures-metacognitive and online error monitoring. Frontal lobe frontal lesion patients exhibited impaired metacognitive awareness and also showed deficits in monitoring errors as they occurred. In addition, frontal lobe lesion patients also showed reduced autonomic response to aware errors. Online and metacognitive awareness were not, however, significantly correlated, suggesting that distinct neuroanatomical systems may underpin these two types of awareness deficit. We hypothesize that while metacognitive awareness depends on both left and right frontal regions, accurate moment-to-moment processing of errors depends more on the right than on the left prefrontal cortex. (c) 2012 Elsevier Ltd. All rights reserved.	[Hoerold, Doreen; Robertson, Ian H.] Trinity Coll Dublin, Trinity Coll, Inst Neurosci, Dublin 2, Ireland; [Hoerold, Doreen; Robertson, Ian H.] Trinity Coll Dublin, Sch Psychol, Dublin 2, Ireland; [Pender, Niall P.] Beaumont Hosp, Dept Psychol, Dublin 9, Ireland	Hoerold, D (corresponding author), Kings Coll London, Inst Psychiat, Denmark Hill, London SE5 8AF, England.	doreen.hoerold@kcl.ac.uk		Pender, Niall/0000-0002-4172-0704; Robertson, Ian H/0000-0001-8637-561X	Health Research Board (HRB) Ireland grant	This research was supported by a Health Research Board (HRB) Ireland grant to D.H.	Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Abu-Akel A, 2011, NEUROPSYCHOLOGIA, V49, P2971, DOI 10.1016/j.neuropsychologia.2011.07.012; Beauregard M, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-18-j0001.2001; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Duncan J., 1993, ATTENTION SELECTION, P53; Fleming JM, 1996, BRAIN INJURY, V10, P1; Grace J, 2002, FRONTAL SYSTEMS BEHA; Jenkinson PM, 2009, CONSCIOUS COGN, V18, P458, DOI 10.1016/j.concog.2008.12.005; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Nelson HE, 1982, NATL ADULT READING T; O'Keeffe FM, 2007, BRAIN, V130, P753, DOI 10.1093/brain/awl367; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Orfei MD, 2007, BRAIN, V130, P3075, DOI 10.1093/brain/awm106; Partington J. E., 1949, PSYCHOL SERVICE CTR, V1, P9; Pia L, 2004, CORTEX, V40, P367, DOI 10.1016/S0010-9452(08)70131-X; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Schacter D. L., 1991, AWARENESS DEFICIT BR, P258; Spreen O., 1998, COMPENDIUM NEUROPSYC; STARKSTEIN SE, 1995, ARCH NEUROL-CHICAGO, V52, P415, DOI 10.1001/archneur.1995.00540280105024; Stern R.M., 2001, PSYCHOPHYSIOLOGICAL; Stuss D. T., 2001, FRONTAL LOBES NEUROP, P101; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Venneri A, 2004, NEUROPSYCHOLOGIA, V42, P230, DOI 10.1016/S0028-3932(03)00171-4; Vocat R, 2010, BRAIN, V133, P3578, DOI 10.1093/brain/awq297; Wechsler D, 1998, WECHSLER MEMORY SCAL; Worrall BB, 2005, NEUROLOGY, V65, P500, DOI 10.1212/WNL.65.3.500; Zahn TP, 1999, NEUROPSYCHOLOGIA, V37, P1227, DOI 10.1016/S0028-3932(99)00020-2; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	21	21	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	FEB	2013	51	3					385	391		10.1016/j.neuropsychologia.2012.11.019			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	106PU	WOS:000316158000001	23196146				2021-06-18	
J	Wang, T; Chou, DYT; Ding, JY; Fredrickson, V; Peng, CY; Schafer, S; Guthikonda, M; Kreipke, C; Rafols, JA; Ding, YC				Wang, Tony; Chou, David Yu-Te; Ding, Jamie Y.; Fredrickson, Vance; Peng, Changya; Schafer, Steven; Guthikonda, Murali; Kreipke, Christian; Rafols, Jose A.; Ding, Yuchuan			Reduction of brain edema and expression of aquaporins with acute ethanol treatment after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						blood-brain barrier; cognitive behavior; rat; motor behavior; ethanol; neuroprotection; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; MESSENGER-RNA; WATER CHANNELS; HEAD-INJURY; ALCOHOL; RATS; INTOXICATION; MODEL; PATHOPHYSIOLOGY; ASTROCYTES	Object. Previous studies have demonstrated that traumatic brain injury (TBI) causes brain edema by allowing excessive water passage through aquaporin (AQP) proteins. To establish the potential neuroprotective properties of ethanol as a post-TBI therapy, in the present study the authors determined the effect of ethanol on brain edema, AQP expression, and functional outcomes in a post-TBI setting. Methods. Adult male Sprague-Dawley rats weighing between 425 and 475 g received a closed head TBI in which Maramarou's impact-acceleration method was used. Animals were given a subsequent intraperitoneal injection of 0.5 g/kg or 1.5 g/kg ethanol at 60 minutes post-TBI and were killed 24 hours after TBI. Brains were subsequently examined for edema along with AQP mRNA and protein expression. Additional animals treated with either 0.5 g/kg or 1.5 g/kg ethanol at 60 minutes post-TBI were designated for cognitive and motor testing for 3 weeks. Results. Ethanol administration post-TBI led to significantly (p < 0.05) lower levels of brain edema as measured by brain water content. This downregulation in brain edema was associated with significantly (p < 0.05) reduced levels of AQP mRNA and protein expression as compared with TBI without treatment. These findings concur with cognitive studies in which ethanol-treated animals exhibited significantly (p < 0.05) faster radial maze completion times. Motor behavioral testing additionally demonstrated significant (p < 0.05) beneficial effects of ethanol, with treated animals displaying improved motor coordination when compared with untreated animals. Conclusions. The present findings suggest that acute ethanol administration after a TBI decreases AQP expression, which may lead to reduced cerebral edema. Ethanol-treated animals additionally showed improved cognitive and motor outcomes compared with untreated animals. (http://thejns.org/doi/abs/10.3171/2012.8.JNS12736)	[Wang, Tony; Chou, David Yu-Te; Fredrickson, Vance; Peng, Changya; Guthikonda, Murali; Ding, Yuchuan] Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; [Schafer, Steven; Rafols, Jose A.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Kreipke, Christian] Vet Adm Hosp, Detroit, MI USA; [Ding, Jamie Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Ding, YC (corresponding author), Wayne State Univ, Sch Med, Dept Neurol Surg, Lande Bldg,Room 48,550 E Canfield St, Detroit, MI 48201 USA.	yding@med.wayne.edu			Department of Neurological Surgery Fund; NIH NS Grant [39860]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER	This work was partially supported by the Department of Neurological Surgery Fund (Dr. Y. Ding) and NIH NS Grant No. 39860 (Dr. Rafols). The authors have no conflicts of interest.	Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Collins MA, 2009, ALCOHOL CLIN EXP RES, V33, P206, DOI 10.1111/j.1530-0277.2008.00828.x; Ding YC, 2003, NEUROSCI LETT, V353, P173, DOI 10.1016/j.neulet.2003.09.055; Ding YC, 2002, BEHAV BRAIN RES, V132, P29, DOI 10.1016/S0166-4328(01)00405-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gerard HC, 2002, J RHEUMATOL, V29, P1827; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Kawai N, 2001, BRAIN RES, V895, P50, DOI 10.1016/S0006-8993(01)02026-1; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.physiol.58.1.619; Kreipke CW, 2007, NEUROL RES, V29, P388, DOI 10.1179/016164107X204710; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Moykkynen T, 2012, BASIC CLIN PHARMACOL, V111, P4, DOI 10.1111/j.1742-7843.2012.00879.x; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang F, 2012, STROKE, V43, P205, DOI 10.1161/STROKEAHA.111.629576; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Zeng XW, 2012, BRAIN RES, V1437, P127, DOI 10.1016/j.brainres.2011.12.012	35	21	21	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					390	396		10.3171/2012.8.JNS12736			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900024	23198799				2021-06-18	
J	Girgis, H; Palmier, B; Croci, N; Soustrat, M; Plotkine, M; Marchand-Leroux, C				Girgis, Haymen; Palmier, Bruno; Croci, Nicole; Soustrat, Mathieu; Plotkine, Michel; Marchand-Leroux, Catherine			Effects of selective and non-selective cyclooxygenase inhibition against neurological deficit and brain oedema following closed head injury in mice	BRAIN RESEARCH			English	Article						Traumatic brain injury; Animal model; Cyclooxygenase; Behaviour; Brain oedema	FOCAL CEREBRAL-ISCHEMIA; INTRACEREBRAL HEMORRHAGE; INFLAMMATORY RESPONSE; BARRIER DISRUPTION; CELL-DEATH; RATS; NIMESULIDE; RECOVERY; ALPHA; MODEL	The implication of cyclooxygenase (COX) type 2 in post-traumatic consequences is so far controversial. In experimental models of traumatic brain injury (TBI), genetic disruption or pharmacological inhibition of COX-2 has been shown to be neuroprotective, deleterious or without effect. Therefore, the aim of our study was to investigate the effect of COX-2 inhibition against neurological deficit and brain oedema after TBI that was induced by mechanical percussion in male Swiss mice. Despite the increased level and activity of COX-2, its inhibition either with nimesulide (12 mg/kg) or meloxicam (2 mg/kg) modified neither the neurological score nor the brain water content that were evaluated at 6 and 24h after injury. Interestingly, the non-selective COX inhibition with indomethacin (5 mg/kg) significantly promoted neurological recovery at 6 and 24 h after trauma, without improving brain oedema. In conclusion, the present study yields considerable evidence that COX-2 may not solely constitute an interesting target for the treatment of TBI consequences. Our data point to a potentially deleterious role of COX-1 in the development of neurological impairment in brain-injured mice. However, the neuroprotective mechanism of indomethacin remains to be clarified. (C) 2012 Elsevier B.V. All rights reserved.	[Girgis, Haymen; Palmier, Bruno; Croci, Nicole; Soustrat, Mathieu; Plotkine, Michel; Marchand-Leroux, Catherine] Univ Paris 05, Lab Pharmacol Circulat Cerebrale, EA 4475, Fac Sci Pharmaceut & Biol, Paris, France	Marchand-Leroux, C (corresponding author), Univ Paris 05, Lab Pharmacol Circulat Cerebrale, EA 4475, Fac Sci Pharmaceut & Biol, Paris, France.	catherine.marchand@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348	Academie Nationale de Medecine; Union des Blesses de la Face et de la Tete -Les Gueules Cassees-	This work was financially supported by "Academie Nationale de Medecine" and the "Union des Blesses de la Face et de la Tete -Les Gueules Cassees-".	Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Aid S, 2010, J CEREBR BLOOD F MET, V30, P370, DOI 10.1038/jcbfm.2009.223; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BOULU RG, 1981, EUR NEUROL, V20, P230, DOI 10.1159/000115240; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Candelario-Jalil E, 2004, BRAIN RES, V1007, P98, DOI 10.1016/j.brainres.2004.01.078; Candelario-Jalil E, 2002, EUR J PHARMACOL, V453, P189, DOI 10.1016/S0014-2999(02)02422-6; Candelario-Jalil E., 2007, J NEUROINFLAMM, V10, P4; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Candelario-Jalil E, 2007, J NEUROCHEM, V100, P1108, DOI 10.1111/j.1471-4159.2006.04280.x; Candelario-Jalil E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-3; Candelario-Jalil E, 2009, AGING-US, V1, P350, DOI 10.18632/aging.100039; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Choi SH, 2008, FASEB J, V22, P1491, DOI 10.1096/fj.07-9411com; Choi SH, 2009, AGING-US, V1, P234, DOI 10.18632/aging.100021; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gong C, 2001, BRAIN RES, V901, P38, DOI 10.1016/S0006-8993(01)02186-2; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hakan T, 2010, NEUROL RES, V32, P629, DOI 10.1179/016164109X12464612122731; Hara K, 1998, NEUROSCI LETT, V256, P53, DOI 10.1016/S0304-3940(98)00755-1; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	49	21	21	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 23	2013	1491						78	87		10.1016/j.brainres.2012.10.049			10	Neurosciences	Neurosciences & Neurology	081KR	WOS:000314321600009	23122881				2021-06-18	
J	Mountney, A; Leung, LY; Pedersen, R; Shear, D; Torte, F				Mountney, Andrea; Leung, Lai Yee; Pedersen, Rebecca; Shear, Deborah; Torte, Frank			Longitudinal assessment of gait abnormalities following penetrating ballistic-like brain injury in rats	JOURNAL OF NEUROSCIENCE METHODS			English	Article						TBI; CatWalk; Gait analysis; PBBI; Longitudinal profile	MODEL; STROKE; MOTOR; IMPAIRMENT; LOCOMOTION; MOVEMENT; RECOVERY; DEFICITS; NUCLEUS; LESIONS	Traumatic brain injury (TBI) results in enduring motor and cognitive dysfunction. Although gait disturbances have been documented among TBI patients, few studies have profiled gait abnormalities in animal models of TBI. We sought to obtain a comprehensive longitudinal analysis of gait function following severe penetrating ballistic-like brain injury (PBBI) in rats. Rats were subjected to either unilateral frontal PBBI, probe insertion alone, or sham surgery. Sensorimotor performance was assessed using the CatWalk automated gait analysis system. Baseline measurements were taken 3 days prior to injury and detailed analysis of gait was performed at 1, 3, 7, 14, and 28 days post-injury. Both PBBI and probe-inserted rats displayed altered static and dynamic gait parameters that were primarily evident during the early (<7 days) post-injury phase and were resolved by 1 month post-injury. PBBI produced more severe deficits compared to probe-alone which were reflected in the number, magnitude, and resolution time of abnormal gait parameters. While altered parameters were detected in all four paws, they were more apparent on the contralateral side. Gait parameters including paw pressure, print area, swing speed, and stride length were significantly decreased whereas stance, swing, and step cycle duration were increased compared to sham. Overall, altered gait patterns detected using the CatWalk system in the PBBI model were injury-severity dependent, resolved at later time points, and appeared similar to those reported in severe TBI patients. These results indicate that the CatWalk may be most useful for neuroprotection studies that focus on the acute/subacute recovery period after TBI. Published by Elsevier B.V.	[Mountney, Andrea; Leung, Lai Yee; Pedersen, Rebecca; Shear, Deborah; Torte, Frank] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect & Nemorestorat Branch, Silver Spring, MD 20910 USA	Mountney, A (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect & Nemorestorat Branch, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Andrea.Mountney@amedd.army.mil	Leung, Lai Yee/H-8204-2013		Army Combat Casualty Care Research Program; National Research Council Research Associateship Award at Walter Reed Army Institute of Research	The authors are grateful for the technical assistance provided by Weihong Yang. This research was funded by the Army Combat Casualty Care Research Program and performed while the author held a National Research Council Research Associateship Award at Walter Reed Army Institute of Research	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chen ZY, 2012, J NEUROTRAUM, V29, P268, DOI 10.1089/neu.2011.2057; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Fanardjian V. V., 2000, Neural Plasticity, V7, P261, DOI 10.1155/NP.2000.261; Gabriel AF, 2007, J NEUROSCI METH, V163, P9, DOI 10.1016/j.jneumeth.2007.02.003; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Johnk K, 1999, RESTOR NEUROL NEUROS, V14, P143; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Lorincz E, 1997, BEHAV NEUROSCI, V111, P892; Lu XCM, 2011, J NEUROTRAUM, V28, P71, DOI 10.1089/neu.2010.1471; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; NAUS C, 1985, EXP BRAIN RES, V59, P365; NAUS CG, 1985, J COMP NEUROL, V239, P453, DOI 10.1002/cne.902390411; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Noskin O, 2008, J NEUROL NEUROSUR PS, V79, P401, DOI 10.1136/jnnp.2007.118463; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Shear DA, 2011, J NEUROTRAUM; Shear DA, 2011, J NEUROTRAUM, V28, P2185, DOI 10.1089/neu.2011.1916; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Terashima Anatomy T, 1995, NEUROSCI RES, V22, P139; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Vandeputte C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-92; Vlamings R, 2007, NEUROSCIENCE, V148, P815, DOI 10.1016/j.neuroscience.2007.06.043; Vogelaar CF, 2004, BRAIN RES, V1027, P67, DOI 10.1016/j.brainres.2004.08.036; Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013	36	21	21	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	JAN 15	2013	212	1					1	16		10.1016/j.jneumeth.2012.08.025			16	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	068UB	WOS:000313390600001	22981945				2021-06-18	
J	Indyk, JA; Candido-Vitto, C; Wolf, IM; Venkataraman, S; Munoz, R; Saladino, RA; Witchel, SF; DeFranco, DB				Indyk, Justin A.; Candido-Vitto, Cristina; Wolf, Irene M.; Venkataraman, Shekhar; Munoz, Ricardo; Saladino, Richard A.; Witchel, Selma F.; DeFranco, Donald B.			Reduced Glucocorticoid Receptor Protein Expression in Children with Critical Illness	HORMONE RESEARCH IN PAEDIATRICS			English	Article						Glucocorticoid receptor; Pediatrics; Cortisol; Sepsis; Adrenal insufficiency	SEPTIC SHOCK; SEVERE SEPSIS; ADRENAL AXIS; CORTISOL; THERAPY; IDENTIFICATION; INSUFFICIENCY; MEDICINE	Background/Aims: The diagnostic criteria for critical illness-related corticoid insufficiency (CIRCI) are not well established, particularly for children. In addition to alterations in adrenal function, cellular resistance to glucocorticoid action could contribute to CIRCI due to alterations in the functioning of the intracellular receptor protein for corticosteroids, the glucocorticoid receptor (GR). Methods: We have therefore undertaken a pilot, prospective study to assess whether cellular GR activity can be measured in peripheral blood mononuclear cells (PBMCs) from critically ill children. Results: Total and cytoplasmic, but not nuclear GR levels were significantly lower in PBMCs from critically ill children (i.e. sepsis/septic shock and traumatic brain injury) compared to healthy controls. While total cortisol concentrations did not differ between test groups, salivary and serum-free cortisol concentrations were significantly greater in both groups of children with critical illness. Cortisol-binding globulin levels were significantly lower in patients with sepsis/septic shock. Conclusions: The lower total and cytoplasmic receptor levels in critically ill children suggest that the GR-mediated response to exogenous glucocorticoid therapy may be limited. However, the nuclear transport of GR in critically ill patients suggests that residual receptors in these patients retain functionality and may be accessible to therapeutic treatments that maximize their activity. Copyright (c) 2013 S. Karger AG, Basel	[Indyk, Justin A.; Candido-Vitto, Cristina; Witchel, Selma F.] Univ Pittsburgh, Sch Med, Div Pediat Endocrinol, Pittsburgh, PA USA; [Saladino, Richard A.] Univ Pittsburgh, Sch Med, Emergency Med Dept Pediat, Pittsburgh, PA USA; [Venkataraman, Shekhar; Munoz, Ricardo] Univ Pittsburgh, Sch Med, UPMC, Childrens Hosp Pittsburgh,Dept Crit Care Med, Pittsburgh, PA 15224 USA; [Wolf, Irene M.; DeFranco, Donald B.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Witchel, SF (corresponding author), Univ Pittsburgh, Sch Med, UPMC, Childrens Hosp Pittsburgh,Dept Crit Care Med, Pittsburgh, PA 15224 USA.	selma.witchel@chp.edu	Indyk, Justin A/C-8965-2013	Indyk, Justin/0000-0002-5576-8872			Annane D, 2009, JAMA-J AM MED ASSOC, V301, P2362, DOI 10.1001/jama.2009.815; Arafah BM, 2006, J CLIN ENDOCR METAB, V91, P3725, DOI 10.1210/jc.2006-0674; Biddie SC, 2012, RHEUMATOLOGY, V51, P403, DOI 10.1093/rheumatology/ker215; Cardona ML, 1950, ACTA PEDIAT ESP, V8, P421; Chrousos GP, 2007, STRESS, V10, P213, DOI 10.1080/10253890701292119; Cohen J, 2009, CRIT CARE RESUSC, V11, P287; Cooper Mark Stuart, 2007, J Intensive Care Med, V22, P348, DOI 10.1177/0885066607307832; De Bosscher K, 2009, MOL ENDOCRINOL, V23, P281, DOI 10.1210/me.2008-0283; DeFranco DB, 2002, MOL ENDOCRINOL, V16, P1449, DOI 10.1210/me.16.7.1449; den Brinker M, 2008, INTENS CARE MED, V34, P163, DOI 10.1007/s00134-007-0836-3; Flaster H, 2007, MOL ENDOCRINOL, V21, P1267, DOI 10.1210/me.2007-0065; Heitzer MD, 2007, REV ENDOCR METAB DIS, V8, P321, DOI 10.1007/s11154-007-9059-8; Henley DE, 2011, NEUROSCIENCE, V180, P1, DOI 10.1016/j.neuroscience.2011.02.053; Ho JT, 2006, J CLIN ENDOCR METAB, V91, P105, DOI 10.1210/jc.2005-0265; Jewell CM, 2007, J CLIN ENDOCR METAB, V92, P3268, DOI 10.1210/jc.2007-0642; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; Manary MJ, 2006, METABOLISM, V55, P550, DOI 10.1016/j.metabol.2005.11.009; Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba; Marketon JIW, 2010, TOXINS, V2, P1357, DOI 10.3390/toxins2061357; Menon K, 2007, PEDIATR CRIT CARE ME, V8, P276, DOI 10.1097/01.PCC.0000262796.38637.15; Mesotten D, 2008, NAT CLIN PRACT ENDOC, V4, P496, DOI 10.1038/ncpendmet0921; MOLIJN GJ, 1995, CLIN ENDOCRINOL, V43, P197, DOI 10.1111/j.1365-2265.1995.tb01915.x; Nicolaides NC, 2010, STEROIDS, V75, P1, DOI 10.1016/j.steroids.2009.09.002; Oakley RH, 2011, J BIOL CHEM, V286, P3177, DOI 10.1074/jbc.R110.179325; Samarasinghe RA, 2011, P NATL ACAD SCI USA, V108, P16657, DOI 10.1073/pnas.1102821108; SCHLECHTE JA, 1982, J STEROID BIOCHEM, V16, P69, DOI 10.1016/0022-4731(82)90145-5; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Siebig S, 2010, ANAESTH INTENS CARE, V38, P133, DOI 10.1177/0310057X1003800122; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; van den Akker ELT, 2009, INTENS CARE MED, V35, P1247, DOI 10.1007/s00134-009-1468-6; Venkataraman S, 2007, REV ENDOCR METAB DIS, V8, P365, DOI 10.1007/s11154-007-9058-9; Venkatesh B, 2011, BEST PRACT RES CL EN, V25, P719, DOI 10.1016/j.beem.2011.04.007; Wolf IM, 2008, J CELL BIOCHEM, V104, P1580, DOI 10.1002/jcb.21755; Wong HR, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-34; Yehuda R, 2002, BIOL PSYCHIAT, V52, P393, DOI 10.1016/S0006-3223(02)01357-4; Zimmerman JJ, 2007, PEDIATR CRIT CARE ME, V8, P530, DOI 10.1097/01.PCC.0000288710.11834.E6; Zimmerman JJ, 2011, PEDIATR CRIT CARE ME, V12, P525, DOI 10.1097/PCC.0b013e3181fe4474; Zimmerman JJ, 2011, PEDIATR CRIT CARE ME, V12, P2, DOI 10.1097/PCC.0b013e3181d903f6; Zimmerman JJ, 2010, INTENS CARE MED, V36, P1914, DOI 10.1007/s00134-010-2007-1	39	21	25	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1663-2818			HORM RES PAEDIAT	Horm. Res. Paediatr.		2013	79	3					169	178		10.1159/000348290			10	Endocrinology & Metabolism; Pediatrics	Endocrinology & Metabolism; Pediatrics	138AS	WOS:000318481200007	23548248				2021-06-18	
J	Sorita, E; N'Kaoua, B; Larrue, F; Criquillon, J; Simion, A; Sauzeon, H; Joseph, PA; Mazaux, JM				Sorita, Eric; N'Kaoua, Bernard; Larrue, Florian; Criquillon, Julie; Simion, Audrey; Sauzeon, Helene; Joseph, Pierre-Alain; Mazaux, Jean-Michel			Do patients with traumatic brain injury learn a route in the same way in real and virtual environments?	DISABILITY AND REHABILITATION			English	Article						Cognitive rehabilitation; topographical disorientation; transfer; virtual reality	TOPOGRAPHICAL DISORIENTATION; COGNITIVE REHABILITATION; SPATIAL INFORMATION; TRAINING PEOPLE; NAVIGATION; DEFICITS; DISABILITY; KNOWLEDGE; VALIDATION; MANAGEMENT	An increasing number of studies address the use of virtual environments (VE) in the cognitive assessment of spatial abilities. However, the differences between learning in a VE and a real environment (RE) remain controversial. Purpose: To compare the topographical behavior and spatial representations of patients with traumatic brain injury navigating in a real environment and in a virtual reproduction of this environment. Methods: Twenty-seven subjects with moderate to severe traumatic brain injury were consecutively included and allocated to one of two groups. The subjects were taught the same route in either the virtual environment or the real environment and had to recall it twice immediately after learning the route and once after a delay. At the end of these sessions, the subjects were asked to complete three representational tests: a map test, a map recognition test recognition and a scene arrangement test. Results: No significant difference was found between the two groups with regards to demographics, severity of brain injury or episodic memory. As a main result, the number of error rates did not significantly differ between the real and virtual environment [F (1, 25) = 0.679; p = 0.4176)]. Scores on the scene arrangement test were higher in the real environment [U = 32.5; p = 0.01]. Conclusions: Although spatial representations probably differ between the real and virtual environment, virtual reality remains a trusty assessment tool for spatial abilities.	[Sorita, Eric; Criquillon, Julie; Simion, Audrey; Joseph, Pierre-Alain; Mazaux, Jean-Michel] Univ Hosp Bordeaux, Rehabil Med Unit, Bordeaux, France; [Sorita, Eric; N'Kaoua, Bernard; Larrue, Florian; Sauzeon, Helene; Joseph, Pierre-Alain; Mazaux, Jean-Michel] Univ Bordeaux Segalen, Res Grp Handicap & Nervous Syst, Bordeaux, France	Sorita, E (corresponding author), Univ Hosp Pellegrin, Rehabil Med Unit, F-33076 Bordeaux, France.	eric.sorita@chu-bordeaux.fr	N'Kaoua, Bernard/T-3577-2019; Sauzeon, Helene/T-1178-2019; Sorita, eric/T-5004-2019	Sauzeon, Helene/0000-0001-5781-9891; Sorita, eric/0000-0002-5841-0972	association France Traumatisme Cranien; Fondation des Gueules Cassees, Paris, France	This study was granted by the association France Traumatisme Cranien and the Fondation des Gueules Cassees, Paris, France. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.	BARRASH J, 1993, J CLIN EXP NEUROPSYC, V15, P66; Barrash J, 1998, J CLIN EXP NEUROPSYC, V20, P807, DOI 10.1076/jcen.20.6.807.1114; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; Brooks BM, 2002, DISABIL REHABIL, V24, P622, DOI 10.1080/09638280110111397; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; Brunsdon R, 2007, NEUROPSYCHOL REHABIL, V17, P34, DOI 10.1080/09602010500505021; Carelli L, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-6; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Crosbie JH, 2007, DISABIL REHABIL, V29, P1139, DOI 10.1080/09638280600960909; Cushman LA, 2008, NEUROLOGY, V71, P888, DOI 10.1212/01.wnl.0000326262.67613.fe; Edmans J, 2009, CLIN REHABIL, V23, P106, DOI 10.1177/0269215508095875; Farrell MJ, 2003, J EXP PSYCHOL-APPL, V9, P219, DOI 10.1037/1076-898X.9.4.219; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Foo P, 2005, J EXP PSYCHOL LEARN, V31, P195, DOI 10.1037/0278-7393.31.2.195; Foreman N, 2000, BEHAV BRAIN RES, V112, P53, DOI 10.1016/S0166-4328(00)00159-5; Geusgens CAV, 2007, J REHABIL MED, V39, P425, DOI 10.2340/16501977-0092; Gillner S, 1998, J COGNITIVE NEUROSCI, V10, P445, DOI 10.1162/089892998562861; Golledge RG, 1999, WAYFINDING BEHAVIOR, P5; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; Iaria G, 2009, NEUROPSYCHOLOGIA, V47, P30, DOI 10.1016/j.neuropsychologia.2008.08.021; Josman N, 2008, P 7 INT C DIS VIRT R, P33; Kurtz MM, 2007, SCHIZOPHRENIA BULL, V33, P1162, DOI 10.1093/schbul/sbl039; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Lloyd J, 2009, CYBERPSYCHOL BEHAV, V12, P423, DOI 10.1089/cpb.2008.0326; Lloyd J, 2009, NEUROPSYCHOL REHABIL, V19, P98, DOI 10.1080/09602010802117392; Maguire EA, 2006, BRAIN, V129, P2894, DOI 10.1093/brain/awl286; Mittelstaedt H, 1973, FORTSCHR ZOOL, V21, P46; MITTELSTAEDT ML, 1980, NATURWISSENSCHAFTEN, V67, P566, DOI 10.1007/BF00450672; Morganti F, 2007, COMPUT HUM BEHAV, V23, P1982, DOI 10.1016/j.chb.2006.02.006; Muller D, 1998, DISABIL REHABIL, V20, P97; Newman EL, 2007, COGNITION, V104, P231, DOI 10.1016/j.cognition.2006.05.013; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Reid D., 2009, TECHNOL DISABIL, V21, P43; Riva G, 1998, ST HEAL T, V58, P191; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AS, 2002, DISABIL REHABIL, V24, P567, DOI 10.1080/09638280110111315; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Rose FD, 2002, DISABIL REHABIL, V24, P627, DOI 10.1080/09638280110111405; Siegle AW, 1975, ADV CHILD DEV BEHAV, P9; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Spiers HJ, 2007, HIPPOCAMPUS, V17, P618, DOI 10.1002/hipo.20298; Stanney KM, 2002, HUM PERFORM, V15, P339, DOI 10.1207/S15327043HUP1504_03; Toglia J. P., 2005, COGNITION OCCUPATION, P29; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Tyndiuck F, 2005, P ACM S VIRT REAL SO, P117; Waller D, 1998, PRESENCE-TELEOP VIRT, V7, P129, DOI 10.1162/105474698565631; Waller D, 2000, J EXP PSYCHOL-APPL, V6, P307, DOI 10.1037//1076-898X.6.4.307; Wallet G., 2008, P 2008 ACM S VIRT RE, P175; Wallet G, 2009, J VIRT REAL BROAD, V6; Wallet G, 2011, CYBERPSYCH BEH SOC N, V14, P417, DOI 10.1089/cyber.2009.0187; Wallet G, 2010, STUD HEALTH TECHNOL, V154, P145, DOI 10.3233/978-1-60750-561-7-145; Weniger G, 2009, NEUROPSYCHOLOGIA, V47, P59, DOI 10.1016/j.neuropsychologia.2008.08.018; Wiener JM, 2009, SPAT COGN COMPUT, V9, P152, DOI 10.1080/13875860902906496; Wiener JM, 2004, J ENVIRON PSYCHOL, V24, P475, DOI 10.1016/j.jenvp.2004.09.006; Wilson PN, 1996, DISABIL REHABIL, V18, P633, DOI 10.3109/09638289609166328; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530; Witmer BG, 1996, INT J HUM-COMPUT ST, V45, P413, DOI 10.1006/ijhc.1996.0060; Wolbers T, 2010, TRENDS COGN SCI, V14, P138, DOI 10.1016/j.tics.2010.01.001; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; Zimmermann P, 1995, TEST ATTENTIONAL PER	62	21	21	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2013	35	16					1371	1379		10.3109/09638288.2012.738761			9	Rehabilitation	Rehabilitation	178RN	WOS:000321465200007	23244232				2021-06-18	
J	Zemek, R; Osmond, MH; Barrowman, N				Zemek, Roger; Osmond, Martin H.; Barrowman, Nick		Pediat Emergency Res Canada PERC	Predicting and preventing postconcussive problems in paediatrics (5P) study: protocol for a prospective multicentre clinical prediction rule derivation study in children with concussion	BMJ OPEN			English	Article							TRAUMATIC BRAIN-INJURY; STATES EMERGENCY-DEPARTMENTS; SPORTS-RELATED CONCUSSION; HEAD-INJURY; EARLY INTERVENTION; SYMPTOMS; IMPACT; EPIDEMIOLOGY; IMPAIRMENT; MANAGEMENT	Introduction: Persistent postconcussive symptoms (PCSs) is the persistence of somatic, cognitive, physical, psychological and/or behavioural changes lasting more than 1 month following concussion. Persistent concussion impacts the quality of life through impaired cognition, memory and attention affecting school performance, mood and social engagement. No large epidemiological studies have determined the true prevalence of persistent concussion symptoms. Validated, easy-to-use prognosticators do not exist for clinicians to identify children at highest risk. The goal of Predicting and Preventing Postconcussive Problems in Pediatrics study is to derive a clinical prediction rule for the development of persistent postconcussion symptoms in children and adolescents presenting to emergency department following acute head injury. Methods and analysis: This study is a prospective, multicentre cohort study across nine academic Canadian paediatric emergency departments. We will recruit the largest prospective epidemiological cohort of children with concussion. Eligible children will be followed using Post-Concussion Symptom Inventory, a validated tool in children as young as 5 years. Patients will follow-up at 1, 2, 4, 8 and 12 weeks postinjury. The main outcome will be the presence/absence of PCSs defined as three or more persistent concussion symptoms 1 month following the injury. 1792 patients provide adequate power to derive a clinical decision rule using multivariate analyses to find predictor variables sensitive for detecting cases of persistent postconcussion symptoms. Ethics and dissemination: Results of this large prospective study will enable clinicians to identify children at highest risk, optimise treatment and provide families with realistic and appropriate anticipatory guidance. Ethics has been obtained through the Children's Hospital of Eastern Ontario Research Ethics Board. Results will be disseminated at international conferences and in four manuscripts to peer-reviewed journals.	[Zemek, Roger; Osmond, Martin H.] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Zemek, Roger; Osmond, Martin H.] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Zemek, Roger; Osmond, Martin H.; Barrowman, Nick] Childrens Hosp Eastern Ontario Res Inst, Ottawa, ON, Canada	Zemek, R (corresponding author), Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada.	rzemek@cheo.on.ca	Barrowman, Nick/AAL-3166-2020; Zemek, Roger/H-1039-2018; Meijer, Anna/K-5118-2016; Richer, Lawrence/D-3622-2009; Freedman, Stephen/H-9102-2012	Barrowman, Nick/0000-0002-4704-9595; Richer, Lawrence/0000-0002-6897-8668; Freedman, Stephen/0000-0003-2319-6192; Gravel, Jocelyn/0000-0001-5901-4990; Osmond, Martin/0000-0001-8275-8381; Craig, William/0000-0002-4804-194X	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP:126197]; Canadian Institute of Health Research (CIHR) mild Traumatic Brain Injury Team Grant [TM1:127047]	This study is supported by a Canadian Institute of Health Research (CIHR) Operating Grant (MOP: # 126197) as well as by a Canadian Institute of Health Research (CIHR) mild Traumatic Brain Injury Team Grant (TM1: #127047).	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; [Anonymous], DYN; [Anonymous], GROOV PEGB TEST; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bouwmeester W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001221; Breiman L., 1983, CLASSIFICATION REGRE; Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; Callahan JM, 2010, J PEDIATR-US, V157, P873, DOI 10.1016/j.jpeds.2010.08.039; Carroll L J, 2011, CONCUSSION CRISIS AN; Conners C, 2004, CONNERS CONTINUOUS P; Conners C. K., 2008, CONNERS, V3rd; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Forsyth R, 2012, CAN MED ASSOC J, V184, P1257, DOI 10.1503/cmaj.111045; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2008, J INT NEUROPSYCH SOC, V14, P204; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1111/1469-7610.00494; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Junpeng M., 2011, COCHRANE DB SYST REV, V1; Kelsall D, 2012, CAN MED ASSOC J, V184, P189, DOI 10.1503/cmaj.112129; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Maguire JL, 2011, PEDIATRICS, V128, pE666, DOI 10.1542/peds.2011-0043; Marchie A, 2003, CAN MED ASSOC J, V169, P124; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Center for Injury Prevention and Control, 2010, TRAUMATIC BRAIN INJU; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Rivara FP, 2012, ARCH PEDIAT ADOL MED, V166, P666, DOI 10.1001/archpediatrics.2011.1602; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Sen AP, 2010, NEUROTHERAPEUTICS, V7, P91, DOI 10.1016/j.nurt.2009.10.014; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Wechsler D., 2004, WECHSLER INTELLIGENC; Wechsler D., 2001, WECHSLER INDIVIDUAL; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zafonte R, 2011, JAMA-J AM MED ASSOC, V306, P79, DOI 10.1001/jama.2011.819; Zemek R, ACAD EMERG MED; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	72	21	21	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2013	3	8							e003550	10.1136/bmjopen-2013-003550			10	Medicine, General & Internal	General & Internal Medicine	301VX	WOS:000330561300065	23906960	DOAJ Gold, Green Published			2021-06-18	
J	Boutte, AM; Yao, CP; Kobeissy, F; Lu, XCM; Zhang, ZQ; Wang, KK; Schmid, K; Tortella, FC; Dave, JR				Boutte, Angela M.; Yao, Changping; Kobeissy, Firas; Lu, Xi-Chun May; Zhang, Zhiqun; Wang, Kevin K.; Schmid, Kara; Tortella, Frank C.; Dave, Jitendra R.			Proteomic analysis and brain-specific systems biology in a rodent model of penetrating ballistic-like brain injury	ELECTROPHORESIS			English	Article						Biomarker; Penetrating ballistic-like brain injury; Proteomics; Systems biology; UCH-L1	C-TERMINAL HYDROLASE-L1; PROLIFERATION MARKER; BARRIER PERMEABILITY; METABOLIC CRISIS; RAT MODEL; BIOMARKER; SERUM; SUPPLEMENTATION; MICRODIALYSIS; INFLAMMATION	Proteomics and systems biology have significantly contributed to biomarker discovery in the field of brain injury. This study utilized 2D-DIGE-PMF-MS as a preliminary screen to detect biomarkers in a rat model of penetrating ballistic-like brain injury (PBBI). Brain-specific systems biology analysis of brain tissue identified 386 proteins having a fold change of more than 2, of which 321 proteins were increased and 65 were decreased 24 h after PBBI compared to sham controls. The majority of upregulated proteins were cytoskeletal (10.5%), nucleic acid binding (9.3%), or kinases (8.9%). Most proteins were involved in protein metabolism (22.7%), signal transduction (20.4%), and development (9.6%). Pathway analysis indicated that these proteins were involved in neurite outgrowth and cell differentiation. Semiquantitative Western blotting of 6, 24, 48, and 72 h after PBBI indicated ubiquitin carboxyl-terminal hydrolase isozyme L1 (a proposed traumatic brain injury biomarker in human clinical trials), tyrosine hydroxylase, and syntaxin-6 were found to be consistently elevated in brain tissue and cerebral spinal fluid after PBBI compared to sham controls. Combining proteomics and brain-specific systems biology can define underlying mechanisms of traumatic brain injury and provide valuable information in biomarker discovery that, in turn, may lead to novel therapeutic targets.	[Dave, Jitendra R.] Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Kobeissy, Firas; Zhang, Zhiqun; Wang, Kevin K.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA	Dave, JR (corresponding author), Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Div Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	jit.dave@amedd.army.mil	Kobeissy, Firas/E-7042-2017; Dave, Jitendra R/A-8940-2011	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473	Banyan Biomarkers, Inc.	The authors have declared the following potential conflict of interest: Drs. Kevin K. W. Wang and Ronald L. Hayes, an executive officer at Banyan Biomarkers, Inc., own stock and receive royalties from Banyan Biomarkers, Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Cadosch D, 2010, ANZ J SURG, V80, P542, DOI 10.1111/j.1445-2197.2010.05268.x; Chen ZY, 2009, J NEUROTRAUM, V26, P1987, DOI 10.1089/neu.2008.0863; Crawford F, 2012, J NEUROTRAUM, V29, P246, DOI 10.1089/neu.2011.1789; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Garcia-Bonilla L, 2007, J NEUROCHEM, V103, P1368, DOI 10.1111/j.1471-4159.2007.04844.x; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Johnson VE, 2012, EXP NEUROL; Kabayama H, 2008, NEUROSCI LETT, V436, P340, DOI 10.1016/j.neulet.2008.03.061; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Lau KM, 2010, ONCOGENE, V29, P5475, DOI 10.1038/onc.2010.287; Liberatore GT, 1999, EXP NEUROL, V159, P565, DOI 10.1006/exnr.1999.7152; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220; Setsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007; Shear DA, 2011, J NEUROTRAUM, V28, P2185, DOI 10.1089/neu.2011.1916; Shear DA, 2009, PHARMACOL BIOCHEM BE, V94, P56, DOI 10.1016/j.pbb.2009.07.006; Staropoli JF, 2005, J MOL NEUROSCI, V27, P175, DOI 10.1385/JMN:27:2:175; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Sun X, 2012, NEUROBIOL DIS, V45, P601, DOI 10.1016/j.nbd.2011.09.018; Thom M, 2005, J NEUROPATH EXP NEUR, V64, P194, DOI 10.1093/jnen/64.3.194; Todovov IT, 1998, LAB INVEST, V78, P73; Torres GE, 2006, J NEUROCHEM, V97, P3, DOI 10.1111/j.1471-4159.2006.03719.x; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Villoslada P, 2012, J NEUROIMMUNOL, V248, P58, DOI 10.1016/j.jneuroim.2012.01.001; von Bohlen und Halbach O, 2011, CELL TISSUE RES, V345, P1, DOI 10.1007/s00441-011-1196-4; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Wharton SB, 2001, NEUROPATH APPL NEURO, V27, P305, DOI 10.1046/j.0305-1846.2001.00333.x; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Won SJ, 2002, J BIOCHEM MOL BIOL, V35, P67, DOI 10.5483/BMBRep.2002.35.1.067; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; Yao CP, 2009, J NEUROTRAUM, V26, P1295, DOI [10.1089/neu.2008.0811, 10.1089/neu.2008-0811]	53	21	21	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	DEC	2012	33	24			SI		3693	3704		10.1002/elps.201200196			12	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	057FT	WOS:000312548900012	23161467				2021-06-18	
J	Driscoll, DM; Dal Monte, O; Solomon, J; Krueger, F; Grafman, J				Driscoll, David M.; Dal Monte, Olga; Solomon, Jeffrey; Krueger, Frank; Grafman, Jordan			Empathic Deficits in Combat Veterans with Traumatic Brain Injury: A Voxel-Based Lesion-Symptom Mapping Study	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						empathy; emotion; prefrontal cortex; traumatic brain injury; voxel-based lesion-symptom mapping	GENDER-DIFFERENCES; SOCIAL-BEHAVIOR; EMOTION; SYSTEMS; MECHANISMS; RESONANCE; ABILITIES; COGNITION; PEOPLE; CORTEX	Objective: To understand better which brain regions support emotional empathy. Background: Emotional empathy, the ability to interpret and share the affective states of others, is a key component in human social interaction. Previous research has suggested that emotional empathy relies on several distinct brain regions, although further evidence from human lesion studies is needed to determine which regions are critical. Methods: We studied 192 male Vietnam combat veterans who had sustained focal penetrating traumatic brain injuries, and 54 non-brain-injured veterans. We used voxel-based lesion-symptom mapping on computed tomographic scans to elucidate the neural bases of self-reported emotional empathy as measured by the Balanced Emotional Empathy Scale. Results: Damage in several brain regions, particularly the ventrolateral prefrontal cortex, left and right posterior temporal lobes, and insula, was associated with diminished emotional empathy. Conclusions: These findings provide further insight into the neural substrates of emotional empathy, and are consistent with the notion that emotional empathy is supported by a distributed network of brain regions. Additional work may advance our understanding of the empathic deficits commonly observed in patients with neurologic and psychiatric disorders.	[Driscoll, David M.; Dal Monte, Olga] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Driscoll, David M.; Dal Monte, Olga] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Dal Monte, Olga] Univ Turin, Dept Neuropsychol, Turin, Italy; [Solomon, Jeffrey] Expert Image Anal LLC, Potomac, MD USA; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Grafman, Jordan] Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, W Orange, NJ USA	Driscoll, DM (corresponding author), Nebraska Western Iowa Hlth Care Syst, Dept Vet Affairs, 600 S 70th St, Lincoln, NE 68510 USA.	david.driscoll@va.gov	Dal Monte, Olga/P-3759-2018	Dal Monte, Olga/0000-0002-7823-4769; Grafman, Jordan H./0000-0001-8645-4457	US National Institute of Neurological Disorders and Stroke Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Center for Neuroscience and Regenerative Medicine via the Henry M. Jackson Foundation; National Naval Medical Center	Supported in part by the US National Institute of Neurological Disorders and Stroke Intramural Research Program and a project grant from the US Army Medical Research and Material Command administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study). D.M.D. and O.D.M. were supported with funding from the Center for Neuroscience and Regenerative Medicine via the Henry M. Jackson Foundation.; The authors thank all of the Vietnam veterans who participated in this study for their long-term commitment to improving the health care of veterans; the National Naval Medical Center for their support and provision of their facilities; and S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding, and G. Tasick for their invaluable help with organizing the study and testing the participants.	Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 1996, J NEUROSCI, V16, P7678; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 1960, ARM FORC QUAL TEST A; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Beer JS, 2006, J COGNITIVE NEUROSCI, V18, P871, DOI 10.1162/jocn.2006.18.6.871; Benedetti F, 2009, SCHIZOPHR RES, V114, P154, DOI 10.1016/j.schres.2009.06.021; Blair RJR, 2005, CONSCIOUS COGN, V14, P698, DOI 10.1016/j.concog.2005.06.004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bora E, 2008, PSYCHIAT RES, V160, P23, DOI 10.1016/j.psychres.2007.05.017; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Decety J, 2008, DEV PSYCHOPATHOL, V20, P1053, DOI 10.1017/S0954579408000503; Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Decety J, 2010, DEV NEUROSCI-BASEL, V32, P257, DOI 10.1159/000317771; Dolcos F, 2006, J NEUROSCI, V26, P2072, DOI 10.1523/JNEUROSCI.5042-05.2006; EISENBERG N, 1983, PSYCHOL BULL, V94, P100, DOI 10.1037/0033-2909.94.1.100; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Glascher J, 2009, NEURON, V61, P681, DOI 10.1016/j.neuron.2009.01.026; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Gross JJ, 1997, PSYCHOL AGING, V12, P590, DOI 10.1037/0882-7974.12.4.590; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Hynes CA, 2006, NEUROPSYCHOLOGIA, V44, P374, DOI 10.1016/j.neuropsychologia.2005.06.011; Iacoboni M, 1999, SCIENCE, V286, P2526, DOI 10.1126/science.286.5449.2526; Jabbi M, 2007, NEUROIMAGE, V34, P1744, DOI 10.1016/j.neuroimage.2006.10.032; Krueger F, 2009, P NATL ACAD SCI USA, V106, P22486, DOI 10.1073/pnas.0912568106; Krueger F, 2009, TRENDS COGN SCI, V13, P103, DOI 10.1016/j.tics.2008.12.005; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Mayer JD, 2003, EMOTION, V3, P97, DOI 10.1037/1528-3542.3.1.97; Maylor EA, 2002, BRIT J PSYCHOL, V93, P465, DOI 10.1348/000712602761381358; Mcrae K, 2008, GROUP PROCESS INTERG, V11, P143, DOI 10.1177/1368430207088035; Mehrabian A., 2000, MANUAL BALANCED EMOT; Moll J, 2002, J NEUROSCI, V22, P2730, DOI 10.1523/JNEUROSCI.22-07-02730.2002; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; Perry RJ, 2001, NEUROCASE, V7, P145, DOI 10.1093/neucas/7.2.145; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Rankin KP, 2006, BRAIN, V129, P2945, DOI 10.1093/brain/awl254; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Schulte-Ruther M, 2008, NEUROIMAGE, V42, P393, DOI 10.1016/j.neuroimage.2008.04.180; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; SCHWARTZ GE, 1975, SCIENCE, V190, P286, DOI 10.1126/science.1179210; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Singer T., 2008, NEUROECONOMICS DECIS, P233; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wechsler D, 1997, WAIS 3 ADM SCORING M; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Young A., 2002, FACIAL EXPRESSIONS E	55	21	22	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1543-3633	1543-3641		COGN BEHAV NEUROL	Cogn. Behav. Neurol.	DEC	2012	25	4					160	166		10.1097/WNN.0b013e318280cf4e			7	Behavioral Sciences; Clinical Neurology	Behavioral Sciences; Neurosciences & Neurology	062TB	WOS:000312944200002	23277137				2021-06-18	
J	Kennedy, CH; Evans, JP; Chee, S; Moore, JL; Barth, JT; Stuessi, KA				Kennedy, Carrie H.; Evans, J. Porter; Chee, Shawnna; Moore, Jeffrey L.; Barth, Jeffrey T.; Stuessi, Keith A.			Return to Combat Duty after Concussive Blast Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Head injury; Traumatic Brain Injury; Posttraumatic stress; Disorder	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; NEUROPSYCHOLOGICAL PERFORMANCE; IRAQI FREEDOM; HEAD-INJURY; AFGHANISTAN; SYMPTOMS; SOLDIERS; OPERATIONS; DEPLOYMENT	Little data exist regarding the acute assessment of blast concussion and the course of recovery in the combat zone, as most research has examined service members long after they have returned home. This manuscript examined a case series of 377 service members seen for acute concussion evaluation following medical evacuation from the battlefield in Helmand Province, Afghanistan. Of these, 111 were assessed for concussion prior to their return to the continental USA for other severe physical injuries. Of the remainder, and when comparing those who returned to duty (RTD)/recovered from concussion in the combat zone and those who did not, data indicate that those who did not RTD were older and were more likely to endorse symptoms of combat stress. Quicker recovery times were associated with less severe headaches and fewer acute symptoms at the time of injury as well as the absence of combat stress reaction. Variables that were not associated with RTD and/or recovery were Military Acute Concussion Evaluation (MACE) cognitive scores and whether or not individuals suffered loss of consciousness. While MACE scores were not associated with recovery, they were deemed clinically useful as a part of a serial concussion evaluation if the initial MACE was given within 6 h of the blast. Implications for battlefield concussion assessment and management as well as future research directions are discussed.	[Kennedy, Carrie H.] Marine Corps Embassy Secur Grp, Dept Behav Sci, Quantico, VA 22134 USA; [Evans, J. Porter; Chee, Shawnna; Barth, Jeffrey T.] Univ Virginia, Dept Neuropsychol, Charlottesville, VA USA; [Moore, Jeffrey L.] USN, Operat Med Inst, Robert E Mitchell Prisoner War Studies Ctr, Pensacola, FL USA; [Stuessi, Keith A.] USN, Hosp Camp Pendleton, Dept Sports Med, Camp Pendleton, CA USA	Kennedy, CH (corresponding author), Marine Corps Embassy Secur Grp, Dept Behav Sci, 2007 Elliot Rd, Quantico, VA 22134 USA.	carriehillkennedy@gmail.com					Barth J., 2010, MILITARY NEUROPSYCHO, P127; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bowles SV, 2010, MIL MED, V175, P382, DOI 10.7205/MILMED-D-10-00099; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Burgess Paula, 2010, J Emerg Trauma Shock, V3, P164, DOI 10.4103/0974-2700.62120; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Defense and Veterans Brain Injury Center [DVBIC], 2012, MIL AC CONC EV; Defense and Veterans Brain Injury Center [DVBIC], 2009, TBI FACTS; Department of Defense Directive Type Memorandum (DTM), 2010, POL GUID MAN CONC MI; DVBIC, 2007, MIL AC CONC EV; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; FRENCH LM, 2010, MILITARY NEUROPSYCHO, P101; Friedl KE, 2007, ARCH CLIN NEUROPSYCH, V22, pS7, DOI 10.1016/j.acn.2006.10.002; Goldberg MS, 2010, MIL MED, V175, P220, DOI 10.7205/MILMED-D-09-00130; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; KAUR C, 1995, NEUROPATHOLOGY APPL, V21, P787; Kelly JP, 1997, NEUROLOGY, V48, P581; KENNEDY CH, 2010, MILITARY NEUROPSYCHO, P1; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Lew HL, 2007, J REHABIL RES DEV, V44, P963, DOI 10.1682/JRRD.2006.12.0169; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mundie TG, 2000, J TRAUMA, V48, P1115, DOI 10.1097/00005373-200006000-00019; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Polusny MA, 2009, MIL MED, V174, P353, DOI 10.7205/MILMED-D-01-1608; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schneiderman A. I., 2008, J HEAD TRAUMA REHAB, V24, P14; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg R. D., HLTH OUTCOM IN PRESS; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	50	21	21	0	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2012	27	8					817	827		10.1093/arclin/acs092			11	Psychology, Clinical; Psychology	Psychology	044RO	WOS:000311641000001	23059351	Bronze			2021-06-18	
J	Russo, AC				Russo, Arthur C.			Symptom Validity Test Performance and Consistency of Self-Reported Memory Functioning of Operation Enduring Freedom/Operation Iraqi Freedom Veterans with Positive Veteran Health Administration Comprehensive Traumatic Brain Injury Evaluations	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						TBI; symptom validity testing; WMT; veterans	NEUROPSYCHOLOGICAL PERFORMANCE; COMPLAINTS; ACADEMY; BIAS	Operation Enduring Freedom and Operation Iraqi Freedom combat veterans given definite diagnoses of mild Traumatic Brain Injury (TBI) during the Veteran Health Administration (VHA) Comprehensive TBI evaluation and reporting no post-deployment head injury were examined to assess (a) consistency of self-reported memory impairment and (b) symptom validity test (SVT) performance via a two-part study. Study 1 found that while 49 of 50 veterans reported moderate to very severe memory impairment during the VHA Comprehensive TBI evaluation, only 7 had reported any memory problem at the time of their Department of Defense (DOD) post-deployment health assessment. Study 2 found that of 38 veterans referred for neuropsychological evaluations following a positive VHA Comprehensive TBI evaluation, 68.4 failed the Word Memory Test, a forced choice memory recognition symptom validity task. Together, these studies raise questions concerning the use of veteran symptom self-report for TBI assessments and argue for the inclusion of SVTs and the expanded use of contemporaneous DOD records to improve the diagnostic accuracy of the VHA Comprehensive TBI evaluation.	[Russo, Arthur C.] Vet Adm New York Harbor Healthcare Syst, Dept Psychol, Brooklyn, NY USA	Russo, AC (corresponding author), Vet Adm New York Harbor Healthcare Syst, Psychol Dept 116B, 800 Poly Pl, Brooklyn, NY 11209 USA.	arthur.russo@va.gov					Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2000, CLIN NEUROPSYCHOL, V14, P344, DOI 10.1076/1385-4046(200008)14:3;1-P;FT344; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Branca B, 1996, HEADACHE, V36, P300, DOI 10.1046/j.1526-4610.1996.3605300.x; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Defense and Veterans Brain Injury Center, 2012, DOD WORLDW NUMB TBI; Department of Defense, 2002, MCM000602 DEP DEF JO; Department of Defense, 2003, ENH POSTP HLTH ASS U; Department of Defense, 2006, 649003 DEP DEF; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Frueh BC, 2005, BRIT J PSYCHIAT, V186, P467, DOI 10.1192/bjp.186.6.467; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2005, GREENS WORD MEMORY T; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hepp U, 2006, BRIT J PSYCHIAT, V188, P278, DOI 10.1192/bjp.bp.104.008102; Hoge C., 2010, ONCE WARRIOR ALWAYS; Hoge CW, 2008, NEW ENGL J MED, V358, P2179; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson G., 1999, J COGNITIVE REHABILI, P2; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; McCrea M, 2008, MILD TRAUMATIC BRAIN; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Roca V, 2001, AM J PSYCHIAT, V158, P1738, DOI 10.1176/appi.ajp.158.10.1738-a; Roemer L, 1997, AM J PSYCHIAT, V154, P1628, DOI 10.1176/ajp.154.11.1628; Rohling ML, 2000, ARCH CLIN NEUROPSYCH, V15, P843, DOI 10.1016/S0887-6177(00)80349-2; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Veterans Health Administration, 2010, TRAUM BRAIN INJ; Veterans Health Administration, 2010, SCREEN EV POSS TRAUM; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020	48	21	21	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2012	27	8					840	848		10.1093/arclin/acs090			9	Psychology, Clinical; Psychology	Psychology	044RO	WOS:000311641000003	23059350	Bronze			2021-06-18	
J	Yu, WH; Dong, XQ; Hu, YY; Huang, M; Zhang, ZY				Yu, Wen-Hua; Dong, Xiao-Qiao; Hu, Yue-Yu; Huang, Man; Zhang, Zu-Yong			Ginkgolide B Reduces Neuronal Cell Apoptosis in the Traumatic Rat Brain: Possible Involvement of Toll-like Receptor 4 and Nuclear Factor Kappa B Pathway	PHYTOTHERAPY RESEARCH			English	Article						traumatic brain injury; ginkgolide B; toll-like receptor 4; nuclear factor kappa B; inflammatory cytokine; neuronal cell apoptosis	PLATELET-ACTIVATING-FACTOR; 5-YEAR DOUBLE-BLIND; ENDOTHELIAL-CELLS; MEMORY IMPAIRMENT; RANDOMIZED-TRIAL; ELDERLY-PEOPLE; UP-REGULATION; EGB 761(R); INJURY; PAF	Ginkgolide B (GB) has been demonstrated to have a variety of pharmacological actions. Accumulating evidence indicates that GB may exert a protective effect on brain injury. The study was designed to investigate the influence of GB on toll-like receptor 4 (TLR-4) and nuclear factor kappa B (NF-kappa B)-dependent inflammatory responses and neuronal cell apoptosis after traumatic brain injury (TBI). Wistar rats were subjected to 5, 10 and 20 mg/kg GB daily for 5 days, intraperitoneally, following TBI. Rats were sacrificed at hour 2, 6 and 12, as well as day 1, 2, 3 and 5 after TBI. The administration of 10 and 20 mg/kg GB could significantly (least-significant difference test: p<0.05) suppress gene expressions of TLR-4 and NF-kappa B, lessen concentrations of tumour necrosis factor a, interleukin-1 beta and interleukin-6, as well as reduce the number of apoptotic neuronal cells in traumatic rat brain tissues, but the administration of 5 mg/kg GB did not (p>0.05). However, a clear concentrationresponse relationship was not found. Thus, GB may inhibit TLR-4 and NF-kappa B-dependent inflammatory responses, and furthermore lessen neuronal cell apoptosis after TBI, which may support the use of GB for the treatment of TBI. Copyright (c) 2012 John Wiley & Sons, Ltd.	[Yu, Wen-Hua; Dong, Xiao-Qiao; Zhang, Zu-Yong] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, Hangzhou 310000, Zhejiang, Peoples R China; [Hu, Yue-Yu; Huang, Man] Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Dept Intens Care Unit, Hangzhou 310000, Zhejiang, Peoples R China	Dong, XQ (corresponding author), Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310000, Zhejiang, Peoples R China.	dxqhyy@163.com			Traditional Chinese Medicine Department of Zhejiang Province [2011ZA077]	This work is financially supported by the Traditional Chinese Medicine Department of Zhejiang Province, No. 2011ZA077.	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akiba S, 1998, BIOCHEM MOL BIOL INT, V46, P1243; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Andrieu S, 2008, CURR ALZHEIMER RES, V5, P406, DOI 10.2174/156720508785132271; ATTELLA MJ, 1989, EXP NEUROL, V105, P62, DOI 10.1016/0014-4886(89)90172-6; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bate C, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-4; Begley DJ, 2003, PROG DRUG RES, V61, P39; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; BRAQUET P, 1991, J ETHNOPHARMACOL, V32, P135, DOI 10.1016/0378-8741(91)90111-P; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Clark WM, 2001, STROKE, V32, P1000, DOI 10.1161/01.STR.32.4.1000; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; Desouza IA, 2002, TOXICON, V40, P1709, DOI 10.1016/S0041-0101(02)00237-4; DESQUAND S, 1986, EUR J PHARMACOL, V127, P83, DOI 10.1016/0014-2999(86)90208-6; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DRIEU K, 1986, PRESSE MED, V15, P1455; Fang WR, 2010, EUR J PHARM SCI, V39, P8, DOI 10.1016/j.ejps.2009.10.002; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FOLDESFILEP E, 1987, BIOCHEM BIOPH RES CO, V148, P1412; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Guidetti C, 2001, J PHARM PHARMACOL, V53, P387, DOI 10.1211/0022357011775442; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hotter G, 1997, FREE RADICAL BIO MED, V22, P947, DOI 10.1016/S0891-5849(96)00494-7; Huang Jian-Ying, 2008, Zhongguo Yaolixue Tongbao, V24, P269; Ihl R, 2010, J NEUROL SCI, V299, P184, DOI 10.1016/j.jns.2010.08.033; KIMURA H, 1995, INT J RADIAT ONCOL, V33, P627, DOI 10.1016/0360-3016(95)00205-D; KLEIJNEN J, 1992, LANCET, V340, P1136, DOI 10.1016/0140-6736(92)93158-J; KURIHARA K, 1989, J ALLERGY CLIN IMMUN, V83, P83, DOI 10.1016/0091-6749(89)90480-6; Li R, 2009, J PHARMACOL SCI, V110, P362, DOI 10.1254/jphs.08275FP; Li SQ, 2007, CHINESE MED J-PEKING, V120, P1529, DOI 10.1097/00029330-200709010-00012; Ling NS, 2002, J HARBIN U COMMERCE, V18, P83; Liu BJ, 1996, CHINESE MED J-PEKING, V109, P467; Liu Yong-Gang, 2010, Zhong Yao Cai, V33, P578; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maclennan KM, 2002, PROG NEUROBIOL, V67, P235, DOI 10.1016/S0301-0082(02)00015-1; Nie Zhen-gui, 2004, Yaoxue Xuebao, V39, P415; Peng Shan-ying, 2010, Yaoxue Xuebao, V45, P1103; Qin B, 2005, CHINESE J INTEGRATED, V12, P17; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Schmidt H, 1996, J SURG RES, V60, P29, DOI 10.1006/jsre.1996.0006; Smith PF, 1996, J ETHNOPHARMACOL, V50, P131, DOI 10.1016/0378-8741(96)01379-7; van Dongen M, 2003, J CLIN EPIDEMIOL, V56, P367, DOI 10.1016/S0895-4356(03)00003-9; van Dongen MCJM, 2000, J AM GERIATR SOC, V48, P1183, DOI 10.1111/j.1532-5415.2000.tb02589.x; VARGAFTIG BB, 1983, TRENDS PHARMACOL SCI, V4, P341, DOI 10.1016/0165-6147(83)90433-9; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; Vellas B, 2006, NEUROLOGY, V67, pS6, DOI 10.1212/WNL.67.9_suppl_3.S6; Wang JH, 2000, NEUROCHEM RES, V25, P613, DOI 10.1023/A:1007550801444; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Wu XM, 2009, J CELL MOL MED, V13, P4474, DOI 10.1111/j.1582-4934.2008.00551.x; Xia SH, 2007, CHINESE MED J-PEKING, V120, P922, DOI 10.1097/00029330-200705020-00013; Xiao QA, 2010, EUR J PHARMACOL, V647, P48, DOI 10.1016/j.ejphar.2010.08.002; Yang ZZ, 2011, J ETHNOPHARMACOL, V136, P117, DOI 10.1016/j.jep.2011.04.027; Zhang S, 2011, J CARDIOVASC PHARM, V57, P721, DOI 10.1097/FJC.0b013e31821a50a8; [张硕峰 Zhang Shuofeng], 2006, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V29, P836; Zhou Long-en, 2001, Yaoxue Xuebao, V36, P92	58	21	22	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0951-418X	1099-1573		PHYTOTHER RES	Phytother. Res.	DEC	2012	26	12					1838	1844		10.1002/ptr.4662			7	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	056IP	WOS:000312481900012	22422608				2021-06-18	
J	Behnke, NMK; Redjal, HR; Nguyen, VT; Zinar, DM				Behnke, Nicole M. K.; Redjal, Hamid R.; Nguyen, Virginia T.; Zinar, Daniel M.			Internal Fixation of Diaphyseal Fractures of the Forearm: A Retrospective Comparison of Hybrid Fixation Versus Dual Plating	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						both-bone forearm fracture; intramedullary nailing; open reduction and internal fixation	MEDULLARY FIXATION; BONES; REFRACTURE; REMOVAL; ADULTS; PLATES; RADIUS; NAIL; ULNA	Objectives: To compare open reduction and internal fixation using dual plating to a hybrid fixation construct with intramedullary nailing of the ulna and plate fixation of the radius in both-bone forearm fractures. Design: Retrospective comparison study. Setting: Level I trauma center. Patients: A total of 56 skeletally mature individuals treated surgically for acute both-bone forearm fractures between July 2005 and December 2009. Monteggia, Galeazzi, and pathologic fractures, patients treated with external fixation and patients with traumatic brain injuries were excluded. Intervention: Twenty-seven patients were treated with dual plate fixation, and 29 patients were treated using a hybrid fixation construct. Main Outcome Measures: Time to union, range of motion as assessed using a Grace and Eversmann score, and presence of complications. Results: There was no significant difference in either time to union or Grace and Eversmann scores between the 2 groups. There was 1 nonunion in each of the 2 groups. Nine overall complications, outside nonunions, were reported: 5 in the dual plating group and 4 in the hybrid fixation group. Conclusions: Hybrid fixation, using open reduction and internal fixation with a plate-and-screw construct on the radius and closed-or minimally open-reduction and interlocked intramedullary fixation of the ulna, is an acceptable method for treating both-bone diaphyseal forearm fractures in skeletally mature patients.	[Behnke, Nicole M. K.; Redjal, Hamid R.; Zinar, Daniel M.] Harbor UCLA Med Ctr, Dept Orthopaed Surg, Torrance, CA 90509 USA; [Nguyen, Virginia T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	Behnke, NMK (corresponding author), Harbor UCLA Med Ctr, Dept Orthopaed Surg, 1000 W Carson Ave,2nd Floor,Box 422, Torrance, CA 90509 USA.	nmbehnke@gmail.com					ANDERSON LD, 1975, J BONE JOINT SURG AM, VA 57, P287, DOI 10.2106/00004623-197557030-00001; Beaupre GS, 1996, J ORTHOP TRAUMA, V10, P87, DOI 10.1097/00005131-199602000-00003; CHAPMAN MW, 1989, J BONE JOINT SURG AM, V71A, P159, DOI 10.2106/00004623-198971020-00001; Crenshaw AH, 1997, SURG TECHNIQUE FORES; Crenshaw Andrew H, 2002, Instr Course Lect, V51, P279; DELUCA PA, 1988, J BONE JOINT SURG AM, V70A, P1372, DOI 10.2106/00004623-198870090-00015; Droll KP, 2007, J BONE JOINT SURG AM, V89A, P2619, DOI 10.2106/JBJS.F.01065; Goldfarb CA, 2005, J BONE JOINT SURG BR, V87B, P374, DOI 10.1302/0301-620X.87B3; GRACE TG, 1980, J BONE JOINT SURG AM, V62, P433, DOI 10.2106/00004623-198062030-00013; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HADDEN WA, 1983, INJURY, V15, P44, DOI 10.1016/0020-1383(83)90162-6; Hertel R, 2006, ROCKWOOD GREENS FRAC, P965; HIDAKA S, 1984, J BONE JOINT SURG AM, V66A, P1241, DOI 10.2106/00004623-198466080-00012; Hong G, 2005, J ORTHOP TRAUMA, V19, P384, DOI 10.1097/01.bot.0000157911.76433.db; LABOSKY DA, 1990, J HAND SURG-AM, V15A, P294, DOI 10.1016/0363-5023(90)90112-5; LANGKAMER VG, 1991, INJURY, V22, P97, DOI 10.1016/0020-1383(91)90063-K; Lee YH, 2008, J BONE JOINT SURG AM, V90A, P1891, DOI 10.2106/JBJS.G.01636; Lindvall EM, 2006, J ORTHOP TRAUMA, V20, P157, DOI 10.1097/00005131-200603000-00001; MAREK FM, 1961, J BONE JOINT SURG AM, V43, P1099, DOI 10.2106/00004623-196143080-00003; Martin WN, 2002, INJURY, V33, P530, DOI 10.1016/S0020-1383(02)00029-3; MATTHEWS LS, 1982, J BONE JOINT SURG AM, V64, P14, DOI 10.2106/00004623-198264010-00003; McAuliffe JA, 1997, HAND CLIN, V13, P689; MIH AD, 1994, CLIN ORTHOP RELAT R, P256; Myers GJC, 2004, J BONE JOINT SURG BR, V86B, P581, DOI 10.1302/0301-620X.8684.13750; Rehman S, 2010, HAND CLIN, V26, P391, DOI 10.1016/j.hcl.2010.04.002; Reinhardt KR, 2008, J PEDIATR ORTHOPED, V28, P403, DOI 10.1097/BPO.0b013e31816d71f2; ROSSON J, 1991, J BONE JOINT SURG BR, V73, P283; ROSSON JW, 1991, J BONE JOINT SURG BR, V73, P415; SAGE FP, 1959, J BONE JOINT SURG AM, V41, P1489, DOI 10.2106/00004623-195941080-00010; SCHEMITSCH EH, 1992, J BONE JOINT SURG AM, V74A, P1068, DOI 10.2106/00004623-199274070-00014; Shah AS, 2010, J ORTHOP TRAUMA, V24, P440, DOI 10.1097/BOT.0b013e3181ca343b; Shea KG, 1997, HAND CLIN, V13, P737; SLATIS P, 1980, CAN J SURG, V23, P247; SMITH H, 1957, J BONE JOINT SURG AM, V39, P91, DOI 10.2106/00004623-195739010-00010; STREET DM, 1986, CLIN ORTHOP RELAT R, P219; TARR RR, 1986, CLIN ORTHOP RELAT R, P10; TARR RR, 1984, J BONE JOINT SURG AM, V66A, P65, DOI 10.2106/00004623-198466010-00010; UHTHOFF HK, 1994, J BONE JOINT SURG AM, V76A, P1507, DOI 10.2106/00004623-199410000-00010; Visna P, 2008, ACTA CHIR BELG, V108, P333, DOI 10.1080/00015458.2008.11680232; Weckbach A, 2006, ARCH ORTHOP TRAUM SU, V126, P309, DOI 10.1007/s00402-006-0122-9; Wei SY, 1999, J TRAUMA, V46, P1045, DOI 10.1097/00005373-199906000-00011; Wright RR, 1997, J ORTHOP TRAUMA, V11, P288, DOI 10.1097/00005131-199705000-00012; Zinar DM, 2006, FRACTURES, P157	43	21	23	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	NOV	2012	26	11					611	616		10.1097/BOT.0b013e31824aee8e			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	028WR	WOS:000310456200005	22487905				2021-06-18	
J	Glushakova, OY; Jeromin, A; Martinez, J; Johnson, D; Denslow, N; Streeter, J; Hayes, RL; Mondello, S				Glushakova, Olena Y.; Jeromin, Andreas; Martinez, Juan; Johnson, Danny; Denslow, Nancy; Streeter, Jackson; Hayes, Ronald L.; Mondello, Stefania			Cerebrospinal Fluid Protein Biomarker Panel for Assessment of Neurotoxicity Induced by Kainic Acid in Rats	TOXICOLOGICAL SCIENCES			English	Article						biomarkers; neurotoxicity; kainic acid; CSF; GFAP; UCH-L1; SBDP150; SBDP145; SBDP120	ALPHA-II-SPECTRIN; TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL CELL-PROLIFERATION; C-TERMINAL HYDROLASE-L1; BREAKDOWN PRODUCTS; NERVOUS-SYSTEM; FLUORO-JADE; NEUROLOGICAL COMPLICATIONS; ADJUVANT CHEMOTHERAPY; MOLECULAR-MECHANISMS	Glutamate excitotoxicity plays a key role in the etiology of a variety of neurological, psychiatric, and neurodegenerative disorders. The goal of this study was to investigate spatiotemporal distribution in the brain and cerebrospinal fluid (CSF) concentrations of ubiquitin C-terminal hydrolase-1 (UCH-L1), glial fibrillary acidic protein (GFAP), II-spectrin breakdown products (SBDP150, SBDP145, and SBDP120), and their relationship to neuropathology in an animal model of kainic acid (KA) excitotoxicity. Triple fluorescent labeling and Fluoro-Jade C staining revealed a reactive gliosis in brain and specific localization of degenerating neurons in hippocampus and entorhinal cortex of KA-treated rats. Immunohistochemistry showed upregulation of GFAP expression in hippocampus and cortex beginning 24h post KA injection and peaking at 48h. At these time points concurrent with extensive neurodegeneration all SBDPs were observed throughout the brain. At 24h post KA injection, a loss of structural integrity was observed in cellular distribution of UCH-L1 that correlated with an increase in immunopositive material in the extracellular matrix. CSF levels of UCH-L1, GFAP, and SBDPs were significantly increased in KA-treated animals compared with controls. The temporal increase in CSF biomarkers correlated with brain tissue distribution and neurodegeneration. This study provided evidence supporting the use of CSF levels of glial and neuronal protein biomarkers to assess neurotoxic damage in preclinical animal models that could prove potentially translational to the clinic. The molecular nature of these biomarkers can provide critical information on the underlying mechanisms of neurotoxicity that might facilitate the development of novel drugs and allow physicians to monitor drug safety.	[Glushakova, Olena Y.; Jeromin, Andreas; Martinez, Juan; Johnson, Danny; Streeter, Jackson; Hayes, Ronald L.; Mondello, Stefania] Banyan Biomarkers Inc, Alachua, FL 32615 USA; [Denslow, Nancy] Univ Florida, Ctr Environm & Human Toxicol, Dept Physiol Sci, Gainesville, FL 32611 USA	Mondello, S (corresponding author), Banyan Biomarkers Inc, 13400 Progress Blvd, Alachua, FL 32615 USA.	smondello@banyanbio.com	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614	Department of Defense (DoD)United States Department of Defense [W81XWH-06-1-0517, W81XWH-10-C-0251]	Department of Defense (DoD; W81XWH-06-1-0517 and W81XWH-10-C-0251).	Araujo IM, 2008, J NEUROCHEM, V105, P666, DOI 10.1111/j.1471-4159.2007.05181.x; Arnaoutakis GJ, 2011, J THORAC CARDIOV SUR, V142, P902, DOI 10.1016/j.jtcvs.2011.06.027; Bajda M, 2011, CURR MED CHEM, V18, P4949, DOI 10.2174/092986711797535245; Barry JD, 2011, NEUROL CLIN, V29, P539, DOI 10.1016/j.ncl.2011.05.006; Benskey M, 2012, NEUROTOXICOLOGY, V33, P321, DOI 10.1016/j.neuro.2012.02.001; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Bi X, 1997, NEUROSCIENCE, V81, P1123, DOI 10.1016/S0306-4522(97)00218-2; Bi XN, 1996, BRAIN RES, V726, P98, DOI 10.1016/0006-8993(95)01360-1; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Cai Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037599; Cardali S, 2006, J Neurosurg Sci, V50, P25; Cox CD, 2008, J NEUROTRAUM, V25, P1355, DOI 10.1089/neu.2008.0671; Crespo-Biel N, 2010, BIPOLAR DISORD, V12, P425, DOI 10.1111/j.1399-5618.2010.00825.x; Dietrich Joerg, 2006, J Biol, V5, P22, DOI 10.1186/jbiol50; Dietrich J, 2010, ADV EXP MED BIOL, V678, P77; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Doshi Shachee, 2009, Front Biosci (Schol Ed), V1, P466, DOI 10.2741/s38; Doyle KM, 2011, J CELL MOL MED, V15, P2025, DOI 10.1111/j.1582-4934.2011.01374.x; Ehrenreich H, 2011, MOL MED, V17, P1306, DOI 10.2119/molmed.2011.00259; ELLIOTT EM, 1993, J NEUROCHEM, V61, P57, DOI 10.1111/j.1471-4159.1993.tb03537.x; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Gilliams-Francis KL, 2003, EXP NEUROL, V184, P359, DOI 10.1016/j.expneurol.2003.07.003; Grant KS, 2010, NEUROTOXICOL TERATOL, V32, P132, DOI 10.1016/j.ntt.2009.09.005; Grill MF, 2011, BRIT J CLIN PHARMACO, V72, P381, DOI 10.1111/j.1365-2125.2011.03991.x; Haddad PM, 2008, HUM PSYCHOPHARM CLIN, V23, P15, DOI 10.1002/hup.918; Hopkins KJ, 2000, BRAIN RES, V864, P69, DOI 10.1016/S0006-8993(00)02137-5; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Jansen CE, 2011, SUPPORT CARE CANCER, V19, P1647, DOI 10.1007/s00520-010-0997-4; Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kondratyev A, 2004, MOL BRAIN RES, V121, P86, DOI 10.1016/j.molbrainres.2003.11.005; Lewis SB, 2007, J NEUROSURG, V107, P792, DOI 10.3171/JNS-07/10/0792; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Menon KN, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.000042; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Nath R, 1998, J NEUROCHEM, V71, P186; Newton HB, 2012, HAND CLINIC, V105, P903, DOI 10.1016/B978-0-444-53502-3.00031-8; O'Callaghan James P, 2005, Expert Opin Drug Saf, V4, P433, DOI 10.1517/14740338.4.3.433; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Pivovarova NB, 2010, FEBS J, V277, P3622, DOI 10.1111/j.1742-4658.2010.07754.x; Plunkett LM, 2007, LANCET, V369, P821, DOI 10.1016/S0140-6736(07)60396-1; Rajdev S, 2000, TOXICOL PATHOL, V28, P105, DOI 10.1177/019262330002800113; Rao DB, 2011, TOXICOL PATHOL, V39, P463, DOI 10.1177/0192623311401044; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rodriguez Manuel J, 2009, Curr Drug Abuse Rev, V2, P99; Salloway S, 2008, ALZHEIMERS DEMENT, V4, P65, DOI 10.1016/j.jalz.2007.10.001; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Seigers R, 2008, BEHAV BRAIN RES, V186, P168, DOI 10.1016/j.bbr.2007.08.004; Seigers R, 2009, BEHAV BRAIN RES, V201, P279, DOI 10.1016/j.bbr.2009.02.025; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stewart A, 2008, PSYCHO-ONCOLOGY, V17, P122, DOI 10.1002/pon.1210; Sun L, 2011, J RHEUMATOL, V38, P454, DOI 10.3899/jrheum.100550; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tsai GC, 1998, ANNU REV MED, V49, P173; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Wang Y, 2010, APOPTOSIS, V15, P1382, DOI 10.1007/s10495-010-0481-0; Warren MW, 2007, ACTA NEUROPATHOL, V114, P277, DOI 10.1007/s00401-007-0259-9; Wefel JS, 2012, CURR NEUROL NEUROSCI, V12, P267, DOI 10.1007/s11910-012-0264-9; Wefel JS, 2004, CANCER-AM CANCER SOC, V100, P2292, DOI 10.1002/cncr.20272; Weiss ES, 2009, ANN THORAC SURG, V88, P543, DOI 10.1016/j.athoracsur.2009.04.016; Yan XX, 2012, CURR GERIATR REP, V1, P85, DOI 10.1007/s13670-012-0009-2; Zheng XY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/457079	76	21	21	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080	1096-0929		TOXICOL SCI	Toxicol. Sci.	NOV	2012	130	1					158	167		10.1093/toxsci/kfs224			10	Toxicology	Toxicology	025CV	WOS:000310163200014	22790971	Bronze			2021-06-18	
J	Ma, XL; Sun, XL; Wan, CY; Ma, JX; Tian, P				Ma, Xin-Long; Sun, Xiao-Lei; Wan, Chun-You; Ma, Jian-Xiong; Tian, Peng			Significance of circulating endothelial progenitor cells in patients with fracture healing process	JOURNAL OF ORTHOPAEDIC RESEARCH			English	Article						endothelial progenitor cell; fracture healing; neovascularization	TRAUMATIC BRAIN-INJURY; OSTEOBLAST-LINEAGE CELLS; BONE-MARROW; PRECURSOR CELLS; CD34(+) CELLS; MUSCULOSKELETAL TRAUMA; MYOCARDIAL-INFARCTION; INDUCED MOBILIZATION; ACTIVATED PLATELETS; STEM-CELLS	Fracture healing is a complex bone formation process, and neovascularization may contribute to new bone regeneration. The circulating endothelial progenitor cell (EPC) mobilization and homing could involve in neovascularization and vasculogenesis. In this study, we investigate the changes of circulating EPC during bone fracture healing, and the possible contribution of EPCs to increased neovascularization and fracture healing. The number of circulating EPCs was monitored in twenty-four patients with long bone traumatic fracture within the first 48?h and at 3, 5, 10, and 14 days post-fracture. The mononuclear cells which isolated from peripheral blood were analyzed by flow cytometry. Peripheral blood counts of leukocytes and platelets were measured by hematology analyzer. The amount of peripheral EPCs significantly increased in patients with fracture compared to age-matched healthy control subjects within the first 48?h after injury, and peaked at 3 days post-fracture. There was no significant difference in the change trend of early EPCs between male and female, but the number of early EPCs was significantly greater in younger patients compared to older patients. A comparison of the EPCs levels between patients with severe injury (ISS?>?16) and patients with mild injury (ISS?=?16) revealed no statistically significant difference. The level of early EPCs was inverse correlation with the level of plate after fracture, but no correlation with the level of peripheral leucocytes. These findings suggest traumatic fracture may induce the mobilization of EPCs into the peripheral circulation. The increased EPCs may contribute to neovascularization and involve in fracture healing. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:18601866, 2012	[Ma, Xin-Long; Sun, Xiao-Lei; Wan, Chun-You; Tian, Peng] Tianjin Hosp, Tianjin 300211, Peoples R China; [Ma, Xin-Long; Ma, Jian-Xiong] Tianjin Med Univ, Gen Hosp, Dept Orthopaed, Tianjin, Peoples R China	Tian, P (corresponding author), Tianjin Hosp, Tianjin 300211, Peoples R China.	tianpeng007@foxmail.com			Scientific Research Fund of Tianjin Public Health Bureau [10KG111]	This work was supported by funding from Scientific Research Fund of Tianjin Public Health Bureau (10KG111). The authors would like to thank Jing Yang and Shangkun Zhao for technical support.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Atesok K, 2010, J ORTHOP RES, V28, P1007, DOI 10.1002/jor.21083; Buma P, 2004, BIOMATERIALS, V25, P1487, DOI 10.1016/S0142-9612(03)00492-7; Busse JW, 2002, CAN MED ASSOC J, V166, P437; Cobellis G, 2010, TRANSPL P, V42, P2816, DOI 10.1016/j.transproceed.2010.04.047; Condon ET, 2004, SURGERY, V135, P657, DOI 10.1016/j.surg.2003.10.012; de Boer HC, 2006, ARTERIOSCL THROM VAS, V26, P1653, DOI 10.1161/01.ATV.0000222982.55731.f1; Eghbali-Fatourechi GZ, 2007, BONE, V40, P1370, DOI 10.1016/j.bone.2006.12.064; Eghbali-Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264; Eguchi Masamichi, 2007, Clin Exp Nephrol, V11, P18, DOI 10.1007/s10157-006-0448-1; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Gill M, 2001, CIRC RES, V88, P167; Grigoryan M, 2003, ACAD RADIOL, V10, P1267, DOI 10.1016/S1076-6332(03)00467-7; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Herbrig K, 2006, ANN RHEUM DIS, V65, P157, DOI 10.1136/ard.2005.035378; Hristov M, 2004, J CELL MOL MED, V8, P498, DOI 10.1111/j.1582-4934.2004.tb00474.x; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kang HJ, 2001, BRIT J HAEMATOL, V113, P962, DOI 10.1046/j.1365-2141.2001.02694.x; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004; Kooistra BW, 2010, J ORTHOP TRAUMA, V24, pS71, DOI 10.1097/BOT.0b013e3181ca3fbd; Kuroda R, 2011, CELL TRANSPLANT, V20, P1491, DOI 10.3727/096368910X550189; Laing AJ, 2007, J BONE JOINT SURG BR, V89B, P116, DOI 10.1302/0301-620X.89B1.18222; Laing AJ, 2007, J ORTHOP RES, V25, P44, DOI 10.1002/jor.20228; Langer H, 2006, CIRC RES, V98, pE2, DOI 10.1161/01.RES.0000201285.87524.9e; Lee DY, 2008, BONE, V42, P932, DOI 10.1016/j.bone.2008.01.007; Lev EI, 2005, J VASC RES, V42, P408, DOI 10.1159/000087370; Lev EI, 2006, THROMB HAEMOSTASIS, V96, P498, DOI 10.1160/TH06-05-0250; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Liew A, 2008, DIABETES OBES METAB, V10, P353, DOI 10.1111/j.1463-1326.2007.00754.x; Liew A, 2006, BIOESSAYS, V28, P261, DOI 10.1002/bies.20372; Liu L, 2011, CRIT CARE MED, V39, P1760, DOI 10.1097/CCM.0b013e3182186cee; Marsboom Glenn, 2008, Expert Rev Cardiovasc Ther, V6, P687, DOI 10.1586/14779072.6.5.687; Massberg S, 2006, J EXP MED, V203, P1221, DOI 10.1084/jem.20051772; Masuda H, 2000, Hum Cell, V13, P153; Matsumoto T, 2008, J CELL PHYSIOL, V215, P234, DOI 10.1002/jcp.21309; Matsumoto T, 2006, AM J PATHOL, V169, P1440, DOI 10.2353/ajpath.2006.060064; Morii T, 1994, Rinsho Ketsueki, V35, P649; Morshed S, 2008, J BONE JOINT SURG AM, V90A, P62, DOI 10.2106/JBJS.G.01556; Murayama T, 2005, HANDB EXP PHARM, V170, P777; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Patil S, 2009, J ORTHOP RES, V27, P281, DOI 10.1002/jor.20572; Patschan SA, 2011, CRIT CARE, V15, DOI 10.1186/cc10100; Pihusch V, 2005, THROMB RES, V116, P233, DOI 10.1016/j.thromres.2004.12.010; Pintucci G, 2002, THROMB HAEMOSTASIS, V88, P834; Quaranta N, 2011, ACTA OTO-LARYNGOL, V131, P347, DOI 10.3109/00016489.2010.536990; Sadoun E, 2003, J HISTOCHEM CYTOCHEM, V51, P1119, DOI 10.1177/002215540305100902; Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140-6736(06)68891-0; Sen S, 2011, CLIN SCI, V120, P263, DOI 10.1042/CS20100429; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Takahashi T, 1999, NAT MED, V5, P434; Terrace JD, 2007, STEM CELLS DEV, V16, P771, DOI 10.1089/scd.2007.0016; Tian B, 2010, CHINESE MED J-PEKING, V123, P2265, DOI 10.3760/cma.j.issn.0366-6999.2010.16.020; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Wei HJ, 2011, J NEUROSCI RES, V89, P1822, DOI 10.1002/jnr.22696; Xie XX, 2011, MED HYPOTHESES, V76, P365, DOI 10.1016/j.mehy.2010.10.041; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035	59	21	24	1	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0736-0266			J ORTHOP RES	J. Orthop. Res.	NOV	2012	30	11					1860	1866		10.1002/jor.22134			7	Orthopedics	Orthopedics	015OL	WOS:000309455700023	22528744	Bronze			2021-06-18	
J	Turner, TH; Horner, MD; VanKirk, KK; Myrick, H; Tuerk, PW				Turner, Travis H.; Horner, Michael D.; VanKirk, Kathryn K.; Myrick, Hugh; Tuerk, Peter W.			A Pilot Trial of Neuropsychological Evaluations Conducted via Telemedicine in the Veterans Health Administration	TELEMEDICINE AND E-HEALTH			English	Article						military medicine; telepsychiatry; telemedicine	TRAUMATIC BRAIN-INJURY; SERVICES; RELIABILITY; DEMENTIA; TELEHEALTH; PROVISION; DISORDER; MEMORY; AREAS	Introduction: Many veterans live in rural areas distant from Veterans Affairs Medical Centers (VAMCs) and receive primary medical care from community-based outpatient clinics (CBOCs). These veterans often must travel great distances to the nearest VAMC for neuropsychological evaluations, resulting in poor access to care, travel reimbursement costs, fee-basis evaluations of uncontrolled quality, and driving safety concerns. Return trips for feedback compound complications. Accordingly, we initiated a pilot trial of neuropsychological evaluation and feedback via telemedicine (i.e., clinical videoconferencing). Subjects and Methods: Participants were veterans referred for neuropsychological evaluation from a rural CBOC 115 miles from the regional VAMC. All veterans were given the choice to undergo evaluation at the CBOC via telemedicine or in-person at the VAMC. Telemedicine equipment allowed presentation of digitized material with simultaneous patient observation. Testing materials were organized in numbered folders and given to veterans by CBOC clerks immediately prior to evaluation. Clerks returned completed materials via facsimile. Results: Fifteen veterans from the rural CBOC were seen for neuropsychological evaluation. Eight chose telemedicine evaluation. Groups based on evaluation modality appeared similar on demographics, referral basis, resulting neuropsychiatric diagnoses, and follow-through on recommendations. No significant technical or clinical difficulties were encountered, and veterans reported satisfaction with telemedicine. All veterans requested feedback via telemedicine. Conclusions: Neuropsychological evaluation via telemedicine is feasible and appears comparable to in-person evaluation. Experiences are encouraging and consistent with the broader literature on the acceptance of and satisfaction with clinical videoconferencing. Future studies will assess possible psychometric issues in clinical populations.	[Turner, Travis H.; Horner, Michael D.; VanKirk, Kathryn K.; Myrick, Hugh; Tuerk, Peter W.] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv Line, Charleston, SC USA; [Turner, Travis H.; Horner, Michael D.; VanKirk, Kathryn K.; Myrick, Hugh; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; [Turner, Travis H.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA	Turner, TH (corresponding author), Ralph H Johnson Vet Adm Med Ctr, Mental Hlth Serv Line, 109 Bee St,MH 116, Charleston, SC 29401 USA.	turnertr@musc.edu					Allott K, 2009, APPL NEUROPSYCHOL, V16, P193, DOI 10.1080/09084280903098760; Amarendran V, 2011, TELEMED E-HEALTH, V17, P223, DOI 10.1089/tmj.2010.0144; Beachler M, 2003, J RURAL HEALTH, V19, P301; Beck AT., 1996, BECK DEPRESSION INVE, V2; BENTON A L, 1978, Archives of Neurology, V35, P364; Benton A. L., 1994, CONTROLLED ORAL WORD; Brodey BB, 2000, PSYCHIATR SERV, V51, P1305, DOI 10.1176/appi.ps.51.10.1305; Clement PF, 2001, MIL MED, V166, P382; Clemmensen P, 2010, J ELECTROCARDIOL, V43, P615, DOI 10.1016/j.jelectrocard.2010.06.012; Conners CK, 1998, J CLIN PSYCHIAT, V59, P24; Cullum CM, 2006, ASSESSMENT, V13, P385, DOI 10.1177/1073191106289065; Defense Manpower Data Center, 2009, CTS DEPL FIL BAS REP; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Elmore D, 2003, MONITOR PSYCHOL, V34, P32; Goodglass H., 1983, ASSESSMENT APHASIA R; Gorsuch RL., 1983, MANUAL STATE ANXIETY; Green P., 1996, MANUAL COMPUTERISED; Heaton K, 2003, WISCONSIN CARD SORTI; Hess DC, 2006, LANCET NEUROL, V5, P275, DOI 10.1016/S1474-4422(06)70377-5; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobsen SE, 2003, J INT NEUROPSYCH SOC, V9, P472, DOI 10.1017/S1355617703930128; Jamora CW, 2008, NEUROREHABILITATION, V23, P381; Kaplan E., 1983, BOSTON NAMING TEST; McEachern W, 2008, CAN J NEUROL SCI, V35, P643, DOI 10.1017/S0317167100009458; Meyers J., 1995, REY COMPLEX FIGURE T; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Poon P, 2005, INT J GERIATR PSYCH, V20, P285, DOI 10.1002/gps.1282; RAO SM, 1989, NEUROLOGY, V39, P161, DOI 10.1212/WNL.39.2.161; Reger MA, 2004, NEUROPSYCHOLOGY, V18, P85, DOI 10.1037/0894-4105.18.1.85; Rogers R., 1992, SIRS STRUCTURED INTE; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; TROSTER AI, 1995, J COMMUNITY PSYCHOL, V23, P85, DOI 10.1002/1520-6629(199501)23:1<85::AID-JCOP2290230108>3.0.CO;2-6; Tuerk PW, 2010, TELEMED J E-HEALTH, V16, P115, DOI 10.1089/tmj.2009.0144; Veterans Health Administration, 2010, RES IMPR CAR VET RUR; WARD MF, 1993, AM J PSYCHIAT, V150, P885; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; White T., 2003, NEUROPSYCHOLOGICAL A; Wolfson D., 1993, HALSTEAD REITAN NEUR; Zarate CA, 1997, J CLIN PSYCHIAT, V58, P22, DOI 10.4088/JCP.v58n0104; Zaylor C, 2000, J TELEMED TELECARE, V6, P93, DOI 10.1258/1357633001934294	44	21	21	0	17	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627			TELEMED E-HEALTH	Telemed. e-Health	NOV	2012	18	9					662	667		10.1089/tmj.2011.0272			6	Health Care Sciences & Services	Health Care Sciences & Services	034BX	WOS:000310846200002	23050802				2021-06-18	
J	Rathore, FA; Gosney, JE; Reinhardt, JD; Haig, AJ; Li, JN; DeLisa, JA				Rathore, Farooq A.; Gosney, James E.; Reinhardt, Jan D.; Haig, Andrew J.; Li, Jianan; DeLisa, Joel A.			Medical Rehabilitation After Natural Disasters: Why, When, and How?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Amputation; Disability evaluation; Disasters; Occupational therapy; Outcome assessment; Rehabilitation; Spinal cord injuries	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; 2005 PAKISTAN EARTHQUAKE; QUALITY-OF-LIFE; WENCHUAN EARTHQUAKE; HEALTH; MANAGEMENT; OCTOBER; HAITI; EPIDEMIOLOGY	Rathore FA, Gosney JE, Reinhardt JD, Haig AJ, Li J, DeLisa JA. Medical rehabilitation after natural disasters: why, when, and how? Arch Phys Med Rehabil 2012;93:1875-81. Natural disasters can cause significant numbers of severe, disabling injuries, resulting in a public health emergency and requiring foreign assistance. However, since medical rehabilitation services are often poorly developed in disaster-affected regions and not highly prioritized by responding teams, physical and rehabilitation medicine (PRM) has historically been underemphasized in global disaster planning and response. Recent development of the specialties of "disaster medicine" and "disaster rehabilitation" has raised awareness of the critical importance of rehabilitation intervention during the immediate postdisaster emergency response. The World Health Organization Liaison Sub-Committee on Rehabilitation Disaster Relief of the International Society of Physical and Rehabilitation Medicine has authored this report to assess the role of emergency rehabilitation intervention after natural disasters based on current scientific evidence and subject matter expert accounts. Major disabling injury types are identified, and spinal cord injury, limb amputation, and traumatic brain injury are used as case studies to exemplify the challenges to effective management of disabling injuries after disasters. Evidence on the effectiveness of disaster rehabilitation interventions is presented. The authors then summarize the current state of disaster-related research, as well as lessons learned from PRM emergency rehabilitation response in recent disasters. Resulting recommendations for greater integration of PRM services into the immediate emergency disaster response are provided. This report aims to stimulate development of research and practice in the emerging discipline of disaster rehabilitation within organizations that provide medical rehabilitation services during the postdisaster emergency response.	[Rathore, Farooq A.] Armed Forces Inst Rehabil Med, Spinal Rehabil Unit, Rawalpindi 46000, Pakistan; [Rathore, Farooq A.; Gosney, James E.; Reinhardt, Jan D.; Haig, Andrew J.; Li, Jianan; DeLisa, Joel A.] Rehabil Disaster Relief Comm, Int Soc Phys & Rehabil Med, Geneva, Switzerland; [Rathore, Farooq A.] World Assoc Disaster & Emergency Med, Madison, WI USA; [Reinhardt, Jan D.] Swiss Parapleg Res, Nottwil, Switzerland; [Reinhardt, Jan D.] Univ Lucerne, Dept Hlth Sci & Hlth Policy, Luzern, Switzerland; [Haig, Andrew J.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Rathore, Farooq A.; Gosney, James E.; Haig, Andrew J.] Int Rehabil Forum Emergency Rehabil Work Grp, Ann Arbor, MI USA; [Li, Jianan] Nanjing Med Univ, Dept Rehab Med, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [DeLisa, Joel A.] Univ Hosp, Newark, NJ USA; [DeLisa, Joel A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA	Rathore, FA (corresponding author), Armed Forces Inst Rehabil Med, Spinal Rehabil Unit, Abid Majeed Rd, Rawalpindi 46000, Pakistan.	farooqrathore@gmail.com	Rathore, Farooq Azam/B-8232-2008; Haig, Andrew/B-5206-2013	Rathore, Farooq Azam/0000-0002-4759-0453; 			Ahrari M N, 2006, Electromyogr Clin Neurophysiol, V46, P59; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; [Anonymous], 1980, WHO CHRON, V34, P96; Anonymous, 2011, Morbidity and Mortality Weekly Report, V59, P1673; [Anonymous], 2010, WORLD CONFEDERAT APR, P1; Athukorala P.C., 2005, ASIAN EC PAP, V4, DOI [https://doi.org/10.1162/asep.2005.4.1.1, DOI 10.1162/ASEP.2005.4.1.1]; Bai XD, 2009, CHIN J TRAUMATOL, V12, P122, DOI 10.3760/cma.j.issn.1008-1275.2009.02.012; Bathla BS, 2005, ARCH PHYS MED REHAB, V86, pE31; Bhatti SH, 2008, JCPSP-J COLL PHYSICI, V18, P22, DOI 01.2008/JCPSP.2226; Brandeau ML, 2009, MED DECIS MAKING, V29, P438, DOI 10.1177/0272989X09340346; Bremer Rannveig, 2003, Prehosp Disaster Med, V18, P372; Butt BA, 2010, DISASTER MED PUBLIC, V4, P8, DOI 10.1017/S1935789300002317; Chen Jin, 2009, J Evid Based Med, V2, P270, DOI 10.1111/j.1756-5391.2009.01053.x; Chiou-Tan FY, 2007, AM J PHYS MED REHAB, V86, P762, DOI 10.1097/PHM.0b013e31813e61cc; Dai ZY, 2010, ULUS TRAVMA ACIL CER, V16, P503; Farfel A, 2011, EUR J PEDIATR, V170, P519, DOI 10.1007/s00431-011-1423-8; Gosney J, 2011, J REHABIL MED, V43, P965, DOI 10.2340/16501977-0890; Haig AJ, 2009, ARCH PHYS MED REHAB, V90, P2074, DOI 10.1016/j.apmr.2009.05.025; Haig AJ, 2009, J REHABIL MED, V41, P401, DOI 10.2340/16501977-0367; He HC, 2011, HONG KONG J EMERG ME, V18, P324; Hu XR, 2012, J REHABIL MED, V44, P200, DOI 10.2340/16501977-0944; IASC and Global Health Cluster, 2012, COORD REG PROV FOR M; IDNDR, 1994, YOK STRAT PLAN ACT S; Iezzoni LI, 2010, ANN INTERN MED, V152, P812, DOI 10.7326/0003-4819-152-12-201006150-00234; IRIN Global, 2012, HAIT EM SHEDS LIGHT; Killian L., 2002, METHODS DISASTER RES, P21; Knowlton LM, 2011, PREHOSP DISASTER MED, V26, P438, DOI 10.1017/S1049023X12000076; Krogh K, 2009, SPINAL CORD, V47, P230, DOI 10.1038/sc.2008.102; Landry MD, 2010, DISABIL REHABIL, V32, P1616, DOI 10.3109/09638288.2010.500345; LECHAT MF, 1979, B WORLD HEALTH ORGAN, V57, P11; Li Yuanfeng, 2009, J Evid Based Med, V2, P258, DOI 10.1111/j.1756-5391.2009.01045.x; Mallick M, 2010, East Mediterr Health J, V16 Suppl, pS98; Mateen FJ, 2010, ANN NEUROL, V68, P282, DOI 10.1002/ana.22135; Mulvey JM, 2008, INJURY, V39, P554, DOI 10.1016/j.injury.2007.07.025; Nixon SA, 2010, PHYSIOTHER CAN, V62, P167, DOI 10.3138/physio.62.3.167; Officer A, 2011, WORLD REPORT DISABIL, P21; Pang Hee-Nee, 2011, J Orthop Surg (Hong Kong), V19, P3; Phalkey R, 2011, GLOBAL HEALTH ACTION, V4, DOI 10.3402/gha.v4i0.7196; Rathore FA, 2008, ARCH PHYS MED REHAB, V89, P579, DOI 10.1016/j.apmr.2007.09.027; Rathore FA, 2011, DISASTER MED PUBLIC, V5, P174, DOI 10.1001/dmp.2011.66; Rathore MFA, 2008, SPINAL CORD, V46, P461, DOI 10.1038/sj.sc.3102162; Rathore MFA, 2007, SPINAL CORD, V45, P658, DOI 10.1038/sj.sc.3102023; Rauch A, 2011, J REHABIL MED, V43, P969, DOI 10.2340/16501977-0896; Redmond AD, 2011, LANCET, V377, P1054, DOI 10.1016/S0140-6736(11)60319-X; Reinhardt JD, 2011, GLOBAL HEALTH ACTION, V4, DOI 10.3402/gha.v4i0.7191; Roy N, 2006, PREHOSP DISASTER MED, V21, P310, DOI 10.1017/S1049023X00003939; Sami F, 2009, PREHOSP DISASTER MED, V24, P535, DOI 10.1017/S1049023X00007470; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sapir D.G., 2006, ASIAN DISASTER MANAG, V12, P9; Sphere Project, 2012, SPHER HDB HUM CHART; Stier-Jarmer M, 2011, J REHABIL MED, V43, P113, DOI [10.2340/16501977-0617, 10.2340/16501977-0659]; Stucki G, 2009, J REHABIL MED, V41, P843, DOI 10.2340/16501977-0431; The Johanniter International Assistance, 2012, HAIT LONG TERM ASS I; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Twisk J, 2009, J CLIN EPIDEMIOL, V62, P953, DOI 10.1016/j.jclinepi.2008.10.003; Uddin MT, 2008, J REHABIL MED S46, P24; Umer Masood, 2006, J Pak Med Assoc, V56, P370; Wade D T, 1988, Int Disabil Stud, V10, P64; WHO Department of Injuries and Violence Prevention, 2012, DIS DIS REH; World Confederation for Physical Therapy, 2012, DAT BAS EXP; Zhang Lei, 2009, Injury, V40, P84, DOI 10.1016/j.injury.2008.08.045; Zhang X, 2012, J REHABIL MED, V44, P206, DOI 10.2340/16501977-0945; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	63	21	23	0	27	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2012	93	10					1875	1881		10.1016/j.apmr.2012.05.018			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	018FP	WOS:000309645800028	22676904				2021-06-18	
J	Won, SJ; Kim, JH; Yoo, BH; Sohn, M; Kauppinen, TM; Park, MS; Kwon, HJ; Liu, JL; Suh, SW				Won, Seok Joon; Kim, Jin Hee; Yoo, Byung Hoon; Sohn, Min; Kauppinen, Tiina M.; Park, Man-Seong; Kwon, Hyung-Joo; Liu, Jialing; Suh, Sang Won			Prevention of hypoglycemia-induced neuronal death by minocycline	JOURNAL OF NEUROINFLAMMATION			English	Article						Hypoglycemia; Minocycline; Neuronal death; Microglia	ISCHEMIC BRAIN-INJURY; MICROGLIAL ACTIVATION; COGNITIVE IMPAIRMENT; TEMPORAL EVOLUTION; CEREBRAL-ISCHEMIA; AUTONOMIC FAILURE; GENE-EXPRESSION; NITRIC-OXIDE; MOUSE MODEL; RAT	Diabetic patients who attempt strict management of blood glucose levels frequently experience hypoglycemia. Severe and prolonged hypoglycemia causes neuronal death and cognitive impairment. There is no effective tool for prevention of these unwanted clinical sequelae. Minocycline, a second-generation tetracycline derivative, has been recognized as an anti-inflammatory and neuroprotective agent in several animal models such as stroke and traumatic brain injury. In the present study, we tested whether minocycline also has protective effects on hypoglycemia-induced neuronal death and cognitive impairment. To test our hypothesis we used an animal model of insulin-induced acute hypoglycemia. Minocycline was injected intraperitoneally at 6 hours after hypoglycemia/glucose reperfusion and injected once per day for the following 1 week. Histological evaluation for neuronal death and microglial activation was performed from 1 day to 1 week after hypoglycemia. Cognitive evaluation was conducted 6 weeks after hypoglycemia. Microglial activation began to be evident in the hippocampal area at 1 day after hypoglycemia and persisted for 1 week. Minocycline injection significantly reduced hypoglycemia-induced microglial activation and myeloperoxidase (MPO) immunoreactivity. Neuronal death was significantly reduced by minocycline treatment when evaluated at 1 week after hypoglycemia. Hypoglycemia-induced cognitive impairment is also significantly prevented by the same minocycline regimen when subjects were evaluated at 6 weeks after hypoglycemia. Therefore, these results suggest that delayed treatment (6 hours post-insult) with minocycline protects against microglial activation, neuronal death and cognitive impairment caused by severe hypoglycemia. The present study suggests that minocycline has therapeutic potential to prevent hypoglycemia-induced brain injury in diabetic patients.	[Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA; [Won, Seok Joon; Yoo, Byung Hoon; Kauppinen, Tiina M.; Suh, Sang Won] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; [Won, Seok Joon; Yoo, Byung Hoon; Kauppinen, Tiina M.; Liu, Jialing; Suh, Sang Won] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Yoo, Byung Hoon] Inje Univ, Inje Paik Hosp, Sch Med, Dept Anesthesiol, Seoul 139707, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Inchon 402751, South Korea; [Park, Man-Seong; Kwon, Hyung-Joo] Hallym Univ, Sch Med, Dept Microbiol, Chunchon 200702, South Korea; [Kim, Jin Hee; Suh, Sang Won] Hallym Univ, Sch Med, Dept Physiol, Chunchon 200702, South Korea	Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu; swsuh@hallym.ac.kr	Park, Man-Seong/AAF-1207-2020; Liu, Jialing/A-8627-2012; Kauppinen, Tiina/I-1009-2019	Liu, Jialing/0000-0003-4420-4382; SOHN, MIN/0000-0003-4021-2051; Kauppinen, Tiina/0000-0001-7219-9862	Department of Veterans AffairsUS Department of Veterans Affairs; Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A120202]	This work was supported by the Department of Veterans Affairs (JL) and by the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120202) to SWS.	AUER RN, 1993, BAILLIERE CLIN ENDOC, V7, P611, DOI 10.1016/S0950-351X(05)80210-1; AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; AUER RN, 1984, DIABETES, V33, P1090, DOI 10.2337/diabetes.33.11.1090; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Ben-Ami H, 1999, ARCH INTERN MED, V159, P281, DOI 10.1001/archinte.159.3.281; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cryer PE, 2001, AM J PHYSIOL-ENDOC M, V281, pE1115; Cryer PE, 2004, NEW ENGL J MED, V350, P2272, DOI 10.1056/NEJMra031354; Davis EA, 1998, J PEDIATR ENDOCR MET, V11, P177; DERESKI MO, 1993, ACTA NEUROPATHOL, V85, P327; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Ennis K, 2008, BRAIN RES, V1224, P119, DOI 10.1016/j.brainres.2008.06.003; Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GOLDEN MP, 1989, DIABETES CARE, V12, P89, DOI 10.2337/diacare.12.2.89; Hershey T, 2005, DIABETES CARE, V28, P2372, DOI 10.2337/diacare.28.10.2372; Hunter CL, 2004, ANN NEUROL, V56, P675, DOI 10.1002/ana.20250; Iadecola C, 1997, J NEUROSCI, V17, P9157; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Johnson EA, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-41; KALIMO H, 1980, ACTA NEUROL SCAND, V62, P345; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Keck T, 2002, GASTROENTEROLOGY, V122, P188, DOI 10.1053/gast.2002.30348; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; LANGAN SJ, 1991, DIABETOLOGIA, V34, P337, DOI 10.1007/BF00405006; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; MALOUF R, 1985, ANN NEUROL, V17, P421, DOI 10.1002/ana.410170502; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Metz LM, 2004, ANN NEUROL, V55, P756, DOI 10.1002/ana.20111; Mizoguchi H, 2008, PSYCHOPHARMACOLOGY, V196, P233, DOI 10.1007/s00213-007-0955-0; Moller JC, 1996, GLIA, V17, P121; Nogawa S, 1997, J NEUROSCI, V17, P2746; Rovet J, 1997, DIABETES CARE, V20, P803, DOI 10.2337/diacare.20.5.803; RYAN CM, 1990, J PEDIATR-US, V117, P32, DOI 10.1016/S0022-3476(05)82440-0; Ryu JK, 2004, GLIA, V48, P85, DOI 10.1002/glia.20051; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Shin BS, 2010, J CEREBR BLOOD F MET, V30, P390, DOI 10.1038/jcbfm.2009.229; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, GLIA, V55, P1280, DOI 10.1002/glia.20440; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2003, J NEUROSCI, V23, P10681; Takizawa S, 2002, J CEREBR BLOOD F MET, V22, P50, DOI 10.1097/00004647-200201000-00006; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zemke D, 2004, CLIN NEUROPHARMACOL, V27, P293, DOI 10.1097/01.wnf.0000150867.98887.3e	55	21	21	1	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	SEP 22	2012	9								225	10.1186/1742-2094-9-225			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	045YW	WOS:000311733700001	22998689	DOAJ Gold, Green Published			2021-06-18	
J	Belousov, AB; Wang, YF; Song, JH; Denisova, JV; Berman, NE; Fontes, JD				Belousov, Andrei B.; Wang, Yongfu; Song, Ji-Hoon; Denisova, Janna V.; Berman, Nancy E.; Fontes, Joseph D.			Neuronal gap junctions play a role in the secondary neuronal death following controlled cortical impact	NEUROSCIENCE LETTERS			English	Article						Gap junctions; Connexin 36; Traumatic brain injury; Glutamate; Neuronal death	GLOBAL-ISCHEMIA; CELL-DEATH; IN-VIVO; INJURY; VULNERABILITY; MECHANISMS; GLUTAMATE; CONNEXINS; INCREASES; STROKE	In the mammalian CNS, excessive release of glutamate and overactivation of glutamate receptors are responsible for the secondary (delayed) neuronal death following neuronal injury, including ischemia, traumatic brain injury (TBI) and epilepsy. Recent studies in mice showed a critical role for neuronal gap junctions in NMDA receptor-mediated excitotoxicity and ischemia-mediated neuronal death. Here, using controlled cortical impact (CCI) in adult mice, as a model of TBI, and Fluoro-jade B staining for analysis of neuronal death, we set to determine whether neuronal gap junctions play a role in the CCI-mediated secondary neuronal death. We report that 24 h post-CCI, substantial neuronal death is detected in a number of brain regions outside the injury core, including the striatum. The striatal neuronal death is reduced both in wild-type mice by systemic administration of mefloquine (a relatively selective blocker of neuronal gap junctions) and in knockout mice lacking connexin 36 (neuronal gap junction protein). It is also reduced by inactivation of group II metabotropic glutamate receptors (with LY341495) which, as reported previously, control the rapid increase in neuronal gap junction coupling following different types of neuronal injury. The results suggest that neuronal gap junctions play a critical role in the CO-induced secondary neuronal death. (c) 2012 Elsevier Ireland Ltd. All rights reserved.	[Belousov, Andrei B.; Wang, Yongfu; Song, Ji-Hoon; Denisova, Janna V.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Berman, Nancy E.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Fontes, Joseph D.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Belousov, AB (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 2146 W 39th Ave, Kansas City, KS 66160 USA.	abelousov@kumc.edu		Fontes, Joseph/0000-0003-4796-343X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS064256, R21 NS076925]; University of Kansas Medical Center funds; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064256, R21NS076925] Funding Source: NIH RePORTER	This research was supported by NIH (R01 NS064256 and R21 NS076925) and the University of Kansas Medical Center funds to A.B.B. Core support was provided by NIH HD002528.	Arumugam H, 2005, NAT NEUROSCI, V8, P1720, DOI 10.1038/nn1588; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Chang QA, 2000, J NEUROSCI, V20, P674, DOI 10.1523/JNEUROSCI.20-02-00674.2000; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Cruikshank SJ, 2004, P NATL ACAD SCI USA, V101, P12364, DOI 10.1073/pnas.0402044101; de Pina-Benabou MH, 2005, STROKE, V36, P2232, DOI 10.1161/01.STR.0000182239.75969.d8; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Gajda Z, 2003, EPILEPSIA, V44, P1596, DOI 10.1111/j.0013-9580.2003.25803.x; Garrett FG, 2008, NEURON GLIA BIOL, V4, P295, DOI 10.1017/S1740925X09990093; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Oguro K, 2001, J NEUROSCI, V21, P7534; Ohsumi A, 2006, ACTA NEUROCHIR SUPPL, V96, P148; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Park WM, 2011, J NEUROSCI, V31, P5909, DOI 10.1523/JNEUROSCI.6787-10.2011; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; Striedinger K, 2005, EUR J NEUROSCI, V22, P605, DOI 10.1111/j.1460-9568.2005.04228.x; Vaccari JCDR, 2007, J NEUROPHYSIOL, V98, P2878, DOI 10.1152/jn.00362.2007; Wang YF, 2012, J NEUROSCI, V32, P713, DOI 10.1523/JNEUROSCI.3872-11.2012; Wang YF, 2010, J NEUROPHYSIOL, V104, P3551, DOI 10.1152/jn.00656.2010; Xu LL, 2004, J LIQ CHROMATOGR R T, V27, P1627, DOI 10.1081/JLC-120034096	20	21	21	1	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 22	2012	524	1					16	19		10.1016/j.neulet.2012.06.065			4	Neurosciences	Neurosciences & Neurology	000LA	WOS:000308386600004	22781494	Green Accepted			2021-06-18	
J	Bellastella, A; Bizzarro, A; Colella, C; Bellastella, G; Sinisi, AA; De Bellis, A				Bellastella, Antonio; Bizzarro, Antonio; Colella, Caterina; Bellastella, Giuseppe; Sinisi, Antonio A.; De Bellis, Annamaria			Subclinical diabetes insipidus	BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article						subclinical central diabetes insipidus; autoimmunity; AVPcAb; isohormonal therapy	VASOPRESSIN-CELL ANTIBODIES; POSTERIOR PITUITARY-FUNCTION; LYMPHOCYTIC HYPOPHYSITIS; MAGNETIC-RESONANCE; TRANSSPHENOIDAL SURGERY; ADRENOCORTICAL FAILURE; SPONTANEOUS REMISSION; ADDISONS-DISEASE; NATURAL-HISTORY; AUTOIMMUNE	Subclinical central diabetes insipidus (CDI) can be the outcome of a number of diseases that affect the hypothalamus-infundibulum-post hypophysis axis. One of the most common forms of subclinical CDI is linked to an autoimmune pathogenesis even if other causes may be also responsible. Among these, pregnancy, traumatic and surgical brain injury and some infiltrative, vascular, infectious and neoplastic diseases have been reported with increasing frequency. The natural history of autoimmune CDI seems to evolve through 4 functional stages according to the presence of antibodies to vasopressin-secreting cells (AVPcAb) and the relationship between their behavior overtime, the variations of posterior pituitary function and the characteristics of hypothalamic-hypophyseal region on magnetic resonance imaging. This staging is of crucial importance for the therapeutic strategy, taking into account that some stages could be still reversible. Several medical treatments have been suggested to interrupt the progression toward clinical CDI but the results are still discussed. (C) 2011 Elsevier Ltd. All rights reserved.	[Bellastella, Antonio; Colella, Caterina; Bellastella, Giuseppe; Sinisi, Antonio A.; De Bellis, Annamaria] Univ Naples 2, Dept Cardiothorac & Resp Sci, Monaldi Hosp, I-80131 Naples, Italy; [Bizzarro, Antonio] Univ Naples 2, Dept Clin & Expt Med & Surg, I-80131 Naples, Italy	Bellastella, A (corresponding author), Univ Naples 2, Dept Cardiothorac & Resp Sci, Monaldi Hosp, Via Leonardo Bianchi, I-80131 Naples, Italy.	antonio.bellastella@unina2.it		DE BELLIS, Annamaria/0000-0002-0611-4506			Abe T, 2008, BRAIN TUMOR PATHOL, V25, P59, DOI 10.1007/s10014-008-0234-8; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Aleksandrov N, 2010, J OBSTET GYNAECOL CA, V32, P225, DOI 10.1016/S1701-2163(16)34448-6; Ananthakrishnan S, 2009, ENDOCR PRACT, V15, P377, DOI 10.4158/EP09090.RA; Atmaca H, 2007, EUR J ENDOCRINOL, V156, P563, DOI 10.1530/EJE-06-0727; Bellastella A, 2003, EUR J ENDOCRINOL, V149, P363, DOI 10.1530/eje.0.1490363; Betterle C, 1997, J CLIN ENDOCR METAB, V82, P932, DOI 10.1210/jc.82.3.932; BETTERLE C, 1993, CLIN ENDOCRINOL, V39, P35, DOI 10.1111/j.1365-2265.1993.tb01748.x; BHAN GL, 1982, POSTGRAD MED J, V58, P165, DOI 10.1136/pgmj.58.677.165; Bihan H, 2007, MEDICINE, V86, P259, DOI 10.1097/MD.0b013e31815585aa; BOTTAZZO GF, 1986, IMMUNOL REV, V94, P137, DOI 10.1111/j.1600-065X.1986.tb01168.x; Bueno JAS, 2005, EUR J OBSTET GYN R B, V118, P251, DOI 10.1016/j.ejogrb.2004.04.036; CACCIARI E, 1990, ARCH DIS CHILD, V65, P1199, DOI 10.1136/adc.65.11.1199; Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011; DAVIDSON JM, 1984, AM J PHYSIOL, V246, P105; DAVISON JM, 1988, J CLIN INVEST, V81, P798, DOI 10.1172/JCI113386; De Bellis A, 2005, BEST PRACT RES CL EN, V19, P67, DOI 10.1016/j.beem.2004.11.007; De Bellis A, 1999, J CLIN ENDOCR METAB, V84, P3047, DOI 10.1210/jc.84.9.3047; De Bellis A, 2002, J CLIN ENDOCR METAB, V87, P3825, DOI 10.1210/jc.87.8.3825; De Bellis A, 2001, J CLIN ENDOCR METAB, V86, P675, DOI 10.1210/jc.86.2.675; De Bellis A, 2004, IMMUNOENDOCRINOLOGY, P439; De Bellis A, 2011, CONTEMP ENDOCRINOL S, P547, DOI 10.1007/978-1-60327-478-4_33; DEBELLIS A, 1993, J CLIN ENDOCR METAB, V76, P1002, DOI 10.1210/jc.76.4.1002; DEBELLIS A, 1995, HORM RES, V44, P142, DOI 10.1159/000184614; DEBELLIS A, 1994, CLIN ENDOCRINOL, V40, P173; DIAMOND MP, 1987, SOUTHERN MED J, V80, P773, DOI 10.1097/00007611-198706000-00026; Dogan M., 2008, Experimental Oncology, V30, P324; Domiciano DS, 2010, ACTA REUMATOL PORT, V35, P232; Silva CMD, 2008, ARQ NEURO-PSIQUIAT, V66, P415, DOI 10.1590/S0004-282X2008000300028; DURR JA, 1987, NEW ENGL J MED, V316, P1070, DOI 10.1056/NEJM198704233161707; Edouard T, 2009, HORM RES, V72, P57, DOI 10.1159/000224342; Eisenbarth GS, 1998, WILLIAMS TXB ENDOCRI, P1651; El-Hennawy A S, 2003, J Matern Fetal Neonatal Med, V14, P349, DOI 10.1080/713606703; Ellidokuz E, 2006, J OBSTET GYNAECOL RE, V32, P602, DOI 10.1111/j.1447-0756.2006.00464.x; EPSTEIN S, 1971, BRIT MED J, V2, P267, DOI 10.1136/bmj.2.5756.267; Falorni A, 2002, ENDOCRIN METAB CLIN, V31, P369, DOI 10.1016/S0889-8529(01)00010-X; Fatourechi V, 2001, MAYO CLIN PROC, V76, P413; Finken MJJ, 2011, HORM RES PAEDIAT, V76, P22, DOI 10.1159/000324115; Fluteau-Nadler S, 1998, PRESSE MED, V27, P1095; Hansen LK, 1997, TRENDS ENDOCRIN MET, V8, P363, DOI 10.1016/S1043-2760(97)00157-4; Hensen J, 1999, CLIN ENDOCRINOL, V50, P431, DOI 10.1046/j.1365-2265.1999.00666.x; HIETT AK, 1990, OBSTET GYNECOL, V76, P982; Hime M C, 1978, Obstet Gynecol Surv, V33, P375, DOI 10.1097/00006254-197806000-00001; Hsu Y-J, ACTA NEUROLOGICA SCA, V107, P382; Huang CH, 2005, AM J KIDNEY DIS, V45, P197, DOI 10.1053/j.ajkd.2004.09.033; Imura H, 1993, NEW ENGL J MED; Inaba H, 2010, MED PRIN PRACT, V19, P79, DOI 10.1159/000252841; IWASAKI Y, 1991, NEW ENGL J MED, V324, P522, DOI 10.1056/NEJM199102213240803; Jennifer AL, 2007, ENDOCRINOL METAB, V3, P489; Kaijvama H, 2004, J RHEUMATOL, V31, P1218; Kalelioglu I, 2007, PITUITARY, V10, P87, DOI 10.1007/s11102-007-0006-1; KALLEN BAJ, 1995, EUR J ENDOCRINOL, V132, P144, DOI 10.1530/eje.0.1320144; Knip M, 2002, HORM RES, V57, P6, DOI 10.1159/000053305; KUCHARCZYK J, 1989, AM J ROENTGENOL, V152, P153, DOI 10.2214/ajr.152.1.153; Laureti S, 1999, J CLIN ENDOCR METAB, V84, P1762, DOI 10.1210/jc.84.5.1762; Lethagen AL, 2002, J CLIN ENDOCR METAB, V87, P1177, DOI 10.1210/jc.87.3.1177; LINDER N, 1986, AM J PERINAT, V3, P165, DOI 10.1055/s-2007-999859; Maghnie M, 1997, AM J NEURORADIOL, V18, P1749; Maghnie M, 2000, NEW ENGL J MED, V343, P998, DOI 10.1056/NEJM200010053431403; Marchand I, 2011, J CLIN ENDOCRINOLOGY; MARCOCCI C, 1991, J CLIN ENDOCR METAB, V72, P209, DOI 10.1210/jcem-72-1-209; Matsui K, 1979, Horumon To Rinsho, V27, P891; MCCONNELL EM, 1953, ANAT RECORD, V115, P175, DOI 10.1002/ar.1091150204; MCLEOD JF, 1993, J CLIN ENDOCR METAB, V77, pA599, DOI 10.1210/jcem.77.3.8370682; MILLER M, 1970, ANN INTERN MED, V73, P721, DOI 10.7326/0003-4819-73-5-721; Molitch ME, 1998, SEMIN PERINATOL, V22, P457, DOI 10.1016/S0146-0005(98)80026-8; MOSES AM, 1992, AM J NEURORADIOL, V13, P1273; NAGAE A, 1994, J INTERN MED, V235, P75, DOI 10.1111/j.1365-2796.1994.tb01035.x; Nagasaki K, 2009, ENDOCR J, V56, P721, DOI 10.1507/endocrj.K09E-045; Nemergut EC, 2005, J NEUROSURG, V103, P448, DOI 10.3171/jns.2005.103.3.0448; OHSHIMA K, 1989, J ENDOCRINOL INVEST, V12, P713, DOI 10.1007/BF03350038; Pivonello R, 2003, J CLIN ENDOCR METAB, V88, P1629, DOI 10.1210/jc.2002-020791; Ray J G, 1998, Obstet Gynecol Surv, V53, P450, DOI 10.1097/00006254-199807000-00025; Rittig S, 2002, J CLIN ENDOCR METAB, V87, P3351, DOI 10.1210/jc.87.7.3351; Rivera Juan-Andres, 2006, Pituitary, V9, P35, DOI 10.1007/s11102-006-6598-z; Robinson AG, 2008, WILLIAMS TXB ENDOCRI, P263; SCHERBAUM WA, 1983, DEUT MED WOCHENSCHR, V108, P1053, DOI 10.1055/s-2008-1069691; SCHERBAUM WA, 1983, LANCET, V1, P897; Scherbaum WA, 1987, BAILLIERE CLIN IMMUN, P237; Scherbaum WA, 1982, ENDOCRINOLOGY S, V110, P84; Shin JH, 2001, KOREAN J RADIOL, V2, P222, DOI 10.3348/kjr.2001.2.4.222; Sills ES, 1995, J MATERN FETAL MED, V4, P81; Smith D, 2002, J CLIN ENDOCR METAB, V87, P4564, DOI 10.1210/jc.2002-020090; THOMPSON CJ, 1987, Q J MED, V65, P853; Tubridy N, 2001, J NEUROL NEUROSUR PS, V71, P798, DOI 10.1136/jnnp.71.6.798; Verbalis J, 1984, DIABETES INSIPIDUS M, P247; Verrees M, 2004, NEUROSURG FOCUS, V16, P1; Vomacka Zdenek, 1993, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V135, P17; WILLIAMS DJ, 1993, CLIN ENDOCRINOL, V38, P595, DOI 10.1111/j.1365-2265.1993.tb02140.x; Xue J, 2009, RHEUMATOL INT, V29, P1213, DOI 10.1007/s00296-008-0774-6; Yamazaki M, 2010, INTERNAL MED, V49, P1885, DOI 10.2169/internalmedicine.49.3381; Yaun X-Q, 1991, FRONT NEUROENDOCRIN, V12, P209	93	21	22	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1521-690X			BEST PRACT RES CL EN	Best Pract. Res. Clin. Endoc. Metab.	AUG	2012	26	4					471	483		10.1016/j.beem.2011.11.008			13	Endocrinology & Metabolism	Endocrinology & Metabolism	994FY	WOS:000307917500008	22863389				2021-06-18	
J	Masel, BE; Bell, RS; Brossart, S; Grill, RJ; Hayes, RL; Levin, HS; Rasband, MN; Ritzel, DV; Wade, CE; DeWitt, DS				Masel, Brent E.; Bell, Randy S.; Brossart, Shawn; Grill, Raymond J.; Hayes, Ronald L.; Levin, Harvey S.; Rasband, Matthew N.; Ritzel, David V.; Wade, Charles E.; DeWitt, Douglas S.			Galveston Brain Injury Conference 2010: Clinical and Experimental Aspects of Blast Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; blast-induced neurotrauma; neurocritical care; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; AMYLOID PRECURSOR PROTEIN; CONTROLLED CORTICAL IMPACT; COMBAT-CASUALTY-CARE; MILD HEAD-INJURY; PERSISTENT POSTCONCUSSIVE SYMPTOMS; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CENTRAL-NERVOUS-SYSTEM; AXON INITIAL SEGMENT; LONG-TERM SURVIVAL	Blast injury is the most prevalent source of mortality and morbidity among combatants in Operations Iraqi and Enduring Freedom. Blast-induced neurotrauma (BINT) is a common cause of mortality, and even mild BINT may be associated with chronic cognitive and emotional deficits. In addition to military personnel, the increasing use of explosives by terrorists has resulted in growing numbers of blast injuries in civilian populations. Since the medical and rehabilitative communities are likely to be faced with increasing numbers of patients suffering from blast injury, the 2010 Galveston Brain Injury Conference focused on topics related to the diagnosis, treatment, and mechanisms of BINT. Although past military actions have resulted in large numbers of blast casualties, BINT is considered the signature injury of the conflicts in Iraq and Afghanistan. The attention focused on BINT has led to increased financial support for research on blast effects, contributing to the development of better experimental models of blast injury and a clearer understanding of the mechanisms of BINT. This more thorough understanding of blast injury mechanisms will result in novel and more effective therapeutic and rehabilitative strategies designed to reduce injury and facilitate recovery, thereby improving long-term outcomes in patients suffering from the devastating and often lasting effects of BINT. The following is a summary of the 2010 Galveston Brain Injury Conference, that included presentations related to the diagnosis and treatment of acute BINT, the evaluation of the long-term neuropsychological effects of BINT, summaries of current experimental models of BINT, and a debate about the relative importance of primary blast effects on the acute and long-term consequences of blast exposure.	[DeWitt, Douglas S.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Masel, Brent E.] Univ Texas Med Branch, Dept Neurol, Galveston, TX 77555 USA; [Bell, Randy S.] Natl Naval Med Ctr, Dept Neurosurg, Bethesda, MD USA; [Brossart, Shawn] Transit Learning Ctr, Project Victory, Galveston, TX USA; [Grill, Raymond J.] Univ Texas Houston, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX USA; [Hayes, Ronald L.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey S.] Banyan Biomarkers, Alachua, FL USA; [Rasband, Matthew N.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Ritzel, David V.] Dyn Fx Consulting Ltd, Amherstburg, ON, Canada; [Wade, Charles E.] Univ Texas Houston, Sch Med, Dept Surg, Houston, TX USA	DeWitt, DS (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, 301 Univ Blvd,Suite 2A, Galveston, TX 77555 USA.	ddewitt@utmb.edu		Rasband, Matthew/0000-0001-8184-2477	Transitional Learning Center; Moody Endowment; Center for Rehabilitation Sciences, School of Health Professions at University of Texas Medical Branch Health	The 2010 Galveston Brain Injury Conference was supported by the Transitional Learning Center, the Moody Endowment, and the Center for Rehabilitation Sciences, School of Health Professions at University of Texas Medical Branch Health, with assistance from the Moody Center for Traumatic Brain & Spinal Cord Injury Research/Mission Connect. The authors are grateful for the skilled and indispensable assistance of Ms. Georgina Eastmond with the conference organization. We are especially indebted to Mr. Robert Moody for his many years of generous support for research on traumatic brain injury.	AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Alvarez L., 2008, NY TIMES        0829; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; Bell RS, 2010, NEUROSURGERY, V66, P66, DOI 10.1227/01.NEU.0000361285.50218.A8; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Benzinger T., 1950, GERMAN AVIATION MED, V2, P1225; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bolander R., 2012, MULTISPECIES ANAL BI; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; Bowen I.G., 1962, TRANSLATIONAL EFFECT; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Brewin CR, 2010, PSYCHOL REV, V117, P210, DOI 10.1037/a0018113; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1996, CHINESE J TRAUMATOL, V12, P28; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Chiffelle T. L., 1966, DA49146XY055 DEP DEF; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cosgrove KP, 2007, BIOL PSYCHIAT, V62, P847, DOI 10.1016/j.biopsych.2007.03.001; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Cushing H, 1918, BRIT J SURG, V5, P558; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b; EDWARDS OM, 1986, MEDICINE, V65, P281; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Freidlander F.G., 1946, P ROY SOC LOND A MAT, VA186, P322; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Hai T, 1999, GENE EXPRESSION, V7, P321; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hayes RL, 2009, METHODS MOL BIOL, V566, P303, DOI 10.1007/978-1-59745-562-6_20; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Institute of Medicine, 2009, GULF WAR HLTH, V7; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006-3495(00)76432-0; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MATSON D, 1958, MANAGEMENT ACUTE CRA; MAYHEW TM, 1990, J ANAT, V172, P191; McNatt SA, 2005, NEUROSURGERY, V57, pE191, DOI [10.1227/01.NEU.0000175727.76530.94, 10.1227/01.NEU.0000164174.07281.F9]; Mei Y, 2008, NEUROSCIENCE, V151, P771, DOI 10.1016/j.neuroscience.2007.10.057; Menascu S, 2010, PEDIATR NEUROSURG, V46, P82, DOI 10.1159/000319004; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rasband MN, 2010, NAT REV NEUROSCI, V11, P552, DOI 10.1038/nrn2852; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rice D, 2000, TACTICAL EDGE J  SUM, P53; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Ritzel D.V., 1997, 21 INT S SHOCK WAV G; Ritzel D.V., 2011, NATO RTO HFM 207 S H; Ritzel D.V., 2007, 26 INT S SHOCK WAV G; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sahin B., 2011, IMAGE ANAL STEREOL, V20, P9, DOI [10.5566/ias.v20.p9-13, DOI 10.5566/IAS.V20.P9-13]; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sisodiya S, 1996, J ANAT, V188, P425; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Stuhmiller J., 2008, BLAST INJURY TRANSLA, P1; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Terrisse L, 1998, J NEUROCHEM, V71, P1643; Unterberg AW, 1997, ACT NEUR S, V70, P106; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wade C.E., 2008, EXPLOSIONS BLAST REL; Wang ZG, 1998, CHINESE MED J-PEKING, V111, P109; Whalen MJ, 1998, ACT NEUR S, V71, P212; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yamashima T, 2009, PROG NEUROBIOL, V89, P343, DOI 10.1016/j.pneurobio.2009.09.003; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	169	21	21	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2143	2171		10.1089/neu.2011.2258			29	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900004	22655746				2021-06-18	
J	Hunter, JM; Cirrito, JR; Restivo, JL; Kinley, RD; Sullivan, PM; Holtzman, DM; Koger, D; Delong, C; Lin, SZ; Zhao, LZ; Liu, F; Bales, K; Paul, SM				Hunter, Jesse M.; Cirrito, John R.; Restivo, Jessica L.; Kinley, Robert D.; Sullivan, Patrick M.; Holtzman, David M.; Koger, Deanna; Delong, Cynthia; Lin, Suizhen; Zhao, Lingzhi; Liu, Feng; Bales, Kelly; Paul, Steven M.			Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice	BRAIN RESEARCH			English	Article						Apolipoprotein E; Alzheimer; Epilepsy; Seizure; Amyloid beta	TEMPORAL-LOBE EPILEPSY; ALZHEIMERS-DISEASE RELATION; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; E POLYMORPHISM; POSTTRAUMATIC SEIZURES; RECEPTOR-BINDING; EEG ALTERATIONS; ONSET SEIZURES	The apolipoprotein 64 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) and is associated with earlier age of onset. The incidence of spontaneous seizures has been reported to be increased in sporadic AD as well as in the early onset autosomal dominant forms of AD. We now report the emergence of a seizure phenotype in aged apolipoprotein E4 (apoE4) targeted replacement (TR) mice but not in age-matched apoE2 TR or apoE3-TR mice. Tonic-clonic seizures developed spontaneously after 5 months of age in apoE4 TR mice and are triggered by mild stress. Female mice had increased seizure penetrance compared to male mice, but had slightly reduced overall seizure severity. The majority of seizures were characterized by head and neck jerks, but 25% of aged apoE4 TR mice had more severe tonic-clonic seizures which occasionally progressed to tonic extension and death. Aged apoE4 TR mice progressed through pentylenetetrazol-induced seizure stages more rapidly than did apoE3 TR and apoE2 TR mice. Electroencephalographic (EEG) recordings revealed more frequent bursts of synchronous theta activity in the hippocampus of apoE4 TR mice than in apoE2 TR or apoE3 TR mice. Cortical EEG recordings also revealed sharp spikes and other abnormalities in apoE4 TR mice. Taken together, these findings demonstrate the emergence of an age-dependent seizure phenotype in old apoE4 TR mice in the absence of human amyloid-beta peptide (A beta) overexpression, suggesting increased central nervous system neural network excitability. (c) 2012 Published by Elsevier B.V.	[Paul, Steven M.] Cornell Univ, Weill Cornell Med Coll, Helen & Robert Appel Alzheimers Dis Res Inst, New York, NY 10065 USA; [Hunter, Jesse M.; Kinley, Robert D.; Koger, Deanna; Delong, Cynthia; Lin, Suizhen; Zhao, Lingzhi; Liu, Feng; Bales, Kelly] Eli Lilly & Co, Neurosci Discovery, Indianapolis, IN 46285 USA; [Cirrito, John R.; Restivo, Jessica L.; Holtzman, David M.] Washington Univ, Hope Ctr Neurol Disorders, Knight Alzheimers Dis Res Ctr, St Louis, MO 63110 USA; [Sullivan, Patrick M.] Duke Univ, Durham VA Med Ctr, Div Geriatr, Durham, NC 27710 USA	Paul, SM (corresponding author), Cornell Univ, Weill Cornell Med Coll, Helen & Robert Appel Alzheimers Dis Res Inst, 1300 York Ave,8th Floor,LC 802, New York, NY 10065 USA.	jeshnt@gmail.com; cirritoj@neuro.wustl.edu; restivoj@neuro.wustl.edu; KINLEY_ROBERT@lilly.com; p.sullivan@duke.edu; holtzman@neuro.wustl.edu; koger_deanna@lilly.com; DELONG_CYNTHIA_A@lilly.com; LIN_SUIZHEN@lilly.com; liz2010@med.cornell.edu; liu_feng_fl@lilly.com; Kelly.Bales@Pfizer.com; smpaulmd@gmail.com	Paul, Steve/ABE-5400-2020				Alexander DM, 2007, BIOL PSYCHOL, V75, P229, DOI 10.1016/j.biopsycho.2007.03.001; Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Arab L, 2010, J ALZHEIMERS DIS, V20, P785, DOI 10.3233/JAD-2010-091573; Baker N. L., 2010, ALZH ASS INT C ALZH, pS469; Bales KR, 2009, J NEUROSCI, V29, P6771, DOI 10.1523/JNEUROSCI.0887-09.2009; Bales KR, 2002, MOL INTERV, V2, P339, DOI DOI 10.1124/MI.2.6.363; Bertram L, 2010, NEURON, V68, P270, DOI 10.1016/j.neuron.2010.10.013; Blumcke I, 1997, NEUROREPORT, V8, P1235; Bour A, 2008, BEHAV BRAIN RES, V193, P174, DOI 10.1016/j.bbr.2008.05.008; Briellmann RS, 2000, NEUROLOGY, V55, P435, DOI 10.1212/WNL.55.3.435; Busch RM, 2007, NEUROLOGY, V68, P409, DOI 10.1212/01.wnl.0000253021.60887.db; Castellani RJ, 2010, DM-DIS MON, V56, P484, DOI 10.1016/j.disamonth.2010.06.001; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Colom LV, 2006, J NEUROPHYSIOL, V95, P3645, DOI 10.1152/jn.00040.2006; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Espeseth T, 2009, NEUROSCI LETT, V459, P91, DOI 10.1016/j.neulet.2009.04.053; FRANDSEN A, 1987, EPILEPSY RES, V1, P107, DOI 10.1016/0920-1211(87)90015-5; Frye Cheryl A, 2006, Expert Rev Neurother, V6, P1061, DOI 10.1586/14737175.6.7.1061; Frye CA, 2008, INT REV NEUROBIOL, V83, P27, DOI 10.1016/S0074-7742(08)00003-2; Gambardella T, 2005, EPILEPSIA, V46, P110, DOI 10.1111/j.0013-9580.2005.15804.x; Garcia-Hernandez A, 2010, EXP NEUROL, V222, P86, DOI 10.1016/j.expneurol.2009.12.010; Gilby KL, 2007, EPILEPSIA, V48, P114, DOI 10.1111/j.1528-1167.2007.01298.x; Gouras GK, 1997, ANN NEUROL, V41, P402, DOI 10.1002/ana.410410317; Grootendorst J, 2005, BEHAV BRAIN RES, V159, P1, DOI 10.1016/j.bbr.2004.09.019; HAUSER WA, 1986, NEUROLOGY, V36, P1226, DOI 10.1212/WNL.36.9.1226; Hirsch Lawrence J, 2007, Epilepsy Curr, V7, P149, DOI 10.1111/j.1535-7511.2007.00208.x; Irizarry MC, 2012, ARCH NEUROL-CHICAGO, V69, P368, DOI 10.1001/archneurol.2011.830; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Korwek KM, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-21; Kramer G, 2008, CLIN NEUROPHYSIOL, V119, P2727, DOI 10.1016/j.clinph.2008.08.019; Kurschner VC, 1998, BRAIN RES, V780, P1, DOI 10.1016/S0006-8993(97)01081-0; Larner AJ, 2011, EPILEPSY BEHAV, V21, P20, DOI 10.1016/j.yebeh.2011.03.022; Lehtovirta M, 1996, NEUROBIOL AGING, V17, P523; Lehtovirta M, 2000, DEMENT GERIATR COGN, V11, P29, DOI 10.1159/000017210; Lehtovirta M, 1996, NEUROLOGY, V46, P413, DOI 10.1212/WNL.46.2.413; LERMA J, 1984, ELECTROEN CLIN NEURO, V57, P532, DOI 10.1016/0013-4694(84)90089-0; Li G, 2009, CELL STEM CELL, V5, P634, DOI 10.1016/j.stem.2009.10.015; Loscher W, 2009, EUR J PHARMACOL, V610, P1, DOI 10.1016/j.ejphar.2009.03.025; Luttjohann A, 2009, PHYSIOL BEHAV, V98, P579, DOI 10.1016/j.physbeh.2009.09.005; Mendez MF, 2003, DRUG AGING, V20, P791, DOI 10.2165/00002512-200320110-00001; MILLER JW, 1994, EPILEPSY RES, V18, P195, DOI 10.1016/0920-1211(94)90040-X; Murphy C, 2009, ANN NY ACAD SCI, V1170, P647, DOI 10.1111/j.1749-6632.2009.04486.x; Nakken KO, 2005, EPILEPSY BEHAV, V6, P85, DOI 10.1016/j.yebeh.2004.11.003; PALAYOOR ST, 1986, J NEUROCHEM, V46, P1370, DOI 10.1111/j.1471-4159.1986.tb01749.x; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Palop JJ, 2006, NATURE, V443, P768, DOI 10.1038/nature05289; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Pinikahana J, 2009, EPILEPSY BEHAV, V15, P513, DOI 10.1016/j.yebeh.2009.06.004; Ponomareva NV, 2008, NEUROBIOL AGING, V29, P819, DOI 10.1016/j.neurobiolaging.2006.12.019; Ponomareva NV, 2003, NEUROPSYCHOBIOLOGY, V48, P152, DOI 10.1159/000073633; Raber J, 2008, HORM BEHAV, V53, P706, DOI 10.1016/j.yhbeh.2008.02.012; Rabinowicz AL, 2000, ALZ DIS ASSOC DIS, V14, P231, DOI 10.1097/00002093-200010000-00008; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; ROMANELLI MF, 1990, ARCH NEUROL-CHICAGO, V47, P847, DOI 10.1001/archneur.1990.00530080029006; Roses AD, 1996, ANN NY ACAD SCI, V777, P146, DOI 10.1111/j.1749-6632.1996.tb34413.x; Scarmeas N, 2009, ARCH NEUROL-CHICAGO, V66, P992, DOI 10.1001/archneurol.2009.130; Spatt J, 1998, SEIZURE-EUR J EPILEP, V7, P391, DOI 10.1016/S1059-1311(05)80008-1; Sporis D, 2005, J CELL MOL MED, V9, P698, DOI 10.1111/j.1582-4934.2005.tb00500.x; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sullivan PM, 2011, NEUROBIOL AGING, V32, P791, DOI 10.1016/j.neurobiolaging.2009.05.011; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Thies W, 2011, ALZHEIMERS DEMENT, V7, P175, DOI [10.1016/j.jalz.2011.02.004, 10.1016/j.jalz.2011.02.002]; Trommer BL, 2005, NEUROBIOL DIS, V18, P75, DOI 10.1016/j.nbd.2004.08.011; Trommer BL, 2004, NEUROREPORT, V15, P2655, DOI 10.1097/00001756-200412030-00020; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; Yeni SN, 2005, EUR J NEUROL, V12, P103, DOI 10.1111/j.1468-1331.2004.00956.x; Yun SH, 2005, J NEUROSCI RES, V82, P771, DOI 10.1002/jnr.20684; Yun SH, 2007, HIPPOCAMPUS, V17, P1153, DOI 10.1002/hipo.20357; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059	76	21	22	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 27	2012	1467						120	132		10.1016/j.brainres.2012.05.048			13	Neurosciences	Neurosciences & Neurology	994CT	WOS:000307909200013	22682924				2021-06-18	
J	Grinsell, MM; Butz, K; Gurka, MJ; Gurka, KK; Norwood, V				Grinsell, Matthew M.; Butz, Kirsten; Gurka, Matthew J.; Gurka, Kelly K.; Norwood, Victoria			Sport-Related Kidney Injury Among High School Athletes	PEDIATRICS			English	Article						kidney; sports; wounds and injuries	AMERICAN FOOTBALL; BRAIN-INJURY; PARTICIPATION; PATTERNS; CHILDREN	BACKGROUND AND OBJECTIVE: The American Academy of Pediatrics recommends a "qualified yes" for participation by athletes with single kidneys in contact/collision sports. Despite this recommendation, most physicians continue to discourage participation in contact/collision sports for patients with single kidneys. A major concern is the lack of prospective data quantifying the incidence of sport-related kidney injury. The objective was to quantify the incidence of sport-related kidney injury among high school varsity athletes and compare it with sport-related injuries of other organ systems. METHODS: Data from the National Athletic Trainers' Association High School Injury Surveillance Study, an observational cohort study collected during the 1995-1997 academic years, were used. Incidence rates for sport-specific injuries to select organs were computed and compared. RESULTS: Over 4.4 million athlete-exposures, defined as 1 athlete participating in 1 game or practice, and 23 666 injuries were reported. Eighteen kidney injuries, none of which were catastrophic or required surgery, were reported compared with 3450 knee, 2069 head/neck/spine, 1219 mild traumatic brain, 148 eye, and 17 testicle injuries. Student athletes incurring kidney injuries were most often playing football (12 injuries) or girls' soccer (2 injuries). Sport-specific rates of kidney injury were significantly lower than sport-specific rates of mild traumatic brain, head/neck/spine, and knee injuries for all sports as well as rates of baseball-and basketball-specific eye injuries (P < .01). CONCLUSIONS: Kidney injuries occur significantly less often than other injuries during sport. These data do not support limiting sport participation by athletes with single kidneys. Pediatrics 2012;130:e40-e45	[Grinsell, Matthew M.] Univ Utah, Sch Med, Dept Pediat, Div Nephrol & Hypertens, Salt Lake City, UT 84132 USA; [Butz, Kirsten] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA; [Gurka, Matthew J.; Norwood, Victoria] Univ Virginia, Dept Pediat, Charlottesville, VA USA; [Gurka, Matthew J.; Gurka, Kelly K.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA; [Gurka, Matthew J.; Gurka, Kelly K.] W Virginia Univ, Dept Community Med, Morgantown, WV 26506 USA; [Gurka, Kelly K.] W Virginia Univ, Injury Control Res Ctr, Morgantown, WV 26506 USA	Grinsell, MM (corresponding author), Univ Utah, Sch Med, Dept Pediat, Div Nephrol & Hypertens, 30 North 1900 East,Room 2A100, Salt Lake City, UT 84132 USA.	matt.grinsell@hsc.utah.edu	Gurka, Kelly K./M-2004-2014	Gurka, Kelly K./0000-0003-2779-3234	NATA Research and Education Foundation; National Athletic Trainers' Association	Research support was provided by a grant from the NATA Research and Education Foundation.; We extend our sincere thanks to John Powell, PhD, as well as to the National Athletic Trainers' Association for their support of this project.	Anderson C R, 1995, Arch Fam Med, V4, P885, DOI 10.1001/archfami.4.10.885; Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Bonett DG, 2006, STAT MED, V25, P3039, DOI 10.1002/sim.2440; Brophy RH, 2008, AM J SPORT MED, V36, P85, DOI 10.1177/0363546507308940; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; DORSEN PJ, 1986, PHYSICIAN SPORTSMED, V14, P130, DOI 10.1080/00913847.1986.11709129; Eisenmann JC, 2005, AM HEART J, V149, P46, DOI 10.1016/j.ahj.2004.07.016; Grinsell MM, 2006, PEDIATRICS, V118, P1019, DOI 10.1542/peds.2006-0663; Johnson B, 2005, J UROLOGY, V174, P686, DOI 10.1097/01.ju.0000164719.91332.42; Krasnow S, 1990, SPORTS ILLUSTRA 0507, P1; Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Psooy Karen, 2006, Can J Urol, V13, P3120; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; RISSER WL, 1994, PEDIATRICS, V94, P757; Robson W L, 1995, Adv Pediatr, V42, P575; Salem Hosni Khairy, 2007, J Pediatr Urol, V3, P223, DOI 10.1016/j.jpurol.2006.07.006; Sharp DS, 2002, J UROLOGY, V168, P1811, DOI 10.1016/S0022-5347(05)64420-5; Spruijt-Metz D, 2011, J RES ADOLESCENCE, V21, P129, DOI 10.1111/j.1532-7795.2010.00719.x; STOKES M. E., 2000, CATEGORICAL DATA ANA; Wan J, 2003, J UROLOGY, V170, P1525, DOI 10.1097/01.ju.0000084430.96658.05; Washington RL, 2001, PEDIATRICS, V107, P1205; WICHMANN S, 1992, PHYSICIAN SPORTSMED, V20, P176, DOI 10.1080/00913847.1992.11947420	26	21	22	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2012	130	1					E40	E45		10.1542/peds.2011-2082			6	Pediatrics	Pediatrics	967KH	WOS:000305905900006	22711726				2021-06-18	
J	Lei, BL; Mace, B; Bellows, ST; Sullivan, PM; Vitek, MP; Laskowitz, DT; James, ML				Lei, Beilei; Mace, Brian; Bellows, Steven T.; Sullivan, Patrick M.; Vitek, Michael P.; Laskowitz, Daniel T.; James, Michael L.			Interaction Between Sex and Apolipoprotein E Genetic Background in a Murine Model of Intracerebral Hemorrhage	TRANSLATIONAL STROKE RESEARCH			English	Article						Apolipoprotein E; Sex differences; Murine; Intracerebral hemorrhage; Female	TRAUMATIC BRAIN-INJURY; MELBOURNE STROKE INCIDENCE; CLOSED-HEAD INJURY; APOE GENOTYPE; ISCHEMIC-STROKE; CASE-FATALITY; GENDER; MORTALITY; PEPTIDE; INFLAMMATION	Emerging evidence suggests sex and apolipoprotein E (APOE) genotype separately modify outcomes after intracerebral hemorrhage (ICH). We test the hypothesis that an interaction exists between sex and APOE polymorphism in modifying outcomes after ICH and is altered by administration of exogenous apoE-mimetic peptide. To define the effects of sex and APOE polymorphism in ICH, we created collagenase-induced ICH in male and female APOETR mice (targeted replacement mice homozygous for APOE3 or APOE4 alleles; n=12/group) and assessed performance on Rotarod (RR) and Morris water maze (MWM). To evaluate hematoma formation, we used hematoxylin and eosin staining at 24 h after injury (n=8/group). Using separate cohorts (n=12/group), apoE-mimetic peptide (COG1410 at 2 mg/kg) was administered after ICH, and mice were assessed by RR and MWM. Female mice outperformed male mice via RR and MWM by over 190% improvement through 7 days (RR) and 32 days (MWM) of testing after ICH (p<0.01). Female APOE3TR mice demonstrated improved function compared with all other groups (p<0.05) without any difference in hematoma volume at 24 h after injury in any group. Administration of a therapeutic apoE-mimetic peptide improved RR latencies through 7 days after ICH in male and female APOE4TR mice and MWM latencies over days 28-32 after ICH in male APOE4TR mice (p<0.05). Sex and APOE polymorphism influence functional outcomes in our murine model of ICH. Moreover, administration of exogenous apoE-mimetic peptide after injury differentially modifies the interaction between sex and APOE polymorphism.	[Bellows, Steven T.; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Dept Med Neurol, Durham, NC USA; [Lei, Beilei; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Multidisciplinary Neuroprotect Labs, Durham, NC USA; [Lei, Beilei; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Dept Anesthesiol, Durham, NC USA; [Mace, Brian; Sullivan, Patrick M.] Duke Univ, Dept Geriatr Med, Durham, NC USA; [Mace, Brian; Sullivan, Patrick M.] Durham Vet Affairs, Geriatr Res Educ & Clin Ctr, Durham, NC USA; [Laskowitz, Daniel T.] Duke Univ, Dept Neurobiol, Durham, NC USA; [Vitek, Michael P.] Cognosci Inc, Durham, NC USA	James, ML (corresponding author), Duke Univ, Dept Med Neurol, Durham, NC USA.	michael.james@duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210; Vitek, Michael/0000-0001-8140-8048	American Heart Association Scientist Development GrantAmerican Heart Association; Foundation for Anesthesia Education and Research Mentored Research Training Grant	This project was funded by grants from the American Heart Association Scientist Development Grant and Foundation for Anesthesia Education and Research Mentored Research Training Grant (MLJ). Dr. Laskowitz has previously served as a consultant for Cognosci, Inc. Dr. Vitek is Chief Executive Officer of Cognosci, Inc. COG1410 was provided by Cognosci, Inc.	ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Brait VH, 2010, J CEREBR BLOOD F MET, V30, P1306, DOI 10.1038/jcbfm.2010.14; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Cadilhac DA, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-49; Caligioni CS, 2009, CURR PROTOC NEUROSCI; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Colton CA, 2005, NEUROBIOL AGING, V26, P363, DOI 10.1016/j.neurobiolaging.2004.08.001; De Silva TM, 2009, STROKE, V40, P1091, DOI 10.1161/STROKEAHA.108.531707; Diringer MN, 1998, STROKE, V29, P1352, DOI 10.1161/01.STR.29.7.1352; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gromadzka G, 2007, ACTA NEUROL SCAND, V116, P392, DOI 10.1111/j.1600-0404.2007.00880.x; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Holscher C, 1999, BEHAV BRAIN RES, V100, P225, DOI 10.1016/S0166-4328(98)00134-X; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Khan FA, 2005, NEUROEPIDEMIOLOGY, V24, P26, DOI 10.1159/000081046; Kimura Y, 1998, INTERNAL MED, V37, P736, DOI 10.2169/internalmedicine.37.736; Labovitz DL, 2005, NEUROLOGY, V65, P518, DOI 10.1212/01.wnl.0000172915.71933.00; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2012, NEUROCRIT CARE, V16, P316, DOI 10.1007/s12028-011-9641-5; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Liu MY, 2008, J NEUROSCI METH, V171, P214, DOI 10.1016/j.jneumeth.2008.03.002; Liu MY, 2009, RESTOR NEUROL NEUROS, V27, P163, DOI 10.3233/RNN-2009-0467; Liu MY, 2007, J CEREBR BLOOD F MET, V27, P135, DOI 10.1038/sj.jcbfm.9600331; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nakamura T, 2004, J CEREBR BLOOD F MET, V24, P487, DOI 10.1097/00004647-200405000-00002; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Qureshi AI, 1999, CRIT CARE MED, V27, P480, DOI 10.1097/00003246-199903000-00021; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Sacco RL, 1998, AM J EPIDEMIOL, V147, P259, DOI 10.1093/oxfordjournals.aje.a009445; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Thrift AG, 2009, NEUROEPIDEMIOLOGY, V32, P11, DOI 10.1159/000170086; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Tzourio C, 2008, NEUROLOGY, V70, P1322, DOI 10.1212/01.wnl.0000308819.43401.87; Vaartjes I, 2009, CEREBROVASC DIS, V28, P564, DOI 10.1159/000247600; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Vemmos KN, 1999, STROKE, V30, P363, DOI 10.1161/01.STR.30.2.363; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Woo D, 2005, STROKE, V36, P1874, DOI 10.1161/01.STR.0000177891.15082.b9; Zhang LF, 2003, STROKE, V34, P2091, DOI 10.1161/01.STR.0000087149.42294.8C; Zia E, 2009, STROKE, V40, P3567, DOI 10.1161/STROKEAHA.109.556324	51	21	22	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	JUL	2012	3			1	SI		S94	S101		10.1007/s12975-012-0176-7			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	961AT	WOS:000305436500012	23935764	Green Accepted			2021-06-18	
J	Radford, K; Lah, S; Thayer, Z; Say, MJ; Miller, LA				Radford, Kylie; Lah, Suncica; Thayer, Zoe; Say, Miranda J.; Miller, Laurie A.			Improving Memory in Outpatients with Neurological Disorders Using a Group-Based Training Program	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Prospective memory; Rehabilitation; Brain lesions; Stroke; Epilepsy; Neuropsychological outcome	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; EVERYDAY MEMORY; SELF-AWARENESS; STRESS SCALES; ADULTS; EPILEPSY; AIDS; REMEDIATION; RELIABILITY	Memory problems are common in patients with a range of neurological conditions, but there have been few attempts to provide and evaluate the usefulness of memory training for groups of neurological outpatients. We used a waitlist-controlled trial design to assess the effectiveness of a newly created, 6-session intervention, which involved training in the use of compensatory strategies as well as education regarding memory function, neurological damage, sleep and lifestyle factors that have an impact on memory. Fifty-six patients with neurological conditions (e.g., stroke, epilepsy) and memory complaints completed the training and assessments. Outcomes were evaluated in terms of reported strategy use as well as objective and subjective measures of anterograde and prospective memory. Training resulted in significant improvements on number of strategies used, scores on the Rey Auditory Verbal Learning Test (total learning and delayed recall) and self-report on the Comprehensive Assessment of Prospective Memory. Improvements were stable at 3-month follow-up. Better individual outcomes were related to lower baseline memory scores, fewer symptoms of depression and greater self-awareness of memory function. Overall the study provides encouraging results to indicate that patients with neurological conditions such as stroke and epilepsy can show improvements in memory after a relatively short group-based intervention. (JINS, 2012, 18, 738-748)	[Thayer, Zoe; Miller, Laurie A.] Royal Prince Alfred Hosp, Neuropsychol Unit, Camperdown, NSW 2050, Australia; [Radford, Kylie; Lah, Suncica; Miller, Laurie A.] Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia; [Say, Miranda J.] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia	Miller, LA (corresponding author), Royal Prince Alfred Hosp, Neuropsychol Unit, Camperdown, NSW 2050, Australia.	laurie.miller@sydney.edu.au	; Radford, Kylie/D-5338-2011	Lah, Suncica/0000-0003-2282-4812; Thayer, Zoe/0000-0003-3801-9236; Miller, Laurie/0000-0001-6329-2969; Radford, Kylie/0000-0001-8095-5314			Andrewes DG, 1996, EXP AGING RES, V22, P305, DOI 10.1080/03610739608254013; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Craik FIM, 2007, J INT NEUROPSYCH SOC, V13, P132, DOI 10.1017/S1355617707070166; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Evans S., 2004, MINIM ALLOCATION MIN; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Furst C., 1986, COGNITIVE REHABILITA, V4, P24; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; GEFFEN GM, 1994, ARCH CLIN NEUROPSYCH, V9, P303, DOI 10.1016/0887-6177(94)90018-3; Hampstead BM, 2008, J INT NEUROPSYCH SOC, V14, P883, DOI 10.1017/S1355617708081009; Helmstaedter C, 2008, EPILEPSY BEHAV, V12, P402, DOI 10.1016/j.yebeh.2007.11.010; Hildebrandt H, 2006, J NEUROL, V253, P512, DOI 10.1007/s00415-006-0013-6; Howell D.C., 2007, STAT METHODS PSYCHOL, V6th ed.; INTONSPETERSON MJ, 1986, J EXP PSYCHOL GEN, V115, P267, DOI 10.1037/0096-3445.115.3.267; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jennett S M, 1991, Int Disabil Stud, V13, P83; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; MALEC EA, 1991, NEUROPSYCHOLOGY, V5, P29, DOI DOI 10.1037/0894-4105.5.1.29; Mateer C.A., 1988, NEUROPSYCHOLOGICAL S; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Miller L., 2010, MAKING MOST YOUR MEM; Nair RD, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002293.pub2; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; Ownsworth T, 2008, BRAIN INJURY, V22, P858, DOI 10.1080/02699050802446697; Radford K, 2011, EPILEPSY BEHAV, V22, P272, DOI 10.1016/j.yebeh.2011.06.021; Radford KA, 2011, CLIN NEUROPSYCHOL, V25, P127, DOI 10.1080/13854046.2010.529463; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Rey A., 1958, LEXAMEN CLINIQUE PSY; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Tabachnick B., 2001, USING MULTIVARIATE S; Thickpenny-Davis KL, 2007, J HEAD TRAUMA REHAB, V22, P303, DOI 10.1097/01.HTR.0000290975.09496.93; THOMPSON PJ, 1992, EPILEPSIA, V33, pS18; Wilson, 1991, NATL ADULT READING T; Wilson B.A., 1992, CLIN MANAGEMENT MEMO, V2nd; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	52	21	21	1	25	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2012	18	4					738	748		10.1017/S1355617712000379			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	978BN	WOS:000306714600012	22594962				2021-06-18	
J	Xia, L; Jiang, ZL; Wang, GH; Hu, BY; Ke, KF				Xia, Lei; Jiang, Zheng-Lin; Wang, Guo-Hua; Hu, Bao-Yin; Ke, Kai-Fu			Treatment with ginseng total saponins reduces the secondary brain injury in rat after cortical impact	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						ginseng total saponins; traumatic brain injury; oxidative stress; nitrative stress; inflammatory response; neuronal apoptosis	SUPPRESSING OXIDATIVE STRESS; NF-KAPPA-B; PANAX-GINSENG; RED GINSENG; HEAD-INJURY; PC12 CELLS; HIPPOCAMPAL-NEURONS; MOTOR-PERFORMANCE; INDUCED APOPTOSIS; GINSENOSIDES	The present study was designed to investigate the neuroprotective effect of ginseng total saponins (GTSs) and its underlying mechanisms in a rat model of traumatic brain injury (TBI). Rats were injected with GTSs (20 mg/kg, i.p.) or vehicle for 14 days after TBI. Neurological functions were determined using beam balance and prehensile traction tests at 114 days after trauma. Brain samples were extracted at 1 day after trauma for determination of water content, Nissl staining, enzyme-linked immunosorbent assay, immunohistochemistry, terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick end labeling, and measurement of oxidative stress variables and inflammatory cytokines. Moreover, the dose response of the neuroprotective effect and time window of the efficacy of GTSs were also determined. We found that treatment of GTSs 1) improved the neurological function with an effective dosage of 580 mg/kg and an efficacy time window of 36 hr after TBI; 2) reduced brain water content and neuronal loss in the hippocampal CA3 area; 3) increased the activity of superoxide dismutase and decreased the activity of nitric oxide synthase and the amount of malondialdehyde and nitric oxide; 4) down-regulated interleukin-1 beta, interleukin-6, and tumor necrosis factor-a and upregulated interleukin-10 in the cortical area surrounding the injured core; and 5) inhibited the apoptotic cell death and expression of caspase-3 and bax and raised the expression of bcl-2. These findings suggest that administration of GTSs after TBI could reduce the secondary injury through inhibiting oxidative and nitrative stress, attenuating inflammatory response, and reducing apoptotic cell death. (c) 2012 Wiley Periodicals, Inc.	[Xia, Lei; Jiang, Zheng-Lin; Wang, Guo-Hua; Hu, Bao-Yin] Nantong Univ, Dept Neuropharmacol, Inst Naut Med, Nantong 226001, Jiangsu, Peoples R China; [Xia, Lei] Nanjing Med Univ, Dept Neurol, Huaian Peoples Hosp 1, Huaian, Peoples R China; [Ke, Kai-Fu] Nantong Univ, Dept Neurol, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China	Jiang, ZL (corresponding author), Nantong Univ, Dept Neuropharmacol, Inst Naut Med, 19 Qixiu Rd, Nantong 226001, Jiangsu, Peoples R China.	jiangzl@ntu.edu.cn			Administration of Science and Technology of Nantong [S2008011]; Priority Academic Program Development of Jiangsu Higher Education Institutions	Contract grant sponsor: Administration of Science and Technology of Nantong; Contract grant number: S2008011; Contract grant sponsor: Priority Academic Program Development of Jiangsu Higher Education Institutions.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Chen LM, 2008, J ASIAN NAT PROD RES, V10, P439, DOI 10.1080/10286020801892292; Chen XC, 2005, ACTA PHARMACOL SIN, V26, P56, DOI 10.1111/j.1745-7254.2005.00019.x; Chen XC, 2003, EUR J PHARMACOL, V473, P1, DOI 10.1016/S0014-2999(03)01945-9; Cho WCS, 2006, EUR J PHARMACOL, V550, P173, DOI 10.1016/j.ejphar.2006.08.056; Choi K, 2007, NEUROSCI LETT, V421, P37, DOI 10.1016/j.neulet.2007.05.017; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; DEGRABA TJ, 1994, J CEREBR BLOOD F MET, V14, P262, DOI 10.1038/jcbfm.1994.33; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hwang YP, 2010, TOXICOL APPL PHARM, V242, P18, DOI 10.1016/j.taap.2009.09.009; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Ji YC, 2005, J KOREAN MED SCI, V20, P291, DOI 10.3346/jkms.2005.20.2.291; JIANG S, 2003, J APOPLEXY NERVOUS D, V20, P415; Jiang Z.L., 2001, CHIN J APPL PHYSL, V17, P105; Joo SS, 2006, FOOD SCI BIOTECHNOL, V15, P244; Kiefer D, 2003, AM FAM PHYSICIAN, V68, P1539; Kim KR, 2010, BIOL PHARM BULL, V33, P604, DOI 10.1248/bpb.33.604; Kim ND, 2007, PHARMAZIE, V62, P933, DOI 10.1691/ph.2007.12.7533; Li N, 2007, J ETHNOPHARMACOL, V111, P458, DOI 10.1016/j.jep.2006.12.015; Li XY, 2010, CLIN EXP PHARMACOL P, V37, P199, DOI 10.1111/j.1440-1681.2009.05286.x; Liao BS, 2002, EXP NEUROL, V173, P224, DOI 10.1006/exnr.2001.7841; Lim JH, 1997, NEUROSCI RES, V28, P191, DOI 10.1016/S0168-0102(97)00041-2; Lin WM, 2007, J NEURAL TRANSM-SUPP, P105; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Lopez MVN, 2007, BBA-GEN SUBJECTS, V1770, P1308, DOI 10.1016/j.bbagen.2007.06.008; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; Park EK, 2004, INT ARCH ALLERGY IMM, V133, P113, DOI 10.1159/000076383; Park JS, 2009, J NEUROIMMUNOL, V209, P40, DOI 10.1016/j.jneuroim.2009.01.020; Park JK, 2005, LIFE SCI, V76, P1013, DOI 10.1016/j.lfs.2004.10.011; Park J, 2009, AFR J BIOTECHNOL, V8, P3682; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rudakewich M, 2001, PLANTA MED, V67, P533, DOI 10.1055/s-2001-16488; Samukawa K, 2008, BIORHEOLOGY, V45, P689, DOI 10.3233/BIR-2008-0516; Shen LH, 2003, NEUROSCI LETT, V344, P1, DOI 10.1016/S0304-3940(03)00318-5; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Soares HD, 1995, J NEUROSCI, V15, P8223; Tu LH, 2009, CELL MOL NEUROBIOL, V29, P1257, DOI 10.1007/s10571-009-9421-3; Wu CF, 2007, INT IMMUNOPHARMACOL, V7, P313, DOI 10.1016/j.intimp.2006.04.021; Xie JT, 2006, EUR J PHARMACOL, V532, P201, DOI 10.1016/j.ejphar.2006.01.001; Yang Xiao-feng, 2005, Chin J Traumatol, V8, P96; Ye RD, 2008, BIOL PHARM BULL, V31, P1923, DOI 10.1248/bpb.31.1923; Ye RD, 2009, NEUROSCI RES, V64, P306, DOI 10.1016/j.neures.2009.03.016; Yoo YI, 2009, FOOD SCI BIOTECHNOL, V18, P262; Zhang B, 1998, J Stroke Cerebrovasc Dis, V7, P1, DOI 10.1016/S1052-3057(98)80015-3; Zhang YF, 2008, EUR J PHARMACOL, V586, P90, DOI 10.1016/j.ejphar.2007.12.037; Zhao HF, 2009, BRAIN RES, V1256, P111, DOI 10.1016/j.brainres.2008.12.031; 姜正林, 2000, 中华航海医学杂志, V7, P28	57	21	22	1	12	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL	2012	90	7					1424	1436		10.1002/jnr.22811			13	Neurosciences	Neurosciences & Neurology	939YQ	WOS:000303857400013	22434648				2021-06-18	
J	Chao, PK; Lu, KT; Jhu, JY; Wo, YYP; Huang, TC; Ro, LS; Yang, YL				Chao, Po-Kuan; Lu, Kwok-Tung; Jhu, Ji-Yi; Wo, Yu-Yuan Peter; Huang, Tai-Chun; Ro, Long-Sun; Yang, Yi-Ling			Indomethacin protects rats from neuronal damage induced by traumatic brain injury and suppresses hippocampal IL-1 beta release through the inhibition of Nogo-A expression	JOURNAL OF NEUROINFLAMMATION			English	Article						Nogo-A; Traumatic brain injury; Inflammation; IL-1 beta	CLOSED-HEAD INJURY; INTERLEUKIN-1 RECEPTOR ANTAGONIST; MONOCLONAL-ANTIBODY IN-1; SPINAL-CORD-INJURY; ADULT-RAT; INTRACRANIAL-PRESSURE; AXONAL REGENERATION; NERVOUS-SYSTEM; INFLAMMATION; MICE	Background: Nogo-A is a member of the reticulon family of membrane-associated proteins and plays an important role in axonal remodeling. The present study aimed to investigate alterations in Nogo-A expression following traumatic brain injury (TBI)-induced inflammation and neuronal damage. Methods: A weight-drop device was used to deliver a standard traumatic impact to rats. Western blot, RT-PCR and ELISA were used to analyze the expression of Nogo-A and IL-1 beta. Nogo-A antisense, and an irrelevant control oligonucleotide was intracerebroventricularly infused. We also performed H & E staining and luxol fast blue staining to evaluate the neuronal damage and demyelination resulting from TBI and various treatments. Results: Based on RT-PCR and western blot analyses, the expression of Nogo-A was found to be significantly upregulated in the hippocampus beginning eight hours after TBI. In addition, TBI caused an apparent elevation in IL-1 beta levels and severe neuronal damage and demyelination in the tested animals. All of the TBI-associated molecular and cellular consequences could be effectively reversed by treating the animals with the anti-inflammatory drug indomethacin. More importantly, the TBI-associated stimulation in the levels of both Nogo-A and IL-1 beta could be effectively inhibited by a specific Nogo-A antisense oligonucleotide. Conclusions: Our findings suggest that the suppression of Nogo-A expression appears to be an early response conferred by indomethacin, which then leads to decreases in the levels of IL-1 beta and TBI-induced neuron damage.	[Jhu, Ji-Yi; Wo, Yu-Yuan Peter; Yang, Yi-Ling] Natl Chia Yi Univ, Inst Biochem Sci & Technol, Chiayi, Taiwan; [Chao, Po-Kuan; Lu, Kwok-Tung; Huang, Tai-Chun] Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; [Ro, Long-Sun] Chang Gung Mem Hosp, Dept Neurol, Taipei 10591, Taiwan; [Ro, Long-Sun] Chang Gung Univ, Taipei 10591, Taiwan	Yang, YL (corresponding author), Natl Chia Yi Univ, Inst Biochem Sci & Technol, 300 Univ Rd, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw			National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC 97-2320-B-415-006-MY3, 97-2320-B-003-001-MY3, 100-2320-B-003-004]; National Taiwan Normal University	This work was supported by grants NSC 97-2320-B-415-006-MY3 (Y-LY) and 97-2320-B-003-001-MY3 (K-TL), 100-2320-B-003-004 (K-TL) from the National Science Council, Taiwan. The publication fee was supported by National Taiwan Normal University.	Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Butterworth RF, 2011, NEUROCHEM INT, V59, P830, DOI 10.1016/j.neuint.2011.07.014; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cheatwood JL, 2008, STROKE, V39, P2091, DOI 10.1161/STROKEAHA.107.507426; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; David S, 2008, TRENDS NEUROSCI, V31, P221, DOI 10.1016/j.tins.2008.02.002; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hanell A, 2010, J NEUROTRAUM, V27, P1297, DOI 10.1089/neu.2009.1255; Huber AB, 2002, J NEUROSCI, V22, P3553; Hunt D, 2003, MOL CELL NEUROSCI, V24, P1083, DOI 10.1016/j.mcn.2003.09.002; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Kraus JF, 1996, OCCUP MED, V11, P201; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Mackrell PJ, 2001, SURGERY, V130, P826, DOI 10.1067/msy.2001.116669; Marklund N, 2009, NEUROSCIENCE, V163, P540, DOI 10.1016/j.neuroscience.2009.06.042; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Slavik RS, 1999, NEUROL RES, V21, P491; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tian DS, 2009, J NEUROCHEM, V109, P1658, DOI 10.1111/j.1471-4159.2009.06077.x; Tofteng F, 2004, J CEREBR BLOOD F MET, V24, P798, DOI 10.1097/01.WCB.0000125648.03213.1D; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Wang H, 2006, BRAIN RES, V1114, P212, DOI 10.1016/j.brainres.2006.07.056; Yan ZP, 2004, CELL IMMUNOL, V232, P116, DOI 10.1016/j.cellimm.2005.03.001; Yuan RD, 2007, INT J OPHTHALMOL, V7, P354; Z'Graggen WJ, 2000, J NEUROSCI, V20, P6561, DOI 10.1523/JNEUROSCI.20-17-06561.2000; Zagrebelsky M, 2010, J NEUROSCI, V30, P13220, DOI 10.1523/JNEUROSCI.1044-10.2010	49	21	22	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 7	2012	9								121	10.1186/1742-2094-9-121			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	986SM	WOS:000307364900001	22676811	DOAJ Gold, Green Published			2021-06-18	
J	Ahnstedt, H; Stenman, E; Cao, L; Henriksson, M; Edvinsson, L				Ahnstedt, H.; Stenman, E.; Cao, L.; Henriksson, M.; Edvinsson, L.			Cytokines and growth factors modify the upregulation of contractile endothelin ETA and ETB receptors in rat cerebral arteries after organ culture	ACTA PHYSIOLOGICA			English	Article						basic fibroblast growth factor; endothelin receptors; epidermal growth factor; interleukin-1 ss; platelet-derived growth factor; tumour necrosis factor-a	ANEURYSMAL SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN-INJURY; B RECEPTORS; ISCHEMIC-STROKE; MEK/ERK PATHWAY; SMOOTH-MUSCLE; MEDIATED CONTRACTION; MESSENGER-RNA; DOUBLE-BLIND; BLOOD-FLOW	Aim: Experimental cerebral ischaemia and organ culture of cerebral arteries induce an increased endothelin ETB receptormediated contraction. The aim of this study was to examine whether cytokines and growth factors, known to be activated in ischaemia, can influence the expression and function of endothelin receptors after organ culture. Methods: Rat middle cerebral arteries were cultured for 24h at 37 degrees C in humidified 5% CO2 and air in culture medium alone, or with tumour necrosis factor-a (TNF-alpha), interleukin-1 beta (IL-1 beta), platelet-derived growth factor (PDGF), epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF). Concentrationresponse curves were obtained for sarafotoxin 6c (ETB receptor agonist) and endothelin-1 (here ETA receptor agonist, because of ETB receptor desensitization). The receptor mRNA expression was examined by real-time PCR and the protein expression by immunohistochemistry and Western blot. Results: Tumour necrosis factor-a (100ngmL-1) and EGF (20ngmL-1) potentiated the ETB receptormediated contraction (increase in pEC50 without change in Emax). bFGF (10ngmL-1) and IL-1 beta (10ngmL-1) induced an enhanced ETA receptormediated contraction. bFGF (10ngmL-1) significantly increased the ETB mRNA level, and EGF (20ngmL-1) increased the ETA receptor protein. Increased ETB receptor mRNA and protein level also were observed after treatment with IL-1 beta (10ngmL-1). Conclusion: This study shows that TNF-a, IL-1 beta, EGF and bFGF can modify the expression and function of endothelin receptors during organ culture. Because there is similar receptor upregulation in experimental stroke, the effect of cytokines and growth factors on endothelin receptor upregulation is an interesting aspect to study in vivo.	[Ahnstedt, H.; Stenman, E.; Cao, L.; Henriksson, M.; Edvinsson, L.] Lund Univ, Div Expt Vasc Res, Dept Clin Sci, SE-22184 Lund, Sweden	Ahnstedt, H (corresponding author), Lund Univ, Div Expt Vasc Res, Dept Clin Sci, Solvegatan 17,BMC A13, SE-22184 Lund, Sweden.	Hilda.Ahnstedt@med.lu.se		Edvinsson, Lars/0000-0002-1805-1346			Adner M, 1996, BRIT J PHARMACOL, V119, P1159, DOI 10.1111/j.1476-5381.1996.tb16018.x; Ansar S, 2008, STROKE, V39, P185, DOI 10.1161/STROKEAHA.107.487827; Ansar S, 2009, J NEUROSURG, V111, P978, DOI 10.3171/2007.3.16738; Armstead WM, 2011, NEUROL RES, V33, P133, DOI 10.1179/016164111X12881719352174; BARONE FC, 1995, J CARDIOVASC PHARM, V26, pS404; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; Bhardwaj A, 2000, J CEREBR BLOOD F MET, V20, P499, DOI 10.1097/00004647-200003000-00008; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; Chuquet J, 2002, STROKE, V33, P3019, DOI 10.1161/01.STR.0000039401.48915.9F; Crowley RW, 2011, STROKE, V42, P919, DOI 10.1161/STROKEAHA.110.597005; Dai XL, 2006, EXP BIOL MED, V231, P746; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Duan Shu-Rong, 2008, Zhonghua Yi Xue Za Zhi, V88, P3337; Edvinsson LIH, 2011, J CEREBR BLOOD F MET, V31, P1554, DOI 10.1038/jcbfm.2011.70; Etminan N, 2011, J CEREBR BLOOD F MET, V31, P1443, DOI 10.1038/jcbfm.2011.7; Evans NJ, 2008, CAN J PHYSIOL PHARM, V86, P526, DOI 10.1139/Y08-050; Evans NJ, 2008, BIOPHYS J, V95, P483, DOI 10.1529/biophysj.107.119206; Gregan B, 2004, J BIOL CHEM, V279, P27679, DOI 10.1074/jbc.M403601200; Hansen-Schwartz J, 2003, NEUROSURGERY, V52, P1188, DOI 10.1227/01.NEU.0000058467.82442.64; Henriksson M, 2004, BRIT J PHARMACOL, V142, P1155, DOI 10.1038/sj.bjp.0705803; Henriksson M, 2003, STROKE, V34, P1479, DOI 10.1161/01.STR.0000072984.79136.79; HOGESTATT ED, 1983, ACTA PHYSIOL SCAND, V117, P49, DOI 10.1111/j.1748-1716.1983.tb07178.x; Kallakuri S, 2010, NEUROSCIENCE, V168, P820, DOI 10.1016/j.neuroscience.2010.01.018; Kreipke CW, 2011, NEUROL RES, V33, P208, DOI 10.1179/016164111X12881719352570; Lampl Y, 1997, STROKE, V28, P1951, DOI 10.1161/01.STR.28.10.1951; Larsen CC, 2011, J NEUROSURG, V114, P1143, DOI 10.3171/2010.6.JNS1018; Leseth KH, 1999, NEUROREPORT, V10, P2355, DOI 10.1097/00001756-199908020-00025; Lodge NJ, 1995, EUR J PHARMACOL, V287, P279, DOI 10.1016/0014-2999(95)00494-7; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Maddahi A, 2011, J CEREBR BLOOD F MET, V31, P144, DOI 10.1038/jcbfm.2010.62; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; Maddahi A, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-85; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; Patel TR, 1996, J CEREBR BLOOD F MET, V16, P950, DOI 10.1097/00004647-199609000-00019; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001; Renner O, 2003, MOL BRAIN RES, V113, P44, DOI 10.1016/S0169-328X(03)00085-8; Sabri M, 2011, STROKE, V42, P1454, DOI 10.1161/STROKEAHA.110.604728; Sauvageau S, 2006, EXP BIOL MED, V231, P840; Sauvageau S, 2009, PULM PHARMACOL THER, V22, P311, DOI 10.1016/j.pupt.2009.01.006; Stenman E, 2002, STROKE, V33, P2311, DOI 10.1161/01.STR.0000028183.04277.32; Stenman E, 2007, EUR J PHARMACOL, V570, P142, DOI 10.1016/j.ejphar.2007.05.049; Tatlisumak T, 1998, STROKE, V29, P850, DOI 10.1161/01.STR.29.4.850; Thampatty BP, 2011, NEUROCRIT CARE, V15, P19, DOI 10.1007/s12028-011-9508-9; Thorin E, 2010, ADV PHARMACOL, V60, P1, DOI [10.1016/S1054-3589(10)60009-9, 10.1016/B978-0-12-385061-4.00001-5]; Uddman E, 1999, EUR J PHARMACOL, V376, P223, DOI 10.1016/S0014-2999(99)00381-7; UMEMURA K, 1995, EUR J PHARMACOL, V275, P17, DOI 10.1016/0014-2999(94)00725-M; Vatter H, 2007, J NEUROSURG, V107, P121, DOI 10.3171/JNS-07/07/0121; Vatter H, 2007, NEUROSURGERY, V60, P1100, DOI 10.1227/01.NEU.0000255471.75752.4B; Wang J, 2007, CURR TOP MED CHEM, V7, P1364; Watts SW, 2010, AM J PHYSIOL-REG I, V298, pR254, DOI 10.1152/ajpregu.00584.2009; White LR, 2000, EUR J PHARMACOL, V406, P117, DOI 10.1016/S0014-2999(00)00642-7; Xu CB, 2002, BIOCHEM PHARMACOL, V64, P497, DOI 10.1016/S0006-2952(02)01189-9	54	21	22	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-1708	1748-1716		ACTA PHYSIOL	Acta Physiol.	JUN	2012	205	2					266	278		10.1111/j.1748-1716.2011.02392.x			13	Physiology	Physiology	930CU	WOS:000303115100009	22145714				2021-06-18	
J	Prisco, L; Iscra, F; Ganau, M; Berlot, G				Prisco, L.; Iscra, F.; Ganau, M.; Berlot, G.			Early predictive factors on mortality in head injured patients: a retrospective analysis of 112 traumatic brain injured patients	JOURNAL OF NEUROSURGICAL SCIENCES			English	Article						Brain injuries; Hyperglycemia; Hospital mortality	GLASGOW COMA SCALE; HYPERGLYCEMIA; HYPOXIA; PRESSURE; SCORE; AGE	Aim. Early hyperglycemia is a feature of traumatic brain injured (TBI patients. The aim of our study was to analyze the impact of early hyperglycemia on in-ICU mortality in isolated TBI and its correlations with other factors responsible for secondary injury. Methods. We studied admission values (AV) and worse values in the first 48 hours (WV 48 h) of 112 ICU TBI patients (mortality 29.6%) of blood glucose (BG), base excess (BE), mean arterial pressure (MAP), PaO2/FiO(2) ratio and serum hemoglobin (Hb). Predictive strength as the area under the receiver operating curves (AUROC) and correlation between all variables were calculated. Results. Data are expressed as median, 1st-3rd quartile. Both BG AV (147.5, 126-182 mg/dL; AUROC 0.716, P=0.0002) and WV 48 h (156.5, 132-192 mg/dL; AUROC 0.721, P=0.0001) are predictive of mortality. AV and WV 48 h are respectively: PaO2/FiO(2) (366.8, 237.2-477.6 vs. 320,214.4.426; P=0.05), MAP (90,80-100.5 vs. 75,66-83 mmHg; P<0.0001) and Hb (11.4,9.7-13.1 vs. 10.6,9-12.2 g/dL; P<0.02). BG AV and WV 48 h correlates with: age (r=0.419, P<0.0001 and r=0.489, P<0.0001), PaO2/FiO(2) AV (r -0.223, P<0.03 and r -0.236, P<0.02), PaO2/FiO(2) WV 48 h (r -0.215, P<0.03 and r -0.279, P<0.005) and MAP WV 48 h (r -0.216, P<0.03 and r -0.261, P<0.007). Conclusion. Early hyperglycemia is a major predictor of mortality and correlates with other factors responsible for secondary injury. Early hyperglycemia seems to be a marker of inflammatory reaction responsible for early cardiovascular and respiratory impairment.	[Prisco, L.; Iscra, F.; Berlot, G.] Univ Mista, Dept Perioperat Med Intens Care & Emergency, Osped Rimini Trieste, Aziendct Osped,Cattinara Hosp, Trieste, Italy; [Ganau, M.] Univ Trieste, Grad Sch Nanotechnol, Trieste, Italy	Prisco, L (corresponding author), Via San Francesco 12, I-34133 Trieste, Italy.	sisifo31@hotmail.com	Ganau, Mario/AAY-7233-2020; Prisco, Lara/X-9310-2018; Prisco, Lara/I-9267-2019	Ganau, Mario/0000-0002-8676-1147; Prisco, Lara/0000-0001-6727-7870; BERLOT, GIORGIO/0000-0002-9231-8555			Akopian G, 2007, AM SURGEON, V73, P447; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Donnelly M, 2007, J TRAUMA, V63, P351, DOI 10.1097/01.ta.0000251599.80602.d1; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Lee EJ, 2001, J NEUROL SCI, V190, P3, DOI 10.1016/S0022-510X(01)00567-6; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; TOUHO H, 1989, NEUROSURGERY, V25, P762, DOI 10.1227/00006123-198911000-00011; Turina M, 2006, CRIT CARE MED, V34, pS291, DOI 10.1097/01.ccm.0000231887.84751.04; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Vogelzang M, 2006, J TRAUMA, V60, P873, DOI 10.1097/01.ta.0000195715.63978.80; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Winn HR, 2004, YOUMANS NEUROLOGICAL; WRAY NP, 1978, AM REV RESPIR DIS, V118, P783, DOI 10.1164/arrd.1978.118.4.783; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	28	21	23	0	2	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0390-5616	1827-1855		J NEUROSURG SCI	J. Neurosurg. Sci.	JUN	2012	56	2					131	136					6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	970SO	WOS:000306152800006	22617175				2021-06-18	
J	Schober, ME; Block, B; Requena, DF; Hale, MA; Lane, RH				Schober, Michelle Elena; Block, Benjamin; Requena, Daniela F.; Hale, Merica A.; Lane, Robert H.			Developmental traumatic brain injury decreased brain derived neurotrophic factor expression late after injury	METABOLIC BRAIN DISEASE			English	Article						Anesthesia; Controlled cortical impact; Brain derived neurotrophic factor; Developmental; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; DEVELOPING RAT-BRAIN; GENE-EXPRESSION; MATERNAL-DEPRIVATION; HIPPOCAMPAL-NEURONS; SYNAPTIC PLASTICITY; SPATIAL MEMORY; BDNF; DEATH; PERFORMANCE	Pediatric traumatic brain injury (TBI) is a major cause of acquired cognitive dysfunction in children. Hippocampal Brain Derived Neurotrophic Factor (BDNF) is important for normal cognition. Little is known about the effects of TBI on BDNF levels in the developing hippocampus. We used controlled cortical impact (CCI) in the 17 day old rat pup to test the hypothesis that CCI would first increase rat hippocampal BDNF mRNA/protein levels relative to SHAM and Na < ve rats by post injury day (PID) 2 and then decrease BDNF mRNA/protein by PID14. Relative to SHAM, CCI did not change BDNF mRNA/protein levels in the injured hippocampus in the first 2 days after injury but did decrease BDNF protein at PID14. Surprisingly, BDNF mRNA decreased at PID 1, 3, 7 and 14, and BDNF protein decreased at PID 2, in SHAM and CCI hippocampi relative to Na < ve. In conclusion, TBI decreased BDNF protein in the injured rat pup hippocampus 14 days after injury. BDNF mRNA levels decreased in both CCI and SHAM hippocampi relative to Na < ve, suggesting that certain aspects of the experimental paradigm (such as craniotomy, anesthesia, and/or maternal separation) may decrease the expression of BDNF in the developing hippocampus. While BDNF is important for normal cognition, no inferences can be made regarding the cognitive impact of any of these factors. Such findings, however, suggest that meticulous attention to the experimental paradigm, and possible inclusion of a Na < ve group, is warranted in studies of BDNF expression in the developing brain after TBI.	[Schober, Michelle Elena; Block, Benjamin; Requena, Daniela F.; Hale, Merica A.; Lane, Robert H.] Univ Utah, Salt Lake City, UT 84112 USA	Schober, ME (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.	michelle.schober@hsc.utah.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD001410] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER		Aid T, 2007, J NEUROSCI RES, V85, P525, DOI 10.1002/jnr.21139; Aisa B, 2009, HIPPOCAMPUS, V19, P1222, DOI 10.1002/hipo.20586; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cook JL, 1998, BRAIN RES PROTOC, V3, P1, DOI 10.1016/S1385-299X(98)00012-9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Hamatake M, 2011, J BIOL CHEM, V286, P21478, DOI 10.1074/jbc.M110.195859; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Kikusui T, 2009, PSYCHONEUROENDOCRINO, V34, P762, DOI 10.1016/j.psyneuen.2008.12.009; Kim JK, 2007, NEUROSCIENCE, V146, P1128, DOI 10.1016/j.neuroscience.2007.02.017; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lessmann V, 1998, GEN PHARMACOL-VASC S, V31, P667; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Liu D, 2000, NAT NEUROSCI, V3, P799; Liu Y, 2001, DEV BRAIN RES, V127, P51, DOI 10.1016/S0165-3806(01)00111-0; Lu LX, 2006, APOPTOSIS, V11, P1603, DOI 10.1007/s10495-006-8762-3; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Ming Z, 2001, BRAIN RES, V920, P117, DOI 10.1016/S0006-8993(01)03044-X; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Roceri M, 2002, MOL PSYCHIATR, V7, P609, DOI 10.1038/sj.mp.4001036; Schober ME, 2010, J NEUROTRAUMA; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stansberg C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-94; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	38	21	27	0	15	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	JUN	2012	27	2					167	173		10.1007/s11011-012-9309-7			7	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	940BO	WOS:000303865200008	22527999	Green Accepted			2021-06-18	
J	Ziu, M; Savage, JG; Jimenez, DF				Ziu, Mateo; Savage, Jennifer Gentry; Jimenez, David F.			Diagnosis and treatment of cerebrospinal fluid rhinorrhea following accidental traumatic anterior skull base fractures	NEUROSURGICAL FOCUS			English	Article						craniomaxillofacial trauma; head trauma; cerebrospinal fluid rhinorrhea; meningitis; dural repair; endoscopic surgery; skull base fracture	BETA-TRACE-PROTEIN; TRANSNASAL ENDOSCOPIC REPAIR; MAGNETIC-RESONANCE CISTERNOGRAPHY; PROSTAGLANDIN-D SYNTHASE; ANTIBIOTIC-PROPHYLAXIS; MR CISTERNOGRAPHY; GADOPENTETATE DIMEGLUMINE; INTRATHECAL FLUORESCEIN; BACTERIAL-MENINGITIS; CSF RHINORRHEA	Cerebrospinal fluid rhinorrhea is a serious and potentially fatal condition because of an increased risk of meningitis and brain abscess. Approximately 80% of all cases occur in patients with head injuries and craniofacial fractures. Despite technical advances in the diagnosis and management of CSF rhinorrhea caused by craniofacial injury through the introduction of MRI and endoscopic extracranial surgical approaches, difficulties remain. The authors review here the pathophysiology, diagnosis, and management of CSF rhinorrhea relevant exclusively to traumatic anterior skull base injuries and attempt to identify areas in which further work is needed. (http://thejns.org/doi/abs/10.3171/2012.4.FOCUS1244)	[Ziu, Mateo; Savage, Jennifer Gentry; Jimenez, David F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA	Ziu, M (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, 7703 Floyd Curl Dr,MC 7843, San Antonio, TX 78229 USA.	ziu@uthscsa.edu	Ziu, Mateo/AAR-4991-2020	Ziu, Mateo/0000-0002-3671-2638			Anand Vijay K., 1995, Rhinology (Utrecht), V33, P212; [Anonymous], 2001, J TRAUMA, V51, pS29; [Anonymous], 1942, Proc R Soc Med, V35, P805; Araujo Filho Bernardo Cunha, 2005, Braz J Otorhinolaryngol, V71, P472; Arrer E, 2002, CLIN CHEM, V48, P939; Aydin K, 2004, NEURORADIOLOGY, V46, P75, DOI 10.1007/s00234-003-1004-2; Aydin K, 2008, NEUROSURGERY, V62, P584, DOI 10.1227/01.neu.0000317306.39203.24; Bachmann G, 2002, NEUROSURGERY, V50, P571, DOI 10.1097/00006123-200203000-00027; Bachmann G, 2000, ANN OTO RHINOL LARYN, V109, P1099, DOI 10.1177/000348940010901202; Banks CA, 2009, OTOLARYNG HEAD NECK, V140, P826, DOI 10.1016/j.otohns.2008.12.060; Bell RB, 2004, J ORAL MAXIL SURG, V62, P676, DOI 10.1016/j.joms.2003.08.032; Bernal-Sprekelsen M, 2005, RHINOLOGY, V43, P277; Bhalodiya NH, 2009, INDIAN J OTOLARYNGOL, V61, P120, DOI 10.1007/s12070-009-0049-x; Bibas AG, 2000, BRIT J NEUROSURG, V14, P49; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Briggs RJS, 2004, J CLIN NEUROSCI, V11, P597, DOI 10.1016/j.jocn.2003.09.011; Brodie HA, 1997, AM J OTOL, V18, P188; BROWN EM, 1994, LANCET, V344, P1547; BULLOCK R, 1990, BRIT MED J, V300, P1576, DOI 10.1136/bmj.300.6739.1576; Burns JA, 1996, LARYNGOSCOPE, V106, P1080, DOI 10.1097/00005537-199609000-00007; Cairns H., 1937, J LARYNG, V52, P589, DOI 10.1017/S0022215100043991; Campbell EH, 1928, ANN OTO RHINOL LARYN, V37, P865; Casiano RR, 1999, OTOLARYNG HEAD NECK, V121, P745, DOI 10.1053/hn.1999.v121.a98754; Cassano M, 2009, RHINOLOGY, V47, P362, DOI 10.4193/Rhin08.175; Castelnuovo P, 2001, AM J RHINOL, V15, P333, DOI 10.1177/194589240101500509; Castillo L., 1999, Rhinology (Utrecht), V37, P33; Chin GY, 2003, LARYNGOSCOPE, V113, P136, DOI 10.1097/00005537-200301000-00025; Choi D, 1996, BRIT J NEUROSURG, V10, P571, DOI 10.1080/02688699646880; Cukurova I, 2008, ACTA NEUROCHIR, V150, P897, DOI 10.1007/s00701-008-0005-7; Dagi FT, 2006, SCHMIDEK SWEET OPERA, V1, P130; Dalgic A, 2007, J NEUROL SCI, V24, P280; Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001; Dandy WE, 1944, ARCH SURG-CHICAGO, V49, P75, DOI 10.1001/archsurg.1944.01230020080001; Darakchiev Borimir J, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P404, DOI 10.1097/01.moo.0000134442.22229.2c; DICHIRO G, 1985, RADIOLOGY, V157, P373, DOI 10.1148/radiology.157.2.4048444; DODSON EE, 1994, OTOLARYNG HEAD NECK, V111, P600, DOI 10.1016/S0194-5998(94)70527-5; DOHLMAN G, 1948, Acta Otolaryngol Suppl, V67, P20; Eftekhar B, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-2; El Gammal T, 1998, AM J NEURORADIOL, V19, P627; ELGAMMAL T, 1994, AM J NEURORADIOL, V15, P1647; ELJAMEL M S, 1990, British Journal of Neurosurgery, V4, P381, DOI 10.3109/02688699008992759; ELJAMEL M S M, 1990, British Journal of Neurosurgery, V4, P479, DOI 10.3109/02688699008993796; Eljamel MS, 1998, SURG NEUROL, V50, P387; ELJAMEL MS, 1994, BRIT J NEUROSURG, V8, P433, DOI 10.3109/02688699408995111; ELJAMEL MS, 1993, BRIT J NEUROSURG, V7, P501, DOI 10.3109/02688699308995072; FELGENHAUER K, 1987, KLIN WOCHENSCHR, V65, P764, DOI 10.1007/BF01743251; Friedman JA, 2001, WORLD J SURG, V25, P1062, DOI 10.1007/s00268-001-0059-7; Gendeh BS, 2005, J LARYNGOL OTOL, V119, P866, DOI 10.1258/002221505774783421; Goel G, 2007, J NEUROTRAUM, V24, P1570, DOI 10.1089/neu.2007.0326; Greig JR, 2002, BRIT MED J, V325, P1037; HAND WL, 1970, ANN INTERN MED, V73, P862, DOI 10.7326/0003-4819-73-5-862; Hao SP, 1996, LARYNGOSCOPE, V106, P501; HEALY CE, 1969, CLIN PEDIATR, V8, P239, DOI 10.1177/000992286900800413; Hegazy HM, 2000, LARYNGOSCOPE, V110, P1166, DOI 10.1097/00005537-200007000-00019; HIRSCH O, 1952, AMA ARCH OTOLARYNGOL, V56, P1; Hughes RGM, 1997, J LARYNGOL OTOL, V111, P125, DOI 10.1017/S0022215100136643; Husain M, 2003, SKULL BASE-INTERD AP, V13, P73; Keerl R, 2004, LARYNGOSCOPE, V114, P266, DOI 10.1097/00005537-200402000-00016; Kerr JT, 2005, OTOLARYNG CLIN N AM, V38, P597, DOI 10.1016/j.otc.2005.03.011; KIRSCH AP, 1967, J PEDIATR-US, V71, P718, DOI 10.1016/S0022-3476(67)80210-5; Kirtane MV, 2005, OTOLARYNG HEAD NECK, V132, P208, DOI 10.1016/j.otohns.2004.09.004; Klotch D W, 1998, J Craniomaxillofac Trauma, V4, P30; KOSOY J, 1972, ARCHIV OTOLARYNGOL, V95, P255; Landeiro JA, 2004, MINIM INVAS NEUROSUR, V47, P173, DOI 10.1055/s-2004-818451; Lanza DC, 1996, LARYNGOSCOPE, V106, P1119, DOI 10.1097/00005537-199609000-00015; LAUN A, 1982, ACTA NEUROCHIR, V60, P215, DOI 10.1007/BF01406308; Lee TJ, 2004, LARYNGOSCOPE, V114, P1475, DOI 10.1097/00005537-200408000-00029; LEECH PJ, 1973, LANCET, V1, P1013; Lewin W, 1964, Clin Neurosurg, V12, P237; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; Lindstrom DR, 2004, LARYNGOSCOPE, V114, P969, DOI 10.1097/00005537-200406000-00003; Locatelli D, 2006, NEUROSURGERY, V58, P246, DOI 10.1227/01.NEU.0000193924.65297.3F; Luckett WH, 1913, SURG GYNECOL OBSTET, V17, P237; Lund VJ, 2002, AM J RHINOL, V16, P17, DOI 10.1177/194589240201600104; Lund VJ, 2000, J LARYNGOL OTOL, V114, P988; Madhusudan G, 2006, PLAST RECONSTR SURG, V117, P2382, DOI 10.1097/01.prs.0000218794.28670.07; Mao VH, 2000, OTOLARYNG HEAD NECK, V122, P56, DOI 10.1016/S0194-5998(00)70144-6; Marks SC, 1998, AM J RHINOL, V12, P417, DOI 10.2500/105065898780707900; Marshall AH, 2001, BRIT J NEUROSURG, V15, P8; Martin Timothy J, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P35, DOI 10.1097/MOO.0b013e3280123fce; MATTOX DE, 1990, LARYNGOSCOPE, V100, P857; McMains KC, 2004, LARYNGOSCOPE, V114, P1833, DOI 10.1097/00005537-200410000-00029; Meco C, 2004, LARYNGOSCOPE, V114, P991, DOI 10.1097/00005537-200406000-00007; Meco C, 2003, OTOLARYNG HEAD NECK, V129, P508, DOI 10.1016/S0194-5998(03)01448-7; Meco C, 2007, AM J RHINOL, V21, P729, DOI 10.2500/ajr.2007.21.3105; Melegos DN, 1996, CLIN CHEM, V42, P1984; MEURMAN OH, 1979, ACTA OTO-LARYNGOL, V87, P366, DOI 10.3109/00016487909126434; MINCY JE, 1966, J TRAUM, V6, P618, DOI 10.1097/00005373-196609000-00007; MOSELEY JI, 1978, J NEUROSURG, V48, P765, DOI 10.3171/jns.1978.48.5.0765; Nachtigal D, 1999, J OTOLARYNGOL, V28, P129; OMMAYA AK, 1964, NEUROLOGY, V14, P106, DOI 10.1212/WNL.14.2.106; PAPPAS DG, 1993, CLIN INFECT DIS, V17, P364, DOI 10.1093/clinids/17.3.364; Presutti L, 2009, ACTA OTORHINOLARYNGO, V29, P191; PRICE DJE, 1970, LANCET, V2, P1213; Ratilal B, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004884.pub2; Ray DE, 1998, AM J NEURORADIOL, V19, P1455; Ray DE, 1996, AM J NEURORADIOL, V17, P365; Reiber H, 2003, ACTA NEUROL SCAND, V108, P359, DOI 10.1034/j.1600-0404.2003.00173.x; Rocchi G, 2005, SURG NEUROL, V63, P559, DOI 10.1016/j.surneu.2004.07.047; Sakas DE, 1998, J NEUROSURG, V88, P471, DOI 10.3171/jns.1998.88.3.0471; Schick B, 1997, SKULL BASE SURG, V7, P77, DOI 10.1055/s-2008-1058612; Schlosser RJ, 2004, LARYNGOSCOPE, V114, P255, DOI 10.1097/00005537-200402000-00015; Schnabel C, 2004, CLIN CHEM, V50, P661, DOI 10.1373/clinchem.2003.024158; Scholsem M, 2008, NEUROSURGERY, V62, P463, DOI [10.1227/01.NEU.0000297037.51609.07, 10.1227/01.neu.0000316014.97926.82, 10.1227/01.neu.0000325884.05871.aa]; Schroeder MC, 1944, ARCH OTOLARYNGOL, V40, P206; Senior BA, 2001, AM J RHINOL, V15, P15, DOI 10.2500/105065801781329428; Sethi D. S., 1996, Annals Academy of Medicine Singapore, V25, P724; Silva LRF, 2006, MINIM INVAS NEUROSUR, V49, P88, DOI 10.1055/s-2006-932188; Tali ET, 2002, INVEST RADIOL, V37, P152; TOS M, 1973, ACTA OTO-LARYNGOL, V75, P353, DOI 10.3109/00016487309139745; Tosun F, 2005, MINIM INVAS NEUROSUR, V48, P355, DOI 10.1055/s-2005-915636; Tumani H, 1998, ANN NEUROL, V44, P882, DOI 10.1002/ana.410440606; Tumani H, 1998, NEUROSCI LETT, V242, P5, DOI 10.1016/S0304-3940(98)00021-4; VRABEC DP, 1964, ARCHIV OTOLARYNGOL, V80, P218, DOI 10.1001/archotol.80.2.218; Warnecke A, 2004, ARCH OTOLARYNGOL, V130, P1178, DOI 10.1001/archotol.130.10.1178; WIGAND M E, 1981, Rhinology (Utrecht), V19, P7; Wolf G, 1997, LARYNGO RHINO OTOL, V76, P588; Yilmazlar S, 2006, NEUROSURG REV, V29, P64, DOI 10.1007/s10143-005-0396-3; Zapalac JS, 2002, OTOLARYNG HEAD NECK, V126, P669, DOI 10.1067/mhn.2002.125755; Zeng QY, 1999, AM J ROENTGENOL, V173, P1109, DOI 10.2214/ajr.173.4.10511188; Zweig JL, 2000, OTOLARYNG HEAD NECK, V123, P195, DOI 10.1067/mhn.2000.107452	122	21	23	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2012	32	6							E3	10.3171/2012.4.FOCUS1244			17	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	954DQ	WOS:000304927100005	22655692				2021-06-18	
J	Bir, C; VandeVord, P; Shen, YM; Raza, W; Haacke, EM				Bir, Cynthia; VandeVord, Pamela; Shen, Yimin; Raza, Waqar; Haacke, E. Mark			Effects of variable blast pressures on blood flow and oxygen saturation in rat brain as evidenced using MRI	MAGNETIC RESONANCE IMAGING			English	Article						MRI; Blast; Neurotrauma; Rat model	INJURY	It has been recognized that primary blast waves may result in neurotrauma in soldiers in theater. A new type of contrast used in magnetic resonance imaging (MRI), susceptibility-weighted imaging (SWI), has been developed that is based on the different susceptibility levels in diverse tissues and can detect decreases in cerebral blood flow (CBF) using inferred oxygen saturation changes in tissue. In addition, a continuous arterial spin-labeled (ASL) MRI sequence was used as a direct measure of regional CBF within the brain tissue. Animals were subjected to whole-body blast exposures of various overpressures within a gas-driven shock tube. When exposed to low levels of overpressure, most rats demonstrated no obvious changes between pre- and postexposure in the conventional MR images. CBF changes measured by SWI and ASL were significantly higher for the overpressure exposed groups as compared to the sham group and tended to increase with pressure increases at the highest two pressures. In the hippocampus, all blast animals had a reduction in the CBF consistently in the range of 0-27%. In summary, low levels of primary blast pressure exposure demonstrated a significant physiologic effect to the brain up to 72 h postexposure. (C) 2012 Elsevier Inc. All rights reserved.	[Bir, Cynthia; VandeVord, Pamela; Haacke, E. Mark] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [VandeVord, Pamela] Wayne State Univ, Res & Dev Serv, John D Dingell VA Med Ctr, Detroit, MI 48201 USA; [Shen, Yimin; Raza, Waqar; Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA	Bir, C (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA.	cbir@wayne.edu		Bir, Cynthia/0000-0002-0777-0951	United States Office of Naval ResearchOffice of Naval Research [N000140810585]	This research was supported by the United States Office of Naval Research Award Number N000140810585.	Avila MA, 2008, J CEREBR BLOOD F MET, V28, P1733, DOI 10.1038/jcbfm.2008.66; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Haacke EM, 2007, MAGN RESON MED, V58, P463, DOI 10.1002/mrm.21358; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wycliffe ND, 2004, J MAGN RESON IMAGING, V20, P372, DOI 10.1002/jmri.20130; Zoroya G, 2005, US TODAY	16	21	21	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X			MAGN RESON IMAGING	Magn. Reson. Imaging	MAY	2012	30	4					527	534		10.1016/j.mri.2011.12.003			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	929ST	WOS:000303086700007	22285875				2021-06-18	
J	Le, K; Coelho, C; Mozeiko, J; Krueger, F; Grafman, J				Le, Karen; Coelho, Carl; Mozeiko, Jennifer; Krueger, Frank; Grafman, Jordan			Predicting Story Goodness Performance From Cognitive Measures Following Traumatic Brain Injury	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						discourse analysis; cognition; brain injury; narratives; executive function	CLOSED-HEAD-INJURY; WORKING-MEMORY; DISCOURSE; CHILDREN; ADULTS; REPRESENTATIONS; INFORMATION; NARRATIVES; ABILITIES; LANGUAGE	Purpose: This study examined the prediction of performance on measures of the Story Goodness Index (SGI; Le, Coelho, Mozeiko, & Grafman, 2011) from executive function (EF) and memory measures following traumatic brain injury (TBI). It was hypothesized that EF and memory measures would significantly predict SGI outcomes. Method: One hundred sixty-seven individuals with TBI participated in the study. Story retellings were analyzed using the SGI protocol. Three cognitive measures-Delis-Kaplan Executive Function System (D-KEFS; Delis, Kaplan, & Kramer, 2001) Sorting Test, Wechsler Memory Scale-Third Edition (WMS-III; Wechsler, 1997) Working Memory Primary Index (WMI), and WMS-III Immediate Memory Primary Index (IMI)-were entered into a multiple linear regression model for each discourse measure. Two sets of regression analyses were performed, the first with the Sorting Test as the first predictor and the second with it as the last. Results: The first set of regression analyses identified the Sorting Test and IMI as the only significant predictors of performance on measures of the SGI. The second set identified all measures as significant predictors when evaluating each step of the regression function. Conclusion: The cognitive variables predicted performance on the SGI measures, although there were differences in the amount of explained variance. The results (a) suggest that storytelling ability draws on a number of underlying skills and (b) underscore the importance of using discrete cognitive tasks rather than broad cognitive indices to investigate the cognitive substrates of discourse.	[Grafman, Jordan] Kessler Fdn Res Ctr, W Orange, NJ USA; [Krueger, Frank] George Mason Univ, Fairfax, VA 22030 USA; [Le, Karen; Coelho, Carl; Mozeiko, Jennifer] Univ Connecticut, Storrs, CT USA	Grafman, J (corresponding author), Kessler Fdn Res Ctr, W Orange, NJ USA.	jgrafman@kesslerfoundation.org					Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Baddeley A. D., 1986, WORKING MEMORY; Barrett J., 1998, OLD MCDONALD HAD APA; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Cherney L.R., 1998, ANAL DISCOURSE COMMU; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2003, APHASIOLOGY, V17, P499, DOI 10.1080/02687030344000111; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Cohen N.J., 2001, CONDITIONING CONSCIO; COWAN N, 1988, PSYCHOL BULL, V104, P163, DOI 10.1037/0033-2909.104.2.163; Cowan N, 2010, DEV NEUROPSYCHOL, V35, P447, DOI 10.1080/87565641.2010.494985; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Dimitrov M, 1999, NEUROPSYCHOLOGY, V13, P135, DOI 10.1037/0894-4105.13.1.135; Duff MC, 2008, APHASIOLOGY, V22, P866, DOI 10.1080/02687030701844196; Edgin JO, 2010, J INTELL DISABIL RES, V54, P406, DOI 10.1111/j.1365-2788.2010.01278.x; Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028; FREDERIKSEN CH, 1975, COGNITIVE PSYCHOL, V7, P371, DOI 10.1016/0010-0285(75)90016-X; Gernsbacher MA, 1995, MODELS TEXT UNDERSTA, P289; Gernsbacher Morton Ann, 1999, Discourse Stud, V1, P355, DOI 10.1177/1461445699001003004; GERNSBACHER Morton Ann, 1990, LANGUAGE COMPREHENSI; Grafman J., 1987, NEUROBEHAVIORAL RECO, P43; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Hay E, 2005, AM J SPEECH-LANG PAT, V14, P324, DOI 10.1044/1058-0360(2005/031); Healon R. K, 1993, WISCONSIN CARD SORTI; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Hunt K. W, 1965, 3 NCTE; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Jorgensen M, 2009, BRAIN INJURY, V23, P727, DOI 10.1080/02699050903133954; Kaplan E., 1983, BOSTON NAMING TEST; Kennedy Mary R. T, 2005, Seminars in Speech and Language, V26, P242, DOI 10.1055/s-2005-922103; Kurczek J, 2011, APHASIOLOGY, V25, P700, DOI 10.1080/02687038.2010.537345; Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; Le K, 2011, J SPEECH LANG HEAR R, V54, P118, DOI 10.1044/1092-4388(2010/09-0022); MANDLER JM, 1977, COGNITIVE PSYCHOL, V9, P111, DOI 10.1016/0010-0285(77)90006-8; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; Moran C. A, 2010, EXPOSITORY DISCOURSE, P275; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; Oberauer K, 2002, J EXP PSYCHOL LEARN, V28, P411, DOI 10.1037//0278-7393.28.3.411; Oberauer K, 2005, HDB UNDERSTANDING ME, P393, DOI [DOI 10.4135/9781452233529.N22, 10.4135/9781452233529.n22]; Pickens S, 2010, INT J EVID-BASED HEA, V8, P110, DOI 10.1111/j.1744-1609.2010.00170.x; PLAG JA, 1967, PERS PSYCHOL, V20, P323, DOI 10.1111/j.1744-6570.1967.tb01527.x; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; Stein N., 1979, NEW DIRECTIONS DISCO; Tulving Endel, 1995, P839; U. S. Department of Defense, 1984, TEST MAN ARM SERV VO; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vietnam Head Injury Study-Phase III, 2011, VIETNAM HEAD INJURY; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wilhelm K L, 1995, Appl Neuropsychol, V2, P42, DOI 10.1207/s15324826an0201_8; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	57	21	21	0	7	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY 1	2012	21	2					S115	S125		10.1044/1058-0360(2012/11-0114)			11	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	019SZ	WOS:000309760900008	22294408				2021-06-18	
J	Amyot, F; Zimmermann, T; Riley, J; Kainerstorfer, JM; Chernomordik, V; Mooshagian, E; Najafizadeh, L; Krueger, F; Gandjbakhche, AH; Wassermann, EM				Amyot, Franck; Zimmermann, Trelawny; Riley, Jason; Kainerstorfer, Jana M.; Chernomordik, Victor; Mooshagian, Eric; Najafizadeh, Laleh; Krueger, Frank; Gandjbakhche, Amir H.; Wassermann, Eric M.			Normative database of judgment of complexity task with functional near infrared spectroscopy-Application for TBI	NEUROIMAGE			English	Article						Near infrared spectroscopy; Frameless stereotaxy; Frontal cortex; Group study	TRAUMATIC BRAIN-INJURY; VIETNAM HEAD-INJURY; ACTIVATION; TECHNOLOGY; LOCATIONS	The ability to assess frontal lobe function in a rapid, objective, and standardized way, without the need for expertise in cognitive test administration might be particularly helpful in mild traumatic brain injury (TBI), where objective measures are needed. Functional near infrared spectroscopy (fNIRS) is a reliable technique to noninvasively measure local hemodynamic changes in brain areas near the head surface. In this paper, we are combining fNIRS and frameless stereotaxy which allowed us to co-register the functional images with previously acquired anatomical MRI volumes. In our experiment, the subjects were asked to perform a task, evaluating the complexity of daily life activities, previously shown with fMRI to activate areas of the anterior frontal cortex. We reconstructed averaged oxyhemoglobin and deoxyhemoglobin data from 20 healthy subjects in a spherical coordinate. The spherical coordinate is a natural representation of surface brain activation projection. Our results show surface activation projected from the medial frontopolar cortex which is consistent with previous fMRI results. With this original technique, we will construct a normative database for a simple cognitive test which can be useful in evaluating cognitive disability such as mild traumatic brain injury. Published by Elsevier Inc.	[Amyot, Franck; Riley, Jason; Kainerstorfer, Jana M.; Chernomordik, Victor; Najafizadeh, Laleh; Gandjbakhche, Amir H.] Eunice Kennedy Shriver NICHD, NIH, Program Pediat Imaging & Tissue Sci, Sect Analyt & Funct Biophoton, Bethesda, MD 20892 USA; [Amyot, Franck; Mooshagian, Eric; Najafizadeh, Laleh] Henry M Jackson Fdn, Rockville, MD 20852 USA; [Amyot, Franck; Zimmermann, Trelawny; Mooshagian, Eric; Wassermann, Eric M.] Natl Inst Neurol Disorders & Stroke, Behav Neurol Unit, NIH, Bethesda, MD USA; [Krueger, Frank] George Mason Univ, Krasnow Inst Adv Study, Fairfax, VA 22030 USA	Gandjbakhche, AH (corresponding author), Eunice Kennedy Shriver NICHD, NIH, Program Pediat Imaging & Tissue Sci, Sect Analyt & Funct Biophoton, Bethesda, MD 20892 USA.	amir@helix.nih.gov	Wassermann, Eric M./AAC-9064-2020	Wassermann, Eric M./0000-0003-0628-0210; Mooshagian, Eric/0000-0001-5998-8445	Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [ZIAHD008882, ZIAHD000261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002977] Funding Source: NIH RePORTER	We thank Dr. Jordan Grafman for his valuable suggestions and comments on this project. We also acknowledge the funding of the intramural program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Neurological Disorders and Stroke and Center for Neuroscience and Regenerative Medicine.	Ayaz Hasan, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2671; Benaron DA, 2000, J CEREBR BLOOD F MET, V20, P469, DOI 10.1097/00004647-200003000-00005; Boas DA, 2004, OPT LETT, V29, P1506, DOI 10.1364/OL.29.001506; Boas DA, 2003, PHYS MED BIOL, V48, P2405, DOI 10.1088/0031-9155/48/15/311; Cui X, 2011, NEUROIMAGE, V54, P2808, DOI 10.1016/j.neuroimage.2010.10.069; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; Ferrari M, 2004, CAN J APPL PHYSIOL, V29, P463, DOI 10.1139/h04-031; Fonov V, 2011, NEUROIMAGE, V54, P313, DOI 10.1016/j.neuroimage.2010.07.033; Hanna-Pladdy B, 2007, J Neurol Phys Ther, V31, P119; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Izzetoglu M, 2007, IEEE ENG MED BIOL, V26, P38, DOI 10.1109/MEMB.2007.384094; Kleinschmidt A, 1996, J CEREBR BLOOD F MET, V16, P817, DOI 10.1097/00004647-199609000-00006; Krueger F, 2009, NEUROREPORT, V20, P1093, DOI 10.1097/WNR.0b013e32832e7ea5; Laatsch Linda, 2007, Phys Med Rehabil Clin N Am, V18, P69, DOI 10.1016/j.pmr.2006.11.004; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Okamoto M, 2005, NEUROIMAGE, V26, P18, DOI 10.1016/j.neuroimage.2005.01.018; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; Okamoto M, 2009, CLIN NEUROPHYSIOL, V120, P1320, DOI 10.1016/j.clinph.2009.01.023; Ptito A, 2007, NEUROREHABILITATION, V22, P217; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Sparing R, 2008, HUM BRAIN MAPP, V29, P82, DOI 10.1002/hbm.20360; Villringer A, 1997, TRENDS NEUROSCI, V20, P435, DOI 10.1016/S0166-2236(97)01132-6; Whalen C, 2008, HUM BRAIN MAPP, V29, P1288, DOI 10.1002/hbm.20465; Wishart Heather A, 2002, Curr Psychiatry Rep, V4, P338, DOI 10.1007/s11920-002-0081-y; Wylie GR, 2009, NEUROIMAGE, V47, P473, DOI 10.1016/j.neuroimage.2009.04.056	29	21	21	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 2	2012	60	2					879	883		10.1016/j.neuroimage.2012.01.104			5	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	932ED	WOS:000303272300005	22306800	Green Accepted			2021-06-18	
J	Zhao, TF; Qi, YY; Li, Y; Xu, K				Zhao, Tengfei; Qi, Yiying; Li, Yan; Xu, Kan			PI3 Kinase regulation of neural regeneration and muscle hypertrophy after spinal cord injury	MOLECULAR BIOLOGY REPORTS			English	Article						PI3 Kinase pathway; Axon regeneration; Muscle atrophy; Spinal cord injury	TUBEROUS SCLEROSIS GENE; SKELETAL-MUSCLE; SIGNALING PATHWAY; CELL-GROWTH; AXON GROWTH; TRANSLATION INITIATION; MYOTUBE HYPERTROPHY; NEURONAL POLARITY; PROTEIN-SYNTHESIS; RAPAMYCIN TOR	Spinal cord injury (SCI) is a serious neurotrauma that can lead to life-long disability; to date, no suitable therapeutic strategy exists. Axons do not regenerate after SCI in adult mammals and loss of skeletal muscle mass occurs very rapidly after SCI. Promotion of neurite growth through improving the extracellular environment allows only a limited degree of axon regeneration. The phosphatidylinositol-3 kinase (PI3K)/Akt pathway and its downstream targets ("mammalian target of rapamycin," mTOR, and glycogen synthase kinase-3), which regulate cell growth and proliferation in many tissues, have been suggested to play an important role in regulation of the intrinsic axonal regeneration and muscle hypertrophy. This review is focused on recent progress in our understanding of the PI3K pathway in the modulation of axonal regeneration and muscle hypertrophy after SCI.	[Zhao, Tengfei; Qi, Yiying; Li, Yan; Xu, Kan] Zhejiang Univ, Dept Orthoped Surg, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China	Xu, K (corresponding author), Zhejiang Univ, Dept Orthoped Surg, Affiliated Hosp 2, Sch Med, Jiefang Rd 88, Hangzhou 310009, Zhejiang, Peoples R China.	xukanzju@gmail.com					Alabed YZ, 2010, J NEUROSCI, V30, P5635, DOI 10.1523/JNEUROSCI.6154-09.2010; Asante CO, 2010, J PAIN, V11, P1356, DOI 10.1016/j.jpain.2010.03.013; Bauman W A, 2000, Phys Med Rehabil Clin N Am, V11, P109; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; BRENES G, 1986, ARCH PHYS MED REHAB, V67, P445; Chen W, 2010, AM J PHYSIOL-GASTR L, V299, pG293, DOI 10.1152/ajpgi.00005.2010; Christie KJ, 2010, J NEUROSCI, V30, P9306, DOI 10.1523/JNEUROSCI.6271-09.2010; Codeluppi S, 2009, J NEUROSCI, V29, P1093, DOI 10.1523/JNEUROSCI.4103-08.2009; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cyranoski D, 2007, NATURE, V446, P476, DOI 10.1038/446476b; Dann SG, 2006, FEBS LETT, V580, P2821, DOI 10.1016/j.febslet.2006.04.068; Dill J, 2008, J NEUROSCI, V28, P8914, DOI 10.1523/JNEUROSCI.1178-08.2008; Dreyer HC, 2008, J APPL PHYSIOL, V104, P27, DOI 10.1152/japplphysiol.00736.2007; Dudley GA, 1999, EUR J APPL PHYSIOL O, V80, P394, DOI 10.1007/s004210050609; Filbin MT, 2006, PHILOS T R SOC B, V361, P1565, DOI 10.1098/rstb.2006.1885; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Garshick E, 2005, SPINAL CORD, V43, P408, DOI 10.1038/sj.sc.3101729; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Glass DJ, 2010, CURR TOP MICROBIOL, V346, P267, DOI 10.1007/82_2010_78; Glass DJ, 2005, INT J BIOCHEM CELL B, V37, P1974, DOI 10.1016/j.biocel.2005.04.018; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; Goswami R, 1999, J NEUROSCI RES, V57, P884, DOI 10.1002/(SICI)1097-4547(19990915)57:6<884::AID-JNR14>3.3.CO;2-1; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jaworski J, 2006, MOL NEUROBIOL, V34, P205, DOI 10.1385/MN:34:3:205; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim WY, 2006, NEURON, V52, P981, DOI 10.1016/j.neuron.2006.10.031; Kimball SR, 2002, J APPL PHYSIOL, V93, P1168, DOI 10.1152/japplphysiol.00221.2002; KRAUS JF, 1983, J CHRON DIS, V36, P297, DOI 10.1016/0021-9681(83)90065-6; Krylova O, 2002, NEURON, V35, P1043, DOI 10.1016/S0896-6273(02)00860-7; Ladner KJ, 2003, J BIOL CHEM, V278, P2294, DOI 10.1074/jbc.M207129200; Latres E, 2005, J BIOL CHEM, V280, P2737, DOI 10.1074/jbc.M407517200; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Leger B, 2006, FASEB J, V20, P583, DOI 10.1096/fj.05-5249fje; Leger B, 2009, MUSCLE NERVE, V40, P69, DOI 10.1002/mus.21293; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Liu M, 2008, SPINAL CORD, V46, P488, DOI 10.1038/sj.sc.3102169; Lohmeyer JA, 2008, LANGENBECK ARCH SURG, V393, P317, DOI 10.1007/s00423-008-0289-3; Lynch G S, 2001, Exerc Sport Sci Rev, V29, P141, DOI 10.1097/00003677-200110000-00002; Mao XB, 2011, MOL BIOL REP, V38, P3201, DOI 10.1007/s11033-010-9992-6; NELLIST M, 1993, CELL, V75, P1305; Ozean U, 2008, MOL CELL, V29, P541, DOI [10.1016/j.molcel.2007.12.023, 10.1016/j.moicel.2007.12.023]; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Reiling JH, 2008, MOL CELL, V29, P533, DOI 10.1016/j.molcel.2008.02.011; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03-11-0816; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Schwab ME, 1996, PHYSIOL REV, V76, P319; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Trendelenburg AU, 2009, AM J PHYSIOL-CELL PH, V296, pC1258, DOI 10.1152/ajpcell.00105.2009; Tsuchida K, 2008, ENDOCR J, V55, P11, DOI 10.1507/endocrj.KR-110; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	72	21	22	0	13	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-4851			MOL BIOL REP	Mol. Biol. Rep.	APR	2012	39	4					3541	3547		10.1007/s11033-011-1127-1			7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	903HZ	WOS:000301108500020	21720761				2021-06-18	
J	Miller, AC; Odenkirchen, J; Duhaime, AC; Hicks, R				Miller, A. Cate; Odenkirchen, Joanne; Duhaime, Ann-Christine; Hicks, Ramona			Common Data Elements for Research on Traumatic Brain Injury: Pediatric Considerations	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; bioinformatics; CDE; clinical trials; database; meta-analysis; pediatrics; rehabilitation; research; TBI	PSYCHOLOGICAL HEALTH; OUTCOME MEASURES; WORKING GROUP; RECOMMENDATIONS	Traumatic brain injury (TBI) is a significant global health problem, with a notably high incidence in children and adolescents. Despite the prevalence of TBI and the disabilities that often follow, research on which to base effective treatment is limited by several challenges, including but not limited to the complexity and heterogeneity of TBI. Even when rigorous methods are employed, the utility of the research may be limited by difficulties in comparing findings across studies resulting from the use of different measures to assess similar TBI study variables. Standardization of definitions and data elements is an important step toward accelerating the process of data sharing that will ultimately lead to a stronger evidence base for treatment advances. To address this need, recommendations for common data elements (CDEs) for research on TBI were developed through a 2009 national initiative. To ensure that the TBI CDE recommendations are relevant to pediatric populations, the National Institute on Disability and Rehabilitation Research (NIDRR) and the National Institute of Neurological Disorders and Stroke (NINDS) called for a review of the original recommendations. Following the process used for the original initiative, multidisciplinary work groups composed of pediatric TBI experts were formed (Demographics and Clinical Assessment; Biomarkers; Neuroimaging; and Outcomes Assessment). Recommendations for modifications and additions to the original CDEs were developed by the work groups, vetted at a 2010 workshop and further refined in preparation for publication. The pediatric considerations for TBI CDEs are described in a series of articles in this journal. This article describes the efforts leading to this pediatric CDE initiative and the CDE review and development process. It concludes with general recommendations for future iterations of the CDE initiative.	[Miller, A. Cate] US Dept Educ, Natl Inst Disabil & Rehabil Res, Washington, DC 20202 USA; [Odenkirchen, Joanne; Hicks, Ramona] NINDS, NIH, Bethesda, MD 20892 USA; [Duhaime, Ann-Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA	Miller, AC (corresponding author), US Dept Educ, Natl Inst Disabil & Rehabil Res, 400 Maryland Ave SW, Washington, DC 20202 USA.	cate.miller@ed.gov			National Institute for Disability and Rehabilitation Research of the United States Department of Education (NIDRR/DoE); National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS/NIH)	We gratefully acknowledge the working group members and chairpersons for their dedication of time and expertise to this initiative. Support for the workshop came from the National Institute for Disability and Rehabilitation Research of the United States Department of Education (NIDRR/DoE) and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS/NIH)	Alexander MS, 2009, SPINAL CORD, V47, P582, DOI 10.1038/sc.2009.18; Centers for Disease Control and Prevention, 2010, INJ PREV CONTR TRAUM; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; National Institute of Neurological Disorders and Stroke, 2010, NINDS COMM DAT EL TR; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; World Health Organization, 2006, NEUR DIS PUBL HLTH C	14	21	21	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					634	638		10.1089/neu.2011.1932			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500003	22091862	Green Published			2021-06-18	
J	Vranova, HP; Mares, J; Hlustik, P; Nevrly, M; Stejskal, D; Zapletalova, J; Obereigneru, R; Kanovsky, P				Vranova, Hana Prikrylova; Mares, Jan; Hlustik, Petr; Nevrly, Martin; Stejskal, David; Zapletalova, Jana; Obereigneru, Radko; Kanovsky, Petr			Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease	JOURNAL OF NEURAL TRANSMISSION			English	Article						Parkinson's disease subgroups; Tau protein; Beta-amyloid(1-42); Index tau/beta; CSF	MILD-COGNITIVE-IMPAIRMENT; TRAUMATIC BRAIN-INJURY; DATA-DRIVEN APPROACH; CEREBROSPINAL-FLUID; ALZHEIMER-DISEASE; ALPHA-SYNUCLEIN; AMYLOID-BETA; LEWY BODIES; MOTOR SUBTYPE; DEMENTIA	Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to search for a relationship between neurodegenerative CSF markers (tau protein, beta-amyloid(1-42) and index tau protein/beta-amyloid(1-42)) and the clinical subtypes. PD patients were divided into three subgroups: early disease onset (EDO), tremor-dominant PD (TD-PD), and non-tremor dominant PD (NT-PD) according to the previously published classification. Neurodegenerative markers in the CSF were assessed in these three groups of patients suffering from PD (EDO-17, TD-15, NT-16 patients) and in a control group (CG) of 19 patients suffering from non-degenerative neurological diseases and 18 patients with Alzheimer's disease (AD). The NT-PD patients were found to have significantly higher levels of CSF tau protein and index tau/beta than the control subjects and other Parkinsonian subgroups, but no significant differences in these markers were found between AD and NT-PD patients. In the context of more rapid clinical progression and more pronounced neuropathological changes in the NT-PD patient group, our results corroborate the opinion that CSF level of tau protein may be regarded as a potential laboratory marker of the presence and severity of neurodegeneration.	[Vranova, Hana Prikrylova; Mares, Jan; Hlustik, Petr; Nevrly, Martin; Kanovsky, Petr] Palacky Univ, Univ Hosp Olomouc, Fac Med & Dent, Dept Neurol, Olomouc 77520, Czech Republic; [Stejskal, David] Palacky Univ, Univ Hosp Olomouc, Fac Med & Dent, Dept Biochem, Olomouc 77520, Czech Republic; [Zapletalova, Jana] Palacky Univ, Fac Med & Dent, Dept Med Biophys, Olomouc 77520, Czech Republic; [Obereigneru, Radko] Palacky Univ, Dept Psychol, Philosoph Fac, Olomouc 77520, Czech Republic	Vranova, HP (corresponding author), Palacky Univ, Univ Hosp Olomouc, Fac Med & Dent, Dept Neurol, IP Pavlova 6, Olomouc 77520, Czech Republic.	vranovaha@seznam.cz	Stejskal, David/AAN-6236-2021; Stejskal, David/D-6125-2018; Hlustik, Petr/AAN-7342-2021; Hlustik, Petr/B-9411-2008; OBEREIGNERu, Radko/Q-5239-2016	Stejskal, David/0000-0003-1204-0395; Stejskal, David/0000-0003-1204-0395; Mares, Jan/0000-0003-4760-9123	 [IGA MHCZ NT1222-5/2010]	The study was supported by grant IGA MHCZ NT1222-5/2010.	Alves G, 2010, J NEUROL NEUROSUR PS, V81, P1080, DOI 10.1136/jnnp.2009.199950; Arima K, 1999, BRAIN RES, V843, P53, DOI 10.1016/S0006-8993(99)01848-X; Bibl M, 2006, BRAIN, V129, P1177, DOI 10.1093/brain/awl063; Blennow K, 2004, NEUROLOGY, V62, P159, DOI 10.1212/WNL.62.1.159; Burn DJ, 2006, J NEUROL NEUROSUR PS, V77, P585, DOI 10.1136/jnnp.2005.081711; Buter TC, 2008, NEUROLOGY, V70, P1017, DOI 10.1212/01.wnl.0000306632.43729.24; Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010; Compta Y, 2009, MOVEMENT DISORD, V24, P2203, DOI 10.1002/mds.22594; Esposito A, 2007, NEUROBIOL DIS, V26, P521, DOI 10.1016/j.nbd.2007.01.014; Fagan AM, 2007, ARCH NEUROL-CHICAGO, V64, P343, DOI 10.1001/archneur.64.3.noc60123; GOEL V, 1995, NEUROPSYCHOLOGIA, V33, P623, DOI 10.1016/0028-3932(95)90866-P; Graham JM, 1999, MOVEMENT DISORD, V14, P10; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Hu WT, 2010, ACTA NEUROPATHOL, V120, P385, DOI 10.1007/s00401-010-0723-9; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Jellinger KA, 2002, J NEURAL TRANSM, V109, P329, DOI 10.1007/s007020200027; Jellinger KA, 2008, NEURODEGENER DIS, V5, P118, DOI 10.1159/000113679; Jellinger KA, 2009, BBA-MOL BASIS DIS, V1792, P730, DOI 10.1016/j.bbadis.2008.07.006; Lashley T, 2008, ACTA NEUROPATHOL, V115, P417, DOI 10.1007/s00401-007-0336-0; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis SJG, 2005, J NEUROL NEUROSUR PS, V76, P343, DOI 10.1136/jnnp.2003.033530; Lyros E, 2008, EUR J NEUROL, V15, P262, DOI 10.1111/j.1468-1331.2007.02046.x; Mattila PM, 1998, ACTA NEUROPATHOL, V96, P417, DOI 10.1007/s004010050913; Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064; Mollenhauer B, 2006, DEMENT GERIATR COGN, V22, P200, DOI 10.1159/000094871; Obereigneru R, 2010, EUR J NEUROL, V17, P482; Okonkwo OC, 2010, ARCH NEUROL-CHICAGO, V67, P688, DOI 10.1001/archneurol.2010.118; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pan S, 2007, MOL CELL PROTEOMICS, V6, P1818, DOI 10.1074/mcp.M700158-MCP200; PAULUS W, 1991, J NEUROPATH EXP NEUR, V50, P743, DOI 10.1097/00005072-199111000-00006; Qureshi HY, 2011, J BIOL CHEM, V286, P5055, DOI 10.1074/jbc.M110.178905; Rajput A, 2006, NEUROLOGY, V67, P1506, DOI 10.1212/01.wnl.0000240220.33950.0c; Rajput AH, 2009, NEUROLOGY, V73, P206, DOI 10.1212/WNL.0b013e3181ae7af1; Selikhova M, 2009, BRAIN, V132, P2947, DOI 10.1093/brain/awp234; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Siderowf A, 2010, NEUROLOGY, V75, P1055, DOI 10.1212/WNL.0b013e3181f39a78; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stejskal David, 2005, Biomedical Papers (Olomouc), V149, P265; Sunderland T, 2003, JAMA-J AM MED ASSOC, V289, P2094, DOI 10.1001/jama.289.16.2094; van Rooden SM, 2011, MOVEMENT DISORD, V26, P51, DOI 10.1002/mds.23346; van Rooden SM, 2010, MOVEMENT DISORD, V25, P969, DOI 10.1002/mds.23116; Vranova HP, 2010, J NEURAL TRANSM, V117, P1177, DOI 10.1007/s00702-010-0462-z; Waxman EA, 2011, J NEUROSCI, V31, P7604, DOI 10.1523/JNEUROSCI.0297-11.2011; Williams DR, 2009, INTERN MED J, V39, P7, DOI 10.1111/j.1445-5994.2008.01635.x; Yao CP, 2008, BRAIN INJURY, V22, P723, DOI 10.1080/02699050802304706	45	21	22	0	17	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564			J NEURAL TRANSM	J. Neural Transm.	MAR	2012	119	3					353	362		10.1007/s00702-011-0708-4			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	896RM	WOS:000300587900007	21892760				2021-06-18	
J	Hoffman, JM; Dikmen, S; Temkin, N; Bell, KR				Hoffman, Jeanne M.; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.			Development of Posttraumatic Stress Disorder After Mild Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Traumatic brain injury; Posttraumatic stress disorders; Rehabilitation	HEAD-INJURY; PRACTICAL SCALE; SYMPTOMS; PERSONALITY; PTSD	Hoffman JM, Dikmen S, Temkin N, Bell KR. Development of posttraumatic stress disorder after mild traumatic brain injury. Arch Phys Med Rehabil 2012;93:287-92. Objective: To examine the incidence of and factors associated with the development of posttraumatic stress disorder (PTSD) 6 months after civilian mild traumatic brain injury (MTBI). Design: Secondary analysis of a randomized controlled trial of telephone follow-up versus usual care to reduce MTBI symptoms and improve function. Setting: In-person and telephone interviews. Participants: Prospectively studied participants (N=239) with MTBI enrolled in the emergency department. Interventions: Not applicable. Main Outcome Measures: Secondary analysis with main outcome measure of Posttraumatic Stress Disorder Checklist Civilian Version. Results: At 6 months after MTBI, 17% of participants met criteria for diagnosis of PTSD. Logistic regression predicting PTSD from baseline characteristics showed that participants who were Hispanic versus white, non-Hispanic and who, at the time of injury, described themselves as less happy and believed they would be more affected by their injury were significantly more likely to have PTSD. Conclusions: Rates of PTSD in civilian MTBI in this study are consistent with prior research. Results suggest that personality characteristics and attribution regarding the injury may impact the development of PTSD. Early interventions addressing risk factors may prevent or reduce the likelihood of developing PTSD.	[Hoffman, Jeanne M.; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Hoffman, JM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	jeanneh@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR023226]	Supported by the Centers for Disease Control and Prevention (grant no. R49/CCR023226).	[Anonymous], 2011, ASS ONG EFF TREATM P; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; De Silva M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006422.pub3; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Hatcher MB, 2009, BRIT J HEALTH PSYCH, V14, P541, DOI 10.1348/135910708X373445; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kaloupek DG, 2010, ARCH PHYS MED REHAB, V91, P1684, DOI 10.1016/j.apmr.2010.06.032; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mezuk B, 2010, AM J EPIDEMIOL, V172, P1238, DOI 10.1093/aje/kwq283; Mulligan K, 2011, PSYCHOL MED, V41, P673, DOI 10.1017/S003329171000125X; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nayback AM, 2008, J PSYCHOSOC NURS MEN, V46, P43; Norris F.H., 2004, ASSESSING PSYCHOL TR; Paris J, 2000, HARVARD REV PSYCHIAT, V8, P175, DOI 10.1093/hrp/8.4.175; Rademaker AR, 2011, J ABNORM PSYCHOL, V120, P299, DOI 10.1037/a0021806; Roberts NP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006869.pub2; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Santos MR, 2008, PSYCHIATRY, V71, P234, DOI 10.1521/psyc.2008.71.3.234; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; TEASDALE G, 1974, LANCET, V2, P81; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; van Veldhoven LM, 2011, J NEUROL NEUROSUR PS, V82, P782, DOI 10.1136/jnnp.2010.228254; van Zuiden M, 2011, J PSYCHIATR RES, V45, P713, DOI 10.1016/j.jpsychires.2010.11.013; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Williams AE, 2008, J TRAUMA, V65, P1054, DOI 10.1097/TA.0b013e318184a9ec; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026	42	21	22	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2012	93	2					287	292		10.1016/j.apmr.2011.08.041			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	893ER	WOS:000300338900016	22289239				2021-06-18	
J	Hsieh, MY; Ponsford, J; Wong, D; Schonberger, M; McKay, A; Haines, K				Hsieh, Ming-Yun; Ponsford, Jennie; Wong, Dana; Schoenberger, Michael; McKay, Adam; Haines, Kerrie			A cognitive behaviour therapy (CBT) programme for anxiety following moderate-severe traumatic brain injury (TBI): Two case studies	BRAIN INJURY			English	Article						Anxiety; cognitive behaviour therapy; psychiatric disorders; psychological treatment; traumatic brain injury	HOSPITAL ANXIETY; DEPRESSION SCALE; REHABILITATION; DISORDERS; PATIENT; NEUROREHABILITATION; INTERVENTION; INDIVIDUALS; SUITABILITY; OUTCOMES	Background: CBT is a potentially effective treatment for anxiety disorders following TBI; however, empirical evidence has mainly come from clients with mild TBI. This paper describes a CBT-based anxiety treatment programme adapted for clients with more severe injuries. Two case studies are provided to illustrate the implementation of the programme, as a step toward larger scale testing of the programme's feasibility. Methods and procedures: A manualised adapted CBT treatment manual was used to deliver CBT in a standardised manner to two clients, one with severe and one with moderate TBI. Outcome was evaluated using a single-subject design with repeated measures of anxiety, mood and coping style at pre- and post-CBT. Results: The two clients demonstrated positive treatment response on either a measure of anxiety or a continuous measure of distress. Although neither demonstrated a clinically significant change according to the primary outcome measure (Hospital Anxiety and Depression Scale), they showed significant change in at least one corroborated measure of anxiety. Conclusions: This study suggests the potential utility of the adapted CBT programme for clients with moderate-severe TBI. Limitations of the single case studies were discussed, while noting how they would be addressed in a follow-up randomised controlled trial.	[Hsieh, Ming-Yun; Ponsford, Jennie; Wong, Dana; McKay, Adam; Haines, Kerrie] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Hsieh, Ming-Yun; Ponsford, Jennie] Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Hsieh, Ming-Yun] Victorian Rehabil Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol & Psychotherapy, Freiburg, Germany; [McKay, Adam] Epworth Med Fdn, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	McKay, Adam JD/M-6003-2017; Wong, Dana/AAD-3410-2020	McKay, Adam JD/0000-0002-0479-7681; Wong, Dana/0000-0001-9619-1929	National Health Medical Research Council (NHMRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC)National Health and Medical Research Council of Australia; Monash UniversityMonash University; Victorian Brain Injury Recovery Association	This study is part of a randomised controlled trial funded by the National Health Medical Research Council (NHMRC) and Monash University Strategic Grant. The first author received a scholarship provided by the Victorian Brain Injury Recovery Association, for attendance of professional development activities. The funding sources had no role in study design, data collection and analysis. The authors alone are responsible for the content and writing of the paper.	Andrews G., 2003, TREATMENT ANXIETY DI, V2nd; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Beck JS, 1995, COGNITIVE THERAPY BB; Borckardt JJ, 2008, AM PSYCHOL, V63, P77, DOI 10.1037/0003-066X.63.2.77; Borckardt JJ, 2006, SMA SIMULATION MODEL; Bovend'Eerdt TJH, 2009, CLIN REHABIL, V23, P352, DOI 10.1177/0269215508101741; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Callahan CD, 2005, REHABIL PSYCHOL, V50, P24, DOI 10.1037/0090-5550.50.1.24; Coughlin A, 2007, MEMORY INFORM PROCES; Dahm J, 2009, APS ANN C PERTH AUST; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Devilly GJ, 2005, RELIABLE CLIN CHANGE, V4.0; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; First M.B., 2007, STRUCTURED CLIN INTE; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Frydenberg E., 1996, COPING SCALE ADULTS; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gurr B, 2005, BRAIN INJURY, V19, P481, DOI 10.1080/02699050400005176; Hawton K.E., 1989, COGNITIVE BEHAV THER; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kazdin A. E., 1982, SINGLE CASE RES DESI; KENDALL E, 2001, BRAIN IMPAIR, V2, P81; Kendall PC, 2008, J AM ACAD CHILD PSY, V47, P987, DOI 10.1097/CHI.0b013e31817eed2f; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; KROESE BS, 1997, COGNITIVE BEHAV THER; Leathem J, 2007, HDB HOMEWORK ASSIGNM, P389; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Manchester D, 2001, BRAIN DAM B, P157; Mathias JL, 2007, AUST PSYCHOL, V42, P49, DOI 10.1080/00050060600827599; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Myhr G, 2007, J COGN PSYCHOTHER, V21, P334, DOI 10.1891/088983907782638743; Newburn G, 1998, CNS DRUGS, V9, P441, DOI 10.2165/00023210-199809060-00003; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ownsworth T, 2008, BRAIN INJURY, V22, P858, DOI 10.1080/02699050802446697; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Page AC, 2007, BRIT J CLIN PSYCHOL, V46, P283, DOI 10.1348/014466506X158996; Perna R, 2006, J HEAD TRAUMA REHAB, V21, P82, DOI 10.1097/00001199-200601000-00009; Perna RB, 2001, J COGNITIVE REHABILI, V19, P7; Rasquin SMC, 2009, NEUROPSYCHOL REHABIL, V19, P208, DOI 10.1080/09602010802091159; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; SAFRAN JD, 1993, COGNITIVE THER RES, V17, P23, DOI 10.1007/BF01172738; Sanderson WC, 2006, PRAGMATIC CASE STUDI, V2, P1; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Shallice, 1997, HAYLING BRIXTON TEST; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Soo C, 2007, COCHRANE DATABASE SY, P3; Stanley MA, 2004, BEHAV MODIF, V28, P73, DOI 10.1177/0145445503259259; Tate RL, 2003, NEUROPSYCHOL REHABIL, V13, P43, DOI 10.1080/09602010244000372; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whyte J, 2009, ARCH PHYS MED REHAB, V90, pS3, DOI 10.1016/j.apmr.2009.07.008; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; Wilson, 1991, NATL ADULT READING T; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	71	21	22	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2012	26	2					126	138		10.3109/02699052.2011.635365			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	897NP	WOS:000300658200002	22360519				2021-06-18	
J	Oluigbo, CO; Wilkinson, CC; Stence, NV; Fenton, LZ; McNatt, SA; Handler, MH				Oluigbo, Chima O.; Wilkinson, C. Corbett; Stence, Nicholas V.; Fenton, Laura Z.; McNatt, Sean A.; Handler, Michael H.			Comparison of outcomes following decompressive craniectomy in children with accidental and nonaccidental blunt cranial trauma Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						decompressive craniectomy; nonaccidental trauma; children; outcome; mortality	CEREBRAL PERFUSION-PRESSURE; SHAKEN BABY SYNDROME; BRAIN-INJURY; HEAD-INJURY; INTRACRANIAL-PRESSURE; OPHTHALMOLOGIC FINDINGS; YOUNG-CHILDREN; INFANTS; IMPACT; PATHOPHYSIOLOGY	Object. The goal of this study was to compare clinical outcomes following decompressive craniectomy performed for intracranial hypertension in children with nonaccidental, blunt cranial trauma with outcomes of decompressive craniectomy in children injured by other mechanisms. Methods. All children in a prospectively acquired database of trauma admissions who underwent decompressive craniectomy over a 9-year span, beginning January 1, 2000, are the basis for this study. Clinical records and neuro-imaging studies were systematically reviewed. Results. Thirty-seven children met the inclusion criteria. Nonaccidental head trauma was the most common mechanism of injury (38%). The mortality rate in patients with abusive brain injury (35.7%) was significantly higher (p < 0.05) than in patients with other causes of traumatic brain injury (4.3%). Children with inflicted head injuries had a 12-fold increase in the odds of death and 3-fold increase in the odds of a poor outcome (King's Outcome Scale for Closed Head Injury score of 1,2, or 3). Conclusions. Children with nonaccidental blunt cranial trauma have significantly higher mortality following decompressive craniectomy than do children with other mechanisms of injury. This understanding can be interpreted to mean either that the threshold for decompression should be lower in children with nonaccidental closed head injury or that decompression is unlikely to alter the path to a fatal outcome. If decompressive craniectomy is to be effective in reducing mortality in the setting of nonaccidental blunt cranial trauma, it should be done quite early. (http://thejns.org/doi/abs/10.3171/2011.11.PEDS09449)	[Wilkinson, C. Corbett] Childrens Hosp, Dept Neurosurg, Aurora, CO 80045 USA; Childrens Hosp, Dept Pediat Neuroradiol, Aurora, CO 80045 USA; Univ Colorado, Aurora, CO USA	Wilkinson, CC (corresponding author), Childrens Hosp, Dept Neurosurg, 13123 E 16th Ave, Aurora, CO 80045 USA.	Wilkinson.Charles@tchden.org	Oluigbo, Chima/E-3788-2011	Maliawan, Sri/0000-0003-2389-3481			Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Eleraky MA, 2000, J NEUROSURG, V92, P12, DOI 10.3171/spi.2000.92.1.0012; Feldman KW, 1997, CHILD ABUSE NEGLECT, V21, P199, DOI 10.1016/S0145-2134(96)00145-7; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Golden N, 2005, J CLIN NEUROSCI, V12, P235, DOI 10.1016/j.jocn.2004.11.001; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Kakar V, 2009, BRIT J NEUROSURG, V23, P147, DOI 10.1080/02688690902756702; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2003, ACT NEUR S, V86, P7; Monro A., 1783, OBSERVATIONS STRUCTU, P2; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Saternus KS, 2000, FORENSIC SCI INT, V109, P203, DOI 10.1016/S0379-0738(00)00144-4; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410	37	21	21	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	FEB	2012	9	2					125	132		10.3171/2011.11.PEDS09449			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	882SC	WOS:000299583200004	22295915				2021-06-18	
J	Verkade, MA; Epker, JL; Nieuwenhoff, MD; Bakker, J; Kompanje, EJO				Verkade, Martijn A.; Epker, Jelle L.; Nieuwenhoff, Mariska D.; Bakker, Jan; Kompanje, Erwin J. O.			Withdrawal of Life-Sustaining Treatment in a Mixed Intensive Care Unit: Most Common in Patients with Catastropic Brain Injury	NEUROCRITICAL CARE			English	Article						Intensive care; End-of-life; Withdrawal of treatment; Subarachnoid haemorrhage; Traumatic brain injury	CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; SUPPORT; DEATH; ADMISSION; DECISIONS; DOCUMENTATION; EPIDEMIOLOGY; MORTALITY; ETHICUS	To determine the incidence of withdrawal of life-sustaining treatment in various groups of patients in a mixed intensive care unit (ICU). Observational retrospective. Setting: University hospital mixed medical, neurological, neurosurgical and surgical ICU. All patients admitted to the ICU between 1 November 2006, and 31 October 2007. 1,353 Patients were admitted to our ICU between 1 November 2006, and 31 October 2007. During this period, 218 (16.1%) patients died in the ICU, 10 of which were excluded for further analysis. In 174 (83.7%) of the remaining 208 patients, life-sustaining treatment was withdrawn. Severe CNS injury was in 86 patients (49.4%) being the reason for withdrawal of treatment, followed by MODS in 67 patients (38.5%). Notably, treatment was withdrawn in almost all patients (95%) who died of CNS failure. Patients who died in the ICU were significantly older, more often admitted for medical than surgical reasons, and had higher SOFA and APACHE II scores compared with those who survived their ICU stay. Also, SOFA scores before discharge/death were significantly different from admission scores. Of the 1,135 patients who survived their ICU stay, only 51 patients (4.5%) died within 28 days after ICU discharge. In 83, 7% of patients who die in the mixed ICU life-sustaining treatment is withdrawn. Severe cerebral damage was the leading reason to withdraw life-sustaining treatment.	[Verkade, Martijn A.; Epker, Jelle L.; Nieuwenhoff, Mariska D.; Bakker, Jan; Kompanje, Erwin J. O.] Erasmus Univ, Dept Intens Care Med, Med Ctr Rotterdam, NL-3000 CA Rotterdam, Netherlands	Kompanje, EJO (corresponding author), Erasmus Univ, Dept Intens Care Med, Med Ctr Rotterdam, Room H 324,POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.j.o.kompanje@erasmusmc.nl	Bakker, Jan/A-4011-2009	Bakker, Jan/0000-0003-2236-7391			Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Conlon N, 2008, BRIT J ANAESTH, V100, P219, DOI 10.1093/bja/aem372; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Cook DJ, 2001, LANCET, V358, P1941, DOI 10.1016/S0140-6736(01)06960-4; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Epker JL, 2011, ANESTH ANALG, V112, P628, DOI 10.1213/ANE.0b013e31820ad4d9; Estenssoro E, 2006, CRIT CARE, V10, DOI 10.1186/cc4941; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Laupland KB, 2006, CHEST, V129, P954, DOI 10.1378/chest.129.4.954; Levin PD, 2005, CRIT CARE, V9, P230, DOI 10.1186/cc3487; Luce JM, 2000, AM J RESP CRIT CARE, V162, P2029, DOI 10.1164/ajrccm.162.6.1-00; Mayr VD, 2006, CRIT CARE, V10, DOI 10.1186/cc5086; McLean RF, 2000, CRIT CARE MED, V28, P100, DOI 10.1097/00003246-200001000-00016; Metnitz PGH, 2003, INTENS CARE MED, V29, P241, DOI 10.1007/s00134-002-1584-z; Moselli NM, 2006, ACTA ANAESTH SCAND, V50, P1177, DOI 10.1111/j.1399-6576.2006.01150.x; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Richter J, 2001, J MED ETHICS, V27, P186, DOI 10.1136/jme.27.3.186; Rosenberg AL, 2000, CHEST, V118, P492, DOI 10.1378/chest.118.2.492; Spronk PE, 2009, ANESTH ANALG, V109, P841, DOI 10.1213/ane.0b013e3181acc64a; Sprung CL, 2008, INTENS CARE MED, V34, P271, DOI 10.1007/s00134-007-0927-1; Sprung CL, 2007, INTENS CARE MED, V33, P1732, DOI 10.1007/s00134-007-0693-0; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Vincent JL, 2002, CHEST, V121, P1602, DOI 10.1378/chest.121.5.1602; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042	28	21	21	2	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	FEB	2012	16	1					130	135		10.1007/s12028-011-9567-y			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	881QW	WOS:000299502500018	21660623				2021-06-18	
J	Ye, Z; Wang, N; Xia, PP; Wang, E; Yuan, YJ; Guo, QL				Ye, Zhi; Wang, Na; Xia, Pingping; Wang, E.; Yuan, Yajing; Guo, Qulian			Delayed Administration of Parecoxib, a Specific COX-2 Inhibitor, Attenuated Postischemic Neuronal Apoptosis by Phosphorylation Akt and GSK-3 beta	NEUROCHEMICAL RESEARCH			English	Article						Parecoxib; Apoptosis; Cyclooxygenase-2 (COX-2); Akt/glycogen synthase kinase 3 beta (GSK-3 beta); Cerebral ischemic reperfusion injury	GLYCOGEN-SYNTHASE KINASE-3-BETA; TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; CYTOCHROME-C; CELL-DEATH; RAT-BRAIN; ISCHEMIA; CYCLOOXYGENASE-2; MODEL; NEUROPROTECTION	Parecoxib is a recently described novel COX-2 inhibitor whose functional significance and neuroprotective mechanisms remain elusive. Therefore, in this study, we aimed to investigate whether delayed administration of parecoxib inhibited mitochondria-mediated neuronal apoptosis induced by ischemic reperfusion injury via phosphorylating Akt and its downstream target protein, glycogen synthase kinase 3 beta (GSK-3 beta). Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days. Cerebral infarct volume, apoptotic neuron, caspase-3 immunoreactivity and the protein expression of p-Akt, p-GSK-3 beta and Cytochrome C in cerebral ischemic cortex were evaluated at 96 h after reperfusion. Parecoxib significantly diminished infarct volume and attenuated neuron apoptosis in a dose-independent manner, compared with MCAO group alone. Increased p-Akt and p-GSK-3 beta was observed in the ischemic penumbra of parecoxib group after stroke. Moreover, parecoxib also reduced the release of Cytochrome C from mitochondrial into cytosol and attenuated the caspase-3 immunoreactivity in the penumbra. Taken together, these results suggested that parecoxib ameliorated postischemic mitochondria-mediated neuronal apoptosis induced by focal cerebral ischemia in rats and this neuroprotective potential is involved in phosphorylation of Akt and GSK-3 beta.	[Ye, Zhi; Wang, Na; Xia, Pingping; Wang, E.; Yuan, Yajing; Guo, Qulian] Ctr S Univ, Dept Anesthesiol, Affiliated Xiangya Hosp, Changsha 410078, Hunan, Peoples R China	Guo, QL (corresponding author), Ctr S Univ, Dept Anesthesiol, Affiliated Xiangya Hosp, Changsha 410078, Hunan, Peoples R China.	guoqulian7411@live.cn					Abbate A, 2007, J CARDIOVASC PHARM, V49, P416, DOI 10.1097/FJC.0b013e31804a5e50; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brywe KG, 2005, EUR J NEUROSCI, V21, P1489, DOI 10.1111/j.1460-9568.2005.03982.x; Candelario-Jalil E, 2004, BRAIN RES, V1007, P98, DOI 10.1016/j.brainres.2004.01.078; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Candelario-Jalil E, 2008, CURR PHARM DESIGN, V14, P1401, DOI 10.2174/138161208784480216; Candelario-Jalil E, 2008, PHARMACOL RES, V57, P266, DOI 10.1016/j.phrs.2008.03.003; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Cimarosti H, 2005, NEUROCHEM RES, V30, P191, DOI 10.1007/s11064-004-2441-y; Clodfelder-Miller B, 2005, J BIOL CHEM, V280, P39723, DOI 10.1074/jbc.M508824200; Dembo G, 2005, ANESTHESIOLOGY, V102, P409, DOI 10.1097/00000542-200502000-00026; Dirnagl U, 2004, E SCHERING RES FDN W, V47, P87; Dore S, 2003, ANN NEUROL, V54, P155, DOI 10.1002/ana.10612; Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018-007-7045-7; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; Hakan T, 2010, NEUROL RES, V32, P629, DOI 10.1179/016164109X12464612122731; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Hirai K, 2004, MOL BRAIN RES, V124, P51, DOI 10.1016/j.molbrainres.2004.02.009; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kelsen J, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-31; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Li J, 2008, NEUROSCI LETT, V438, P210, DOI 10.1016/j.neulet.2008.04.054; Li LL, 2008, EUR J PHARMACOL, V586, P106, DOI 10.1016/j.ejphar.2008.02.073; Nishimoto T, 2008, J NEUROSCI RES, V86, P1096, DOI 10.1002/jnr.21567; Nogawa S, 1997, J NEUROSCI, V17, P2746; Norregaard R, 2010, AM J PHYSIOL-REG I, V298, pR1017, DOI 10.1152/ajpregu.00336.2009; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Ohtsuki T, 1996, BRAIN RES, V736, P353, DOI 10.1016/S0006-8993(96)00948-1; Patel NSA, 2007, EUR J PHARMACOL, V562, P148, DOI 10.1016/j.ejphar.2007.01.079; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; Polascheck N, 2010, EXP NEUROL, V224, P219, DOI 10.1016/j.expneurol.2010.03.014; Raphael J, 2006, J PHARMACOL EXP THER, V318, P186, DOI 10.1124/jpet.105.100537; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Salloum FN, 2009, J CARDIOVASC PHARM, V53, P495, DOI 10.1097/FJC.0b013e3181a7b5b6; Song JQ, 2009, APOPTOSIS, V14, P1299, DOI 10.1007/s10495-009-0398-7; Sugimoto K, 2003, BRAIN RES, V960, P273, DOI 10.1016/S0006-8993(02)03805-2; Wang HY, 2009, BRAIN RES, V1297, P177, DOI 10.1016/j.brainres.2009.08.054; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wu T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-22; Xiang Z, 2007, CURR NEUROVASC RES, V4, P274, DOI 10.2174/156720207782446342; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zheng Z, 2004, NEUROL RES, V26, P884, DOI 10.1179/016164104X2357	49	21	27	0	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	FEB	2012	37	2					321	329		10.1007/s11064-011-0615-y			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	920KU	WOS:000302404100012	21964800				2021-06-18	
J	Kincses, ZT; Szabo, N; Valalik, I; Kopniczky, Z; Dezsi, L; Klivenyi, P; Jenkinson, M; Kiraly, A; Babos, M; Voros, E; Barzo, P; Vecsei, L				Kincses, Zsigmond Tamas; Szabo, Nikoletta; Valalik, Istvan; Kopniczky, Zsolt; Dezsi, Livia; Klivenyi, Peter; Jenkinson, Mark; Kiraly, Andras; Babos, Magor; Voeroes, Erika; Barzo, Pal; Vecsei, Laszlo			Target Identification for Stereotactic Thalamotomy Using Diffusion Tractography	PLOS ONE			English	Article							DEEP BRAIN-STIMULATION; ESSENTIAL TREMOR; PARKINSONS-DISEASE; THALAMIC-STIMULATION; MULTIPLE-SCLEROSIS; VIM THALAMOTOMY; HIGH-RESOLUTION; NUCLEUS; SEGMENTATION; VALIDATION	Background: Stereotactic targets for thalamotomy are usually derived from population-based coordinates. Individual anatomy is used only to scale the coordinates based on the location of some internal guide points. While on conventional MR imaging the thalamic nuclei are indistinguishable, recently it has become possible to identify individual thalamic nuclei using different connectivity profiles, as defined by MR diffusion tractography. Methodology and Principal Findings: Here we investigated the inter-individual variation of the location of target nuclei for thalamotomy: the putative ventralis oralis posterior (Vop) and the ventral intermedius (Vim) nucleus as defined by probabilistic tractography. We showed that the mean inter-individual distance of the peak Vop location is 7.33 mm and 7.42 mm for Vim. The mean overlap between individual Vop nuclei was 40.2% and it was 31.8% for Vim nuclei. As a proof of concept, we also present a patient who underwent Vop thalamotomy for untreatable tremor caused by traumatic brain injury and another patient who underwent Vim thalamotomy for essential tremor. The probabilistic tractography indicated that the successful tremor control was achieved with lesions in the Vop and Vim respectively. Conclusions: Our data call attention to the need for a better appreciation of the individual anatomy when planning stereotactic functional neurosurgery.	[Kincses, Zsigmond Tamas; Szabo, Nikoletta; Dezsi, Livia; Klivenyi, Peter; Kiraly, Andras; Vecsei, Laszlo] Univ Szeged, Albert Szent Gyorgy Clin Ctr, Dept Neurol, Szeged, Hungary; [Kincses, Zsigmond Tamas] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Valalik, Istvan] St Johns Hosp, Dept Neurosurg, Budapest, Hungary; [Kopniczky, Zsolt; Barzo, Pal] Univ Szeged, Albert Szent Gyorgy Clin Ctr, Dept Neurosurg, Szeged, Hungary; [Jenkinson, Mark] Univ Oxford, John Radcliffe Hosp, FMRIB Ctr, Dept Clin Neurol, Oxford OX3 9DU, England; [Babos, Magor] Euromed Diagnost Hungary Ltd, Szeged, Hungary; [Voeroes, Erika] Univ Szeged, Albert Szent Gyorgy Clin Ctr, Dept Radiol, Szeged, Hungary	Kincses, ZT (corresponding author), Univ Szeged, Albert Szent Gyorgy Clin Ctr, Dept Neurol, Szeged, Hungary.	kincsesz@nepsy.szote.u-szeged.hu	Kincses, Zsigmond Tamas/A-6507-2012; Vecsei, Laszlo/B-2066-2010; Kincses, Zsigmond Tamas/N-4849-2015; Jenkinson, Mark/AAC-8861-2019; Kopniczky, Zsolt/G-7771-2012	Kincses, Zsigmond Tamas/0000-0002-1442-4475; Vecsei, Laszlo/0000-0001-8037-3672; Kincses, Zsigmond Tamas/0000-0002-1442-4475; Jenkinson, Mark/0000-0001-6043-0166; Klivenyi, Peter/0000-0002-5389-3266	Medical Research Council (ETT)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [026-04]; Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged; Hungarian Academy of SciencesHungarian Academy of Sciences; International Research Center (FNUSA-ICRC) [CZ.1.05/1.1.00/02.0123]; European Regional Development FundEuropean Commission; Creating the Center of Excellence at the University of Szeged [TAMOP-4.2.1/B-09/1/KONV-2010-0005]	Dr. Laszlo Vecsei was supported by the Medical Research Council (ETT 026-04) and the "Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged.". Dr. Zsigmond Tamas Kincses was supported by the Bolyai Scholarship Programme of the Hungarian Academy of Sciences and by the project International Research Center (FNUSA-ICRC, no. CZ.1.05/1.1.00/02.0123) from the European Regional Development Fund. Dr. Vecsei, Dr. Kincses, Dr. Szabo and Dr. Klivenyi were supported by "TAMOP-4.2.1/B-09/1/KONV-2010-0005 - Creating the Center of Excellence at the University of Szeged'' grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alusi SH, 2001, BRAIN, V124, P1576, DOI 10.1093/brain/124.8.1576; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; Bittar RG, 2005, J CLIN NEUROSCI, V12, P638, DOI 10.1016/j.jocn.2004.09.008; Blomstedt P, 2007, BRIT J NEUROSURG, V21, P504, DOI 10.1080/02688690701552278; Broggi G, 2006, ACTA NEUROCHIR SUPPL, V99, P13, DOI 10.1007/978-3-211-35205-2_2; BROGGI G, 1993, MOVEMENT DISORD, V8, P206, DOI 10.1002/mds.870080217; Chen H, 2010, CHINESE MED J-PEKING, V123, P695, DOI 10.3760/cma.j.issn.0366-6999.2010.06.011; Critchley GR, 1998, BRIT J NEUROSURG, V12, P559, DOI 10.1080/02688699844439; Crum WR, 2006, IEEE T MED IMAGING, V25, P1451, DOI 10.1109/TMI.2006.880587; Deoni SCL, 2005, HUM BRAIN MAPP, V25, P353, DOI 10.1002/hbm.20117; Deoni SCL, 2007, NEUROIMAGE, V34, P117, DOI 10.1016/j.neuroimage.2006.09.016; Dormont D, 1997, AM J NEURORADIOL, V18, P1093; Flora ED, 2010, MOVEMENT DISORD, V25, P1550, DOI 10.1002/mds.23195; Foote KD, 2006, NEUROSURGERY, V58, P280, DOI 10.1227/01.NEU.0000192692.95455.FD; Franzini A, 2011, J NEURAL TRANSM; Gallay MN, 2008, BRAIN STRUCT FUNCT, V212, P443, DOI 10.1007/s00429-007-0170-0; GUIOT G, 1968, NEUROCHIRURGIE, V14, P553; Hamani C, 2006, NEUROSURGERY, V58, P146, DOI 10.1227/01.NEU.0000192166.62017.C1; Hassler R, 1954, NERVENARZT, V25, P441; Hooper AK, 2008, STEREOT FUNCT NEUROS, V86, P147, DOI 10.1159/000120426; Hyam JA, 2011, NEUROSURGERY; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Kim MC, 2002, J NEUROL NEUROSUR PS, V73, P453, DOI 10.1136/jnnp.73.4.453; Macchi G, 1997, J NEUROSURG, V86, P670, DOI 10.3171/jns.1997.86.4.0670; Molnar GF, 2005, J NEUROPHYSIOL, V93, P3094, DOI 10.1152/jn.00881.2004; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; Muthusamy KA, 2007, J NEUROSURG, V107, P814, DOI 10.3171/JNS-07/10/0814; NARABAYASHI H, 1980, APPL NEUROPHYSIOL, V43, P222; Nowinski WL, 2005, STEREOT FUNCT NEUROS, V83, P190, DOI 10.1159/000091082; Nowinski WL, 2002, STEREOT FUNCT NEUROS, V79, P1, DOI 10.1159/000069499; Pahwa R, 2006, J NEUROSURG, V104, P506, DOI 10.3171/jns.2006.104.4.506; Sanborn MR, 2009, STEREOT FUNCT NEUROS, V87, P128, DOI 10.1159/000207201; Sedrak M, 2011, NEUROSURGERY; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Traynor C, 2010, NEUROIMAGE; Yamada K, 2010, AM J NEURORADIOL, V31, P732, DOI 10.3174/ajnr.A1870; Zesiewicz TA, 2005, NEUROLOGY, V64, P2008, DOI 10.1212/01.WNL.0000163769.28552.CD	42	21	21	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2012	7	1							e29969	10.1371/journal.pone.0029969			7	Multidisciplinary Sciences	Science & Technology - Other Topics	902VE	WOS:000301070200062	22238685	DOAJ Gold, Green Published			2021-06-18	
J	Alston, M; Jones, J; Curtin, M				Alston, Margaret; Jones, Jennifer; Curtin, Michael			Women and Traumatic Brain Injury: "It's not visible damage''	AUSTRALIAN SOCIAL WORK			English	Article						Women; Acquired Brain Injury; Poststructural Feminism; Embodied Self; Caring		With advances in medical technology, more people are surviving major trauma experiences. Those with a traumatic brain injury are one such group who may survive for several decades with significant health consequences including physical, cognitive, and psychosocial sequelae. Traumatic brain injury sufferers are typically young males with a premorbid history of risk taking. Consequently, the differential needs of female traumatic brain injury survivors are less likely to be acknowledged in the literature or by allied health workers. A large quantitative and qualitative study of people with traumatic brain injury was conducted in rural areas of New South Wales, Australia in 2004-2005. The qualitative component of the study included in-depth interviews with 11 women and 21 men. This paper focuses on the interviews with the 11 women who live in two rural areas of New South Wales. These data illustrate the psychosocial consequences of traumatic brain injury for women. They reveal that women are particularly vulnerable to isolation, disempowerment, and in extreme cases, abuse, and are less likely to have a carer. The need for gender to be a factor in ongoing social work and allied health treatment and support of traumatic brain injury sufferers and their carers is evident from this research.	[Alston, Margaret] Monash Univ, Melbourne, Vic 3004, Australia; [Jones, Jennifer; Curtin, Michael] Charles Sturt Univ, Albury, NSW, Australia	Alston, M (corresponding author), Monash Univ, Melbourne, Vic 3004, Australia.	margaret.alston@monash.edu	Curtin, Michael/G-2650-2014; Jones, Jennifer/N-1940-2015	Curtin, Michael/0000-0002-2152-7501; Jones, Jennifer/0000-0003-1855-2674; Alston, Margaret/0000-0001-9057-7767			ABS (Australian Bureau of Statistics), 1993, DIS AG CAR AUSTR BRA; Alston M., 2008, PARTICIPATION FOLLOW; Australian Bureau of Statistics [ABS], 2000, CAR COMM; Australian Bureau of Statstics [ABS], 2003, ABS YB AUSTR; Bartky S. L., 1990, FEMININITY DOMINATIO; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Bourdieu P., 1977, OUTLINE THEORY PRACT; Bourdieu P., 1992, INVITATION REFLEXIVE; Brookshire R. H., 2003, INTRO NEUROGENIC COM; Butler J., 1990, GENDER TROUBLE SUBVE; Callaway L., 2005, AUSTR OCCUPATIONAL T, V52, P257, DOI [10.1111/j.1440-1630.2005.00492, DOI 10.1111/J.1440-1630.2005.00492]; Connell RW, 2002, GENDER; Cunningham JM, 1999, HLTH CARE DISABILITY, P475; Curtin M., 2008, PARTICIPATION FOLLOW; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Fine M, 2005, AGEING SOC, V25, P601, DOI 10.1017/S0144686X05003600; Foucault Michel., 1995, DISCIPLINE PUNISH BI; Graham H., 1983, LABOUR LOVE WOMEN WO, P13; Gwynn R., 2003, DISCOURSE BODY IDENT, P209; Howes H, 2005, PSYCHOL HEALTH, V20, P129, DOI 10.1080/0887044042000272903; Jones J, 2010, QUAL HEALTH RES, V20, P942, DOI 10.1177/1049732310365501; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Lupton D, 2003, DISCOURSE BODY IDENT, P246; Mukherjee D, 2003, WOMEN THER, V26, P3, DOI 10.1300/J015v26n01_01; O'Rance L., 2007, B AIHW, V55; Ponsford J., 1995, TRAUMATIC BRAIN INJU; *QSR INT, 2006, NVIVO 7 COMP SOFTW; Rees RJ, 1996, AUST J SOC ISSUES, V31, P392, DOI 10.1002/j.1839-4655.1996.tb01286.x; Reichard AA, 2007, J HEAD TRAUMA REHAB, V22, P390, DOI 10.1097/01.HTR.0000300234.36361.b1; Reidpath DD, 2005, SOCIOL HEALTH ILL, V27, P468, DOI 10.1111/j.1467-9566.2005.00452.x; Shildrick Margrit, 1997, LEAKY BODIES BOUNDAR; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808	32	21	21	1	8	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1447-0748			AUST SOC WORK	Aust. Soc. Work		2012	65	1					39	53		10.1080/0312407X.2011.594898			15	Social Work	Social Work	910VO	WOS:000301671500004					2021-06-18	
J	Barden, AE; Corcoran, TB; Mas, E; Durand, T; Galano, JM; Roberts, LJ; Paech, M; Muchatuta, NA; Phillips, M; Mori, TA				Barden, Anne E.; Corcoran, Tomas B.; Mas, Emilie; Durand, Thierry; Galano, Jean-Marie; Roberts, L. Jackson, II; Paech, Michael; Muchatuta, Neil A.; Phillips, Michael; Mori, Trevor A.			Is There a Role for Isofurans and Neuroprostanes in Pre-Eclampsia and Normal Pregnancy?	ANTIOXIDANTS & REDOX SIGNALING			English	Article							TRAUMATIC BRAIN-INJURY; LIPID-PEROXIDATION; OXIDATIVE STRESS; PLASMA	Pre-eclampsia is a complex disorder of pregnancy that adversely affects the mother and baby. Arachidonic acid and docosahexaenoic acid are essential for fetal development and can undergo free radical oxidation to F(2)-isoprostanes (F(2)-IsoPs) and isofurans (IsoFs); and F(4)-neuroprostanes (F(4)-NeuroPs), respectively. These metabolites may be relevant to pre-eclampsia and fetal development. We examined IsoFs, F(4)-NeuroPs, and F(2)-IsoPs in maternal plasma and cord blood plasma of 23 women with pre-eclampsia and 21 normal pregnancies. Women with pre-eclampsia had significantly elevated maternal IsoFs and F(4)-NeuroPs, but not F(2)-IsoPs. Cord blood F(4)-NeuroPs were elevated among neonates of women with pre-eclampsia. In women with pre-eclampsia, birth weight was predicted by gestation at delivery. The latter was also true in normal pregnancy, but birth weight was negatively related to maternal F(2)-IsoPs, IsoFs, and F(4)-NeuroPs. We have shown that in women with pre-eclampsia, IsoFs and F(4)-NeuroPs are elevated, and cord blood F(4)-NeuroPs are increased. The inverse relationship between maternal F(2)-IsoPs, IsoFs, and F(4)-NeuroPs and birth weight may be relevant as predictors of low birth weight in normal pregnancy. Future studies should examine whether these markers in maternal blood at early stages of pregnancy relate to subsequent maternal, fetal, and neonatal complications. Antioxid. Redox Signal. 16, 165-169.	[Barden, Anne E.; Corcoran, Tomas B.; Mas, Emilie; Paech, Michael; Mori, Trevor A.] Univ Western Australia, Sch Med & Pharmacol, Cardiovasc Res Ctr, Perth, WA 6847, Australia; [Corcoran, Tomas B.] Royal Perth Hosp, Dept Anaesthesia & Pain Med, Perth, WA, Australia; [Durand, Thierry; Galano, Jean-Marie] UM II, UM 1, CNRS, Fac Pharm,IBMM,UMR 5247, Montpellier, France; [Roberts, L. Jackson, II] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA; [Paech, Michael; Muchatuta, Neil A.] King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Perth, WA, Australia; [Phillips, Michael] Univ Western Australia, Western Australian Inst Med Res, Perth, WA 6847, Australia	Barden, AE (corresponding author), Univ Western Australia, Sch Med & Pharmacol, Cardiovasc Res Ctr, GPO Box X 2213, Perth, WA 6847, Australia.	anne.barden@uwa.edu.au	Mori, Trevor/H-5485-2014	Mori, Trevor/0000-0002-5264-9229; Phillips, Michael/0000-0002-0252-9085; PAECH, MICHAEL/0000-0001-9023-6575	National Heart Foundation of AustraliaNational Heart Foundation of Australia; West Australian Institute of Medical Research; University of Western Australia; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM42056]; University Montpellier 1 [BQR-2008]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R37GM042056, R01GM042056] Funding Source: NIH RePORTER	The study was supported by grants from the National Heart Foundation of Australia, and by a grant from the Neurotrauma Research Program of the West Australian Institute of Medical Research and the University of Western Australia. The synthesis of the IsoFs (Prof Roberts II LJ) was supported by a National Institutes of Health Grant GM42056. The synthesis of the neuroprostanes (Dr Durand T) was supported by a University Montpellier 1 Grant BQR-2008.	Barden A, 1996, CLIN SCI, V91, P711, DOI 10.1042/cs0910711; Barden A, 2001, HYPERTENSION, V38, P803, DOI 10.1161/hy1101.092969; Corcoran TB, 2011, ANTIOXID REDOX SIGN, V15, P2663, DOI 10.1089/ars.2011.4125; Harsem NK, 2006, EUR J OBSTET GYN R B, V128, P209, DOI 10.1016/j.ejogrb.2005.11.014; Harsem NK, 2008, HYPERTENS PREGNANCY, V27, P374, DOI 10.1080/10641950802000968; Ishihara O, 2004, FREE RADICAL RES, V38, P913, DOI 10.1080/10715760412331273421; Roberts LJ, 2004, CHEM PHYS LIPIDS, V128, P173, DOI 10.1016/j.chemphyslip.2003.09.016; Stein TP, 2008, FREE RADICAL RES, V42, P841, DOI 10.1080/10715760802510069; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005	9	21	22	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1523-0864			ANTIOXID REDOX SIGN	Antioxid. Redox Signal.	JAN	2012	16	2					165	169		10.1089/ars.2011.4214			5	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	852DK	WOS:000297327800006	21827297	Green Published			2021-06-18	
J	Huisinga, JM; Filipi, ML; Stergiou, N				Huisinga, Jessie M.; Filipi, Mary L.; Stergiou, Nicholas			Supervised Resistance Training Results in Changes in Postural Control in Patients with Multiple Sclerosis	MOTOR CONTROL			English	Article						exercise; motor control; rehabilitation; strength training	TIME-SERIES ANALYSIS; CEREBRAL CONCUSSION; IMPROVES STRENGTH; EXERCISE; PERFORMANCE; MOBILITY; BALANCE; WALKING; ADULTS; FATIGUE	Postural disturbances are one of the first reported symptoms in patients with Multiple Sclerosis (MS). The purpose of this study was to investigate the effect of supervised resistance training on postural control in MS patients. Postural control was assessed using amount of sway variability [Root Mean Square (RMS)] and temporal structure of sway variability [Lyapunov Exponent (LyE)] from 15 MS patients. Posture was evaluated before and after completion of three months of resistance training. There were significant differences between MS patients pretraining and healthy controls for both LyE (p = .000) and RMS = .002), but no differences between groups after training. There was a significant decrease in RMS (p = .025) and a significant increase in LyE (p = .049) for MS patients pre- to posttraining. The findings suggested that postural control of MS patients could be affected by a supervised resistance training intervention.	[Huisinga, Jessie M.; Stergiou, Nicholas] Univ Nebraska, Nebraska Biomech Core Facil, Omaha, NE 68182 USA; [Filipi, Mary L.] Univ Nebraska Med Ctr, Coll Nursing, Omaha, NE 68198 USA; [Stergiou, Nicholas] Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE USA	Huisinga, JM (corresponding author), Univ Nebraska, Nebraska Biomech Core Facil, Omaha, NE 68182 USA.				MARS Foundation in Ames, IA; Clinical Research Center at the University of Nebraska Medical Center; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K25 HD047194]; Nebraska Research Initiative; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K25HD047194] Funding Source: NIH RePORTER	This work was supported by the MARS Foundation in Ames, IA, by the Clinical Research Center at the University of Nebraska Medical Center, the National Institutes of Health (K25 HD047194), and the Nebraska Research Initiative.	Abarbanel H., 1996, ANAL OBSERVED CHAOTI; Barrett C, 2002, AUST J PHYSIOTHER, V48, P215, DOI 10.1016/S0004-9514(14)60226-9; Buchanan JJ, 2001, EXP BRAIN RES, V139, P482, DOI 10.1007/s002210100798; Cakit BD, 2010, AM J PHYS MED REHAB, V89, P446, DOI 10.1097/PHM.0b013e3181d3e71f; Cameron MH, 2008, SOMATOSENS MOT RES, V25, P113, DOI 10.1080/08990220802131127; Cattaneo D, 2007, CLIN REHABIL, V21, P771, DOI 10.1177/0269215507077602; Cattaneo D, 2009, MULT SCLER, V15, P59, DOI 10.1177/1352458508096874; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chiari L, 2002, CLIN BIOMECH, V17, P666, DOI 10.1016/S0268-0033(02)00107-9; Chung LH, 2008, MED SCI SPORT EXER, V40, P1717, DOI 10.1249/MSS.0b013e31817e32a3; Dalgas U, 2008, MULT SCLER J, V14, P35, DOI 10.1177/1352458507079445; DeBolt LS, 2004, ARCH PHYS MED REHAB, V85, P290, DOI 10.1016/j.apmr.2003.06.003; Delignieres D, 2003, J MOTOR BEHAV, V35, P86, DOI 10.1080/00222890309602124; Dingwell JB, 2000, CHAOS, V10, P848, DOI 10.1063/1.1324008; FRANKLIN BA, 2000, ACSMS GUIDELINES EXE; Frzovic D, 2000, ARCH PHYS MED REHAB, V81, P215, DOI 10.1053/apmr.2000.0810215; Fulk George D, 2005, J Neurol Phys Ther, V29, P34; Giesser B, 2007, MULT SCLER, V13, P224, DOI 10.1177/1352458506070663; Gutierrez GM, 2005, ARCH PHYS MED REHAB, V86, P1824, DOI 10.1016/j.apmr.2005.04.008; Harbourne RT, 2009, PHYS THER, V89, P284, DOI 10.2522/ptj.20080130.ar; Harbourne RT, 2003, DEV PSYCHOBIOL, V42, P368, DOI 10.1002/dev.10110; HORAK FB, 1994, J NEUROPHYSIOL, V72, P479; JONES DA, 1987, J PHYSIOL-LONDON, V391, P1; Karst Gregory M, 2005, J Neurol Phys Ther, V29, P170; Kuo AD, 1998, EXP BRAIN RES, V122, P185, DOI 10.1007/s002210050506; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Kyvelidou A, 2010, ARCH PHYS MED REHAB, V91, P1593, DOI 10.1016/j.apmr.2010.06.027; Lamoth CJC, 2009, GAIT POSTURE, V29, P546, DOI 10.1016/j.gaitpost.2008.12.006; Lockhart T, 2008, ERGONOMICS, V51, P1860, DOI 10.1080/00140130802567079; Motl RW, 2006, RES NURS HEALTH, V29, P597, DOI 10.1002/nur.20161; NELSON SR, 1995, ANN OTO RHINOL LARYN, V104, P62, DOI 10.1177/000348949510400110; Newell K. M., 1997, DEGREES FREEDOM DEV, P63; Newell K. M., 1997, APPL NONLINEAR DYNAM, P63; Newman MA, 2007, MULT SCLER, V13, P113, DOI 10.1177/1352458506071169; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Romberg A, 2004, NEUROLOGY, V63, P2034, DOI 10.1212/01.WNL.0000145761.38400.65; RUTHERFORD OM, 1986, EUR J APPL PHYSIOL O, V55, P100, DOI 10.1007/BF00422902; Ryushi Tomoo, 2000, Journal of Physiological Anthropology and Applied Human Science, V19, P143, DOI 10.2114/jpa.19.143; Snook EM, 2009, NEUROREHAB NEURAL RE, V23, P108, DOI 10.1177/1545968308320641; Sosnoff JJ, 2010, ARCH PHYS MED REHAB, V91, P93, DOI 10.1016/j.apmr.2009.09.013; Soyuer F, 2006, NEUROL RES, V28, P555, DOI 10.1179/016164105X49373; Sprott J.C., 1998, CHAOS DATAS ANAL PRO; Stergiou N, 2004, INNOVATIVE ANAL HUMA, P63; Van Emmerik REA, 2010, GAIT POSTURE, V32, P608, DOI 10.1016/j.gaitpost.2010.09.002; Weiss A, 2000, AM J PHYS MED REHAB, V79, P369, DOI 10.1097/00002060-200007000-00009; White LJ, 2004, SPORTS MED, V34, P1077, DOI 10.2165/00007256-200434150-00005; White LJ, 2004, MULT SCLER J, V10, P668, DOI 10.1191/1352458504ms1088oa; Woollacott, 2001, MOTOR CONTROL THEORY; Yamada N, 1995, HUM MOVEMENT SCI, V14, P711, DOI 10.1016/0167-9457(95)00032-1	51	21	21	1	9	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1087-1640	1543-2696		MOTOR CONTROL	Motor Control	JAN	2012	16	1					50	63		10.1123/mcj.16.1.50			14	Neurosciences; Sport Sciences	Neurosciences & Neurology; Sport Sciences	911FH	WOS:000301702200004	22402220				2021-06-18	
J	Macera, CA; Aralis, HJ; MacGregor, AJ; Rauh, MJ; Galarneau, MR				Macera, Caroline A.; Aralis, Hilary J.; MacGregor, Andrew J.; Rauh, Mitchell J.; Galarneau, Michael R.			Postdeployment symptom changes and traumatic brain injury and/or posttraumatic stress disorder in men	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blasts; deployment; males; military; odds ratio; percent change; Post-Deployment Health Assessment; posttraumatic stress disorder; symptoms; traumatic brain injury	HEALTH PROBLEMS; MILITARY; IRAQ; DEPLOYMENT; AFGHANISTAN; VETERANS; CHALLENGES; OUTCOMES; HISTORY; CARE	In Operation Iraqi Freedom and Operation Enduring Freedom, blast-related injuries associated with combat are frequent and can result in traumatic brain injury (TBI) symptoms that may be difficult to distinguish from psychological problems. Using data from the Post-Deployment Health Assessment and Reassessment, we identified 12,046 male U.S. Navy sailors and Marines with reported combat exposure from 2008 to 2009. Symptoms potentially associated with blast-related TBI and posttraumatic stress disorder (PTSD) that were reported immediately after deployment were compared with symptoms present several months later. Our study supports others that have found that subjects with blast-related injuries may experience the development or worsening of symptoms during the months following deployment. Additionally, our study found that those who screened positive for PTSD and TBI formed a unique group, with the presence of TBI exacerbating development of PTSD symptoms at reassessment. Providers should recognize the late development of symptoms, consider the possibility of comorbidity, and be prepared to treat multiple symptoms rather than a specific diagnostic category.	[Macera, Caroline A.; Aralis, Hilary J.; Rauh, Mitchell J.] USN, Hlth Res Ctr, Warfighter Performance Dept, San Diego, CA 92106 USA; [MacGregor, Andrew J.; Galarneau, Michael R.] USN, Hlth Res Ctr, Med Modeling Simulat & Mission Support Dept, San Diego, CA 92106 USA	Aralis, HJ (corresponding author), USN, Hlth Res Ctr, Warfighter Performance Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.	Hilary.Aralis@gmail.com		MacGregor, Andrew/0000-0003-1020-7390	U.S. Navy Bureau of Medicine and Surgery [60818]	This material was based on work supported by the U.S. Navy Bureau of Medicine and Surgery, under Work Unit No. 60818.	Bahraini NH, 2009, MIL MED, V174, P1005, DOI 10.7205/MILMED-D-00-9509; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Cameron R. P., 2003, PRIMARY CARE PSYCHIA, V9, P9; Deployment Health Clinical Center, POSTD HLTH ASS PDHA; Deployment Health Clinical Center, POSTD HLTH REASS PDH; Helmick KM, 2007, FEDERAL PRACTITIONER, V24, P58; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Jaffee MS, 2009, J REHABIL RES DEV, V46, P655, DOI 10.1682/JRRD.2008.09.0114; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Mernoff Stephen T, 2010, Med Health R I, V93, P16; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sharkey JM, 2011, MIL MED, V176, P915, DOI 10.7205/MILMED-D-10-00366; Smith TC, 2009, PUBLIC HEALTH REP, V124, P90, DOI 10.1177/003335490912400112; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanielian T, 2008, INVISIBLE WOUNDS WAR, P96; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	33	21	21	0	6	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	8					1197	1208		10.1682/JRRD.2011.07.0131			12	Rehabilitation	Rehabilitation	149FA	WOS:000319303200007	23341312	Bronze			2021-06-18	
J	Urakami, Y				Urakami, Yuko			Relationship Between Sleep Spindles and Clinical Recovery in Patients With Traumatic Brain Injury: A Simultaneous EEG and MEG Study	CLINICAL EEG AND NEUROSCIENCE			English	Article						diffuse axonal injury; electroencephalography; magneoencephalography; recovery; sleep spindles		Few methods can predict the prognosis and outcome of traumatic brain injury. Electroencephalographic (EEG) examinations have prognostic significance in the acute stage of posttraumatic coma, and some EEG variables have been correlated with outcome. Furthermore, spindle activity and reactivity in the acute stage have been associated with good recovery. Assessments of consciousness based on EEG and magnetoencephalographic (MEG) recordings provide valuable information for evaluating residual function, forming differential diagnoses and estimating prognosis. This study objectively investigated how fast spindles could relate to the recovery of consciousness and cognitive function during the post-acute to chronic stages of diffuse axonal injuries (DAIs). Sleep stage 2 was examined in 7 healthy participants and 8 patients with DAIs. Simultaneous EEG and MEG recordings were performed in the post-acute (mean 80 days) and chronic (mean 151 days) stages of recovery. Magnetoencephalography enabled equivalent current dipole estimates of fast spindle sources. Clinical recovery was evaluated by consciousness, neuropsychological examination, and outcome. Six severe and two moderate injuries were studied in patients with favorable 1-year outcomes. In the sub-acute stage, significant decreases were detected in the frequency, amplitude, and cortical activation source strengths of spindle activities, but these recovered during the chronic stage. In the chronic stage, the Wechsler adult intelligence factor scale and subset patterning revealed significant improvement in cognitive function. These results suggested that spindles may reflect recovery of consciousness and cognitive function following a DAI.	Natl Rehabil Ctr Persons Disabil, Dept Med Treatment 1, Tokorozawa, Saitama 3598555, Japan	Urakami, Y (corresponding author), Natl Rehabil Ctr Persons Disabil, Dept Med Treatment 1, 4-1 Namiki, Tokorozawa, Saitama 3598555, Japan.	urakami-yuko@rehab.go.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23500473] Funding Source: KAKEN		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BRICOLO A, 1976, CLIN ELECTROENCEPHAL, V7, P184, DOI 10.1177/155005947600700402; CHATRIAN GE, 1990, CURRENT PRACTICE CLI, P425; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Gibbs FA, 1964, ATLAS ELECTROENCEPHA, V3, P90; Gottselig JM, 2002, BRAIN, V125, P373, DOI 10.1093/brain/awf021; HAMALAINEN M, 1993, REV MOD PHYS, V65, P413, DOI 10.1103/RevModPhys.65.413; Ilonka M, 2003, CLIN NEUROPHYSIOL, V113, P1937; Kaplan PW, 2004, J CLIN NEUROPHYSIOL, V21, P307; Lopes da Silva F., 2005, ELECTROENCEPHALOGRAP, P107; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Merrit HH, 1990, MERRITS PRACTICE CLI, P425; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Morel A, 2005, EUR J NEUROSCI, V21, P1007, DOI 10.1111/j.1460-9568.2005.03921.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Reilly E. L., 2005, ELECTROENCEPHALOGRAP, P139; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P420, DOI 10.1016/0013-4694(83)90224-9; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Urakami Y, 2008, J CLIN NEUROPHYSIOL, V25, P13, DOI 10.1097/WNP.0b013e318162a8a4; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031	26	21	22	2	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1550-0594	2169-5202		CLIN EEG NEUROSCI	Clin. EEG Neurosci.	JAN	2012	43	1					39	47		10.1177/1550059411428718			9	Clinical Neurology; Neurosciences; Neuroimaging; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	952FT	WOS:000304777400007	22423550				2021-06-18	
J	Yu, GF; Huang, Q; Dai, WM; Jie, YQ; Fan, XF; Wu, A; Lv, Y; Li, YP; Yan, XJ				Yu, Guo-Feng; Huang, Qiang; Dai, Wei-Min; Jie, Yuan-Qing; Fan, Xiao-Feng; Wu, An; Lv, Yao; Li, Yun-Ping; Yan, Xin-Jiang			Prognostic value of copeptin: One-year outcome in patients with traumatic brain injury	PEPTIDES			English	Article						Copeptin; Traumatic brain injury; 1-Year outcome	VASOPRESSIN PRECURSOR; STABLE PEPTIDE; CEREBRAL-ISCHEMIA; V-2 RECEPTORS; HEART-FAILURE; MORTALITY; DAMAGE; STROKE	High plasma copeptin level has been associated with one-month mortality after traumatic brain injury. However, not much is known regarding its relation with long-term outcome. Thus, we investigated the ability of copeptin to predict 1-year outcome in patients with traumatic brain injury. One hundred and six healthy controls and 106 patients with acute severe traumatic brain injury were included. Plasma samples were obtained on admission. Its concentration was measured by enzyme-linked immunosorbent assay. Forty-eight patients (45.3%) suffered from unfavorable outcome (Glasgow Outcome Scale score of 1-3) and 31 patients (29.2%) died in 1 year after traumatic brain injury. Upon admission, plasma copeptin level in patients was substantially higher than that in healthy controls. A forward stepwise logistic regression selected plasma copeptin level as an independent predictor for 1-year unfavorable outcome and mortality of patients. A receiver operating characteristic curve analysis showed plasma copeptin level predicted 1-year unfavorable outcome and mortality obviously. The predictive value of the copeptin concentration was thus similar to that of Glasgow Coma Scale score for the prediction of unfavorable outcome and mortality after 1 year. In a combined logistic-regression model, copeptin improved the area under curve of Glasgow Coma Scale score for the prediction of unfavorable outcome and mortality after 1 year, but the differences were not significant. Thus, copeptin level is a useful, complementary tool to predict functional outcome and mortality 1 year after traumatic brain injury. (C) 2011 Elsevier Inc. All rights reserved.	[Yu, Guo-Feng; Huang, Qiang; Dai, Wei-Min; Jie, Yuan-Qing; Fan, Xiao-Feng; Wu, An; Lv, Yao; Li, Yun-Ping; Yan, Xin-Jiang] Quzhou Peoples Hosp, Dept Neurosurg, Quzhou 324000, Peoples R China	Huang, Q (corresponding author), Quzhou Peoples Hosp, Dept Neurosurg, 2 Zhongloudi Rd, Quzhou 324000, Peoples R China.	quzhouhuangqiang@163.com					Asfar P, 2006, CRIT CARE CLIN, V22, P131, DOI 10.1016/j.ccc.2005.08.007; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Dong XQ, 2011, PEPTIDES, V32, P253, DOI 10.1016/j.peptides.2010.11.021; Itoi K, 2004, J NEUROENDOCRINOL, V16, P348, DOI 10.1111/j.0953-8194.2004.01172.x; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Katan M, 2008, NEUROENDOCRINOL LETT, V29, P341; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Kelly D, 2008, J CARD FAIL, V14, P739, DOI 10.1016/j.cardfail.2008.07.231; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Molnar AH, 2008, ACTA NEUROCHIR, V150, P265, DOI 10.1007/s00701-007-1400-1; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morgenthaler NG, 2007, SHOCK, V28, P219, DOI 10.1097/SHK.0b013e318033e5da; Stoiser B, 2006, EUR J CLIN INVEST, V36, P771, DOI 10.1111/j.1365-2362.2006.01724.x; Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Urwyler SA, 2010, STROKE, V41, P1564, DOI 10.1161/STROKEAHA.110.584649; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Xu Miao, 2007, Chin J Traumatol, V10, P90; Zweifel C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-34	23	21	24	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0196-9781	1873-5169		PEPTIDES	Peptides	JAN	2012	33	1					164	169		10.1016/j.peptides.2011.11.017			6	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	889KR	WOS:000300073100022	22138140				2021-06-18	
J	Peterson, EC; Chesnut, RM				Peterson, Eric Cecala; Chesnut, Randall M.			Talk and Die Revisited: Bifrontal Contusions and Late Deterioration	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic Brain Injury; Bifrontal Contusions; Late Deterioration	PROGRESSION; HEMORRHAGE	Background: Severe bifrontal contusions in an awake traumatic brain injury (TBI) patient is a challenging clinical picture, as they are prone to late deterioration. We evaluated our series of patients with severe bifrontal contusions, characterizing their clinical course and suggestions for management. Methods: We examined a prospectively collected database of TBIs for patients with severe bifrontal contusions, defined as >30 cm(3). Only patients with Glasgow Coma Scale score of 10 or greater were included. Patients were divided into two groups: deterioration and nondeterioration. Clinical variables were compared between the two groups. Results: Thirteen patients met the above criteria. The mean Glasgow Coma Scale score was 13, and all were low mechanism injuries. All patients were managed with intensive care unit observation and hyperosmolar therapy to maintain serum osmolarity >300. Overall, 7 of 13 (54%) suffered an acute clinical deterioration a mean of 4.5 days postinjury. Of those managed with immediate surgical decompression, all had good outcomes and returned to work. There was no difference in contusion or edema volumes between the two groups. Conclusions: Awake patients with bifrontal contusions represent a unique cohort of TBI patients who are prone to rapid deterioration late in their clinical course. They have extensive frontal edema and mass effect, yet we were unable to find a correlation between edema volumes and incidence of deterioration. Based on this series and our experience in other TBI patients, we no longer utilize prophylactic infusions of hypertonic saline in the setting of TBI. We recommend managing these patients with intensive care unit admission and early intracranial pressure monitoring. If they do deteriorate despite these measures, rapid bifrontal decompression can lead to good functional outcomes.	[Peterson, Eric Cecala; Chesnut, Randall M.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Peterson, EC (corresponding author), Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.	ericpete@uw.edu		Chesnut, Randall/0000-0001-6377-3666			Alahmadi H, 2009, J NEUROSURG; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Lee TT, 1997, SURG NEUROL, V48, P333, DOI 10.1016/S0090-3019(96)00483-1; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Rehman Tausif, 2008, Cases J, V1, P203, DOI 10.1186/1757-1626-1-203; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f	13	21	22	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2011	71	6					1588	1592		10.1097/TA.0b013e31822b791d			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	869RT	WOS:000298616400025	22182868				2021-06-18	
J	Bechtel, K; Le, K; Martin, KD; Shah, N; Leventhal, JM; Colson, E				Bechtel, Kirsten; Le, Kim; Martin, Kimberly D.; Shah, Niyati; Leventhal, John M.; Colson, Eve			Impact of an Educational Intervention on Caregivers' Beliefs About Infant Crying and Knowledge of Shaken Baby Syndrome	ACADEMIC PEDIATRICS			English	Article						abusive head trauma; infant crying; parent education; shaken baby syndrome	TRAUMATIC BRAIN-INJURY; ABUSIVE HEAD TRAUMA; ADMISSIONS	OBJECTIVE: Shaken baby syndrome (SBS) is the leading cause of traumatic infant death. We examined whether the message about not shaking an infant should be included in the newborn anticipatory guidance provided by pediatric residents. The aim of this study was to determine the impact of an educational intervention (Take 5 Safety Plan for Crying) delivered by pediatric residents at newborn hospital discharge on beliefs about infant crying and knowledge of SBS among caregivers of young infants being treated in an urban primary care center. METHODS: Structured interviews were done in one convenience sample of caregivers before (historical control group) and in a second set of different caregivers after (intervention group) an educational intervention was implemented at hospital discharge. Logistic regression was used to calculate adjusted associations between the intervention and caregivers' beliefs/knowledge. RESULTS: One hundred ten caregivers were in the historical control group and 112 in the intervention group. The intervention group had more mothers and the infants were younger. Controlling for these differences, intervention group caregivers were more likely to state they would take a break if frustrated with infant crying (OR 3.10, 95% CI, 1.62-5.93), were more likely to state frustration caused infant shaking (OR 2.21, 95% CI, 1.20-4.20), and to state their knowledge of SBS was from hospital staff (OR 3.39, 95% CI, 1.61-4.20). CONCLUSION: This targeted postpartum intervention incorporated into newborn anticipatory guidance can influence caregivers' beliefs about infant crying and knowledge of SBS.	[Bechtel, Kirsten; Le, Kim; Shah, Niyati; Leventhal, John M.; Colson, Eve] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Martin, Kimberly D.] Yale Univ, Sch Publ Hlth, New Haven, CT 06510 USA	Bechtel, K (corresponding author), Yale New Haven Childrens Hosp, Sect Pediat Emergency Med, 100 York St,Suite 1F, New Haven, CT 06504 USA.	kirsten.bechtel@yale.edu	Bechtel, Kirsten/K-2147-2019		Connecticut Children's Trust, Hartford, Connecticut	This study was funded by the Connecticut Children's Trust Fund, Hartford, Connecticut (principal investigators John M. Leventhal and Kirsten Bechtel).	Adamsbaum C, 2010, PEDIATRICS, V126, P546, DOI 10.1542/peds.2009-3647; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2009, CAN MED ASSOC J, V180, P727, DOI 10.1503/cmaj.081419; Barr RG, 2009, PEDIATRICS, V123, P972, DOI 10.1542/peds.2008-0908; Chiesa A, 2009, PEDIATR CLIN N AM, V56, P317, DOI 10.1016/j.pcl.2009.02.001; Colson ER, 2002, ARCH PEDIAT ADOL MED, V156, P717, DOI 10.1001/archpedi.156.7.717; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; HELFER RE, 1987, CHILD ABUSE NEGLECT, V11, P11, DOI 10.1016/0145-2134(87)90028-7; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kesler H, 2008, J NEUROSURG-PEDIATR, V1, P351, DOI 10.3171/PED/2008/1/5/351; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; McRury JM, 2010, J AM BOARD FAM MED, V23, P315, DOI 10.3122/jabfm.2010.03.090142; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Russell BS, 2008, CHILD ABUSE NEGLECT, V32, P949, DOI 10.1016/j.chiabu.2008.05.002; Schnitzer PG, 2005, PEDIATRICS, V116, pE687, DOI 10.1542/peds.2005-0296; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454	18	21	22	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1876-2859	1876-2867		ACAD PEDIATR	Acad. Pediatr.	NOV-DEC	2011	11	6					481	486		10.1016/j.acap.2011.08.001			6	Pediatrics	Pediatrics	851MU	WOS:000297276000009	21940233				2021-06-18	
J	Rieder, C; Jansen, P				Rieder, Cornelia; Jansen, Petra			No Neuropsychological Consequence in Male and Female Soccer Players after a Short Heading Training	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						heading training; acute head impacts; neuropsychological measurements; headache; concussion	SEX-DIFFERENCES; CONCUSSION SYMPTOMS; SPORTS; TRAUMA; PERFORMANCE; FREQUENCY; RECOVERY	The impact of heading on neuropsychological performance is a subject of controversy. In this experimental study, a controlled group design was used to investigate the possible effects of a short heading training session on neuropsychological performance. Ninety-one participants matched by age, sex, and intelligence were assigned to one of the following groups: A heading-training group, a placebo control group, and a waiting control group. All participants completed a neuropsychological test battery for attention and working memory (D2 Test, Benton Visual Retention Test, Paced Auditory Serial Addition Task Test). After 1 week, they received heading training, football (e.g., soccer) training without heading, or no training. Immediately after this training, the neuropsychological tests were conducted again. There was no neuropsychological deficit which could only be attributed to the heading training. However, within the heading group, women complained more about headache than men.	[Rieder, Cornelia; Jansen, Petra] Univ Regensburg, Inst Sport Sci, D-93047 Regensburg, Germany	Jansen, P (corresponding author), Univ Regensburg, Inst Sport Sci, D-93047 Regensburg, Germany.	petra.jansen@psk.uni-regensburg.de					Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Benton A. L., 1996, BENTON TEST; BENTON AL, 1950, AMA ARCH NEUROL PSY, V64, P699, DOI 10.1001/archneurpsyc.1950.02310290095010; Brickenkamp R., 2002, TEST D2 AUFMERKSAMKE; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Etnier JL, 2009, J SPORT EXERCISE PSY, V31, P469, DOI 10.1123/jsep.31.4.469; FREYTAG HW, 1979, ARCH PSYCHIAT NERVEN, V227, P109; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jordan S. E., 1996, AM J SPORTS MED, V24, P105; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lambourne K, 2010, MED SCI SPORT EXER, V42, P1396, DOI 10.1249/MSS.0b013e3181cbee11; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McCaffrey RJ, 2001, ARCH CLIN NEUROPSYCH, V16, P9, DOI 10.1016/S0887-6177(99)00055-4; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Oswald W. D., 1987, ZAHLEN VERBINDUNGS T; Poeck K., 2006, NEUROLOGIE, V12; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Reitan RM, 1956, TRAIL MAKING TEST MA; Rieder C., 2010, BRENNPUNKTE SPORTWIS, P63; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Rutherford A., 2007, FOCUS COGNITIVE DISO, P181; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Talavage T. M., 2010, J NEUROTRAUMA; VERNON PA, 1993, PERS INDIV DIFFER, V14, P35, DOI 10.1016/0191-8869(93)90172-Y; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Wechsler D., 1964, MESSUNG INTELLIGENZ; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	44	21	21	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2011	26	7					583	591		10.1093/arclin/acr055			9	Psychology, Clinical; Psychology	Psychology	836FF	WOS:000296094800002	21750329	Bronze, Green Published			2021-06-18	
J	Zeng, GW; Wang, GP; Guan, FX; Chang, KL; Jiao, HL; Gao, WQ; Xi, SM; Yang, B				Zeng, Guangwei; Wang, Gongping; Guan, Fangxia; Chang, Keliang; Jiao, Hongliang; Gao, Wanqin; Xi, Shoumin; Yang, Bo			Human amniotic membrane-derived mesenchymal stem cells labeled with superparamagnetic iron oxide nanoparticles: the effect on neuron-like differentiation in vitro	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article						Amniotic membrane; Mesenchymal stem cells; Neuron-like differentiation; Superparamagnetic iron oxide nanoparticles	TRAUMATIC BRAIN-INJURY; UMBILICAL-CORD BLOOD; HUMAN BONE-MARROW; ADIPOSE-TISSUE; MODEL; TRANSPLANTATION; MIGRATION; SURVIVAL; THERAPY	Mesenchymal stem cells (MSCs) have the potential for self-renewal and multipotential differentiation to regenerate damaged tissues or recover functional absence in diseases. Superparamagnetic iron oxide nanoparticles (SPIONs) are used as contrast agents in magnetic resonance imaging (MRI) for labeling cells in vitro and for tracking SPION-labeled cells after transplantation in vivo. Human amniotic membrane-derived mesenchymal stem cells (hAM-dMSCs) have the capacity for neuron-like differentiation that could be used to cure central nervous system (CNS) diseases. The study investigated the impacts of cytotoxicity of SPIONs on neuron-like differentiation of hAM-dMSCs in both single (1x) and multiple (4x) SPIONs-labeled methods. hAM-dMSCs could be efficiently labeled at safe concentrations of SPIONs (a parts per thousand currency sign14 mu g/ml) without significantly affecting their viability (> 80% after a MTT assay), special surface antigens (CD29, CD44, CD90, CD105 through flow cytometry), and neuron-like differentiation (nestin and neuron-specific enolase through immunocytochemistry and reverse transcription polymerase chain reaction). Compared with multiple (4x) SPION-labeled methods, a single (1x) SPION-labeled method avoided multiple SPION-labeled hAM-dMSCs and minimized the impact of cytotoxicity of SPIONs on neuron-like differentiation of hAM-dMSCs. Under safe concentrations of SPIONs, a single (1x) SPION-labeled method provided appropriate viability for SPIONs-labeled hAM-dMSCs and facilitated the MRI evaluation of hAM-dMSCs after transplantation.	[Zeng, Guangwei; Chang, Keliang; Jiao, Hongliang; Yang, Bo] Zhengzhou Univ, Hosp 1, Dept Neurosurg, Zhengzhou 450052, Henan Province, Peoples R China; [Zeng, Guangwei] Henan Univ Sci & Technol, Hosp 1, Dept Plast Reconstruct & Burns Surg, Luoyang 471003, Henan Province, Peoples R China; [Wang, Gongping] Henan Univ Sci & Technol, Hosp 1, Dept Onchol, Luoyang 471003, Henan Province, Peoples R China; [Guan, Fangxia] Zhengzhou Univ, Dept Bioengn, Zhengzhou 450001, Henan Province, Peoples R China; [Gao, Wanqin] Henan Univ Sci & Technol, Hosp 1, Dept Radiol, Luoyang 471003, Henan Province, Peoples R China; [Xi, Shoumin] Henan Univ Sci & Technol, Dept Pharmacol, Sch Med, Luoyang 471003, Henan Province, Peoples R China	Yang, B (corresponding author), Zhengzhou Univ, Hosp 1, Dept Neurosurg, Zhengzhou 450052, Henan Province, Peoples R China.	zgwnw11@126.com			Health Department of Henan Province, People's Republic of China [200702003, 2005018]	This research was supported by Henan Medical Science and Technology Research Projects of Health Department of Henan Province, People's Republic of China (No. 200702003); Henan Medical Technological Innovation Projects of Health Department of Henan Province, People's Republic of China (No. 2005018).	Alviano F, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-11; Brohlin M, 2009, NEUROSCI RES, V64, P41, DOI 10.1016/j.neures.2009.01.010; Chalmers J.J., 2007, MAGNETIC CELL SEPARA, P32; Chao YX, 2009, J NEUROIMMUNOL, V216, P39, DOI 10.1016/j.jneuroim.2009.09.003; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Daldrup-Link HE, 2005, RADIOLOGY, V234, P197, DOI 10.1148/radiol.2341031236; Fallahi-Sichani M, 2007, CELL BIOL INT, V31, P299, DOI 10.1016/j.cellbi.2006.11.011; Han K, 2008, CELL PROLIFERAT, V41, P709, DOI 10.1111/j.1365-2184.2008.00553.x; Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071; Ishige I, 2009, INT J HEMATOL, V90, P261, DOI 10.1007/s12185-009-0377-3; Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342; Khoo MLM, 2008, STEM CELLS DEV, V17, P883, DOI 10.1089/scd.2007.0185; Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341; LI GX, 2006, ZHENGZHOU DAXUE XUEB, V412, P244; Lu FZ, 2005, J LAB CLIN MED, V146, P271, DOI 10.1016/j.lab.2005.07.003; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Marcus AJ, 2008, J CELL MOL MED, V12, P1256, DOI 10.1111/j.1582-4934.2008.00180.x; Pawelczyk E, 2008, STEM CELLS, V26, P1366, DOI 10.1634/stemcells.2007-0707; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Song SJ, 2007, STEM CELLS DEV, V16, P747, DOI 10.1089/scd.2007.0027; Wang Gong-ping, 2008, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V33, P926; Weissleder R, 1997, J MAGN RESON IMAGING, V7, P258, DOI 10.1002/jmri.1880070140; Wolbank S, 2009, TISSUE ENG PT A, V15, P1843, DOI 10.1089/ten.tea.2008.0205; Zhao P, 2005, TRANSPLANTATION, V79, P528, DOI 10.1097/01.TP.0000149503.92433.39	24	21	24	0	23	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	NOV	2011	357	1-2					331	341		10.1007/s11010-011-0904-4			11	Cell Biology	Cell Biology	834EF	WOS:000295941500036	21625950				2021-06-18	
J	Yang, CC; Shih, NC; Chang, WC; Huang, SK; Chien, CW				Yang, Chih-Chieh; Shih, Nai-Ching; Chang, Wen-Chiung; Huang, San-Kuei; Chien, Ching-Wen			Long-term medical utilization following ventilator-associated pneumonia in acute stroke and traumatic brain injury patients: a case-control study	BMC HEALTH SERVICES RESEARCH			English	Article						ventilator-associated pneumonia; medical utilization; longitudinal study; ICU; traumatic brain injury; acute hemorrhagic stroke; acute ischemic stroke	INTENSIVE-CARE-UNIT; LARGE US DATABASE; NOSOCOMIAL PNEUMONIA; MORTALITY-RATE; IMPACT; EPIDEMIOLOGY; OUTCOMES; SYSTEM; COST	Background: The economic burden of ventilator-associated pneumonia (VAP) during the index hospitalization has been confirmed in previous studies. However, the long-term economic impact is still unclear. The aim of this study is to examine the effect of VAP on medical utilization in the long term. Methods: This is a retrospective case-control study. Study subjects were patients experiencing their first traumatic brain injury, acute hemorrhagic stroke, or acute ischemic stroke during 2004. All subjects underwent endotracheal intubation in the emergency room (ER) on the day of admission or the day before admission, were transferred to the intensive care unit (ICU) and were mechanically ventilated for 48 hours or more. A total of 943 patients who developed VAP were included as the case group, and each was matched with two control patients without VAP by age (+/- 2 years), gender, diagnosis, date of admission (+/- 1 month) and hospital size, resulting in a total of 2,802 patients in the study. Using robust regression and Poisson regression models we examined the effect of VAP on medical utilization including hospitalization expenses, outpatient expenses, total medical expenses, number of ER visits, number of readmissions, number of hospitalization days and number of ICU days, during the index hospitalization and during the following 2-year period. Results: Patients in the VAP group had higher hospitalization expenses, longer length of stay in hospital and in ICU, and a greater number of readmissions than the control group patients. Conclusions: VAP has a significant impact on medical expenses and utilization, both during the index hospitalization during which VAP developed and in the longer term.	[Chien, Ching-Wen] Natl Yang Ming Univ, Insti Hosp & Hlth Care Adm, Taipei 112, Taiwan; [Yang, Chih-Chieh; Shih, Nai-Ching] Lotung Poh Al Hosp, Dept Emergency Med & Traumatol, Lotung 265, Yilan, Taiwan; [Chang, Wen-Chiung] Natl Taiwan Univ, Inst Hlth Policy & Management, Taipei 10764, Taiwan; [Huang, San-Kuei] Dept Hlth, Bur Natl Hlth Insurance, Taipei, Taiwan	Chien, CW (corresponding author), Natl Yang Ming Univ, Insti Hosp & Hlth Care Adm, 155,Sec 2,Linong St, Taipei 112, Taiwan.	ihhca@yahoo.com.tw					Arabi Y, 2008, INT J INFECT DIS, V12, P505, DOI 10.1016/j.ijid.2008.02.010; Bercault N, 2001, CRIT CARE MED, V29, P2303, DOI 10.1097/00003246-200112000-00012; Cocanour Christine S, 2005, Surg Infect (Larchmt), V6, P65, DOI 10.1089/sur.2005.6.65; Dietrich ES, 2002, INFECTION, V30, P61, DOI 10.1007/s15010-002-1083-8; Eachempati SR, 2010, SURG INFECT, V11, P13, DOI 10.1089/sur.2008.025; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Erbay Riza Hakan, 2004, BMC Pulm Med, V4, P3, DOI 10.1186/1471-2466-4-3; Gikas A, 2010, INFECTION, V38, P165, DOI 10.1007/s15010-010-0007-2; Hortal J, 2009, CRIT CARE, V13, DOI 10.1186/cc7896; Hugonnet S, 2004, INFECT CONT HOSP EP, V25, P1090, DOI 10.1086/502349; Kollef MH, 2005, CHEST, V128, P3854, DOI 10.1378/chest.128.6.3854; Muscedere JG, 2008, J CRIT CARE, V23, P5, DOI 10.1016/j.jcrc.2007.11.012; *NAT HLTH RES I, 2007, CLIN PRACT GUID PNEU; Nseir S, 2005, CHEST, V128, P1650, DOI 10.1378/chest.128.3.1650; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Sheng WH, 2005, J FORMOS MED ASSOC, V104, P318; Suka M, 2007, INFECT CONT HOSP EP, V28, P307, DOI 10.1086/511997; Walkey AJ, 2009, INFECT CONT HOSP EP, V30, P319, DOI 10.1086/596103; Warren DK, 2003, CRIT CARE MED, V31, P1312, DOI 10.1097/01.CCM.0000063087.93157.06; Weigelt JA, 2010, AM J INFECT CONTROL, V38, P112, DOI 10.1016/j.ajic.2009.06.010; Zhan CL, 2006, HEALTH AFFAIR, V25, P1386, DOI 10.1377/hlthaff.25.5.1386	22	21	25	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1472-6963			BMC HEALTH SERV RES	BMC Health Serv. Res.	OCT 31	2011	11								289	10.1186/1472-6963-11-289			7	Health Care Sciences & Services	Health Care Sciences & Services	848LF	WOS:000297052400002	22040214	DOAJ Gold, Green Published			2021-06-18	
J	Irie, F; Le Brocque, R; Kenardy, J; Bellamy, N; Tetsworth, K; Pollard, C				Irie, Fumiko; Le Brocque, Robyne; Kenardy, Justin; Bellamy, Nicholas; Tetsworth, Kevin; Pollard, Cliff			Epidemiology of Traumatic Epidural Hematoma in Young Age	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Epidemiology; Traumatic epidural hematoma; Young age group	BRAIN-INJURY; EXTRADURAL HEMATOMAS; HEAD-INJURY; CHILDREN; MANAGEMENT; INTUBATION; CRANIECTOMY; EXPERIENCE; AUSTRALIA; INFANTS	Background: Epidural hematoma (EDH) is a major traumatic brain injury and a potentially life-threatening condition, with the mortality rate in the young age group varying across studies. The aim of this analysis was to investigate the magnitude of traumatic EDH in young patients aged 0 year to 24 years in Queensland, Australia. Methods: Study patients presented to the emergency department of 14 public hospitals participating in the Queensland Trauma Registry during 2005 to 2007 and were diagnosed and admitted for treatment of EDH. Age group comparisons were performed for demographic, injury, treatment, operation details, and outcome-related variables. Results: We identified 224 young patients with traumatic EDH. The most frequent cause of injury was a fall in the 0 year to 9 years age groups and road traffic crash in those aged 10 years to 24 years. Almost 81% of the EDH cases were due to accidental injury, 17% due to assault, with the remainder due to self-harm and undetermined intent. Skull fracture was present in 75% of the study patients. Neurosurgical operations were performed on 40%. The overall Injury Severity Score adjusted in-hospital mortality rate was 4.8%. The odds of in-hospital mortality was 2.5 (95% confidence interval, 0.8-8.2) compared with older patients (25-64 years). Conclusions: The results indicate that the Injury Severity Score adjusted in-hospital mortality rates for young patients with EDH were 4.8%. Given the limited information on morbidity resulting from EDH, further analysis to examine modifiable factors for better management and to evaluate survivor's long-term health outcomes via a longitudinal follow-up study is warranted.	[Irie, Fumiko; Le Brocque, Robyne; Bellamy, Nicholas; Tetsworth, Kevin; Pollard, Cliff] Univ Queensland, Ctr Natl Res Disabil & Rehabil Med CONROD, Brisbane, Qld, Australia; [Tetsworth, Kevin; Pollard, Cliff] Royal Brisbane Womens Hosp, Brisbane, Qld, Australia	Irie, F (corresponding author), Univ Queensland, RBWH, Edith Cavell Bldg, Herston, Qld 4029, Australia.	f.irie@uq.edu.au	Tetsworth, Kevin/A-8005-2013; Kenardy, Justin/F-2085-2010; Le Brocque, Robyne/F-4848-2010; Kenardy, Justin A/H-6603-2014	Tetsworth, Kevin/0000-0002-3069-4141; Le Brocque, Robyne/0000-0002-4574-1254; Kenardy, Justin A/0000-0001-9475-8450	Motor Accident Insurance Commission (MAIC); Queensland Health (QH); QTR; Trauma Registry Nurse Coordinators	We acknowledge the support and contributions of the Motor Accident Insurance Commission (MAIC), Queensland Health (QH), core QTR staff, and Trauma Registry Nurse Coordinators, and all the clinical, administrative, and managerial staff at each of the hospitals where the QTR is located.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS9; Aitken L, 2006, QUEENSLAND TRAUMA RE; Balmer B, 2006, CHILD NERV SYST, V22, P363, DOI 10.1007/s00381-005-1254-x; Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; Ben Abraham R, 2000, PEDIATR NEUROSURG, V33, P70, DOI 10.1159/000028990; Beni-Adani L, 1999, J TRAUMA, V46, P306, DOI 10.1097/00005373-199902000-00018; Bernard Stephen A, 2006, Emerg Med Australas, V18, P221, DOI 10.1111/j.1742-6723.2006.00850.x; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Browne GJ, 2002, PEDIATR EMERG CARE, V18, P86, DOI 10.1097/00006565-200204000-00006; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; Dallow N, 2010, QUEENSLAND TRAUMA RE; Davis DP, 2008, RESUSCITATION, V76, P333, DOI 10.1016/j.resuscitation.2007.08.004; De Souza M, 2007, J TRAUMA, V63, P370, DOI 10.1097/TA.0b013e318124a95b; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DOSSANTOS ALM, 1994, PEDIATR NEUROSURG, V21, P50; Ehrlich PF, 2004, J PEDIATR SURG, V39, P1376, DOI 10.1016/j.jpedsurg.2004.05.010; Finkelhor D, 2005, CHILD MALTREATMENT, V10, P5, DOI 10.1177/1077559504271287; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gemma M, 2002, J NEUROSURG ANESTH, V14, P50, DOI 10.1097/00008506-200201000-00010; Gerlach R, 2009, PEDIATR EMERG CARE, V25, P164, DOI 10.1097/PEC.0b013e31819a8966; Glaeser P, 2000, JAMA-J AM MED ASSOC, V283, P797, DOI 10.1001/jama.283.6.797; Hammell CL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1683; HELFER RE, 1977, PEDIATRICS, V60, P533; Irie F, 2010, INJURY, V41, P964, DOI 10.1016/j.injury.2009.09.002; Lecky F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001429.pub2; Lee ACW, 1997, J PAEDIATR CHILD H, V33, P446; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; Maggi G, 1998, J Neurosurg Sci, V42, P95; Marion DW, 2006, NEUROSURGERY, V58, P655; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PASAOGLU A, 1990, ACTA NEUROCHIR, V106, P136, DOI 10.1007/BF01809456; PILLAY R, 1995, S AFR MED J, V85, P672; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Rocchi G, 2005, J CHILD NEUROL, V20, P569, DOI 10.1177/08830738050200070501; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shugerman RP, 1996, PEDIATRICS, V97, P664; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; Taussky P, 2008, SWISS MED WKLY, V138, P281, DOI 2008/19/smw-12056; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202	45	21	22	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					847	853		10.1097/TA.0b013e3182032c9a			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	833ZT	WOS:000295925700019	21336188				2021-06-18	
J	Su, TM; Lee, TH; Huang, YH; Su, FW; Chen, WF				Su, Tsung-Ming; Lee, Tsung-Han; Huang, Yu-Hua; Su, Feng-Wen; Chen, Wu-Fu			Contralateral Subdural Effusion After Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury: Clinical Features and Outcome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Contralateral subdural effusion; Decompressive craniectomy; Traumatic brain injury	HEAD-INJURY; COMPLICATIONS; SURGERY	Background: Contralateral subdural effusion (SDE) is usually considered as an uncommon complication after decompressive craniectomy (DC) for head trauma. This complication may need more aggressive treatment because of its tendency to cause midline shift and neurologic deterioration. In this article, we present our experience with this group of patients and discuss the diagnosis and management of this entity. Methods: This study included 13 patients with severe traumatic brain injury who developed contralateral SDE after DC. Clinical and radiographic information was obtained through a retrospective review of the medical records and the radiographs. Results: The average time from the procedure of DC to the diagnosis of contralateral SDE was 13 days. Deterioration of clinical condition or appearance of new symptoms/signs related to the contralateral SDE was noted in four patients. In the remaining nine patients without apparent clinical deterioration, the contralateral SDE was discovered on routine computed tomography scan. Six patients were treated conservatively and the contralateral SDE resolved gradually. In six patients who underwent burr hole craniectomy to evacuate the SDE, the operation had successfully drained the SDE in four patients. Two patients received subsequent subduroperitoneal shunt to manage the reaccumulation of SDE. In one patient, subduroperitoneal shunt and cranioplasty were performed simultaneously to treat the SDE. Subsequently, six patients (46.2%) developed hydrocephalus and underwent ventriculoperitoneal shunt operation. Conclusions: Contralateral SDE may not be a rare complication after DC. Its diagnosis may be delayed or missed when it is asymptomatic or the clinical condition of the patient masks its clinical manifestations. It may be reasonable to repeat a computed tomography scan to detect contralateral SDE 2 weeks to 3 weeks after DC, irrespective of the clinical condition. In addition, posttraumatic hydrocephalus is a common late consequence in these patients. Close surveillance in these patients is indicated to prompt appropriate management.	[Su, Tsung-Ming; Lee, Tsung-Han; Huang, Yu-Hua; Su, Feng-Wen; Chen, Wu-Fu] Chang Gung Univ, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Neurosurg,Coll Med, Kaohsiung Hsien, Taiwan; [Chen, Wu-Fu] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan	Chen, WF (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Neurosurg,Coll Med, 123 Ta Pei Rd, Kaohsiung Hsien, Taiwan.	wfchen@ms29.hinet.net					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Ban SP, 2010, J KOREAN NEUROSURG S, V48, P244, DOI 10.3340/jkns.2010.48.3.244; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; JENNETT B, 1975, LANCET, V1, P480; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Su FW, 2008, J CLIN NEUROSCI, V15, P305, DOI 10.1016/j.jocn.2006.08.019; Su TM, 2008, J TRAUMA, V65, P1298, DOI 10.1097/TA.0b013e31815885d9; Yang XF, 2009, MED PRIN PRACT, V18, P16, DOI 10.1159/000163040	13	21	30	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					833	837		10.1097/TA.0b013e31821b092a			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	833ZT	WOS:000295925700017	21610528				2021-06-18	
J	Lv, LQ; Hou, LJ; Yu, MK; Ding, XH; Qi, XQ; Lu, YC				Lv, Li-Quan; Hou, Li-Jun; Yu, Ming-Kun; Ding, Xue-Hua; Qi, Xiang-Qian; Lu, Yi-Cheng			Hyperbaric Oxygen Therapy in the Management of Paroxysmal Sympathetic Hyperactivity After Severe Traumatic Brain Injury: A Report of 6 Cases	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Case report: Hyperbaric oxygen therapy; Paroxysmal sympathetic hyperactivity; Rehabilitation; Traumatic brain injuries	INTRACRANIAL-PRESSURE; DYSAUTONOMIA	Lv L-Q, Hou L-J, Yu M-K, Ding X-H, Qi X-Q, Lu Y-C. Hyperbaric oxygen therapy in the management of paroxysmal sympathetic hyperactivity after severe traumatic brain injury: a report of 6 cases. Arch Phys Med Rehabil 2011;92:1515-8. Paroxysmal sympathetic hyperactivity (PSH) after severe brain injury is detrimental to the recovery of patients. Pharmacologic management of PSH is difficult and efficacy is unpredictable or incomplete. This report presents 6 cases of PSH after extremely severe traumatic brain injury in which hyperbaric oxygen therapy (HBOT) controlled paroxysmal autonomic changes and posturing in the early subacute phase after limited success with conventional medication regimens. Thus, HBOT may present an option for the management of PSH in addition to pharmacologic therapy. Potential mechanisms for these effects are discussed.	[Lv, Li-Quan; Hou, Li-Jun; Yu, Ming-Kun; Ding, Xue-Hua; Qi, Xiang-Qian; Lu, Yi-Cheng] Second Mil Med Univ, Shanghai Inst Neurosurg, Dept Neurosurg, Shanghai Changzheng Hosp, Shanghai, Peoples R China	Hou, LJ (corresponding author), 415 Feng Yang Rd, Shanghai 200003, Peoples R China.	neuro_hlj@yahoo.com.cn			National Natural Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30600635]	Supported by the National Natural Foundation of China (grant no. 30600635).	ARTRU F, 1976, EUR NEUROL, V14, P310, DOI 10.1159/000114753; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Eschenfelder CC, 2008, CEREBROVASC DIS, V25, P193, DOI 10.1159/000113856; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Golden Z, 2006, DISABIL REHABIL, V28, P1379, DOI 10.1080/09638280600638364; Harch Paul G, 2009, Cases J, V2, P6538, DOI 10.4076/1757-1626-2-6538; Hardy P, 2007, J NEUROL SCI, V253, P94, DOI 10.1016/j.jns.2006.12.005; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; MILLER JD, 1971, ARCH NEUROL-CHICAGO, V24, P210, DOI 10.1001/archneur.1971.00480330038003; Ostrowski RP, 2006, ACTA NEUROCHIR SUPPL, V96, P188; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; SUKOFF MH, 1982, NEUROSURGERY, V10, P29, DOI 10.1227/00006123-198201000-00006; Voigt C, 2008, ACTA NEUROCHIR SUPPL, V102, P441, DOI 10.1007/978-3-211-85578-2_86; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	23	21	25	2	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2011	92	9					1515	1518		10.1016/j.apmr.2011.01.014			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	826YG	WOS:000295390900024	21620375				2021-06-18	
J	Mannix, RC; Zhang, J; Park, J; Lee, C; Whalen, MJ				Mannix, Rebekah C.; Zhang, Jimmy; Park, Juyeon; Lee, Christopher; Whalen, Michael J.			Detrimental Effect of Genetic Inhibition of B-Site App-Cleaving Enzyme 1 on Functional Outcome after Controlled Cortical Impact in Young Adult Mice	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PROTEIN DEPOSITION; ALZHEIMERS-DISEASE; BETA-SECRETASE; HEAD-INJURY; RISK-FACTOR; AGE; ASSOCIATION; PEPTIDE	beta-Amyloid (A beta) peptides, most notably associated with Alzheimer's disease, have been implicated in the pathogenesis of secondary injury after traumatic brain injury (TBI). A prior study has demonstrated that blocking the beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (Bace1) required for production of A beta from APP improved functional and histologic outcomes after controlled cortical impact (CCI) in aged mice. However, the majority of patients with severe TBI are young adults under the age of 40. Prior experimental models have suggested age-dependent differences in A beta clearance, and a recent study in our lab suggests that young animals remediate acute elevations in A beta after CCI better than older animals. We therefore tested the hypothesis that Bace1 deletion in young adult mice would not be protective after CCI. Male Bace1 knockout (Bace1(-/-)) and wild-type Bace1(+/+) (C57BL/6) mice (2-3 months old) were subjected to CCI (n=18-23/group) or sham injury (n=10-12/group). Functional outcomes were assessed with wire grip (motor) and the Morris water maze (MWM; spatial memory). Soluble A beta levels were assessed at 48 h after CCI. Histopathological outcomes were assessed by lesion and hippocampal volume. Clustered ordinal logistic regression showed overall significant impairment in motor performance in injured Bace1(-/-) versus Bace1(+/+) animals (p=0.003). No significant differences in MWM performance were found on repeated-measures ANOVA (p=0.11) between groups. Probe scores were significantly worse in injured Bace1(-/-) versus Bace1(+/+) mice (p=0.0009). Soluble A beta(40) was significantly lower in ipsilateral hemispheres of Bace1(-/-) than in Bace1(+/+) animals after CCI (0.9 [IQR 0.88-0.94] pmol/g protein versus 3.8 [IQR 2.4-6.0] pmol/g protein; p=0.005). Lesion and hippocampal volumes did not differ between injured groups. The data suggest that therapies targeting Bace1 may need to be tailored according to age and injury severity, as their use may exacerbate functional deficits after TBI in younger or less severely injured patients.	[Mannix, Rebekah C.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med,Dept Med, Boston, MA 02115 USA; [Mannix, Rebekah C.; Zhang, Jimmy; Park, Juyeon; Lee, Christopher; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA; [Zhang, Jimmy; Park, Juyeon; Lee, Christopher; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA USA	Mannix, RC (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med,Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		National Institute of Child Health & Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HD052896]; Charles Hood Foundation; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD052896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from the National Institute of Child Health & Human Development 5K12HD052896 (R.C.M.), the Charles Hood Foundation (R.C.M.), and the National Institute of Neurological Disorders and Stroke 5RO1NS047447 (M.J.W.).	Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Brewer GJ, 1998, NEUROBIOL AGING, V19, P561, DOI 10.1016/S0197-4580(98)00091-8; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Giuffrida ML, 2009, J NEUROSCI, V29, P10582, DOI 10.1523/JNEUROSCI.1736-09.2009; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; Miners JS, 2010, BRAIN PATHOL, V20, P794, DOI 10.1111/j.1750-3639.2010.00375.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Placanica L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005088; Plant LD, 2003, J NEUROSCI, V23, P5531; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vassar R, 2009, J NEUROSCI, V29, P12787, DOI 10.1523/JNEUROSCI.3657-09.2009; Venkitaramani DV, 2007, J NEUROSCI, V27, P11832, DOI 10.1523/JNEUROSCI.3478-07.2007	38	21	22	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1855	1861		10.1089/neu.2011.1759			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000016	21639727	Green Published			2021-06-18	
J	Carlsson, A; Linder, A; Davidsson, J; Hell, W; Schick, S; Svensson, M				Carlsson, Anna; Linder, Astrid; Davidsson, Johan; Hell, Wolfram; Schick, Sylvia; Svensson, Mats			Dynamic Kinematic Responses of Female Volunteers in Rear Impacts and Comparison to Previous Male Volunteer Tests	TRAFFIC INJURY PREVENTION			English	Article						Whiplash; Volunteers; Crash testing; Rear impact; Sled testing	WHIPLASH; DRIVERS; HEAD; FREQUENCY	Objectives: The objective was to quantify dynamic responses of 50th percentile females in rear impacts and compare to those from similar tests with males. The results will serve as a basis for future work with models, criteria, and safety systems. Methods: A rear impact sled test series with 8 female volunteers was performed at velocity changes of 5 and 7 km/h. The following dynamic response corridors were generated for the head, T1 (first thoracic vertebra) and head relative to T1: (1) accelerations in posterior anterior direction, (2) horizontal and vertical displacements, (3) angular displacements for 6 females close to the 50th percentile in size. Additionally, the head-to-head restraint distance and contact time and neck injury criterion (NIC) were extracted from the data set. These data were compared to results from previously performed male volunteer tests, representing the 50th percentile male, in equivalent test conditions. T-tests were performed with the statistical significance level of .05 to quantify the significance of the parameter value differences for the males and females. Results: At 7 km/h, the females showed 29 percent earlier head-to-head restraint contact time (p = .0072); 27 percent shorter horizontal rearward head displacement (p = .0017); 36 percent narrower head extension angle (p = .0281); and 52 percent lower NIC value (p = .0239) than the males in previous tests. This was mainly due to 35 percent shorter initial head-to-head restraint distance for the females (p = .0125). The peak head acceleration in the posterior anterior direction was higher and occurred earlier for the females. Conclusions: The overall result indicated differences in the dynamic response for the female and male volunteers. The results could be used in developing and evaluating a mechanical and/or mathematical average-sized female dummy model for rear impact safety assessment. These models can be used as a tool in the design of protective systems and for further development and evaluation of injury criteria.	[Carlsson, Anna] Chalmers, Appl Mech SAFER, Vehicle Safety Div, Appl Mech SAFER Ctr, SE-41296 Gothenburg, Sweden; [Linder, Astrid] Swedish Natl Rd & Transport Res Inst, VTI, Gothenburg, Sweden; [Hell, Wolfram; Schick, Sylvia] Univ Munich, Inst Legal Med, Dept Biomech & Accid Res, Munich, Germany	Carlsson, A (corresponding author), Chalmers, Appl Mech SAFER, Vehicle Safety Div, Appl Mech SAFER Ctr, SE-41296 Gothenburg, Sweden.	anna.carlsson@chalmers.se	Davidsson, Johan/A-3229-2016; Svensson, Mats Yngve/A-6014-2013	Davidsson, Johan/0000-0002-1717-1514; Svensson, Mats Yngve/0000-0002-8304-1398; Carlsson, Anna/0000-0002-3216-8145	Swedish Governmental Agency for Innovation Systems (VINNOVA)Vinnova	This study was funded by the Swedish Governmental Agency for Innovation Systems (VINNOVA). Special thanks for valuable help to Stefan Horion and Kristin Thorsteinsdottir at LMU and Carsten Reinkemeyer at Allianz.	Bostrom O, 2000, ACCIDENT ANAL PREV, V32, P321, DOI 10.1016/S0001-4575(99)00105-0; BOSTROM O, 1996, IRCOBI C SEPT 11 13; Carlsson A, 2010, IRCOBI C SEPT 15 16; Chapline JF, 2000, ACCIDENT ANAL PREV, V32, P287, DOI 10.1016/S0001-4575(99)00126-8; Croft AC, 2002, IRCOBI C SEPT 18 20; Davidsson J, 1999, 43 STAPP CAR CRASH C; DAVIDSSON J, 1998, IRCOBI C SEPT 16 18; Dolinis J, 1997, INJURY, V28, P173, DOI 10.1016/S0020-1383(96)00186-6; Eichberger A, 1996, IRCOBI C SEPT 11 13; Farmer Charles M, 2003, Traffic Inj Prev, V4, P83, DOI 10.1080/15389580309867; Hell W, 1999, IRCOBI C SEPT 23 24; Jakobsson Lotta, 2004, Traffic Inj Prev, V5, P156, DOI 10.1080/15389580490435989; Jonsson Bertil, 2007, Traffic Inj Prev, V8, P87, DOI 10.1080/15389580600911010; Jonsson B, 2008, TRAFFIC INJ PREV, V9, P568, DOI 10.1080/15389580802308312; Kihlberg JK, 1969, 13 ASS ADV AUT MED O; Krafft M., 1998, IRCOBI C SEPT 16 18; Krafft M., 2002, TRAFFIC INJ PREV, V3, P141, DOI [10.1080/15389580212001, DOI 10.1080/15389580212001]; Krafft Maria, 2003, Traffic Inj Prev, V4, P136, DOI 10.1080/15389580309862; Kullgren A, 2010, IRCOBI C SEPT 15 16; Kullgren A, 2007, 20 ESV C JUN 18 21 L; Kullgren A, 2003, 18 ESV C MAY 19 22 N; Linder A, 2004, IRCOBI C SEPT 22 24; Linder A, 2008, TRAFFIC INJ PREV, V9, P592, DOI 10.1080/15389580802384669; Maag U, 1990, IRCOBI C SEPT 12 14; Minton R, 1997, IRCOBI C SEPT 24 26; Mordaka J, 2003, ACTA POLITECHNICA, V43, P47; MORRIS A, 1996, 40 STAPP CAR CRASH C; NARRAGON EA, 1965, VJ1823R15 CAL INC; NYGREN A, 1985, 10 INT TECHN C EXP S, P1; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; Ono K, 2006, IRCOBI C SEPT 20 22; OTREMSKI I, 1989, INJURY, V20, P349, DOI 10.1016/0020-1383(89)90011-9; Philippens M, 2002, Stapp Car Crash J, V46, P461; Richter M, 2000, EUR SPINE J, V9, P109, DOI 10.1007/s005860050220; *SAE, 2003, J2111 SAE; SCHICK S, 2008, 2 INT C NOV 18 19 ER; SCHNEIDER LW, 1983, UMTRI83531, P53; SCOTT MW, 1993, SAESP93945; SIEGMUND GP, 1997, 41 STAP CAR CRASH C; States JD, 1972, 16 STAPP CAR CRASH C; Stemper BD, 2003, J BIOMECH, V36, P1281, DOI 10.1016/S0021-9290(03)00159-3; Storvik Steven G, 2009, Biomed Sci Instrum, V45, P244; Svensson MY, 1993, SAESP93963; SZABO TJ, 1994, 38 STAP CAR CRASH C; The Whiplash Commission, 2005, WHIPL COMM FIN REP; THOMAS C, 1982, IRCOBI C SEPT 8 10; Vasavada AN, 2008, J BIOMECH, V41, P114, DOI 10.1016/j.jbiomech.2007.07.007; Viano David C, 2003, Traffic Inj Prev, V4, P228, DOI 10.1080/15389580309880; Watanabe Y, 2000, ACCIDENT ANAL PREV, V32, P243, DOI 10.1016/S0001-4575(99)00082-2; Welcher JB, 2001, ACCIDENT ANAL PREV, V33, P289, DOI 10.1016/S0001-4575(00)00043-9; WELSH R, 2001, 45 ASS ADV AUT MED S; ZOBEL J, 1998, IRCOBI C SEPT 16 18; 2004, FED GEG, V69, P74848	53	21	21	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1538-9588			TRAFFIC INJ PREV	Traffic Inj. Prev.	AUG	2011	12	4					347	357		10.1080/15389588.2011.585408			11	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	817UN	WOS:000294702200008	21823943				2021-06-18	
J	Yeoman, P; Pattani, H; Silcocks, P; Owen, V; Fuller, G				Yeoman, Paddy; Pattani, Hina; Silcocks, Paul; Owen, Victoria; Fuller, Gordon			Validation of the IMPACT Outcome Prediction Score Using the Nottingham Head Injury Register Dataset	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Glasgow outcome scale; Mortality; Prognosis; Statistical models; Traumatic brain injury; Validation studies	TRAUMATIC BRAIN-INJURY; GUIDELINES; ADMISSIONS; MANAGEMENT; CARE	Background: Comparison of traumatic brain injury (TBI) outcomes is severely limited by the absence of a universally accepted and validated outcome prediction score. The IMPACT group recently reported models predicting mortality and unfavorable outcome after TBI, based on the outcomes of patients with moderate and severe head injury reported in two large clinical trials. Methods: We have used prospectively collected data from 1,276 adult patients from the Nottingham Head Injury Register admitted to a single UK neurosurgical unit during a 10-year period to validate the IMPACT score models. The two models were validated for discrimination, calibration, and accuracy, using multiple imputation to adjust for missing data. Results: One thousand sixty-one patients (83%) had a complete set of data. For the multiply imputed analysis, the IMPACT prognostic models showed satisfactory discrimination (area under the receiver operator curve for mortality, 0.835; 95% confidence interval, 0.811-0.858; unfavorable outcome, 0.828; 95% confidence interval, 0.805-0.851) and accuracy (Brier Accuracy Score for mortality, 0.403, p < 0.01; unfavorable outcome, 0.371, p < 0.01). Good calibration was evident for unfavorable outcome, but mortality risk was underestimated by the scoring system in our sample (Hosmer-Lemeshow test: mortality: p < 0.01; unfavorable outcome: p = 0.6). These results were not significantly changed when repeated using patients with complete data only. Conclusion: The 2005 IMPACT model for unfavorable outcome performs well when used to predict outcome in adults with moderate and severe TBI presenting to a British neurosurgical center. However, the model for mortality fitted less well, slightly overestimating mortality in the higher-risk groups.	[Yeoman, Paddy; Pattani, Hina; Fuller, Gordon] Nottingham Univ Hosp NHS Trust, Intens Care Unit, Nottingham, England; [Silcocks, Paul] Univ Nottingham, Sch Med, Sch Community Hlth Sci, Nottingham Clin Trials Unit, Nottingham, England; [Owen, Victoria] Univ Nottingham, NIHR Res Design Serv E Midlands, Nottingham NG7 2RD, England	Fuller, G (corresponding author), 85 Main St, Loughborough LE12 5PE, Leics, England.	gordonwfuller@doctors.net.uk		Fuller, Gordon Ward/0000-0001-8532-3500			*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP D, P1; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; [Anonymous], 2008, BMJ-BRIT MED J, V336, P425, DOI DOI 10.1136/bmj.39461.643438.25; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Nakamura N, 2006, NEUROL MED-CHIR, V46, P567, DOI 10.2176/nmc.46.567; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Royston P, 2005, STATA J, V5, P279, DOI 10.1177/1536867X0500500212; Rubin DB., 1987, MULTIPLE IMPUTATION; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; Stranjalis G, 2008, J TRAUMA, V65, P789, DOI 10.1097/TA.0b013e3181469e26; TEASDALE G, 1974, LANCET, V2, P81; TWEEDIE IE, 2008, CARE CRITICALLY ILL, V24, P143; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e	34	21	21	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2011	71	2					387	392		10.1097/TA.0b013e31820ceadd			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	806XH	WOS:000293850200037	21427619				2021-06-18	
J	Dolce, G; Lucca, LF; Candelieri, A; Rogano, S; Pignolo, L; Sannita, WG				Dolce, Giuliano; Lucca, Lucia F.; Candelieri, Antonio; Rogano, Stefania; Pignolo, Loris; Sannita, Walter G.			Visual Pursuit in the Severe Disorder of Consciousness	JOURNAL OF NEUROTRAUMA			English	Article						consciousness; minimally conscious state; outcome; prognosis; vegetative state; visual tracking	TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; SCALE; COMA; PROGNOSIS; RECOVERY	Visual pursuit is a key descriptor of the minimally conscious state (above 80% of cases). It is also observable in about 20% of subjects in vegetative state. Its reappearance after severe brain damage anticipates a favorable outcome, with recovery of consciousness in 73% of subjects (45% in the absence of it). We considered retrospectively 395 subjects in vegetative state because of traumatic (63%), massive acute vascular (30%), or diffuse anoxic-hypoxic (7%) brain damage consecutively admitted to one dedicated unit during the years 1998 - 2008. Visual tracking was observed in 290 subjects (73.4%) and was already detectable within 50 days from brain injury in about 60% of post-traumatic or vascular subjects and 21% of anoxic-hypoxic patients. After 230 days of follow-up or more, it was observed in 89% and 88% of post-traumatic and vascular subjects and in 67% of anoxic-hypoxic patients. Rating with the Glasgow Outcome Scale (GOS) was better in those subjects with recovered visual tracking and inversely correlated with the time of reappearance in post-traumatic and vascular subjects; also the subjects with late recovery of eye tracking (230 days or more) had better GOS outcome than those without it. The observation of visual tracking reappearing in subjects in vegetative state would reflect recuperation of the brainstem-cortical interaction and overall brain functional organization that are thought to sustain consciousness and are interfered with by the "functional disconnection," resulting in the vegetative state.	[Dolce, Giuliano; Lucca, Lucia F.] S Anna Inst, Semiintens Care Unit Vegetat State, Crotone, Italy; [Candelieri, Antonio] Univ Calabria, Lab Decis Engn Hlth Care Delivery, I-87036 Cosenza, Italy; [Sannita, Walter G.] Univ Genoa, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; [Sannita, Walter G.] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA	Dolce, G (corresponding author), S Anna Inst, Semiintens Care Unit Vegetat State, Via Siris 11, Crotone, Italy.	giulianodolce@libero.it	/AAI-7627-2021	/0000-0003-1431-576X	S. Anna-RAN Institute	This study was supported by the S. Anna-RAN Institute through funds dedicated to research. Thanks are due to Professor L. Sazbon (the University of Tel Aviv, Israel) for continuing support and valuable advice.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285; Borer-Alafi N, 2002, BRAIN INJURY, V16, P593, DOI 10.1080/02699050110119484; BOUSSAOUD D, 1990, J COMP NEUROL, V296, P462, DOI 10.1002/cne.902960311; Bruno MA, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-35; Dolce G, 2008, BRAIN INJURY, V22, P617, DOI 10.1080/02699050802132503; DOLCE G, 2010, BRAIN INJURY, V24, P13; Dolce G., 2002; Dolce G, 2010, BRAIN INJURY, V24, P1628, DOI 10.3109/02699052.2010.523055; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOTTLIEB JP, 1994, J NEUROPHYSIOL, V72, P1634; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagen C., 1972, LEVELS COGNITIVE FUN; Hassler R., 1972, PATHOPHISIOLOGIE BEW, P1; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 2002, VEGETATIVE STATE; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; JUNG R, 1967, PSYCHIAT GEGENWART, P612; Kim JS, 2001, J VESTIBUL RES-EQUIL, V11, P3; KIRK C, 1975, LANCET, V1, P1180; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Pignolo L, 2009, BRAIN INJURY, V23, P1, DOI 10.1080/02699050802595873; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosano C, 2002, CEREB CORTEX, V12, P107, DOI 10.1093/cercor/12.2.107; Royal College of Physicians, 1996, GUID DIAGN MAN REP W; *ROYAL HOSP NEUR D, 1996, INT WORK PART MAN VE; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Taylor CM, 2007, ARCH PHYS MED REHAB, V88, P521, DOI 10.1016/j.apmr.2007.01.013; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Wijdicks Eelco F M, 2006, Rev Neurol Dis, V3, P109; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	47	21	21	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2011	28	7					1149	1154		10.1089/neu.2010.1405			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	794BL	WOS:000292869600003	21175278				2021-06-18	
J	Piilgaard, H; Witgen, BM; Rasmussen, P; Lauritzen, M				Piilgaard, Henning; Witgen, Brent M.; Rasmussen, Peter; Lauritzen, Martin			Cyclosporine A, FK506, and NIM811 ameliorate prolonged CBF reduction and impaired neurovascular coupling after cortical spreading depression	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral blood flow; migraine; mitochondria; spreading depression; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; NITRIC-OXIDE SYNTHASE; MIGRAINE AURA; REACTIVITY; DEPOLARIZATION; INHIBITION; HEMOGLOBIN; MECHANISMS; ISCHEMIA; PATHWAY	Cortical spreading depression (CSD) is associated with mitochondrial depolarization, increasing intracellular Ca2+, and the release of free fatty acids, which favor opening of the mitochondrial permeability transition pore (mPTP) and activation of calcineurin (CaN). Here, we test the hypothesis that cyclosporine A (CsA), which blocks both mPTP and CaN, ameliorates the persistent reduction of cerebral blood flow (CBF), impaired vascular reactivity, and a persistent rise in the cerebral metabolic rate of oxygen (CMRO2) following CSD. In addition to CsA, we used the specific mPTP blocker NIM811 and the specific CaN blocker FK506. Cortical spreading depression was induced in rat frontal cortex. Electrocortical activity was recorded by glass microelectrodes, CBF by laser Doppler flowmetry, and tissue oxygen tension with polarographic microelectrodes. Electrocortical activity, basal CBF, CMRO2, and neurovascular and neurometabolic coupling were unaffected by all three drugs under control conditions. NIM811 augmented the rise in CBF observed during CSD. Cyclosporine A and FK506 ameliorated the persistent decrease in CBF after CSD. All three drugs prevented disruption of neurovascular coupling after CSD; the rise in CMRO2 was unchanged. Our data suggest that blockade of mPTP formation and CaN activation may prevent persistent CBF reduction and vascular dysfunction after CSD. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1588-1598; doi: 10.1038/jcbfm.2011.28; published online 23 March 2011	[Lauritzen, Martin] Univ Copenhagen, Glostrup Hosp, Dept Clin Neurophysiol, DK-2600 Glostrup, Denmark; [Piilgaard, Henning; Witgen, Brent M.; Rasmussen, Peter; Lauritzen, Martin] Univ Copenhagen, Panum Inst, Ctr Hlth Aging, Dept Neurosci & Pharmacol, DK-2200 Copenhagen N, Denmark	Lauritzen, M (corresponding author), Univ Copenhagen, Glostrup Hosp, Dept Clin Neurophysiol, DK-2600 Glostrup, Denmark.	marlau03@glo.regionh.dk	Ernst-Rasmussen, Peter Bonde/B-8203-2013	Ernst-Rasmussen, Peter Bonde/0000-0003-1761-4562; Lauritzen, Martin/0000-0002-1517-1131	Lundbeck Foundation via the Lundbeck Foundation Centre for Neurovascular Signalling (LU-CENS); NOVO Nordisk FoundationNovo Nordisk Foundation; Danish Medical Research CouncilDanish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); NORDEA foundation for Center for Healthy Aging; Foundation LeducqLeducq Foundation	This study was supported by the Lundbeck Foundation via the Lundbeck Foundation Centre for Neurovascular Signalling (LU-CENS), the NOVO Nordisk Foundation, the Danish Medical Research Council, the NORDEA foundation for Center for Healthy Aging, and Foundation Leducq.	Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P1172, DOI 10.1097/01.WCB.0000137057.92786.F3; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Busija DW, 2008, PROG NEUROBIOL, V86, P379, DOI 10.1016/j.pneurobio.2008.09.008; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Chang JC, 2010, BRAIN, V133, P996, DOI 10.1093/brain/awp338; Chuquet J, 2007, J NEUROSCI, V27, P4036, DOI 10.1523/JNEUROSCI.0721-07.2007; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; Enager P, 2009, J CEREBR BLOOD F MET, V29, P976, DOI 10.1038/jcbfm.2009.23; FABRICIUS M, 1995, AM J PHYSIOL-HEART C, V269, pH23; FLORENCE G, 1994, AM J PHYSIOL, V266, pR1136; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Gabbott PLA, 1997, BRAIN RES, V747, P352, DOI 10.1016/S0006-8993(96)01376-5; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Hazelton JL, 2009, J NEUROSCI RES, V87, P1250, DOI 10.1002/jnr.21921; Hoffmeyer HW, 2007, J CEREBR BLOOD F MET, V27, P575, DOI 10.1038/sj.jcbfm.9600372; Kruger H, 1996, NEUROREPORT, V7, P2733; LACOMBE P, 1992, EXP NEUROL, V117, P278, DOI 10.1016/0014-4886(92)90137-F; LAURITZEN M, 1990, J CEREBR BLOOD F MET, V10, P115, DOI 10.1038/jcbfm.1990.14; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lindauer U, 1999, AM J PHYSIOL-HEART C, V277, pH799; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Park L, 2008, P NATL ACAD SCI USA, V105, P1073, DOI 10.1073/pnas.0708823105; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Ruiz F, 2000, EUR J PHARMACOL, V404, P29, DOI 10.1016/S0014-2999(00)00584-7; Scheckenbach KEL, 2006, EXP NEUROL, V202, P449, DOI 10.1016/j.expneurol.2006.07.007; Seitz I, 2004, J CEREBR BLOOD F MET, V24, P526, DOI 10.1097/00004647-200405000-00006; Sierra-Paredes G, 2008, CNS NEUROSCI THER, V14, P36, DOI 10.1111/j.1527-3458.2008.00036.x; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Sukhotinsky I, 2010, J CEREBR BLOOD F MET, V30, P1168, DOI 10.1038/jcbfm.2009.285; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Zhou N, 2010, CEREB CORTEX, V20, P2614, DOI 10.1093/cercor/bhq018	40	21	21	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2011	31	7					1588	1598		10.1038/jcbfm.2011.28			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	786FD	WOS:000292287800011	21427730	Green Published, Bronze			2021-06-18	
J	Feng, JF; Van, KC; Gurkoff, GG; Kopriva, C; Olszewski, RT; Song, M; Sun, SF; Xue, M; Neale, JH; Yuen, PW; Lowe, DA; Zhou, J; Lyeth, BG				Feng, Jun-Feng; Van, Ken C.; Gurkoff, Gene G.; Kopriva, Christina; Olszewski, Rafal T.; Song, Minsoo; Sun, Shifeng; Xue, Man; Neale, Joseph H.; Yuen, Po-Wai; Lowe, David A.; Zhou, Jia; Lyeth, Bruce G.			Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI	BRAIN RESEARCH			English	Article						Traumatic brain injury (TBI); Glutamate; N-acetylaspartylglutamate (NAAG); Hippocampus; Morris water maze	LATERAL FLUID-PERCUSSION; TRAUMATIC BRAIN-INJURY; METABOTROPIC GLUTAMATE RECEPTORS; ACUTE NEURONAL DEGENERATION; N-ACETYLASPARTYLGLUTAMATE; NAALADASE INHIBITION; BEHAVIORAL DEFICITS; FLUORO-JADE; RAT; RELEASE	Traumatic brain injury (TBI) leads to a rapid and excessive increase in glutamate concentration in the extracellular milieu, which is strongly associated with excitotoxicity and neuronal degeneration. N-acetylaspartylglutamate (NAAG), a prevalent peptide neurotransmitter in the vertebrate nervous system, is released along with glutamate and suppresses glutamate release by actions at pre-synaptic metabotropic glutamate autoreceptors. Extracellular NAAG is hydrolyzed to N-acetylaspartate and glutamate by peptidase activity. In the present study PGI-02776, a newly designed di-ester prodrug of the urea-based NAAG peptidase inhibitor ZJ-43, was tested for neuroprotective potential when administered intraperitoneally 30 min after lateral fluid percussion TBI in the rat. Stereological quantification of hippocampal CA2-3 degenerating neurons at 24 h post injury revealed that 10 mg/kg PGI-02776 significantly decreased the number of degenerating neurons (p<0.05). Both average latency analysis of Morris water maze performance and assessment of 24-hour memory retention revealed significant differences between sham-TBI and TBI-saline. In contrast, no significant difference was found between sham-TBI and PGI-02776 treated groups in either analysis indicating an improvement in cognitive performance with PGI-02776 treatment. Histological analysis on day 16 post-injury revealed significant cell death in injured animals regardless of treatment. In vitro NAAG peptidase inhibition studies demonstrated that the parent compound (ZJ-43) exhibited potent inhibitory activity while the mono-ester (PGI-02749) and di-ester (PGI-02776) prodrug compounds exhibited moderate and weak levels of inhibitory activity, respectively. Pharmacokinetic assays in uninjured animals found that the di-ester (PGI-02776) crossed the blood-brain barrier. PGI-02776 was also readily hydrolyzed to both the mono-ester (PGI-02749) and the parent compound (ZJ-43) in both blood and brain. Overall, these findings suggest that post-injury treatment with the ZJ-43 prodrug PGI-02776 reduces both acute neuronal pathology and longer term cognitive deficits associated with TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Feng, Jun-Feng; Van, Ken C.; Gurkoff, Gene G.; Kopriva, Christina; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Gurkoff, Gene G.] Univ Calif Davis, NSF Ctr Biophoton Sci & Technol, Sacramento, CA 95817 USA; [Olszewski, Rafal T.; Neale, Joseph H.] Georgetown Univ, Dept Biol, Washington, DC 20057 USA; [Song, Minsoo; Yuen, Po-Wai; Lowe, David A.; Zhou, Jia] PsychoGenics Inc, Tarrytown, NY 10591 USA; [Sun, Shifeng; Xue, Man] Pharmaron Inc, Irvine, CA 92618 USA; [Feng, Jun-Feng] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Renji Hosp, Shanghai 200027, Peoples R China	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	 [NIHNS61352];  [NIHNS38080];  [NIHNS29995]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, R01NS038080, R43NS061352] Funding Source: NIH RePORTER	This research was supported by NIHNS61352 (JZ), NIHNS38080 (JHN) and NIHNS29995 (BGL).	BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bzdega T, 2004, J NEUROCHEM, V89, P627, DOI 10.1111/j.1471-4159.2004.02361.x; Bzdega T, 1997, J NEUROCHEM, V69, P2270; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hunsaker MR, 2008, HIPPOCAMPUS, V18, P699, DOI 10.1002/hipo.20429; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; Sanabria ERG, 2004, J NEUROPHYSIOL, V91, P182, DOI 10.1152/jn.00465.2003; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schweitzer C, 2000, NEUROPHARMACOLOGY, V39, P1700, DOI 10.1016/S0028-3908(99)00265-8; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Tsukamoto T, 2007, DRUG DISCOV TODAY, V12, P767, DOI 10.1016/j.drudis.2007.07.010; Wroblewska B, 1997, J NEUROCHEM, V69, P174; Wroblewska B, 1998, GLIA, V24, P172, DOI 10.1002/(SICI)1098-1136(199810)24:2<172::AID-GLIA2>3.0.CO;2-6; Wroblewska B, 2006, J NEUROCHEM, V96, P1071, DOI 10.1111/j.1471-4159.2005.03569.x; Xi ZX, 2002, J PHARMACOL EXP THER, V300, P162, DOI 10.1124/jpet.300.1.162; Yamamoto T, 2004, EUR J NEUROSCI, V20, P483, DOI 10.1111/j.1460-9568.2004.03504.x; Zhang W, 2006, J NEUROL SCI, V247, P217, DOI 10.1016/j.jns.2006.05.052; Zhao J, 2001, EUR J NEUROSCI, V13, P340, DOI 10.1046/j.1460-9568.2001.01396.x; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266	43	21	22	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 13	2011	1395						62	73		10.1016/j.brainres.2011.04.022			12	Neurosciences	Neurosciences & Neurology	788DQ	WOS:000292426000008	21565332	Green Accepted			2021-06-18	
J	Bales, JW; Yan, HQ; Ma, XC; Li, YM; Samarasinghe, R; Dixon, CE				Bales, James W.; Yan, Hong Q.; Ma, Xiecheng; Li, Youming; Samarasinghe, Ranmal; Dixon, C. Edward			The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: A novel therapeutic target in traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						DARPP-32; TBI; Striatum; Amantadine; Dopamine	WATER MAZE PERFORMANCE; CORTICAL IMPACT MODEL; PROTEIN PHOSPHATASE-1; PARKINSONS-DISEASE; SYNAPTIC PLASTICITY; PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS; GLUTAMATE SIGNALS; RAT; DEPHOSPHORYLATION	Traumatic brain injury (TBI) causes persistent neurologic deficits. Current therapies, predominantly focused upon cortical and hippocampal cellular survival, have limited benefit on cognitive outcomes. Striatal damage is associated with deficits in executive function, learning, and memory. Dopamine and cAMP regulated phosphoprotein 32 (DARPP-32) is expressed within striatal medium spiny neurons and regulates striatal function. We found that controlled cortical impact injury in rats produces a chronic decrease in DARPP-32 phosphorylation at threonine-34 and an increase in protein phosphatase-1 activity. There is no effect of injury on threonine-75 phosphorylation or on DARPP-32 protein. Amantadine, shown to be efficacious in treating post-TBI cognitive deficits, given daily for two weeks is able to restore the loss of DARPP-32 phosphorylation and reduce protein phosphatase-1 activity. Amantadine also decreases the phosphorylation of threonine-75 consistent with activity as a partial N-methyl-D-aspartate (NMDA) receptor antagonist and partial dopamine agonist. These data demonstrate that targeting the DARPP-32 signaling cascade represents a promising novel therapeutic approach in the treatment of persistent deficits following a TBI. Published by Elsevier Inc.	[Bales, James W.; Yan, Hong Q.; Ma, Xiecheng; Li, Youming; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Bales, James W.; Samarasinghe, Ranmal; Dixon, C. Edward] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Bales, James W.; Samarasinghe, Ranmal] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Brain Trauma Res Ctr, 201 Hill Bldg,3434 5th Ave, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS060672-02, 2P50NS030318]; Veterans AffairsUS Department of Veterans Affairs [B6761R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS060672] Funding Source: NIH RePORTER	We acknowledge the support of NIH/NINDS grant 5R01NS060672-02; NIH/NINDS grant 2P50NS030318; and the Veterans Affairs grant B6761R. We also thank Kristin Macfarlane for her assistance in preparing the data for this study.	Ahn JH, 2007, P NATL ACAD SCI USA, V104, P9876, DOI 10.1073/pnas.0703589104; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Baldo BA, 2007, PSYCHOPHARMACOLOGY, V191, P439, DOI 10.1007/s00213-007-0741-z; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Bateup HS, 2008, NAT NEUROSCI, V11, P932, DOI 10.1038/nn.2153; Bertran-Gonzalez J, 2008, J NEUROSCI, V28, P5671, DOI 10.1523/JNEUROSCI.1039-08.2008; BRENNER M, 1989, J NEUROL, V236, P153, DOI 10.1007/BF00314331; Calabresi P, 2007, TRENDS NEUROSCI, V30, P211, DOI 10.1016/j.tins.2007.03.001; Centonze D, 2001, EUR J NEUROSCI, V13, P1071, DOI 10.1046/j.0953-816x.2001.01485.x; Choe ES, 2004, J NEUROCHEM, V89, P383, DOI 10.1111/j.1471-4159.2003.02334.x; Coccurello R, 2004, NEUROPSYCHOPHARMACOL, V29, P1451, DOI 10.1038/sj.npp.1300444; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Fernandez E, 2006, PLOS COMPUT BIOL, V2, P1619, DOI 10.1371/journal.pcbi.0020176; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Genoux D, 2002, NATURE, V418, P970, DOI 10.1038/nature00928; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; Hakansson K, 2004, PARKINSONISM RELAT D, V10, P281, DOI 10.1016/j.parkreldis.2004.02.010; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; Hamada M, 2005, J PHARMACOL EXP THER, V315, P872, DOI 10.1124/jpet.105.090852; HEMMINGS HC, 1986, PROG BRAIN RES, V69, P149; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HOVDA DA, 1990, ACT NEUR S, V51, P331; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Koch K, 2008, NEUROSCIENCE, V153, P54, DOI 10.1016/j.neuroscience.2008.01.063; Kochanek P M, 1993, Crit Care Med, V21, pS333, DOI 10.1097/00003246-199309001-00016; Kopnisky KL, 2003, NEUROSCIENCE, V116, P425, DOI 10.1016/S0306-4522(02)00573-0; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Lang UE, 2007, CELL PHYSIOL BIOCHEM, V20, P687, DOI 10.1159/000110430; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Merims D, 2008, INT REV PSYCHIATR, V20, P364, DOI 10.1080/09540260802095123; Nairn AC, 2004, NEUROPHARMACOLOGY, V47, P14, DOI 10.1016/j.neuropharm.2004.05.010; Nishi A, 2002, J NEUROCHEM, V81, P832, DOI 10.1046/j.1471-4159.2002.00876.x; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Peinemann A, 2005, J NEUROL SCI, V239, P11, DOI 10.1016/j.jns.2005.07.007; PENNARTZ CMA, 1991, J NEUROSCI, V11, P2838; Ridley RM, 2006, BEHAV BRAIN RES, V166, P253, DOI 10.1016/j.bbr.2005.08.007; Sawamoto N, 2007, NEUROLOGY, V68, P1062, DOI 10.1212/01.wnl.0000257821.28992.db; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102; Vertes RP, 2006, NEUROSCIENCE, V142, P1, DOI 10.1016/j.neuroscience.2006.06.027; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X	60	21	21	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2011	229	2					300	307		10.1016/j.expneurol.2011.02.013			8	Neurosciences	Neurosciences & Neurology	774XF	WOS:000291419400014	21376040	Green Accepted			2021-06-18	
J	Gomez-Pinilla, F; Gomez, AG				Gomez-Pinilla, Fernando; Gomez, Alexis G.			The Influence of Dietary Factors in Central Nervous System Plasticity and Injury Recovery	PM&R			English	Article							TRAUMATIC BRAIN-INJURY; SATURATED-FAT DIET; SYNAPTIC PLASTICITY; NEUROTROPHIC FACTOR; SPINAL-CORD; DOCOSAHEXAENOIC ACID; COGNITIVE FUNCTION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; EXERCISE	Although feeding is an essential component of life, it is only recently that the actions of foods on brain plasticity and function have been scrutinized. There is evidence that select dietary factors are important modifiers of brain plasticity and can have an impact on central nervous system health and disease. Results of new research indicate that dietary factors exert their effects by affecting molecular events related to the management of energy metabolism and synaptic plasticity. Recent study results show that select dietary factors have mechanisms similar to those of exercise, and that, in some cases, dietary factors can complement the action of exercise. Abundant research findings in animal models of central nervous system injury support the idea that nutrients can be taken in through whole foods and dietary supplements to reduce the consequences of neural damage. Therefore, exercise and dietary management appear as a noninvasive and effective strategy to help counteract neurologic and cognitive disorders. PM R 2011;3:S111-S116	[Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando; Gomez, Alexis G.] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465-06, NS068473, NS56413]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC1NS068473, R01NS056413, R01NS050465] Funding Source: NIH RePORTER	Research support: This work was supported by National Institutes of Health Awards NS50465-06, NS068473, and NS56413.	ASSUNCAO M, 2009, NEUROBIOL AGING 0501; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Chandra V, 2001, NEUROLOGY, V57, P985, DOI 10.1212/WNL.57.6.985; Cota D, 2006, BRAIN RES REV, V51, P85, DOI 10.1016/j.brainresrev.2005.10.004; Daffner KR, 2010, J ALZHEIMERS DIS, V19, P1101, DOI 10.3233/JAD-2010-1306; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Gomez-Pinilla F, 2008, SURG NEUROL, V70, P333, DOI 10.1016/j.surneu.2008.05.023; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Gomez-Pinilla F, 2008, EUR J NEUROSCI, V28, P2278, DOI 10.1111/j.1460-9568.2008.06524.x; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Jacka FN, 2010, AM J PSYCHIAT, V167, P305, DOI 10.1176/appi.ajp.2009.09060881; Jiang J, 2007, EUR J PHARMACOL, V561, P54, DOI 10.1016/j.ejphar.2006.12.028; Jones CR, 1997, NEUROCHEM RES, V22, P663, DOI 10.1023/A:1027341707837; Kalantari H, 2010, BIOFACTORS, V36, P401, DOI 10.1002/biof.100; Kaur T, 2008, BRAIN COGNITION, V67, P25, DOI 10.1016/j.bandc.2007.10.003; Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032; Kuriyama S, 2006, AM J CLIN NUTR, V83, P355; Lin MS, 2011, J SURG RES, V166, P280, DOI 10.1016/j.jss.2009.07.001; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Molteni R, 2004, P NATL ACAD SCI USA, V101, P8473, DOI 10.1073/pnas.0401443101; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Nagappan G, 2005, TRENDS NEUROSCI, V28, P464, DOI 10.1016/j.tins.2005.07.003; Ng TP, 2006, AM J EPIDEMIOL, V164, P898, DOI 10.1093/aje/kwj267; Pasinetti Giulio Maria, 2007, V35, P159; Plunet WT, 2008, EXP NEUROL, V213, P28, DOI 10.1016/j.expneurol.2008.04.011; POWELL KE, 1994, MED SCI SPORT EXER, V26, P851; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Shukitt-Hale B, 2009, NUTR NEUROSCI, V12, P135, DOI 10.1179/147683009X423292; Spencer JPE, 2009, GENES NUTR, V4, P243, DOI 10.1007/s12263-009-0136-3; Unno K, 2007, BIOGERONTOLOGY, V8, P89, DOI 10.1007/s10522-006-9036-8; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Vaynman S, 2006, J NEUROSCI RES, V84, P699, DOI 10.1002/jnr.20979; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Ye K, 2010, J RADIAT RES, V51, P473, DOI 10.1269/jrr.10009; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015; Zhang S, 2010, NEUROL RES, V32, P963, DOI 10.1179/016164110X12700393823570; Zuccato C, 2009, NAT REV NEUROL, V5, P311, DOI 10.1038/nrneurol.2009.54	50	21	21	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2011	3	6		S			S111	S116		10.1016/j.pmrj.2011.03.001			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	961BB	WOS:000305437800018	21703566	Green Accepted			2021-06-18	
J	Dardier, V; Bernicot, J; Delanoe, A; Vanberten, M; Fayada, C; Chevignard, M; Delaye, C; Laurent-Vannier, A; Dubois, B				Dardier, Virginie; Bernicot, Josie; Delanoe, Anaig; Vanberten, Melanie; Fayada, Catherine; Chevignard, Mathilde; Delaye, Corinne; Laurent-Vannier, Anne; Dubois, Bruno			Severe traumatic brain injury, frontal lesions, and social aspects of language use: A study of French-speaking adults	JOURNAL OF COMMUNICATION DISORDERS			English	Article						Severe traumatic brain injury; Frontal lesion; Pragmatics; Metapragmatics; Language production; Language comprehension; Requests; Communication	CLOSED-HEAD-INJURY; EXECUTIVE DYSFUNCTION; DAMAGED PATIENTS; VERBAL FLUENCY; YOUNG-CHILDREN; MIND; ABILITY; IMPAIRMENT; DISCOURSE; REQUESTS	The purpose of this study was to gain insight into the social (pragmatic) aspects of language use by French-speaking individuals with frontal lesions following a severe traumatic brain injury. Eleven participants with traumatic brain injury performed tasks in three areas of communication: production (interview situation), comprehension (direct requests, conventional indirect requests, and hints), and metapragmatic knowledge. The results of the patients pointed out some strengths (turn-taking in production, and request comprehension, including hints and the speaker's intention) and some weaknesses (topic maintenance in production and metapragmatic knowledge). The patients' good comprehension of requests and their difficulty expressing metapragmatic knowledge suggest that they differ from controls in how they "explain the world": their knowledge of the event sequence was not based on verbally expressible knowledge about the relationship between the structural characteristics of a request utterance and those of its social production context. The pragmatic skills of persons with traumatic brain injury seem to vary across tasks: these individuals have specific strengths and weaknesses in different domains. In addition, marked interindividual differences were noted among the patients: three of them had only one weak point, topic maintenance. These interindividual differences were not systematically linked to performance on executive function tests, but lesion unilaterality (right or left) seems to help preserve patients' pragmatic and metapragmatic skills. The discussion stresses the need to take each patient's strengths and weaknesses into account in designing remediation programs. Learning outcomes: As a result of this activity, the reader will be able to explain the social/pragmatic aspects of language in typical and atypical participants with TBI. As a result of this activity, the reader will be able to identify social/pragmatic weaknesses and strengths. (C) 2011 Elsevier Inc. All rights reserved.	[Bernicot, Josie] Univ Poitiers, CNRS, Ctr Rech Apprentissage & Cognit, CeRCA MSHS, F-86000 Poitiers, France; [Dardier, Virginie; Delanoe, Anaig] Univ Europeenne Bretagne Rennes 2, Ctr Rech Psychol Cognit & Commun EA 1285, F-35043 Rennes, France; [Vanberten, Melanie] Ctr Med & Peciagog Rennes Beaulieu, F-35700 Rennes, France; [Fayada, Catherine; Dubois, Bruno] Groupement hosp Univ Est Federat Maladies Syst Ne, Hop La Pitie Salpetriere, F-75651 Paris, France; [Chevignard, Mathilde; Delaye, Corinne; Laurent-Vannier, Anne] Hop Natl St Maurice, Serv Reeducat Pathol Neurol Acquises, F-94415 St Maurice, France	Bernicot, J (corresponding author), Univ Poitiers, CNRS, Ctr Rech Apprentissage & Cognit, CeRCA MSHS, Betiment A5-5,Rue Theodore Lefebvre, F-86000 Poitiers, France.	virginie.dardier@uhb.fr; josie.bernicot@univ-poitiers.fr; melanie.vanberten@laposte.net; catherine.fayada@psl.ap-hop-paris.fr; m.chevignard@hopital-saint-maurice.fr; c.delaye@hopital-saint-maurice.fr; a.laurentvannier@hopital-saint-maurice.fr; b.dubois@psl.aphp.fr					ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Austin John L, 1962, DO THINGS WORDS, Vsecond; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bechara A, 1999, J NEUROSCI, V19, P5473; BERNICOT J, 1987, CAH PSYCHOL COGN, V7, P267; Bernicot J, 2001, INT J LANG COMM DIS, V36, P245; BERNICOT J, 1991, INT J BEHAV DEV, V14, P285, DOI 10.1177/016502549101400303; BERNICOT J, 1994, EUR J PSYCHOL EDUC, V9, P311, DOI 10.1007/BF03172904; BERNICOT J, 2001, PSYCHOL INTERACTION, V13, P139; Bernicot J, 2007, J PRAGMATICS, V39, P2115, DOI 10.1016/j.pragma.2007.05.009; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; BRADY M, 2006, J NEUROLINGUIST, V19, P39; BROOKS DN, 1984, CLOSED HEAD INJURY P; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; Brune M, 2005, SCHIZOPHR RES, V75, P233, DOI 10.1016/j.schres.2004.11.006; Cabeza Roberto, 2000, Current Opinion in Neurology, V13, P415, DOI 10.1097/00019052-200008000-00008; Champagne M, 2003, BRAIN COGNITION, V53, P152, DOI 10.1016/S0278-2626(03)00099-X; Champagne M, 2004, BRAIN LANG, V91, P172, DOI 10.1016/j.bandl.2004.06.089; Champagne M, 2002, BRAIN LANG, V83, P214; Champagne-Lavau M, 2010, J NEUROLINGUIST, V23, P285, DOI 10.1016/j.jneuroling.2009.08.009; Champagne-Lavau M, 2009, J NEUROLINGUIST, V22, P413, DOI 10.1016/j.jneuroling.2009.02.002; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Channon S, 2007, NEUROPSYCHOLOGIA, V45, P1725, DOI 10.1016/j.neuropsychologia.2006.12.021; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Chantraine Y, 1998, J NEUROLINGUIST, V11, P21, DOI 10.1016/S0911-6044(98)00003-7; CHAPMAN SB, 1999, BRAIN DAM B, P235; CLYNE M, 1998, CONCISE ENCY PRAGMAT; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Cutica I, 2006, BRAIN LANG, V98, P12, DOI 10.1016/j.bandl.2006.01.001; Deloche G, 1997, TEST DENOMINATION OR; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GARDNER H, 1975, SHATTERED MIND PERSO; GLEASON JB, 2001, DEV LANGUAGE; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; HALLIDAY MAK, 1975, SHORT INTRO FUNCTION; HARDEN WD, 1995, J COMMUN DISORD, V28, P247, DOI 10.1016/0021-9924(94)00012-O; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Joanette Y., 2004, PROTOCOLE MONTREAL E; Joanette Y, 1990, RIGHT HEMISPHERE VER; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kilov AM, 2009, APHASIOLOGY, V23, P584, DOI 10.1080/02687030701855382; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Krueger F, 2009, TRENDS COGN SCI, V13, P103, DOI 10.1016/j.tics.2008.12.005; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; Mazaux J.-M., 1981, ECHELLE EVALUATION A; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; McDonald S., 2002, AWARENESS SOCIAL INF; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MILLER E, 1984, BRIT J CLIN PSYCHOL, V23, P53, DOI 10.1111/j.2044-8260.1984.tb00626.x; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; MULLER F, 2009, CORTEX, P1; Myers P.S., 1999, RIGHT HEMISPHERE DAM; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Noveck IA, 2004, PALG STUD PRAGM LANG, P1, DOI 10.1057/9780230524125; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Penn C, 1999, BRAIN LANG, V68, P535, DOI 10.1006/brln.1999.2127; Penn C, 1988, Brain Inj, V2, P3, DOI 10.3109/02699058809150928; Penn C, 2010, APHASIOLOGY, V24, P288, DOI 10.1080/02687030902958399; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Prutting C., 1983, PRAGMATIC ASSESSMENT, P29; Reilly J, 2005, PERSPECTIVES ON LANGUAGE AND LANGUAGE DEVELOPMENT, P303, DOI 10.1007/1-4020-7911-7_22; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; Searle John, 1969, SPEECH ACTS; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1999, APHASIOLOGY, V13, P709, DOI 10.1080/026870399401821; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Turkstra LS, 2001, J COMMUN DISORD, V34, P151, DOI 10.1016/S0021-9924(00)00046-0; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; van Daal J, 2004, J SPEECH LANG HEAR R, V47, P1411, DOI 10.1044/1092-4388(2004/105); Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Verschueren J., 1999, UNDERSTANDING PRAGMA; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; Yang FG, 2010, NEUROPSYCHOLOGIA, V48, P1923, DOI 10.1016/j.neuropsychologia.2010.03.011	99	21	22	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	MAY-JUN	2011	44	3					359	378		10.1016/j.jcomdis.2011.02.001			20	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	770KV	WOS:000291086300008	21458824				2021-06-18	
J	Himanen, L; Portin, R; Hamalainen, P; Hurme, S; Hiekkanen, H; Tenovuo, O				Himanen, Leena; Portin, Raija; Hamalainen, Paivi; Hurme, Saija; Hiekkanen, Heli; Tenovuo, Olli			Risk factors for reduced survival after traumatic brain injury: A 30-year follow-up study	BRAIN INJURY			English	Article						Brain injuries; follow-up studies; survival; cognition	HEAD-INJURY; PSYCHIATRIC-DISORDERS; POPULATION; MORTALITY; RETURN; DEATH; SEVERITY; OUTCOMES; SUICIDE; COHORT	Primary objective: To evaluate risk factors for reduced survival in subjects with traumatic brain injury (TBI). Participants and methods: A retrospective follow-up of three decades included 192 subjects with TBI. Cognitive testing was carried out on average 2 years after the injury (at mean age of 39.0 years), during the years 1966-1972. Cox's regression and logistic regression analyses were used and the survival of the subjects was compared with the general population using the standardized mortality ratio (SMR). Results: Reduced survival was significantly associated with age at injury (p < 0.001) and vocational outcome (p = 0.003). Vocational outcome in turn was associated with age (p = 0.010), TBI severity (p < 0.001), cognitive impairment (p = 0.010), later TBIs (p = 0.007) and alcohol abuse (p = 0.015). Mortality in the younger patient group (age at death <40 years) was higher than in the general population (SMR 4.50, 95% CI = 2.02-10.01). Conclusions: A reduced working ability, influenced by age-, injury- and lifestyle-related factors, is associated with long-term survival after TBI. The mortality among younger patients is high, a finding which should be considered when planning the care after TBI.	[Himanen, Leena; Portin, Raija; Hiekkanen, Heli; Tenovuo, Olli] Turku Univ Hosp, Dept Neurol, FIN-20521 Turku, Finland; [Hamalainen, Paivi] Masku Rehabil Ctr, Masku, Finland; [Hurme, Saija] Univ Turku, Dept Biostat, SF-20500 Turku, Finland	Himanen, L (corresponding author), Turku Univ Hosp, Dept Neurol 720, PL 52, FIN-20521 Turku, Finland.	ls.himanen@pp1.inet.fi		Himanen, Leena/0000-0001-7261-8027	Jenny and Antti Wihuri foundation	Supported by a grant from the Jenny and Antti Wihuri foundation.	Baguley I, 2000, BRAIN INJURY, V14, P505; BENTON AL, 1963, REVISED VISUAL RETEN; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dischinger PC, 2001, J TRAUMA, V51, P877, DOI 10.1097/00005373-200111000-00009; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; KUJALA P, 1994, BRAIN, V117, P1115, DOI 10.1093/brain/117.5.1115; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223	33	21	21	0	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2011	25	5					443	452		10.3109/02699052.2011.556580			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	745KQ	WOS:000289164700002	21401369				2021-06-18	
J	Ramanathan, DM; Wardecker, BM; Slocomb, JE; Hillary, FG				Ramanathan, Deepa M.; Wardecker, Britney M.; Slocomb, Julia E.; Hillary, Frank G.			Dispositional optimism and outcome following traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; dispositional optimism; psychological distress; cognitive ability; functional outcome	QUALITY-OF-LIFE; GLASGOW COMA SCALE; ARTERY BYPASS-SURGERY; HEAD-INJURY; COPING STRATEGIES; SOCIAL SUPPORT; SEVERITY; VARIABLES; RECOVERY; MODERATE	Objective: Despite vast literature examining the predictors of patient outcome following traumatic brain injury (TBI), the complicated relationship between personality and psychological, cognitive and functional outcomes remains poorly understood. The present study examined the relationship between the personality trait of dispositional optimism (DO) and outcome after moderate and severe TBI in the context of a proposed theoretical model. Methods: Forty-five individuals who had sustained moderate-to-severe TBI were recruited through mailings and completed the Symptom Checklist Questionnaire-90 Revised (SCL-90-R), the Telephone Interview for Cognitive Status (TICS), the Craig Handicap Assessment Reporting Technique (CHART) and the Life Orientation Test-Revised (LOT-R). Analyses were conducted to test a model predicting the relationship between personality and patient outcome after TBI. Results: DO was significantly correlated with psychological distress, but did not predict functional outcome. In addition, two significant mediating relationships were demonstrated: (1) psychological distress was shown to mediate the relationship between dispositional optimism and cognitive ability and (2) cognitive ability mediated the relationship between psychological distress and functional outcome. Conclusion: These findings illustrate that higher levels of DO in individuals sustaining moderate-to-severe TBI are related to better psychological functioning which in turn predicts improved cognitive and functional outcomes.	[Ramanathan, Deepa M.; Wardecker, Britney M.; Hillary, Frank G.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Slocomb, Julia E.; Hillary, Frank G.] Hershey Med Ctr, Dept Neurol, Hershey, PA USA	Ramanathan, DM (corresponding author), Penn State Univ, Dept Psychol, 610 Moore Bldg, University Pk, PA 16802 USA.	deepar@psu.edu	Hillary, Frank/AAN-8622-2021	Wardecker, Britney/0000-0003-2168-538X; Ramanathan-Elion, Deepa/0000-0001-7723-7346			AFFLECK G, 2001, OPTIMISM PESSIMISM I; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; CARVER CS, 1987, COGNITIVE THER RES, V11, P449, DOI 10.1007/BF01175355; Chiu WT, 2006, J NEUROTRAUM, V23, P1609, DOI 10.1089/neu.2006.23.1609; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CURBOW B, 1993, J BEHAV MED, V16, P423, DOI 10.1007/BF00844815; Dancy BL, 2004, NURS OUTLOOK, V52, P234, DOI 10.1016/j.outlook.2004.04.012; DEROGATIS LR, 1977, SCL 90 ADM ACORING P; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; ELSADR W, 1992, JAMA-J AM MED ASSOC, V267, P954, DOI 10.1001/jama.267.7.954; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FITZGERALD TE, 1993, J BEHAV MED, V16, P25, DOI 10.1007/BF00844753; Fleming J, 1999, BRAIN INJURY, V13, P417; Folstein M, 1988, NEUROPSY NEUROPSY BE, V1, P111; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GIBB MA, 2004, THESIS RAND AFRIKAAN; GOLDSTEIN FC, 1990, TRAUMATIC BRAIN INJU; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KAMENSIEGEL L, 1991, HEALTH PSYCHOL, V10, P229, DOI 10.1037/0278-6133.10.4.229; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MARSHALL GN, 1992, J PERS SOC PSYCHOL, V62, P1067, DOI 10.1037/0022-3514.62.6.1067; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; ODDY M, 1984, CLOSED HEAD INJURY; Pais-Ribeiro J, 2007, EPILEPSY BEHAV, V11, P33, DOI 10.1016/j.yebeh.2007.04.010; Peleg G, 2009, BRAIN INJURY, V23, P800, DOI 10.1080/02699050903196696; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Riskind J. H., 1996, J COGN PSYCHOTHER, V10, P105, DOI DOI 10.1891/0889-8391.23.4.350; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Schou I, 2005, PSYCHO-ONCOLOGY, V14, P718, DOI 10.1002/pon.896; Schweizer K, 1999, PSYCHOL REP, V84, P627, DOI 10.2466/PR0.84.2.627-636; Segerstrom SC, 1998, J PERS SOC PSYCHOL, V74, P1646, DOI 10.1037/0022-3514.74.6.1646; Seligman M. E., 1975, HELPLESSNESS DEPRESS; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; TAYLOR SE, 1992, J PERS SOC PSYCHOL, V63, P460, DOI 10.1037/0022-3514.63.3.460; Taylor SE, 1991, HLTH PSYCHOL; TENNEN H, 1992, CAN J BEHAV SCI, V24, P186, DOI 10.1037/h0078709; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vogenthaler D R, 1987, Brain Inj, V1, P113; Whiteneck GG, 1992, GUIDE USE CHART CRAI; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	65	21	21	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2011	25	4					328	337		10.3109/02699052.2011.554336			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	739RL	WOS:000288735600002	21314277				2021-06-18	
J	Hoffmeister, PG; Donat, CK; Schuhmann, MU; Voigt, C; Walter, B; Nieber, K; Meixensberger, J; Bauer, R; Brust, P				Hoffmeister, Peter-Georg; Donat, Cornelius K.; Schuhmann, Martin U.; Voigt, Cornelia; Walter, Bernd; Nieber, Karen; Meixensberger, Juergen; Bauer, Reinhard; Brust, Peter			Traumatic Brain Injury Elicits Similar Alterations in alpha 7 Nicotinic Receptor Density in Two Different Experimental Models	NEUROMOLECULAR MEDICINE			English	Article						Traumatic brain injury; alpha 7 nAChR; Autoradiography; Cholinergic system; alpha-Bungarotoxin	VESICULAR ACETYLCHOLINE TRANSPORTER; FLUID PERCUSSION INJURY; SEVERE HEAD-INJURY; RAT-BRAIN; IN-VIVO; BUNGAROTOXIN RECEPTORS; CALCIUM PERMEABILITY; CHOLINERGIC MARKERS; IMMATURE BRAIN; GABA RECEPTORS	Traumatic brain injury (TBI) is a major cause of death and disability worldwide, especially in children and young adults. Previous studies have shown alterations in the central cholinergic neurotransmission after TBI. We therefore determined alpha 7 nicotinic acetylcholine receptor (nAChR) densities in newborn piglets and adult rats after experimental TBI. Thirteen newborn piglets (post-TBI survival time: 6 h) underwent fluid percussion (FP) injury (n = 7) or sham operation (n = 6). Furthermore, adult rats randomized into three groups of post-TBI survival times (2, 24, 72 h) received controlled cortical impact injury (CCI, n = 8) or sham operation (n = 8). Brains were frozen, sagittally cut and incubated with the alpha 7-specific radioligand [I-125]alpha-bungarotoxin for autoradiography. In injured newborn piglets, decreased alpha 7 receptor densities were observed in the hippocampus (-38%), the hippocampus CA1 (-40%), thalamus (-30%) and colliculus superior (-30%). In adult rats, CCI decreased the receptor densities (between -16 and -47%) in almost any brain region within 2 and 24 h. In conclusion, widespread and significantly lowered alpha 7 nAChR densities were demonstrated in both TBI models. Our results suggest that a nearly similar TBI-induced decrease in the alpha 7 density in the brain of immature and adult animals is found, even with the differences in species, age and experimental procedures. The alterations make the alpha 7 nAChR a suitable target for drug development and neuroimaging after TBI.	[Hoffmeister, Peter-Georg; Donat, Cornelius K.; Brust, Peter] Res Ctr Dresden Rossendorf, Inst Radiopharm, D-04318 Leipzig, Germany; [Schuhmann, Martin U.; Voigt, Cornelia; Meixensberger, Juergen] Univ Leipzig, Dept Neurosurg, Leipzig, Germany; [Walter, Bernd] Zent Klin Bad Berka, Dept Neurosurg, Bad Berka, Germany; [Walter, Bernd; Bauer, Reinhard] Univ Jena, Inst Mol Cell Biol, Jena, Germany; [Nieber, Karen] Univ Leipzig, Inst Pharm, Leipzig, Germany	Donat, CK (corresponding author), Res Ctr Dresden Rossendorf, Inst Radiopharm, Permoserstr 15, D-04318 Leipzig, Germany.	c.donat@fzd.de		, Peter/0000-0001-5555-7058			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Alexander SPH, 2006, BRIT J PHARMACOL, V147, pS1; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; BROIDE RS, 1995, NEUROSCIENCE, V67, P83, DOI 10.1016/0306-4522(94)00623-D; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; Burnashev N, 1998, CELL CALCIUM, V24, P325, DOI 10.1016/S0143-4160(98)90056-2; Carnevale D., 2007, CNS & Neurological Disorders-Drug Targets, V6, P388; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; Conejero-Goldberg C, 2008, NEUROSCI BIOBEHAV R, V32, P693, DOI 10.1016/j.neubiorev.2007.10.007; de Jonge WJ, 2007, BRIT J PHARMACOL, V151, P915, DOI 10.1038/sj.bjp.0707264; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DOBBING J, 1982, BRIT MED J, V284, P1725, DOI 10.1136/bmj.284.6331.1725; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Donat CK, 2010, NEUROPATH APPL NEURO, V36, P225, DOI 10.1111/j.1365-2990.2009.01050.x; Donat CK, 2010, INT J DEV NEUROSCI, V28, P31, DOI 10.1016/j.ijdevneu.2009.10.001; Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059; Donat CK, 2007, BRAIN INJURY, V21, P1031, DOI 10.1080/02699050701630359; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Dwyer JB, 2009, PHARMACOL THERAPEUT, V122, P125, DOI 10.1016/j.pharmthera.2009.02.003; Dwyer Jennifer B., 2008, Birth Defects Research, V84, P30, DOI 10.1002/bdrc.20118; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Forster E, 2006, NAT REV NEUROSCI, V7, P259, DOI 10.1038/nrn1882; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; IMPERATO A, 1993, EUR J PHARMACOL, V238, P135, DOI 10.1016/0014-2999(93)90518-M; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Lauder JM, 1999, ENVIRON HEALTH PERSP, V107, P65, DOI 10.2307/3434473; Levin ED, 2002, J NEUROBIOL, V53, P633, DOI 10.1002/neu.10151; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCann CM, 2006, P NATL ACAD SCI USA, V103, P5149, DOI 10.1073/pnas.0600847103; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER MM, 1982, BRAIN RES, V247, P355, DOI 10.1016/0006-8993(82)91261-6; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; Moor E, 1998, EUR J PHARMACOL, V359, P119, DOI 10.1016/S0014-2999(98)00642-6; Mortazavi S, 1999, ANESTHESIOLOGY, V90, P1070, DOI 10.1097/00000542-199904000-00021; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Radcliffe KA, 1998, J NEUROSCI, V18, P7075; Rangwala F, 1997, J NEUROSCI, V17, P8201; Rasmusson DD, 2000, BEHAV BRAIN RES, V115, P205, DOI 10.1016/S0166-4328(00)00259-X; ROMIJN HJ, 1991, EARLY HUM DEV, V26, P61, DOI 10.1016/0378-3782(91)90044-4; Rosas-Ballina M, 2009, J INTERN MED, V265, P663, DOI 10.1111/j.1365-2796.2009.02098.x; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Scremin OU, 2006, BRAIN RES, V1124, P155, DOI 10.1016/j.brainres.2006.09.062; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Slotkin TA, 2004, TOXICOL APPL PHARM, V198, P132, DOI 10.1016/j.taap.2003.06.001; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Suzuki T, 2006, J NEUROSCI RES, V83, P1461, DOI 10.1002/jnr.20850; Tellez S, 1997, J NEUROCHEM, V68, P778; Terry AV, 2005, NEUROSCIENCE, V136, P519, DOI 10.1016/j.neuroscience.2005.08.006; Tribollet E, 2004, NEUROSCIENCE, V124, P405, DOI 10.1016/j.neuroscience.2003.09.028; Vargo JM, 1999, J TRAUMA, V47, P265, DOI 10.1097/00005373-199908000-00008; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Walter B, 2004, J NEUROTRAUM, V21, P1076, DOI 10.1089/0897715041651024; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang Yan, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P591; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; WISDEN W, 1992, J NEUROSCI, V12, P1040	80	21	23	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1535-1084	1559-1174		NEUROMOL MED	Neuromol. Med.	MAR	2011	13	1					44	53		10.1007/s12017-010-8136-4			10	Neurosciences	Neurosciences & Neurology	726VB	WOS:000287753400013	20857232				2021-06-18	
J	Strong, CAH; Tiesma, D; Donders, J				Strong, Carrie-Ann H.; Tiesma, David; Donders, Jacobus			Criterion Validity of the Delis-Kaplan Executive Function System (D-KEFS) Fluency Subtests After Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neuropsychological assessment; Executive functioning; Verbal fluency; Design fluency; Classification accuracy; Clinical utility	CARD SORTING TEST; FRONTAL-LOBE LESIONS; TEST-PERFORMANCE; DESIGN FLUENCY; OLDER-ADULTS; PREDICTION; IMPAIRMENTS; DYSFUNCTION; DISEASE; MEMORY	The performance of 65 patients with complicated mild severe traumatic brain injury was evaluated on the Verbal and Design Fluency subtests of the Delis-Kaplan Executive Function System (D-KEFS), and compared with that of 65 demographically matched healthy controls. There were statistically significant group differences on Letter Fluency and Category Switching but not on any of the Design Fluency tasks. Combined, these two Verbal Fluency subtests had a classification accuracy of 65.39%, associated with a likelihood ratio of 1.87. The impact of length of coma on Letter Fluency performance but not Category Switching was mediated at least in part by processing speed. The findings suggest modest criterion validity of some of the D KEFS Verbal Fluency subtests in the assessment of patients with complicated mild severe traumatic brain injury. (JINS, 2011, 17, 230-237)	[Strong, Carrie-Ann H.; Donders, Jacobus] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; [Tiesma, David] Calvin Coll, Dept Psychol, Grand Rapids, MI 49506 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson P., 2008, EXECUTIVE FUNCTIONS; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Bittner RM, 2007, BRAIN INJURY, V21, P709, DOI 10.1080/02699050701468917; Crawford MA, 2007, J INT NEUROPSYCH SOC, V13, P178, DOI 10.1017/S135561770707021X; Delis DC, 2001, DELISKAPLAN EXECUTIV; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; Green P., 2003, GREENS WORD MEMORY T; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Heaton R., 1993, WISCONSIN CARD SORTI; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Houston WS, 2005, J INT NEUROPSYCH SOC, V11, P863, DOI 10.1017/S1355617705051015; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JUDY PA, 2010, J INT NEUROPSYCH SOC, V16, P640; Jurado MA, 2000, BRAIN INJURY, V14, P789; Kramer JH, 2007, J INT NEUROPSYCH SOC, V13, P386, DOI 10.1017/S1355617707070567; LeBlanc J, 2006, BRAIN INJURY, V20, P1391, DOI 10.1080/02699050601081927; Lucas JA, 2006, CLIN NEUROPSYCHOLOGY, P351; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MCDONALD S, 2008, EXECUTIVE FUNCTIONS; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Mitchell M, 2008, J CLIN EXP NEUROPSYC, V30, P683, DOI 10.1080/13803390701679893; Nemoto T, 2005, BEHAV NEUROL, V16, P217, DOI 10.1155/2005/386932; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Razani J, 2007, APPL NEUROPSYCHOL, V14, P208, DOI 10.1080/09084280701509125; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Reitan R.M., 1993, HALSTEADREITAN NEURO; Ruff R. M., 1988, RUFF FIGURAL FLUENCY; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Strong CAH, 2008, J CLIN EXP NEUROPSYC, V30, P885, DOI 10.1080/13803390701858224; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tombaugh TN, 1996, TEST MEMORY MALINGER; Trahan D, 1988, CONTINUOUS VISUAL ME; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wecker NS, 2005, NEUROPSYCHOLOGY, V19, P345, DOI 10.1037/0894-4105.19.3.345; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205	45	21	22	0	22	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					230	237		10.1017/S1355617710001451			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900003	21122190				2021-06-18	
J	Ueno, T; Ohori, Y; Ito, J; Hoshikawa, S; Yamamoto, S; Nakamura, K; Tanaka, S; Akai, M; Tobimatsu, Y; Ogata, T				Ueno, T.; Ohori, Y.; Ito, J.; Hoshikawa, S.; Yamamoto, S.; Nakamura, K.; Tanaka, S.; Akai, M.; Tobimatsu, Y.; Ogata, T.			Hyperphosphorylated neurofilament NF-H as a biomarker of the efficacy of minocycline therapy for spinal cord injury	SPINAL CORD			English	Article						biomarker; pNF-H; minocycline; spinal cord injury	TRAUMATIC BRAIN-INJURY; SERUM BIOMARKER; DEATH; RECOVERY; ENOLASE; BLOOD; MODEL; RATS	Study design: An in vivo study in a rat model of acute spinal cord contusion. Objectives: To assess the efficacy of novel therapies for acute spinal cord injury (SCI), methods to evaluate accurately the effects of these therapies should be developed. Although neurological examination is commonly used for this purpose, unstable clinical conditions and the spontaneous recovery of neurological function in the acute and subacute phases after injury make this measurement unreliable. Recent studies have reported that the phosphorylated form of the high-molecular-weight neurofilament subunit NF-H (pNF-H), a new biomarker for axonal degeneration, can be measured in serum samples in experimental SCI animals. Therefore, we aimed to investigate the use of plasma pNF-H as an indicator of the efficacy of minocycline, a neuroprotective drug, for treating SCI. Setting: This study was carried out at Saitama, Japan. Methods: Spinal cord injured rats received either minocycline or saline intraperitoneally. The plasma pNF-H levels and functional hind limb score were determined after the injury. Results: Minocycline treatment reduced plasma pNF-H levels at 3 and 4 days post-injury (dpi). Rats with lower plasma pNF-H levels at 3 dpi had higher hind limb motor score at 28 dpi. Conclusions: pNF-H levels may serve as a biomarker for evaluating the efficacy of therapies for SCI. Spinal Cord (2011) 49, 333-336; doi:10.1038/sc.2010.116; published online 31 August 2010	[Ueno, T.; Ohori, Y.; Ito, J.; Hoshikawa, S.; Yamamoto, S.; Ogata, T.] Natl Rehabil Ctr Persons Disabil, Res Inst, Dept Rehabil Movement Funct, Tokorozawa, Saitama, Japan; [Ueno, T.; Ohori, Y.; Ito, J.; Nakamura, K.; Tanaka, S.] Univ Tokyo, Grad Sch Med, Dept Orthopaed Surg, Tokyo, Japan; [Akai, M.; Tobimatsu, Y.] Natl Rehabil Ctr Persons Disabil, Rehabil Hosp, Tokorozawa, Saitama, Japan	Ogata, T (corresponding author), Natl Rehabil Ctr Persons Disabil, Res Inst, Dept Rehabil Movement Funct, 4-1 Namiki, Tokorozawa, Saitama, Japan.	ogata-toru@rehab.go.jp	Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414			BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2; Marquardt G, 2009, ACTA NEUROCHIR, V151, P1439, DOI 10.1007/s00701-009-0408-0; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Pouw MH, 2009, SPINAL CORD, V47, P519, DOI 10.1038/sc.2008.176; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007	16	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	MAR	2011	49	3					333	336		10.1038/sc.2010.116			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	730ZH	WOS:000288075600004	20805831	Bronze			2021-06-18	
J	Wang, YB; Liu, J; Yang, ZX				Wang, Yan-Bin; Liu, Jing; Yang, Zhao-Xu			Effects of intestinal mucosal blood flow and motility on intestinal mucosa	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Traumatic brain injury; Intestinal mucosa barrier; Stress; Intestinal mucosa blood flow; Intestinal motility	EXPERIMENTAL ACUTE-PANCREATITIS; BARRIER FUNCTION; TRAUMA PATIENTS; RATS; PERMEABILITY; STRESS; INJURY; RESTRAINT; INHIBITION; ACTIVATION	AIM: To investigate the role of intestinal nnucosal blood flow (IMBF) and motility in the damage of intestinal mucosal barrier in rats with traumatic brain injury. METHODS: Sixty-four healthy male Wistar rats were divided randomly into two groups: traumatic brain injury (TBI) group (n = 32), rats with traumatic brain injury; and control group (n = 32), rats with sham-operation. Each group was divided into four subgroups (n = 8) as 6, 12, 24 and 48 h after operation. Intestinal motility was measured by the propulsion ratio of a semi-solid colored marker (carbon-ink). IMBF was measured with the laser-Doppler technique. Endotoxin and D-xylose levels in plasma were measured to evaluate the change of intestinal mucosal barrier function following TBI. RESULTS: The level of endotoxin was significantly higher in TBI group than in the control group at each time point (0.382 +/- 0.014 EU/mL vs 0.102 +/- 0.007 EU/mL, 0.466 +/- 0.018 EU/mL vs 0.114 +/- 0.021 EU/mL, 0.478 +/- 0.029 EU/mL vs 0.112 +/- 0.018 EU/mL and 0.412 +/- 0.036 EU/mL vs 0.108 +/- 0.011 EU/mL, P < 0.05). D-xylose concentrations in plasma in TBI group were significantly higher than in the control group (6.68 +/- 2.37 mmol/L vs 3.66 +/- 1.07 mmol/L, 8.51 +/- 2.69 mmol /L vs 3.15 +/- 0.95 mmol/L, 11.68 +/- 3.24 mmol/L vs 3.78 +/- 1.12 mmol/L and 10.23 +/- 2.83 mmol/L vs 3.34 +/- 1.23 mmol/ L, P < 0.05). The IMBF in TBI group was significantly lower than that in the control group (38.5 +/- 2.8 PU vs 45.6 +/- 4.6 PU, 25.2 +/- 3.1 PU vs 48.2 +/- 5.3 PU, 21.5 +/- 2.7 PU vs 44.9 +/- 2.8 PU, 29. 4 +/- 3.8 PU vs 46.7 +/- 3.2 PU) (P < 0.05). Significant decelerations of intestinal propulsion ratio in TBI groups were found compared with the control group (0.48% +/- 0.06% VS 0.62% +/- 0.03%, 0.37% +/- 0.05% VS 0.64% +/- 0.01%, 0.39% +/- 0.07% VS 0.63% +/- 0.05% and 0.46% +/- 0.03% VS 0.65% +/- 0.02%) (P < 0.05). CONCLUSION: The intestinal mucosal permeability is increased obviously in TBI rats. Decrease of intestinal motility and IMBF occur early in TBI, both are important pathogenic factors for stress-related damage of the intestinal mucosal barrier in TBI. (C) 2011 Baishideng. All rights reserved.	[Liu, Jing] Beijing Dianli Hosp, Dept Neurol, Beijing 100073, Peoples R China; [Wang, Yan-Bin; Yang, Zhao-Xu] Capital Med Univ, Dept Gastroenterol, Beijing Tiantan Hosp, Beijing 100050, Peoples R China	Liu, J (corresponding author), Beijing Dianli Hosp, Dept Neurol, Beijing 100073, Peoples R China.	maogou0806@sina.com					Arumugam TV, 2003, BRIT J PHARMACOL, V140, P71, DOI 10.1038/sj.bjp.0705402; Ballabeni V, 2002, LIFE SCI, V71, P2025, DOI 10.1016/S0024-3205(02)01966-5; Cenac N, 2004, J PHYSIOL-LONDON, V558, P913, DOI 10.1113/jphysiol.2004.061721; Cerqueira Nereide Freire, 2005, Acta Cir. Bras., V20, P336, DOI 10.1590/S0102-86502005000400013; CHEN CL, 2008, DISAN JUNYI DAXUE XU, V30, P1434; Dervenis Christos, 2003, J Hepatobiliary Pancreat Surg, V10, P415, DOI 10.1007/s00534-002-0727-5; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Farhadi A, 2007, WORLD J GASTROENTERO, V13, P3027; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; GANGAROSA EJ, 1977, POSTGRAD MED, V62, P113, DOI 10.1080/00325481.1977.11714583; Kawano S, 2000, J GASTROEN HEPATOL, V15, pD1; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; Leveau P, 1996, INT J PANCREATOL, V20, P119; Li S, 2008, WORLD J GASTROENTERO, V14, P3254, DOI 10.3748/wjg.14.3254; Liu ZH, 2009, WORLD J GASTROENTERO, V15, P5732, DOI 10.3748/wjg.15.5732; MacFie J, 2000, NUTRITION, V16, P606, DOI 10.1016/S0899-9007(00)00249-5; Ogawa M, 1998, PANCREAS, V16, P312, DOI 10.1097/00006676-199804000-00017; RAYBOULD HE, 1988, AM J PHYSIOL, V255, pG242; Schwarz M, 2000, SURGERY, V127, P427, DOI 10.1067/msy.2000.104116; Shi HL, 2003, ZHONGGUO XINGWEI YIX, V12, P251; Soderholm JD, 2001, AM J PHYSIOL-GASTR L, V280, pG7; Sun YJ, 2008, WORLD J GASTROENTERO, V14, P5868, DOI 10.3748/wjg.14.5868; Tominaga G, 1998, J TRAUMA, V44, P1035; Tsukada F, 2002, BIOL PHARM BULL, V25, P122, DOI 10.1248/bpb.25.122; Tsukada F, 2001, BIOL PHARM BULL, V24, P488, DOI 10.1248/bpb.24.488; Tsukada F, 2001, BIOL PHARM BULL, V24, P1332, DOI 10.1248/bpb.24.1332; WANG YB, 2007, ZHONGHUA XIAOHUA ZAZ, V27, P103, DOI DOI 10.3760/J.ISSN:0254-1432.2007.02.008; WANG YB, 2007, ZHONGGUO SHIYAN DONG, V15, P220; Wang ZT, 2004, WORLD J GASTROENTERO, V10, P1619, DOI 10.3748/wjg.v10.i11.1619; WANG ZJ, 1985, GASTROINTESTINAL HOR, P2; XU XZ, 2000, ZHONGGUO WEIZHONGBIN, V6, P362	31	21	26	0	4	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1007-9327	2219-2840		WORLD J GASTROENTERO	World J. Gastroenterol.	FEB 7	2011	17	5					657	661		10.3748/wjg.v17.i5.657			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	725EJ	WOS:000287627700015	21350716	Other Gold, Green Published			2021-06-18	
J	Rosa, CM; Luigi, B; Antonio, D; Nicoletta, A; Gloria, L; Marco, G				Rosa, Calvi Maria; Luigi, Beretta; Antonio, Dell'Acqua; Nicoletta, Anzalone; Gloria, Licini; Marco, Gemma			Early Prognosis After Severe Traumatic Brain Injury With Minor or Absent Computed Tomography Scan Lesions	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Coma; MRI; Prognosis; Diffuse axonal injury	DIFFUSE AXONAL INJURY; SEVERE HEAD-INJURY; CONSENSUS CONFERENCE; STEM LESIONS; COMA; CLASSIFICATION; DEFINITIONS; FEATURES; FAILURE; STATE	Background: To assess the prognostic value of corpus callosum lesions (CCL) and brain stem lesions (BSL) in diffuse axonal injury (DAI) patients. Methods: From December 1989 to December 2008, 102 consecutive patients with pure DAI were admitted to our neurosurgical intensive care unit. Age, gender, Acute Physiology and Chronic Health Evaluation score, Glasgow Coma Score (GCS), pupillary light reactivity on admission, brain magnetic resonance imaging (MRI) 24 hours to 72 hours after trauma and sepsis, shock, adult respiratory distress syndrome, renal failure, neurosurgery, high intracranial pressure during the 6 months posttrauma were studied with multiple logistic regression, and Cox's proportional hazards, respectively, considering the Glasgow Outcome Scale and the time to recovery of consciousness as outcome variables. Results: Four variables predicted unfavorable Glasgow Outcome Scale (likelihood ratio p < 0.0001; Area Under the Receiver Operator Curve (AUROC) = 0.92; Naglekerke's R-2 = 0.64; Goodness-of-Fit p = 0.8679): age (5-year odds ratio [OR], 1.44; 95% CI, 1.14-1.82; p = 0.002), bilateral absence of light reflexes (OR, 11.11; 95% CI, 2.19-57.67; p = 0.004), multiplicity of CCL (OR, 29.23; 95% CI, 7.06-121.01; p < 0.001), and multiplicity of BSL (OR, 9.43; 95% CI, 2.44-36.42; p = 0.001). Four variables affected time to recovery of consciousness: age (hazard ratio, 0.98; 95% CI, 0.97-0.99; p = 0.009), bilateral absence of light reflexes (hazard ratio, 0.51; 95% CI, 0.27-0.97; p = 0.041), multiplicity of CCL (hazard ratio, 0.40; 95% CI, 0.25-0.66; p = 0.001), and total GCS on admission (hazard ratio, 1.45; 95% CI, 1.23-1.71; p < 0.001). Conclusions: In DAI patients, bad outcome is predicted by age, bilateral absence of pupillary light reflexes, multiplicity of CCL, and BSL on MRI. Time to recovery of consciousness is predicted by age, bilateral absence of light reflexes, multiplicity of CCL on MRI, and GCS on admission.	[Rosa, Calvi Maria; Luigi, Beretta; Antonio, Dell'Acqua; Gloria, Licini; Marco, Gemma] Ist Sci San Raffaele, Dept Head & Neck Anesthesia & Intens Care, I-20132 Milan, Italy; [Nicoletta, Anzalone] Ist Sci San Raffaele, Dept Neuroradiol, I-20132 Milan, Italy	Marco, G (corresponding author), Ist Sci San Raffaele, Dept Head & Neck Anesthesia & Intens Care, Via Olgettina 60, I-20132 Milan, Italy.	gemma.marco@hsr.it	anzalone, nicoletta/I-8752-2018	anzalone, nicoletta/0000-0002-4249-2723; Gemma, Marco/0000-0002-9543-3831			ADAMS JH, 1984, LANCET, V2, P1420; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; BERETTA L, 1994, INTRACRANIAL PRESSUR, V9, P284; Beretta L, 2010, J NEUROTRAUM, V27, P509, DOI 10.1089/neu.2009.1054; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GODERSKY JC, 1990, ACT NEUR S, V51, P311; JANIN Y, 2000, TXB CRITICAL CARE, P1037; JENNETT B, 1975, LANCET, V1, P480; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Park SJ, 2009, J KOREAN NEUROSURG S, V46, P205, DOI 10.3340/jkns.2009.46.3.205; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; WONG CW, 1993, SURG NEUROL, V39, P37, DOI 10.1016/0090-3019(93)90107-C; Zheng WB, 2007, NEURORADIOLOGY, V49, P271, DOI 10.1007/s00234-006-0187-8	24	21	22	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2011	70	2					447	451		10.1097/TA.0b013e3182095e14			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	719FV	WOS:000287187700042	21307746				2021-06-18	
J	Landi, A; Marotta, N; Mancarella, C; Marruzzo, D; Salvati, M; Delfini, R				Landi, Alessandro; Marotta, Nicola; Mancarella, Cristina; Marruzzo, Daniele; Salvati, Maurizio; Delfini, Roberto			Basal ganglia stroke due to mild head trauma in pediatric age - clinical and therapeutic management: a case report and 10 year literature review	ITALIAN JOURNAL OF PEDIATRICS			English	Article							ISCHEMIC-STROKE; BRAIN-INJURY; CHILDHOOD; MIGRAINE; CHILDREN	Ischemia of the basal ganglia as an immediate consequence of minor head injury in children is rare (< 2% of all ischemic stroke in childhood) and is due to vasospasm of the lenticulostriate arteries. The clinical history of these lesions is particularly favourable because they are usually small, and also because the facial-brachial-crural hemiparesis typical of this pathology usually regresses after a period ranging from several weeks to several months, despite the persistence of an ischemic area on MRI. This is due to the well known neuronal plasticity of the CNS, in particular, of the primary motor cortex. The most effective therapeutic approach appears to be the conservative one, although the best treatment regimen is still not well defined. Young patients should be closely monitored and treated conservatively with osmotic diuretics to reduce perilesional edema. At the same time, however, it is very important to exclude, by means of instrumental and laboratory studies, conditions that could favour the onset of ischemia, including emboligen heart disease, thrombophilia and acute traumatic arterial dissections. Generally speaking, the prognosis in these cases is good. The authors describe their experience treating a 10-month old baby girl, with a left lenticular nucleus ischemia and report a literature review.	[Landi, Alessandro; Marotta, Nicola; Mancarella, Cristina; Marruzzo, Daniele; Delfini, Roberto] Univ Rome Sapienza Rome, Dept Neurosurg Sci, Rome, Italy; [Salvati, Maurizio] Univ Rome Sapienza Rome, Dept Neurosurg, INM Neuromed, Pozzilli IS, Rome, Italy	Landi, A (corresponding author), Univ Rome Sapienza Rome, Dept Neurosurg Sci, Rome, Italy.	link55@libero.it		Landi, Alessandro/0000-0003-4303-6110			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bernard TJ, 2008, ANN NEUROL, V63, P679, DOI 10.1002/ana.21406; BODENSTEINER JB, 1992, AM J DIS CHILD, V146, P100, DOI 10.1001/archpedi.1992.02160130102029; Buompadre MC, 2009, J CHILD NEUROL, V24, P685, DOI 10.1177/0883073808330163; DHARKER SR, 1993, NEUROSURGERY, V33, P863; Fullerton HJ, 2001, NEUROLOGY, V57, P1155, DOI 10.1212/WNL.57.7.1155; HAAS DC, 1975, ARCH NEUROL-CHICAGO, V32, P727, DOI 10.1001/archneur.1975.00490530049003; Kieslich M, 2002, J NEUROL NEUROSUR PS, V73, P13, DOI 10.1136/jnnp.73.1.13; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; MAKI I, 1980, CHILDS BRAIN, V7, P113; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Nabika S, 2007, PEDIATR NEUROSURG, V43, P312, DOI 10.1159/000103313; Rana KS, 2006, INDIAN PEDIATR, V43, P994; Ruff RM, 1993, J HEAD TRAUMA REHAB, V8, P86; Shaffer L, 2003, ARCH DIS CHILD, V88, P267, DOI 10.1136/adc.88.3.267; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; UMANSKY F, 1985, J NEUROSURG, V62, P261, DOI 10.3171/jns.1985.62.2.0261	18	21	23	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1720-8424			ITAL J PEDIATR	Ital. J. Pediatr.	JAN 6	2011	37								2	10.1186/1824-7288-37-2			7	Pediatrics	Pediatrics	798VV	WOS:000293241200002	21210991	DOAJ Gold, Green Published			2021-06-18	
J	Cullen, NK; Weisz, K				Cullen, Nora K.; Weisz, Karen			Cognitive correlates with functional outcomes after anoxic brain injury: A case-controlled comparison with traumatic brain injury	BRAIN INJURY			English	Article						Brain injuries; hypoxia; brain; rehabilitation	DISABILITY RATING-SCALE; NEUROPSYCHOLOGICAL ASSESSMENT; REHABILITATION; VALIDITY; PERFORMANCE; SEQUELAE	Objectives: To assess the effectiveness of inpatient rehabilitation in adults who have sustained an anoxic brain injury (AnBI). Secondly, to identify areas of cognition that predict functional outcomes at discharge. Design: Retrospective, matched case-controlled study. Methods: Ten patients with moderate-to-severe AnBI and 10 patients with traumatic brain injury (TBI), treated in an inpatient neurorehabilitation programme, were matched on age, acute care length of stay and admission Functional Independence Measure (FIM). Functional outcome was assessed using the FIM and Disability Rating Scale (DRS). Results: Patients with AnBI performed worse on all measures of functional outcome relative to patients with TBI. Patients with AnBI achieved significantly lower FIM motor and cognitive gain compared with patients with TBI (11.5, SD 13.6 vs. 31.0, SD 19.7 and 2.4, SD 3.9 vs. 7.5, SD 4.2, respectively (p < 0.02)). DRS data showed similar trends of functional improvement between the groups. Several neuropsychometric tests correlated with functional outcome (p < 0.01). Conclusions: Patients with AnBI had worse functional outcomes following rehabilitation than patients with TBI, confirming the results of previous reports. Poor cognitive function predicted poor functional outcomes on the FIM and somewhat on the DRS. Research is needed to assess why these differences occur and to improve or develop new effective rehabilitation treatments for AnBI.	[Cullen, Nora K.] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Cullen, Nora K.] Univ Toronto, Div Physiatry, Toronto, ON, Canada; [Weisz, Karen] Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada	Cullen, NK (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	cullen.nora@torontorehab.on.ca		Cullen, Nora/0000-0001-6359-9418	Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario; Physicians' Services Foundation Inc. [06-43]; Canada Foundation for Innovation and the Province of Ontario	Thank you to the Physicians' Services Incorporated Foundation for funding this study. The Clinical Team at Toronto Rehabilitation Institute is greatly appreciated for their assistance in collection of data for this study. The authors also acknowledge the support of Toronto Rehabilitation Institute which receives funding under the Provincial Rehabilitation Research Program from the Ontario Ministry of Health and Long-Term Care. The views expressed herein do not necessarily reflect those of the Ministry.; Declaration of Interest: This study was supported by the Physicians' Services Foundation Inc. (grant no. 06-43). Equipment and space have been funded with grants from the Canada Foundation for Innovation and the Province of Ontario. The authors report no conflicts of interest.	Ashley MJ, 1997, BRAIN INJURY, V11, P677; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Burke DT, 2005, BRAIN INJURY, V19, P675, DOI 10.1080/02699050400024953; Caine D, 2000, J INT NEUROPSYCH SOC, V6, P86, DOI 10.1017/S1355617700611116; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Cullen NK, 2009, PM&R, V1, P1069, DOI 10.1016/j.pmrj.2009.09.013; Cullen NK, 2008, BRAIN INJURY, V22, P1013, DOI 10.1080/02699050802530581; DAMS JH, 2000, BRAIN, V123, P1327; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Fertl E, 2000, RESUSCITATION, V47, P231, DOI 10.1016/S0300-9572(00)00239-2; GROSWASSER Z, 1989, ARCH PHYS MED REHAB, V70, P186; Gualtieri CT, 2002, BRAIN INJURY MENTAL; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P957, DOI 10.1017/S1355617704107108; Kaplan CP, 1999, BRAIN INJURY, V13, P305, DOI 10.1080/026990599121674; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Neese LE, 2000, BRAIN INJURY, V14, P719; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, pS16, DOI 10.1016/S0003-9993(98)90115-0; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ravaud JF, 1999, SCAND J REHABIL MED, V31, P31; Schmidt JG, 1997, J NEUROL REHABIL, V11, P189; SCHURR A, 1992, HIPPOCAMPUS, V2, P221, DOI 10.1002/hipo.450020303; Shah MK, 2004, BRAIN INJURY, V18, P111, DOI 10.1080/0269905031000149551; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; UDS Data Management Service, 1995, GUID UN DAT SYST MED; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	32	21	21	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2011	25	1					35	43		10.3109/02699052.2010.531691			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700005	21121706				2021-06-18	
J	Isik, HS; Gokyar, A; Yildiz, O; Bostanci, U; Ozdemir, C				Isik, Hasan Serdar; Gokyar, Ahmet; Yildiz, Omer; Bostanci, Ugur; Ozdemir, Cengiz			Pediatric head injuries, retrospective analysis of 851 patients: an epidemiological study	ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY			Turkish	Article						Childhood; epidemiology; head injury	TRAUMATIC BRAIN-INJURY; CHILDREN YOUNGER; CHILDHOOD; FALLS; CITY; HOSPITALIZATIONS; MORTALITY	BACKGROUND The aim of this study was to contribute to the epidemiological database of our country about pediatric head injuries. METHODS We retrospectively analyzed 851 patients younger than 14 years old with head injury, treated in the Neurosurgery Department of Samsun Mehmet Aydin Education and Research Hospital between January 2003 and June 2008. RESULTS Five hundred and fifty (65%) patients were male and 301 (35%) were female. Falls (70%) were the most common cause of head injury. According to Glasgow Coma Score (GCS), 74% of patients had mild (13-15), 22% moderate (9-12) and 4% severe (3-8) head injury. Eighty-seven (10.5%) patients were operated. The commonest operations were performed for depressed fractures and epidural hematomas. The mortality rate was 3.8% (33). Common causes of mortality were traffic accidents and falls from heights. CONCLUSION Other reported studies and this study show that the majority of pediatric head injuries occur as a result of preventable causes. It is important to have local epidemiological studies and data about head injuries in order to prevent these traumas before their occurrence.	[Isik, Hasan Serdar] Ordu Univ, Fac Med, Dept Neurosurg, Ordu, Turkey; [Gokyar, Ahmet] Med Pk Hosp, Dept Neurosurg, Samsun, Turkey; [Yildiz, Omer; Bostanci, Ugur; Ozdemir, Cengiz] Mehmet Aydm Training & Res Hosp, Dept Neurosurg, Samsun, Turkey	Isik, HS (corresponding author), 1068 Sok,Zirvekent Sitesi C Blok,D 4, Ordu, Turkey.	serdarisik1@hotmail.com	Gokyar, Ahmet/N-9877-2018	Gokyar, Ahmet/0000-0003-1942-587X			Al B, 2009, ULUS TRAVMA ACIL CER, V15, P141; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Brudvik C, 2000, INJURY, V31, P761, DOI 10.1016/S0020-1383(00)00093-0; Diamond IR, 2009, J TRAUMA, V66, P1189, DOI 10.1097/TA.0b013e31819adbb3; Durkin MS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e74; Gill JR, 2009, ARCH PATHOL LAB MED, V133, P619, DOI 10.1043/1543-2165-133.4.619; Guzel A, 2007, ULUS TRAVMA ACIL CER, V13, P211; Gurses Dolunay, 2002, Ulus Travma Derg, V8, P156; Guzel Ahmet, 2006, Ulus Travma Acil Cerrahi Derg, V12, P299; Guzel A, 2009, ULUS TRAVMA ACIL CER, V15, P277; HALL JR, 1989, J TRAUMA, V29, P1273, DOI 10.1097/00005373-198909000-00015; Klin B, 2009, INJURY, V40, P1011, DOI 10.1016/j.injury.2009.01.135; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Love PF, 2009, J TRAUMA, V67, pS12, DOI 10.1097/TA.0b013e3181ac7f22; Marsh E, 2000, Int J Trauma Nurs, V6, P117, DOI 10.1067/mtn.2000.110620; National Center for Injury Prevention and Control, WEB BAS INJ STAT QUE; Okten A, 1996, ULUSAL TRAVMA DERGIS, V2, P94; Sahin S, 2002, ULUDAG TIP FAK DERG, V28, P45; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shah S, 2007, INJURY PREV, V13, P316, DOI 10.1136/ip.2007.016048; Simsek Osman, 2005, Ulus Travma Acil Cerrahi Derg, V11, P310; Tabish A, 2006, INJURY, V37, P410, DOI 10.1016/j.injury.2006.01.039; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Melo JRT, 2009, CHILD NERV SYST, V25, P1077, DOI 10.1007/s00381-009-0924-5; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; Verma S, 2009, INDIAN PEDIATR, V46, P168; Yanagawa Y, 2009, PEDIATR EMERG CARE, V25, P572, DOI 10.1097/PEC.0b013e3181b4f60e; Yeung JHH, 2009, INJURY, V40, P555, DOI 10.1016/j.injury.2008.08.015	28	21	21	2	6	TURKISH ASSOC TRAUMA EMERGENCY SURGERY	ISTANBUL	KOPRULU MEHMET PASA SOC, DENIZ ABDAL MAH, DADASOGLU AP, 25-1 SEHREMINI, ISTANBUL, 00000, TURKEY	1306-696X			ULUS TRAVMA ACIL CER	Ulus. Travma Acil Cerrahi Derg.		2011	17	2					166	172		10.5505/tjtes.2011.22800			7	Emergency Medicine	Emergency Medicine	742TX	WOS:000288968900013	21644096	Bronze			2021-06-18	
B	Iverson, GL; Lange, RT		Schoenberg, MR; Scott, JG		Iverson, Grant L.; Lange, Rael T.			Post-Concussion Syndrome	LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH			English	Article; Book Chapter							TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; CONTROLLED HISTORICAL COHORT; COMPLAINT BASE RATES; POSTCONCUSSION-SYNDROME; STEREOTYPE THREAT; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE PERFORMANCE; BEHAVIORAL SEQUELAE; DIAGNOSIS THREAT	The post-concussion syndrome (a.k.a., post-concussive disorder and post concussional disorder) has been controversial for decades. Without question, an acute post-concussion syndrome can be caused by the neurobiology of a mild traumatic brain injury (MTBI). Without question, a post-concussion syndrome can be worsened by psychological distress, social psychological factors (e.g., the nocebo effect, iatrogenesis, and misattributions), personality characteristics, and co-occurring conditions (e.g., chronic pain and insomnia). If due to the neurobiological effects of an injury to the brain, a post-concussion syndrome should be present in the first week post injury. Evaluating someone long after an injury, obtaining a cross-section of symptoms, and then attributing those symptoms to the remote injury can easily result in misdiagnosis. The widely-cited estimate of 10-20% of patients suffering a long-term post-concussion syndrome is both confusing and incorrect. It is confusing because there is often an assumption that if a person reports symptoms long after an MTBI, that the symptoms are causally-related to the biological effects of the injury (by logical inference, the symptoms are related to damage to the structure or function of the brain). However, it is well established that these symptoms could be caused, maintained, or worsened by a large number of factors that are unrelated to traumatically-induced cellular damage. It is incorrect because the constellation of symptoms comprising the post-concussion syndrome likely occurs in far fewer than 10-20% of patients with remote MTBIs. The estimates of 10-20% have typically been based on selected, non-representative samples of the entire population of people who sustain an MTBI, and some of the literature has been misinterpreted as showing evidence of a syndrome when it in fact illustrates isolated, non-specific symptom reporting. It is emphasized in this chapter that the post-concussion syndrome is a non-specific cluster of symptoms that can be mimicked by a number of pre-existing or comorbid conditions. The biologically-based, traumatically-induced syndrome, theoretically, can also occur in tandem with these conditions.	[Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Iverson, Grant L.; Lange, Rael T.] British Columbia Mental Hlth & Addict Serv, Coquitlam, BC, Canada	Iverson, GL (corresponding author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.	giverson@interchange.ubc.ca; rlange@dvbic.org					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Aronson J, 1999, J EXP SOC PSYCHOL, V35, P29, DOI 10.1006/jesp.1998.1371; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1990, PEDIATRICS, V86, P337; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOONE KB, 1995, J CLIN PSYCHOL, V51, P457, DOI 10.1002/1097-4679(199505)51:3<457::AID-JCLP2270510322>3.0.CO;2-7; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Croizet JC, 1998, PERS SOC PSYCHOL B, V24, P588, DOI 10.1177/0146167298246003; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Heilbronner RL, 1993, TRIAL DIPLOMACY J, V16, P161; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LeesHaley PR, 1996, PSYCHOL REP, V79, P811, DOI 10.2466/pr0.1996.79.3.811; LeesHaley PR, 1997, BRAIN INJURY, V11, P791; Levy B, 1996, J PERS SOC PSYCHOL, V71, P1092, DOI 10.1037/0022-3514.71.6.1092; Leyens JP, 2000, PERS SOC PSYCHOL B, V26, P1189, DOI 10.1177/0146167200262002; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; MATEER CA, 2000, NEUROPSYCHOLOGICAL M; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Naugle, 1999, J FORENSIC NEUROPSYC, V1, P5, DOI [10.1300/J151v01n04_02, DOI 10.1300/J151V01N04_02]; Necajauskaite Olga, 2005, Medicina (Kaunas), V41, P457; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Rohling Martin L, 2002, CNS Spectr, V7, P387; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spencer SJ, 1999, J EXP SOC PSYCHOL, V35, P4, DOI 10.1006/jesp.1998.1373; Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037/0003-066X.52.6.613; STEELE CM, 1995, J PERS SOC PSYCHOL, V69, P797, DOI 10.1037/0022-3514.69.5.797; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Sumanti M, 2006, CLIN NEUROPSYCHOL, V20, P754, DOI 10.1080/13854040500428467; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Temple RO, 2003, CLIN NEUROPSYCHOL, V17, P402, DOI 10.1076/clin.17.3.402.18080; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Walsh M, 1999, SEX ROLES, V41, P219, DOI 10.1023/A:1018854212358; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 INT STAT CLAS; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	100	21	21	0	11	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES			978-0-387-70703-7				2011							745	763		10.1007/978-0-387-76978-3_24	10.1007/978-0-387-76978-3		19	Clinical Neurology; Neurosciences; Psychology	Neurosciences & Neurology; Psychology	BTF43	WOS:000286799800024					2021-06-18	
J	Man, DWK; Fleming, J; Hohaus, L; Shum, D				Man, David W. K.; Fleming, Jennifer; Hohaus, Lydia; Shum, David			Development of the Brief Assessment of Prospective Memory (BAPM) for use with traumatic brain injury populations	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Prospective memory; Questionnaire; Self-report; Reliability; Validity; Rehabilitation	COMPREHENSIVE ASSESSMENT; PSYCHOMETRIC PROPERTIES; RETROSPECTIVE MEMORY; SELF-AWARENESS; NORMATIVE DATA; QUESTIONNAIRE; ADULTS; PERFORMANCE; CAPM	Impairment of prospective memory (PM) is a common problem following traumatic brain injury (TBI) which can affect functional outcomes. PM failures in everyday life can be assessed using self-report questionnaires; however, existing measures tend to be lengthy, which may be problematic for individuals with fatigue and other cognitive impairments. This study aimed to develop a short form of the Comprehensive Assessment of Prospective Memory (CAPM) and examine its psychometric properties. Using theoretical and statistical considerations, the number of items on the CAPM was reduced to 16 including equal numbers representing the basic activities of daily living (BADL) and instrumental activities of daily living (IADL) subscales. The psychometric properties of the new measure, named the Brief Assessment of Prospective Memory (BAPM), were examined by secondary analysis of data from two samples of community dwelling adults (aged 17 to 91 years, n = 527, and 15 to 60 years, n = 95) with no history of brain injury, and a sample of rehabilitation patients with moderate to severe TBI (n = 45). Results indicate that the BAPM has a robust factor structure, strong agreement with the original CAPM, acceptable internal consistency and test-retest reliability, and evidence of criterion-related validity with psychosocial integration as the point of reference for people with TBI.	[Man, David W. K.] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China; [Fleming, Jennifer] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Fleming, Jennifer] Queensland Hlth, Ctr Functioning & Hlth Res, Metro S Hlth Serv Dist, Brisbane, Qld, Australia; [Hohaus, Lydia; Shum, David] Griffith Univ, Behav Basis Hlth Program, Griffith Hlth Inst, Brisbane, Qld 4111, Australia; [Hohaus, Lydia; Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia	Man, DWK (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.	david.man@polyu.edu.hk	Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262	Griffith UniversityGriffith University	Preparation of this manuscript was partly supported by a Griffith University Jackson Memorial Visiting Fellowship awarded to David Man.	Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; Edwards P, 2004, CONTROL CLIN TRIALS, V25, P31, DOI 10.1016/j.cct.2003.08.013; Fleming J, 2009, BRAIN IMPAIR, V10, P34, DOI 10.1375/brim.10.1.34; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Herrmann D. J., 1983, EVERYDAY MEMORY ACTI, P133; Hobart JC, 2001, CLINICAL TRIALS IN NEUROLOGY, P17; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Levin H., 1989, HDB NEUROPSYCHOLOGY; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Raskin SA, 2009, BRAIN IMPAIR, V10, P23, DOI 10.1375/brim.10.1.23; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Uttl B, 2011, CAN J EXP PSYCHOL, V65, P57, DOI 10.1037/a0022843; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Waugh N., 1999, THESIS GRIFFITH U BR; Wilson B., 2005, CAMBRIDGE PROSPECTIV; World Health Organization, 2001, INT CLASS FUNCT DIS	23	21	22	1	8	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	6					884	898		10.1080/09602011.2011.627270			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	885OT	WOS:000299789200007	22150453				2021-06-18	
J	McCrory, P				McCrory, Paul			Future Advances and Areas of Future Focus in the Treatment of Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Sports concussion; Athletic injuries; Chronic traumatic encephalopathy; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; NATIONAL-FOOTBALL-LEAGUE; RUGBY UNION FOOTBALL; PROFESSIONAL FOOTBALL; HEAD-INJURIES; RECURRENT CONCUSSION; PLAYERS; DEPRESSION; ENCEPHALOPATHY; RISK	The occurrence and management of sports concussion provokes more debate and concern than virtually all other sports injuries combined. In the past 3 decades, clinicians have gone from mostly anecdotal strategies to an international consensus based approach and the early evolution of evidence-based practice. There is increasing engagement by mainstream neuroscientists in this field, which had previously been dominated by sports team physicians. However, the interchange has largely taken place in the media rather than through scientific journals. Legislators have proposed regulatory measures that restrict medical management of concussion in ways that apply to no other medical condition. This paper examines some of the key areas that are likely to be the focus of research in the next few years.	[McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [McCrory, Paul] Univ Melbourne, Brain Res Inst, Parkville, Vic 3010, Australia	McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568	National Health & Medical Research Council of AustraliaNational Health and Medical Research Council of Australia; Australian Research CouncilAustralian Research Council; International Rugby Board; Victorian Department of Health; Australian Sports Commission; International Olympic Commission; Federation Internationale de Football Association; CogState Inc.	the author has received research funding and conference support from the National Health & Medical Research Council of Australia, the Australian Research Council, the International Rugby Board, Victorian Department of Health, Australian Sports Commission, the International Olympic Commission, Federation Internationale de Football Association, and CogState Inc.	Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Blatter JS, 2010, SCAND J MED SCI SPOR, V20, DOI 10.1111/j.1600-0838.2010.01114.x; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Casson Ira R, 2006, Neurosurgery, V59, pE1152; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Dietze PM, 2008, MED J AUSTRALIA, V189, P479, DOI 10.5694/j.1326-5377.2008.tb02138.x; Dvorak J, 2009, BRIT J SPORT MED, V43, P317, DOI 10.1136/bjsm.2009.059618; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; HERRING S, 2006, MED SCI SPORTS EXERC, V38, P395, DOI DOI 10.1249/01.MSS.0000202025.48774.31; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, pV, DOI 10.1097/00001199-199804000-00001; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, J SCI MED SPORT, V5, P169, DOI 10.1016/S1440-2440(02)80002-0; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Peretti-Watel P, 2003, ADDICTION, V98, P1249, DOI 10.1046/j.1360-0443.2003.00490.x; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sullivan SJ, 2008, BRIT J SPORT MED, V42, P175, DOI 10.1136/bjsm.2007.039297; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Zazryn T, 2007, SPORTS MED, V37, P467	64	21	21	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					201	+		10.1016/j.csm.2010.08.002			10	Sport Sciences	Sport Sciences	691XR	WOS:000285114800018	21074093				2021-06-18	
S	Tang, JY; Ai, JL; Macdonald, RL		Zhang, JH; Colohan, A		Tang, Jingyang; Ai, Jinglu; Macdonald, R. Loch			Developing a Model of Chronic Subdural Hematoma	INTRACEREBRAL HEMORRHAGE RESEARCH: FROM BENCH TO BEDSIDE	Acta Neurochirurgica Supplementum		English	Article; Book Chapter						Chronic subdural hematoma; Acute subdural hematoma; Subdural hygroma; Animal models; Mild traumatic brain injury	SURGICAL-TREATMENT; PHYSIOPATHOGENESIS; RECURRENCE; HEMORRHAGE; PATHOLOGY; GROWTH; ORIGIN	Chronic subdural hematoma (CSDH) is a common neurosurgical condition that has a high incidence in the increasing elderly population of many countries. Pathologically, it is defined as a persistent liquefied hematoma in the subdural space more than 3 weeks old that is generally encased by a membraneous capsule. CSDHs likely originate after minor head trauma, with a key factor in its development being the potential for a subdural cavity to permit its expansion within, which is usually due to craniocerebral disproportion. The pathogenesis of CSDH has been attributed to osmotic or oncotic pressure differences, although measurements of these factors in the CSDH fluid do not support this theory. Current belief is that CSDH arises from recurrent bleeding in the subdural space, caused by a cycle of local angiogenesis, inflammation, coagulation and ongoing fibrinolysis. However, because of a lack of detailed knowledge about the precise mechanisms, treatment is often limited to surgical interventions that are invasive and often prone to recurrence. Thus, it is possible that an easily reproducible and representative animal model of CSDH would facilitate research in the pathogenesis of CSDH and aid with development of treatment options.	[Tang, Jingyang; Ai, Jinglu; Macdonald, R. Loch] St Michaels Hosp, Div Neurosurg, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Macdonald, R. Loch] Univ Toronto, Dept Surg, Toronto, ON, Canada	Macdonald, RL (corresponding author), St Michaels Hosp, Div Neurosurg, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	macdonaldlo@smh.ca		AI, JINGLU/0000-0001-7414-0207			AIKAWA H, 1987, J NEUROSURG, V67, P710, DOI 10.3171/jns.1987.67.5.0710; APFELBAUM RI, 1974, J NEUROSURG, V40, P336, DOI 10.3171/jns.1974.40.3.0336; Cenic A, 2005, CAN J NEUROL SCI, V32, P501, DOI 10.1017/S0317167100004510; FUJISAWA H, 1991, SURG NEUROL, V35, P441, DOI 10.1016/0090-3019(91)90177-B; Fujisawa H, 2006, NEUROL MED-CHIR, V46, P333, DOI 10.2176/nmc.46.333; Gardner JW, 1932, ARCH NEUROL PSYCHIAT, V1932, P847; GLOVER D, 1976, J NEUROSURG, V45, P393, DOI 10.3171/jns.1976.45.4.0393; GOLDEN J, 1994, CLIN NEUROPATHOL, V13, P12; Hong HJ, 2009, SURG NEUROL, V71, P161, DOI 10.1016/j.surneu.2008.01.023; Killeffer JA, 2000, NEUROSURG CLIN N AM, V11, P407, DOI 10.1016/S1042-3680(18)30102-5; KUDO H, 1992, Neurologia Medico-Chirurgica, V32, P207, DOI 10.2176/nmc.32.207; Labadie E L, 1974, Can J Neurol Sci, V1, P222; LABADIE EL, 1976, J NEUROSURG, V45, P382, DOI 10.3171/jns.1976.45.4.0382; Lee KS, 1998, BRAIN INJURY, V12, P901; Lee Kyeong-Seok, 1997, Journal of Korean Medical Science, V12, P353; Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371; Putnam TJ, 1925, ARCH SURG-CHICAGO, V11, P329, DOI 10.1001/archsurg.1925.01120150002001; Ramachandran R, 2007, SURG NEUROL, V67, P367, DOI 10.1016/j.surneu.2006.07.022; Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6; Stoodley M, 2000, NEUROSURGERY, V46, P1193, DOI 10.1097/00006123-200005000-00034; Trotter W, 1914, BRIT J SURG, V2, P271, DOI 10.1002/bjs.1800020608; Virchow R., 1857, VERH PHYS MED GES WU, V7, P134; WATANABE S, 1972, J NEUROSURG, V37, P552, DOI 10.3171/jns.1972.37.5.0552; Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937; Yamashima T, 2000, NEUROSURG CLIN N AM, V11, P413, DOI 10.1016/S1042-3680(18)30103-7	25	21	21	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, A-1201 VIENNA, AUSTRIA	0065-1419		978-3-7091-0692-1	ACTA NEUROCHIR SUPPL	Acta Neurochir. Suppl.		2011	111						25	29		10.1007/978-3-7091-0693-8_5	10.1007/978-3-7091-0693-8		5	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	BGT35	WOS:000324076300005	21725727				2021-06-18	
J	Whiteside, D; Wald, D; Busse, M				Whiteside, Douglas; Wald, Danielle; Busse, Michelle			Classification Accuracy of Multiple Visual Spatial Measures in the Detection of Suspect Effort	CLINICAL NEUROPSYCHOLOGIST			English	Article						Symptom validity testing; Effort; Neuropsychological evaluation; Visual spatial	MALINGERED NEUROCOGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; RECOGNITION; PERFORMANCE; INDICATORS; VALIDATION; TESTS	A wide variety of cognitive measures, particularly memory measures, have been studied for their ability to detect suspect effort, or biased responding on neuropsychological assessment instruments. However, visual spatial measures have received less attention. The purpose of this study was to evaluate the classification accuracy of several commonly used visual spatial measures, including the Judgment of Line Orientation Test, the Benton Facial Recognition Test, the Hooper Visual Organization Test, and the Rey Complex Figure Test-Copy and Recognition trials. Participants included 491 consecutive referrals who participated in a comprehensive neuropsychological assessment and met study criteria. Participants were divided into two groups identified as either unbiased responding (UR, N = 415) or biased responding (BR, N = 30) based on their performance on two measures of effort. The remaining participants (N = 46) had discrepant performance on the symptom validity measures and were excluded from further analysis. The groups differed significantly on all measures. Additionally, receiver operating characteristic (ROC) analysis indicated all of the measures had acceptable classification accuracy, but a measure combining scores from all of the measures had excellent classification accuracy. Results indicated that various cut-off scores on the measures could be used depending on the context of the evaluation. Suggested cut-off scores for the measures had sensitivity levels of approximately 32-46%, when specificity was at least 87%. When combined, the measures suggested cut-off scores had sensitivity increase to 57% while maintaining the same level of specificity (87%). The results were discussed in the context of research advocating the use of multiple measures of effort.	[Whiteside, Douglas] Argosy Univ Seattle, Amer Sch Profess Psychol, Seattle, WA 98105 USA	Whiteside, D (corresponding author), Argosy Univ Seattle, Amer Sch Profess Psychol, 2601 A Elliott Ave, Seattle, WA 98105 USA.	dwhiteside@argosy.edu	Whiteside, Douglas/AAK-6396-2020	Whiteside, Douglas/0000-0002-8454-4413			Benton A., 1968, CORTEX, V4, P344, DOI DOI 10.1016/S0010-9452(68)80018-8; Benton A. L., 1994, CONTRIBUTIONS NEUROP; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; Boone K. B., 2002, DOT COUNTING TEST MA; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; BOONE KB, 2007, ASSESSMENT MALINGERE, P27; CONDER R, 1992, COMPUTERIZED ASSESSM; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2004, APPL NEUROPSYCHOL, V11, P222; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein M. F., 1994, PSYCHOL ASSESSMENT, V18, P573; GREIFFENSTEIN MF, 2007, ASSESSMENT MALINGERE, P100; Hooper H.E., 1958, HOOPER VISUAL ORG TE; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Iverson G L, 2001, Appl Neuropsychol, V8, P167, DOI 10.1207/S15324826AN0803_6; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P80; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Meyers J, 1995, REY COMPLEX FIGURE R; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; *PSYCH CORP, 2001, WECHL TEST AD READ; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr J. A., 2007, ASSESSMENT MALINGERE, P80; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tranel D, 2009, J CLIN EXP NEUROPSYC, V31, P219, DOI 10.1080/13803390802317542	34	21	21	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	2					287	301	PII 931806742	10.1080/13854046.2010.538436			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	722DX	WOS:000287412500006	21331981				2021-06-18	
S	Yang, KH; Mao, HJ; Wagner, C; Zhu, F; Chou, CC; King, AI		Bilston, LE		Yang, King H.; Mao, Haojie; Wagner, Christina; Zhu, Feng; Chou, Clifford C.; King, Albert I.			Modeling of the Brain for Injury Prevention	NEURAL TISSUE BIOMECHANICS	Studies in Mechanobiology Tissue Engineering and Biomaterials		English	Article; Book Chapter							FINITE-ELEMENT-ANALYSIS; CORTICAL CONTUSION INJURY; FILLED SPHERICAL-SHELL; HUMAN HEAD; DYNAMIC-RESPONSE; ELASTIC MODEL; IMPACT; SIMULATION; PREDICTION; CONSEQUENCES	From an ethical point of view, it is extremely difficult to propose a well-controlled human subject study aimed at understanding brain injury mechanisms and establishing the associated tolerance values. For this reason, many numerical models of the human and animal head or brain have been developed over the past several decades in an attempt to obtain in-depth insights into brain injury biomechanics, minimizing the need for human subject research. This chapter highlights and contrasts the essence of human and animal head numerical models developed for studying blunt impact and blast-induced brain injuries. Even with the vast amount of literature produced by these investigations and studies, the precise mechanisms of brain injury have not yet been fully established to date. Through this review, it is clear that a lot of information can be garnered by numerical brain modeling but few efforts have been devoted so far to using these numerical models to provide guidelines in the discovery of brain injury mechanisms. Based on the brain models reported in the current literature, there are some inherent deficiencies. However, with further revisions and improvements to the currently available models, as opposed to developing new models from scratch, these issues can be overcome, and the slate of the art can be advanced. More research effort into brain injury mechanisms, especially under in vivo conditions, is needed for computational model improvements so that the injury mechanisms can be thoroughly understood and effective countermeasures for protecting human from traumatic brain injury can be developed.	[Yang, King H.; Mao, Haojie; Wagner, Christina; Zhu, Feng; Chou, Clifford C.; King, Albert I.] Wayne State Univ, Detroit, MI 48202 USA	Yang, KH (corresponding author), Wayne State Univ, Detroit, MI 48202 USA.	aa0007@wayne.edu	Mao, Haojie/Q-7514-2018	Mao, Haojie/0000-0002-7563-9234			ABEL JM, 1978, 22 STAPP CAR CRASH C; ALBSHARAT A, 1999, 43 STAPP CAR CRASH C; ALEM NM, 1974, P 18 STAPP CAR CRASH; Allsop D, 1988, P 32 STAPP CAR CRASH; ANDERSON RW, 2000, STUDY BIOMECHANICS A; Bandak F, 1994, 38 STAPP CAR CRASH C; BANDAK FA, 1995, J NEUROTRAUM, V12, P679, DOI 10.1089/neu.1995.12.679; BANDAK FA, 1995, J NEUROTRAUM, V12, P635, DOI 10.1089/neu.1995.12.635; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands D W, 2000, Stapp Car Crash J, V44, P249; BRANDS DWA, 2002, P 46 STAPP CAR CRASH, P103; Chafi MS, 2008, PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION 2007, VOL 2, P211; CHAFI MS, 2009, ANN BIOMED ENG E PUB; Chakrabarty SP, 2009, MATH BIOSCI, V219, P129, DOI 10.1016/j.mbs.2009.03.005; CHAN HS, 1974, J BIOMECH, V7, P43, DOI 10.1016/0021-9290(74)90069-4; CHAN HS, 1974, P 18 STAPP CAR CRASH; Chen M, 2009, J NEUROSCI METH, V179, P111, DOI 10.1016/j.jneumeth.2009.01.010; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; CHU CS, 1994, J BIOMECH, V27, P187, DOI 10.1016/0021-9290(94)90208-9; CLAESSENS M, 1997, P 41 ANN STAPP CAR C; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Couper Z, 2008, BIOMECH MODEL MECHAN, V7, P105, DOI 10.1007/s10237-007-0079-9; Desantis Klinich Kathleen, 2002, Stapp Car Crash J, V46, P165; DIMASI F, 1991, AUTO TRAFFIC SAFETY, V1; DiMasi F.P., 1995, P 39 STAPP CAR CRASH; ENGIN AE, 1970, J BIOMECH, V3, P11, DOI 10.1016/0021-9290(70)90047-3; EPPINGER R, 1994, P NHTSA 14 INT TECHN; FAN WRS, 1971, P 15 STAPP CAR CRASH; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fitch MT, 1999, J NEUROSCI, V19, P8182; FRANKLYN M, 2005, STAPP CAR CRASH J, V50; Franklyn Melanie, 2007, Critical Reviews in Biomedical Engineering, V35, P197; Fredriksson R, 2007, STAPP CAR CRASH JO, V51, P155; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gao CP, 2008, ACTA NEUROCHIR SUPPL, V102, P279, DOI 10.1007/978-3-211-85578-2_52; Gao CP, 2005, P ANN INT IEEE EMBS, P4337; Goldsmith W., 1966, P HEAD INJURY C, P350; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hagemann A, 2002, MED IMAGE ANAL, V6, P375, DOI 10.1016/S1361-8415(02)00059-2; HARDY CH, 1971, 8 DIV ENG BROWN U; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; HODGSON VR, 1968, P 12 STAPP CAR CRASH; HODGSON VR, 1967, P 11 STAPP CAR CRASH; Holmberg P, 2009, CURR NEUROVASC RES, V6, P1; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hosey R. R., 1982, FINITE ELEMENTS BIOM, P379; Hu JW, 2007, J NEUROSURG, V106, P164, DOI 10.3171/jns.2007.106.1.164; Huang HM, 2000, MED BIOL ENG COMPUT, V38, P253, DOI 10.1007/BF02347044; JIN X, 2010, J BIOMECH; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Jin X, 2007, STAPP CAR CRASH JO, V51, P115; Johnson EAC, 2005, J BIOMECH, V38, P39, DOI 10.1016/j.jbiomech.2004.03.018; KANG HS, 1997, 41 STAPP CAR CRASH C; KHALIL TB, 1977, J BIOMECH, V10, P119, DOI 10.1016/0021-9290(77)90075-6; KHALIL TB, 1974, INT J MECH SCI, V16, P609, DOI 10.1016/0020-7403(74)90061-7; KHALIL TB, 1982, P 26 STAPP CAR CRASH; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; KING AI, 1976, J BIOMECH, V9, P301, DOI 10.1016/0021-9290(76)90052-X; KING AI, 1999, P 1999 BIOENG C ASME, P269; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KRABBEL G, 1995, J NEUROTRAUM, V12, P735, DOI 10.1089/neu.1995.12.735; KUIJPERS AHWM, 1995, J NEUROTRAUM, V12, P715, DOI 10.1089/neu.1995.12.715; Kumaresan S, 1996, MED BIOL ENG COMPUT, V34, P27, DOI 10.1007/BF02637019; Kurosawa Y, 2008, IEEE ENG MED BIO, P4090, DOI 10.1109/IEMBS.2008.4650108; KURTZ SM, 1998, P 8 INJ PREV BIO S W; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lee M-C, 1987, 31 STAPP CAR CRASH C; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Li JR, 2007, BIOMED SCI INSTRUM, V43, P24; Lighthall J.W., 1989, P 12 INT TECHN C EXP, P627; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; MARTINEZ JL, 1968, P 12 STAPP CAR CRASH; MERCHANT HC, 1974, J BIOMECH, V7, P295, DOI 10.1016/0021-9290(74)90022-0; Meyer R., 2002, EXPLOSIVES; MILLER RT, 1998, 42 STAPP CAR CRASH C; MILLER RT, 1999, 43 STAPP CAR CRASH C; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss W.C., 2009, J ACOUST SOC AM, V125, P2650; NAHUM A, 1980, P 24 STAPP CAR CRASH; Nahum A. M., 1977, P 21 STAPP CAR CRASH; NAHUM AM, 1981, 25 STAPP CAR CRASH C; NAHUM AM, 1979, P 23 STAPP CAR CRASH; Newman J, 2000, 44 STAPP CAR CRASH C; Nyquist G. W., 1986, P 30 STAPP CAR CRASH; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Pena A, 2005, ACT NEUR S, V95, P333; PINTAR FA, 1995, P 39 STAPP CAR CRASH; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PRANGE MT, 1999, STAPP CAR CRASH C S; PRANGE MT, 2000, P 44 STAPP CAR CRASH; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Roth S, 2008, COMPUT METH PROG BIO, V90, P262, DOI 10.1016/j.cmpb.2008.01.007; Roth S, 2007, INT J LEGAL MED, V121, P223, DOI 10.1007/s00414-006-0129-3; Roth S, 2009, COMPUT METH PROG BIO, V93, P32, DOI 10.1016/j.cmpb.2008.08.001; Rousseau Philippe, 2010, Stapp Car Crash J, V54, P37; Ruan J, 2001, Stapp Car Crash J, V45, P395; RUAN JS, 1995, J NEUROTRAUM, V12, P725, DOI 10.1089/neu.1995.12.725; Ruan JS, 2006, J BIOMECH, V39, P383, DOI 10.1016/j.jbiomech.2005.03.004; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; RUAN JS, 1993, STAPP C P SAE; RUAN JS, 1994, P 38 STAPP CAR CRASH; Saberi H, 2007, COMPUT AIDED SURG, V12, P131, DOI 10.1080/10929080701294828; SACZALSKI KJ, 1978, AVIAT SPACE ENVIR MD, V49, P114; Sarron JC, 2000, J TRAUMA, V49, P923, DOI 10.1097/00005373-200011000-00021; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shafieian M, 2009, J BIOMECH, V42, P2136, DOI 10.1016/j.jbiomech.2009.05.041; SHREIBER DI, 1997, 41 STAPP CAR CRASH C; SHUGAR TA, 1975, P 19 STAPP CAR CRASH; SLATTENSCHEK A, 1971, P 15 STAPP CAR CRASH; Sotudehchafi M, 2007, PROCEEDING OF THE ASME SUMMER BIOENGINEERING CONFERENCE - 2007, P349; Soza Grzegorz, 2003, Comput Aided Surg, V8, P241, DOI 10.3109/10929080309146059; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts EG, 2008, STAPP CAR C, V52, P1; Takizawa Hideo, 1994, Neurologia Medico-Chirurgica, V34, P65, DOI 10.2176/nmc.34.65; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; THIBAULT KT, 1997, P WINT ANN M ASME; THUNNISSEN J, 1995, P 39 STAPP CAR CRASH; THURMAN DL, 2000, TRAUMATIC BRAIN INJU; Trosseille X., 1992, P 36 STAPP CAR CRASH, DOI 10.4271/922527; Turquier F, 1996, 40 STAPP CAR CRASH C; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Ward C., 1980, 24 STAPP CAR CRASH C; WARD C, 1975, 19 STAPP CAR CRASH C; WARD C, 1982, P 26 STAPP CAR CRASH; WARD CC, 1978, AVIAT SPACE ENVIR MD, V49, P136; WILLINGER CM, 1992, NEW CONCEPT CONTRECO, P283; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; WILLINGER R, 1995, HEAD BIOMECHANICS FI, P245; Wittek A, 2008, COMPUT METHOD BIOMEC, V11, P135, DOI [10.1080/10255840701688095, 10.1080/10255840802296665]; WITTEK A, 2005, BRAIN SHIFT COMPUT 2, V8, P583; Xu Wei, 2008, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V25, P556; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1; Zhang Jiangyue, 2009, Biomed Sci Instrum, V45, P119; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1995, P 39 STAPP CAR CRASH; ZHOU C, 1994, 38 STAPP CAR CRASH C; Zhu Feng, 2010, Stapp Car Crash J, V54, P211; Zhu Q, 2006, DEV NEUROSCI-BASEL, V28, P388, DOI 10.1159/000094165; Zong Z, 2006, J BIOMECH, V39, P284, DOI 10.1016/j.jbiomech.2004.11.015; ZOROYA G, 2005, KEY IRAQ WOUND BRAIN	167	21	21	0	11	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	1868-2006		978-3-642-13889-8	STUD MECHANOBIOL TIS	Stud. Mechanobiol. Tissue Eng. Biomater.		2011	3						69	120		10.1007/8415_2010_62	10.1007/978-3-642-13890-4		52	Biotechnology & Applied Microbiology; Engineering, Biomedical; Neurosciences	Biotechnology & Applied Microbiology; Engineering; Neurosciences & Neurology	BWN19	WOS:000294272200005					2021-06-18	
J	Zlotnik, A; Ohayon, S; Gruenbaum, BF; Gruenbaum, SE; Mohar, B; Boyko, M; Klin, Y; Sheiner, E; Shaked, G; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Ohayon, Sharon; Gruenbaum, Benjamin F.; Gruenbaum, Shaun E.; Mohar, Boaz; Boyko, Matthew; Klin, Yael; Sheiner, Eyal; Shaked, Gad; Shapira, Yoram; Teichberg, Vivian I.			Determination of Factors Affecting Glutamate Concentrations in the Whole Blood of Healthy Human Volunteers	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						glutamate; neurotoxicity; traumatic brain injury; glutamate-pyruvate transaminase (GPT); glutamate-oxaloacetate transaminase (GOT)	MONOSODIUM L-GLUTAMATE; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; AMINO-ACIDS; SCAVENGING ACTIVITY; EXCESS GLUTAMATE; PLASMA GLUTAMATE; ISCHEMIC-STROKE; BRAIN	Background: Abnormally high concentrations of glutamate in brain fluids have been shown to be neurotoxic and correlate with a poor neurological outcome following traumatic brain injury (TBI). Since brain fluid glutamate can be reduced by scavenging blood glutamate, the purpose of this study was to investigate factors that may potentially influence levels of blood glutamate, glucose, and the enzymes glutamate-pyruvate transaminase (GPT) and glutamate-oxaloacetate transaminase (GOT) in healthy individuals. Methods: Factors that were examined included age, gender, time of last meal or drink, and recent consumption of coffee. A total of 112 healthy volunteers between 18 and 70 years of age participated in the study. The average participant was 38 years old, and the sample consisted of 48 males and 64 females. Five milliliters of venous blood was collected from participants' cubital vein and blood glutamate, glucose, GOT and GPT levels were determined. Participants were then asked to complete a questionnaire addressing their gender, age, time of last meal, time of last drink, and whether coffee was consumed within the last 6 hours. Results: Blood glutamate concentrations were significantly higher in males than in females (P < 0.001) and may be due to effects of estrogen and progesterone. Concentrations of GOT were significantly higher in males than in females (P < 0.01). Concentrations of GPT were significantly higher in males than in females (P < 0.01). There were no other significant differences demonstrated. Conclusions: Understanding the factors that affect blood glutamate levels may give new insight into mechanisms that protect the brain from excess glutamate and result in a better neurological outcome following TBI.	[Zlotnik, Alexander; Ohayon, Sharon; Gruenbaum, Benjamin F.; Boyko, Matthew; Shapira, Yoram] Ben Gurion Univ Negev, Dept Anesthesiol & Crit Care, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; [Sheiner, Eyal] Ben Gurion Univ Negev, Dept Obstet & Gynecol, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; [Shaked, Gad] Soroka Univ, Dept Gen Surg, Med Ctr, Beer Sheva, Israel; [Mohar, Boaz; Klin, Yael; Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Gruenbaum, Shaun E.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA	Zlotnik, A (corresponding author), Ben Gurion Univ Negev, Dept Anesthesiol & Crit Care, Soroka Med Ctr, IL-84105 Beer Sheva, Israel.	zlotnika@bgu.ac.il	Mohar, Boaz/H-6398-2011; SHEINER, EYAL/F-1488-2012	Mohar, Boaz/0000-0002-8613-2869; Boyko, Matthew/0000-0003-3116-1643			Andreadou E, 2008, IN VIVO, V22, P137; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Ferrarese C, 2001, NEUROLOGY, V57, P671, DOI 10.1212/WNL.57.4.671; Gazzaley AH, 1996, J NEUROSCI, V16, P6830; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Koura SS, 1998, ACT NEUR S, V71, P244; Liang Z, 2002, J NEUROCHEM, V80, P807, DOI 10.1046/j.0022-3042.2002.00779.x; MARLISS EB, 1971, J CLIN INVEST, V50, P814, DOI 10.1172/JCI106552; Nehlig A, 1999, NEUROSCI BIOBEHAV R, V23, P563, DOI 10.1016/S0149-7634(98)00050-5; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; Reeds PJ, 1996, AM J PHYSIOL-ENDOC M, V270, pE413; Sailasuta N, 2008, MAGN RESON IMAGING, V26, P667, DOI 10.1016/j.mri.2007.06.007; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; Slooter AJC, 1999, J NEUROL NEUROSUR PS, V67, P779, DOI 10.1136/jnnp.67.6.779; Spranger M, 1996, J NEUROL SCI, V143, P126, DOI 10.1016/S0022-510X(96)00197-9; STEGINK LD, 1985, AM J CLIN NUTR, V42, P220; STEGINK LD, 1983, J NUTR, V113, P1851; Stover JF, 2005, ACTA NEUROCHIR, V147, P847, DOI 10.1007/s00701-005-0562-y; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Tsai PJ, 2000, J NUTR, V130, p1002S, DOI 10.1093/jn/130.4.1002S; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2010, EXP NEUROL, V224, P465, DOI 10.1016/j.expneurol.2010.05.009; Zlotnik A, 2009, J NEUROSURG ANESTH, V21, P235, DOI 10.1097/ANA.0b013e3181a2bf0b	33	21	21	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2011	23	1					45	49		10.1097/ANA.0b013e3181f82a8f			5	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	692FC	WOS:000285137200009	21248494				2021-06-18	
J	Dams-O'Connor, K; Gordon, WA				Dams-O'Connor, Kristen; Gordon, Wayne A.			Role and Impact of Cognitive Rehabilitation	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Cognitive rehabilitation; Cognitive impairment; Brain injury	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; NEUROPSYCHOLOGIC REHABILITATION; SELF-AWARENESS; EVERYDAY MEMORY; CHRONIC APHASIA; PAGING SYSTEM; INDIVIDUALS; DEPRESSION; MANAGEMENT	Cognitive rehabilitation interventions are theoretically based and empirically validated treatments designed to ameliorate the cognitive, behavioral, and emotional impairments commonly experienced by individuals with traumatic brain injury (TBI) Cognitive rehabilitation can play many roles in facilitating recovery after TBI such as improving impaired cognitive functions increasing awareness of injury-related deficits improving mood facilitating vocational and community involvement, and reducing the probability of secondary disability The considerable evidence documenting the impact of cognitive rehabilitation on improving the day-to-day function of individuals with TBI is described	[Dams-O'Connor, Kristen; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Dams-O'Connor, K (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.				NCIPC CDC HHS [5R49-CE-001171] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001171] Funding Source: NIH RePORTER		[Anonymous], 1999, JAMA, V282, P974; Ashman TA, 2006, MT SINAI J MED, V73, P999; Beck A. T., 1979, COGNITIVE THERAPY DE; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Brain Injury Association of America, SUBST AB ISS TRAUM B; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dams-O Connor K, 2009, AM C REH MED DENV CO; Dams-O Connor K, ENCY CLIN N IN PRESS; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2003, PSYCHOSOMATICS, V44, P161; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Gordon WA, 2005, TXB TRAUMATIC BRAIN, P655; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; Hibbard M. R., 2005, COGNITIVE BEHAV THER, P189; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kasten E, 2001, J CLIN EXP NEUROPSYC, V23, P297, DOI 10.1076/jcen.23.3.297.1180; Kendall E, 2006, J VOCAT REHABIL, V25, P149; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Lebowitz M, 2009, AM C REH MED DENV CO; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK M, 2004, NEUROPSYCOLOGICAL AS; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Meinzer M, 2005, STROKE, V36, P1462, DOI 10.1161/01.STR.0000169941.29831.2a; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; Merzenich MM, 1999, RES PER NEUROSCI, P169; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Poggel DA, 2004, NEUROLOGY, V63, P2069, DOI 10.1212/01.WNL.0000145773.26378.E5; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; Sherer M, 2010, J HEAD TRAUMA REHAB, V25, P92, DOI 10.1097/HTR.0b013e3181c9d887; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Silver JM, 2005, TXB TRAUMATIC BRAIN; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Tsaousides T, 2010, 8 WORLD C BRAIN INJ; Waldmann C, 2007, APHA 135 ANN M EXP P; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	78	21	21	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	DEC	2010	33	4					893	+		10.1016/j.psc.2010.08.002			13	Psychiatry	Psychiatry	694TA	WOS:000285320700010	21093684				2021-06-18	
J	Haney, SB; Starling, SP; Heisler, KW; Okwara, L				Haney, Suzanne B.; Starling, Suzanne P.; Heisler, Kurt W.; Okwara, Leonore			Characteristics of Falls and Risk of Injury in Children Younger Than 2 Years	PEDIATRIC EMERGENCY CARE			English	Article						falls; injury patterns; accident	CARE CENTERS; INFANTS; BED	Introduction: Although many studies have shown that short falls by children rarely result in serious injury, no recent study in the United States has assessed the prevalence and the characteristics of such falls. Because the history of a short fall often is given in the instance of suspected child abuse, data addressing the characteristics, the frequency, and the severity of such falls would assist in abuse investigations. Methods: Anonymous questionnaires were distributed at primary care offices to parents of children younger than 5 years. Parents answered a series of questions regarding any falls their children had sustained before the age of 2 years. Information gathered included the age of the child at the time of the fall, the details about the fall, the medical attention sought, and any injuries sustained. Results: We received a total of 307 eligible surveys. There were 209 falls reported for 122 children. Only 24% of those children sustained any injury as a result of the fall. Most (85%) of the children who sustained injuries had a bruise or a bump. Of the 20% (40 children) who were brought for medical care, only 13 children received medical treatment. The most severe injuries were in 2 children who sustained concussions; only 4 children had permanent injury (cutaneous scars). Children who fell on a hard surface were 6 times more likely to have an injury compared with children who fell on a soft surface (P = 0.001) In addition, for every 1 unit increase in fall height, risk of injury increased by a factor of 2.3. Conclusions: In short falls, ground surface and fall height were significant predictors of injury risk. The results of this study also support the opinion that short falls rarely cause injury. Therefore, a history of a short fall in a seriously injured child should raise the suspicion of child abuse.	[Haney, Suzanne B.; Starling, Suzanne P.] Childrens Hosp Kings Daughters, Norfolk, VA USA; [Haney, Suzanne B.; Starling, Suzanne P.; Heisler, Kurt W.; Okwara, Leonore] Eastern Virginia Med Sch, Norfolk, VA USA	Haney, SB (corresponding author), Project Harmony, 7110 F St, Omaha, NE 68117 USA.	shaneymd@projectharmony.com					ALKON A, 1994, PEDIATRICS, V94, P1043; Alkon A, 1999, ARCH PEDIAT ADOL MED, V153, P1248, DOI 10.1001/archpedi.153.12.1248; BARLOW B, 1983, J PEDIATR SURG, V18, P509, DOI 10.1016/S0022-3468(83)80210-3; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; HELFER RE, 1977, PEDIATRICS, V60, P533; Hoke JR, 1988, RAMSEY SLEEPER ARCHI; Kotch J B, 1997, Inj Prev, V3, P267, DOI 10.1136/ip.3.4.267; KRAVITZ H, 1969, PEDIATRICS, V44, P869; Lallier M, 1999, J PEDIATR SURG, V34, P1060, DOI 10.1016/S0022-3468(99)90564-X; LYONS TJ, 1993, PEDIATRICS, V92, P125; Macarthur C, 2000, ACCIDENT ANAL PREV, V32, P377, DOI 10.1016/S0001-4575(99)00079-2; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; Warrington SA, 2001, ARCH DIS CHILD, V85, P104, DOI 10.1136/adc.85.2.104; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005	16	21	21	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	DEC	2010	26	12					914	918		10.1097/PEC.0b013e3181fe9139			5	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	689QP	WOS:000284943800008	21088634				2021-06-18	
J	Iaci, JF; Ganguly, A; Finklestein, SP; Parry, TJ; Ren, JM; Saha, S; Sietsma, DK; Srinivas, M; Vecchione, AM; Caggiano, AO				Iaci, Jennifer F.; Ganguly, Anindita; Finklestein, Seth P.; Parry, Tom J.; Ren, JingMei; Saha, Subhash; Sietsma, Dana K.; Srinivas, Maya; Vecchione, Andrea M.; Caggiano, Anthony O.			Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke	NEUROPHARMACOLOGY			English	Article						Neuregulin; Ischemia; GGF2; MCAO; Recovery	EXTENDED THERAPEUTIC WINDOW; PLASMINOGEN-ACTIVATOR; TRAUMATIC BRAIN; ANIMAL-MODELS; NEUREGULIN-1; NEUROPROTECTION; LOCALIZATION; WIDESPREAD; INHIBITION; EXPRESSION	Neuregulins are a family of growth factors essential for normal cardiac and nervous system development. The EGF-like domain of neuregulins contains the active site which binds and activates signaling cascades through ErbB receptors. A neuregulin-1 gene EGF-like fragment demonstrated neuroprotection in the transient middle cerebral artery occlusion (MCAO) stroke model and drastically reduced infarct volume (Xu et al., 2004). Here we use a permanent MCAO rat model to initially compare two products of the neuregulin-1 gene and also assess levels of recovery with acute versus delayed time to treatment. In the initial study full-length glial growth factor 2 (GGF2) and an EGF-like domain fragment were compared with acute intravenous delivery. In a second study GGF2 only was delivered starting at 24 h, 3 days or 7 days after permanent ischemia was induced. In both studies daily intravenous administration continued for 10 days. Recovery of neurological function was assessed using limb placing and body swing tests. GGF2 had similar functional improvements compared to the EGF-like domain fragment at equimolar doses, and a higher dose of GGF2 demonstrated more robust functional improvements compared to a lower dose. GGF2 improved sensorimotor recovery with all treatment paradigms, even enhancing recovery of function with a delay of 7 days to treatment. Histological assessments did not show any associated reduction in infarct volume at either 48 h or 21 days post-ischemic event. Neurorestorative effects of this kind are of great potential clinical importance, given the difficulty of delivering neuroprotective therapies within a short time after an ischemic event in human patients. If confirmed by additional work including additional data on mechanism(s) of improved outcome with verification in other stroke models, one can make a compelling case to bring GGF2 to clinical trials as a neurorestorative approach to improving outcome following stroke injury. (C) 2010 Elsevier Ltd. All rights reserved.	[Iaci, Jennifer F.; Ganguly, Anindita; Parry, Tom J.; Saha, Subhash; Srinivas, Maya; Vecchione, Andrea M.; Caggiano, Anthony O.] Acorda Therapeut Inc, Hawthorne, NY 10532 USA; [Finklestein, Seth P.; Ren, JingMei; Sietsma, Dana K.] Biotrofix Inc, Waltham, MA 02451 USA	Iaci, JF (corresponding author), Acorda Therapeut Inc, 15 Skyline Dr, Hawthorne, NY 10532 USA.	jiaci@acorda.com					Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Bin Kwon O, 2008, P NATL ACAD SCI USA, V105, P15587, DOI 10.1073/pnas.0805722105; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Buonanno A., 2008, NOVART FDN SYMP, V289, P177; BUONANNO A, 2008, NOVART FDN SYMP, V289, P193; Buonanno Andres, 2008, Novartis Found Symp, V289, P165; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Chen Yong-jun, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P1771; Cheng Yu Dennis, 2004, NeuroRx, V1, P36, DOI 10.1602/neurorx.1.1.36; COMELLI MC, 1993, NEUROSCIENCE, V55, P473, DOI 10.1016/0306-4522(93)90517-J; Cramer SC, 2008, ANN NEUROL, V63, P549, DOI 10.1002/ana.21412; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; DERYCK M, 1992, BRAIN RES, V573, P44; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Di Segni A, 2005, J MOL NEUROSCI, V26, P57, DOI 10.1385/JMN:26:1:057; Dimayuga FO, 2003, J NEUROIMMUNOL, V136, P67, DOI 10.1016/S0165-5728(03)00003-1; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; FINKLESTEIN SP, 1990, STROKE, V21, P122; Fischbach GD, 2007, NEURON, V54, P495, DOI 10.1016/j.neuron.2007.05.009; Flores AI, 2000, J NEUROSCI, V20, P7622; Foley Norine C, 2003, Top Stroke Rehabil, V10, P1; Furlan Anthony J., 2003, Curr Treat Options Cardiovasc Med, V5, P171, DOI 10.1007/s11936-003-0001-4; Heiss WD, 1998, J CEREBR BLOOD F MET, V18, P1298, DOI 10.1097/00004647-199812000-00004; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; Komjati K, 2004, INT J MOL MED, V13, P373; LEMKE G, 2006, SCI STKE, pPE11; Li B, 2007, NEURON, V54, P583, DOI 10.1016/j.neuron.2007.03.028; Li Q, 2002, EXP NEUROL, V177, P531, DOI 10.1006/exnr.2002.7994; Li YG, 2007, BRAIN RES, V1184, P277, DOI 10.1016/j.brainres.2007.09.037; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Loeb JA, 2007, NEUROLOGY, V68, pS38, DOI 10.1212/01.wnl.0000275231.97764.43; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mauler F, 2005, J CEREBR BLOOD F MET, V25, P451, DOI 10.1038/sj.jcbfm.9600038; Mei L, 2008, NAT REV NEUROSCI, V9, P437, DOI 10.1038/nrn2392; Neddens Jorg, 2009, Commun Integr Biol, V2, P261; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; Que M, 1999, NEUROSCI LETT, V273, P77, DOI 10.1016/S0304-3940(99)00598-4; Redecker C, 2002, J CEREBR BLOOD F MET, V22, P1463, DOI 10.1097/01.WCB.0000034149.72481.BD; RUDD A, 2002, HOSP PHARM, V9, P5; Saver JL, 2009, STROKE, V40, P2433, DOI 10.1161/STROKEAHA.108.543561; Saver JL, 2009, STROKE, V40, P2594, DOI 10.1161/STROKEAHA.109.552554; Savitz SI, 2007, EXP NEUROL, V205, P20, DOI 10.1016/j.expneurol.2007.03.003; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Schulz JB, 1998, CELL DEATH DIFFER, V5, P847, DOI 10.1038/sj.cdd.4400420; Sun HS, 2008, STROKE, V39, P2544, DOI 10.1161/STROKEAHA.107.506048; Tamura A, 1986, No To Shinkei, V38, P747; Tan Kiat T, 2003, Curr Atheroscler Rep, V5, P245, DOI 10.1007/s11883-003-0046-6; Taveggia C, 2008, GLIA, V56, P284, DOI 10.1002/glia.20612; ter Laak MP, 2000, J NEUROSCI RES, V60, P237, DOI 10.1002/(SICI)1097-4547(20000415)60:2<237::AID-JNR13>3.0.CO;2-5; Wahlgren N G, 2000, J Stroke Cerebrovasc Dis, V9, P32, DOI 10.1053/jscd.2000.19320; Woo RS, 2007, NEURON, V54, P599, DOI 10.1016/j.neuron.2007.04.009; Xu ZF, 2006, J CEREBR BLOOD F MET, V26, P527, DOI 10.1038/sj.jcbfm.9600212; Xu ZF, 2005, NEUROBIOL DIS, V19, P461, DOI 10.1016/j.nbd.2005.01.027; Xu ZF, 2004, BIOCHEM BIOPH RES CO, V322, P440, DOI 10.1016/j.bbrc.2004.07.149; Zhang LX, 2004, J NEUROCHEM, V91, P1358, DOI 10.1111/j.1471-4159.2004.02817.x	60	21	22	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	DEC	2010	59	7-8					640	649		10.1016/j.neuropharm.2010.07.017			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	682XN	WOS:000284436400011	20691195				2021-06-18	
J	Klein, AH; Wendroth, SM; Drewes, LR; Andrews, MT				Klein, Amanda H.; Wendroth, Scott M.; Drewes, Lester R.; Andrews, Matthew T.			SMALL-VOLUME D-beta-HYDROXYBUTYRATE SOLUTION INFUSION INCREASES SURVIVABILITY OF LETHAL HEMORRHAGIC SHOCK IN RATS	SHOCK			English	Article						Hibernation; melatonin; hemorrhage; ketone; hypothermia; fluid resuscitation	TRAUMATIC BRAIN-INJURY; KETONE-BODIES; ISCHEMIA-REPERFUSION; THERAPEUTIC IMPLICATIONS; MELATONIN PRODUCTION; PULMONARY APOPTOSIS; FREE-RADICALS; HIBERNATION; ISCHEMIA/REPERFUSION; MODEL	A small-volume therapeutic approach based on the biochemistry of hibernating mammals was evaluated to test the hypothesis that passive hypothermia and systemic administration of D-beta-hydroxybutyrate (D-BHB) plus melatonin will increase survival of animals subjected to hemorrhagic shock ([HS] 60% blood loss). Anesthetized Sprague-Dawley male rats (320 +/- 23 g) underwent controlled loss of 60% blood volume. Rats were instrumented to measure mean arterial pressure, body temperature (T-b), and heart rate. A passive decrease in rat T-b in response to HS significantly increased survival over animals maintained at 37 degrees C (n = 5-6). Infusion of 4 M D-BHB, at a volume of only 5.5% of the total blood removed, significantly prolonged survival to a mean of 3 h compared with 90 min using equal osmolar 4 M NaCl (n = 6). In experiments where the shed blood was returned after 1 h of 60% blood loss, 4% fluid replacement with 4 M D-BHB plus 43 mM melatonin significantly prolonged survival up to 10 days after blood return compared with 4 M NaCl plus 43 mM melatonin and other control solutions (n = 10). We conclude that a slow decrease in animal T-b resulting from 60% blood loss, combined with infusion of 4 M D-BHB plus 43 mM melatonin, was beneficial for long-term survival after return of shed blood. This HS therapy is designed as a portable low-volume solution for further evaluation in a large-animal model and is ultimately intended for use in HS patients by first responders.	[Klein, Amanda H.; Wendroth, Scott M.; Andrews, Matthew T.] Univ Minnesota, Dept Biol, Duluth, MN 55812 USA; [Drewes, Lester R.] Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA	Andrews, MT (corresponding author), Univ Minnesota, Dept Biol, 1035 Kirby Dr, Duluth, MN 55812 USA.	mandrews@d.umn.edu	Drewes, Lester R/X-9794-2018	Drewes, Lester R/0000-0002-7440-0387	Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [W911NF-05-1-0432, W911NF-06-0088]	This study was supported by the Defense Advanced Research Projects Agency (contracts W911NF-05-1-0432 and W911NF-06-0088).	Alam HB, 2007, SURG CLIN N AM, V87, P55, DOI 10.1016/j.suc.2006.09.015; Alam HB, 2006, SURGERY, V140, P307, DOI 10.1016/j.surg.2006.03.015; Alam HB, 2004, J TRAUMA, V57, P961, DOI 10.1097/01.TA.0000149549.72389.3F; Alam HB, 2001, J AM COLL SURGEONS, V193, P255, DOI 10.1016/S1072-7515(01)01004-3; Andrews MT, 2007, BIOESSAYS, V29, P431, DOI 10.1002/bies.20560; Andrews MT, 2009, AM J PHYSIOL-REG I, V296, pR383, DOI 10.1152/ajpregu.90795.2008; Bardutzky J, 2005, J CEREBR BLOOD F MET, V25, P968, DOI 10.1038/sj.jcbfm.9600095; Carey HV, 2003, PHYSIOL REV, V83, P1153, DOI 10.1152/physrev.00008.2003; Cervantes M, 2008, J PINEAL RES, V45, P1, DOI 10.1111/j.1600-079X.2007.00551.x; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Dark J, 2005, ANNU REV NUTR, V25, P469, DOI 10.1146/annurev.nutr.25.050304.092514; Di Giorgio AM, 2008, RESTOR NEUROL NEUROS, V26, P501; Drew KL, 2001, FREE RADICAL BIO MED, V31, P563, DOI 10.1016/S0891-5849(01)00628-1; Dutton Richard P, 2007, Anesthesiol Clin, V25, P23, DOI 10.1016/j.atc.2006.11.007; Engel FL, 1943, J EXP MED, V77, P397, DOI 10.1084/jem.77.5.397; Fukudome EY, 2009, CRIT CARE MED, V37, pS265, DOI 10.1097/CCM.0b013e3181aa60ac; Harkness JE, 1995, BIOL MED RABBITS ROD; HAUPTMAN JG, 1989, AM J PHYSIOL, V257, pR439; Henry PG, 2007, J NEUROCHEM, V101, P1505, DOI 10.1111/j.1471-4159.2007.04514.x; HIRAIDE A, 1991, EUR SURG RES, V23, P250, DOI 10.1159/000129160; Institute of Medicine and Committee on Fluid Resuscitation for Combat Casualties, 1999, FLUID RES STAT SCI T; Kacmaz A, 2005, SURG TODAY, V35, P744, DOI 10.1007/s00595-005-3027-2; KATAYAMA M, 1994, JPEN-PARENTER ENTER, V18, P442, DOI 10.1177/0148607194018005442; Koustova E, 2003, SURGERY, V134, P267, DOI 10.1067/msy.2003.245; Larkin JE, 2003, PHYSIOL BIOCHEM ZOOL, V76, P577, DOI 10.1086/375436; Lin T, 2005, J TRAUMA, V59, P1191, DOI 10.1097/01.ta.0000188646.86995.9d; LITTLE JR, 1981, NEUROSURGERY, V9, P34, DOI 10.1227/00006123-198107000-00006; Lomas-Niera JL, 2005, SHOCK, V24, P33, DOI 10.1097/01.shk.0000191411.48719.ab; Majde JA, 2003, J TRAUMA, V54, pS100, DOI 10.1097/01.TA.0000064503.24416.F4; MOORE TJ, 1976, AM J PHYSIOL, V230, P619; Reiter RJ, 2007, J PHYSIOL PHARMACOL, V58, P5; Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016/S0008-6363(02)00827-1; ROBINSON AM, 1980, PHYSIOL REV, V60, P143; SATO K, 1995, FASEB J, V9, P651; SCOFIELD RF, 1983, METABOLISM, V32, P1009, DOI 10.1016/0026-0495(83)90144-0; Sener G, 2002, J UROLOGY, V167, P2624, DOI 10.1016/S0022-5347(05)65048-3; Sharp PE, 1998, LAB RAT; Spaniol Joseph R, 2007, J Trauma Nurs, V14, P152; STANTON TL, 1986, J EXP ZOOL, V239, P247, DOI 10.1002/jez.1402390212; Tan DX, 2005, ENDOCRINE, V27, P149, DOI 10.1385/ENDO:27:2:149; Taylor JH, 2004, SHOCK, V21, P58, DOI 10.1097/01.shk.0000101674.49265.93; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Yildirim A, 2009, INT J MORPHOL, V27, P519, DOI 10.4067/S0717-95022009000200036	45	21	21	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	DEC	2010	34	6					565	572		10.1097/SHK.0b013e3181e15063			8	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	680LW	WOS:000284234400004	20386494				2021-06-18	
J	Sacho, RH; Vail, A; Rainey, T; King, AT; Childs, C				Sacho, Raphael H.; Vail, Andy; Rainey, Timothy; King, Andrew T.; Childs, Charmaine			The Effect of Spontaneous Alterations in Brain Temperature on Outcome: A Prospective Observational Cohort Study in Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain; mortality; outcome; pupil responses; temperature; traumatic brain injury	SEVERE HEAD-INJURY; INTENSIVE-CARE; HYPOTHERMIA; HYPERTHERMIA; HEMORRHAGE; GUIDELINES; MANAGEMENT; PYREXIA; OXYGEN; FEVER	There are few prospective studies reporting the effect of spontaneous temperature changes on outcome after severe traumatic brain injury (TBI). Where studies have been conducted, results are based on systemic rather than brain temperature per se. However, body temperature is not a reliable surrogate for brain temperature. Consequently, the effect of brain temperature changes on outcome in the acute phase after TBI is not clear. Continuous intraparenchymal brain temperature was measured in consecutive admissions of severe TBI patients during the course of the first 5 days of admission to the intensive care unit (ICU). Patients received minimal temperature altering therapy during their ICU stay. Logistic regression was used to explore the relationship between the initial, the 24-h mean, and the 48-h mean brain temperature with outcome for mortality at 30 days and outcome at 3 months. Multifactorial analysis was performed to account for potential confounders. At the 24-h time point, brain temperature within the range of 36.5 degrees C to 38 degrees C was associated with a lower probability of death (10-20%). Brain temperature outside of this range was associated with a higher probability of death and poor 3-month neurological outcome. After adjusting for other predictors of outcome, low brain temperature was independently associated with a worse outcome. Lower brain temperatures (below 37 degrees C) are independently associated with a higher mortality rate after severe TBI. The results suggest that, contrary to current opinion, temperatures within the normal to moderate fever range during the acute post-TBI period do not impose an additional risk for a poor outcome after severe TBI.	[Sacho, Raphael H.; King, Andrew T.] Salford Royal NHS Fdn Trust, Dept Neurosurg, Salford, Lancs, England; [Vail, Andy] Univ Manchester, Hlth Methodol Res Grp, Manchester M13 9PL, Lancs, England; [Sacho, Raphael H.; Rainey, Timothy; King, Andrew T.; Childs, Charmaine] Univ Manchester, Brain Injury Res Grp, Manchester M13 9PL, Lancs, England	Childs, C (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Alice Lee Ctr, Block E3A Level 3,Engn Dr 1, Singapore 117574, Singapore.	Raphael.Sacho@postgrad.manchester.ac.uk; charmaine_childs@nuhs.edu.sg	King, Andrew/AAR-1656-2020; Childs, Charmaine/G-9928-2012	Vail, Andy/0000-0001-8274-2726; King, Andrew/0000-0002-6546-7248			ACKERMAN D, 1980, J PHYSIOL-LONDON, V307, P59, DOI 10.1113/jphysiol.1980.sp013423; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Cairns Chris J S, 2002, Curr Opin Crit Care, V8, P106, DOI 10.1097/00075198-200204000-00003; Childs C, 2005, ANAESTHESIA, V60, P759, DOI 10.1111/j.1365-2044.2005.04193.x; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fernandez A, 2007, NEUROLOGY, V68, P1013, DOI 10.1212/01.wnl.0000258543.45879.f5; Gentilello LM, 1997, ANN SURG, V226, P439, DOI 10.1097/00000658-199710000-00005; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; HAYWARD JN, 1969, BRAIN RES, V16, P417, DOI 10.1016/0006-8993(69)90236-4; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Johnston NJ, 2006, RESUSCITATION, V70, P254, DOI 10.1016/j.resuscitation.2006.02.010; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Jurkovich GJ, 2007, SURG CLIN N AM, V87, P247, DOI 10.1016/j.suc.2006.10.003; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kirk D, 2009, CRIT CARE, V13, DOI 10.1186/cc7898; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marion D, 2008, NEUROSURGERY, V62, P872; Marion DW, 2004, CRIT CARE MED, V32, pS43, DOI 10.1097/01.CCM.0000110731.69637.16; MCILVOY L, 2004, J NEUROSCI NURS, P9; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; SACHO RH, 2008, BRIT J NEUROSURG, P1; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Sessler DI, 1997, NEW ENGL J MED, V336, P1730, DOI 10.1056/NEJM199706123362407; Shafi S, 2005, J TRAUMA, V59, P1081, DOI 10.1097/01.ta.0000188647.03665.fd; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Spiotta AM, 2008, NEUROSURGERY, V62, P864, DOI 10.1227/01.neu.0000316900.63124.ce; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	36	21	23	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2157	2164		10.1089/neu.2010.1384			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400005	20822465				2021-06-18	
J	Van Dyke, SA; Axelrod, BN; Schutte, C				Van Dyke, Sarah A.; Axelrod, Bradley N.; Schutte, Christian			Test-Retest Reliability of the Traumatic Brain Injury Screening Instrument	MILITARY MEDICINE			English	Article							DEPLOYMENT; IRAQ; AFGHANISTAN	The Traumatic Brain Injury Screening Instrument (TBISI) was implemented in Veterans Affairs medical facilities in an attempt to identify Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans with possible mild TBI. Despite its widespread implementation, the reliability and validity of the screening tool has not yet been established. The current study reports preliminary findings on the test-retest reliability of the TBISI in 44 OEF/OIF veterans referred for neuropsychological evaluation following a positive TBI screen. Results suggest overall poor test-retest reliability of the TBI screening tool with regard to type of event, injuries sustained, and resulting sequelae. These findings underscore the importance of further investigation of its psychometric properties to promote accurate identification and referral of veterans with possible TBI.	[Van Dyke, Sarah A.; Axelrod, Bradley N.; Schutte, Christian] John D Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA	Van Dyke, SA (corresponding author), John D Dingell Vet Affairs Med Ctr, 4646 John R St, Detroit, MI 48201 USA.				Department of Veterans Affairs Predoctoral-Associated Health Rehabilitation Research Fellowship Program	This work was supported by the Department of Veterans Affairs Predoctoral-Associated Health Rehabilitation Research Fellowship Program.	COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; McCrea M, 2008, MILD TRAUMATIC BRAIN; Schwab KA, 2006, NEUROLOGY, V66, pA235; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; *US GOV ACC OFF, 2008, GAO08276	9	21	21	0	4	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	DEC	2010	175	12					947	949		10.7205/MILMED-D-10-00337			3	Medicine, General & Internal	General & Internal Medicine	691KO	WOS:000285078900005	21265299	Bronze			2021-06-18	
J	von Morze, C; Kelley, DAC; Shepherd, TM; Banerjee, S; Xu, DA; Hess, CP				von Morze, Cornelius; Kelley, Douglas A. C.; Shepherd, Timothy M.; Banerjee, Suchandrima; Xu, Duan; Hess, Christopher P.			Reduced field-of-view diffusion-weighted imaging of the brain at 7 T	MAGNETIC RESONANCE IMAGING			English	Article						Field of view; Diffusion-weighted imaging; Brain	OUTER VOLUME SUPPRESSION; SPINAL-CORD; RF PULSES; DESIGN; EPI; RELAXATION; TENSOR; RESOLUTION; MOTION; DWI	Ventral and rostral regions of the brain are of emerging importance for the MRI characterization of early dementia, traumatic brain injury and epilepsy. Unfortunately, standard single-shot echo planar diffusion-weighted imaging of these regions at high fields is contaminated by severe imaging artifacts in the vicinity of air tissue interfaces. To mitigate these artifacts and improve visualization of the temporal and frontal lobes at 7 T, we applied a reduced field-of-view strategy, enabled by outer volume suppression (OVS) with novel quadratic phase radiofrequency (RF) pulses, combined with partial Fourier and parallel imaging methods. The new acquisition greatly reduced the level of artifacts in six human subjects (including four patients with early symptoms of dementia). (C) 2010 Elsevier Inc. All rights reserved.	[von Morze, Cornelius; Kelley, Douglas A. C.; Shepherd, Timothy M.; Xu, Duan; Hess, Christopher P.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94158 USA; [Kelley, Douglas A. C.; Banerjee, Suchandrima] GE Healthcare, San Francisco, CA USA	von Morze, C (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, MC 2512, San Francisco, CA 94158 USA.	morze@radiology.ucsf.edu	Shepherd, Timothy M/N-1730-2019; Xu, Duan/B-3197-2013	Shepherd, Timothy M/0000-0003-0232-1636; Xu, Duan/0000-0003-0550-4235; Hess, Christopher/0000-0002-5132-5302	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EB009756]; NIH/NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32 EB001631]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009756, T32EB001631] Funding Source: NIH RePORTER	We acknowledge grant support from NIH R01EB009756. TMS was supported by the NIH/NIBIB T32 EB001631 training fellowship.	Concha L, 2010, J NEUROSCI, V30, P996, DOI 10.1523/JNEUROSCI.1619-09.2010; COX EF, 2008, P INT SOC MAGN RESON, V16; Deoni SCL, 2009, J MAGN RESON IMAGING, V30, P411, DOI 10.1002/jmri.21849; Gelman N, 1999, RADIOLOGY, V210, P759, DOI 10.1148/radiology.210.3.r99fe41759; HAMMOND KE, 2006, P INT SOC MAGN RESON, V14; Holdsworth SJ, 2008, EUR J RADIOL, V65, P36, DOI 10.1016/j.ejrad.2007.09.016; Jaermann T, 2004, MAGN RESON MED, V51, P230, DOI 10.1002/mrm.10707; Kalus P, 2006, NEUROIMAGE, V30, P713, DOI 10.1016/j.neuroimage.2005.10.035; KELLEY DA, 2008, P INT SOC MAGN RESON, V16; Larkman DJ, 2007, PHYS MED BIOL, V52, pR15, DOI 10.1088/0031-9155/52/7/R01; Le Roux P, 1998, JMRI-J MAGN RESON IM, V8, P1022, DOI 10.1002/jmri.1880080505; Mao H, 2007, J NEUROIMAGING, V17, P292, DOI 10.1111/j.1552-6569.2007.00146.x; Mukherjee P, 2008, MAGN RESON IMAGING, V26, P171, DOI 10.1016/j.mri.2007.05.011; Neema M, 2009, NEUROIMAGE, V46, P633, DOI 10.1016/j.neuroimage.2009.03.001; PAULY J, 1991, IEEE T MED IMAGING, V10, P53, DOI 10.1109/42.75611; Pipe JG, 2006, MAGN RESON MED, V55, P380, DOI 10.1002/mrm.20768; ROHRER JD, NEUROIMAGE IN PRESS; Saritas EU, 2008, MAGN RESON MED, V60, P468, DOI 10.1002/mrm.21640; Schulte RF, 2007, J MAGN RESON, V186, P167, DOI 10.1016/j.jmr.2007.02.004; Schulte RF, 2004, J MAGN RESON, V166, P111, DOI 10.1016/j.jmr.2003.10.009; Skare S, 2007, MAGN RESON MED, V57, P881, DOI 10.1002/mrm.21176; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stanisz GJ, 2005, MAGNET RESON MED, V54, P507, DOI 10.1002/mrm.20605; Van AT, 2009, IEEE T MED IMAGING, V28, P1770, DOI 10.1109/TMI.2009.2023212; Wheeler-Kingshott CAM, 2002, MAGN RESON MED, V47, P24, DOI 10.1002/mrm.10016; Wilm BJ, 2007, MAGN RESON MED, V57, P625, DOI 10.1002/mrm.21167; Yang QX, 2004, MAGN RESON MED, V52, P1016, DOI 10.1002/mrm.20245	27	21	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X			MAGN RESON IMAGING	Magn. Reson. Imaging	DEC	2010	28	10					1541	1545		10.1016/j.mri.2010.06.025			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	687ZD	WOS:000284816400017	20850242	Green Accepted			2021-06-18	
J	McMahon, CG; Kenny, R; Bennett, K; Little, R; Kirkman, E				McMahon, C. Geraldine; Kenny, RoseAnne; Bennett, Katherine; Little, Rod; Kirkman, Emrys			The Effect of Acute Traumatic Brain Injury on the Performance of Shock Index	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Brain injuries; Trauma; Hemorrhagic shock; Shock index	HEMORRHAGIC-SHOCK; VITAL SIGNS; RESPONSES; RATS; RESUSCITATION; STIMULATION; HYPOVOLEMIA; BRADYCARDIA; MORPHINE; DEATHS	Background: Shock index (SI) is recognized to be a more reliable early indicator of hemorrhage than traditional vital signs. Acute traumatic brain injury (TBI) can be associated with autonomic uncoupling and may therefore alter the reliability of SI in patients with combined TBI and peripheral hemorrhage. The aim of this study was to evaluate the performance of SI when acute TBI of mild and moderate severity were associated with progressive simple hemorrhage. Methods: This study was undertaken in a laboratory setting. Brian injury was induced using the lateral fluid percussion model in anesthetized rats. The fluid percussion device delivered an applied cortical pressure of 1.2 atm and 1.8 atm, producing mild and moderate TBI, respectively. Control animals underwent identical procedures but with no applied cortical pressure. Hemorrhage was induced 10 minutes after brain injury, at a rate of 2% of blood volume per minute until 40% blood volume was withdrawn. Results: The SI response to increasing volume of hemorrhage was unaltered when control and mild TBI groups were compared (test of interaction p = 0.39). There was a 50% mortality rate observed 20 to 60 minutes after hemorrhage in the moderate TBI group. The SI response to hemorrhage in the moderate TBI group compared with the control group became significantly different at 40% blood volume loss (test of interaction p = 0.048). Comparison of the SI response with hemorrhage between survivors and nonsurvivors of moderate TBI revealed a significant difference (p = 0.007). SI was markedly attenuated in the presence of increasing hemorrhage in the nonsurvivor subgroup of moderate TBI. Conclusions: SI significantly underestimated underlying hemorrhage in the presence of acute TBI of moderate severity where attenuation of the biphasic heart rate and blood pressure response was also most pronounced.	[McMahon, C. Geraldine] St James Hosp, Dept Emergency Med, Trinity Coll, Dublin, Ireland; [Kenny, RoseAnne] Trinity Coll Dublin, Dept Geriart Med, Inst Neurosci, Dublin, Ireland; [Bennett, Katherine] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Trinity Med Sch, Dublin, Ireland; [Little, Rod] Univ Manchester, Manchester, Lancs, England	McMahon, CG (corresponding author), St James Hosp, Dept Emergency Med, Trinity Coll, Dublin, Ireland.	gmcmahon@stjames.ie	McMahon, C Geraldine/M-8684-2019	McMahon, C Geraldine/0000-0002-9870-3104	Medical Research Council, UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	Funding received from Medical Research Council, UK, as part of the North West Injury Research Program Grant.	Allgower M, 1968, Ger Med Mon, V13, P14; ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; ANDERSON ID, 1990, J TRAUMA, V30, P974, DOI 10.1097/00005373-199008000-00005; Barcroft H, 1944, LANCET, V1, P489; Birkhahn RH, 2005, AM J EMERG MED, V23, P323, DOI 10.1016/j.ajem.2005.02.029; ELEBUTE EA, 1978, CLIN SCI MOL MED, V54, P431, DOI 10.1042/cs0540431; Evans RG, 2001, CLIN EXP PHARMACOL P, V28, P479, DOI 10.1046/j.1440-1681.2001.03473.x; FEUERSTEIN G, 1986, CIRC SHOCK, V19, P293; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; LITTLE RA, 1995, J ACCID EMERG MED, V12, P1; LITTLE RA, 1990, UPDATE INTENSIVE CAR, P505; Mackway-Jones K, 1999, J TRAUMA, V47, P481, DOI 10.1097/00005373-199909000-00008; Majde JA, 2003, J TRAUMA, V54, pS100, DOI 10.1097/01.TA.0000064503.24416.F4; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McMahon CG, 2008, CRIT CARE MED, V36, P216, DOI 10.1097/01.CCM.0000295425.41831.85; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Nakasone Y, 2007, CARDIOVASC INTER RAD, V30, P861, DOI 10.1007/s00270-007-9131-5; OBERG B, 1973, ACTA PHYSIOL SCAND, V88, P8, DOI 10.1111/j.1748-1716.1973.tb05429.x; Ohnishi M, 1998, J TRAUMA, V45, P1024, DOI 10.1097/00005373-199812000-00009; RADY MY, 1992, RESUSCITATION, V23, P227, DOI 10.1016/0300-9572(92)90006-X; RADY MY, 1994, ANN EMERG MED, V24, P685, DOI 10.1016/S0196-0644(94)70279-9; REDFERN WS, 1984, Q J EXP PHYSIOL CMS, V69, P763, DOI 10.1113/expphysiol.1984.sp002867; SECHER NH, 1984, CIRC SHOCK, V14, P267; TIMMS RJ, 1981, PFLUG ARCH EUR J PHY, V391, P49, DOI 10.1007/BF00580694; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; YUAN XQ, 1992, SURG GYNECOL OBSTET, V174, P305; YUAN XQ, 1991, CIRC SHOCK, V35, P231	31	21	21	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2010	69	5					1169	1175		10.1097/TA.0b013e3181cc8889			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	678VK	WOS:000284110100040	20571456				2021-06-18	
J	Engel, T; Caballero-Caballero, A; Schindler, CK; Plesnila, N; Strasser, A; Prehn, JHM; Henshall, DC				Engel, Tobias; Caballero-Caballero, Aurelien; Schindler, Clara K.; Plesnila, Nikolaus; Strasser, Andreas; Prehn, Jochen H. M.; Henshall, David C.			BH3-only protein Bid is dispensable for seizure-induced neuronal death and the associated nuclear accumulation of apoptosis-inducing factor	JOURNAL OF NEUROCHEMISTRY			English	Article						AIF; Bax; Bcl-2; hippocampus; neuroprotection; epilepsy	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; CYTOCHROME-C RELEASE; PROGRAMMED CELL-DEATH; STATUS-EPILEPTICUS; HIPPOCAMPAL-NEURONS; DEFICIENT MICE; KAINIC ACID; CALPAIN-I	P>Prolonged seizures activate members of the Bcl-2 homology domain 3-only sub-group of the Bcl-2 protein family, which are essential for initiation of apoptosis signaling. Bid is a potent pro-apoptotic Bcl-2 homology domain 3-only protein, which upon proteolytic activation translocates to mitochondria to promote activation of the Bax/Bak sub-group of the pro-apoptotic Bcl-2 family and thereby contributes to release of apoptogenic molecules, such as cytochrome c and possibly apoptosis-inducing factor (AIF). Bid-deficient mice have been reported to show reduced lesion volumes after ischemia and trauma in vivo but a causal role for Bid in the setting of seizure-induced neuronal death has not been investigated. In this study, we studied Bid activation following status epilepticus in mice and compared hippocampal damage between wild-type and Bid-deficient animals. Full-length Bid was detected in normal mouse hippocampus and the cleaved (activated) p15 fragment of Bid was detected shortly after status epilepticus. Bid-deficient mice underwent equivalent electrographic seizure responses during status epilepticus as wild-type animals. Hippocampal counts of degenerating neurons and surviving neuron-specific nuclear protein-positive cells were not significantly different between wild-type and Bid-deficient mice. Additionally, nuclear translocation of AIF was not reduced in Bid-deficient compared with wild-type animals subjected to status epilepticus. The present study demonstrates that AIF is not dependent on Bid for mitochondrial release and nuclear import in this model and that while Bid is cleaved during seizure-induced neuronal death, it may be functionally redundant or even not essential.	[Engel, Tobias; Caballero-Caballero, Aurelien; Plesnila, Nikolaus; Prehn, Jochen H. M.; Henshall, David C.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; [Schindler, Clara K.] Robert S Dow Neurobiol Labs, Portland, OR USA; [Strasser, Andreas] Univ Melbourne, Dept Mol Med, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia	Henshall, DC (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	dhenshall@rcsi.ie	Prehn, Jochen HM/A-3928-2010; Henshall, David/C-3364-2012; Plesnila, Nikolaus/T-7522-2019; Strasser, Andreas/C-7581-2013	Prehn, Jochen HM/0000-0003-3479-7794; Strasser, Andreas/0000-0002-5020-4891; Engel, Tobias/0000-0001-9137-0637; Henshall, David/0000-0001-6237-9632	Health Research Board Ireland [RP/2005/24, RP/2007/37]; Science Foundation IrelandScience Foundation IrelandEuropean Commission [08/IN1/B1875, 08/RFP/NSC1745]; Irish Research Council for Science Engineering and TechnologyIrish Research Council for Science, Engineering and TechnologyCGIAR; Health Research Board; NHMRCNational Health and Medical Research Council of Australia	This work was supported by Health Research Board Ireland (RP/2005/24, RP/2007/37), Science Foundation Ireland (08/IN1/B1875 and 08/RFP/NSC1745), post-doctoral fellowships from the Irish Research Council for Science Engineering and Technology and Health Research Board (to T. E.) and the NHMRC (AS).	Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Culmsee C, 2006, BIOCHEM SOC T, V34, P1334, DOI 10.1042/BST0341334; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Engel T, 2010, NEUROSCIENCE, V168, P443, DOI 10.1016/j.neuroscience.2010.03.057; Engel T, 2010, FASEB J, V24, P853, DOI 10.1096/fj.09-145870; Engel Tobias, 2009, Int J Physiol Pathophysiol Pharmacol, V1, P97; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2004, ANN NEUROL, V55, P485, DOI 10.1002/ana.20001; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Ju KL, 2008, EXP NEUROL, V210, P602, DOI 10.1016/j.expneurol.2007.12.008; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Konig HG, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-7; Krajewska M, 2002, CELL DEATH DIFFER, V9, P145, DOI 10.1038/sj/cdd/4400934; Landshamer S, 2008, CELL DEATH DIFFER, V15, P1553, DOI 10.1038/cdd.2008.78; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li Tian-Fu, 2005, Shengli Xuebao, V57, P310; Li TF, 2006, BRAIN RES, V1098, P204, DOI 10.1016/j.brainres.2006.04.131; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; MELDRUM BS, 1994, NEUROLOGY, V44, P14; Mouri G, 2008, BRAIN RES, V1213, P140, DOI 10.1016/j.brainres.2008.03.061; Murphy BM, 2010, CELL DEATH DIFFER, V17, P459, DOI 10.1038/cdd.2009.134; Murphy B, 2007, AM J PATHOL, V171, P1258, DOI 10.2353/ajpath.2007.070269; NEDERGAARD M, 1988, ACTA NEUROL SCAND, V77, P81, DOI 10.1111/j.1600-0404.1988.tb05878.x; Noh HS, 2006, J NEUROSCI RES, V84, P1829, DOI 10.1002/jnr.21057; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Schindler CK, 2006, J CEREBR BLOOD F MET, V26, P583, DOI 10.1038/sj.jcbfm.9600219; Shinoda S, 2004, J NEUROSCI RES, V76, P121, DOI 10.1002/jnr.20064; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Upton JP, 2008, MOL CELL BIOL, V28, P3943, DOI 10.1128/MCB.00013-08; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang SH, 2008, BRAIN RES BULL, V76, P90, DOI 10.1016/j.brainresbull.2007.12.006; Ward MW, 2006, J BIOL CHEM, V281, P5837, DOI 10.1074/jbc.M511562200; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Yin XM, 1999, NATURE, V400, P886; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhao SP, 2010, J NEUROSCI RES, V88, P1727, DOI 10.1002/jnr.22338	52	21	21	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2010	115	1					92	101		10.1111/j.1471-4159.2010.06909.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	650DF	WOS:000281828200009	20646170	Bronze			2021-06-18	
J	Kelley-Quon, L; Min, L; Morley, E; Hiatt, JR; Cryer, H; Tillou, A				Kelley-Quon, Lorraine; Min, Lillian; Morley, Eric; Hiatt, Jonathan R.; Cryer, Henry; Tillou, Areti			Functional Status after Injury: A Longitudinal Study of Geriatric Trauma	AMERICAN SURGEON			English	Article							PROSPECTIVE MULTICENTER TRIAL; LIVING OLDER PERSONS; FOLLOW-UP; UNITED-STATES; BRAIN-INJURY; RESOURCE USE; CARE; DISABILITY; COMMUNITY; OUTCOMES	We evaluated self-rated functional status measured longitudinally in the year after injury in a geriatric trauma population. The longitudinal (L) group included 37 of 60 eligible trauma patients aged 65 years or older admitted December 2006 to November 2007 for greater than 24 hours who completed a Short Functional Status questionnaire (SFS) at 3, 6, and 12 months after injury. The SFS yields scores of 0 to 5 (5 = independent in all five activities of daily living [ADLs]) and has been validated among community-dwelling elders. The control (C) group included 63 trauma patients aged 65 years or older admitted December 2007 to July 2009 for greater than 24 hours who reported their preinjury functional status using the SFS at hospital admission. We used characteristics and scores of the C group to impute preinjury ADL scores for the L group. The groups were similar in baseline characteristics (age, ethnicity, Injury Severity Score, Charlson Comorbidity Index, and living arrangement; P > 0.05). For the C group, the preinjury ADL score was 4.6 (SD = 0.9). For the L group, ADL scores declined at all intervals reaching statistical significance at 12 months. We conclude that in the year after traumatic injury, geriatric patients lost the equivalent of approximately one ADL, increasing their risk of further functional decline, loss of independence, and death.	[Kelley-Quon, Lorraine; Min, Lillian; Morley, Eric; Hiatt, Jonathan R.; Cryer, Henry; Tillou, Areti] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA	Tillou, A (corresponding author), 10833 Le Conte Ave,CHS Room 72-231, Los Angeles, CA 90095 USA.	atillou@mednet.ucla.edu			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024824] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG024824] Funding Source: Medline		Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; CARRILLO EH, 1993, SURG GYNECOL OBSTET, V176, P559; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Covinsky KE, 2003, J AM GERIATR SOC, V51, P492, DOI 10.1046/j.1532-5415.2003.51157.x; DEMARIA EJ, 1987, J TRAUMA, V27, P1200; Fallon WF, 2006, J TRAUMA, V61, P1040, DOI 10.1097/01.ta.0000238652.48008.59; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Inaba K, 2003, J TRAUMA, V54, P486, DOI 10.1097/01.TA.0000051588.05542.D6; Jacobs DG, 2003, J TRAUMA, V54, P391, DOI 10.1097/01.TA.0000042015.54022.BE; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; McKevitt EC, 2003, CAN J SURG, V46, P211; Min LC, 2008, J AM GERIATR SOC, V56, P1932, DOI 10.1111/j.1532-5415.2008.01921.x; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Rzepka SG, 2001, J CLIN EPIDEMIOL, V54, P627, DOI 10.1016/S0895-4356(00)00337-1; Saliba D, 2000, J GERONTOL A-BIOL, V55, pM750, DOI 10.1093/gerona/55.12.M750; Stenvall M, 2007, J REHABIL MED, V39, P232, DOI 10.2340/16501977-0045; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TSUJI I, 1994, J AM GERIATR SOC, V42, P153, DOI 10.1111/j.1532-5415.1994.tb04944.x; VANAALST JA, 1991, J TRAUMA, V31, P1096	25	21	21	0	1	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	OCT	2010	76	10					1055	1058					4	Surgery	Surgery	663AO	WOS:000282855600006	21105608				2021-06-18	
J	McCarthy, TJ; De Taboada, L; Hildebrandt, PK; Ziemer, EL; Richieri, SP; Streeter, J				McCarthy, Thomas J.; De Taboada, Luis; Hildebrandt, Paul K.; Ziemer, Ellen L.; Richieri, Steven P.; Streeter, Jackson			Long-Term Safety of Single and Multiple Infrared Transcranial Laser Treatments in Sprague-Dawley Rats	PHOTOMEDICINE AND LASER SURGERY			English	Article							NEUROLOGICAL DEFICITS; SPONTANEOUS TUMORS; EMBOLIC STROKES; ISCHEMIC-STROKE; BRAIN-TUMORS; THERAPY; RABBITS; LIGHT; MICE	Background and Objective: Growing interest exists in the use of near-infrared laser therapies for the treatment of numerous neurologic conditions, including acute ischemic stroke, traumatic brain injury, Parkinson's disease, and Alzheimer's disease. In consideration of these trends, the objective of this study was to evaluate the long-term safety of transcranial laser therapy with continuous-wave (CW) near-infrared laser light (wavelength, 808 +/- 10 nm, 2-mm diameter) with a nominal radiant power of 70 mW; power density, 2,230 mW/cm(2), and energy density, 268 J/cm(2) at the scalp (10 mW/cm(2) and 1.2 J/cm(2) at the cerebral cortical surface) in healthy Sprague-Dawley rats. Materials and Methods: In this study, 120 anesthetized rats received sequential transcranial laser treatments to the right and left parietal areas of the head on the same day (minimum of 5 min between irradiation of each side), on either Day 1 or on each of Days 1, 3, and 5. Sixty anesthetized rats served as sham controls. Rats were evaluated 1 year after treatment for abnormalities in clinical hematology and brain and pituitary gland histopathology. Results: No toxicologically important differences were found in the clinical hematology results between sham-control and laser-treated rats for any hematologic parameters examined. All values fell within historic control reference ranges for aged Sprague-Dawley rats. Similarly, brain and pituitary gland histopathology showed no treatment-related abnormalities or induced neoplasia. Conclusions: Single and multiple applications of transcranial laser therapy with 808-nm CW laser light at a nominal power density of 10 mW/cm(2) at the surface of the cerebral cortex appears to be safe in Sprague-Dawley rats 1 year after treatment.	[McCarthy, Thomas J.; De Taboada, Luis; Richieri, Steven P.; Streeter, Jackson] PhotoThera Inc, Carlsbad, CA 92008 USA; [Hildebrandt, Paul K.] Colorado Histo Prep, Ft Collins, CO USA; [Ziemer, Ellen L.] Rougemont Preclin Serv LLC, Bahama, NC USA	McCarthy, TJ (corresponding author), PhotoThera Inc, 5925 Priestly Dr,Suite 120, Carlsbad, CA 92008 USA.	tmccarthy@photothera.com		De Taboada, Luis/0000-0002-0153-6419	PhotoThera, Inc., Carlsbad, CA	This study was funded by PhotoThera, Inc., Carlsbad, CA Drs. McCarthy and Streeter, Mr. DeTaboada, and Mr. Richieri are employees of PhotoThera, Inc. Each holds equity interests in PhotoThera, Inc.	Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Giknis MLA, 2004, COMPILATION SPONTANE; GOPINATH C, 1986, FOOD CHEM TOXICOL, V24, P113, DOI 10.1016/0278-6915(86)90345-5; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; KRINKE G, 1985, J COMP PATHOL, V95, P175, DOI 10.1016/0021-9975(85)90004-0; Krinke GJ, 2000, TOXICOL PATHOL, V28, P178, DOI 10.1177/019262330002800123; *LAB CORP AM, 2003, HEM RANG SPRAG DAWL; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; MITSUMORI K, 1987, VET PATHOL, V24, P50, DOI 10.1177/030098588702400109; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; PREJEAN JD, 1973, CANCER RES, V33, P2768; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Yarbrough C, 2009, J AM ACAD DERMATOL, V60, P877, DOI 10.1016/j.jaad.2008.10.050; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	20	21	21	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1549-5418	1557-8550		PHOTOMED LASER SURG	Photomed. Laser Surg.	OCT	2010	28	5					663	667		10.1089/pho.2009.2581			5	Surgery	Surgery	668FA	WOS:000283252800014	20961232				2021-06-18	
J	Moon, RJ; Sutton, T; Wilson, PM; Kirkham, FJ; Davies, JH				Moon, Rebecca Jane; Sutton, Timothy; Wilson, Peter Murray; Kirkham, Fenella Jane; Davies, Justin Huw			Pituitary Function at Long-Term Follow-Up of Childhood Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone deficiency; pituitary; traumatic brain injury	QUALITY-OF-LIFE; GROWTH-HORMONE DEFICIENCY; BODY-COMPOSITION; REFERENCE CURVES; INTENSIVE-CARE; HYPOPITUITARISM; CHILDREN; PREVALENCE; INSUFFICIENCY; RELIABILITY	Pituitary dysfunction is a recognized sequela of traumatic brain injury (TBI), occurring in 10-83% of adult patients, but there are few data on the prevalence or natural history in childhood. Our objective was to determine pituitary function in children and young adults at least 4 years after TBI requiring pediatric intensive care unit (PICU) admission. The effects of TBI and hypopituitarism on height, adiposity, and quality of life (QOL) were also evaluated. Unselected patients discharged from the regional PICU with TBI (age<18 years at injury) from 1999-2004 were recruited. Blood and urine samples were collected for baseline pituitary function testing. Height and weight were measured. Adiposity was assessed by mid-upper arm and waist circumferences, and body fat percentage estimation using four-site skinfold thickness and bioelectrical impedance. Auxology and adiposity data were compared to local age-and sex-matched healthy control data. QOL questionnaires (PedsQL 4.0 and QOL-AGHDA) were completed. Twenty subjects (median age 16.7 years, range 9.2-23.3 years, 13 male) of 127 who were eligible agreed to participate at a median of 6.8 years (range 4.2-10.3 years) since TBI. Markers of injury were higher in those recruited than those who were not. Biochemical evidence of hypopituitarism was identified in only one case, possibly related to comorbid pre-existing attention deficit-hyperactivity disorder. Height, weight, and adiposity were similar to healthy controls. Poor QOL was seen in patients with chronic functional deficits or comorbidities. Overall, pituitary dysfunction was less prevalent than in previous studies in adults and children. The results of this study do not support the use of routine endocrine evaluation of children following TBI.	[Wilson, Peter Murray; Davies, Justin Huw] Southampton Univ Hosp NHS Trust, Paediat Intens Care Unit, Southampton SO16 6YD, Hants, England	Davies, JH (corresponding author), Southampton Univ Hosp NHS Trust, Paediat Intens Care Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.	justin.davies@suht.swest.nhs.uk	Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958; Davies, Justin/0000-0001-7560-6320	Pfizer Ltd.Pfizer	Peer-review funding from Pfizer Ltd. grant scheme contributed to funding of this study.	Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Benvenga S, 2004, AM J MED, V116, P767, DOI 10.1016/j.amjmed.2003.12.038; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; DURNIN JVG, 1967, BRIT J NUTR, V21, P681, DOI 10.1079/BJN19670070; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Elmlinger MW, 2004, CLIN CHEM LAB MED, V42, P654, DOI 10.1515/CCLM.2004.112; Faraone SV, 2008, J AM ACAD CHILD PSY, V47, P994, DOI [10.1097/CHI.0b013e31817e0ea7, 10.1097/CHI.ObO13e31817eOea7]; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Gandrud LM, 2004, GROWTH HORM IGF RES, V14, P185, DOI 10.1016/j.ghir.2003.11.003; Gasco V, 2008, PITUITARY, V11, P121, DOI 10.1007/s11102-008-0110-x; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Ghigo E, 1996, J CLIN ENDOCR METAB, V81, P3323, DOI 10.1210/jc.81.9.3323; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Goldman M, 1997, PEDIATR NEUROL, V17, P339, DOI 10.1016/S0887-8994(97)00168-9; Hoeck HC, 1999, GROWTH HORM IGF RES, V9, P18, DOI 10.1054/ghir.1998.0085; Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990; JENNETT B, 1975, LANCET, V1, P480; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kreitschmann-Andermahr I, 2008, GROWTH HORM IGF RES, V18, P472, DOI 10.1016/j.ghir.2008.08.007; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; Makimura H, 2008, J CLIN ENDOCR METAB, V93, P4254, DOI 10.1210/jc.2008-1333; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Moon RJ, 2009, ARCH DIS CHILD, V94, P699, DOI 10.1136/adc.2008.145235; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; PESCE MA, 2007, NELSON TXB PEDIAT, P2943; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; Salehi F, 2007, BRAIN INJURY, V21, P651, DOI 10.1080/02699050701426956; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Secco A, 2009, J CLIN ENDOCR METAB, V94, P4251, DOI 10.1210/jc.2009-0779; Srinivasan L, 2009, BRAIN INJURY, V23, P639, DOI 10.1080/02699050902970778; Stanley TL, 2009, J CLIN ENDOCR METAB, V94, P4875, DOI 10.1210/jc.2009-1369; Stouthart PJHM, 1999, J PEDIATR ENDOCR MET, V12, P335; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Verhelst J, 2009, EUR J ENDOCRINOL, V161, pS41, DOI 10.1530/EJE-09-0291; Wachter D, 2009, J CLIN NEUROSCI, V16, P202, DOI 10.1016/j.jocn.2008.01.009	53	21	21	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1827	1835		10.1089/neu.2010.1408			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600007	20684673				2021-06-18	
J	Banos, JH; Novack, TA; Brunner, R; Renfroe, S; Lin, HY; Meythaler, J				Banos, James H.; Novack, Thomas A.; Brunner, Robert; Renfroe, Sharon; Lin, Hui-Yi; Meythaler, Jay			Impact of Early Administration of Sertraline on Cognitive and Behavioral Recovery in the First Year After Moderate to Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior; cognition; sertraline hydrochloride; traumatic brain injury	DEPRESSION FOLLOWING MILD; SEROTONIN; AGONIST	Objective: To assess the efficacy of sertraline administered in the first 3 months after moderate to severe traumatic brain injury (TBI) in improving cognitive and behavioral outcomes. Design: Double-blind, randomized controlled trial. Setting: Academic medical center. Participants: Ninety-nine individuals randomized to placebo (n = 50) or sertraline 50 mg (n = 49) conditions. There were no group differences in age, gender, education, or severity of injury. Interventions: Participants were enrolled an average of 21 days after injury (none > 8 weeks), followed by oral administration of placebo or sertraline 50 mg for 3 months. Main Outcome Measures: Wechsler Memory Scale-Third Edition Logical Memory, Trail Making Test, Wechsler Adult Intelligence Scale-Third Edition Working Memory Index, Symbol-DigitModalities Test, Wisconsin Card Sorting Test (64-item), Neurobehavioral Functioning Inventory administered 3, 6, and 12 months after the onset of injury. Results: Early administration of sertraline did not result in improved cognitive functioning during the year after injury compared with placebo administration. Those receiving placebo performed marginally better than the treatment group on a measure of executive function, but this appeared to be inauthentic. The treatment group followed expected recovery patterns based on existing literature. The placebo group performed better than expected on some measures, primarily due to differential dropout. Conclusions: Sertraline does not appear to prevent development of cognitive and behavioral problems following TBI, although this does not negate evidence for the treatment (as opposed to prophylactic) role of sertraline to address emotional and neurobehavioral problems in individuals with TBI.	[Banos, James H.; Novack, Thomas A.; Brunner, Robert; Renfroe, Sharon] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA; [Lin, Hui-Yi] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat, Tampa, FL 33612 USA; [Meythaler, Jay] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA	Banos, JH (corresponding author), Univ Alabama Birmingham, Dept Phys Med & Rehabil, SRC 530,619 19th St S, Birmingham, AL 35249 USA.	banos@uab.edu		Lin, Hui-Yi/0000-0002-3307-5549	National Institute on Disability and Rehabilitation Research [H133A980010]	This project was supported by the National Institute on Disability and Rehabilitation Research grant H133A980010, Traumatic Brain Injury Model System Project.	Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; HOLM S, 1979, SCAND J STAT, V6, P65; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; JACOBS BL, 1992, PHYSIOL REV, V72, P165; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Karakucuk EI, 1997, NEUROPEPTIDES, V31, P259, DOI 10.1016/S0143-4179(97)90057-3; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kongs SK, 2000, WISCONSIN CARD SORTI; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Ohman J, 2001, J NEUROTRAUM, V18, P1313, DOI 10.1089/08977150152725614; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Smith A., 1982, SYMBOL DIGIT MODALIT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; WHITAKERAZMITIA PM, 1990, ANN NY ACAD SCI, V600, P315, DOI 10.1111/j.1749-6632.1990.tb16892.x; Zauner A, 1996, TRAUMATIC BRAIN INJU, P97	24	21	21	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					357	361		10.1097/HTR.0b013e3181d6c715			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400008	20220529				2021-06-18	
J	Dudek, FE; Bertram, EH				Dudek, F. Edward; Bertram, Edward H.			COUNTERPOINT TO "WHAT IS AN EPILEPTIC SEIZURE?" BY D'AMBROSIO AND MILLER	EPILEPSY CURRENTS			English	Article							COMPLEX PARTIAL SEIZURES; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC EPILEPSY; LONG; RATS; EEG	D'Ambrosio and Miller argue that brief (i.e., one to a few seconds), rhythmic electrographic events accompanied by behavioral arrest, which they have observed in rats after lateral fluid percussion (i.e., in an animal model of traumatic brain injury), should be considered seizures in this model of posttraumatic epilepsy (1). A counter argument is that these events are not characteristic of the seizures seen clinically in posttraumatic epilepsy or in other forms of acquired epilepsy. Furthermore, several types of brief, rhythmic activity can be recorded in the electroencephalogram (EEG) of animals and humans without epilepsy. One cannot exclude the possibility that such events represent normal electrical activity, which may (or even may not) occur more often after brain injury. Thus, caution is required. In this counterpoint to "What Is an Epileptic Seizure?" by D'Ambrosio and Miller, the assertion is made that experimental studies on animal models of acquired epilepsy that claim electrographic events to be seizures, when the possibility exists that they may not be seizures characteristic of human acquired epilepsy, could be counterproductive, since research resources could be focused on animal models that may not actually demonstrate acquired epilepsy.	[Dudek, F. Edward] Univ Utah, Sch Med, Dept Physiol, Salt Lake City, UT 84108 USA; [Bertram, Edward H.] Univ Virginia, Hlth Sci Ctr, Dept Neurol, Charlottesville, VA 22908 USA	Dudek, FE (corresponding author), Univ Utah, Sch Med, Dept Physiol, 420 Chipeta Way,Suite 1700, Salt Lake City, UT 84108 USA.	ed.dudek@hsc.utah.edu					Afra P, 2008, EPILEPSIA, V49, P677, DOI 10.1111/j.1528-1167.2007.01420.x; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Benbadis SR, 2008, EUR NEUROL, V59, P267, DOI 10.1159/000115641; Bye AME, 2000, J PAEDIATR CHILD H, V36, P244, DOI 10.1046/j.1440-1754.2000.00496.x; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; DEVINSKY O, 1988, NEUROLOGY, V38, P1347, DOI 10.1212/WNL.38.9.1347; Dube C, 2006, BRAIN, V129, P911, DOI 10.1093/brain/awl018; ENGEL J, 1989, SEIZURES EPILEPSY; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Jenssen S, 2006, EPILEPSIA, V47, P1499, DOI 10.1111/j.1528-1167.2006.00622.x; Kelly Kevin M, 2004, Epilepsy Curr, V4, P160, DOI 10.1111/j.1535-7597.2004.44015.x; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; RAKHADE S, 2008, SOC NEUR ABSTR; Santoshkumar B, 2009, CLIN NEUROPHYSIOL, V120, P856, DOI 10.1016/j.clinph.2009.03.005; Shaw FZ, 2004, J NEUROPHYSIOL, V91, P63, DOI 10.1152/jn.00487.2003; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; THEODORE WH, 1994, NEUROLOGY, V44, P1403, DOI 10.1212/WNL.44.8.1403; THEODORE WH, 1983, NEUROLOGY, V33, P1115; WILLIAMSON PD, 1985, ANN NEUROL, V18, P497, DOI 10.1002/ana.410180413	24	21	22	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1535-7597			EPILEPSY CURR	Epilepsy Curr.	JUL-AUG	2010	10	4					91	94		10.1111/j.1535-7511.2010.01368.x			4	Clinical Neurology	Neurosciences & Neurology	652PY	WOS:000282022800007	20697504	Green Published			2021-06-18	
J	Immonen, R; Heikkinen, T; Tahtivaara, L; Nurmi, A; Stenius, TK; Puolivali, J; Tuinstra, T; Phinney, AL; Van Vliet, B; Yrjanheikki, J; Grohn, O				Immonen, Riikka; Heikkinen, Taneli; Tahtivaara, Leena; Nurmi, Antti; Stenius, Taina-Kaisa; Puolivali, Jukka; Tuinstra, Tinka; Phinney, Amie L.; Van Vliet, Bernard; Yrjanheikki, Juha; Grohn, Olli			Cerebral blood volume alterations in the perilesional areas in the rat brain after traumatic brain injury-comparison with behavioral outcome	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral blood volume; iron oxide MRI contrast agent; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FLOW; DIFFUSION; EDEMA; MODEL; NEUROTRAUMA; METABOLISM; HYPEREMIA; PERFUSION; ISCHEMIA	In the traumatic brain injury (TBI) the initial impact causes both primary injury, and launches secondary injury cascades. One consequence, and a factor that may contribute to these secondary changes and functional outcome, is altered hemodynamics. The relative cerebral blood volume (CBV) changes in rat brain after severe controlled cortical impact injury were characterized to assess their interrelations with motor function impairment. Magnetic resonance imaging (MRI) was performed 1, 2, 4 h, and 1, 2, 3, 4, 7, and 14 days after TBI to quantify CBV and water diffusion. Neuroscore test was conducted before, and 2, 7, and 14 days after the TBI. We found distinct temporal profile of CBV in the perilesional area, hippocampus, and in the primary lesion. In all regions, the first response was drop of CBV. Perifocal CBV was reduced for over 4 days thereafter gradually recovering. After the initial drop, the hippocampal CBV was increased for 2 weeks. Neuroscore demonstrated severely impaired motor functions 2 days after injury (33% decrease), which then slowly recovered in 2 weeks. This recovery parallelled the recovery of perifocal CBV. CBV MRI can detect cerebrovascular pathophysiology after TBI in the vulnerable perilesional area, which seems to potentially associate with time course of sensory-motor deficit. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 1318-1328; doi:10.1038/jcbfm.2010.15; published online 10 February 2010	[Immonen, Riikka; Grohn, Olli] Univ Eastern Finland, Biomed NMR Grp, Dept Neurobiol, AI Virtanen Inst Mol Sci, Kuopio, Finland; [Heikkinen, Taneli; Tahtivaara, Leena; Nurmi, Antti; Stenius, Taina-Kaisa; Puolivali, Jukka; Yrjanheikki, Juha] Cerebricon Ltd, Kuopio, Finland; [Tuinstra, Tinka; Phinney, Amie L.; Van Vliet, Bernard] Solvay Pharmaceut BV, Cp Weesp, Netherlands	Immonen, R (corresponding author), Univ Kuopio, Biomed NMR Grp, Dept Neurobiol, AI Virtanen Inst Mol Sci, POB 1627, FIN-70211 Kuopio, Finland.	riikka.immonen@uku.fi			Solvay Pharmaceuticals	The data have been collected as a part of contract-based study by Cerebricon Ltd, funded by Solvay Pharmaceuticals.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunn JF, 2004, MAGN RESON MED, V51, P55, DOI 10.1002/mrm.10660; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Grohn OHJ, 2000, J CEREBR BLOOD F MET, V20, P1457; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plesnila N, 2003, NEUROSCI LETT, V345, P85, DOI 10.1016/S0304-3940(03)00396-3; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Soares HD, 1995, J NEUROSCI, V15, P8223; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Wu EX, 2003, MAGNET RESON MED, V49, P765, DOI 10.1002/mrm.10425	40	21	22	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2010	30	7					1318	1328		10.1038/jcbfm.2010.15			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	619CY	WOS:000279408000007	20145657	Green Published, Bronze			2021-06-18	
J	McLellan, T; Bishop, A; McKinlay, A				McLellan, T.; Bishop, A.; McKinlay, A.			Community attitudes toward individuals with traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI. Head injury; Brain injuries; Public attitudes; Stigmatization; Stereotype; Social Discrimination	IMPLICIT ASSOCIATION TEST; SOCIAL DISTANCE; MENTAL-ILLNESS; PEOPLE; FAMILIARITY; DEPRESSION; PREJUDICE; OUTCOMES; STIGMA	Explicit and implicit attitudes toward people who have sustained traumatic brain injury (TBI) were investigated to determine if negative attitudes exist and if the terminology used (brain vs. head injury) exacerbated predicted negativity. Participants (n = 103) rated Tony (brain/head injury) and Peter (limb-injury) on 10 characteristics using a 7-point scale. Familiarity with brain injury was also measured. Implicit Association Tests (IAT) assessed potential negative bias. Tony (M = 36.84) was judged more negatively than Peter (M = 31.69). The term "brain" versus "head" injury resulted in more negative evaluations (Ms = 38.72 vs. 34.78). Participants familiar with TBI were more positive toward Tony than those unfamiliar (Ms = 34.98 vs. 39.80). Only those unfamiliar with TBI demonstrated implicit negative bias. Negative attitudes toward TBI are expressed explicitly with individuals openly endorsing less desirable characteristics. When people have more knowledge about or experience with brain injury, they are less likely to endorse negative stereotypes. (JINS, 2010, 16, 705-710.)	[McLellan, T.; Bishop, A.; McKinlay, A.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand	McKinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	audrey.mckinlay@canterbury.ac.nz		McKinlay, Audrey/0000-0001-9846-8514	Health Research Council of New ZealandHealth Research Council of New Zealand; Accident Compensation Corporation; University of Canterbury; Tertiary Education Commission of New Zealand (TEC)	The research was conducted during tenure of an ACC Post-Doctoral Research Career Development Award from the Health Research Council of New Zealand and the Accident Compensation Corporation awarded to Audrey McKinlay. Alana Bishop was supported by a Summer Scholarship 2009-2010 jointly funded by the University of Canterbury and the Tertiary Education Commission of New Zealand (TEC). This research received ethical approval from the Human Ethics Committee, University of Canterbury, New Zealand. We acknowledge that the information in this manuscript and the manuscript itself has never been published either electronically or in print. The authors have no conflict of interest in the production of this manuscript.	Angermeyer MC, 2004, SCHIZOPHR RES, V69, P175, DOI 10.1016/S0920-9964(03)00186-5; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bessenoff GR, 2000, SOC COGNITION, V18, P329, DOI 10.1521/soco.2000.18.4.329; Corrigan PW, 2001, SCHIZOPHRENIA BULL, V27, P219, DOI 10.1093/oxfordjournals.schbul.a006868; Fogel J, 2004, J PSYCHOSOM RES, V56, P75, DOI 10.1016/S0022-3999(03)00563-4; Greenwald AG, 1998, J PERS SOC PSYCHOL, V74, P1464, DOI 10.1037/0022-3514.74.6.1464; Greenwald AG, 2003, J PERS SOC PSYCHOL, V85, P197, DOI 10.1037/0022-3514.85.2.197; Greenwald AG, 2009, J PERS SOC PSYCHOL, V97, P17, DOI 10.1037/a0015575; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Linden MA, 2006, ARCH CLIN NEUROPSYCH, V21, P763, DOI 10.1016/j.acn.2006.08.010; Link BG, 2006, LANCET, V367, P528, DOI 10.1016/S0140-6736(06)68184-1; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MCKINLAY A, CHANGING TE IN PRESS; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Rydell RJ, 2007, EUR J SOC PSYCHOL, V37, P867, DOI 10.1002/ejsp.393; Teachman BA, 2006, J SOC CLIN PSYCHOL, V25, P75, DOI 10.1521/jscp.2006.25.1.75; Wolkenstein L, 2009, INT J SOC PSYCHIATR, V55, P124, DOI 10.1177/0020764008092410	21	21	21	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2010	16	4					705	710		10.1017/S1355617710000524			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	619HE	WOS:000279419100015	20478103				2021-06-18	
J	Weaver, AS; Su, YP; Begun, DL; Miller, JD; Alford, AI; Goldstein, SA				Weaver, Aaron S.; Su, Yu-Ping; Begun, Dana L.; Miller, Joshua D.; Alford, Andrea I.; Goldstein, Steven A.			The effects of axial displacement on fracture callus morphology and MSC homing depend on the timing of application	BONE			English	Article						Mesenchymal stem cells; Mechanical strain; Fracture healing; MSC homing; Rat model	MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; BONE-MARROW; OSTEOGENESIS IMPERFECTA; LONG BONES; IN-VIVO; TISSUE; DISTRACTION; BIOLOGY	The local mechanical environment and the availability of mesenchymal stem cells (MSC) have both been shown to be important factors in bone fracture healing. This study was designed to investigate how the timing of an applied axial displacement across a healing fracture affects callus properties as well as the migration of systemically introduced MSC. Bilateral osteotomies were created in male, Sprague-Dawley rats. Exogenous MSC were injected via the tail vein, and a controlled micro-motion was applied to one defect starting 0, 3, 10, or 24 days after surgery. The results showed that fractures stimulated 10 days after surgery had more mineral, less cartilage, and greater mechanical properties at 48 days than other groups. Populations of MSC were found in osteotomies 48 days after surgery, with the exception of the group that was stimulated 10 days after surgery. These results demonstrate that the timing of mechanical stimulation affects the physical properties of the callus and the migration of MSC to the fracture site. Published by Elsevier Inc.	[Goldstein, Steven A.] Univ Michigan, Orthopaed Res Labs, Dept Orthopaed Surg, Ann Arbor, MI 48109 USA; [Weaver, Aaron S.] NASA, Glenn Res Ctr, Cleveland, OH USA; [Su, Yu-Ping] Natl Yang Ming Univ, Sch Med, Dept Surg, Taipei 112, Taiwan	Goldstein, SA (corresponding author), Univ Michigan, Orthopaed Res Labs, Dept Orthopaed Surg, 109 Zina Pitcher Pl,Room 2001, Ann Arbor, MI 48109 USA.	stevegld@umich.edu		Su, Yu-Ping/0000-0002-5390-4113	Department of DefenseUnited States Department of Defense [W81XWH-06-1-0107]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR51504]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051504] Funding Source: NIH RePORTER	We would like to thank Kathy Sweet, Bonnie Nolan, Charles Roehm, Dennis Kayner, Jaclynn Kreider, John Baker, Rochele Taylor, Michael Paschke, Stephanie A. Goldstein, Ralph Zade, David Lee, Srikanth Volvalou, and Eric Lee for their enormous contributions to this work. The study was funded by grants from the Department of Defense (W81XWH-06-1-0107) and the National Institutes of Health (AR51504).	Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927, DOI 10.2106/00004623-200310000-00010; Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.0.CO;2-6; Case ND, 2003, TISSUE ENG, V9, P587, DOI 10.1089/107632703768247296; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Claes L, 2002, J ORTHOP RES, V20, P1099, DOI 10.1016/S0736-0266(02)00044-X; CLAES LE, 1995, CLIN BIOMECH, V10, P227, DOI 10.1016/0268-0033(95)99799-8; Claes LE, 1998, CLIN ORTHOP RELAT R, pS132; Day S., 2000, ORTHOPAEDIC BASIC SC, P371; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7; EINHORN TA, 1990, J BONE JOINT SURG AM, V72A, P1374, DOI 10.2106/00004623-199072090-00016; FROST HM, 1989, CLIN ORTHOP RELAT R, P283; Gardner MJ, 2006, J ORTHOP RES, V24, P1679, DOI 10.1002/jor.20230; GOODSHIP AE, 1985, J BONE JOINT SURG BR, V67, P650; Hansen-Algenstaedt N, 2003, J ORTHOP RES, V21, P805, DOI 10.1016/S0736-0266(03)00060-3; HOLBEIN O, 1995, J ORTHOP RES, V13, P629, DOI 10.1002/jor.1100130420; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Kaspar D, 2003, J ORTHOP RES, V21, P320, DOI 10.1016/S0736-0266(02)00134-1; Kon E, 2000, J BIOMED MATER RES, V49, P328; Kraus KH, 2006, VET SURG, V35, P232, DOI 10.1111/j.1532-950X.2006.00142.x; LENNON DP, 1995, EXP CELL RES, V219, P211, DOI 10.1006/excr.1995.1221; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lucas TS, 1997, CLIN ORTHOP RELAT R, P267; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449; RHINELANDER FW, 1974, CLIN ORTHOP RELAT R, P34; WALLACE AL, 1994, CLIN ORTHOP RELAT R, P281; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Weiss S, 2002, J BONE MINER RES, V17, P1280, DOI 10.1359/jbmr.2002.17.7.1280; WOLF JW, 1981, J BONE JOINT SURG AM, V63, P805, DOI 10.2106/00004623-198163050-00016; Yamaji T, 2001, J Orthop Sci, V6, P571, DOI 10.1007/s007760100014; Zhang P, 2007, J BONE MINER RES, V22, P1979, DOI 10.1359/JBMR.070803; Zimmermann G, 2005, BONE, V36, P779, DOI 10.1016/j.bone.2005.02.011	37	21	21	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	8756-3282	1873-2763		BONE	Bone	JUL	2010	47	1					41	48		10.1016/j.bone.2010.03.008			8	Endocrinology & Metabolism	Endocrinology & Metabolism	615QN	WOS:000279150400005	20303421	Green Accepted			2021-06-18	
J	Lima, FB; Bethea, CL				Lima, F. B.; Bethea, C. L.			Ovarian steroids decrease DNA fragmentation in the serotonin neurons of non-injured rhesus macaques	MOLECULAR PSYCHIATRY			English	Article						apoptosis; TUNEL; estrogen; progesterone; serotonin; dorsal raphe nucleus	TRAUMATIC BRAIN-INJURY; APOPTOTIC CELL-DEATH; PROGESTIN RECEPTORS; MESSENGER-RNA; RAPHE NEURONS; ESTROGEN; NEUROPROTECTION; MECHANISMS; EXPRESSION; ISCHEMIA	We previously found that ovarian steroids promote neuroprotection in serotonin neurons by decreasing the expression of pro-apoptotic genes and proteins in the dorsal raphe nucleus of rhesus macaques, even in the absence of overt injury. In this study, we questioned whether these actions would lead to a reduction in DNA fragmentation in serotonin neurons. Ovariectomized (OVX) rhesus monkeys were implanted with silastic capsules that were empty (placebo) or containing estradiol (E), progesterone (P) or estradiol and progesterone (E+P) for 1 month. In all animals, eight levels of the dorsal raphe nucleus in a rostral-to-caudal direction were immunostained using the terminal deoxynucleotidyl transferase nick end labeling (TUNEL) method. Two staining patterns were observed, which are referred to as type I, with complete dark staining of the nucleus, and type II, with peripheral staining in the perinuclear area. A montage of the dorsal raphe was created at each level with a Marianas Stereology Microscope and Slidebook 4.2, and the TUNEL-positive cells were counted. In direct comparison with OVX animals, P treatment and E+P treatment significantly reduced the total number of TUNEL-positive cells (Mann-Whitney test, both treatments P = 0.04) and E+P treatment reduced the number of TUNEL-positive cells per mm(3) (Mann-Whitney test, P = 0.04). Double immunocytochemistry for TUNEL and tryptophan hydroxylase (TPH) indicated that DNA fragmentation was prominent in serotonin neurons. These data suggest that in the absence of ovarian steroids, a cascade of gene and protein expression leads to an increase in DNA fragmentation in serotonin neurons. Conversely, ovarian steroids have a neuroprotective role in the non-injured brain and prevent DNA fragmentation and cell death in serotonin neurons of nonhuman primates. Molecular Psychiatry (2010) 15, 657-668; doi: 10.1038/mp.2009.97; published online 13 October 2009	[Lima, F. B.; Bethea, C. L.] Oregon Natl Primate Res Ctr, Div Reprod Sci, Beaverton, OR 97006 USA; [Bethea, C. L.] Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA	Bethea, CL (corresponding author), Oregon Natl Primate Res Ctr, Div Reprod Sci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	betheac@ohsu.edu	Lima, Fernanda B/G-3670-2015	Lima, Fernanda B/0000-0002-9177-0814	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH 62677]; Oregon National Primate Research Center [U54-HD18185, RR00163]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD018185] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000163, K01RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS061800] Funding Source: NIH RePORTER	We are deeply grateful to the dedicated staff of the Division of Animal Resources, including the staff of the Departments of Surgery and Pathology, for their expertise and helpfulness in all aspects of monkey management. We especially thank Dr Jessica Henderson for cutting the midbrain brain blocks and organizing the sections. We are indebted to the Endocrine Services Laboratory for radioimmunoassay of steroid hormones. This research was supported by the National Institutes of Health Grants MH 62677 ( to CLB), and Grants U54-HD18185 and RR00163 in support of the Oregon National Primate Research Center.	Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Benninghoff J, 2002, J NEURAL TRANSM, V109, P947, DOI 10.1007/s007020200078; Bethea CL, 2006, J PSYCHIATR NEUROSCI, V31, P105; Bethea CL, 2005, NEUROSCIENCE, V132, P151, DOI 10.1016/j.neuroscience.2004.11.022; BETHEA CL, 1994, NEUROENDOCRINOLOGY, V60, P50, DOI 10.1159/000126719; BETHEA CL, 1993, NEUROENDOCRINOLOGY, V57, P1, DOI 10.1159/000126334; Bethea CL, 2002, FRONT NEUROENDOCRIN, V23, P41, DOI 10.1006/frne.2001.0225; Bethea CL, 2008, J NEUROCHEM, V105, P1129, DOI 10.1111/j.1471-4159.2008.05213.x; Bethea CL, 2008, MOL NEUROBIOL, V38, P199, DOI 10.1007/s12035-008-8042-z; Brinton RD, 2005, ANN NY ACAD SCI, V1052, P57, DOI 10.1196/annals.1347.005; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Corasaniti MT, 2005, NEUROTOXICOLOGY, V26, P893, DOI 10.1016/j.neuro.2005.01.019; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Faubel S., 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P269, DOI 10.2174/1568008054863754; Frey Benicio N, 2008, Menopause Int, V14, P123, DOI 10.1258/mi.2008.008019; Fuchs E, 2004, EUR NEUROPSYCHOPHARM, V14, pS481, DOI 10.1016/j.euroneuro.2004.09.002; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Gorman AM, 1998, NEUROREPORT, V9, pR49, DOI 10.1097/00001756-199807130-00001; Gundlah C, 2001, MOL BRAIN RES, V91, P14, DOI 10.1016/S0169-328X(01)00108-5; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; ISACSON O, 1993, TRENDS NEUROSCI, V16, P306, DOI 10.1016/0166-2236(93)90104-T; Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Krantic S, 2007, PROG NEUROBIOL, V81, P179, DOI 10.1016/j.pneurobio.2006.12.002; Lu NZ, 2003, MOL PSYCHIATR, V8, P353, DOI 10.1038/sj.mp.4001243; Lu NZ, 2002, NEUROPSYCHOPHARMACOL, V27, P12, DOI 10.1016/S0893-133X(01)00423-7; Maggi A, 2004, ANNU REV PHYSIOL, V66, P291, DOI 10.1146/annurev.physiol.66.032802.154945; Manji H K, 2001, Psychopharmacol Bull, V35, P5; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Paxinos G., 2000, RHESUS MONKEY BRAIN; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Piantadosi CA, 1997, EXP NEUROL, V147, P103, DOI 10.1006/exnr.1997.6584; Reddy AP, 2005, PSYCHOPHARMACOLOGY, V180, P125, DOI 10.1007/s00213-005-2154-1; RINK A, 1995, AM J PATHOL, V147, P1575; Schmidt PJ, 2000, AM J OBSTET GYNECOL, V183, P414, DOI 10.1067/mob.2000.106004; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shughrue PJ, 1997, ENDOCRINOLOGY, V138, P5476, DOI 10.1210/en.138.12.5476; Simpkins JW, 2005, CELL MOL LIFE SCI, V62, P271, DOI 10.1007/s00018-004-4382-2; Singh M, 2006, EXP BIOL MED, V231, P514; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Suzuki S, 2006, ENDOCRINE, V29, P209, DOI 10.1385/ENDO:29:2:209; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Teeling JL, 2009, NEUROSCIENCE, V158, P1062, DOI 10.1016/j.neuroscience.2008.07.031; TEJANIBUTT SM, 1995, NEUROREPORT, V6, P1207, DOI 10.1097/00001756-199505300-00033; Tokuyama Y, 2008, NEUROSCIENCE, V154, P720, DOI 10.1016/j.neuroscience.2008.03.056; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Yao MZ, 2007, J NEUROSCI, V27, P1422, DOI 10.1523/JNEUROSCI.2382-06.2007; Zhao LQ, 2005, BRAIN RES REV, V49, P472, DOI 10.1016/j.brainresrev.2005.01.009	62	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	JUN	2010	15	6					657	668		10.1038/mp.2009.97			12	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	599DZ	WOS:000277891800009	19823180	Bronze, Green Accepted			2021-06-18	
J	Lippi, G; Cervellin, G				Lippi, Giuseppe; Cervellin, Gianfranco			Disseminated Intravascular Coagulation in Trauma Injuries	SEMINARS IN THROMBOSIS AND HEMOSTASIS			English	Article						Trauma; hemostasis; coagulation; disseminated intravascular coagulation	PROTEIN-C PATHWAY; HEAD-INJURY; BRAIN-INJURY; SEVERITY SCORE; EARLY COAGULOPATHY; TISSUE FACTOR; POSTTRAUMA COAGULATION; ORGAN DYSFUNCTION; COMBAT CASUALTIES; IMPROVES ACCURACY	Physical injuries, especially road traffic injuries, are a leading cause of death and morbidity worldwide, ranking fifth among the leading causes of death in the United States. Immediate and early trauma deaths are mainly determined by primary brain injuries and/or hemorrhages, whereas late mortality is caused by secondary brain injuries, host defense failure, and superimposed complications including also disseminated intravascular coagulation (DIC). Trauma patients are particularly susceptible to the early development of coagulopathy, and the most severely injured patients are coagulopathic on hospital admission. The zenith of the problem is typically seen in patients with head injuries and in those who are massively injured and transfused. The resulting coagulopathy is characterized by nonsurgical bleeding from mucosal lesions, serosal surfaces, and wound and vascular access sites. DIC associated with traumatic injury results from multiple independent but interplaying mechanisms, involving tissue trauma, shock, and inflammation. As such, the multifaceted derangement of hemostasis occurring after massive traumatic injuries, especially those involving the brain, is mainly sustained by release of procoagulants (fats, phospholipids) and constitutive tissue factor from the injured tissue into the circulation, associated with a systemic inflammatory response that also promotes tissue factor hyperexpression on monocytes and the other cells. The excessive, non-wound-related thrombin generation is insufficiently antagonized by physiological anticoagulant pathways and amplified by impaired endogenous fibrinolysis. The resulting burst of systemic thrombin generation, coupled with platelet hyperaggregability, shock, hypothermia, and tissue hypoperfusion, further contribute to the development of DIC and microvascular bleeding.	[Lippi, Giuseppe] Azienda Osped Univ Parma, UO Diagnost Ematochim, Dipartimento Patol & Med Lab, I-43126 Parma, Italy; [Cervellin, Gianfranco] Azienda Osped Univ Parma, UO Pronto Soccorso & Med Urgenza, I-43126 Parma, Italy	Lippi, G (corresponding author), Azienda Osped Univ Parma, UO Diagnost Ematochim, Dipartimento Patol & Med Lab, Via Gramsci 14, I-43126 Parma, Italy.	glippi@ao.pr.it	Lippi, Giuseppe/X-7198-2018	Lippi, Giuseppe/0000-0001-9523-9054			AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Brohi K, 2007, CURR OPIN CRIT CARE, V13, P680, DOI 10.1097/MCC.0b013e3282f1e78f; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chatzizisis YS, 2008, EUR J INTERN MED, V19, P568, DOI 10.1016/j.ejim.2007.06.037; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; DEHAVEN H, 1952, SITE FREQUENCY DANGE; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; Dunbar NM, 2009, TRANSFUSION, V49, P2652, DOI 10.1111/j.1537-2995.2009.02335.x; *EUR COMM, HLTH STAT ATL MORT E; Franchini M, 2006, THROMB J, V4, DOI 10.1186/1477-9560-4-4; Gadzhiev M R, 1991, Zh Vopr Neirokhir Im N N Burdenko, P8; Gando S, 1998, THROMB HAEMOSTASIS, V79, P1111; Gando S, 1997, CRIT CARE MED, V25, P1820, DOI 10.1097/00003246-199711000-00019; Gando S, 2006, SEMIN THROMB HEMOST, V32, P48, DOI 10.1055/s-2006-933340; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943; Gando S, 2001, SEMIN THROMB HEMOST, V27, P585, DOI 10.1055/s-2001-18864; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Heron M, NATL VITAL STAT REPO; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kushimoto S, 2008, THROMB HAEMOSTASIS, V100, P1099, DOI 10.1160/TH08-05-0306; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Levi M, 2007, CRIT CARE MED, V35, P2191, DOI 10.1097/01.CCM.0000281468.94108.4B; MENENDEZ LR, 1995, CLIN ORTHOP RELAT R, P185; Mirdad TM, 2000, E AFR MED J, V77, P663; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; PITTS SR, 2008, NATL HLTH STAT REPOR, V7, P1; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; Sawamura A, 2009, THROMB RES, V124, P608, DOI 10.1016/j.thromres.2009.06.034; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schrieber M, 2007, J TRAUMA, V63, P1261; Sethi D, 2007, J EPIDEMIOL COMMUN H, V61, P842, DOI 10.1136/jech.2007.063081; Soderstrom CA, 1997, J TRAUMA, V43, P925; STRINCHINI A, 1974, LANCET, V2, P957; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; TEASDALE G, 1974, LANCET, V2, P81; Tieu BH, 2007, WORLD J SURG, V31, P1055, DOI 10.1007/s00268-006-0653-9; van der Poll T, 2001, SEMIN THROMB HEMOST, V27, P639, DOI 10.1055/s-2001-18868; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; World Health Organization, INT CLASS EXT CAUS I; YAMAMOTO H, 1995, J ORTHOP TRAUMA, V9, P449, DOI 10.1097/00005131-199505000-00016; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024; Zhu YJ, 2009, CHIN J TRAUMATOL, V12, P203, DOI 10.3760/cma.j.issn.1008-1275.2009.04.003	56	21	22	0	1	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0094-6176	1098-9064		SEMIN THROMB HEMOST	Semin. Thromb. Hemost.	JUN	2010	36	4					378	387		10.1055/s-0030-1254047			10	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	605HI	WOS:000278338100003	20614390				2021-06-18	
J	Schatz, P; Neidzwski, K; Moser, RS; Karpf, R				Schatz, Philip; Neidzwski, Katherine; Moser, Rosemarie Scolaro; Karpf, Robin			Relationship Between Subjective Test Feedback Provided by High-School Athletes During Computer-Based Assessment of Baseline Cognitive Functioning and Self-Reported Symptoms	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						baseline assessment; concussion; concussion symptoms; ImPACT; neuropsychological testing	CONCUSSION; RELIABILITY; PERFORMANCE; RECOVERY; NOISE	Subjective feedback about distractions or problems encountered during computerized assessment was provided by 538 out of a pool of 1659 high-school athletes who completed baseline testing using ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing). Three types of feedback were included: (a) environmental, (b) computer-based (mechanical), and (c) instruction-based (associated with difficulty understanding test instructions). One-way analyses of variance were conducted and revealed relationships between greater symptom reporting and any type of feedback, environmental feedback, and instruction-based feedback. Increased symptom reporting was noted for female students. Additional relationships were noted between providing computer-based feedback and faster reaction time; and between history of concussion and providing instruction-based feedback. Athletes endorsing more symptoms at baseline scored significantly worse on ImPACT, as reflected in decreased visual memory performance. Results suggest that feedback provided during computerized assessment may yield information about symptom reporting and test-taking style, which may also be of particular interpretive utility when athletes minimize their symptoms.	[Schatz, Philip; Neidzwski, Katherine] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Moser, Rosemarie Scolaro] RSM Psychol Ctr LLC, Lawrenceville, NJ USA; [Karpf, Robin] Lawrenceville Sch, Lawrenceville, NJ USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall,5600 City Ave, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			BADDELEY A, 1993, J EXP PSYCHOL LEARN, V19, P862, DOI 10.1037/0278-7393.19.4.862; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; BARTRAM D, 1984, J OCCUP PSYCHOL, V57, P221, DOI 10.1111/j.2044-8325.1984.tb00164.x; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Chen Z, 2006, J EXP PSYCHOL HUMAN, V32, P1452, DOI 10.1037/0096-1523.32.6.1452; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Corneil BD, 1996, J NEUROSCI, V16, P8193; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; IVERSON G, 2004, J INT NEUROPSYCH SOC, V10, P1; IVERSON GL, 2003, NORMATIVE DATA FOXPR; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Lovell MR, 2007, IMPACT VERSION 6 0 C; Lovell MR, 2002, NEUROLOGIC ATHLETIC, P32; Macken WJ, 2009, PSYCHON B REV, V16, P139, DOI 10.3758/PBR.16.1.139; PIERCE RC, 1963, J CONSULT PSYCHOL, V27, P536, DOI 10.1037/h0038844; Podell K, 2004, STUD NEUROPSYCHOL DE, P375; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; SPACE LG, 1981, BEHAV RES METH INSTR, V13, P595, DOI 10.3758/BF03202072; Trimmel M, 2006, ERGONOMICS, V49, P202, DOI 10.1080/00140130500434986; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wechsler D., 1955, MANUAL WECHSLER ADUL; WEINSTEIN ND, 1974, J APPL PSYCHOL, V59, P548, DOI 10.1037/h0037338; WILSON SL, 1991, MICROCOMPUTERS CLIN, P79; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503	34	21	21	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2010	25	4					285	292		10.1093/arclin/acq022			8	Psychology, Clinical; Psychology	Psychology	600KL	WOS:000277984600003	20363733	Bronze			2021-06-18	
J	Bergquist, TF; Thompson, K; Gehl, C; Pineda, JM				Bergquist, Thomas F.; Thompson, Kelsey; Gehl, Carissa; Pineda, Jorge Munoz			Satisfaction Ratings After Receiving Internet-Based Cognitive Rehabilitation in Persons with Memory Impairments After Severe Acquired Brain Injury	TELEMEDICINE JOURNAL AND E-HEALTH			English	Article						technology; telecommunications; telemedicine	PATIENT SATISFACTION; TELEREHABILITATION; CARE; TELEMEDICINE; FEASIBILITY; STROKE; HOME	Objective: This study looked at patient satisfaction with an Internet-based cognitive rehabilitation program, which has been previously shown to be associated with functional improvements. Materials and Methods: Fourteen individuals with documented traumatic brain injury and memory impairments completed this study. Participants completed 60 sessions of Internet-based cognitive rehabilitation: 30 sessions of an active calendar intervention and 30 sessions of a control diary intervention. A four-question satisfaction questionnaire (responses were generated using a seven-point Likert scale) was completed after 30 sessions and again after 60 sessions. Results: No significant differences in satisfaction were found between time of assessment and treatment condition. In addition, a higher level of calendar use prior to beginning the study was associated with greater satisfaction at study completion. Conclusion: These results suggest that persons with traumatic brain injury are not only willing to use the Internet to receive cognitive rehabilitation treatment, but are generally highly satisfied with the treatment. Further, individuals with some baseline compensatory strategies may be particularly well suited to this method of treatment.	[Bergquist, Thomas F.] Mayo Clin, Coll Med, Rochester, MN 55905 USA; [Thompson, Kelsey] St Olaf Coll, Northfield, MN 55057 USA; [Gehl, Carissa] Iowa City VAMC, Iowa City, IA USA; [Pineda, Jorge Munoz] Gustavus Adolphus Coll, St Peter, MN 56082 USA	Bergquist, TF (corresponding author), Mayo Clin, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	bergquist.thomas@mayo.edu			National Institute for Disability and Rehabilitation Research (NIDRR)	This research was supported by a TBI Model System grant from the National Institute for Disability and Rehabilitation Research (NIDRR).	Bergquist T, 2008, BRAIN INJURY, V22, P891, DOI 10.1080/02699050802405487; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Day SX, 2002, J COUNS PSYCHOL, V49, P499, DOI 10.1037/0022-0167.49.4.499; Gustke SS, 2000, TELEMED J, V6, P5, DOI 10.1089/107830200311806; Holden D, 2008, TELEMED J E-HEALTH, V14, P381, DOI 10.1089/tmj.2007.0054; Huijgen BCH, 2008, J TELEMED TELECARE, V14, P249, DOI 10.1258/jtt.2008.080104; Kairy D, 2009, DISABIL REHABIL, V31, P427, DOI 10.1080/09638280802062553; Keith RA, 1998, ARCH PHYS MED REHAB, V79, P1122, DOI 10.1016/S0003-9993(98)90182-4; Lai JCK, 2004, J TELEMED TELECARE, V10, P199, DOI 10.1258/1357633041424340; Locke Dona E C, 2008, J Support Oncol, V6, P383; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; Nieves JE, 2009, J TELEMED TELECARE, V15, P51, DOI 10.1258/jtt.2008.080706; Piron L, 2008, J TELEMED TELECARE, V14, P257, DOI 10.1258/jtt.2008.080304; Randolph C., 1998, RBANS MANUAL REPEATA; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Vaccaro M, 2007, DISABIL REHABIL-ASSI, V2, P85, DOI 10.1080/17483100601167586; Williams TL, 2001, TELEMED J E-HEALTH, V7, P293, DOI 10.1089/15305620152814700; Wright B.A., 1983, PHYS DISABILITY PSYC, V2nd edition; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	23	21	21	1	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627			TELEMED J E-HEALTH	Telemed. J. e-Health	MAY	2010	16	4					417	423		10.1089/tmj.2009.0118			7	Health Care Sciences & Services	Health Care Sciences & Services	601ZI	WOS:000278107000042	20420542				2021-06-18	
J	Groh, GI; Wirth, MA; Rockwood, CA				Groh, Gordon I.; Wirth, Michael A.; Rockwood, Charles A., Jr.			Results of treatment of luxatio erecta (inferior shoulder dislocation)	JOURNAL OF SHOULDER AND ELBOW SURGERY			English	Article						Luxatio erecta; inferior shoulder dislocation; results of treatment	INSTABILITY	Hypothesis: Traumatic inferior shoulder dislocation (luxatio erecta) injuries are rare, comprising less than 0.5% of all shoulder dislocations. Few cases have been reported, and the outcome of treatment has been ill defined. Materials and methods: Between 1968 and 2000, 18 patients (20 shoulders) with luxatio erecta were evaluated at our institution. Two patients (2 shoulders) were lost to follow-up, leaving 16 patients (18 shoulders) for long-term follow-up (average, 9 years). Associated injuries included peripheral nerve injury, humeral fracture, acromial fracture, and rotator cuff tear. All patients were initially managed with closed reduction, which was successful in 9 shoulders. The remaining 9 shoulders required operative treatment. Results: Patients were evaluated with respected to pain, function, range of motion, strength, and patient satisfaction, according to the University of California at Los Angeles Rating Scale. Overall, 13 of the 16 patients were graded as good or excellent. Patients treated with closed reduction or operative treatment compared favorably in terms of improvements in ratings for pain, strength, motion, and the ability to perform work and sports. Discussion: Our experience suggests that treatment of luxatio erecta is largely successful, with good or excellent results obtained in 83% of the shoulders. Half of the patients evaluated, required only closed reduction as their definitive treatment. Operative treatment is typically indicated for associated displaced humeral head fractures or patients with recurrent instability. Recurrent instability appears to be more likely in patients with a previous history of dislocation. Associated neurologic or vascular injury did not affect the final outcome. Level of evidence: Level IV; Case Series; Therapeutic Study (C) 2010 Journal of Shoulder and Elbow Surgery Board of Trustees.	[Groh, Gordon I.] Blue Ridge Bone & Joint Clin, Asheville, NC 28801 USA; [Wirth, Michael A.; Rockwood, Charles A., Jr.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthopaed, San Antonio, TX 78229 USA	Groh, GI (corresponding author), Blue Ridge Bone & Joint Clin, 129 McDowell, Asheville, NC 28801 USA.	ggroh@brbj.com	Groh, Gordon/AAH-8571-2020	Groh, Gordon/0000-0001-7994-225X			ADAR R, 1980, J TRAUMA, V21, P323; AMSTUTZ HC, 1981, CLIN ORTHOP RELAT R, P7; BURKHEAD WZ, 1992, J BONE JOINT SURG AM, V74A, P890, DOI 10.2106/00004623-199274060-00010; DAVIDS JR, 1990, CLIN ORTHOP RELAT R, P144; Garcia R, 2006, J TRAUMA, V60, P1132, DOI 10.1097/01.ta.0000217246.64718.02; GARDHAM JRC, 1979, INJURY, V11, P155, DOI 10.1016/S0020-1383(79)80014-5; Mallon W J, 1990, J Orthop Trauma, V4, P19; Nho SJ, 2006, J ORTHOP TRAUMA, V20, P419, DOI 10.1097/00005131-200607000-00010; Nutton RW, 1997, J BONE JOINT SURG BR, V79B, P73, DOI 10.1302/0301-620X.79B1.7225; Rockwood CA, 1996, FRACTURES ADULTS, P1193; Sewecke Jeffrey J, 2006, Am J Orthop (Belle Mead NJ), V35, P578; Tornetta P 3rd, 1993, Orthop Rev, V22, P855; Tsuchida T, 2001, J SHOULDER ELB SURG, V10, P595, DOI 10.1067/mse.2001.115987; Wirth MA, 1996, J BONE JOINT SURG AM, V78A, P246, DOI 10.2106/00004623-199602000-00012; Yamamoto Tetsuji, 2003, Am J Orthop (Belle Mead NJ), V32, P601	15	21	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	1058-2746			J SHOULDER ELB SURG	J. Shoulder Elbow Surg.	APR	2010	19	3					423	426		10.1016/j.jse.2009.07.062			4	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	582SW	WOS:000276620100014	19836975				2021-06-18	
J	Nordstrom, CH				Nordstrom, Carl-Henrik			Cerebral energy metabolism and microdialysis in neurocritical care	CHILDS NERVOUS SYSTEM			English	Article						Microdialysis; Cerebral metabolism; Traumatic brain injury; Monitoring	VOLUME-TARGETED THERAPY; SEVERE BRAIN TRAUMA; INJURED HUMAN BRAIN; INTRACEREBRAL MICRODIALYSIS; RAT HIPPOCAMPUS; LUND CONCEPT; PRINCIPLES; TRANSPORT; PRESSURE; MORPHINE	It is of obvious clinical importance to monitor cerebral metabolism-in particular, cerebral energy metabolism and indicators of cellular damage-online at the bedside. The technique of cerebral microdialysis provides the opportunity for continuous monitoring of metabolic changes in the tissue before they are reflected in peripheral blood chemistry or in systemic physiological parameters. The basic idea of microdialysis is to mimic the function of a blood capillary by positioning a thin dialysis tube in the tissue and to be used to analyze the chemical composition of the interstitial fluid. The biochemical variables used during routine monitoring were chosen to cover important aspects of cerebral energy metabolism (glucose, pyruvate and lactate), to indicate excessive interstitial levels of excitatory transmitter substance (glutamate) and to give indications of degradation of cellular membranes (glycerol). Furthermore, pharmokinetic studies can be conducted using microdialysis. This article discusses technical and physiological aspects of microdialysis, and its clinical applications in brain injury.	Univ Lund Hosp, Dept Clin Sci, Div Neurosurg, SE-22185 Lund, Sweden	Nordstrom, CH (corresponding author), Univ Lund Hosp, Dept Clin Sci, Div Neurosurg, SE-22185 Lund, Sweden.	carl-henrik.nordstrom@med.lu.se					Amer-Wahlin I, 2009, J MATERN-FETAL NEO M, V10, P1, DOI [10.1080/14767050903067360, DOI 10.1080/14767050903067360]; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; BLASBERG RG, 1983, J CEREBR BLOOD F MET, V3, P8, DOI 10.1038/jcbfm.1983.2; Ederoth P, 2004, BRIT J CLIN PHARMACO, V57, P427, DOI 10.1046/j.1365-2125.2003.02032.x; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Gardenfors A, 2002, ACTA NEUROCHIR, V144, P601, DOI 10.1007/s00701-002-0954-1; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; HAGSTROMTOFT E, 1993, J CLIN ENDOCR METAB, V76, P392, DOI 10.1210/jc.76.2.392; HAMBERGER A, 1984, NEUROCHEM RES, V9, P1181, DOI 10.1007/BF00973033; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; Nordstrom CH, 2005, NEUROCRIT CARE, V2, P83, DOI 10.1385/NCC:2:1:083; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; NORDSTROM CH, 2003, NEUROSURG FOCUS, V15; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rosdahl H, 2000, INT J BIOL MACROMOL, V28, P69, DOI 10.1016/S0141-8130(00)00148-3; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Stahl N, 2003, ACTA NEUROL SCAND, V108, P211, DOI 10.1034/j.1600-0404.2003.00095.x; Tunblad K, 2004, ACTA ANAESTH SCAND, V48, P294, DOI 10.1111/j.0001-5172.2003.0311.x; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Ungerstedt U., 1974, B SCHWEIZ AKAD MED, V1278, P1	25	21	22	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	APR	2010	26	4					465	472		10.1007/s00381-009-1035-z			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	568QI	WOS:000275537100008	19937248				2021-06-18	
J	Spulber, S; Schultzberg, M				Spulber, Stefan; Schultzberg, Marianne			Connection between inflammatory processes and transmittor function-Modulatory effects of interleukin-1	PROGRESS IN NEUROBIOLOGY			English	Article; Proceedings Paper	Conference on Chemical Neuroanatomy held in honor of Nils Ake Hikkarp	DEC, 2008	Stockholm, SWEDEN			Ageing; Alzheimer's disease; Cytokine; Development; Inflammation; Neurodegeneration; Neurogenesis; IL-1 receptor antagonist	MESENCEPHALIC PROGENITOR CELLS; LONG-TERM POTENTIATION; CLOSED-HEAD INJURY; RAT ADRENAL-GLAND; RECEPTOR ANTAGONIST; ALZHEIMERS-DISEASE; KAINIC ACID; MESSENGER-RNA; IMMUNE-SYSTEM; AGED MICE	Cells in the nervous system can respond to different kinds of stress, e.g. injury, with production and release of inflammatory molecules, including cytokines. One of the most important proinflammatory cytokines is interleukin-1, affecting most organs of the body. The high constitutive expression of interleukin-1 in the adrenal gland provides a source for local and systemic actions, in addition to activated monocytes. In the brain, the constitutive expression is low, but activated microglia produce and release interleukin-1 during pathological conditions such as neurodegenerative disorders (e.g. stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease). Interleukin-1 has an important role in mediating 'sickness symptoms' such as fever, in response to infections. Its role in neurodegeneration is not fully elucidated, but there is evidence for involvement in both amyloidosis and tau pathology, major neuropathological hallmarks of Alzheimer's disease. The interleukin-1 family at present consists of 11 members, one of which is the endogenous receptor antagonist. Overexpression of this antagonist in the CNS in a transgenic mouse strain, Tg hsIL-1ra, has allowed studies on morphological and functional effects of blocking interleukin-1 receptor-mediated activity in the brain. Marked alterations of brain morphology such as reduced hippocampal and cortical volume correlate with behavioural deficits. Decreased anxiety and impaired long-term memory are among the consequences. Intact interleukin-1 signalling is important for the brain's ability to adapt to acute and chronic neuroinflammation. Increased amplitude and prolongation of proinflammatory cytokine production underly the behavioural alterations characteristic for ageing. Moreover, deregulated expression of interleukin-1 is associated with ageing-related chronic neurodegenerative disorders. (C) 2009 Elsevier Ltd. All rights reserved.	[Spulber, Stefan; Schultzberg, Marianne] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Neurodegenerat, SE-14186 Stockholm, Sweden	Schultzberg, M (corresponding author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Neurodegenerat, Floor 5, SE-14186 Stockholm, Sweden.	Marianne.Schultzberg@ki.se	Schultzberg, Marianne/E-7076-2014; Spulber, Stefan/J-2989-2012	Schultzberg, Marianne/0000-0002-8314-0927; Spulber, Stefan/0000-0001-8122-6738			AKANEYA Y, 1995, EXP NEUROL, V136, P44, DOI 10.1006/exnr.1995.1082; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; ANDERSSON C, 1992, NEUROSCIENCE, V47, P481, DOI 10.1016/0306-4522(92)90262-Z; Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x; ATKINS E, 1955, J EXP MED, V101, P519, DOI 10.1084/jem.101.5.519; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BRENNEMAN DE, 1992, J NEUROCHEM, V58, P454, DOI 10.1111/j.1471-4159.1992.tb09743.x; Butterfield DA, 2005, EXP GERONTOL, V40, P774, DOI 10.1016/j.exger.2005.05.007; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CACABELOS R, 1991, METHOD FIND EXP CLIN, V13, P455; Carvey PM, 2001, EXP NEUROL, V171, P98, DOI 10.1006/exnr.2001.7735; Coogan AN, 1999, NEUROSCIENCE, V93, P57, DOI 10.1016/S0306-4522(99)00100-1; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dantzer R, 2007, BRAIN BEHAV IMMUN, V21, P153, DOI 10.1016/j.bbi.2006.09.006; de la Mano A, 2007, CYTOKINE, V37, P128, DOI 10.1016/j.cyto.2007.03.004; DEL BR, 1995, NEUROSCI LETT, V188, P70; Deniz-Naranjo MC, 2008, EUR J NEUROL, V15, P1080, DOI 10.1111/j.1468-1331.2008.02252.x; Dilger RN, 2008, J LEUKOCYTE BIOL, V84, P932, DOI 10.1189/jlb.0208108; DINARELLO CA, 1994, FASEB J, V8, P1314; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; DOLPHIN A, 1979, MOL PHARMACOL, V15, P1; Dong HX, 2003, J NEUROSCI, V23, P1742; Dunn AJ, 2006, CLIN NEUROSCI RES, V6, P52, DOI 10.1016/j.cnr.2006.04.002; DUNN AJ, 1988, LIFE SCI, V43, P429, DOI 10.1016/0024-3205(88)90522-X; Dziegielewska KM, 2000, CELL TISSUE RES, V299, P335; Engstrom L, 2008, ENDOCRINOLOGY, V149, P1436, DOI 10.1210/en.2007-1456; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; Eriksson C, 1998, MOL BRAIN RES, V58, P195, DOI 10.1016/S0169-328X(98)00125-9; Eriksson C, 2000, J NEUROSCI RES, V60, P266, DOI 10.1002/(SICI)1097-4547(20000415)60:2<266::AID-JNR16>3.0.CO;2-P; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Garlind A, 1999, BRAIN RES, V826, P112, DOI 10.1016/S0006-8993(99)01092-6; GIULIAN D, 1988, J NEUROSCI, V8, P709; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Guzowski JF, 2001, J NEUROSCI, V21, P5089, DOI 10.1523/JNEUROSCI.21-14-05089.2001; Hattiangady B, 2008, NEUROBIOL AGING, V29, P129, DOI 10.1016/j.neurobiolaging.2006.09.015; Johansson S, 2002, J COMP NEUROL, V443, P237, DOI 10.1002/cne.10119; KABIERSCH A, 1988, Brain Behavior and Immunity, V2, P267, DOI 10.1016/0889-1591(88)90028-1; Kinoshita D, 2009, PHYSIOL BEHAV, V96, P328, DOI 10.1016/j.physbeh.2008.10.018; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Li YK, 2003, J NEUROSCI, V23, P1605; Lindberg C, 2005, J MOL NEUROSCI, V27, P1, DOI 10.1385/JMN:27:1:001; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; LUNDBERG JM, 1986, REGUL PEPTIDES, V13, P169, DOI 10.1016/0167-0115(86)90224-7; Lundkvist J, 1999, AM J PHYSIOL-REG I, V276, pR644; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; NOBEL CSI, 1995, NEUROIMMUNOMODULAT, V2, P61, DOI 10.1159/000096873; O'Neill LAJ, 2008, IMMUNOL REV, V226, P10, DOI 10.1111/j.1600-065X.2008.00701.x; Oprica M, 2007, J CELL MOL MED, V11, P810, DOI 10.1111/j.1582-4934.2007.00074.x; Oprica M, 2005, BRAIN BEHAV IMMUN, V19, P223, DOI 10.1016/j.bbi.2004.07.006; Parish CL, 2002, J NEUROSCI, V22, P8034; Priebe K, 2005, DEV PSYCHOBIOL, V47, P398, DOI 10.1002/dev.20098; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; Riaz SS, 2004, DEV BRAIN RES, V153, P39, DOI 10.1016/j.devbrainres.2004.07.006; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Rosmaninho-Salgado J, 2007, PEPTIDES, V28, P310, DOI 10.1016/j.peptides.2006.11.015; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; SCHULTZBERG M, 1989, NEUROSCIENCE, V30, P805, DOI 10.1016/0306-4522(89)90171-1; SCHULTZBERG M, 1995, J INTERF CYTOK RES, V15, P721, DOI 10.1089/jir.1995.15.721; SCHULTZBERG M, 1978, NEUROSCIENCE, V3, P1169, DOI 10.1016/0306-4522(78)90137-9; Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7; Sheng JG, 2000, EXP NEUROL, V163, P388, DOI 10.1006/exnr.2000.7393; Sparkman NL, 2008, NEUROIMMUNOMODULAT, V15, P323, DOI 10.1159/000156474; SPULBER S, 2008, THESIS KAROLINSKA I; Spulber S, 2008, EUR J NEUROSCI, V27, P549, DOI 10.1111/j.1460-9568.2008.06050.x; Spulber S, 2009, J NEUROIMMUNOL, V208, P46, DOI 10.1016/j.jneuroim.2009.01.010; Storch A, 2001, EXP NEUROL, V170, P317, DOI 10.1006/exnr.2001.7706; Stroemer RP, 1997, J CEREBR BLOOD F MET, V17, P597; Tanji K, 2003, NEUROREPORT, V14, P413, DOI 10.1097/01.wnr.0000059783.23521.7c; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Vawter MP, 1996, EXP NEUROL, V142, P179, DOI 10.1006/exnr.1996.0189; Yang GY, 1998, J CEREBR BLOOD F MET, V18, P840, DOI 10.1097/00004647-199808000-00004; Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; Yirmiya R, 2002, NEUROBIOL LEARN MEM, V78, P379, DOI 10.1006/nlme.2002.4072; Zaharia MD, 1996, PSYCHOPHARMACOLOGY, V128, P227, DOI 10.1007/s002130050130	85	21	27	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0301-0082	1873-5118		PROG NEUROBIOL	Prog. Neurobiol.	FEB 9	2010	90	2			SI		256	262		10.1016/j.pneurobio.2009.10.015			7	Neurosciences	Neurosciences & Neurology	578KZ	WOS:000276293700014	19853010				2021-06-18	
J	Mann, CM; Lee, JHT; Hillyer, J; Stammers, AMT; Tetzlaff, W; Kwon, BK				Mann, Cody M.; Lee, Jae H. T.; Hillyer, Jessica; Stammers, Anthea M. T.; Tetzlaff, Wolfram; Kwon, Brian K.			Lack of robust neurologic benefits with simvastatin or atorvastatin treatment after acute thoracic spinal cord contusion injury	EXPERIMENTAL NEUROLOGY			English	Article						Simvastatin; Atorvastatin; Neuroprotection; Spinal cord injury	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; MORPHOLOGICAL CONSEQUENCES; NEUROPROTECTIVE AGENT; INFLAMMATORY RESPONSE; LOCOMOTOR RECOVERY; ISCHEMIC BRAIN; STATINS; RATS; ERYTHROPOIETIN	Although much progress has been made in the clinical care of patients with acute spinal cord injuries, there are no reliably effective treatments, which minimize secondary damage and improve neurologic Outcome. The time and expense needed to establish de novo pharmacologic or biologic therapies for acute SCI has encouraged the development of neuroprotective treatments based oil drugs that are already in clinical use and, therefore, have the advantage of a well-characterized safety and pharmacokinetic profile in humans. Statins are the most commonly prescribed class of lipid-lowering drugs, and recently, it has been recognized that statins also have powerful immunomodulatory and anti-inflammatory effects. This paper describes a series of experiments that were performed to evaluate the comparative neuroprotective effects of simvastatin and atorvastatin. We observed a promising signal of neurologic benefit with simvastatin in our first experiment, but in repeated attempts to replicate that effect in three subsequent experiments, we failed to reveal any behavioral OF histologic improvements. We Would conclude that simvastatin given orally or subcutaneously at doses previously reported by other investigators to be effective in different neurologic conditions does not confer a significant neurologic benefit in a thoracic contusion injury model (OSU Impactor) when administered with a I-h delay in intervention. We contend that further preclinical investigation of atorvastatin and simvastatin is warranted before considering their translation into human SCI. (C) 2009 Elsevier Inc. All rights reserved.	[Mann, Cody M.; Lee, Jae H. T.; Hillyer, Jessica; Stammers, Anthea M. T.; Tetzlaff, Wolfram; Kwon, Brian K.] Univ British Columbia, ICORD, Vancouver, BC V5Z 1M9, Canada; [Kwon, Brian K.] Univ British Columbia, Dept Orthopaed, CNOSP, Vancouver, BC V5Z 1M9, Canada; [Tetzlaff, Wolfram] Univ British Columbia, Dept Zool, Vancouver, BC V5Z 1M9, Canada	Kwon, BK (corresponding author), Univ British Columbia, Dept Orthopaed, Vancouver Gen Hosp, D6 Heather Pavil,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.	brian.kwon@vch.ca	Tetzlaff, Wolfram/AAY-4430-2020		Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); UBC; Wings for Life Spinal Cord Injury Foundation; Scoliosis Research Society	BKK holds a New Investigator Award from the Canadian Institutes for Health Research and WT is the Rick Hansen Man in Motion Chair of Spinal Cord Injury Research, UBC. This research was supported by the Wings for Life Spinal Cord Injury Foundation and Scoliosis Research Society.	Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Balduini W, 2001, STROKE, V32, P2185, DOI 10.1161/hs0901.094287; Bartesaghi S, 2005, NEUROTOXICOLOGY, V26, P923, DOI 10.1016/j.neuro.2005.01.016; Basso DM, 2004, J NEUROTRAUM, V21, P395, DOI 10.1089/089771504323004548; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Cimino A, 2005, NEUROTOXICOLOGY, V26, P929, DOI 10.1016/j.neuro.2005.03.009; Cimino M, 2007, NEUROSCIENTIST, V13, P208, DOI 10.1177/1073858406297121; Dery MA, 2009, NEUROSCI LETT, V453, P73, DOI 10.1016/j.neulet.2009.01.062; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; HOLMBERG E, 2008, EXP NEUROL; Holmberg E, 2006, J NEUROTRAUM, V23, P1366, DOI 10.1089/neu.2006.23.1366; Hurlbert RJ, 2008, CAN J NEUROL SCI, V35, P41, DOI 10.1017/S031716710000754X; Igel M, 2001, EUR J CLIN PHARMACOL, V57, P357, DOI 10.1007/s002280100329; Igel M, 2002, J CLIN PHARMACOL, V42, P835, DOI 10.1177/009127002401102731; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Kugi M, 2002, CARDIOVASC DRUG THER, V16, P203, DOI 10.1023/A:1020692220701; KWON BK, 2009, J NEUROTRAUMA; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Pinzon A, 2008, EXP NEUROL, V213, P129, DOI 10.1016/j.expneurol.2008.05.018; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Romano M, 2000, LAB INVEST, V80, P1095, DOI 10.1038/labinvest.3780115; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Steward O, 2008, EXP NEUROL, V209, P446, DOI 10.1016/j.expneurol.2007.12.010; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Stuve O, 2003, CURR OPIN NEUROL, V16, P393, DOI 10.1097/01.wco.0000073942.19076.d1; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zacco A, 2003, J NEUROSCI, V23, P11104	40	21	21	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2010	221	2					285	295		10.1016/j.expneurol.2009.11.006			11	Neurosciences	Neurosciences & Neurology	556BD	WOS:000274560800003	19931252				2021-06-18	
J	Katz-Leurer, M; Rotem, H; Keren, O; Meyer, S				Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley			Heart rate and heart rate variability at rest and during exercise in boys who suffered a severe traumatic brain injury and typically-developed controls	BRAIN INJURY			English	Article						Autonomic nervous system diseases; traumatic brain injury; heart rate; parasympathetic nervous system; sympathetic nervous system; rehabilitation	AEROBIC CAPACITY; HRV	Objectives: To measure heart rate (HR) and heart rate variability (HRV) at rest and during exercise in children with post-severe traumatic brain injury as compared to age-matched typically-developed controls. Design: Comparative study. Setting: Out-patient rehabilitation department. Participants: Twelve boys post-severe traumatic brain injury (TBI) (aged 7-13 years) and 18 typically-developed (TD) boys matched for age. Interventions: HR and HRV were determined at rest and at a steady functional walking rate on the treadmill. Main outcome measures: HR and HRV parameters include: time domain parameters: standard deviation of the R-R interval, square root of the mean squared differences of successive R-R differences at rest and during steady-state exercise. Results: Children post-TBI demonstrated higher mean HR values at rest (TBI 91.8 +/- 7.0 beats per minute vs 72.0 +/- 7.1 beats per minute in controls, p < 0.05) and during exercise (TBI 123.4 +/- 15.5 beats per minute vs 113.0 +/- 9.1 beats per minute in controls, p < 0.05). At rest, the time domain measures of HRV were significantly lower in the TBI group (p < 0.05). Time domain mean values decreased significantly during exercise only among the TD children. Conclusions: The findings of this study suggest that among children post-severe TBI, the cardiac autonomic mechanism is less efficient at rest and less adaptive to exercise and activity as compared to TD children.	[Katz-Leurer, Michal] Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Phys Therapy Dept, IL-69978 Tel Aviv, Israel; [Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley] Alyn Childrens Orthoped Hosp, Jerusalem, Israel; [Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley] Rehabil Ctr, Jerusalem, Israel	Katz-Leurer, M (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Phys Therapy Dept, IL-69978 Tel Aviv, Israel.	michalkz@post.tau.ac.il					ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; Iellamo F, 1999, CIRCULATION, V100, P27, DOI 10.1161/01.CIR.100.1.27; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Katz-Leurer M, 2005, NEUROREHABILITATION, V20, P91; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; King ML, 1997, BRAIN INJURY, V11, P445; KORPELAINEN JT, 1994, STROKE, V25, P787, DOI 10.1161/01.STR.25.4.787; Korpelainen JT, 1999, CLIN AUTON RES, V9, P325, DOI 10.1007/BF02318379; Korpelainen JT, 1996, ACTA NEUROL SCAND, V94, P337, DOI 10.1111/j.1600-0404.1996.tb07076.x; LAROVERE MT, 1992, CHEST, V101, pS299, DOI 10.1378/chest.101.5.299S; Mossberg KA, 2008, PHYS THER, V88, P77, DOI 10.2522/ptj.20070022; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Palmer-McLean K, 2003, ACSMS EXERCISE MANAG, P238; ROBINSON BF, 1966, CIRC RES, V19, P400, DOI 10.1161/01.RES.19.2.400; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; TEASDALE G, 1974, LANCET, V2, P81; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; YAMOUR BJ, 1980, AM HEART J, V99, P294, DOI 10.1016/0002-8703(80)90343-9	24	21	21	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	2					110	114		10.3109/02699050903508234			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	597BF	WOS:000277729500006	20085448				2021-06-18	
J	Kilts, JD; Tupler, LA; Keefe, FJ; Payne, VM; Hamer, RM; Naylor, JC; Calnaido, RP; Morey, RA; Strauss, JL; Parke, G; Massing, MW; Youssef, NA; Shampine, LJ; Marx, CE				Kilts, Jason D.; Tupler, Larry A.; Keefe, Francis J.; Payne, Victoria M.; Hamer, Robert M.; Naylor, Jennifer C.; Calnaido, Rohana P.; Morey, Rajendra A.; Strauss, Jennifer L.; Parke, Gillian; Massing, Mark W.; Youssef, Nagy A.; Shampine, Lawrence J.; Marx, Christine E.		Vet Affairs MidAtlantic Mental	Neurosteroids and Self-Reported Pain in Veterans Who Served in the U.S. Military after September 11, 2001	PAIN MEDICINE			English	Article						Neuroactive Steroid; Allopregnanolone; Pregnenolone; DHEA; Nociception; Pain; Neurosteroid	TRAUMATIC BRAIN-INJURY; PROGESTERONE METABOLITE 5-ALPHA-PREGNAN-3-ALPHA-OL-20-ONE; STEROID-HORMONE METABOLITES; GABA-A RECEPTOR; PREGNENOLONE-SULFATE; ANTINOCICEPTIVE PROPERTIES; NEUROACTIVE STEROIDS; MENTAL-HEALTH; ANXIOLYTIC ACTIVITY; ALZHEIMERS-DISEASE	Objective. Nearly half of Operation Enduring Freedom/Operation Iraqi Freedom veterans experience continued pain post-deployment. Several investigations report analgesic effects of allopregnanolone and other neurosteroids in animal models, but few data are currently available focusing on neurosteroids in clinical populations. Allopregnanolone positively modulates GABA(A) receptors and demonstrates pronounced analgesic and anxiolytic effects in rodents, yet studies examining the relationship between pain and allopregnanolone in humans are limited. We thus hypothesized that endogenous allopregnanolone and other neurosteroid levels may be negatively correlated with self-reported pain symptoms in humans. Design. We determined serum neurosteroid levels by gas chromatography/mass spectrometry (allopregnanolone, pregnenolone) or radioimmunoassay (dehydroepiandrosterone [DHEA], progesterone, DHEA sulfate [DHEAS]) in 90 male veterans who served in the U.S. military after September 11, 2001. Self-reported pain symptoms were assessed in four areas (low back pain, chest pain, muscle soreness, headache). Stepwise linear regression analyses were conducted to investigate the relationship between pain assessments and neurosteroids, with the inclusion of smoking, alcohol use, age, and history of traumatic brain injury as covariates. Setting. Durham VA Medical Center. Results. Allopregnanolone levels were inversely associated with low back pain (P = 0.044) and chest pain (P = 0.013), and DHEA levels were inversely associated with muscle soreness (P = 0.024). DHEAS levels were positively associated with chest pain (P = 0.001). Additionally, there was a positive association between traumatic brain injury and muscle soreness (P = 0.002). Conclusions. Neurosteroids may be relevant to the pathophysiology of self-reported pain symptoms in this veteran cohort, and could represent future pharmacological targets for pain disorders.	[Kilts, Jason D.; Tupler, Larry A.; Keefe, Francis J.; Payne, Victoria M.; Naylor, Jennifer C.; Morey, Rajendra A.; Strauss, Jennifer L.; Shampine, Lawrence J.; Marx, Christine E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27705 USA; [Hamer, Robert M.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA; [Hamer, Robert M.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA	Marx, CE (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 508 Fulton St,Mental Hlth Serv Line 116A, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Youssef, Nagy A/F-5869-2019; Morey, Rajendra A/P-3079-2018	Youssef, Nagy A/0000-0002-1922-9396; Morey, Rajendra A/0000-0002-6517-6969	VA Mid-Atlantic MIRECC [K23 MH 65080]; VA Advanced Research Career Development Award; VA Career Development Award; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH065080] Funding Source: NIH RePORTER	This work was supported by the following sources: VA Mid-Atlantic MIRECC, K23 MH 65080 (C.E.M.), VA Advanced Research Career Development Award (C.E.M.), VA Career Development Award (J.L.S.). Dr Marx discloses that she is a co-applicant on pending U.S. patent applications on the use of neurosteroids and derivatives for the treatment of central nervous system disorders and for lowering cholesterol, and she is an unpaid scientific advisor and unpaid board member of NeuroScience Pharmaceuticals. The remaining authors have no potential conflicts of interest to disclose. The views expressed in this presentation are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health.	Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; BELELLI D, 1989, EUR J PHARMACOL, V166, P325, DOI 10.1016/0014-2999(89)90077-0; Bitran D, 2000, PSYCHOPHARMACOLOGY, V151, P31, DOI 10.1007/s002130000472; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Chen SC, 2004, BRAIN RES, V1027, P196, DOI 10.1016/j.brainres.2004.08.053; Chen SC, 2006, BIOCHEM BIOPH RES CO, V349, P626, DOI 10.1016/j.bbrc.2006.08.076; CRAWLEY JN, 1986, BRAIN RES, V398, P382, DOI 10.1016/0006-8993(86)91500-3; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; DEVAUD LL, 1995, ALCOHOL CLIN EXP RES, V19, P350, DOI 10.1111/j.1530-0277.1995.tb01514.x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Enna SJ, 2006, ADV PHARMACOL, V54, P1, DOI 10.1016/S1054-3589(06)54001-3; Finckh A, 2005, J RHEUMATOL, V32, P1336; Finset A, 2004, PSYCHONEUROENDOCRINO, V29, P49, DOI 10.1016/S0306-4530(02)00134-8; FRYE CA, 1994, BRAIN RES, V643, P194, DOI 10.1016/0006-8993(94)90025-6; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Genazzani A R, 2004, Aging Male, V7, P133; Genazzani AD, 2002, EUR J ENDOCRINOL, V146, P347, DOI 10.1530/eje.0.1460347; Genazzani AR, 1998, J CLIN ENDOCR METAB, V83, P2099, DOI 10.1210/jc.83.6.2099; Ghezzi P, 2000, EUR CYTOKINE NETW, V11, P464; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gilron I, 1996, ANESTHESIOLOGY, V84, P572, DOI 10.1097/00000542-199603000-00013; Girdler SS, 2001, BIOL PSYCHIAT, V49, P788, DOI 10.1016/S0006-3223(00)01044-1; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Goodchild CS, 2001, BRIT J ANAESTH, V86, P528, DOI 10.1093/bja/86.4.528; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Helmer DA, 2009, PAIN MED, V10, P1174, DOI 10.1111/j.1526-4637.2009.00723.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Imamura M, 1998, BIOCHEM BIOPH RES CO, V243, P771, DOI 10.1006/bbrc.1998.8177; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jain NS, 2005, NEUROPHARMACOLOGY, V48, P627, DOI 10.1016/j.neuropharm.2004.11.016; KAVALIERS M, 1988, PSYCHOPHARMACOLOGY, V95, P488; KAVALIERS M, 1987, BRAIN RES, V415, P393, DOI 10.1016/0006-8993(87)90228-9; Kavaliers M, 2000, NEUROSCIENCE, V95, P807; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Khoromi S, 2006, J CLIN ENDOCR METAB, V91, P4313, DOI 10.1210/jc.2006-1122; Kokate TG, 1996, NEUROPHARMACOLOGY, V35, P1049, DOI 10.1016/S0028-3908(96)00021-4; KOKATE TG, 1994, J PHARMACOL EXP THER, V270, P1223; Korneyev A, 1996, HORM BEHAV, V30, P37, DOI 10.1006/hbeh.1996.0006; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LANDGREN S, 1987, ACTA PHYSIOL SCAND, V131, P33, DOI 10.1111/j.1748-1716.1987.tb08202.x; MAJEWSKA MD, 1990, EUR J PHARM-MOLEC PH, V189, P307, DOI 10.1016/0922-4106(90)90124-G; MAJEWSKA MD, 1987, BRAIN RES, V404, P355; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MAJEWSKA MD, 1990, BRAIN RES, V526, P143, DOI 10.1016/0006-8993(90)90261-9; Marx CE, 2006, PSYCHOPHARMACOLOGY, V186, P462, DOI 10.1007/s00213-005-0226-x; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Mechlin B, 2007, PAIN, V131, P142, DOI 10.1016/j.pain.2006.12.027; Mellon S, 2004, ENDOCR RES, V30, P727, DOI 10.1081/ERC-200044016; MOK WM, 1990, BRAIN RES, V533, P42, DOI 10.1016/0006-8993(90)91792-F; MORROW AL, 1987, EUR J PHARMACOL, V142, P483, DOI 10.1016/0014-2999(87)90094-X; Nadeson R, 2001, BRIT J ANAESTH, V86, P704, DOI 10.1093/bja/86.5.704; Park-Chung M, 1999, BRAIN RES, V830, P72, DOI 10.1016/S0006-8993(99)01381-5; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; Peebles JE, 2001, SPINE, V26, P766, DOI 10.1097/00007632-200104010-00014; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Smith CD, 2006, PSYCHOPHARMACOLOGY, V186, P481, DOI 10.1007/s00213-005-0186-1; Tanielian T, 2008, INVISIBLE WOUNDS WAR; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; *VHA OFF PUBL HLTH, 2008, REP RET COMB VET; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; WIELAND S, 1991, BRAIN RES, V565, P263, DOI 10.1016/0006-8993(91)91658-N; WINFREE CJ, 1992, LIFE SCI, V50, P1007, DOI 10.1016/0024-3205(92)90095-7; Winter L, 2003, ANESTH ANALG, V97, P798, DOI 10.1213/01.ANE.0000075835.73967.F3; Yokoro CM, 2001, BRAZ J MED BIOL RES, V34, P397, DOI 10.1590/S0100-879X2001000300015; Zou XJ, 2002, BRAIN RES, V958, P322, DOI 10.1016/S0006-8993(02)03621-1	71	21	21	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1526-2375			PAIN MED	Pain Med.		2010	11	10					1469	1476		10.1111/j.1526-4637.2010.00927.x			8	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	656YA	WOS:000282375800006	20735755	Bronze, Green Accepted			2021-06-18	
J	Nott, MT; Chapparo, C; Heard, R; Baguley, IJ				Nott, Melissa T.; Chapparo, Christine; Heard, Robert; Baguley, Ian J.			Patterns of agitated behaviour during acute brain injury rehabilitation	BRAIN INJURY			English	Article						Agitation; cognition; rehabilitation; post-traumatic amnesia	POSTTRAUMATIC AMNESIA PTA; TRAUMATIC HEAD-INJURY; SCALE; RECOVERY; DURATION	Objective: To monitor daily shift-by-shift changes in agitated behaviour during adult brain injury rehabilitation. Design: A prospective, descriptive study. Methods: Eight participants were monitored daily for up to 28 days. The Agitated Behaviour Scale (ABS) evaluated behaviour during three nursing shifts (morning, afternoon, night). Severity of agitation, peak intensity and concomitant behaviours were calculated. Shift differences and patterns of behavioural changes were analysed. Results: Four hundred and seven recordings were taken with the ABS. All participants demonstrated multiple agitated behaviours (between 3-13 concomitant behaviours per person); the most common behaviours were representative of the ABS Disinhibition sub-scale. Weekly peak intensity ranged from 14-55 on the ABS. Mean ABS scores were highest during the afternoon shift and lowest at night. Improved cognition was associated with resolving agitated behaviour; while persistent agitated behaviour was associated with low levels of cognition. Minimal agitated behaviour was observed in participants who emerged from post-traumatic amnesia. Conclusions: Agitated behaviour during acute brain injury rehabilitation has a complex clinical presentation. High levels of agitation observed during the afternoon shift may be associated with low levels of structured activities available at that time, higher levels of environmental stimuli during visiting times and increased cognitive fatigue. Lower cognitive ability was related to consistently higher levels of agitated behaviour and vice-versa.	[Nott, Melissa T.; Baguley, Ian J.] Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia; [Chapparo, Christine; Heard, Robert] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Baguley, Ian J.] Univ Sydney, Sydney Med Sch, Dept Rehabil Med, Sydney, NSW 2006, Australia	Nott, MT (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 355, Wentworthville, NSW 2145, Australia.	melissan@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013; Nott, Melissa T/M-6778-2018	Baguley, Ian J/0000-0001-5650-3705; Nott, Melissa T/0000-0001-7088-5826			Ahmed S, 2000, BRAIN INJURY, V14, P765; Beaulieu C, 2008, J HEAD TRAUMA REHAB, V23, P304, DOI 10.1097/01.HTR.0000336843.60961.b7; BERMANN DE, 1988, HEAD INJURY GUIDE FU, P45; BOGNER J, 1995, NEUROREHABILITATION, V5, P293, DOI 10.3233/NRE-1995-5403; Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Burnett DM, 1999, NEUROREHABILITATION, V13, P165; COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77, DOI 10.1093/geronj/44.3.M77; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Ducharme JM, 1999, BRAIN INJURY, V13, P645, DOI 10.1080/026990599121232; Fluharty G, 2001, BRAIN INJURY, V15, P995, DOI 10.1080/02699050010025795; Geffen G., 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; GILES GM, 1999, REHABILITATION SEVER, P97; GURKA JA, 2005, BRAIN INJURY S1, V19, P1; Hagen C, 1979, REHABILITATION HEAD, P87; HAGEN C, 2001, RELEARNING TIMES, V8, P1; Herbel K, 1990, Rehabil Nurs, V15, P66; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; MYSIW WJ, 1988, AM J PHYS MED REHAB, V67, P29, DOI 10.1097/00002060-198802000-00006; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; Plylar P A, 1989, J Neurosci Nurs, V21, P353; Pryor J, 2004, DISABIL REHABIL, V26, P974, DOI 10.1080/09638280410001702397; Radomski MV, 2008, OCCUPATIONAL THERAPY; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Riedel D, 1997, Rehabil Nurs, V22, P36; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tate RL, 2001, J HEAD TRAUMA REHAB, V16, P525, DOI 10.1097/00001199-200112000-00002; van der Naalt J, 2000, BRAIN INJURY, V14, P781; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; WILSON J, 1999, REHABILITATION SEVER, P54	40	21	21	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	10					1214	1221		10.3109/02699052.2010.506858			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MJ	WOS:000283197100008	20715891				2021-06-18	
S	Zhang, ZQ; Larner, SF; Kobeissy, F; Hayes, RL; Wang, KKW		Yan, Q		Zhang, Zhiqun; Larner, Stephen F.; Kobeissy, Firas; Hayes, Ronald L.; Wang, Kevin K. W.			Systems Biology and Theranostic Approach to Drug Discovery and Development to Treat Traumatic Brain Injury	SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Biomarkers; Brain injury; Theranostics; Systems biology	SPECTRIN BREAKDOWN PRODUCTS; ALPHA-II-SPECTRIN; CEREBROSPINAL-FLUID; IDENTIFICATION; PROTEOME; RATS	Traumatic brain injury is a significant disease affecting 1.4 to 2 million patients every year in the USA. Currently, there are no FDA-approved therapeutic remedies to treat TBI despite the fact that there have been over 200 clinical drug trials, all which have failed. These drugs used the traditional single drug-to-target approach of drug discovery and development. An alternative based upon the advances in genomics, proteomics, bioinformatic tools, and systems biology software has enabled us to use a Systems Biology-based approach to drug discovery and development for TBI. It focuses on disease-relevant converging pathways as potential therapeutic intervention points and is accompanied by downstream biomarkers that allow for the tracking of drug targeting and appears to correlate with disease mitigation. When realized, one is able to envision that a companion diagnostic will be codeveloped along the therapeutic compound. This "theranostic" approach is perfectly positioned to align with the emerging trend toward "personalized medicine".	[Zhang, Zhiqun; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Kobeissy, Firas; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32611 USA	Zhang, ZQ (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA.		Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Beltrao P, 2007, CURR OPIN STRUC BIOL, V17, P378, DOI 10.1016/j.sbi.2007.05.005; CAMPAGNE F, 2004, SCI STKE, pI11; Chen S. S., 2007, DATA MINING BIOMEDIC, P1; Hinman LM, 2006, PHARMACOGENOMICS J, V6, P375, DOI 10.1038/sj.tpj.6500392; Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015; Jayapandian M, 2007, NUCLEIC ACIDS RES, V35, pD566, DOI 10.1093/nar/gkl859; Katz Russell, 2004, NeuroRx, V1, P189, DOI 10.1602/neurorx.1.2.189; Kobeissy FH, 2008, EXPERT REV PROTEOMIC, V5, P293, DOI 10.1586/14789450.5.2.293; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Nickerson D, 2005, P ANN INT IEEE EMBS, P6096, DOI 10.1109/IEMBS.2005.1615884; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Rifai N, 2006, NAT BIOTECHNOL, V24, P971, DOI 10.1038/nbt1235; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Romeo MJ, 2005, EXPERT REV PROTEOMIC, V2, P57, DOI 10.1586/14789450.2.1.57; Vastrik I, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-r39; Vitzthum F, 2005, J PROTEOME RES, V4, P1086, DOI 10.1021/pr050080b; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Warner S, 2004, SCIENTIST, V18, P38	22	21	21	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-60761-799-0	METHODS MOL BIOL	Methods Mol. Biol.		2010	662						317	329		10.1007/978-1-60761-800-3_16	10.1007/978-1-60761-800-3		13	Biochemical Research Methods; Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	BRH19	WOS:000282703900016	20824479				2021-06-18	
J	Gould, TE; Piland, SG; Shin, J; McNair, O; Hoyle, CE; Nazarenko, S				Gould, Trenton E.; Piland, Scott G.; Shin, Junghwan; McNair, Olivia; Hoyle, Charles E.; Nazarenko, Sergei			Characterization of mouthguard materials: Thermal properties of commercialized products	DENTAL MATERIALS			English	Article						Mouthguard materials; Differential scanning calorimetry; Dynamic mechanical analysis; Ethylene vinyl acetate; Dental materials; Material characterization	CONCUSSION; PREVENTION	Objectives. Several mechanisms have been purported to describe how mouthguards protect the orofacial complex against injury. As the properties needed for these mechanisms to be effective are temperature and frequency dependent, the specific aim of this study was to provide a comprehensive thermal characterization of commercial mouthguard materials. Methods. Five commercially representative thermoplastic mouthguard materials (Essix(TM) Resin, Erkoflex(TM), Proform(TM)-regular, Proform(TM)-laminate, and Polyshok(TM)) were tested. Differential scanning calorimetry (DSC) and dynamic mechanical analysis (DMA) techniques were implemented to measure thermal transitions and mechanical properties. Measurements were conducted three times per sample. One-way ANOVA and one-sample t-tests were used to test for differences between commercial products on selected mean thermal property values. Results. The DSC measurements indicated no differences between commercial materials for mean glass transition (p = 0.053), onset melt (p = 0.973), or peak melt (p = 0.436) temperatures. Likewise, DMA measurements revealed no differences between commercial materials for the mean glass transition (p = 0.093), storage modulus (p = 0.257), or loss modulus (p = 0.172) properties, respectively. The one-sample t-tests revealed that glass transition temperatures were different from intra-oral temperature (p < 0.005) for all materials. Significance. Commercialized mouthguard materials are sensitive to repetitive heating and cooling cycles, prolonged thermal treatment, and have glass transitions well below their end-use intra-oral temperature. As such, these materials are functioning as elastomers and not optimal mechanical damping materials. Dental clinicians, healthcare practitioners, or end-users should be aware that these materials are at best problematic with respect to this protective mechanism. Published by Elsevier Ltd on behalf of Academy of Dental Materials.	[Gould, Trenton E.] Univ So Mississippi, Sport & High Performance Mat Program, Sch Human Performance, Hattiesburg, MS 39406 USA; [Shin, Junghwan; McNair, Olivia; Hoyle, Charles E.; Nazarenko, Sergei] Univ So Mississippi, Sch Polymers & High Performance Mat, Hattiesburg, MS 39406 USA	Gould, TE (corresponding author), Univ So Mississippi, Sport & High Performance Mat Program, Sch Human Performance, 118 Coll Dr,5142, Hattiesburg, MS 39406 USA.	Trent.Gould@usm.edu			Alliance for Graduate Education in Mississippi (AGEM); National Science FoundationNational Science Foundation (NSF)	Ms. Olivia McNair was supported by the Alliance for Graduate Education in Mississippi (AGEM), a National Science Foundation funded grant designed to increase the number of under represented minorities that pursue graduate education in science, technology, engineering, and mathematics. Additionally, in the course of completing this article for print, our dear colleague, Dr. Charles E. Hoyle, suddenly and tragically passed away. Charlie, as most referred to him, was an internationally renowned polymer scientist, a dedicated teacher, and beloved mentor. This manuscript is dedicated in his memory.	*AM NAT STAND I AM, 2001, 99 AM NAT STAND I AM; *ASTM INT, 2000, 69700 ASTM INT; *AUSTR IND, 2003, STAND; DODD JW, 1987, THERMAL METHODS; GOULD TE, 2007, MAT SPORTS EQUIPMENT; Gould TE, 2009, DENT MATER, V25, P771, DOI 10.1016/j.dental.2008.12.005; KIM ST, 1997, IDW 97 SID NAG, P155; Knapik JJ, 2007, SPORTS MED, V37, P117, DOI 10.2165/00007256-200737020-00003; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; Meng FH, 2007, DENT MATER, V23, P1492, DOI 10.1016/j.dental.2007.01.006; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Moly KA, 2005, EUR POLYM J, V41, P1410, DOI 10.1016/j.eurpolymj.2004.10.016; Seymour RB, 1981, POLYM CHEM INTRO; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; Winters JE, 2001, J ATHL TRAINING, V36, P339; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x	17	21	22	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0109-5641	1879-0097		DENT MATER	Dent. Mater.	DEC	2009	25	12					1593	1602		10.1016/j.dental.2009.08.003			10	Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials	Dentistry, Oral Surgery & Medicine; Materials Science	515LN	WOS:000271472400017	19796800				2021-06-18	
J	Lu, XCM; Si, YZ; Williams, AJ; Hartings, JA; Gryder, D; Tortella, FC				Lu, Xi-Chun M.; Si, Yuanzheng; Williams, Anthony J.; Hartings, Jed A.; Gryder, Divina; Tortella, Frank C.			NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain ischemia; EEG; NNZ-2566; rats; seizures	GLYCINE-PROLINE-GLUTAMATE; N-TERMINAL TRIPEPTIDE; INTENSIVE-CARE UNIT; GROWTH-FACTOR-I; STATUS EPILEPTICUS; EPILEPSY; INJURY; INFLAMMATION; PATHOPHYSIOLOGY; ACTIVATION	Ischemic and traumatic brain injuries often induce non-convulsive seizures (NCSs), which likely contribute to the worsening of neurological outcomes. Here, we evaluated the effect of glycyl-L-methylprolyl-L-glutamic acid (NNZ-2566) to lessen the severity of NCSs caused by permanent middle cerebral artery occlusion (pMCAo). Continuous electroencephalographic recordings were performed in rats during pMCAo. Glycyl-L-methylprolyl-L-glutamic acid (3, 10, or 100 mg/kg bolus followed by an infusion of a fixed dose of 3 mg/kg per hour for 12 h) was delivered at 20 mins after pMCAo (before the first NCS event) or delayed until immediately after the first NCS event occurred. Control rats received pMCAo and saline treatment. The results revealed that 91% of the saline-treated animals had NCSs (23 episodes per rat and 1238 secs per rat) with an onset latency of 35 mins after injury. When NNZ-2566 was administered before the NCS events, it dose-dependently reduced the NCS incidence to 36%-80%, decreased NCS frequency to 5-16 episodes per rat, and shortened the total duration of NCS to 251-706 secs per rat. The two high doses significantly reduced the infarct volume by 28%-30%. Delayed treatment also attenuated NCS duration but had no effect on the infarct volume. Results indicate that NNZ-2566 possesses a unique therapeutic potential as a safe prophylactic agent that synergistically provides neuroprotection and reduces injury-induced seizures. Journal of Cerebral Blood Flow & Metabolism (2009) 29, 1924-1932; doi:10.1038/jcbfm.2009.109; published online 29 July 2009	[Lu, Xi-Chun M.; Si, Yuanzheng; Williams, Anthony J.; Hartings, Jed A.; Gryder, Divina; Tortella, Frank C.] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, Silver Spring, MD 20910 USA	Lu, XCM (corresponding author), Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	may.lu@us.army.mil		Hartings, Jed/0000-0001-8583-3471	CRADA (Cooperative Research and Development Agreement) with Neuren Pharmaceuticals Ltd. [W81XWH-050074]	We would like to thank Ms Angela Fleming, Ms Xiaofang Yang, Mr Paul Guevarra, and Ms Ying Cao for their invaluable assistance in the technical aspects of this study, and Ms Christine Gallo for her review and comments on the paper. These studies were supported in part by a CRADA (Cooperative Research and Development Agreement) with Neuren Pharmaceuticals Ltd. (W81XWH-050074).	Amantea D, 2009, FEBS J, V276, P13, DOI 10.1111/j.1742-4658.2008.06766.x; Baker AM, 2005, NEUROPEPTIDES, V39, P81, DOI 10.1016/j.npep.2004.11.001; Batchelor DC, 2003, ANAL BIOCHEM, V323, P156, DOI 10.1016/j.ab.2003.08.032; Bickerdike MJ, 2009, J NEUROL SCI, V278, P85, DOI 10.1016/j.jns.2008.12.003; Choi J, 2008, YONSEI MED J, V49, P1, DOI 10.3349/ymj.2008.49.1.1; Fabene PF, 2008, NAT MED, V14, P1377, DOI 10.1038/nm.1878; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Maganti R, 2008, EPILEPSY BEHAV, V12, P572, DOI 10.1016/j.yebeh.2007.12.002; Ravizza T, 2006, NEUROBIOL DIS, V24, P128, DOI 10.1016/j.nbd.2006.06.003; Ravizza T, 2006, NEUROSCIENCE, V137, P301, DOI 10.1016/j.neuroscience.2005.07.063; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rizzi M, 2003, NEUROBIOL DIS, V14, P494, DOI 10.1016/j.nbd.2003.08.001; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Svedin P, 2007, DEV NEUROSCI-BASEL, V29, P393, DOI 10.1159/000105480; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vezzani A, 2008, BRAIN BEHAV IMMUN, V22, P797, DOI 10.1016/j.bbi.2008.03.009; Vezzani A, 2008, EPILEPSIA, V49, P24, DOI 10.1111/j.1528-1167.2008.01490.x; Viviani B, 2003, J NEUROSCI, V23, P8692; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Wei H, 2008, J NEUROTRAUM, V25, P917; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Williams AJ, 2008, NEUROSCI LETT, V430, P7, DOI 10.1016/j.neulet.2007.09.052; Williams AJ, 2006, J PHARMACOL EXP THER, V318, P947, DOI 10.1124/jpet.106.105999	28	21	21	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2009	29	12					1924	1932		10.1038/jcbfm.2009.109			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	524ZJ	WOS:000272182600007	19638995	Bronze			2021-06-18	
J	Lancioni, GE; Singh, NN; O'Reilly, MF; Sigafoos, J; Buonocunto, F; Sacco, V; Colonna, F; Navarro, J; Oliva, D; Signorino, M; Megna, G				Lancioni, Giulio E.; Singh, Nirbhay N.; O'Reilly, Mark F.; Sigafoos, Jeff; Buonocunto, Francesca; Sacco, Valentina; Colonna, Fabio; Navarro, Jorge; Oliva, Doretta; Signorino, Mario; Megna, Gianfranco			Microswitch- and VOCA-assisted programs for two post-coma persons with minimally conscious state and pervasive motor disabilities	RESEARCH IN DEVELOPMENTAL DISABILITIES			English	Article						Microswitch; VOCA; Learning principles; Post-coma; Minimally conscious state; Motor disabilities	PROFOUND MULTIPLE DISABILITIES; TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; RECOVERY SCALE; REHABILITATION; TECHNOLOGY; DISORDERS; PEOPLE; ADULTS	Intervention programs, based on learning principles and assistive technology, were assessed in two studies with two post-coma men with minimally conscious state and pervasive motor disabilities. Study I assessed a program that included (a) an optic microswitch, activated via double blinking, which allowed a man direct access to brief music intervals, and (b) a voice output communication aid (VOCA) with two channels, activated via different hand-closure movements, which allowed the man to call his mother and a research assistant who provided stimulation events. Study H assessed a program that included (a) a pressure microswitch, activated via head movements, which allowed a man direct access to video-clips and music, and (b) a VOCA device, activated via prolonged eyelid closure, which allowed the man to call the caregiver (i.e., a research assistant) who provided attention and sang to him. Each of the two participants had significant increases in both microswitch- and VOCA-related responses during the intervention phases of the studies. Moreover, purposeful choice seemed to occur between the two VOCA responses in Study 1. Implications of the findings for improving the situation of post-coma persons with minimally conscious state and pervasive motor disabilities are discussed. (C) 2009 Elsevier Ltd. All rights reserved.	[Lancioni, Giulio E.] Univ Bari, Dept Psychol, I-70100 Bari, Italy; [Singh, Nirbhay N.] ONE Res Inst, Midlothian, VA USA; [O'Reilly, Mark F.] Univ Texas Austin, Meadows Ctr Preventing Educ Risk, Austin, TX 78712 USA; [Sigafoos, Jeff] Victoria Univ Wellington, Wellington, New Zealand; [Buonocunto, Francesca; Sacco, Valentina; Colonna, Fabio; Navarro, Jorge] S Raffaele Rehabil Ctr, Ceglie Messapica, Italy; [Oliva, Doretta; Signorino, Mario] Lega F DOro Res Ctr, Osimo, Italy	Lancioni, GE (corresponding author), Univ Bari, Dept Psychol, Via Quintino Sella 268, I-70100 Bari, Italy.	g.lancioni@psico.uniba.it	Singh, Nouratan/N-9377-2017	Singh, Nouratan/0000-0002-8063-8375; Lancioni, Giulio/0000-0002-6515-5690; Navarro solano, Jorge/0000-0003-1508-6727			Avesani R, 2006, BRAIN INJURY, V20, P333, DOI 10.1080/02699050500487605; Baker PMA, 2008, ASSIST TECHNOL, V20, P149, DOI 10.1080/10400435.2008.10131942; BARLOW D, 2009, SINGLE CASE EXPT DES; Bekinschtein T, 2005, NEUROPSYCHOL REHABIL, V15, P307, DOI 10.1080/09602010443000443; Bernat JL, 2007, NEUROLOGY, V68, P885, DOI 10.1212/01.wnl.0000258973.95355.68; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Coleman MR, 2005, NEUROPSYCHOL REHABIL, V15, P161, DOI 10.1080/09602010443000669; Elliott L, 2005, NEUROPSYCHOL REHABIL, V15, P480, DOI 10.1080/09602010443000506; Giacino JT, 2005, NEUROPSYCHOL REHABIL, V15, P166, DOI 10.1080/09602010443000498; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, J HEAD TRAUMA REHAB, V19, P254, DOI 10.1097/00001199-200405000-00006; Holburn S, 2004, BEHAV INTERVENT, V19, P25, DOI 10.1002/bin.147; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; KAZDIN AE, 2001, BEHAV MODIFICATION A; Kennedy K, 2005, SINGLE CASE DESIGNS; Keren O, 2001, BRAIN INJURY, V15, P633, DOI 10.1080/02699050010009568; Lancioni GE, 2008, EUR J PHYS REHAB MED, V44, P449; Lancioni GE, 2007, PERCEPT MOTOR SKILL, V104, P1027, DOI 10.2466/PMS.104.3.1027-1034; Lancioni G E, 2006, Pediatr Rehabil, V9, P137, DOI 10.1080/13638490500235466; LANCIONI GE, DISABILITY IN PRESS; Lancioni GE, 2007, DISABIL REHABIL-ASSI, V2, P293, DOI 10.1080/17483100701308635; Lancioni GE, 2008, J DEV PHYS DISABIL, V20, P379, DOI 10.1007/s10882-008-9104-x; Lancioni GE, 2008, PERCEPT MOTOR SKILL, V106, P355, DOI 10.2466/PMS.106.2.355-370; Lancioni GE, 2008, J DEV PHYS DISABIL, V20, P209, DOI 10.1007/s10882-008-9105-9; Lancioni Giulio E, 2005, Cogn Process, V6, P177, DOI 10.1007/s10339-005-0003-0; Lancioni GE, 2009, DEV NEUROREHABIL, V12, P24, DOI 10.1080/17518420902776995; Lancioni GE, 2009, RES DEV DISABIL, V30, P1034, DOI 10.1016/j.ridd.2009.02.006; Leong B, 2002, BRAIN INJURY, V16, P217, DOI 10.1080/02699050110103283; Lombardi F, 2007, FUNCT NEUROL, V22, P47; Mcnaughton D, 2007, AUGMENT ALTERN COMM, V23, P217, DOI 10.1080/07434610701573856; Naude K, 2005, NEUROPSYCHOL REHABIL, V15, P514, DOI 10.1080/09602010443000470; Noda R, 2004, BRAIN INJURY, V18, P509, DOI 10.1080/02699050310001645810; Petry K, 2005, J APPL RES INTELLECT, V18, P35, DOI 10.1111/j.1468-3148.2004.00209.x; Siegel S., 1988, NONPARAMETRIC STAT; Tsuchiya N, 2007, TRENDS COGN SCI, V11, P158, DOI 10.1016/j.tics.2007.01.005; Wales L., 2005, BRIT J OCCUPATIONAL, V68, P486; Wilson FC, 2007, DISABIL REHABIL, V29, P1751, DOI 10.1080/09638280601118432	38	21	21	2	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0891-4222			RES DEV DISABIL	Res. Dev. Disabil.	NOV-DEC	2009	30	6					1459	1467		10.1016/j.ridd.2009.07.006			9	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	511ZT	WOS:000271212100038	19660902				2021-06-18	
J	Radomski, MV; Davidson, L; Voydetich, D; Erickson, MW				Radomski, Mary Vining; Davidson, Leslie; Voydetich, Deborah; Erickson, Mary W.			Occupational Therapy for Service Members With Mild Traumatic Brain Injury	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						brain injuries; evidence-based practice; military personnel; occupational therapy; physical therapy; practice guidelines	POSTTRAUMATIC-STRESS-DISORDER; SELF-IDENTIFIED GOALS; HEAD-INJURY; COGNITIVE REHABILITATION; SYMPTOMS; ADULTS; ACHIEVEMENT; AFGHANISTAN; GUIDELINES; AWARENESS	More occupational therapists are needed to provide client-centered, evidence-based rehabilitation to the large numbers of service members who sustained mild traumatic brain injury (mTBI) while deployed in Afghanistan and Iraq. The Proponency for Rehabilitation and Reintegration tasked a team of occupational and physical therapists to assemble evidence-based best practices specific to mTBI. Despite the fact that evidence-based reviews, guidelines, and research regarding occupational therapy for mTBI are sparse, the team developed the Clinical Practice Guidance: Occupational Therapy and Physical Therapy for Mild Traumatic Brain Injury. Occupational therapy practice recommendations specific to client education, vision, cognition, resumption of roles, and emotional well-being are summarized for civilians and characterized as practice standards or practice options. By using evidence-informed and holistic services, occupational therapists have the potential to lead rehabilitation and reintegration efforts for service members with mTBI and advance changes in the profession itself.	[Davidson, Leslie] Shenandoah Univ, Winchester, VA USA; [Voydetich, Deborah] Dept Vet Affairs Med Ctr, Polytrauma Transit Rehabil Program, Minneapolis, MN USA; [Erickson, Mary W.] Off Surg Gen, Reintegrat Branch, Proponency Off Rehabil & Reintegrat, Falls Church, VA USA		mary.radomski@allina.com					Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Occupational Therapy Association, 2008, AM J OCCUPATIONAL TH, V62, P625, DOI DOI 10.5014/AJOT.62.6.625; Baron K., 2006, USERS MANUAL OCCUPAT; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; BROWN M, 2006, INTRO PARTICIPATION; BRYAN VL, 2004, TRAUMATIC BRAIN INJU, P455; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen A H, 1992, J Am Optom Assoc, V63, P530; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; *DEF VET BRAIN INJ, 2006, DVBIC WORK GROUP AC; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DOUGHERTY PM, 1993, COGNITIVE REHABILITA; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Eriksson Gunilla, 2005, Scand J Occup Ther, V12, P40, DOI 10.1080/11038120510027630; Fleming JM, 1996, BRAIN INJURY, V10, P1; Forsyth K.A., 1999, BRIT J OCCUPATIONAL, V62, P69, DOI DOI 10.1177/030802269906200208; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Gerardi S. M., 2004, US ARMY MED DEP J, P20; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hedlund, 1999, WORK, V12, P71; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jackson George L, 2008, N C Med J, V69, P43; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Law M., 1994, CANADIAN OCCUPATIONA; MALEC J, 2005, INTRO MAYO PORTLAND; MAPLES WC, 1995, NO STATE U COLL OPTO; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McColl MA, 2002, AM J OCCUP THER, V56, P350, DOI 10.5014/ajot.56.3.350; Michel J A, 2006, Eura Medicophys, V42, P59; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; MORTERA M, 2004, DEV COGNITIVE SCREEN; MORTERA M, 2006, PHYS DISABILITIES SP, V29, P1; Myers CS, 1915, LANCET, V1, P316; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; PADULA W, 2007, BRAIN INJURY MED, P511; PADULA WV, 1994, BRAIN INJURY, V8, P125, DOI 10.3109/02699059409150964; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PRIGATANO GP, 1991, AWARENESS DEFICITS B; RADOMSKI MV, 1995, AM J OCCUP THER, V49, P487, DOI 10.5014/ajot.49.6.487; RADOMSKI MV, 2008, OCCUPATIONAL THERAPY, P748; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Scheiman M., 2002, UNDERSTANDING MANAGI; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Stein F, 2001, WORK, V17, P235; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Toglia J. P., 2005, COGNITION OCCUPATION, P29; Toglia JP, 1993, CONTEXTUAL MEMORY TE; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; *US DEP DEF, 2007, TRAUM BRAIN INJ DEF; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warren M., 1998, BRAIN INJURY VISUAL; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Zasler N, 2007, BRAIN INJURY MED PRI; Zoltan B, 2007, VISION PERCEPTION CO, V4th	76	21	21	1	17	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2009	63	5			SI		646	655		10.5014/ajot.63.5.646			10	Rehabilitation	Rehabilitation	493SG	WOS:000269757700016	19785265				2021-06-18	
J	Venturi, L; Miranda, M; Selmi, V; Vitali, L; Tani, A; Margheri, M; De Gaudio, AR; Adembri, C				Venturi, Luna; Miranda, Marco; Selmi, Valentina; Vitali, Luca; Tani, Alessia; Margheri, Martina; De Gaudio, Angelo Raffaele; Adembri, Chiara			Systemic Sepsis Exacerbates Mild Post-Traumatic Brain Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; glial cell response to injury; inflammation; secondary insult; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CECAL LIGATION; EXPERIMENTAL-MODELS; ANIMAL-MODELS; MICROGLIA; MEMORY; DEFICITS; PUNCTURE; CNS; COMPLICATIONS	The development of sepsis in patient suffering from traumatic brain injury (TBI) represents a frequent complication that has been associated with worsened global and neurological outcome. In an effort to better characterize the influence of sepsis following TBI, we developed an in vivo model of combined TBI and sepsis in the rat by coupling two validated models: (1) Controlled Cortical Impact (CCI) and (2) Cecal Ligation and Puncture (CLP). Possible contributing effects of sepsis on post-traumatic outcome were evaluated as mortality rate, body weight change, neurological motor (beam balance), cognitive (Morris water maze [MWM] for memory and learning) function, histopathological damage (lesion volume, cell counts in the CA1 and CA3 hippocampal areas), and morphological indices of inflammation (activated microglia and astrocytes) for the 14-day study period. In this study, we produced a mild TBI characterized by a low mortality rate, a transient delay in weight gain, and a transient impairment in motor and cognitive functions. The histological counterpart was represented by a cortical lesion in the area of impact at 14 days post-injury, associated with cell loss in the CA1 and CA3 hippocampal regions, and scarce infiltration of microglia. The superimposition of sepsis on this mild TBI model resulted in worsening of post-injury mortality and weight loss, significant exacerbation of post-injury motor deficit and cognitive impairments, and further exacerbation of neuronal cell death in the CA3 area together with over-expression and activation of microglial cells in the peri-lesional area. Altogether, our findings indicate that sepsis, when superimposed on TBI, exerts a negative effect on the evolution of post-traumatic damage.	[Venturi, Luna; Miranda, Marco; Selmi, Valentina; Vitali, Luca; De Gaudio, Angelo Raffaele; Adembri, Chiara] Univ Florence, Crit Care Dept, Sect Anesthesiol & IC, I-50134 Florence, Italy; [Tani, Alessia; Margheri, Martina] Univ Florence, Dept Anat Histol & Forens Med, I-50134 Florence, Italy	Adembri, C (corresponding author), Univ Florence, Crit Care Dept, Sect Anesthesiol & IC, Viale Morgagni 85, I-50134 Florence, Italy.	chiara.adembri@unifi.it			University of Florence; Ente Cassa di Risparmio di FirenzeFondazione Cassa Risparmio Firenze	We thank D. M. Morales for the initial setup of the CCI device and Prof. T. K. McIntosh for helpful discussion and suggestions. This work was partly supported by a University of Florence grant to C. A. The CCI device was purchased with a "Ente Cassa di Risparmio di Firenze'' grant.	Ashman TA, 2006, MT SINAI J MED, V73, P999; Bae JS, 2005, WORLD J GASTROENTERO, V11, P810, DOI 10.3748/wjg.v11.i6.810; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96; Brooks HF, 2007, METAB BRAIN DIS, V22, P353, DOI 10.1007/s11011-007-9058-1; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Danton GH, 2004, AM J NEURORADIOL, V25, P181; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Fabregas N, 2002, Minerva Anestesiol, V68, P285; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GEHRMANN J, 1994, NEUROPATH APPL NEURO, V20, P180; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hoover L, 2006, J TRAUMA, V61, P310, DOI 10.1097/01.ta.0000229052.75460.c2; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Maier S, 2004, SHOCK, V21, P505, DOI 10.1097/01.shk.0000126906.52367.dd; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Messaris E, 2004, CRIT CARE MED, V32, P1764, DOI 10.1097/01.CCM.0000135744.30137.B4; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nau R, 2004, NEUROLOGY, V62, P509, DOI 10.1212/01.WNL.0000106826.82670.30; Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F; Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Semmler A, 2007, EXP NEUROL, V204, P733, DOI 10.1016/j.expneurol.2007.01.003; Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x; Singleton KD, 2003, EUR SURG RES, V35, P486, DOI 10.1159/000073387; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Streck EL, 2008, NEUROCHEM RES, V33, P2171, DOI 10.1007/s11064-008-9671-3; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Walley ER, 1996, INFECT IMMUN, V64, P4733, DOI 10.1128/IAI.64.11.4733-4738.1996; Zygun D, 2005, CURR OPIN CRIT CARE, V11, P139, DOI 10.1097/01.ccx.0000155356.86241.c0	48	21	24	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1547	1556		10.1089/neu.2008.0723			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200011	19257801				2021-06-18	
J	Turkoglu, OF; Eroglu, H; Okutan, O; Gurcan, O; Bodur, E; Sargon, MF; Oner, L; Beskonakli, E				Turkoglu, Omer Faruk; Eroglu, Hakan; Okutan, Ozerk; Gurcan, Oktay; Bodur, Ebru; Sargon, Mustafa F.; Oener, Levent; Beskonakli, Etem			Atorvastatin efficiency after traumatic brain injury in rats	SURGICAL NEUROLOGY			English	Article						Atorvastatin; Brain edema; Traumatic brain injury; Lipid peroxidation	DEXAMETHASONE SODIUM-PHOSPHATE; NERVOUS-SYSTEM; NITRIC-OXIDE; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; BLOOD-FLOW; STROKE; SUPEROXIDE; MECHANISMS; STATINS	Background: The neuroprotective effects of statins possibly depend on their pleiotropic effect such as antioxidative and anti-inflammatory properties. In this study, we have evaluated the efficiency of atorvastatin on brain edema, lipid peroxidation, and ultrastructural changes in TBI animal model. Methods: Modified Feeney method has been used for the trauma model in rats. Only craniectomy for group A and trauma after craniectomy for group B was the procedure for animals. For the trauma, rods weighing 24 g were dropped on a foot plate just over the dura. Atorvastatin (1 mg/kg, IP) was administered to the animals in group C after craniectomy and trauma; but on the other hand, animals in group D received only 0.5 mL PEG as the vehicle. Brains were harvested 24 hours after the trauma for the assays of wet-dry weight, lipid peroxidation level, and ultrastructural investigations. Lipid peroxidation levels, TEM, and UNGS were the investigated parameters. The statistical comparisons between the groups were investigated by 1-way ANOVA and post hoc analysis by Duncan and Dunnett T3 test within the groups at the significance level P = .05. Results: Trauma increased water contents of the brain tissues and lipid peroxidation levels in groups B and D. When compared with the results of group B (brain edema, 84.694% +/- 1.510%; lipid peroxidation, 74.932 +/- 2.491 nmol/g tissue), atorvastatin (1 mg/kg) significantly decreased brain edema (77.362% +/- 1.448%), lipid peroxidation level (58.335 +/- 3.980 nmol/g tissue), and UNGS scores in group C (P < 0.05). Conclusion: In this descriptive study, the remarkable improvements of atorvastatin on brain edema, lipid peroxidation, and ultrastructural investigations encouraged us for a further dose optimization study. (C) 2009 Elsevier Inc. All rights reserved.	[Turkoglu, Omer Faruk; Okutan, Ozerk; Beskonakli, Etem] Ankara Ataturk Res & Educ Hosp, Dept Neurol Surg, TR-06800 Ankara, Turkey; [Eroglu, Hakan; Oener, Levent] Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06100 Ankara, Turkey; [Gurcan, Oktay] Ankara Numune Training & Res Hosp, Dept Neurol Surg, TR-06100 Ankara, Turkey; [Bodur, Ebru] Hacettepe Univ, Fac Med, Dept Biochem, TR-06100 Ankara, Turkey; [Sargon, Mustafa F.] Hacettepe Univ, Fac Med, Dept Anat, TR-06100 Ankara, Turkey	Turkoglu, OF (corresponding author), Ankara Ataturk Res & Educ Hosp, Dept Neurol Surg, TR-06800 Ankara, Turkey.	ofturkoglu@yahoo.com	BODUR, EBRU/I-8382-2013; EROGLU, HAKAN/J-1040-2013; BODUR, EBRU/AAR-8545-2020; ONER, LEVENT/J-1032-2013	BODUR, EBRU/0000-0001-5829-5487; BODUR, EBRU/0000-0001-5829-5487; ONER, LEVENT/0000-0002-6510-7680; Sargon, Mustafa Fevzi/0000-0001-6360-6008; Eroglu, Hakan/0000-0001-6361-0074			BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Blanco M, 2007, NEUROLOGY, V69, P904, DOI 10.1212/01.wnl.0000269789.09277.47; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Buttmann M, 2007, J NEUROCHEM, V102, P1001, DOI 10.1111/j.1471-4159.2007.04563.x; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Cottrell JR, 2000, J NEUROPHYSIOL, V84, P1573; Eroglu H, 2001, J MICROENCAPSUL, V18, P603; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; Hayashi T, 2005, BRAIN RES, V1037, P52, DOI 10.1016/j.brainres.2004.12.051; Hong H, 2006, AM J PHYSIOL-HEART C, V291, pH2210, DOI 10.1152/ajpheart.01270.2005; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kuipers HF, 2007, BIOMED PHARMACOTHER, V61, P400, DOI 10.1016/j.biopha.2007.06.005; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lipton SA, 2007, CURR DRUG TARGETS, V8, P621, DOI 10.2174/138945007780618472; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; MAXWELL RE, 1971, J NEUROSURG, V34, P477, DOI 10.3171/jns.1971.34.4.0477; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Riad A, 2007, EUR J PHARMACOL, V569, P204, DOI 10.1016/j.ejphar.2007.04.065; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Sparks D L, 2002, J Nutr Health Aging, V6, P324; Tsubokawa T, 2007, STROKE, V38, P1057, DOI 10.1161/01.STR.0000257978.70312.1d; Turkoglu OF, 2008, J CLIN NEUROSCI, V15, P60, DOI 10.1016/j.jocn.2007.03.005; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; WEI EP, 1986, AM J PHYSIOL, V251, pH693; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zacco A, 2003, J NEUROSCI, V23, P11104	39	21	22	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	AUG	2009	72	2					146	152		10.1016/j.surneu.2008.07.004			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	481CY	WOS:000268785900008	18786717				2021-06-18	
J	Walker, PA; Harting, MT; Baumgartner, JE; Fletcher, S; Strobel, N; Cox, CS				Walker, Peter A.; Harting, Matthew T.; Baumgartner, James E.; Fletcher, Stephen; Strobel, Nathan; Cox, Charles S., Jr.			Modern Approaches to Pediatric Brain Injury Therapy	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	National Summit on Pediatric Disaster and Emergency Services	SEP 11-12, 2008	Los Angeles, CA	Eastern Assoc Surg Trauma, Trauma Assoc Canada, Western Trauma Assoc		Traumatic brain injury; Treatment; Therapy; Stem cells; Progenitor cells; Hypothermia; Hypertonic saline; Review	MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; HYPERTONIC SALINE; CEREBROSPINAL-FLUID; HEAD-INJURY; HEMORRHAGIC-SHOCK; OXIDATIVE DAMAGE; LACTATED RINGERS; MOUSE MODEL; TIME-COURSE	Each year, pediatric traumatic brain injury (TBI) accounts for 435,000 emergency department visits, 37,000 hospital admissions, and approximately 2,500 deaths in the United States. TBI results in immediate injury from direct mechanical force and shear. Secondary injury results from the release of biochemical or inflammatory factors that alter the loco-regional milieu in the acute, subacute, and delayed intervals after a mechanical insult. Preliminary preclinical and clinical research is underway to evaluate the benefit from progenitor cell therapeutics, hypertonic saline infusion, and controlled hypothermia. However, all phase III clinical trials investigating pharmacologic monotherapy for TBI have shown no benefit. A recent National Institutes of Health consensus statement recommends research into multimodality treatments for TBI. This article will review the complex pathophysiology of TBI as well as the possible therapeutic mechanisms of progenitor cell transplantation, hypertonic saline infusion, and controlled hypothermia for possible utilization in multimodality clinical trials.	[Walker, Peter A.; Harting, Matthew T.; Baumgartner, James E.; Fletcher, Stephen; Cox, Charles S., Jr.] Univ Texas Houston, Sch Med, Dept Pediat Surg, Houston, TX 77030 USA; [Strobel, Nathan] Childrens Mem Hermann Hosp, Dept Pediat, Houston, TX USA	Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat Surg, 6431 Fannin St,MSB 5-234, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558, UL1RR024148] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR02558, M01 RR002558, UL1 RR024148-03] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [N01 HB037163, P018/N01 HB 37163] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008792, T32 GM 08 79201] Funding Source: Medline		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Aguilar S, 2007, STEM CELLS, V25, P1586, DOI 10.1634/stemcells.2006-0762; Baker KS, 2003, J CLIN ONCOL, V21, P1352, DOI 10.1200/JCO.2003.05.108; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bing Mei, 2007, Chin J Traumatol, V10, P263; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Froehler MT, 2007, J NEUROL SCI, V261, P118, DOI 10.1016/j.jns.2007.04.042; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Harada K, 2002, J NEUROSCI RES, V67, P664, DOI 10.1002/jnr.10159; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; *HLTH NIO, 2008, COMB THER TRAUM BRAI; Holzer M, 2002, NEW ENGL J MED, V346, P549; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Inamasu J, 2001, NEUROL RES, V23, P105, DOI 10.1179/016164101101198217; Infanti JL, 2008, J NEUROSCI NURS, V40, P362, DOI 10.1097/01376517-200812000-00009; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kim JM, 2007, BRAIN RES, V1183, P43, DOI 10.1016/j.brainres.2007.09.005; Lampl C, 2002, EUR NEUROL, V47, P3, DOI 10.1159/000047939; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lansman SL, 1999, ANN THORAC SURG, V67, P1975, DOI 10.1016/S0003-4975(99)00419-1; LAPTOOK AR, 1995, STROKE, V26, P1240, DOI 10.1161/01.STR.26.7.1240; LAPTOOK AR, 1995, PEDIATR RES, V38, P919, DOI 10.1203/00006450-199512000-00015; Lei BP, 1997, NEUROSCI LETT, V222, P91, DOI 10.1016/S0304-3940(97)13349-3; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Maeda H, 2007, THER APHER DIAL, V11, P309, DOI 10.1111/j.1744-9987.2007.00469.x; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; McCullough JN, 1999, ANN THORAC SURG, V67, P1895, DOI 10.1016/S0003-4975(99)00441-5; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; MOSS GS, 1988, AM J SURG, V155, P425, DOI 10.1016/S0002-9610(88)80106-5; Nonaka M, 1998, J NEUROL SCI, V157, P25, DOI 10.1016/S0022-510X(98)00062-8; Noppens R, 2004, EXP TOXICOL PATHOL, V56, P113, DOI 10.1016/j.etp.2004.04.005; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Pinto FCG, 2006, J TRAUMA, V60, P758, DOI 10.1097/01.ta.0000214581.89316.73; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qu RJ, 2007, NEUROPATHOLOGY, V27, P355, DOI 10.1111/j.1440-1789.2007.00792.x; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Samant UB, 2008, J NEUROTRAUM, V25, P495, DOI 10.1089/neu.2007.0491; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Wallace GQ, 2008, AM J PATHOL, V173, P792, DOI 10.2353/ajpath.2008.080259; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; Weiner Leslie P., 2008, V438, P3, DOI 10.1007/978-1-59745-133-8_1; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	87	21	22	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2009	67	2		S			S120	S127		10.1097/TA.0b013e3181ad323a			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	482OM	WOS:000268898600015	19667844	Green Accepted			2021-06-18	
J	Yao, CP; Williams, AJ; Ottens, AK; Lu, XCM; Liu, MC; Hayes, RL; Wang, KK; Tortella, FC; Dave, JR				Yao, Changping; Williams, Anthony J.; Ottens, Andrew K.; Lu, X. -C. May; Liu, Ming Cheng; Hayes, Ronald L.; Wang, Kevin K.; Tortella, Frank C.; Dave, Jitendra R.			P43/pro-EMAPII: A Potential Biomarker for Discriminating Traumatic Versus Ischemic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury biomarkers; diagnostic biomarker; middle cerebral artery occlusion; penetrating ballistic-like brain injury; protein expression	TRANSFER-RNA SYNTHETASE; POLYPEPTIDE-II; EMAP-II; PROINFLAMMATORY CYTOKINE; LESIONAL EXPRESSION; P43; RAT; CELLS; ACCUMULATION; MONOCYTES	To gain additional insights into the pathogenic cellular and molecular mechanisms underlying different types of brain injury (e. g., trauma versus ischemia), recently attention has focused on the discovery and study of protein biomarkers. In previous studies, using a high-throughput immunoblotting (HTPI) technique, we reported changes in 29 out of 998 proteins following acute injuries to the rat brain (penetrating traumatic versus focal ischemic). Importantly, we discovered that one protein, endothelial monocyte-activating polypeptide II precursor (p43/pro-EMAPII), was differentially expressed between these two types of brain injury. Among other functions, p43/pro-EMAPII is a known pro-inflammatory cytokine involved in the progression of apoptotic cell death. Our current objective was to verify the changes in p43/pro-EMAPII expression, and to evaluate the potentially important implications that the differential regulation of this protein has on injury development. At multiple time points following either a penetrating ballistic-like brain injury (PBBI), or a transient middle cerebral artery occlusion (MCAo) brain injury, tissue samples (6-72 h), CSF samples (24 h), and blood samples (24 h) were collected from rats for analysis. Changes in protein expression were assessed by Western blot analysis and immunohistochemistry. Our results indicated that p43/pro-EMAPII was significantly increased in brain tissues, CSF, and plasma following PBBI, but decreased after MCAo injury compared to their respective sham control samples. This differential expression of p43/pro-EMAPII may be a useful injury-specific biomarker associated with the underlying pathologies of traumatic versus ischemic brain injury, and provide valuable information for directing injury-specific therapeutics.	[Dave, Jitendra R.] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, Silver Spring, MD 20910 USA; [Ottens, Andrew K.] Virginia Commonwealth Univ, Richmond, VA USA; [Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Wang, Kevin K.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Liu, Ming Cheng; Hayes, Ronald L.; Wang, Kevin K.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA	Dave, JR (corresponding author), Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	jit.dave@amedd.army.mil	Dave, Jitendra R/A-8940-2011; Ottens, Andrew/K-3352-2012	Wang, Kevin/0000-0002-9343-6473; Ottens, Andrew/0000-0002-2118-3796	Department of DefenseUnited States Department of Defense [DAMD-03-1-0066]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS04917501-A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER	The authors thank Mrs. Christine Murphy for her critical comments and suggestions for improving the manuscript. The authors thank Mr. Zhilin Liao, Ms. Xiaofang Yang, S. P. C. Monika Torres, and SPC Franco Antinia for their excellent technical assistance in these studies. The authors would also like to acknowledge the support of Department of Defense grant DAMD-03-1-0066, and NIH grant R01NS04917501-A1.	Bate C, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-5; Brabeck C, 2002, EXP NEUROL, V177, P341, DOI 10.1006/exnr.2002.7985; Chen RW, 2003, J NEUROCHEM, V84, P566, DOI 10.1046/j.1471-4159.2003.01548.x; HORSSEN RV, 2006, CYTOKINE GROWTH F R, V17, P339; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Ko YG, 2001, J BIOL CHEM, V276, P23028, DOI 10.1074/jbc.M101544200; Liu J, 2006, EXP CELL RES, V312, P2231, DOI 10.1016/j.yexcr.2006.03.024; Matschurat S, 2003, AM J PATHOL, V162, P93, DOI 10.1016/S0002-9440(10)63801-1; Mueller CA, 2003, J NEUROTRAUM, V20, P1007, DOI 10.1089/089771503770195858; Mueller CA, 2003, NEUROSCI LETT, V339, P215, DOI 10.1016/S0304-3940(03)00024-7; Mueller CA, 2003, J NEUROIMMUNOL, V135, P1, DOI 10.1016/S0165-5728(02)00427-7; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Murray JC, 2004, J IMMUNOL, V172, P274, DOI 10.4049/jimmunol.172.1.274; Park SG, 2005, AM J PATHOL, V166, P387, DOI 10.1016/S0002-9440(10)62262-6; Park SG, 2002, J BIOL CHEM, V277, P45243, DOI 10.1074/jbc.M207934200; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; WEI G, 2008, 38 ANN M SOC NEUR; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Won SJ, 2002, J BIOCHEM MOL BIOL, V35, P67, DOI 10.5483/BMBRep.2002.35.1.067; Yao C, 2005, LIFE SCI, V77, P1116, DOI 10.1016/j.lfs.2005.02.008; Yao CP, 2008, BRAIN INJURY, V22, P723, DOI 10.1080/02699050802304706; Zhang ZY, 2007, J CELL MOL MED, V11, P307, DOI 10.1111/j.1582-4934.2007.00019.x	28	21	23	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1295	1305		10.1089/neu.2008.0811			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900012	19317603	Green Published			2021-06-18	
J	Solmaz, I; Kural, C; Temiz, C; Secer, HI; Duz, B; Gonul, E; Izci, Y				Solmaz, Iiker; Kural, Cahit; Temiz, Caglar; Secer, Halil Ibrahim; Duz, Buelent; Gonul, Engin; Izci, Yusuf			Traumatic Brain Injury Due To Gunshot Wounds: A Single Institution's Experience With 442 Consecutive Patients	TURKISH NEUROSURGERY			English	Article						Traumatik brain injury; Gunshot wounds; Surgery; Prognosis; Brain injury	PENETRATING CRANIOCEREBRAL INJURIES; HEAD-INJURY; POSTTRAUMATIC EPILEPSY; RETROSPECTIVE ANALYSIS; MISSILE INJURIES; VIETNAM; IRAQ; WAR; INFECTIONS; MANAGEMENT	AIM: Traumatic brain injury (TBI) caused by a gunshot wound is a complex injury with a broad spectrum of symptoms and high rates of mortality and morbidity. This study presents an evaluation of TBI caused by gunshot Wounds presenting at a single institution and discusses possible predictive factors for the outcome of surgical intervention. MATERIAL and METHODS: The study sample consisted of 442 patients who underwent surgery for TBI over a 16-year period. All injuries were caused by gunshot wounds, Such as bullets and shrapnel. All patients underwent Surgical intervention. RESULTS: Almost all patients (99.3%) were male, and the mean patient age was 22.3 years. Wounds were caused by shrapnel in 68 percent of patients. The Glasgow Coma Scale (GCS) score at admission was below 8 in 116 patients (26.2%,=) and above 8 in 326 patients (73.8%). In total, 47 patients (10.6%) died despite surgical management, with diffuse brain injury the most common cause of death. CONCLUSION: Low GCS scores, ventricular injuries and bihemispheric injuries are correlated with poor Prognosis. Early and less invasive surgery in conjunction with short transportation time to the hospital could decrease mortality rates.	[Solmaz, Iiker; Kural, Cahit; Temiz, Caglar; Secer, Halil Ibrahim; Duz, Buelent; Gonul, Engin; Izci, Yusuf] Gulhane Mil Med Acad, Dept Neurosurg, Ankara, Turkey	Izci, Y (corresponding author), Gulhane Mil Med Acad, Dept Neurosurg, Ankara, Turkey.	yusufizci@yahoo.com	DUZ, Bulent/F-6772-2011				AARABI B, 1989, NEUROSURGERY, V25, P923, DOI 10.1227/00006123-198912000-00011; Aarabi B, 2003, NEUROSURG QUART, V13, P87, DOI 10.1097/00013414-200306000-00004; Aarabi Bizhan, 2001, Journal of Trauma Injury Infection and Critical Care, V51, pS1; ADAMS G, TRAUMATIC BRAIN INJU; Allen MB, 1995, ESSENTIALS NEUROSURG; [Anonymous], TRAUMATIC BRAIN INJU; Bakir A, 2005, NEUROL MED-CHIR, V45, P281, DOI 10.2176/nmc.45.281; Bayston R, 2000, LANCET, V355, P1813, DOI 10.1016/S0140-6736(00)02275-3; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAREY ME, 1972, SURG GYNECOL OBSTETR, V135, P386; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; COOPER PR, 1979, NEUROSURGERY, V4, P373, DOI 10.1227/00006123-197905000-00001; Erdogan E, 2004, MIL MED, V169, P691, DOI 10.7205/MILMED.169.9.691; Erdogan E, 2002, NEUROSURG QUART, V12, P1, DOI 10.1097/00013414-200203000-00001; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; Gonul E, 1999, MINIM INVAS NEUROSUR, V42, P207, DOI 10.1055/s-2008-1053401; GONUL E, 1999, TURKISH NEUROSURGERY, V9, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Izci Y, 2005, EMERG MED J, V22, P409, DOI 10.1136/emj.2004.014704; Izci Y, 2003, TOHOKU J EXP MED, V201, P39, DOI 10.1620/tjem.201.39; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KENNEDY K, 2007, TRAUMATIC BRAIN INJU; KIM PE, 1995, NEUROSURG CLIN N AM, V6, P669; LEVY ML, 1993, NEUROSURGERY, V33, P1018; Liebenberg WA, 2005, NEUROSURGERY, V57, P293, DOI 10.1227/01.NEU.0000166662.77797.EC; MATSON DD, 1981, J NEUROSURG, V54, P44; Meirowsky A., 1965, NEUROLOGICAL SURGERY, P103; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Secer HI, 2007, ACTA NEUROCHIR, V149, P777, DOI 10.1007/s00701-007-1236-8; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; STRICH SJ, 1961, LANCET, V2, P443; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; TSAI FY, 1978, J COMPUT ASSIST TOMO, V2, P323, DOI 10.1097/00004728-197807000-00018; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; Xiong Y, 2001, HEAD TRAUMA, P257; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; ZIMMERMAN RA, 1978, RADIOLOGY, V174, P393	42	21	23	1	1	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	JUL	2009	19	3					216	223					8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	476PQ	WOS:000268455100002	19621284				2021-06-18	
J	Thompson, HJ				Thompson, Hilaire J.			A Critical Analysis of Measures of Caregiver and Family Functioning Following Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE NURSING			English	Article							SOCIAL SUPPORT; PSYCHOLOGICAL DISTRESS; BURDEN; PREDICTORS; CARERS; NEEDS; TBI; SATISFACTION; INDIVIDUALS; APPRAISAL	More than 5.3 million Americans are living with long-term disability following traumatic brain injury (TBI), and approximately 40% of TBI survivors report at least one unmet need at 1 year postinjury. The totality of the problem of TBI may therefore put increased responsibilities on the significant other and the family. The purpose of this work was to conduct an integrative review of the literature to identify available instruments that might be useful to researchers and clinicians interested in the effects of TBI on family functioning. A review of the literature was undertaken using CINAHL Plus, Family Systems Abstracts, and PubMed from 1998 to 2008. Thirty-five articles were identified in the initial search, and 8 were excluded, leaving 27 articles for full review and analysis. Conceptual and methodological issues identified across the studies resulted in an inability to recommend any of the instruments used in the present studies for use without further study. The issues identified included a lack of conceptual framework for construct validity, variability in injury characteristics, issues with sampling methodology, a lack of longitudinal designs, comparison group issues, and an inability to compare instruments across studies.	Univ Washington, Seattle, WA 98195 USA	Thompson, HJ (corresponding author), Univ Washington, Seattle, WA 98195 USA.	hilairet@u.washington.edu			Building Geriatric Academic Nursing Capacity Program; John A. Hartford Foundation; National Institutes of Health Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [KL2RR025015-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000423] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR025015] Funding Source: NIH RePORTER	This work was funded in part by the Building Geriatric Academic Nursing Capacity Program, John A. Hartford Foundation, and the National Institutes of Health Roadmap for Medical Research (Grant KL2RR025015-01). The author thanks Dr. Karen Schepp for thoughtful discussions regarding this work.	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; *DEP HLTH HUM SERV, 2000, HLTH PEOPL 2010, V2; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Godfrey HPD, 2003, BRAIN INJURY, V17, P427, DOI 10.1080/0269905031000066201; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hopkins R., 2007, KINGSTON CAREGIVER S; Hutchison C, 1999, J ADV NURS, V29, P1520, DOI 10.1046/j.1365-2648.1999.01041.x; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lawton M., 1989, J GERONTOL, V44, P61, DOI [DOI 10.1093/GER0NJ/44.3.P61, 10.1093/geronj/44.3.P61]; Layman DE, 2005, BRAIN INJURY, V19, P909, DOI 10.1080/02699050500109928; Lazarus R.S., 1984, STRESS APPRAISAL COP; Man DWK, 2002, BRAIN INJURY, V16, P1025, DOI 10.1080/0269905021000010087; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Marwit SJ, 2006, BRAIN INJURY, V20, P1419, DOI 10.1080/02699050601082214; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Murray HM, 2006, BRAIN INJURY, V20, P575, DOI 10.1080/02699050600664590; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; *NAT CTR INJ PREV, 2002, INJ FACT BOOK; OREILLY P, 1988, SOC SCI MED, V26, P863, DOI 10.1016/0277-9536(88)90179-7; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rapport LJ, 2006, J HEAD TRAUMA REHAB, V21, P432, DOI 10.1097/00001199-200609000-00055; Sander AM, 2007, NEUROREHABILITATION, V22, P9; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Thornton M, 2003, J GERONTOL B-PSYCHOL, V58, pS127, DOI 10.1093/geronb/58.2.S127; Watanabe Y, 2001, DISABIL REHABIL, V23, P370; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	40	21	21	0	11	AMER ASSOC NEUROSCIENCE NURSES	GLENVIEW	4700 W LAKE AVENUE, GLENVIEW, IL 60025 USA	0888-0395			J NEUROSCI NURS	J. Neurosci. Nurs.	JUN	2009	41	3					148	158		10.1097/JNN.0b013e3181a23eda			11	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	516XK	WOS:000271576500005	19517765	Green Accepted			2021-06-18	
J	Levine, J; Greenwald, BD				Levine, Jaime; Greenwald, Brian D.			Fatigue in Parkinson Disease, Stroke, and Traumatic Brain Injury	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Fatigue; Traumatic brain injury; Parkinson disease; Stroke; Cerebrovascular accident; Post-stroke syndrome	QUALITY-OF-LIFE; EXCESSIVE DAYTIME SLEEPINESS; DOUBLE-BLIND; POSTSTROKE FATIGUE; AMBULATORY ACTIVITY; PHYSICAL FATIGUE; MILD STROKE; LONG-TERM; FOLLOW-UP; PLACEBO	Fatigue is a disabling symptom common to many neurologic conditions, including Parkinson disease, post-stroke syndromes, and traumatic brain injury. Fatigue in the neurologic population is defined differently from that in the general population, and this has implications for assessment, research, and treatment. A considerable amount of research has been done in recent years aiming to describe, quantify, and ultimately treat this problem. There are relatively few proven treatments for fatigue in these populations, but the mainstays of therapy can be divided into pharmacologic and nonpharmacologic approaches.	[Levine, Jaime] St Vincents Med Ctr, Dept Phys Med & Rehabil, New York, NY 10011 USA; [Greenwald, Brian D.] Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA	Levine, J (corresponding author), St Vincents Med Ctr, Dept Phys Med & Rehabil, 170 W 12th St,Link 103, New York, NY 10011 USA.	rehabdoc@mac.com					Alves G, 2004, NEUROLOGY, V63, P1908, DOI 10.1212/01.WNL.0000144277.06917.CC; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; BELZA BL, 1993, NURS RES, V42, P93; Borek LL, 2006, CNS SPECTRUMS, V11, P541, DOI 10.1017/S1092852900013560; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Buck D, 2004, CEREBROVASC DIS, V17, P143, DOI 10.1159/000075783; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carlsson GE, 2004, DISABIL REHABIL, V26, P1373, DOI 10.1080/09638280400000211; Carlsson GE, 2003, CEREBROVASC DIS, V16, P383, DOI 10.1159/000072561; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Choi-Kwon S, 2007, CEREBROVASC DIS, V23, P103, DOI 10.1159/000097045; Culbertson WC, 2004, ASSESSMENT, V11, P27, DOI 10.1177/1073191103258590; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FRIEDMAN J, 1993, NEUROLOGY, V43, P2016, DOI 10.1212/WNL.43.10.2016; Garber CE, 2003, NEUROLOGY, V60, P1119, DOI 10.1212/01.WNL.0000055868.06222.AB; Havlikova E, 2008, EUR J NEUROL, V15, P475, DOI 10.1111/j.1468-1331.2008.02103.x; Herlofson K, 2003, ACTA NEUROL SCAND, V107, P1, DOI 10.1034/j.1600-0404.2003.02033.x; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Jaracz K, 2007, NEUROL NEUROCHIR POL, V41, P36; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Karlsen K, 1999, MOVEMENT DISORD, V14, P237, DOI 10.1002/1531-8257(199903)14:2<237::AID-MDS1006>3.3.CO;2-O; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; Lou JS, 2003, MOVEMENT DISORD, V18, P1108, DOI 10.1002/mds.10505; Lou JS, 2001, MOVEMENT DISORD, V16, P190, DOI 10.1002/mds.1042; Lynch J, 2007, J PSYCHOSOM RES, V63, P539, DOI 10.1016/j.jpsychores.2007.08.004; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Mead G, 2007, STROKE, V38, P2090, DOI 10.1161/STROKEAHA.106.478941; Meindorfner C, 2005, MOVEMENT DISORD, V20, P832, DOI 10.1002/mds.20412; Mendonca DA, 2007, MOVEMENT DISORD, V22, P2070, DOI 10.1002/mds.21656; Michael K, 2007, TOP STROKE REHABIL, V14, P5, DOI 10.1310/tsr1402-5; Michael KM, 2006, REHABIL NURS, V31, P210, DOI 10.1002/j.2048-7940.2006.tb00137.x; Naess H, 2006, STROKE, V37, P1232, DOI 10.1161/01.STR.0000217652.42273.02; Nutt JG, 2007, ARCH NEUROL-CHICAGO, V64, P319, DOI 10.1001/archneur.64.3.319; Okun MS, 2006, ARCH NEUROL-CHICAGO, V63, P729, DOI 10.1001/archneur.63.5.729; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ondo WG, 2005, J NEUROL NEUROSUR PS, V76, P1636, DOI 10.1136/jnnp.2005.065870; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Oved D, 2006, MOVEMENT DISORD, V21, P1257, DOI 10.1002/mds.20929; Pucci E, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002818.pub2; Rahman S, 2008, MOVEMENT DISORD, V23, P1428, DOI 10.1002/mds.21667; Ripley DL, 2006, J HEAD TRAUMA REHAB, V21, P85, DOI 10.1097/00001199-200601000-00010; Rochester L, 2004, ARCH PHYS MED REHAB, V85, P1578, DOI 10.1016/j.apmr.2004.01.025; Rochester L, 2006, DISABIL REHABIL, V28, P1365, DOI 10.1080/09638280600638034; Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005; Shulman LM, 2001, MOVEMENT DISORD, V16, P507, DOI 10.1002/mds.1099; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Uc EY, 2006, NEUROLOGY, V67, P1774, DOI 10.1212/01.wnl.0000245086.32787.61; van de Port IGL, 2007, CEREBROVASC DIS, V23, P40, DOI 10.1159/000095757; van de Port IGL, 2006, STROKE, V37, P167, DOI 10.1161/01.STR.0000195180.69904.f2; VANHILTEN JJ, 1993, J NEURAL TRANSM-PARK, V5, P235; WELLS MR, 2003, FDN OSTEOPATHIC MED, P63; Zesiewicz TA, 2007, DISABIL REHABIL, V29, P1934, DOI 10.1080/09638280701257247; Zesiewicz Theresa A, 2006, Expert Rev Neurother, V6, P1811, DOI 10.1586/14737175.6.12.1811; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	63	21	21	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2009	20	2					347	+		10.1016/j.pmr.2008.12.006			16	Rehabilitation	Rehabilitation	450KC	WOS:000266398400006	19389616				2021-06-18	
J	Schmidt, B; Klingelhofer, J; Perkes, I; Czosnyka, M				Schmidt, Bernhard; Klingelhoefer, Juergen; Perkes, Iain; Czosnyka, Marek			Cerebral Autoregulatory Response Depends on the Direction of Change in Perfusion Pressure	JOURNAL OF NEUROTRAUMA			English	Article						cerebral autoregulation; cerebral blood flow; cerebral perfusion pressure; transcranial Doppler ultrasonography	BLOOD-PRESSURE; SPONTANEOUS FLUCTUATIONS; HEAD-INJURY; HUMANS; FLOW	The purpose of cerebral autoregulation is to keep cerebral blood flow constant during variations of cerebral perfusion pressure (CPP). Recently, the autoregulatory response was reported to be greater during arterial blood pressure (ABP) increase than during decrease following repeated induced changes in ABP in 14 brain-injured subjects. The goal of this study was to further investigate the asymmetry of autoregulation during spontaneous increases and decreases of CPP in a larger group of brain injury patients. Data recordings (N = 727) of CPP and cerebral blood flow velocity (CBFV) in 210 subjects with traumatic brain injury (TBI) were studied. Autoregulation was assessed using moving correlation indices (Mx) between CPP and CBFV. Periods of increasing and decreasing CPP were separately correlated to corresponding CBFV in order to assess autoregulatory responses to upward (upMx) and downward (downMx) changes of CPP. These correlation indices range from -1 to +1; negative or zero values indicate intact autoregulation, whereas positive values indicate impaired autoregulation. Only data with defined strong CPP variations were evaluated. Strong CPP variations were found in 84 recordings of 53 patients. On average (+/- SD) upMx was significantly lower than downMx (0.05 +/- 0.49 versus 0.14 +/- 0.54; p < 0.005). Despite this difference, upMx and downMx were strongly correlated with each other (R = 0.82; p < 0.001). In conclusion, the autoregulatory response was significantly greater during increase than during decrease in CPP. The results may indicate non-linear behavior of cerebral autoregulation.	[Schmidt, Bernhard; Klingelhoefer, Juergen] Chemnitz Med Ctr, Dept Neurol, D-09131 Chemnitz, Germany; [Perkes, Iain] Univ Cambridge, Dept Med, Div Anaesthesia, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Czosnyka, Marek] Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England	Schmidt, B (corresponding author), Chemnitz Med Ctr, Dept Neurol, Dresdner Str 178, D-09131 Chemnitz, Germany.	B.Schmidt@skc.de	Perkes, Iain/J-7001-2017	Perkes, Iain/0000-0001-8028-9032	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390] Funding Source: Medline; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aaslid R, 2007, STROKE, V38, P1465, DOI 10.1161/STROKEAHA.106.473462; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; DIEHL RR, 1989, STROKE, V20, P1; Enevoldsen E, 1986, Acta Neurochir Suppl (Wien), V36, P133; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; ENEVOLDSEN EM, 1977, ACTA NEUROL SCAND, V56, P514; Giller CA, 2003, MED ENG PHYS, V25, P633, DOI 10.1016/S1350-4533(03)00028-6; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; LASSEN NA, 1974, CIRC RES, V34, P749, DOI 10.1161/01.RES.34.6.749; LUNDBERG N, 1960, ACTA PSYCHIATRICA  S, V149, P1; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Schmidt B, 2000, J NEUROSURG, V92, P793, DOI 10.3171/jns.2000.92.5.0793; SHIGEMORI M, 1989, Neurological Research, V11, P165; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; ZABOLOTNY W, 1994, INTRACRANIAL PRESSUR, V9, P439; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zhang R, 2000, AM J PHYSIOL-HEART C, V278, pH1848	22	21	24	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					651	656		10.1089/neu.2008.0784			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500001	19281414				2021-06-18	
J	Chen-Roetling, J; Li, Z; Chen, M; Awe, OO; Regan, RF				Chen-Roetling, Jing; Li, Zhi; Chen, Mai; Awe, Olatilewa O.; Regan, Raymond F.			Heme oxygenase activity and hemoglobin neurotoxicity are attenuated by inhibitors of the MEK/ERK pathway	NEUROPHARMACOLOGY			English	Article						Cell culture; Free radical; Hemoglobin toxicity; Intracerebral hemorrhage; Mouse; Oxidative stress	SIGNAL-REGULATED KINASE; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; PROTEIN-KINASE; IN-VITRO; FOREBRAIN ISCHEMIA; TIN-MESOPORPHYRIN; NEURONS; INDUCTION	Hemoglobin breakdown produces an iron-dependent neuronal injury after experimental CNS hemorrhage that may be attenuated by heme oxygenase (HO) inhibitors. The HO enzymes are phosphoproteins that are activated by phosphorylation in vitro. While testing the effect of kinase inhibitors in cortical cell cultures, we observed that HO activity was consistently decreased by the MEK inhibitor U0126. The present study tested the hypothesis that MEK/ERK pathway inhibitors reduce HO activity and neuronal vulnerability to hemoglobin. The MEK inhibitors U0126 and SL327 and the ERK inhibitor FR180204 reduced baseline culture HO activity by 35-50%, without altering the activity of recombinant HO-1 or HO-2; negative control compounds U0124 and FR180289 had no effect. Hemoglobin exposure for 16 h produced widespread neuronal injury, manifested by release of 59.2 +/- 7.8% of neuronal lactate dehydrogenase and a twelve-fold increase in malondialdehyde; kinase inhibitors were highly protective. HO-1 induction after hemoglobin treatment was also decreased by U0126, SL327, and FR180204. These results suggest that reduction in HO activity may contribute to the protective effect of MEK and ERK inhibitors against heme-mediated neuronal injury. (C) 2009 Elsevier Ltd. All rights reserved.	[Chen-Roetling, Jing; Li, Zhi; Chen, Mai; Awe, Olatilewa O.; Regan, Raymond F.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA	Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,Thompson Bldg Room 239, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu	LI, Zhi/Q-4790-2018	LI, Zhi/0000-0003-4422-4914	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS050662]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050662] Funding Source: NIH RePORTER	Funding for this study was provided by a grant from the National Institutes of Health (NS050662).	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Benvenisti-Zarom L, 2006, NEUROSCI LETT, V398, P230, DOI 10.1016/j.neulet.2006.01.003; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen-Roetling J, 2008, CURR NEUROVASC RES, V5, P193, DOI 10.2174/156720208785425684; Chen-Roetling J, 2006, BIOCHEM BIOPH RES CO, V350, P233, DOI 10.1016/j.bbrc.2006.09.036; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Dennery PA, 2003, FREE RADICAL BIO MED, V34, P124, DOI 10.1016/S0891-5849(02)01295-9; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Geijsen N, 2000, FEBS LETT, V471, P83, DOI 10.1016/S0014-5793(00)01373-9; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Gong Y, 2006, ACTA NEUROCHIR SUPPL, V96, P232; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; Koeppen AH, 2002, J NEUROPATH EXP NEUR, V61, P689, DOI 10.1093/jnen/61.8.689; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; Kress GJ, 2002, J NEUROSCI, V22, P5848; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; Moos T, 2004, ANN NY ACAD SCI, V1012, P14, DOI 10.1196/annals.1306.002; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ohori M, 2005, BIOCHEM BIOPH RES CO, V336, P357, DOI 10.1016/j.bbrc.2005.08.082; Otani N, 2007, J CLIN NEUROSCI, V14, P42, DOI 10.1016/j.jocn.2005.11.044; Panahian N, 1999, J NEUROCHEM, V72, P1187; Parfenova H, 2008, CURR PHARM DESIGN, V14, P443, DOI 10.2174/138161208783597380; Qu Y, 2007, J NEUROSURG, V106, P428, DOI 10.3171/jns.2007.106.3.428; Regan RF, 1998, J NEUROCHEM, V70, P77; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; Salinas M, 2004, FEBS LETT, V578, P90, DOI 10.1016/j.febslet.2004.10.077; Saura J, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-26; Scherle PA, 2000, J BIOL CHEM, V275, P37086, DOI 10.1074/jbc.M006168200; Schipper HM, 2004, FREE RADICAL BIO MED, V37, P1995, DOI 10.1016/j.freeradbiomed.2004.09.015; Taketani S, 2005, TOHOKU J EXP MED, V205, P297, DOI 10.1620/tjem.205.297; Takizawa S, 1998, J CEREBR BLOOD F MET, V18, P559, DOI 10.1097/00004647-199805000-00011; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; Wang ZQ, 2004, BRAIN RES, V996, P55, DOI 10.1016/j.brainres.2003.09.074; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367	47	21	25	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2009	56	5					922	928		10.1016/j.neuropharm.2009.01.022			7	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	441MY	WOS:000265774500010	19371583	Green Accepted			2021-06-18	
J	Ornstein, TJ; Levin, HS; Chen, S; Hanten, G; Ewing-Cobbs, L; Dennis, M; Barnes, M; Max, JE; Logan, GD; Schachar, R				Ornstein, Tisha J.; Levin, Harvey S.; Chen, Shirley; Hanten, Gerri; Ewing-Cobbs, Linda; Dennis, Maureen; Barnes, Marcia; Max, Jeffrey E.; Logan, Gordon D.; Schachar, Russell			Performance monitoring in children following traumatic brain injury	JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY			English	Article						Performance monitoring; traumatic brain injury; children; head injury; neuropsychology; pediatrics	MEDIAL FRONTAL-CORTEX; CLOSED-HEAD INJURY; ANTERIOR CINGULATE; STOP-SIGNAL; RESPONSE-INHIBITION; SOCIAL OUTCOMES; MOTOR CONTROL; CONFLICT; COGNITION; RECOVERY	Executive control deficits are common sequelae of childhood traumatic brain injury (TBI). The goal of the current study was to assess a specific executive control function, performance monitoring, in children following TBI. Thirty-one children with mild-moderate TBI, 18 with severe TBI, and 37 control children without TBI, of comparable age and sex, performed the stop signal task, a speeded choice reaction time task. On occasion, they were presented with a signal to stop their responses. Performance monitoring was defined as the extent of slowing in go-task reaction time following failure to stop responses. The TBI group as a whole demonstrated less post-error slowing than did controls. This finding suggested impaired error monitoring performance. In addition, time since injury and socioeconomic status predicted less slowing after stopped responses. We suggest that alterations in performance monitoring expressed as the inability to notice, regulate and adjust behavior to changing situations are an effect of TBI in children.	[Chen, Shirley; Schachar, Russell] Hosp Sick Children, Dept Psychiat, Toronto, ON M5N 2L1, Canada; [Ornstein, Tisha J.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada; [Levin, Harvey S.; Hanten, Gerri] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Ctr, Houston, TX USA; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON M5N 2L1, Canada; [Barnes, Marcia] Univ Guelph, Guelph, ON N1G 2W1, Canada; [Max, Jeffrey E.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Max, Jeffrey E.] Childrens Hosp & Hlth Ctr, San Diego, CA USA; [Logan, Gordon D.] Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA	Schachar, R (corresponding author), Hosp Sick Children, Dept Psychiat, 555 Univ Ave, Toronto, ON M5N 2L1, Canada.	russell.schachar@sickkids.ca		Schachar, Russell/0000-0002-2015-4395; Logan, Gordon/0000-0002-8301-7726	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [M0P44070, NET 54016]; National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; Mental Health Research Fellowship, Department of Psychiatry, University of TorontoUniversity of Toronto; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grants from the Canadian Institutes of Health Research (M0P44070; NET 54016) and the National Institute of Neurological Diseases and Stroke (NS-21889). TO was supported by a Mental Health Research Fellowship, Department of Psychiatry, University of Toronto.	ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Bakker K, 1999, Pediatr Rehabil, V3, P149; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Chevrier AD, 2007, HUM BRAIN MAPP, V28, P1347, DOI 10.1002/hbm.20355; Christ SE, 2003, NEUROPSYCHOLOGY, V17, P171, DOI 10.1037/0894-4105.17.1.171; Coles MGH, 2001, BIOL PSYCHOL, V56, P173, DOI 10.1016/S0301-0511(01)00076-X; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Gehring WJ, 2000, PSYCHOL SCI, V11, P1, DOI 10.1111/1467-9280.00206; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kelly T P, 1999, Pediatr Rehabil, V3, P187; Kramer UM, 2007, J NEUROSCI, V27, P14190, DOI 10.1523/JNEUROSCI.4229-07.2007; Krusch DA, 1996, J ABNORM CHILD PSYCH, V24, P633, DOI 10.1007/BF01670104; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LOGAN GD, 1985, J EXP PSYCHOL LEARN, V11, P675, DOI 10.1037/0278-7393.11.1-4.675; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Logan Gordon D., 1994, P189; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; Nieuwenhuis S, 2002, COGN AFFECT BEHAV NE, V2, P19, DOI 10.3758/CABN.2.1.19; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; RABBITT P, 1977, Q J EXP PSYCHOL, V29, P727, DOI 10.1080/14640747708400645; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Ridderinkhof KR, 2004, BRAIN COGNITION, V56, P129, DOI 10.1016/j.bandc.2004.09.016; RYLANDER G, 1947, RES PUBLICATIONS ASS, P691; Schachar RJ, 2004, J ABNORM CHILD PSYCH, V32, P285, DOI 10.1023/B:JACP.0000026142.11217.f2; Scheffers MK, 2000, J EXP PSYCHOL HUMAN, V26, P141, DOI 10.1037/0096-1523.26.1.141; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Tarazi RA, 2007, REHABIL PSYCHOL, V52, P196, DOI 10.1037/0090-5550.52.2.196; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TOW PM, 1953, J NEUROL NEUROSUR PS, V16, P186, DOI 10.1136/jnnp.16.3.186; Ullsperger M, 2006, INT J PSYCHOPHYSIOL, V59, P59, DOI 10.1016/j.ijpsycho.2005.06.010; van Boxtel GJM, 2001, BIOL PSYCHOL, V58, P229, DOI 10.1016/S0301-0511(01)00117-X; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Wechsler D., 1991, MANUAL WECHSLER INTE; Wiersema JR, 2007, NEUROPSYCHOLOGIA, V45, P1649, DOI 10.1016/j.neuropsychologia.2007.01.004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92	61	21	21	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9630	1469-7610		J CHILD PSYCHOL PSYC	J. Child Psychol. Psychiatry	APR	2009	50	4					506	513		10.1111/j.1469-7610.2008.01997.x			8	Psychology, Developmental; Psychiatry; Psychology	Psychology; Psychiatry	424KB	WOS:000264564500016	19207625				2021-06-18	
J	Broomhall, LGJ; Clark, CR; McFarlane, AC; O'Donnell, M; Bryant, R; Creamer, M; Silove, D				Broomhall, Luke G. J.; Clark, C. Richard; McFarlane, Alexander C.; O'Donnell, Meagan; Bryant, Richard; Creamer, Mark; Silove, Derek			Early Stage Assessment and Course of Acute Stress Disorder After Mild Traumatic Brain Injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						Acute stress disorder; mild traumatic brain injury; posttraumatic stress disorder	POSTTRAUMATIC-STRESS; PSYCHOMETRIC PROPERTIES; PSYCHIATRIC MORBIDITY; HEAD-INJURY; CONSEQUENCES; ACCIDENTS; SCALE; PTSD	Although it has been established that acute stress disorder (ASD) and posttraumatic stress disorder occur after mild traumatic brain injury (MTBI) the qualitative differences in symptom presentation between injury survivors with and without a MTBI have not been explored in depth. This study aimed to compare the ASD and posttraumatic stress disorder symptom presentation of injury survivors with and without MTBI. One thousand one hundred sixteen participants between the ages of 17 to 65 years (mean age: 38.97 years, SD: 14.23) were assessed in the acute hospital after a traumatic injury. Four hundred seventy-five individuals met the criteria for MTBI. Results showed a trend toward higher levels of ASD in the MTBI group compared with the non-MTBI group. Those with a MTBI and ASD had longer hospital admissions and higher levels of distress associated with their symptoms. Although many of the ASD symptoms that the MTBI group scored significantly higher were also part of a postconcussive syndrome, higher levels of avoidance symptoms may suggest that this group is at risk for longer term poor psycho logical adjustment. Mild TBI patients may represent a injury group at risk for poor psychological adjustment after traumatic injury.	[Broomhall, Luke G. J.; Clark, C. Richard] Flinders Univ S Australia, Sch Psychol, Adelaide, SA 5001, Australia; [McFarlane, Alexander C.] Flinders Univ S Australia, Sch Psychiat, Adelaide, SA 5001, Australia; [O'Donnell, Meagan; Creamer, Mark] Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia; [Bryant, Richard; Silove, Derek] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Broomhall, LGJ (corresponding author), Flinders Univ S Australia, Sch Psychol, GPO Box 2100, Adelaide, SA 5001, Australia.	luke.broomhall@flinders.edu.au	clark, christopher richard/B-3525-2012; Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	National Health and Medical Research Council ProgramNational Health and Medical Research Council of Australia [300304]; Victorian Trauma Foundation [V- 11]; National Health and Medical Research Council Australian Clinical ResearchNational Health and Medical Research Council of Australia [359284]	Supported by a National Health and Medical Research Council Program Grant (300304), a Victorian Trauma Foundation grant (V- 11), and a National Health and Medical Research Council Australian Clinical Research Fellowship (359284).	American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blake DD, 1998, CLIN ADM PTSD SCALE; Bryant RA, 2005, PSYCHOL SCI, V16, P749, DOI 10.1111/j.1467-9280.2005.01608.x; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant Richard A, 2005, J Trauma Dissociation, V6, P5, DOI 10.1300/J229v06n02_02; Carty J, 2006, J AFFECT DISORDERS, V90, P257, DOI 10.1016/j.jad.2005.11.011; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; FAO EB, 1989, BEHAV THER, V20, P155; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rees R, 2005, INTERRUPTED LIVES RE; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schnyder U, 2001, AM J RESP CRIT CARE, V164, P653, DOI 10.1164/ajrccm.164.4.2008087; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029	27	21	23	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	MAR	2009	197	3					178	181		10.1097/NMD.0b013e318199fe7f			4	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	420BL	WOS:000264263300006	19282684				2021-06-18	
J	Hartig, W; Reichenbach, A; Voigt, C; Boltze, J; Bulavina, L; Schuhmann, MU; Seeger, J; Schusser, GF; Freytag, C; Grosche, J				Haertig, Wolfgang; Reichenbach, Andreas; Voigt, Cornelia; Boltze, Johannes; Bulavina, Larysa; Schuhmann, Martin U.; Seeger, Johannes; Schusser, Gerald F.; Freytag, Christiane; Grosche, Jens			Triple fluorescence labelling of neuronal, glial and vascular markers revealing pathological alterations in various animal models	JOURNAL OF CHEMICAL NEUROANATOMY			English	Article						Multiple fluorescence labelling; Potato lectin; Rat; Triple transgenic mouse; Horse small intestine; NeuN; HuC/D	FIBRILLARY ACIDIC PROTEIN; BLOOD-BRAIN-BARRIER; FOCAL CEREBRAL-ISCHEMIA; ENTERIC NERVOUS-SYSTEM; GENE-PRODUCT 9.5; ALZHEIMERS-DISEASE; LECTIN HISTOCHEMISTRY; GLUTAMINE-SYNTHETASE; MYENTERIC PLEXUS; NEUROENDOCRINE CELLS	The simultaneous detection of glia, vessels and neurons facilitates insights into the complex chemoarchitecture of the central nervous system. Here, we present a simple, robust and versatile approach for the carbocyanine triple fluorescence labelling of neuronal, vascular and glial markers. The usefulness of this procedure is shown for rat brain tissue under physiological conditions, after traumatic brain injury caused by controlled cortical impact injury, and after stroke following middle cerebral artery occlusion. Moreover, the versatility of the method is verified by its application to sections from old triple transgenic mice with age-dependent P-amyloidosis and tau hyperphosphorylation in the hippocampus, modelling neuropathological alterations in Alzheimer's disease. To exemplify the usefulness of the approach for analysis of the enteric nervous system, it was applied to whole mounts from the horse intestine. The biotinylated lectin from potato (Solanum tuberosum) is presented as an excellent tool to detect both vessels and microglia. Furthermore, this lectin revealed macrophages after experimental insults, and senile plaques in aged triple transgenic mice. A large portion of astroglia was demonstrated by immunolabelling of glial fibrillary acidic protein. Neurons were detected by monoclonal antibodies directed against neuronal nuclei and, in horse tissues, mouse-anti-HuC/D recognizing a conserved nuclear protein. Confocal laser-scanning microscopy elucidated spatial relationships of the relevant markers and their pathological alterations after experimental insults and in transgenic mice with Alzheimer-like lesions. (C) 2008 Elsevier B.V. All rights reserved.	[Haertig, Wolfgang; Reichenbach, Andreas; Voigt, Cornelia; Freytag, Christiane; Grosche, Jens] Univ Leipzig, Paul Flechsig Inst Brain Res, D-04109 Leipzig, Germany; [Voigt, Cornelia; Schuhmann, Martin U.] Univ Leipzig, Clin & Polyclin Neurosurg, D-04103 Leipzig, Germany; [Voigt, Cornelia; Boltze, Johannes; Bulavina, Larysa] Fraunhofer Inst Cell Therapy & Immunol, D-04103 Leipzig, Germany; [Boltze, Johannes] Translat Ctr Regenerat Med TRM, D-04103 Leipzig, Germany; [Schuhmann, Martin U.] Univ Tubingen, Dept Neurosurg, Univ Hosp, D-72076 Tubingen, Germany; [Seeger, Johannes; Freytag, Christiane] Univ Leipzig, Dept Anat Histol & Embryol, Fac Vet Med, D-04103 Leipzig, Germany; [Schusser, Gerald F.; Freytag, Christiane] Univ Leipzig, Large Anim Clin Internal Med, Fac Vet Med, D-04103 Leipzig, Germany; [Grosche, Jens] Univ Leipzig, Fac Med, Interdisciplinary Ctr Clin Res IZKF, D-04103 Leipzig, Germany	Hartig, W (corresponding author), Univ Leipzig, Paul Flechsig Inst Brain Res, Jahnallee 59, D-04109 Leipzig, Germany.	hartig@medizin.uni-leipzig.de	Reichenbach, Andreas/B-2510-2017	Boltze, Johannes/0000-0003-3956-4164			ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Bazwinsky I, 2008, J CHEM NEUROANAT, V35, P158, DOI 10.1016/j.jchemneu.2007.10.003; Betz T, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2114788; BIGNAMI A, 1979, EXP EYE RES, V28, P63; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BJORKLUND H, 1985, NEUROSCI LETT, V54, P363, DOI 10.1016/S0304-3940(85)80061-6; Brulport M, 2007, HEPATOLOGY, V46, P861, DOI 10.1002/hep.21745; Byers MR, 2004, MICROSC RES TECHNIQ, V65, P295, DOI 10.1002/jemt.20130; Carroll JC, 2007, J NEUROSCI, V27, P13357, DOI 10.1523/JNEUROSCI.2718-07.2007; Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328; Cornford Eain M, 2005, NeuroRx, V2, P27, DOI 10.1602/neurorx.2.1.27; DAMJANOV I, 1987, NEUROSURGERY, V20, P722, DOI 10.1227/00006123-198705000-00008; DERMIETZEL R, 1991, INT REV CYTOL, V127, P57; Derouiche A, 1996, J ANAT, V189, P363; Dobrenis K, 1998, METHODS, V16, P320, DOI 10.1006/meth.1998.0688; DUIJVESTIJN AM, 1992, LAB INVEST, V66, P459; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ERIKSDOTTERNILSSON M, 1986, J NEUROSCI METH, V17, P275, DOI 10.1016/0165-0270(86)90128-7; ERIKSDOTTERNILSSON M, 1987, EXP BRAIN RES, V69, P155; Franciosi S, 2007, J NEUROSCI METH, V163, P76, DOI 10.1016/j.jneumeth.2007.02.020; GABELLA G, 1981, NEUROSCIENCE, V6, P425, DOI 10.1016/0306-4522(81)90135-4; Ganns D, 2006, HISTOL HISTOPATHOL, V21, P41, DOI 10.14670/HH-21.41; GERSHON MD, 1978, J COMP NEUROL, V180, P467, DOI 10.1002/cne.901800305; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; GROSCHE J, 1995, NEUROSCI LETT, V185, P119, DOI 10.1016/0304-3940(94)11239-F; HALLERMAYER K, 1984, BRAIN RES, V295, P1, DOI 10.1016/0006-8993(84)90810-2; Halliday GM, 1996, NEUROSCI LETT, V209, P29, DOI 10.1016/0304-3940(96)12592-1; HANANI M, 1994, CELL TISSUE RES, V278, P153; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harkany T, 2004, J NEUROSCI, V24, P4978, DOI 10.1523/JNEUROSCI.4884-03.2004; Harkany T, 2002, NEUROREPORT, V13, P767, DOI 10.1097/00001756-200205070-00007; Hartig W, 2003, J COMP NEUROL, V465, P1, DOI 10.1002/cne.10789; HARTIG W, 1995, J NEUROCYTOL, V24, P507, DOI 10.1007/BF01179976; Hartig W, 2001, BRAIN RES, V899, P123, DOI 10.1016/S0006-8993(01)02211-9; Horn AK, 2008, J COMP NEUROL, V507, P1317, DOI 10.1002/cne.21598; HUBER G, 1984, J NEUROSCI, V4, P151; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jacobs K, 1997, J COMP NEUROL, V387, P255, DOI 10.1002/(SICI)1096-9861(19971020)387:2<255::AID-CNE7>3.0.CO;2-#; JESSEN KR, 1980, NATURE, V286, P736, DOI 10.1038/286736a0; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kiatipattanasakul W, 1998, ACTA NEUROPATHOL, V95, P261, DOI 10.1007/s004010050796; Kozireski-Chuback D, 1999, DEV BRAIN RES, V115, P201, DOI 10.1016/S0165-3806(99)00062-0; KRUM JM, 1991, EXP NEUROL, V111, P152, DOI 10.1016/0014-4886(91)90002-T; Lin WM, 1997, NEUROREPORT, V8, P2999, DOI 10.1097/00001756-199709290-00002; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Liu ZW, 2007, BRAIN RES, V1149, P172, DOI 10.1016/j.brainres.2007.02.047; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; MANNOJI H, 1986, ACTA NEUROPATHOL, V71, P341, DOI 10.1007/BF00688060; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Matsumoto H, 2007, J NEUROSCI RES, V85, P994, DOI 10.1002/jnr.21198; Meyer W, 2008, ANN ANAT, V190, P264, DOI 10.1016/j.aanat.2007.11.004; MINAMIKAWA T, 1987, HISTOCHEMISTRY, V87, P317, DOI 10.1007/BF00492584; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Murakoshi H, 1999, J NEUROSCI, V19, P1728; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2006, AM J PATHOL, V168, P184, DOI 10.2353/ajpath.2006.050593; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Panchuk-Voloshina N, 1999, J HISTOCHEM CYTOCHEM, V47, P1179, DOI 10.1177/002215549904700910; Pardridge William M, 2003, Methods Mol Med, V89, P385; PERLMUTTER LS, 1990, BRAIN RES, V508, P13, DOI 10.1016/0006-8993(90)91111-S; Phillips RJ, 2004, ANAT EMBRYOL, V209, P19, DOI 10.1007/s00429-004-0426-x; Phillips RJ, 2004, J NEUROSCI METH, V133, P99, DOI 10.1016/j.jneumeth.2003.10.004; Piccinini M, 1996, BIOCHEM J, V318, P711, DOI 10.1042/bj3180711; Pike CJ, 1996, EXP NEUROL, V139, P167, DOI 10.1006/exnr.1996.0091; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Rosario ER, 2006, J NEUROSCI, V26, P13384, DOI 10.1523/JNEUROSCI.2514-06.2006; Ruhl A, 2004, NEUROGASTROENT MOTIL, V16, P44, DOI 10.1111/j.1743-3150.2004.00474.x; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schnell SA, 1999, J HISTOCHEM CYTOCHEM, V47, P719, DOI 10.1177/002215549904700601; Schusser GF, 1997, J AM VET MED ASSOC, V210, P928; Seeger G, 1997, J NEUROSCI RES, V48, P465, DOI 10.1002/(SICI)1097-4547(19970601)48:5<465::AID-JNR7>3.0.CO;2-C; SIMIONESCU M, 1974, J CELL BIOL, V60, P128, DOI 10.1083/jcb.60.1.128; SMITT PAES, 1993, ACTA HISTOCHEM, V95, P13, DOI 10.1016/S0065-1281(11)80381-8; SPICER SS, 1992, J HISTOCHEM CYTOCHEM, V40, P1, DOI 10.1177/40.1.1370305; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; THEILEN H, 1992, J CEREBR BLOOD F MET, V12, P347, DOI 10.1038/jcbfm.1992.47; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Traystman RJ, 2003, ILAR J, V44, P85, DOI 10.1093/ilar.44.2.85; Van Damme EJM, 2004, PLANT J, V37, P34, DOI 10.1046/j.1365-313X.2003.01929.x; VANELDIK LJ, 1994, BBA-MOL CELL RES, V1223, P398, DOI 10.1016/0167-4889(94)90101-5; WESSENDORF MW, 1992, HISTOCHEMISTRY, V98, P81, DOI 10.1007/BF00716998; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8	86	21	21	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0891-0618	1873-6300		J CHEM NEUROANAT	J. Chem. Neuroanat.	MAR	2009	37	2					128	138		10.1016/j.jchemneu.2008.10.003			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	411BR	WOS:000263623300009	19028564				2021-06-18	
J	Sokol, RZ				Sokol, Rebecca Z.			Endocrinology of Male Infertility: Evaluation and Treatment	SEMINARS IN REPRODUCTIVE MEDICINE			English	Article						Male infertility; hypogonadism; testosterone; luteinizing hormone; follicle-stimulating hormone	FOLLICLE-STIMULATING-HORMONE; HUMAN CHORIONIC-GONADOTROPIN; TRAUMATIC BRAIN-INJURY; ANDROGEN-RECEPTOR GENE; KLINEFELTER-SYNDROME; HYPOGONADOTROPIC HYPOGONADISM; FREE TESTOSTERONE; CANCER INCIDENCE; AZOOSPERMIC MEN; SEX-DIFFERENCES	A normal functioning reproductive endocrine system is a prerequisite for normal male fertility. Any disruption of the delicately coordinated interaction between the components of the hypothalamic-pituitary-testicular axis may lead to hypogonadism and/or infertility. The goal of the clinical evaluation is to determine if the patient has an abnormality of testosterone production or action, the etiology of the abnormality, and if hormone therapy will correct the infertility. Based on a careful history, physical examination, and evaluation of the hormones of the reproductive axis, the physician will ascertain if the patient's hypogonadism is (1) prepubertal or postpubertal in onset; (2) the result of an abnormality in the hypothalamic-pituitary axis, the testes, or the androgen receptor; or (3) associated with another underlying medical condition. This information will place the patient into one of four diagnostic categories: hypogonadotropic hypogonadism, testicular failure, 5 alpha-reductase deficiency, or androgen resistance. Within each category are disorders with identifiable pathogenic mechanisms. Recent studies have added to these lists and have provided insights into the molecular basis and inheritance patterns of several of these endocrinopathies.	[Sokol, Rebecca Z.] Univ So Calif, Keck Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA	Sokol, RZ (corresponding author), Womens & Childrens Hosp, 1240 N Mission Rd,Room 8K3, Los Angeles, CA 90033 USA.	rsokol@usc.edu					ATTIA AM, 2006, COCHRANE DB SYST REV, V1; BAIN J, 1988, FERTIL STERIL, V49, P123; Bayrak A, 2005, FERTIL STERIL, V84, P181, DOI 10.1016/j.fertnstert.2005.01.102; Bhagavath B, 2006, FERTIL STERIL, V85, P706, DOI 10.1016/j.fertnstert.2005.08.044; Bilezikjian LM, 2004, MOL CELL ENDOCRINOL, V225, P29, DOI 10.1016/j.mce.2004.02.010; Bojesen A, 2006, J CLIN ENDOCR METAB, V91, P1254, DOI 10.1210/jc.2005-0697; Bojesen A, 2003, J CLIN ENDOCR METAB, V88, P622, DOI 10.1210/jc.2002-021491; Bouloux P, 2002, FERTIL STERIL, V77, P270, DOI 10.1016/S0015-0282(01)02973-9; Bouloux PMG, 2003, J ANDROL, V24, P604; Bunin GR, 1998, J NEUROSURG, V89, P547, DOI 10.3171/jns.1998.89.4.0547; CARRUTHERS M, 2004, ANDROGEN DEFICIENCY; Catlin DH, 1996, J MASS SPECTROM, V31, P397; CILENTO BG, 2007, MALE REPROD DYSFUNCT, P161; Davis-Dao CA, 2007, J CLIN ENDOCR METAB, V92, P4319, DOI 10.1210/jc.2007-1110; de Kretser DM, 2004, MOL CELL ENDOCRINOL, V225, P57, DOI 10.1016/j.mce.2004.07.008; Ding EL, 2006, JAMA-J AM MED ASSOC, V295, P1288, DOI 10.1001/jama.295.11.1288; Dowsing AT, 1999, LANCET, V354, P640, DOI 10.1016/S0140-6736(98)08413-X; FINKEL DM, 1985, NEW ENGL J MED, V313, P651, DOI 10.1056/NEJM198509123131102; Foresta C, 2005, FERTIL STERIL, V84, P654, DOI 10.1016/j.fertnstert.2005.03.055; Fukagai T, 2005, UROLOGY, V65, DOI 10.1016/j.urology.2004.09.017; Geschwind DH, 2000, MENT RETARD DEV D R, V6, P107, DOI 10.1002/1098-2779(2000)6:2<107::AID-MRDD4>3.0.CO;2-2; Ghazi AAM, 2003, J ENDOCRINOL INVEST, V26, P84, DOI 10.1007/BF03345128; Gillam MP, 2006, ENDOCR REV, V27, P485, DOI 10.1210/er.2005-9998; Giltay JC, 2004, FERTIL STERIL, V81, P693, DOI 10.1016/j.fertnstert.2003.07.030; Goldstone AP, 2008, FRONT HORM RES, V36, P37, DOI 10.1159/000115336; Goodman-Gruen D, 2000, DIABETES CARE, V23, P912, DOI 10.2337/diacare.23.7.912; GRIFFIN JE, 1992, NEW ENGL J MED, V326, P611; HAMMAR M, 1990, SCAND J UROL NEPHROL, V24, P17, DOI 10.3109/00365599009180353; Hammoud AO, 2006, J ANDROL, V27, P619, DOI 10.2164/jandrol.106.000125; Handelsman DJ, 2007, J CLIN ENDOCR METAB, V92, P4505, DOI 10.1210/jc.2007-1431; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HAUSER R, 1995, FERTIL STERIL, V63, P631, DOI 10.1016/S0015-0282(16)57437-8; HOFFMAN AR, 1982, NEW ENGL J MED, V307, P1237, DOI 10.1056/NEJM198211113072003; Holsberger DR, 2005, CELL TISSUE RES, V322, P133, DOI 10.1007/s00441-005-1082-z; Hughes IA, 2001, ENDOCRINOLOGY, V142, P3281, DOI 10.1210/en.142.8.3281; Hultborn R, 1997, ANTICANCER RES, V17, P4293; Ismail AAA, 2001, ANN CLIN BIOCHEM, V38, P596, DOI 10.1258/0004563011900993; Jarow JP, 2005, ANN NY ACAD SCI, V1061, P208, DOI 10.1196/annals.1336.023; Kamischke A, 2003, J ANDROL, V24, P41; Karavitaki N, 2006, ENDOCR REV, V27, P371, DOI 10.1210/er.2006-0002; Kleiman SE, 2008, FERTIL STERIL, V89, P1728, DOI [10.1016/j.fertnstert.2007.05.068, 10.1016/j.fertnstert.2007.12.033]; KLIESCH S, 1994, EUR J ENDOCRINOL, V131, P347, DOI 10.1530/eje.0.1310347; Kolb BA, 2000, FERTIL STERIL, V74, P234, DOI 10.1016/S0015-0282(00)00641-5; Lanfranco F, 2004, LANCET, V364, P273, DOI 10.1016/S0140-6736(04)16678-6; LEWIS AS, 2008, PITUITARY       0413; LEY SB, 1985, J CLIN ENDOCR METAB, V61, P746, DOI 10.1210/jcem-61-4-746; Liu PY, 2003, HUM REPROD UPDATE, V9, P9, DOI 10.1093/humupd/dmg002; Liu PY, 1999, HUM REPROD, V14, P1540, DOI 10.1093/humrep/14.6.1540; LONGCOPE C, 1984, J CLIN ENDOCR METAB, V58, P1089, DOI 10.1210/jcem-58-6-1089; Lue YH, 2005, ENDOCRINOLOGY, V146, P4148, DOI 10.1210/en.2005-0278; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; Marchetti Francesco, 2005, Birth Defects Res C Embryo Today, V75, P112, DOI 10.1002/bdrc.20040; Meikle AW, 1996, J CLIN ENDOCR METAB, V81, P1832, DOI 10.1210/jc.81.5.1832; Melmed S, 2008, J CLIN ENDOCR METAB, V93, P331, DOI 10.1210/jc.2007-1409; Meschede D, 1997, MOL HUM REPROD, V3, P419, DOI 10.1093/molehr/3.5.419; Murialdo G, 2002, J ENDOCRINOL INVEST, V25, P650, DOI 10.1007/BF03345093; Nachtigall LB, 1997, NEW ENGL J MED, V336, P410, DOI 10.1056/NEJM199702063360604; Pavlovich CP, 2001, J UROLOGY, V165, P837, DOI 10.1016/S0022-5347(05)66540-8; Petersen C, 2006, HORM RES, V66, P153, DOI 10.1159/000094142; Raman JD, 2002, J UROLOGY, V167, P624, DOI 10.1016/S0022-5347(01)69099-2; Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864; Ross JL, 2008, AM J MED GENET A, V146A, P708, DOI 10.1002/ajmg.a.32232; Saeger W, 2007, EUR J ENDOCRINOL, V156, P203, DOI 10.1530/eje.1.02326; Schiff JD, 2005, J CLIN ENDOCR METAB, V90, P6263, DOI 10.1210/jc.2004-2322; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Simpson JL, 2003, GENET MED, V5, P460, DOI 10.1097/01.GIM.0000095626.54201.D0; SKARIN G, 1982, J CLIN ENDOCR METAB, V55, P723, DOI 10.1210/jcem-55-4-723; SOKOL RZ, 1982, FERTIL STERIL, V37, P425; SOKOL RZ, 1981, J CLIN ENDOCR METAB, V52, P929, DOI 10.1210/jcem-52-5-929; SOKOL RZ, 1997, INFERTILITY CONTRACE, P547; SOKOL RZ, 1997, INFERTILITY MALE, P10; SPRATT DI, 1993, J CLIN ENDOCR METAB, V76, P1548, DOI 10.1210/jc.76.6.1548; Stikkelbroeck NMML, 2001, J CLIN ENDOCR METAB, V86, P5721, DOI 10.1210/jc.86.12.5721; Swerdloff RS, 2000, J CLIN ENDOCR METAB, V85, P4500, DOI 10.1210/jc.85.12.4500; Swerdlow AJ, 2001, ANN HUM GENET, V65, P177, DOI 10.1017/S0003480001008569; Thomas NS, 2003, HUM REPROD UPDATE, V9, P309, DOI 10.1093/humupd/dmg028; Tong S, 2003, CLIN ENDOCRINOL, V58, P115, DOI 10.1046/j.1365-2265.2003.01686.x; Trarbach EB, 2005, J ENDOCRINOL, V187, P361, DOI 10.1677/joe.1.06103; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; Vernaeve V, 2004, HUM REPROD, V19, P1135, DOI 10.1093/humrep/deh253; Wang C, 2004, J CLIN ENDOCR METAB, V89, P534, DOI 10.1210/jc.2003-031287; Whitten SJ, 2006, FERTIL STERIL, V86, P1664, DOI 10.1016/j.fertnstert.2006.05.042; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577; Zitzmann M, 2006, FERTIL STERIL, V86, P339, DOI 10.1016/j.fertnstert.2005.12.058	85	21	22	0	7	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	1526-8004	1526-4564		SEMIN REPROD MED	Semin. Reprod. Med.	MAR	2009	27	2					149	158		10.1055/s-0029-1202303			10	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	413YY	WOS:000263832300007	19247916				2021-06-18	
J	Oda, Y; Tsuruta, R; Kasaoka, S; Inoue, T; Maekawa, T				Oda, Yasutaka; Tsuruta, Ryosuke; Kasaoka, Shunji; Inoue, Takeshi; Maekawa, Tsuyoshi			The cutoff values of intrathecal interleukin 8 and 6 for predicting the neurological outcome in cardiac arrest victims	RESUSCITATION			English	Article						Interleukin 8; Interleukin 6; Cerebrospinal fluid; Cardiopulmonary arrest; Ischemia reperfusion injury	TRAUMATIC BRAIN INJURY; SUCCESSFUL CARDIOPULMONARY-RESUSCITATION; GROWTH-FACTOR PRODUCTION; NEURON-SPECIFIC ENOLASE; TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; CEREBROSPINAL-FLUID; REGAINING CONSCIOUSNESS; SERUM INTERLEUKIN-8; S-100 PROTEIN	Objectives: To evaluate the changes in inflammatory cytokines, such as interleukin (IL)-8 and IL-6, in the cerebrospinal fluid (CSF) and serum, and to identify any correlations with the neurological outcomes in patients resuscitated from cardiopulmonary arrest (CPA). Materials and methods: This study was designed as a prospective clinical trial. Thirteen patients, who were resuscitated from out-of-hospital CPA and survived for more than 48 h, were enrolled in this study. Arterial blood was taken from the patients at 48 h after the return of spontaneous circulation (ROSC) and CSF was taken by lumbar puncture at the same time. Results: In the CSF, the median levels of IL-8 and IL-6 in the patients resuscitated from CPA were significantly higher than those in the control subjects (1311 pg/ml vs 82 pg/ml, P < 0.001; 2040 pg/ml vs 1 pg/ml, P < 0.001, respectively). The Glasgow outcome Scale (GOS) score evaluated at 6 months after the ROSC correlated significantly with the levels of IL-8 and IL-6. The cutoff values and sensitivity values with 100% specificity for the prediction of an unfavorable neurological outcome were 1423 pg/ml and 86% for IL-8, and 2708 pg/ml and 86% for IL-6, respectively. Conclusion: We demonstrated the cutoff values of IL-8 and IL-6 in the CSF to predict the neurological outcome in the patients resuscitated from CPA. The excessive inflammatory cytokine reactions in the brain might therefore be related to the poor neurological outcome in patients with post-resuscitation encephalopathy. (c) 2008 Elsevier Ireland Ltd. All rights reserved.	[Oda, Yasutaka; Tsuruta, Ryosuke] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi 7558505, Japan; [Kasaoka, Shunji; Inoue, Takeshi; Maekawa, Tsuyoshi] Yamaguchi Univ, Grad Sch Med, Dept Stress & Bioresponse Med, Yamaguchi 7558505, Japan	Oda, Y (corresponding author), Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.	yasutaka-ygc@umin.ac.jp					Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Adrie Christophe, 2004, Curr Opin Crit Care, V10, P208, DOI 10.1097/01.ccx.0000126090.06275.fe; ARAUJO DM, 1993, BRAIN RES, V600, P49, DOI 10.1016/0006-8993(93)90400-H; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BANKS WA, 1994, NEUROSCI LETT, V179, P53, DOI 10.1016/0304-3940(94)90933-4; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bottiger BW, 2001, CIRCULATION, V103, P2694; Ekmektzoglou KA, 2007, RESUSCITATION, V75, P219, DOI 10.1016/j.resuscitation.2007.03.016; Hachimi-Idrissi S, 2005, RESUSCITATION, V64, P187, DOI 10.1016/j.resuscitation.2004.08.008; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; Ito T, 2001, RESUSCITATION, V51, P47, DOI 10.1016/S0300-9572(01)00382-3; JENNETT B, 1975, LANCET, V1, P480; Kettritz R, 1998, KIDNEY INT, V53, P84, DOI 10.1046/j.1523-1755.1998.00741.x; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Madl Christian, 2004, Curr Opin Crit Care, V10, P213, DOI 10.1097/01.ccx.0000127542.32890.fa; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; MARTICH GD, 1991, J EXP MED, V173, P1021, DOI 10.1084/jem.173.4.1021; Matsumoto T, 1997, LAB INVEST, V77, P119; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Shyu KG, 1997, AM HEART J, V134, P551, DOI 10.1016/S0002-8703(97)70094-2; SIESJO BK, 1995, ANN THORAC SURG, V59, P1316, DOI 10.1016/0003-4975(95)00077-X; Snyder-Ramos SA, 2003, RESTOR NEUROL NEUROS, V21, P123; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WHITE M, 2000, FAMILY THERAPY FIELD, V1, P33	33	21	21	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	FEB	2009	80	2					189	193		10.1016/j.resuscitation.2008.10.001			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	408OB	WOS:000263443200010	19010583				2021-06-18	
J	Capitani, E; Rosci, C; Saetti, MC; Laiacona, M				Capitani, Erminio; Rosci, Chiara; Saetti, Maria Cristina; Laiacona, Marcella			Mirror asymmetry of Category and Letter fluency in traumatic brain injury and Alzheimer's patients	NEUROPSYCHOLOGIA			English	Article						Verbal fluency; Traumatic brain injury; Alzheimer's disease	VERBAL FLUENCY; SEMANTIC MEMORY; PERFORMANCE; DEMENTIA	In this study we contrasted the Category fluency and Letter fluency performance of 198 normal subjects, 57 Alzheimer's patients and 57 patients affected by traumatic brain injury (TBI). The aim was to check whether, besides the prevalence of Category fluency deficit often reported among Alzheimer's patients, the TBI group presented the opposite dissociation. According to some recent claims, in fact, the deficit of TBI would be equally severe for both fluency types. The inquiry followed different approaches for data analysis, including the evaluation of a unique index (Fluency Type Index or FTI), independent of the overall fluency and aimed at expressing at individual subject level the relationship between Category and Letter fluency. The results confirmed that Alzheimer's patients are more defective on Category than Letter fluency, and also clearly indicated that an opposite pattern applies to TBI patients. TBI seems to cause a relatively more severe impairment of Letter than Category fluency, probably due to its impact on the frontal lobe structures. We discuss whether, on the basis of the statistical distribution of our data, it is worth considering as homogeneous populations broadly defined groups as Alzheimer's or TBI patients. (C) 2008 Elsevier Ltd. All rights reserved.	[Capitani, Erminio; Saetti, Maria Cristina] Univ Milan, Milan, Italy; [Rosci, Chiara] S Paolo Hosp, Milan, Italy; [Laiacona, Marcella] Veruno Med Ctr, S Maugeri Fdn, Veruno, Italy	Capitani, E (corresponding author), Univ Milan, Milan, Italy.	erminio.capitani@unimi.it		SAETTI, MARIA CRISTINA/0000-0001-5867-5981	Milan University	This project was partly supported by a PRIN 2005 Grant to E.C. and by a FIRST Grant from Milan University. Rita Frosio and Micol Vecchio kindly assisted with the collection of normal subjects' data. Monica Fabiani, Valeria Masiello and Daniela Sacco assisted with the examination of TBI patients. Preliminary findings were presented at the 46th Annual Meeting of the Academy of Aphasia, Turku, 2008.; Rosemary Allpress revised the English text.	ACKERMANN H, 1985, MEHRIMENSIONALE NICH; Beldarrain MG, 1999, NEUROLOGY, V52, P1853, DOI 10.1212/WNL.52.9.1853; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGIA, V42, P1212, DOI 10.1016/j.neuropsychologia.2004.02.001; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Jurado MA, 2000, BRAIN INJURY, V14, P789; LAIACONA M, 1989, CORTEX, V25, P261, DOI 10.1016/S0010-9452(89)80042-5; METHA C, 2004, STATXACT; MONSCH AU, 1992, ARCH NEUROL-CHICAGO, V49, P1253, DOI 10.1001/archneur.1992.00530360051017; MURPHY RB, 1948, ANN MATH STAT, V19, P581, DOI 10.1214/aoms/1177730154; NATRELLA MG, 1966, EXPT STAT; NEBES RD, 1984, J ABNORM PSYCHOL, V93, P321, DOI 10.1037/0021-843X.93.3.321; OBER BA, 1986, J CLIN EXP NEUROPSYC, V8, P75, DOI 10.1080/01688638608401298; Reverberi C, 2006, NEUROPSYCHOLOGIA, V44, P469, DOI 10.1016/j.neuropsychologia.2005.05.011; ROY SN, 1953, ANN MATH STAT, V24, P513, DOI 10.1214/aoms/1177728912; Schwartz S, 2003, BRAIN LANG, V87, P400, DOI 10.1016/S0093-934X(03)00141-X; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Suhr JA, 1998, ARCH CLIN NEUROPSYCH, V13, P447, DOI 10.1016/S0887-6177(97)00040-1; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Wilks SS, 1941, ANN MATH STAT, V12, P91, DOI 10.1214/aoms/1177731788	20	21	21	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JAN	2009	47	2					423	429		10.1016/j.neuropsychologia.2008.09.016			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	413TL	WOS:000263815300015	18929584				2021-06-18	
J	Ghosh, A; Wilde, EA; Hunter, JV; Bigler, ED; Chu, ZL; Li, XQ; Vasquez, AC; Menefee, D; Yallampalli, R; Levin, HS				Ghosh, Alokananda; Wilde, Elisabeth A.; Hunter, Jill V.; Bigler, Erin D.; Chu, Zili; Li, Xiaoqi; Vasquez, Ana C.; Menefee, Deleene; Yallampalli, Ragini; Levin, Harvey S.			The relation between Glasgow Coma Scale score and later cerebral atrophy in paediatric traumatic brain injury	BRAIN INJURY			English	Article						Paediatric; neuroimaging; Glasgow Coma Scale (GCS); traumatic brain injury; MR imaging; children	CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; QUANTITATIVE-ANALYSIS; CHILDREN; PREDICTORS; SEVERITY; MODERATE; MRI; CONSCIOUSNESS; ADOLESCENTS	Primary objective: To examine initial Glasgow Coma Scale (GCS) score and its relationship with later cerebral atrophy in children with traumatic brain injury (TBI) using Quantitative Magnetic Resonance Imaging (QMRI) at 4 months post-injury. It was hypothesized that a lower GCS score would predict later generalized atrophy. As a guide in assessing paediatric TBI patients, the probability of developing chronic cerebral atrophy was determined based on the initial GCS score. Methods and procedures: The probability model used data from 45 paediatric patients (mean age = 13.6) with mild-to-severe TBI and 41 paediatric (mean age = 12.4) orthopaedically-injured children. Results: This study found a 24% increase in the odds of developing an abnormal ventricle-to-brain ratio (VBR) and a 27% increase in the odds of developing reduced white matter percentage on neuroimaging with each numerical drop in GCS score. Logistic regression models with cut-offs determined by normative QMRI data confirmed that a lower initial GCS score predicts later atrophy. Conclusion: GCS is a commonly used measure of injury severity. It has proven to be a prognostic indicator of cognitive recovery and functional outcome and is also predictive of later parenchymal change.	[Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Ghosh, Alokananda] Presbyterian Med Ctr, Dallas, TX USA; [Ghosh, Alokananda; Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Yallampalli, Ragini] Univ Houston, Dept Psychol, Houston, TX USA	Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS021889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grant NS021889 awarded to Harvey S. Levin, PhD, by the National Institutes of Health. We gratefully acknowledge the assistance of Summer Lane and Lori Cook for their assistance in patient recruitment and Stacey K. Martin for her assistance in manuscript preparation. We would also like to acknowledge the generous support of Mission Connect of the TIRR Foundation.	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BERRYHILL P, 1995, NEUROSURGERY, V37, P399; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; BIGLER ED, 2005, NEUROPSYCHIATRY TRAU, P79; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; Diringer MN, 1997, ARCH NEUROL-CHICAGO, V54, P606, DOI 10.1001/archneur.1997.00550170078017; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1997, NEUROSURGERY, V40, P440; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; TEASDALE G, 1974, LANCET, V2, P81; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Verger K, 2001, BRAIN INJURY, V15, P211; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	38	21	24	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	3					228	233	PII 908612472	10.1080/02699050802672789			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	406AJ	WOS:000263267100006	19205959				2021-06-18	
J	Holm, S; Schonberger, M; Poulsen, I; Caetano, C				Holm, Sara; Schonberger, Michael; Poulsen, Ingrid; Caetano, Carla			Patients' and relatives' experience of difficulties following severe traumatic brain injury: The sub-acute stage	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Subjective experience; Traumatic brain injury; European Brain Injury Questionnaire; Quality of Life; Sub-acute treatment	SEVERE HEAD-INJURY; QUALITY-OF-LIFE; FUNCTIONAL INDEPENDENCE MEASURE; GLASGOW OUTCOME SCALE; SUBJECTIVE EXPERIENCE; CLOSE RELATIVES; REHABILITATION; AWARENESS; ADULTS; DISABILITY	The present study aimed to (1) identify the difficulties most frequently reported by individuals with severe traumatic brain injury (TBI) at the time of discharge from a sub-acute rehabilitation brain injury unit as well as difficulties reported by their relatives, (2) compare patients' and relatives' reports of patient difficulties, and (3) explore the role of injury severity, disability and other factors on subjective experience of difficulties. The primary measure was the European Brain Injury Questionnaire (EBIQ) administered to patients and to one of their close relatives at discharge. Results from 52 patients and 50 relatives indicate that the most frequent complaints in both groups related to somatic and cognitive problems. Relatives reported significantly more difficulties than patients on all subscales of the EBIQ. However, the level of complaints in both patients and relatives was low compared to other studies using the EBIQ. Furthermore, the effects of injury severity and general level of functioning had limited impact on the subjective experience of difficulties. Implications of these findings, specifically as they pertain to the sub-acute stage are discussed.	[Holm, Sara; Poulsen, Ingrid] Univ Copenhagen, Hvidovre Hosp, Brain Injury Unit, DK-2650 Hvidovre, Denmark; [Schonberger, Michael] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia; [Schonberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Caetano, Carla] Univ Copenhagen, Ctr Rehabil Brain Injury, DK-1168 Copenhagen, Denmark	Holm, S (corresponding author), 354 Hvidovre Hosp, Dept Neurol Rehabil, Kettegard 30, DK-2650 Hvidovre, Denmark.	sara_holm@hotmail.com	Poulsen, ingrid/AAH-2052-2019				Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HALL KM, 1999, REHABILITATION ADULT, P131; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P142, DOI 10.1097/00001199-200603000-00007; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lustig D.C., 2003, J APPL REHABILITATIO, V34, P30; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P561, DOI 10.1080/09602010500263084; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale T W, 1995, Appl Neuropsychol, V2, P116; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; Wilson BA, 2002, J HEAD TRAUMA REHAB, V17, P542, DOI 10.1097/00001199-200212000-00006	30	21	21	1	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	3					444	460	PII 902917230	10.1080/09602010802296402			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	435UO	WOS:000265369000006	18815939				2021-06-18	
J	Larrabee, GJ				Larrabee, Glenn J.			MALINGERING SCALES FOR THE CONTINUOUS RECOGNITION MEMORY TEST AND THE CONTINUOUS VISUAL MEMORY TEST	CLINICAL NEUROPSYCHOLOGIST			English	Article						Continuous Recognition Memory Test; Continuous Visual Memory Test; Malingering	VERBAL-LEARNING TEST; FAKE-BAD SCALE; CONSTRUCT-VALIDITY; INCOMPLETE EFFORT; SUSPECT EFFORT; HEAD-INJURY; MMPI-2	Continuous Visual Memory Test (CVMT) and Continuous Recognition Memory Test (CRM) scores of 24 litigants with definite malingered neurocognitive dysfunction (definite MND) were contrasted with those of 27 patients with moderate (n=12) and severe (n=15) traumatic brain injury (TBI). Analysis with chi-square identified 20 CVMT and 33 CRM items that discriminated the definite MND from TBI cases. Receiver operating characteristic (ROC) area under curve (AUC) was 0.918 for the CVMT scale, and 0.962 for the CRM scale, p=0.184. Cutting scores were derived yielding sensitivity and specificity of 0.83 and 0.889 for the 20-item CVMT scale, and 0.875 and 0.93 for the 33-item CRM scale. On cross-validation contrasting performance of 17 litigants with evidence of probable MND and non-litigating psychiatric (n=14) and neurologic (n=13) patients, ROC AUC was 0.779 for the CVMT scale, and 0.847 for the CRM scale, p=0.447. Sensitivity and specificity were 0.35 and 0.93 for the CVMT, and 0.529 and 0.96 for the CRM, using the cutting scores from the derivation sample. ROC AUC differences contrasting values for the definite MND/TBI comparison to the probable MND/neurologic and psychiatric comparison approached significance for the CRM SVT scale (p=0.059), and for the CVMT SVT scale (p=0.082). These data suggest that the malingering scales for the CVMT and CRM are more sensitive to definite rather than probable MND, and these scales are better at ruling in than ruling out malingered visual memory deficits.		Larrabee, GJ (corresponding author), 2650 Bahia Vista St,Suite 308, Sarasota, FL 34239 USA.	GLarrabee@aol.com					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Benton A. L., 1994, CONTRIBUTIONS NEUROP; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; DRAKE AI, 1992, J CLIN EXP NEUROPSYC, V14, P539, DOI 10.1080/01688639208402843; Fuchs KL, 1999, CLIN NEUROPSYCHOL, V13, P54, DOI 10.1076/clin.13.1.54.1977; Green P., 2005, GREENS WORD MEMORY T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREVE KW, CLIN NEUROP IN PRESS; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; Heaton R., 1993, WISCONSIN CARD SORTI; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; LARRABEE GJ, 1992, ARCH CLIN NEUROPSYCH, V7, P395, DOI 10.1016/0887-6177(92)90152-D; LARRABEE GJ, CLIN NEUROP IN PRESS; Larrabee GJ, 1988, NEUROPSYCHOLOGY, V2, P173, DOI 10.1037//0894-4105.2.3-4.173; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; McNichol D, 1972, PRIMER SIGNAL DETECT; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; STRAUS SE, 2005, EVIDENCE BASED MED R; SUHR JA, 2007, ASSESSMENT MALINGERE, P287; Tombaugh TN, 1996, TEST MEMORY MALINGER; Trahan D, 1988, CONTINUOUS VISUAL ME; TRAHAN DE, 1986, EXP AGING RES, V12, P147; TRAHAN DE, 1990, J CLIN EXP NEUROPSYC, V12, P857, DOI 10.1080/01688639008401027; TRAHAN DE, 1989, CLIN NEUROPSYCHOL, V3, P169, DOI DOI 10.1080/13854048908403290; Trahan DE, 1988, NEUROPSYCHOLOGY, V2, P29, DOI 10.1037//0894-4105.2.1.29; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wolfson D., 1993, HALSTEAD REITAN NEUR	41	21	21	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	1					167	180		10.1080/13854040801968443			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	399LR	WOS:000262801900010	18609339				2021-06-18	
J	Llorente, AM; Voigt, RG; Williams, J; Frailey, JK; Satz, P; D'Elia, LF				Llorente, Antolin M.; Voigt, Robert G.; Williams, Jane; Frailey, J. Kennard; Satz, Paul; D'Elia, Louis F.			Children's Color Trails Test 1 2: Test-Retest Reliability and Factorial Validity	CLINICAL NEUROPSYCHOLOGIST			English	Article						ADHD; Attention; Children's Color Trails Test; Factorial validity; Test-retest reliability	PATTERNS	This investigation examined the test-retest reliability and the factorial validity of the Children's Color Trails Test 1 2 (CCTT) using two distinct and independent studies and their respective research samples. The reliability of the CCTT was evaluated in a study with 6-12-year-old children (n = 54) strictly selected and diagnosed with attention-deficit/hyperactivity disorder from an interventional protocol using test-retest coefficients at 8- and 16-week time intervals. Factorial validity was investigated using groups of children with traumatic brain injury (TBI) (n = 137), children with other types of trauma than brain or head injury (Other Injury) (n = 132), and healthy controls (n = 114) from a protocol assessing the neuropsychological sequelae of traumatic brain injury. The results revealed completion time test-retest reliability in the moderate range, which may be considered modest (rtt =.46-.68) in this sample of children with ADHD. Interference reliability coefficients were greater and in the moderate-high range (rtt =.75-.78). Factorial analytic results revealed a three-factor structure solution for all three groups (TBI, Other Injury, and controls). As a result of CCTT's factorial loadings, Factor 1 was labeled speed of perceptual tracking and susceptibility to interference, Factor 2 was labeled inattention and impulsivity, and Factor 3 was labeled simple inattention. Relative limitations and strengths associated with this investigation including practice effects associated with repeated CCTT administrations also were addressed within the context of the extant findings and existing trail-making test literature.	[Llorente, Antolin M.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21209 USA; [Voigt, Robert G.] Mayo Clin, Div Dev & Behav Pediat, Rochester, MN USA; [Williams, Jane] Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Winston Salem, NC 27103 USA; [Frailey, J. Kennard] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Satz, Paul; D'Elia, Louis F.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Satz, Paul; D'Elia, Louis F.] Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Los Angeles, CA 90024 USA	Llorente, AM (corresponding author), Univ Maryland, Sch Med, Dept Pediat, 1708 W Rogers Ave, Baltimore, MD 21209 USA.	allorente@mwph.org	Voigt, Robert/AAO-6336-2021		Martek Biosciences Corporation, Columbia, Maryland, USA	Portions of this research were supported in part by grants from Martek Biosciences Corporation, Columbia, Maryland, USA to Antolin M. Llorente and Robert G. Voigt.	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anastasi A., 1988, PSYCHOL TESTING; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Baron I., 2004, NEUROPSYCHOLOGICAL E; BASSA F M, 1984, South African Journal of Psychology, V14, P118; BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510; CARREON JL, 1989, PERCEPT MOTOR SKILL, V68, P627; Costello A., 2005, PRACT ASSESS RES EVA, V10, DOI 10.7275/jyj1-4868.; DElia L.F., 1994, COLOR TRAILS TEST PR; DYE OA, 1979, PERCEPT MOTOR SKILL, V48, P296, DOI 10.2466/pms.1979.48.1.296; Goldstein G, 1989, CLIN NEUROPSYCHOL, V3, P265, DOI DOI 10.1080/13854048908404088; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Leark R, 1996, TOVA TEST VARIABLES; Lee TMC, 2000, J CLIN EXP NEUROPSYC, V22, P772, DOI 10.1076/jcen.22.6.772.954; Llorente AM., 2003, CHILDRENS COLOR TRAI; MAJ M, 1993, ARCH CLIN NEUROPSYCH, V8, P123, DOI 10.1016/0887-6177(93)90030-5; MAJ M, 1994, ARCH GEN PSYCHIAT, V51, P51; Majovski L. V., 1997, HDB CLIN CHILD NEURO, P63; MATARAZZO JD, 1974, J NERV MENT DIS, V158, P37, DOI 10.1097/00005053-197401000-00006; Mok N, 2008, APPL NEUROPSYCHOL, V15, P123, DOI 10.1080/09084280802083962; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REITAN RM, 1985, J CLIN PSYCHOL, V41, P643, DOI 10.1002/1097-4679(198509)41:5<643::AID-JCLP2270410510>3.0.CO;2-A; Reitan RM, 1979, MANUAL ADM NEUROPSYC; ROSIN J, 1989, South African Journal of Psychology, V19, P6; ROSIN J, 1989, South African Journal of Psychology, V19, P14; ROURKE BP, 1975, J ABNORM PSYCHOL, V84, P412; Sattler JM, 1988, ASSESSMENT CHILDREN; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tabachnick BG, 2007, USING MULTIVARIATE S; TSOI MM, 1989, PROF PSYCHOL-RES PR, V20, P248, DOI 10.1037/0735-7028.20.4.248; Voigt RG, 2001, J PEDIATR-US, V139, P189, DOI 10.1067/mpd.2001.116050; WILLIAMS J, 1995, ARCH CLIN NEUROPSYCH, V10, P211, DOI 10.1016/0887-6177(94)00041-N; WINSBERG BG, 1982, PSYCHOPHARMACOLOGY, V76, P329, DOI 10.1007/BF00449120	34	21	21	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	4					645	660	PII 904602995	10.1080/13854040802427795			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	442VQ	WOS:000265869100111	18942031				2021-06-18	
J	O'Hara, R; Luzon, A; Hubbard, J; Zeitzer, JM				O'Hara, Ruth; Luzon, Avinoam; Hubbard, Jeffrey; Zeitzer, Jamie M.			Sleep apnea, apolipoprotein epsilon 4 allele, and TBI: Mechanism for cognitive dysfunction and development of dementia	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						Alzheimer disease; apolipoprotein epsilon 4; cognition; daytime sleepiness; dementia; mild cognitive impairment; obstructive sleep apnea; sleep apnea; sleep disordered breathing; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; APOE EPSILON-4; OLDER-ADULTS; MOUSE MODEL; ASSOCIATION; PERFORMANCE; IMPAIRMENT	Sleep apnea is prevalent among patients with traumatic brain injuries (TBIs), and initial studies suggest it is associated with cognitive impairments in these patients. Recent studies found that the apolipoprotein epsilon 4 (APOE epsilon 4) allele increases the risk for sleep disordered breathing, particularly sleep apnea. The APOE epsilon 4 allele is associated with cognitive decline and the development of dementia in the general population as well as in patients with TBI. These findings raise the question of whether patients with TBI who are APOE epsilon 4 allele carriers are more vulnerable to the negative effects of sleep apnea on their cognitive functioning. While few treatments are available for cognitive impairment, highly effective treatments are available for sleep apnea. Here we review these different lines of evidence, making a case that the interactive effects of sleep apnea and the APOE epsilon 4 allele represent an important mechanism by which patients with TBI may develop a range of cognitive and neurobehavioral impairments. Increased understanding of the relationships among sleep apnea, the APOE epsilon 4 allele, and cognition could improve our ability to ameliorate one significant source of cognitive impairment and risk for dementia associated with TBI.	[O'Hara, Ruth; Hubbard, Jeffrey; Zeitzer, Jamie M.] Sierra Pacific Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; [O'Hara, Ruth; Luzon, Avinoam; Hubbard, Jeffrey; Zeitzer, Jamie M.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	O'Hara, R (corresponding author), Sierra Pacific Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs Palo Alto Hlth Care Syst, 151-Y,3801 Miranda Ave, Palo Alto, CA 94304 USA.	roh@stanford.edu	Zeitzer, Jamie M/A-1168-2007; Zeitzer, Jamie/AAO-2103-2020; Longo, Kenneth A/A-5631-2010; Hubbard, Jeffrey/Y-4777-2019	Zeitzer, Jamie M/0000-0001-6174-5282; Zeitzer, Jamie/0000-0001-6174-5282; Hubbard, Jeffrey/0000-0002-0405-9398	VA Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); Stanford/VA Alzheimer's Research Center; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH 070886, AG 18784, AG 17824]; State of California Department of Health Services [06-55310]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH070886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG017824, P01AG018784] Funding Source: NIH RePORTER	This work was supported in part by the VA Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); the Stanford/VA Alzheimer's Research Center; the National Institutes of Health (grants MH 070886, AG 18784, and AG 17824); and the State of California Department of Health Services (grant 06-55310).	Aloia MS, 2003, J PSYCHOSOM RES, V54, P71, DOI 10.1016/S0022-3999(02)00548-2; AMADUCCI LA, 1986, NEUROLOGY, V36, P1497, DOI 10.1212/WNL.36.11.1497; Ancoli-Israel S, 1989, Clin Geriatr Med, V5, P347; ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; ANCOLIISRAEL S, 1991, BIOFEEDBACK SELF-REG, V16, P349, DOI 10.1007/BF00999989; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; BLIWISE DL, 1995, J BEHAV THER EXP PSY, V26, P17, DOI 10.1016/0005-7916(94)00073-U; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CARSKADON MA, 1981, J GERONTOL, V36, P420, DOI 10.1093/geronj/36.4.420; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chestnut R M, 1998, Evid Rep Technol Assess (Summ), P1; Cohen-Zion M, 2001, J AM GERIATR SOC, V49, P1622, DOI 10.1111/j.1532-5415.2001.49270.x; Cosentino FII, 2008, SLEEP MED, V9, P831, DOI 10.1016/j.sleep.2007.10.015; Decary A, 2000, SLEEP, V23, P369; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; DURON B, 1966, REV NEUROL-FRANCE, V115, P562; Ellen RLB, 2006, J CLIN SLEEP MED, V2, P193; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gottlieb DJ, 2004, NEUROLOGY, V63, P664, DOI 10.1212/01.WNL.0000134671.99649.32; Gottlieb S, 2000, BRIT MED J, V321, P1100; Gozal D, 2007, NEUROLOGY, V69, P243, DOI 10.1212/01.wnl.0000265818.88703.83; Gozal E, 2001, NEUROSCI LETT, V305, P197, DOI 10.1016/S0304-3940(01)01853-5; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; GUILLEMINAULT C, 1976, ANNU REV MED, V27, P465, DOI 10.1146/annurev.me.27.020176.002341; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hartman RE, 2002, J NEUROSCI, V22, P10083; HAURI PJ, 1991, SLEEP HYGIENE RELAXA, P65, DOI DOI 10.1007/978-1-4757-9586-8; Horstmann S, 2000, SLEEP, V23, P383; Ikonomovic MD, 2007, ARCH NEUROL-CHICAGO, V64, P1312, DOI 10.1001/archneur.64.9.1312; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kadotani H, 2001, JAMA-J AM MED ASSOC, V285, P2888, DOI 10.1001/jama.285.22.2888; Kalra M, 2008, SLEEP MED, V9, P260, DOI 10.1016/j.sleep.2007.05.001; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Khaime Ts B, 1976, Zh Nevropatol Psikhiatr Im S S Korsakova, V76, P1028; KREIS P, 1983, WESTERN J MED, V139, P171; KRIEGER J, 1980, Revue d'Electroencephalographie et de Neurophysiologie Clinique, V10, P177, DOI 10.1016/S0370-4475(80)80051-7; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mauri M, 2006, FUNCT NEUROL, V21, P223; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Moffat SD, 2000, ARCH INTERN MED, V160, P2193, DOI 10.1001/archinte.160.14.2193; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mustafa Masroor, 2005, Sleep Breath, V9, P57, DOI 10.1007/s11325-005-0016-z; Naegele B, 1998, SLEEP, V21, P392, DOI 10.1093/sleep/21.4.392; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; O'Hara R, 2005, NEUROLOGY, V65, P642, DOI 10.1212/01.wnl.0000173055.75950.bf; O'Hara R, 2001, Dialogues Clin Neurosci, V3, P191; O'Hara R, 1998, J AM GERIATR SOC, V46, P1493, DOI 10.1111/j.1532-5415.1998.tb01532.x; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rami A, 2003, NEUROSCI RES, V47, P373, DOI 10.1016/j.neures.2003.07.002; Redline S, 1997, SLEEP, V20, P160, DOI 10.1093/sleep/20.2.160; Robbins J, 2005, J CLIN SLEEP MED, V1, P159; ROSNER G, 2003, JEMS, V28, P118; Rosner Gregg, 2003, JEMS, V28, P100; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schwartz DJ, 2007, J CLIN SLEEP MED, V3, P631; Sharafkhaneh A, 2005, SLEEP, V28, P1405, DOI 10.1093/sleep/28.11.1405; Shea TB, 2004, J ALZHEIMERS DIS, V6, P269; Small GW, 2000, P NATL ACAD SCI USA, V97, P6037, DOI 10.1073/pnas.090106797; SOININEN H, 1995, NEUROLOGY, V45, P391, DOI 10.1212/WNL.45.2.391; Stepanski EJ, 2003, SLEEP MED REV, V7, P215, DOI 10.1053/smrv.2001.0246; SULLIVAN CE, 1981, LANCET, V1, P862; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; VERDI FJ, 1991, CLEFT PALATE-CRAN J, V28, P301, DOI 10.1597/1545-1569_1991_028_0301_cotspf_2.3.co_2; Victor LD, 1999, AM FAM PHYSICIAN, V60, P2279; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Yaffe K, 1998, J AM GERIATR SOC, V46, P816, DOI 10.1111/j.1532-5415.1998.tb02713.x; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608	90	21	21	0	14	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					837	850		10.1682/JRRD.2008.10.0140			14	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100015	20104407	Bronze			2021-06-18	
J	Penn, PR; Rose, FD; Johnson, DA				Penn, P. R.; Rose, F. D.; Johnson, D. A.			Virtual enriched environments in paediatric neuropsychological rehabilitation following traumatic brain injury: Feasibility, benefits and challenges	DEVELOPMENTAL NEUROREHABILITATION			English	Article						Environmental enrichment; virtual reality; paediatric neuropsychological rehabilitation	SEROTONIN RECEPTOR EXPRESSION; FUNCTIONAL RECOVERY; COGNITIVE PERFORMANCE; NEUROTROPHIN LEVELS; NEURAL PLASTICITY; STROKE PATIENTS; CORTICAL DEPTH; MOTOR FUNCTION; MOUSE MODEL; REALITY	A frequent consequence of traumatic brain injury (TBI) is a significant reduction in patients' cerebral activation/arousal, which clinicians agree is not conducive to optimal rehabilitation outcomes. In the context of paediatric rehabilitation, sustained periods of inactivity are particularly undesirable, as contemporary research has increasingly called into question the Kennard principle that youth inherently promotes greater neural plasticity and functional recovery following TBI. Therefore, the onus to create rehabilitation conditions most conducive to harnessing plasticity falls squarely on the shoulders of clinicians. Having noted the efficacy of environmental enrichment in promoting neural plasticity and positive functional outcomes in the animal literature, some researchers have suggested that the emerging technology of Virtual Reality (VR) could provide the means to increase patients' cerebral activation levels via the use of enriched Virtual Environments (VEs). However, 10 years on, this intuitively appealing concept has received almost no attention from researchers and clinicians alike. This paper overviews recent research on the benefits of enriched environments in the injured brain and identifies the potential and challenges associated with implementing VR-based enrichment in paediatric neuropsychological rehabilitation.	[Penn, P. R.; Rose, F. D.] Univ E London, Sch Psychol, London E15 4LZ, England; [Johnson, D. A.] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland	Penn, PR (corresponding author), Univ E London, Sch Psychol, Romford Rd, London E15 4LZ, England.	p.r.penn@uel.ac.uk					Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Allred RP, 2005, RESTOR NEUROL NEUROS, V23, P297; Amaral OB, 2008, PHYSIOL BEHAV, V93, P388, DOI 10.1016/j.physbeh.2007.09.009; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Andin J, 2007, BRAIN RES, V1174, P18, DOI 10.1016/j.brainres.2007.06.101; Aram DM, 1986, DEV NEUROPSYCHOL, V2, P155, DOI 10.1080/87565648609540339; Behr KM, 2005, PRESENCE-TELEOP VIRT, V14, P668, DOI 10.1162/105474605775196535; Bennett JC, 2006, NEUROBIOL LEARN MEM, V85, P139, DOI 10.1016/j.nlm.2005.09.003; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Broeren J, 2007, ACTA NEUROL SCAND, V116, P157, DOI 10.1111/j.1600-0404.2007.00821.x; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; BROOKS BM, 2002, DISABILITY REHABILIT, V24, P11; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809; Celnik PA, 2004, RESTOR NEUROL NEUROS, V22, P261; CHUGANI HT, 1993, EPILEPSIA, V34, P764, DOI 10.1111/j.1528-1157.1993.tb00459.x; Cracchiolo JR, 2007, NEUROBIOL LEARN MEM, V88, P277, DOI 10.1016/j.nlm.2007.07.007; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Dahlqvist P, 2003, NEUROSCIENCE, V119, P643, DOI 10.1016/S0306-4522(03)00195-7; de Azevedo CS, 2007, APPL ANIM BEHAV SCI, V102, P329, DOI 10.1016/j.applanim.2006.05.034; De Weerdt W, 2000, DISABIL REHABIL, V22, P181, DOI 10.1080/096382800296872; DeBow SB, 2004, CAN J PHYSIOL PHARM, V82, P231, DOI 10.1139/Y04-013; Deutsch JE, 2006, 2006 INTERNATIONAL WORKSHOP ON VIRTUAL REHABILITATION, P140, DOI 10.1109/IWVR.2006.1707542; DEWIT L, 2005, J AM HEART ASS; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1966, J COMP NEUROL, V128, P117, DOI 10.1002/cne.901280110; Duffy SN, 2001, LEARN MEMORY, V8, P26, DOI 10.1101/lm.36301; Elliott BM, 2005, BEHAV BRAIN RES, V165, P187, DOI 10.1016/j.bbr.2005.06.025; Faherty CJ, 2005, MOL BRAIN RES, V134, P170, DOI 10.1016/j.molbrainres.2004.08.008; Faherty CJ, 2003, DEV BRAIN RES, V141, P55, DOI 10.1016/S0165-3806(02)00642-9; Garner JP, 2005, ILAR J, V46, P106, DOI 10.1093/ilar.46.2.106; Gil AM, 2003, J SCHOOL PSYCHOL, V41, P337, DOI 10.1016/S0022-4405(03)00085-2; Glass M, 2004, NEUROSCIENCE, V123, P207, DOI 10.1016/S0306-4522(03)00595-5; Glover S, 2006, J COGNITIVE NEUROSCI, V18, P833, DOI 10.1162/jocn.2006.18.5.833; Gobbo OL, 2004, BEHAV BRAIN RES, V152, P231, DOI 10.1016/j.bbr.2003.10.017; Gold JI, 2006, CYBERPSYCHOL BEHAV, V9, P207, DOI 10.1089/cpb.2006.9.207; Gramann K, 2005, J EXP PSYCHOL HUMAN, V31, P1199, DOI 10.1037/0096-1523.31.6.1199; GREALY MA, 2001, DEV NEUROREHABIL, V4, P41; Hannigan JH, 2007, NEUROSCI BIOBEHAV R, V31, P202, DOI 10.1016/j.neubiorev.2006.06.019; HART K, 1988, J CLIN PSYCHOL, V44, P780, DOI 10.1002/1097-4679(198809)44:5<780::AID-JCLP2270440519>3.0.CO;2-1; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hebb D. O., 1947, AM PSYCHOL, V2, P306, DOI DOI 10.1037/H0028720; Henderson A, 2007, TOP STROKE REHABIL, V14, P52, DOI 10.1310/tsr1402-52; Herrera G, 2008, AUTISM, V12, P143, DOI 10.1177/1362361307086657; Hoffman HG, 2006, CNS SPECTRUMS, V11, P45, DOI 10.1017/S1092852900024202; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Hovorka R., 2006, INT J DISABIL HUM DE, V5, P351, DOI DOI 10.1515/IJDHD.2006.5.4.351; Humm JL, 1999, EXP NEUROL, V157, P349, DOI 10.1006/exnr.1999.7061; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Jadavji NM, 2006, NEUROSCIENCE, V140, P1127, DOI 10.1016/j.neuroscience.2006.03.027; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; JOHNSON DA, 2003, J HEAD TRAUMA REHAB, V18, P342; Jung KE, 2006, ANN REV CYBERTHERAPY, V4, P45; Jung SH, 2005, ARCH PHYS MED REHAB, V86, P2218, DOI 10.1016/j.apmr.2005.04.015; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kleim JA, 2003, NEUROL RES, V25, P789, DOI 10.1179/016164103771953862; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; KLINE S, 2006, ARCH PHYS MED REHAB, V87, P2; Koh S, 2007, EPILEPSY BEHAV, V10, P26, DOI 10.1016/j.yebeh.2006.11.008; Kwakkel G, 2004, RESTOR NEUROL NEUROS, V22, P281; Laatsch L, 2006, BRAIN INJURY, V20, P1367, DOI 10.1080/02699050600983743; Lankhorst AJ, 2001, J NEUROTRAUM, V18, P203, DOI 10.1089/08977150150502622; Lazic SE, 2006, EUR J NEUROSCI, V23, P1829, DOI 10.1111/j.1460-9568.2006.04715.x; Lee JH, 2005, APPL PSYCHOPHYS BIOF, V30, P195, DOI 10.1007/s10484-005-6377-z; Lee JH, 2003, CYBERPSYCHOL BEHAV, V6, P383, DOI 10.1089/109493103322278763; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; LINCOLN NB, 1997, STROKE, V28, P543; Lippert-Gruner M, 2007, PHYSIOL RES, V56, P359; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Lo Priore C, 2003, CYBERPSYCHOL BEHAV, V6, P281, DOI 10.1089/109493103322011579; Maguire EA, 1998, J COGNITIVE NEUROSCI, V10, P61, DOI 10.1162/089892998563789; Marashi V, 2003, HORM BEHAV, V43, P281, DOI 10.1016/S0018-506X(03)00002-3; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Meinzer M, 2007, NEUROPSYCHOLOGIA, V45, P1247, DOI 10.1016/j.neuropsychologia.2006.10.003; Monfils MH, 2004, NEUROSCIENCE, V125, P329, DOI 10.1016/j.neuroscience.2004.01.048; Morganti F, 2004, ST HEAL T, V99, P55; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Naka F, 2005, BRAIN DEV-JPN, V27, P275, DOI 10.1016/j.braindev.2004.07.006; Newall JT, 1997, CLIN REHABIL, V11, P146, DOI 10.1177/026921559701100208; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Padgett LS, 2006, J PEDIATR PSYCHOL, V31, P65, DOI 10.1093/jpepsy/jsj030; Parslow DM, 2004, NEUROPSYCHOLOGY, V18, P450, DOI 10.1037/0894-4105.18.3.450; Parsons TD, 2007, CHILD NEUROPSYCHOL, V13, P363, DOI 10.1080/13825580600943473; Penn PR, 2005, ANN REV CYBERTHERAPY, V3, P31; PENN PR, 2008, BRAIN INJURY EXECUTI, P255; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Rampon C, 2000, NAT NEUROSCI, V3, P238; Restivo L, 2005, P NATL ACAD SCI USA, V102, P11557, DOI 10.1073/pnas.0504984102; Rizzo AA, 2004, COMPUTER, V37, P87, DOI 10.1109/MC.2004.23; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; ROBBINS JA, 2007, J SPEECH LANG HEAR R, V50, P276; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Rose FD, 2000, ERGONOMICS, V43, P494, DOI 10.1080/001401300184378; ROSE FD, 1998, VIRTUAL ENV CLIN PSY, P233; ROSENZWEIG MR, 1961, B BRIT PSYCHOL SOC, pA6; Saucier DM, 2007, BRAIN RES, V1170, P31, DOI 10.1016/j.brainres.2007.07.020; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Shieh E. Y., 2000, Journal of Neurotrauma, V17, P986; Shipman SL, 2008, BEHAV BRAIN RES, V187, P433, DOI 10.1016/j.bbr.2007.10.014; SHOPLAND N, 2004, P 5 INT C DIS VIRT R, P69; Slobounov S, 2006, BIOL PSYCHOL, V72, P188, DOI 10.1016/j.biopsycho.2005.10.005; Tang YP, 2001, NEUROPHARMACOLOGY, V41, P779, DOI 10.1016/S0028-3908(01)00122-8; Tarou LR, 2007, APPL ANIM BEHAV SCI, V102, P189, DOI 10.1016/j.applanim.2006.05.026; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Titov N, 2005, BRAIN INJURY, V19, P315, DOI 10.1080/02699050400013725; Turkstra LS, 2003, ARCH PHYS MED REHAB, V84, P604, DOI 10.1053/apmr.2003.50146; VONSTEINBUCHEL N, 1993, BEHAV BRAIN RES, V56, P1, DOI 10.1016/0166-4328(93)90017-K; Weinberger NM, 2004, NAT REV NEUROSCI, V5, P279, DOI 10.1038/nrn1366; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wolfer DP, 2004, NATURE, V432, P821, DOI 10.1038/432821a; Wurbel H, 2001, TRENDS NEUROSCI, V24, P207, DOI 10.1016/S0166-2236(00)01718-5; Wurbel H., 2007, REFINEMENT RODENT RE; Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019; Yen HL, 2007, ANN ACAD MED SINGAP, V36, P62; You SH, 2005, DEV MED CHILD NEUROL, V47, P628, DOI 10.1017/S0012162205001234; Zhu SW, 2006, BEHAV BRAIN RES, V169, P10, DOI 10.1016/j.bbr.2005.11.024; Zimmermann A, 2001, BEHAV BRAIN RES, V121, P11, DOI 10.1016/S0166-4328(00)00377-6	123	21	21	1	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	1					32	43		10.1080/17518420902739365			12	Clinical Neurology; Pediatrics; Rehabilitation	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FJ	WOS:000207787600005	19283532				2021-06-18	
J	Shigaki, CL; Johnstone, B; Schopp, LH				Shigaki, Cheryl L.; Johnstone, Brick; Schopp, Laura H.			Financial and vocational outcomes 2 years after traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Brain injuries; cost of illness; social security; employment; financial support	QUALITY-OF-LIFE; EMPLOYMENT; WORK; RETURN	Purpose. To determine outcomes for persons with traumatic brain injury (TBI) in terms of employment status, income and public assistance received at 2 years after injury. Method. This study was part of a non-experimental, longitudinal survey. Participants included 49 persons with new TBI from one US national Traumatic Brain Injury Model Systems centre. Main outcome measures included employment status, earned monthly income and monthly income from public sources, at the time of injury and at 2-years follow-up. Results. At 2-year follow-up, individuals with TBI reported higher levels of employment and earned income than was previously reported for 1-year post-injury, but continued to experience declines relative to pre-injury baseline. Frequency and amount of major public agency payments continued to be increased relative to baseline. Conclusions. The costs associated with brain injury remain high for individuals, families and society, as those with TBI move into the more chronic phase of recovery.	[Shigaki, Cheryl L.; Johnstone, Brick; Schopp, Laura H.] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA	Shigaki, CL (corresponding author), Univ Missouri, Dept Hlth Psychol, 1 Hosp Dr,DC116-88, Columbia, MO 65212 USA.	shigakic@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649	National Institute on Disability and Rehabilitation Research [H133A980008]; US Department of EducationUS Department of Education	This study was completed as part of the Missouri Model Brain Injury System, funded by the National Institute on Disability and Rehabilitation Research (#H133A980008), US Department of Education. Opinions expressed do not reflect those of NIDRR or the Department of Education. The authors thank Ashley Sherman, M. A., and John Hewett, Ph.D. for their statistical assistance. I would also like to thank Kelly Lora Franklin for her assistance with managing references and editorial support in the preparation of this manuscript.	[Anonymous], 1998, REH PERS TRAUM BRAIN; Bell GD, 1998, B AM METEOROL SOC, V79, pS1; *CDC, 1999, TRAUM BRAIN INJ US; *CDCP, TRAUM BRAIN INJ FACT; CRISP R, 1992, J REHABIL, V58, P27; FINKELSTEIN E, 2006, CDCP RTI INT PAC I R; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MILLIS S, 2004, WINTER, V10, P8; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US GOV PRESS OFF, 2007, PRESS OFF FACT SHEET; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	18	21	21	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2009	31	6					484	489	PII 905995375	10.1080/09638280802240449			6	Rehabilitation	Rehabilitation	434RW	WOS:000265292800006	19034724				2021-06-18	
J	Waldron-Perrine, B; Rapport, LJ; Ryan, KA; Harper, KT				Waldron-Perrine, Brigid; Rapport, Lisa J.; Ryan, Kelly A.; Harper, Kaja Telmet			Predictors of life satisfaction among caregivers of individuals with multiple sclerosis	CLINICAL NEUROPSYCHOLOGIST			English	Article						Multiple sclerosis; Caregiver; Social support; Awareness of deficit; Illness uncertainty	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; IMPAIRED AWARENESS; EXECUTIVE FUNCTION; DISTRESS; UNCERTAINTY; ILLNESS; CARERS; BURDEN; MS	Research on life satisfaction among caregivers of persons with multiple sclerosis (MS) is sparse. This study examined the extent to which MS-specific disease and psychosocial characteristics predict caregiver life satisfaction. Participants were 64 caregivers of patients with MS and the patients for whom they care. Multiple regression analysis indicated that caregiver perception of illness uncertainty and patients' unawareness of deficits have unique value in predicting caregiver life satisfaction, even after accounting for general financial status. Gender and level of social support were also important contributing factors to caregiver life satisfaction. The findings suggest that duration and severity of the patients' illness take a greater toll on life satisfaction of caregivers with low versus high social support, particularly among women caregivers.	[Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 5057 Woodward Ave, Detroit, MI 48202 USA.	rapport@sun.science.wayne.edu			Blue Cross Blue Shield of Michigan; Wayne State University Thesis Research Grant	This research was supported in part by a grant from Blue Cross Blue Shield of Michigan and a Wayne State University Thesis Research Grant. The authors thank Drs. Robert Lisak and Omar Khan and their staff at the MS Clinic of University Health Center, Detroit Medical Center, Detroit, MI for their assistance in the data collection process. Kelly Ryan is now at the University of Michigan.	Aronson KJ, 1997, NEUROLOGY, V48, P74, DOI 10.1212/WNL.48.1.74; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BENTON A, 1994, BENTON VISUAL NAMING; BOYLE EA, 1991, ARCH NEUROL-CHICAGO, V48, P1150, DOI 10.1001/archneur.1991.00530230058022; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Carone DA, 2005, J INT NEUROPSYCH SOC, V11, P574, DOI 10.1017/S135561770505068X; Chipchase SY, 2001, DISABIL REHABIL, V23, P768; Cottrell SS, 1926, J NEUROL PSYCHOPATHO, V7, P1; CUTRONA C, 1987, ADV PERSONAL RELATIO, P37; DEROSIER MB, 1992, REHABIL NURS, V17, P87; Diener E., 2002, HDB POSITIVE PSYCHOL, P63, DOI DOI 10.1093/OXFORDHB/9780195187243.013.0017; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Foong J, 1997, BRAIN, V120, P15, DOI 10.1093/brain/120.1.15; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Good D M, 1995, J Neurosci Nurs, V27, P305; Goode KT, 1998, HEALTH PSYCHOL, V17, P190, DOI 10.1037/0278-6133.17.2.190; Gulick EE, 1998, NURS RES, V47, P137, DOI 10.1097/00006199-199805000-00004; Halstead WC, 1985, HALSTEAD REITAN NEUR; Kenealy PM, 2000, J CLIN EXP NEUROPSYC, V22, P125, DOI 10.1076/1380-3395(200002)22:1;1-8;FT125; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; Kooptiwoot S, 2006, SOFT COMPUT, V10, P369, DOI 10.1007/s00500-005-0496-6; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Lucas RE, 1996, J PERS SOC PSYCHOL, V71, P616, DOI 10.1037/0022-3514.71.3.616; Maor Y, 2001, MULT SCLER, V7, P131, DOI 10.1177/135245850100700209; McKeown LP, 2003, CLIN REHABIL, V17, P234, DOI 10.1191/0269215503cr618oa; Middleton LS, 2006, ARCH CLIN NEUROPSYCH, V21, P487, DOI 10.1016/j.acn.2006.06.008; Mishel M H, 1987, West J Nurs Res, V9, P43, DOI 10.1177/019394598700900106; MISHEL MH, 1984, RES NURS HEALTH, V7, P163, DOI 10.1002/nur.4770070304; MISHEL MH, 1981, NURS RES, V30, P258; Mullins LL, 2001, REHABIL PSYCHOL, V46, P139, DOI 10.1037/0090-5550.46.2.139; O'Brien M T, 1993, J Community Health Nurs, V10, P123, DOI 10.1207/s15327655jchn1003_1; OBRIEN MT, 1995, SCHOLARLY INQUIRY NU, V9, P323; Padilla G V, 1992, Qual Life Res, V1, P155, DOI 10.1007/BF00635615; Pakenham KI, 2005, DISABIL REHABIL, V27, P985, DOI 10.1080/09638280500052583; Pakenham KI, 2005, J CLIN PSYCHOL MED S, V12, P25, DOI 10.1007/s10880-005-0910-3; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pozzilli C, 2004, MULT SCLER, V10, P442, DOI 10.1191/1352458504ms1046oa; Provinciali L, 1999, ACTA NEUROL SCAND, V100, P156; Rao S., 1990, MANUAL BRIEF REPEATA; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; Regard M, 1981, THESIS U VICTORIA; Ryan KA, 2007, CLIN NEUROPSYCHOL, V21, P239, DOI 10.1080/13854040600582460; Rymer S, 2002, ALZ DIS ASSOC DIS, V16, P248, DOI 10.1097/00002093-200210000-00006; Seltzer B, 1997, GERONTOLOGIST, V37, P20, DOI 10.1093/geront/37.1.20; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sherman TE, 2007, MULT SCLER, V13, P238, DOI 10.1177/1352458506070754; Smith A., 1973, SYMBOL DIGIT MODALIT; Spreen O., 1991, COMPENDIUM NEUROPSYC; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; Tabachnick BG, 2007, USING MULTIVARIATE S; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; Weinert C., 1993, FAM COMMUNITY HEALTH, V16, P46; WOLLIN J, 1999, INT J MS CARE, V1, P6	59	21	21	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	3					462	478	PII 901634984	10.1080/13854040802279683			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	423QH	WOS:000264510300006	18720271				2021-06-18	
J	Yang, XF; Wen, L; Li, G; Zhan, RY; Ma, L; Liu, WG				Yang, X. F.; Wen, L.; Li, G.; Zhan, R. Y.; Ma, L.; Liu, W. G.			Contralateral Subdural Effusion Secondary to Decompressive Craniectomy Performed in Patients with Severe Traumatic Brain Injury: Incidence, Clinical Presentations, Treatment and Outcome	MEDICAL PRINCIPLES AND PRACTICE			English	Article						Traumatic brain injury; Decompressive craniectomy; Subdural effusion, complication, incidence rate	SURGICAL DECOMPRESSION; FLUID COLLECTION; DURAPLASTY	Objective: This study was performed to better understand postoperative contralateral subdural effusion, an uncommon but serious complication secondary to decompressive craniectomy in patients with head trauma. Subjects and Methods: Data from medical records of 169 patients who underwent decompressive craniectomy after head trauma between 2003 and 2006 were collected. The data included demographics, clinical presentations, treatment and outcome. Results: Of the 169 patients, 11 (6.5%) had contralateral subdural effusion. On the average, this complication was found 14 days after decompressive craniectomy. Of the 11 patients, conservative treatment was effective in 7 with a gradual resolution which lasted 52.7 days on average. The effusion in the remaining 4 patients led to progressive deterioration of clinical presentation, and surgical intervention was necessary: subduroperitoneal shunting in 3 cases and burr hole drainage in the remaining 1 case. Conclusions: Our findings confirmed that postoperative contralateral subdural effusion was not an uncommon complication secondary to decompressive craniectomy. Most contralateral subdural effusions resolved spontaneously after conservative management, but surgical management may be necessary if the patients develop deteriorating clinical manifestations or the subdural effusion has an apparent mass effect. Copyright (C) 2008 S. Karger AG, Basel	[Yang, X. F.; Wen, L.; Li, G.; Zhan, R. Y.] Zhejiang Univ, Affiliated Hosp 1, Dept Neurosurg, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China; [Ma, L.; Liu, W. G.] Zhejiang Univ, Affiliated Hosp 2, Dept Neurosurg, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China; [Yang, X. F.; Wen, L.; Li, G.; Zhan, R. Y.; Ma, L.; Liu, W. G.] Zhejiang Univ, Inst Brain Med, Hangzhou 310003, Zhejiang, Peoples R China	Wen, L (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Neurosurg, Coll Med, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.	wenlneuron@126.com					Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Andre C, 2003, ARQ NEURO-PSIQUIAT, V61, P682, DOI 10.1590/S0004-282X2003000400030; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; FRENCH BN, 1978, SURG NEUROL, V9, P145; Hutchinson PJ, 2005, ACTA NEUROCHIR, V147, P1, DOI 10.1007/s00701-004-0400-7; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Miyake H, 2002, CHILD NERV SYST, V18, P500, DOI 10.1007/s00381-002-0596-x; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; SHULMAN K, 1963, J NEUROSURG, V20, P1040, DOI 10.3171/jns.1963.20.12.1040; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; TABADDOR K, 1976, J NEUROSURG, V44, P506, DOI 10.3171/jns.1976.44.4.0506; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Vinchon M, 2006, J NEUROSURG, V104, P383, DOI 10.3171/ped.2006.104.6.383; Wagner S, 2001, J NEUROSURG, V94, P693, DOI 10.3171/jns.2001.94.5.0693; YAMADA H, 1980, SURG NEUROL, V13, P441; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99	19	21	29	1	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1011-7571	1423-0151		MED PRIN PRACT	Med. Princ. Pract.		2009	18	1					16	20		10.1159/000163040			5	Medicine, General & Internal	General & Internal Medicine	379GX	WOS:000261385800003	19060485	Bronze			2021-06-18	
J	da Silva, PSL; Reis, ME; Aguiar, VE				Lucas da Silva, Paulo Sergio; Reis, Maria Eunice; Aguiar, Vania Euzebio			Value of Repeat Cranial Computed Tomography in Pediatric Patients Sustaining Moderate to Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Children; CT scan; Traumatic brain injury; Glasgow Coma Scale; Pediatric intensive care unit	MINIMAL HEAD-INJURY; INTRACRANIAL INJURY; CLINICAL-EFFICACY; CHILDREN; UTILITY; MANAGEMENT; RADIATION; COHORT; SCAN	Background: Repeat head computed tomography (CT) is standard practice for traumatic brain injury (TBI) at many centers. The few studies available in children remain unclear over the value of repeat CT within 24 hours to 48 hours of lesion in such patients. The purpose of the present study was to assess the value of repeat cranial CT in children presenting moderate or severe TBI. Methods: A retrospective study performed within a pediatric intensive care unit between January 2000 and December 2006. All patients with moderate and severe TBI who survived the first 24 hours after admission were included. Clinical data collected included age, lesion mechanism, time between first and second CTs, disease severity score at admission, and Glasgow Coma Scale (GCS) both at admission and (lay of repeat CT. Results: A total of 63 children were assessed whose mean age was 72 months (48-112). The time between the first and the second CT scans averaged 25.78 hours +/- 13.75 hours (range, 6-48 hours). The reasons for ordering repeat CT scans were divided as follows: follow-up (78%), neurologic deterioration (20.4%.), and increased intracranial pressure (1.6%). The change on the follow-tip CT scan was compared with the GCS score. The GCS score was improved in 66.6% of patients, remained the same in 15.9%, and worsened in 17.5%. The appearance on the CT scans was better, the same or worse in 41.3%, 34.9%, and 23.8% of patients, respectively. There was a significant association between GCS and changes in findings on repeat CT (OR = 34.5, confidence interval [5.98-199.04], p = 0.000009). The positive and negative predictive values were 82% and 89%, respectively. One patient with a worsened GCS required surgical intervention based on the repeat CT scan. Conclusion: An unchanged or improving neurologic examination in children sustaining moderate or severe TBI who are appropriately monitored may be adequate to exclude the possibility of neurosurgical intervention and, hence, repeat head CT scan.	[Lucas da Silva, Paulo Sergio; Reis, Maria Eunice; Aguiar, Vania Euzebio] Hosp Servidor Publ Municipal, Dept Pediat, Pediat Intens Care Unit, Sao Paulo, Brazil	da Silva, PSL (corresponding author), Rua Aroeiras 30 Ap 22, BR-09090000 Sao Paulo, Brazil.	psls.nat@terra.com.br	Silva, Paulo Sergio L/P-5182-2018				Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Durham SR, 2006, J NEUROSURG, V105, P365, DOI 10.3171/ped.2006.105.5.365; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Gruen JP, 1996, SURG CLIN N AM, V76, P905, DOI 10.1016/S0039-6109(05)70487-4; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; HURST JM, 1992, J TRAUMA, V33, P582, DOI 10.1097/00005373-199210000-00015; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LOBATO RD, 1997, ACTA NEUROCHIR WIEN, V139, P395; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Stearley H E, 1998, Am J Crit Care, V7, P282; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	26	21	21	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2008	65	6					1293	1297		10.1097/TA.0b013e318156866c			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	383WV	WOS:000261706000019	19077616				2021-06-18	
J	Mehta, S; Routt, MLC				Mehta, Samir; Routt, M. L. Chip, Jr.			Irreducible Fracture-Dislocations of the Femoral Head Without Posterior Wall Acetabular Fractures	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						femoral head fracture; irreducible hip fracture-dislocation; Smith-Petersen exposure	TERM-FOLLOW-UP; TRAUMATIC DISLOCATION; HIP DISLOCATIONS; INJURY	Objective: To define the unique clinical and radiographic features, operative treatment, and complications of irreducible femoral head fracture-dislocation without associated posterior wall fracture. Design: Retrospective clinical study from a prospectively gathered trauma database. Setting: Level I trauma center. Patients/Participants: During a 6-year period (from January 2000 until August 2006), 72 patients with fractures of the femoral head (OTA 31 C) were treated at a level I trauma center. Seven (9.7%) patients had irreducible femoral head fracture-dislocations without associated posterior wall acetabular fractures and underwent operative management. Intervention: Open reduction and internal fixation of the irreducible femoral head fracture-dislocation with miniature fragment screw fixation using a Smith-Petersen exposure. Main Outcome Measures: Clinical and radiographic markers of irreducibility, surgical findings, fixation methods, reduction accuracy, and injury- and treatment-related complications. Results: Standardized postoperative pelvic computed tomography scans revealed that all 7 femoral head fractures were accurately reduced. Two patients with delayed operative management developed femoral head aseptic necrosis and underwent hip arthroplasty. Conclusions: Irreducible femoral head fracture-dislocations without associated posterior wall fractures occur rarely., but are heralded by unique clinical and radiographic features. These patients warrant special consideration in terms of recognition and management. The physical examination findings and specific radiographic markers should alert the Surgeon to this injury pattern and its related complications. Closed reduction of this fracture-dislocation should not be attempted. Delayed operative management may be related to femoral head aseptic necrosis. Accurate reduction and stable fixation can successfully be performed through a Smith-Petersen surgical exposure using small or miniature fragment cortical screws alone.	[Mehta, Samir] Hosp Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA; [Routt, M. L. Chip, Jr.] Univ Washington, Harborview Med Ctr, Dept Orthopaed & Sport Med, Seattle, WA 98104 USA	Mehta, S (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	samir.mehta@uphs.upenn.edu					BOSSE MJ, 1988, J BONE JOINT SURG AM, V70A, P1231, DOI 10.2106/00004623-198870080-00016; Brumback R J, 1987, Hip, P181; BUTLER JE, 1981, J BONE JOINT SURG AM, V63, P1292, DOI 10.2106/00004623-198163080-00011; CANALE ST, 1979, J BONE JOINT SURG AM, V61, P7, DOI 10.2106/00004623-197961010-00003; CHAKRABORTI S, 1975, INJURY, V7, P134, DOI 10.1016/0020-1383(75)90011-X; DELEE JC, 1980, J BONE JOINT SURG AM, V62, P960, DOI 10.2106/00004623-198062060-00012; EPSTEIN HC, 1974, J BONE JOINT SURG AM, VA 56, P1103, DOI 10.2106/00004623-197456060-00001; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, P9; HOUGAARD K, 1986, ARCH ORTHOP TRAUM SU, V106, P32, DOI 10.1007/BF00435649; Kaempffe F A, 1991, J Orthop Trauma, V5, P439, DOI 10.1097/00005131-199112000-00009; Kim Yoon Taek, 2003, J Orthop Sci, V8, P232, DOI 10.1007/s007760300039; LANGSTEVENSON A, 1987, INJURY, V18, P264, DOI 10.1016/0020-1383(87)90011-8; Marchetti ME, 1996, J ORTHOP TRAUMA, V10, P455, DOI 10.1097/00005131-199610000-00002; Matta JM, 1996, J BONE JOINT SURG AM, V78A, P1632, DOI 10.2106/00004623-199611000-00002; McKee MD, 1998, J ORTHOP TRAUMA, V12, P223, DOI 10.1097/00005131-199805000-00001; Mostafa MM, 2001, INT ORTHOP, V25, P51, DOI 10.1007/s002640000209; Sahin V, 2003, J TRAUMA, V54, P520, DOI 10.1097/01.TA.0000020394.32496.52; Stannard JP, 2000, CLIN ORTHOP RELAT R, P44; Swiontkowski M F, 1992, J Orthop Trauma, V6, P437, DOI 10.1097/00005131-199212000-00008; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; TRUETA J, 1953, J BONE JOINT SURG BR, V35, P442; YANG RS, 1991, CLIN ORTHOP RELAT R, P218; Yue JJ, 1996, J ORTHOP TRAUMA, V10, P447, DOI 10.1097/00005131-199610000-00001	23	21	21	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	NOV-DEC	2008	22	10					686	692		10.1097/BOT.0b013e31818e2a86			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	371GO	WOS:000260820000003	18978543				2021-06-18	
J	Craig, M; Bir, C; Viano, D; Tashman, S				Craig, Matthew; Bir, Cynthia; Viano, David; Tashman, Scott			Biomechanical response of the human mandible to impacts of the chin	JOURNAL OF BIOMECHANICS			English	Article						Mandible; Impact biomechanics; Response corridors	HUMAN TEMPOROMANDIBULAR-JOINT; PROFESSIONAL FOOTBALL; CONCUSSION; CORRIDORS; INJURIES; FRACTURE; BONE	The purpose of this study was to determine the force-time and force-displacement response of the human mandible under direct loading at the chin. Sub-fracture response of the mandible and temporomandibular joint (TMJ) were analyzed from 10 cadavers that were impacted at the chin with a 2.8-kg mass at drop heights of 300, 400 and 500 mm and a 5.2-kg mass at 500 mm. Motion of radio-opaque markers adhered to the surface of the bone was recorded at 1000 Hz by a bi-planar X-ray and converted to three-dimensional coordinates. Peak force ranged from 0.90 to 4.54kN causing chin displacement of 1.2-4.4 mm. A bi-linear response was observed with stiffness of 475.1 +/- 199.8 kN/m for chin displacement resulting from loading up to 0.6 kN and 2381.6 +/- 495.7 kN/m for loads from 0.6 to 3.25 kN. This defines the biomechanical response of the mandible for chin motion under impact loading. The response of different segments of the mandible and TMJ are also documented. Force-time and force-displacement response corridors for the mandible can be used for finite element model and/or the development and validation of a biomechanical surrogate. (c) 2008 Elsevier Ltd. All rights reserved.	[Craig, Matthew; Bir, Cynthia; Viano, David] Wayne State Univ, Ctr Bioengn, Detroit, MI 48202 USA; [Tashman, Scott] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA	Bir, C (corresponding author), Wayne State Univ, Ctr Bioengn, 818 W Hancock, Detroit, MI 48202 USA.	cbir@wayne.edu	; Tashman, Scott/A-8951-2011	Bir, Cynthia/0000-0002-0777-0951; Tashman, Scott/0000-0003-0534-3785			Beek M, 2001, J DENT RES, V80, P876, DOI 10.1177/00220345010800030601; Bir C, 2004, J BIOMECH, V37, P73, DOI 10.1016/S0021-9290(03)00238-0; BYARS EF, 1970, 1970 ASME WINT ANN M; Giesen EBW, 2003, CLIN BIOMECH, V18, P358, DOI 10.1016/S0268-0033(03)00018-4; Hardy W N, 2001, Stapp Car Crash J, V45, P1; HODGSON VR, 1967, AM J ANAT, V120, P113, DOI 10.1002/aja.1001200109; Hopper R. H., 1994, P 38 STAPP CAR CRASH; Hu K, 2003, MED ENG PHYS, V25, P107, DOI 10.1016/S1350-4533(02)00191-1; Hubbard RP, 1973, HUMAN IMPACT RESPONS, P129; HUELKE DF, 1983, J ORAL MAXIL SURG, V41, P241, DOI 10.1016/0278-2391(83)90266-5; KING AI, 1995, J TRAUMA, V38, P564, DOI 10.1097/00005373-199504000-00016; Kroell CK, 1971, P 15 STAPP CAR CRASH; Lai WFT, 1998, J OROFAC PAIN, V12, P153; Maltese Matthew R, 2002, Stapp Car Crash J, V46, P321; MELVIN J, 1989, HYBRID, V3, P453; MELVIN J, 1995, P 39 STAPP CAR CRASH; NAHUM AM, 1975, LARYNGOSCOPE, V85, P140, DOI 10.1288/00005537-197501000-00011; NAHUM AM, 1968, P 12 STAPP CAR CRASH; Newman J. A., 1984, P 28 STAPP CAR CRASH; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PRETI G, 1982, J PROSTHET DENT, V47, P445, DOI 10.1016/S0022-3913(82)80099-1; SCHNEIDER DC, 1972, P 16 STAPP CAR CRASH; Stemper B D, 2001, Biomed Sci Instrum, V37, P239; Tanaka E, 2001, J ORAL REHABIL, V28, P273, DOI 10.1111/j.1365-2842.2001.tb01677.x; Tashman S, 2003, J BIOMECH ENG-T ASME, V125, P238, DOI 10.1115/1.1559896; Unnewehr M, 2003, INT J LEGAL MED, V117, P326, DOI 10.1007/s00414-003-0391-6; WALILKO TJ, 2004, THESIS WAYNE STATE U; Wheeldon JA, 2006, J BIOMECH, V39, P375, DOI 10.1016/j.jbiomech.2004.11.014	30	21	21	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	OCT 20	2008	41	14					2972	2980		10.1016/j.jbiomech.2008.07.020			9	Biophysics; Engineering, Biomedical	Biophysics; Engineering	373PZ	WOS:000260985700012	18805529				2021-06-18	
J	Kincaid, MS				Kincaid, M. Sean			Transcranial Doppler ultrasonography: a diagnostic tool of increasing utility	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						carotid endarterectomy; cerebral vasospasm; ischemic stroke; migraine; patent foramen ovale; sickle cell; transcranial Doppler ultrasonography; traumatic brain injury	PATENT FORAMEN OVALE; CAROTID-ARTERY STENOSIS; TISSUE-PLASMINOGEN ACTIVATOR; FULMINANT HEPATIC-FAILURE; TRAUMATIC BRAIN-INJURY; SICKLE-CELL-DISEASE; TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; DYNAMIC CEREBRAL AUTOREGULATION; ATRIAL SEPTAL ANEURYSM; ACADEMY-OF-NEUROLOGY	Purpose of review Since its introduction in 1982, transcranial Doppler ultrasonography has become an important diagnostic and monitoring tool in patients with surgical disease. It has applications in the perioperative period, as well as in the intensive care unit. It is therefore appropriate for the anesthesiologist to maintain an understanding of its current utility. Recent findings Transcranial Doppler has an established role in diagnosing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage and for guiding transfusion therapy in children with sickle cell disease. It has application in the preoperative evaluation of patients with cerebrovascular disease, as well as that of an intraoperative monitor in carotid endarterectomy and carotid stenting. It is useful for detecting right-to-left shunts in settings in which transesophageal echocardiography is not desirable. Its value in settings such as traumatic brain injury, hepatic failure, and migraine headache has yet to be fully clarified. Summary Although there are several settings in which transcranial Doppler has well established usefulness, there are many more in which it is likely valuable, such as traumatic brain injury, ischemic stroke, and fulminant hepatic failure. Further research is needed in these fields to elucidate the exact role for transcranial Doppler.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Anesthesiol, Seattle, WA 98104 USA	Kincaid, MS (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Anesthesiol, Seattle, WA 98104 USA.	kincaid@u.washington.edu					AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1986, NEURORADIOLOGY, V28, P11, DOI 10.1007/BF00341759; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Abdo A, 2003, TRANSPLANT P, V35, P1859, DOI 10.1016/S0041-1345(03)00592-X; Ackerstaff RGA, 2005, J VASC SURG, V41, P618, DOI 10.1016/j.jvs.2005.01.034; Ackerstaff RGA, 2000, STROKE, V31, P1817, DOI 10.1161/01.STR.31.8.1817; ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Anzola GP, 1999, NEUROLOGY, V52, P1622, DOI 10.1212/WNL.52.8.1622; Arauz A, 2006, CEREBROVASC DIS, V22, P150, DOI 10.1159/000093244; Ardizzone G, 2004, TRANSPLANT P, V36, P3060, DOI 10.1016/j.transproceed.2004.11.014; Barbut D, 1996, STROKE, V27, P87, DOI 10.1161/01.STR.27.1.87; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Belvis R, 2006, J NEUROIMAGING, V16, P133, DOI 10.1111/j.1552-6569.2006.00021.x; BRASS LM, 1990, STROKE, V21, P484, DOI 10.1161/01.STR.21.3.484; Burch CM, 1996, J NEUROIMAGING, V6, P8, DOI 10.1111/jon1996618; CABANES L, 1993, STROKE, V24, P1865, DOI 10.1161/01.STR.24.12.1865; CAPLAN LR, 1986, STROKE, V17, P648, DOI 10.1161/01.STR.17.4.648; Carod-Artal FJ, 2006, CEPHALALGIA, V26, P934, DOI 10.1111/j.1468-2982.2006.01156.x; Chaturvedi S, 2005, NEUROLOGY, V65, P794, DOI 10.1212/01.wnl.0000176036.07558.82; Chernyshev OY, 2005, STROKE, V36, P32, DOI 10.1161/01.STR.0000150496.27584.e3; Czosnyka M, 2003, ACT NEUR S, V86, P581; Daffertshofer M, 2005, STROKE, V36, P1441, DOI 10.1161/01.STR.0000170707.86793.1a; Domitrz I, 2007, HEADACHE, V47, P1311, DOI 10.1111/j.1526-4610.2006.00724.x; Dowson A, 2008, CIRCULATION, V117, P1397, DOI 10.1161/CIRCULATIONAHA.107.727271; Ederle J, 2006, EUR J RADIOL, V60, P3, DOI 10.1016/j.ejrad.2006.05.021; Estrera AL, 2005, J THORAC CARDIOV SUR, V129, P277, DOI 10.1016/j.jtcvs.2004.08.052; FRANCIS CW, 1995, ULTRASOUND MED BIOL, V21, P419, DOI 10.1016/0301-5629(94)00119-X; Gao S, 2004, STROKE, V35, P2832, DOI 10.1161/01.STR.0000147035.31297.b6; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Hadani M, 1999, INTENS CARE MED, V25, P822, DOI 10.1007/s001340050958; Halliday A, 2004, LANCET, V363, P1491; HALSEY JH, 1992, STROKE, V23, P1583, DOI 10.1161/01.STR.23.11.1583; HERZIG R, 2004, REV BIOMED PAP MED F, V148, P119; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Iguchi Y, 2008, J NEUROL NEUROSUR PS, V79, P253, DOI 10.1136/jnnp.2007.123414; JORGENSEN LG, 1993, EUR J VASCULAR SURG, V7, P370, DOI 10.1016/S0950-821X(05)80252-X; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Komoribayashi N, 2006, J CEREBR BLOOD F MET, V26, P878, DOI 10.1038/sj.jcbfm.9600244; Komotar RJ, 2006, NEUROSURGERY, V59, P284, DOI 10.1227/01.NEU.0000223340.89958.8D; Laman DM, 2002, J VASC SURG, V36, P278, DOI 10.1067/mva.2002.125796; Lamy C, 2002, STROKE, V33, P706, DOI 10.1161/hs0302.104543; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; Lysakowski C, 2001, STROKE, V32, P2292, DOI 10.1161/hs1001.097108; Markus H, 2001, BRAIN, V124, P457, DOI 10.1093/brain/124.3.457; Markus HS, 2005, CIRCULATION, V111, P2233, DOI 10.1161/01.CIR.0000163561.90680.1C; Markus HS, 2005, STROKE, V36, P971, DOI 10.1161/01.STR.0000162717.62684.40; Mas JL, 2001, NEW ENGL J MED, V345, P1740, DOI 10.1056/NEJMoa011503; Mazumdar M, 2007, PEDIATRICS, V120, pe1107, DOI 10.1542/peds.2006-2002; Molina CA, 2006, STROKE, V37, P425, DOI 10.1161/01.STR.0000199064.94588.39; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P445, DOI 10.1097/00000542-199303000-00007; Molloy J, 1999, STROKE, V30, P1440, DOI 10.1161/01.STR.30.7.1440; Moritz S, 2007, ANESTHESIOLOGY, V107, P563, DOI 10.1097/01.anes.0000281894.69422.ff; NAYLOR AR, 1991, BRIT J SURG, V78, P1264, DOI 10.1002/bjs.1800781038; Naylor AR, 2000, J VASC SURG, V32, P750, DOI 10.1067/mva.2000.108007; Norenberg MD, 2005, METAB BRAIN DIS, V20, P303, DOI 10.1007/s11011-005-7911-7; Ogasawara K, 2007, J NEUROSURG, V107, P1130, DOI 10.3171/JNS-07/12/1130; Orlandi G, 2005, ARCH NEUROL-CHICAGO, V62, P1208, DOI 10.1001/archneur.62.8.1208; PIEPGRAS DG, 1988, J NEUROSURG, V68, P532, DOI 10.3171/jns.1988.68.4.0532; PUGSLEY W, 1994, STROKE, V25, P1393, DOI 10.1161/01.STR.25.7.1393; Puppo C, 2008, NEUROCRIT CARE, V8, P344, DOI 10.1007/s12028-008-9069-8; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Reisman M, 2005, J AM COLL CARDIOL, V45, P493, DOI 10.1016/j.jacc.2004.10.055; RILES TS, 1994, J VASC SURG, V19, P206, DOI 10.1016/S0741-5214(94)70096-6; Saqqur M, 2007, STROKE, V38, P948, DOI 10.1161/01.STR.0000257304.21967.ba; Sastry S, 2006, J AM COLL CARDIOL, V48, P686, DOI 10.1016/j.jacc.2006.02.074; Silvestrini M, 2000, JAMA-J AM MED ASSOC, V283, P2122, DOI 10.1001/jama.283.16.2122; Sloan M. A., 1997, NEW TRENDS CEREBRAL, P221; SLOAN MA, 1989, NEUROLOGY, V39, P1514, DOI 10.1212/WNL.39.11.1514; Sloan MA, 2004, NEUROLOGY, V62, P1468, DOI 10.1212/WNL.62.9.1468; SLOAN MA, 1994, STROKE, V25, P2187, DOI 10.1161/01.STR.25.11.2187; Soustiel JF, 2002, STROKE, V33, P72, DOI 10.1161/hs0102.100484; Spence JD, 2005, STROKE, V36, P2373, DOI 10.1161/01.STR.0000185922.49809.46; Sreeram GM, 2004, J CARDIOTHOR VASC AN, V18, P548, DOI 10.1053/j.jvca.2004.07.010; Sviri GE, 2006, NEUROSURGERY, V59, P360, DOI 10.1227/01.NEU.0000223502.93013.6E; Tan H, 2001, Chin J Traumatol, V4, P156; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Tofteng F, 2004, METAB BRAIN DIS, V19, P207, DOI 10.1023/B:MEBR.0000043970.34533.04; Vaquero J, 2005, LIVER TRANSPLANT, V11, P1581, DOI 10.1002/lt.20625; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; Vernieri F, 2001, STROKE, V32, P1552, DOI 10.1161/01.STR.32.7.1552; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WILCOX WD, 1983, J PEDIATR-US, V102, P294, DOI 10.1016/S0022-3476(83)80546-0; Wong KS, 2000, STROKE, V31, P2641, DOI 10.1161/01.STR.31.11.2641; Wong KSL, 2005, EUR NEUROL, V53, P132, DOI 10.1159/000085569; Wozniak MA, 1996, J NEUROIMAGING, V6, P87, DOI 10.1111/jon19966287	95	21	21	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0952-7907			CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2008	21	5					552	559		10.1097/ACO.0b013e32830edc0b			8	Anesthesiology	Anesthesiology	398ER	WOS:000262715900005	18784478				2021-06-18	
J	Llompart-Pou, JA; Raurich, JM; Perez-Barcena, J; Barcelo, A; Ibanez, J; Ayestaran, JI				Llompart-Pou, Juan A.; Raurich, Joan M.; Perez-Barcena, Jon; Barcelo, Antonia; Ibanez, Jordi; Ayestaran, Jose I.			Acute hypothalamic-pituitary-adrenal response in traumatic brain injury with and without extracerebral trauma	NEUROCRITICAL CARE			English	Article						traumatic brain injury; extracerebral trauma; adrenal insufficiency; cortisol; HPA axis; adrenocorticotrophin hormone; risk factors; outcome	HEAD-INJURY; INSUFFICIENCY; HYPOPITUITARISM; SEVERITY; ADRENOCORTICOTROPIN; CLASSIFICATION; ABNORMALITIES; CORTISOL; HORMONE	Objective Endocrine disturbances are common after traumatic brain injury (TBI). Hypothalamic-pituitary-adrenal (HPA) axis response in TBI patients may be related with hemodynamic status. However, its relationship with outcome is unclear. Our objective was to evaluate HPA axis response in the acute phase after TBI in patients with or without extracerebral trauma (ECT), and to investigate the impact of systemic injury and the mechanisms underlying HPA response. Methods We prospectively studied 165 patients with moderate to severe TBI. Between 24 and 48 h after TBI, blood samples were taken for plasma adrenocorticotrophin hormone (ACTH) and baseline cortisol measurements. Afterwards, a short corticotrophin hormone test (250 mu g Synacthen) was performed and samples were obtained at 30 and 60 min. We compared HPA response in TBI patients presenting with and without ECT and investigate potential mechanisms underlying this response. Results One hundred and eight patients presented with isolated TBI, whereas 57 patients presented associated ECT. Both groups were comparable. Overall, 23.6% of patients fulfilled adrenal insufficiency (AI) criteria. Patients with plasma ACTH < 9 pg/ml and patients presenting with hemorrhagic shock were more likely to present adrenal impairment. Variables associated with mortality were Injury Severity Score, Glasgow Coma Scale, Traumatic Coma Data Bank classification different than type II, need of second level measures to control intracranial pressure and plasma ACTH > 9 pg/ml. Conclusion Patients with TBI presenting with or without associated ECT present similar acute HPA response. AI is present in 23.6% of patients. Risk is increased in patients with low plasma ACTH levels and in patients with hemorrhagic shock. Both primary and secondary mechanisms of HPA failure were found. However, AI did not affect outcome.	[Llompart-Pou, Juan A.; Raurich, Joan M.; Perez-Barcena, Jon; Ibanez, Jordi; Ayestaran, Jose I.] Hosp Univ Son Dureta, Serv Med Intens, Palma de Mallorca 07014, Illes Balears, Spain; [Barcelo, Antonia] Hosp Univ Son Dureta, Illes Balears, Spain	Llompart-Pou, JA (corresponding author), Hosp Univ Son Dureta, Serv Med Intens, C Andrea Doria 55, Palma de Mallorca 07014, Illes Balears, Spain.	jallompart@hsd.es		Barcelo Bennasar, Antonia/0000-0002-3170-5439			Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Bernard F, 2006, BRIT J ANAESTH, V96, P72, DOI 10.1093/bja/aei277; Bernard F, 2006, NEUROCRIT CARE, V5, P176, DOI 10.1385/NCC:5:3:176; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Dimopoulou I, 2005, INTENS CARE MED, V31, P1020, DOI 10.1007/s00134-005-2689-y; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Edwards P, 2005, LANCET, V365, P1957; Gannon TA, 2006, AM SURGEON, V72, P373; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hoen S, 2002, ANESTHESIOLOGY, V97, P807, DOI 10.1097/00000542-200210000-00010; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Llompart-Pou JA, 2007, J ENDOCRINOL INVEST, V30, P393, DOI 10.1007/BF03346316; Llompart-Pou JA, 2007, J TRAUMA, V62, P1457, DOI 10.1097/01.ta.0000219143.69483.71; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Rushing GD, 2006, AM SURGEON, V72, P552; Rushing GD, 2006, ANN SURG, V243, P652, DOI 10.1097/01.sla.0000216759.36819.1b; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; Urban RJ, 2006, GROWTH HORM IGF RES, V16, pS25, DOI 10.1016/j.ghir.2006.03.017	28	21	25	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2008	9	2					230	236		10.1007/s12028-008-9115-6			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	351RC	WOS:000259441300010	18551387				2021-06-18	
J	Turegano-Fuentes, F; Perez-Diaz, D; Sanz-Sanchez, M; Alonso, JO				Turegano-Fuentes, Fernando; Perez-Diaz, Dolores; Sanz-Sanchez, Mercedes; Ortiz Alonso, Javier			Overall Asessment of the Response to Terrorist Bombings in Trains, Madrid, 11 March 2004	EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY			English	Article						Blast injury; Mass casualty incident; Injury Severity Score; Terrorist attack; Injury pattern; Preparedness; Surge capacity	BLAST INJURIES; MANAGEMENT; DISASTERS; INCIDENTS; LONDON	Objectives: To provide an overall assessment of the response to the terrorist bombings in Madrid, 11 March 2004, which were considered the deadliest terrorist attack on European soil in modern times. Materials and Methods: Overall data on the number of victims treated at the scenes and at primary care facilities and hospitals, as well as the logistics involved, were reported by the EMS and the Health Authority of the Comunidad de Madrid local government. Data were mainly obtained by retrospective chart review, and did not include casualties who had only emotional shock, superficial bruises or transient hearing loss from barotraumas without eardrum perforation. We defined as critical any casualty with an Injury Severity Score (ISS) > 15. Results: Over 70,000 personnel were mobilized in the care of the victims. EMS response and total evacuation times at the four blast scenes averaged 7 and 99 min, respectively. There were around 2,000 casualties, and a typical bimodal distribution of deaths, with 177 immediate fatalities and 14 subsequent in-hospital deaths. Almost 6o% of casualties were taken to the two closest hospitals. Problems related to security, identification of casualties and record-keeping were encountered at the closest hospital. Closed doors increased the immediate fatality rate in the trains. Most survivors had noncritical injuries, but 14% of the 512 casualties assessed had an ISS > 15. The critical mortality rate was 19.5%. The most frequently injured body regions were the head/neck and face. In all, 124 major surgical interventions were performed on 82 victims in the first 24 h, and orthopedic trauma procedures accounted for 50% of the case load. Most patients with lung injuries from the blasts required intubation and mechanical ventilation, and their survival rate was 88.3%. Also, 35% of laparotomies were either negative or nontherapeutic. Conclusion: There was a rapid EMS response and evacuation, but also overtriage, uneven distribution of casualties and difficulties in communication. The sizes and resources of the closest hospitals, as well as the early hour, were probably decisive in the adequacy of the overall response.	[Turegano-Fuentes, Fernando; Perez-Diaz, Dolores; Sanz-Sanchez, Mercedes; Ortiz Alonso, Javier] Univ Hosp Gregorio Maranon, Dept Gen Surg & Emergency Surg 2, Madrid, Spain	Turegano-Fuentes, F (corresponding author), Univ Hosp Gregorio Maranon, Dept Gen Surg & Emergency Surg 2, Madrid, Spain.	fturegano.hgugm@salud.madrid.org					Almogy G, 2005, ARCH SURG-CHICAGO, V140, P390, DOI 10.1001/archsurg.140.4.390; Avidan V, 2005, AM J SURG, V190, P927, DOI 10.1016/j.amjsurg.2005.08.022; Aylwin CJ, 2006, LANCET, V368, P2219, DOI 10.1016/S0140-6736(06)69896-6; Born CT, 2005, SCAND J SURG, V94, P279, DOI 10.1177/145749690509400406; CEBALLOS JPD, 2005, CRIT CARE MED, V33, pS107; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Frykberg ER, 2004, ANN SURG, V239, P319, DOI 10.1097/01.sla.0000116001.97770.ce; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; Frykberg ER, 2005, CRIT CARE, V9, P20, DOI 10.1186/cc2997; Hamilton-Farrell M, 2004, INJURY, V35, P359, DOI 10.1016/j.injury.2003.08.020; Hirshberg A, 2005, J TRAUMA, V58, P686, DOI 10.1097/01.TA.0000159243.70507.86; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Lennquist S, 2007, J TRAUMA, V62, P1321, DOI 10.1097/TA.0b013e31805ba373; Lucci EB, 2006, SURG CLIN N AM, V86, P579, DOI 10.1016/j.suc.2006.03.001; Stein M, 2005, SCAND J SURG, V94, P286, DOI 10.1177/145749690509400407; Stein M, 1999, SURG CLIN N AM, V79, P1537, DOI 10.1016/S0039-6109(05)70091-8; TANIELIAN T, 2005, EXEMPLARY PRACTICES; Turegano-Fuentes F, 2006, LANCET, V368, P2188, DOI 10.1016/S0140-6736(06)69871-1	18	21	21	0	15	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-9933	1863-9941		EUR J TRAUMA EMERG S	Eur. J. Trauma Emerg. Surg.	OCT	2008	34	5					433	441		10.1007/s00068-008-8805-2			9	Emergency Medicine	Emergency Medicine	360FH	WOS:000260042300003	26815987				2021-06-18	
J	Weant, KA; Sasaki-Adams, D; Dziedzic, K; Ewend, M				Weant, Kyle A.; Sasaki-Adams, Deanna; Dziedzic, Kathryn; Ewend, Matthew			ACUTE RELATIVE ADRENAL INSUFFICIENCY AFTER ANEURYSMAL SUBARACHNOID HEMORRHAGE	NEUROSURGERY			English	Article						Adrenal insufficiency; Aneurysmal subarachnoid hemorrhage; Brain injury; Steroids	TRAUMATIC BRAIN-INJURY; SURVIVING SEPSIS CAMPAIGN; SEPTIC SHOCK; CEREBRAL VASOSPASM; MEDICAL PROGRESS; FREE CORTISOL; NITRIC-OXIDE; ILL PATIENTS; HYDROCORTISONE; GUIDELINES	OBJECTIVE: The hypothalamic-pituitary-adrenal axis is an important part of the body's natural response to acute illness. Adrenal insufficiency has the potential to lead to hemodynamic instability and electrolyte imbalances, limit the body's ability to respond to stress, and worsen overall clinical outcome. in this case series, we describe 16 patients evaluated for acute adrenal insufficiency after aneurysmal subarachnoid hemorrhage. CLINICAL PRESENTATION: Over a 2-year period, the medical records of 16 patients admitted to the adult neurosurgery service for aneurysmal subarachnoid hemorrhage who were nonresponsive to vasopressor therapy and received cosyntropin for the evaluation of adrenal insufficiency within 14 days of their event were reviewed. INTERVENTION: The median baseline cortisol in this population was 22.5 mu g/dL, with a poststimulation cortisol level of 31 mu g/dL. Of the population surveyed, a total of 11 patients met the preestablished criteria for adrenal insufficiency, 3 with baseline cortisol levels of less than 15 mu g/dL and 11 with poststimulation concentration changes of less than 9 mu g/dL. Baseline serum cortisol concentrations were significantly correlated with hospital stay (P = 0.045), intensive care unit stay (P = 0.005), and ventilator days (P = 0.006). CONCLUSION: To date, this is the only investigation evaluating the incidence of acute relative adrenal insufficiency in this population. In our cohort, 69% of the patients met the preestablished criteria for relative adrenal insufficiency. The impact of low-dose corticosteroid therapy in this population also needs review, as it could have significant implications for the management of cerebral vasospasm.	[Weant, Kyle A.] Univ Kentucky Healthcare, Serv Pharm, Lexington, KY 40536 USA; [Weant, Kyle A.] Univ Kentucky, Coll Pharm, Dept Pharm Practice & Sci, Lexington, KY USA; [Sasaki-Adams, Deanna; Ewend, Matthew] Univ N Carolina, Div Neurol Surg, Chapel Hill, NC USA; [Dziedzic, Kathryn] Univ N Carolina Hosp, Dept Pharm, Chapel Hill, NC USA; [Dziedzic, Kathryn] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA	Weant, KA (corresponding author), Univ Kentucky Healthcare, Serv Pharm, 800 Rose St,H109A, Lexington, KY 40536 USA.	kawean2@email.uky.edu		Weant, Kyle/0000-0003-0835-7955			ADAMS JH, 1966, J NEUROL NEUROSUR PS, V29, P545, DOI 10.1136/jnnp.29.6.545; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Alhashemi JA, 2001, BRIT J ANAESTH, V86, P138, DOI 10.1093/bja/86.1.138; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Beishuizen A, 2001, INTENS CARE MED, V27, P1584, DOI 10.1007/s001340101073; Bernard F, 2006, BRIT J ANAESTH, V96, P72, DOI 10.1093/bja/aei277; Briegel J, 1999, CRIT CARE MED, V27, P723, DOI 10.1097/00003246-199904000-00025; Brisman JL, 2006, NEW ENGL J MED, V355, P928, DOI 10.1056/NEJMra052760; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; DANIEL PM, 1959, LANCET, V2, P927; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; ECKER A, 1951, J NEUROSURG, V8, P660, DOI 10.3171/jns.1951.8.6.0660; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; KASSELL NF, 1984, STROKE, V15, P566, DOI 10.1161/01.STR.15.3.566; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490; Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022; MORAN JL, 1994, INTENS CARE MED, V20, P489, DOI 10.1007/BF01711901; Ohkuma H, 2000, STROKE, V31, P1621, DOI 10.1161/01.STR.31.7.1621; Pluta RM, 2005, PHARMACOL THERAPEUT, V105, P23, DOI 10.1016/j.pharmthera.2004.10.002; ROTHWELL PM, 1991, LANCET, V337, P582, DOI 10.1016/0140-6736(91)91641-7; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Sehba FA, 2005, J NEUROSURG, V102, P1094, DOI 10.3171/jns.2005.102.6.1094; Sehba FA, 2004, NEUROSURGERY, V55, P671, DOI 10.1227/01.NEU.0000134557.82423.B2; Sehba FA, 2006, NEUROL RES, V28, P381, DOI 10.1179/016164106X114991; Sesmilo Gemma, 2007, Hormones (Athens), V6, P132; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173	34	21	23	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2008	63	4					645	649		10.1227/01.NEU.0000325728.50939.15			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	367UR	WOS:000260578600014	18824943				2021-06-18	
J	Zhao, XR; Gorin, FA; Berman, RF; Lyeth, BG				Zhao, Xueren; Gorin, Fredric A.; Berman, Robert F.; Lyeth, Bruce G.			Differential Hippocampal Protection when Blocking Intracellular Sodium and Calcium Entry during Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		astrocyte; glia; hippocampus; ion exchangers; lateral fluid percussion injury; neuronal degeneration; sodium; traumatic brain injury	FATTY-ACID EFFLUX; NA+-H+ EXCHANGE; LATERAL FLUID-PERCUSSION; EXCITATORY AMINO-ACIDS; SENSING ION CHANNELS; CEREBRAL-CORTEX; NEURONAL DEGENERATION; NA+/CA2+ EXCHANGE; HYPOXIC/HYPOGLYCEMIC INJURY; ARBITRARY PARTICLES	This study investigated the contributions of the reverse mode of the sodium-calcium exchanger (NCX) and the type 1 sodium-proton antiporter (NHE-1) to acute astrocyte and neuronal pathology in the hippocampus following fluid percussion traumatic brain injury (TBI) in the rat. KB-R7943, EIPA, or amiloride, which respectively inhibit NCX, NHE-1, or NCX, NHE-1, and ASIC1a (acid-sensing ion channel type 1a), was infused intraventricularly over a 60-min period immediately prior to TBI. Astrocytes were immunostained for glial fibrillary acidic protein (GFAP), and degenerating neurons were identified by Fluoro-Jade staining at 24 h after injury. Stereological analysis of the CA2/3 sub-regions of the hippocampus demonstrated that higher doses of KB-R7943 (2 and 20 nmoles) significantly reduced astrocyte GFAP immunoreactivity compared to vehicle-treated animals. EIPA (2-200 nmoles) did not alter astrocyte GFAP immunoreactivity. Amiloride (100 nmoles) significantly attenuated the TBI-induced acute reduction in astrocyte GFAP immunoreactivity. Of the three compounds examined, only amiloride (100 nmoles) reduced hippocampal neuronal degeneration assessed with Fluoro-Jade. The results provide additional evidence of acute astrocyte pathology in the hippocampus following TBI, while suggesting that activation of NHE-1 and the reverse mode of NCX contribute to both astrocyte and neuronal pathology following experimental TBI.	[Zhao, Xueren; Berman, Robert F.; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Gorin, Fredric A.] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039090, R01NS029995, R01NS045136, R01NS040489] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS029995-13, R01 NS045136, NS29995, R01 NS045136-04, R01 NS029995, NS40489, NS39090, NS45136] Funding Source: Medline		Alexander SPH, 2008, BRIT J PHARMACOL, V153, pS1, DOI 10.1038/sj.bjp.0707746; ANDREEVA N, 1992, NEUROSCIENCE, V49, P175, DOI 10.1016/0306-4522(92)90085-G; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Bernardinelli Y, 2006, GLIA, V54, P460, DOI 10.1002/glia.20387; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; Breder J, 2000, NEUROPHARMACOLOGY, V39, P1779, DOI 10.1016/S0028-3908(00)00027-7; BRIERLEY GP, 1994, J BIOENERG BIOMEMBR, V26, P519, DOI 10.1007/BF00762736; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; Chattou S, 2000, J MOL CELL CARDIOL, V32, P1181, DOI 10.1006/jmcc.2000.1151; Cho JH, 2008, J NEUROPHYSIOL, V99, P426, DOI 10.1152/jn.00940.2007; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ENKVIST MOK, 1989, GLIA, V2, P397, DOI 10.1002/glia.440020602; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Jenkins L.W., 1984, RECENT PROGR STUDY T, P523; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kempski O, 1990, Adv Neurol, V52, P39; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KIMELBERG HK, 1992, ASTROCYTES PHARM FUN; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; NOBLE LJ, 1992, J NEUROTRAUM, V9, P255, DOI 10.1089/neu.1992.9.255; Ouyang YB, 2007, J NEUROSCI, V27, P4253, DOI 10.1523/JNEUROSCI.0211-07.2007; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Phillis JW, 1999, BRAIN RES, V839, P199, DOI 10.1016/S0006-8993(99)01705-9; Phillis JW, 2000, BRAIN RES, V884, P155, DOI 10.1016/S0006-8993(00)02938-3; Phillis JW, 1998, BRAIN RES, V812, P297, DOI 10.1016/S0006-8993(98)00984-6; Pignataro G, 2007, BRAIN, V130, P151, DOI 10.1093/brain/awl325; Pilitsis JG, 2001, BRAIN RES, V913, P156, DOI 10.1016/S0006-8993(01)02760-3; Pilitsis JG, 2001, BRAIN RES, V916, P192, DOI 10.1016/S0006-8993(01)02896-7; Rogister F, 2001, EUR J MED CHEM, V36, P597, DOI 10.1016/S0223-5234(01)01247-8; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Schroder UH, 1999, NEUROPHARMACOLOGY, V38, P319, DOI 10.1016/S0028-3908(98)00198-1; SIEGL PKS, 1984, P NATL ACAD SCI-BIOL, V81, P3238, DOI 10.1073/pnas.81.10.3238; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; Silver IA, 1997, GLIA, V21, P35, DOI 10.1002/(SICI)1098-1136(199709)21:1<35::AID-GLIA4>3.0.CO;2-0; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Takahashi M, 1997, J EXP BIOL, V200, P401; VIGNE P, 1983, BIOCHEM BIOPH RES CO, V116, P86, DOI 10.1016/0006-291X(83)90384-4; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Wangemann P, 1996, HEARING RES, V94, P94, DOI 10.1016/0378-5955(96)00008-1; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x	63	21	24	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1195	1205		10.1089/neu.2008.0635			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200008	18847376	Green Accepted, Green Published			2021-06-18	
J	Baranova, AI; Wei, EP; Ueda, Y; Sholley, MM; Kontos, HA; Povlishock, JT				Baranova, Anna I.; Wei, Enoch P.; Ueda, Yuji; Sholley, Milton M.; Kontos, Hermes A.; Povlishock, John T.			Cerebral vascular responsiveness after experimental traumatic brain injury: the beneficial effects of delayed hypothermia combined with superoxide dismutase administration - Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						brain injury; hypothermia; pial vasculature; rat; vasoreactivity	POSTISCHEMIC HYPOTHERMIA; BLOOD-FLOW; POSTTRAUMATIC HYPOTHERMIA; HEAD-INJURY; AUTOREGULATION; RESPONSES; CATS; RATS; MICROCIRCULATION; ABNORMALITIES	Object. Traumatic brain injury (TBI) induces cerebral vascular dysfunction reflected in altered responses to vasodilators such as acetylcholine and hypercapnia. It has been demonstrated that the use of either posttraumatic hypothermia or free radical scavengers offered vascular protection when those treatments were delivered early after the injury, losing efficacy when the initiation of either treatment was delayed. Because immediate posttraumatic treatment is not realistic in the clinical setting, the authors undertook this study to investigate whether the combination of delayed hypothermia and the delayed administration of the free radical scavenger superoxide dismutase (SOD) could result in improved vascular protection. Methods. Male Sprague-Dawley rats were anesthetized and subjected to either an impact-acceleration or sham injury. Animals were treated either with hypothermia (32 degrees C) initiated 60 minutes after TBI, delayed SOD (60 U/ml) applied 90 minutes after TBI, or a combination of delayed hypothermia (32 degrees C) and delayed SOD (60 U/ml) applied 15 minutes prior to the cessation of hypothermia. In this investigation, the diameter of cerebral pial arterioles was measured at rest and then challenged with vasodilator acetylcholine and hypercapnia. Four vessels were assessed per animal prior to injury and then again tip to 6 hours after injury. Results. Delayed SOD treatment did not enhance vascular function, while delayed hypothermia treatment only partially preserved pial vascular function. However, the combination of delayed hypothermia and delayed SOD significantly preserved vascular function after the injury. Conclusions. The results of these studies demonstrate that delayed hypothermia partially preserves vascular function after TBI, while expanding the therapeutic window over which agents such as SOD can now provide enhanced protection.	[Baranova, Anna I.; Wei, Enoch P.; Sholley, Milton M.; Kontos, Hermes A.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Wei, Enoch P.; Kontos, Hermes A.] Virginia Commonwealth Univ, Med Ctr, Dept Med, Richmond, VA 23298 USA; [Ueda, Yuji] Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpoviis@vcu.edu			 [HD055813];  [NS057175]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS057175] Funding Source: NIH RePORTER	This study was supported by grants HD055813 and NS057175.	BERING EA, 1961, AM J PHYSIOL, V200, P417; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1981, FED PROC, V40, P2326; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Zhao H, 2004, STROKE, V35, P572, DOI 10.1161/01.STR.0000110787.42083.58	25	21	21	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2008	109	3					502	509		10.3171/JNS/2008/109/9/0502			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	344CX	WOS:000258904400023	18759584				2021-06-18	
J	Evans, CC; Sherer, M; Nakase-Richardson, R; Mani, T; Irby, JW				Evans, Clea C.; Sherer, Mark; Nakase-Richardson, Risa; Mani, Tanja; Irby, James W., Jr.			Evaluation of an interdisciplinary team intervention to improve therapeutic alliance in post-acute brain injury rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; rehabilitation; therapeutic alliance; treatment outcomes	FAMILY ASSESSMENT DEVICE; WORKING ALLIANCE; AWARENESS	Objective: Evaluate an intervention to improve an alliance between an interdisciplinary team and clients with traumatic brain injury attending post-acute brain injury rehabilitation. Design: Prospective design, 2 consecutive samples-historical control (CNT) and treatment (TX). Methods: Sample of 104 clients (69 CNT, 35 TX) admitted to post-acute brain injury rehabilitation completed admit/discharge questionnaires. Results: The TX group had higher functional status at discharge than the CNT group. Stronger team alliance was associated with program completion, return to productivity, stronger client alliance, less family discord, and fewer depressive symptoms. Conclusions: Findings provide direction for a larger study examining the effectiveness of this intervention to improve outcome after traumatic brain injury.	[Evans, Clea C.; Sherer, Mark; Nakase-Richardson, Risa; Mani, Tanja; Irby, James W., Jr.] Methodist Rehabil Ctr, Jackson, MS USA; [Evans, Clea C.; Nakase-Richardson, Risa] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA; [Nakase-Richardson, Risa] Tampa VA Med Ctr, Tampa, FL USA	Evans, CC (corresponding author), 1350 E Woodrow Wilson D, Jackson, MS 39047 USA.	cevans@mmrcrebab.org					Bordin E. S., 1979, PSYCHOTHER-THEOR RES, V16, P252, DOI DOI 10.1037/H0085885; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Gaston L., 1994, WORKING ALLIANCE THE, P85; HORVATH AO, 1994, WORKING ALLIANCE THE; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Lambert MJ, 2001, PSYCHOTHERAPY, V38, P357, DOI 10.1037/0033-3204.38.4.357; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Safran J. D., 1991, PSYCHOL ASSESSMENT J, V3, P188, DOI DOI 10.1037/1040-3590.3.2.188; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Summers RE, 2003, ACAD PSYCHIATR, V27, P160, DOI 10.1176/appi.ap.27.3.160	21	21	21	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2008	23	5					329	338		10.1097/01.HTR.0000336845.06704.bc			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357GN	WOS:000259834400007	18815509				2021-06-18	
J	Monnerie, H; Le Roux, PD				Monnerie, Hubert; Le Roux, Peter D.			Glutamate alteration of glutamic acid decarboxylase (GAD) in GABAergic neurons: The role of cysteine proteases	EXPERIMENTAL NEUROLOGY			English	Article						calpain; cathepsin; cerebral cortex; excitotoxicity; GABA; CAD; glutamate; neuron	CALPAIN-MEDIATED CLEAVAGE; CULTURED CORTICAL-NEURONS; TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; MESSENGER-RNA; CATHEPSIN-L; HIPPOCAMPAL-NEURONS; TRANSIENT ISCHEMIA; 67-KDA ISOFORM; I ACTIVATION	Brain cell vulnerability to neurologic insults varies greatly, depending on their neuronal subpopulation. Among cells that Survive a pathological insult such as ischemia or brain trauma, some may undergo morphological and/or biochemical changes that could compromise brain function. We previously reported that Surviving cortical GABAergic neurons exposed to glutamate in vitro displayed an NMDA receptor (NMIDAR)-mediated alteration in the levels of the GABA synthesizing enzyme glutamic acid decarboxylase (GAD65/67) [Monnerie, H., Le Roux, R, 2007. Reduced dendrite growth and altered glutamic acid decarboxylase (GAD) 65- and 67-kDa isoform protein expression from mouse cortical GABAergic neurons following excitotoxic injury in vitro. Exp. Neurol. 205,367-382]. In this study, we examined the mechanisms by which glutamate excitotoxicity Caused a change in cortical GABAergic neurons' GAD protein levels. Removing extracellular Calcium prevented the NMDAR-mediated decrease in GAD protein levels, measured using Western blot techniques, whereas inhibiting calcium entry through voltage-gated calcium channels had no effect. Glutamate's effect on GAD protein isoforms was significantly attenuated by preincubation with the cysteine protease inhibitor N-Acetyl-L-Leucyl-L-Leucyl-norleucinal (ALLN). Using class-specific protease inhibitors, we observed that ALLN's effect resulted from the blockade of calpain and cathepsin protease activities. Cell-free proteolysis assay confirmed that both proteases were involved in glutamate-induced alteration in GAD protein levels. Together these results suggest that glutamate-induced excitotoxic stimulation of NMDAR in Cultured cortical neurons leads to altered GAD protein levels from GABAergic neurons through intracellular Calcium increase and protease activation including calpain and cathepsin. Biochemical alterations in Surviving cortical GABAergic neurons in various disease states may contribute to the altered balance between excitation and inhibition that is often observed after injury. (C) 2008 Elsevier Inc. All rights reserved.	[Monnerie, Hubert; Le Roux, Peter D.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA	Le Roux, PD (corresponding author), Univ Penn, Dept Neurosurg, 330 S 9th St,4th Floor, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu					Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Akashiba H, 2006, J NEUROCHEM, V99, P733, DOI 10.1111/j.1471-4159.2006.04100.x; Asada H, 1997, P NATL ACAD SCI USA, V94, P6496, DOI 10.1073/pnas.94.12.6496; BAO J, 1995, J BIOL CHEM, V270, P6464, DOI 10.1074/jbc.270.12.6464; Boland B, 2004, NEUROBIOL AGING, V25, P83, DOI 10.1016/S0197-4580(03)00034-4; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; Centonze D, 2001, PROG NEUROBIOL, V63, P687, DOI 10.1016/S0301-0082(00)00037-X; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Fatemi SH, 2002, BIOL PSYCHIAT, V52, P805, DOI 10.1016/S0006-3223(02)01430-0; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Graber S, 2004, NEUROPHARMACOLOGY, V47, P706, DOI 10.1016/j.neuropharm.2004.08.004; HADDAD GG, 1993, PROG NEUROBIOL, V40, P277, DOI 10.1016/0301-0082(93)90014-J; Hajimohammadreza I, 1997, J NEUROCHEM, V69, P1006; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; Husi H, 2000, NAT NEUROSCI, V3, P661; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kitao Y, 2001, J CLIN INVEST, V108, P1439, DOI 10.1172/JCI200112978; Kohda Y, 1996, BIOCHEM BIOPH RES CO, V228, P616, DOI 10.1006/bbrc.1996.1706; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Manor D, 1996, NEUROCHEM RES, V21, P1031, DOI 10.1007/BF02532413; Monnerie H, 2007, EXP NEUROL, V205, P367, DOI 10.1016/j.expneurol.2007.02.007; NAJLERAHIM A, 1992, EXP NEUROL, V118, P352, DOI 10.1016/0014-4886(92)90193-T; NAJLERAHIM A, 1992, EXP BRAIN RES, V90, P332; NAKAMURA Y, 1991, NEUROSCI LETT, V130, P195, DOI 10.1016/0304-3940(91)90395-A; Namchuk M, 1997, J BIOL CHEM, V272, P1548, DOI 10.1074/jbc.272.3.1548; Neder L, 2002, CELL MOL NEUROBIOL, V22, P689, DOI 10.1023/A:1021852907068; Nixon RA, 2001, J ALZHEIMERS DIS, V3, P97, DOI 10.3233/JAD-2001-3114; OBENAUS A, 1993, J NEUROSCI, V13, P4470; Olney J W, 1986, Adv Neurol, V44, P857; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; RIBAK CE, 1979, SCIENCE, V205, P211, DOI 10.1126/science.109922; Sheng M, 2000, NAT NEUROSCI, V3, P633, DOI 10.1038/76576; Shetty AK, 2000, J NEUROSCI, V20, P8788; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102; SIMON RP, 1984, J CEREBR BLOOD F MET, V4, P350, DOI 10.1038/jcbfm.1984.52; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; Torrey EF, 2005, BIOL PSYCHIAT, V57, P252, DOI 10.1016/j.biopsych.2004.10.019; Tsuchiya K, 1999, EXP NEUROL, V155, P187, DOI 10.1006/exnr.1998.6988; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; Wu HV, 2006, MOL NEUROBIOL, V33, P215, DOI 10.1385/MN:33:3:215; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Yamashima T, 2003, HIPPOCAMPUS, V13, P791, DOI 10.1002/hipo.10127; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yoshida M, 2002, ACTA NEUROPATHOL, V104, P267, DOI 10.1007/s00401-002-0554-4; Yoshiyama Y, 2000, NEUROSCI LETT, V290, P125, DOI 10.1016/S0304-3940(00)01326-4; Zakharov VV, 2007, J NEUROCHEM, V101, P1539, DOI 10.1111/j.1471-4159.2007.04452.x; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078	56	21	25	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2008	213	1					145	153		10.1016/j.expneurol.2008.05.013			9	Neurosciences	Neurosciences & Neurology	344QX	WOS:000258943500018	18599042				2021-06-18	
J	Timaru-Kast, R; Meissner, A; Heimann, A; Hoelper, B; Kempski, O; Alessandri, B				Timaru-Kast, Ralph; Meissner, Anke; Heimann, Axel; Hoelper, Bernd; Kempski, Oliver; Alessandri, Beat			Acute Subdural Hematoma in Pigs: Role of Volume on Multiparametric Neuromonitoring and Histology	JOURNAL OF NEUROTRAUMA			English	Article						acute subdural hematoma; intracranial pressure (ICP); microdialysis; neuromonitoring; neurotransmitters; pig; ptiO2; SEP; somatosensory evoked potentials; tissue oxygen tension; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; MATURATION-DEPENDENT RESPONSE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; COMATOSE PATIENTS; FELINE BRAIN; MICRODIALYSIS; MODEL	Traumatic brain injury (TBI) is often complicated by acute subdural hemorrhage (ASDH) with a high mortality rate. The pathophysiological mechanisms behind such an injury type and the contribution of blood to the extent of an injury remain poorly understood. Therefore, the goals of this study were to establish a porcine ASDH model in order to investigate pathomechanisms of ASDH and to compare effects induced by blood or sheer volume. Thus, we infused 2, 5, and 9 mL of blood (up to 15% of intracranial volume), and we compared a 5-mL blood and paraffin oil volume to separate out effects of extravasated blood on brain tissue. An extended neuromonitoring was applied that lasted up to 12 h after injury and included intracranial pressure (ICP), cerebral perfusion pressure (CPP), tissue oxygen concentration (ptiO(2)), biochemical markers (glutamate, lactate), somatosensory evoked potentials (SEP), brain water content, and histological assessment (Lesion Index [LI]). Volume-dependent changes were detected mainly during the first hours after injury. ICP increased to significant levels (p < 0.05) of 36.89 +/- 1.59, 15.52 +/- 0.48, and 11.25 +/- 0.35 mm Hg after 9, 5, and 2 mL of subdural blood, respectively (sham, 4.85 +/- 0.06 mm Hg). The ptiO(2) dropped drastically after 9 mL of subdural blood without recovery in both hemispheres to below 20% of baseline, but was affected little after 2 and 5 mL in the acute monitoring period (maximal drop to 71% of baseline). Later, 5 mL of blood led to a significant increase of ptiO2 compared to 2 mL ipsilaterally (p < 0.05). Glutamate and lactate showed a comparable pattern with a long-lasting increase after 9 mL of blood and short-lasting changes after 2 and 5 mL. The two smaller volumes caused an increased brain swelling (2 mL, 80.60 +/- 0.34%; 5 mL, 81.20 +/- 0.66%; p < 0.05 vs. sham), a significant LI (sham, 6.4 +/- 1.4; 2 mL, 30.0 +/- 0.95; 5 mL, 32.1 +/- 1.2; p < 0.05 vs. sham), and a reduced SEP amplitude (5 mL, p < 0.05 vs. baseline) at the end of the experiment. A 9-mL led to herniation during the experiment causing dramatical brain swelling and acute histological damage. Comparison of blood volume with paraffin oil showed no significance, indicating that volume alone determines the acute pathophysiological processes leading to a rapidly developing histological damage. Additional effects due to blood contact with brain tissue (e.g., inflammation) may be detected only at later time points (< 12 h).	[Timaru-Kast, Ralph; Meissner, Anke; Heimann, Axel; Hoelper, Bernd; Kempski, Oliver; Alessandri, Beat] Johannes Gutenberg Univ Mainz, Inst Neurosurg Pathophysiol, Mainz, Rheinland Pfalz, Germany	Alessandri, B (corresponding author), Johannes Gutenberg Univ Mainz, Inst Neurosurg Pathophysiol, Langenbeckstr 1, Mainz, Rheinland Pfalz, Germany.	alessandri@nc-patho.klinik.uni-mainz.de		Heimann, Axel/0000-0003-2510-3228	Schwerpunkt Neurowissenschaften Mainz; Deutsche Forschungsgemeinschaft, DFGGerman Research Foundation (DFG) [KE338/6-2]	We gratefully thank A. Ehlert, M. Malzahn, and L. Kopacz for their excellent technical assistance. The study was supported by Schwerpunkt Neurowissenschaften Mainz (to R.T.) and by a grant of Deutsche Forschungsgemeinschaft, DFG (KE338/6-2; to B. A. and O.K.). The data shown in the paper are part of the inaugural dissertations of Anke Meissner and Ralph Timaru-Kast.	ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Alessandri B, 2006, BRAIN RES, V1111, P196, DOI 10.1016/j.brainres.2006.06.105; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Alessandri B, 1999, ACT NEUR S, V75, P25; ALESSANDRI B, 2006, J NEUROTRAUMA, V23; Bauer R, 1999, PEDIATR NEUROSURG, V30, P62, DOI 10.1159/000028765; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1990, ACT NEUR S, V51, P274; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock R, 1997, HEAD INJURY PATHOPHY, P121; Chiari P, 2000, J HEART LUNG TRANSPL, V19, P675, DOI 10.1016/S1053-2498(00)00127-3; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Depreitere B, 2006, J NEUROSURG, V104, P950, DOI 10.3171/jns.2006.104.6.950; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Felix B, 1999, BRAIN RES BULL, V49, P1, DOI 10.1016/S0361-9230(99)00012-X; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Kempski O, 1990, Adv Neurol, V52, P219; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kiening KL, 1998, ACT NEUR S, V71, P172; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Marion DW, 2006, NEUROSURGERY, V58, P655; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; Moulton RJ, 1997, HEAD INJURY PATHOPHY, V1997, P229; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; ORLIN JR, 1992, ACTA NEUROCHIR, V118, P146, DOI 10.1007/BF01401300; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Reilly P, 1997, HEAD INJURY PATHOPHY; SARRAFZADEH A, 2000, NEUROSURG FOCUS, V15, pE2; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; Server A, 2001, ACTA RADIOL, V42, P254; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vespa Paul, 2003, Neurosurg Focus, V15, pE4; Yilmazlar S, 1997, J Neurosurg Sci, V41, P379; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zhang H, 2001, CLIN CHEM, V47, P1458; ZWETNOW NN, 1993, ACTA NEUROCHIR, V121, P58, DOI 10.1007/BF01405184	53	21	22	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1107	1119		10.1089/neu.2008.0517			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900007	18771396				2021-06-18	
J	Soustiel, JF; Palzur, E; Vlodavsky, E; Veenman, L; Gavish, M				Soustiel, J. F.; Palzur, E.; Vlodavsky, E.; Veenman, L.; Gavish, M.			The effect of oxygenation level on cerebral post-traumatic apoptotsis is modulated by the 18-kDa translocator protein (also known as peripheral-type benzodiazepine receptor) in a rat model of cortical contusion	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						apoptosis; brain injury; hyperbaric oxygen; mitochondria; peripheral-type benzodiazepine receptor	TRAUMATIC BRAIN-INJURY; COLORECTAL-CANCER CELLS; IN-VITRO; APOPTOSIS; LIGANDS; PROLIFERATION; MITOCHONDRIA; EXPRESSION; INDUCTION; THERAPY	Aims: Hyperbaric hyperoxia has been shown to reduce apoptosis in brain injury. As the 18-kDa translocator protein (TSPO), also known as peripheral-type benzodiazepine receptor, is closely associated with the mitochondrial transition pore and because of its role in mitochondrial respiration and apoptosis, we hypothesized that reduction of apoptosis by hyperoxia may involve the TSPO. Methods: TSPO and transferase-mediated dUTP nick end labelling (TUNEL) immunopositivity was first assessed in cortical contusion, created by dynamic cortical deformation, by immunohistochemistry in rats exposed to normoxia [(dynamic cortical deformation (DCD)], normobaric hyperoxia or hyperbaric hyperoxia [hyperbaric oxygen therapy (HBO)]. In a second step, transmembrane mitochondrial potential (Delta psi(M)) and caspase 9 activity were assessed in the injured area in comparison with the noninjured hemisphere. Measurements were performed in DCD and HBO groups. A third group receiving both HBO and the TSPO ligand PK11195 was investigated as well. Results: TSPO correlated quantitatively and regionally with TUNEL immunopositivity in the perilesional area. Hyperoxia reduced both the number of TSPO expressing and TUNEL positive cells in the perilesional area, and this effect proved to be pressure dependent. After contusion, we demonstrated a dissipation of Delta psi(M) in isolated mitochondria and an elevation of caspase 9 activity in tissue homogenates from the contused area, both of which could be substantially reversed by hyperbaric hyperoxia. This protective effect of hyperoxia was reversed by PK11195. Conclusions: The present findings suggest that the protective effect of hyperoxia may be due to a negative regulation of the proapoptotic function of mitochondrial TSPO, including conservation of the mitochondrial membrane potential.	[Veenman, L.; Gavish, M.] Technion Israel Inst Technol, Rappaport Family Inst Res, Dept Pharmacol, Fac Med, IL-31096 Haifa, Israel; [Soustiel, J. F.; Palzur, E.] Technion Israel Inst Technol, Acute Brain Injury Res Lab, IL-31096 Haifa, Israel; [Vlodavsky, E.] Rambam Med Ctr, Inst Pathol, Haifa, Israel	Gavish, M (corresponding author), Technion Israel Inst Technol, Rappaport Family Inst Res, Dept Pharmacol, Fac Med, Ephron St,POB 9649, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il; mgavish@tx.technion.ac.il					Azarashvili T, 2007, CELL CALCIUM, V42, P27, DOI 10.1016/j.ceca.2006.11.004; Bono F, 1999, BIOCHEM BIOPH RES CO, V265, P457, DOI 10.1006/bbrc.1999.1683; Carmel I, 1999, BIOCHEM PHARMACOL, V58, P273, DOI 10.1016/S0006-2952(99)00093-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Decaudin D, 2002, CANCER RES, V62, P1388; GARNIER M, 1994, MOL PHARMACOL, V45, P201; GAVISH M, 1992, J NEUROCHEM, V58, P1589, DOI 10.1111/j.1471-4159.1992.tb10030.x; Golani I, 2001, BIOCHEMISTRY-US, V40, P10213, DOI 10.1021/bi010431+; Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; HIRSCH JD, 1989, MOL PHARMACOL, V35, P157; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Levin E, 2005, BIOCHEMISTRY-US, V44, P9924, DOI 10.1021/bi050150s; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Maaser K, 2005, BIOCHEM BIOPH RES CO, V332, P646, DOI 10.1016/j.bbrc.2005.05.005; Maaser K, 2001, BRIT J CANCER, V85, P1771, DOI 10.1054/bjoc.2001.2181; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MORENOSANCHEZ R, 1991, BIOCHEM PHARMACOL, V41, P1479, DOI 10.1016/0006-2952(91)90564-L; O'Hara MF, 2003, REPROD TOXICOL, V17, P365, DOI 10.1016/S0890-6238(03)00035-2; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Papadopoulos V, 2006, NEUROSCIENCE, V138, P749, DOI 10.1016/j.neuroscience.2005.05.063; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; RAGHAVENDRA RV, 2000, EXP NEUROL, V161, P102, DOI DOI 10.1006/exnr.1999.7269; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; STAROSTARUBINSTEIN S, 1987, P NATL ACAD SCI USA, V84, P891, DOI 10.1073/pnas.84.3.891; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Veenman L, 2002, J NEUROCHEM, V80, P917, DOI 10.1046/j.0022-3042.2002.00769.x; Veenman L, 2007, CURR PHARM DESIGN, V13, P2385; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Vlodavsky E, 2007, J NEURO-ONCOL, V81, P1, DOI 10.1007/s11060-006-9199-9; Wada K, 2000, ACT NEUR S, V76, P285; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P753, DOI 10.1073/pnas.81.3.753; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	42	21	24	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	AUG	2008	34	4					412	423		10.1111/j.1365-2990.2007.00906.x			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	327CB	WOS:000257706100004	17973904				2021-06-18	
J	Degeneffe, CE; Olney, MF				Degeneffe, Charles Edmund; Olney, Marjorie F.			Future Concerns of Adult Siblings of Persons With Traumatic Brain Injury	REHABILITATION COUNSELING BULLETIN			English	Article						family adaptations; traumatic brain injury; stress and coping; adjustment; sibling caregiving	MENTAL-RETARDATION; DISABILITIES; CHILDREN	This study examined future concerns conveyed by adult siblings who provided regular caregiving support to their brothers and sisters with traumatic brain injury (TBI). The authors surveyed a national sample of 280 adult siblings of persons with TBI. Using a constant comparative approach to text analysis, the authors analyzed responses to the question "What are your concerns regarding the future for your sibling with TBI?" Common themes of such concerns were related to the caregiving siblings' roles as future caregivers and their perceptions of the quality of professional care provided to their injured family members. Also, participants endorsed concerns for their injured siblings' independence, recovery, and relationships with family and friends. Clinical, advocacy, and research implications of these findings are discussed.	[Degeneffe, Charles Edmund; Olney, Marjorie F.] San Diego State Univ, Dept Adm Rehabil & Postsecondary Educ, San Diego, CA 92182 USA	Degeneffe, CE (corresponding author), San Diego State Univ, Dept Adm Rehabil & Postsecondary Educ, San Diego, CA 92182 USA.						Bishop M, 2006, AUST J REHABIL COUNS, V12, P73, DOI 10.1375/jrc.12.2.73; Bogdan R. C., 1998, QUALITATIVE RES ED I; *BRAIN INJ ASS AM, 2007, COSTS CAUS TRAUM BRA; Carson P, 1993, J Neurosci Nurs, V25, P165; Cunningham J. M., 2005, CASE MANAGEMENT REHA, P91; Degeneffe CE, 2006, REHABIL COUNS BULL, V49, P130, DOI 10.1177/00343552060490030101; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Denzin N. K., 1994, HDB QUALITATIVE RES; DEPUIS PR, 1994, HYPERRESEARCH; Gephart R, 1997, J ORGAN BEHAV, V18, P583, DOI 10.1002/(SICI)1099-1379(199711)18:1+<583::AID-JOB908>3.0.CO;2-T; Gilbride D, 2003, REHABIL COUNS BULL, V46, P130, DOI 10.1177/00343552030460030101; Gill D. J., 2000, REHABILITATION NURSI, V25, P48, DOI [DOI 10.1002/J.2048-7940.2000.TB01862.X, 10.1002/j.2048-7940.2000.tb01862.x]; Glaser B. G., 1967, DISCOVERY GROUNDED T; GRIFFITHS DL, 1994, FAM RELAT, V43, P221, DOI 10.2307/585326; HAGNER DC, 1994, REHABIL COUNS BULL, V37, P290; HARDGROVE H, 1991, HEAD INJURY FAMILY M, P25; Hodder I., 1994, HDB QUALITATIVE RES, P393; HORWITZ AV, 1993, J MARRIAGE FAM, V55, P623, DOI 10.2307/353343; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Krauss MW, 1996, MENT RETARD, V34, P83; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KUO C, 2005, THESIS OHIO STATE U; LOBATO D, 1983, J AUTISM DEV DISORD, V13, P347, DOI 10.1007/BF01531585; McMahon MA, 2001, J HEAD TRAUMA REHAB, V16, P587, DOI 10.1097/00001199-200112000-00006; *NAT I HLTH, 1999, REPORT NIH CONSENSUS; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199303000-00010, 10.1097/00001199-199303000-00010]; Pruchno RA, 1996, FAM RELAT, V45, P318, DOI 10.2307/585504; REDMOND G, 1989, THESIS BOSTON COLL; Rosenthal M., 1989, TRAUMATIC BRAIN INJU, P191; SACHS PR, 1991, TREATING FAMILIES BR; SELTZER GB, 1991, FAM RELAT, V40, P310, DOI 10.2307/585017; Seltzer MM, 1997, FAM RELAT, V46, P395, DOI 10.2307/585099; Spearman RC, 2001, J HEAD TRAUMA REHAB, V16, P47, DOI 10.1097/00001199-200102000-00007; SPRIGGS VT, 1998, PROMOTING CULTURAL C, P149; Strauss A, 1988, BASICS QUALITATIVE R; Tian Y, 2006, CORP COMMUN, V11, P13, DOI 10.1108/13563280610643516; WESOLOWSKI MD, 1994, PRACTICAL GUIDE HEAD; ZETLIN AG, 1986, AM J MENT DEF, V91, P217	38	21	21	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0034-3552			REHABIL COUNS BULL	Rehabil. Couns. Bull.	JUL	2008	51	4					240	250		10.1177/0034355207311319			11	Rehabilitation	Rehabilitation	390MB	WOS:000262167300005					2021-06-18	
J	Grathwohl, KW; Black, IH; Spinella, PC; Sweeney, J; Robalino, J; Helminiak, J; Grimes, J; Gullick, R; Wade, CE				Grathwohl, Kurt W.; Black, Ian H.; Spinella, Phillip C.; Sweeney, Jason; Robalino, Joffre; Helminiak, Joseph; Grimes, Jamie; Gullick, Richard; Wade, Charles E.			Total intravenous anesthesia including ketamine versus volatile gas anesthesia for combat-related operative traumatic brain injury	ANESTHESIOLOGY			English	Article							CEREBRAL-BLOOD-FLOW; WARTIME NEUROSURGICAL EXPERIENCE; GLASGOW OUTCOME SCALE; INTRACRANIAL-PRESSURE; CRANIOCEREBRAL INJURIES; SEVOFLURANE ANESTHESIA; PROPOFOL ANESTHESIA; PERFUSION-PRESSURE; OXYGEN-CONSUMPTION; HEMORRHAGIC-SHOCK	Background: Traumatic brain injury is a leading cause of death and severe neurologic disability. The effect of anesthesia techniques on neurologic outcomes in traumatic brain injury and potential benefits of total intravenous anesthesia (TIVA) compared with volatile gas anesthesia (VGA), although proposed, has not been well evaluated. The purpose of this study was to compare TIVA versus VGA in patients with combat-related traumatic brain injury. Methods: The authors retrospectively reviewed 252 patients who had traumatic brain injury and underwent operative neurosurgical intervention. Statistical analyses, including propensity score and matched analyses, were performed to assess differences between treatment groups (TWA vs. VGA) and good neurologic outcome. Results: Two hundred fourteen patients met inclusion criteria and were analyzed; 120 received VGA and 94 received TIVA. Good neurologic outcome (Glasgow Outcome Score 4-5) and decreased mortality were associated with TIVA compared with VGA (75% vs. 54%; P = 0.002 and 5% vs. 16%; P = 0.02, respectively). Multivariate logistic regression found admission Glasgow Coma Scale score of 8 or greater (odds ratio, 13.3; P < 0.001) and TIVA use (odds ratio, 2.3; P = 0.05) to be associated with good neurologic outcomes. After controlling for confounding factors using propensity analysis and repeated one-to-one matching of patients receiving TIVA with those receiving VGA with regard to Injury Severity Score, Glasgow Coma Scale score, base deficit, Head Abbreviated injury Score, and craniectomy or craniotomy, the authors could not find an association between treatment and neurologic outcome. Conclusion: Total intravenous anesthesia often including ketamine was not associated with improved neurologic outcome compared with VGA. Multiple confounders limit conclusions that can be drawn from this retrospective study.	[Grathwohl, Kurt W.] Brooke Army Med Ctr, Div Anesthesiol Crit Care Med, San Antonio Uniformed Serv Hlth Educ Consortium, San Antonio, TX 78234 USA; [Grathwohl, Kurt W.] Univ Texas Hlth Sci Ctr San Antonio, Trauma Div, San Antonio, TX USA; [Black, Ian H.] Uniformed Serv Univ Hlth Sci, Brooke Army Med Ctr, TARGIT, Bethesda, MD 20814 USA; [Spinella, Phillip C.] Connecticut Childrens Med Ctr, Hartford, CT USA; [Sweeney, Jason] Elmendorf AF Base, Anchorage, AK USA; [Robalino, Joffre] Walter Reed Army Med Ctr, Washington, DC 20307 USA; [Helminiak, Joseph] William Beaumont Army Med Ctr, El Paso, TX 79920 USA; [Grimes, Jamie] Brooke Army Med Ctr, San Antonio Uniformed Serv Hlth Educ Consortium, Program Director Transit Year, San Antonio, TX USA; [Wade, Charles E.] USA, Inst Surg Res, San Antonio, TX USA; Brooke Army Med Ctr, TARGIT, Div Anesthesiol Crit Care Med, Dept Anesthesia & Operat Services, San Antonio, TX USA	Grathwohl, KW (corresponding author), Brooke Army Med Ctr, Div Anesthesiol Crit Care Med, San Antonio Uniformed Serv Hlth Educ Consortium, Bldg 3600,3851 Roger Brooke Dr, San Antonio, TX 78234 USA.	kurt.grathwohl@amedd.army.mil					Adembri C, 2006, ANESTHESIOLOGY, V104, P80, DOI 10.1097/00000542-200601000-00014; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; Basagan-Mogol E, 2005, J NEUROSURG ANESTH, V17, P20; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bayona NA, 2004, ANESTHESIOLOGY, V100, P1151, DOI 10.1097/00000542-200405000-00017; Bedell Eric, 2002, Anesthesiol Clin North Am, V20, P417, DOI 10.1016/S0889-8537(01)00010-4; Breslow N.E., 1980, STAT METHODS CANC RE, V1; BROWN WR, 2006, TRAUMATIC BRAIN INJU; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; ESCH JSA, 1978, ACTA NEUROCHIR, V45, P15; FINKELSTEIN EA, 2006, INCIDENCE EC BURDEN, P55; Fraga M, 2003, ANESTHESIOLOGY, V98, P1085, DOI 10.1097/00000542-200305000-00010; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; FUJIKAWA DG, 1995, EPILEPSIA, V36, P186, DOI 10.1111/j.1528-1157.1995.tb00979.x; Furuya A, 2001, EUR J ANAESTH, V18, P88; Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hans P, 2006, CURR OPIN ANESTHESIO, V19, P498, DOI 10.1097/01.aco.0000245274.69292.ad; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; JENNETT B, 1975, LANCET, V1, P480; Johnson KB, 2004, ANESTHESIOLOGY, V101, P647, DOI 10.1097/00000542-200409000-00013; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; Kaisti KK, 2002, ANESTHESIOLOGY, V96, P1358, DOI 10.1097/00000542-200206000-00015; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; Kawasaki T, 1999, ANESTH ANALG, V89, P665; Langsjo JW, 2003, ANESTHESIOLOGY, V99, P614, DOI 10.1097/00000542-200309000-00016; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Marval PD, 2005, ANESTH ANALG, V100, P835, DOI 10.1213/01.ANE.0000146522.84181.D3; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; PAGEL PS, 2005, CARDIOVASCULAR PHARM, P191; Petersen KD, 2003, ANESTHESIOLOGY, V98, P329, DOI 10.1097/00000542-200302000-00010; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; PFENNINGER E, 1985, ACTA NEUROCHIR, V78, P113, DOI 10.1007/BF01808689; Sagara Y, 1999, J NEUROCHEM, V73, P2524, DOI 10.1046/j.1471-4159.1999.0732524.x; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Summors AC, 1999, ANESTH ANALG, V88, P341, DOI 10.1097/00000539-199902000-00022; Taniguchi T, 2001, ANESTHESIOLOGY, V95, P928, DOI 10.1097/00000542-200110000-00022; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007; *USA I SURG RES, 1970, WOUND DAT MUN EFF TE; *USA I SURG RES, 2006, JOINT THEAT TRAUM RE; VELISEK L, 1993, PHARMACOL BIOCHEM BE, V45, P889, DOI 10.1016/0091-3057(93)90136-H; WONG DHW, 1975, CAN ANAESTH SOC J, V22, P339, DOI 10.1007/BF03004843; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021; Zhao P, 2004, ANESTHESIOLOGY, V101, P695, DOI 10.1097/00000542-200409000-00018	54	21	23	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUL	2008	109	1					44	53		10.1097/ALN.0b013e31817c02e3			10	Anesthesiology	Anesthesiology	319AX	WOS:000257135300008	18580171	Bronze			2021-06-18	
J	Klementiev, B; Novikova, T; Korshunova, I; Berezin, V; Bock, E				Klementiev, B.; Novikova, T.; Korshunova, I.; Berezin, V.; Bock, E.			The NCAM-derived P2 peptide facilitates recovery of cognitive and motor function and ameliorates neuropathology following traumatic brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						adult rat; motor and cognitive deficit; NCAM; neuropathology; traumatic brain injury	CELL-ADHESION MOLECULE; CEREBRAL-ARTERY OCCLUSION; HOMOPHILIC BINDING-SITE; LONG-TERM-MEMORY; DENTATE GYRUS; SOCIAL RECOGNITION; BEHAVIORAL RECOVERY; NEURITE OUTGROWTH; MIMETIC PEPTIDES; NERVOUS-SYSTEM	The neural cell adhesion molecule (NCAM) plays a crucial role during development and regeneration of the nervous system, mediating neuronal differentiation, survival and plasticity. Moreover, NCAM regulates learning and memory. A peptide termed P2, corresponding to a 12-amino-acid sequence in the second immunoglobulin (Ig)-like module of NCAM, represents the natural cis-binding site for the first NCAM Ig module. The P2 peptide targets NCAM, thereby inducing a number of intracellular signaling events leading to the stimulation of neurite outgrowth and promotion of neuronal survival in vitro. The present study evaluated the effect of the P2 peptide on functional and histological outcomes following traumatic brain injury inflicted by a cortical cryogenic lesion. Lesioned rats were injected subcutaneously with P2 peptide, 5 mg/kg daily for 15 days beginning 2 h after injury. This treatment significantly improved postlesion recovery of motor and cognitive function, reduced neuronal degeneration, protected cells against oxidative stress, and increased reactive astrogliosis and neuronal plasticity in the sublesional area. P2 appeared rapidly in blood and cerebrospinal fluid after subcutaneous administration and remained detectable in blood for up to 5 h. The results suggest that P2 has therapeutic potential for the treatment of traumatic brain injury.	[Klementiev, B.; Novikova, T.; Korshunova, I.] ENKAM Pharmaceut AS, Copenhagen, Denmark; [Klementiev, B.] Univ Copenhagen, Panum Inst, Prot Lab, Dept Neurosci & Pharmacol,Sch Med, DK-2200 Copenhagen, Denmark	Klementiev, B (corresponding author), Univ Copenhagen, Panum Inst, Prot Lab, Dept Neurosci & Pharmacol,Sch Med, Blegdamsvej 3C,Bldg 6-2, DK-2200 Copenhagen, Denmark.	klement@plab.ku.dk		Korshunova, Irina/0000-0003-1921-6170			Andersen MB, 1997, PHARMACOL BIOCHEM BE, V56, P719, DOI 10.1016/S0091-3057(96)00414-5; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; BENOWITZ LI, 1990, MOL BRAIN RES, V8, P17, DOI 10.1016/0169-328X(90)90004-W; Berezin V, 2004, J MOL NEUROSCI, V22, P33, DOI 10.1385/JMN:22:1-2:33; Berezin V, 2000, Curr Opin Drug Discov Devel, V3, P605; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Burman OHP, 2000, APPL ANIM BEHAV SCI, V67, P241, DOI 10.1016/S0168-1591(99)00120-3; Cambon K, 2004, J NEUROSCI, V24, P4197, DOI 10.1523/JNEUROSCI.0436-04.2004; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; COTMAN CW, 1981, PHYSIOL REV, V61, P684; Covolan L, 2000, HIPPOCAMPUS, V10, P169, DOI 10.1002/(SICI)1098-1063(2000)10:2<169::AID-HIPO6>3.3.CO;2-N; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ditlevsen DK, 2007, EUR J NEUROSCI, V25, P1678, DOI 10.1111/j.1460-9568.2007.05436.x; Emery DL, 2000, J COMP NEUROL, V424, P521; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HAKIM AM, 1987, CAN J NEUROL SCI, V14, P557; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Hinsby AM, 2004, J NEUROCHEM, V91, P694, DOI 10.1111/j.1471-4159.2004.02772.x; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Hotta N, 2005, MOL BRAIN RES, V133, P71, DOI 10.1016/j.molbrainres.2004.09.027; Jellinger KA, 2003, J NEURAL TRANSM-SUPP, P101; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kiryushko D, 2006, MOL CELL BIOL, V26, P3625, DOI 10.1128/MCB.26.9.3625-3638.2006; Kiselyov VV, 2005, J NEUROCHEM, V94, P1169, DOI 10.1111/j.1471-4159.2005.03284.x; Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6; Krushel LA, 1999, J BIOL CHEM, V274, P2432, DOI 10.1074/jbc.274.4.2432; Larsen E, 2006, ONCOGENE, V25, P2425, DOI 10.1038/sj.onc.1209284; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Li SZ, 2005, BIOCHEMISTRY-US, V44, P5034, DOI 10.1021/bi0480133; Liu JL, 1998, J NEUROSCI, V18, P7768; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MILLER PD, 1994, J NEUROSCI, V14, P4217; NG SC, 1988, NEURON, V1, P133, DOI 10.1016/0896-6273(88)90197-3; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pedersen MV, 2004, J NEUROSCI RES, V75, P55, DOI 10.1002/jnr.10812; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Popik P, 1998, PROG BRAIN RES, V119, P415; Povlsen GK, 2003, NEUROCHEM RES, V28, P127, DOI 10.1023/A:1021660531484; Prediger RDS, 2005, NEUROBIOL AGING, V26, P957, DOI 10.1016/j.neurobiolaging.2004.08.012; Reier P J, 1988, Adv Neurol, V47, P87; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; Royle SJ, 1999, BRAIN RES, V816, P337, DOI 10.1016/S0006-8993(98)01122-6; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SAWYER TF, 1984, BEHAV NEUROSCI, V98, P908, DOI 10.1037/0735-7044.98.5.908; Schmid RS, 1999, J NEUROBIOL, V38, P542, DOI 10.1002/(SICI)1097-4695(199903)38:4<542::AID-NEU9>3.0.CO;2-1; SCHOEN SW, 1994, EXP NEUROL, V127, P106, DOI 10.1006/exnr.1994.1084; SEKIGUCHI R, 1991, PHYSIOL BEHAV, V50, P1253, DOI 10.1016/0031-9384(91)90591-B; Shanina EV, 2006, NEUROSCIENCE, V139, P1495, DOI 10.1016/j.neuroscience.2006.01.016; Soroka V, 2003, STRUCTURE, V11, P1291, DOI 10.1016/j.str.2003.09.006; Soroka V, 2002, J BIOL CHEM, V277, P24676, DOI 10.1074/jbc.M109694200; Stepanichev MY, 2003, BRAIN RES BULL, V61, P197, DOI 10.1016/S0361-9230(03)00118-7; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; THOR DH, 1982, J COMP PHYSIOL PSYCH, V96, P1000, DOI 10.1037/0735-7036.96.6.1000; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Walmod PS, 2004, NEUROCHEM RES, V29, P2015, DOI 10.1007/s11064-004-6875-z; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	82	21	21	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUN	2008	27	11					2885	2896		10.1111/j.1460-9568.2008.06245.x			12	Neurosciences	Neurosciences & Neurology	313BV	WOS:000256717000009	18540884				2021-06-18	
J	Alvarez, XA; Sampedro, C; Figueroa, J; Tellado, I; Gonzalez, A; Garcia-Fantini, M; Cacabelos, R; Muresanu, D; Moessler, H				Anton Alvarez, X.; Sampedro, Carolina; Figueroa, Jesus; Tellado, Ivan; Gonzalez, Andres; Garcia-Fantini, Manuel; Cacabelos, Ramon; Muresanu, Dafin; Moessler, Herbert			Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury	JOURNAL OF NEURAL TRANSMISSION			English	Article						Cerebrolysin; EEG power ratio; quantitative EEG; qEEG slowing; cognitive performance; traumatic brain injury	DOUBLE-BLIND; ALZHEIMERS-DISEASE; ALPHA; DEFICITS; SERUM; HEAD; ELECTROENCEPHALOGRAPHY; PERFORMANCE; COGNITION; CHILDREN	Changes in quantitative EEG (qEEG) recordings over a 1-year period and the effects of Cerebrolysin (Cere) on qEEG slowing and cognitive performance were investigated in postacute moderate-severe traumatic brain injury (TBI) patients. Time-related changes in qEEG activity frequency bands (increases of alpha and beta, and reductions of theta and delta relative power) and in qEEG slowing (reduction of EEG power ratio) were statistically significant in patients with a disease progress of less than 2 years at baseline, but not in those patients having a longer disease progress time. Slowing of qEEG activity was also found to be significantly reduced in TBI patients after 1 month of treatment with Cere and 3 months later. Therefore, Cere seems to accelerate the time-related reduction of qEEG slowing occurring in untreated patients. The decrease of qEEG slowing induced by Cere correlated with the improvement of attention and working memory. Results of this exploratory study suggest that Cere might improve the functional recovery after brain injury and encourage the conduction of further controlled clinical trials.	[Anton Alvarez, X.; Sampedro, Carolina; Figueroa, Jesus; Tellado, Ivan; Gonzalez, Andres; Cacabelos, Ramon] EuroEspes Biomed Res Ctr, Dept Neuropharmacol, Bergondo 15166, A Coruna, Spain; [Garcia-Fantini, Manuel] Hosp Juan Canalejo, La Coruna, Spain; [Muresanu, Dafin] Univ Cluj, Neurol Clin, Cluj Napoca, Romania; [Moessler, Herbert] EBEWE Pharma, Unterach, Austria	Alvarez, XA (corresponding author), EuroEspes Biomed Res Ctr, Dept Neuropharmacol, Bergondo 15166, A Coruna, Spain.	xantonal@yahoo.es	Muresanu, Fior-Dafin/AAI-8120-2021				AKAI F, 1992, HISTOL HISTOPATHOL, V7, P213; ALBRECHT E, 1993, ADV BIOSCI, V87, P341; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P281; Alvarez XA, 2006, EUR J NEUROL, V13, P43, DOI 10.1111/j.1468-1331.2006.01222.x; Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; Alvarez XA, 1999, METHOD FIND EXP CLIN, V21, P633; Alvarez XA, 1999, 1ST INTERNATIONAL CONGRESS ON VASCULAR DEMENTIA, P233; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P315; Angelakis E, 2004, CLIN NEUROPHYSIOL, V115, P887, DOI 10.1016/j.clinph.2003.11.034; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Bae CY, 2000, J AM GERIATR SOC, V48, P1566, DOI 10.1111/j.1532-5415.2000.tb03865.x; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Boado RJ, 1999, NEUROSCI RES, V34, P217, DOI 10.1016/S0168-0102(99)00056-5; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Cacabelos R, 1996, ANN NY ACAD SCI, V777, P399, DOI 10.1111/j.1749-6632.1996.tb34452.x; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Funke M, 1998, J NEURAL TRANSM-SUPP, P385; Gschanes A, 1998, J NEURAL TRANSM-SUPP, P313; Hutter-Paier B, 1998, J NEURAL TRANSM-SUPP, P351; HutterPaier B, 1996, J NEURAL TRANSM-SUPP, P267; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1998, ELECTROEN CLIN NEURO, V106, P244, DOI 10.1016/S0013-4694(97)00141-7; Kazanis I, 2004, EXP NEUROL, V186, P221, DOI 10.1016/j.expneurol.2003.12.004; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lombardi VRM, 1999, METHOD FIND EXP CLIN, V21, P331, DOI 10.1358/mf.1999.21.5.541910; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Magnoni S, 2003, J NEUROTRAUM, V20, P251, DOI 10.1089/089771503321532833; Masliah E, 1999, PHARMACOL BIOCHEM BE, V62, P239, DOI 10.1016/S0091-3057(98)00144-0; NAGATA K, 1989, ELECTROEN CLIN NEURO, V72, P16, DOI 10.1016/0013-4694(89)90027-8; Overall J E, 1992, J Geriatr Psychiatry Neurol, V5, P220; Panisset M, 2002, J NEURAL TRANSM, V109, P1089, DOI 10.1007/s007020200092; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reinprecht I, 1999, HISTOCHEM J, V31, P394; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rockenstein E, 2002, J NEURAL TRANSM-SUPP, P327; Ruether E, 2002, J NEURAL TRANSM-SUPP, P265; Ruether E, 2001, INT CLIN PSYCHOPHARM, V16, P253, DOI 10.1097/00004850-200109000-00002; SALETU B, 1995, INT J CLIN PHARM TH, V33, P249; Satou T., 1994, JPN PHARMACOL THER, V22, P205; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Thornton K, 2003, ARCH CLIN NEUROPSYCH, V18, P363, DOI 10.1016/S0887-6177(02)00139-7; Valente M, 2002, CLIN NEUROPHYSIOL, V113, P1798, DOI 10.1016/S1388-2457(02)00218-3; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Wallace BE, 2001, J HEAD TRAUMA REHAB, V16, P165, DOI 10.1097/00001199-200104000-00006; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039	56	21	21	0	5	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	MAY	2008	115	5					683	692		10.1007/s00702-008-0024-9			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	308ZY	WOS:000256430700004	18273537				2021-06-18	
J	Gong, SW; Lee, HP; Lu, C				Gong, S. W.; Lee, H. P.; Lu, C.			Computational simulation of the human head response to non-contact impact	COMPUTERS & STRUCTURES			English	Article						impact biomechanics; finite element model; multibody system; ATB model; human head; traumatic brain injury; head injury criterion (HIC)	FINITE-ELEMENT MODELS	This paper deals with the human head response to a sudden motion without direct contact with another solid object, i.e. to non-contact impact. A computational simulation approach is presented for this study, which is accomplished by the integration of a coated articulated total body (ATB) model with a finite element (FE) head model. The present approach includes two major aspects: one is to simulate the sudden motion of the human head with the whole body by means of the ATB model; and the other is to predict the head deformation and stress induced by the sudden motion through using the FE head model. The agreement between the simulation results and the published experimental data [Wismans J, Hermans J. MADYMO 3D simulations of hybrid III dummy sled tests. In: Backailis SH, Mertz HJ, editors. Hybrid III: the first human-like crash test dummy, SAE PT-44; 1994. p. 735-49; Nahum AM, Smith R, War CC. Intracranial pressure dynamic during head injury. In: 21st Stapp car crash conference proceedings, SAE 770922; 1977] is obtained. The intracranial pressure response and the head stress response are then predicted using the present approach. The correlation between the head motion and the brain stresses are also explored. In addition, the head injury induced by the non-contact impact is evaluated. (C) 2007 Elsevier Ltd. All rights reserved.	[Gong, S. W.; Lee, H. P.; Lu, C.] Inst High Performance Comp, Singapore 117528, Singapore; [Lee, H. P.] Natl Univ Singapore, Dept Mech Engn, Singapore 117576, Singapore	Gong, SW (corresponding author), Inst High Performance Comp, 1 Sci Pk Rd,01-01 Capricorn,Singapore Sci Pk 2, Singapore 117528, Singapore.	gongsw@ihpc.a-star.edu.sg	Lee, Heow Pueh/I-7834-2014; LU, Chun/A-4653-2010	Lee, Heow Pueh/0000-0002-4380-3888; LU, Chun/0000-0001-7941-4879			Advani SH, 1982, HUMAN BODY DYNAMICS; [Anonymous], 2003, LS DYNA KEYW US MAN; Emily Sun R.S, 1998, DEV IMPROVED INJURY; Fox B, 1999, IEEE T BIO-MED ENG, V46, P1199, DOI 10.1109/10.790496; Gadd C, 1961, NATL RES COUNCIL PUB, P141; GOLDSMITH W, 1972, BIOMECHANICS ITS F O, P585; Gong SW, 2007, IEEE T BIO-MED ENG, V54, P956, DOI 10.1109/TBME.2006.889158; Gong SW, 1999, INT J IMPACT ENG, V22, P397, DOI 10.1016/S0734-743X(98)00058-X; Gong SW, 1996, AIAA J, V34, P1619, DOI 10.2514/3.13280; GONG SW, 2005, P 20 C INT SOC BIOM, P938; GONG SW, 2000, P 71 SHOCK VIBR S AR; HERMANN LR, 1968, CPIA PUBLICATION, V177; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; HUAINING C, 1998, ARTICULATED TOTAL BO; John OL., 2006, LS DYNA THEORY MANUA; Johnson EAC, 2005, J BIOMECH, V38, P39, DOI 10.1016/j.jbiomech.2004.03.018; KENNER VH, 1973, J BIOMECH, V6, P1, DOI 10.1016/0021-9290(73)90032-8; KOENIG H, 1998, MODERN COMPUTATIONAL; LAM KY, 1999, P NAV TECHN SEM PLAT, V5, P1; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; MCHENRY BG, 2004, 2004 ATB US C; *MSC SOFTW CORP, 2002, MSC DYTRAN US MAN; Nahum A, 1977, 21 STAPP CAR CRASH C; OGLESBY DB, 1998, P 69 SHOCK VIBR S ST; OMMAYA A, 1984, BIOMECHANICS TRAUMA; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; RUAN JS, 1995, J NEUROTRAUM, V12, P247; Schmitt K-U, 2004, TRAUMA BIOMECHANICS; Shabana A A, 2001, COMPUTATIONAL DYNAMI; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; *TNO, 2001, MAD V6 0 TNO AUT; Versace J., 1971, REV SEVERITY INDEX; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; WISMANS J, 1994, HYBRID, V3, P735; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; ZHOU C, 1995, THESIS WAYNE STATE U; Zong Z, 2006, J BIOMECH, V39, P284, DOI 10.1016/j.jbiomech.2004.11.015	37	21	22	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0045-7949	1879-2243		COMPUT STRUCT	Comput. Struct.	APR	2008	86	7-8					758	770		10.1016/j.compstruc.2007.06.003			13	Computer Science, Interdisciplinary Applications; Engineering, Civil	Computer Science; Engineering	297FO	WOS:000255602700014					2021-06-18	
J	Horner, MD; Selassie, AW; Lineberry, L; Ferguson, PL; Labbate, LA				Horner, Michael D.; Selassie, Anbesaw W.; Lineberry, Lee; Ferguson, Pamela L.; Labbate, Lawrence A.			Predictors of psychological symptoms 1 year after traumatic brain injury: A population-based, epidemiological study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety; brain damage; chronic; depression; epidemiologic studies,follow-up studies; mood disorders	NATIONAL PROBABILITY SAMPLE; AMERICAN DRINKING PRACTICES; PSYCHIATRIC-DISORDERS; AXIS-I; DEPRESSION; REHABILITATION; QUESTIONNAIRE; INDIVIDUALS; OUTPATIENTS; CONCUSSION	Objective: To examine self-reported psychological symptoms 1 year after traumatic brain injury (TBI) in a populationbased sample. Participants: There were 1560 adults who had sustained TBI. Design: A telephone survey with questions about recent mood and anxiety symptoms, and diagnoses since TBI. Polychotomous logistic regression with 3 response levels (probable, possible, and no mood or anxiety symptoms) identified predictors of psychological symptoms. Results: Overall, 40% of participants had clinically significant mood or anxiety symptoms-12.6% with probable symptoms and 27.5% with possible symptoms. Main risk factors for probable symptoms included younger age, poor physical functioning, inadequate social support, and being a white woman. Other risk factors included being retired or unemployed, and pre-TBI psychiatric disorder or multiple concussions. Conclusions: These findings suggest the need for careful screening of persons with TBI who are at particular risk of developing psychological symptoms, and persons who have recently sustained TBI and their families to be educated about the possibility of developing such symptoms.	[Horner, Michael D.; Labbate, Lawrence A.] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA; [Horner, Michael D.; Labbate, Lawrence A.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; [Selassie, Anbesaw W.; Lineberry, Lee; Ferguson, Pamela L.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA	Horner, MD (corresponding author), Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.	hornermd@musc.edu					ALLISON PD, 1991, LOGISTIC REGRESSION, P48; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; BARRERA M, 1983, AM J COMMUN PSYCHOL, V11, P133; Beck A. T., 1996, BECK DEPRESSION INVE; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; Center for Injury Research and Policy of The Johns Hopkins University School of Public Health, 1997, ICDMAP 90 SOFTW; Centers for Disease Control and Prevention, 2003, BEH RISK FACT SURV S; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; Darlington GA, 1998, ENCY BIOSTATISTICS, P788; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jorge R, 2002, NEUROREHABILITATION, V17, P311; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LAWRENCE RH, 1995, J AGING HEALTH, V7, P74, DOI 10.1177/089826439500700104; LEAVY RL, 1983, J COMMUNITY PSYCHOL, V11, P3, DOI 10.1002/1520-6629(198301)11:1<3::AID-JCOP2290110102>3.0.CO;2-E; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Moore J. C, 1988, J OFF STAT, V4, P155; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SAS Institute Inc, 2006, STAT AN SOFTW; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; STOKES ME, 1995, CATEGORICAL DATA ANA, P241; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ., 1995, GUIDELINES SURVEILLA; WARDEN DL, 2005, TXB TRAUMATIC BRAIN, P231; WARE JE, 1994, SF36 PHYS MENTAL HLT; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	49	21	22	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2008	23	2					74	83		10.1097/01.HTR.0000314526.01006.c8			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	280KW	WOS:000254426700002	18362761				2021-06-18	
J	Langley, J; Kypri, K; Cryer, C; Davie, G				Langley, John; Kypri, Kypros; Cryer, Colin; Davie, Gabrielle			Assessing the validity of potential alcohol-related non-fatal injury indicators	ADDICTION			English	Article						alcohol; bias; case ascertainment; face validity; indicators; injury	TRAUMATIC BRAIN-INJURY; NEW-ZEALAND; TRENDS; RATES	Aim To assess critically the face validity of the World Health Organization's (WHO's) International Guide for Monitoring Alcohol Consumption and Related Harm (MACRH) for deriving indicators, for the purposes of developing non-fatal alcohol-related injury indicators in New Zealand. Design MACRH's five solutions for deriving indicators are: (i) use only alcohol-specific cases; (ii) identify subsets of events known to be highly alcohol-related; (iii) utilize control indicators that are rarely alcohol-related; (iv) estimate alcohol attributable fractions (AAFs) and adjust indicators accordingly; and (v) develop composite indicators. These were assessed in terms of their face validity with particular reference to New Zealand. Findings There are significant face validity issues with each of the five options. Solution 4 offers the greatest promise, provided that: (i) valid AAFs can be derived and they are updated regularly; and (ii) appropriate adjustment is made for extraneous influences on the estimates of alcohol-related harm. To date, the latter has not been carried out. Conclusions Most potential sources of data on alcohol-related harm are subject to extraneous influences, which vary over time and space. While the attempt by WHO to offer solutions to this problem is laudable, the solutions do not address the problem adequately. MACRH guidelines need to be revised to include criteria for a valid outcome indicator.	[Langley, John; Kypri, Kypros; Cryer, Colin; Davie, Gabrielle] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin, New Zealand	Langley, J (corresponding author), Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Injury Prevent Res Unit, POB 913, Dunedin, New Zealand.	john.langley@ipru.otago.ac.nz	Kypri, Kypros/D-2809-2009	Kypri, Kypros/0000-0002-9657-9904; Davie, Gabrielle/0000-0001-5466-5364			Alsop J, 2001, ACCIDENT ANAL PREV, V33, P353, DOI 10.1016/S0001-4575(00)00049-X; Boufous S, 2007, INJURY PREV, V13, P211, DOI 10.1136/ip.2006.014654; CHIKRITZHS T, 2003, AUSTR ALCOHOL INDICA; Connor J, 2004, EPIDEMIOLOGY, V15, P337, DOI 10.1097/01.ede.0000120045.58295.86; Connor J, 2002, BRIT MED J, V324, P1125, DOI 10.1136/bmj.324.7346.1125; CONNOR J, 2005, ALAC OCCASIONAL PUBL, V32; Cryer C, 2006, INJURY PREV, V12, P202, DOI 10.1136/ip.2006.011635; Cryer C, 2002, PUBLIC HEALTH, V116, P257, DOI 10.1038/sj.ph.1900878; CRYER C, 2003, INT COLLABORATIVE EF; Cryer C, 2006, CHARTBOOK NZ INJURY; Cummings P, 2006, INJURY PREV, V12, P148, DOI 10.1136/ip.2005.010975; English D., 1995, QUANTIFICATION DRUG; Haworth N., 1997, 120 MON U ACC RES CT; *IRTAD, 2007, ORG EC COOP DEV; Langley J, 2002, INJ PREV, V8, P332, DOI 10.1136/ip.8.4.332; Langley J, 2000, AUSTR EPIDEMIOLOGIST, V7, P5; Langley John, 2003, Traffic Inj Prev, V4, P291, DOI 10.1080/714040487; Lyons R A, 2006, Int J Inj Contr Saf Promot, V13, P63, DOI 10.1080/17457300500258682; Lyons Ronan A, 2005, Int J Inj Contr Saf Promot, V12, P207, DOI 10.1080/17457300500172776; Ridolfo B., 2001, QUANTIFICATION DRUG; Roberts I, 1996, BRIT MED J, V313, P1239, DOI 10.1136/bmj.313.7067.1239; Rosman DL, 2001, ACCIDENT ANAL PREV, V33, P81, DOI 10.1016/S0001-4575(00)00018-X; Shepherd J, 2005, INJURY PREV, V11, P324, DOI 10.1136/ip.2005.09761; Stephenson S, 2004, INJURY PREV, V10, P379, DOI 10.1136/ip.2004.005561; Stockwell T, 2000, J SUBST ABUSE, V12, P139, DOI 10.1016/S0899-3289(00)00046-8; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; World Health Organization, 2000, INT GUID MON ALC CON	28	21	22	0	0	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0965-2140			ADDICTION	Addiction	MAR	2008	103	3					397	404		10.1111/j.1360-0443.2007.02089.x			8	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	259TU	WOS:000252964600009	18190665				2021-06-18	
J	Lu, DC; Binder, DK; Chien, B; Maisel, A; Manley, GT				Lu, Daniel C.; Binder, Devin K.; Chien, Bonnie; Maisel, Alan; Manley, Geoffrey T.			Cerebral salt wasting and elevated brain natriuretic peptide levels after traumatic brain injury: 2 case reports	SURGICAL NEUROLOGY			English	Article						brain natriuretic peptide; traumatic brain injury; cerebral salt-wasting syndrome	CENTRAL-NERVOUS-SYSTEM; SUBARACHNOID HEMORRHAGE; HYPONATREMIA; RECEPTORS; SECRETION; HEART	Background: Historically, hyponatremia in patients with varying brain diseases was termed cerebral salt wasting. Hyponatremia secondary to CSW was reported to be a distinct entity from SIADH, with the distinguishing feature of decreased extracellular fluid volume. Brain natriuretic peptide, a peptide with natriuretic, vasorelaxant, and aldosterone-inhibiting properties, was recently implicated in aneurysmal SAH patients with CSW. Here, we describe 2 cases of CSW in TBI patients with elevated BNP levels. This phenomenon has not been previously described. Case Description: Two patients with TBI and hyponatremia were subject to analysis. Central lines were placed to assess volume status. Levels of BNP were measured at the onset of hypertonic saline infusion. Electrocardiogram and cardiac enzyme studies were performed to assess cardiac function. Serial imaging was performed to assess the extent of brain injury. Conclusions: These patients with TBI had findings consistent with CSW with elevated BNP levels in the setting of normal cardiac function. In both cases, a high BNP level was observed after declining plasma Na levels despite aggressive hypertonic saline infusion. High BNP levels may be associated with CSW. Further studies are necessary to establish a causative role for BNP in TBI-induced CSW. (c) 2008 Elsevier Inc. All rights reserved.	[Lu, Daniel C.; Binder, Devin K.; Chien, Bonnie; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Maisel, Alan] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Lu, DC (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, POB 0112, San Francisco, CA 94143 USA.	ludan@neurosurg.ucsf.edu					Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; COOPER WC, 1965, ARCH INTERN MED, V116, P113, DOI 10.1001/archinte.1965.03870010115014; CORT JH, 1954, LANCET, V1, P752; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; GOLDBERG M, 1960, NEW ENGL J MED, V263, P1037, DOI 10.1056/NEJM196011242632101; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; HOSODA K, 1991, HYPERTENSION, V17, P1152, DOI 10.1161/01.HYP.17.6.1152; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.ph.54.030192.000303; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50; MOSES AM, 1994, HARRISONS PRINCIPLES, P1921; Munagala VK, 2004, CURR PROB CARDIOLOGY, V29, P707, DOI 10.1016/j.cpcardiol.2004.07.002; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; Scotland RS, 2005, PHARMACOL THERAPEUT, V105, P85, DOI 10.1016/j.pharmthera.2004.08.011; STINGO AJ, 1992, AM J PHYSIOL, V263, pH1318; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Wang TJ, 2004, NEW ENGL J MED, V350, P655, DOI 10.1056/NEJMoa031994; WELT LG, 1952, ARCH INTERN MED, V90, P355, DOI 10.1001/archinte.1952.00240090076007	19	21	23	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	MAR	2008	69	3					226	229		10.1016/j.surneu.2007.02.051			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	275SJ	WOS:000254091600005	18325424				2021-06-18	
J	Reid, WM; Hamm, RJ				Reid, Wendy M.; Hamm, Robert J.			Post-injury atomoxetine treatment improves cognition following experimental traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						animal study; atomoxetine; dopamine; fluid-percussion injury; morris water maze; norepinephrine; traumatic brain injury	ATTENTION DEFICIT/HYPERACTIVITY DISORDER; WATER MAZE PERFORMANCE; FRONTAL-CORTEX DAMAGE; WORKING-MEMORY; PREFRONTAL CORTEX; RAT; NOREPINEPHRINE; DOPAMINE; RECOVERY; DEFICITS	Catecholaminergic neurotransmission is regionally altered following injury, and drugs aimed at these systems offer promising avenues for post - traumatic brain injury ( TBI) pharmacotherapies. Atomoxetine is a selective norepinephrine transporter ( NET) inhibitor currently indicated for treatment of attention-deficit hyperactivity disorder ( ADHD). The current study was designed to test the efficacy of atomoxetine in treating cognitive deficits following experimental TBI in animals and to determine an optimal dose and therapeutic window for drug treatment. Sprague-Dawley rats were subjected to lateral fluid-percussion injury ( L-FPI) of moderate severity ( 2.08 atm +/- 0.05). Two experiments were performed. In the first study, atomoxetine ( 0.3, 1, 3, or 9 mg/ kg) or vehicle was administered daily on post-injury days ( PID) 1 - 15. Cognitive assessment was performed using the Morris water maze on PID 11 - 15. L-FPI resulted in significant cognitive impairment when compared to Sham-Injury. Treatment with lower doses of atomoxetine ( 0.3, 1, and 3 mg/ kg) significantly attenuated the cognitive deficits in injured animals. Treatment with the higher dosage ( 9 mg/ kg) of atomoxetine resulted in animals that were not significantly different than injured-vehicle treated animals. The optimal response was achieved using 1 mg/ kg atomoxetine. In the second study, treatment with atomoxetine ( 1 mg/ kg) or vehicle was delayed for 11 days post-injury. Rats were administered atomoxetine daily for 15 days, and cognitive assessment was performed on PID 25 - 29. In this study, treatment with atomoxetine ( 1 mg/ kg) did not result in improved cognitive performance. In conclusion, this is the first study to show low-dose atomoxetine initiated early after experimental TBI results in improved cognition.	[Reid, Wendy M.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23284 USA; [Hamm, Robert J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA USA	Reid, WM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Box 980709,Med Coll Virginia Campus,1101 E Marsha, Richmond, VA 23284 USA.	murdockwm@vcu.edu					Baranova AI, 2006, J NEUROTRAUM, V23, P1233, DOI 10.1089/neu.2006.23.1233; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; Bymaster FP, 2002, NEUROPSYCHOPHARMACOL, V27, P699, DOI 10.1016/S0893-133X(02)00346-9; Chen MJ, 2007, CELL SIGNAL, V19, P114, DOI 10.1016/j.cellsig.2006.05.028; Christman AK, 2004, PHARMACOTHERAPY, V24, P1020, DOI 10.1592/phco.24.11.1020.36146; D'Sa C, 2002, BIPOLAR DISORD, V4, P183, DOI 10.1034/j.1399-5618.2002.01203.x; DELLO RC, 2004, J NEUROINFLAMM, V1, P1; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Emery DL, 2000, J COMP NEUROL, V424, P521; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; Forsyth RJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003984.pub2; Foster DJ, 2006, ARCH PHYS MED REHAB, V87, P216, DOI 10.1016/j.apmr.2005.08.131; Fujinaka T, 2003, NEUROL RES, V25, P35, DOI 10.1179/016164103101201094; GEHLERT DR, 1993, NEUROSCI LETT, V157, P203, DOI 10.1016/0304-3940(93)90737-6; Gladstone DJ, 2000, CAN J NEUROL SCI, V27, P97; Goldstein Larry B, 2006, NeuroRx, V3, P451, DOI 10.1016/j.nurx.2006.07.010; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; Gu Q, 2002, NEUROSCIENCE, V111, P815, DOI 10.1016/S0306-4522(02)00026-X; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; KOLB B, 1992, J NEUROSCI, V12, P2321; Laifenfeld D, 2002, J NEUROCHEM, V83, P1054, DOI 10.1046/j.1471-4159.2002.01215.x; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; Madrigal JLM, 2005, J NEUROSCI RES, V81, P390, DOI 10.1002/jnr.20481; Marien MR, 2004, BRAIN RES REV, V45, P38, DOI 10.1016/j.brainresrev.2004.02.002; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; Mattiuz EL, 2003, DRUG METAB DISPOS, V31, P88, DOI 10.1124/dmd.31.1.88; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Moron JA, 2002, J NEUROSCI, V22, P389, DOI 10.1523/JNEUROSCI.22-02-00389.2002; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; PRASAD MR, 1995, RESTOR NEUROL NEUROS, V9, P65; Ripley DL, 2006, J HEAD TRAUMA REHAB, V21, P85, DOI 10.1097/00001199-200601000-00010; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; SUTHERLAND RJ, 1982, NEUROSCI LETT, V32, P125, DOI 10.1016/0304-3940(82)90261-0; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V9, P1; Swanson CJ, 2006, NEUROPHARMACOLOGY, V50, P755, DOI 10.1016/j.neuropharm.2005.11.022; Tzavara ET, 2006, MOL PSYCHIATR, V11, P187, DOI 10.1038/sj.mp.4001763; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WHITING MD, 2004, PHYS REHABIL MED, V16, P273; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	57	21	22	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2008	25	3					248	256		10.1089/neu.2007.0389			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	282PJ	WOS:000254579400008	18352838				2021-06-18	
J	Vickery, CD; Sepehri, A; Evans, CC				Vickery, Chad D.; Sepehri, Arash; Evans, Clea C.			Self-esteem in an acute stroke rehabilitation sample: a control group comparison	CLINICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; DEPRESSIVE SYMPTOMS; SOCIAL SUPPORT; VALIDATION; SCALE	Objective: To compare ratings of self-esteem and depressive mood in a sample of stroke survivors in an acute inpatient rehabilitation setting to those of a matched control group. Design: Stroke survivors (n=80) were matched on age and education to a group of neurologically intact community-dwelling control participants. Between-group analysis compared mean ratings of self-esteem and depressive measures. Within-group correlational analyses explored the relationship between self-esteem and mood. Between-group comparison of the correlations between self-esteem and mood explored differences in the strength of association between these constructs. Regression analyses explored the relationship of self-esteem measures after controlling for depressive mood. Main measures: Visual Analogue Self-Esteem Scale, Rosenberg Self-Esteem Scale, Geriatric Depression Scale. Results: Stroke survivors rated significantly lower mean levels of self-esteem- on the Visual Analogue Self-Esteem Scale (37 versus 41) and the Rosenberg Self-Esteem Scale (21 versus 24) than the control group. Stroke survivors also rated higher mean levels of depressive mood on the Geriatric Depression Scale (9 versus 6). Significantly higher correlations between self-esteem and mood ratings were noted in the stroke group than in the control group. Lower self-esteem ratings do not appear to be a byproduct of depressive mood. Conclusions: Self-esteem is negatively impacted by stroke and is strongly, but independently, associated with depressive mood. Clinicians may better facilitate the emotional adjustment of the survivor by considering this facet of psychological impact and intervening to address self-esteem.	[Vickery, Chad D.] Methodist Rehabil Ctr, Neuropsychol Dept, Jackson, MS 39216 USA	Vickery, CD (corresponding author), Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	chadvickery@hotmail.com					Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BRINKMANN JR, 1979, PHYS THER, V59, P859; Brown JD, 2001, COGNITION EMOTION, V15, P615; Brumfitt SM, 1999, BRIT J CLIN PSYCHOL, V38, P387, DOI 10.1348/014466599162980; Chang AM, 1999, J CLIN NURS, V8, P477, DOI 10.1046/j.1365-2702.1999.0196a.x; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Ellis-Hill CS, 2000, CLIN REHABIL, V14, P279, DOI 10.1191/026921500671231410; Fung LCL, 2006, J CLIN NURS, V15, P505, DOI 10.1111/j.1365-2702.2006.01328.x; Heatherton TF, 2000, J PERS SOC PSYCHOL, V78, P725, DOI 10.1037/0022-3514.78.4.725; HEATHERTON TF, 1991, J PERS SOC PSYCHOL, V60, P895, DOI 10.1037/0022-3514.60.6.895; Keppel CC, 2000, NEUROPSYCHOL REHABIL, V10, P15, DOI 10.1080/096020100389273; Koehler M L, 1989, Rehabil Nurs, V14, P9; KRAVETZ S, 1995, BRAIN INJURY, V9, P131, DOI 10.3109/02699059509008186; Li L, 1998, J SOC PSYCHOL, V138, P13, DOI 10.1080/00224549809600349; Lincoln NB, 1997, CLIN REHABIL, V11, P114, DOI 10.1177/026921559701100204; Ng JYY, 2000, PERCEPT MOTOR SKILL, V91, P107; OVERHOLSER JC, 1993, REHABIL PSYCHOL, V38, P187, DOI 10.1037/0090-5550.38.3.187; Penninx BWJH, 1998, HEALTH PSYCHOL, V17, P551, DOI 10.1037/0278-6133.17.6.551; PYSZCZYNSKI T, 1985, PERS SOC PSYCHOL B, V11, P179, DOI 10.1177/0146167285112006; Rosenberg M., 1979, CONCEIVING SELF; RULE B G, 1989, Clinical Gerontologist, V9, P37; Schroevers MJ, 2003, SOC SCI MED, V57, P375, DOI 10.1016/S0277-9536(02)00366-0; Vickery CD, 2006, REHABIL PSYCHOL, V51, P30, DOI 10.1037/0090-5550.51.1.30; VICKERY CD, UNPUB PSYCHOMETRIC C; VICKERY CD, IN PRESS REHABIL PSY; Vickery CD, 2006, CLIN REHABIL, V20, P1075, DOI 10.1177/0269215506071269; Westin L, 1997, J INTERN MED, V242, P239, DOI 10.1046/j.1365-2796.1997.00203.x; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	28	21	23	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	FEB	2008	22	2					179	187		10.1177/0269215507080142			9	Rehabilitation	Rehabilitation	276NV	WOS:000254150100008	18212038				2021-06-18	
J	Faria, JCM; Rodrigues, ML; Scopel, GP; Kowalski, LP; Ferreira, MC				Faria, Jose Carlos Marques; Rodrigues, Monica Lucia; Scopel, Gean Paulo; Kowalski, Luiz Paulo; Ferreira, Marcus Castro			The versatility of the free lateral arm flap in head and neck soft tissue reconstruction: clinical experience of 210 cases	JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY			English	Article						lateral arm; free flap; head and neck; reconstruction	DONOR	A study of the authors' experience with 210 free lateral arm flaps used to repair head and neck oncological. defects over an 8-year period. Patients' ages ranged from 4 to 83 years (average: 49.7 years). One hundred and forty-one were mate and 66 female. Three patients received two consecutive flaps each. They were used to reconstruct: the tongue, 53 cases; retromolar trigone, 42 cases; soft/hard palate, 34 cases; skin/facial contour, 19 cases; hypopharynx, 17 cases; buccal. mucosa, 12 cases; lips, five cases. Flap cutaneous dimensions ranged from 4 x 2 cm to 17 x 8 cm. Flap was composed of: skin and fascia, 18 cases; sensate (neurovascular) skin, six cases; subcutaneous fat tissue, five cases; skin and vascularised nerve graft, three cases, skin and partial triceps muscle, three cases. Nerve coaptations were performed for all lip reconstructions. All flaps survived except for nine (success rate: 95.2%). Severe postoperative clinical complications preceded flap failure and death in two cases. All. but six donor sites were closed primarily. Complications related to the donor site were: paresthesia of the forearm, 210 cases; dog ear, 16 cases; hypertropic scar, 14 cases; weakness, nine cases; haematoma, five cases; seroma, three cases; dehiscence, one case. Radial nerve injury was not observed in this series. The lateral arm flap can be considered safe and versatile for most soft tissue head and neck microsurgical reconstructions. The possibility of sensory recovery through neural anastomoses and low donor site morbidity enhances its efficiency. (c) 2007 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.	[Faria, Jose Carlos Marques; Rodrigues, Monica Lucia] Hosp Canc AC Camargo, Microsurg Surg Div, Sao Paulo, Brazil; [Kowalski, Luiz Paulo] Hosp Canc AC Camargo, Head & Neck Surg & Otorhinolaryngol Dept, Sao Paulo, Brazil; [Faria, Jose Carlos Marques; Scopel, Gean Paulo; Ferreira, Marcus Castro] Hosp & Clin, Div Plast Surg, Sao Paulo, Brazil	Faria, JCM (corresponding author), 377 Cjs 58-86,Rua Maestro Cardim, BR-01323 Sao Paulo, Brazil.	microcirurgia@terra.com.br	Kowalski, Luiz P/D-1701-2012; de Faria, Jose Carlos Marques/D-3577-2013	Kowalski, Luiz P/0000-0002-0481-156X; de Faria, Jose Carlos Marques/0000-0002-7072-5651			Aviv JE, 1997, ARCH OTOLARYNGOL, V123, P154; Blackwell KE, 1997, ARCH OTOLARYNGOL, V123, P1332; BOYD B, 1994, PLAST RECONSTR SURG, V93, P1350, DOI 10.1097/00006534-199406000-00003; Chen I-Chen, 2003, J Chin Med Assoc, V66, P544; Civantos FJ, 1997, ARCH OTOLARYNGOL, V123, P830; Eckardt A, 2003, J CRANIO MAXILL SURG, V31, P197, DOI 10.1016/S1010-5182(03)00039-8; Fogdestam I, 1996, SCAND J PLAST RECONS, V30, P49, DOI 10.3109/02844319609072404; Gellrich NC, 2000, INT J ORAL MAX SURG, V29, P104, DOI 10.1016/S0901-5027(00)80006-5; GRAHAM B, 1992, J HAND SURG-BRIT EUR, V17B, P189, DOI 10.1016/0266-7681(92)90086-H; HAGE JJ, 2005, ANN PLAST SURG, V54, P53; Haughey BH, 2001, OTOLARYNG HEAD NECK, V125, P10, DOI 10.1067/mhn.2001.116788; Hidalgo DA, 1998, PLAST RECONSTR SURG, V102, P722, DOI 10.1097/00006534-199809030-00016; Karamursel S, 2005, J RECONSTR MICROSURG, V21, P107, DOI 10.1055/s-2005-864843; KATSAROS J, 1984, ANN PLAS SURG, V12, P489, DOI 10.1097/00000637-198406000-00001; KUEK LBK, 1991, J RECONSTR MICROSURG, V7, P167, DOI 10.1055/s-2007-1006775; Nahabedian MY, 2001, ANN PLAS SURG, V46, P501, DOI 10.1097/00000637-200105000-00008; Reinert S, 2000, J CRANIO MAXILL SURG, V28, P69, DOI 10.1054/jcms.2000.0118; Rosenthal E, 2004, HEAD NECK-J SCI SPEC, V26, P930, DOI 10.1002/hed.20076; Ross DA, 1996, LARYNGOSCOPE, V106, P14, DOI 10.1097/00005537-199601000-00004; Sieg P, 2003, INT J ORAL MAX SURG, V32, P544, DOI 10.1054/ijom.2002.0397; SONG RY, 1982, CLIN PLAST SURG, V9, P27; Urken ML, 2003, LARYNGOSCOPE, V113, P1473, DOI 10.1097/00005537-200309000-00008; WENIG BL, 1993, OTOLARYNG HEAD NECK, V109, P116, DOI 10.1177/019459989310900121	23	21	22	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1748-6815	1878-0539		J PLAST RECONSTR AES	J. Plast. Reconstr. Aesthet. Surg.		2008	61	2					172	179		10.1016/j.bjps.2007.10.035			8	Surgery	Surgery	265GJ	WOS:000253346800009	18042444				2021-06-18	
J	Pearce, JMS				Pearce, J. M. S.			Observations on concussion	EUROPEAN NEUROLOGY			English	Article						concussion, definitions of; commotio cerebri; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; WHITE MATTER; HEAD-INJURY; LESIONS; MEMORY	The word 'concussion' has several meanings and applications that are controversial. This paper attempts to trace the historical origins and evolution of the descriptive classifications of concussive head injuries. It is suggested that head injuries should be described on the available evidence of the severity and duration of altered consciousness, traumatic amnesia and, when present, the variably associated neurological, physiological and imaging signs. The word concussion reflects an overenthusiastic trend in medical labelling. Since our understanding of types of brain injury and their symptoms and sequelae has advanced, the term should be abandoned. Copyright (C) 2007 S. Karger AG, Basel.	[Pearce, J. M. S.] Hull Royal Infirm, Dept Neurol, Kingston Upon Hull HU3 2JZ, N Humberside, England	Pearce, JMS (corresponding author), 304 Beverley Rd, Anlaby HU10 7BG, E Yorks, England.						ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BENSON DF, 1967, J NEUROL NEUROSUR PS, V30, P539, DOI 10.1136/jnnp.30.6.539; Berner O, 1930, VIRCHOWS ARCH A, V277, P386, DOI 10.1007/BF02275335; BLONSTEIN JL, 1957, LANCET, V1, P362; BOIREL A, 1674, TRAITE PLAIES TETE; Breasted JH, 1930, E SMITH SURG PAPYRUS; Bright R., 1827, REPORTS MED CASES SE; BRYANT R, 1878, PRACTICE SURG; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; DECAPRI JB, 1518, TRACTATUS FRACTURA C; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DURET H, 1920, TRAUMATISMS CRANIOCE; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; FANO S, 1853, MEM SOC CHIR PARIS, V3, P162; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; FLAMM E S, 1972, Medical History, V16, P194; GERSDORPF H, 1517, FELDBUCH WUNDARTZNEI; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KOCH W, 1874, ARCH KLIN CHIR, V17, P190; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LITTRE M, 1705, HIST ACAD ROYALE SCI, P54; *LOEB CLASS LIBR, 1923, HIPP WOUNDS HEAD HIP; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; MCLATCHIE G, 1994, BRIT MED J, V308, P1620, DOI 10.1136/bmj.308.6944.1620; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARE A, 1634, OEUVRES COMPLETES; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYMONDS C, 1962, LANCET, V1, P1; Trotter W, 1924, LANCET, V1, P935; Vance BM, 1927, ARCH SURG-CHICAGO, V14, P1023, DOI 10.1001/archsurg.1927.01130170071005; VONBERGMANN E, 1880, LEHRE KOPFVERLETZUNG, V30; *WORLD FED NEUR, NEWSL; YARNELL PR, 1970, LANCET, V1, P863; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; AM HERITAGE SCI DICT	52	21	21	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-3022	1421-9913		EUR NEUROL	Eur. Neurol.		2008	59	3-4					113	119		10.1159/000111872			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	265PA	WOS:000253371700001	18057896	Bronze			2021-06-18	
J	Sherman, TE; Rapport, LJ; Ryan, KA				Sherman, Tanya E.; Rapport, Lisa J.; Ryan, Kelly A.			Awareness of deficit in multiple sclerosis	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; IMPACT SCALE MSIS-29; SELF-REPORT; CONSEQUENCES; METAMEMORY; IMPAIRMENT; PREDICTORS; PROFILES; SYMPTOMS	The present study examined awareness of deficits among individuals with multiple sclerosis (MS). A total of 74 pairs of persons with MS and their significant others participated. Awareness of cognitive deficit was measured by discrepancy scores between patient reports of their cognitive abilities and objective test results. Awareness of functional deficit was measured by the discrepancy between the patient and significant other reports of the functional abilities of the patient. Results suggest that about one third of MS patients have diminished awareness of their cognitive and/or functional deficits. Unawareness of deficit was more common among patients with secondary-progressive MS than among those with relapse-remitting MS. Executive dysfunction was strongly associated with unawareness of cognitive deficits but not unawareness of functional deficits. Unawareness of cognitive deficits and unawareness of functional deficits appear to be tapping different aspects of unawareness of deficit.	[Sherman, Tanya E.] Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; [Sherman, Tanya E.; Rapport, Lisa J.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Rapport, Lisa J.; Ryan, Kelly A.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA	Sherman, TE (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Rm 555,261 Mack Blvd, Detroit, MI 48201 USA.	tsherman@dmc.org					Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Benedict RHB, 2004, J NEUROIMAGING, V14, p36S, DOI 10.1111/j.1552-6569.2004.tb00277.x; Benito-Leon J, 2002, EUR J NEUROL, V9, P497, DOI 10.1046/j.1468-1331.2002.00450.x; BENTON AL, 1978, ARCH NEUROL-CHICAGO, V35, P364, DOI 10.1001/archneur.1978.00500300038006; BOYLE EA, 1991, ARCH NEUROL-CHICAGO, V48, P1150, DOI 10.1001/archneur.1991.00530230058022; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Carone DA, 2005, J INT NEUROPSYCH SOC, V11, P574, DOI 10.1017/S135561770505068X; Charcot J.M., 1877, LECT DIS NERVOUS SYS, P157; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Cottrell SS, 1926, J NEUROL PSYCHOPATHO, V7, P1; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; DELIS DC, 2000, CVLT2 CALIFORINA VER; Diaz-Olavarrieta C, 1999, J NEUROPSYCH CLIN N, V11, P51, DOI 10.1176/jnp.11.1.51; Duke LM, 2002, NEUROPSYCHOLOGY, V16, P359, DOI 10.1037//0894-4105.16.3.359; Fishman I, 2004, J NEUROPSYCH CLIN N, V16, P350, DOI 10.1176/appi.neuropsych.16.3.350; Foong J, 1997, BRAIN, V120, P15, DOI 10.1093/brain/120.1.15; Goverover Y, 2005, MULT SCLER J, V11, P203, DOI 10.1191/1352458505ms1153oa; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Heaton R. K, 1981, WISCONSIN CARD SORTI; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hobart J, 2001, BRAIN, V124, P962, DOI 10.1093/brain/124.5.962; Hoogervorst ELJ, 2001, NEUROLOGY, V56, P934, DOI 10.1212/WNL.56.7.934; Kaszniak AW, 1996, LEARN INDIVID DIFFER, V8, P355, DOI 10.1016/S1041-6080(96)90023-0; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; KNIGHT RG, 1992, NEUROPSYCHOLOGY DEGE, P131; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McGuigan C, 2004, J NEUROL NEUROSUR PS, V75, P266; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; O'Brien R A, 1995, Sch Inq Nurs Pract, V9, P323; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; Provinciali L, 1999, ACTA NEUROL SCAND, V100, P156; *PSYCH CORP, 1997, WAIS3 WMS3 TECHN MAN; RABINS PV, 1986, BRAIN, V109, P585, DOI 10.1093/brain/109.4.585; Rabins PV, 1990, NEUROBEHAVIORAL ASPE, P180; Randolph JJ, 2001, CLIN NEUROPSYCHOL, V15, P357, DOI 10.1076/clin.15.3.357.10278; REGARD M, 1981, UNPUB COGNITIVE RIGI; RON MA, 1989, PSYCHOL MED, V19, P887, DOI 10.1017/S0033291700005602; Ryan KA, 2007, CLIN NEUROPSYCHOL, V21, P239, DOI 10.1080/13854040600582460; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P80, DOI 10.1080/13854049608406666; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherman TE, 2007, MULT SCLER, V13, P238, DOI 10.1177/1352458506070754; Smith A., 1973, SYMBOL DIGIT MODALIT; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; Spreen O., 1991, COMPENDIUM NEUROPSYC; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Zakzanis KK, 2000, ARCH CLIN NEUROPSYCH, V15, P115, DOI 10.1016/S0887-6177(98)00157-7	51	21	21	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2008	30	3					301	311		10.1080/13803390701380617			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	269NJ	WOS:000253655500004	17852617				2021-06-18	
J	Van Baalen, B; Odding, E; Stam, HJ				Van Baalen, B.; Odding, E.; Stam, H. J.			Cognitive status at discharge from the hospital determines discharge destination in traumatic brain injury patients	BRAIN INJURY			English	Article						cognitive status; discharge destination; hospital; traumatic brain injury	HEAD-INJURY; RATING-SCALE; REHABILITATION; COMA	Purpose: To determine which basic and functional status characteristics of patients with a moderate or severe traumatic brain injury (TBI) are associated with discharge destination. Method: Cross-sectional study among TBI patients. The study included 111 patients aged 16-67 years with a moderate-to-severe TBI (Glasgow Coma Scale (GCS) score 3-14). Functional outcome was assessed with Barthel Index (BI), Functional Independence Measurement (FIM), Level of Cognitive Functioning Scale (LCFS), Functional Assessment Measurement (FAM), Supervision Rating Scale (SRS) and Neurobehavioural Rating Scale (NRS). Patients were interviewed at the time of being discharged from hospital. Outcome variable was discharge destination; (1) home vs. institution and (2) rehabilitation centre vs. nursing home. Results: Gender, age and length of stay were not associated with discharge destination. TBI severity, physical status, level of arousal and cognitive status were univariately associated. Multivariate analyses, however, showed that the risk of being admitted to an institution was significantly higher for those with severe TBI (adjusted OR = 14) and/or lowered cognitive status at the time of discharge from hospital (adjusted OR = 12). Conclusions: Discharge destination is associated with TBI-severity at admittance to the hospital and cognitive status at discharge from the hospital.	[Van Baalen, B.; Odding, E.; Stam, H. J.] Erasmus MC, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands	Van Baalen, B (corresponding author), Erasmus MC, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands.	j.t.m.vanbaalen@erasmusmc.nl					Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Collin C, 1988, Int Disabil Stud, V10, P61; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hall KM, 1997, ARCH PHYS MED REHAB, V78, pS5, DOI 10.1016/S0003-9993(97)90149-0; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; TEASDALE G, 1974, LANCET, V2, P81; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Unsworth CA, 1993, CLIN REHABIL, V7, P181; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Weimar C, 2002, J NEUROL, V249, P888, DOI 10.1007/s00415-002-0755-8; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	21	21	21	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	1					25	32		10.1080/02699050701810662			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	250QF	WOS:000252314400004	18183506				2021-06-18	
J	Vilar-Lopez, R; Gomez-Rio, M; Caracuel-Romero, A; Llamas-Elvira, J; Perez-Garcia, M				Vilar-Lopez, Raquel; Gomez-Rio, Manuel; Caracuel-Romero, Alfonso; Llamas-Elvira, Jose; Perez-Garcia, Miguel			Use of specific malingering measures in a Spanish sample	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SYMPTOM VALIDITY TEST; TRAUMATIC BRAIN-INJURY; SIMULATED MEMORY IMPAIRMENT; FORCED-CHOICE METHOD; REY 15-ITEM TEST; NEUROPSYCHOLOGICAL TESTS; CROSS-VALIDATION; HEAD-INJURY; PERFORMANCE; PROFILES	There are an increasing number of tests available for detecting malingering. However, these tests have not been validated for using in Spanish speakers. The purpose of this study is to explore the value of three specific malingering tests in the Spanish population. This study used a known-groups design, together with a group of analog students. The results show that both the Victoria Symptom Validity Test and the b Test can be used to detect malingering in Spanish population. However, some restrictions must be applied when the Rey 15-Item Test is administered and interpreted.	[Vilar-Lopez, Raquel; Caracuel-Romero, Alfonso; Perez-Garcia, Miguel] Univ Granada, Dept Personalidad Evaluac & Tratamiento, Granada, Spain; [Gomez-Rio, Manuel; Llamas-Elvira, Jose] Hosp Univ Nieves, Granada, Spain	Vilar-Lopez, R (corresponding author), Univ N Carolina, Dept Psychol, Wilmington, NC 28403 USA.	vilarlopez@uncw.edu	Vilar-Lopez, Raquel/I-7847-2016; Caracuel, Alfonso/V-3695-2019; Garcia, Miguel Perez/F-9630-2010	Vilar-Lopez, Raquel/0000-0001-9639-0143; Caracuel, Alfonso/0000-0002-9738-8456; Garcia, Miguel Perez/0000-0003-4775-7556; Llamas-Elvira, Jose Manuel/0000-0002-4661-5030			ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Boone K., 2002, B TEST MANUAL; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; BUREREYES A, 2007, 115 ANN C AM PSYCH A; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; GOLDBERG JO, 1986, J CLIN PSYCHOL, V42, P792, DOI 10.1002/1097-4679(198609)42:5<792::AID-JCLP2270420519>3.0.CO;2-8; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Hilsabeck RC, 2005, ARCH CLIN NEUROPSYCH, V20, P1025, DOI 10.1016/j.acn.2005.05.003; HISCOCK CK, 1994, J PSYCHOPATHOL BEHAV, V16, P95, DOI 10.1007/BF02232721; Holmquist LA, 2002, ARCH CLIN NEUROPSYCH, V17, P143, DOI 10.1016/S0887-6177(00)00106-2; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lee A, 2000, CLIN NEUROPSYCHOL, V14, P303, DOI 10.1076/1385-4046(200008)14:3;1-P;FT303; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Macciocchi SN, 2006, ARCH CLIN NEUROPSYCH, V21, P395, DOI 10.1016/j.acn.2006.06.003; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; O'Bryant SE, 2004, ARCH CLIN NEUROPSYCH, V19, P489, DOI 10.1016/j.acn.2003.07.001; PUENTE AE, 2000, HDB MULTICULTURAL ME, P419; PUENTE AE, 2000, HDB PSYCHOL ASSESSME, P527; Rey A., 1964, EXAMEN CLINIQUE PSYC; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; ROGERS R, 1983, J PSYCHIAT LAW, V11, P443; ROGERS R, 2003, HDB PSYCHOL, V11, P109; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 2003, CLIN NEUROPSYCHOL, V17, P390, DOI 10.1076/clin.17.3.390.18090; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Taylor LA, 2003, BRAIN INJURY, V17, P295, DOI 10.1080/0269905021000038401; THOMPSON GB, 2002, J FORENSIC NEUROPSYC, V2, P43; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; VICTORIA S, 1997, PSYCHOL ASSESSMENT R; Vilar-Lopez R, 2007, ARCH CLIN NEUROPSYCH, V22, P379, DOI 10.1016/j.acn.2007.01.012; VILARLOPEZ R, 2007, THESIS U GRANADA GRA; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	54	21	23	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2008	30	6					710	722		10.1080/13803390701684562			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	323SS	WOS:000257469300011	18612877				2021-06-18	
J	Wright, DW; Hoffman, SW; Virmani, S; Stein, DG				Wright, David W.; Hoffman, Stuart W.; Virmani, Sharad; Stein, Donald G.			Effects of medroxyprogesterone acetate on cerebral oedema and spatial learning performance after traumatic brain injury in rats	BRAIN INJURY			English	Article						traumatic brain injury; psychopharmacology; trauma; intervention	REPLACEMENT THERAPY; NERVOUS-SYSTEM; PROGESTERONE; ESTROGEN; PROGESTINS; NEUROPROTECTION; NEUROSTEROIDS; BENEFITS; RISKS	Background: Given after brain injury (TBI), progesterone reduces cerebral oedema and facilitates functional recovery. Progesterone analogues have been synthesized for use in many medical conditions and exhibit different chemical and biological properties. Medroxyprogesterone acetate (MPA) is widely used in clinical practice, but oestrogen/MPA combinations may increase the risk of stroke and cardiovascular disease rather than preventing them. In some conditions, MPA can exhibit pharmacological actions that are different from those of natural progesterone. Primary objective and hypothesis: Using laboratory rats, this study assessed the efficacy of MPA to determine whether this progestin and natural progesterone exert similar effects as a treatment after bilateral injury to the frontal cortex. Main outcomes and results: MPA produced a dose-related reduction of cerebral oedema at 48 hours post-TBI but neither 4 nor 16 mg/kg doses of MPA enhanced behavioural recovery. Conclusion: These findings help to clarify the divergent results from prior positive progesterone studies and the negative MPA clinical trials for hormone replacement therapy. The results can be taken to suggest that the control of cerebral oedema, while clearly desirable, is not the only contributor to progesterone-induced behavioural recovery.	[Wright, David W.; Hoffman, Stuart W.; Virmani, Sharad; Stein, Donald G.] Emory Univ, Dept Emergency Med, Sch Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Sch Med, 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	dstei04@emory.edu	Wright, David/F-1209-2013; Stein, Donald/AAJ-5139-2020	Wright, David/0000-0002-7145-9105; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD044857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040825] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R21 HD44857] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS40825] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [5R01NSO48451] Funding Source: Medline		Bamberger CM, 1999, J CLIN ENDOCR METAB, V84, P4055, DOI 10.1210/jc.84.11.4055; Bernardi F, 2006, NEUROENDOCRINOLOGY, V83, P348, DOI 10.1159/000095400; Cagnacci A, 2004, MATURITAS, V48, P456, DOI 10.1016/j.maturitas.2003.10.003; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Garcia-Becerra R, 2004, J STEROID BIOCHEM, V91, P21, DOI 10.1016/j.jsbmb.2004.02.003; GUENNOUN R, 2007, IN PRESS BRAIN RES R; Hapgood JP, 2004, TRENDS PHARMACOL SCI, V25, P554, DOI 10.1016/j.tips.2004.09.005; Koubovec D, 2005, MOL CELL ENDOCRINOL, V242, P23, DOI 10.1016/j.mce.2005.07.001; Kuhl H, 2006, GYNECOL ENDOCRINOL, V22, P303, DOI 10.1080/09513590600717368; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; Nilsen J, 2006, GYNECOL ENDOCRINOL, V22, P355, DOI 10.1080/09513590600863337; Rasmussen Kristin., 2007, ENCY MEASUREMENT STA, P1057; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Shadoan MK, 2007, METABOLISM, V56, P830, DOI 10.1016/j.metabol.2007.01.014; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Singh M, 2007, Minerva Endocrinol, V32, P95; Singh M, 2006, ENDOCRINE, V29, P271, DOI 10.1385/ENDO:29:2:271; STEIN DG, 2007, IN PRESS ANN EMERGEN; STEIN DG, 2007, IN PRESS BRAIN RES; Stein DG, 2006, FUTUR NEUROL, V1, P429, DOI 10.2217/14796708.1.4.429; Thomas T, 2003, CLIMACTERIC, V6, P293, DOI 10.1080/713605430; VANLANDINGHAM JW, 2007, IN PRESS NEUROSCIENC; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534	32	21	23	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					107	113		10.1080/02699050701867399			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600001	18240039				2021-06-18	
J	Jacobsson, LJ; Westerberg, M; Lexell, J				Jacobsson, L. J.; Westerberg, M.; Lexell, J.			Demographics, injury characteristics and outcome of traumatic brain injuries in northern Sweden	ACTA NEUROLOGICA SCANDINAVICA			English	Article						accidental falls; accidents; traffic; brain; injuries; Glasgow Outcome Scale; rehabilitation	GLASGOW-COMA-SCALE; CHRONIC SUBDURAL-HEMATOMA; HEAD-INJURIES; FOLLOW-UP; EPIDEMIOLOGY; MORTALITY; WORSE	Objectives - To describe demographics, injury characteristics and outcome of traumatic brain injury (TBI) in northern Sweden over 10 years. Materials and methods - Data were retrospectively collected on those individuals (n = 332) in Norrbotten, northern Sweden, with a TBI who had been transferred for neurosurgical care from 1992 to 2001. Results - A majority were older men with a mild TBI and an acute or chronic subdural hematoma following a fall. Younger individuals were fewer but had more often a severe TBI from a traffic accident. Most individuals received post-acute care and brain injury rehabilitation. A majority had a moderate or severe disability, but many were discharged back home with no major changes in their physical or social environment. Conclusions - Our data confirm the relationship between age, cause of injury, injury severity and outcome in relation to TBI and underscore the need for prevention as well as the importance of TBI as a cause of long-term disability.	Univ Lund Hosp, Dept Rehabil, S-22185 Lund, Sweden; Kalix Hosp, Dept Gen Med, Med Rehabil Sect, Kalix, Sweden; Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden; Lulea Univ Technol, Dept Business Adm & Social Sci, S-95187 Lulea, Sweden	Lexell, J (corresponding author), Univ Lund Hosp, Dept Rehabil, Orupssjukhuset, S-22185 Lund, Sweden.	jan.lexell@skane.se	Westerberg, Mats/C-3300-2012	Westerberg, Mats/0000-0001-5464-9292; Lexell, Jan/0000-0001-5294-3332; Jacobsson, Lars/0000-0002-1127-1178			Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Asghar M, 2002, J ROY SOC MED, V95, P290, DOI 10.1258/jrsm.95.6.290; Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Dahl E, 2006, INJURY, V37, P402, DOI 10.1016/j.injury.2005.09.008; Eker C, 2000, BRAIN INJURY, V14, P605; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Harmon RL, 1996, BRAIN INJURY, V10, P139, DOI 10.1080/026990596124638; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; JENNETT B, 1975, LANCET, V1, P480; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; JOHNSTONE AJ, 1993, BRAIN INJURY, V7, P501, DOI 10.3109/02699059309008177; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kannus P, 2001, J CLIN EPIDEMIOL, V54, P597, DOI 10.1016/S0895-4356(00)00346-2; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Sundbarg G, 1989, Brain Inj, V3, P283, DOI 10.3109/02699058909029641; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; TESSERIS J, 1991, ACTA NEUROCHIR, V110, P65, DOI 10.1007/BF01402050; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	33	21	21	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	NOV	2007	116	5					300	306		10.1111/j.1600-0404.2007.00896.x			7	Clinical Neurology	Neurosciences & Neurology	218BC	WOS:000249990000004	17922723				2021-06-18	
J	Mazzeo, AT; Bullock, R				Mazzeo, Anna Teresa; Bullock, Ross			Monitoring brain tissue oxymetry: Will it change management of critically ill neurologic patients?	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						brain oxygenation; tissue oxygen tension; cerebral ischemia; neuromonitoring; traumatic brain injury	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; OXYGEN-TENSION; CARBON-DIOXIDE; PARTIAL-PRESSURE; SUBARACHNOID HEMORRHAGE; SUBSTRATE DELIVERY; ANEURYSM SURGERY; METABOLISM; PH	Based on the assumption that brain ischemia and hypoxia are central causes of brain damage, the maintenance of an adequate tissue oxygenation is a primary objective in the field of neurocritical care. Thus, monitoring brain tissue oxymetry, allowing the possibility to discriminate between normal and critically impaired tissue oxygenation, is recognized as an essential part of the management of the neurological critically ill patient. The clinical usefulness of this neuromonitoring tool in the area of neurosciences (traumatic brain injury, aneurysm surgery, arteriovenous malformation resection, brain tumors) is discussed. Monitoring brain tissue oxymetry not only allows the detection of impending cerebral ischemia, thus providing the clinician with essential information for the management and correction of harmful intracerebral events, but it also helps in understanding the pathophysiology of neuro-injury. It can also be used as a "surrogate end point" to evaluate putative therapies, targeting therapy towards improved cerebral oxygenation. As brain tissue oxygenation correlates closely with outcome, several outcome categories have been differentiated, aiding in predicting prognosis after injury. The rationale for monitoring brain tissue oxygenation is to provide essential information about oxygen supply and utilization in this specific tissue bed, thus reducing secondary brain damage and improving neurological outcome. (C) 2007 Elsevier B.V. All rights reserved.	Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, Messina, Italy; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Neurosci Intens Care Unit, Richmond, VA 23298 USA	Mazzeo, AT (corresponding author), Viale Regina Margherita 59, I-98121 Messina, Italy.	annateresainazzeo@unime.it		Mazzeo, Anna Teresa/0000-0002-8454-7243			Baunach S, 1998, ACT NEUR S, V71, P241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Critchley GR, 1998, NEUROL RES, V20, pS44; CRUICKSHANK GS, 1994, ACT NEUR S, V60, P375; Daugherty WP, 2004, NEUROSURGERY, V54, P1223, DOI 10.1227/01.NEU.0000119238.68938.5D; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Fandino J, 1999, ACTA NEUROCHIR, V141, P825, DOI 10.1007/s007010050383; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gupta A K, 2002, J Postgrad Med, V48, P218; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Hoelper BM, 2003, NEUROSURGERY, V52, P970, DOI 10.1227/01.NEU.0000053033.98317.A3; Hoffman WE, 1997, NEUROSURGERY, V40, P294, DOI 10.1097/00006123-199702000-00012; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Jodicke A, 2003, J NEUROSURG, V98, P515, DOI 10.3171/jns.2003.98.3.0515; JOHNSON BA, 1991, CRIT CARE MED, V19, P1432, DOI 10.1097/00003246-199111000-00021; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KAYAMA T, 1991, J NEUROSURG, V74, P55, DOI 10.3171/jns.1991.74.1.0055; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Menzel M, 2003, J NEUROSURG ANESTH, V15, P33, DOI 10.1097/00008506-200301000-00006; Pennings FA, 2003, J NEUROSURG ANESTH, V15, P1, DOI 10.1097/00008506-200301000-00001; Scheufler KM, 2004, TRANSFUS APHER SCI, V31, P45, DOI 10.1016/j.transci.2004.06.001; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Siegemund M, 1999, INTENS CARE MED, V25, P1044, DOI 10.1007/s001340051011; Stiefel MF, 2004, J NEUROSURG, V101, P594, DOI 10.3171/jns.2004.101.4.0594; Stocchetti N, 1998, ACT NEUR S, V71, P162; Szelenyi A, 2002, NEUROL RES, V24, P555, DOI 10.1179/016164102101200528; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vovenko E, 1999, PFLUG ARCH EUR J PHY, V437, P617, DOI 10.1007/s004240050825; Zauner A, 1998, NEUROL RES, V20, pS85; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	54	21	21	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2007	261	1-2					1	9		10.1016/j.jns.2007.04.026			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	216JO	WOS:000249874500001	17537460				2021-06-18	
J	Hofgren, C; Esbjornsson, E; Aniansson, H; Sunnerhagen, KS				Hofgren, Caisa; Esbjornsson, Eva; Aniansson, Hans; Sunnerhagen, Katharina Stibrant			Application and validation of the barrow neurological institute screen for higher cerebral functions in a control population and in patient groups commonly seen in neurorehabilitation	JOURNAL OF REHABILITATION MEDICINE			English	Article						BNIS; cognition; stroke; traumatic brain injury; anoxia; Parkinson's disease; neuro-rehabilitation	MINI-MENTAL-STATE; COGNITIVE STATUS EXAMINATION; TRAUMATIC BRAIN-INJURY; BNI SCREEN; PERFORMANCE; COGNISTAT; SEQUELAE	Objective: To determine whether the Barrow Neurological Institute Screen for Higher Cerebral Functions (BNIS) can differentiate brain-dysfunctional patients from controls. Design: A case-control study. Subjects: A total of 92 controls and 120 patients from a neuro-rehabilitation clinic with a diagnosis of: right and left hemisphere stroke, traumatic brain injury, Parkinson's disease or anoxic brain damage. Methods: The BNIS has a maximum total score of 50 points, < 47 indicates cognitive dysfunction. Group comparisons and exploration of variables influencing the BNIS total score were made. Results: A significant difference was found between the control group and the total patient group for the BNIS total score and for the subscales (p < 0.0005). Sensitivity was 88% and specificity 78%. Presence of disease and educational level had the greatest influence on the results of the BNIS. Patients with Parkinson's disease were shown to be the least cognitively affected and those with anoxic brain damage the most affected. Conclusion: The BNIS has potential value as a screening instrument for cognitive functions and is sufficiently sensitive to differentiate brain-dysfunctional patients from a control population. It appears to be applicable in a neurological rehabilitation setting, and can be used early in the process, giving a baseline cognitive functional level.	Inst Neurosci & Physiol Rehabil Med, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil Med, Gothenburg, Sweden	Hofgren, C (corresponding author), Inst Neurosci & Physiol Rehabil Med, Guldhedsgatan 19, SE-41345 Gothenburg, Sweden.	caisa.hofgren@rehab.gu.se	Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400			Borgaro SR, 2003, J HEAD TRAUMA REHAB, V18, P284, DOI 10.1097/00001199-200305000-00006; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Denvall V, 2002, J REHABIL MED, V34, P153, DOI 10.1080/16501970213231; Drane DL, 2003, J CLIN EXP NEUROPSYC, V25, P133, DOI 10.1076/jcen.25.1.133.13628; Drane DL, 1997, ARCH CLIN NEUROPSYCH, V12, P139, DOI 10.1016/S0887-6177(96)00057-1; FEHER EP, 1992, ARCH NEUROL-CHICAGO, V49, P87, DOI 10.1001/archneur.1992.00530250091022; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Lai F.D.M., 2004, BARROW Q, V20, P16; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Macaulay C, 2003, ARCH CLIN NEUROPSYCH, V18, P463, DOI 10.1016/S0887-6177(02)00141-5; MOMTAZI R, 2004, BARROW Q, V20, P13; Muslimovic D, 2005, NEUROLOGY, V65, P1239, DOI 10.1212/01.wnl.0000180516.69442.95; Prigatano G., 1991, BNI Q, V7, P2; Prigatano G. P., 2004, BARROW Q, V20, P4; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Prigatano GP, 1993, BNI Q, V9, P2; Prigatano GP, 1995, ADM SCORING MANUAL B; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; Rosenstein LD, 1997, NEUROPSY NEUROPSY BE, V10, P113; Spreen O., 1998, COMPENDIUM NEUROPSYC; Strickland TL, 2005, CLIN NEUROPSYCHOL, V19, P87, DOI 10.1080/13854040490887243; Strub R, 1985, MENTAL STATUS EXAMIN; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Truelle JL., 2004, BARROW Q, V20, P19	24	21	21	0	4	TAYLOR & FRANCIS AS	OSLO	PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY	1650-1977			J REHABIL MED	J. Rehabil. Med.	SEP	2007	39	7					547	553		10.2340/16501977-0085			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	213IS	WOS:000249660700007	17724554	DOAJ Gold			2021-06-18	
J	Mungan, NK				Mungan, Nils K.			Update on shaken baby syndrome: ophthalmology	CURRENT OPINION IN OPHTHALMOLOGY			English	Article						child abuse; inflicted traumatic brain injury; nonaccidental head injury; retinal hemorrhage; shaken baby syndrome	TRAUMATIC BRAIN-INJURY; INFLICTED CHILDHOOD NEUROTRAUMA; PERIMACULAR RETINAL FOLDS; HEAD-INJURY; SERUM BIOMARKERS; YOUNG-CHILDREN; AXONAL INJURY; HEMORRHAGES; INFANTS; NEUROPATHOLOGY	Purpose of review Shaken baby syndrome is a common problem with a high morbidity and mortality. Ophthalmologists help manage this condition and therefore must keep abreast of current advances. Recent findings Clinical updates include the discovery that retinal folds and traumatic retinoschisis can very rarely occur after crush head injury, but remain specific for shaken baby syndrome in other scenarios. Pathology updates include new studies on orbital histology and woodpecker anatomy that suggest the retinal and optic nerve hemorrhages in shaken baby syndrome are caused by shaking itself rather than secondary to intracranial pathology. Regarding this shaking injury, some primary prevention strategies have proven surprisingly effective. In the near future, serum biomarkers may be used as a screening tool for inflicted neurotrauma. Animal models such as the neonatal pig and computer models using finite element analysis are promising experimental techniques for studying shaken baby syndrome. Finally, child abuse recently became an accredited subspecialty of pediatrics, which will lead to further advances in patient care, education, research and prevention. Summary Ophthalmologists play a key role in the diagnosis of shaken baby syndrome. In addition, they are in a unique position to study ophthalmic aspects of the syndrome, which in turn furthers the overall understanding of this devastating condition.	Univ Mississippi, Med Ctr, Dept Ophthalmol, Jackson, MS 39216 USA	Mungan, NK (corresponding author), Univ Mississippi, Med Ctr, Dept Ophthalmol, 2500 N State St, Jackson, MS 39216 USA.	nmungan@ophth.umsmed.edu					Arlotti SA, 2007, J AAPOS, V11, P175, DOI 10.1016/j.jaapos.2006.09.023; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Biron DL, 2007, J PAEDIATR CHILD H, V43, P60, DOI 10.1111/j.1440-1754.2007.01004.x; Block RW, 2006, J PEDIATR-US, V148, P711, DOI 10.1016/j.jpeds.2006.01.033; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; COUPER Z, 2007, BIOMECH MODEL M 0302; Curtis TH, 2007, J AAPOS, V11, P509, DOI 10.1016/j.jaapos.2007.02.010; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Feldman KW, 1997, CHILD ABUSE NEGLECT, V21, P199, DOI 10.1016/S0145-2134(96)00145-7; Forbes BJ, 2004, J PEDIAT OPHTH STRAB, V41, P80, DOI 10.3928/0191-3913-20040301-07; Ganesh A, 2004, OPHTHALMOLOGY, V111, P1428, DOI 10.1016/j.ophtha.2003.10.028; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; Ghatan S, 2002, NEUROSURG CLIN N AM, V13, P227, DOI 10.1016/S1042-3680(01)00002-X; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; Goldman M, 2006, J PEDIATR-US, V148, P835, DOI 10.1016/j.jpeds.2005.12.052; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Herr S, 2004, PEDIATRICS, V113, P1658, DOI 10.1542/peds.113.6.1658; Hughes LA, 2006, J AAPOS, V10, P102, DOI 10.1016/j.jaapos.2005.12.005; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Levin AV, 2006, ARCH OPHTHALMOL-CHIC, V124, P1773, DOI 10.1001/archopht.124.12.1773; Levin AV, 2002, NEUROSURG CLIN N AM, V13, P201, DOI 10.1016/S1042-3680(02)00004-9; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; MINNS RA, 2005, EDINB, V35, P5; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Newton AW, 2005, CURR OPIN PEDIATR, V17, P246, DOI 10.1097/01.mop.0000158730.56669.b1; OBI E, 2007, J AAPOS, V11, P99, DOI DOI 10.1016/J.JAAPOS.2007.01.031; Odom A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e3; Ou JI, 2006, ARCH OPHTHALMOL-CHIC, V124, P913, DOI 10.1001/archopht.124.6.913; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; ROTH S, 2006, INT J LEGAL MED 0908; Schloff S, 2002, OPHTHALMOLOGY, V109, P1472, DOI 10.1016/S0161-6420(02)01086-2; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Simon J, 2005, J PEDIAT OPHTH STRAB, V42, P18; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Stoodley N, 2006, BRIT J RADIOL, V79, P550, DOI 10.1259/bjr/23921951; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; Vinger PF, 2005, ARCH OPHTHALMOL-CHIC, V123, P833, DOI 10.1001/archopht.123.6.833; Wygnanski-Jaffe T, 2007, EYE, V21, P83, DOI 10.1038/sj.eye.6702163; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	65	21	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-8738	1531-7021		CURR OPIN OPHTHALMOL	Curr. Opin. Ophthalmol.	SEP	2007	18	5					392	397		10.1097/ICU.0b013e3282a167f0			6	Ophthalmology	Ophthalmology	208EE	WOS:000249301800007	17700232				2021-06-18	
J	Marten-Lobenhoffer, J; Sulyok, E; Czeiterc, E; Buki, A; Kohl, J; Firsching, R; Troger, U; Bode-Boger, SM				Marten-Lobenhoffer, Jens; Sulyok, Endre; Czeiterc, Endre; Buki, Andras; Kohl, Jana; Firsching, Raimund; Troeger, Uwe; Bode-Boeger, Stefanie M.			Determination of cerebrospinal fluid concentrations of arginine and dimethylarginines in patients with subarachnoid haemorrhage	JOURNAL OF NEUROSCIENCE METHODS			English	Article						CSF; traumatic brain injury; subarachnoid haemorrhage; L-arginine; ADMA; SDMA	NITRIC-OXIDE SYNTHASE; DELAYED CEREBRAL VASOSPASM; DIMETHYL-L-ARGININE; ASYMMETRIC DIMETHYLARGININE; BIOLOGICAL-FLUIDS; CHROMATOGRAPHY/MASS SPECTROMETRY; IN-VIVO; DIMETHYLAMINOHYDROLASE; DERIVATIZATION; METABOLITES	Elevated cerebrospinal fluid (CSF) concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), are assumed to be related to delayed vasospasm after subarachnoid haemorrhage (SAH). However, data on CSF concentrations Of L-arginine, ADMA and its structural isomer symmetric dimethylarginine (SDMA) are very sparse in humans. We here present a new hydrophilic interaction chromatography-tandem mass spectrometry (HILIC-MS-MS) method for the precise determination of these substances in CSF. The method requires only minimal sample preparation and features isotope labeled internal standards. First data of patients with SAH showed that on the day of admission CSF concentration values Of L-arginine and ADMA were not significantly different from controls, but increased markedly during the course of the hospital stay. The decrease of the L-arginine to ADMA ratio points to a progressive impairment of the NO production rate in the brain after SAH which is confirmed by a simultaneous decrease in nitrate and nitrite concentrations in CSF. (C) 2007 Elsevier B.V. All rights reserved.	Otto Von Guericke Univ, Inst Clin Pharmacol, D-39120 Magdeburg, Germany; Univ Pecs, Fac Hlth Sci, Dept Hlth Promot & Family Care, Pecs, Hungary; Univ Pecs, Fac Med, Dept Neurosurg, Pecs, Hungary; Otto Von Guericke Univ, Dept Neurosurg, Magdeburg, Germany	Marten-Lobenhoffer, J (corresponding author), Otto Von Guericke Univ, Inst Clin Pharmacol, Leipziger Str 44, D-39120 Magdeburg, Germany.	jens.martens-lobenhoffer@medizin.uni-magdeburg.de	Buki, Andras/B-1960-2010	Bode-Boger, Stefanie/0000-0002-5132-6591			BodeBoger SM, 1996, BIOCHEM BIOPH RES CO, V219, P598, DOI 10.1006/bbrc.1996.0279; Conte C, 2005, ANAL BIOCHEM, V338, P347, DOI 10.1016/j.ab.2004.11.018; Cooke JP, 2004, CIRCULATION, V109, P1813, DOI 10.1161/01.CIR.0000126823.07732.D5; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; Fedele E, 1999, PROG NEUROBIOL, V58, P89, DOI 10.1016/S0301-0082(98)00077-X; Jung CS, 2004, J NEUROSURG, V101, P836, DOI 10.3171/jns.2004.101.5.0836; MacAllister RJ, 1996, BRIT J PHARMACOL, V119, P1533, DOI 10.1111/j.1476-5381.1996.tb16069.x; Martens-Lobenhoffer J, 2006, CLIN CHEM, V52, P488, DOI 10.1373/clinchem.2005.060152; Martens-Lobenhoffer J, 2004, J MASS SPECTROM, V39, P1287, DOI 10.1002/jms.684; Mulder C, 2002, J NEURAL TRANSM, V109, P1203, DOI 10.1007/s00702-002-0760-1; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; OGAWA T, 1989, J BIOL CHEM, V264, P10205; Pluta RM, 2005, J NEUROSURG, V103, P731, DOI 10.3171/jns.2005.103.4.0731; Pluta RM, 2005, PHARMACOL THERAPEUT, V105, P23, DOI 10.1016/j.pharmthera.2004.10.002; Pluta RM, 2006, NEUROL RES, V28, P730, DOI 10.1179/016164106X152052; RAWAL N, 1995, J NEUROL SCI, V129, P186, DOI 10.1016/0022-510X(94)00277-U; Rejdak K, 2004, J NEUROL SCI, V219, P71, DOI 10.1016/j.jns.2003.12.011; Shou WZ, 2005, J CHROMATOGR B, V825, P186, DOI 10.1016/j.jchromb.2005.01.011; Sydow K, 2003, ATHEROSCLEROSIS SUPP, V4, P41, DOI 10.1016/S1567-5688(03)00033-3; Tsikas D, 2000, ANAL CHEM, V72, P4064, DOI 10.1021/ac9913255; Woszczyk A, 2003, ACTA NEUROCHIR, V145, P257, DOI 10.1007/s00701-003-0004-7	21	21	22	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	AUG 15	2007	164	1					155	160		10.1016/j.jneumeth.2007.04.005			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	191ZK	WOS:000248170300017	17512604				2021-06-18	
J	Chin, KR; Ahn, J				Chin, Kingsley R.; Ahn, Jaimo			Controlled cervical extension osteotomy for Ankylosing spondylitis utilizing the Jackson operating table - Technical note	SPINE			English	Article						pedicle subtraction; osteotomy; osteoclasis; ankylosing spondylitis; cervicothoracic kyphosis	SPINAL OSTEOTOMY; DEFORMITY	Study Design. Technical note. Objective. To demonstrate a controlled extension osteotomy technique of the cervical spine in a prone position and using the head elevator mechanism on the Jackson operating table to correct a chin-on-chest deformity in a patient with ankylosing spondylitis. Summary of Background Data. Catastrophic cord injury causing quadriplegia and death has been associated with correction of chin-on-chest deformity in patients with ankylosing spondylitis. Manual control of spinal column motion during and after osteoclasis or osteotomy can be difficult, inexact, and anxiety inducing. Methods. A 45-year-old woman with ankylosing spondylitis and severe chin-on-chest deformity underwent a posterior C7 pedicle subtraction osteotomy, deformity correction, and instrumented fusion in a prone position on the Jackson operating table. Results. By using the elevator mechanism attached to the head of the operating table and Mayfield tongs, the patient's cervicothoracic junction was placed into extension by over 30 in controlled increments. Conclusion. We present a technique for controlled extension osteotomy correction of chin-on-chest deformity in a prone position. Use of the operating table mechanism in conjunction with a closing-wedge osteotomy diminishes the risk of translation, decreases risk of air embolus associated with a sitting position, and promotes greater opportunity for fusion through the osteotomy, and the stability allows for placement of modern instrumentation.	Univ Penn, Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA	Chin, KR (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	kingsleychin@hotmail.com					Belanger TA, 2005, J BONE JOINT SURG AM, V87A, P1732, DOI 10.2106/JBJS.C.01472; Kubiak EN, 2005, J AM ACAD ORTHOP SUR, V13, P267, DOI 10.5435/00124635-200507000-00006; LAW WA, 1962, J BONE JOINT SURG AM, V41, P1119; Liew SM, 1998, ORTHOP CLIN N AM, V29, P779, DOI 10.1016/S0030-5898(05)70047-X; MASON C, 1953, Calif Med, V79, P244; MCMASTER MJ, 1985, J BONE JOINT SURG BR, V67, P204; McMaster MJ, 1997, J BONE JOINT SURG BR, V79B, P197, DOI 10.1302/0301-620X.79B2.7095; SIMMONS EH, 1972, CLIN ORTHOP RELAT R, P132, DOI 10.1097/00003086-197207000-00019; URIST MR, 1958, J BONE JOINT SURG AM, V40, P833, DOI 10.2106/00004623-195840040-00007; Willems KF, 2005, SPINE, V30, P101, DOI 10.1097/00007632-200501010-00018	10	21	21	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	AUG 1	2007	32	17					1926	1929		10.1097/BRS.0b013e31811327fe			4	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	199LV	WOS:000248698200018	17762303				2021-06-18	
J	Martin, RT; Whyte, J				Martin, Robert T.; Whyte, John			The effects of methylphenidate on command following and yes/no communication in persons with severe disorders of consciousness - A meta-analysis of n-of-1 studies	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						brain injuries; vegetative state; minimally conscious state; methylphenidate; n-of-1 studies	TRAUMATIC BRAIN-INJURY; ATTENTION; DEFICITS; MEMORY	Objective: To determine the effects of methylpheniclate (MPH) on. command following and yes/no communication in brain injured patients with severe disorders of consciousness (DOC). Design: A meta-analysis of a series of single-subject repeated crossover trials, using doses ranging from 7.5 to 25 mg (median dose: 10 mg), generally given twice a day. A Wilcoxon signed ranks test was performed,, comparing mean responsiveness and accuracy by drug condition. Drug effect sizes were calculated for the full group and for participant subgroups of interest. Results: No significant effect of MPH was seen on either responsiveness or on accuracy in the whole group. None of the patient subgroups examined showed a substantial drug effect size. Conclusions: This study did not identify a clinically meaningful effect of MPH in the doses used on responsiveness or accuracy in standardized command-following protocols in the overall study group of patients with severe DOC, or in any subgroup that was assessed. Because MPH has been shown to have some positive effects in higher-level patients with TBI, more research is needed to, define the types of individuals with TBI who do and do not benefit from this drug, and/or the dose that provides optimal benefit.	Albert Einstein Healthcare Network, Moss Rehab Res Inst, Philadelphia, PA USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Whyte, J (corresponding author), Moss Rehab Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474			Braha RED, 1999, NEUROREHABILITATION, V12, P201; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Glenn MB, 2002, J HEAD TRAUMA REHAB, V17, P273, DOI 10.1097/00001199-200208000-00002; GRAHAM DI, 1999, REHABILITATION ADULT, P19; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Laborde A, 1997, J HEAD TRAUMA REHAB, V12, P90, DOI 10.1097/00001199-199708000-00009; MACMILLAN NA, 1991, DETECTION THEORY USE, P88; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Portney LG, 1993, FDN CLIN RES APPL PR, P651; TRAVERNI J, 1998, BRAIN INJURY, V12, P77; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; Whyte J., 1999, REHABILITATION ADULT, P435; ZAFONTE R, 1999, REHABILITATION ADULT, P536; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; 1994, N ENGL J MED, V3300, P1499	25	21	22	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2007	86	8					613	620		10.1097/PHM.0b013e3181154a84			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	194ZX	WOS:000248383400003	17667191				2021-06-18	
J	Feary, DJ; Magdesian, KG; Aleman, MA; Rhodes, DM				Feary, Darien J.; Magdesian, K. Gary; Aleman, Monica A.; Rhodes, Diane M.			Traumatic brain injury in horses: 34 cases (1994-2004)	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article; Proceedings Paper	12th Annual Symposium of the International-Veterinary-Emergency-and-Critical-Card-Society	SEP 08, 2006	San Antonio, TX	Int Vet Emergency & Crit Care Soc			SEVERE HEAD-INJURY; ELEVATED INTRACRANIAL-PRESSURE; PLACEBO-CONTROLLED TRIAL; BASILAR SKULL FRACTURES; SPINAL-CORD INJURY; HYPERTONIC SALINE; MRC CRASH; HYPERGLYCEMIA; METHYLPREDNISOLONE; CORTICOSTEROIDS	Objective- To investigate the clinical, clinicopathologic, and diagnostic characteristics; treatment; and outcome associated with acute traumatic brain injury (TBI) in horses and assess risk factors for nonsurvival in TBI-affected horses. Design- Retrospective case series. Animals- 34 horses with TBI. Procedures- Medical records of horses that had sustained trauma to the head and developed neurologic signs were reviewed. Data that included signalment, clinicopathologic findings, diagnosis, treatment, and outcome were analyzed. Clinicopathologic variables among horses in survivor and nonsurvivor groups were compared, and risk factors for nonsurvival were determined. Results- Median age of affected horses was 12 months. Findings of conventional survey radiography of the head alone failed to identify all horses with fractures of the calvarium. Horses with basilar bone fractures were 75 times as likely not to survive as horses without this type of fracture. Depending on clinical signs, horses received supportive care, osmotic or diuretic treatments, antimicrobials, anti-inflammatory drugs, analgesics, or anticonvulsants. Twenty-one (62%) horses survived to discharge from the hospital. In the nonsurvivor group, mean PCV was significantly higher, compared with the value in the survivor group (40% vs 33%). Risk factors associated with nonsurvival included recumbency of more than 4 hours' duration after initial evaluation (odds ratio, 18) and fracture of the basilar bone (odds ratio, 75). Conclusions and Clinical Relevance- Results suggest that prognosis for survival in horses with acute TBI may be more favorable than previously reported. Among horses with TBI, persistent recumbency and fractures involving the basilar bones were associated with a poor prognosis.	Univ Calif Davis, Vet Med Teaching Hosp, Sch Vet Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA	Magdesian, KG (corresponding author), Equine Med Ctr Ocala, 7107 W Hwy 326, Ocala, FL 34482 USA.						ACKERMAN N, 1974, AM VET RADIOL SOC, V15, P79; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bernard F, 2006, CRIT CARE MED, V34, P583, DOI 10.1097/01.CCM.0000199042.80034.A8; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Brosnan RJ, 2002, AM J VET RES, V63, P1252, DOI 10.2460/ajvr.2002.63.1252; BUTLER JA, 1993, CLIN RADIOLOGY HORSE, P285; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; Edwards P, 2005, LANCET, V365, P1957; Feige K, 2000, EQUINE VET EDUC, V12, P220, DOI 10.1111/j.2042-3292.2000.tb00044.x; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; Gomes JA, 2005, CRIT CARE MED, V33, P1214, DOI 10.1097/01.CCM.0000166389.85273.38; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; KORTZ GD, 1995, AM J VET RES, V56, P1351; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LITTLE CB, 1985, AUST VET J, V62, P89, DOI 10.1111/j.1751-0813.1985.tb14146.x; MacKay RJ, 2004, VET CLIN N AM-EQUINE, V20, P199, DOI 10.1016/j.cveq.2003.11.006; MAGDESIAN KG, 2000, 4 ANN UC DAV SVECCS, P137; Marmarou A, 2005, ACT NEUR S, V95, P277; Mayhew IG, 1989, LARGE ANIMAL NEUROLO, P113; MCGRAW CP, 1983, J NEUROSURG, V3, P269; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Pusterla N, 2006, SCHWEIZ ARCH TIERH, V148, P161, DOI 10.1024/0036-7281.148.3.161; RAGLE CA, 1988, VET RADIOLOGY, V29, P206, DOI 10.1111/j.1740-8261.1988.tb01500.x; RAGLE CA, 1993, VET CLIN N AM-EQUINE, V9, P171, DOI 10.1016/S0749-0739(17)30422-4; Ramirez O, 1998, VET RADIOL ULTRASOUN, V39, P391, DOI 10.1111/j.1740-8261.1998.tb01624.x; REED SM, 1993, VET CLIN N AM-EQUINE, V15, P270; Rhoney Denise H, 2006, Nutr Clin Pract, V21, P462, DOI 10.1177/0115426506021005462; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; STICK JA, 1980, J AM VET MED ASSOC, V176, P228; STICKLE R, 1998, TXB VET DIAGNOSTIC R, P105; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P531; Tonnesen A S, 1995, New Horiz, V3, P499; TYLER CM, 1993, AUST VET J, V70, P445, DOI 10.1111/j.1751-0813.1993.tb00846.x; Vogelzang M, 2006, J TRAUMA, V60, P873, DOI 10.1097/01.ta.0000195715.63978.80; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115; ZORNOW MH, 1990, ACT NEUR S, V51, P324; 2000, J NEUROTRAUMA, V19, P149	50	21	22	1	16	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488	1943-569X		JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	JUL 15	2007	231	2					259	266		10.2460/javma.231.2.259			8	Veterinary Sciences	Veterinary Sciences	190AD	WOS:000248029200029	17630894				2021-06-18	
J	Prause, G; Wildner, G; Kainz, J; Bossner, T; Gemes, G; Dacar, D; Magerl, S				Prause, G.; Wildner, G.; Kainz, J.; Boessner, T.; Gemes, G.; Dacar, D.; Magerl, S.			Strategies for quality assessment of emergency helicopter rescue systems - The Graz model	ANAESTHESIST			German	Article						emergency intervention; quality management; rescue helicopter; emergency medical doctor's experience	PREHOSPITAL ENDOTRACHEAL INTUBATION; TRAUMATIC BRAIN-INJURY; LIFE-SUPPORT; MEDICINE; EXPERIENCE; MORTALITY; SURVIVAL; EFFICACY; MODERATE	Purpose. Preclinical emergency medical treatment necessitates a comprehensive interdisciplinary knowledge by the emergency physician as well as a high level of manual dexterity. The quality of treatment therefore depends on the level of education and continuous training in emergency medical techniques. Based on an evaluation of the frequency of life-saving interventions by a physician-staffed rescue helicopter system, strategies for in-hospital training of relevant skills are suggested. Material and methods. At the outset, 10 important areas of treatment (e.g. intubation, chest tube etc.) and their frequency in emergency medical services were defined as the standard to be attained by emergency physicians within 1 year. The selection of the areas of treatment was based to some extent on international recommendations. The actual frequencies of the prehospital interventions were compared to the required minimum numbers by retrospective analysis of the helicopter rescue database (NACA-X). Results. During the observation period of 1 year, 20 emergency physicians responded to 956 prehospital emergency calls. A life-threatening condition requiring an on-site intervention occurred in only 521 (54.5%) patients, so that the majority of physicians did not perform the required minimum number of interventions. In order to maintain their level of skill, the emergency physicians were required to undertake additional training at the local university hospital. Conclusion. The frequency of on-site life-saving interventions in emergency medicine is insufficient to fulfill the quota necessary to maintain adequate training of emergency physicians. Only a link-up program at a hospital for primary care can ensure an adequate training level.	Med Univ Graz, Univ Klin Anasthesiol & Intens Med, Graz, Austria; Univ Klinikum Graz, Chirurg Univ Klin, Graz, Austria; Med Corps Grazer Rettung, Graz, Austria	Prause, G (corresponding author), Med Univ Graz, Univ Klin Anasthesiol & Intens Med, Graz, Austria.	gerhard.prause@meduni-graz.at					Birk Hans O, 2002, Prehosp Disaster Med, V17, P167; Cooke MW, 1999, BRIT MED J, V319, P1150, DOI 10.1136/bmj.319.7218.1150; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Fischer M, 2003, ANASTH INTENSIV NOTF, V38, P630; Garza AG, 2003, J EMERG MED, V25, P251, DOI 10.1016/S0736-4679(03)00198-7; Gries A., 2005, NOTFALL RETTUNGSMEDI, V8, P391, DOI DOI 10.1007/s10049-005-0756-0; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; HUF R, 1993, INTENSIV MED NOTFALL, V30, P377; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Ljosland M, 2000, Tidsskr Nor Laegeforen, V120, P2247; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Mitchell RG, 1997, J ACCID EMERG MED, V14, P274; Moecke H, 1997, ANAESTHESIST, V46, P787, DOI 10.1007/s001010050470; Morrison LJ, 2000, JAMA-J AM MED ASSOC, V283, P2686, DOI 10.1001/jama.283.20.2686; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; POHLMEUTHEN U, 1999, RETTUNGSDIENST STAAT; Prause G, 1991, Anaesthesiol Reanim, V16, P227; Regel G, 1997, Acta Anaesthesiol Scand Suppl, V110, P71; Ruchholtz S, 2002, J TRAUMA, V52, P879, DOI 10.1097/00005373-200205000-00010; RUCHHOLTZ S, 1994, UNFALLCHIRURG, V97, P285; SCHUSTER HP, 1994, ANAESTHESIST, V43, P30, DOI 10.1007/s001010050031; Schuttler J, 1995, ANAESTHESIST, V44, P850, DOI 10.1007/s001010050221; Shy Bradley D, 2004, Prehosp Emerg Care, V8, P394, DOI 10.1016/j.prehos.2004.06.013; TRIMMEL H, 1996, NOTARZT, V12, P47; Wang H E, 2001, Prehosp Emerg Care, V5, P10, DOI 10.1080/10903120190940254; Wang HE, 2005, CRIT CARE MED, V33, P1718, DOI 10.1097/01.CCM.0000171208.07895.2A; Wang HE, 2003, ACAD EMERG MED, V10, P717, DOI 10.1111/j.1553-2712.2003.tb00065.x	28	21	21	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	MAY	2007	56	5					461	465		10.1007/s00101-007-1174-0			5	Anesthesiology	Anesthesiology	171JF	WOS:000246731400008	17437072				2021-06-18	
J	Wang, MC; Temkin, NR; Deyo, RA; Jurkovich, GJ; Barber, J; Dikmen, S				Wang, Marjorie C.; Temkin, Nancy R.; Deyo, Richard A.; Jurkovich, Gregory J.; Barber, Jason; Dikmen, Sureyya			Timing of surgery after multisystem injury with traumatic brain injury: Effect on neuropsychological and functional outcome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	54th Annual Meeting of the Congress-of-Neurological-Surgeons	OCT 16-21, 2004	San Francisco, CA	Congress Neurol Surg		timing of surgery; multisystem injury; traumatic brain injury; neuropsychological outcome; functional outcome	SEVERE HEAD-INJURIES; FRACTURE FIXATION; RANDOMIZED-TRIAL; MAJOR FRACTURES; PRACTICAL SCALE; MANAGEMENT; STABILIZATION; OSTEOSYNTHESIS; VALPROATE; DAMAGE	Objective: The optimal timing for noncranial surgery after multisystem injury is not known. Early surgery may lead to decreased pulmonary complications and length of stay, but also predispose to secondary brain injury if decreased cerebral perfusion occurs intraoperatively. Previous work has not consistently evaluated neuropsychological or functional outcome. We sought to determine whether 6-month neuropsychologieal and functional outcome was associated with timing of noncranial surgery after traumatic brain injury. Materials: We performed a cohort study to evaluate the effect of the timing of non-neurosurgical operative interventions on neuropsychological and functional outcome, morbidity, and mortality. Early surgery was defined as <= 24 hours after injury, and late surgery, >24 hours after injury but during the same admission. Patients with a nonoperative brain injury and an operative facial or orthopedic fracture were selected from two randomized trials previously performed at our Level I trauma center. Data were abstracted from medical records and outcome had been prospectively gathered as part of the two clinical trials. Results: Patients undergoing early or late surgery had similar demographics, overall injury severity, traumatic brain injury severity, and admission characteristics. The early group had more open orthopedic fractures, but also underwent multiple operations more often than did the late group. At 6 months postinjury, patients in the early group had a better composite neuropsychological score than did those in the late group on unadjusted analysis and after including a propensity score. After adjusting for potential confounders, this difference was significant. No significant differences in return to work or Glasgow Outcome Score were noted. The late group had a higher incidence of pneumonia and a longer hospital stay (p < 0.10). Conclusions: In traumatic brain injury patients with multisystem trauma, early timing of orthopedic and facial fracture fixation under general anesthesia was not associated with worse neuropsychological or functional outcome when compared with the outcomes associated with late surgery. Clinical conclusions may be limited by inherent selection bias and unmeasured confounding. However, these results contribute to equipoise regarding timing of surgery after multiple injuries, and emphasize the need for a randomized trial.	Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; Univ Washington, Ctr Cost & Outcomes Res Surg Rehabil, Dept Neurosurg, Seattle, WA 98195 USA; Univ Washington, Ctr Cost & Outcomes Res Surg Rehabil, Dept Internal Med, Seattle, WA 98195 USA	Wang, MC (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	mwang@mcw.edu					Anglen JO, 2003, J TRAUMA, V54, P1166, DOI 10.1097/01.TA.0000057232.66613.AC; BEHRMAN SW, 1990, J TRAUMA, V30, P792, DOI 10.1097/00005373-199007000-00005; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BROOS PLO, 1987, INJURY, V18, P235, DOI 10.1016/0020-1383(87)90004-0; Brundage SI, 2002, J TRAUMA, V52, P299, DOI 10.1097/00005373-200202000-00016; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Dunham CM, 2001, J TRAUMA, V50, P958, DOI 10.1097/00005373-200105000-00037; DYER FN, 1973, MEM COGNITION, V1, P106, DOI 10.3758/BF03198078; FAKHRY SM, 1994, J TRAUMA, V37, P255, DOI 10.1097/00005373-199408000-00018; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; HOFMAN PAM, 1991, J TRAUMA, V31, P261, DOI 10.1097/00005373-199131020-00020; Hunt JP, 1999, SURGERY, V126, P191, DOI 10.1067/msy.1999.98749; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; JENNETT B, 1975, LANCET, V1, P480; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; Kalb DC, 1998, SURGERY, V124, P739, DOI 10.1067/msy.1998.91395; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; KOTWICA Z, 1990, ACTA NEUROCHIR, V102, P19, DOI 10.1007/BF01402180; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, MEMORY NEUROPSYCHOLO; LOZMAN J, 1986, ARCH SURG-CHICAGO, V121, P992; McKee MD, 1997, J TRAUMA, V42, P1041, DOI 10.1097/00005373-199706000-00009; Orosz GM, 2004, JAMA-J AM MED ASSOC, V291, P1738, DOI 10.1001/jama.291.14.1738; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; RIXECKER H, 1980, J CLIN PSYCHOL, V36, P465, DOI 10.1002/jclp.6120360213; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; TEMKIN NR, 2005, 23 ANN NAT NEUR SOC; Townsend RN, 1998, J TRAUMA, V44, P977, DOI 10.1097/00005373-199806000-00008; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wolfson D., 1993, HALSTEAD REITAN NEUR	36	21	23	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2007	62	5					1250	1258		10.1097/01.ta.0000215581.50234.56			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	168OF	WOS:000246533200036	17495732				2021-06-18	
J	Briassoulis, G; Papassotiriou, I; Mavrikiou, M; Lazaropoulou, C; Margeli, A				Briassoulis, George; Papassotiriou, Ioannis; Mavrikiou, Maria; Lazaropoulou, Christina; Margeli, Alexandra			Longitudinal course and clinical significance of TGF-beta 1, sL- and sE-Selectins and sICAM-1 levels during severe acute stress in children	CLINICAL BIOCHEMISTRY			English	Article						TGF-beta 1; sclectins; sICAM-1; sepsis; traumatic brain injury; ARDS	RESPIRATORY-DISTRESS-SYNDROME; INTERCELLULAR-ADHESION MOLECULE-1; GROWTH-FACTOR-BETA; SYSTEMIC INFLAMMATORY RESPONSE; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; SOLUBLE L-SELECTIN; TRANSFORMING GROWTH-FACTOR-BETA-1; CONSENSUS CONFERENCE; MAJOR TRAUMA	Objectives: To elucidate the potential role of circulating levels of transforming growth factor-beta1 (TGF-beta 1), soluble intercellular adhesion molecule-1 (sICAM-1), soluble L- and sE-Selectins (sL- and sE-Selectins) in children with sepsis, traumatic brain injury (TB1) or acute respiratory distress syndrome (ARDS). Design and methods: Levels of TGF-beta 1, sICAM-1, L- and sE-Selectins were determined using solid-phase sandwich enzyme-linked immunosorbent assay in plasma of 10 patients with sepsis, 10 patients with TBI, 10 patients with ARDS, compared to 10 ventilated controls with chronic illness but not in acute stress, on days 1, 3, 5, 7 and 10. Results: The highest values of sICAM-1 were observed in patients with TBI (p < 0.001) and those of sE-Selectin in patients with sepsis (p=0.0001). Patients in the control group did not show an elevation of sE-Selectin and sICAM-1 levels longitudinally. Increased levels of measured molecules (TGF-beta 1, p < 0.02, sE-Selectin, p < 0.02, sL-Selectin, p=0.06, sICAM-1, p < 0.03) were demonstrated among survivors in the sepsis and ARDS groups of patients and were positively correlated with length of stay (p < 0.04) and mechanical ventilation (p < 0.001). Conclusions: A sustained increase of adhesion molecules occurs during acute stress in children which may contribute to morbidity in patients with sepsis (sE-Selectin) or traumatic brain injury (sICAM-1). Suppression of the expected response of sE-Selectins, s-ICAM-1 and TGF-beta 1 is associated with poor outcome. (c) 2007 Published by The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.	Aghia Sophia Childrens Hosp, Dept Clin Biochem, Athens 11527, Greece; Aghia Sophia Childrens Hosp, Paediat Intens Care Med, Athens, Greece; Univ Hosp Heraklion, Paediat Intens Care Unit, Iraklion, Greece	Papassotiriou, I (corresponding author), Aghia Sophia Childrens Hosp, Dept Clin Biochem, Athens 11527, Greece.	biochem@paidon-agiasofia.gr					Agouridakis P, 2002, RESPIR RES, V3, DOI 10.1186/rr193; Armstrong L, 2000, AM J RESP CELL MOL, V22, P68, DOI 10.1165/ajrcmb.22.1.3728; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Beck-Schimmer B, 2002, EUR RESPIR J, V19, P1142, DOI 10.1183/09031936.02.00236602; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Dhainaut JF, 2003, CRIT CARE MED, V31, pS258, DOI 10.1097/01.CCM.0000057901.92381.75; DONNELLY SC, 1994, LANCET, V344, P215, DOI 10.1016/S0140-6736(94)92995-5; Fahy RJ, 2003, AM J RESP CELL MOL, V28, P499, DOI 10.1165/rcmb.2002-0092OC; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kourtis AP, 2003, CLIN IMMUNOL, V109, P224, DOI 10.1016/S1521-6616(03)00209-2; Krein PM, 2002, CHEST, V122, p289S, DOI 10.1378/chest.122.6_suppl.289S; Laudes IJ, 2004, AM J PATHOL, V164, P1435, DOI 10.1016/S0002-9440(10)63230-0; Laun RA, 2003, SHOCK, V19, P16, DOI 10.1097/00024382-200301000-00004; MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062; Megarbane B, 2004, INTENS CARE MED, V30, P867, DOI 10.1007/s00134-004-2253-1; Miura M, 2004, PEDIATR INFECT DIS J, V23, P931, DOI 10.1097/01.inf.0000142171.91235.fc; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Moss M, 1996, CRIT CARE MED, V24, P1782, DOI 10.1097/00003246-199611000-00004; Muller JC, 1998, J TRAUMA, V45, P705, DOI 10.1097/00005373-199810000-00013; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; PUGIN J, 1996, AM J RESP CRIT CARE, V153, P1820; Puthothu B, 2006, GENES IMMUN, V7, P322, DOI 10.1038/sj.gene.6364302; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; RINALDO JE, 1990, CLIN CHEST MED, V11, P621; Seidelin JB, 2002, INTENS CARE MED, V28, P1613, DOI 10.1007/s00134-002-1501-5; SHANLEY TP, 1995, MOL MED TODAY, V1, P40, DOI 10.1016/1357-4310(95)80019-0; Stengel D, 2001, J SURG RES, V99, P321, DOI 10.1006/jsre.2001.6173; SternerKock A, 1996, IMMUNOLOGY, V87, P454; Stoll G, 2004, BRAIN PATHOL, V14, P51, DOI 10.1111/j.1750-3639.2004.tb00497.x; Torii K, 1997, AM J RESP CRIT CARE, V155, P43, DOI 10.1164/ajrccm.155.1.9001287; Torre D, 2000, MEDIAT INFLAMM, V9, P193, DOI 10.1080/09629350020002912; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Yeh FL, 2002, BURNS, V28, P631, DOI 10.1016/S0305-4179(02)00113-4	36	21	26	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	MAR	2007	40	5-6					299	304		10.1016/j.clinbiochem.2006.11.015			6	Medical Laboratory Technology	Medical Laboratory Technology	147IU	WOS:000244997400003	17291476				2021-06-18	
J	Nakabayashi, M; Suzaki, S; Tomita, H				Nakabayashi, Motoaki; Suzaki, Shinichiro; Tomita, Hiroki			Neural injury and recovery near cortical contusions: a clinical magnetic resonance spectroscopy study	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; contusion; choline; creatine; N-acetylaspartate; proton magnetic resonance spectroscopy	TRAUMATIC BRAIN-INJURY; N-ACETYL-ASPARTATE; CLOSED-HEAD INJURY; IN-VIVO; H-1 MRS; H-1-NMR SPECTROSCOPY; AXONAL INJURY; MITOCHONDRIAL DYSFUNCTION; CEREBRAL CONTUSIONS; METABOLIC-CHANGES	Object. Proton magnetic resonance (MR) spectroscopy can detect neural metabolic alterations noninvasively after traumatic brain injury (TBI) even in areas that appear normal. Unlike metabolic depression in diffuse TBI, focal metabolic alterations near cortical contusions in humans have not been previously investigated in a longitudinal study. The object of this study was to identify these alterations and examine their course. Methods. At 1 week and 1 month after mild to moderate TBI involving cortical contusion, 30 patients underwent H-1 MR spectroscopy examination that focused bilaterally on normal-appearing frontal and temporal white matter. Levels of N-acetylaspartate (NAA), choline (Cho) compounds, and creatine (Cr) were measured to obtain two metabolite ratios, NAA/Cr and Cho/Cr. The ratios were compared with those of 11 healthy individuals. At 1 week after TBI, the NAA/Cr ratio was significantly lower near cortical contusions than it was in white matter remote from the injury or in controls, while the Cho/Cr ratios did not differ significantly. At 1 month, the decreased NAA/Cr ratios near contusions had increased significantly from 1 week, as had the Cho/Cr ratio. Conclusions. Metabolic depression reflecting neural injury was apparent in subjacent normal-appearing white matter at I week after cortical contusion; this had normalized substantially at 1 month.	Musashino Red Cross Hosp, Dept Emergency Med, Musashino, Tokyo 1808610, Japan; Musashino Red Cross Hosp, Dept Neurosurg, Musashino, Tokyo 1808610, Japan	Nakabayashi, M (corresponding author), Musashino Red Cross Hosp, Dept Emergency Med, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan.	mnkb@mac.com					Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Alessandri B, 2000, NEUROL RES, V22, P705; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; JENNETT B, 1975, LANCET, V1, P480; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Son BC, 2000, ACT NEUR S, V76, P13; SUTTON LN, 1995, PEDIATR NEUROSURG, V22, P81, DOI 10.1159/000120881; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Zampolini M, 1997, EUR J NEUROL, V4, P246, DOI 10.1111/j.1468-1331.1997.tb00343.x	42	21	22	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2007	106	3					370	377		10.3171/jns.2007.106.3.370			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	145KV	WOS:000244864700002	17367057				2021-06-18	
J	Zheng, WB; Liu, GR; Li, LP; Wu, RH				Zheng, W. B.; Liu, G. R.; Li, L. P.; Wu, R. H.			Prediction of recovery from a post-traumatic coma state by diffusion-weighted imaging (DWI) in patients with diffuse axonal injury	NEURORADIOLOGY			English	Article						diffuse axonal injury; magnetic resonance imaging; diffusion-weighted imaging; apparent diffusion coefficient	CLOSED-HEAD INJURY; TRAUMATIC BRAIN-INJURY; MR; DIAGNOSIS; STROKE; TISSUE; EDEMA; MODEL; WATER	Introduction To determine whether diffusion-weighted magnetic resonance (MR) imaging findings combined with initial clinical factors indicate the depth of shearing lesions in the brain structure and therefore relate to coma duration in diffuse axonal injury (DAI). Methods A total of 74 adult patients (48 male and 26 female) with DAI were examined with conventional MR imaging and diffusion-weighted MR imaging between 2 hours and 20 days after injury. Apparent diffusion coefficient (ADC) maps were obtained and the mean ADC values of each region of interest (ROI) were measured using MRI console software. The involvement of the brainstem, deep gray matter, and corpus callosum was determined for each sequence separately as well as for the combination of all sequences. The correlations between MR imaging findings indicating the presence of apparent brain injury combined with initial clinical factors were determined. Results Clinical characteristics, such as initial score on the Glasgow coma scale (GCS), age and number of all lesions, and ADC scores were predictive of the duration of coma. Conclusion It was possible to predict post-traumatic coma duration in DAI from cerebral MR imaging findings combined with clinical prognostic factors in the acute to subacute stage after head injury. Age, ADC scores, GCS score and number of lesions were highly significant in predicting coma duration. The technique presented here might provide a tool for in vivo detection of DAI to allow the prediction of the coma duration during the early stages in patients with traumatic brain injury.	Shantou Univ, Coll Med, Dept Radiol, Shantou 515041, Guangdong, Peoples R China; Shantou Univ, Coll Med, Injury Prevent Res Ctr, Shantou 515031, Guangdong, Peoples R China	Zheng, WB (corresponding author), Shantou Univ, Coll Med, Dept Radiol, Shantou 515041, Guangdong, Peoples R China.	hwenb@21cn.com					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P573; [Anonymous], 2000, J Neurotrauma, V17, P563; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Brockstedt S, 1998, MAGN RESON IMAGING, V16, P877, DOI 10.1016/S0730-725X(98)00002-2; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHEN B, 2003, MED J W CHINA, V1, P185; Ebisu T, 1997, RADIOLOGY, V203, P823, DOI 10.1148/radiology.203.3.9169711; EIS M, 1995, MAGN RESON MED, V34, P835, DOI 10.1002/mrm.1910340608; Filippi M, 1998, ANN NEUROL, V43, P809, DOI 10.1002/ana.410430616; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1994, RADIOLOGY, V191, P1; GIDEON P, 1994, JMRI-J MAGN RESON IM, V4, P185, DOI 10.1002/jmri.1880040216; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Helenius J, 2002, AM J NEURORADIOL, V23, P194; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Lai SM, 1999, STROKE, V30, P1840, DOI 10.1161/01.STR.30.9.1840; Lang P, 1998, Magn Reson Imaging Clin N Am, V6, P579; Le Bihan DJ, 1998, RADIOLOGY, V207, P305, DOI 10.1148/radiology.207.2.9577472; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; SRIVASTAVA MS, 1983, INTRO APPL MULTIVARI, P134; SZAFER A, 1995, MAGNET RESON MED, V33, P697, DOI 10.1002/mrm.1910330516; Szafer A, 1995, NMR BIOMED, V8, P289, DOI 10.1002/nbm.1940080704; TEASDALE G, 1974, LANCET, V2, P81; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	41	21	28	0	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	MAR	2007	49	3					271	279		10.1007/s00234-006-0187-8			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	139SV	WOS:000244453800012	17203299				2021-06-18	
J	Cherubini, A; Luccichenti, G; Peran, P; Hagberg, GE; Barba, C; Formisano, R; Sabatini, U				Cherubini, Andrea; Luccichenti, Giacomo; Peran, Patrice; Hagberg, Gisela E.; Barba, Carmen; Formisano, Rita; Sabatini, Umberto			Multimodal MRI tractography in normal subjects and in clinically recovered traumatic brain injury patients	NEUROIMAGE			English	Article						probabilistic tractography; connectivity; functional MRI; motor pathways; motor-deficit; cortical plasticity	WHITE-MATTER TRACTOGRAPHY; MEDIAL FRONTAL-CORTEX; IN-VIVO; DIFFUSION TRACTOGRAPHY; PYRAMIDAL TRACTS; FUNCTIONAL MRI; HUMAN THALAMUS; MOTOR CORTEX; CONNECTIVITY; SYSTEM	In this study, we defined an operator-independent protocol for reconstructing the anatomical connections originating from fMRI activations in order to demonstrate that results obtained with this protocol are affected by alterations of functional activations. Seven healthy volunteers and two patients who sustained traumatic brain injury underwent an fMRI with a finger tapping task and a DTI scan. Cortical fMRI activations were used directly as seed mask for tractography for the reconstruction of individual motor pathways. On patients we observed a different motor network if compared to healthy subjects. However, when the activations of healthy subjects were used as seed masks for the tractography in patients, we observed for the patients a pattern of connectivity more similar to what was observed for healthy subjects. At the same time, when the activations of patients were used for the tractography on healthy subjects, we obtained patterns of connectivity similar to those obtained for patients. These results show the potential of the integration of fMR1 and tractography for clarifying the mechanisms of cortical plasticity in the recovery of motor functions. (c) 2006 Elsevier Inc. All rights reserved.	IRCCS, Fdn Santa Lucia, Neuroimaging Lab, I-00179 Rome, Italy	Cherubini, A (corresponding author), IRCCS, Fdn Santa Lucia, Neuroimaging Lab, Via Ardeatina 306, I-00179 Rome, Italy.	a.cherubini@hsantalucia.it	Sabatini, Umberto/A-8484-2010; Cherubini, Andrea/D-1327-2009; Peran, Patrice/N-7561-2015; Sabatini, Umberto/K-4659-2016; Hagberg, Gisela E/A-2134-2010	Cherubini, Andrea/0000-0002-5946-4390; Peran, Patrice/0000-0001-7200-0139; Sabatini, Umberto/0000-0001-5321-8626; Hagberg, Gisela E/0000-0003-2176-7086; barba, carmen/0000-0001-5445-5842			Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2006, NEUROIMAGE, V30, P220, DOI 10.1016/j.neuroimage.2005.09.036; Behrens TEJ, 2005, PHILOS T R SOC B, V360, P903, DOI 10.1098/rstb.2005.1640; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Burgel U, 2006, NEUROIMAGE, V29, P1092, DOI 10.1016/j.neuroimage.2005.08.040; Celnik PA, 2004, RESTOR NEUROL NEUROS, V22, P261; Ciccarelli O, 2003, NEUROIMAGE, V19, P1545, DOI 10.1016/S1053-8119(03)00190-3; Ciccarelli O, 2003, NEUROIMAGE, V18, P348, DOI 10.1016/S1053-8119(02)00042-3; Conturo TE, 1999, P NATL ACAD SCI USA, V96, P10422, DOI 10.1073/pnas.96.18.10422; Guye M, 2003, NEUROIMAGE, V19, P1349, DOI 10.1016/S1053-8119(03)00165-4; Holodny AI, 2001, AM J NEURORADIOL, V22, P83; Johansen-Berg H, 2004, P NATL ACAD SCI USA, V101, P13335, DOI 10.1073/pnas.0403743101; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Jones DK, 1999, MAGN RESON MED, V42, P37, DOI 10.1002/(SICI)1522-2594(199907)42:1<37::AID-MRM7>3.0.CO;2-O; Kamada K, 2005, NEUROSURGERY, V57, P121, DOI 10.1227/01.NEU.0000163526.60240.B6; Kamada Kyousuke, 2005, Neurosurgery, V56, P98; Koch MA, 2002, NEUROIMAGE, V16, P241, DOI 10.1006/nimg.2001.1052; Krings T, 2001, J NEUROSURG, V95, P816, DOI 10.3171/jns.2001.95.5.0816; Krings T, 2001, NEUROSCI LETT, V307, P192, DOI 10.1016/S0304-3940(01)01928-0; Lazar M, 2003, HUM BRAIN MAPP, V18, P306, DOI 10.1002/hbm.10102; Lori NF, 2002, NMR BIOMED, V15, P493, DOI 10.1002/nbm.779; Mayka MA, 2006, NEUROIMAGE, V31, P1453, DOI 10.1016/j.neuroimage.2006.02.004; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; NOLODNY AI, 2005, ANN NY ACAD SCI, V1064, P88; Parker GJM, 2002, NEUROIMAGE, V15, P797, DOI 10.1006/nimg.2001.0994; Parker GJM, 2003, LECT NOTES COMPUT SC, V2732, P684; Rademacher J, 2001, BRAIN, V124, P2232, DOI 10.1093/brain/124.11.2232; Ramnani N, 2004, BIOL PSYCHIAT, V56, P613, DOI 10.1016/j.biopsych.2004.02.004; Smith SK, 2004, POPUL RES POLICY REV, V23, P1, DOI 10.1023/B:POPU.0000019918.24143.c9; Tailarach J., 1988, COPLANAR STEREOTAXIC; Thottakara P, 2006, NEUROIMAGE, V29, P868, DOI 10.1016/j.neuroimage.2005.08.051; Toosy AT, 2004, NEUROIMAGE, V21, P1452, DOI 10.1016/j.neuroimage.2003.11.022	35	21	23	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	FEB 15	2007	34	4					1331	1341		10.1016/j.neuroimage.2006.11.024			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	138GA	WOS:000244349900002	17197198				2021-06-18	
J	Hey, JG; Chu, XP; Seeds, J; Simon, RP; Xiong, ZG				Hey, Jessica G.; Chu, Xiang-Ping; Seeds, Joshua; Simon, Roger P.; Xiong, Zhi-Gang			Extracellular zinc protects against acidosis-induced injury of cells expressing Ca2+-permeable acid-sensing ion channels	STROKE			English	Article; Proceedings Paper	25th Princeton Conference on Cerebrovascular Disease	MAY 19-20, 2006	Portland, OR	AstraZeneca, Bayers, Cardinal Hlth, Johnson & Johnson, Legacy Hlth Syst, Merck, Neurobiol Technol, Novo Nordisk, Oregon Hlth & Sci, Univ Neurol, Pfizer Inc, Portland Dev Commiss, Renovious, Virogen & Wyeth		acid; cell injury; HEK293; zinc	METHYL-D-ASPARTATE; CORTICAL-NEURONS; HIPPOCAMPAL-NEURONS; DAMAGE; INHIBITION; RECEPTORS; ISCHEMIA; RELEASE; CALCIUM; STROKE	Acidosis is a common feature of neurological conditions including brain ischemia, epileptic seizures, and neurotrauma. Activation of Ca2+-permeable acid-sensing ion channels (ASIC1a) is involved in acidosis-mediated ischemic brain injury. Zn2+ is a divalent cation concentrated in nerve terminals in various brain regions, and is released into the extracellular space during excitatory stimulation. Our previous studies have demonstrated that the activities of ASIC1a containing channels and acid-induced increased intracellular Ca2+ concentrations are inhibited dramatically by the physiological concentration of extracellular Zn2+. In this report, we demonstrate that decreasing the concentration of the extracellular Zn2+ significantly enhances acid-induced injury of HEK 293 cells, a cell line expressing homomeric ASIC1a-like channels, whereas increasing the concentration of extracellular Zn2+ appears to be protective. Although increased concentrations of intracellular Zn2+ have been shown to be detrimental to neurons, our findings may suggest that the physiological concentration of extracellular Zn2+ might play a protective role in acidosis-induced, ASIC1a-mediated neuronal injury.	Legacy Clin Res Ctr, Robert S Dow Neurobiol Labs, Portland, OR 97232 USA	Xiong, ZG (corresponding author), Legacy Clin Res Ctr, Robert S Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	zxiong@Downeurobiology.org		Chu, Xiang-Ping/0000-0002-6781-0468	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS47506, R01NS049470] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049470, R01NS047506] Funding Source: NIH RePORTER		Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Benveniste M, 2005, NEW ENGL J MED, V352, P85, DOI 10.1056/NEJMcibr045010; Blasco-Ibanez JM, 2004, NEUROSCI LETT, V355, P101, DOI 10.1016/j.neulet.2003.10.053; CHOI DW, 1988, NEUROSCIENCE, V24, P67, DOI 10.1016/0306-4522(88)90312-0; Chu XP, 2006, J NEUROSCI, V26, P5329, DOI 10.1523/JNEUROSCI.0938-06.2006; Chu XP, 2004, J NEUROSCI, V24, P8678, DOI 10.1523/JNEUROSCI.2844-04.2004; Cole TB, 2000, EPILEPSY RES, V39, P153, DOI 10.1016/S0920-1211(99)00121-7; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Huang YZ, 2004, CELL, V118, P665, DOI 10.1016/j.cell.2004.09.004; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581; Paoletti P, 1997, J NEUROSCI, V17, P5711; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; Siesjo BK, 1996, ADV NEUROL, V71, P209; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100	22	21	22	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2007	38	2					670	673		10.1161/01.STR.0000251443.68897.99			4	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	134ZE	WOS:000244122600804	17261712	Bronze			2021-06-18	
J	Lenartova, L; Janciak, I; Wilbacher, I; Rusnak, M; Mauritz, W				Lenartova, Lucia; Janciak, Ivan; Wilbacher, Ingrid; Rusnak, Martin; Mauritz, Walter		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria III: Prehospital status and treatment	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; outcome; prehospital; Glasgow Coma Scale; vital signs; fluid administration; transport	SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; GLASGOW COMA SCALE; ENDOTRACHEAL INTUBATION; FLUID RESUSCITATION; SALINE; VENTILATION; PROGNOSIS; SURVIVAL; MODERATE	OBJECTIVES: The goal of this paper is to describe prehospital status and treatment of patients with severe TBI in Austria. PATIENTS AND METHODS: Data sets from 396 patients with severe TBI (Glasgow Coma Scale score < 9) included by 5 Austrian hospitals were available. The analysis focused on incidence and/or degree of severity of typical clinical signs, frequency of use of different management options, and association with outcomes for both. ICU mortality, 90-day mortality, final outcome (favorable = good recovery or moderate disability; unfavorable = severe disability, vegetative state, or death) after 6 or 12 months, and ratio of observed (90-day) to predicted mortality (O/E ratio) are reported for the selected parameters. Chi(2)-test, t-test, Fisher's exact test, and logistic regression were used to identify significant (p < 0.05) differences for association with survival and favorable outcome (both coded as 1). RESULTS: The majority of patients were male (72%), mean age was 49 +/- 21 years, mean injury severity score (ISS) was 27 +/- 17, mean first GCS score was 5.6 +/- 2.9, and expected hospital survival was 63 +/- 30%. ICU mortality was 32%, 90-day mortality was 37%, and final outcome was favorable in 35%, unfavorable in 53%, unknown in 12%. We found that age > 60 years, ISS > 50 points, GCS score < 4, bilateral changes in pupil size and reactivity, respiratory rate < 10/min, systolic blood pressure (SBP) < 90 mm Hg, and heart rate < 60/min were associated with significantly higher ICU and 90-day mortality rates, and lower rates of favorable outcome. With regard to prognostic value the GCS motor response score is identical to the full GCS score. Administration of > 1000 ml of fluid and helicopter transport were associated with better outcomes than expected, while endotracheal intubation in the field had neither a positive nor a negative effect on outcomes. Administration of no or < 500 ml of fluids was associated with worse outcomes than expected. Outcomes were better than expected in the few patients (5%) who received hypertonic saline. CONCLUSIONS: Age, ISS, and initial neuro status are the factors most closely associated with outcome. Hypotension must be avoided. Fluids should be given to restore and/or maintain SBP > 110 mm Hg. Helicopter transport should be arranged for more seriously injured patients.	INRO, Med Advisory Board, A-1080 Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anesthesia & Crit Care Med, Vienna, Austria	Mauritz, W (corresponding author), INRO, Med Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Rusnak, Martin/K-9349-2016	Rusnak, Martin/0000-0003-3321-1042; Mauritz, Walter/0000-0001-9043-3712			American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Lal Dave, 2003, Prehosp Disaster Med, V18, P20; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz Walter, 2002, Eur J Emerg Med, V9, P315; Neff TA, 2003, ANESTH ANALG, V96, P1453, DOI 10.1213/01.ANE.0000061582.09963.FD; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Soreide E, 2005, INJURY, V36, P1001, DOI 10.1016/j.injury.2005.01.002; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Werner C, 1997, ANAESTHESIST, V46, pS55, DOI 10.1007/PL00002466; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Wright KD, 1996, INJURY, V27, P719, DOI 10.1016/S0020-1383(96)00119-2; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011; 2000, J NEUROTRAUMA, V17, P457	34	21	23	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					35	45		10.1007/s00508-006-0762-3			11	Medicine, General & Internal	General & Internal Medicine	142GQ	WOS:000244637800009	17318749				2021-06-18	
J	Corrigan, JD; Bogner, J				Corrigan, John D.; Bogner, Jennifer			Interventions to promote retention in substance abuse treatment	BRAIN INJURY			English	Article						traumatic brain injury; substance abuse; premature termination	TRAUMATIC BRAIN-INJURY; DRUG-ABUSE; THERAPEUTIC ALLIANCE; ALCOHOL-ABUSE; READINESS; PREDICTOR; INCENTIVES; ATTENDANCE; FRAMEWORK; BEHAVIOR	Objectives: Compare two methods of improving retention in substance abuse treatment for persons with traumatic brain injury. Design: Randomized clinical trial with control group comparison. Interventions: Provision of a financial incentive and reduction of logistical barriers. Outcome measures: Treatment attendance, perceived therapeutic alliance, premature termination. Results: Provision of a financial incentive was highly effective for facilitating early attendance and appeared to promote eventual successful treatment completion. Reduction of logistical barriers did not significantly improve attendance or successful discharge. The hypothesized role of improved therapeutic alliance as a consequence of intervention and a mediator for preventing premature termination was not supported. However, results suggested that intervention, particularly financial incentives, promoted congruence between counsellor and client perceived therapeutic alliance. Conclusions: For clients with traumatic brain injuries, provision of a financial incentive at an early point in substance abuse treatment substantially improves attendance and reduces the likelihood of premature termination. The basis for this effect appears to involve more than enhancement of the therapeutic alliance. We posit that concrete incentives can provide an opportunity for successful rule- governed behaviour that may generalize to other areas of improved impulse control.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011				Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; Barber JP, 2001, J CONSULT CLIN PSYCH, V69, P119, DOI 10.1037/0022-006X.69.1.119; Barber JP, 1999, PSYCHOTHER RES, V9, P54, DOI 10.1093/ptr/9.1.54; Bates ME, 2006, PSYCHOL ADDICT BEHAV, V20, P241, DOI 10.1037/0893-164X.20.3.241; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Becker M H, 1980, J Community Health, V6, P113, DOI 10.1007/BF01318980; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BEUTLER LE, 1991, J CONSULT CLIN PSYCH, V59, P1; Bickel WK, 2001, ADDICTION, V96, P73, DOI 10.1046/j.1360-0443.2001.961736.x; BLAKELY E, 1987, BEHAV ANALYST, V10, P183, DOI 10.1007/BF03392428; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; CAREY KB, 1990, J BEHAV THER EXP PSY, V21, P205, DOI 10.1016/0005-7916(90)90008-9; Cicerone KD, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P246; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; Corrigan JD, 2005, PSYCHOL ADDICT BEHAV, V19, P131, DOI 10.1037/0893-164X.19.2.131; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; CORRIGAN JD, 2005, REHABILITATION TRAUM, P133; CORRIGAN JD, 1999, REHABILITATION ADULT; *CTR SUBST AB TREA, 1998, SUBST US DIS TREATM; De Weert-Van Oene GH, 2001, J SUBST ABUSE TREAT, V20, P253, DOI 10.1016/S0740-5472(01)00160-X; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EATHER N, 1993, READINESS CHANGE QUE; Fantino E, 2004, BEHAV PROCESS, V66, P279, DOI 10.1016/j.beproc.2004.03.009; HEATHER N, 1993, ADDICTION, V88, P1667, DOI 10.1111/j.1360-0443.1993.tb02042.x; Higgins S T, 1993, NIDA Res Monogr, V137, P97; Higgins ST, 2002, ADDICT BEHAV, V27, P887, DOI 10.1016/S0306-4603(02)00297-6; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; Kudadjie-Gyamfi E, 2002, BEHAV PROCESS, V57, P29, DOI 10.1016/S0376-6357(01)00205-4; LANGLEY MJ, 1991, WORK WORTH DOING ADV; LEZAK MD, 1999, NEUROPSYCHOLOGICAL A; Luborsky L, 1996, J Psychother Pract Res, V5, P260; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; MCLELLAN AT, 1990, ADDICTION SEVERITY I; Meier P. S., 2006, J SUBST USE, V11, P73, DOI DOI 10.1080/14659890500137004; Meier PS, 2005, ADDICTION, V100, P304, DOI 10.1111/j.1360-0443.2004.00935.x; Monterosso J, 2001, ADDICTION, V96, P1825, DOI 10.1046/j.1360-0443.2001.9612182512.x; Newman C F, 1997, NIDA Res Monogr, V165, P181; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Petry NM, 2001, PSYCHOPHARMACOLOGY, V154, P243, DOI 10.1007/s002130000638; Reitan RM, 2005, APPL NEUROPSYCHOL, V12, P181, DOI 10.1207/s15324826an1204_1; Rhodes GL, 2003, AM J DRUG ALCOHOL AB, V29, P759, DOI 10.1081/ADA-120026259; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; ROWANSZAL G, 1994, J SUBST ABUSE TREAT, V11, P217, DOI 10.1016/0740-5472(94)90078-7; Silverman K, 1996, DRUG ALCOHOL DEPEN, V41, P157, DOI 10.1016/0376-8716(96)01246-X; Simpson DD, 2004, J SUBST ABUSE TREAT, V27, P99, DOI 10.1016/j.jsat.2004.06.001; SIMPSON DD, 1981, ARCH GEN PSYCHIAT, V38, P875; Simpson DD, 1997, DRUG ALCOHOL DEPEN, V47, P227; SIMPSON DD, 1993, PSYCHOTHER, V30, P357, DOI 10.1037/0033-3204.30.2.357; Simpson DD, 1997, J SUBST ABUSE TREAT, V14, P565, DOI 10.1016/S0740-5472(97)00181-5; SNOW RE, 1991, J CONSULT CLIN PSYCH, V59, P205, DOI 10.1037/0022-006X.59.2.205; SOBELL MB, 1992, BEHAV THER, V23, P43, DOI 10.1016/S0005-7894(05)80307-7; Verdejo-Garcia A, 2004, NEUROPSYCHOL REV, V14, P1, DOI 10.1023/B:NERV.0000026647.71528.83; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604	63	21	21	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	4					343	356		10.1080/02699050701253103			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600001	17487633				2021-06-18	
J	Eilander, HJ; Timmerman, RBW; Scheirs, JGM; Van Heugten, CM; De Kort, PLM; Prevo, AJH				Eilander, H. J.; Timmerman, R. B. W.; Scheirs, J. G. M.; Van Heugten, C. M.; De Kort, P. L. M.; Prevo, A. J. H.			Children and young adults in a prolonged unconscious state after severe brain injury: Long-term functional outcome as measured by the DRS and the GOSE after early intensive neurorehabilitation	BRAIN INJURY			English	Article						consciousness; brain-injured children; functional recovery; long-term functioning; minimally conscious state; neurorehabilitation; severe brain injury; vegetative state; youngsters	DISABILITY RATING-SCALE; PERSISTENT VEGETATIVE STATE; SEVERE HEAD-INJURY; POSTTRAUMATIC UNAWARENESS; LIFE SATISFACTION; PRACTICAL SCALE; MEDICAL ASPECTS; RECOVERY; CONSCIOUSNESS; GUIDELINES	Objective: To investigate the long-term (2-15 years) functional outcome of children and young adults who received an early intensive neurorehabilitation programme (EINP) after a prolonged period of unconsciousness due to severe brain injury; to differentiate between traumatic brain injury (TBI) and non-traumatic brain injury (nTBI); and to compare the results on two different outcome scales: the Disability Rating Scale (DRS) and the Glasgow Outcome Scale Extended (GOSE). Subjects: One hundred and forty-five patients, who were admitted to EINP between December 1987 and January 2001. Outcome measures: The Post-Acute Level of Consciousness scale (PALOC-s), the DRS, including categorized scores (DRScat), and the GOSE. Results: The long-term functional level of 90 patients could be determined, of whom 25 were deceased. The mean DRSscore of the surviving patients was 6.8 (SD = 6.6) - the mean score on the GOSE was 4.5 (SD = 1.7). There was a significant difference in the outcome amongst traumatic and non-traumatic patients (t((88)) = 4.21; 3 p < 0.01). The correlation between the DRS and the GOSE was high (Spearman rho = 0.85; p < 0.01), as well as the correlation between the categorized scores of the DRS and the GOSE (Spearman rho = 0.81; p < 0.01). The distribution of outcome scores on the DRScat is more diverse than on the GOSH. Especially item 7 of the DRS, measuring functional independence, showed considerable variance in discriminating between different outcome levels. Conclusions: More patients with TBI than expected reached a (semi-) independent level of functioning, indicating a possible effect of EINP. Patients suffering from nTBI did not demonstrate these outcome levels. Only a few patients stayed in a vegetative state for more than a couple of years. In this cohort of severe brain-injured young people, the DRS offered the best investigative possibilities for long-term level of functioning.	Rehabil Ctr, Div Res, Project VLBNAH, NL-5004 EA Tilburg, Netherlands; Tilburg Univ, Fac Social Sci, Dept Psychol & Hlth, NL-5000 LE Tilburg, Netherlands; Inst Rehabil Res, iRv, Hoensbroek, Netherlands; Maastricht Univ, Maastricht, Netherlands; St Elizabeth Hosp, Div Neurol, Tilburg, Netherlands; UMC Utrecht, Rudolf Magnus Inst Neurosci, Rehabil Ctr De Hoogstr, Utrecht, Netherlands	Eilander, HJ (corresponding author), Rehabil Ctr, Div Res, Project VLBNAH, Leijpk POB 5022, NL-5004 EA Tilburg, Netherlands.	H.J.Eilander@hccnet.nl	Eilander, Henk/D-9643-2016				ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; BULLOCK RM, 2002, NEUROSURGICAL FOCUS, V13, P1; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; *CTR OUTC MEAS BRA, 2000, GLASG OUTC SCAL; *CTR OUTC MEAS BRA, 2002, EXT GLASG OUTC SCAL; *CTR OUTC MEAS BRA, 2000, DIS RAT SCAL DRS; DOMAN RJ, 1960, JAMA-J AM MED ASSOC, V174, P257, DOI 10.1001/jama.1960.03030030037007; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; EILANDER HJ, UNPUB RELIABILITY VA; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Gray DB, 2000, ARCH PHYS MED REHAB, V81, pS10, DOI 10.1053/apmr.2000.20616; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lollar DJ, 2000, ARCH PHYS MED REHAB, V81, pS46, DOI 10.1053/apmr.2000.20624; LOMBARDI F, 2003, COCHRANE LIB, P1; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; McKevitt C, 2001, STROKE, V32, P681, DOI 10.1161/01.STR.32.3.681; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; Stewart DG, 1998, NEUROREHABILITATION, V10, P13, DOI 10.3233/NRE-1998-10103; Stucki G, 2005, DISABIL REHABIL, V27, P353, DOI 10.1080/09638280400014105; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Whyte J, 2006, J HEAD TRAUMA REHAB, V21, P99, DOI 10.1097/00001199-200603000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	38	21	23	1	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2007	21	1					53	61		10.1080/02699050601151795			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600007	17364520				2021-06-18	
J	Hanten, G; Li, XQ; Chapman, SB; Swank, P; Gamino, J; Roberson, G; Levin, HS				Hanten, Gerri; Li, Xiaoqi; Chapman, Sandra B.; Swank, Paul; Gamino, Jacque; Roberson, Garland; Levin, Harvey S.			Development of verbal selective learning	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; RECALL; MEMORY; REHEARSAL; CHILDREN; ADOLESCENCE; INHIBITION; INCENTIVES; STRATEGY	Using incentive-based auditory word recall we studied the efficiency of selective learning in children ages 6-18 years. We found effects of age or both selective learning efficiency and for total words recalled, which differed in developmental trajectory. The number of words recalled showed a nonlinear component, reflecting a negatively accelerated increase with age. In contrast, the measure of selective learning was linear with age. Overall, selective learning efficiency was not related to the total number of words recalled. The findings provide a framework for interpretation of studies of selective learning in clinical populations.	Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Texas, Ctr BrainHlth, Dallas, TX 75230 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA	Hanten, G (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		APPEL LF, 1972, CHILD DEV, V43, P1365, DOI 10.2307/1127522; BAUER R, 1991, J GEN PSYCHOL, V117, P447; Bjork R. A., 1989, VARIETIES MEMORY CON, P309; Bjorklund DF, 2004, DEV REV, V24, P343, DOI 10.1016/j.dr.2004.08.002; BJORKLUND DF, 1989, J EXP CHILD PSYCHOL, V48, P451, DOI 10.1016/0022-0965(89)90052-0; BRAY NW, 1985, DEV PSYCHOL, V21, P290, DOI 10.1037/0012-1649.21.2.290; BRAY NW, 1978, INTELLIGENCE, V2, P153; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Castel AD, 2002, MEM COGNITION, V30, P1078, DOI 10.3758/BF03194325; DEMPSTER FN, 1981, PSYCHOL BULL, V89, P63, DOI 10.1037/0033-2909.89.1.63; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; DUSEK JB, 1978, DEV PSYCHOL, V14, P115, DOI 10.1037/0012-1649.14.1.115; ENGLE RW, 1995, PSYCHOL SCI, V6, P122, DOI 10.1111/j.1467-9280.1995.tb00318.x; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; GUTTENTAG RE, 1984, J EXP CHILD PSYCHOL, V37, P92, DOI 10.1016/0022-0965(84)90060-2; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; HANTEN G, 2001, SELECTIVE LEARNING D; Harnishfeger KK, 1996, J EXP CHILD PSYCHOL, V62, P292, DOI 10.1006/jecp.1996.0032; KEENEY TJ, 1967, CHILD DEV, V38, P953, DOI 10.1111/j.1467-8624.1967.tb04373.x; KUNZINGER EL, 1984, J GENET PSYCHOL, V144, P19; MILLER PH, 1991, J EXP CHILD PSYCHOL, V52, P149, DOI 10.1016/0022-0965(91)90057-Y; MOELY BE, 1969, DEV PSYCHOL, V1, P26, DOI 10.1037/h0026804; OSULLIVAN JT, 1993, J EXP CHILD PSYCHOL, V55, P396, DOI 10.1006/jecp.1993.1022; Posthuma D, 2003, TWIN RES, V6, P131, DOI 10.1375/twin.6.2.131; VACHHA B, 2005, CEREBROSPINAL FLUID, V17, P2; WATKINS MJ, 1999, UNPUB SELECTIVITY ME	27	21	22	0	10	LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS	PHILADELPHIA	325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2007	32	1					585	596		10.1080/87565640701361112			12	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	197QF	WOS:000248570000005	17650995				2021-06-18	
J	Lippert-Gruener, M; Lefering, R; Svestkova, O				Lippert-Gruener, M.; Lefering, R.; Svestkova, O.			Functional outcome at 1 vs. 2 years after severe traumatic brain injury	BRAIN INJURY			English	Article						outcome; rehabilitation; traumatic brain injury; professional reintegration; activities of daily living; need of care	SEVERE HEAD-INJURY; REHABILITATION; THERAPY; MODERATE	Purpose: The aim of the study was to evaluate the outcome of patients with severe traumatic brain injury (STBI) after 12 and 24 months (Glasgow Coma Scale GCS <= 8 points for at least 24 hours). Methods: A total of 51 patients underwent a multidisciplinary early rehabilitation treatment until they were discharged from hospital and local ambulatory care was deemed sufficient. The follow-up examination took place 12 and 24 months after the STBI. Results: Data revealed a high level of independence in activities of daily living (mean Barthel Index after 1 year 92.7 points, after 2 years 93.7 points). After 1 and 2 years, 74.5% and 80.4% of the patients, respectively, were completely independent of need for care. Nevertheless, more than half of the patients had sensorimotor, behavioural, speech, visual and/or auditory disturbances. Return to work rates improved between 1 - 2 years after trauma, as evidenced by the rate of patients being back to full time work at 1 year ( n = 14, 28%) and 2 years ( n = 20, 40%) post- STBI; although none of these changes reached statistical significance. Conclusion: In summary, there are still changes in both impairment and disability related areas between 1 - 2 years post STBI, but the degree of improvement is variable depending on the area being considered. Clinicians should remain aware of the fact that modulation of impairment and disability appear to continue well beyond 1 year post- STBI, which may impact on decisions regarding the provision and intensity of further rehabilitation efforts.	Univ Hosp Cologne, Dept Neurosurg, D-50931 Cologne, Germany; Univ Witten Herdecke, Fac Med, IFOM, Cologne, Germany; Gen Teaching Hosp Prague, Dept Rehabil Med, Prague, Czech Republic	Lippert-Gruener, M (corresponding author), Univ Hosp Cologne, Dept Neurosurg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	lippert.gruener@medizin.uni-koeln.de	Svetkova, Olga/O-1062-2017	Svetkova, Olga/0000-0002-4271-4795			Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; BAEHR M, 1997, KLIN NEUROBIOLOGIE M; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; BROOCKS N, 1986, J NEUROL NEUROSUR PS, V46, P336; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; Hoffmann B, 2002, ACT NEUR S, V79, P33; Hoofien D, 2001, BRAIN INJURY, V15, P189; KIRCHBERGER S, 1993, SPEKTRUM NEUROREHABI, P91; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; LIPPERTGRUNER M, 2003, ORTHOPADISCHE PRAXIS, V39, P334; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MAYER K, 1994, TAGUNGSBERICHT KURAT, P8; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUSK HA, 1968, MED CLIN N AM, V53, P677; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SCHONLE PW, 1993, SPEKTRUM NEUROREHABI, P125; UNTERBERG A, 1999, GRUNDLAGEN NEUROCHIR, P201	30	21	21	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	10					1001	1005		10.1080/02699050701468933			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600001	17891561				2021-06-18	
J	Trudel, TM; Nidiffer, FD; Barth, JT				Trudel, Tina M.; Nidiffer, F. Don; Barth, Jeffrey T.			Community-integrated brain injury rehabilitation: Treatment models and challenges for civilian, military, and veteran populations	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain injury; cognitive rehabilitation; community-integrated rehabilitation; community integration; community reentry; Defense and Veterans Brain Injury Center; functional rehabilitation; home-based rehabilitation; neurobehavioral rehabilitation; treatment manuals	RANDOMIZED CONTROLLED-TRIAL; COMPREHENSIVE DAY TREATMENT; COGNITIVE-BEHAVIOR THERAPY; POSTACUTE REHABILITATION; NEUROREHABILITATION PROGRAM; COST-EFFECTIVENESS; TREATMENT MANUALS; RATING-SCALE; HEAD-INJURY; DISABILITY	Traumatic brain injury (TBI) is a major health problem in civilian, military, and veteran populations. Individuals experiencing moderate to severe TBI require a continuum of care involving acute hospitalization and postacute rehabilitation, including community reintegration and, one would hope, a return borne to function as a productive member of the community. In the military, the goal is to help individuals with TBI return to active duty or make an optimal return to civilian life if the extent of their injuries necessitates a "medical board" discharge. Whether civilian, military, or veteran with TBI, individuals who move beyond the need to live in a facility must be reintegrated back into the community. This article discusses four treatment models for community reintegration, reviews treatment standardization and outcome issues, and describes a manualized rehabilitation pilot program designed to provide community reintegration and return to duty/work for civilians, veterans, and military personnel with TBI.	[Trudel, Tina M.; Nidiffer, F. Don; Barth, Jeffrey T.] Univ Virginia, Sch Med, Lakeview Healthcare Syst, Def & Vet Brain Injury Ctr Virgina Neurocare, Charlottesville, VA 22902 USA	Trudel, TM (corresponding author), Univ Virginia, Sch Med, Lakeview Healthcare Syst, Def & Vet Brain Injury Ctr Virgina Neurocare, 1101-B E High St, Charlottesville, VA 22902 USA.	ttrudel@lakeview.ws					Bach AK, 2004, BEHAV THER, V35, P55, DOI 10.1016/S0005-7894(04)80004-2; Bach-y-Rita P, 2003, ARCH PHYS MED REHAB, V84, P1100, DOI 10.1016/S0003-9993(03)00312-5; Ball Jillian, 2004, Eat Disord, V12, P303, DOI 10.1080/10640260490521389; Bazelmans Ellen, 2004, Cognitive Behaviour Therapy, V33, P143, DOI 10.1080/16506070410025823; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; BLANCHARD EB, 2001, IRRITABLE BOWEL SYND; Bowen A, 1999, NEUROREHABILITATION, V13, P147; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1073, DOI 10.1016/j.apmr.2005.01.003; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Coetzer R, 2005, INT J REHABIL RES, V28, P361, DOI 10.1097/00004356-200512000-00010; Cooper Z, 2003, COGNITIVE BEHAV TREA; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Davis LW, 2005, J REHABIL RES DEV, V42, P35, DOI 10.1682/JRRD.2003.05.0083; DELOCHE G, 2000, INT HDB NEUROPSYCHOL, P83; Duncan EAS, 2004, BEHAV COGN PSYCHOTH, V32, P199, DOI 10.1017/S135246580400116X; Glenn MB, 2005, J HEAD TRAUMA REHAB, V20, P393, DOI 10.1097/00001199-200509000-00001; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Hashimoto K, 2006, J REHABIL MED, V38, P20, DOI 10.1080/16501970510038473; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; *HM JACKSON FDN AD, 2007, DEFENSE VETERANS BRA; Hunsley J, 1999, J CLIN PSYCHOL, V55, P1507, DOI 10.1002/(SICI)1097-4679(199912)55:12<1507::AID-JCLP8>3.0.CO;2-A; IPSEN SM, 1986, EDUC TRAIN MENT RET, V21, P153; JEFFREY DB, 1973, J AM COLL HEALTH ASS, V21, P455; Klinger E, 2005, CYBERPSYCHOL BEHAV, V8, P76, DOI 10.1089/cpb.2005.8.76; KREUTZER JS, 2001, JUDGMENT SAFETY SCRE, P56; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Linden M, 2005, PSYCHOTHER PSYCHOSOM, V74, P36, DOI 10.1159/000082025; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malinowski A., 2003, J SUBST USE, V8, P223, DOI DOI 10.1080/14659890310001636107; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Miranda J, 2003, JAMA-J AM MED ASSOC, V290, P57, DOI 10.1001/jama.290.1.57; Morley Stephen, 2004, Cognitive Behaviour Therapy, V33, P1, DOI 10.1080/16506070310001794; Munoz RF, 2005, J CONSULT CLIN PSYCH, V73, P790, DOI 10.1037/0022-006X.73.5.790; O'Connor K., 2005, COGNITIVE BEHAV MANA; Pace GM, 1999, BRAIN INJURY, V13, P535; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Sholomskas DE, 2005, J CONSULT CLIN PSYCH, V73, P106, DOI 10.1037/0022-006X.73.1.106; Stith SA, 2002, J MARITAL FAM THER, V28, P21, DOI 10.1111/j.1752-0606.2002.tb01168.x; Taylor J., 2005, ANGER TREATMENT PEOP; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 2001, HEAD TRAUMA THERAPEU; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Turner-Stokes L, 2004, CLIN MED, V4, P10, DOI 10.7861/clinmedicine.4-1-10; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Vander Laan R, 2001, NEUROREHABILITATION, V16, P17; Vanderploeg RD, 2006, J HEAD TRAUMA REHAB, V21, P179, DOI 10.1097/00001199-200603000-00010; Warden DL, 2000, J HEAD TRAUMA REHAB, V15, P1092, DOI 10.1097/00001199-200010000-00003; Whyte J, 2002, ARCH PHYS MED REHAB, V83, P1320, DOI 10.1053/apmr.2002.34807; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; Wood RL, 1999, NEUROPSYCHOL REHABIL, V9, P505, DOI 10.1080/096020199389554; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746	61	21	22	0	19	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					1007	1016		10.1682/JRRD.2006.12.0167			10	Rehabilitation	Rehabilitation	253NL	WOS:000252524800013	18075957	Bronze			2021-06-18	
J	Yang, TC; Lo, YL; Huang, YC; Yang, ST				Yang, Tao-Chieh; Lo, Yang-Lan; Huang, Yin-Chen; Yang, Shun-Tai			Traumatic anterior cerebral artery aneurysm following blunt craniofacial trauma	EUROPEAN NEUROLOGY			English	Article						traumatic anterior cerebral artery aneurysms; delayed-onset rebleeding; pericallosal artery; callosomarginal artery; transarterial embolization	INTRACRANIAL ANEURYSMS; HEMORRHAGE; CHILDHOOD; RUPTURE	Background: Traumatic aneurysms of the anterior cerebral artery ( ACA) were retrospectively reviewed in an effort to identify patients at high risk of ACA aneurysm. Methods: Blunt craniofacial trauma patients featuring vascular injuries over the region of the ACA were studied. Results: Six patients featuring eight ACA aneurysms were diagnosed between June 1992 and December 2005, inclusively. Seven aneurysms were located at nonbranched sites and one was located over the right ACA-anterior communicating artery junction. One patient died immediately of massive intracranial lobar hemorrhage (ICH). The other 5 patients experienced rebleeding during a period of from 1 to 29 days. Brain computed tomography revealed subarachnoid hemorrhage ( SAH) in 1 of these 6 patients, ICH over the medial frontal area or cingulated gyrus in 4 patients, intraventricular hemorrhage ( IVH) in 3 patients, and an interhemispheric subdural hematoma ( SDH) in 2 patients. Conclusion: Delayed-onset deterioration of neurological deficit is the most common clinical presentation of traumatic ACA aneurysms. Midline hemorrhage such as medial frontal hemorrhage or cingulate gyrus hemorrhage, and the presence of an interhemispheric SDH associated with SAH and IVH subsequent to blunt craniofacial trauma should be further evaluated, as they present a high risk of traumatic ACA aneurysms to patients. Copyright (c) 2007 S. Karger AG, Basel.	Chang Gung Univ, Chang Gung Mem Hosp, Dept Neurosurg, Tao Yuan, Kwei Shan Count, Taiwan	Yang, ST (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Dept Neurosurg, 5 Fu Shin St, Tao Yuan, Kwei Shan Count, Taiwan.	yst0708@yahoo.com.tw					ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; Cohen JE, 2005, J NEUROSURG, V102, P555, DOI 10.3171/jns.2005.102.3.0555; Cummings TJ, 2000, NEUROL RES, V22, P165, DOI 10.1080/01616412.2000.11741055; HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009; Ishibashi Akira, 1995, Neurologia Medico-Chirurgica, V35, P882, DOI 10.2176/nmc.35.882; Kumar M, 1998, NEUROSURG CLIN N AM, V9, P577; NAKSTAD P, 1986, NEURORADIOLOGY, V28, P335, DOI 10.1007/BF00333440; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PERLMUTTER D, 1978, J NEUROSURG, V49, P204, DOI 10.3171/jns.1978.49.2.0204; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Sasaoka Y, 1997, NEUROL SURG TOKYO, V25, P337; VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125; YOKOTA H, 1983, Neurological Surgery, V11, P521	15	21	22	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-3022	1421-9913		EUR NEUROL	Eur. Neurol.		2007	58	4					239	245		10.1159/000107970			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	227KN	WOS:000250655700009	17851246				2021-06-18	
J	Greve, KW; Bianchini, KJ				Greve, Kevin W.; Bianchini, Kevin J.			Classification accuracy of the Portland Digit Recognition Test in traumatic brain injury: Results of a known-groups analysis	CLINICAL NEUROPSYCHOLOGIST			English	Article							MALINGERED NEUROCOGNITIVE DYSFUNCTION; ADULT INTELLIGENCE SCALE; CARD SORTING TEST; MILD HEAD TRAUMA; COGNITIVELY INTACT; NORMATIVE DATA; RESPONSE BIAS; TOMM; PERFORMANCE; DEPRESSION	The present study used a known-groups design to examine the accuracy of the Portland Digit Recognition Test (PDRT) in the detection of malingering in traumatic brain injury (TBI). Data were derived from 262 TBI patients who were classified as not malingering, possibly malingering, and malingering based on the Slick, Sherman, and Iverson (1999) criteria. The original PDRT cutoffs detected between 20 and 50% of malingering TBI patients with a false positive error rate of 5% or less. When the false positive error rate was held at 5%, across all item sets, sensitivity was as high as 70%. The results show that the original PDRT cutoffs are conservative and that higher scores detect more MND patients without causing the false positive error rate to become unacceptably high. Clinical application and future research needs are discussed.	Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1993, PORTLAND DIGIT RECOG; BINDER LM, 2002, J FORENSIC NEUROPSYC, V2, P27; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Doane BM, 2005, CLIN NEUROPSYCHOL, V19, P99, DOI 10.1080/13854040490524100; Gouvier WD, 1998, CRIT ISS NE, P55; Greene R. L., 1991, MMPI 2 INTERPRETIVE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; GREVE KW, IN PRESS J CLIN EXPT; Gunstad J, 2001, CLIN NEUROPSYCHOL, V15, P397, DOI 10.1076/clin.15.3.397.10271; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; Heaton SK, 1993, WISCONSIN CARD SORTI; Hennekens CH, 1987, EPIDEMIOLOGY MED; Ju D, 2000, Appl Neuropsychol, V7, P201, DOI 10.1207/S15324826AN0704_1; KAGEHIRO DK, 1990, PSYCHOL SCI, V1, P194, DOI 10.1111/j.1467-9280.1990.tb00197.x; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; *U MINN, 1989, MINN MULT PERS INV 2; Wechsler D., 1987, WECHSLER ADULT INTEL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	46	21	21	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2006	20	4					816	830		10.1080/13854040500346610			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	085IE	WOS:000240597000016	16980264				2021-06-18	
J	Kunik, CL; Flowers, L; Kazanjian, T				Kunik, Cherie L.; Flowers, Laura; Kazanjian, Terri			Time to rehabilitation admission and associated outcomes for patients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; length of stay; outcome assessment (health care); rehabilitation	LENGTH-OF-STAY; MULTICENTER ANALYSIS; OLDER-ADULTS; THERAPY; CHARGES	Objective: To examine the association between time from injury to rehabilitation admission and outcomes for patients with traumatic brain injuries (TBIs). Design: Retrospective chart review. Setting: One hundred-bed inpatient rehabilitation facility with a 20-bed brain injury unit. Participants: Patients with TBIs discharged from initial inpatient rehabilitation between 2003 and 2004 (N= 158). Interventions: Not applicable. Main Outcome Measures: Outcomes examined were functional independence at discharge (motor, cognitive, total FIM scores), rehabilitation length of stay (LOS), and rehabilitation cost. Results: Significant linear trends were observed for time to admission and motor FIM scores, total FIM scores, rehabilitation LOS, and cost. All linear regression models contained time to admission as a significant predictor of rehabilitation outcomes. Over half of the variability in outcomes was explained by predictors including time to admission and case-mix group or individual FIM scores with the exception of discharge motor FIM score, for which only 45% of the variability was explained. Conclusions: Patients who progress to rehabilitation earlier do better functionally and have lower costs and shorter LOSS. Furthermore, the time to rehabilitation admission is easily calculated and could be used by rehabilitation providers in adjunct with admission FIM scores to estimate resource utilization.	Shepherd Ctr, Crawford Res Inst, Atlanta, GA 30309 USA	Flowers, L (corresponding author), Shepherd Ctr, Crawford Res Inst, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.	Laura_Flowers@shepherd.org					Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Deshpande AA, 1997, ARCH PHYS MED REHAB, V78, P350, DOI 10.1016/S0003-9993(97)90224-0; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; HAGEN C, 1972, LOS AMIGOS SCALE FUN; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Mayer NH, 2003, ARCH PHYS MED REHAB, V84, P242, DOI 10.1053/apmr.2003.50101; McCullagh P., 1989, GEN LINEAR MODELS; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Stineman MG, 1998, ARCH PHYS MED REHAB, V79, P241, DOI 10.1016/S0003-9993(98)90001-6; *TRAUM BRAIN INJ M, 2006, TRAUM BRAIN INJ FACT, V12; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; 2000, FED REG, V65, P66410	16	21	21	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2006	87	12					1590	1596		10.1016/j.apmr.2006.09.001			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	114OH	WOS:000242675000006	17141638				2021-06-18	
J	Monroe, RK; Halvorsen, SW				Monroe, Richard K.; Halvorsen, Stanley W.			Mercury abolishes neurotrophic factor-stimulated Jak-STAT signaling in nerve cells by oxidative stress	TOXICOLOGICAL SCIENCES			English	Article						ciliary neurotrophic factor; gp130; tyrosine kinase; cytokine; interferon-gamma; transition metals; signal transduction; neurotoxicity	NEUROBLASTOMA-CELLS; MOTOR-NEURONS; CILIARY; ACTIVATION; CHLORIDE; SURVIVAL; BRAIN; RAT; PROTEINS; RECEPTOR	Mercury is a potent neurotoxin that can delay neurological development in neonates, and has been proposed to be an environmental risk factor for several neurodegenerative conditions. The mechanisms by which environmental factors may influence the propagation of neurodegenerative diseases are not yet well delineated. However, it is known that neurons require trophic factor support for maintenance and survival following traumatic physical and toxic insults. We found that divalent mercury (HgCl2) inhibited ciliary neurotrophic factor and interferon-gamma receptor-mediated Janus tyrosine kinase (Jak)/signal transducers and activators of transcription (STAT) pathway activation in SK-N-BE(2)-C neuroblastoma cell cultures, but did not inhibit the fibroblast growth factor receptor tyrosine kinase. Results of dichlorofluorescein experiments showed increased levels of oxidative stress in HgCl2-treated cells that was similar in magnitude to that caused by treatment with H2O2. The antioxidant agents glutathione, N-acetylcysteine, and sodium ascorbate each protected neurons against HgCl2-induced inhibition of STAT activation. HgCl2 also inhibited Jak-STAT signaling in cultures of chick retina neurons, but did not affect signaling in nonneuronal HepG2 cells and chick skeletal myotubes. The specific inhibition of growth factor-mediated Jak-STAT signaling pathways in neurons by HgCl2-induced oxidative stress offers a new mechanism by which mercury may produce neurotoxic symptoms in the developing nervous system, promote neurodegeneration in mature neurons, and inhibit recovery following neurotrauma.	SUNY Buffalo, Program Neurosci, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Pharmacol & Toxicol, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	Halvorsen, SW (corresponding author), SUNY Buffalo, Program Neurosci, Buffalo, NY 14214 USA.	stanh@buffalo.edu		Halvorsen, Stanley/0000-0002-2430-4610			Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; Arciello M, 2005, BIOCHEM BIOPH RES CO, V327, P454, DOI 10.1016/j.bbrc.2004.12.022; BARTOLOME J, 1984, TOXICOL LETT, V22, P101, DOI 10.1016/0378-4274(84)90052-3; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; BIEDLER JL, 1978, CANCER RES, V38, P3751; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Brawer JR, 1998, NEUROTOXICOLOGY, V19, P767; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Chen F, 2002, CRIT REV ONCOL HEMAT, V42, P105, DOI 10.1016/S1040-8428(01)00211-6; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Crump KS, 1998, RISK ANAL, V18, P701, DOI 10.1023/B:RIAN.0000005917.52151.e6; Daniels WMU, 2004, METAB BRAIN DIS, V19, P79, DOI 10.1023/B:MEBR.0000027419.79032.bd; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Droge W, 2002, PHYSIOL REV, V82, P47; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; El-Demerdash FM, 2001, J ENVIRON SCI HEAL B, V36, P489, DOI 10.1081/PFC-100104191; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finn TP, 1998, J NEUROBIOL, V34, P283, DOI 10.1002/(SICI)1097-4695(19980215)34:3<283::AID-NEU7>3.0.CO;2-Z; Grandjean P, 2003, AMBUL PEDIATR, V3, P18, DOI 10.1367/1539-4409(2003)003<0018:NRCBSA>2.0.CO;2; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hussain S, 1997, J ENVIRON SCI HEAL B, V32, P395, DOI 10.1080/03601239709373094; IP NY, 1991, J NEUROSCI, V11, P3124; Jiao JW, 2003, MOL BRAIN RES, V116, P135, DOI 10.1016/S0169-328X(03)00286-9; Kaur N, 2005, J NEUROCHEM, V92, P1521, DOI 10.1111/j.1471-4159.2004.02990.x; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Konigsberg M, 2001, J APPL TOXICOL, V21, P323; Koshlukova S, 1996, NEUROSCIENCE, V72, P821, DOI 10.1016/0306-4522(95)00560-9; Krantz A, 2004, DM-DIS MON, V50, P220, DOI 10.1016/j.disamonth.2004.04.001; Krejsa CM, 1998, ENVIRON HEALTH PERSP, V106, P1179, DOI 10.2307/3433983; Kumagai Y, 1997, BRAIN RES, V769, P178, DOI 10.1016/S0006-8993(97)00846-9; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Leonard SS, 2004, FREE RADICAL BIO MED, V37, P1921, DOI 10.1016/j.freeradbiomed.2004.09.010; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lotz B, 1996, NEUROLOGY, V46, P1244; Maher P, 2000, CELL MOL LIFE SCI, V57, P1287, DOI 10.1007/PL00000766; Malek RL, 1997, J NEUROBIOL, V32, P81, DOI 10.1002/(SICI)1097-4695(199701)32:1<81::AID-NEU8>3.3.CO;2-U; MANTHORPE M, 1985, FED PROC, V44, P2753; Monroe RK, 2006, FREE RADICAL BIO MED, V41, P493, DOI 10.1016/j.freeradbiomed.2006.04.023; Ninomiya T, 1995, ENVIRON RES, V70, P47, DOI 10.1006/enrs.1995.1045; OYAMA Y, 1994, BRAIN RES, V635, P113, DOI 10.1016/0006-8993(94)91429-X; Pamphlett R, 1998, J NEUROL SCI, V159, P121, DOI 10.1016/S0022-510X(98)00161-0; Patrick Lyn, 2002, Altern Med Rev, V7, P456; PHILBERT MA, 1991, TOXICOL APPL PHARM, V107, P215, DOI 10.1016/0041-008X(91)90204-R; Pourahmad J, 2001, FREE RADICAL BIO MED, V30, P89, DOI 10.1016/S0891-5849(00)00450-0; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Wang X, 1998, NEUROSCI LETT, V240, P9, DOI 10.1016/S0304-3940(97)00927-0; Wishingrad MA, 1997, J BIOL CHEM, V272, P19752, DOI 10.1074/jbc.272.32.19752; Yamaoka K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-253	57	21	23	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080	1096-0929		TOXICOL SCI	Toxicol. Sci.	NOV	2006	94	1					129	138		10.1093/toxsci/kfl073			10	Toxicology	Toxicology	092KL	WOS:000241095300013	16896058	Bronze			2021-06-18	
J	Schonberger, M; Humle, F; Zeeman, P; Teasdale, TW				Schoenberger, Michael; Humle, Frank; Zeeman, Peter; Teasdale, Thomas W.			Patient compliance in brain injury rehabilitation in relation to awareness and cognitive and physical improvement	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SUBJECTIVE EXPERIENCE; CLOSE RELATIVES; INTERVENTION; EXERCISE; STROKE	The purpose of the present study was to investigate the relationship between patients' compliance and awareness and outcome of brain injury rehabilitation. Subjects were 98 patients who underwent a holistic neuropsychological outpatient rehabilitation programme. Patients had suffered a traumatic brain injury (n = 26), a cerebrovascular accident (n = 58), or another neurological insult (n = 14). Measures: Two staff members, a neuropsychologist and a physiotherapist, retrospectively and separately rated patients' awareness and their compliance. Outcome was measured with the d2 test of concentration, measures of oxygen uptake, strength endurance, running speed, and patients' and relatives' ratings of patients' cognitive, physical, and overall problems on the European Brain Injury Questionnaire (EBIQ). The discrepancy between patients' and relatives' ratings on the EBIQ was incorporated as a second measure of patients' awareness. Results: The neuropsychologist's compliance ratings were significantly related to measures of insight, improvement of d2 performance accuracy and stability, improvement of oxygen uptake, and reduction of cognitive and overall problems as reported by the patients, while the physiotherapist's compliance ratings were related to measures of insight, improvement of d2 performance speed, improvement of oxygen uptake and strength endurance, and all three EBIQ patient scales. Discussion: The results suggest a differential relationship between situation-specific compliance and outcome.	Univ Copenhagen, Ctr Rehabil Brain Injury, DK-2300 Copenhagen S, Denmark	Schonberger, M (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	michael@cfh.ku.dk					Astrand P.O., 1986, TXB WORK PHYSL; Brickenkamp R., 1981, AUFMERKSAMKEITS BELA; CAETANO C, 2000, INT HDB NEUROPSYCHOL, P259; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FLEMING J, 1995, BRIT J OCCUPATIONAL, V98, P55; Hesse S, 2001, ARCH PHYS MED REHAB, V82, P1547, DOI 10.1053/apmr.2001.26607; Katz Noomi, 2002, Can J Occup Ther, V69, P281; Kime SK, 1996, BRAIN INJURY, V10, P17; Kramer AF, 2003, J MOL NEUROSCI, V20, P213, DOI 10.1385/JMN:20:3:213; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; Meichenbaum D., 1987, FACILITATING TREATME; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pepping M, 2003, NEURO S B C, P313; PETERMANN F, 1998, COMPLIANCE SELBSTMAN, P73; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; RASMUSSEN G, 1995, PHYSIOTHERAPY STROKE, P295; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; SCHONBERGER M, 2004, UNAWARENESS; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SOHLBERG MM, 2001, COGNITIVE REHABILIAT; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Sturm W, 2004, NEUROPSYCHOLOGIA, V42, P434, DOI 10.1016/j.neuropsychologia.2003.09.001; STURM W, 1993, DEV ASSESSMENT REHAB, P49; STURM W, 1999, APPL NEUROPSYCHOLOGY; Sturm W., 1994, Z NEUROPSYCHOLOGIE, V5, P15; Stuss D. T., 1999, COGNITIVE NEUROREHAB, P188; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; VOLMER T, 1998, COMPLIANCE SELBSTMAN, P45; Wannamethee SG, 1999, J CARDIOVASC RISK, V6, P213	34	21	21	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT	2006	16	5					561	578		10.1080/09602010500263084			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	096FI	WOS:000241362600003	16952893				2021-06-18	
J	Coronel, MF; Musolino, PL; Villar, MJ				Coronel, Maria Florencia; Musolino, Patricia Leonor; Villar, Marcelo Jose			Selective migration and engraftment of bone marrow mesenchymal stem cells in rat lumbar dorsal root ganglia after sciatic nerve constriction	NEUROSCIENCE LETTERS			English	Article						stem cell trafficking; primary afferent neurons; peripheral nerve lesion; peripheral neuropathies	STROMAL CELLS; SPINAL-CORD; ADHESION MOLECULE; SCHWANN-CELLS; DRG NEURONS; EXPRESSION; TRANSPLANTATION; DIFFERENTIATION; REGENERATION; RECEPTOR	Bone marrow mesenchymal stem cells (MSCs) preferentially migrate to the injured hemisphere when administered intravenously to rats with traumatic or ischemic brain injuries. In this study, we have investigated the localization of MSCs injected into the lumbar-4 dorsal root ganglion (L4-DRG) of rats with a sciatic nerve single ligature nerve constriction (SLNC). NISCs were isolated by their adherence to plastic, cultured until confluence and labelled with Hoechst. Animals with a unilateral injection of MSCs were subjected to an ipsilateral, bilateral or contralateral SLNC. After 9 days, they were perfused and the lumbar DRGs were dissected out, cut in a cryostat and observed with a fluorescence microscope. Large numbers of Hoechst-positive cells were observed in the injected L4-DRG, distributed around primary afferent neurons, resembling the anatomical localization of glial cells. In animals with an ipsilateral SLNC, some cells were detected in the ipsilateral L3, L5 or L6-DRGs but not in the contralateral ganglia. In animals with a bilateral lesion, NISCs migrated to both the ipsilateral and contralateral DRGs whereas in animals with a contralateral ligature, MSCs migrated to the contralateral DRGs. These results suggest that NISCs preferentially engraft in DRGs hosting primary sensory neurons affected by a lesion of their peripheral branches. Further studies should be carried out in order to elucidate the molecular mechanisms involved in this migration and homing, in order to evaluate the possible use of NISCs as a new therapeutic strategy for the treatment of peripheral nerve neuropathies. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Austral Univ, Sch Biomed Sci, RA-1629 Buenos Aires, DF, Argentina	Villar, MJ (corresponding author), Austral Univ, Sch Biomed Sci, Av Pte Peron 1500, RA-1629 Buenos Aires, DF, Argentina.	mvillar@cas.austral.edu.ar		Musolino, Patricia L./0000-0001-8724-5649			Abouelfetouh A, 2004, BRAIN RES, V1029, P114, DOI 10.1016/j.brainres.2004.07.092; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Brumovsky PR, 2004, BRAIN RES, V1006, P87, DOI 10.1016/j.brainres.2003.09.085; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.3.CO;2-3; Corti S, 2002, J NEUROSCI RES, V70, P721, DOI 10.1002/jnr.10455; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Gleichmann M, 2000, EUR J NEUROSCI, V12, P1857, DOI 10.1046/j.1460-9568.2000.00048.x; Hiroi S, 2003, FEBS LETT, V554, P311, DOI 10.1016/S0014-5793(03)01176-1; Itoh K, 1997, J NEUROBIOL, V33, P735, DOI 10.1002/(SICI)1097-4695(19971120)33:6<735::AID-NEU3>3.0.CO;2-A; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Liu Li-Hui, 2005, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V13, P417; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Mimura T, 2004, J NEUROSURG, V101, P806, DOI 10.3171/jns.2004.101.5.0806; Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X; OWEN M, 1988, CIBA F SYMP, V136, P42; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067; Soares S, 2005, EUR J NEUROSCI, V21, P1169, DOI 10.1111/j.1460-9568.2005.03961.x; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Wang Lei, 2002, Hematology, V7, P113; ZAMBONI L, 1967, J CELL BIOL, V35, pA148; Zhang PX, 2004, ARTIF CELL BLOOD SUB, V32, P509, DOI 10.1081/BIO-200039608	28	21	22	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 11	2006	405	1-2					5	9		10.1016/j.neulet.2006.06.018			5	Neurosciences	Neurosciences & Neurology	079IO	WOS:000240169500002	16806704				2021-06-18	
J	Farchi, S; Rossi, PG; Chini, F; Camilloni, L; Di Giorgio, M; Guasticchi, G; Borgia, P				Farchi, Sara; Rossi, Paolo Giorgi; Chini, Francesco; Camilloni, Laura; Di Giorgio, Maurizio; Guasticchi, Gabriella; Borgia, Piero			Unintentional home injuries reported by an emergency-based surveillance system: Incidence, hospitalisation rate and mortality	ACCIDENT ANALYSIS AND PREVENTION			English	Article						unintentional home injury; record linkage; surveillance; emergency department	TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVAL; US CHILDREN; RESIDENTIAL INJURIES; DEATH CERTIFICATES; NONFATAL INJURIES; UNITED-STATES; RISK-FACTORS; FALLS; EPIDEMIOLOGY	Objective: The aim of this study is to quantify the incidence of home injuries using an integrated surveillance system. It aims to estimate home accident mortality. Material and methods: The sources of data for this epidemiological descriptive study were the emergency information system, the hospital information system and the mortality registry of Lazio Region, 2000-2001. We selected all emergency department (ED) visits for unintentional traumas that occurred at home. We calculated incidence of ED visits, hospitalisation and mortality rates by sex and age. Results: In the year 2000, 145 101 persons visited the ED (2700/100 000), 8.1% of whom were then admitted to the hospital. Incidence was higher among children and older people. We observed 620 fatalities, a rate of 0.43%. The mortality registry reported 1042 deceased, a home accident-related mortality rate of 31.1/100 000. Conclusions: Unintentional injuries in the home are a relevant public health problem. Since none of the databases used in the study give a complete measure of the burden of home injuries, we combined the data from all of them to estimate the mortality and the burden of home injuries. Interventions for prevention must identify the specific accidents/injuries they are trying to reduce in order to focus their intervention on the appropriate population. (c) 2006 Elsevier Ltd. All rights reserved.	Publ Hlth Agcy Lazio Reg, I-00198 Rome, Italy	Farchi, S (corresponding author), Publ Hlth Agcy Lazio Reg, Via Santa Constanza, I-00198 Rome, Italy.	farchi@asplazio.it; giorgirossi@asplazio.it; chini@asplazio.it; camilloni@asplazio.it; digiorgio@asplazio.it; guasticchi@asplazio.it; borgia@asplazio.it	Rossi, Paolo Giorgi/K-6367-2016	Rossi, Paolo Giorgi/0000-0001-9703-2460			Ancona C, 2000, J EPIDEMIOL COMMUN H, V54, P930, DOI 10.1136/jech.54.12.930; Arkovitz MS, 1997, J TRAUMA, V42, P49, DOI 10.1097/00005373-199701000-00009; BALLARD JE, 1992, AM J EPIDEMIOL, V135, P26, DOI 10.1093/oxfordjournals.aje.a116198; Ballesteros MF, 2003, INJURY PREV, V9, P173, DOI 10.1136/ip.9.2.173; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bath PA, 1999, EUR J EPIDEMIOL, V15, P65, DOI 10.1023/A:1007531101765; Bienefeld M, 1996, Chronic Dis Can, V17, P21; BRENNAN J, 2003, OSTEOPOROS INT  0430; Cameron CM, 2005, J TRAUMA, V59, P639, DOI 10.1097/01.ta.0000183222.79685.23; D'Amico M, 1999, EUR J EPIDEMIOL, V15, P141, DOI 10.1023/A:1007570405888; Dedoukou X, 2004, ARCH PEDIAT ADOL MED, V158, P1002, DOI 10.1001/archpedi.158.10.1002; Dewar DJ, 2004, J BURN CARE REHABIL, V25, P224, DOI 10.1097/01.BCR.0000124821.22553.24; Geusens Piet, 2003, J Br Menopause Soc, V9, P101, DOI 10.1258/136218003100322314; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Gulliver P, 2005, AUST NZ J PUBL HEAL, V29, P29, DOI 10.1111/j.1467-842X.2005.tb00744.x; *HOM SAF COUNC, 2002, STAT HOM SAF AM FACT; Johansson LA, 2002, J EPIDEMIOL COMMUN H, V56, P301, DOI 10.1136/jech.56.4.301; Kopjar B, 1996, AM J EPIDEMIOL, V144, P456; Kron M, 2003, AM J EPIDEMIOL, V158, P645, DOI 10.1093/aje/kwg203; Lundebjerg N, 2001, J AM GERIATR SOC, V49, P664, DOI 10.1046/j.1532-5415.2001.49115.x; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; McGwin G, 2000, J TRAUMA, V49, P470, DOI 10.1097/00005373-200009000-00014; Migliaccio J, 2004, GENERATIONS, V28, P20; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; Morrongiello BA, 2004, INJURY PREV, V10, P62, DOI 10.1136/ip.2003.003624; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; Nagaraja J, 2005, PEDIATRICS, V116, P454, DOI 10.1542/peds.2004-1415; Olson CJ, 2003, J TRAUMA, V55, P45, DOI 10.1097/01.TA.0000071291.17287.57; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Phelan KJ, 2005, PUBLIC HEALTH REP, V120, P63, DOI 10.1177/003335490512000111; Posner JC, 2004, PEDIATRICS, V113, P1603, DOI 10.1542/peds.113.6.1603; Powell EC, 2002, PEDIATRICS, V110, P792, DOI 10.1542/peds.110.4.792; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Rogmans W, 2000, Sante Publique, V12, P283; Rossi PG, 2005, ANN EMERG MED, V46, P152, DOI 10.1016/j.annemergmed.2005.01.033; Rossi RG, 2004, INT J TUBERC LUNG D, V8, P528; Runyan CW, 2005, AM J PREV MED, V28, P80, DOI 10.1016/j.amepre.2004.09.017; Runyan CW, 2005, AM J PREV MED, V28, P73, DOI 10.1016/j.amepre.2004.09.010; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Saluja Gitanjali, 2004, Inj Control Saf Promot, V11, P17, DOI 10.1076/icsp.11.1.17.26310; Shinoda-Tagawa T, 2003, INJURY PREV, V9, P214, DOI 10.1136/ip.9.3.214; Stalenhoef PA, 2002, J CLIN EPIDEMIOL, V55, P1088, DOI 10.1016/S0895-4356(02)00502-4; Uitenbroek DG, 1996, RES Q EXERCISE SPORT, V67, P380, DOI 10.1080/02701367.1996.10607969; Villalba-Cota J, 2004, ANN TROP PAEDIATR, V24, P53, DOI 10.1179/027249304225013259; Weiss Steven J, 2003, Prehosp Emerg Care, V7, P79, DOI 10.1080/10903120390937148; Zuckerbraun NS, 2004, PEDIATR EMERG CARE, V20, P361, DOI 10.1097/01.pec.0000133609.04581.9f	46	21	21	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	SEP	2006	38	5					843	853		10.1016/j.aap.2006.02.009			11	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	070NA	WOS:000239528200003	16574047				2021-06-18	
J	Figaji, AA; Fieggen, AG; Argent, A; Peter, JC				Figaji, A. A.; Fieggen, A. G.; Argent, A.; Peter, J. C.			Surgical treatment for 'brain compartment syndrome' in children with severe head injury	SAMJ SOUTH AFRICAN MEDICAL JOURNAL			English	Article							BIFRONTAL DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL HYPERTENSION; CEREBRAL EDEMA; PRESSURE; CRANIOTOMY; MANAGEMENT; MANNITOL; FAILURE	Objectives. Traumatic brain injury accounts for a high percentage of deaths in children. Raised intracrainal pressure (ICP) due to brain swelling within the closed compartment of the skull leads to death or severe neurological disability if not effectively treated. We report our experience with 12 children who presented with cerebral herniation due to traumatic brain swelling in whom decompressive craniectomy was used as an emergency. Design. Prospective, observational. Setting. Red Cross Children's Hospital. Subjects. Children with severe traumatic brain injury and cerebral swelling. Outcome measures. Computed tomography (CT) scanning, ICP control, clinical outcome. Results. Despite the very poor clinical condition of these children preoperatively, aggressive management of the raised pressure resulted in unexpectedly good outcomes. Conclusion. Aggressive surgical measures to decrease ICP in the emergency situation can be of considerable benefit; the key concepts are selection of appropriate patients and early intervention.	Univ Cape Town, Sch Child & Adolescent Hlth, Div Paediat Neurosurg, ZA-7700 Rondebosch, South Africa; Univ Cape Town, Sch Child & Adolescent Hlth, Div Paediat Crit Care, ZA-7700 Rondebosch, South Africa; Red Cross War Mem Childrens Hosp, Rondebosch, South Africa	Figaji, AA (corresponding author), Univ Cape Town, Sch Child & Adolescent Hlth, Div Paediat Neurosurg, ZA-7700 Rondebosch, South Africa.	afigaji@ich.uct.ac.za	Argent, Andrew/J-1605-2019	Argent, Andrew/0000-0001-9333-2036; Figaji, Anthony/0000-0002-3357-6490; Fieggen, Graham/0000-0001-6541-8377			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; BRADSHAW D, 2003, 3 MRC; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Gondim FDA, 2005, J NEUROSURG, V103, P444; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; HATASHITA S, 1985, STROKE, V16, P661, DOI 10.1161/01.STR.16.4.661; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Marshall LF, 2006, NEUROSURGERY, V59, P289; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; RINALDI A, 1990, ACT NEUR S, V51, P394; ROBERTS I, 2000, COCHRANE DB SYST REV, V2; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHAPIRO K, 1985, J NEUROSURG, V63, P76, DOI 10.3171/jns.1985.63.1.0076; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	33	21	22	0	2	SA MEDICAL ASSOC	PRETORIA	BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3, PRETORIA, 0002, SOUTH AFRICA	0256-9574	2078-5135		SAMJ S AFR MED J	SAMJ S. Afr. Med. J.	SEP	2006	96	9	2				969	975					7	Medicine, General & Internal	General & Internal Medicine	092OX	WOS:000241108300025	17077927	DOAJ Gold			2021-06-18	
J	Witgen, BM; Lifshitz, J; Grady, MS				Witgen, Brent M.; Lifshitz, Jonathan; Grady, M. Sean			Inbred mouse strains as a tool to analyze hippocampal neuronal loss after brain injury: A stereological study	JOURNAL OF NEUROTRAUMA			English	Article						head injury; hippocampus; optical disector; optical fractionator; stereology; traumatic brain injury	ENRICHED-ENVIRONMENT; OPTICAL FRACTIONATOR; DENTATE GYRUS; HEAD-INJURY; CELL LOSS; NUMBER; RAT; MODEL; DEATH; MICE	Traumatic brain injury (TBI) damages the hippocampus both in experimental animal models and in humans. In particular, the mechanical injury in combination with the genetic susceptibility to injury may result in neuronal loss from the hippocampus. This report explores the time-course of neuronal loss in the four primary subregions of the mouse hippocampus after a lateral fluid percussion injury (FPI) to the brain, and how subtle genetic differences between C57BL/6J and C57BL/10J mouse strains influence the extent and time course of neuronal loss. Using design-based stereological procedures, our results indicate negligible neuronal loss ipsilateral to the injury at 2 days postinjury in C57BL/6J mice, whereas a significant number (30-40%) of neurons are lost across all subregions of the hippocampus (dentate, hilus, area CA3, and area CA1) by 1 week, which does not appear to progress at I month, compared to sham. Additionally, neuronal counts after lateral FPI in a genetically similar, yet kainic acid-sensitive, mouse strain (C57BL/10J) showed no statistically significant differences in neuron number compared to the C57BL/6J strain in response to brain injury. Hippocampal neuronal loss after lateral FPI and its consequent circuit disruption may depend more on factors related to the mechanics and secondary consequences of the injury, as opposed to subtle genetic variations between inbred mouse strains. The loss of neurons appears to be restricted to the first week post-injury, and the remaining neurons may serve as a substrate for recovery.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Grady, MS (corresponding author), 3 Silverstein Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	Sean.Grady@uphs.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD-049343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS-043126, R01 NS-05098] Funding Source: Medline		Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Calhoun ME, 1998, NEUROBIOL AGING, V19, P599, DOI 10.1016/S0197-4580(98)00098-0; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Dorph-Petersen KA, 2001, J MICROSC-OXFORD, V204, P232, DOI 10.1046/j.1365-2818.2001.00958.x; FERRARO TN, 1995, EPILEPSIA, V36, P301, DOI 10.1111/j.1528-1157.1995.tb00999.x; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Gobbo OL, 2004, BEHAV BRAIN RES, V152, P231, DOI 10.1016/j.bbr.2003.10.017; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hartman RE, 2002, J NEUROSCI, V22, P10083; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McKhann GM, 2003, NEUROSCIENCE, V122, P551, DOI 10.1016/S0306-4522(03)00562-1; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Shuttleworth CW, 2003, J NEUROSCI, V23, P3196; Shuttleworth CWR, 2001, J NEUROSCI, V21, P4225, DOI 10.1523/JNEUROSCI.21-12-04225.2001; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	41	21	21	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1320	1329		10.1089/neu.2006.23.1320			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900004	16958584				2021-06-18	
J	Rush, BK; Malec, JF; Brown, AW; Moessner, AM				Rush, Beth K.; Malec, James F.; Brown, Allen W.; Moessner, Anne M.			Personality and functional outcome following traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; personality; outcome	SELF-AWARENESS; HEAD-INJURY; PREDICTION; SEVERITY; TRAITS; IMPACT	Obiective: To investigate pre- to postinjury personality change in relation to outcomes following traumatic brain injury (TBI). Design: Prospective analysis of personality ratings, depression, and outcome using multiple regression analyses. Participants: Cohort of 3 clinical trauma groups (mild TBI, moderate-severe TBI, orthopedic injury) and their significant others (SO). Outcome Measures: Independent Living Scale, Vocational Independence Scale, and Mayo-Portland Adaptability Inventory, 1-2 years postinjury. Predictor Variables: Posttraumatic amnesia (PTA); patient and SO NEO Personality Inventory-Revised ratings of preinjury personality taken at 1-2 months postinjury. Results: Personality function was normal for all groups (regardless of rating source) and stable over time. Neuroticism, and specifically depression, accounted for small proportions of variance in functional outcome, beyond PTA. Conclusions: There is little empirical evidence for significant personality disturbance or change up to 2 years post-TBI. Personality and depression contribute modestly to functional outcomes. Results support a distinction between "personality change" and behavior change following TBI.	Mayo Clin, Dept Psychiat & Psychol, Coll Med, Jacksonville, FL 32224 USA; Mayo Clin, Dept Psychiat Med & Rehabil, Coll Med, Jacksonville, FL 32224 USA; Mayo Clin, Dept Nursing, Coll Med, Jacksonville, FL 32224 USA; Mayo Clin, Coll Med, Dept Psychiat & Psychol, Jacksonville, FL 32224 USA	Rush, BK (corresponding author), Mayo Clin, Dept Psychiat & Psychol, Coll Med, 4500 San Pablo Rd,Minnesota Campus, Jacksonville, FL 32224 USA.	rush.beth@mayo.edu		Brown, Allen W./0000-0001-7228-3351			Bond T.G., 2001, APPL RASCH MODEL FUN; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; COSTA JPT, 1992, PROFESSIONAL MANUAL; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Golden Z, 2003, INT J NEUROSCI, V113, P733, DOI 10.1080/00207450390200044; GOLDSTEIN FC, 1989, INTEGRATING THEORY P, P217; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JOHNSON O, 1991, POLYCYCL AROMAT COMP, V2, P155; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MALEC JF, 2003, ANN M INT BRAIN INJ; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P854; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; MERBITZ C, 1989, ARCH PHYS MED REHAB, V70, P308; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rush BK, 2004, REHABIL PSYCHOL, V49, P275, DOI 10.1037/0090-5550.49.4.275; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Tate RL, 2003, NEUROPSYCHOL REHABIL, V13, P43, DOI 10.1080/09602010244000372	26	21	21	0	5	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2006	51	3					257	264		10.1037/0090-5550.51.3.257			8	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	072OK	WOS:000239682500009					2021-06-18	
J	Troen, AM; Shukitt-Hale, B; Chao, WH; Albuquerque, B; Smith, DE; Selhub, J; Rosenberg, IH				Troen, Aron M.; Shukitt-Hale, Barbara; Chao, Wei-Hsun; Albuquerque, Bina; Smith, Donald E.; Selhub, Jacob; Rosenberg, Irwin H.			The cognitive impact of nutritional homocysteinemia in Apolipoprotein-E deficient mice	JOURNAL OF ALZHEIMERS DISEASE			English	Article						ApoE; folate; homocysteine; methionine; nutrition; behavior; cognition; model; dementia; neurodegeneration	E KNOCKOUT MICE; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; MORRIS WATER MAZE; FOLATE-DEFICIENCY; MEMORY DEFICITS; INDUCED HYPERHOMOCYSTEINEMIA; CHOLINERGIC IMPAIRMENTS; PLASMA HOMOCYSTEINE	Homocysteinemia is associated with cognitive dysfunction in the elderly ranging from subtle cognitive decline to dementia. Homocysteine is generated from methionine as a product of biological methylation reactions and is disposed of through reactions that require folate and vitamins B12 and B6. While different disruptions in these reactions can result in homocysteinemia, it is unclear if they will also result in homocysteine-mediated cognitive dysfunction. Young ApoE-deficient mice were fed one of four diets with differing methionine and B-vitamin content for eight weeks, before undergoing psychomotor tests, the Morris Water Maze test of spatial memory and learning, and measurement of home-cage activity. B-vitamin deficiency induced homocysteinemia and selectively impaired Morris Water Maze performance without affecting other behavioral measures. The cognitive deficits occurred in the absence of overt histologic neurodegeneration but in association with moderate impairments of brain methylation potential. Diets that yielded cognitive deficits were different from those that exacerbated aortic pathology. These findings are inconsistent with a single mechanism linking homocysteinemia to neurological dysfunctions mediated by homocysteine vasotoxicity. Instead, they indicate that different "types" of homocysteinemia, or in other words different impairments of nutritional metabolism affecting homocysteine levels, may lead to different end organ dysfunctions and/or diseases.	Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Troen, AM (corresponding author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	aron.troen@tufts.edu		Chao, Wei-Hsun/0000-0003-3789-1276; Shukitt-Hale, Barbara/0000-0002-3810-1910			AKESSON B, 1982, BRIT J NUTR, V47, P505, DOI 10.1079/BJN19820063; Anderson R, 1998, NEUROSCIENCE, V85, P93, DOI 10.1016/S0306-4522(97)00598-8; Anderson R, 1997, PSYCHOPHARMACOLOGY, V132, P135, DOI 10.1007/s002130050329; Bottiglieri T, 1996, NUTR REV, V54, P382, DOI 10.1111/j.1753-4887.1996.tb03851.x; Buttini M, 1999, J NEUROSCI, V19, P4867; Casadesus G, 2001, MECH AGEING DEV, V122, P1887, DOI 10.1016/S0047-6374(01)00324-4; Champagne D, 2002, NEUROSCIENCE, V114, P641, DOI 10.1016/S0306-4522(02)00313-5; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Christie LA, 2005, NEUROSCI LETT, V373, P119, DOI 10.1016/j.neulet.2004.09.072; Crawley JN, 2003, COMPARATIVE MED, V53, P140; Dayal S, 2005, CIRCULATION, V112, P737, DOI 10.1161/CIRCULATIONAHA.104.529248; Duan W, 2002, J NEUROCHEM, V80, P101, DOI 10.1046/j.0022-3042.2001.00676.x; Dufouil C, 2003, ANN NEUROL, V53, P214, DOI 10.1002/ana.10440; Duthie SJ, 2002, AM J CLIN NUTR, V75, P908; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fisher A, 1998, J NEUROCHEM, V70, P1991; GALLAGHER M, 1993, BEHAV BRAIN RES, V57, P155, DOI 10.1016/0166-4328(93)90131-9; Garcia A, 2004, J GERONTOL A-BIOL, V59, P1323, DOI 10.1093/gerona/59.12.1323; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; Genis I, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P733; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Gordon I, 1996, MOL CHEM NEUROPATHOL, V28, P97, DOI 10.1007/BF02815210; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; GOSPE SM, 1995, PHYSL BEHAV, V58; GROOME N, 1988, J NEUROIMMUNOL, V19, P305, DOI 10.1016/0165-5728(88)90011-2; Halliday GM, 1996, NEUROSCI LETT, V209, P29, DOI 10.1016/0304-3940(96)12592-1; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Higuchi Y, 2002, J RADIAT RES, V43, pS219; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; INGRAM DK, 1994, PATHOBIOLOGY AGING R, V2, P149; JOSEPH JA, 1983, NEUROBIOL AGING, V4, P313, DOI 10.1016/0197-4580(83)90008-8; Kim JM, 2002, J NUTR, V132, P3418; KIM YI, 1994, J NUTR, V124, P2197; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Krzywkowski P, 1999, NEUROSCIENCE, V92, P1273, DOI 10.1016/S0306-4522(99)00061-5; Lee HY, 2004, BRAIN RES, V996, P139, DOI 10.1016/j.brainres.2003.10.027; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Lomnitski L, 1999, J NEUROSCI RES, V58, P586; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; McCaddon A, 2001, DEMENT GERIATR COGN, V12, P309, DOI 10.1159/000051275; Mihalick SM, 2003, NEUROMOL MED, V4, P197, DOI 10.1385/NMM:4:3:197; MILLER JW, 1992, AM J CLIN NUTR, V55, P1154; Montine TJ, 1999, EXP NEUROL, V158, P234, DOI 10.1006/exnr.1999.7067; Nagy Z, 1999, ACTA NEUROPATHOL, V97, P346, DOI 10.1007/s004010050997; Ogura T, 2005, NEUROSCI RES, V51, P299, DOI 10.1016/j.neures.2004.12.006; Oitzl MS, 1997, BRAIN RES, V752, P189, DOI 10.1016/S0006-8993(96)01448-5; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Puolivali J, 2000, NEUROSCIENCE, V96, P291, DOI 10.1016/S0306-4522(99)00545-X; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; REYNOLDS EH, 1976, CLIN HAEMATOL, V5, P661; Riggs KM, 1996, AM J CLIN NUTR, V63, P306; Robertson TA, 1998, NEUROSCIENCE, V82, P171; ROSENBERG IH, 1992, AM J CLIN NUTR, V55, P1237; Sachdev PS, 2003, DEMENT GERIATR COGN, V15, P155, DOI 10.1159/000068481; SAUBERLICH HE, 1991, MICRONUTRIENTS HLTH, P187; Schneede J, 2000, SEMIN THROMB HEMOST, V26, P263, DOI 10.1055/s-2000-8471; Scott TM, 2004, AM J GERIAT PSYCHIAT, V12, P631, DOI 10.1176/appi.ajgp.12.6.631; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Selhub J, 2000, AM J CLIN NUTR, V71, p614S; Shea TB, 2004, J ALZHEIMERS DIS, V6, P269; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Shukitt-Hale B, 1998, EXP GERONTOL, V33, P615, DOI 10.1016/S0531-5565(98)00024-2; Shukitt-Hale B, 2000, RADIAT RES, V154, P28, DOI 10.1667/0033-7587(2000)154[0028:SLAMDI]2.0.CO;2; Stabler SP, 2004, CLIN CHEM, V50, P365, DOI 10.1373/clinchem.2003.026252; Streck EL, 2004, BEHAV BRAIN RES, V153, P377, DOI 10.1016/j.bbr.2003.12.013; Streck EL, 2003, BBA-MOL BASIS DIS, V1637, P187, DOI 10.1016/S0925-4439(03)00019-X; TAANMAN JW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P95, DOI 10.1016/0925-4439(93)90128-N; Teunissen C E, 2003, J Nutr Health Aging, V7, P153; Troen AM, 2005, PROG NEURO-PSYCHOPH, V29, P1140, DOI 10.1016/j.pnpbp.2005.06.025; Troen AM, 2003, P NATL ACAD SCI USA, V100, P15089, DOI 10.1073/pnas.2436385100; Troen Aron, 2005, Semin Vasc Med, V5, P209, DOI 10.1055/s-2005-872406; Veinbergs I, 1999, NEUROSCIENCE, V91, P401, DOI 10.1016/S0306-4522(98)00602-2; Weir DG, 1999, BRIT MED BULL, V55, P669, DOI 10.1258/0007142991902547; WEIR DG, 1995, BAILLIERE CLIN HAEM, V8, P479, DOI 10.1016/S0950-3536(05)80217-3; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhou J, 2003, ATHEROSCLEROSIS, V168, P255, DOI 10.1016/S0021-9150(03)00138-2; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582; ZITTOUN J, 1995, BAILLIERE CLIN HAEM, V8, P603, DOI 10.1016/S0950-3536(05)80222-7	80	21	21	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.	AUG	2006	9	4					381	392					12	Neurosciences	Neurosciences & Neurology	097JZ	WOS:000241444800003	16917146				2021-06-18	
J	Snodgrass, C; Knott, F				Snodgrass, Clare; Knott, Fiona			Theory of mind in children with traumatic brain injury	BRAIN INJURY			English	Article						social cognition; theory of mind; paediatric traumatic brain injury; frontal lobes	CLOSED-HEAD-INJURY; STORY COMPREHENSION; ADOLESCENTS; CHILDHOOD; BEHAVIOR; EMOTION; DAMAGE; INHIBITION; IMPAIRMENT; ATTENTION	Objective: This study was designed to examine the existence of deficits in mentalizing or theory of mind (ToM) in children with traumatic brain injury (TBI). Research design: ToM functioning was assessed in 12 children aged 6-12 years with TBI and documented frontal lobe damage and compared to 12 controls matched for age, sex and verbal ability. Brief measures of attention and memory were also included. Main outcome and results: The TBI group was significantly impaired relative to controls on the advanced ToM measure and a measure of basic emotion recognition. No difference was found in a basic measure of ToM. Conclusion: Traumatic brain damage in childhood may disrupt the developmental acquisition of emotion recognition and advanced ToM skills. The clinical and theoretical importance of these findings is discussed and the implications for the assessment and treatment of children who have experienced TBI are outlined.	Old Sandy Rd Clin, Direct Access Serv, Glasgow G11 6HE, Lanark, Scotland; Univ Reading, Sch Psychol, Reading, Berks, England	Snodgrass, C (corresponding author), Old Sandy Rd Clin, Direct Access Serv, 12 Sandy Rd, Glasgow G11 6HE, Lanark, Scotland.	clare.snodgrass@glacomen.scot.nhs.uk		Knott, Fiona/0000-0002-5334-7206			Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Baron-Cohen S, 2001, J DEV LEARNING DISOR, V5, P47, DOI DOI 10.1111/J.1467-7687.2008.00720.X; Baron-Cohen S, 2000, UNDERSTANDING OTHER, V2, P3, DOI DOI 10.1093/ACPROF:OSO/9780199692972.001.0001; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Beaulieu CL, 2002, SURG CLIN N AM, V82, P393, DOI 10.1016/S0039-6109(02)00009-9; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Cronin AF, 2001, AM J OCCUP THER, V55, P377, DOI 10.5014/ajot.55.4.377; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Doody GA, 1998, PSYCHOL MED, V28, P397, DOI 10.1017/S003329179700648X; Dunn L.M., 1997, BRIT PICTURE VOCABUL; Ekman P., 1976, PICTURES FACIAL AFFE; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Fahie CM, 2003, J APPL DEV PSYCHOL, V24, P51, DOI 10.1016/S0193-3973(03)00024-8; Fine C, 2001, BRAIN, V124, P287, DOI 10.1093/brain/124.2.287; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Frith ChrisD., 2000, UNDERSTANDING OTHER, V2nd, P334; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Garth J, 1997, Pediatr Rehabil, V1, P99; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; HOBSON RP, 1986, J CHILD PSYCHOL PSYC, V27, P321, DOI 10.1111/j.1469-7610.1986.tb01836.x; Hughes C, 1998, J CHILD PSYCHOL PSYC, V39, P981, DOI 10.1017/S0021963098003059; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; JENNETT B, 1986, DIS NERV SYST, P1282; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Leppanen JM, 2001, SCAND J PSYCHOL, V42, P429, DOI 10.1111/1467-9450.00255; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1984, AGING RECOVERY FUNCT, P314; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Perner J., 2000, UNDERSTANDING OTHER, P150; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Russell TA, 2000, AM J PSYCHIAT, V157, P2040, DOI 10.1176/appi.ajp.157.12.2040; Siegal M, 1996, BRAIN LANG, V53, P40, DOI 10.1006/brln.1996.0035; Simonian SJ, 2001, CHILD PSYCHIAT HUM D, V32, P137, DOI 10.1023/A:1012298707253; SODIAN B, 1992, J CHILD PSYCHOL PSYC, V33, P591, DOI 10.1111/j.1469-7610.1992.tb00893.x; Stone V. E., 2000, UNDERSTANDING OTHER, P253; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2000, DEV NEUROPSYCHOL, V18, P273, DOI 10.1207/S1532694201Tranel; TUKSTRA LS, 1998, J HEAD TRAUMA REHAB, V16, P469; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; Waterhouse L., 1997, HDB AUTISM PERVASIVE, P901; Weschler D, 1992, WECHSLER INTELLIGENC; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson B. A., 1990, CLIN PSYCHOL FORUM, V30, P8; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	61	21	21	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					825	833		10.1080/02699050600832585			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300005	17060149				2021-06-18	
J	Urban, RJ				Urban, Randall J.			Hypopituitarism after acute brain injury	GROWTH HORMONE & IGF RESEARCH			English	Article; Proceedings Paper	19th Annual National Cooperative Growth Study/1st Annual National Cooperative Metabolic Study Investigator Meeting	NOV 03-05, 2005	San Francisco, CA			traumatic brain injury; anterior pituitary hormone deficiencies; screening	NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; PREVALENCE; SURVIVORS	Acute brain injury has many causes, but the most common is trauma. There are 1.5-2.0 million traumatic brain injuries (TBI) in the United States yearly, with an associated cost exceeding $10 billion. TBI is the most common cause of death and disability in young adults less than 35 years of age. The consequences of TBI can be severe, including disability in motor function, speech, cognition, and psychosocial and emotional skills. Recently, clinical studies have documented the occurrence of pituitary dysfunction after TBI and another cause of acute brain injury, subarachnoid hemorrhage (SAH). These studies have consistently demonstrated a 30-40% occurrence of pituitary dysfunction involving at least one anterior pituitary hormone following a moderate to severe TBI or SAH. Growth hormone (GH) deficiency is the most common pituitary hormone disorder, occurring in approximately 20% of patients when multiple tests of GH deficiency are used. Within 7-21 days of acute brain injury, adrenal insufficiency is the primary concern. Pituitary function can fluctuate over the first year after TBI, but it is well established by I year. Studies are ongoing to assess the effects of hormone replacement on motor function and cognition in TBI patients. Any subject with a moderate to severe acute brain injury should be screened for pituitary dysfunction. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	Urban, RJ (corresponding author), Univ Texas, Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.	rurban@utmb.edu					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; AIMARETTI G, 2005, J CLIN ENDOCRINOL ME; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Brazil K, 1992, Int J Rehabil Res, V15, P93, DOI 10.1097/00004356-199206000-00001; DANIEL PM, 1959, LANCET, V2, P927; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; RAY BS, 1969, J NEUROSURG, V30, P399, DOI 10.3171/jns.1969.30.4.0399; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; 1998, NIH CONSENSUS STATEM, V16, P1	22	21	27	0	4	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1096-6374	1532-2238		GROWTH HORM IGF RES	Growth Horm. IGF Res.	JUL	2006	16			A			S25	S29		10.1016/j.ghir.2006.03.017			5	Cell Biology; Endocrinology & Metabolism	Cell Biology; Endocrinology & Metabolism	074OG	WOS:000239821100006	16697673				2021-06-18	
J	Weiss, AH; Phillips, JO				Weiss, Avery H.; Phillips, James O.			Congenital and compensated vestibular dysfunction in childhood: An overlooked entity	JOURNAL OF CHILD NEUROLOGY			English	Article; Proceedings Paper	30th Annual Meeting of the American-Association-for-Pediatric-Ophthalmology-and-Strabismus	MAR 27-31, 2004	Washington, DC	Amer Assoc Pediat Ophthalmol & Strabismus			VESTIBULOOCULAR REFLEX; SQUIRREL-MONKEY; VISUAL-ACUITY; CHILDREN; INTEGRATION; PHYSIOLOGY; DISORDERS	We report five children with previously unrecognized vestibular dysfunction detected by clinical examination and confirmed by quantitative vestibular testing. Patient I presented with fluctuating visual acuity and intermittent nystagmus. Patient 2 had congenital hearing loss associated with imbalance, delayed motor development, and cyclic vomiting. Patient 3 had neurotrophic keratitis with an intermittent head tilt, imbalance, and motor delays. Patient 4 showed ataxia and eye movement abnormalities following traumatic brain injury and had reading difficulties. Patient 5 had episodic vertigo and eye movement abonormalities from infancy. Clinical vestibular testing emphasized spontaneous nystagmus, rapid head thrust, and assessment of post-rotatory nystagmus. Quantitative vestibular testing included the sinusoidal chair rotation and velocity step tests, measurement of dynamic visual acuity, post-head-shake nystagmus, and computerized platform posturography. Pediatric neurologists encounter children with congenital and compensated vestibular dysfunction, which can be recognized on the basis of relevant history and clinical abnormalities of the ocular-ocular reflex.	Childrens Hosp & Reg Med Ctr, Div Ophthalmol, Seattle, WA 98115 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Otolaryngol, Seattle, WA 98195 USA	Weiss, AH (corresponding author), Childrens Hosp & Reg Med Ctr, Div Ophthalmol, 4800 Sand Point Way NE,G0035, Seattle, WA 98115 USA.	avery.weiss@seattlechildrens.org					Ahmed ZM, 2003, CLIN GENET, V63, P431, DOI 10.1034/j.1399-0004.2003.00109.x; AVIATOR L, 1994, OTOLORYNGOL CLIN N A, V27, P557; Baloh RW, 2003, ARCH NEUROL-CHICAGO, V60, P835, DOI 10.1001/archneur.60.6.835; Baloh RW, 2003, NEW ENGL J MED, V348, P1027, DOI 10.1056/NEJMcp021154; Bodensteiner JB, 2003, J CHILD NEUROL, V18, P171, DOI 10.1177/08830738030180030701; BROOME J, 1991, ECON PHILOS, V7, P1, DOI 10.1017/S0266267100000882; CYR DG, 1980, ANN OTO RHINOL LARYN, V89, P63; Eviatar L, 1986, Pediatr Neurol, V2, P61, DOI 10.1016/0887-8994(86)90058-5; FERNANDEZ C, 1976, J NEUROPHYSIOL, V39, P996; Fife TD, 2000, NEUROLOGY, V55, P1431, DOI 10.1212/WNL.55.10.1431; FINOCCHIO DV, 1991, VISION RES, V31, P1717, DOI 10.1016/0042-6989(91)90022-W; FUKUSHIMA K, 1995, NEUROSCI RES, V22, P249, DOI 10.1016/0168-0102(95)00904-8; FUKUSHIMA K, 1992, PROG NEUROBIOL, V39, P609, DOI 10.1016/0301-0082(92)90016-8; Furman JM, 1999, NEW ENGL J MED, V341, P1590, DOI 10.1056/NEJM199911183412107; Galvez MJN, 2002, AM J OTOLARYNG, V23, P99, DOI 10.1053/ajot.2002.30635; GOLDBERG JM, 1971, J NEUROPHYSIOL, V34, P635; Hotson JR, 1998, NEW ENGL J MED, V339, P680, DOI 10.1056/NEJM199809033391007; HUYGEN PLM, 1993, INT J PEDIATR OTORHI, V25, P39, DOI 10.1016/0165-5876(93)90008-Q; Kaga K, 1999, INT J PEDIATR OTORHI, V49, P215, DOI 10.1016/S0165-5876(99)00206-2; Kumar A, 2002, OTOL NEUROTOL, V23, P727, DOI 10.1097/00129492-200209000-00021; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LEIGH RJ, 1991, NEUROLOGY EYE MOVEME; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; MCDONALD M, 1985, INVEST OPHTH VIS SCI, V26, P1158; Mencher G T, 2001, Am J Audiol, V10, P3; Mets M B, 2000, Trans Am Ophthalmol Soc, V98, P237; Mets MB, 2000, T AM OPHTHAL SOC, V98, P243; Parent A, 1996, CARPENTERS HUMAN NEU; Parving A, 1996, INT J PEDIATR OTORHI, V34, P9, DOI 10.1016/0165-5876(95)01227-3; PATTON HD, 1989, TXB PHYSL; Phillips JO, 2002, OTOLARYNG CLIN N AM, V35, P765, DOI 10.1016/S0030-6665(02)00062-2; RIACH CL, 1987, DEV MED CHILD NEUROL, V29, P650; ROBINSON DA, 1968, SCIENCE, V161, P1219, DOI 10.1126/science.161.3847.1219; Selz PA, 1996, OTOLARYNG HEAD NECK, V115, P70, DOI 10.1016/S0194-5998(96)70139-0; SHERMAN KR, 1986, INVEST OPHTH VIS SCI, V27, P1154; Tian JR, 2002, EXP BRAIN RES, V142, P486, DOI 10.1007/s00221-001-0959-7; TUSA RJ, 1994, J CHILD NEUROL, V9, P261, DOI 10.1177/088307389400900308; VARTIAINEN E, 1985, INT J PEDIATR OTORHI, V9, P135, DOI 10.1016/S0165-5876(85)80013-6; Vatovec J, 2001, SCAND AUDIOL, V30, P191, DOI 10.1080/010503901300007498; WAESPE W, 1985, SCIENCE, V228, P199, DOI 10.1126/science.3871968; WARD PH, 1969, ANN OTO RHINOL LARYN, V78, P227, DOI 10.1177/000348946907800203; WESTHEIMER G, 1975, J OPT SOC AM, V65, P847, DOI 10.1364/JOSA.65.000847	42	21	21	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	JUL	2006	21	7					572	579		10.1177/08830738060210071501			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	075SR	WOS:000239906000005	16970846				2021-06-18	
J	Sandford, AA; Davidson, TM; Herrera, N; Gilbert, P; Magit, AE; Haug, K; Gutglass, D; Murphy, C				Sandford, Amanda A.; Davidson, Terence M.; Herrera, Norma; Gilbert, Paul; Magit, Anthony E.; Haug, Kevin; Gutglass, David; Murphy, Claire			Olfactory dysfunction: A sequela of pediatric blunt head trauma	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						head injuries; closed; olfactory nerve diseases; smell disorder; smell; olfaction; evoked potentials	EVENT-RELATED POTENTIALS; OF-PENNSYLVANIA SMELL; BRAIN-INJURY; TASTE; IMPAIRMENT; ANOSMIA; ODOR; FMRI	Objective: To evaluate olfactory function in children with blunt head trauma. Methods: Eligible subjects were consecutive children presenting at San Diego Children's Hospital Emergency Department or Trauma Service with blunt head trauma. Thirty-seven head injured children mean age 10.11 +/- 2.74 were evaluated; 36 healthy age and gender matched community children, mean age 10.08 +/- 2.99, served as controls. The medical record was reviewed for clinical measures related to head injury (HI). All children underwent olfactory assessment with the San Diego Children's Odor Identification Test (SDOIT). Olfactory event-related potentials were recorded on a subset of head injured and control children. Results: Three of 37 head injured children had olfactory dysfunction. The head injured hyposmics had signs of more severe head injury represented by lower Glasgow Coma Scores (GCS), 10.33 +/- 5.51, when compared to their normosmic counterparts with mean GCS of 14.06 +/- 2.82. When stratifying the head injured children by clinical measures, lower Glasgow Coma Score, and abnormalities on head CT scan were associated with poorer olfactory performance. Conclusion: Children with blunt head injury may suffer post-traumatic olfactory impairment. More severe head injuries are more likely to produce olfactory deficits. In cases of significant head injury, cranial nerve I evaluation is imperative. (C) 2005 Elsevier Ireland Ltd. All rights reserved.	San Diego State Univ, Ctr Lifespan Human Senses, Dept Psychol, San Diego, CA 92120 USA	Murphy, C (corresponding author), San Diego State Univ, Ctr Lifespan Human Senses, Dept Psychol, 6363 ALvarado Court,Ste 101, San Diego, CA 92120 USA.	cmurphy@sciences.sdsu.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG004085, AG04085] Funding Source: Medline; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC02064] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG004085, R37AG004085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC002064] Funding Source: NIH RePORTER		Blomqvist EH, 2004, RHINOLOGY, V42, P189; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; COMETTOMUNIZ JE, 1991, PHARMACOL BIOCHEM BE, V39, P983, DOI 10.1016/0091-3057(91)90063-8; COSTANZO RM, 1987, ANN NY ACAD SCI, V510, P242; Costanzo RM, 1986, CLIN MEASUREMENTS TA, P565; Costanzo RM, 1991, SMELL TASTE HLTH DIS, P711; DAVIDSON TM, 1993, WESTERN J MED, V159, P71; DAVIDSON TM, 1987, WESTERN J MED, V146, P434; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; DINARDO LJ, 1997, TASTE SMELL DISORDER, P79; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; EKMAN G, 1967, SCAND J PSYCHOL, V8, P177, DOI 10.1111/j.1467-9450.1967.tb01392.x; Ferdon S, 2003, NEUROIMAGE, V20, P12, DOI 10.1016/S1053-8119(03)00276-3; Geisler MW, 1999, J CLIN NEUROPHYSIOL, V16, P77, DOI 10.1097/00004691-199901000-00008; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; HARRIS R, IN PRESS CLIN EVALUA; Jackson JH, 1864, LOND HOSP REP, V1, P470; JACOBI G, 1986, Acta Paediatrica Hungarica, V27, P173; Kalavrezos ND, 2000, J ROY COLL SURG EDIN, V45, P359; Kobal G, 2003, HDB OLFACTION GUSTAT, P229; Leigh AD, 1943, LANCET, V1, P38; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; Lorig TS, 1999, BEHAV RES METH INS C, V31, P370, DOI 10.3758/BF03207734; Mann NM, 2002, CLEV CLIN J MED, V69, P329, DOI 10.3949/ccjm.69.4.329; MENDELSOHN B, UNPUB OERP YOUNG CHI; Miwa T, 2001, ARCH OTOLARYNGOL, V127, P497, DOI 10.1001/archotol.127.5.497; Morgan CD, 1997, EVOKED POTENTIAL, V104, P351, DOI 10.1016/S0168-5597(97)00020-8; Murphy C, 2000, INT J PSYCHOPHYSIOL, V36, P133, DOI 10.1016/S0167-8760(99)00107-5; MURPHY C, 1994, CHEM SENSES, V19, P47, DOI 10.1093/chemse/19.1.47; Murphy C, 2002, JAMA-J AM MED ASSOC, V288, P2307, DOI 10.1001/jama.288.18.2307; MURPHY C, OLFACTION TASTE, V11, P609; National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention, 2000, TRAUM BRAIN INJ US A; Ogawa T, 1999, ACTA OTO-LARYNGOL, P50; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; Renzi G, 2002, ANN PLAS SURG, V48, P355, DOI 10.1097/00000637-200204000-00003; Roberts M A, 1996, Appl Neuropsychol, V3, P86, DOI 10.1207/s15324826an0302_7; RUTHERFORD WH, 1977, LANCET, V1, P1; Santos DV, 2004, ARCH OTOLARYNGOL, V130, P317, DOI 10.1001/archotol.130.3.317; Seiden AM, 2001, LARYNGOSCOPE, V111, P9, DOI 10.1097/00005537-200101000-00002; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; TEASDALE G, 1974, LANCET, V2, P81; TEMMEL A, 2002, ARCH OTOLARNGOL HEAD, V128; THESEN T, 2000, INT J PSYCHOPHYSIOL, P2; TORNER JC, 1999, TRAUMATIC BRAIN INJU, P9; Vigouroux M, 2005, J NEUROSCI METH, V142, P35, DOI 10.1016/j.jneumeth.2004.07.010; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	50	21	22	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	JUN	2006	70	6					1015	1025		10.1016/j.ijporl.2005.10.013			11	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	047FB	WOS:000237864100009	16360887				2021-06-18	
J	Tricco, AC; Colantonio, A; Chipman, M; Liss, G; McLellan, B				Tricco, Andrea C.; Colantonio, Angela; Chipman, Mary; Liss, Gary; McLellan, Barry			Work-related deaths and traumatic brain injury	BRAIN INJURY			English	Article						brain injury; mortality; accidents (occupational); coroners and medical examiners	MORTALITY; FATALITIES; OUTCOMES; CANADA; COUNTY	Background: Traumatic brain injury (TBI) at the workplace is a significant contributor to the number of work-related deaths that occur per year. This study aimed to quantify and characterize these deaths in Ontario. Methods: The study design was a case series with analytic and surveillance components. Data was obtained from the Chief Coroner's Office of Ontario from 1996 - 2000. Results: A total of 488 work-related injury fatalities were identified. Evidence of TBI was apparent in 45% of these cases (n = 211). Industries with the highest rate of work-related TBI mortality expressed per 100 000 working population included primary industry (59.1), agriculture (24.5), construction (20.0) and transportation/communications/utilities industries (13.9). Deaths involving TBI were more likely to be due to falls than non-TBI-related deaths among workers (p = 0.0001). Conclusions: Results from this research indicate that prevention programmes should focus on decreasing falls at all ages and increasing the use of personal protective equipment.	Univ Toronto, Toronto, ON, Canada; Toronto Rehabil Inst, Toronto, ON, Canada; Minist Labor, Toronto, ON, Canada; Off Chief Coroner Ontario, Toronto, ON, Canada	Colantonio, A (corresponding author), Saunderson Family Chair Acquired Brain Injury Res, Dept Occupat Sci & Occupat Therapy, 500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Tricco, Andrea/B-9920-2011	Tricco, Andrea/0000-0002-4114-8971; Colantonio, Angela/0000-0003-2094-4765			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Band PR, 1996, AM J EPIDEMIOL, V143, P137; Baron J, 1998, OCCUP MED-OXFORD, V48, P199, DOI 10.1093/occmed/48.3.199; *BUR LAB STAT, 1997, FAT WORKPL INJ 1995; *BUR STAT, 1980, STAND IND CLASS; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Davis GG, 2000, J FORENSIC SCI, V45, P392; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; *GEN ACC OFF, 1998, TRAUM BRAIN INJ PROG; Gordis L., 2000, EPIDEMIOLOGY; GUIDOTTI TL, 1993, AM J IND MED, V23, P921, DOI 10.1002/ajim.4700230608; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Janicak CA, 1998, J OCCUP ENVIRON MED, V40, P347, DOI 10.1097/00043764-199804000-00009; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; Lett Ronald, 2002, Inj Control Saf Promot, V9, P199, DOI 10.1076/icsp.9.3.199.8708; Lipscomb H J, 2000, Appl Occup Environ Hyg, V15, P569; MCDOUGAL L, 1992, AM J IND MED, V21, P595, DOI 10.1002/ajim.4700210415; MCVITTIE DJ, 1995, OCCUP MED, V10, P285; Pickett W, 1999, CAN MED ASSOC J, V160, P1843; Pickett W, 1995, Inj Prev, V1, P97, DOI 10.1136/ip.1.2.97; RIVARA FP, 2001, INJURY CONTROL GUIDE; *STAT CAN, 1996, LAB FORC SURV; *STAT CAN, 1993, STAND OCC CLASS; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; 1997, INT CLASSIFICATION D	25	21	23	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2006	20	7					719	724		10.1080/02699050600664640			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200006	16809204				2021-06-18	
J	O'Jile, JR; Ryan, LM; Betz, B; Parks-Levy, J; Hilsabeck, RC; Rhudy, JL; Gouvier, WD				O'Jile, Judith R.; Ryan, Laurie M.; Betz, Brian; Parks-Levy, Judith; Hilsabeck, Robin C.; Rhudy, Jamie L.; Gouvier, Wm. Drew			Information processing following mild head injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						MTBI; PASAT; brain	SERIAL ADDITION TEST; MULTIPLE-SCLEROSIS; POSTCONCUSSION SYMPTOMS; WORKING-MEMORY; DEFICITS; CONCUSSION; RECOVERY	Research has shown that individuals who have sustained mild head injury demonstrate a slowed speed of processing that is exacerbated by fatigue/stress. We administered the Paced Auditory Serial Addition Test (PASAT) at the beginning and at the end of a 4-h experimental protocol to determine whether fatigue or a stressor would result in poorer scores for individuals who had previously sustained mild head injury. A significant improvement was found between the first and second administration for both head-injured and control subjects, but difference scores revealed a significant between-groups difference for the first of the four trials, with the head-injured participants performing worse than controls. Apparently, head-injured participants were slower to develop, as well as slower to regain, a means of efficiently processing rapidly presented information. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA; Def & Vet Brain Injury Ctr, Dept Neurol, Washington, DC USA; USC, Rancho Los Amigos Natl Rehabil Ctr, Geriatr Neurobehav & Alzheimer Ctr, Downey, CA USA; Matrix Inc, Baton Rouge, LA USA; Texas Tech Univ, Hlth Sci Ctr, Dept Neuropsychiat & Behav Sci, Lubbock, TX 79409 USA; Univ Tulsa, Dept Psychol, Tulsa, OK 74104 USA; Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA	O'Jile, JR (corresponding author), Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, 2500 N State St, Jackson, MS 39216 USA.	jojile@psychiatry.umsmed.edu	Hilsabeck, Robin/ABC-5093-2020				Aupperle RL, 2002, MULT SCLER J, V8, P382, DOI 10.1191/1352458502ms832oa; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Chan RCK, 2001, BRAIN INJURY, V15, P71, DOI 10.1080/02699050118215; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Fisk JD, 2001, J INT NEUROPSYCH SOC, V7, P363, DOI 10.1017/S1355617701733103; Fos L A, 2000, Appl Neuropsychol, V7, P140, DOI 10.1207/S15324826AN0703_4; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Shawaryn MA, 2002, MULT SCLER J, V8, P310, DOI 10.1191/1352458502ms808oa; Shucard JL, 2004, J INT NEUROPSYCH SOC, V10, P35, DOI 10.1017/S1355617704101057; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; WOOD F, 1984, INT J PSYCHIAT MED, V14, P277	17	21	21	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2006	21	4					293	296		10.1016/j.acn.2006.03.003			4	Psychology, Clinical; Psychology	Psychology	067GI	WOS:000239289500005	16765017	Bronze			2021-06-18	
J	Dyson, R; Buchanan, M; Hale, T				Dyson, R; Buchanan, M; Hale, T			Incidence of sports injuries in elite competitive and recreational windsurfers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article								Objective: To investigate the incidence of injury in windsurfing and to consider methods of prevention. Methods: A total of 107 raceboard (RB) and wave/slalom (WS) national/international competitors and recreational (REC) windsurfers completed a questionnaire on injury incidence over two years. Recurrent injury, ability level, and any preventive measures taken were noted. Results: Overall the injury incidence was 1.5/person/year. The WS group suffered more injuries (2.0/person/ year) than the RB (1.0) or REC (1.2) group. The most common injury was muscle strain at 35% of new injuries, much higher than in earlier studies. Overall 45% of new injuries were muscle/tendon strains (RB 55%, WS 42%, and REC 43%) and 8% were ligament sprains. In the WS group cuts and abrasions were common. The WS and REC groups reported five and one case of concussion respectively. Nearly a quarter (22%) of new lower body injuries were lower back muscular strain, with 34% of recurrent injuries. Approximately 60% of the remaining lower body soft tissue injuries involved the knee or lower leg, with the ankle/foot most often involved. The shoulder, upper arm, and elbow were the sites of 41% of new upper body soft tissue injuries. The WS group reported 250% more recurrent muscular strains than the RB group. Recurrent ligament injuries (particularly knee) were most common in the WS group. The RB group reported recurrent serious bruising to the lower leg. Conclusion: The injury incidence was 1.5/person/year with a high incidence of new and recurrent muscular strain. Lower back muscular strain was prevalent, indicating the need for preventive measures. Wave/slalom was associated with more new and recurrent injuries and the need for head protection.	Univ Chichester, Chichester PO19 6PE, W Sussex, England	Dyson, R (corresponding author), Univ Chichester, Coll Lane, Chichester PO19 6PE, W Sussex, England.	r.dyson@ucc.ac.uk					ALLEN GD, 1989, AUST J SCI MED SPORT, V21, P12; DUBRANA F, 1993, J TRAUMATOLOGIE SPOR, V10, P14; Dyson RJ, 1996, J SPORT SCI, V14, P125, DOI 10.1080/02640419608727694; Gosheger G, 2001, SPORTVERLETZ SPORTSC, V15, P50, DOI 10.1055/s-2001-14815; Jablecki CK, 2000, SEMIN NEUROL, V20, P219, DOI 10.1055/s-2000-9831; Kalogeromitros A, 2002, Eur J Emerg Med, V9, P149, DOI 10.1097/00063110-200206000-00009; LABADIE JC, 1981, CINESIOLOGIE, V80, P251; LOCKE S, 1992, MED SCI SPORT EXER, V24, P964; McCormick D P, 1988, Br J Sports Med, V22, P95; Nathanson AT, 1999, WILD ENVIRON MED, V10, P218, DOI 10.1580/1080-6032(1999)010[0218:WIROAP]2.3.CO;2; Petersen W, 2003, SPORTVERLETZ SPORTSC, V17, P118; Prymka M, 1999, SPORTVERLETZ SPORTSC, V13, P107, DOI 10.1055/s-2007-993325; Rosenbaum DA, 2002, PHYSICIAN SPORTSMED, V30, P15, DOI 10.3810/psm.2002.05.280; Salvi M, 1997, J SPORT TRAUMATOL, V19, P30; ULLIS KC, 1984, PHYSICIAN SPORTSMED, V12, P86; Witt J., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P311	16	21	23	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2006	40	4					346	350		10.1136/bjsm.2005.023077			5	Sport Sciences	Sport Sciences	024VI	WOS:000236224000014	16556791	Green Published			2021-06-18	
J	Starkstein, SE; Jorge, R; Mizrahi, R				Starkstein, Sergio E.; Jorge, Ricardo; Mizrahi, Romina			The prevalence, clinical correlates and treatment of apathy in Alzheimer's disease	EUROPEAN JOURNAL OF PSYCHIATRY			English	Article						dementia; Alzheimer's disease; geriatric; psychiatry; apathy	TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; NEUROPSYCHIATRIC INVENTORY; DEMENTIA; DEPRESSION; TRIAL; METHYLPHENIDATE; IRRITABILITY; AMANTADINE; MOTIVATION	The aim for this article is to review the frequency, clinical correlates and treatment of apathy in Alzheimer's disease. Apathy is currently defined as diminished motivation as expressed in poor goal-oriented behaviours and cognitions. A structured clinical interview and a specific set of diagnostic criteria to diagnose apathy in dementia have been recently validated. There are several valid and reliable scales to measure the severity of apathy in adults with neuropsychiatric disorders. Apathy is present in about 20% of patients with mild dementia and in 60% of those with severe dementia. Among patients with Alzheimer's disease, apathy is significantly associated with older age, the presence of depression, and more severe cognitive and functional deficits, and also predicts a faster cognitive and functional decline. The mechanism of apathy in neuropsychiatric disorders is still unknown, but several studies suggest an important role for frontal lobe and basal ganglia dysfunction. There are no specific randomized controlled trials of psychoactive compounds to treat apathy in neuropsychiatric disorders. Evidence from case reports and small case series suggest the usefulness of psychostimulants to treat apathy in traumatic brain injury, whereas pharmacological trials for behavioural and psychological problems in dementia suggest that anticholinesterases may have some efficacy.	Fremantle Hosp, Fremantle, WA 6959, Australia; Univ Western Australia, Sch Psychiat & Clin Neurosci, Nedlands, WA 6009, Australia; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Psychiat, Iowa City, IA USA; PET Ctr Addict & Mental Hlth, Clarke Div, Toronto, ON, Canada	Starkstein, SE (corresponding author), Fremantle Hosp, Educ Bldg T-7, Fremantle, WA 6959, Australia.	ses@cyllene.uwa.edu.au	Mizrahi, Romina/H-9530-2013	Mizrahi, Romina/0000-0001-6667-7928			Aalten P, 2003, DEMENT GERIATR COGN, V15, P99, DOI 10.1159/000067972; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Boyle JR, 1999, NEW FOREST, V17, P1; BURNS A, 1990, J NERV MENT DIS, V178, P20, DOI 10.1097/00005053-199001000-00004; Cummings Jeffrey L, 2005, Am J Geriatr Pharmacother, V3, P137, DOI 10.1016/S1543-5946(05)80020-0; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Fahn S., 1987, RECENT DEV PARKINSON, P153; Freo U, 2002, J NEURAL TRANSM, V109, P857, DOI 10.1007/s007020200070; Frisoni GB, 1999, DEMENT GERIATR COGN, V10, P130, DOI 10.1159/000017113; Habib M, 2004, J NEUROPSYCH CLIN N, V16, P509, DOI 10.1176/appi.neuropsych.16.4.509; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; LEVY R, IN PRESS CEREB CORTE; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P708, DOI 10.1176/appi.ajp.157.5.708; Marin RA, 2005, TXB TRAUMATIC BRAIN, P337; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1994, J NERV MENT DIS, V182, P235, DOI 10.1097/00005053-199404000-00008; Marit RS, 2005, J HEAD TRAUMA REHAB, V20, P377, DOI 10.1097/00001199-200507000-00009; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Mirakhur A, 2004, INT J GERIATR PSYCH, V19, P1035, DOI 10.1002/gps.1203; Newburn G, 2005, BRAIN INJURY, V19, P149, DOI 10.1080/02699050410001719989; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Politis AM, 2004, INT J GERIATR PSYCH, V19, P1087, DOI 10.1002/gps.1215; Ready RE, 2004, J NEUROL NEUROSUR PS, V75, P1323, DOI 10.1136/jnnp.2003.032284; Robert PH, 2002, INT J GERIATR PSYCH, V17, P1099, DOI 10.1002/gps.755; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Starkstein SE, 2005, J NEUROL NEUROSUR PS, V76, P1070, DOI 10.1136/jnnp.2004.052795; Starkstein SE, 2000, INT PSYCHOGERIATR, V12, P135, DOI 10.1017/S1041610200006918; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.6.872; Starkstein SE, 1995, EUR J NEUROL, V2, P540, DOI 10.1111/j.1468-1331.1995.tb00171.x; STARKSTEIN SE, IN PRESS J NEUROL NE; Strauss ME, 2002, NEUROPSY NEUROPSY BE, V15, P176, DOI 10.1097/01.WNN.0000020010.79870.C3; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	40	21	22	0	8	EUROPEAN JOURNAL OF PSYCHIATRY	ZARAGOZA	FAC MED, DEPT PSYCHIATRY PROF A LOBO, DOMINGO MIRAL S-N, 50009 ZARAGOZA, SPAIN	0213-6163			EUR J PSYCHIAT	Eur. J. Psychiat.	APR-JUN	2006	20	2					96	106					11	Psychiatry	Psychiatry	070HY	WOS:000239513700005		Other Gold			2021-06-18	
J	Liu, J; Chau, CH; Liu, HY; Jang, BR; Li, XG; Chan, YS; Shum, DKY				Liu, J; Chau, CH; Liu, HY; Jang, BR; Li, XG; Chan, YS; Shum, DKY			Upregulation of chondroitin 6-sulphotransferase-1 facilitates Schwann cell migration during axonal growth	JOURNAL OF CELL SCIENCE			English	Article						chondroitin sulphate proteoglycans; development; dorsal root ganglion; sciatic nerve crush; nerve regeneration	MOLECULAR-CLONING; SCIATIC-NERVES; SULFATE PROTEOGLYCANS; NG2 PROTEOGLYCAN; REGENERATION; EXPRESSION; INJURY; BRAIN; CNS; GLYCOSAMINOGLYCANS	Cell migration is central to development and post-traumatic regeneration. The differential increase in 6-sulphated chondroitins during axonal growth in both crushed sciatic nerves and brain development suggests that chondroitin 6-sulphotransferase-1 (C6ST-1) is a key enzyme that mediates cell migration in the process. We have cloned the cDNA of the C6ST-1 gene (C6st1) (GenBank accession number AF178689) from crushed sciatic nerves of adult rats and produced ribonucleotide probes accordingly to track signs of 6-sulphated chondroitins at the site of injury. We found C6st1 mRNA expression in Schwann cells emigrating from explants of both sciatic nerve segments and embryonic dorsal root ganglia. Immunocytochemistry indicated pericellular 6-sulphated chondroitin products around C6ST-1-expressing frontier cells. Motility analysis of frontier cells in cultures subjected to staged treatment with chondroitinase ABC indicated that freshly produced 6-sulphated chondroitin moieties facilitated Schwann cell motility, unlike restrictions resulting from proteoglycan interaction with matrix components. Sciatic nerve crush provided further evidence of in vivo upregulation of the C6ST-1 gene in mobile Schwann cells that guided axonal regrowth 1-14 days post crush; downregulation then accompanied declining mobility of Schwarm cells as they engaged in the myelination of re-growing axons. These findings are the first to identify upregulated C6st1 gene expression correlating with the motility of Schwann cells that guide growing axons through both developmental and injured environments.	Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Physiol, Hong Kong, Hong Kong, Peoples R China; Peking Union Coll Hosp, Dept Neurol, Beijing, Peoples R China	Shum, DKY (corresponding author), Univ Hong Kong, Fac Med, Dept Biochem, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	shumdkhk@hkucc.hku.hk		Chan, Ying Shing/0000-0002-6228-1595			BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P792, DOI 10.1111/j.1460-9568.1995.tb00682.x; Bunge MB, 2001, NEUROSCIENTIST, V7, P325, DOI 10.1177/107385840100700409; CATERSON B, 1985, FED PROC, V44, P386; Chandramouli V, 1997, ANALOG INTEGR CIRC S, V14, P9, DOI 10.1023/A:1008274123958; Chau CH, 2004, FASEB J, V18, P194, DOI 10.1096/fj.03-0196fje; Chau CH, 1999, EUR J NEUROSCI, V11, P1914, DOI 10.1046/j.1460-9568.1999.00615.x; Cheng C, 2002, NEUROSCIENCE, V115, P321, DOI 10.1016/S0306-4522(02)00291-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RAF, 2004, J INVEST DERMATOL, V122, P266, DOI 10.1046/j.0022-202X.2004.22205.x; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; FernaudEspinosa I, 1996, J NEUROBIOL, V30, P410, DOI 10.1002/(SICI)1097-4695(199607)30:3<410::AID-NEU9>3.0.CO;2-7; Fukaya K, 2003, J NEUROPATH EXP NEUR, V62, P162, DOI 10.1093/jnen/62.2.162; Fukuda M, 2001, J BIOL CHEM, V276, P47747, DOI 10.1074/jbc.R100049200; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Henke CA, 1996, J CLIN INVEST, V97, P2541, DOI 10.1172/JCI118702; Hirata K, 2000, EUR J NEUROSCI, V12, P4147, DOI 10.1046/j.1460-9568.2000.00307.x; Horie H, 2004, J NEUROSCI, V24, P1873, DOI 10.1523/JNEUROSCI.4483-03.2004; Ito Y, 2005, GLYCOBIOLOGY, V15, P593, DOI 10.1093/glycob/cwi036; Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746; JESSEN KR, 1990, DEVELOPMENT, V109, P91; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Levy D, 2000, EUR J NEUROSCI, V12, P2323, DOI 10.1046/j.1460-9568.2000.00129.x; LIU J, 2001, SOC NEUR ABSTR; Lyons DA, 2005, CURR BIOL, V15, P513, DOI 10.1016/j.cub.2005.02.030; Martin S, 2001, J NEUROSCI, V21, P8119; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; Mueller M, 2001, AM J PATHOL, V159, P2187, DOI 10.1016/S0002-9440(10)63070-2; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; Prydz K, 2000, J CELL SCI, V113, P193; Rezajooi K, 2004, MOL CELL NEUROSCI, V25, P572, DOI 10.1016/j.mcn.2003.10.009; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Schneider S, 2001, J NEUROSCI, V21, P920; Scott JE, 2003, J PHYSIOL-LONDON, V553, P335, DOI 10.1113/jphysiol.2003.050179; SCOTT JE, 1992, EUR J BIOCHEM, V209, P675, DOI 10.1111/j.1432-1033.1992.tb17335.x; Shum DKY, 1999, J AM SOC NEPHROL, V10, pS397; Shum DKY, 1996, J NEUROSCI RES, V46, P465, DOI 10.1002/(SICI)1097-4547(19961115)46:4<465::AID-JNR8>3.0.CO;2-E; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Snow DM, 2003, EXP NEUROL, V182, P310, DOI 10.1016/S0014-4886(03)00034-7; Torigoe K, 1996, EXP NEUROL, V137, P301, DOI 10.1006/exnr.1996.0030; Tseng CY, 2003, J RECONSTR MICROSURG, V19, P331; TURLEY EA, 1980, NATURE, V283, P268, DOI 10.1038/283268a0; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Zuo J, 1998, J NEUROBIOL, V34, P41, DOI 10.1002/(SICI)1097-4695(199801)34:1<41::AID-NEU4>3.3.CO;2-4	49	21	21	0	2	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0021-9533	1477-9137		J CELL SCI	J. Cell Sci.	MAR 1	2006	119	5					933	942		10.1242/jcs.02796			10	Cell Biology	Cell Biology	027AO	WOS:000236385300015	16495484	Bronze			2021-06-18	
J	Bradley, LJ; Kirker, SGB; Corteen, E; Seeley, HM; Pickard, JD; Hutchinson, PJ				Bradley, LJ; Kirker, SGB; Corteen, E; Seeley, HM; Pickard, JD; Hutchinson, PJ			Inappropriate acute neurosurgical bed occupancy and short falls in rehabilitation: implications for the National Service Framework	BRITISH JOURNAL OF NEUROSURGERY			English	Article						head injury; rehabilitation; subarachnoid haemorrhage	SEVERE HEAD-INJURY; CARE	Patients undergoing neurosurgical intervention may require different types of organized rehabilitation. A prospective study was performed of the care needs of neurosurgical inpatients between the ages of 16 and 70 years who were in acute wards for more than 2 weeks. Only 58% of bed occupancy days were devoted to essential acute neurosurgical ward management. This figure was even lower for patients admitted with subarachnoid haemorrhage (36%) or traumatic brain injury (38%). Overall, 21% of bed days would have more appropriately spent in 'rapid access'/ acute rehabilitation beds, 13% in 'active participation' rehabilitation beds and 5% in cognitive/behavioural rehabilitation units. Addressing this unmet need would increase the availability of acute neurosurgery beds, without needing to build and staff more neurosurgery wards.	Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Rehabil Med, Cambridge CB2 2QQ, England	Hutchinson, PJ (corresponding author), Addenbrookes Hosp, Dept Acad Neurosurg, Hills Rd, Cambridge CB2 2QQ, England.	pjah2@cam.ac.uk		Corteen, Elizabeth/0000-0002-3069-9655	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390] Funding Source: Medline		Department of Health, 2005, NAT SERV FRAM LONG T; Evans A, 2001, LANCET, V358, P1586, DOI 10.1016/S0140-6736(01)06652-1; Greenwood R, 2004, BRIT J NEUROSURG, V18, P573, DOI 10.1080/02688690400022888; Greenwood RJ, 2004, BRIT J NEUROSURG, V18, P462, DOI 10.1080/02688690400012327; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Pickard JD, 2004, J ROY SOC MED, V97, P384, DOI 10.1258/jrsm.97.8.384; *RCS, 1999, REP WORK PART MAN PA; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Sirois MJ, 2004, ARCH PHYS MED REHAB, V85, P184, DOI 10.1016/j.apmr.2003.06.009	10	21	21	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	FEB	2006	20	1					36	39		10.1080/02688690600600855			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	037RC	WOS:000237163600006	16698607				2021-06-18	
J	Greiffenstein, MF; Baker, WJ				Greiffenstein, MF; Baker, WJ			Miller was (mostly) right: Head injury severity inversely related to simulation	LEGAL AND CRIMINOLOGICAL PSYCHOLOGY			English	Article							COMPENSATION NEUROSIS; BRAIN-DAMAGE; BASE RATES; MMPI-2; SYMPTOMS; RECOVERY; DEFICITS; PERFORMANCE; CONCUSSION; SCORES	Purpose. British neurologist Henry Miller (196 1; Miller & Cartlidge, 1972) provoked controversy by asserting late post-concussion syndrome (LPCS) is explained by simulation. The present study examines Miller's inverse dose-response assertion; the more minor the compensable injury, the greater the likelihood of deficit simulation. Method. We examined the prevalence of three types of simulation (memory, motor, and psychiatric) in two archival cohorts of compensation seekers (N = 391 and 368) representing a broad range of cranio-cervical injury severity. A moderate-severe brain injured group provided two sets of performance floors to establish 'possible' or 'probable' pseudoabnormalities. Instruments included the Rey word recognition list, the Smedley dynamometer, the Test of Memory Malingering, and the MMPI-2 infrequency scale. Results. Chronic whiplash and minor head-injury litigants produced more invalid signs than severely injured persons on measures of simulated memory and motor deficits irrespective of definitional stringency. ANOVA revealed striking inverse linear trends as a function of severity. Under a 'possible' rule, at least one pseudoabnormality was present in 80% of LPCS claimants. Memory and motor pseudoabnormalities were more common than psychotic ones. Conclusions. These findings support Miller and Cartlidge's (1972) observations that embellishment rises as injury severity decreases in a compensable context. Simulating litigants may 'tailor' performance to fit aetiological expectations, as we found a low prevalence of psychosis simulation.	Psychol Syst Inc, Royal Oak, MI 48067 USA	Greiffenstein, MF (corresponding author), Psychol Syst Inc, Suite 103, Royal Oak, MI 48067 USA.	mfgreiff@yahoo.com					Albers JW, 2000, NEUROL CLIN, V18, P741, DOI 10.1016/S0733-8619(05)70221-8; Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; Alexander Michael P, 2003, Pain Res Manag, V8, P19; Alexander MP, 1998, NEUROLOGY, V51, P336, DOI 10.1212/WNL.51.2.336; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; BENTON AL, 1989, MILD HEAD INJURY, P1; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1991, J CLIN CONSULTING PS, V3, P171; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BUTCHER J, 1989, MMMPI 2 MANUAL ADM S; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; FAUST D, 1995, NEUROL CLIN, V13, P255; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Frederick R.I., 2003, J FORENSIC NEUROPSYC, V2, P1, DOI [DOI 10.1300/J151v02n03_01, 10.1300/J151v02n03_01, DOI 10.1300/J151V02N03_01]; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P, 2001, NEUROREHABILITATION, V16, P237; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; GREENE R, 2000, MMMPI MMPI 2 INTERPR; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein M. F., 2000, BRAIN INJURY SOURCE, V4, P39; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; GUDJONSSON GH, 1986, BRIT J CLIN PSYCHOL, V25, P35, DOI 10.1111/j.2044-8260.1986.tb00668.x; HAALAND KY, 1981, NEUROPSYCHOLOGIA, V19, P17; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; Kanaya T, 2003, AM PSYCHOL, V58, P778, DOI 10.1037/0003-066X.58.10.778; KAY DWK, 1971, LANCET, V2, P1052; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MENDELSON G, 1991, THEOR MED, V12, P227, DOI 10.1007/BF00489608; MENDELSON G, 1995, J PSYCHOSOM RES, V39, P695, DOI 10.1016/0022-3999(94)00154-W; MENDELSON G, 1982, MED J AUSTRALIA, V2, P132, DOI 10.5694/j.1326-5377.1982.tb124267.x; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MILLER H, 1972, LANCET, V1, P580; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; OLSNES BT, 1989, ACTA NEUROL SCAND, V80, P584, DOI 10.1111/j.1600-0404.1989.tb03931.x; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; PEARCE JMS, 1994, NEUROLOGY, V44, P1993, DOI 10.1212/WNL.44.11.1993; Peterson DI, 1998, NEUROLOGIST, V4, P131, DOI 10.1097/00127893-199805000-00004; Pliskin NH, 1998, J TRAUMA, V44, P709, DOI 10.1097/00005373-199804000-00027; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rogers R., 1997, CLIN ASSESSMENT MALI, V2nd; RUFF R, 1989, MILD HEAD INJURY, P179; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; TOMBAUGH T, 1995, TESTS MEMORY MALINGE; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Volbrecht ME, 2000, ARCH CLIN NEUROPSYCH, V15, P251, DOI 10.1016/S0887-6177(99)00016-5; Wechsler D, 1980, WECHSLER ADULT INTEL; Wechsler D., 2001, WECHSLER TEST ADULT; WECHSLER D, 2000, MANUAL WECHSLER ABBR; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	69	21	21	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-3259	2044-8333		LEGAL CRIMINOL PSYCH	Legal Criminol. Psychol.	FEB	2006	11		1				131	145		10.1348/135532505X49828			15	Criminology & Penology; Law; Psychology, Multidisciplinary	Criminology & Penology; Government & Law; Psychology	010ZC	WOS:000235236400009					2021-06-18	
J	Cai, Y; Wu, P; Ozen, M; Yu, Y; Wang, J; Ittmann, M; Liu, M				Cai, Y; Wu, P; Ozen, M; Yu, Y; Wang, J; Ittmann, M; Liu, M			Gene expression profiling and analysis of signaling pathways involved in priming and differentiation of human neural stem cells	NEUROSCIENCE			English	Article						gene expression array; human neural stem cells; hNSCs; stem cell priming and differentiation; cell signaling pathways; GTP-binding proteins	DEPENDENT PROTEIN-KINASE; NEURONAL DIFFERENTIATION; GROWTH-FACTORS; EPH RECEPTORS; LYMPHOCYTE DEVELOPMENT; PHOSPHOLIPASES A(2); MICROARRAY ANALYSIS; NEURITE OUTGROWTH; PROGENITOR CELLS; NERVOUS-SYSTEM	Human neural stem cells have the ability to differentiate into all three major cell types in the CNS including neurons, astrocytes and oligodendrocytes. The multipotency of human neural stem cells shed a light on the possibility of using stem cells as a therapeutic tool for various neurological disorders including neurodegenerative diseases and neurotrauma that involve a loss of functional neurons. We have discovered previously a priming procedure to direct primarily cultured human neural stem cells to differentiate into almost pure neurons when grafted into adult CNS. However, the molecular mechanism underlying this phenomenon is still unknown. To unravel transcriptional changes of human neural stem cells upon priming, cDNA microarray was used to study temporal changes in human neural stem cell gene expression profile during priming and differentiation. As a result, transcriptional levels of 520 annotated genes were detected changed in at least at two time points during the priming process. In addition, transcription levels of more than 3000 hypothetical protein encoding genes and EST genes were modulated during the priming and differentiation processes of human neural stem cells. We further analyzed the named genes and grouped them into 14 functional categories. Of particular interest, key cell signal transduction pathways, including the G-protein-mediated signaling pathways (heterotrimeric and small monomeric GTPase pathways), the Wnt signaling pathway and the TGF-beta pathway, are modulated by the neural stem cell priming, suggesting important roles of these key signaling pathways in priming and differentiation of human neural stem cells. (c) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.	Texas A&M Univ Syst, Ctr Sci, Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ Syst, Ctr Sci, Dept Med Biochem & Genet, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Neurosci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Radiat Oncol, Galveston, TX 77555 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Michael E DeBakey Dept, Vet Affairs Med Ctr, Houston, TX 77030 USA	Liu, M (corresponding author), Texas A&M Univ Syst, Ctr Sci, Alkek Inst Biosci & Technol, 2121 W Holcombe, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu	wu, Ping/G-8958-2011	Ozen, Mustafa/0000-0002-6142-5294	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064792] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5R01HL064792] Funding Source: Medline		Abu-Amer Y, 1999, J BONE MINER RES, V14, P1855, DOI 10.1359/jbmr.1999.14.11.1855; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arakawa Y, 2003, J CELL BIOL, V161, P381, DOI 10.1083/jcb.200210149; Berger JA, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-194; Beyer C, 2000, J NEUROSCI RES, V59, P107, DOI 10.1002/(SICI)1097-4547(20000101)59:1<107::AID-JNR13>3.0.CO;2-W; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Bryan B, 2004, J BIOL CHEM, V279, P45824, DOI 10.1074/jbc.M406216200; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cai Y, 2005, ONCOGENE, V24, P4293, DOI 10.1038/sj.onc.1208593; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Collins SJ, 2002, LEUKEMIA, V16, P1896, DOI 10.1038/sj.leu.2402718; Dawbarn D, 2003, NEUROPATH APPL NEURO, V29, P211, DOI 10.1046/j.1365-2990.2003.00487.x; Devouassoux-Shisheboran M, 2003, APMIS, V111, P212, DOI 10.1034/j.1600-0463.2003.11101251.x; Drescher U, 2000, CELL, V103, P1005, DOI 10.1016/S0092-8674(00)00204-X; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Gurrieri S, 2003, J INVEST DERMATOL, V121, P156, DOI 10.1046/j.1523-1747.2003.12315.x; HEASLEY LE, 1991, CELL REGUL, V2, P479; Hoang T, 2004, ONCOGENE, V23, P7188, DOI 10.1038/sj.onc.1207937; Kawasoe T, 2000, CANCER RES, V60, P3354; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Le Borgne R, 2003, DEV CELL, V5, P139, DOI 10.1016/S1534-5807(03)00187-4; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Liu JP, 1998, DEVELOPMENT, V125, P5055; Liu ZY, 2002, J BIOL CHEM, V277, P37832, DOI 10.1074/jbc.M205908200; Luo YQ, 2002, J NEUROCHEM, V83, P1481, DOI 10.1046/j.1471-4159.2002.01260.x; McKay RD, 2004, PHILOS T R SOC B, V359, P851, DOI 10.1098/rstb.2004.1472; Messam CA, 2000, EXP NEUROL, V161, P585, DOI 10.1006/exnr.1999.7319; Moroni E, 2002, J HEMATOTH STEM CELL, V11, P19, DOI 10.1089/152581602753448513; Nakamura Y, 2003, EMBO J, V22, P2981, DOI 10.1093/emboj/cdg302; Nakashima S, 2003, BIOCHEM J, V376, P655, DOI 10.1042/BJ20030830; Nosaka T, 2000, INT J HEMATOL, V71, P309; Ohishi K, 2003, SEMIN CELL DEV BIOL, V14, P143, DOI 10.1016/S1084-9521(02)00183-0; Ohishi K, 2002, INT J HEMATOL, V75, P449, DOI 10.1007/BF02982106; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Piper DR, 2000, J NEUROPHYSIOL, V84, P534; PUNT CJA, 1992, LEUKEMIA RES, V16, P551, DOI 10.1016/0145-2126(92)90001-N; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; Reya T, 2003, RECENT PROG HORM RES, V58, P283, DOI 10.1210/rp.58.1.283; Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776-003-0702-2; Ruscetti FW, 2001, INT J HEMATOL, V74, P18, DOI 10.1007/BF02982545; Sanchez S, 2004, NEUROCHEM INT, V44, P231, DOI 10.1016/S0197-0186(03)00150-5; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; Schumann H, 2000, CARDIOVASC RES, V45, P720, DOI 10.1016/S0008-6363(99)00376-4; SEGER R, 1995, FASEB J, V9, P726; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Stachowiak EK, 2003, J NEUROCHEM, V84, P1296, DOI 10.1046/j.1471-4159.2003.01624.x; Strubing C, 1997, EUR J NEUROSCI, V9, P824, DOI 10.1111/j.1460-9568.1997.tb01432.x; Svendsen C N, 2000, Prog Brain Res, V127, P13; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Svendsen CN, 1999, TRENDS NEUROSCI, V22, P357, DOI 10.1016/S0166-2236(99)01428-9; Tago K, 2000, GENE DEV, V14, P1741; Tarasenko YI, 2004, J NEUROSCI RES, V78, P625, DOI 10.1002/jnr.20316; Tojima T, 2003, J NEUROSCI RES, V74, P829, DOI 10.1002/jnr.10754; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Wen TQ, 2002, CELL MOL NEUROBIOL, V22, P407, DOI 10.1023/A:1021059520618; WHITFIELD JF, 1995, J CELL BIOCHEM, P74; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wu DM, 2003, EUR J NEUROSCI, V17, P1571, DOI 10.1046/j.1460-9568.2003.02591.x; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	70	21	24	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	138	1					133	148		10.1016/j.neuroscience.2005.11.041			16	Neurosciences	Neurosciences & Neurology	020XU	WOS:000235947400014	16414199				2021-06-18	
J	Childs, C; Vail, A; Leach, P; Rainey, T; Protheroe, R; King, A				Childs, Charmaine; Vail, Andy; Leach, Paul; Rainey, Timothy; Protheroe, Richard; King, Andrew			Brain temperature and outcome after severe traumatic brain injury	NEUROCRITICAL CARE			English	Article						brain; temperature; outcome; survival; injury severity	CEREBRAL-BLOOD-FLOW; BODY-TEMPERATURE; INTRACEREBRAL TEMPERATURE; SYSTEMIC TEMPERATURE; RECTAL TEMPERATURES; HYPERTHERMIA; STROKE; FEVER; CARE	Introduction: In human's, raised body temperature is linked to poor outcome after brain injury. Because deviations between brain and body temperature have been reported after severe traumatic brain injury (TBI), the aim of this study was to explore the relationship between initial and, mean brain temperature and survival at 3 months. Methods: Intraparenchymal temperature was measured 3-4 cm within white matter. Logistic regression was used to explore linear and quadratic relationships between initial and average brain temperature and survival at 3 months. Results: In 36 patients, initial brain temperatures ranged from 33.5 to 39.2 degrees C (median 37.4 degrees C). There was no evidence of an association between initial brain temperature and risk of death, either linear (odds ratio [OR] 95% confidence interval [Cl] = 1.3 [0.68 to 2.5], p = 0.42) or quadratic (p = 0.26). Assuming a linear relationship, patients with higher mean brain temperatures were less likely to die: OR (95% Cl) for death per 1 degrees C was 0.31 (0.09 to 1.1), p = 0.06. However, by fitting the quadratic relationship, there was a suggestion that both high and low temperatures were associated with increased risk of death: p = 0.06. Conclusion: Initial brain temperature measured shortly after admission did not predict outcome. There is a suggestion that patients with "middle range" temperatures were less likely to die.	Univ Manchester, Hope Hosp, Dept Neurosurg, Salford M6 8HD, Lancs, England; Univ Manchester, Hope Hosp, Div Med & Neurosci, Salford M6 8HD, Lancs, England; Univ Manchester, Hope Hosp, Biostat Grp, Salford M6 8HD, Lancs, England	Childs, C (corresponding author), Univ Manchester, Hope Hosp, Dept Neurosurg, Eccles Old Rd, Salford M6 8HD, Lancs, England.	cchilds@manchester.ac.uk	Childs, Charmaine/G-9928-2012; King, Andrew/AAR-1656-2020	Vail, Andy/0000-0001-8274-2726			AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Boysen G, 2001, STROKE, V32, P413, DOI 10.1161/01.STR.32.2.413; Brinnel H., 1987, P CSIRO DIV AN PROD, P209; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Childs C, 2005, ANAESTHESIA, V60, P759, DOI 10.1111/j.1365-2044.2005.04193.x; Childs C, 2004, ANAESTHESIA, V59, P192, DOI 10.1111/j.1365-2044.2003.03638.x; Childs C, 1999, ARCH DIS CHILD, V80, P262, DOI 10.1136/adc.80.3.262; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; GUPTA AK, 2000, BRIT J NEUROSURG, V14, P208; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; LITTLE RA, 1981, BRIT J SURG, V68, P221, DOI 10.1002/bjs.1800680402; Manno EM, 2004, CRIT CARE MED, V32, P1611, DOI 10.1097/01.CCM.0000131864.83506.86; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; MELLERGARD P, 1994, ACTA NEUROCHIR, P485; MELLERGARD P, 1995, SURG NEUROL, V43, P91, DOI 10.1016/0090-3019(95)80049-M; Otawara Y, 2003, SURG NEUROL, V60, P159, DOI 10.1016/S0090-3019(03)00083-1; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; STONER HB, 1986, SCI BASIS CARE CRITI, P215; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008	28	21	24	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2006	5	1					10	14		10.1385/NCC:5:1:10			5	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	073UB	WOS:000239767000003	16960288				2021-06-18	
J	Okonkwo, DO; Reece, TB; Laurent, JJ; Hawkins, AS; Ellman, PI; Linden, J; Kron, IL; Tribble, CG; Stone, JR; Kern, JA				Okonkwo, DO; Reece, TB; Laurent, JJ; Hawkins, AS; Ellman, PI; Linden, J; Kron, IL; Tribble, CG; Stone, JR; Kern, JA			A comparison of adenosine A(2A) agonism and methylprednisolone in attenuating neuronal damage and improving functional outcome after experimental traumatic spinal cord injury in rabbits	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; trauma; adenosine; A(2A) receptor; methylprednisolone; rabbit	SODIUM SUCCINATE ESTER; TUMOR-NECROSIS-FACTOR; REPERFUSION INJURY; BLOOD-FLOW; CELL-DEATH; VASCULAR MECHANISMS; RECEPTOR AGONISTS; CONTROLLED-TRIAL; FACTOR-ALPHA; ACTIVATION	Object. Steroid agents remain the lone pharmacological treatment in widespread use For acute spinal cord injury (SCI), although their utility remains ill dispute in the neurotrauma literature. Adenosine A, receptor activation with ATL-146e, a selective A(2A) agonist, has shown potential benefit in treating SCI; however, it has not been compared with the gold standard, methylprednisolone. The authors of this study evaluated ATL-146e and methylprednisolone for their ability to preserve neuronal viability and motor function in experimental SCI. Methods. New Zealand White rabbits Sustained SCI or sham injury via the Allen weight-drop technique. Ten minutes postinjury, animals received ATL-146e (ATL group, 0.06 mu g/kg/min intravenously for 3 hours), methylprednisolone (steroid group, 30 mg/kg intravenously), or saline (trauma control group). Hindlimb motor function was recorded every 12 hours using the Tarlov motor grading scale (0, paralysis-5, normal hop). At 48 hours, fixed spinal cord tissue was evaluated for neuronal viability. Hindlimb motor function in animals treated with ATL-146e was equivalent to that of sham-injured animals and was significantly better than that of trauma control animals at all time points and that of steroid-treated animals at 12 hours (p = 0.05). Motor function in steroid-treated animals was worse than in those given ATL-146e and better than that of 0 trauma control animals at later time points, but was not statistically significant (both p > 0.05). Neuronal viability (measured in neurons/hpf) was significantly higher in both treatment groups compared with the trauma control group (12.1 +/- 1.4 neurons/hpf for the ATL and 13.3 +/- 1.4 neurons/hpf for the steroid group compared with 7.5 +/- 1.5 neurons/hpf for the trauma control group; both p < 0.04). Neuronal viability did not differ among ATL-146e-treated. steroid-treated, and sham-injured groups. Conclusions. The use of ATL-146e is at least as effective as methylprednisolone in preserving function and is equivalent to methylprednisolone in preserving the structure of spinal cord tissue after blunt SCI. Adenosine A(2A) receptor activation may be an effective treatment for acute SCI while avoiding the adverse effects of steroid agents.	Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Surg, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA	Okonkwo, DO (corresponding author), Univ Virginia Hlth Syst, Dept Neurol Surg, Box 800212, Charlottesville, VA 22908 USA.	doo5a@hscmail.mcc.virginia.edu	Linden, Joel/AAH-5690-2020				BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BERNE RM, 1983, FED PROC, V42, P3136; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; BRAUGHLER JM, 1982, DRUG METAB DISPOS, V10, P551; BRAUGHLER JM, 1983, J NEUROSURG, V58, P538; BRUNSTOCK G, 1998, CARDIOVASCULAR BIOL; Cassada DC, 2002, J VASC SURG, V35, P994, DOI 10.1067/mva.2002.123091; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cassada DC, 2001, SURGERY, V130, P230, DOI 10.1067/msy.2001.115838; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Ferreira JM, 2001, BRAIN RES, V900, P169, DOI 10.1016/S0006-8993(01)02279-X; GEORGE ER, 1995, AM SURGEON, V61, P659; GERHART KA, 1995, PARAPLEGIA, V33, P316, DOI 10.1038/sc.1995.71; Glover DK, 2001, CIRCULATION, V104, P1181, DOI 10.1161/hc3601.093983; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hinschen AK, 2003, J CARDIOVASC PHARM, V41, P73, DOI 10.1097/00005344-200301000-00010; Hugenholtz H, 2002, CAN J NEUROL SCI, V29, P227, DOI 10.1017/S0317167100001992; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jacobson KA, 1999, APOPTOSIS, V4, P197, DOI 10.1023/A:1009666707307; Kitagawa H, 2002, NEUROL RES, V24, P317, DOI 10.1179/016164102101199819; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; LAYCOCK J R D, 1984, Neurological Research, V6, P75; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; McDonald JW, 2002, J NEUROSURG, V97, P252, DOI 10.3171/spi.2002.97.2.0252; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; Nemecek S, 1978, Adv Neurol, V20, P395; Ngai AC, 2001, AM J PHYSIOL-HEART C, V280, pH2329; Nicholls J., 2002, Autonomic & Autacoid Pharmacology, V22, P209, DOI 10.1046/j.1474-8673.2002.00259.x; Nieri P, 2001, BRIT J PHARMACOL, V134, P745, DOI 10.1038/sj.bjp.0704301; Okusa MD, 1999, AM J PHYSIOL-RENAL, V277, pF404; Pan WH, 2003, J NEUROIMMUNOL, V134, P111, DOI 10.1016/S0165-5728(02)00426-5; Reece TB, 2004, J SURG RES, V121, P130, DOI 10.1016/j.jss.2004.04.006; Rieger JM, 2001, J MED CHEM, V44, P531, DOI 10.1021/jm0003642; Ross SC, 1999, J HEART LUNG TRANSPL, V18, P994, DOI 10.1016/S1053-2498(99)00066-2; Schwab ME, 1996, PHYSIOL REV, V76, P319; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; Shin HK, 2000, LIFE SCI, V67, P1435, DOI 10.1016/S0024-3205(00)00737-2; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Sullivan Gail W, 2003, Curr Opin Investig Drugs, V4, P1313; Sullivan GW, 2004, J LEUKOCYTE BIOL, V75, P127, DOI 10.1189/jlb.0603300; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Vinten-Johansen J, 2003, ANN THORAC SURG, V75, pS691, DOI 10.1016/S0003-4975(02)04694-5; VonLubitz DKJE, 1995, EUR J PHARMACOL, V287, P295, DOI 10.1016/0014-2999(95)00498-X; Wei MX, 2001, CHEST, V120, P860, DOI 10.1378/chest.120.3.860; Wirkner K, 2000, BRIT J PHARMACOL, V130, P259, DOI 10.1038/sj.bjp.0703234; Yan P, 2003, EXP NEUROL, V183, P286, DOI 10.1016/S0014-4886(03)00135-3; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045; Yin XM, 2000, J MOL MED-JMM, V78, P203, DOI 10.1007/s001090000099; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116; Zhao ZQ, 2001, J MOL CELL CARDIOL, V33, P57, DOI 10.1006/jmcc.2000.1275	59	21	21	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	JAN	2006	4	1					64	70		10.3171/spi.2006.4.1.64			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	001OZ	WOS:000234547500010	16506468				2021-06-18	
S	Sharma, HS; Lundstedt, T; Boman, A; Lek, P; Seifert, E; Wiklund, L; Ali, SF		Ali, SF; Fornai, F		Sharma, Hari S.; Lundstedt, Torbjorn; Boman, Arne; Lek, Per; Seifert, Elisabeth; Wiklund, Lars; Ali, Syed F.			A potent serotonin-modulating compound AP-267 attenuates morphine withdrawal-induced blood-brain barrier dysfunction in rats	CELLULAR AND MOLECULAR MECHANISMS OF DRUGS OF ABUSE AND NEUROTOXICITY: COCAINE, GHB, AND SUBSTITUTED AMPHETAMINES	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Satellite Meeting on Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity - Cocaine, GHB and Substituted Amphetamines	AUG 16-19, 2005	Venice Int Univ, Venice, ITALY	Int Soc Neurochem, Neuromed Pozzilli, FDA, Natl Ctr Toxicol Res	Venice Int Univ	morphine; withdrawal symptoms; dependence; spontaneous withdrawal; AP-267; serotonin; 5-HT2c receptor; blood-brain barrier; Evans blue; radioiodine	5-HT3 RECEPTOR ANTAGONISTS; SPINAL-CORD; GUANYLATE-CYCLASE; ADENYLATE-CYCLASE; TRAUMATIC INJURY; NITRIC-OXIDE; PERMEABILITY; FLOW; 5-HYDROXYTRYPTAMINE; LEVEL	The possibility that a serotonin 5-HT2c receptor-modulating compound, AP-267, will influence spontaneous morphine withdrawal symptoms and the alterations in the brain fluid microenvironment was examined in a rat model. Daily administration of morphine (10 mg/kg, i.p.) for 10 days resulted in dependence of rats as seen by loss of analgesic response. On the 11th day, no morphine administration was given. This resulted in profound withdrawal symptoms 24 h after morphine withdrawal. The magnitude and severity of these symptoms were increased further 48 h after withdrawal. Measurement of the blood-brain barrier (BBB) permeability, a measure of perturbed brain fluid microenvironment showed leakage of Evans blue and radioiodine tracers in several parts of the brain in rats showing withdrawal symptoms. Whereas, rats treated with AP-267 either on the 1st day or 2nd day morphine withdrawal showed much less symptoms and leakage of the BBB. Taken together, these observations suggest that (a) stress associated with the withdrawal symptoms are sufficient enough to induce breakdown of the BBB function, and (b) modulation of serotonin 5-HT2c receptors may have some protective influence on the stress symptoms and the BBB disruption.	Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden; US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Neurochem Lab, Jefferson, AR 72079 USA; Acure Pharma AB, SE-75643 Uppsala, Sweden; Uppsala Univ, Dept Organ & Pharmaceut Chem, SE-74123 Uppsala, Sweden	Sharma, HS (corresponding author), Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden.	Sharma@surgsci.uu.se					ANANTH US, 1987, J NEUROCHEM, V48, P253, DOI 10.1111/j.1471-4159.1987.tb13156.x; AUER LM, 1985, J CEREBR BLOOD F MET, V5, P517, DOI 10.1038/jcbfm.1985.78; Azmitia EC, 2001, BRAIN RES BULL, V56, P413, DOI 10.1016/S0361-9230(01)00614-1; AZMITIA EC, 1990, BRAIN RES, V510, P97, DOI 10.1016/0006-8993(90)90732-Q; BACA GM, 1978, BLOOD VESSELS, V15, P286; BARNES JM, 1990, NEUROPHARMACOLOGY, V29, P1037, DOI 10.1016/0028-3908(90)90110-D; BARNES NM, 1992, BRIT J PHARMACOL, V107, P233, DOI 10.1111/j.1476-5381.1992.tb14492.x; BLAUW GJ, 1988, LIFE SCI, V43, P1441, DOI 10.1016/0024-3205(88)90255-X; CARBONI E, 1988, EUR J PHARMACOL, V151, P159, DOI 10.1016/0014-2999(88)90710-8; CURZON G, 1990, TRENDS PHARMACOL SCI, V11, P181, DOI 10.1016/0165-6147(90)90109-L; Dawson VL, 1996, J NEUROSCI, V16, P2479; EDVINSSON L, 1976, PHARMACOL REV, V28, P275; GERZER R, 1986, BIOCHIM BIOPHYS ACTA, V886, P383, DOI 10.1016/0167-4889(86)90173-4; GIANUTSOS G, 1975, PSYCHOPHARMACOLOGIA, V43, P43, DOI 10.1007/BF00437613; GIANUTSOS G, 1975, METHODS NARCOTIC RES, P293; GUAN XM, 1989, BRAIN RES BULL, V23, P541, DOI 10.1016/0361-9230(89)90198-6; GULLIS RJ, 1975, BIOCHEM J, V148, P197, DOI 10.1042/bj1480197; HAUBRICH DR, 1973, BRIT J PHARMACOL, V48, P80, DOI 10.1111/j.1476-5381.1973.tb08224.x; HIGGINS GA, 1992, PSYCHOPHARMACOLOGY, V106, P315, DOI 10.1007/BF02245411; HOYER D, 1994, PHARMACOL REV, V46, P157; HUANG M, 1983, J NEUROCHEM, V40, P719, DOI 10.1111/j.1471-4159.1983.tb08038.x; HUI SCG, 1993, BRIT J PHARMACOL, V110, P1341, DOI 10.1111/j.1476-5381.1993.tb13966.x; JOO F, 1985, NEUROCHEM INT, V7, P1, DOI 10.1016/0197-0186(85)90002-6; JOO F, 1983, BRAIN RES, V278, P165, DOI 10.1016/0006-8993(83)90235-4; KARNUSHINA I, 1980, BRAIN RES, V189, P588, DOI 10.1016/0006-8993(80)90374-1; KILPATRICK GJ, 1987, NATURE, V330, P746, DOI 10.1038/330746a0; Lucaites VL, 1996, LIFE SCI, V59, P1081, DOI 10.1016/0024-3205(96)00423-7; MANYHAN WG, 1999, AM J PHYSIOL, V276, pC1148; MENGOD G, 1990, BRAIN RES, V524, P139, DOI 10.1016/0006-8993(90)90502-3; PALMER GC, 1983, PHYSL PHARM MICROCIR, V1, P1; PAZOS A, 1984, EUR J PHARMACOL, V106, P539, DOI 10.1016/0014-2999(84)90057-8; PERRY RJ, 1990, J AEROSOL MED, V3, P187, DOI 10.1089/jam.1990.3.187; RAY AK, 1980, ARCH INT PHARMACOD T, V246, P108; ROYCHOUDHURY M, 1986, METHOD FIND EXP CLIN, V18, P677; Sharma, 2004, BLOOD SPINAL CORD BR, P437; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P231; SHARMA HS, 1991, NEUROSCI RES, V10, P211; SHARMA HS, 1990, BRAIN RES, V517, P215, DOI 10.1016/0006-8993(90)91029-G; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P407, DOI 10.1196/annals.1344.036; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; Sharma HS, 2003, ACT NEUR S, V86, P383; SHARMA HS, 1987, NEUROPHARMACOLOGY, V26, P85, DOI 10.1016/0028-3908(87)90049-9; Sharma HS, 2003, INT J HYPERTHER, V19, P325, DOI 10.1080/0265673021000054621; SHARMA HS, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P303; Sharma HS, 1998, PROG BRAIN RES, V115, P297; SHARMA HS, 1989, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1988, P317; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1987, BRAIN RES, V424, P153, DOI 10.1016/0006-8993(87)91205-4; Sharma HS, 1996, BEHAV BRAIN RES, V72, P189; Sharma HS, 2004, BLOOD SPINAL CORD BR; SHARMA HS, ANN NY ACAD SCI; Sharma HS, 1999, ACTA U UPSAL, V830, P1; SHARMA HS, 2005, RECENT MODALITIES BR, P97; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WESTERGAARD E, 1975, ACTA NEUROPATHOL, V32, P27, DOI 10.1007/BF00686065; WESTERGAARD E, 1977, ACTA NEUROPATHOL, V39, P181, DOI 10.1007/BF00691695; Westergaard E, 1980, Adv Neurol, V28, P55; WINKLER T, 1995, NEUROSCIENCE, V68, P1097, DOI 10.1016/0306-4522(95)00194-N; YAGALOFF KA, 1985, J NEUROSCI, V5, P3178	61	21	21	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER STREET, HOBOKEN, NJ, UNITED STATES	0077-8923		1-57331-629-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2006	1074						482	496		10.1196/annals.1369.049			15	Cell Biology; Substance Abuse; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Cell Biology; Substance Abuse; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BFJ04	WOS:000242168100049	17105947				2021-06-18	
J	Suz, P; Vavilala, MS; Souter, M; Muangman, S; Lam, AM				Suz, P; Vavilala, MS; Souter, M; Muangman, S; Lam, AM			Clinical features of fever associated with poor outcome in severe pediatric traumatic brain injury	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						pyrexia; children; temperature; head trauma; fever	INTENSIVE-CARE; EARLY HYPERTHERMIA; TEMPERATURE; CHILDREN; RISK; MECHANISMS; STATE; RATS	We describe the incidence and etiology of fever and the relationship between fever characteristics and outcome in children with severe traumatic brain injury (TBI). We conducted a retrospective study of children <14 years and with Glasgow Coma Scale (GCS) score of <9 admitted to a level I pediatric trauma center intensive care unit (PICU) between 1998 and 2003. We examined whether fever characteristics were associated with poor outcome (hospital discharge GCS score <13 and discharge disposition of either death or discharge to a skilled nursing facility). PICU length of stay (LOS) and hospital LOS were also examined. Data are presented as means and medians (SD), and P < 0.05 reflects significance. Ninety-three records were reviewed. Patients were 5.7 (SD 4.1) years old, 70% were male, and the average admission GCS score was 5. Mortality rate was 14%. Forty-eight (52%) patients had fever, and 23 (48%) of those patients had infectious fever. Each additional febrile episode was associated with a twofold higher risk of patients having a hospital discharge GCS score of < 13 (odds ratio 2.4, 95% confidence interval 1.2-5.0) and having a 0.4-day longer PICU LOS (P < 0.001). Patients with infections fever had a 0.9-day longer PICU LOS (P < 0.001). Patients with any fever in the PICU had an increased HLOS (0.9 days; P < 0.001). Our data suggest that in severe pediatric TBI, both fever and infection were common, and both were associated with longer LOS. Patients with higher fever burden had poor hospital discharge GCS score.	Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Box 359724,325 9th Ave, Seattle, WA 98104 USA.	vavilala@u.washington.edu	Souter, Michael/ABE-1890-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: Medline		Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHILDERS MK, 1994, BRAIN INJURY, V8, P335, DOI 10.3109/02699059409150984; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Sarginson RE, 2004, CRIT CARE MED, V32, P839, DOI 10.1097/01.CCM.0000117319.17600.E8; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1	17	21	21	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2006	18	1					5	10		10.1097/01.ana.0000189079.26212.37			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	000YF	WOS:000234497700002	16369134				2021-06-18	
J	Tanriverdi, T; Uzan, M; Sanus, GZ; Baykara, O; Is, M; Ozkara, C; Buyra, N				Tanriverdi, T; Uzan, M; Sanus, GZ; Baykara, O; Is, M; Ozkara, C; Buyra, N			Lack of association between the IL1A gene (-889) polymorphism and outcome after head injury	SURGICAL NEUROLOGY			English	Article						cytokine; head injury; interleukin 1 alpha; outcome	INTERLEUKIN-1-ALPHA GENE POLYMORPHISM; ALZHEIMERS-DISEASE; IL-1-ALPHA; BRAIN; RISK; MECHANISMS; EXPRESSION; IL-1-BETA	Background: Interleukin (IL) I is a proinflammatory cytokine that has been identified as an important mediator of neurodegeneration induced by ischemia or traumatic brain injury. Accumulating evidence to date has suggested that the major cytokine contributing to neurodegeneration after head injury is IL-1 beta rather than IL-1 alpha; however, there is no sufficient data regarding IL-1 alpha in literature, and there may be an association between IL1A gene polymorphism and outcome after head injury. Methods: We performed a prospective clinical study and included a recruited series of 71 patients who had head injury and were admitted to our neurosurgical unit. Severity of initial injury was assessed by the Glasgow Coma Scale. Outcome at 6 months after injury was assessed by means of the Glasgow Outcome Score. Interleukin la genotypes were determined from blood samples by standard methods. Results: Of 40 patients with ILIA*2, 18 (45%) had an unfavorable outcome (dead, vegetative state, or severe disability) compared with 7 (22.5%) of 31 without ILIA*2 (P =.08). Conclusion: Our findings show that there is no genetic association between ILIA gene polymorphism and outcome after head injury. Further clinical studies should be designed to confirm and further evaluate these findings. (c) 2006 Elsevier Inc. All rights reserved.	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Med Biol, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Neurol, Istanbul, Turkey; Duzce Izzet Baysal Univ, Med Fac, Dept Neurosurg, Duzce, Turkey	Uzan, M (corresponding author), POB 5, TR-34301 Istanbul, Turkey.	uzan@istanbul.edu.tr	Baykara, Onur/V-5990-2018; Buyru, Nur/D-1810-2019; Sanus, Galip Zihni/D-6715-2019; Uzan, Mustafa/D-6571-2019; Tanriverdi, Taner/C-9003-2019; Ozkara, Cigdem/AAA-2562-2020	Baykara, Onur/0000-0002-9754-8456; Buyru, Nur/0000-0002-6920-1455; Ozkara, Cigdem/0000-0003-0548-1838; Sanus, Galip Zihni/0000-0001-6539-7254; Uzan, Mustafa/0000-0001-7214-380X			Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Boutin H, 2001, J NEUROSCI, V21, P5528; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Green EK, 2002, NEUROLOGY, V58, P1566, DOI 10.1212/WNL.58.10.1566; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; Hedley R, 2002, ANN NEUROL, V51, P795, DOI 10.1002/ana.10196; Kanemoto K, 2000, ANN NEUROL, V47, P571, DOI 10.1002/1531-8249(200005)47:5<571::AID-ANA3>3.0.CO;2-A; Ki CS, 2001, ANN NEUROL, V49, P817, DOI 10.1002/ana.1067; Kornman K S, 1998, Ann Periodontol, V3, P327, DOI 10.1902/annals.1998.3.1.327; MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210; Minster RL, 2000, ANN NEUROL, V48, P817, DOI 10.1002/1531-8249(200011)48:5<817::AID-ANA22>3.0.CO;2-S; Moller JC, 2004, NEUROSCI LETT, V359, P195, DOI 10.1016/j.neulet.2004.01.058; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; Nishimura M, 2004, NEUROSCI LETT, V368, P140, DOI 10.1016/j.neulet.2004.06.076; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650; Pirskanen M, 2002, DEMENT GERIATR COGN, V14, P123, DOI 10.1159/000063603; Rebeck GW, 2000, NEUROSCI LETT, V293, P75, DOI 10.1016/S0304-3940(00)01487-7; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Schulte T, 2002, NEUROSCI LETT, V326, P70, DOI 10.1016/S0304-3940(02)00301-4; SHENG JG, 1994, J NEUROCHEM, V63, P1872; STEINKASSERER A, 1992, GENOMICS, V13, P654, DOI 10.1016/0888-7543(92)90137-H; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Touzani O, 2002, J NEUROSCI, V22, P38, DOI 10.1523/JNEUROSCI.22-01-00038.2002; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Tsai SJ, 2003, NEUROSCI LETT, V343, P93, DOI 10.1016/S0304-3940(03)00333-1; Uzan M, 2005, ACTA NEUROCHIR, V147, P715, DOI 10.1007/s00701-005-0529-z	30	21	26	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JAN	2006	65	1					7	10		10.1016/j.surneu.2005.05.024			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	004SX	WOS:000234773600003	16378839				2021-06-18	
J	Clark, RSB; Bayir, H; Jenkins, LW				Clark, RSB; Bayir, H; Jenkins, LW			Posttranslational protein modifications	CRITICAL CARE MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; S-NITROSOTHIOLS; KINASE-C; MECHANISMS; QUANTITATION; ACETYLATION; SURVIVAL; PATHWAYS; ISCHEMIA		Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15213 USA.						Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Bommhardt U, 2004, J IMMUNOL, V172, P7583, DOI 10.4049/jimmunol.172.12.7583; Clark RSB, 1999, FASEB J, V13, P813; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Huntington JA, 2005, J THROMB HAEMOST, V3, P1861, DOI 10.1111/j.1538-7836.2005.01363.x; JENKINS L, 2001, MO CL BI CC, V2, P163; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Mendoza-Alvarez H, 1999, BIOCHEMISTRY-US, V38, P3948, DOI 10.1021/bi982148p; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Padmaperuma B, 1996, BRAIN RES, V714, P19, DOI 10.1016/0006-8993(95)01579-5; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tyurin VA, 2002, METHOD ENZYMOL, V352, P347; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015	32	21	21	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2005	33	12		S			S407	S409		10.1097/01.CCM.0000191712.96336.51			3	Critical Care Medicine	General & Internal Medicine	000ZK	WOS:000234501300004	16340406				2021-06-18	
J	Du, T; Ciuffreda, KJ; Kapoor, N				Du, T; Ciuffreda, KJ; Kapoor, N			Elevated dark adaptation thresholds in traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; dark adaptation; photosensitivity; cortical gain control; vision dysfunction	VISUAL ADAPTATION; HEAD-INJURY; LIGHT; SENSITIVITY; SOUND; CELLS	Primary objective: To expand upon earlier findings of elevated dark adaptation ( scotopic) thresholds in photosensitive individuals with traumatic brain injury (TBI). Methods and procedures: To assess scotopic thresholds in individuals with TBI (n = 17) manifesting varying degrees of photosensitivity ( mild, moderate or marked), but without retinal dysfunction, to those of non-photosensitive, visually-normal individuals (n = 21) using a hand-held dark adaptometer. Main outcomes and results: The group mean scotopic threshold for the TBI group was significantly higher than that of the visually-normal group. Over 50% (nine out of 17) of the TBI group exhibited elevated thresholds. There was no correlation between the threshold value and degree of photosensitivity. Conclusion: The elevated scotopic thresholds suggest an abnormality in cortical gain control. An anomalous adaptive response may develop due to cortical damage, thereby attenuating subjective light sensation.	SUNY Coll Optometry, Dept Vis Sci, New York, NY 10036 USA; SUNY Coll Optometry, Dept Clin Sci, New York, NY 10036 USA	Ciuffreda, KJ (corresponding author), SUNY Coll Optometry, Dept Vis Sci, 33 W 42nd St, New York, NY 10036 USA.	kciuffreda@sunyopt.edu			NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [T32 EY07079-17] Funding Source: Medline		BIGLER ED, 1989, TRAUMATIC BRAIN INJU, P13; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; DOWLING JE, 1967, SCIENCE, V155, P273, DOI 10.1126/science.155.3760.273; DOWLING JE, 1987, RETINA APPROACHABLE, P187; ENROTHCUGELL C, 1975, J PHYSIOL-LONDON, V247, P551, DOI 10.1113/jphysiol.1975.sp010947; FREED S, 1997, J OPTOMETRIC VISION, V30, P58; FUSTER JM, 1990, ANN NY ACAD SCI, V608, P318, DOI 10.1111/j.1749-6632.1990.tb48901.x; Hecht S, 1937, J GEN PHYSIOL, V20, P831, DOI 10.1085/jgp.20.6.831; Jackowski MM, 1996, NEUROREHABILITATION, V6, P193, DOI 10.3233/NRE-1996-6305; JACKOWSKI MM, 2001, VISUAL VESTIBULAR CO, P145; JONSSON CO, 1967, ACTA NEUROL SCAND, V43, P158, DOI 10.1111/j.1600-0404.1967.tb05725.x; Kaplan E., 2004, VISUAL NEUROSCIENCES, P481; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; LIDVALL HF, 1974, ACTA NEUROL SCAND, V56, P50; Raymond MJ, 1996, NEUROREHABILITATION, V6, P229, DOI 10.3233/NRE-1996-6309; REEVES A, 2004, VISUAL NEUROSCIENCES, P851; Rosen S. A., 2001, VISUAL VESTIBULAR CO, P174; RUSHTON WAH, 1965, PROC R SOC SER B-BIO, V162, P20, DOI 10.1098/rspb.1965.0024; SCHNAPF JL, 1987, SCI AM, V256, P40, DOI 10.1038/scientificamerican0487-40; SKANDRIES W, 1988, CLIN VISION SCI, V3, P45; SUCHOFF IB, 2000, LIGHTHOUSE HDB VISIO, P517; VIRSU V, 1977, EXP BRAIN RES, V27, P35; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; WALD G, 1954, SCIENCE, V119, P887, DOI 10.1126/science.119.3104.887; ZIHL J, 1990, CLIN VISION SCI, V5, P185	26	21	21	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	13					1125	1138		10.1080/02699050500149817			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZD	WOS:000233270000007	16286326				2021-06-18	
J	Moran, C; Gillon, G				Moran, C; Gillon, G			Inference comprehension of adolescents with traumatic brain injury: A working memory hypothesis	BRAIN INJURY			English	Article						traumatic brain injury; language comprehension; adolescents	CLOSED-HEAD-INJURY; INDIVIDUAL-DIFFERENCES; SENTENCE COMPREHENSION; CHILDREN; LANGUAGE; CHILDHOOD; ADULTS; DAMAGE	This study investigated inference comprehension performance in adolescents who had suffered a traumatic brain injury (TBI). Using stimuli adapted from Lehman-Blake and Tompkins, participants listened to short paragraphs that varied according to the working memory demands of the task and answered comprehension questions that required inferences to be generated. Six adolescents, aged 12-16 years, who had suffered a TBI prior to the age of 10 years, were assessed and their performance was compared to six individually age-matched peers with typical development. Analysis revealed that individuals with TBI did not differ from non-injured peers in their understanding of inferences when the storage demands of the task were minimized. However, when storage demands were high, adolescents with TBI performed poorly compared to their age-matched peers. Results are discussed relative to a working-memory hypothesis of impairment following TBI.	Univ Canterbury, Fac Sci, Dept Speech & Language Therapy, Christchurch 1, New Zealand	Moran, C (corresponding author), Univ Canterbury, Fac Sci, Dept Speech & Language Therapy, Private Bag 4800, Christchurch 1, New Zealand.	catherine.moran@canterbury.ac.nz		Gillon, Gail/0000-0001-9501-8147			*ACC REH COMP INS, 1998, TRAUM BRAIN INJ REH; BEUKELMAN DR, 1991, COMMUNICATION DISORD; Cain K, 2001, MEM COGNITION, V29, P850, DOI 10.3758/BF03196414; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; Carpenter P.A., 1994, HDB PSYCHOLINGUISTIC, P1075; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; DOSHER BA, 1982, MEM COGNITION, V10, P531, DOI 10.3758/BF03202435; ENGLE RW, 1992, J EXP PSYCHOL LEARN, V18, P972, DOI 10.1037/0278-7393.18.5.972; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Granier JP, 2000, APHASIOLOGY, V14, P501, DOI 10.1080/026870300401270; HAMMILL DD, 1994, TEST ADOLESCENT LANG; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HARTLEY L, 1991, BRAIN INJURY, V6, P271; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P729, DOI 10.1080/026990596123990; JORDAN FM, 1993, APHASIOLOGY, V7, P503, DOI 10.1080/02687039308248626; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; KING J, 1991, J MEM LANG, V30, P580, DOI 10.1016/0749-596X(91)90027-H; Leathem JM, 1997, BRAIN INJURY, V11, P565, DOI 10.1080/026990597123269; Lehman MT, 2000, APHASIOLOGY, V14, P485, DOI 10.1080/026870300401261; Lehman-Blake MT, 2001, J SPEECH LANG HEAR R, V44, P639, DOI 10.1044/1092-4388(2001/052); LEINONEN E, 2000, CHILDRENS PRAGMETIC; Letts C, 2001, INT J LANG COMM DIS, V36, P307; MCDOWELL L, 1992, ANTIPODE, V24, P56, DOI 10.1111/j.1467-8330.1992.tb00428.x; MCKOON G, 1992, PSYCHOL REV, V99, P440, DOI 10.1037/0033-295X.99.3.440; MIYAKE A, 1994, COGNITIVE NEUROPSYCH, V11, P671, DOI 10.1080/02643299408251989; Moran C, 2004, BRAIN INJURY, V18, P273, DOI 10.1080/02699050310001617415; MORAN C, 2002, LANGUAGE COMPREHENSI; Nippold M., 1998, LATER LANGUAGE DEV S; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Swinney D., 1990, INFERENCES TEXT COMP, P17; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1994, J SPEECH HEAR RES, V37, P896, DOI 10.1044/jshr.3704.896; Turkstra LS, 1999, LANG SPEECH HEAR SER, V30, P132, DOI 10.1044/0161-1461.3002.132; Turkstra LS, 1998, J SPEECH LANG HEAR R, V41, P137, DOI 10.1044/jslhr.4101.137; Warr-Leeper G.A., 1989, LANGUAGE, V20, P420, DOI [10.1044/0161-1461.2004.420, DOI 10.1044/0161-1461.2004.420]	44	21	22	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2005	19	10					743	751		10.1080/02699050500110199			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800001	16175835				2021-06-18	
J	Mossberg, KA; Greene, BP				Mossberg, KA; Greene, BP			Reliability of graded exercise testing after traumatic brain injury: Submaximal and peak responses	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the American-Physical-Therapy-Association	JUL   01, 2004	Chicago, IL	Amer Phys Therapy Assoc		head injury; treadmill testing; consistency; minimal detectable change; rehabilitation	AEROBIC CAPACITY; TREADMILL TEST; ADOLESCENTS; REPRODUCIBILITY; PROTOCOLS; PERFORMANCE; VALIDITY; CHILDREN; WOMEN	Objective: To assess the reliability of the submaximal and peak responses to a treadmill graded exercise test in individuals recovering from traumatic brain injury. Design: A total of 15 individuals (11 men, 4 women; 28.5 +/- 9.2 yrs) with moderate to severe traumatic brain injury admitted into a postacute residential treatment center 10 +/- 7 mos after injury performed two treadmill graded exercise tests separated by 4-8 days. Heart rate, oxygen consumption (in milliliters per minute per kilogram), minute ventilation (in liters per minute), and respiratory exchange ratio (carbon dioxide output/oxygen consumption) were continuously monitored at 1-min intervals. Submaximal and peak values were analyzed for absolute level of agreement using the intraclass correlation coefficient. Results: The submaximal intraclass correlation coefficient values for all variables between minutes 3 and 7 ranged from 0.80 to 0.93. Submaximal intraclass correlation coefficients before and in the subsequent minutes were less than optimal for heart rate and minute ventilation. Lower intensity workloads elicited slightly better agreement than higher intensity workloads. The peak response intraclass correlation coefficients ranged from 0.77 (heart rate) to 0.92 (oxygen consumption). Conclusion: Despite the presence of other co-morbidities, subjects recovering from traumatic brain injury provided consistent individual responses, allowing for reliable assessments of Gardiorespiratory conditioning programs. Assessments of ambulatory efficiency, endurance, and aerobic fitness adaptations as a result of treatment for persons with traumatic brain injury should include analyses of submaximal responses to graded exercise.	Univ Texas, Med Branch, Dept Phys Therapy, Galveston, TX 77555 USA	Mossberg, KA (corresponding author), Univ Texas, Med Branch, Dept Phys Therapy, 301 Univ Blvd, Galveston, TX 77555 USA.						[Anonymous], 2000, ACSMS GUIDELINES EXE; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Bhambhani Y, 2003, ARCH PHYS MED REHAB, V84, P1629, DOI 10.1053/S0003-9993(03)00343-5; *CDCP, 2001, INJ FB 2001 2002; DEAN E, 1989, ARCH PHYS MED REHAB, V70, P599; Dobrovolny CL, 2003, ARCH PHYS MED REHAB, V84, P1308, DOI 10.1016/S0003-9993(03)00150-3; FERNHALL B, 1990, ARCH PHYS MED REHAB, V71, P1065; Fielding RA, 1997, MED SCI SPORT EXER, V29, P1109, DOI 10.1097/00005768-199708000-00018; FOSTER VL, 1986, MED SCI SPORT EXER, V18, P425; FROELICHER VF, 1974, CHEST, V65, P512, DOI 10.1378/chest.65.5.512; Gaskill SE, 2001, MED SCI SPORT EXER, V33, P1841, DOI 10.1097/00005768-200111000-00007; HO BL, 1982, AVIAT SPACE ENVIR MD, V53, P112; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; Larsen GE, 2002, RES Q EXERCISE SPORT, V73, P66, DOI 10.1080/02701367.2002.10608993; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; Noonan V, 2000, PHYS THER REHABIL J, V80, P782, DOI 10.1093/ptj/80.8.782; OTTENBACHER KJ, 1993, AM J PHYS MED REHAB, V72, P266, DOI 10.1097/00002060-199310000-00003; Pitetti KH, 1999, ADAPT PHYS ACT Q, V16, P362, DOI 10.1123/apaq.16.4.362; Pitetti KH, 2000, ADAPT PHYS ACT Q, V17, P322, DOI 10.1123/apaq.17.3.322; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; SHEPHARD RJ, 1984, SPORTS MED, V1, P99, DOI 10.2165/00007256-198401020-00002; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; TENINE R, 1988, J GERONTOL, V43, pM101; THOMAS SG, 1987, CAN J SPORT SCI, V12, P144; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; Zeimetz G, 1985, J CARDIOPULM REHABIL, V5, P525	28	21	21	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2005	84	7					492	500		10.1097/01.phm.0000166883.97562.cd			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	938XN	WOS:000230036800002	15973085				2021-06-18	
J	Kleindienst, A; Tolias, CM; Corwin, FD; Muller, C; Marmarou, A; Fatouros, P; Bullock, MR				Kleindienst, A; Tolias, CM; Corwin, FD; Muller, C; Marmarou, A; Fatouros, P; Bullock, MR			Assessment of cerebral S100B levels by proton magnetic resonance spectroscopy after lateral fluid-percussion injury in the rat	JOURNAL OF NEUROSURGERY			English	Article						proton magnetic resonance spectroscopy; S100B protein; traumatic brain injury; prognosis; rat	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; CORTICAL IMPACT INJURY; CEREBROSPINAL-FLUID; NEURITE EXTENSION; PROTEIN S100B; GROWTH-FACTOR; SERUM-LEVELS; HEAD-INJURY; S-100	Object. After traumatic brain injury (TBI), S100B protein is released by astrocytes. Furthermore, cerebrospinal fluid (CSF) and serum S100B levels have been correlated to outcome. Given that no data exist about the temporal profile of cerebral S100B levels following TBI and their correlation to serum levels, the authors examined whether proton magnetic resonance (MR) spectroscopy is capable of measuring S100B. Methods. Results of in vitro proton MR spectroscopy experiments (2.35-tesla magnet, 25 G/cm, point-resolved spatially localized spectroscopy) revealed an S100B-specific peak at 4.5 ppm and confirmed a positive correlation between different S100B concentrations (10 nM-1 mu M) and the area under the curve (AUC) for the S100B peak (r = 0.991, p < 0.001). Thereafter, proton MR spectroscopy was performed in male Sprague-Dawley rats (7 X 5 X 5-mm voxel in each hemisphere, TR 3000 msec, TE 30 msec, 256 acquisitions). Exogenously increased CSF S100B levels (similar to 200 ng/ml) through the intraventricular infusion of S100B increased the AUC of the S100B peak from 0.06 +/- 0.02 to 0.44 +/- 0.06 (p < 0.05), whereas serum S100B levels remained normal. Two hours after lateral fluid-percussion injury, serum S100B levels increased to 0.61 +/- 0.09 ng/ml (p < 0.01) and rapidly returned to normal levels, whereas the AUC of the S100B peak increased to 0.19 +/- 0.04 at 2 hours postinjury and 0.41 +/- 0.07 (p < 0.05) on Day 5 postinjury. Conclusions. Proton MR spectroscopy proves a strong correlation between the AUC of the S100B peak and S100B concentrations. Following experimental TBI, serum S100B levels increased for only a very short period, whereas cerebral S100B levels were increased up to Day 5 postinjury. Given that experimental data indicate that S100B is actively released following TBI, proton MR spectroscopy may represent a new tool to identify increased cerebral S100B levels in patients after injury, thus allowing its biological function to be better understood.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiol, Richmond, VA USA; Humboldt Univ, Inst Lab Med & Pathobiochem, Berlin, Germany	Kleindienst, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Med Coll Virginia Campus, Richmond, VA 23284 USA.	akleindienst@vcu.edu	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587-26] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Agelink MW, 2001, J NEUROL NEUROSUR PS, V71, P394, DOI 10.1136/jnnp.71.3.394; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; ESOUZA MT, 2000, PHYSIOL BEHAV, V71, P29; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hilton G, 1994, Orthop Nurs, V13, P25, DOI 10.1097/00006416-199407000-00006; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KRAGH J, 1993, BIOL PSYCHIAT, V33, P794, DOI 10.1016/0006-3223(93)90020-E; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Li YK, 1998, J NEUROCHEM, V71, P1421; MATSUTANI T, 1985, NEUROCHEM RES, V10, P1155, DOI 10.1007/BF00965889; ODowd BS, 1997, NEUROBIOL LEARN MEM, V67, P197, DOI 10.1006/nlme.1997.3766; Peskind ER, 2001, NEUROCHEM INT, V39, P409, DOI 10.1016/S0197-0186(01)00048-1; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; RICKMANN M, 1995, BRAIN RES, V688, P8, DOI 10.1016/0006-8993(95)00495-C; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	44	21	21	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2005	102	6					1115	1121		10.3171/jns.2005.102.6.1115			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	938NL	WOS:000230010000024	16028772				2021-06-18	
J	Sanchez-Olmedo, JI; Flores-Cordero, JM; Rincon-Ferrari, MD; Perez-Ale, M; Munoz-Sanchez, MA; Dominguez-Roldan, JM; Murillo-Cabezas, F				Sanchez-Olmedo, JI; Flores-Cordero, JM; Rincon-Ferrari, MD; Perez-Ale, M; Munoz-Sanchez, MA; Dominguez-Roldan, JM; Murillo-Cabezas, F			Brain death after severe traumatic brain injury: The role of systemic secondary brain insults	TRANSPLANTATION PROCEEDINGS			English	Article							HEAD-INJURY; ORGAN DONORS	Secondary brain insults predominantly due to hypotension are frequent among patients with fatal traumatic brain injury. We assessed the correlation between different systemic secondary brain insults and brain death in 404 patients admitted to our intensive care unit (ICU) after severe traumatic brain injury. We collated data on hypoxemia and hypotension prior to as well as the occurrence of hypoxemia, hypotension, shock, anemia, hyperglycemia, and hyperthermia within the first 24 hours after ICU admission. We also considered both the presence of extracranial injuries and the category of traumatic brain injury using computerized tomography. The 59 patients (14.6%) who developed brain death, were significantly older than patients without a fatal neurological outcome (46.1 +/- 22 vs 29.5 +/- 14.9 years; P < .0001). Intracranial mass lesions, whether surgically evacuated were more frequent among brain-dead patients. The systemic secondary brain insults significantly associated with brain death were hypoxemia, hypotension, shock, anemia, and hyperglycemia within the first 24 hours after ICU admission. After multivariate analysis, the factors that independently predicted brain death were the occurrence of shock (odds ratio [OR], 6.74; 95% confidence interval [CI], 2.85-15.84; P =.001) and older age (OR, 1.05; 95% CI, 1.03-1.07; P =.003). In conclusion, early shock seems to be the major systemic secondary brain insult associated with brain death in patients with severe traumatic brain injury. Prevention of or correction of shock might help to either decrease the occurrence of a fatal neurological outcome or in brain-dead patients to preserve organs in better condition for procurement.	Hosp Traumatol Virgen Rocio, Intens Care Unit, Dept Emergency & Crit Care, Seville 4103, Spain	Flores-Cordero, JM (corresponding author), Hosp Traumatol Virgen Rocio, Intens Care Unit, Dept Emergency & Crit Care, Avda Manuel Siurot S-N, Seville 4103, Spain.	juanflores@inicla.es	IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021; Dominguez-Roldan, Jose-Maria/M-1728-2016	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478			ANGSTWURM H, 1984, TRANSPLANT P, V16, P95; Bullock MR, 1996, J NEUROTRAUM, V13, P719; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cuende N, 2002, TRANSPLANTATION, V73, P1360, DOI 10.1097/00007890-200204270-00033; Dominguez-Roldan JM, 1999, TRANSPL P, V31, P2595, DOI 10.1016/S0041-1345(99)00516-3; Hauptman PJ, 1997, NEW ENGL J MED, V336, P422, DOI 10.1056/NEJM199702063360607; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Port FK, 2002, TRANSPLANTATION, V74, P1281, DOI 10.1097/00007890-200211150-00014; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; WERKMAN HA, 1991, TRANSPLANT P, V23, P2553	11	21	22	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0041-1345	1873-2623		TRANSPL P	Transplant. Proc.	JUN	2005	37	5					1990	1992		10.1016/j.transproceed.2005.03.048			3	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	938TB	WOS:000230024800003	15964320				2021-06-18	
J	Busch, RM; Booth, JE; McBride, A; Vanderploeg, RD; Curtiss, G; Duchnick, JJ				Busch, RM; Booth, JE; McBride, A; Vanderploeg, RD; Curtiss, G; Duchnick, JJ			Role of executive functioning in verbal and visual memory	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	111th Annual Convention of the American-Psychological-Association	AUG 07-10, 2003	Toronto, CANADA	Amer Psychol Assoc		memory; material-specific memory; executive functions	DIFFUSE AXONAL INJURY; EPISODIC MEMORY; PREFRONTAL CORTEX; BRAIN-DAMAGE; SEX-DIFFERENCES; ATTENTION; PERFORMANCE; DYSFUNCTION; IMPAIRMENT; OLD	G. Tremont, S. Halpert, D. J. Javorsky, and R. A. Stern (2000) found that individuals with executive dysfunction were more impaired on less structured versus more structured verbal memory tasks. In the present study, the authors investigated the relationship between executive functions and memory in patients with a history of traumatic brain injury by examining the effect of executive functioning on more structured and less structured verbal and visual memory tasks at baseline and 1-year follow-up. Matched subgroups controlled for differences in severity of neuropsychological impairment unrelated to specific executive functions. The G. Tremont et al. (2000) findings were not replicated. Results showed that when acuteness and severity of injury were controlled, executive impairment played no significant role in performance on either more or less structured memory tasks. However, regardless of structure, executive functions played a role in visual memory performance, suggesting that visual memory may be a more fluid ability than verbal memory.	Univ S Florida, James A Haley Vet Hosp, Psychol Serv 116B, Tampa, FL 33612 USA; Univ Cincinnati, Cincinnati, OH 45221 USA; Univ Texas, Austin, TX 78712 USA	Vanderploeg, RD (corresponding author), Univ S Florida, James A Haley Vet Hosp, Psychol Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; BADDELEY AD, 1974, RECENT ADV LEARNING, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; BARRON JH, 1992, ARCH CLIN NEUROPSYCH, V7, P175, DOI 10.1016/0887-6177(92)90011-B; BECKER JT, 1983, ALCOHOL CLIN EXP RES, V7, P213, DOI 10.1111/j.1530-0277.1983.tb05444.x; Benton A, 1989, MULTILINGUAL APHASIA; Delis DC, 1987, CALIFORNIA VERBAL LE; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; FABIAN MS, 1984, J NERV MENT DIS, V172, P16, DOI 10.1097/00005053-198401000-00005; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Fletcher PC, 1998, BRAIN, V121, P1239, DOI 10.1093/brain/121.7.1239; Fletcher PC, 1998, BRAIN, V121, P1249, DOI 10.1093/brain/121.7.1249; FUNAHASHI S, 1991, J NEUROPHYSIOL, V65, P1464; Goldberg E., 1987, FRONTAL LOBES REVISI, P159; GOLDMANRAKIC PS, 1992, SCI AM, V267, P111; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Henson RNA, 1999, BRAIN, V122, P1367, DOI 10.1093/brain/122.7.1367; Horn, 1982, AGING COGNITIVE PROC, V8, DOI [10.1007/978-1-4684-4178-9_14, DOI 10.1007/978-1-4684-4178-9_14]; HORN JL, 1976, ANNU REV PSYCHOL, V27, P437, DOI 10.1146/annurev.ps.27.020176.002253; INGLIS J, 1981, SCIENCE, V212, P693, DOI 10.1126/science.7221560; JONES B, 1971, ARCH GEN PSYCHIAT, V24, P71; Kaplan E., 1983, BOSTON NAMING TEST; KRAMER JH, 1989, J CONSULT CLIN PSYCH, V57, P257, DOI 10.1037/0022-006X.57.2.257; LEBER WR, 1981, J CLIN PSYCHOL, V37, P192, DOI 10.1002/1097-4679(198101)37:1<192::AID-JCLP2270370140>3.0.CO;2-M; Lezak M.D., 1987, NEUROPSYCHOL REHABIL, P41; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Maccoby E.E., 1978, PSYCHOL SEX DIFFEREN, VVol. 2; MALEC JF, 1991, PSYCHOL ASSESSMENT J, V3, P82; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCGLONE J, 1978, CORTEX, V14, P122, DOI 10.1016/S0010-9452(78)80015-X; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MESULAM MM, 1986, ANN NEUROL, V19, P320, DOI 10.1002/ana.410190403; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MIGLIOLI M, 1979, J NERV MENT DIS, V167, P212, DOI 10.1097/00005053-197904000-00003; NIXON SJ, 1987, J CLIN EXP NEUROPSYC, V9, P311, DOI 10.1080/01688638708405053; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; REITAN RM, 1958, HALSTEAD REITAN NEUR; RUSSELL EW, 1980, PERCEPT MOTOR SKILL, V51, P121, DOI 10.2466/pms.1980.51.1.121; RUSSELL EW, 1979, J CLIN PSYCHOL, V35, P611, DOI 10.1002/1097-4679(197907)35:3<611::AID-JCLP2270350325>3.0.CO;2-V; RUSSELL EW, 2000, CLIN GUIDE NEUROPSYC, P483; RYAN C, 1980, ALCOHOL CLIN EXP RES, V4, P288, DOI 10.1111/j.1530-0277.1980.tb04816.x; Shallice T., 1990, NEUROPSYCHOLOGY MENT; SHERER M, 1992, ARCH CLIN NEUROPSYCH, V7, P499, DOI 10.1016/0887-6177(92)90139-E; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Stuss D.T., 1986, FRONTAL LOBES; TEASDALE G, 1974, LANCET, V2, P81; Tong BSK, 2002, BRAIN INJURY, V16, P987, DOI 10.1080/02699050210147202; Tremont G, 2000, CLIN NEUROPSYCHOL, V14, P295, DOI 10.1076/1385-4046(200008)14:3;1-P;FT295; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; WITTIG MA, 1979, SEX RELATED DIFFEREN	56	21	22	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2005	19	2					171	180		10.1037/0894-4105.19.2.171			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	906DE	WOS:000227619900004	15769201				2021-06-18	
J	Fink, EL; Marco, CD; Donovan, HA; Alexander, H; Dixon, CE; Jenkins, LW; Stange, CJ; Kochanek, PM; Clark, RSB				Fink, EL; Marco, CD; Donovan, HA; Alexander, H; Dixon, CE; Jenkins, LW; Stange, CJ; Kochanek, PM; Clark, RSB			Brief induced hypothermia improves outcome after asphyxial cardiopulmonary arrest in juvenile rats	DEVELOPMENTAL NEUROSCIENCE			English	Article						hypothermia; asphyxial cardiac arrest; neurodegeneration	TRAUMATIC BRAIN-INJURY; CARDIAC-ARREST; WATER MAZE; THERAPEUTIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; RESUSCITATION; SURVIVAL; GENDER; ISCHEMIA; DAMAGE	The American Heart Association has endorsed the use of mild hypothermia for adults after cardiopulmonary arrest. However, there are no contemporary trials testing hypothermia in children after cardiopulmonary arrest and extrapolation from adult studies is problematic given differences in brain development and primary etiology (asphyxia in children vs. ventricular arrhythmia in adults). Accordingly, we tested the effects of mild postresuscitative hypothermia on functional and histopathological outcome after asphyxial cardiac arrest in juvenile rats. Postnatal day 17 rats were subjected to 8 min of asphyxia-induced cardiac arrest followed by resuscitation. Rats were randomized to normothermic (37 degrees C), hypothermic (32 degrees C), or unregulated temperature groups (n = 7-8/group) to begin after return of spontaneous circulation for a duration of 1 h. Brain temperature in the unregulated group dropped to 34.0 +/- 0.4 degrees C at 1 h. The hypothermic group had improved motor function assessed using beam balance and inclined plane tests vs. the normothermic group. The depth of hypothermia was associated with increased CA1 hippocampal neuron survival at 5 weeks. Neurodegeneration in the CA1 hippocampus assessed using Fluoro-Jade B labeling at 5 weeks was not detected in the 32 degrees C group, whereas 2/7 and 4/7 rats in the 34 and 37 degrees C groups, respectively, showed neurodegeneration. Brief treatment with moderate induced hypothermia improved functional outcome and prevented long-term neurodegeneration in a model that mimics the clinical and histopathological scenario of pediatric cardiac arrest. Similar to adults, infants and children may benefit from induced hypothermia after cardiopulmonary arrest, warranting further study. Copyright (c) 2005 S. Karger AG, Basel.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Clark, RSB (corresponding author), Pediat Crit Care Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32 HD 40686, R01 HD045968] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318, R01 NS38620] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P50NS030318] Funding Source: NIH RePORTER		Agnew DM, 2003, PEDIATR RES, V54, P253, DOI 10.1203/01.PDR.0000072783.22373.FF; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BIGGART MJ, 1990, J PEDIATR-US, V117, P179, DOI 10.1016/S0022-3476(05)80526-8; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Fink Ericka L, 2004, Pediatr Crit Care Med, V5, P139, DOI 10.1097/01.PCC.0000112376.29903.8F; Hachimi-Idrissi S, 2001, RESUSCITATION, V49, P73, DOI 10.1016/S0300-9572(00)00268-9; Hagberg H, 1997, ACTA PAEDIATR, V86, P85; Hickey RW, 1996, PEDIATR RES, V39, P77, DOI 10.1203/00006450-199601000-00011; Hickey RW, 2000, CRIT CARE MED, V28, P3511, DOI 10.1097/00003246-200010000-00027; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hurvitz E A, 1999, Pediatr Rehabil, V3, P43; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; KUISMA M, 1995, RESUSCITATION, V30, P141, DOI 10.1016/0300-9572(95)00888-Z; Loidl CF, 2000, PHYSIOL BEHAV, V68, P263, DOI 10.1016/S0031-9384(99)00125-0; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Nelson A, 1997, BEHAV BRAIN RES, V85, P93, DOI 10.1016/S0166-4328(96)00167-2; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Shukitt-Hale B, 2004, NEUROBIOL AGING, V25, P223, DOI 10.1016/S0197-4580(03)00041-1; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Vaagenes P, 1997, RESUSCITATION, V35, P41, DOI 10.1016/S0300-9572(97)01108-8; Vannucci SJ, 2001, J CEREBR BLOOD F MET, V21, P52, DOI 10.1097/00004647-200101000-00007; Xiao F, 1998, AM J EMERG MED, V16, P17, DOI 10.1016/S0735-6757(98)90059-6; Young KD, 1999, ANN EMERG MED, V33, P195, DOI 10.1016/S0196-0644(99)70394-X; YOUNG R S K, 1983, Stroke, V14, P929	30	21	22	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2005	27	2-4			SI		191	199		10.1159/000085992			9	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	947XA	WOS:000230679400015	16046854				2021-06-18	
J	Iverson, GL; Lange, RT; Franzen, MD				Iverson, GL; Lange, RT; Franzen, MD			Effects of mild traumatic brain injury cannot be differentiated from substance abuse	BRAIN INJURY			English	Article; Proceedings Paper	21st Annual Conference of the National-Academy-of-Neuropsychology	OCT 31-NOV 03, 2001	SAN FRANCISCO, CA	Natl Acad Neuropsychol			NEUROPSYCHOLOGICAL TEST-PERFORMANCE; CHRONIC COCAINE ABUSERS; HEAD-INJURY; SOCIAL DRINKERS; LONG-TERM; COMPUTERIZED-TOMOGRAPHY; POLYSUBSTANCE ABUSE; CHRONIC-ALCOHOLISM; OLDER ADULTS; IMPAIRMENT	Primary objective: Patients involved in litigation relating to mild traumatic brain injury (MTBI) typically undergo a forensic neuropsychological evaluation. However, if cognitive problems are identified, it is difficult to know whether these are related to the MTBI or other factors such as pre- and/or post-injury substance abuse. The purpose of this study was to compare the neuropsychological test performances of 73 patients with acute, uncomplicated MTBIs to a sample of 73 patients from an inpatient substance abuse programme. Methods and procedures: Patients were perfectly matched on age, education and gender. Ten cognitive measures were used that included the Trail Making Test (TMT) and selected sub-tests from the Wechsler Memory Scale-Revised. Main outcomes and results: Patients with MTBI demonstrated poorer performances on Digits Backwards ( p < 0.028) and TMTA ( p < 0.032). There were no significant differences between the two groups on the remaining cognitive measures. The clinical usefulness of these measures to differentiate between the groups, using discriminant function analysis, was very poor. Conclusions: Patients with uncomplicated MTBIs could not be reliably differentiated from patients with substance abuse problems on these measures of concentration, memory and processing speed.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Akshoomoff N A, 1989, Arch Clin Neuropsychol, V4, P275, DOI 10.1016/0887-6177(89)90018-8; ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; ARDILA A, 1991, INT J NEUROSCI, V57, P73, DOI 10.3109/00207459109150348; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Bates ME, 1999, ASSESSMENT OF NEUROPSYCHOLOGICAL FUNCTIONS IN PSYCHIATRIC DISORDERS, P373; Beatty M. E., 1994, DRUG ALCOHOL DEPEN, V37, P247; BRANDT J, 1983, ARCH GEN PSYCHIAT, V40, P435; CARLIN AS, 1996, NEUROPSYCHOLOGICAL A, P486; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Drubach D A, 1993, Md Med J, V42, P989; EMMERSON RY, 1988, ALCOHOL CLIN EXP RES, V12, P625, DOI 10.1111/j.1530-0277.1988.tb00254.x; ERRICO AL, 1990, PSYCHOL ASSESSMENT, V2, P45, DOI DOI 10.1037/1040-3590.2.1.45; ERRICO AL, 1991, PSYCHOL ASSESSMENT, V3, P305; FABIAN MS, 1983, J ABNORM PSYCHOL, V92, P87, DOI 10.1037/0021-843X.92.1.87; Fein G, 1998, ALCOHOL CLIN EXP RES, V22, p196S, DOI 10.1111/j.1530-0277.1998.tb04000.x; FRENCH BN, 1977, SURG NEUROL, V7, P171; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; GORDON SM, 1988, J SUBST ABUSE TREAT, V5, P99, DOI 10.1016/0740-5472(88)90019-0; GRANT I, 1987, J CLIN PSYCHIAT, V48, P319; GRANT I, 1987, J CONSULT CLIN PSYCH, V55, P310, DOI 10.1037/0022-006X.55.3.310; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heaton R.K., 1991, COMPREHENSIVE NORMS; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; Hoff AL, 1996, PSYCHIAT RES, V60, P167, DOI 10.1016/0165-1781(96)02758-8; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 1999, ARCH CLIN NEUROPSYCH, V14, P781; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; IVERSON GL, 1997, J NEUROPSYCHIATRY CL, V9, P638; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; JERNIGAN T, 1992, IMAGING ALCOHOL RES, P121; KRAMER JH, 1989, ALCOHOL CLIN EXP RES, V13, P240, DOI 10.1111/j.1530-0277.1989.tb00320.x; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LONG JA, 1974, Q J STUD ALCOHOL, V35, P1220; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACVANE J, 1982, J STUD ALCOHOL, V43, P81, DOI 10.15288/jsa.1982.43.81; MEEK PS, 1989, J PSYCHOACTIVE DRUGS, V21, P153, DOI 10.1080/02791072.1989.10472155; MORRIS JA, 1998, ALCOHOLISM TREATMENT, V16, P101; MUURONEN A, 1989, ALCOHOL CLIN EXP RES, V13, P137, DOI 10.1111/j.1530-0277.1989.tb00298.x; Nixon SJ, 1999, PSYCHOL SCI, V10, P181, DOI 10.1111/1467-9280.00130; OMALLEY S, 1992, AM J DRUG ALCOHOL AB, V18, P131, DOI 10.3109/00952999208992826; Paraherakis A, 2001, SUBST USE MISUSE, V36, P257, DOI 10.1081/JA-100102625; PARKER ES, 1982, ALCOHOL CLIN EXP RES, V6, P46, DOI 10.1111/j.1530-0277.1982.tb05380.x; Parsons OA, 1998, ALCOHOL CLIN EXP RES, V22, P954, DOI 10.1097/00000374-199806000-00029; PARSONS OA, 1993, NEUROL CLIN, V11, P205; PARSONS OA, 1987, ACTA MED SCAND, P33; PARSONS OA, 1990, ADDICT BEHAV, V15, P297, DOI 10.1016/0306-4603(90)90073-7; PARSONS OA, 1990, ALCOHOL CLIN EXP RES, V14, P746, DOI 10.1111/j.1530-0277.1990.tb01239.x; PARSONS OA, 1996, NEUROPSYCHOLOGY CLIN, P175; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; POPE HG, 1995, DRUG ALCOHOL DEPEN, V38, P25, DOI 10.1016/0376-8716(95)01097-I; PRIFITERA CA, 1992, UNPUB NORMATIVE DELA; Reitan R. M., 1992, TRAIL MAKING TEST MA; Rosselli M, 1996, J CLIN EXP NEUROPSYC, V18, P122, DOI 10.1080/01688639608408268; ROURKE SB, 1996, NEUROPSYCHOLOGICAL A, P423; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ryan J. J., 1988, CLIN NEUROPSYCHOL, V2, P173; SACHS H, 1987, ARCH NEUROL-CHICAGO, V44, P1242, DOI 10.1001/archneur.1987.00520240024007; SANDER AM, 1989, J CONSULT CLIN PSYCH, V57, P705; Selby MJ, 1998, DRUG ALCOHOL DEPEN, V50, P39, DOI 10.1016/S0376-8716(98)00002-7; SLICK DJ, 2000, J INT NEUROPSYCH SOC, V6, P184; Spreen O., 1998, COMPENDIUM NEUROPSYC; STRANG J, 1989, BRIT J ADDICT, V84, P1011; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOHMAN JR, 1987, J NERV MENT DIS, V175, P219, DOI 10.1097/00005053-198704000-00005; YOHMAN JR, 1985, ALCOHOL CLIN EXP RES, V9, P114, DOI 10.1111/j.1530-0277.1985.tb05530.x	74	21	21	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2005	19	1					11	18		10.1080/02699050410001720068			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	875AS	WOS:000225392600002	15762097				2021-06-18	
S	Kulkarni, AP; Kellaway, LA; Kotwal, GJ		Kotwal, GJ; Lahiri, DK		Kulkarni, AP; Kellaway, LA; Kotwal, GJ			Herbal complement inhibitors in the treatment of neuroinflammation - Future strategy for neuroprotection	NATURAL PRODUCTS AND MOLECULAR THERAPY	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	1st International Conference on Natural Products and Molecular Medicine	JAN 13-15, 2005	Univ Cape Town, Cape Town, SOUTH AFRICA		Univ Cape Town	neuroprotection; neurodegeneration; complement inhibitors; herbal ingredients; alternate pathway; classical pathway; cyclooxygenases; vaccinia virus complement control protein (VCP); Alzheimer's disease (AD); HIV-associated dementia (HAD); Parkinson's disease (PD)	SPINAL-CORD-INJURY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIAL; ALZHEIMERS-DISEASE; IN-VITRO; CONTROL PROTEIN; ATNICOMPLEMENTARY ACTIVITY; ANTICOMPLEMENTARY ACTIVITY; IMMUNOMODULATORY ACTIVITY; ISOPYRUM-THALICTROIDES	The upregulated complement system plays a damaging role in disorders of the central nervous system (CNS). The classical and alternate pathways are two major pathways activated in neuroinflammatory disorders such as Alzheimer's disease, multiple sclerosis, traumatic brain injury, spinal cord injury, HIV-associated dementia, Parkinson's disease, and mad cow disease. Failure of currently available anti-inflammatory agents, especially cycloxygenase inhibitors, in offering significant neuroprotection in large epidemiologic clinical trials of CNS disorders suggests an urgent need for the development of new neuroprotective agents. The positive preclinical outcomes in treating CNS disorders by complement regulatory molecules, such as vaccinia virus complement control protein, suggest the possibility of using complement-inhibitory molecules as neuroprotective agents. Several active ingredients of herbal origin are found to have complement-inhibitory activity. These herbal ingredients along with other anti-inflammatory roles might be useful in treating neuroinflammation associated with CNS disorders. Active ingredients of herbal origin with complement inhibitory ingredients are summarized and classified according to their chemical nature and specificity towards the major pathways activating the complement system. The structure activity relationship of some specific examples is also discussed in this report. This information might be helpful in formulating a natural panacea against complement-mediated neuroinflammation.	Univ Cape Town, Med Sch, Div Med Virol, ZA-7925 Cape Town, South Africa; Univ Cape Town, Sch Med, Div Neurosci, ZA-7925 Cape Town, South Africa	Kotwal, GJ (corresponding author), Univ Cape Town, Med Sch, Div Med Virol, Anzio Rd, ZA-7925 Cape Town, South Africa.	gjkotw01@yahoo.com			Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Aisen PS, 2000, NEUROLOGY, V54, P588, DOI 10.1212/WNL.54.3.588; Aisen PS, 2002, NEUROLOGY, V58, P1050, DOI 10.1212/WNL.58.7.1050; Al-Sereiti M. R., 1999, Indian Journal of Experimental Biology, V37, P124; Anderson AJ, 2004, J NEUROTRAUM, V21, P1831, DOI 10.1089/0897715042664894; Apers S, 2002, PHYTOCHEM ANALYSIS, V13, P202, DOI 10.1002/pca.642; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Barrington R, 2001, IMMUNOL REV, V180, P5, DOI 10.1034/j.1600-065X.2001.1800101.x; Benencia F, 2000, J ETHNOPHARMACOL, V71, P293, DOI 10.1016/S0378-8741(00)00192-6; Blondin C, 1996, BIOMATERIALS, V17, P597, DOI 10.1016/0142-9612(96)88710-2; Bruder C, 2004, MOL IMMUNOL, V40, P949, DOI 10.1016/j.molimm.2003.10.016; Chen C, 2005, J NEUROPHYSIOL, V93, P929, DOI 10.1152/jn.00696.2004; Chiou WF, 2003, PLANTA MED, V69, P9, DOI 10.1055/s-2003-37041; Cimanga K, 2003, J NAT PROD, V66, P97, DOI 10.1021/np020215h; CIMANGA K, 1995, J NAT PRODUCTS, V58, P372, DOI 10.1021/np50117a005; Davoust N, 1999, J IMMUNOL, V163, P6551; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Gasque P, 2002, MOL NEUROBIOL, V25, P1, DOI 10.1385/MN:25:1:001; Geetha T, 1999, GEN PHARMACOL-VASC S, V32, P495, DOI 10.1016/S0306-3623(98)00212-2; HART LA, 1988, J ETHNOPHARMACOL, V23, P61, DOI 10.1016/0378-8741(88)90115-8; HART LA, 1989, PLANTA MED, P509, DOI 10.1055/s-2006-962082; Henderson VW, 2005, J NEUROL NEUROSUR PS, V76, P103, DOI 10.1136/jnnp.2003.024927; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Ivanovska N, 1999, INT J IMMUNOPHARMACO, V21, P337, DOI 10.1016/S0192-0561(99)00015-6; Ivanovska N, 1999, INT J IMMUNOPHARMACO, V21, P325, DOI 10.1016/S0192-0561(99)00014-4; IVANOVSKA ND, 1995, J ETHNOPHARMACOL, V47, P135, DOI 10.1016/0378-8741(95)01273-G; Jauneau AC, 2003, FEBS LETT, V537, P17, DOI 10.1016/S0014-5793(03)00060-7; Kanatani K, 2004, J PHYSIOL PHARMACOL, V55, P207; Kapil A, 1997, J ETHNOPHARMACOL, V58, P89, DOI 10.1016/S0378-8741(97)00086-X; Kaplan Mariana, 2002, Curr Opin Investig Drugs, V3, P1017; Kawakami F, 2003, J BIOCHEM, V133, P231, DOI 10.1093/jb/mvg028; KIYOSHI N, 2000, J NEUROSCI, V20, P763; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; KOSASI S, 1989, J ETHNOPHARMACOL, V27, P81, DOI 10.1016/0378-8741(89)90080-9; Kotwal GJ, 2002, ANN NY ACAD SCI, V973, P317, DOI 10.1111/j.1749-6632.2002.tb04659.x; Kroes BH, 1997, IMMUNOLOGY, V90, P115, DOI 10.1046/j.1365-2567.1997.00131.x; KROES BH, 1993, J ETHNOPHARMACOL, V40, P117, DOI 10.1016/0378-8741(93)90056-B; Kulkarni AP, 2004, ANN NY ACAD SCI, V1035, P147, DOI 10.1196/annals.1332.010; Lee EO, 2004, J NEUROIMMUNOL, V155, P21, DOI 10.1016/j.jneuroim.2004.05.012; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Manderson AP, 2001, J EXP MED, V194, P747, DOI 10.1084/jem.194.6.747; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Min BS, 2003, BIOL PHARM BULL, V26, P1042, DOI 10.1248/bpb.26.1042; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Nicholl DS, 2001, J ETHNOPHARMACOL, V78, P39, DOI 10.1016/S0378-8741(01)00319-1; Nores MM, 1997, J ETHNOPHARMACOL, V55, P99, DOI 10.1016/S0378-8741(96)01480-8; Park SH, 1999, CHEM PHARM BULL, V47, P1484, DOI 10.1248/cpb.47.1484; PEAKE PW, 1991, INT J IMMUNOPHARMACO, V13, P853, DOI 10.1016/0192-0561(91)90036-7; Pieroni A, 1996, PHARMAZIE, V51, P765; Pieroni A, 2000, J ETHNOPHARMACOL, V70, P213, DOI 10.1016/S0378-8741(99)00169-5; Reines SA, 2004, NEUROLOGY, V62, P66, DOI 10.1212/WNL.62.1.66; Reynolds DN, 2004, ANN NY ACAD SCI, V1035, P165, DOI 10.1196/annals.1332.011; Reynolds DN, 2003, ANN NY ACAD SCI, V1010, P534, DOI 10.1196/annals.1299.099; Rodriguez LAG, 2004, CIRCULATION, V109, P3000, DOI 10.1161/01.CIR.0000132491.96623.04; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Romi F, 2005, J NEUROIMMUNOL, V158, P191, DOI 10.1016/j.jneuroim.2004.08.002; Sahu A, 1999, BIOCHEM PHARMACOL, V57, P1439, DOI 10.1016/S0006-2952(99)00044-1; SANDERS ME, 1986, J IMMUNOL, V136, P4456; Sayah S, 2003, MOL BRAIN RES, V112, P53, DOI 10.1016/S0169-328X(03)00046-9; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Sellebjerg F, 1998, J NEUROL SCI, V157, P168, DOI 10.1016/S0022-510X(98)00086-0; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shahat AA, 2003, PLANTA MED, V69, P1153, DOI 10.1055/s-2003-818009; Shahat AA, 1996, PLANTA MED, V62, P10, DOI 10.1055/s-2006-957786; Shen Y, 1997, BRAIN RES PROTOC, V1, P186, DOI 10.1016/S1385-299X(96)00026-8; Shernan SK, 2004, ANN THORAC SURG, V77, P942, DOI 10.1016/j.athoracsur.2003.08.054; Spielman L, 2002, ACTA NEUROPATHOL, V103, P157, DOI 10.1007/s004010100447; Stoiber H, 2005, MOL IMMUNOL, V42, P153, DOI 10.1016/j.molimm.2004.06.024; STRUNK RC, 1979, PEDIATR RES, V13, P188, DOI 10.1203/00006450-197903000-00012; Tacnet-Delorme P, 2001, J IMMUNOL, V167, P6374, DOI 10.4049/jimmunol.167.11.6374; Takahashi N, 2000, HEARTWEB, V5, pU1; Takano T, 2001, AM J PHYSIOL-RENAL, V281, pF841, DOI 10.1152/ajprenal.0048.2001; TEATHER LA, 2000, LEARN MEMORY, V9, P41; THABREW MI, 1991, J ETHNOPHARMACOL, V33, P63, DOI 10.1016/0378-8741(91)90162-7; THEOHARIDES TC, 1990, LIFE SCI, V46, P607, DOI 10.1016/0024-3205(90)90129-F; Thomet OAR, 2001, BIOCHEM PHARMACOL, V61, P1041, DOI 10.1016/S0006-2952(01)00552-4; VANDENBERG AJJ, 1995, FEBS LETT, V358, P215, DOI 10.1016/0014-5793(94)01405-P; VANDERNAT JM, 1989, J ETHNOPHARMACOL, V27, P15, DOI 10.1016/0378-8741(89)90073-1; Verrico MM, 2003, ANN PHARMACOTHER, V37, P1203, DOI 10.1345/aph.1A212; Verrier ED, 2004, JAMA-J AM MED ASSOC, V291, P2319, DOI 10.1001/jama.291.19.2319; Whiss Per A, 2002, Curr Opin Investig Drugs, V3, P870; Wolfe F, 2004, J RHEUMATOL, V31, P1143; Woolhiser MR, 2004, CLIN IMMUNOL, V110, P172, DOI 10.1016/j.clim.2003.11.007; YAMADA H, 1985, MOL IMMUNOL, V22, P295; ZHAO JF, 1993, PHYTOCHEMISTRY, V34, P719, DOI 10.1016/0031-9422(93)85346-S	87	21	21	0	8	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-595-8; 1-57331-594-X	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2005	1056						413	429		10.1196/annals.1352.020			17	Biochemistry & Molecular Biology; Integrative & Complementary Medicine; Medicine, Research & Experimental; Multidisciplinary Sciences	Biochemistry & Molecular Biology; Integrative & Complementary Medicine; Research & Experimental Medicine; Science & Technology - Other Topics	BDU43	WOS:000235433100035	16387706				2021-06-18	
J	Ling, GSF; Neal, CJ				Ling, GSF; Neal, CJ			Maintaining cerebral perfusion pressure is a worthy clinical goal	NEUROCRITICAL CARE			English	Article						cerebral perfusion pressure; traumatic brain injury; critical care; intracranial pressure	SECONDARY ISCHEMIC INSULTS; TRAUMATIC BRAIN-INJURY; TISSUE OXYGEN; BLOOD-FLOW; THERAPY; AUTOREGULATION; HYPERTENSION; MANAGEMENT; VOLUME	Cerebral perfusion pressure (CPP) is one aspect of an all-encompassing approach in the management of traumatic brain injury (TBI). The clinical use of CPP is based on theoretical considerations that optimal cerebral blood flow is necessary to meet the metabolic needs of the injured brain. The goal is to preserve the ischemic penumbra and avoid secondary insults. Unfortunately, lack of objective measures of local tissue response and randomized controlled clinical trials prevents confirmation that these goals are being met when actively treating CPP. The present recommended threshold CPP for intervention in the literature is 70 mmHg. However, this specific CPP level is being challenged. There is increasing evidence that this and higher CPP thresholds are not necessary and that a lower CPP may be as clinically effective. There are clinical prospective, but not randomized, human trials showing that CPP 60 to 70 mmHg may be reasonable. Recently, the Brain Trauma Foundation updated their Web-based recommendation of a lower CPP goal of 60 mmHg. However, the lack of definitive data, such as from a randomized prospective intention-to-treat clinical trials, leaves this goal open to controversy. Therefore, for a variety of reasons, the physician may be most prudent to use the published CPP guideline of 70 mmHg until a consensus statement is published advocating a different value.	Uniformed Serv Univ Hlth Sci, Dept Neurol, Div Crit Care Med, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Natl Capital Neurosurg Consortium, Washington, DC 20307 USA	Ling, GSF (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, Div Crit Care Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gling@usuhs.mil					*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P507; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P457; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; [Anonymous], 2001, J TRAUMA S, V51, pS3; *BRAIN TRAUM FDN, MAN PROGN SEV TRAUM; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHRISTER E, 1998, CRIT CARE MED, V26, P1881; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; Czosnyka M, 1996, CEREBROVAS BRAIN MET, V8, P273; Czosnyka M, 2003, ACT NEUR S, V86, P581; Czosnyka M, 2000, ACT NEUR S, V76, P483; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; Nordstrom CH, 2003, ACTA NEUROCHIR SUPPL, V86, P355; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Poon WS, 2002, ACT NEUR S, V81, P335; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson C, 2000, CRIT CARE MED, V28, P3358, DOI 10.1097/00003246-200009000-00046; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 1991, Minerva Anestesiol, V57, P327; Thomson A D, 2000, Alcohol Alcohol Suppl, V35, P2; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; CEREBRAL PERFUSION P	36	21	23	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2005	2	1					75	81		10.1385/NCC:2:1:075			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	945FU	WOS:000230489200015	16174974				2021-06-18	
J	Geddes, JF; Whitwell, HL				Geddes, JF; Whitwell, HL			Inflicted head injury in infants	FORENSIC SCIENCE INTERNATIONAL			English	Article						infant head injury; non-accidental injury; hypoxia; craniocervical injury; subdural haemorrhage; retinal haemorrhages	DIFFUSE AXONAL INJURY; SHAKEN BABY SYNDROME; BRAIN-INJURY; NEUROPATHOLOGY; HEMORRHAGE; CHILDREN; LESIONS; TRAUMA; HYPEREXTENSION; DIAGNOSIS	There is scant neuropathological information in the child abuse literature; even the best reviews include assumptions based on the findings of a few inadequate early studies. Our recent series of 53 fatal cases (Brain 124 (2001) 1290, 1299 [1,2]) demonstrated age-related patterns of brain injury and showed the substrate of severe encephalopathy in the infants to be hypoxic brain damage, not diffuse traumatic axonal injury ("DAI"), as had previously been thought. About one-third had craniocervical injuries, particularly in the brain stem, suggestive of stretch injury to the neuraxis. Our interpretation was that this finding implied a mechanism of injury-brain stem damage from stretch injury to the neck with resultant apnoea-that could account for the clinical scenario in many cases, and for which violence would not necessarily be required. Since publishing this study we have turned our attention to the subgroup of infants who die without objective signs of injury, such as skull fracture or impact, whose carers are accused of abuse, usually, "violent shaking", on the pathologic findings alone. Given the striking discrepancy that there often is in such cases between the relatively trivial findings in the brain and the accusations of violence, we have been looking at the pathogenesis of the typical intracranial bleeding. A histologic study of dura from 50 paediatric autopsies, none of whom had suffered a head injury, has led us to propose that the subdural and retinal bleeding in such cases may well have a physiological aetiology, rather than being caused directly by trauma. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Royal London Hosp, Dept Histopathol & Morbid Anat, London E1 1BB, England; Univ London Queen Mary Coll, Dept Histopathol & Morbid Anat, London E1 4NS, England; Univ Sheffield, Dept Forens Pathol, Sheffield, S Yorkshire, England	Geddes, JF (corresponding author), Royal London Hosp, Dept Histopathol & Morbid Anat, London E1 1BB, England.	j.f.geddes@doctors.org.uk					Anteby II, 2001, J AAPOS, V5, P90, DOI 10.1067/mpa.2001.113841; BIAGGIONI I, 1994, HYPERTENSION, V23, P491, DOI 10.1161/01.HYP.23.4.491; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Chase W. H., 1930, SURG GYNECOL OBSTET, V51, P31; David TJ, 1999, J ROY SOC MED, V92, P556, DOI 10.1177/014107689909201105; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; FERRARIO CM, 1981, HYPERTENSION, V3; Friede RL, 1989, DEV NEUROPATHOLOGY, P44; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, CURR TOPICS PATHOL, V95, P101; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; GOVAERT P, 1993, CRANIAL HAEMORRHAGE, P52; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; Green PM, 1999, FETAL DIAGN THER, V14, P275, DOI 10.1159/000020938; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HARDMAN JM, 1979, COMPLICATIONS NERVOU, P15; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; Maxeiner H, 2001, Med Law, V20, P463; Maxeiner H, 2001, J FORENSIC SCI, V46, P85; Maxeiner H, 1997, FORENSIC SCI INT, V89, P103, DOI 10.1016/S0379-0738(97)00124-2; Medele RJ, 1998, J NEUROSURG, V88, P851, DOI 10.3171/jns.1998.88.5.0851; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; RIGGS JE, 1995, MIL MED, V160, P94; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Stoodley N, 2002, LANCET, V360, P271, DOI 10.1016/S0140-6736(02)09563-6; Volpe J., 2001, NEUROLOGY NEWBORN, V4th ed.; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185	36	21	23	0	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	DEC 16	2004	146	2-3					83	88		10.1016/S0379-0738(03)00283-4			6	Medicine, Legal	Legal Medicine	879OZ	WOS:000225728400003	15542267				2021-06-18	
J	Fuchtmeier, B; Maghsudi, M; Neumann, C; Hente, R; Roll, C; Nerlich, M				Fuchtmeier, B; Maghsudi, M; Neumann, C; Hente, R; Roll, C; Nerlich, M			The minimally invasive stabilization of the dorsal pelvic ring with the transiliacal internal fixator (TIFI) - Surgical technique and first clinical findings	UNFALLCHIRURG			German	Article							ILIOSACRAL SCREW PLACEMENT; SACRAL FRACTURES; SACROILIAC JOINT; OPEN REDUCTION; INJURIES; DISRUPTIONS; OSTEOSYNTHESIS; EXPERIENCES; MANAGEMENT; THERAPY	The Trans Iliacal Internal Fixator (TIFI) is a minimally invasive technique for the stabilization of sacro-iliac joint ruptures and fractures lateral to the sacral ala or through the sacral foramen. In this study, 7.0 mm pedicle screws of the Universal-Spine-System (USS, Synthes) were inserted 1-2 cm on the cranial side of the posterior superior iliac spine and parallel to the superior gluteal line. The connecting bar was inserted subfascially and fixed with the locking head pedicle screws to form an fixed-angle construction. In a prospective study 31 patients with vertical shear injuries of the pelvis were treated with the TIFI. There were two wound infections and one loosening of a pedicle screw. None of the screws were incorrectly positioned and no neuro-vascular lesions were caused by the implant. 2 years postoperatively we found 50% good and excellent results for type C pelvic ring injuries. Early findings show that the TIFI is well suited to stabilization of sacro-iliac joint ruptures and fractures of the lateral sacrum. Closed reduction and minimally invasive insertion technique are possible. The implant leads to sufficient biomechanical stability but there is a very low intraoperative risk of neuro-vascular lesion.	Klinikum Univ Regensburg, Abt Unfallchirurg, D-93042 Regensburg, Germany	Fuchtmeier, B (corresponding author), Klinikum Univ Regensburg, Abt Unfallchirurg, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.	bernd.fuechtmeier@klinik.uni-regensburg.de					Altman DT, 1999, J ORTHOP TRAUMA, V13, P220, DOI 10.1097/00005131-199903000-00011; Barei DP, 2001, INJURY, V32, P33, DOI 10.1016/S0020-1383(01)00059-6; DENIS F, 1988, CLIN ORTHOP RELAT R, P67; FUCHTMEIER B, 2002, HEFTE UNFALLCHIRURG, V284, P393; Gansslen A, 2003, ZBL CHIR, V128, P40, DOI 10.1055/s-2003-37318; GANZ R, 1991, CLIN ORTHOP RELAT R, P71; GOLDSTEIN A, 1986, J TRAUMA, V26, P325; Grutzner PA, 2002, UNFALLCHIRURG, V105, P254, DOI 10.1007/s001130100339; Heini PF, 1996, INJURY, V27, P38, DOI 10.1016/S0020-1383(96)90110-2; Hufner T, 2002, CLIN ORTHOP RELAT R, P231; JOSTEN C, 1994, CHIRURG, V65, P970; KACH K, 1994, UNFALLCHIRURG, V97, P28; KELLAM JF, 1987, ORTHOP CLIN N AM, V18, P25; Lehmann J, 1934, ZENTRALBL CHIR, V37, P2149; Matta JM, 1996, CLIN ORTHOP RELAT R, P129; MATTA JM, 1989, CLIN ORTHOP RELAT R, P83; NELSON DW, 1991, RADIOLOGY, V180, P527, DOI 10.1148/radiology.180.2.2068323; Nepola JV, 1999, J TRAUMA, V46, P1024, DOI 10.1097/00005373-199906000-00007; Nerlich M, 1996, INJURY, V27, P29, DOI 10.1016/S0020-1383(96)90109-6; Pohlemann T, 1996, INJURY, V27, P31, DOI 10.1016/S0002-9378(15)33150-1; Pohlemann T, 1996, UNFALLCHIRURG, V99, P160; RAGNARSSON B, 1993, ACTA ORTHOP SCAND, V64, P138, DOI 10.3109/17453679308994554; Rommens PM, 2002, J ORTHOP TRAUMA, V16, P92, DOI 10.1097/00005131-200202000-00004; Routt MLC, 2000, CLIN ORTHOP RELAT R, P15; SIMPSON LA, 1987, J TRAUMA, V27, P1332, DOI 10.1097/00005373-198712000-00003; Stockle U, 2002, UNFALLCHIRURG, V105, P886, DOI 10.1007/s00113-002-0438-z; Templeman D, 1996, CLIN ORTHOP RELAT R, P194; TILE M, 1988, J BONE JOINT SURG BR, V70, P1; Tonetti J, 1998, CLIN ORTHOP RELAT R, P103; Tscherne H, 2000, ZBL CHIR, V125, P717, DOI 10.1055/s-2000-10662	30	21	25	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0177-5537	1433-044X		UNFALLCHIRURG	Unfallchirurg	DEC	2004	107	12					1142	1151		10.1007/s00113-004-0824-9			10	Emergency Medicine; Surgery	Emergency Medicine; Surgery	884HZ	WOS:000226076800004	15338033				2021-06-18	
J	Pastorek, NJ; Hannay, HJ; Contant, CS				Pastorek, NJ; Hannay, HJ; Contant, CS			Prediction of global outcome with acute neuropsychological testing following closed-head injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	29th Annual INS Meeting	FEB, 2001	Chicago, IL	INS		closed-head injury; assessment; outcome	TRAUMATIC BRAIN-INJURY; DISABILITY RATING-SCALE; POSTTRAUMATIC AMNESIA; VERBAL IMPAIRMENT; PRACTICAL SCALE; RECOVERY; MEMORY; COMA; REHABILITATION; HYPOTHERMIA	Delaying assessment until emergence from post-traumatic amnesia increases completion rates, but this practice causes variable time delays front the date of injury to testing, which can complicate the interpretation of research findings. In the current study, the performance of 105 head injury Survivors Oil simple tests of language comprehension and attention was used to predict global outcome. It was hypothesized that 1 month performance on these measures would aid in the prediction of Disability Rating Scale (DRS) and Glasgow Outcome Scale (GOS) scores collected at 6 months post injury. Only raw scores on the modified Test of Complex Ideational Material accounted for a significant amount of the variance in DRS scores (4.4%) above that accounted for by age, education. Glasgow Coma Scale score, and pupil response. However, testability at 1 month post injury oil all four tests consistently accounted for a larger portion of the variance in DRS scores (10.1-13.2%) and significantly improved prediction of GOS scores. Galveston Orientation and Amnesia Test scores collected at 1 month post injury accounted for Substantially less variance in DRS scores (7.7-8.4%). Neuropsychological data, including the testability of patients, collected uniformly at 1 month following injury can contribute to the prediction of global Outcome.	Univ Houston, Dept Psychol, Houston, TX 77204 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Hannay, HJ (corresponding author), Univ Houston, Dept Psychol, 4800 Calhoun, Houston, TX 77204 USA.	jhannay@uh.edu		Hannay, H. Julia/0000-0001-7023-912X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660, P01-NS27616] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B40002] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660, P01NS027616] Funding Source: NIH RePORTER		Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Borenstein M., 1988, STAT POWER ANAL COMP; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Goodglass H., 1983, ASSESSMENT APHASIA O; GOODMAN JC, 1995, NEUROCHEMICAL MONITO, P78; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; Hannay HJ, 1996, NEUROTRAUMA, P723; HANNAY HJ, 1994, 22 ANN INS M CINC OH; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KOURA SS, 1988, ACTA NEUROCHIR, V71, P244; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1988, UNPUB ACUTE BATTERY; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Maxwell S.E., 2000, DESIGNING EXPT ANAL; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; MEYERS CA, 1992, NEUROPSY NEUROPSY BE, V39, P1011; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; *SPSS INC, 1999, SPSS WIND REL 10 0 1; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tabachnick B., 2001, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	49	21	22	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	OCT	2004	10	6					807	817		10.1017/S1355617704106012			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	862PB	WOS:000224502000001	15637771				2021-06-18	
J	Bayly, PV; Ji, S; Song, SK; Okamoto, RJ; Massouros, P; Genin, GM				Bayly, PV; Ji, S; Song, SK; Okamoto, RJ; Massouros, P; Genin, GM			Measurement of strain in physical models of brain injury: A method based on HARP analysis of tagged magnetic resonance images (MRI)	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							DIFFUSE AXONAL INJURY; SPATIAL MODULATION; MECHANICAL STRETCH; MOTION; HEART; IMPACT; TRAUMA	Two-dimensional (2-D) strain fields were estimated non-invasively in two simple experimental models of closed-head brain injury. In the first experimental model, shear deformation of a gel was induced by angular acceleration of its spherical container. In the second model the brain of a euthanized rat pup was deformed by indentation of its skull. Tagged magnetic resonance images (MRI) were obtained by gated image acquisition during repeated motion. Harmonic phase (HARP) images corresponding to the spectral peaks of the original tagged MRI were obtained, following procedures proposed by Osman, McVeigh and Prince [1]. Two methods of HARP strain analysis were applied, one based on the displacement of tag line intersections, and the other based on the gradient of harmonic phase. Strain analysis procedures were also validated on simulated images of deformed grids. Results show that it is possible to visualize deformation and to quantify strain efficiently in animal models of closed head injury.	Washington Univ, St Louis, MO 63130 USA	Bayly, PV (corresponding author), Washington Univ, 1 Brookings Dr,Box 1185, St Louis, MO 63130 USA.	pvb@me.wustl.edu		Bayly, Philip/0000-0003-4303-0704; Okamoto, Ruth/0000-0002-3085-3878	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24 CA083060] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL042950, R01 HL073315] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS045237-01A1, R21 NS045237, R21 NS045237-02, NS45237] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24CA083060] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL042950, R01HL073315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS045237] Funding Source: NIH RePORTER		Al-Bsharat AS, 1999, P 43 STAPP CAR CRASH; AXEL L, 1989, RADIOLOGY, V172, P349, DOI 10.1148/radiology.172.2.2748813; AXEL L, 1989, RADIOLOGY, V171, P841, DOI 10.1148/radiology.171.3.2717762; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy W.N., 1997, ASME PUBLICATION AMD, V225, P241; Holbourn AHS, 1943, LANCET, V2, P438; Kraitchman DL, 2003, CIRCULATION, V107, P2025, DOI 10.1161/01.CIR.0000062684.47526.47; Kuijer JPA, 2001, MAGN RESON MED, V46, P993; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Osman NF, 2000, IEEE T MED IMAGING, V19, P186, DOI 10.1109/42.845177; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Smith DH, 1999, J NEUROSCI, V19, P4263; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sosin DM, 1996, BRAIN INJURY, V10, P47; Szabo B., 1991, FINITE ELEMENT ANAL; YOUNG AA, 1993, RADIOLOGY, V188, P101, DOI 10.1148/radiology.188.1.8511281; ZERHOUNI EA, 1988, RADIOLOGY, V169, P59, DOI 10.1148/radiology.169.1.3420283; ZHANG L, 2001, ASME BED, V50, P831	24	21	21	0	2	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	AUG	2004	126	4					523	528		10.1115/1.1785811			6	Biophysics; Engineering, Biomedical	Biophysics; Engineering	864YI	WOS:000224668800017	15543872	Green Accepted			2021-06-18	
J	Orme, DR; Johnstone, B; Hanks, R; Novack, T				Orme, DR; Johnstone, B; Hanks, R; Novack, T			The WRAT-3 reading subtest as a measure of premorbid intelligence among persons with brain injury	REHABILITATION PSYCHOLOGY			English	Article							PRACTICAL SCALE; IQ	Objective: To examine whether the Wide Range Achievement Test-3 (WRAT-3) Reading subtest (S. Jastak & G. S. Wilkenson, 1984; G. S. Wilkinson, 1993) measures premorbid intelligence in persons with traumatic brain injury (TBI). Participants: Sixty individuals (63% male, 78% Caucasian, mean age = 38 years) tested during acute rehabilitation hospitalization following TBI and I year later. Results: Slight (4.4 points) increase in WRAT-3 Reading scores was observed but with greater, although nonsignificant (p = .12), increase for those with greater injury severity. Conclusions: The WRAT-3 Reading subtest is a better hold test for individuals who sustain mild TBI.	Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA; Inst Rehabil, Detroit, MI USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA	Orme, DR (corresponding author), Univ Missouri, Dept Hlth Psychol, 1 Hosp Dr,DC 046-46, Columbia, MO 65212 USA.	ormed@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; Jastak S, 1984, WIDE RANGE ACHIEVEME; Johnstone B, 1996, J Int Neuropsychol Soc, V2, P282; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; KAREKEN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P147, DOI 10.1016/0887-6177(94)E0012-E; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Orme D, 2001, ARCH CLIN NEUROPSYCH, V16, P679, DOI 10.1016/S0887-6177(00)00091-3; REITAN R, 1985, HALSTEAD REITAN NEUO; Reynolds C. R., 1997, ARCH CLIN NEUROPSYCH, V12; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1987, MANUAL WECHSLER MEMO; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	14	21	21	0	2	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2004	49	3					250	253		10.1037/0090-5550.49.3.250			4	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	847BX	WOS:000223364900008					2021-06-18	
J	Wennberg, R				Wennberg, R			Collision frequency in elite hockey on North American versus international size rinks	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							ICE HOCKEY; CONCUSSIONS; LEAGUE	Objective: Body impact or collision is the risk factor underlying all sports-related concussions. This study sought to determine whether collision rates in elite hockey differ between games played on North American size rinks as compared to games played on larger international size ice surfaces. Methods: Videotapes of games from the 2001 and 2002 National Hockey League Stanley Cup finals, World Junior championships and the 2002 Winter Olympics were analyzed, with all collisions counted and separated into various categories (player/player bodycheck, player/player into boards, player/boards, player/ice, head/stick, head/puck). Further subdivisions included collisions involving the head directly or indirectly. Twenty-two games were analyzed, 11 played on the small ice and 11 on the big ice. Results: Significantly more collisions of all types (in all categories and subdivisions within categories) were found to occur on the smaller North American ice surface (P value differences from 0.01 to 0.00001). Conclusions: The results of this study showed significantly fewer collisions of all types in elite hockey games played on the international size ice surface. The comparison groups studied here did differ in some aspects other than ice size and so replication of the findings with even more closely matched groups will be needed before definitive conclusions can be drawn. However, if these findings are replicable, it would suggest that a change to uniform usage of the larger international rinks, with no rule changes or other alterations in the game, could provide direct primary prevention to reduce the number of collisions, and, by extension, concussions, that occur in the sport.	Univ Toronto, Toronto Western Hosp, Div Neurol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Krembil Neurosci Ctr, Univ Hlth Network, Toronto, ON M5T 2S8, Canada	Wennberg, R (corresponding author), Univ Toronto, Toronto Western Hosp, Div Neurol, 399 Bathurst St,5W444, Toronto, ON M5T 2S8, Canada.						Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Marchie A, 2003, CAN MED ASSOC J, V169, P124; Watson RC, 1997, CLIN J SPORT MED, V7, P192, DOI 10.1097/00042752-199707000-00007; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596	4	21	21	0	5	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	AUG	2004	31	3					373	377		10.1017/S0317167100003474			5	Clinical Neurology	Neurosciences & Neurology	849OZ	WOS:000223549600015	15376483	Bronze			2021-06-18	
J	Stocchetti, N; Canavesi, K; Magnoni, S; Valeriani, V; Conte, V; Rossi, S; Longhi, L; Zanier, ER; Colombo, A				Stocchetti, N; Canavesi, K; Magnoni, S; Valeriani, V; Conte, V; Rossi, S; Longhi, L; Zanier, ER; Colombo, A			Arterio-jugular difference of oxygen content and outcome after head injury	ANESTHESIA AND ANALGESIA			English	Article							TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; INTRACRANIAL HYPERTENSION; SATURATION; METABOLISM; MANAGEMENT; HYPOXIA	This study investigated AJDo(2) (arterio-jugular difference of oxygen content) in a large sample of severely head-injured patients to identify its pattern during the first days after injury and to describe the relationship of AJDo(2) with acute neurological severity and with outcome 6 mo after trauma. In 229 comatose head-injured patients, we monitored intracranial pressure, cerebral perfusion pressure, and AJDo(2). Outcome was defined 6 mo after injury. Jugular hemoglobin oxygen saturation (Sjo(2)) averaged 68%. The mean AJDo(2) was 4.24 vol% (SD, 1.3 vol%). There were 80 measurements (4.6%) with Sjo(2) <55% and 304 (17.6%) with saturation >75%. AJDo(2) was higher than 8.7 vol% in 8 measurements (0.4%) and was lower than 3.9 vol% in 718 (42%) measurements. AJDo(2) was higher during the first tests and decreased steadily over the next few days. Cases with a favorable outcome had a higher mean AJDo(2) (4.3 vol%; SD, 0.3 vol%) than patients with severe disability or vegetative status (3.8 vol%; so, 1.3 vol%) and patients who died (3.6 vol%; so, 1 vol%). This difference was significant (P < 0.001). We conclude that low levels of AJDo(2) are correlated with a poor prognosis, whereas normal or high levels of AJDo(2) are predictive of better results.	Univ Milan, Ist Anestesia & Rianimaz, Policlin, Osped Maggiore Policlin,IRCCS, I-20122 Milan, Italy	Stocchetti, N (corresponding author), Univ Milan, Ist Anestesia & Rianimaz, Policlin, Osped Maggiore Policlin,IRCCS, Via F Sforza,35, I-20122 Milan, Italy.	stocchet@policlinico.mi.it	Stocchetti, Nino/O-7444-2017; Zanier, Elisa/AAA-8095-2020	Stocchetti, Nino/0000-0003-3250-6834; Zanier, Elisa/0000-0002-3011-8718; Rossi, Sandra/0000-0002-9963-8121			BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; CRUZ J, 1992, J NEUROSURG, V77, P162; CRUZ J, 1991, SNAAC NEWSLETT   SPR, P4; DESALLES AF, 1997, NEUROSURGERY, V21, P45; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Henson LC, 1998, ANESTHESIOLOGY, V88, P58, DOI 10.1097/00000542-199801000-00011; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Latronico N, 2000, NEUROSURGERY, V46, P1131, DOI 10.1097/00006123-200005000-00021; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MEYER JS, 1965, NEUROLOGY, V15, P892, DOI 10.1212/WNL.15.10.892; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WOODMAN T, 1996, NEUROTRAUMA, pCH36	24	21	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2004	99	1					230	234		10.1213/01.ane.0000130393.08355.d4			5	Anesthesiology	Anesthesiology	832GW	WOS:000222256400044	15281535				2021-06-18	
J	Ozisik, K; Yildirim, E; Kaplan, S; Solaroglu, I; Sargon, MF; Kilinc, K				Ozisik, K; Yildirim, E; Kaplan, S; Solaroglu, I; Sargon, MF; Kilinc, K			Ultrastructural changes of rat cardiac myocytes in a time-dependent manner after traumatic brain injury	AMERICAN JOURNAL OF TRANSPLANTATION			English	Article						heart; histology; rat; reactive oxygen species	LIPID-PEROXIDATION; PULMONARY-EDEMA; DEATH; TISSUES	We suggest an ultrastructural scoring system to evaluate the degree of damage in a time-dependent manner in cardiac myocytes after traumatic brain injury (TBI). Forty Wistar-Albino female rats weighing 170-200 g were randomly allocated into five groups. Group 1 was the control and Group 2 was the sham-operated group. Group 3, Group 4 and Group 5 were trauma groups. Weight-drop technique was used for achieving TBI. Lipid peroxidation was estimated by thiobarbituric acid test. An electron microscopic scoring model was used to grade the subcellular changes. Results of heart injury score (HIS) showed that the 24-h trauma group had statistically significant levels in nuclear damage compared with the other groups (p<0.05). Sarcoplasmic reticulum and mitochondria scores of all trauma groups were significantly different from the control and sham groups (p<0.05). The results showed that lipid per oxidation levels were statistically significant different between the control and all trauma groups (p<0.05). The electron microscopic scoring model worked well in depicting the traumatic changes, which were supported by lipid peroxidation levels. Traumatic brain injury produced obvious gradual damage on the ultrastructure of the cardiac myocytes and this damage was more significant in the 24-h trauma group.	Ankara Numune Educ & Res Hosp, Dept Thorac & Cardiovasc Surg, Ankara, Turkey; TYIH, Dept Cardiovasc Surg, Ankara, Turkey; Ankara Numune Educ & Res Hosp, Dept Neurosurg, Ankara, Turkey; Hacettepe Univ, Fac Med, Dept Biochem, TR-06100 Ankara, Turkey	Ozisik, K (corresponding author), Ankara Numune Educ & Res Hosp, Dept Thorac & Cardiovasc Surg, Ankara, Turkey.	sozisik2002@yahoo.com	Solaroglu, Ihsan/ABF-7606-2020; Solaroglu, Ihsan/ABE-8816-2020	Solaroglu, Ihsan/0000-0002-9472-1735; Sargon, Mustafa Fevzi/0000-0001-6360-6008			Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Bruinsma GJBB, 1997, J SURG RES, V68, P7, DOI 10.1006/jsre.1997.5002; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; GALINANES M, 1992, CIRC RES, V71, P1213, DOI 10.1161/01.RES.71.5.1213; GILBERT EM, 1988, J THORAC CARDIOV SUR, V95, P1003; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; Hall SRR, 2002, ANESTH ANALG, V94, P948; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; KOLIN A, 1984, STROKE, V15, P990, DOI 10.1161/01.STR.15.6.990; NOVITZKY D, 1986, TRANSPLANT P, V18, P609; Palac Robert T, 2003, Prog Transplant, V13, P42; Pyeron A M, 2001, J Neurosci Nurs, V33, P203; Rathore N, 1998, PHARMACOL RES, V38, P297, DOI 10.1006/phrs.1998.0365; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; YILDIRIM E, 2004, J HEART LUNG TRANSPL	16	21	23	0	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	1600-6135			AM J TRANSPLANT	Am. J. Transplant.	JUN	2004	4	6					900	904		10.1111/j.1600-6143.2004.00448.x			5	Surgery; Transplantation	Surgery; Transplantation	820VM	WOS:000221417600010	15147423	Bronze			2021-06-18	
J	Siu, TLT; Chandran, KN; Newcombe, RL; Fuller, JW; Pik, JHT				Siu, TLT; Chandran, KN; Newcombe, RL; Fuller, JW; Pik, JHT			Snow sports related head and spinal injuries: an eight-year survey from the neurotrauma centre for the Snowy Mountains, Australia	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						head injury; spinal injury; ski; snowboard; biomechanics	SKIING INJURIES; SNOWBOARDERS; SKIERS; CHILDREN; TRENDS; RISK	Neurotrauma from snow-sports related injuries is infrequently documented in the literature. In Australia no collective data has ever been published. The aim of this study is to document the injury pattern of snow sports related neurotrauma admissions to The Canberra Hospital, the regional trauma centre for the Snowy Mountains. A computerised hospital record search conducted between January 1994 and July 2002 revealed 25 head and 66 spinal injury admissions. The incidence of severe injuries requiring referral to tertiary trauma hospital was estimated to be 7.4 per 100,000 skier-days and for head and spinal injury 1.8 per 1,000,000 skier-days and 5.6 per 1,000,000 skier-days, respectively. Collision with a stationary object was disproportionately associated with head injury (p < 0.01) and falling forward with spinal injury (p < 0.005). Snowboarders; tended to sustain cervical fractures more often than skiers (p = 0.009). The importance of helmet usage in buffering the impact of head-on collision and the proposition of having both feet fastened to a snowboard in leading to cervical injury were highlighted. (C) 2003 Elsevier Ltd. All rights reserved.	Canberra Hosp, Dept Neurosurg, Garran, ACT 2605, Australia	Siu, TLT (corresponding author), Canberra Hosp, Dept Neurosurg, Yamba Dr, Garran, ACT 2605, Australia.	siloti@tpg.com.au		Siu, Timothy/0000-0001-8050-891X; Fuller, John/0000-0002-9825-9103			ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; BLADIN C, 1993, AM J SPORT MED, V21, P701, DOI 10.1177/036354659302100511; BREATHOUR, COMMUNICATION; Chissell HR, 1996, SPORTS MED, V22, P141, DOI 10.2165/00007256-199622030-00001; *CO TRAUM I, 1995, COLORADO TRAUMA B, V1, P1; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; Floyd T, 2001, ARCH ORTHOP TRAUM SU, V121, P433, DOI 10.1007/s004020100267; FRIERMOOD TG, 1994, J ORTHOP TRAUMA, V8, P116, DOI 10.1097/00005131-199404000-00007; Fukuda O, 2001, AM J SPORT MED, V29, P437, DOI 10.1177/03635465010290040901; Holmes JF, 2001, ACAD EMERG MED, V8, P866, DOI 10.1111/j.1553-2712.2001.tb01146.x; HUTCHINGS J, 1969, MED J AUSTRALIA, V2, P174, DOI 10.5694/j.1326-5377.1969.tb105690.x; KELLY P, 1991, ANN EMERG MED, V20, P852, DOI 10.1016/S0196-0644(05)81426-X; Koo D W, 1999, J Spinal Cord Med, V22, P246; Levy AS, 2000, SEMIN NEUROL, V20, P233, DOI 10.1055/s-2000-9833; MCLENNAN JC, 1991, J MUSCULOSKELETAL ME, V8, P75; MYLES ST, 1992, CAN J SURG, V35, P643; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; O'Neill DF, 1999, AM J SPORT MED, V27, P94; OH S, 1984, INT J SPORTS MED, V5, P268, DOI 10.1055/s-2008-1025918; *PER RANG RES, 2002, PER BLUE SKI RES SKI; Prall JA, 1995, J TRAUMA, V39, P1115, DOI 10.1097/00005373-199512000-00018; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; SHERRY E, 1991, MED J AUSTRALIA, V155, P513, DOI 10.5694/j.1326-5377.1991.tb93885.x; SHERRY E, 1984, MED J AUSTRALIA, V140, P530, DOI 10.5694/j.1326-5377.1984.tb108226.x; SHERRY E, 1988, MED J AUSTRALIA, V149, P615, DOI 10.5694/j.1326-5377.1988.tb120803.x; Shorter NA, 1996, J TRAUMA, V40, P997, DOI 10.1097/00005373-199606000-00024; Tarazi F, 1999, AM J SPORT MED, V27, P177, DOI 10.1177/03635465990270021101; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Yamakawa H, 2001, J TRAUMA, V50, P1101, DOI 10.1097/00005373-200106000-00020; ZELCER J, 1976, ORTHOP CLIN N AM, V7, P37	32	21	21	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2004	11	3					236	242		10.1016/j.jocn.2003.08.003			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	804RQ	WOS:000220316200002	14975409				2021-06-18	
J	Slemmer, JE; Weber, JT; De Zeeuw, CI				Slemmer, JE; Weber, JT; De Zeeuw, CI			Cell death, glial protein alterations and elevated S-100 beta release in cerebellar cell cultures following mechanically induced trauma	NEUROBIOLOGY OF DISEASE			English	Article						NSE; Purkinje cell; stretch; GLAST; bergmann glia; in vitro injury; neuronal death	STRETCH-INDUCED INJURY; NEURON-SPECIFIC ENOLASE; BRAIN INJURY; FLUORESCENT PROTEIN; CORTICAL-NEURONS; DAMAGE; ASTROCYTES; MICE; RAT; ACTIVATION	Recent studies in vivo have shown that cells of the cerebellum, and particularly Purkinje neurons (PNs), are susceptible to damage following traumatic brain injury (TBI). To investigate more closely the effects of TBI at the cellular level, we subjected cerebellar cell cultures to injury using an in vitro model of stretch-induced mechanical trauma and found increased cell damage and neuronal loss with increasing levels of injury and time post-injury. The release of neuron-specific enolase and S-100beta were also elevated after injury. Compared to our previous findings in hippocampal cells, S-100beta levels were much higher in cerebellar cultures after injury, suggesting that cells from different brain regions show variable responses to mechanical trauma. Lastly, the addition of exogenous S-100beta to uninjured cerebellar cells caused no overt change in cell viability or overall neuronal number; there were, however, fewer calbindin-positive PNs, similar to findings after stretch injury. (C) 2004 Elsevier Inc. All rights reserved.	Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands	Weber, JT (corresponding author), Erasmus MC, Dept Neurosci, Dr Molenwaterpl 50, NL-3000 DR Rotterdam, Netherlands.	j.weber@erasmusmc.nl					Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; Allen GV, 2001, NEUROSCIENCE, V102, P603, DOI 10.1016/S0306-4522(00)00519-4; Azmitia EC, 2002, PROG BRAIN RES, V136, P87; AZMITIA EC, 1990, BRAIN RES, V516, P354, DOI 10.1016/0006-8993(90)90942-5; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; CAJAL SR, 1933, CAJALS DEGENERATION, P91; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Lossi L, 1995, J ANAT, V187, P709; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Metzger F, 2002, EUR J NEUROSCI, V15, P40, DOI 10.1046/j.0953-816x.2001.01837.x; OHearn E, 1997, J NEUROSCI, V17, P8828; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Pinto SS, 2000, FEBS LETT, V486, P203, DOI 10.1016/S0014-5793(00)02301-2; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Sheng JG, 2000, J NEUROCHEM, V74, P295, DOI 10.1046/j.1471-4159.2000.0740295.x; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Stepanova T, 2003, J NEUROSCI, V23, P2655; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whitaker-Azmitia PM, 1997, BRAIN RES, V776, P51, DOI 10.1016/S0006-8993(97)01002-0; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Yamada Keiko, 2002, Anatomical Science International, V77, P94, DOI 10.1046/j.0022-7722.2002.00021.x; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	37	21	22	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	APR	2004	15	3					563	572		10.1016/j.nbd.2003.11.027			10	Neurosciences	Neurosciences & Neurology	811UL	WOS:000220796700015	15056464				2021-06-18	
J	Biberthaler, P; Mussack, T; Kanz, KG; Linsenmaier, U; Pfeifer, KJ; Mutschler, W; Jochum, M				Biberthaler, P; Mussack, T; Kanz, KG; Linsenmaier, U; Pfeifer, KJ; Mutschler, W; Jochum, M			Identification of high-risk patients after minor craniocerebral trauma. Measurement of nerve tissue protein S100	UNFALLCHIRURG			German	Article						minor head trauma; S100; neurotrauma; cranial computed tomography; CCT	CALCIUM-BINDING PROTEINS; SEVERE HEAD-INJURY; COMPUTED-TOMOGRAPHY; S-100B PROTEIN; WHOLE-BLOOD; SERUM; MARKER; S-100-BETA; S100-BETA; SURGERY	The indication for an initial cranial computed tomography (CCT) in minor head trauma (MHT) patients remains the subject of discussion. The aim of this study was to investigate whether a newly developed, rapid test system (ELECSYS S100, Roche Diagnostics) might allow a diagnostically valid, reproducible measurement of S 100 in MHT patients. Blood samples were drawn from 75 MHT patients, a CCT scan was performed, and those with a post-traumatic intracranial lesion counted as CCT+. Results were compared to a healthy control group (n=17). Of the 75 patients included in the study, 14 were stratified as CCT+. The systemic concentration of S 100 in these CCT+ patients was significantly increased (0.31 mug/l) compared to the healthy control group (0.04 mug/l) as well as to the CCT-negative patients (0.08 mug/l). The ELECSYS S100 system allows a rapid,valid,and reproducible assessment of S 100B in patient serum and this concentration is significantly elevated in patients suffering from intracranial lesions as shown by initial CCT scan. Hence,this study is the basis for a multicenter trial currently.	Univ Munich, Chirurg Klin & Poliklin Innesnstadt, D-80336 Munich, Germany; Univ Munich, Inst Radiol Diagnost Innestadt, Munich, Germany; Univ Munich, Abt Klin Chem & Biochem Innenstadt, Munich, Germany	Biberthaler, P (corresponding author), Univ Munich, Chirurg Klin & Poliklin Innesnstadt, Nussbaumstr 20, D-80336 Munich, Germany.	peter.biberthaler@med.uni-muenchen.de					Bergmann M, 1999, SHOCK, V12, P421, DOI 10.1097/00024382-199912000-00002; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; COCCHIA D, 1981, NATURE, V294, P85, DOI 10.1038/294085a0; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ettinger A, 1999, ANN THORAC SURG, V68, P2196, DOI 10.1016/S0003-4975(99)00849-8; HAIMOTO H, 1987, LAB INVEST, V57, P489; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Jonsson H, 1999, ANN THORAC SURG, V68, P2202, DOI 10.1016/S0003-4975(99)00851-6; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; Pellegrini JD, 2000, J SURG RES, V88, P200, DOI 10.1006/jsre.1999.5797; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Ruchholtz S, 2002, CHIRURG, V73, P194, DOI 10.1007/s00104-002-0424-6; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TOENNIS W, 1953, AERZTL PRAXIS 5, V36, P13; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	27	21	24	0	0	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0177-5537			UNFALLCHIRURG	Unfallchirurg	MAR	2004	107	3					197	202		10.1007/s00113-004-0730-1			6	Emergency Medicine; Surgery	Emergency Medicine; Surgery	813GI	WOS:000220895200004	15042301				2021-06-18	
J	Zafonte, R; Elovic, EP; Lombard, L				Zafonte, R; Elovic, EP; Lombard, L			Acute care management of post-TBI spasticity	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute care; intensive care; spasticity; TBI	UPPER-LIMB SPASTICITY; TRAUMATIC BRAIN-INJURY; BOTULINUM TOXIN; LONG-TERM; INTRATHECAL BACLOFEN; DOUBLE-BLIND; ELECTRICAL-STIMULATION; FUNCTIONAL RECOVERY; DANTROLENE SODIUM; FLEXOR SPASTICITY	The management of persons with traumatic brain injury (TBI) who have acute spasticity remains a challenge. A correct stratification is essential to clinical care and determination of efficacy from proposed interventions. The secondary severe sequlae of spasticity after TBI can result in profound functional impairment. These concerns are often best addressed early in the patient's course. Limited research in the area of the acute care treatment of severe spasticity is available. The authors employ a review of the available data as well as recount their own clinical experience in the acute care management of severe spasticity to assist in developing an order for the plethora of potential treatments available to clinicians and researchers. We propose to use a case example to emphasize key clinic points in the management of spasticity in the acute care setting.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA	Zafonte, R (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201,Kuafman Bldg, Pittsburgh, PA 15213 USA.	zafonterd@upmc.edu					Albert TA, 2002, ARCH PHYS MED REHAB, V83, P692, DOI 10.1053/apmr.2002.32307; Albright AL, 2003, J NEUROSURG, V98, P291, DOI 10.3171/jns.2003.98.2.0291; BAJD T, 1985, ARCH PHYS MED REHAB, V66, P515; BARNARD P, 1984, PHYS THER, V64, P1540, DOI 10.1093/ptj/64.10.1540; Barnes M, 2003, J REHABIL MED, V35, P56, DOI 10.1080/16501960310010151; Brashear A, 2003, ARCH PHYS MED REHAB, V84, P103, DOI 10.1053/apmr.2003.50070; BRASHEAR A, 2002, NEJM; CASTELLANO C, 1989, BEHAV NEURAL BIOL, V52, P170, DOI 10.1016/S0163-1047(89)90285-9; CHAN CH, 1990, NEUROLOGY, V40, P1427, DOI 10.1212/WNL.40.9.1427; Childers MK, 1999, ARCH PHYS MED REHAB, V80, P714, DOI 10.1016/S0003-9993(99)90178-8; Childers MK, 1997, BRAIN INJURY, V11, P537, DOI 10.1080/713802187; Cho S, 2003, ANESTH ANALG, V96, P1369, DOI 10.1213/01.ANE.0000055805.27590.FB; Chou TC, 1999, THROMB RES, V96, P299, DOI 10.1016/S0049-3848(99)00114-0; Coffey RJ, 2002, ARCH PHYS MED REHAB, V83, P735, DOI 10.1053/apmr.2002.32820; Corbett M, 1972, Paraplegia, V10, P19; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Cutter NC, 2000, ARCH PHYS MED REHAB, V81, P164, DOI 10.1016/S0003-9993(00)90135-7; DAHM LS, 1989, STEREOT FUNCT NEUROS, V53, P85, DOI 10.1159/000099523; DAHM LS, 2000, EUR J NEUROL, V7, P741; Dall JT, 1996, BRAIN INJURY, V10, P453; Dalyan M, 1998, SPINAL CORD, V36, P405, DOI 10.1038/sj.sc.3100620; Dewald J P, 1996, IEEE Trans Rehabil Eng, V4, P231, DOI 10.1109/86.547923; DONOVAN WH, 1988, ARCH PHYS MED REHAB, V69, P193; Dunevsky A, 1998, AM J PHYS MED REHAB, V77, P451, DOI 10.1097/00002060-199809000-00020; DURHAM JA, 1984, DRUG CHEM TOXICOL, V7, P23, DOI 10.3109/01480548409014171; Elovic E, 2001, Phys Med Rehabil Clin N Am, V12, P793; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Francisco GE, 2002, AM J PHYS MED REHAB, V81, P355, DOI 10.1097/00002060-200205000-00007; GERTZEN P, 1997, PEDIATR NEUROSURG, V27, P40; Gilman TM, 1996, J CLIN PHARMACOL, V36, P64, DOI 10.1002/j.1552-4604.1996.tb04153.x; Glenn MB, 1997, J HEAD TRAUMA REHAB, V12, P40, DOI 10.1097/00001199-199712000-00005; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; Gracies JM, 1997, ARCH PHYS MED REHAB, V78, P1066, DOI 10.1016/S0003-9993(97)90129-5; Gracies JM, 2000, ARCH PHYS MED REHAB, V81, P1547, DOI 10.1053/apmr.2000.16346; Groves L, 1998, ADV THER, V15, P241; Gruenthal M, 1997, SPINAL CORD, V35, P686, DOI 10.1038/sj.sc.3100481; Hinderer S R, 2001, Phys Med Rehabil Clin N Am, V12, P733; Keren O, 2001, BRAIN INJURY, V15, P633, DOI 10.1080/02699050010009568; KING TI, 1982, AM J OCCUP THER, V36, P671, DOI 10.5014/ajot.36.10.671; KNUTSSON E, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P159; Langeron O, 1999, ANESTH ANALG, V89, P466; Lannin NA, 2003, ARCH PHYS MED REHAB, V84, P297, DOI 10.1053/apmr.2003.50031; MAYNARD FM, 1986, PARAPLEGIA, V24, P175, DOI 10.1038/sc.1986.24; McGuire J R, 2001, Top Stroke Rehabil, V8, P47; MEDICI M, 1989, CURR MED RES OPIN, V11, P398, DOI 10.1185/03007998909110141; Megna JL, 2002, ANN PHARMACOTHER, V36, P12; MEYLER WJ, 1979, EUR J CLIN PHARMACOL, V16, P203, DOI 10.1007/BF00562062; Meythaler JA, 2001, ARCH PHYS MED REHAB, V82, P1155, DOI 10.1053/apmr.2001.25141; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; MIGLIETTA O, 1973, AM J PHYS MED REHAB, V52, P198; Miller LJ, 2001, ANN PHARMACOTHER, V35, P427; MILLS VM, 1984, PHYS THER, V64, P190, DOI 10.1093/ptj/64.2.190; MIZUNO J, 2002, MASUI, V15, P781; Mueller ME, 1997, ARCH PHYS MED REHAB, V78, P521, DOI 10.1016/S0003-9993(97)90168-4; Nakayama R, 2002, ANESTHESIOLOGY, V96, P705, DOI 10.1097/00000542-200203000-00029; Nance P W, 1994, J Am Paraplegia Soc, V17, P150; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; OTIS JC, 1985, J PEDIATR ORTHOPED, V5, P682, DOI 10.1097/01241398-198511000-00010; Pohl M, 2003, CLIN REHABIL, V17, P373, DOI 10.1191/0269215503cr636oa; Pohl M, 2002, ARCH PHYS MED REHAB, V83, P784, DOI 10.1053/apmr.2002.32821; Popescu BO, 2002, J CELL MOL MED, V6, P555, DOI 10.1111/j.1582-4934.2002.tb00454.x; Priebe MM, 1997, SPINAL CORD, V35, P171, DOI 10.1038/sj.sc.3100366; Richardson D, 2000, J NEUROL NEUROSUR PS, V69, P499, DOI 10.1136/jnnp.69.4.499; Rossier P, 2000, EUR J NEUROL, V7, P741, DOI 10.1046/j.1468-1331.2000.00142.x; SANDYK R, 1985, CLIN NEUROPHARMACOL, V8, P294, DOI 10.1097/00002826-198509000-00011; Scheker LR, 1999, J HAND SURG-BRIT EUR, V24B, P226, DOI 10.1054/jhsb.1998.0002; SEIB TP, 1994, ARCH PHYS MED REHAB, V75, P746; SEINBERG F, 1975, J AM GERIATR SOC, V23, P70; Singer BJ, 2003, BRAIN INJURY, V17, P309, DOI 10.1080/0269905021000013237; Singer BJ, 2003, ARCH PHYS MED REHAB, V84, P483, DOI 10.1053/apmr.2003.50041; Smith SJ, 2000, CLIN REHABIL, V14, P5, DOI 10.1191/026921500666642221; Soni BM, 2003, SPINAL CORD, V41, P586, DOI 10.1038/sj.sc.3101471; STARRING DT, 1988, PHYS THER, V68, P314, DOI 10.1093/ptj/68.3.314; TARICCO M, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001131; TERRENCE CF, 1983, ARCH NEUROL-CHICAGO, V40, P28, DOI 10.1001/archneur.1983.04050010048011; TREMBLAY F, 1990, SCAND J REHABIL MED, V22, P171; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Wallace AE, 1999, RESTOR NEUROL NEUROS, V14, P35; Ward AB, 2003, J REHABIL MED, V35, P98, DOI 10.1080/16501970306112; WEINGARDEN SI, 1992, ARCH PHYS MED REHAB, V73, P876; WUIS EW, 1990, INT J CLIN PHARM RES, V10, P203; YABLON SA, 1993, AM J PHYS MED REHAB, V72, P154, DOI 10.1097/00002060-199306000-00009; Zafonte R D, 2001, Phys Med Rehabil Clin N Am, V12, P817	84	21	21	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2004	19	2					89	100		10.1097/00001199-200403000-00002			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	809NR	WOS:000220643900002	15247820				2021-06-18	
J	Brewer, KL; Hardin, JS				Brewer, KL; Hardin, JS			Neuroprotective effects of nicotinamide after experimental spinal cord injury	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the SAEM	MAY, 2003	BOSTON, MASSACHUSETTS	SAEM		neurotrauma; neuroprotection; excitotoxicity; vitamin B3	FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; WISTAR RATS; POLY(ADP-RIBOSE) POLYMERASE; GENE-EXPRESSION; MESSENGER-RNA; CHRONIC PAIN; METHYLPREDNISOLONE; INFARCTION; BEHAVIOR	Objective: To investigate the ability of nicotinamide to protect against secondary damage in spinal cord tissue after an experimental injury. Trauma to the spinal cord induces a cascade of cellular events that lead to progressive tissue injury over time. Nicotinamide has been shown to affect many elements of this cascade, including excitatory amino acid release, inflammation, apoptosis, and cellular energy balance. Methods: Male Long-Evans (n=12) rats received an excitotoxic spinal cord injury by intraspinal injection of quisqualic acid (QUIS), a glutamate receptor agonist. A second set of rats (n=4) received intraspinal saline as a sham injury. Thirty minutes after injury, animals that had QUIS injections received an intraperitoneal injection of either saline (control, n=4) or nicotinamide (500 mg/kg, n=8). Seven days postinjury, the spinal cords were removed, and serial sections were cut, mounted on slides, and stained. By using light microscopy, the extent of tissue damage was assessed at the epicenter of injury as well as sections up to 450-mum rostral and 450-mum caudal to the epicenter. Results: Only those animals receiving QUIS injections showed damaged tissue. There was no significant difference in the amount of damage at the epicenter of injury between the saline- and nicotinamide-treated animals. However, when comparing the total amounts of damage over the 975-mum length of cord examined, the rostro-caudal extent of injury was significantly reduced in the nicotinamide-treated animals compared with the saline-treated animals. Conclusions: Systemic nicotinamide serves to limit the rostro-caudal extent of cell death after experimental spinal cord injury.	E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Greenville, NC 27858 USA	Brewer, KL (corresponding author), E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Phys Quadrangle,Bldg M, Greenville, NC 27858 USA.	brewerk@mail.ecu.edu					Abraham KE, 2001, NEUROSCIENCE, V104, P863, DOI 10.1016/S0306-4522(01)00134-8; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bracken MB, 2001, SPINE, V26, pS47, DOI 10.1097/00007632-200112151-00010; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Burke DA, 2001, SPINAL CORD, V39, P274, DOI 10.1038/sj.sc.3101158; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Fujimura M, 1997, NEUROSCI LETT, V228, P107, DOI 10.1016/S0304-3940(97)00373-X; Hall E D, 2001, J Spinal Cord Med, V24, P142; Hugenholtz H, 2002, CAN J NEUROL SCI, V29, P227, DOI 10.1017/S0317167100001992; Hurlbert RJ, 2002, CAN J NEUROL SCI, V29, P236, DOI 10.1017/S0317167100002006; Klaidman LK, 2001, BBA-GEN SUBJECTS, V1525, P136, DOI 10.1016/S0304-4165(00)00181-1; Knip M, 2000, DIABETOLOGIA, V43, P1337, DOI 10.1007/s001250051536; Liu CL, 2002, CHINESE MED J-PEKING, V115, P740; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; LONGUEMARE MC, 1995, J NEUROSCI RES, V40, P379, DOI 10.1002/jnr.490400312; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; Molloy S, 2002, INJURY, V33, P575, DOI 10.1016/S0020-1383(02)00142-0; O'Connor P, 2002, ACCIDENT ANAL PREV, V34, P405, DOI 10.1016/S0001-4575(01)00036-7; Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Santoscopy C, 2002, NEUROSCI LETT, V330, P94, DOI 10.1016/S0304-3940(02)00716-4; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Turner JA, 2001, ARCH PHYS MED REHAB, V82, P501, DOI 10.1053/apmr.2001.21855; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Walter JS, 2002, J REHABIL RES DEV, V39, P53; Widerstrom-Noga EG, 2001, ARCH PHYS MED REHAB, V82, P1571, DOI 10.1053/apmr.2001.26068; Xu M, 2000, EXP NEUROL, V161, P472, DOI 10.1006/exnr.1999.7278; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5; Yezierski R P, 2000, Prog Brain Res, V129, P429; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445	36	21	23	0	1	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	FEB	2004	11	2					125	130		10.1197/j.aem.2003.09.010			6	Emergency Medicine	Emergency Medicine	771GQ	WOS:000188777600001	14759952				2021-06-18	
J	Gauggel, S; Heinemann, AW; Bocker, M; Lammler, G; Borchelt, M; Steinhagen-Thiessen, E				Gauggel, S; Heinemann, AW; Bocker, M; Lammler, G; Borchelt, M; Steinhagen-Thiessen, E			Patient-staff agreement on Barthel Index scores at admission and discharge in a sample of elderly stroke patients	REHABILITATION PSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; FUNCTIONAL INDEPENDENCE MEASURE; IMPAIRED AWARENESS; INPATIENT REHABILITATION; SELF-AWARENESS; ADL INDEX; BEHAVIORAL LIMITATIONS; HEAD-INJURY; DISABILITY; RELATIVES	Objective: To investigate the congruence and influence of lesion side on staff and patient ratings of activity limitations. Study Design: Retrospective study of activity limitations at admission and discharge using the Rasch model and rating scale analysis. Participants: One-hundred twenty elderly stroke patients. Setting: Outpatient geriatric rehabilitation center. Main Outcome Measure: Barthel Index (BI). Results: High patient-staff agreement was found with the lowest agreement on the bathing item of the BI, Although staff rated the degree of activity limitations significantly higher than patients, the effect size was low at admission and discharge. The discrepancy between patient and staff reports did not change during rehabilitation and was equivalent between patients with right and patients with left hemisphere lesions. Conclusion: Patients with a stroke slightly overestimated their competency compared with rehabilitation staff and remained consistent during rehabilitation.	Univ Technol Chemnitz, Dept Psychol, D-09107 Chemnitz, Germany; Rehabil Inst Chicago, Chicago, IL 60611 USA; Geriatr Ctr Berlin, Berlin, Germany	Gauggel, S (corresponding author), Univ Technol Chemnitz, Dept Psychol, Wilhelm Raabe Str 43, D-09107 Chemnitz, Germany.	siegfried.gauggel@phil.tu-chemnitz.de	Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326; Gauggel, Siegfried/0000-0002-2742-4917			BABINSKI MJ, 1914, REV NEUROL, V12, P845; BLONDER LX, 1994, NEUROPSY NEUROPSY BE, V7, P260; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; BOND TG, 2001, APPL RASCH MODE FUND; Brink TL., 1982, CLIN GERONTOLOGIST, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; Collin C, 1988, Int Disabil Stud, V10, P61; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Embretson S.E., 2013, ITEM RESPONSE THEORY; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gatterer G, 1990, ALTERS KONZENTRATION; Gauggel S, 2000, J HEAD TRAUMA REHAB, V15, P710, DOI 10.1097/00001199-200002000-00009; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Gosman-Hedstrom G, 2000, DISABIL REHABIL, V22, P702, DOI 10.1080/09638280050191972; Harlacher R, 1999, Z GERONTOL GERIATR, V32, P200, DOI 10.1007/s003910050105; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heilman KM, 1998, PHILOS T R SOC B, V353, P1903, DOI 10.1098/rstb.1998.0342; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hsueh IP, 2002, J NEUROL NEUROSUR PS, V73, P188, DOI 10.1136/jnnp.73.2.188; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LINACRE JM, 1999, WINSTEPS PC COMPATIB; Mahoney FI, 1965, MD STATE MED J, V14, P56; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Newman AC, 2000, BRAIN INJURY, V14, P333; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RANHOFF AH, 1993, AGE AGEING, V22, P171, DOI 10.1093/ageing/22.3.171; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Schacter D. L., 1991, AWARENESS DEFICIT BR, P258; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stone MH., 1979, BEST TEST DESIGN; Taylor JG, 1998, NEUROREPORT, V9, P1787, DOI 10.1097/00001756-199806010-00021; Tennant A., 1996, CLIN REHABIL, V10, P301, DOI [10.1177/026921559601000407, DOI 10.1177/026921559601000407]; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; van der Putten JJMF, 1999, J NEUROL NEUROSUR PS, V66, P480, DOI 10.1136/jnnp.66.4.480; WAGNER MT, 1994, ARCH CLIN NEUROPSYCH, V9, P57, DOI 10.1016/0887-6177(94)90014-0; WATSON YI, 1993, J AM GERIATR SOC, V41, P1235, DOI 10.1111/j.1532-5415.1993.tb07308.x; WELLWOOD I, 1995, AGE AGEING, V24, P54, DOI 10.1093/ageing/24.1.54; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; WYLLER TB, 1995, AGE AGEING, V24, P398, DOI 10.1093/ageing/24.5.398; Wyller TB, 1996, DISABIL REHABIL, V18, P454, DOI 10.3109/09638289609165909	48	21	21	0	1	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2004	49	1					21	27		10.1037/0090-5550.49.1.21			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	771RQ	WOS:000188800200004					2021-06-18	
J	Gunnarsson, T; Fehlings, MG				Gunnarsson, T; Fehlings, MG			Acute neurosurgical management of traumatic brain injury and spinal cord injury	CURRENT OPINION IN NEUROLOGY			English	Article						management; spinal cord injury; traumatic brain injury	SEVERE HEAD-INJURY; APOLIPOPROTEIN-E POLYMORPHISM; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; CERVICAL-SPINE; TISSUE OXYGEN; METHYLPREDNISOLONE; HYPOTHERMIA; HYPEROXIA; OUTCOMES	Purpose of review This review discusses some of the recent advances and current controversies in the acute clinical management of traumatic brain injury (TBI) and spinal cord injury (SCI). Recent findings Several key risk factors for adverse prognosis in TBI have been identified, including female sex. In the management of intracranial hypertension antibiotic impregnated intraventricular catheters have been found to reduce the risk for infection, and new studies have examined the roles of mannitol, hyperventilation, and hypothermia. Moderate hypothermia has also been found to improve outcome. Hyperoxia is now being explored as a treatment option for improving brain metabolism in TBI. That acute SCI continues to be a challenging diagnosis is supported by a recent study that showed that 9.1 % of SCIs are missed initially. The diagnosis and management of spinal instability has been studied in different patient groups. In SCI without radiographic abnormality, the presence of normal magnetic resonance imaging findings was associated with a good prognosis. New studies in the field of early decompression and the prevention of thromboembolism in SCI have also been published. Guidelines for the management of acute SCI recommend methylprednisolone and GM-1 ganglioside only as options. Summary In neurotrauma some established treatments have been reexamined and their efficacy proven, whereas others that were once considered the standard of care in SCI, such as methylprednisolone, have been questioned. Large multicenter trials are needed to assess treatments such as early decompression in SCI and decompressive craniectomy in TBI. A truly effective neuroprotective therapy in neurotrauma remains elusive.	Univ Toronto, Toronto Western Hosp, Spinal Program, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Spinal Program, Div Neurosurg, 399 Bathurst St,W Wing,4W-499, Toronto, ON M5T 2S8, Canada.	michael@uhnres.utoronto.ca	Gunnarsson, Thorsteinn/AAA-1238-2019	Gunnarsson, Thorsteinn/0000-0001-6657-4187; Fehlings, Michael/0000-0002-5722-6364			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; [Anonymous], 2002, NEUROSURGERY S, V50, pS100; [Anonymous], 2002, NEUROSURGERY S, V50, pS36; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Bosch PP, 2002, SPINE, V27, P2788, DOI 10.1097/00007632-200212150-00009; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRACKEN MB, 2002, NEUROSURGERY, V502, pS14; Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P513; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; CHIANG MF, 2003, IN PRESS ACTA NEUROC; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; Dare AO, 2002, J NEUROSURG, V97, P33, DOI 10.3171/spi.2002.97.1.0033; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Fehlings MG, 2001, SPINE, V26, pS101, DOI 10.1097/00007632-200112151-00017; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Guest J, 2002, J NEUROSURG, V97, P25, DOI 10.3171/spi.2002.97.1.0025; Hadley MN, 2002, NEUROSURGERY, V50, pS63; Hadley MN, 2002, NEUROSURGERY, V50, pS166; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Hugenholtz H, 2002, CAN J NEUROL SCI, V29, P227, DOI 10.1017/S0317167100001992; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hurlbert RJ, 2002, CAN J NEUROL SCI, V29, P236, DOI 10.1017/S0317167100002006; Insko EK, 2002, J TRAUMA, V53, P426, DOI 10.1097/00005373-200209000-00005; Jacobs WB, 2003, NEUROSURGERY, V53, P943, DOI 10.1227/01.NEU.0000083592.74383.B1; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marion Donald W, 2002, Curr Opin Crit Care, V8, P111, DOI 10.1097/00075198-200204000-00004; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Merli G, 2003, J TRAUMA, V54, P1111, DOI 10.1097/01.TA.0000042159.90102.C2; Merli G, 2003, J TRAUMA, V54, P1116, DOI 10.1097/01.TA.0000066385.10596.71; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Molloy S, 2002, INJURY, V33, P575, DOI 10.1016/S0020-1383(02)00142-0; Mower WR, 2002, J TRAUMA, V53, P1198, DOI 10.1097/00005373-200212000-00039; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; POLLACK IF, 1988, J NEUROSURG, V69, P177, DOI 10.3171/jns.1988.69.2.0177; Poonnoose PM, 2002, J TRAUMA, V53, P314, DOI 10.1097/00005373-200208000-00021; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Schneider GH, 2002, ACT NEUR S, V81, P77; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P497; Thumbikat P, 2002, SPINAL CORD, V40, P416, DOI 10.1038/sj.sc.3101325; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vellman WP, 2003, SPINE, V28, P941; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725; 2000, J NEUROTRAUMA, V17, P479; 2002, NEUROSURGERY, V50, pS1	63	21	32	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2003	16	6					717	723		10.1097/00019052-200312000-00012			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	805MU	WOS:000220371200012	14624082				2021-06-18	
J	Gorski, TF; Gorski, YC; McLeod, G; Suh, D; Cordero, R; Essien, F; Berry, D; Dada, F				Gorski, TF; Gorski, YC; McLeod, G; Suh, D; Cordero, R; Essien, F; Berry, D; Dada, F			Patterns of injury and outcomes associated with motocross accidents	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Meeting of the Southern California Chapter of the American-College-of-Surgeons	JAN 24-26, 2003	SANTA BARBARA, CALIFORNIA	Amer Coll Surg, SO Calif Chapter			MOTORCYCLE-HELMET-USE; CRASHES	Motocross has become a popular recreation activity in Southern California, particularly in the Inland Empire area. In order to evaluate the patterns of injury and outcomes associated with motocross accidents, the Trauma Registry data and charts of all patients with motocross-related injuries from January 2000 to December 2001 were reviewed. Of the 270 patients studied, 265 were males and 5 were females, with a mean age of 26 years (range, 5-61). The mean Injury Severity Score was 6.8 (range, 1-38). Injuries involved extremity trauma in 52 per cent of patients closed head injuries in 33 per cent, blunt chest trauma in 23 per cent, abdominal trauma in 15 per cent, spinal trauma in 14 per cent, and pelvic trauma in 8 per cent. Surgery was required in 96 patients (36%), most commonly for treatment of orthopedic injuries. After initial evaluation, 179 patients were admitted (66%), 60 were discharged home (22%), 29 were transferred for higher level of care (11%), and two expired (1%). The mean hospital length of stay was 2.3 days (range, 1-9). Motocross accidents are most commonly associated with extremity injuries and closed head trauma. Although the overall mortality is low, the morbidity is high, with a large proportion of patients requiring surgery.	Inland Valley Reg Med Ctr, Dept Surg, Wildomar, CA USA	Gorski, TF (corresponding author), 800 Magnolia Ave 107, Corona, CA 92879 USA.						Ankarath S, 2002, INJURY, V33, P473, DOI 10.1016/S0020-1383(02)00048-7; Brandt MM, 2002, J TRAUMA, V53, P469, DOI 10.1097/00005373-200209000-00012; DRYSDALE WF, 1975, J TRAUMA, V15, P99, DOI 10.1097/00005373-197502000-00003; Kraus JF, 2002, J TRAUMA, V52, P548, DOI 10.1097/00005373-200203000-00022; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; KUPPFERSCHMID JP, 1989, J TRAUMA, V29, P593; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; *NAT HIGHW TRAFF S, 2002, ANN EMERG MED, V39, P195; Robertson A, 2002, J TRAUMA, V53, P5, DOI 10.1097/00005373-200207000-00002; Yates JM, 2002, INJURY, V33, P479, DOI 10.1016/S0020-1383(02)00007-4; ZETTAS JP, 1979, J TRAUMA, V19, P833, DOI 10.1097/00005373-197911000-00007	11	21	21	0	3	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	OCT	2003	69	10					895	898					4	Surgery	Surgery	729KD	WOS:000185771600015	14570370				2021-06-18	
J	Kahraman, S; Ozgurtas, T; Kayali, H; Atabey, C; Kutluay, T; Timurkaynak, E				Kahraman, S; Ozgurtas, T; Kayali, H; Atabey, C; Kutluay, T; Timurkaynak, E			Monitoring of serum ionized magnesium in neurosurgical intensive care unit: preliminary results	CLINICA CHIMICA ACTA			English	Article						head injury; intensive care; ionized magnesium; neurotrauma	TRAUMATIC BRAIN-INJURY; CALCIUM; DECLINE	Background: Our purpose was to determine the values for serum ionized magnesium (Mg) concentrations in traumatic brain injury and its effect on the prognostic scores of patients. Methods: We prospectively measured serum ionized magnesium concentrations in 30 patients that were classified into three groups (severe, moderate, mild) by Glasgow Coma Scale Score. Serum ionized magnesium concentrations were measured during posttraumatic 5 days. Thirty patients with head trauma were followed in a neurosurgical intensive care unit with monitoring serum ionized magnesium concentrations. All patients were treated conservatively. Results: We found significant difference of serum ionized magnesium concentrations when we compared all groups with each other (p<0.001). Conclusions: Based on this clinical preliminary study, traumatic brain injury is associated with graded deficit in serum ionized magnesium concentrations. Thus, measurement of serum ionized magnesium concentrations can be used as a clinical marker in traumatic brain injury. (C) 2003 Elsevier B.V. All rights reserved.	Gulhane Mil Med Acad, Dept Neurosurg, TR-06018 Etlik, Turkey; Gulhane Mil Med Acad, Dept Biochem, TR-06018 Etlik, Turkey	Kahraman, S (corresponding author), Gulhane Mil Med Acad, Dept Neurosurg, TR-06018 Etlik, Turkey.	skahraman@gata.edu.tr	OZGURTAS, TANER/X-4768-2019; Atabey, Cem/A-1391-2018; Kahraman, Serdar/K-4658-2019	Atabey, Cem/0000-0002-9047-196X; Kahraman, Serdar/0000-0003-2489-3854			Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HRISTOVA EN, 1995, CLIN CHEM, V41, P1649; Huijgen HJ, 1999, CLIN CHEM LAB MED, V37, P465, DOI 10.1515/CCLM.1999.075; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; Polderman KH, 2000, CRIT CARE MED, V28, P2022, DOI 10.1097/00003246-200006000-00057; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; Saris NEL, 2000, CLIN CHIM ACTA, V294, P1, DOI 10.1016/S0009-8981(99)00258-2; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SIESJO BK, 1986, EUR NEUROL, V25, P45, DOI 10.1159/000116060; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; VANINGEN HE, 1994, CLIN CHEM, V40, P52; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1991, MAGNES TRACE ELEM, V92, P1	25	21	24	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	AUG	2003	334	1-2					211	215		10.1016/S0009-8981(03)00235-3			5	Medical Laboratory Technology	Medical Laboratory Technology	706XZ	WOS:000184481500023	12867294				2021-06-18	
J	Ang, BT; Yap, E; Lim, J; Tan, WL; Ng, PY; Ng, I; Yeo, TT				Ang, BT; Yap, E; Lim, J; Tan, WL; Ng, PY; Ng, I; Yeo, TT			Poly(adenosine diphosphate-ribose) polymerase expression in human traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						poly(adenosine diphosphate-ribose) polymerase; human head injury; apoptosis	POLY(ADP-RIBOSE) POLYMERASE; CELL-DEATH; APOPTOSIS; INHIBITION; ACTIVATION; PROTEIN; PARP; SYNTHETASE; ISCHEMIA; CLEAVAGE	Object. This study was designed to elucidate the pattern of expression of poly(adenosine diphosphate-ribose) polymerase (PARP) in human pericontusional brain tissue and to correlate these findings with commonly used clinical parameters. Methods. The expression of PARP was ascertained using immunohistochemical studies in eight specimens of human pericontusional brain tissue obtained when the patients underwent craniotomy for mass effect. The following demographic and clinical parameters were also analyzed for each patient: age, sex, postresuscitation Glasgow Coma Scale score (GCS), computerized tomography findings, intracranial pressure (ICP) recordings during the first 24 hours postsurgery, and the time interval from injury to surgery. The authors observed that PARP was present in neurons of pericontusional tissue and that it conformed to two patterns of subcellular localization; it was found either in the nucleus exclusively or in both nuclear and cytoplasmic compartments. They showed that a preponderance of cytoplasmic staining in neurons was significantly correlated with a short time interval from trauma to surgery (: 4 hours). There was no correlation, however, between the subcellular distribution of PARP and clinical parameters such as admission GCS score and ICP readings obtained intra- and postoperatively. Conclusions. As in earlier studies in which it has been suggested that caspase-cleaved PARP translocates to the cytoplasm during apoptosis, the authors' results indicate that apoptosis may predominate in the initial time frame after head injury. This information may well influence the timing of administration of antiapoptotic neuronal salvage agents for adjunctive therapy of head injury in the future.	Natl Univ Singapore, Natl Inst Neurosci, Dept Neurosurg, Sect Neurotrauma, Singapore 308433, Singapore; Natl Univ Singapore, Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Lab, Singapore 308433, Singapore	Ng, I (corresponding author), Natl Univ Singapore, Natl Inst Neurosci, Dept Neurosurg, Sect Neurotrauma, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.		Yeo, Tseng Tsai/U-8864-2017				BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Cookson MR, 1999, BRAIN RES, V834, P182, DOI 10.1016/S0006-8993(99)01559-0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Amours D, 2001, J CELL SCI, V114, P3771; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLEINICK NL, 1985, RADIAT RES, V101, P29, DOI 10.2307/3576301; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Soldani C, 2001, EXP CELL RES, V269, P193, DOI 10.1006/excr.2001.5293; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; TEASDALE G, 1974, LANCET, V2, P81; Tentori L, 2002, PHARMACOL RES, V45, P73, DOI 10.1006/phrs.2001.0935; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	31	21	22	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2003	99	1					125	130		10.3171/jns.2003.99.1.0125			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	696BN	WOS:000183865500020	12854754				2021-06-18	
J	Swift, EE; Taylor, HG; Kaugars, AS; Drotar, D; Yeates, KO; Wade, SL; Stancin, T				Swift, EE; Taylor, HG; Kaugars, AS; Drotar, D; Yeates, KO; Wade, SL; Stancin, T			Sibling relationships and behavior after pediatric traumatic brain injury	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						traumatic brain injury; sibling relationships	FAMILY RELATIONSHIPS; HEAD-INJURY; CHILDREN; ADAPTATION; CHILDHOOD; PREDICTORS; SCHOOL; ASSOCIATIONS; OUTCOMES; SEVERITY	To evaluate long-term outcomes for siblings of children with traumatic brain injury (TBI), measures of sibling relationships and sibling behavior were collected an average of 4 years postinjury. The study sample included participants in a larger longitudinal study who had school-aged siblings, including 34 with severe TBI, 30 with moderate TBI, and 39 with orthopedic injuries not involving brain insult (ORTHO group). Group comparisons revealed more negative sibling relationships in families of children with TBI than in families of children in the ORTHO group, but only for mixed-gender sibling pairings. Behavior problems in children with TBI predicted both sibling relationships and sibling behavior problems. The findings indicate a need to monitor the adjustment of siblings and sibling relationships after TBI and to include siblings in family interventions.	Rainbow Babies & Childrens Hosp, Div Behav Pediat & Psychol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA; Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; Univ Cincinnati, Sch Med, Childrens Hosp, Ctr Med,Dept Psychol, Cincinnati, OH USA; Metrohlth Med Ctr, Div Psychiat, Cleveland, OH 44109 USA	Taylor, HG (corresponding author), Rainbow Babies & Childrens Hosp, Div Behav Pediat & Psychol, 11100 Euclid Ave, Cleveland, OH 44106 USA.		Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; BOER F, 1992, CHILDRENS SIBLING RE; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; BRODY GH, 1992, CHILD DEV, V63, P391, DOI 10.2307/1131487; BRODY GH, 1982, CHILD DEV, V53, P1364, DOI 10.2307/1129027; BRODY GH, 1985, DEV PSYCHOL, V21, P124, DOI 10.1037/0012-1649.21.1.124; BUHRMESTER D, 1987, CHILD DEV, V58, P1101, DOI 10.2307/1130550; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; COHEN D, 1995, J CLIN PSYCHOL, V50, P303; DROTAR D, 1985, J DEV BEHAV PEDIATR, V6, P355; DUNN J, 1994, DEV PSYCHOL, V30, P315, DOI 10.1037/0012-1649.30.3.315; Dunn J, 1999, J CHILD PSYCHOL PSYC, V40, P1025, DOI 10.1017/S0021963099004369; DYSON LL, 1989, J PEDIATR PSYCHOL, V14, P215, DOI 10.1093/jpepsy/14.2.215; Fisman S, 2000, CAN J PSYCHIAT, V45, P369, DOI 10.1177/070674370004500406; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FURMAN W, 1985, CHILD DEV, V56, P448, DOI 10.1111/j.1467-8624.1985.tb00119.x; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; Hetherington E. M., 1993, J FAM PSYCHOL, V7, P39, DOI [10.1037/0893-3200.7.1.39, DOI 10.1037/0893-3200.7.1.39]; Hetherington E.M., 1988, RELATIONSHIPS FAMILI, P311; HETHERINGTON EM, 1992, MONOGRAPHS SOC RES C, V57, P2, DOI DOI 10.1111/J.1540-5834.1992.TB00300.X; HU Z, 1993, CAN MED ASSOC J, V149, P421; JENKINS J, 1992, CHILDRENS SIBLING RELATIONS, P125; JENNETT B, 1975, LANCET, V1, P480; KAISER HF, 1962, PSYCHOMETRIKA, V1, P83; Kim JE, 1999, CHILD DEV, V70, P1209, DOI 10.1111/1467-8624.00088; KRAUS JF, 1987, PEDIATRICS, V79, P501; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; LOEBER R, 1984, J CONSULT CLIN PSYCH, V52, P759, DOI 10.1037/0022-006X.52.5.759; LOEBER R, 1983, PSYCHOL BULL, V94, P68, DOI 10.1037/0033-2909.94.1.68; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199303000-00010, 10.1097/00001199-199303000-00010]; Patterson G.R., 1984, ADV STUDY AGGRESSION, V1, P173, DOI DOI 10.1016/B978-0-12-037701-5.50010-6; PATTERSON GR, 1986, DEV ANTISOCIAL PROSO; Peretti PO, 1995, INDIAN J CLIN PSYCHO, V22, P23; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Sahler OJZ, 1997, J DEV BEHAV PEDIATR, V18, P233; SAHLER OJZ, 1994, J DEV BEHAV PEDIATR, V15, P353; Stormshak EA, 1996, DEV PSYCHOL, V32, P79, DOI 10.1037/0012-1649.32.1.79; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WILLER B, 1990, CAN J REHABIL, V3, P157; Williams PD, 1997, INT J NURS STUD, V34, P312, DOI 10.1016/S0020-7489(97)00019-9; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	50	21	21	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0196-206X			J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	FEB	2003	24	1					24	31		10.1097/00004703-200302000-00007			8	Behavioral Sciences; Psychology, Developmental; Pediatrics	Behavioral Sciences; Psychology; Pediatrics	645UF	WOS:000180997200006	12584482				2021-06-18	
J	Bittigau, P; Sifringer, M; Felderhoff-Mueser, U; Hansen, HH; Ikonomidou, C				Bittigau, P; Sifringer, M; Felderhoff-Mueser, U; Hansen, HH; Ikonomidou, C			Neuropathological and biochemical features of traumatic injury in the developing brain	NEUROTOXICITY RESEARCH			English	Article						apoptosis; excitotoxicity; neuroprotection	DEVELOPING RAT-BRAIN; NONACCIDENTAL HEAD-INJURY; SHAKEN-BABY SYNDROME; METHYL-D-ASPARTATE; NEURODEGENERATION FOLLOWING TRAUMA; HYPOXIC-ISCHEMIC INJURY; APOPTOTIC CELL-DEATH; CEREBROSPINAL-FLUID; IN-VIVO; CASPASE INHIBITOR	Trauma to the developing brain constitutes a poorly explored field. Some recent studies attempting to model and study pediatric head trauma, the leading cause of death and disability in the pediatric population, revealed interesting aspects and potential targets for future research. Trauma triggers both excitotoxic and apoptotic neurodegeneration in the developing rat brain. Excitotoxic neurodegeneration develops and subsides rapidly (within hours) whereas apoptotic cell death occurs in a delayed fashion over several days following the initial traumatic insult. Apoptotic neurodegeneration contributes in an age-dependent fashion to neuronal injury following head trauma, with the immature brain being exceedingly sensitive. In the most vulnerable ages the apoptosis contribution to the extent of traumatic brain damage far outweighs that of the excitotoxic component. Molecular and biochemical studies indicate that both extrinsic and intrinsic mechanisms are involved in pathogenesis of apoptotic cell death following trauma. Interestingly, in infant rats a pan-caspase inhibitor ameliorated apoptotic neurodegeneration with a therapeutic time window of up to 8 h after trauma. These results help explain unfavorable outcomes of very young pediatric head trauma patients and imply that regimen which target slow active forms of cell death may comprise a successful neuroprotective approach.	Humboldt Univ, Dept Pediat Neurol, D-13353 Berlin, Germany; Humboldt Univ, Charite Childrens Hosp, Dept Neonatol, D-13353 Berlin, Germany; Danish Univ Pharmaceut Sci, Dept Pharmacol, DK-2100 Copenhagen, Denmark	Ikonomidou, C (corresponding author), Humboldt Univ, Dept Pediat Neurol, Augustenburger Pl 1, D-13353 Berlin, Germany.	hrissanthi.ikonomidou@charite.de	Felderhoff-Muser, Ursula/AAU-9682-2020				Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Borovitskaya AE, 1996, MOL BRAIN RES, V35, P19, DOI 10.1016/0169-328X(95)00177-T; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; David TJ, 1999, J ROY SOC MED, V92, P556, DOI 10.1177/014107689909201105; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Downer E, 2001, NEUROREPORT, V12, P3973, DOI 10.1097/00001756-200112210-00024; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrer I, 1996, EUR J NEUROSCI, V8, P1286, DOI 10.1111/j.1460-9568.1996.tb01297.x; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2002, J NEUROCHEM, V82, P154, DOI 10.1046/j.1471-4159.2002.00961.x; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Himi T, 1998, EUR J NEUROSCI, V10, P777, DOI 10.1046/j.1460-9568.1998.00073.x; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; James HE, 1999, ACT NEUR S, V73, P85; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; Liou JC, 1997, J NEUROSCI, V17, P2459; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakashima K, 1999, J NEUROTRAUM, V16, P143, DOI 10.1089/neu.1999.16.143; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; OLIVER JE, 1975, BRIT MED J, V2, P262, DOI 10.1136/bmj.2.5965.262; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schlicker E, 2001, TRENDS PHARMACOL SCI, V22, P565, DOI 10.1016/S0165-6147(00)01805-8; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	100	21	22	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.		2003	5	7					475	490		10.1007/BF03033158			16	Neurosciences	Neurosciences & Neurology	764YB	WOS:000188233300002	14715432				2021-06-18	
J	Hortobagyi, T; Gorlach, C; Benyo, Z; Lacza, Z; Hortobagyi, S; Wahl, M; Harkany, T				Hortobagyi, T; Gorlach, C; Benyo, Z; Lacza, Z; Hortobagyi, S; Wahl, M; Harkany, T			Inhibition of neuronal nitric oxide synthase-mediated activation of poly(ADP-ribose) polymerase in traumatic brain injury: Neuroprotection by 3-aminobenzamide	NEUROSCIENCE			English	Article						apoptosis; brain trauma; cerebral cortex; combined treatment; focal lesion; neuroprotection	ISCHEMIA-REPERFUSION; NERVOUS-SYSTEM; FOCAL ISCHEMIA; STRAND BREAKS; COLD-INJURY; RAT-BRAIN; IN-VITRO; DNA; SYNTHETASE; EXPRESSION	Focal traumatic injury to the cerebral cortex is associated with early activation of the neuronal isoform of nitric oxide synthase (nNOS), where high concentrations of nitric oxide-derived free radicals elicit extensive DNA damage. Subsequent activation of the nuclear repair enzyme poly(ADP-ribose) polymerase (PARP) causes a severe energy deficit leading to the ultimate demise of affected neurons. Little is known about the temporal relationship of nNOS and PARP activation and the neuroprotective efficacy of their selective blockade in traumatic brain injury. To determine the relationship of nNOS and PARP activation, brain injury was induced by cryogenic lesion to the somatosensory cortex applying a pre-cooled cylinder after trephination for 6 s to the intact dura mater. Pre-treatment with 3-bromo-7-nitroindazole (BrNI; 25 mg/kg, i.p.), and pre- or combined pre- and post-treatment with 3-aminobenzamide (AB; 10 mg/kg (i.c.v.) or 10 mg/kg/h (i.p.)) were used to inhibit nNOS and PARP, respectively. Cold lesion-induced changes in the somatosensory cortex and neuroprotection by BrNI and AB were determined using immunocytochemistry and immunodot-blot for detection of poly(ADP-ribose; PAR), the end-product of PARP activation, and the triphenyltetrazolium-chloride assay to assess lesion volume. PAR immunoreactivity reached its peak 30 min post-lesion and was followed by gradual reduction of PAR immunolabeling. BrNI pre-treatment significantly decreased the lesion-induced PAR concentration in damaged cerebral cortex. Pre-treatment by i.c.v. infusion of AB mark-edly diminished cortical PAR immunoreactivity and significantly reduced the lesion volume 24 h post-injury. In contrast, i.p. AB treatment remained largely ineffective. In conclusion, our data indicate early activation of PARP after cold lesion that is, at least in part, related to nNOS induction and supports the relevance of nNOS and/or PARP inhibition to therapeutic approaches of traumatic brain injury. (C) 2003 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Szeged, Dept Pathol, Szeged, Hungary; Univ Munich, Dept Physiol, D-8000 Munich, Germany; Semmelweis Univ, Inst Human Physiol & Expt Clin Res, H-1085 Budapest, Hungary; Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, Stockholm, Sweden	Hortobagyi, T (corresponding author), Inst Psychiat, Dept Neuropathol, POB 076,De Crespigny Pk, London SE5 8AF, England.	t.hortobagyi@iop.kcl.ac.uk	Benyo, Zoltan/C-9184-2009	Benyo, Zoltan/0000-0001-6015-0359			Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Affar EB, 1998, ANAL BIOCHEM, V259, P280, DOI 10.1006/abio.1998.2664; Benyo Z, 2000, BRAIN RES, V877, P79, DOI 10.1016/S0006-8993(00)02611-1; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burkle A, 1999, HISTOCHEM J, V31, P711, DOI 10.1023/A:1003944314206; Ciani E, 2001, BRAIN RES BULL, V56, P29, DOI 10.1016/S0361-9230(01)00589-5; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; ERISKAT J, 1994, ACTA NEUROCHIR, P425; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goldlust EJ, 1996, STROKE, V27, P1657, DOI 10.1161/01.STR.27.9.1657; Gorlach C, 2000, RESTOR NEUROL NEUROS, V17, P71; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hortobagyi T, 2000, PFLUG ARCH EUR J PHY, V441, P409, DOI 10.1007/s004240000441; IKAI K, 1980, J HISTOCHEM CYTOCHEM, V28, P670, DOI 10.1177/28.7.6993553; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Koedel U, 1999, BRAIN PATHOL, V9, P57; Lacza Z, 2003, INT J MOL MED, V12, P153; LACZA Z, 2002, 2372 SOC NEUR; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247; Love S, 1998, NEUROREPORT, V9, P955, DOI 10.1097/00001756-199804200-00001; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Muiras ML, 2000, EXP GERONTOL, V35, P703, DOI 10.1016/S0531-5565(00)00144-3; Nag S, 1996, J NEUROPATH EXP NEUR, V55, P880, DOI 10.1097/00005072-199608000-00003; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Smith S, 1999, J CELL SCI, V112, P3649; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Tatsumi-Miyajima J, 1999, MOL CELL BIOCHEM, V193, P31, DOI 10.1023/A:1006935404987; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; WALLIS RA, 1993, NEUROREPORT, V5, P245; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Wiley CA, 2000, J NEUROPATH EXP NEUR, V59, P955, DOI 10.1093/jnen/59.11.955; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	50	21	22	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2003	121	4					983	990		10.1016/S0306-4522(03)00482-2			8	Neurosciences	Neurosciences & Neurology	741QY	WOS:000186469800018	14580948				2021-06-18	
J	Goda, M; Isono, M; Fujiki, M; Kobayashi, H				Goda, M; Isono, M; Fujiki, M; Kobayashi, H			Both MK801 and NBQX reduce the neuronal damage after impact-acceleration brain injury	JOURNAL OF NEUROTRAUMA			English	Article						impact-acceleration injury; traumatic brain injury; neuronal degeneration; Fluoro-Jade; amyloid precursor protein; MK-801; NBQX	D-ASPARTATE RECEPTOR; ANTICONVULSANT MK-801; GLUTAMATE RECEPTORS; AXONAL INJURY; AMINO-ACIDS; RAT-BRAIN; ANTAGONIST; TRAUMA; MODEL; NMDA	To understand the pathogenesis of diffuse axonal injury, we investigated the temporal and spatial profiles of neuronal degeneration in impact-acceleration injury in rats using Fluoro-Jade (FJ) staining. Impact-acceleration injury was produced in Wistar rats by the method described by Marmarou et al. with some modifications. Animals were sacrificed 1, 2, 7, 14, or 28 days after injury. Paraffin-embedded coronal sections were stained with HE or FJ, or analyzed immunohistochemically for GFAP or amyloid precursor protein (APP). FJ-positive degenerative neurons were found primarily in the dorsal brainstem and thalamus from 1 to 2 days following injury and these were associated with GFAP expression. However, FJ-positive cells were rarely found after 7 days. In all rats, significant expression of APP was observed primarily in the cingulum, cerebral peduncle and pontomedullary junction. FJ also stained these injured axons. Intrathecal administration of both NMDA and AMPA/kinate glutamate receptor antagonists MK-801 and NBQX, respectively, reduced the neuronal injury. NBQX showed more significant effects on axonal injury than MK-801. These observations indicate that not only axonal damage, but also primary neuronal damage occurs in this impact-acceleration injury model. It is also suggested that NBQX can act both directly on neuronal cells and white matter and that NMDA could have a significant protective effect against not only neuronal, but also axonal injury.	Oita Med Univ, Dept Neurosurg, Oita 8795593, Japan	Goda, M (corresponding author), Oita Med Univ, Dept Neurosurg, 1-1 Idaigaoka, Oita 8795593, Japan.		Goda, Makoto/R-3164-2019				Agrawal SK, 1997, J NEUROSCI, V17, P1055; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; Bullock Ross, 1993, Journal of Emergency Medicine, V11, P23; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; Garcia-Barcina JM, 1998, MOL BRAIN RES, V53, P270, DOI 10.1016/S0169-328X(97)00318-5; Gurevich B, 1998, J NEUROSURG, V88, P1066, DOI 10.3171/jns.1998.88.6.1066; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LUEL MS, 1996, PHARMACOTHERAPY, V16, P830; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1987, J NEUROSCI, V7, P3230; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Rosen CJ, 1999, J CLIN DENSITOM, V2, P3, DOI 10.1385/JCD:2:1:3; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIVERMAN JD, 1985, BRAIN RES, V361, P383; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; Williams J. M. G., 1993, J MENTAL HLTH, V2, P3; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; YOSHIDA A, 1991, J COMP NEUROL, V307, P609, DOI 10.1002/cne.903070408	32	21	21	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1445	1456		10.1089/089771502320914679			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500005	12490009				2021-06-18	
J	McCrory, P				McCrory, P			What advice should we give to athletes postconcussion?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CONCUSSION		Univ Melbourne, Ctr Sports Med Res & Educ, Melbourne, Vic 3052, Australia; Univ Melbourne, Inst Brain Res, Melbourne, Vic 3052, Australia	McCrory, P (corresponding author), POB 93, Shoreham, Vic 3916, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth J T, 2000, Dent Clin North Am, V44, P67; Barth JT., 1989, MILD HEAD INJURY, P257; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; GRONWALL D, 1974, LANCET, V2, P605; JENNETT B, 1975, LANCET, V1, P480; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Mayou R, 2002, BRIT MED J, V325, P426, DOI 10.1136/bmj.325.7361.426; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; RICE SG, 1995, SPORTS MED PRIM CARE, V1, P9; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x	15	21	21	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT	2002	36	5					316	318		10.1136/bjsm.36.5.316			3	Sport Sciences	Sport Sciences	602RN	WOS:000178518400003	12351326	Bronze, Green Published			2021-06-18	
